PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Brasel, KJ; Bulger, E; Cook, AJ; Morrison, LJ; Newgard, CD; Tisherman, SA; Kerby, JD; Coimbra, R; Hata, JS; Hoyt, DB				Brasel, Karen J.; Bulger, Eileen; Cook, Andrea J.; Morrison, Laurie J.; Newgard, Craig D.; Tisherman, Sam A.; Kerby, Jeffrey D.; Coimbra, Raul; Hata, J. Steven; Hoyt, David B.		Resuscitation Outcomes Consortium	Hypertonic resuscitation: Design and implementation of a prehospital intervention trial	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							7.5-PERCENT SODIUM-CHLORIDE; SALINE RESUSCITATION; HEMORRHAGIC-SHOCK; TRAUMA PATIENTS; DEXTRAN; HYPOTENSION; INFUSION; EFFICACY; SEQUENCE; INJURY	BACKGROUND: Trauma is the leading cause of death among North Americans between the ages of I and 44 years. Resuscitation with hypertonic saline (7.5%) solutions can reduce mortality in hypotensive and brain-injured patients. STUDY DESIGN: Two multicenter, randomized, clinical trials were designed to compare hypertonic saline resuscitation with or without dextran with conventional isotonic resuscitation in patients with hypovolemic shock or traumatic brain injury. During a 3-year period, 5,848 patients will be randomized, with a primary end point of 28-day survival in the hypovolemic shock cohort and 6-month neurologic outcomes in the traumatic brain injury cohort. RESULTS: This is a report of the study design and implementation of 2 large-scale prehospital intervention trials from the Resuscitation Outcomes Consortium that qualify for exception from informed consent required for emergency research outlined in FDA regulation 21CFR50.24 and the Canadian Tri-Council Agreement for research in emergency health situations (Article 2.8). CONCLUSIONS: We have successfully designed and implemented two prehospital intervention trials. The process has helped define the numerous challenges that must be overcome to pursue exception from informed consent resuscitation research in the prehospital setting. The results of these studies will hopefully advance and improve the early care of the severely injured patient.	[Brasel, Karen J.] Med Coll Wisconsin, Div Trauma Crit Care, Dept Surg, Milwaukee, WI 53226 USA; [Bulger, Eileen] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Cook, Andrea J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Cook, Andrea J.] Grp Hlth Ctr Hlth Studies, Seattle, WA USA; [Morrison, Laurie J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada; [Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy Res Emergency Med, Portland, OR 97201 USA; [Tisherman, Sam A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Kerby, Jeffrey D.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Coimbra, Raul] Univ Calif San Diego, Sch Med, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Hata, J. Steven] Univ Iowa, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA; [Hoyt, David B.] Univ Calif Irvine, Dept Surg, Irvine, CA 92717 USA	Brasel, KJ (corresponding author), Med Coll Wisconsin, Div Trauma Crit Care, Dept Surg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		morrison, laurie J/A-6325-2012; Coimbra, Raul/AAP-3019-2020; Tisherman, Samuel A./AAK-9377-2020; Hata, J./ABI-1484-2020	morrison, laurie J/0000-0001-8369-9774; Coimbra, Raul/0000-0002-3759-6851; Tisherman, Samuel A./0000-0003-3810-3729; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077863] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863] Funding Source: Medline		*BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Browder W, 2005, J TRAUMA, V59, P264; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; BULGER EM, IN PRESS ARCH SURG; Coimbra R, 2005, J TRAUMA, V59, P257, DOI 10.1097/01.ta.0000174678.12523.9f; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holcroft J W, 1989, Prog Clin Biol Res, V299, P331; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Little RJA, 1987, STAT ANAL MISSING DA; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MURRAY CJC, 1996, GLOBAL BURDEN DIS IN, P373; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcommon NJ, 2003, STROKE, V34, P377, DOI 10.1161/01.STR.0000055766.99908.58; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pepe PE, 2001, ANN EMERG MED, V37, pS17, DOI 10.1067/mem.2001.114175; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rizoli SB, 1999, J SURG RES, V83, P130, DOI 10.1006/jsre.1999.5581; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rizoli SB, 1998, J IMMUNOL, V161, P6288; Rubin D. B., 1987, MULTIPLE IMPUTATIONS; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Scheffe H, 1959, ANAL VARIANCE, P88; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SMITH GJ, 1985, J SURG RES, V39, P517, DOI 10.1016/0022-4804(85)90120-9; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VELASCO IT, 1989, CRIT CARE MED, V17, P261, DOI 10.1097/00003246-198903000-00012; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WADE CE, 1989, CIRC SHOCK, V29, P193; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Younes RN, 1997, SHOCK, V7, P79, DOI 10.1097/00024382-199702000-00001; YOUNES RN, 1992, SURGERY, V111, P380	39	49	53	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	FEB	2008	206	2					220	232		10.1016/j.jamcollsurg.2007.07.020			13	Surgery	Surgery	257UA	WOS:000252822900003	18222373				2021-06-18	
J	Baker, F; Wigram, T; Stott, D; McFerran, K				Baker, Felicity; Wigram, Tony; Stott, David; McFerran, Katrina			Therapeutic Songwriting in Music Therapy Part I: Who are the Therapists, Who are the Clients, and Why is Songwriting Used?	NORDIC JOURNAL OF MUSIC THERAPY			English	Article						Songwriting; evidence-based practice; music therapy methods	TRAUMATIC BRAIN-INJURY; SONGS WRITTEN; ADOLESCENTS; PEOPLE; THEMES	Songwriting as a therapeutic intervention has received increasing attention in the field of music therapy over the past decade however much of the publications focus on clinical outcomes rather than methods of practice. This paper, part of a two-part research report into trends in the clinical practice of songwriting, aims to describe the most frequently employed goal areas across a range of clinical populations and compare these findings with the published literature. Responses to a 21-question online survey were obtained from 477 professional music therapists practicing in 29 countries which focused on approaches to songwriting within their practice with a single clinical population. Chi-square or comparable Exact tests (Fisher-Freeman-Halton) were applied to the data and significant associations were found according to different clinical populations particularly with respect to the aims of songwriting in clinical practice and the frequency with which songwriting is employed in practice. The data highlights that songwriting is frequently employed in developmental disability and ASD practice, with reports on songwriting with these diagnostic groups being underrepresented in the music therapy literature. The survey identified that the most frequently endorsed goal areas align with the literature base and included a) experiencing mastery, develop self-confidence, enhance self-esteem; b) choice and decision making; c) develop a sense of self; d) externalising thoughts, fantasies, and emotions; e) telling the client's story; and f) gaining insight or clarifying thoughts and feelings.	[Baker, Felicity] Univ Queensland, Sch Mus, Brisbane, Qld, Australia; [Wigram, Tony] Univ Aalborg, Dept Humanities, Inst Commun & Psychol, Aalborg, Denmark; [Wigram, Tony] Anglia Ruskin Univ, Cambridge, England; [McFerran, Katrina] Univ Melbourne, Fac Mus, Melbourne, Vic 3010, Australia; [Stott, David] Univ Hertfordshire, E England RDSU Hertfordshire, Hatfield AL10 9AB, Herts, England	Baker, F (corresponding author), Univ Queensland, Sch Mus, Brisbane, Qld, Australia.	f.bakerl@uq.edu.au		McFerran, Katrina/0000-0003-0699-3683			Aasgaard T, 2001, J PALLIATIVE CARE, V17, P177; AASGAARD T, 2005, SONGWRITING METHODS; Abad V., 2003, AUSTR J MUSIC THERAP, V14, P20; Baker F, 2005, J MUSIC THER, V42, P111, DOI 10.1093/jmt/42.2.111; Baker F., 2006, MUSIC THERAPY METHOD; Baker F., 2005, AUSTR J MUSIC THERAP, V16, P25; Baker FA, 2007, ART PSYCHOTHER, V34, P321, DOI 10.1016/j.aip.2007.04.005; Cordobes TK, 1997, J MUSIC THER, V34, P46, DOI 10.1093/jmt/34.1.46; Dalton TA, 2005, ART PSYCHOTHER, V32, P131, DOI 10.1016/j.aip.2005.02.002; Dalton TA, 2006, MUSIC THER PERSPECT, V24, P94, DOI 10.1093/mtp/24.2.94; Davidson MB, 2005, NAT REV DRUG DISCOV, V4, P713, DOI 10.1038/nrd1828; Day T., 2005, SONGWRITING METHODS; Derrington P, 2005, SONGWRITING METHODS; DILEO C, 2005, SONGWRITING METHODS; Edgerton C. D., 1990, MUSIC THERAPY PERSPE, V8, P15; Edwards J., 1998, MUSIC THERAPY PERSPE, V16, P21, DOI DOI 10.1093/mtp/16.1.21; FICKEN T, 1976, J MUSIC THER, V13, P163, DOI 10.1093/jmt/13.4.163; FISCHER R, 1991, CASE STUDIES MUSIC T; Freed B. S., 1987, MUSIC THERAPY PERSPE, V4, P13, DOI [10.1093/mtp/4.1.13, DOI 10.1093/MTP/4.1.13]; Gallagher L. M., 2002, MUSIC THERAPY PERSPE, V20, P117, DOI DOI 10.1093/MTP/20.2.117; Gfeller K., 1987, MUSIC THERAPY, V6, P28; Ghetti C. M., 2004, MUSIC THERAPY PERSPE, V22, P84, DOI DOI 10.1093/MTP/22.2.84; GLASSMAN LR, 1991, ART PSYCHOTHER, V18, P149, DOI 10.1016/0197-4556(91)90022-3; GOLDSTEIN SL, 1990, ART PSYCHOTHER, V17, P117, DOI 10.1016/0197-4556(90)90021-H; HADLEY SJ, 1986, AUSTR J MUSIC THERAP, V7, P16; Hilliard R. E., 2001, MUSIC THERAPY PERSPE, V19, P109, DOI DOI 10.1093/MTP/19.2.109]; Jones JD, 2005, J MUSIC THER, V42, P94, DOI 10.1093/jmt/42.2.94; KENNELLY J, 1999, MUSICMEDICINE, V3; KROUT RE, 2005, SONGWRITING METHODS; Krout RE, 2005, MUSIC THER PERSPECT, V23, P118, DOI 10.1093/mtp/23.2.118; Ledger A., 2001, AUSTR J MUSIC THERAP, V12, P21; Lindberg K. A., 1995, MUSIC THERAPY, V13, P93; Mayers KS, 1995, ART PSYCHOTHER, V22, P495, DOI 10.1016/0197-4556(94)00050-6; McFerran K, 2006, EUR EAT DISORD REV, V14, P397, DOI 10.1002/erv.746; MCFERRANSKEWES K, 2001, THESIS U MELBOURNE A; MONTELLO L, 2003, PSYCHODYNAMIC MUSIC; O'Brien E., 2005, SONGWRITING METHODS; O'Callaghan C., 1997, MUSIC THERAPY PERSPE, V15, P32, DOI DOI 10.1093/MTP/15.1.32; OCALLAGHAN C, 1990, AUSTR J MUSIC THERAP, V1, P15; OCallaghan CC, 1996, J MUSIC THER, V33, P74, DOI 10.1093/jmt/33.2.74; Oldfield A., 2005, SONGWRITING METHODS; Rickson DJ, 2003, J MUSIC THER, V40, P283, DOI 10.1093/jmt/40.4.283; ROBARTS J, 2003, PSYCHODYNAMIC MUSIC; Robb S. L., 1996, MUSIC THERAPY PERSPE, V14, P30; Robb Sheri L, 2003, J Pediatr Oncol Nurs, V20, P2, DOI 10.1053/jpon.2003.3; Robb Sheri L, 2003, J Pediatr Oncol Nurs, V20, P16, DOI 10.1053/jpon.2003.4; Roberts M, 2006, AUSTR J MUSIC THERAP, V17, P18; Rolvsjord Randi, 2005, SONGWRITING METHODS; Silber F., 1995, MUSIC THER PERSPECT, V13, P31, DOI [10.1093/mtp/13.1.31, DOI 10.1093/MTP/13.1.31]; Silverman MJ, 2003, ART PSYCHOTHER, V30, P25, DOI 10.1016/S0197-4556(02)00231-9; Slivka H. H., 1986, MUSIC THERAPY A, V6A, P30; Tamplin J., 2006, NORD J MUSIC THER, V15, P177, DOI [10.1080/08098130609478164, DOI 10.1080/08098130609478164]; Turry A. E., 1999, CLIN APPL MUSIC THER; Wigram T., 2005, SONGWRITING METHODS; Wigram T, 2005, SONGWRITING METHODS; Williams SL, 2006, NUTR REV, V64, P93, DOI [10.1301/nr.2006.mar.93-108, 10.1111/j.1753-4887.2006.tb00193.x]	56	49	49	1	30	GRIEG ACADEMY	BERGEN	UNIV BERGEN, DEPT MUSIC, LARS HILLES GATE 3, BERGEN, N-5015, NORWAY	0803-9828			NORD J MUSIC THER	Nord. J. Music Ther.		2008	17	2					105	123		10.1080/08098130809478203			19	Rehabilitation	Rehabilitation	374JT	WOS:000261040300003					2021-06-18	
J	Thomas, KE; Stevens, JA; Sarmiento, K; Wald, MM				Thomas, K. E.; Stevens, J. A.; Sarmiento, K.; Wald, M. M.			Fall-related traumatic brain injury deaths and hospitalizations among older adults - United States, 2005	JOURNAL OF SAFETY RESEARCH			English	Article						traumatic brain injury; elderly; fall		Problem: Among older adults, both unintentional falls and traumatic brain injuries (TBI) result in significant morbidity and mortality; however, only limited national data on fall-related TBI are available. Method: To examine the relationship between older adult falls and TBI deaths and hospitalizations, CDC analyzed 2005 data from the National Center for Health Statistics' National Vital Statistics System and the Agency for Healthcare Research and Quality's Nationwide Inpatient Sample. Results: In 2005, among adults ! 65 years, there were 7946 fall-related TBI deaths and an estimated 56,423 hospitalizations for nonfatal fall-related TBI in the United States. Fall-related TBI accounted for 50.3% of unintentional fall deaths and 8.0% of nonfatal fall-related hospitalizations. Summary: These findings underscore the need for greater dissemination and implementation of evidence-based fall prevention interventions. Published by Elsevier Ltd.	[Thomas, K. E.; Stevens, J. A.; Sarmiento, K.; Wald, M. M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Thomas, KE (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mail Stop F-62, Atlanta, GA 30341 USA.	KEThomas@cdc.gov					*AHRQ, 2007, DES HCUP NAT INP SAM; *CDC, 2007, MMWR-MORBID MORTAL W, V55, P1221; *CDC, 2008, BRIEF AG AM C WASH D; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2005, WEB BAS INJ STAT QUE; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Marr AL., 2004, CENTRAL NERVOUS SYST; *NCHS, 2008, NAT VIT STAT REP, V56; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Stevens JA, 2001, JAMA-J AM MED ASSOC, V286, P2665, DOI 10.1001/jama.286.21.2665; *US CENS BUR, 2007, RES POP NAT POP EST	11	49	49	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375			J SAFETY RES	J. Saf. Res.		2008	39	3					269	272		10.1016/j.jsr.2008.05.001			4	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	327YU	WOS:000257765200003	18571567				2021-06-18	
J	Irle, E; Lange, C; Weniger, G; Sachsse, U				Irle, Eva; Lange, Claudia; Weniger, Godehard; Sachsse, Ulrich			Size abnormalities of the superior parietal cortices are related to dissociation in borderline personality disorder	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						precuneus; postcentral gyros; inferior parietal cortex asymmetry; structural magnetic resonance imaging (3D-MRI); trauma; psychotic symptoms	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HIPPOCAMPAL VOLUME; AUDITORY HALLUCINATIONS; MULTIPLE PERSONALITY; PERSPECTIVE-TAKING; PLANUM TEMPORALE; SEX-DIFFERENCES; WOMEN	Recent evidence suggests that borderline personality disorder (BPD) is related to reduced size of the parietal lobe. Dissociative symptoms occur in the majority of individuals with BPD. Structural magnetic resonance imaging (3D-MRI) was used to assess volumes of the superior (precuneus, postcentral gyrus) and inferior parietal cortices in 30 young women with BPD who had been exposed to severe childhood sexual and physical abuse and 25 healthy control subjects. Compared with control subjects, BPD subjects had significantly smaller right-sided precuneus (-9%) volumes. The left postcentral gyrus of BPD subjects with the comorbid diagnosis of dissociative amnesia (DA) or dissociative identity disorder (DID) was significantly increased compared with controls (+13%) and compared with BPD subjects without these disorders (+11%). In BPD subjects, stronger depersonalization was significantly related to larger right precuneus size. Possibly, larger precuneus size in BPD is related to symptoms of depersonalization. Increased postcentral gyrus size in BPD may be related to the development of DA or DID in the presence of severe childhood abuse. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Univ Gottingen, Dept Psychiat & Psychotherapy, D-37075 Gottingen, Germany; Psychiat State Hosp Lower Saxony, Gottingen, Germany	Irle, E (corresponding author), Univ Gottingen, Dept Psychiat & Psychotherapy, Von-Siebold-Str 5, D-37075 Gottingen, Germany.	eirle@gwdg.de		Weniger, Godehard/0000-0001-8418-4780			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; Berlucchi G, 1997, TRENDS NEUROSCI, V20, P560, DOI 10.1016/S0166-2236(97)01136-3; Blanke O, 2002, NATURE, V419, P269, DOI 10.1038/419269a; BOON S, 1993, AM J PSYCHIAT, V150, P489; BREMNER JD, 1992, AM J PSYCHIAT, V149, P328; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1011; Brunner E., 2002, NONPARAMETRIC ANAL L; Cardenas VA, 2007, NEUROIMAGE, V34, P879, DOI 10.1016/j.neuroimage.2006.10.015; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chu JA, 1999, AM J PSYCHIAT, V156, P749; David D, 1999, J CLIN PSYCHIAT, V60, P29, DOI 10.4088/JCP.v60n0106; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; Driessen M, 2000, ARCH GEN PSYCHIAT, V57, P1115, DOI 10.1001/archpsyc.57.12.1115; First M., 1995, STRUCTURED CLIN INTE; First MB., 1997, STRUCTURED CLIN INTE; Frederikse M, 2000, AM J PSYCHIAT, V157, P422, DOI 10.1176/appi.ajp.157.3.422; Frederikse ME, 1999, CEREB CORTEX, V9, P896, DOI 10.1093/cercor/9.8.896; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gaser C, 2004, CEREB CORTEX, V14, P91, DOI 10.1093/cercor/bhg107; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; GLOOR P, 1982, ANN NEUROL, V12, P129, DOI 10.1002/ana.410120203; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Gurvits TV, 2000, ARCH GEN PSYCHIAT, V57, P181, DOI 10.1001/archpsyc.57.2.181; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; HALGREN E, 1978, BRAIN, V101, P83, DOI 10.1093/brain/101.1.83; HERMAN JL, 1989, AM J PSYCHIAT, V146, P490; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Irle E, 2005, BIOL PSYCHIAT, V57, P173, DOI 10.1016/j.biopsych.2004.10.004; Job DE, 2005, NEUROIMAGE, V25, P1023, DOI 10.1016/j.neuroimage.2005.01.006; Kakigi R, 2005, EUR J PAIN, V9, P581, DOI 10.1016/j.ejpain.2004.12.006; KERNBERG O, 1967, J AM PSYCHOANAL ASS, V15, P641, DOI 10.1177/000306516701500309; Kwon JS, 1999, ARCH GEN PSYCHIAT, V56, P142, DOI 10.1001/archpsyc.56.2.142; Lange C, 2005, PSYCHIAT RES-NEUROIM, V139, P115, DOI 10.1016/j.pscychresns.2005.05.003; Lanius RA, 2002, BIOL PSYCHIAT, V52, P305, DOI 10.1016/S0006-3223(02)01367-7; Lewis DO, 1997, AM J PSYCHIAT, V154, P1703, DOI 10.1176/ajp.154.12.1703; Lou HC, 1999, HUM BRAIN MAPP, V7, P98; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maercker A, 1998, DIAGNOSTICA, V44, P130; Maquet P, 1999, BIOL PSYCHIAT, V45, P327, DOI 10.1016/S0006-3223(97)00546-5; MESULAM MM, 1981, ARCH NEUROL-CHICAGO, V38, P176, DOI 10.1001/archneur.1981.00510030070010; Newberg A, 2003, PERCEPT MOTOR SKILL, V97, P625, DOI 10.2466/PMS.97.6.625-630; Newberg A, 2001, PSYCHIAT RES-NEUROIM, V106, P113, DOI 10.1016/S0925-4927(01)00074-9; Nierenberg J, 2005, AM J PSYCHIAT, V162, P1539, DOI 10.1176/appi.ajp.162.8.1539; Niznikiewicz M, 2000, AM J PSYCHIAT, V157, P428, DOI 10.1176/appi.ajp.157.3.428; PUTTERICH H, 1990, DIAGNOSTISCHES INTER; RADEMACHER J, 1992, J COGNITIVE NEUROSCI, V4, P352, DOI 10.1162/jocn.1992.4.4.352; Rainville P, 1999, J COGNITIVE NEUROSCI, V11, P110, DOI 10.1162/089892999563175; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; Ruby P, 2001, NAT NEUROSCI, V4, P546; Rusch N, 2003, NEUROIMAGE, V20, P385, DOI 10.1016/S1053-8119(03)00297-0; SALANOVA V, 1995, BRAIN, V118, P607, DOI 10.1093/brain/118.3.607; Schmahl C, 2006, ARCH GEN PSYCHIAT, V63, P659, DOI 10.1001/archpsyc.63.6.659; Shapleske J, 1999, BRAIN RES REV, V29, P26, DOI 10.1016/S0165-0173(98)00047-2; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; Simeon D, 2000, AM J PSYCHIAT, V157, P1782, DOI 10.1176/appi.ajp.157.11.1782; Sirigu A, 1996, SCIENCE, V273, P1564, DOI 10.1126/science.273.5281.1564; Skodol AE, 2002, BIOL PSYCHIAT, V51, P936, DOI 10.1016/S0006-3223(02)01324-0; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Steinberg M., 1994, STRUCTURED CLIN INTE; Swayze VW, 2003, INT J EAT DISORDER, V33, P33, DOI 10.1002/eat.10111; vanReekum R, 1996, J PSYCHIATR NEUROSCI, V21, P13; Vermetten E, 2006, AM J PSYCHIAT, V163, P630, DOI 10.1176/appi.ajp.163.4.630; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; Wagner A, 2006, BIOL PSYCHIAT, V59, P291, DOI 10.1016/j.biopsych.2005.06.014; Weiss DS, 1996, IMPACT EVENTS SCALE, P399; Whalley HC, 2005, BRAIN, V128, P2097, DOI 10.1093/brain/awh556; Whalley HC, 2004, BRAIN, V127, P478, DOI 10.1093/brain/awh070; Winter H, 2004, AM J PSYCHIAT, V161, P2194, DOI 10.1176/appi.ajp.161.12.2194; Wittchen H. U., 1997, STRUKTURIERTES KLIN; Wolpert DM, 1998, NAT NEUROSCI, V1, P529, DOI 10.1038/2245; Zanarini MC, 1998, AM J PSYCHIAT, V155, P1733, DOI 10.1176/ajp.155.12.1733; Zanarini MC, 2005, BORDERLINE PERSONALI	75	49	51	1	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	NOV 15	2007	156	2					139	149		10.1016/j.pscychresns.2007.01.007			11	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	233RB	WOS:000251106900005	17826965				2021-06-18	
J	Yang, SH; Xing, D; Lao, YQ; Yang, DW; Zeng, LM; Xiang, LZ; Chen, WR				Yang, Sihua; Xing, Da; Lao, Yeqi; Yang, Diwu; Zeng, Lvming; Xiang, Liangzhong; Chen, Wei R.			Noninvasive monitoring of traumatic brain injury and post-traumatic rehabilitation with laser-induced photoacoustic imaging	APPLIED PHYSICS LETTERS			English	Article								A photoacoustic imaging system was used for noninvasive monitoring of traumatic mouse brain in vivo with high-quality reconstructed images. Traumatic lesions accompanying with hemorrhage in the mouse cortical surface were accurately mapped, and foreign bodies of two small copper wires inserted in the mouse brain were also detected. Furthermore, the time course of morphological changes of cerebral blood during rehabilitation process of a mouse brain with traumatic brain injury was obtained using a series of photoacoustic images. Experimental results demonstrate that photoacoustic technique holds the potential for clinical applications in brain trauma and cerebrovascular disease detection. (c) 2007 American Institute of Physics.	S China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China; S China Normal Univ, Inst Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China	Xing, D (corresponding author), S China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China.	xingda@scnu.edu.cn	Xiang, Liangzhong/C-8458-2016	Xiang, Liangzhong/0000-0002-7228-0510			Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Kruger RA, 1999, RADIOLOGY, V211, P275, DOI 10.1148/radiology.211.1.r99ap05275; Siphanto RI, 2005, OPT EXPRESS, V13, P89, DOI 10.1364/OPEX.13.000089; Wang XD, 2003, NAT BIOTECHNOL, V21, P803, DOI 10.1038/nbt839; Wang XD, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192804; Wang Y, 2004, PHYS MED BIOL, V49, P3117, DOI 10.1088/0031-9155/49/14/006; Xiang LZ, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437752; Yang DW, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2198488; Yang DW, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2119417; Yang SH, 2007, EUR PHYS J-APPL PHYS, V37, P87, DOI 10.1051/epjap:2006136; Yuan Z, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2209883; Zeng YG, 2004, OPT LETT, V29, P1760, DOI 10.1364/OL.29.001760	13	49	58	2	30	AMER INST PHYSICS	MELVILLE	CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USA	0003-6951			APPL PHYS LETT	Appl. Phys. Lett.	JUN 11	2007	90	24							243902	10.1063/1.2749185			3	Physics, Applied	Physics	179QR	WOS:000247305400109					2021-06-18	
J	Covassin, T; Weiss, L; Powell, J; Womack, C				Covassin, Tracey; Weiss, Leigh; Powell, John; Womack, Christopher			Effects of a maximal exercise test on neurocognitive function	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PERFORMANCE; IMPACT; INFORMATION; CONCUSSION; VALIDITY	Objective: To examine the effects of a maximal exercise test on cognitive function in recreational athletes. Design: A repeated-measures design was used to compare baseline with post-cognitive function and fatigue symptoms after a maximal exercise test. Setting: Division 1 American Midwestern University, (Michigan State University, Michigan, USA). Participants: 102 male and female recreational athletes. Intervention: Participants in the experimental group (n = 54) were asked to perform a maximal treadmill exercise test to maximal oxygen uptake (VO2 max). Participants in the control group were asked to rest for 15 min. Main outcome measurements: All participants were administered a neuropsychological test battery called Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) before and after exercise to measure neurocognitive function and fatigue symptoms. Results: Results revealed a significant group (control, experimental) xtime (baseline, post-test 1, post-test 2) interaction for verbal memory composite scores (p = 0.025). Specifically, verbal memory composite scores decreased in the experimental group from baseline to post-test 1 (p = 0.00). These values returned to baseline 3 days after the VO2 max test (p = 0.00). Further analysis on verbal memory composite scores demonstrated significant differences on immediate recall memory (p = 0.00) and delayed recall memory (p = 0.00). No significant differences were observed for visual memory (p = 0.54), motor processing speed (p = 0.68) and reaction time (p = 0.44) composite scores between the experimental and control groups. Conclusion: The results of this study suggest that a maximal exercise test attenuated a limiting effect on cognitive function. When utilising a neuropsychological test battery to evaluate a patient who has sustained a head injury, the test should not be administered immediately after a practice or a game session.	Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; James Madison Univ, Harrisonburg, VA 22807 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Cian C, 2000, J PSYCHOPHYSIOL, V14, P29, DOI 10.1027//0269-8803.14.1.29; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fery YA, 1997, PERCEPT MOTOR SKILL, V84, P291, DOI 10.2466/pms.1997.84.1.291; FLEURY M, 1987, ERGONOMICS, V30, P945, DOI 10.1080/00140138708969790; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GUTIN B, 1968, RES QUART, V39, P81; HANCOCK S, 1986, PERCEPT MOTOR SKILL, V62, P491, DOI 10.2466/pms.1986.62.2.491; Hogervorst E, 1996, PERCEPT MOTOR SKILL, V83, P479, DOI 10.2466/pms.1996.83.2.479; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; ISAACS LD, 1991, J HUM MOVEMENT STUD, V20, P123; IVERSON G, 2002, NEUROPSYCHOLOGIA, V17, P769; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; LEDERC S, 2002, MED SCI SPORT EXER, V34, pS103; LOVELL M, 2005, IMMEDIATE POST CONCU; MCGLYNN GH, 1977, PERCEPT MOTOR SKILL, V44, P1139, DOI 10.2466/pms.1977.44.3c.1139; PAAS FGWC, 1991, ERGONOMICS, V34, P1385, DOI 10.1080/00140139108964879; SALMELA JH, 1986, PERCEPT MOTOR SKILL, V63, P1067, DOI 10.2466/pms.1986.63.3.1067; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Shibuya K, 2004, J SPORT MED PHYS FIT, V44, P215; Shibuya KI, 2004, RESP PHYSIOL NEUROBI, V140, P165, DOI 10.1016/j.resp.2003.11.004; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; WRISBERG C, RES, V47, P839	26	49	49	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2007	41	6					370	374		10.1136/bjsm.2006.032334			5	Sport Sciences	Sport Sciences	171FI	WOS:000246720100010	17224438	Green Published			2021-06-18	
J	Sifringer, M; Stefovska, V; Zentner, I; Hansen, B; Stepulak, A; Knaute, C; Marzahn, J; Ikonomidou, C				Sifringer, Marco; Stefovska, Vanya; Zentner, Ingo; Hansen, Berglind; Stepulak, Andrzej; Knaute, Christiane; Marzahn, Jenny; Ikonomidou, Chrysanthy			The role of matrix metalloproteinases in infant traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article							FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; DEVELOPING RAT-BRAIN; KAPPA-B ACTIVATION; SPINAL-CORD-INJURY; GENE KNOCK-OUT; CELL-DEATH; NEURONAL DEGENERATION; INDUCED APOPTOSIS; UNITED-STATES	Matrix metalloproteinases (MMPs) play an essential role in tissue repair, cell death and morphogenesis and may constitute therapeutic targets for acute brain injuries. In this study, we investigated the expression of 72 kDa and 92 kDa collagenases MMP-2 and MMP-9 at transcriptional, functional and protein expression level following traumatic brain injury in infant rats. Seven-day-old Wistar rats were subjected to head trauma using a weight drop device. Pups were sacrificed at defined time points (2-72 h) after trauma and brains were processed for molecular studies (semiquantitative and real-time PCR, Western blot, gelatin zymography) and histology. Trauma triggered widespread cell death in the cortex, basal ganglia and white matter. mRNA levels for MMP-2 and -9 were increased in the brain at 12-72 h after trauma. Protein expression of the analyzed MMPs and activity of MMP-2 were increased at 12 h and peaked at 24 h after trauma. Intraperitoneal injection of GM6001 (Ilomastat), an MMP inhibitor, 2 h after trauma, substantially attenuated traumatic brain injury in a dose-dependent manner. These findings causally link the MMPs to trauma-induced neuronal cell death in the immature rodent brain. MMPs might serve as useful targets for therapeutic approaches aimed at preserving neuronal function in the immature brain in the context of mechanical injury. (c) 2006 Elsevier Inc. All rights reserved.	Tech Univ Dresden, Dept Pediat Neurol, Childrens Hosp, Med Fac Carl Gustav Carus, D-01307 Dresden, Germany; Med Univ Lublin, Dept Biochem & Mol Biol, PL-20093 Lublin, Poland	Ikonomidou, C (corresponding author), Tech Univ Dresden, Dept Pediat Neurol, Childrens Hosp, Med Fac Carl Gustav Carus, Fetscherstasse 74, D-01307 Dresden, Germany.	hrissanthi.ikonomidou@uniklinikum-dresden.de		Stepulak, Andrzej/0000-0002-1872-394X			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Asahi M, 2001, J NEUROSCI, V21, P7724; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Gary DS, 2001, J NEUROCHEM, V76, P1485, DOI 10.1046/j.1471-4159.2001.00173.x; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; HAGG T, 1989, NEURON, V3, P721, DOI 10.1016/0896-6273(89)90241-9; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; James HE, 1999, ACT NEUR S, V73, P85; Kieseier BC, 1998, ANN NEUROL, V43, P427, DOI 10.1002/ana.410430404; Kieseier BC, 1998, BRAIN, V121, P159, DOI 10.1093/brain/121.1.159; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Montaner J, 2001, STROKE, V32, P1759, DOI 10.1161/01.STR.32.8.1759; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Noble LJ, 2002, J NEUROSCI, V22, P7526; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	54	49	53	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAR	2007	25	3					526	535		10.1016/j.nbd.2006.10.019			10	Neurosciences	Neurosciences & Neurology	145NQ	WOS:000244872200008	17188498				2021-06-18	
J	Haqqani, AS; Hutchison, JS; Ward, R; Stanimirovic, DB				Haqqani, Arsalan S.; Hutchison, James S.; Ward, Roxanne; Stanimirovic, Danica B.		Canadian Critical Care Translational	Protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS	JOURNAL OF NEUROTRAUMA			English	Article						proteomics; S100 beta; serum biomarkers; traumatic head injury	NEURON-SPECIFIC ENOLASE; BARRIER DISRUPTION; GENE-EXPRESSION; ISCHEMIC-STROKE; POSSIBLE MARKER; HEAD-INJURY; DAMAGE; BLOOD; CHILDREN; S-100-BETA	This report is a feasibility study on the utility of gel-free proteomics in identifying peripheral biomarkers of brain injury. The study was performed in six pediatric patients admitted to the intensive care unit for severe traumatic brain injury (TBI). Serum samples collected at admission (less than 8 h after injury) were used for determining the levels of S100 beta by enzyme-linked immunosorbent assay (ELISA) and for proteomics analyses. Serum samples were depleted of high abundant albumin and immunoglobulin, and were compared to a pooled reference from several healthy individuals. After labeling and separation on an ionic column, six different serum fractions were analyzed using Isotope-Coded Affinity Tag (ICAT), followed by tandem mass spectrometry (MS/MS) protein sequencing and identification. Ninety-five unique, differentially expressed proteins were identified, including several with a likely brain origin. Several proteins with pattern similarity to S100 beta identified by hierarchical clustering could be considered for evaluation in a larger patient sample as potential peripheral markers of TBI.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R7, Canada; Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Integrat Biol Program, Toronto, ON M5G 1X8, Canada; Childrens Hosp Eastern Ontario, Res Inst, Chalmers Grp, Ottawa, ON K1H 8L1, Canada	Stanimirovic, DB (corresponding author), Natl Res Council Canada, Inst Biol Sci, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R7, Canada.	danica.stanimirovic@nrc-cnrc.gc.ca					Alaiya A, 2005, J PROTEOME RES, V4, P1213, DOI 10.1021/pr050149f; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Delahunty C, 2005, METHODS, V35, P248, DOI 10.1016/j.ymeth.2004.08.016; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Haqqani AS, 2005, FASEB J, V19, P1809, DOI 10.1096/fj.05-3793com; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Konig R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh027; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, J NEUROSCI, V23, P1949; Matsumoto H, 2001, EUR J BIOCHEM, V268, P3259, DOI 10.1046/j.1432-1327.2001.02221.x; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Mohammed MQ, 2001, MED ONCOL, V18, P109; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Omenn GS, 2005, PROTEOMICS, V5, P3226, DOI 10.1002/pmic.200500358; Pelsers MMAL, 2005, CLIN CHEM LAB MED, V43, P802, DOI 10.1515/CCLM.2005.135; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264; Veenstra TD, 2004, DRUG DISCOV TODAY, V9, P889, DOI 10.1016/S1359-6446(04)03246-5; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zhong Y, 2004, CEREB CORTEX, V14, P1144, DOI 10.1093/cercor/bhh074	38	49	52	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					54	74		10.1089/neu.2006.0079			21	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100006	17263670				2021-06-18	
J	Huh, JW; Widing, AG; Raghupath, R				Huh, Jimmy W.; Widing, Ashley G.; Raghupath, Ramesh			Repetitive mild non-contusive brain trauma in immature rats exacerbates traumatic axonal injury and axonal calpain activation: A preliminary report	JOURNAL OF NEUROTRAUMA			English	Article						calpains; children; cognition; infants; inflicted brain injury; shaken-impact syndrome; traumatic axonal injury	SHAKEN-BABY SYNDROME; HEAD-INJURY; NERVOUS-SYSTEM; MODEL; VULNERABILITY; CHILDREN; INFANTS; IMPACT; NEUROPATHOLOGY; PROTEOLYSIS	Infants who experience inflicted brain injury (shaken-impact syndrome) present with subdural hematoma, brain atrophy, and ventriculomegaly, pathologic features that are suggestive of multiple incidences of brain trauma. To develop a clinically relevant model of inflicted brain injury in infants, the skulls of anesthetized 11-day-old rat pups were subjected to one, two, or three successive mild impacts. While skull fractures were not observed, a single impact to the intact skull resulted in petechial hemorrhages in the subcortical white matter, and double or triple impacts led to hemorrhagic tissue tears at 1 day postinjury. Whereas the singly impacted brain did not exhibit overt damage at 7 days, two impacts resulted in an enlarged ventricle and white matter atrophy; three impacts to the brain led to similar pathology albeit at 3 days postinjury. By 7 days, cortical atrophy was observed following three impacts. Reactive astrocytes were visible in the deep cortical layers below the impact site after two impacts, and through all cortical layers after three impacts. Swellings were observed in intact axons in multiple white matter tracts at 1 day following single impact and progressed to axonal disconnections by 3 days. In contrast, double or triple impacts resulted in axonal disconnections by 1 day postinjury; in addition, three impacts led to extensive axonal injury in the dorsolateral thalamus by 3 days. Calpain activation was observed in axons in subcortical white matter tracts in all brain-injured animals at 1 day and increased with the number of impacts. Despite these pathologic alterations, neither one nor two impacts led to acquisition deficits on the Morris water maze. While indicative of the graded nature of the pathologic response, these data suggest that repetitive mild brain injury in the immature rat results in pathologic features similar to those following inflicted brain injuries in infants.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA	Raghupath, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS053651, R01NS041561] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 053651, R01 NS 41561] Funding Source: Medline		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Gutierrez Farley L, 2004, J Psychosoc Nurs Ment Health Serv, V42, P22; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1	44	49	49	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					15	27		10.1089/neu.2006.0072			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100003	17263667				2021-06-18	
J	Igarashi, T; Potts, MB; Noble-Haeusslein, LJ				Igarashi, Takuji; Potts, Matthew B.; Noble-Haeusslein, Linda J.			Injury severity determines Purkinje cell loss and microglial activation in the cerebellum after cortical contusion injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; controlled cortical impact; neuronal loss; cerebellum; activated microglia; Purkinje cells	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; MORRIS WATER MAZE; IMPACT INJURY; COGNITIVE DEFICITS; HEAD-INJURY; NEURONAL INJURY; TIME-COURSE; RAT; MODEL	Clinical evidence suggests that the cerebellum is damaged after traumatic brain injury (TBI) and experimental studies have validated these observations. We have previously shown cerebellar vulnerability, as demonstrated by Purkinje cell loss and microglial activation, after fluid percussion brain injury. In this study, we examine the effect of graded controlled cortical impact (CCI) injury on the cerebellum in the context of physiologic and anatomical parameters that have been shown by others to be sensitive to injury severity. Adult male rats received mild, moderate, or severe CCI and were euthanized 7 days later. We first validated the severity of the initial injury using physiologic criteria, including apnea and blood pressure, during the immediate postinjury period. Increasing injury severity was associated with an increased incidence of apnea and higher mortality. Severe injury also induced transient hypertension followed by hypotension, while lower grade injuries produced an immediate and sustained hypotension. We next evaluated the pattern of subcortical neuronal loss in response to graded injuries. There was significant neuronal loss in the ipsilateral cortex, hippocampal CA2/CA3, and laterodorsal thalamus that was injury severity-dependent and that paralleled microglial activation. Similarly, there was a distinctive pattern of Purkinje cell loss and microglial activation in the cerebellar vermis that varied with injury severity. Together, these findings emphasize the vulnerability of the cerebellum to TBI. That a selective pattern of Purkinje cell loss occurs regardless of the type of injury suggests a generalized response that is a likely determinant of recovery and a target for therapeutic intervention. (c) 2006 Elsevier Inc. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C-224, San Francisco, CA 94143 USA.	linda.noble@ucsf.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159] Funding Source: Medline		Ai JL, 2004, PHARMACOLOGY, V71, P192, DOI 10.1159/000078085; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Alavi A, 1997, J NUCL MED, V38, P1717; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BIARY N, 1989, NEUROLOGY, V39, P103, DOI 10.1212/WNL.39.1.103; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; DAUM I, 1995, BEHAV BRAIN RES, V67, P201, DOI 10.1016/0166-4328(94)00144-5; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; KOCHANEK PM, 1995, J NEUROTRAUM, V12, P1015; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Louis ED, 1996, ARCH NEUROL-CHICAGO, V53, P450, DOI 10.1001/archneur.1996.00550050080027; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; NAKKI R, 1995, J NEUROSCI, V15, P2097; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; OHearn E, 1997, J NEUROSCI, V17, P8828; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Paxinos G., 1995, RAT NERVOUS SYSTEM; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Rapoport M, 2000, J NEUROPSYCH CLIN N, V12, P193, DOI 10.1176/appi.neuropsych.12.2.193; ROSS CA, 1990, TRENDS NEUROSCI, V13, P216, DOI 10.1016/0166-2236(90)90163-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SILVERMAN J, 1993, LAB ANIM SCI, V43, P210; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; Tang SL, 1997, J CHART INST WATER E, V11, P14; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Wixson S.K., 1997, ANESTHESIA ANALGESIA; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	84	49	50	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2007	203	1					258	268		10.1016/j.expneurol.2006.08.030			11	Neurosciences	Neurosciences & Neurology	123NU	WOS:000243303400028	17045589				2021-06-18	
J	Wang, R; Foniok, T; Wamsteeker, JI; Qiao, M; Tomanek, B; Vivanco, RA; Tuor, UI				Wang, Rong; Foniok, Tadeusz; Wamsteeker, Jaclyn I.; Qiao, Min; Tomanek, Boguslaw; Vivanco, Rodrigo A.; Tuor, Ursula I.			Transient blood pressure changes affect the functional magnetic resonance imaging detection of cerebral activation	NEUROIMAGE			English	Article						hypertension; hypotension; cerebral blood flow; neural activation; electrical stimulation	TRAUMATIC BRAIN-INJURY; BOLD SIGNAL; FLOW; AUTOREGULATION; STIMULATION; RATS; MRI; HYPOTENSION; BARRIER; REST	Functional magnetic resonance imaging (fMRI) provides an indirect measure of cerebral activation that could be altered by factors directly affecting cerebral blood flow independent of changes in neuronal activation. Presently, we investigate how changes in blood pressure (BP) affect the activation detected with fMRI. fMRI scans were acquired in 33 rats under control conditions and following transient BP increases (norepinephrine, IV) or decreases (arfonad, IV) with and without electrical stimulation of the forepaw. Voxels correlating to either the stimulation or the change in BP time courses were identified. During transient hypertension, irrespective of forepaw stimulation, BP increases (i.e., > 10 mm Hg) produced a transient increase in the blood oxygen level-dependent (BOLD) intensity resulting in a significant numbers of voxels correlating to the BP time courses (P < 0.05), and the number of these voxels increased as BP increased, becoming substantial at BP > 30 mm Hg. The activation patterns with BP increases and stimulation overlapped spatially resulting in an enhanced cerebral activation to simultaneous forepaw stimulation (P < 0.05). BP decreases (> 10 mm Hg) produced corresponding decreases in BOLD intensity, causing significant numbers of voxels correlating to the BP decreases (P < 0.005), and these numbers increased as BP decreased (P < 0.001). The BP decreases and stimulation time courses and responses were distinct, and hypotension did not affect the detection of the activation response to forepaw stimulation. The results indicate that substantial hypertension accompanying a stimulation paradigm produces a BOLD response that enhances the cerebral activation detected, whereas hypotension does not affect the detection of neuronal activation but does produce responses that could be interpreted as a 'deactivation'. Crown Copyright (c) 2005 Published by Elsevier Inc. All rights reserved.	Natl Res Council Canada, Inst Biodiagnost W, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Expt Imaging Ctr, Hotchkiss Brain Inst, Calgary, AB, Canada	Tuor, UI (corresponding author), Natl Res Council Canada, Inst Biodiagnost W, B153,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Ursula.Tuor@nrc-cnrc.ge.ca	Tomanek, Boguslaw/AAD-7594-2019; Tomanek, Boguslaw/J-4720-2014	Tomanek, Boguslaw/0000-0003-2602-0280; 			AASLID R, 1994, STROKE, V25, P1297; Bruhn H, 2001, J MAGN RESON IMAGING, V13, P325, DOI 10.1002/jmri.1047; BRUHN H, 1994, J CEREBR BLOOD F MET, V14, P742, DOI 10.1038/jcbfm.1994.95; BUTCHER KS, 1995, AM J PHYSIOL-REG I, V268, pR214; Carter JR, 2005, J PHYSIOL-LONDON, V564, P321, DOI 10.1113/jphysiol.2004.079665; Critchley HD, 2000, J PHYSIOL-LONDON, V523, P259, DOI 10.1111/j.1469-7793.2000.t01-1-00259.x; Czisch M, 2004, EUR J NEUROSCI, V20, P566, DOI 10.1111/j.1460-9568.2004.03518.x; Diehl Rolf R, 2002, Eur J Ultrasound, V16, P31, DOI 10.1016/S0929-8266(02)00048-4; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102; Harper RM, 2000, J COMP NEUROL, V417, P195, DOI 10.1002/(SICI)1096-9861(20000207)417:2<195::AID-CNE5>3.0.CO;2-V; Hempel E, 1999, ROFO-FORTSCHR RONTG, V170, P304; Henderson LA, 2004, J APPL PHYSIOL, V96, P693, DOI 10.1152/japplphysiol.00852.2003; Kalisch R, 2001, NEUROIMAGE, V14, P891, DOI 10.1006/nimg.2001.0890; Kannurpatti SS, 2004, J CEREBR BLOOD F MET, V24, P703, DOI 10.1097/01.WCB.0000121232.04853.46; Kharlamov A, 2004, NEUROSCI LETT, V368, P151, DOI 10.1016/j.neulet.2004.06.079; King AB, 1999, J COMP NEUROL, V413, P572; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; Luo F, 2003, MAGNET RESON MED, V49, P264, DOI 10.1002/mrm.10366; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Matthews PM, 2004, J NEUROL NEUROSUR PS, V75, P6; MENDELOW AD, 1987, J NEUROSURG, V66, P755, DOI 10.3171/jns.1987.66.5.0755; Menon RS, 2001, CURR OPIN NEUROBIOL, V11, P630, DOI 10.1016/S0959-4388(00)00260-9; Morton DW, 2002, AM J NEURORADIOL, V23, P588; Mulderink TA, 2002, NEUROIMAGE, V15, P37, DOI 10.1006/nimg.2001.0973; OPPENHEIMER SM, 1994, CURR OPIN NEUROL, V7, P20, DOI 10.1097/00019052-199402000-00005; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Panerai RB, 2003, MED ENG PHYS, V25, P621, DOI 10.1016/S1350-4533(03)00027-4; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Paulson OB, 2002, EUR NEUROPSYCHOPHARM, V12, P495, DOI 10.1016/S0924-977X(02)00098-6; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Prielipp RC, 2001, ANESTH ANALG, V93, P45; Rochette LM, 2005, INT J PSYCHOPHYSIOL, V56, P81, DOI 10.1016/j.ijpsycho.2004.10.003; Stefurak T, 2003, MOVEMENT DISORD, V18, P1508, DOI 10.1002/mds.10593; Tuor UI, 2002, MAGN RESON IMAGING, V20, P707, DOI 10.1016/S0730-725X(02)00599-4; TUOR UI, 1994, AM J PHYSIOL-HEART C, V267, pH2220; TUOR UI, 1986, AM J PHYSIOL, V251, pH824; Zaharchuk G, 1999, STROKE, V30, P2197, DOI 10.1161/01.STR.30.10.2197	40	49	51	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	MAY 15	2006	31	1					1	11		10.1016/j.neuroimage.2005.12.004			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	049JK	WOS:000238012200001	16460967				2021-06-18	
J	Zhang, Z; Ottens, AK; Larner, SF; Kobeissy, FH; Williams, ML; Hayes, RL; Wang, KKW				Zhang, Zhiqun; Ottens, Andrew K.; Larner, Stephen F.; Kobeissy, Firas H.; Williams, Melissa L.; Hayes, Ronald L.; Wang, Kevin K. W.			Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells	CELLULAR & MOLECULAR BIOLOGY LETTERS			English	Article						neurite outgrowth; ROCK; Y-27632; PC-12; cofilin; actin dynamics	NERVE GROWTH-FACTOR; MYELIN-ASSOCIATED GLYCOPROTEIN; ACTIVATED PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; LIM-KINASE; SIGNAL-TRANSDUCTION; MYOSIN PHOSPHATASE; AXON REGENERATION; PC12 CELLS; PHOSPHORYLATION	Axons fail to regenerate in the adult central nervous system (CNS) following injury. Developing strategies to promote axonal regeneration is therapeutically attractive for various CNS pathologies such as traumatic brain injury, stroke and Alzheimer's disease. Because the RhoA pathway is involved in neurite outgrowth, Rho-associated kinases (ROCKs), downstream effectors of GTP-bound Rho, are potentially important targets for axonal repair strategies in CNS injuries. We investigated the effects and downstream mechanisms of ROCK inhibition in promoting neurite outgrowth in a PC-12 cell model. Robust neurite outgrowth (NOG) was induced by ROCK inhibitors Y-27632 and H-1152 in a time- and dose-dependent manner. Dramatic cytoskeletal reorganization was noticed upon ROCK inhibition. NOG initiated within 5 to 30 minutes followed by neurite extension between 6 and 10 hours. Neurite processes were then sustained for over 24 hours. Rapid cofilin dephosphorylation was observed within 5 minutes of Y-27632 and H-1152 treatment. Re-phosphorylation was observed by 6 hours after Y-27632 treatment, while H-1152 treatment produced sustained cofilin dephosphorylation for over 24 hours. The results suggest that ROCK-mediated dephosphorylation of cofilin plays a role in the initiation of NOG in PC-12 cells.	Univ Florida, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA	Wang, KKW (corresponding author), Univ Florida, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, POB 100256,100 S Newell Dr, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu	Ottens, Andrew/K-3352-2012; duan, hf/F-9166-2011; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473			Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Birkenfeld J, 2001, J NEUROCHEM, V78, P924, DOI 10.1046/j.1471-4159.2001.00500.x; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Brabeck C, 2003, ARCH NEUROL-CHICAGO, V60, P1245, DOI 10.1001/archneur.60.9.1245; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Ellezam B, 2002, PROG BRAIN RES, V137, P371; Fournier AE, 2003, J NEUROSCI, V23, P1416; Fujita A, 2001, NEUROREPORT, V12, P3599, DOI 10.1097/00001756-200111160-00045; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hashimoto R, 1998, BIOCHEM BIOPH RES CO, V245, P407, DOI 10.1006/bbrc.1998.8446; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Kwon Brian K, 2002, Mol Interv, V2, P244, DOI 10.1124/mi.2.4.244; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; McKerracher L, 2004, NAT MED, V10, P1052, DOI 10.1038/nm1004-1052; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Nakajima M, 2003, CANCER CHEMOTH PHARM, V52, P319, DOI 10.1007/s00280-003-0641-9; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Obara Y, 2002, J PHARMACOL EXP THER, V301, P803, DOI 10.1124/jpet.301.3.803; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ozdinler PH, 2001, J COMP NEUROL, V438, P377; Park YH, 2003, J NEUROCHEM, V87, P1546, DOI 10.1046/j.1471-4159.2003.02127.x; Petruska JC, 2004, NEUROSCI LETT, V361, P168, DOI 10.1016/j.neulet.2003.12.012; Revenu C, 2004, NAT REV MOL CELL BIO, V5, P635, DOI 10.1038/nrm1437; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tojima T, 2004, PROG NEUROBIOL, V72, P183, DOI 10.1016/j.pneurobio.2004.03.002; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamashita T, 2005, MOL NEUROBIOL, V32, P105, DOI 10.1385/MN:32:2:105; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	47	49	51	0	5	CELLULAR & MOLECULAR BIOLOGY LETTERS	WROCLAW	UNIV WROCLAW, INST BIOCHEM, DEPT GENETIC BIOCHEMISTRY, PRZBYSZEWSKIEGO 63/77, 51-148 WROCLAW, POLAND	1425-8153			CELL MOL BIOL LETT	Cell. Mol. Biol. Lett.	MAR	2006	11	1					12	29		10.2478/s11658-006-0002-x			18	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	063XB	WOS:000239052100002	16847745	Green Published			2021-06-18	
J	Kapreli, E; Athanasopoulos, S				Kapreli, Eleni; Athanasopoulos, Spyridon			The anterior cruciate ligament deficiency as a model of brain plasticity	MEDICAL HYPOTHESES			English	Article							KNEE-JOINT EFFUSION; INDUCED MOVEMENT THERAPY; UPPER-LIMB AMPUTATION; NERVOUS-SYSTEM; NON-COPERS; SOMATOSENSORY CORTEX; QUADRICEPS STRENGTH; CORTICAL ACTIVATION; DYNAMIC STABILITY; FUNCTIONAL MRI	This paper describes a plausible mechanism for the development of brain plastic changes due to a peripheral joint injury, such as anterior cruciate ligament (ACL) rupture. Evidence for the hypothesis is based on mainly three indications derived from the literature review: (a) the existence of two different categories of ACL patients, the copers and non-copers, presenting different features of functional deficiencies, (b) the demand of a sufficient post-traumatic time (more than 6 months) for the dysfunction development and (c) the fact that the dysfunction is not limited to the injured limb but also concerns the non-injured one. Considering the fact that ACL contains mechanoreceptors, which inform the central nervous system (CNS) about joint sense position and kinaesthesia, it can be suggested that this kind of injury might be regarded as a neurophysiological dysfunction, not being a simple musculoskeletal injury. The rupture of the ACL could lead to the cessation/depletion or differentiation of the ascending afferent pathway from the injured joint towards CNS, inducing to the joint de-afferentation and consequently CNS reorganization and joint de-efferentation. In case of presumable evidence of the proposed hypothesis, its clinical application could concern several aspects of the intervention procedures. For example, a number of clinical findings, such as the functional differences presented between two separate clinical groups of patients (copers and non-copers) could be justified or the rehabilitation strategies might have to be revised, provided that certain therapeutic components have influence on facilitating brain plastic changes that induce to beneficial functional outcomes. (c) 2006 Elsevier Ltd. All rights reserved.	TEI Lamia, Dept Physiotherapy, Athens 35100, Greece; Univ Athens, Sports Physiotherapy Lab, Dept Sports Med & Biol Exercise, Daphne 17237, Greece	Kapreli, E (corresponding author), TEI Lamia, Dept Physiotherapy, 3rd Km Old Natl Rd Lamia, Athens 35100, Greece.	ekapreti@teitam.gr	Kapreli, Eleni/ABB-8982-2020				Alkjaer T, 2003, EUR J APPL PHYSIOL, V89, P301, DOI 10.1007/s00421-002-0787-x; Alkjaer T, 2002, CLIN BIOMECH, V17, P586, DOI 10.1016/S0268-0033(02)00098-0; Bavelier D, 2002, NAT REV NEUROSCI, V3, P443, DOI 10.1038/nrn848; BERCHUCK M, 1990, J BONE JOINT SURG AM, V72A, P871, DOI 10.2106/00004623-199072060-00012; Boerboom AL, 2001, KNEE SURG SPORT TR A, V9, P211, DOI 10.1007/s001670100196; Borsa PA, 1997, AM J SPORT MED, V25, P336, DOI 10.1177/036354659702500311; Cameron M, 1997, AM J SPORT MED, V25, P751, DOI 10.1177/036354659702500605; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; Chmielewski TL, 2002, GAIT POSTURE, V16, P87, DOI 10.1016/S0966-6362(01)00202-8; Chmielewski TL, 2005, J ELECTROMYOGR KINES, V15, P83, DOI 10.1016/j.jelekin.2004.07.003; Chmielewski TL, 2005, J ORTHOP RES, V23, P54, DOI 10.1016/j.orthres.2004.05.011; Chmielewski TL, 2001, CLIN BIOMECH, V16, P586, DOI 10.1016/S0268-0033(01)00050-X; Courtney C, 2005, GAIT POSTURE, V22, P69, DOI 10.1016/j.gaitpost.2004.07.002; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Dettmers C, 1999, NEUROSCI LETT, V263, P41, DOI 10.1016/S0304-3940(99)00105-6; Eastlack ME, 1999, MED SCI SPORT EXER, V31, P210, DOI 10.1097/00005768-199902000-00002; ELMQVIST LG, 1988, EUR J APPL PHYSIOL O, V58, P203, DOI 10.1007/BF00636627; Fischer-Rasmussen T, 2000, SCAND J MED SCI SPOR, V10, P85, DOI 10.1034/j.1600-0838.2000.010002085.x; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; GRIGG P, 1986, J NEUROPHYSIOL, V55, P635; Guido J, 1997, J ORTHOP SPORT PHYS, V25, P208, DOI 10.2519/jospt.1997.25.3.208; Holder-Powell HM, 1999, ARCH PHYS MED REHAB, V80, P717, DOI 10.1016/S0003-9993(99)90179-X; Honda M, 1997, J NEUROL SCI, V146, P117, DOI 10.1016/S0022-510X(96)00291-2; Hopkins JT, 2000, ARCH PHYS MED REHAB, V81, P1199, DOI 10.1053/apmr.2000.6298; Ikeda H, 2002, INT ORTHOP, V26, P374, DOI 10.1007/s00264-002-0402-0; Irie K, 2003, KNEE, V10, P93, DOI 10.1016/S0968-0160(02)00083-2; Jerosch J, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P171; Jerosch J, 1996, ARCH ORTHOP TRAUM SU, V115, P162, DOI 10.1007/BF00434546; Johansson Barbro B., 2004, Keio Journal of Medicine, V53, P231, DOI 10.2302/kjm.53.231; Konishi Y, 2002, SCAND J MED SCI SPOR, V12, P371, DOI 10.1034/j.1600-0838.2002.01293.x; Krings T, 2000, NEUROSCI LETT, V278, P189, DOI 10.1016/S0304-3940(99)00930-1; Lattanzio PJ, 1998, ORTHOPEDICS, V21, P463; Lephart S., 2000, PROPRIOCEPTION NEURO; Lephart SM, 1997, AM J SPORT MED, V25, P130, DOI 10.1177/036354659702500126; LEVINE JD, 1985, J NEUROSCI, V5, P1380; Levy CE, 2001, AM J PHYS MED REHAB, V80, P4, DOI 10.1097/00002060-200101000-00003; Lewek M, 2002, CLIN BIOMECH, V17, P56, DOI 10.1016/S0268-0033(01)00097-3; Liepert J, 1995, ELECTROMYOGR MOTOR C, V97, P382, DOI 10.1016/0924-980X(95)00194-P; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Lysholm M, 1998, SCAND J MED SCI SPOR, V8, P432; MCNAIR PJ, 1995, ARCH PHYS MED REHAB, V76, P566, DOI 10.1016/S0003-9993(95)80512-5; NITZ AJ, 1997, FUNCTIONAL MOVEMENT; O'Connell M, 1998, GAIT POSTURE, V8, P136, DOI 10.1016/S0966-6362(98)00023-X; Patel RR, 2003, AM J SPORT MED, V31, P68, DOI 10.1177/03635465030310012301; Reddy H, 2001, EXP BRAIN RES, V138, P484, DOI 10.1007/s002210100732; Roberts D, 1999, J ORTHOP SPORT PHYS, V29, P587, DOI 10.2519/jospt.1999.29.10.587; Rossini PM, 2000, BRAIN RES REV, V33, P131, DOI 10.1016/S0169-328X(00)00090-5; Rudolph KS, 2004, J ELECTROMYOGR KINES, V14, P565, DOI 10.1016/j.jelekin.2004.03.002; Rudolph KS, 2001, KNEE SURG SPORT TR A, V9, P62, DOI 10.1007/s001670000166; Rudolph KS, 1998, J ELECTROMYOGR KINES, V8, P349, DOI 10.1016/S1050-6411(97)00042-4; Schwenkreis P, 2001, CLIN NEUROPHYSIOL, V112, P627, DOI 10.1016/S1388-2457(01)00486-2; Shelbourne K D, 1998, Am J Knee Surg, V11, P136; SnyderMackler L, 1997, AM J SPORT MED, V25, P191, DOI 10.1177/036354659702500209; Solomonow M, 2001, SCAND J MED SCI SPOR, V11, P64, DOI 10.1034/j.1600-0838.2001.011002064.x; STRATFORD P, 1987, PHYS THER, V67, P1533, DOI 10.1093/ptj/67.10.1533; TIBONE JE, 1993, CLIN ORTHOP RELAT R, V288, P35; Torry MR, 2000, CLIN BIOMECH, V15, P147, DOI 10.1016/S0268-0033(99)00083-2; Urbach D, 1999, MED SCI SPORT EXER, V31, P1691, DOI 10.1097/00005768-199912000-00001; Valeriani M, 1996, BRAIN, V119, P1751, DOI 10.1093/brain/119.5.1751; Valeriani M, 1999, ACTA NEUROL SCAND, V99, P303, DOI 10.1111/j.1600-0404.1999.tb00680.x; Weiss T, 2000, EXP BRAIN RES, V134, P199, DOI 10.1007/s002210000456; Williams GN, 2003, J ORTHOPAED RES, V21, P1131, DOI 10.1016/S0736-0266(03)00106-2; WOJTYS EM, 1994, AM J SPORT MED, V22, P89, DOI 10.1177/036354659402200116; YOUNG A, 1993, ANN RHEUM DIS, V52, P829, DOI 10.1136/ard.52.11.829; Zanette G, 1997, ELECTROMYOGR MOTOR C, V105, P269, DOI 10.1016/S0924-980X(97)00024-6; ZATTERSTROM R, 1994, AM J SPORT MED, V22, P531, DOI 10.1177/036354659402200416	66	49	51	0	7	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2006	67	3					645	650		10.1016/j.mehy.2006.01.063			6	Medicine, Research & Experimental	Research & Experimental Medicine	069RK	WOS:000239465700033	16698187				2021-06-18	
J	Rech, TH; Vieira, SRR; Nagel, F; Brauner, JS; Scalco, R				Rech, Tatiana H.; Rios Vieira, Silvia Regina; Nagel, Fabiano; Brauner, Janete Salles; Scalco, Rosana			Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN INJURY; ANOXIC-ISCHEMIC COMA; CARDIOPULMONARY-RESUSCITATION; EVOKED-POTENTIALS; POSTANOXIC COMA; PROTEIN S-100; HYPOTHERMIA; SURVIVORS; CONSCIOUSNESS; RECOVERY	Introduction Outcome after cardiac arrest is mostly determined by the degree of hypoxic brain damage. Patients recovering from cardiopulmonary resuscitation are at great risk of subsequent death or severe neurological damage, including persistent vegetative state. The early definition of prognosis for these patients has ethical and economic implications. The main purpose of this study was to investigate the prognostic value of serum neuron-specific enolase (NSE) in predicting outcomes in patients early after in-hospital cardiac arrest. Methods Forty-five patients resuscitated from in-hospital cardiac arrest were prospectively studied from June 2003 to January 2005. Blood samples were collected, at any time between 12 and 36 hours after the arrest, for NSE measurement. Outcome was evaluated 6 months later with the Glasgow outcome scale (GOS). Patients were divided into two groups: group 1 (unfavorable outcome) included GOS 1 and 2 patients; group 2 (favorable outcome) included GOS 3, 4 and 5 patients. The Mann - Whitney U test, Student's t test and Fisher's exact test were used to compare the groups. Results The Glasgow coma scale scores were 6.1 +/- 3 in group 1 and 12.1 +/- 3 in group 2 ( means +/- SD; p < 0.001). The mean time to NSE sampling was 20.2 +/- 8.3 hours in group 1 and 28.4 +/- 8.7 hours in group 2 ( p = 0.013). Two patients were excluded from the analysis because of sample hemolysis. At 6 months, favorable outcome was observed in nine patients (19.6%). Thirty patients (69.8%) died and four (9.3%) remained in a persistent vegetative state. The 34 patients (81.4%) in group 1 had significantly higher NSE levels ( median 44.24 ng/ml, range 8.1 to 370) than those in group 2 (25.26 ng/ml, range 9.28 to 55.41; p = 0.034). Conclusion Early determination of serum NSE levels is a valuable ancillary method for assessing outcome after inhospital cardiac arrest.	Hosp Clin Porto Alegre, Serv Med Intens, BR-90035903 Porto Alegre, RS, Brazil; Complexo Hosp Santa Casa Misericordia Porto Alegr, Serv Med Intens, BR-90020090 Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Serv Patol Clin, BR-90035903 Porto Alegre, RS, Brazil	Rech, TH (corresponding author), Hosp Clin Porto Alegre, Serv Med Intens, 2350 Largo Eduardo Z Faraco, BR-90035903 Porto Alegre, RS, Brazil.	tatianarech@terra.com.br	Rech, Tatiana/V-2711-2019				*AM HEART ASS INT, 2000, CIRCULATION S, V102, P105; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; BALLEW KA, 1994, ARCH INTERN MED, V154, P2426, DOI 10.1001/archinte.154.21.2426; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bottiger BW, 2001, CIRCULATION, V103, P2694; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; El-Menyar AA, 2005, CHEST, V128, P2835, DOI 10.1378/chest.128.4.2835; Fernandez RR, 1996, INTENS CARE MED, V22, P1034, DOI 10.1007/BF01699224; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Madl Christian, 2004, Curr Opin Crit Care, V10, P213, DOI 10.1097/01.ccx.0000127542.32890.fa; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Nakabayashi M, 2001, INTENS CARE MED, V27, P1210, DOI 10.1007/s001340100984; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Safar P, 2002, CRIT CARE MED, V30, pS140, DOI 10.1097/00003246-200204001-00004; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	33	49	58	0	2	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2006	10	5							R133	10.1186/cc5046			6	Critical Care Medicine	General & Internal Medicine	185NS	WOS:000247718300009	16978415	DOAJ Gold, Green Published			2021-06-18	
J	Vavilala, MS; Muangman, S; Tontisirin, N; Fisk, D; Roscigno, C; Mitchell, P; Kirkness, C; Zimmerman, JJ; Chesnut, R; Lam, AM				Vavilala, M. S.; Muangman, S.; Tontisirin, Nuj; Fisk, D.; Roscigno, C.; Mitchell, P.; Kirkness, C.; Zimmerman, J. J.; Chesnut, Randall; Lam, A. M.			Impaired cerebral autoregulation and 6-month outcome in children with severe traumatic brain injury: Preliminary findings	DEVELOPMENTAL NEUROSCIENCE			English	Article						cerebral blood flow; cerebral autoregulation; pediatric head injury	BLOOD-FLOW; SEVOFLURANE; HYPERCAPNIA; METABOLISM; DESFLURANE	The objective of this study was to describe the incidence of impaired cerebral autoregulation and to describe the relationship between impaired cerebral autoregulation and outcome after severe pediatric traumatic brain injury (TBI). We prospectively examined cerebral autoregulation in 28 children <= 17 (10 +/- 5) years with a Glasgow coma scale score < 9 within the first 72 h of pediatric intensive care unit admission. Children with isolated focal TBI were excluded. Glasgow outcome scores (GOS) were collected at hospital discharge, as well as 3 and 6 months after severe TBI. GOS < 4 reflected poor outcome. Cerebral autoregulation was impaired in 12/28 children. An autoregulatory index < 0.4 was associated with GOS < 4 at 6 months (p = 0.005). Impaired cerebral autoregulation, early after severe pediatric TBI, was associated with a poor 6-month outcome. Copyright (c) 2006 S. Karger AG, Basel.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Dept Pediat, Seattle, WA 98104 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Dept Biobehav Nursing, Seattle, WA 98104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Chesnut, Randall/0000-0001-6377-3666	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004501] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K23HD0044632-03] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [2R01NR004501-04] Funding Source: Medline		Bedforth NM, 2001, BRIT J ANAESTH, V87, P193, DOI 10.1093/bja/87.2.193; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kaiser JR, 2005, PEDIATR RES, V58, P931, DOI 10.1203/01.pdr.0000182180.80645.0c; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; McCulloch TJ, 2000, ANESTHESIOLOGY, V93, P1205, DOI 10.1097/00000542-200011000-00012; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; ODDEN JP, 1994, BIOL NEONATE, V65, P367; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003	19	49	49	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					348	353		10.1159/000094161			6	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600012	16943658				2021-06-18	
J	David-West, KS; Wilson, NIL; Sherlock, DA; Bennet, GC				David-West, KS; Wilson, NIL; Sherlock, DA; Bennet, GC			Missed Monteggia injuries	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						missed Monteggia variant injury; ulnar plastic deformation	RADIAL-HEAD DISLOCATION; FRACTURE-DISLOCATION; CHILDREN	The classical Monteggia injury comprises a dislocation of the radial head with an associated fracture of the ulna. In the variant type, there is no ulnar fracture merely plastic deformation. We performed a retrospective study of all Monteggia injuries from 1992 to 2001. A total of 39 were reviewed, of which 8 were missed (1 classical and 7 variant). Of those, five were mate and three female with a mean age of 6.3 years. The mean follow-up was 2.5 years, with a mean interval between injury and diagnosis of 33.5 weeks. Two Monteggia injuries diagnosed within 4 weeks were successfully treated by closed manipulation. The other six required ulnar osteotomy, repair of the annular ligament and stabilisation of the radial head with a transcapitellar pin. A protocol for the diagnosis of Monteggia injuries is described. Doubtful cases require an immediate review since early treatment improves the outcome. Acceptable clinical and radiological results in late diagnosed Monteggia injuries can result from ulnar osteotomy, open reduction of the radial head with repair of the annular ligament and transcapitellar pin stabilisation of the reduced radial head. (c) 2004 Elsevier Ltd. All rights reserved.	Royal Hosp Sick Children, Dept Orthopaed Surg, Glasgow G3 8SJ, Lanark, Scotland	David-West, KS (corresponding author), 14 Kirkiag Ave,Dean Pk, Renfrew PA4 0YH, England.	kd-west@ntlworld.com		Wilson, Neil/0000-0002-0427-766X			Bell Tawse A J, 1965, J Bone Joint Surg Br, V47, P718; Devnani AS, 1997, INJURY, V28, P131, DOI 10.1016/S0020-1383(96)00160-X; DORMANS JP, 1990, ORTHOP CLIN N AM, V21, P251; FREEDMAN L, 1988, J BONE JOINT SURG BR, V70, P846; GLEESON AP, 1994, J ACCID EMERG MED, V11, P192; HURST LC, 1983, J PEDIATR ORTHOPED, V3, P227, DOI 10.1097/01241398-198305000-00015; LINCOLN TL, 1994, J PEDIATR ORTHOPED, V14, P454, DOI 10.1097/01241398-199407000-00006; LLOYDROBERTS GC, 1977, J BONE JOINT SURG BR, V59, P402; MILES KA, 1989, INJURY, V20, P365, DOI 10.1016/0020-1383(89)90016-8; RANG M, 2000, STORY ORTHOPAEDICS, P407; STOLL TM, 1992, J BONE JOINT SURG BR, V74, P436; STOREN G, 1969, ACTA CLIN SCAND, V116, P144; Weisman DS, 1999, J PEDIATR ORTHOPED, V19, P523, DOI 10.1097/00004694-199907000-00020	13	49	50	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2005	36	10					1206	1209		10.1016/j.injury.2004.12.033			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	978LJ	WOS:000232874500012	16214464				2021-06-18	
J	Toro, K; Hubay, M; Sotonyi, P; Keller, E				Toro, K; Hubay, M; Sotonyi, P; Keller, E			Fatal traffic injuries among pedestrians, bicyclists and motor vehicle occupants	FORENSIC SCIENCE INTERNATIONAL			English	Article						road accidents; pedestrians; drivers; trauma	ALCOHOL; ACCIDENTS; MANAGEMENT; FRACTURES; DRIVERS; TRAUMA; FRANCE; AGE	The objective of this study was to investigate characteristic injuries of pedestrians and bicyclists (unprotected) compared to motor vehicle occupants' (protected) in fatal traffic accidents. Cases of 664 fatal traffic accidents (371 pedestrians, 45 bicyclists, and 248 motor vehicle occupants) were collected from 1999 to 2001 using the database of the Forensic Institute in Budapest. Autopsy reports were analyzed. Location of injuries, blood alcohol levels, seasonal distribution and natural diseases influencing accident outcome were evaluated. For statistical analysis, odds ratio (OR) with 95% confidence interval (CI) was used by a conditional logistic regression. There were substantial differences in distribution of injuries suffered by pedestrians, bicyclists and motor vehicle occupants. Among pedestrians and bicyclists there was a higher rate of head injuries, such as skull fractures, epidural haemorrhage, subdural haemorrhage, brain contusion, and injuries of the lower extremities. Thoracic damages, such as traumatic aortic rupture, hemothorax, and abdominal damages, like liver rupture were dominant in motor vehicle occupants. Considering existing natural diseases, coronary artery disease was the only one with higher occurrence among motor vehicle occupants 24 (9.7%) compared with pedestrians and bicyclist 36 (8.6%). These results underline the importance of preventive strategies in transportation, pointing out that different methods are necessary to reduce fatal injuries of various traffic participants. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Semmelweis Univ, Fac Med, Dept Forens Med, H-1091 Budapest, Hungary	Toro, K (corresponding author), Semmelweis Univ, Fac Med, Dept Forens Med, Ulloi 93, H-1091 Budapest, Hungary.	torok@igaz.sote.hu		Hubay, Marta/0000-0003-2193-1325			Aronson S C, 1984, R I Med J, V67, P485; Ballesteros MF, 2004, ACCIDENT ANAL PREV, V36, P73, DOI 10.1016/S0001-4575(02)00129-X; Barreto SM, 1996, OCCUP ENVIRON MED, V53, P343, DOI 10.1136/oem.53.5.343; BERTELSEN S, 1972, THORAX, V27, P188, DOI 10.1136/thx.27.2.188; Bhandari M, 2003, CLIN ORTHOP RELAT R, P187, DOI 10.1097/01.blo.0000043051.62337.bd; *CDC PREV, 1999, JAMA-J AM MED ASSOC, V281, P2080; del Rio MC, 1999, FORENSIC SCI INT, V104, P117, DOI 10.1016/S0379-0738(99)00101-2; DERLET R W, 1989, Journal of Emergency Medicine, V7, P5; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; *EEVC WORK GROUP 1, 1998, IMPR TEST METH EV PE; FERRANDO J, 2000, P ANN C ASSOC ADV AU, V44, P445; Fontaine H, 1997, ACCIDENT ANAL PREV, V29, P303, DOI 10.1016/S0001-4575(96)00084-X; Harruff RC, 1998, ACCIDENT ANAL PREV, V30, P11, DOI 10.1016/S0001-4575(97)00057-2; HOLUBOWYCZ OT, 1995, ACCIDENT ANAL PREV, V27, P417, DOI 10.1016/0001-4575(94)00064-S; JOHNSON CL, 1994, AM SURGEON, V60, P899; Kong LB, 1996, J AM COLL SURGEONS, V182, P17; Laapotti S, 1998, ACCIDENT ANAL PREV, V30, P435, DOI 10.1016/S0001-4575(97)00121-8; Landen MG, 1997, JAMA-J AM MED ASSOC, V278, P1755, DOI 10.1001/jama.278.21.1755; MACLAUGHLIN TF, 1993, VEHICLE INTERACTIONS, P539; Macpherson A, 1998, AM J PUBLIC HEALTH, V88, P1840, DOI 10.2105/AJPH.88.12.1840; MASAHITO H, 1999, AM J FOREN MED PATH, V20, P251; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MATSUI Y, 1998, P 16 TECHN C ENH SAF, P2152; Meliker JR, 2004, ACCIDENT ANAL PREV, V36, P1129, DOI 10.1016/j.aap.2004.06.002; MOHAN D, 1995, P 1995 INT IRCOBI C; *NAT CTR STAT AN T, 2001, FAT AN REP SYST; *NHTSA TRAFF SAF F, 1995, NAT HIGHW TRAFF SAF; Nordrum I, 2000, FORENSIC SCI INT, V110, P127, DOI 10.1016/S0379-0738(00)00163-8; OSTROM M, 1993, ACCIDENT ANAL PREV, V25, P171, DOI 10.1016/0001-4575(93)90057-4; Ostrom M, 2001, ACCIDENT ANAL PREV, V33, P173, DOI 10.1016/S0001-4575(00)00028-2; OSTROM M, 1992, ACCIDENT ANAL PREV, V24, P539, DOI 10.1016/0001-4575(92)90062-N; Peng RY, 1999, J AM COLL SURGEONS, V189, P343, DOI 10.1016/S1072-7515(99)00166-0; Reynaud M, 2002, ALCOHOL CLIN EXP RES, V26, P1833, DOI 10.1097/01.ALC.00000420008.34422.54; Rossbach MM, 1998, ANN THORAC SURG, V65, P182, DOI 10.1016/S0003-4975(97)01001-1; Simoncic M, 2001, ACCIDENT ANAL PREV, V33, P147, DOI 10.1016/S0001-4575(00)00025-7; SJOGREN H, 1993, P 37 ANN C AAAM, P237; Swan KG, 2001, J TRAUMA, V51, P970, DOI 10.1097/00005373-200111000-00023; SWEEDLER B, 1997, ALCOHOL DRUGS TRAFFI, P1206; Tatou E, 2000, ANN THORAC SURG, V69, P70, DOI 10.1016/S0003-4975(99)01054-1; Varga T, 1999, FORENSIC SCI INT, V103, pS25, DOI 10.1016/S0379-0738(99)00068-7; VESTRUP JA, 1989, J TRAUMA, V29, P741, DOI 10.1097/00005373-198906000-00007; Yavuz MS, 2003, AM J FOREN MED PATH, V24, P339, DOI 10.1097/01.paf.0000103011.14578.c3; YOSHIDA S, SAE INT C EXP; ZVULUN F, 1996, AM J FOREN MED PATH, V17, P233	44	49	52	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JUL 16	2005	151	2-3					151	156		10.1016/j.forsciint.2005.01.014			6	Medicine, Legal	Legal Medicine	940OZ	WOS:000230155100004	15939146				2021-06-18	
J	Clarke, NMP; Jowett, AJL; Parker, L				Clarke, NMP; Jowett, AJL; Parker, L			The surgical treatment of established congenital dislocation of the hip - Results of surgery after planned delayed intervention following the appearance of the capital femoral ossific nucleus	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						congenital dislocation of the hip; surgical treatment; ossific nucleus	AVASCULAR NECROSIS; CLOSED REDUCTION; DEVELOPMENTAL DYSPLASIA; OPERATIVE TREATMENT; PAVLIK HARNESS; CHILDREN; TRACTION; HEAD; AGE; COMPLICATION	It has been proposed that the presence of the capital femoral ossific nucleus confers protection against ischemic injury or avascular necrosis (AVN) at the time of reduction of a congenitally dislocated hip. The current literature is contradictory. A prospective study was undertaken of the clinical and radiologic outcomes following closed or open reduction. Fifty hips were included in the study. These cases had presented late or had failed conservative treatment. In 28 hips treatment was intentionally delayed until the appearance of the ossific nucleus (but not beyond 13 months) and in 22 the ossific nucleus was present at clinical presentation. Six hips reached the age of 13 months without an ossific nucleus appearing and progressed to treatment. The significant AVN rate (more than grade 1) was 7 % for closed reduction and 14 % for open. However, the amended rate if hips were excluded that had failed Pavlik harness treatment was 0.0 % and 9 %, respectively (4 % overall). Further surgical procedures were necessary in 57 % of hips undergoing closed reduction and 41 % after open, which compares favorably with other series. The authors conclude that the presence of the ossific nucleus is an important factor in the prevention of AVN, particularly after late closed reduction. Intentional delay in the timing of surgery does not condemn a hip to open surgery, but there is a comparable rate of secondary procedures becoming necessary, particularly after closed reduction. A simultaneous pelvic procedure may be appropriate after late closed reduction. The delayed strategy to await the appearance of the ossific nucleus for previously untreated dislocation allows a simple treatment algorithm to be employed that produces good clinical and radiologic outcomes.	Univ Southampton, Univ Orthopaed, Southampton, Hants, England	Clarke, NMP (corresponding author), Univ Orthopaed, Southampton Gen Hosp, MP 817,Tremona Rd, Southampton SO16 6YD, Hants, England.	ortho@soton.ac.uk					BERKELEY ME, 1984, J BONE JOINT SURG AM, V66A, P412, DOI 10.2106/00004623-198466030-00014; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BORGES JLP, 1995, J BONE JOINT SURG AM, V77A, P975, DOI 10.2106/00004623-199507000-00001; BROUGHAM DI, 1990, J BONE JOINT SURG BR, V72, P557; Cashman JP, 2002, J BONE JOINT SURG BR, V84B, P418, DOI 10.1302/0301-620X.84B3.12230; Clarke NMP, 1988, BEHAV GROWTH PLATE, P371; COOPERMAN DR, 1980, J BONE JOINT SURG AM, V62, P247, DOI 10.2106/00004623-198062020-00012; DHAR S, 1990, J BONE JOINT SURG BR, V72, P175; DIMEGLIO A, 1994, J PEDIATR ORTHOP B, V3, P135, DOI 10.1097/01202412-199403020-00003; ESTEVE R, 1960, J BONE JOINT SURG BR, V42, P253; FISHER RL, 1978, INT ORTHOP, V2, P229, DOI 10.1007/BF00266083; FLEISSNER PR, 1994, J PEDIATR ORTHOPED, V14, P631, DOI 10.1097/01241398-199409000-00016; GAGE JR, 1972, J BONE JOINT SURG AM, VA 54, P373, DOI 10.2106/00004623-197254020-00015; GIBSON PH, 1982, J BONE JOINT SURG BR, V64, P169; GREGOSIEWICZ A, 1988, J PEDIATR ORTHOPED, V8, P17, DOI 10.1097/01241398-198801000-00004; Huang SC, 1997, J PEDIATR ORTHOPED, V17, P181, DOI 10.1097/00004694-199703000-00009; ISHII Y, 1978, CLIN ORTHOP RELAT R, P167; KALAMCHI A, 1980, J BONE JOINT SURG AM, V62, P876, DOI 10.2106/00004623-198062060-00002; Langenskiold A, 2000, J PEDIATR ORTHOPED, V20, P471, DOI 10.1097/00004694-200007000-00009; Luhmann SJ, 1998, J BONE JOINT SURG AM, V80A, P1719, DOI 10.2106/00004623-199812000-00001; Luhmann SJ, 2003, J BONE JOINT SURG AM, V85A, P239, DOI 10.2106/00004623-200302000-00009; Morcuende JA, 1997, J BONE JOINT SURG AM, V79A, P810, DOI 10.2106/00004623-199706000-00002; NAITO M, 1992, J ORTHOPAED RES, V10, P800, DOI 10.1002/jor.1100100608; OGDEN JA, 1975, J PEDIATR-US, V86, P732, DOI 10.1016/S0022-3476(75)80358-1; RACE C, 1983, J PEDIATR ORTHOPED, V3, P166, DOI 10.1097/01241398-198305000-00004; RAMSEY PL, 1976, J BONE JOINT SURG AM, V58, P1000, DOI 10.2106/00004623-197658070-00017; ROSS ERS, 1988, J BONE JOINT SURG BR, V70, P680; SALTER RB, 1969, CAN J SURG, V12, P44; Segal LS, 1999, J PEDIATR ORTHOPED, V19, P177, DOI 10.1097/00004694-199903000-00008; Segal LS, 1999, J PEDIATR ORTHOPED, V19, P433, DOI 10.1097/00004694-199907000-00003; Severin E, 1941, ACTA CHIR SCAND, V84, P1; SHERLOCK DA, 1985, J BONE JOINT SURG BR, V67, P390; Sugimoto Nobuyuki, 1993, Bulletin Hospital for Joint Diseases, V53, P30; THOMAS IH, 1989, J PEDIATR ORTHOPED, P9525; Tonnis D, 1990, Acta Orthop Belg, V56, P195; TREVOR D, 1957, J BONE JOINT SURG BR, V39, P611; Ward WT, 1997, J BONE JOINT SURG AM, V79A, P656, DOI 10.2106/00004623-199705000-00004; WEINER DS, 1977, J BONE JOINT SURG AM, V59, P306, DOI 10.2106/00004623-197759030-00002; WILKINSON JA, 1995, CONGENITAL DISPLACEM; ZIONTS LE, 1986, J BONE JOINT SURG AM, V68A, P829, DOI 10.2106/00004623-198668060-00005	40	49	53	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	JUL-AUG	2005	25	4					434	439		10.1097/01.bpo.0000158003.68918.28			6	Orthopedics; Pediatrics	Orthopedics; Pediatrics	939CJ	WOS:000230049600005	15958890				2021-06-18	
J	Rowland, SM; Lam, CS; Leahy, B				Rowland, SM; Lam, CS; Leahy, B			Use of the Beck Depression Inventory-II (BDI-II) with persons with traumatic brain injury: Analysis of factorial structure	BRAIN INJURY			English	Article							INDIVIDUALS; RECOVERY	Primary objective: To determine the factorial structure of the BDI-II in a TBI sample and possible predictor variables of depression following TBI. Research design: Principle components analysis with orthogonal rotation and linear regression analyses. Methods and procedures: Fifty-one individuals with traumatic brain injury (TBI) participated in this study. The factorial structure of the BDI-II, a 21-item self-report measure of depression, was examined with individuals in the early stages following TBI. Time since injury, severity of injury, location of lesion and previous substance abuse were examined as possible predictors of depression following TBI. Results: A three-factor structure of the BDI-II was found for the TBI sample, which included Negative Self-Evaluation, Symptoms of Depression and Vegetative Symptoms of Depression. Time since injury was the only significant predictor of depression following; TBI. Conclusion: Using the BDI-II, symptoms of depression after TBI fall into three key categories. With time since injury being the only significant predictor of depression following TBI, it appears that the depression could be more of a result of psychosocial factors than neurobiological factors. It was concluded that BDI-II can be useful in identifying symptoms of depression in the early stages following TBI.	IIT, Inst Psychol, CRC, Chicago, IL 60616 USA	Lam, CS (corresponding author), IIT, Inst Psychol, CRC, 3101 S Dearborn St, Chicago, IL 60616 USA.	lam@iit.edu					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Christensen BK, 1995, J INT NEUROPSYCH SOC, V1, P121; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Leahy B, 2003, CLIN NEUROPSYCHOL, V17, P474, DOI 10.1076/clin.17.4.474.27941; Levin H. S., 2000, CEREBRAL REORGANIZAT; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Sprinkle SD, 2002, J COUNS PSYCHOL, V49, P381, DOI 10.1037//0022-0167.49.3.381; Steer RA, 1998, J PSYCHOPATHOL BEHAV, V20, P127, DOI 10.1023/A:1023091529735; Stevens J., 1996, APPL MULTIVARIATE ST; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Velicer WF, 1998, PSYCHOL METHODS, V3, P231, DOI 10.1037/1082-989X.3.2.231	27	49	49	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					77	83		10.1080/02699050410001719988			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600001	15841751				2021-06-18	
B	DeLuca, J		DeLuca, J		DeLuca, John			Fatigue, Cognition, and Mental Effort	FATIGUE AS A WINDOW TO THE BRAIN	Issues in Clinical and Cognitive Neuropsychology		English	Article; Book Chapter							MULTIPLE-SCLEROSIS PATIENTS; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; CORTICAL ACTIVATION; BASAL GANGLIA; PERFORMANCE; IMPAIRMENT; MRI; ATTENTION; TASK		[DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [DeLuca, John] Kessler Med Rehabil Res & Educ Corp, Neurosci Res, W Orange, NJ USA	DeLuca, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, 185 S Orange Ave, Newark, NJ 07103 USA.						Abe K, 2000, BEHAV NEUROL, V12, P103, DOI 10.1155/2000/580683; Bakshi R, 1999, NEUROLOGY, V53, P1151, DOI 10.1212/WNL.53.5.1151; Beaumont M, 2001, J SLEEP RES, V10, P265, DOI 10.1046/j.1365-2869.2001.00266.x; BELZA BL, 1993, NURS RES, V42, P93; Blackwood SK, 1998, J NEUROL NEUROSUR PS, V65, P541, DOI 10.1136/jnnp.65.4.541; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Broadbent D. E., 1971, DECISION STRESS; BRUNO RL, 1993, ARCH PHYS MED REHAB, V74, P1061, DOI 10.1016/0003-9993(93)90062-F; Bryant D, 2004, REHABIL PSYCHOL, V49, P114, DOI 10.1037/0090-5550.49.2.114; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chiaravalloti ND, 2003, CLIN REHABIL, V17, P58, DOI 10.1191/0269215503cr586oa; CHIARAVALLOTI ND, J CLIN EXPT IN PRESS; Chollet Francois, 1994, Current Opinion in Neurobiology, V4, P226, DOI 10.1016/0959-4388(94)90077-9; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Claypoole K, 2001, Appl Neuropsychol, V8, P31, DOI 10.1207/S15324826AN0801_5; Colombo B, 2000, J NEUROL, V247, P506, DOI 10.1007/s004150070148; Elkins L E, 2000, Semin Clin Neuropsychiatry, V5, P58; Filippi M, 2002, NEUROIMAGE, V15, P559, DOI 10.1006/nimg.2001.1011; Fisk JD, 2001, J INT NEUROPSYCH SOC, V7, P363, DOI 10.1017/S1355617701733103; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Gandevia S, 1995, FATIGUE NEURAL MUSCU; Heesen C, 2002, PSYCHONEUROENDOCRINO, V27, P505, DOI 10.1016/S0306-4530(01)00071-3; Herndon R. M., 2003, MULTIPLE SCLEROSIS I; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Iriarte J, 2000, MULT SCLER, V6, P124, DOI 10.1191/135245800678827572; JENNEKENSSCHINKEL A, 1988, J NEUROL SCI, V85, P173, DOI 10.1016/0022-510X(88)90154-2; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; Johnson SK, 1998, COGNITIVE NEUROPSYCH, V3, P269, DOI DOI 10.1080/135468098396099; KINKEL RP, 2000, INT J MS CARE S  OCT; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; KUJALA P, 1995, J NEUROL NEUROSUR PS, V59, P77, DOI 10.1136/jnnp.59.1.77; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lamanca John J., 1998, American Journal of Medicine, V105, p59S, DOI 10.1016/S0002-9343(98)00171-5; LANGE G, CHRONIC FATIGU UNPUB; Leocani L, 2001, NEUROIMAGE, V13, P1186, DOI 10.1006/nimg.2001.0759; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lorist MM, 2000, PSYCHOPHYSIOLOGY, V37, P614, DOI 10.1111/1469-8986.3750614; Lorist MM, 2002, J PHYSIOL-LONDON, V545, P313, DOI 10.1113/jphysiol.2002.027938; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Michiels V, 2001, ACTA PSYCHIAT SCAND, V103, P84, DOI 10.1034/j.1600-0447.2001.00017.x; Millikin CP, 2003, J CLIN EXP NEUROPSYC, V25, P201, DOI 10.1076/jcen.25.2.201.13644; Morris TL, 1996, BIOL PSYCHOL, V42, P343, DOI 10.1016/0301-0511(95)05166-X; Mosso A., 1904, FATIGUE; Neri DF, 2002, AVIAT SPACE ENVIR MD, V73, P654; NEWSHOLME EA, 1995, FATIGUE NEURAL MUSCU, V5, P315; Parmenter BA, 2003, MULT SCLER, V9, P111, DOI 10.1191/1352458503ms859oa; Paul MA, 2001, AVIAT SPACE ENVIR MD, V72, P965; Paul RH, 1998, APPL NEUROPSYCHOL, V5, P143, DOI 10.1207/s15324826an0503_5; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; SANDRONI P, 1992, ARCH NEUROL-CHICAGO, V49, P517, DOI 10.1001/archneur.1992.00530290105019; Schmaling KB, 2003, PSYCHOSOM MED, V65, P129, DOI 10.1097/01.PSY.0000038942.33335.9B; Schultheis MT, 2001, NEUROLOGY, V56, P1089, DOI 10.1212/WNL.56.8.1089; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Schwid SR, 2003, MULT SCLER, V9, P503, DOI 10.1191/1352458503ms946oa; Sheean GL, 1997, BRAIN, V120, P299, DOI 10.1093/brain/120.2.299; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SNYDER PJ, 1993, J CLIN EXP NEUROPSYC, V15, P18; Staffen W, 2002, BRAIN, V125, P1275, DOI 10.1093/brain/awf125; STOKES MJ, 1988, BRIT MED J, V297, P1014, DOI 10.1136/bmj.297.6655.1014; Tietzel AJ, 2002, J SLEEP RES, V11, P213, DOI 10.1046/j.1365-2869.2002.00299.x; van der Linden D, 2003, ACTA PSYCHOL, V113, P45, DOI 10.1016/S0001-6918(02)00150-6; Wessely S., 1998, CHRONIC FATIGUE ITS	69	49	49	0	2	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA			978-0-262-25135-8	ISS CLIN COGN NEUROP			2005							37	57					21	Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	BPS59	WOS:000279778900005					2021-06-18	
J	Coles, JP; Steiner, LA; Johnston, AJ; Fryer, TD; Coleman, MR; Smieleweski, P; Chatfield, DA; Aigbirhio, F; Williams, GB; Boniface, S; Rice, K; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Steiner, LA; Johnston, AJ; Fryer, TD; Coleman, MR; Smieleweski, P; Chatfield, DA; Aigbirhio, F; Williams, GB; Boniface, S; Rice, K; Clark, JC; Pickard, JD; Menon, DK			Does induced hypertension reduce cerebral ischaemia within the traumatized human brain?	BRAIN			English	Article						ischaemia; hypertension; cerebral perfusion pressure; positron emission tomography; head injury	POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; ENERGY-METABOLISM; OXYGEN-METABOLISM; NOREPINEPHRINE; INJURY; PERFUSION; DOPAMINE; O-15; PHENYLEPHRINE	Recent changes in published guidelines for the management of patients with severe head injury are based on data showing that aggressive maintenance of cerebral perfusion pressure (CPP) can worsen outcome due to extracranial complications of therapy. However, it remains unclear whether CPP augmentation could reduce cerebral ischaemia, a finding which might prompt the search for CPP augmentation protocols that avoid these extracranial complications. We studied 10 healthy volunteers and 20 patients within 6 days of closed head injury. All subjects underwent imaging of cerebral blood flow (CBF), blood volume (CBV), oxygen metabolism (CMRO2) and oxygen extraction fraction (OEF) using O-15 PET. In addition, for patients, the EEG power ratio index (PRI), burst suppression ratio and somatosensory evoked potentials (SEP) were obtained and CPP was increased from 68 +/- 4 to 90 +/- 4 mmHg using an infusion of norepinephrine and measurements were repeated. Following elevation of CPP, CBF and CBV were increased and CMRO2 and OEF were reduced (P < 0.001 for all comparisons). Regions with a reduction in CMRO2 were associated with the greatest reduction in OEF (r(2) = 0.3; P < 0.0001). Although CPP elevation produced a significant fall in the ischaemic brain volume (IBV) (from 15 +/- 16 to 5 +/- 4 ml; P < 0.01) and improved flow metabolism coupling, the IBV was small and clinically insignificant in the majority of these patients. However, the reduction in IBV was directly related to the baseline IBV (r(2) = 0.97; P < 0.001) and patients with large baseline IBV showed substantial and clinically significant reductions. CPP augmentation increased the EEG PRI (5.0 +/- 1.5 versus 4.3 +/- 1.4, P < 0.01), implying an overall decrease in neural activity, but these changes did not correlate with the reduction in CMRO2 and there was no change in SEP cortical amplitude (N20-P27). These data provide support for recent changes in recommended CPP levels for head injury management across populations of patients with significant head injury. However, they do not provide guidance on whether the intervention may be more appropriate at earlier stages after injury, or in patients selected because of high baseline IBV. It also remains unclear whether CPP values below 65 mmHg can be safely used in this population. Clarification of the significance of a reduction in CMRO2 and neuronal electrical function will require further study.	Addenbrookes Hosp, Dept Clin Neurophysiol, Cambridge CB2 2QQ, England; Univ Cambridge, Div Anaesthesia, Cambridge, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge, England; Univ Cambridge, Dept Neurosurg, Cambridge, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	Menon, DK (corresponding author), Addenbrookes Hosp, Dept Clin Neurophysiol, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Steiner, Luzius/J-1987-2019; Rice, Kenneth M/A-4150-2013; Steiner, Luzius/C-9836-2011	Rice, Kenneth M/0000-0001-5779-4495; 	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline		BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Berridge CW, 1999, NEUROSCIENCE, V93, P1263, DOI 10.1016/S0306-4522(99)00276-6; Berridge CW, 1996, J NEUROSCI, V16, P7010; BONVALLET M, 1954, ELECTROEN CLIN NEURO, V6, P119, DOI 10.1016/0013-4694(54)90011-5; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2003, GUID CER PERF PRESS; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; CORREIA JA, 1985, J CEREBR BLOOD F MET, V5, P591, DOI 10.1038/jcbfm.1985.88; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Gibbs EL, 1942, J BIOL CHEM, V144, P325; HERSCOVITCH P, 1983, J CEREBR BLOOD F MET, V3, P407, DOI 10.1038/jcbfm.1983.66; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; JENNETT B, 1975, LANCET, V1, P480; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; KUSCHINSKY W, 1983, PFLUG ARCH EUR J PHY, V398, P134, DOI 10.1007/BF00581061; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauguiere F, 1999, EEG CL N SU, P255; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; NAGATA K, 1989, ELECTROEN CLIN NEURO, V72, P16, DOI 10.1016/0013-4694(89)90027-8; PHELPS ME, 1979, J NUCL MED, V20, P328; Robertson C S, 1995, New Horiz, V3, P410; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sebban C, 1999, BRIT J PHARMACOL, V128, P1045, DOI 10.1038/sj.bjp.0702894; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stocchetti N, 1998, ACT NEUR S, V71, P162; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; SUBBARAO KV, 1991, J NEUROSCI RES, V28, P399, DOI 10.1002/jnr.490280312; Talairach J., 1988, COPLANAR STEREOTAXIC; Talmor D, 1998, ANESTH ANALG, V87, P574, DOI 10.1097/00000539-199809000-00014; TEASDALE G, 1974, LANCET, V2, P81; TUOR UI, 1986, AM J PHYSIOL, V251, pH824; *WELLC DEP IM NEUR, 1999, STAT PAR MAPP SPM99; 2000, J NEUROTRAUMA, V17, P457	49	49	52	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2004	127		11				2479	2490		10.1093/brain/awh268			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	865LD	WOS:000224703700011	15456706	Bronze			2021-06-18	
J	Lusardi, TA; Rangan, J; Sun, D; Smith, DH; Meaney, DE				Lusardi, TA; Rangan, J; Sun, D; Smith, DH; Meaney, DE			A device to study the initiation and propagation of calcium transients in cultured neurons after mechanical stretch	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						CNS trauma; in vitro model; fura-2	IN-VITRO; TRAUMATIC INJURY; GLUTAMATE RELEASE; CELLS; DEFORMATION; STIMULATION; ASTROCYTES; DEATH; MODEL; WAVES	The brain is generally considered protected from mechanical forces. However, during traumatic events, cells in brain tissue are exposed to complex mechanical events including transient acceleration, pressure, and direct stretch. This paper presents a model to expose cultured cells of the central nervous system (CNS) to a defined stretch insult. The system is designed to apply a single transient uniaxial stretch to cultured cells; control of both the magnitude and rate of stretch allows study of a broad range of conditions, from physiologic to traumatic. Distinct from previous cell-stretching systems, we control the fraction of cells deformed and examine the response of stretched cells or the surrounding population of unstretched cells, the "mechanical penumbra," of the same culture. Finally, we use this new model with cultured neurons, measuring the acute calcium response in traumatically stretched cells and the propagation of this calcium influx in neighboring, but unstretched cells. Stretched neurons exhibit a strain rate and magnitude-dependent response, unstretched exhibit an "all-or-none" response. This model will further our understanding of the complex interaction between mechanical stimuli, resulting biochemical cascades, and interaction between mechanical and other challenges, thereby furthering our understanding of the initiation and evolution of cellular damage following traumatic CNS injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DE (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007	Lusardi, Theresa/0000-0003-0699-5662; Meaney, David/0000-0002-0954-4122	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [NICHD 41699] Funding Source: Medline; DS NIH HHS [NINDS P01 NS08803, NINDS R01 35712] Funding Source: Medline		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Basarsky TA, 1999, J NEUROSCI, V19, P6439; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Brown TD, 2000, J BIOMECH, V33, P3, DOI 10.1016/S0021-9290(99)00177-3; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fayaz I, 2000, J NEUROSCI METH, V102, P69, DOI 10.1016/S0165-0270(00)00282-X; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; Ito Y, 1998, BIOCONJUGATE CHEM, V9, P277, DOI 10.1021/bc970190b; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Katano H, 2001, NEUROSCI LETT, V306, P101, DOI 10.1016/S0304-3940(01)01832-8; KUTNER MHC, 1996, APPL LINEAR STAT MOD, P1408; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; McCulloch C, 2001, WILEY PS TX; McIntosh TK, 1996, LAB INVEST, V74, P315; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MILLER RT, 1998, 42 STAPP CAR CRASH C; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Newman EA, 1997, SCIENCE, V275, P844, DOI 10.1126/science.275.5301.844; OGDEN RW, 1984, NONLINEAR ELASTIC DE, P544; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REGAN RF, 1995, BRAIN RES, V682, P144, DOI 10.1016/0006-8993(95)00330-S; Richards DA, 2003, EUR J NEUROSCI, V17, P2323, DOI 10.1046/j.1460-9568.2003.02671.x; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Thompson DM, 2001, TISSUE ENG, V7, P247, DOI 10.1089/10763270152044125; Venance L, 1997, J NEUROSCI, V17, P1981; VINK R, 1988, J BIOL CHEM, V263, P757; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yoon KW, 1996, STROKE, V27, P122, DOI 10.1161/01.STR.27.1.122; Yuan Q, 1998, SPINE, V23, P1677, DOI 10.1097/00007632-199808010-00012; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	47	49	49	0	12	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	NOV	2004	32	11					1546	1558		10.1114/B:ABME.0000049038.75368.75			13	Engineering, Biomedical	Engineering	873RL	WOS:000225298500008	15636114				2021-06-18	
J	Frederickson, CJ; Burdette, SC; Frederickson, CJ; Sensi, SL; Weiss, JH; Yin, HZ; Balaji, RV; Truong-Tran, AQ; Bedell, E; Prough, DS; Lippard, SJ				Frederickson, CJ; Burdette, SC; Frederickson, CJ; Sensi, SL; Weiss, JH; Yin, HZ; Balaji, RV; Truong-Tran, AQ; Bedell, E; Prough, DS; Lippard, SJ			Method for identifying neuronal cells suffering zinc toxicity by use of a novel fluorescent sensor	JOURNAL OF NEUROSCIENCE METHODS			English	Article						zinc-specific sensor; excitotoxicity; damaged neurons; new cells; dentate gyrus; subgranular strata; brain injury	SYNAPTICALLY-RELEASED ZINC; TRAUMATIC BRAIN-INJURY; INTRACELLULAR ZINC; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; ADULT-RAT; ZN2+; TRANSLOCATION; NEUROGENESIS; ACCUMULATION	During excitotoxic brain damage, injured neurons accumulate an anomalous, pathological burden of weakly bound, rapidly exchangeable Zn2+ that diffusely fills the soma, nucleus and proximal dendrites. Mounting evidence indicates that this Zn2+ is a major contributing factor in the subsequent demise of the damaged neurons. Thus, identifying, imaging, and characterizing zinc-filled cells have become essential steps in understanding excitotoxicity. Here we demonstrate that a new fluorescent stain for zinc can rather selectively and quite vividly label zinc-filled neurons in frozen histologic sections. The method is more sensitive and selective than the existing stain TSQ, and simpler than the Timm-Danscher silver staining techniques. A previously unobserved population of apparently injured cells in the dentate gyrus has been discovered with the new reagent. Whereas cells viewed in situ in normal, healthy tissue virtually never display any perikaryal staining by histochemical methods for zinc [Histochemistry, 71 (1981) 1; Int. Rev. Neurobiol. 31 (1989) 145], injured cells stain intensely for zinc in culture [J. Neurosci. 17 (1997) 9554], acute slice preparations [J. Histochem. Cytochem. 47 (1999) 969; J. Neurosci. 22 (2002) 1273] and in tissue harvested in vivo [Science 272 (1996) 1013; Annu. Rev. Neurosci. 21 (1998) 347]. Thus, the presence of rapidly-exchangeable, "stainable" perikaryal zinc may be taken as an indicator of cell injury [J. Nutr. 130 (2000) 147 IS; Biometals 14 (2001) 353]. (C) 2004 Elsevier B.V. All rights reserved.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77550 USA; NeuroBioTex Inc, Galveston, TX 77550 USA; Univ G DAnnunzio, Dept Neurol, CESI, Ctr Excellence Aging, I-66013 Chieti, Italy; UCI, I-66013 Chieti, Italy; Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychobiol, Irvine, CA 92697 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77550 USA	Lippard, SJ (corresponding author), MIT, Dept Chem, Room 18-498, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019; Prough, Donald S/G-5793-2013; weiss, john/B-4283-2008	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; Prough, Donald S/0000-0001-7994-532X; weiss, john/0000-0001-9323-7813	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM065519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS041682, R43NS041682, R01NS030884, R43NS040215, R01NS038585] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00836, AG00919] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM65519] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38585, NS30884, NS40215, NS41682, NS42894] Funding Source: Medline		Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Budde T, 1997, NEUROSCIENCE, V79, P347, DOI 10.1016/S0306-4522(96)00695-1; Burdette SC, 2001, J AM CHEM SOC, V123, P7831, DOI 10.1021/ja010059l; Burdette SC, 2003, J AM CHEM SOC, V125, P1778, DOI 10.1021/ja0287377; Burdette SC, 2002, INORG CHEM, V41, P6816, DOI 10.1021/ic026048q; BURENKOVA O, 2002, UNPUB; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cuajungco MP, 1998, BRAIN RES, V799, P118, DOI 10.1016/S0006-8993(98)00463-6; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; Frederickson CJ, 2002, NEUROSCIENCE, V115, P471, DOI 10.1016/S0306-4522(02)00399-8; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Li Y, 2001, J NEUROPHYSIOL, V86, P2597; Li Y, 2001, J NEUROSCI, V21, P8015; MARKUSZEWSKI R, 1980, TALANTA, V27, P937, DOI 10.1016/0039-9140(80)80125-1; McCabe BK, 2001, J NEUROSCI, V21, P2094, DOI 10.1523/JNEUROSCI.21-06-02094.2001; MUI BLS, 1994, J BIOL CHEM, V269, P7364; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sharma A, 2002, NEUROBIOL DIS, V11, P246, DOI 10.1006/nbdi.2002.0531; Snitsarev V, 2001, BIOPHYS J, V80, P1538, DOI 10.1016/S0006-3495(01)76126-7; Suh SW, 2000, BRAIN RES, V879, P7, DOI 10.1016/S0006-8993(00)02675-5; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Thompson RB, 1998, ANAL CHEM, V70, P1749, DOI 10.1021/ac971199+; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; Truong-Tran AQ, 2000, AM J PHYSIOL-LUNG C, V279, pL1172; Walkup GK, 2000, J AM CHEM SOC, V122, P5644, DOI 10.1021/ja000868p; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Yin HZ, 2002, J NEUROSCI, V22, P1273, DOI 10.1523/JNEUROSCI.22-04-01273.2002	39	49	50	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2004	139	1					79	89		10.1016/j.jneumeth.2004.04.033			11	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	856KJ	WOS:000224043800009	15351524				2021-06-18	
J	Pannu, R; Won, JS; Khan, M; Singh, AK; Singh, I				Pannu, R; Won, JS; Khan, M; Singh, AK; Singh, I			A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma-mediated inducible nitric oxide synthase gene expression: Implications for neuroinflammatory diseases	JOURNAL OF NEUROSCIENCE			English	Article						iNOS; astrocytes; lactosylceramide; lipopolysaccharide; interferon-gamma; spinal cord injury	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE-CELLS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CREUTZFELDT-JAKOB-DISEASE; TRAUMATIC BRAIN-INJURY; C-FOS EXPRESSION; MULTIPLE-SCLEROSIS	In the present study a possible role of glycosphingolipids (GSLs) in inducible nitric oxide synthase ( iNOS) gene expression and nitric oxide ( NO) production after spinal cord injury (SCI) in rats has been established. In primary rat astrocytes lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) treatment increased the intracellular levels of lactosylceramide ( LacCer) and induced iNOS gene expression. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol . HCI ( PDMP), a glucosylceramide synthase and LacCer synthase ( galactosyltransferase, GalT-2) inhibitor, inhibited LPS/IFN-gamma induced iNOS expression, which was reversed by exogenously supplied LacCer, but not by other glycosphingolipids. LPS/IFN-gamma caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene with the use of antisense oligonucleotides resulted in decreased LPS/IFN-gamma-induced iNOS, TNF-alpha, and IL-1beta gene expression. The PDMP-mediated reduction in LacCer production and inhibition of iNOS expression correlated with decreased Ras and ERK1/2 activation along with decreased IkappaB phosphorylation, NF-kappaB DNA binding activity, and NF-kappaB-luciferase reporter activity. LacCer-mediated Ras activation was redox-mediated and was attenuated by antioxidants N-acetyl cysteine (NAC) and pyrrolidine dithiocarbamate ( PDTC). In vivo administration of PDMP after SCI resulted in improved functional outcome ( Basso, Beattie, Bresnahan score); inhibition of iNOS, TNF-alpha, and IL-1beta expression; decreased neuronal apoptosis; and decreased tissue necrosis and demyelination. The in vivo studies supported the conclusions drawn from cell culture studies and provided evidence for the possible role of GalT-2 and LacCer in SCI-induced inflammation and pathology. To our knowledge this is the first report of a role of LacCer in iNOS expression and the advantage of GSL depletion in attenuating post-SCI inflammation to improve the outcome of SCI.	Med Univ S Carolina, Dept Pediat, Div Dev Neurogenet, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph h Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC 29425 USA	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, Div Dev Neurogenet, 316 CSB, Charleston, SC 29425 USA.	singhi@musc.edu		Won, Jeseong/0000-0003-2408-0386	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034741, R37NS022576, R01NS040810, R01NS040144, R01NS037766, R01NS022576] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37 NS022576, NS-40144, R01 NS037766, NS-40810, R01 NS022576, R01 NS040144, R01 NS034741, NS-37766, NS-22576, R01 NS040810, NS-34741] Funding Source: Medline		Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; ANDO S, 1984, JPN J EXP MED, V54, P229; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brugg B, 1996, J NEUROCHEM, V66, P733; Castro-Palomino JC, 2001, CHEM-EUR J, V7, P2178, DOI 10.1002/1521-3765(20010518)7:10<2178::AID-CHEM2178>3.0.CO;2-E; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; Dawson T M, 1993, NIDA Res Monogr, V136, P258; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Fern R, 2001, Prog Brain Res, V132, P405; Gilg AG, 2000, J NEUROPATH EXP NEUR, V59, P1063, DOI 10.1093/jnen/59.12.1063; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hakomori S, 2003, METHOD ENZYMOL, V363, P191; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Inokuchi J, 1998, ACTA BIOCHIM POL, V45, P479, DOI 10.18388/abp.1998_4241; Iwabuchi K, 2002, BLOOD, V100, P1454, DOI 10.1182/blood.V100.4.1454.h81602001454_1454_1464; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAWAI K, 1994, NEUROSCI LETT, V174, P225, DOI 10.1016/0304-3940(94)90027-2; Khan M, 1998, J NEUROCHEM, V71, P78; KIERNAN JA, 1990, TRENDS PHARMACOL SCI, V11, P316, DOI 10.1016/0165-6147(90)90233-X; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LASSMANN H, 1979, ARCH NEUROL-CHICAGO, V36, P490, DOI 10.1001/archneur.1979.00500440060011; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Marcus JS, 2003, GLIA, V41, P152, DOI 10.1002/glia.10168; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Ohtani Y, 1996, NEURODEGENERATION, V5, P331, DOI 10.1006/neur.1996.0045; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; RENNO T, 1995, J IMMUNOL, V154, P944; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sequeira SM, 1997, NITRIC OXIDE-BIOL CH, V1, P315, DOI 10.1006/niox.1997.0144; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Simon BM, 2002, CELL DEATH DIFFER, V9, P758, DOI 10.1038/sj.cdd.4401027; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1996, FASEB J, V10, P1388; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Won JS, 2004, J NEUROCHEM, V88, P583, DOI 10.1046/j.1471-4159.2003.02165.x; Won JS, 2001, BRAIN RES, V903, P207, DOI 10.1016/S0006-8993(01)02452-0; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yeh LH, 2001, J VASC RES, V38, P551, DOI 10.1159/000051091; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; YU RK, 1974, J NEUROCHEM, V23, P169, DOI 10.1111/j.1471-4159.1974.tb06931.x; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	70	49	49	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 30	2004	24	26					5942	5954		10.1523/JNEUROSCI.1271-04.2004			13	Neurosciences	Neurosciences & Neurology	833PZ	WOS:000222351900011	15229242	Bronze, Green Published			2021-06-18	
J	Liu, DX; Liu, J; Sun, DH; Wen, J				Liu, DX; Liu, J; Sun, DH; Wen, J			The time course of hydroxyl radical formation following spinal cord injury: The possible role of the iron-catalyzed Haber-Weiss reaction	JOURNAL OF NEUROTRAUMA			English	Article						hydrogen peroxide; hydroxyl radical; iron-catalyzed Haber-Weiss/Fenton reaction; microdialysis sampling and administration; reactive oxygen species; secondary spinal cord injury; superoxide anion	MODEL COMBINING MICRODIALYSIS; EXPERIMENTAL HEAD-INJURY; TRAUMATIC BRAIN INJURY; GENERATED IN-VIVO; LIPID-PEROXIDATION; SUPEROXIDE-PRODUCTION; NITRIC-OXIDE; HYDROGEN-PEROXIDE; PROTEIN OXIDATION; IMPACT INJURY	This study explores whether the hydroxyl radical ((OH)-O-.)-one of the most destructive reactive oxygen species-plays a role in secondary spinal cord injury (SCI). First, we measured the time course of (OH)-O-. formation in rat spinal tissue after impact SCI by administering salicylate as a trapping agent into the intrathecal space of the cord and measuring the hydroxylation products of salicylate, 2,3- and 2,5-dihydroxybenzoic acid (2,3- and 2,5-DHBA) by HPLC. The 2,3-DHBA concentration was significantly higher in injured spinal tissue than in sham controls at 5 min, 1 and 3 h, but not at 5 h post-injury. Second, we generated (OH)-O-. by administering H2O2 and FeCl2/EDTA (Fenton's reagents) at the concentrations produced by SCI into the gray matter of the cord for 4 h and found that it induced significant cell loss at 24 h post-(OH)-O-. exposure. Mn (III) tetrakis (4-benzoic acid) porphyrin(MnTBAP)-a broad spectrum reactive species scavenger-significantly reduced (OH)-O-.-induced cell death. Finally, we generated superoxide and administered FeCl3/EDTA in the intrathecal space of the cord at the concentration produced by SCI and measured extracellular (OH)-O-. formation in the gray matter of the cord by microdialysis sampling. We found that the levels of (OH)-O-. significantly increased compared to the pre-administration level, indicating that (OH)-O-. can be produced in vivo by the iron-catalyzed Haber-Weiss reaction. All together, we demonstrated that (OH)-O-. is an endogenous secondary damaging agent following SCI and the metal-catalyzed Haber-Weiss reaction may contribute to early (OH)-O-. formation after SCI.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS44324, NS34048, NS35119] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS034048, R01NS035119, R01NS044324] Funding Source: NIH RePORTER		Aksenova M, 2002, J NEUROTRAUM, V19, P491, DOI 10.1089/08977150252932433; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Brumby P. E., 1967, METHOD ENZYMOL, V10, P463; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Ellerby LM, 2000, METHOD ENZYMOL, V322, P413; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IKEDA Y, 1989, Neurological Research, V11, P213; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRAUSE GS, 1987, ANN EMERG MED, V16, P1200, DOI 10.1016/S0196-0644(87)80224-X; Lander HM, 1997, FASEB J, V11, P118; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1995, FREE RADICAL BIO MED, V18, P571, DOI 10.1016/0891-5849(94)00154-C; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2003, FREE RADICAL BIO MED, V34, P64, DOI 10.1016/S0891-5849(02)01184-X; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; MAITY S, 1992, ANGIOLOGY, V43, P781, DOI 10.1177/000331979204300908; Marsala M, 1995, J NEUROSCI METH, V62, P43, DOI 10.1016/0165-0270(95)00053-4; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; Shacter E, 2000, METHOD ENZYMOL, V319, P428; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SORKIN LS, 1988, J NEUROSCI METH, V23, P131, DOI 10.1016/0165-0270(88)90185-9; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; SUBBARAO KV, 1990, J NEUROSCI RES, V26, P224, DOI 10.1002/jnr.490260212; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WILLMORE LJ, 1986, BRAIN RES, V382, P422; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	64	49	53	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					805	816		10.1089/0897715041269650			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600014	15253806				2021-06-18	
J	Ekshyyan, O; Aw, TY				Ekshyyan, O; Aw, TY			Apoptosis in acute and chronic neurological disorders	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						neuronal apoptosis; apoptosis and neurodegeneration; mitochondrial apoptotic signaling; oxidative stress and apoptosis; apoptosis and cerebrovascular injury; cerebral ischemia/reperfusion; review	TRANSGENIC MOUSE MODEL; HYDROPEROXIDE-INDUCED APOPTOSIS; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; MOTOR-NEURON PROTEIN; SPINAL-CORD-INJURY; CASPASE ACTIVATION; ALPHA-SYNUCLEIN; NITRIC-OXIDE; CELL-DEATH	Programmed cell death or apoptosis is a physiologically important process in neurogenesis wherein similar to50% of the neurons apoptose during maturation of the nervous system. However, premature apoptosis and/or aberrations in apoptosis control contribute to the pathogenesis of a variety of neurological disorders including acute brain injury such as trauma, spinal cord injury, ischemic stroke and ischemia/reperfusion as well as chronic disease states such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, spinal muscular atrophy, and diabetic neuropathy. The current review will focus on two major topics, namely, the general concepts of our current understanding of the apoptosis death machinery, its mediators and regulation, and the relationship between aberrant apoptosis and genesis of neurodegenerative disorders. This knowledge of apoptosis mechanisms will underpin the basis for development of novel therapeutic strategies and treatment modalities that are directed at control of the neuronal apoptotic death program.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	taw@lsuhsc.edu			NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK044510, DK 44510, DK 43785, R01 DK044510-11] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK044510, P01DK043785] Funding Source: NIH RePORTER		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; ANDERSON AJ, 1995, J NEUROCHEM, V65, P1487; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aw TY, 2003, MOLECULAR BASIS FOR MICROCIRCULATORY DISORDERS, P297; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brown RH, 2001, SEMIN NEUROL, V21, P131; Buki A, 2000, J NEUROSCI, V20, P2825; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Floor E, 1998, J NEUROCHEM, V70, P268; Freemerman AJ, 2000, BIOCHEM BIOPH RES CO, V274, P136, DOI 10.1006/bbrc.2000.3091; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hartmann A, 2001, J NEUROSCI, V21, P2247; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JONES BE, 2000, AM J PHYSIOL, V278, pC693; Kalaria RN, 1999, ANN NY ACAD SCI, V893, P113, DOI 10.1111/j.1749-6632.1999.tb07821.x; Kerr DA, 2000, P NATL ACAD SCI USA, V97, P13312, DOI 10.1073/pnas.230364197; Kiechle T, 2002, NEUROMOL MED, V1, P183; Kikuchi S, 1999, J NEUROSCI RES, V57, P280, DOI 10.1002/(SICI)1097-4547(19990715)57:2<280::AID-JNR14>3.3.CO;2-L; Kitagawa A, 2003, J BIOL CHEM, V278, P12130, DOI 10.1074/jbc.M212058200; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lovell MA, 1998, NEUROLOGY, V51, P1562, DOI 10.1212/WNL.51.6.1562; Macho A, 1997, J IMMUNOL, V158, P4612; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Namura S, 1998, J NEUROSCI, V18, P3659; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Pedersen WA, 2000, FASEB J, V14, P913; Pias EK, 2002, FASEB J, V16, DOI 10.1096/fj.01-0784com; Pias EK, 2003, J BIOL CHEM, V278, P13294, DOI 10.1074/jbc.M208670200; Pias EK, 2002, CELL DEATH DIFFER, V9, P1007, DOI 10.1038/sj.cdd.4401064; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Tagami M, 1999, LAB INVEST, V79, P609; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; Tamagno E, 2003, EXP NEUROL, V180, P144, DOI 10.1016/S0014-4886(02)00059-6; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; Troy CM, 2000, J NEUROSCI, V20, P1386; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Vukosavic S, 1999, J NEUROCHEM, V73, P2460, DOI 10.1046/j.1471-4159.1999.0732460.x; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Wang TG, 2000, FASEB J, V14, P1567, DOI 10.1096/fj.14.11.1567; Weiland U, 2000, CARDIOVASC RES, V45, P671, DOI 10.1016/S0008-6363(99)00347-8; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	96	49	55	0	11	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	MAY	2004	9						1567	1576		10.2741/1357			10	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	779ZA	WOS:000189333700044	14977568				2021-06-18	
J	Wade, SL; Wolfe, CR; Pestian, JP				Wade, SL; Wolfe, CR; Pestian, JP			A Web-based family problem-solving intervention for families of children with traumatic brain injury	BEHAVIOR RESEARCH METHODS INSTRUMENTS & COMPUTERS			English	Article; Proceedings Paper	33rd Annual Meeting of the Society-for-Computers-in-Psychology	NOV   06, 2003	Vancouver, CANADA	Soc Comp Psychol			SHORT-TERM; COMPUTER; PREDICTORS; ADOLESCENTS; TELEHEALTH; ADAPTATION; DISORDERS; BEHAVIOR; INTERNET; OUTCOMES	We developed a Web-based intervention for pediatric traumatic brain injury (TBI) and examined its feasibility for participants with limited computer experience. Six families, including parents, siblings, and children with TBI, were given computers, Web cameras, and high-speed Internet access. Weekly videoconferences with the therapist were conducted after participants completed on-line interactive experiences on problem solving, communication, and TBI-specific behavior management. Families were assigned to videoconference with NetMeeting (iBOT cameras) or ViaVideo. Participants ranked the Web site and videoconferences as moderately to very easy to use. ViaVideo participants rated videoconferencing significantly more favorably relative to face-to-face meetings than did NetMeeting participants. Both the Web site and videoconferencing were rated as very helpful. All families demonstrated improved outcomes on one or more target behaviors, including increased understanding of the injury and improved parent-child relationships. All parents and siblings and all but 1 child with TBI said they would recommend the program to others. We conclude that a face-to-face intervention can be successfully adapted to the Web for families with varied computer experience.	Univ Cincinnati, Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA	Wade, SL (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02] Funding Source: Medline		Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Farmer JE, 2001, CLIN PEDIATR, V40, P93, DOI 10.1177/000992280104000205; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gega L, 2004, J CLIN PSYCHOL, V60, P147, DOI 10.1002/jclp.10241; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; GREIST JH, 1973, AM J PSYCHIAT, V130, P1327, DOI 10.1176/ajp.130.12.1327; Greist JH, 1998, PSYCHIAT SERV, V49, P887, DOI 10.1176/ps.49.7.887; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hewson CM, 1996, BEHAV RES METH INSTR, V28, P186, DOI 10.3758/BF03204763; Joinson AN, 1998, PSYCHOL INTERNET INT, P43; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kleiner KD, 2002, PEDIATRICS, V109, P740, DOI 10.1542/peds.109.5.740; Maheu MM, 2003, PSYCHOTHERAPY, V40, P20, DOI 10.1037/0033-3204.40.1-2.20; MAHEU MM, 2000, TELEHEALTHNET; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; RABASCA L, 2000, MONITOR PSYCHOL, V31, P28; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROTONDI AJ, J HEAD TRAUMA; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1997, CHILDREN ACQUIRED BR, P235; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2004, J PEDIATR PSYCHOL, V29, P269, DOI 10.1093/jpepsy/jsh035; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WADE SL, 2004, UNPUB FAMILY INTERVE; WOLFE CR, 2001, LEARNING TEACHING WO; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	43	49	49	0	7	PSYCHONOMIC SOC INC	AUSTIN	1710 FORTVIEW RD, AUSTIN, TX 78704 USA	0743-3808			BEHAV RES METH INS C	Behav. Res. Methods Instr. Comput.	MAY	2004	36	2					261	269		10.3758/BF03195572			9	Psychology, Mathematical; Psychology, Experimental	Psychology	842TH	WOS:000223026600012	15354692	Bronze			2021-06-18	
J	Fischer, S; Trexler, LE; Gauggel, S				Fischer, S; Trexler, LE; Gauggel, S			Awareness of activity limitations and prediction of performance in patients with brain injuries and orthopedic disorders	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						awareness; activity limitations; predicted performance; brain injury	IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; UNAWARENESS; DEFICITS; ADULTS	The aim of this study was to compare the accuracy of performance predictions in experimental tasks with patients' awareness of activity limitations. Participants were 24 patients with brain injuries (i.e., traumatic brain injury and cerebrovascular disorders) and 22 patients with orthopedic disorders. Prediction of performance was examined in a memory task (word list learning) and a motor task (finger tapping). Awareness of activity limitations was measured by comparing patients' self-ratings and staff ratings in the Patient Competency Rating Scale (PCRS). Results for the PCRS showed that patients with orthopedic disorders underestimated and patients with brain injuries (i.e., patients with TBI) overestimated their level of functioning in the total scale and the social/emotional subscale in comparison to staff ratings. Both patient groups agreed with staff ratings in physical/basic self-care items. In the predicted performance tasks a similar pattern could be observed: None of the groups showed an overestimation of performance in the motor task, whereas patients with brain injuries overestimated their competency in the memory task. However, the agreement between both awareness measures (PCRS, predicted performance) was only low, which indicates that they might measure different aspects or levels of self-awareness.	Univ Technol Chemnitz, Dept Psychol, D-09120 Chemnitz, Germany; Praxis Neuropsychol Rehabil Prof Fries, Munich, Germany; Community Hosp Indianapolis, Hook Rehabil Ctr, Indianapolis, IN USA; Indiana Univ, Sch Med, Bloomington, IN 47405 USA	Fischer, S (corresponding author), Univ Technol Chemnitz, Dept Psychol, D-09120 Chemnitz, Germany.	sonja.fischer@s2001.tu-chemnitz.de		Gauggel, Siegfried/0000-0002-2742-4917			Alfano MS, 2000, J CLIN PSYCHOL, V56, P975, DOI 10.1002/1097-4679(200007)56:7<975::AID-JCLP13>3.0.CO;2-Z; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BECK AT, 1996, BDI II MANUAL; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FISCHER S, 1999, Z NEUROPSYCHOLOGIE, V10, P103; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gauggel S, 2002, J CLIN EXP NEUROPSYC, V24, P1070, DOI 10.1076/jcen.24.8.1070.8377; Gauggel S, 2000, J HEAD TRAUMA REHAB, V15, P710, DOI 10.1097/00001199-200002000-00009; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Mazzoni G, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, pIX; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Robins R. W., 1997, HDB PERSONALITY PSYC, P649, DOI DOI 10.1016/B978-012134645-4/50026-3; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Trexler L, 2000, INT HDB NEUROPSYCHOL, P215; WAGNER MT, 1994, ARCH CLIN NEUROPSYCH, V9, P57, DOI 10.1016/0887-6177(94)90014-0; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wyller TB, 1996, DISABIL REHABIL, V18, P454, DOI 10.3109/09638289609165909	37	49	49	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2004	10	2					190	199		10.1017/S1355617704102051			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	780KA	WOS:000189378800005	15012839				2021-06-18	
J	Mainwaring, LM; Bisschop, SM; Green, REA; Antoniazzi, M; Comper, P; Kristman, V; Provvidenza, C; Richards, DW				Mainwaring, LM; Bisschop, SM; Green, REA; Antoniazzi, M; Comper, P; Kristman, V; Provvidenza, C; Richards, DW			Emotional reaction of varsity athletes to sport-related concussion	JOURNAL OF SPORT & EXERCISE PSYCHOLOGY			English	Article						mild traumatic brain injury; profile of mood states; recovery; athletic injury; depression; confusion; longitudinal	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSION SYMPTOMS; RECOVERY; RESPONSES; CONSEQUENCES; PERFORMANCE; PREDICTION; ADJUSTMENT; ADHERENCE	Despite suggestions that emotions influence recovery from injury, there is little research into the emotional sequelae of mild traumatic brain injury (MTBI), or "concussion," in sport. This examination compares emotional functioning of college athletes with MTBI to that of uninjured teammates and undergraduates. A short version of the Profile of Mood States (POMS; Grove & Prapavessis, 1992) assessed baseline emotions in all groups, and serial emotional functioning in the MTBI and undergraduate groups. Whereas preinjury profiles were similar across groups, the MTBI group showed a significant postinjury spike in depression, confusion, and total mood disturbance that was not seen for the other groups. The elevated mood disturbances subsided within 3 weeks postinjury. Given that concussed athletes were highly motivated to return to play, these data could be used as a benchmark of normal emotional recovery from MTBI. Findings are discussed in relation to current literature on emotional reaction to injury and directions for future research.	Univ Toronto, Fac Phys & Hlth Educ, Toronto, ON M5S 2W6, Canada; Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	Mainwaring, LM (corresponding author), Univ Toronto, Fac Phys & Hlth Educ, 55 Harbord St, Toronto, ON M5S 2W6, Canada.		Kristman, Vicki/G-8317-2011	Kristman, Vicki/0000-0001-5508-0552; Bisschop, Sean/0000-0002-3307-292X; Green, Robin/0000-0001-9451-3963			Barth JT., 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BREWER BW, 1995, CLIN J SPORT MED, V5, P241, DOI 10.1097/00042752-199510000-00006; Brewer BW, 2000, REHABIL PSYCHOL, V45, P20, DOI 10.1037/0090-5550.45.1.20; BREWER BW, 2001, COPING SPORT INJURIE, P1; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CHUTE N, 1997, THESIS QUEENS U KING; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; COMPER P, 2002, UNPUB CANADIAN INTER; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; CROSSMAN J, 1985, PERCEPT MOTOR SKILL, V61, P1131, DOI 10.2466/pms.1985.61.3f.1131; DALY JM, 1995, J SPORT REHABIL, V4, P23; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; EVANS L, 1996, J SPORTS SCI, V14, P27; FREY JH, 1991, SOCIOL SPORT J, V8, P136, DOI 10.1123/ssj.8.2.136; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green SL, 2001, J APPL SPORT PSYCHOL, V13, P40, DOI 10.1080/10413200109339003; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; GROVE JR, 1990, ANN M AUSTR SPORTS M; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1998, SPORTS RELATED CONCU, V2, P12; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johnston LH, 1998, J SPORT REHABIL, V7, P206, DOI 10.1123/jsr.7.3.206; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mainwaring L, 1999, CAN J REHABIL, V12, P145; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McDonald SA, 1990, SPORT PSYCHOL, V4, P261; McNair D.M., 1971, MANUAL PROFILE MOOD; MILLER WN, 1998, J APPL SPORT PSYCH S, V10, pS127; Morrey MA, 1999, CLIN J SPORT MED, V9, P63, DOI 10.1097/00042752-199904000-00004; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nixon H.L., 1992, J SPORT SOCIAL ISSUE, V16, P127, DOI [DOI 10.1177/019372359201600208, 10.1177/019372359201600208]; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pearson L., 1992, PHYSIOTHERAPY, V78, P762, DOI DOI 10.1016/S0031-9406(10)61642-2; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Quackenbush N., 1994, Journal of Sport Behavior, V17, P178; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; QUINN AM, 1996, THESIS U MELBOURNE; ROH J, 1998, J APPL SPORT PSYCH S, V10, pS54; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; Smith AM, 1998, MAYO CLIN PROC, V73, P17; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Terry PC, 1996, J SPORTS SCI, V14, P49; Udry E, 1997, J SPORT EXERCISE PSY, V19, P229, DOI 10.1123/jsep.19.3.229; Udry E, 1997, J SPORT EXERCISE PSY, V19, P71, DOI 10.1123/jsep.19.1.71; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	65	49	49	0	21	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0895-2779	1543-2904		J SPORT EXERCISE PSY	J. Sport Exerc. Psychol.	MAR	2004	26	1					119	135		10.1123/jsep.26.1.119			17	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Social Sciences - Other Topics; Psychology; Sport Sciences	801CF	WOS:000220073300007					2021-06-18	
J	Brookshire, B; Levin, HS; Song, JX; Zhang, LF				Brookshire, B; Levin, HS; Song, JX; Zhang, LF			Components of executive function in typically developing and head-injured children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PREFRONTAL CORTEX; BRAIN-DAMAGE; MEMORY; WORKING; PERFORMANCE; INHIBITION; ATTENTION; COGNITION; BEHAVIOR; DEFICITS	To identify the key components of executive functions (EFs) in children following traumatic brain injury (TBI), data from a series of EF tests administered to 286 pediatric TBI patients at least 3 years postinjury were subjected to an exploratory factor analysis. A 5-factor model included discourse, EFs (e.g., problem solving, planning), processing speed (e.g., coding), declarative memory, and motor speed. Confirmatory factor analysis based on data obtained from 265 pediatric TBI patients at 3 months postinjury disclosed that the 5-factor model provided a good fit to the data. A second exploratory analysis of the 3-month postinjury data disclosed a 4-factor model in which processing speed and motor speed measures loaded on a common factor. Severity of TBI and age at test had significant effects on all factors in both the 5- and 4-factor models. Adaptive functioning, as measured by the Vineland Adaptive Behavioral Scale-Revised, was moderately related to factor scores at 3 years or longer postinjury, but weakly related to factor scores obtained at 3 months postinjury. The factor scores could be used in clinical trials to facilitate data reduction and appear to have validity as indicators of TBI outcome.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Bayer Pharmaceut, Dept Biometry, West Haven, CT USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Bentler PM., 1989, EQS STRUCTURAL EQUAT; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Borkowski J. G., 1996, ATTENTION MEMORY EXE, P235; Braver TS, 2001, NEUROIMAGE, V14, P48, DOI 10.1006/nimg.2001.0791; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DELIS D, 1986, CALIFORNIA VERBAL LE; Denckla M.B., 1996, ATTENTION MEMORY EXE, P263; DENCKLA MB, 1974, CORTEX, V10, P184; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; Diamond A, 1997, MONOGR SOC RES CHILD, V62, P1; DIAMOND A, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P339; DREWE E A, 1975, Cortex, V11, P8; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Dunn L., 1981, PEABODY PICTURE VOCA; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; Gioia G.A., 2000, BEHAV RATING INVENTO; GOLDMAN PS, 1974, CNS PLASTICITY RECOV, P149; GOLDMANRAKIC PS, 1998, PREFRONTAL CORTEX EX, P87; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Graham S., 1996, ATTENTION MEMORY EXE, P349; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R., 1993, WISCONSIN CARD SORTI; HISCOCK M, 1987, BRAIN COGNITION, V6, P24, DOI 10.1016/0278-2626(87)90044-3; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; JENNETT B, 1975, LANCET, V1, P480; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Luria A. R., 1966, HIGHER CORTICAL FUNC; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Matthews C, 1964, INSTRUCTION MANUAL A; MAZZOCCO MMM, 1993, J DEV BEHAV PEDIATR, V14, P328; Miller EK, 2000, NEUROIMAGE, V11, P447, DOI 10.1006/nimg.2000.0574; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; Petrides M, 2000, EXP BRAIN RES, V133, P44, DOI 10.1007/s002210000399; PORTEUS SD, 1964, PORTEUS MAZE TEST 50; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; REYNOLDS CR, 1998, BEHAV ASSESSMENT SYS; Roberts RJ, 1996, DEV NEUROPSYCHOL, V12, P105, DOI 10.1080/87565649609540642; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; Vaughn ML, 1997, J CLIN CHILD PSYCHOL, V26, P349, DOI 10.1207/s15374424jccp2604_3; Wechsler D., 1974, WISC R MANUAL WECHSL	64	49	49	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					61	83		10.1207/s15326942dn2501&2_5			23	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700005	14984329				2021-06-18	
J	Schmidt, EA; Czosnyka, M; Steiner, LA; Balestreri, M; Smielewski, P; Piechnik, SK; Matta, BF; Pickard, JD				Schmidt, EA; Czosnyka, M; Steiner, LA; Balestreri, M; Smielewski, P; Piechnik, SK; Matta, BF; Pickard, JD			Asymmetry of pressure autoregulation after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral hemodynamics; transcranial Doppler ultrasonography autoregulation; outcome	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; TRANSCRANIAL DOPPLER; CEREBROVASCULAR REACTIVITY; PRACTICAL SCALE; MANAGEMENT; VALIDATION; GRADIENTS	Object. The aim of this study was to assess the asymmetry of autoregulation between the left and right sides of the brain by using bilateral transcranial Doppler ultrasonography in a cohort of patients with head injuries. Methods. Ninety-six patients with head injuries comprised the study population. All significant intracranial mass lesions were promptly removed. The patients were given medications to induce sedation and paralysis, and artificial ventilation. Arterial blood pressure (ABP) and intracranial pressure (ICP) were monitored in an invasive manner. A strategy based on the patient's cerebral perfusion pressure (CPP = ABP - ICP) was applied: CPP was maintained at a level higher than 70 mm Hg and ICP at a level lower than 25 mm Hg. The left and right middle cerebral arteries were insonated daily, and bilateral flow velocities (FVs) were recorded. The correlation coefficient between the CPP and FV, termed Mx, was calculated and time-averaged over each recording period on both sides. An Mx close to 1 signified that slow fluctuations in CPP produced synchronized slow changes in FV, indicating a defective autoregulation. An Mx close to 0 indicated preserved autoregulation. Computerized tomography scans in all patients were reviewed; the side on which the major brain lesion was located was noted and the extent of the midline shift was determined. Outcome was measured 6 months after discharge. The left-right difference in the Mx between the hemispheres was significantly higher in patients who died than in those who survived (0.16 +/- 0.04 compared with 0.08 +/- 0.01; p = 0.04). The left-right difference in the Mx was correlated with a midline shift (r = -0.42; p = 0.03). Autoregulation was worse on the side of the brain where the lesion was located (p < 0.035). Conclusions. The left-right difference in autoregulation is significantly associated with a fatal outcome. Autoregulation in the brain is worse on the side ipsilateral to the lesion and on the side of expansion in cases in which there is a midline shift.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Anaesthesiol, Cambridge CB2 2QQ, England; Warsaw Univ Technol, Inst Elect Syst, PL-00661 Warsaw, Poland; Hop Univ Toulouse Purpan, Serv Neurochirurg, Toulouse, France	Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, POB 167,Hills Rd, Cambridge CB2 2QQ, England.	mc141@medschl.cam.ac.uk	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011	Piechnik, Stefan K./0000-0002-0268-5221; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; ENEVOLDSEN EM, 1977, ACTA NEUROL SCAND, V56, P514; Gooskens I, 2003, ACTA NEUROCHIR, V145, P527, DOI 10.1007/s00701-003-0045-y; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Hu HH, 1999, J CEREBR BLOOD F MET, V19, P460, DOI 10.1097/00004647-199904000-00012; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MENON DK, 2000, TXB NEUROANAESTHESIA, P17; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Schmidt EA, 2001, J NEUROL NEUROSUR PS, V70, P198, DOI 10.1136/jnnp.70.2.198; SCHMIDT EA, J NEUROIMAGING, V3, P248; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Smielewski P, 1997, INT J CLIN MONIT COM, V14, P185, DOI 10.1023/A:1016901710584; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STEINER LA, 2002, J NEUROTRAUM, V19, P1301; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolfla CE, 1996, J NEUROSURG, V84, P642, DOI 10.3171/jns.1996.84.4.0642; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	43	49	49	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2003	99	6					991	998		10.3171/jns.2003.99.6.0991			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	751VX	WOS:000187111700009	14705726				2021-06-18	
J	Karmy-Jones, R; Hoffer, E; Meissner, MH; Nicholls, S; Mattos, M				Karmy-Jones, R; Hoffer, E; Meissner, MH; Nicholls, S; Mattos, M			Endovascular stent grafts and aortic rupture: A case series	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	33rd Annual Meeting of the Western-Trauma-Association	FEB 23-28, 2003	SNOWBIRD, UT	Western Trauma Assoc		endovascular stent grafts; traumatic rupture of the aorta; endoleak; operative risk	THORACIC AORTA; TRANSECTION	Background. Endovascular stent grafts (EVSGs) offer an alternative in the management of traumatic rupture of the aorta, particularly in patients who are at prohibitive operative risk. Methods We conducted at retrospective review of 11 cases managed by EVSGs over a 4-year period. EVSGs were defined as "noncommercial" (graft material hand sewn over metallic stents) or "commercial" (grafts marketed for infrarenal aortic or thoracic aneurysms). Data collected included the difference between endovascular stent graft length, tear length (apposition length), and location relative to the left subclavian artery. Results: EVSGs (three noncommercial and eight commercial, including AneuRx cuff [six], Talent [one], and Ancure aortic tube graft [one]) were used in 11 patients. Six were placed less than or equal to 8 hours from injury, cone after 14 hours, three after 5 days, and one 10 years after injury. Routes of access included femoral (four), iliac (three), and abdominal aorta (four). Average landing zone diameter was 18.8 +/- 3.5 mm, distance from the left subclavian artery was 2.85 +/- 2.1 cm, and tear length was 1.54 +/- 1.0 cm. In four cases, the apposition length was less than 2 cm. There were two cases of persistent endoleak and two cases of endoleak noted and treated at deployment. Persistent endoleak occurred in two of three noncommercial EVSGs. Endoleak occurred in three of four cases when apposition length was less than 2 cm, one of which was treated successfully at the time of placement by deploying extension grafts. Endoleak occurred in two of six cases when deployment was within 2 cm of the origin of the left subclavian artery. In one case of persistent endoleak, open repair was performed 3 weeks later when the patient had stabilized. Ultimately, there were three deaths, two caused by severe closed head injury and one caused by respiratory failure. Conclusion: Endovascular stent grafts can be placed emergently. Commercial grafts result in better results than noncommercial grafts. Available "cuff extenders" are sufficient for the majority of aortic injuries but often require deployment via the iliac or aorta because of the shorter delivery system. Tears more than 1.5 cm resulting in apposition length less than 2 cm or those near or in the curvature of the aorta are associated with increased endoleak risk. The ideal thoracic EVSG would be available in 5-, 7.5-, 10-, and 15-cm lengths and mounted on a system 80 cm in length.	Univ Washington, Harborview Med Ctr, Div Cardiothorac Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Div Intervent Radiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Div Vasc Surg, Seattle, WA 98104 USA	Karmy-Jones, R (corresponding author), Univ Washington, Harborview Med Ctr, Div Cardiothorac Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	karmy@u.washington.edu					Borsa JJ, 2002, J ENDOVASC THER, V9, P84, DOI 10.1583/1545-1550-9.sp3.84; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; Dake MD, 1998, J THORAC CARDIOV SUR, V116, P689, DOI 10.1016/S0022-5223(98)00455-3; Fujikawa T, 2001, J TRAUMA, V50, P223, DOI 10.1097/00005373-200102000-00006; Green RM, 2003, TRENDS IN VASCULAR SURGERY, P151; Hoffer EK, 2002, J VASC INTERV RADIOL, V13, P1037, DOI 10.1016/S1051-0443(07)61870-3; Kato N, 2003, J VASC SURG, V37, P100, DOI 10.1067/mva.2003.68; Kato N, 1997, RADIOLOGY, V205, P657, DOI 10.1148/radiology.205.3.9393517; Lachat M, 2002, EUR J CARDIO-THORAC, V21, P959, DOI 10.1016/S1010-7940(02)00062-3; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mattison R, 2001, J TRAUMA, V51, P326, DOI 10.1097/00005373-200108000-00016; Orford VP, 2003, ANN THORAC SURG, V75, P106, DOI 10.1016/S0003-4975(02)04331-X	12	49	50	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2003	55	5					805	810		10.1097/01.TA.0000094429.98136.29			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	744EG	WOS:000186614500001	14608148				2021-06-18	
J	Li, DZ; Margaill, I; Palmier, B; Pruneau, D; Plotkine, M; Marchand-Verrecchia, C				Li, DZ; Margaill, I; Palmier, B; Pruneau, D; Plotkine, M; Marchand-Verrecchia, C			LF 16-0687 Ms, a bradykinin B-2 receptor antagonist, reduces ischemic brain injury in a murine modelof transient focal cerebral ischemia	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						bradykinin B-2 receptor antagonist; focal cerebral ischemia; mice; neuroprotection; brain edema; inflammation	KALLIKREIN-KININ SYSTEM; PLATELET-ACTIVATING-FACTOR; CLOSED-HEAD TRAUMA; LF 16-0687 MS; TISSUE KALLIKREIN; RAT MODEL; BARRIER DISRUPTION; ENDOTHELIAL-CELLS; SENSORY NEURONS; TRANSGENIC MICE	1 Bradykinin promotes neuronal damage and brain edema through the activation of the B-2 receptor. The neuroprotective effect of LF 16-0687 Ms, a B-2 receptor antagonist, has been described when given prior to induction of transient focal cerebral ischemia in rat, but there are no data regarding the consequence of a treatment when given after injury. Therefore, in a murine model of transient middle cerebral artery occlusion (MCAO), we evaluated the effect of LF 16-0687 Ms given prior to and/or after the onset of ischemia on neurological deficit, infarct volume and inflammatory responses including cerebral edema, blood-brain barrier (BBB) disruption and neutrophil accumulation. 2 LF 16-0687 Ms (1, 2 and 4 mg kg(-1)) administered 0.5 h before and, 1.25 and 6 h after MCAO, decreased the infarct volume by a maximum of 33% and significantly improved the neurological recovery. 3 When given at 0.25 and 6.25 h after MCAO, LF 16-0687 Ms (1.5, 3 and 6 mg kg(-1)) decreased the infarct volume by a maximum of 25% and improved the neurological score. 4 Post-treatment with LF 16-0687 Ms (1.5 mg kg(-1)) significantly decreased brain edema (-28%), BBB disruption (-60%) and neutrophil accumulation (-65%) induced by ischemia. Physiological parameters were not modified by LF 16-0687 Ms. 5 These data emphasize the role of bradykinin B-2 receptor in the development of infarct lesion, neurological deficit and inflammatory responses resulting from transient focal cerebral ischemia. Therefore, B-2 receptor antagonist might represent a new therapeutic approach in the pharmacological treatment of stroke.	Univ Paris 05, Pharmacol Lab, UPRES EA 2510, F-75006 Paris, France; Ctr Rech, Labs Fournier, Daix, France	Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA 2510, 4 Ave Observ, F-75006 Paris, France.	verrecchia@pharmacie.univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; Margaill, Isabelle/ABA-4362-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Margaill, Isabelle/0000-0002-7941-6644			BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bhoola K, 2001, BIOL CHEM, V382, P77, DOI 10.1515/BC.2001.013; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bhoola KD, 1996, IMMUNOPHARMACOLOGY, V33, P247, DOI 10.1016/0162-3109(96)00067-7; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; Carl VS, 1996, IMMUNOPHARMACOLOGY, V33, P325, DOI 10.1016/0162-3109(96)00055-0; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHRISTOPHER TA, 1994, AM J PHYSIOL, V266, pH867; Costa SKP, 2002, NEUROSCI LETT, V318, P158, DOI 10.1016/S0304-3940(01)02498-3; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1990, NEW TRENDS LIPID MED, P129; FELETOU M, 1994, BRIT J PHARMACOL, V112, P683, DOI 10.1111/j.1476-5381.1994.tb13130.x; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; Gecse A, 1989, Adv Exp Med Biol, V247A, P249; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Gorlach C, 1996, PEPTIDES, V17, P1373, DOI 10.1016/S0196-9781(96)00223-9; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HAASEMANN M, 1994, BRAZ J MED BIOL RES, V27, P1739; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; HOSLI E, 1993, NEUROREPORT, V4, P159; IKEDA Y, 1994, ACTA NEUROCHIR, P119; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; KAMII H, 1994, BRAIN RES, V662, P240, DOI 10.1016/0006-8993(94)90818-4; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; KATUSIC ZS, 1993, STROKE, V24, P392, DOI 10.1161/01.STR.24.3.392; KIZUKI K, 1994, BRAIN RES, V634, P305, DOI 10.1016/0006-8993(94)91934-8; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Lehmberg J, 2000, ACT NEUR S, V76, P39; LEHMBERG J, 1998, CEREBROVASC DIS, V8, P76; Liao SL, 2001, NEUROREPORT, V12, P1943, DOI 10.1097/00001756-200107030-00034; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MAKEVNINA LG, 1994, BRAZ J MED BIOL RES, V27, P1955; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; PRUNEAU D, 2000, RESTOR NEURAL NEUROS, V16, P177; Rachinsky M, 2001, J TRAUMA, V51, P944, DOI 10.1097/00005373-200111000-00020; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V32, P39, DOI 10.1016/0162-3109(96)00007-0; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Raidoo DM, 1998, PHARMACOL THERAPEUT, V79, P105, DOI 10.1016/S0163-7258(98)00011-4; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; Rozsa Z, 1998, GASTROENTEROLOGY, V114, pA411, DOI 10.1016/S0016-5085(98)81664-8; Rydh-Rinder M, 2001, REGUL PEPTIDES, V102, P69, DOI 10.1016/S0167-0115(01)00297-X; SATOH K, 1995, THROMB HAEMOSTASIS, V74, P1335; Schulz J, 2000, ACT NEUR S, V76, P137; Schwaninger M, 1999, J NEUROCHEM, V73, P1461, DOI 10.1046/j.1471-4159.1999.0731461.x; Shigematsu S, 1999, AM J PHYSIOL-HEART C, V277, pH152; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; SORNAS R, 1972, ARCH NEUROL-CHICAGO, V26, P489, DOI 10.1001/archneur.1972.00490120029002; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; VERRECCHIA C, 2000, RESTOR NEUROL NEUROS, V16, P177; Wagner S, 2002, J NEUROL SCI, V202, P75, DOI 10.1016/S0022-510X(02)00208-3; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; WIRTH K, 1991, EUR J PHARMACOL, V205, P217, DOI 10.1016/0014-2999(91)90824-A; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6	75	49	51	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	AUG	2003	139	8					1539	1547		10.1038/sj.bjp.0705385			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	712JZ	WOS:000184795700021	12922942	Green Published			2021-06-18	
J	Rabchevsky, AG; Sullivan, PG; Fugaccia, I; Scheff, SW				Rabchevsky, AG; Sullivan, PG; Fugaccia, I; Scheff, SW			Creatine diet supplement for spinal cord injury: Influences on functional recovery and tissue sparing in rats	JOURNAL OF NEUROTRAUMA			English	Article						neuroprotection; rat; stereology; treatment	PERMEABILITY TRANSITION; CONTUSION; GROWTH; METHYLPREDNISOLONE; CYCLOCREATINE; PROTECTS; RELEASE; MODEL	Creatine-supplemented diet significantly attenuates cortical damage after traumatic brain injury in rodents. The protective mechanism likely involves maintenance of mitochondrial homeostasis. In the present study, we used two separate contusion spinal cord injury (SCI) instruments-the NYU device and the PSI Infinite Horizon (IH) impactor(R)-to assess the efficacy of creatine-supplemented diets on hind limb functional recovery and tissue sparing in adult rats. Rats were fed control versus 2% creatine-supplemented chow for 4-5 weeks prior to SCI (pre-fed), after which most resumed a control diet while some remained on a 2% creatine diet (pre & post-fed). Following long-term behavioral analysis (BBB), the amount of spared spinal cord tissue among the dietary regimen groups was assessed using stereology. Comparatively, both instruments caused similar amounts of gray matter damage while the NYU device rendered a greater loss of white matter, reflected in more severe hind limb functional deficits than with the IH impactor. Relative to the control fed groups injured with either instrument, none of the creatine fed animals showed improvements in hind limb function or white matter tissue sparing. Although creatine did not attenuate gray matter loss in the NYU cohort, it significantly spared gray matter in the IH cohort with pre-fed and pre & post-fed regimens. Such selective sparing of injured spinal cord gray matter with a dietary supplement yields a promising strategy to promote neuroprotection after SCI. The relationship between the efficacy of creatine and the magnitude of the insults is discussed.	Univ Kentucky, ScoBIRC, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat, Lexington, KY 40536 USA	Rabchevsky, AG (corresponding author), Univ Kentucky, ScoBIRC, 236 Hlth Sci Res Bldg, Lexington, KY 40536 USA.	AGRab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915			Andreassen OA, 2001, J NEUROCHEM, V77, P383, DOI 10.1046/j.1471-4159.2001.00188.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Ipsiroglu OS, 2001, LIFE SCI, V69, P1805, DOI 10.1016/S0024-3205(01)01268-1; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kreider RB, 1999, SPORTS MED, V27, P97, DOI 10.2165/00007256-199927020-00003; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Matthews RT, 1998, J NEUROSCI, V18, P156; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Mills CD, 2002, EXP NEUROL, V173, P153, DOI 10.1006/exnr.2001.7828; Mills CD, 2001, J NEUROTRAUM, V18, P1091, DOI 10.1089/08977150152693773; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Weaver LC, 2002, PROG BRAIN RES, V137, P83; Wilken B, 1998, PEDIATR RES, V43, P8, DOI 10.1203/00006450-199801000-00002; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	33	49	53	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2003	20	7					659	669		10.1089/089771503322144572			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	703KL	WOS:000184278500005	12908927				2021-06-18	
J	Raghupathi, R; Strauss, KI; Zhang, C; Krajewski, S; Reed, JC; McIntosh, TK				Raghupathi, R; Strauss, KI; Zhang, C; Krajewski, S; Reed, JC; McIntosh, TK			Temporal alterations in cellular Bax : Bcl-2 ratio following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; beta cl-2; Bax; cell death; head injury	CORTICAL IMPACT INJURY; HUMAN HEAD-INJURY; BCL-X; TRANSGENIC MICE; NEURONAL DEATH; SYMPATHETIC NEURONS; GLOBAL-ISCHEMIA; SUPPRESSOR GENE; MEMORY DEFICITS; UP-REGULATION	Cell death/survival following CNS injury may be a result of alterations in the intracellular ratio of death and survival factors. Using immunohistochemistry, Western analysis and in situ hybridization, the expression of the anti-cell death protein, Bcl-2, and the pro-cell death protein, Bax, was evaluated following lateral fluid-percussion (FP) brain injury of moderate severity (2.3-2.6 atm) in adult male Sprague-Dawley rats. By 2 h post-injury, a marked reduction of cellular Bcl-2-immunoreactivity (IR) and a mild decrease in cellular Bax IR were observed in the temporal and occipital cortices, and in the hippocampal CA3 ipsilateral to the site of impact. These decreases in Bcl-2 and Bax IR appeared to precede the overt cell loss in these regions that was evident at 24 h. Immunoblot analysis supported the immunohistochemical data, with a modest but significant reduction in the intensities of both the Bcl-2 and Bax protein bands at 2 h (p < 0.05 compared to sham levels). However, the Bax:Bcl-2 ratio increased significantly at 2 h (2.28 +/- 0.13) and remained elevated up to 7 days (2.05 +/- 0.13) post-injury compared to sham-injured control tissue (1.62 +/- 0.10, p < 0.05). Furthermore, cortical, but not hippocampal, levels of Bax protein increased by 25% (p < 0.05 compared to sham-injured controls) at 24 h post-injury, and returned to control levels by 7 days. In situ hybridization analysis of Bax mRNA revealed increased cellular grain density in the injured cortex (p < 0.05 compared to sham-injured brains), but not in the CA3 region of the injured hippocampus. No injury-induced changes in the expression of Bcl-2 mRNA were observed in any brain region. Taken together, these data suggest that the association between regional post-traumatic cell death and alterations in the cellular ratio of Bcl-2 and Bax may be, in part, due to alterations in mRNA and/or protein expression of the Bcl-2 family of proteins.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; Burnham Inst, La Jolla, CA 92037 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS038654, R01NS026818, R01NS041561] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS41561, P50-NS08803, R01 NS038654, R01-NS26818, R01 NS041561, P50 NS008803] Funding Source: Medline		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHEN J, 1996, J NEUROCHEM, V67, P1; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHESSELET MF, 1996, IN SITU HYBRIDIZATIO, P79; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FULP CT, 2000, SOC NEUR ABST, V30; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gillardon F, 1996, J NEUROSCI RES, V43, P726, DOI 10.1002/(SICI)1097-4547(19960315)43:6<726::AID-JNR9>3.3.CO;2-Z; Gillardon F, 1996, BRAIN RES, V739, P244, DOI 10.1016/S0006-8993(96)00829-3; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hassouna I, 1996, NEUROSCI LETT, V204, P85, DOI 10.1016/0304-3940(96)12323-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marin MC, 1996, ONCOGENE, V12, P2259; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYASHITA T, 1995, CELL, V80, P293; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STRAUSS KI, 1996, J NEUROTRAUM, V13, P620; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	75	49	53	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					421	435		10.1089/089771503765355504			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900003	12803975	Green Accepted			2021-06-18	
J	Hamberger, A; Huang, YL; Zhu, H; Bao, F; Ding, M; Blennow, K; Olsson, A; Hansson, HA; Viano, D; Haglid, KG				Hamberger, A; Huang, YL; Zhu, H; Bao, F; Ding, M; Blennow, K; Olsson, A; Hansson, HA; Viano, D; Haglid, KG			Redistribution of neurofilaments and accumulation of beta-amyloid protein after brain injury by rotational acceleration of the head	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid; closed head injury; cytoskeleton; diffuse axonal injury; immunocytochemistry; inertial brain trauma; neurofilament subunits	PRESSURE WAVE INJURIES; DIFFUSE AXONAL INJURY; ADULT-RAT BRAIN; PRECURSOR PROTEINS; NF-L; PHOSPHORYLATION; SUBUNITS; NEURONS; DAMAGE; IMPACT	Rotational acceleration of the head, as occurs in falls, car crashes, and sport injuries, may result in diffuse brain damage, with acute and chronic neurological and psychiatric symptoms. The present study addresses the effects of rotational trauma on the neuronal cytoskeleton, which stabilizes perikaryal, dendritic and axonal shape and function. The study focuses upon the distribution of (1) the phosphorylated form of the heavy neurofilament subunit, (2) the light neurofilament subunit, and (3) beta-amyloid, a marker for brain injury. While normally restricted to axons, the phosphorylated heavy neurofilament subunits were drastically decreased in the axons after rotational trauma. Instead, they accumulated in the neuronal perikarya, normally devoid of the phosphorylated subunit. This alteration was seen, not only in the cerebral cortex, but also in the hippocampus, the cervical spinal cord, the cerebellum, the cranial nerves and the pyramidal tract. The distribution of the light subunit of neurofilaments was also altered post trauma. Only a weak beta-amyloid immunoreactivity was detected in the brains of control animals. Promptly after the trauma, a large number of B-amyloid positive neurons appeared. Intensely co-localized immunoreactivity for the light subunit of neurofilaments and of beta-amyloid was seen 3 days after the rotational trauma axons of in the subcortical white matter and in the granule cell layer of the dentate gyrus as well as in neurons of the hypoglossal nucleus. The reported alterations in the central nervous system neurons are similar to those in the human brain after closed head injury and in chronic degenerative diseases. Regions of importance for social behavior, memory and body movement were affected.	Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Inst Clin Neurosci, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, S-41296 Gothenburg, Sweden	Hamberger, A (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, POB 420, SE-40530 Gothenburg, Sweden.						CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; HEDREEN JC, 1994, J NEUROPATH EXP NEUR, V53, P663, DOI 10.1097/00005072-199411000-00013; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KARLSSON JE, 1989, J NEUROCHEM, V53, P759, DOI 10.1111/j.1471-4159.1989.tb11770.x; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Meier J, 1999, J NEUROPATH EXP NEUR, V58, P1099, DOI 10.1097/00005072-199910000-00009; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; OMMAYA AK, 1984, BIOMECHANICS IMPACT, P117; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Pierce JES, 1996, J NEUROSCI, V16, P1083; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SELKOE DJ, 1999, ALZHEIMER DIS, P293; SHAW G, 1986, EUR J CELL BIOL, V42, P1; Siegel G.J., 1999, BASIC NEUROCHEMISTRY; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; TERRY RD, 1999, ALZHEIMER DIS, P187; Torack RM, 2001, NEUROPATH APPL NEURO, V27, P444, DOI 10.1046/j.1365-2990.2001.00355.x; VIANO DC, 1997, INT J CRASHWORTHINES, V2, P191; VOGELSBERGRAGAG.V, 1999, ALZHEIMERS DIS, P359; WANG S, 1991, BRAIN RES, V541, P334, DOI 10.1016/0006-8993(91)91034-X; WANG S, 1994, J NEUROCHEM, V62, P739; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F	46	49	52	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2003	20	2					169	178		10.1089/08977150360547080			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	652XV	WOS:000181406900004	12675970				2021-06-18	
J	Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC				Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC			Noninvasive cerebrovascular autoregulation assessment in traumatic brain injury: Validation and utility	JOURNAL OF NEUROTRAUMA			English	Article						cerebral perfusion pressure; dynamic cerebral pressure autoregulation; intracranial pressure; severe traumatic brain injury; transcranial Doppler ultrasound	BLOOD-FLOW VELOCITY; CEREBRAL AUTOREGULATION; TRANSCRANIAL DOPPLER; HEAD-INJURY; PHASE RELATIONSHIP; PRESSURE; THRESHOLDS; HUMANS	A moving correlation index (Mx-CPP) of cerebral perfusion pressure (CPP) and mean middle cerebral artery blood flow velocity (CBFV) allows continuous monitoring of dynamic cerebral autoregulation (CA) in patients with severe traumatic brain injury (TBI). In this study we validated Mx-CPP for TBI, examined its prognostic relevance, and assessed its relationship with arterial blood pressure (ABP), CPP, intracranial pressure (ICP), and CBFV. We tested whether using ABP instead of CPP for Mx calculation (Mx-ABP) produces similar results. Mx was calculated for each hemisphere in 37 TBI patients during the first 5 days of treatment. All patients received sedation and analgesia. CPP and bilateral CBFV were recorded, and GOS was estimated at discharge. Both Mx indices were calculated from 10,000 data points sampled at 57.411z. Mx-CPP > 0.3 indicates impaired CA; in these patients CPP had a significant positive correlation with CBFV, confirming failure of CA, while in those with Mx < 0.3, CPP was not correlated with CBFV, indicating intact CA. These findings were confirmed for Mx-ABP. We found a significant correlation between impaired CA, indicated by Mx-CPP and Mx-ABP, and poor outcome for TBI patients. ABP, CPP, ICP, and CBFV were not correlated with CA but it must be noted that our average CPP was considerably higher than in other studies. This study confirms the validity of this index to demonstrate CA preservation or failure in TBI. This index is also valid if ABP is used instead of CPP, which eliminates the need for invasive ICP measurements for CA assessment. An unfavorable outcome is associated with early CA failure. Further studies using the Mx-ABP will reveal whether CA improves along with patients' clinical improvement.	Univ Sydney, Dept Neurosurg, Westmead Hosp, Sydney, NSW 2145, Australia; Univ Sydney, Dept Neurol, Westmead Hosp, Sydney, NSW 2145, Australia; Univ Sydney, Dept Intens Care, Westmead Hosp, Sydney, NSW 2145, Australia; Univ Kiel, Dept Neurosurg, Kiel, Germany	Lang, EW (corresponding author), Univ Sydney, Dept Neurosurg, Westmead Hosp, CD Wing,Level 5, Sydney, NSW 2145, Australia.	keeflang@optusnet.com.au	Mehdorn, Maximilian/D-2495-2010				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Carey BJ, 2000, STROKE, V31, P2895, DOI 10.1161/01.STR.31.12.2895; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Heckmann JG, 1999, NEUROL RES, V21, P457, DOI 10.1080/01616412.1999.11740959; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; LING J, 1995, J CLIN MONITOR, V11, P123, DOI 10.1007/BF01617734; Lipsitz LA, 2000, STROKE, V31, P1897, DOI 10.1161/01.STR.31.8.1897; MCHENRY LC, 1974, STROKE, V5, P695, DOI 10.1161/01.STR.5.6.695; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; RINGELSTEIN RB, 1989, PRACTICAL GUIDE TRAN; SCHNITTGER C, 1997, NEW TRENDS CEREBRAL, P638; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; SYMON L, 1971, EUR NEUROL, V6, P11, DOI 10.1159/000114458; Wallis SJ, 1996, STROKE, V27, P2287, DOI 10.1161/01.STR.27.12.2287	29	49	53	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2003	20	1					69	75		10.1089/08977150360517191			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	641BB	WOS:000180723200006	12614589				2021-06-18	
J	Levy, YS; Merims, D; Panet, H; Barhum, Y; Melamed, E; Offen, D				Levy, YS; Merims, D; Panet, H; Barhum, Y; Melamed, E; Offen, D			Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						bone marrow stromal cells; Bcl-2; neuronal plasticity; neuron-specific enolase promoter	TRAUMATIC BRAIN INJURY; MESENCHYMAL STEM-CELLS; INTRACEREBRAL TRANSPLANTATION; DOPAMINE NEURONS; TRANSGENIC MICE; RETINOIC ACID; RAT MODEL; BCL-2; EXPRESSION; PLASTICITY	Mesenchymal stem cells in the adult bone marrow are differentiated to connective tissue, muscle, bone, cartilage, and fat cells. Recent studies in cultures, animal models, and humans demonstrated the plasticity of these cells and their capacity to express neuronal markers. However, questions were raised as to whether the neuronal phenotypes reflect transient changes or even fusion with neurons. In this study, we induced the differentiation of mouse stromal cells to neuron-like cells and observed the activation of the tissue-specific promoter of neuron-specific enolase (NSE). We used transgenic (Tg) mice that carry the antiapoptotic human bcl-2 gene, expressed only in neurons under the NSE promoter. Some previous studies have indicated that the transgene induces neuroprotection in various animal models of neurodegenerative diseases. We found that following induction, the mouse stromal cells demonstrate neuronal phenotype and express the neuronal marker, NeuN (neural nuclei protein). However, most of the stromal cells derived from the Tg mice, but not the wild type, also expressed human Bcl-2, as indicated by immunocytochemistry. Furthermore, these induced neuron-like cells were more resistant to cell death induced by dopamine. In conclusion, our experimental models showed that stromal cells might be induced to neuronal phenotypes and activate neuronal-specific promoters. Moreover, neurons targeted over expression of the human bcl-2 gene and provided high resistance against such apoptotic insults. This novel strategy reveals a new horizon in the improvement of gene therapy, based on stem cell transplantation in neurodegenerative diseases.	Tel Aviv Univ, Sackler Sch Med, Neurosci Lab, Felsenstein Med Res Ctr, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Neurol, Tel Aviv, Israel	Offen, D (corresponding author), Tel Aviv Univ, Sackler Sch Med, Neurosci Lab, Felsenstein Med Res Ctr, Rabin Med ctr Beilinson Campus,Petach Tikva, Tel Aviv, Israel.	doffen@post.tau.ac.il					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bernard R, 1997, DEV NEUROSCI-BASEL, V19, P79, DOI 10.1159/000111188; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P1; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Cicchetti F, 2002, EXP NEUROL, V177, P376, DOI 10.1006/exnr.2002.8007; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gremo F, 2000, INT J DEV NEUROSCI, V18, P271, DOI 10.1016/S0736-5748(99)00095-7; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Hochman A, 1998, J NEUROCHEM, V71, P741; Holden C, 2002, SCIENCE, V296, P2126, DOI 10.1126/science.296.5576.2126; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Lemischka I, 2002, EXP HEMATOL, V30, P848, DOI 10.1016/S0301-472X(02)00876-7; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Moore KD, 1996, MOL CHEM NEUROPATHOL, V29, P107, DOI 10.1007/BF02814996; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Offen D, 2000, J MOL NEUROSCI, V15, P167, DOI 10.1385/JMN:15:3:167; Offen D, 1997, CELL MOL NEUROBIOL, V17, P289, DOI 10.1023/A:1026390201168; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Ziv I, 1997, J NEURAL TRANSM-SUPP, P195	50	49	55	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.		2003	21	2					121	132		10.1385/JMN:21:2:121			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	738HZ	WOS:000186282300004	14593212				2021-06-18	
J	Naunheim, RS; Ryden, A; Standeven, J; Genin, G; Lewis, L; Thompson, P; Bayly, P				Naunheim, RS; Ryden, A; Standeven, J; Genin, G; Lewis, L; Thompson, P; Bayly, P			Does soccer headgear attenuate the impact when heading a soccer ball?	ACADEMIC EMERGENCY MEDICINE			English	Article						soccer; head impact; accelerometer; headgear	INJURIES; CONCUSSION; PLAYERS; HELMETS	There is increasing concern that repetitive blows to the head, such as those from heading a soccer ball, can cause measurable cognitive impairment. Reducing acceleration of impact could reduce neurologic sequelae. Objective: To measure the effectiveness of four different types of soccer headgear in reducing the acceleration of impact. Methods: A standard magnesium headform was instrumented with a triaxial accelerometer. A soccer ball was propelled at the headform at three different speeds known to occur in soccer play: 9, 12, and 15 m/sec (20, 26, and 34 mph). The main outcome was the peak acceleration of the headform associated with these impacts with and without protective headgear. Results: Peak accelerations were found in a range from 144 m/s(2) to 289 m/s(2) (14.67-29.5 G, G = 9.81 m/s(2)). Using multivariate analysis of variance (MANOVA) methods to compare the headbands and controls, there was no significant difference in the measured accelerations at the center of gravity with or without headgear (p = 0.50). However, the interaction term of headbands, pressure, and speed was significant at F = 5.51 and p = 0.00001. Using contrasts within conditions, some headbands were found to cause a decrease in peak acceleration at the highest speed and pressure. Conclusions: Currently available headgear for soccer heading shows little ability to attenuate impact during simulated soccer heading. However, statistically significant decreases are present at the highest speeds and pressures tested, suggesting the headbands may play a role in decreasing impact for more forceful blows.	Washington Univ, Sch Med, Div Emergency Med, Dept Emergency Med, St Louis, MO 63110 USA; Washington Univ, Dept Mech Engn, St Louis, MO 63110 USA; Washington Univ, Dept Biostat, St Louis, MO 63110 USA; Washington Univ, Human Performance Lab, St Louis, MO 63110 USA	Naunheim, RS (corresponding author), Washington Univ, Sch Med, Div Emergency Med, Dept Emergency Med, Campus Box 8072,660 S Euclid Ave, St Louis, MO 63110 USA.			Bayly, Philip/0000-0003-4303-0704			*ASTM, 1997, 1997 ANN BOOK ASTM S, P923; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Gadd CW, 1966, P 10 STAPP CAR CRASH; GENIN GM, 2001, P BIOM ENG SOC ANN M; GRONWALL D, 1975, LANCET, V2, P995; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCDERMOTT FT, 1982, MED J AUSTRALIA, V2, P30, DOI 10.5694/j.1326-5377.1982.tb124205.x; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; TSYVAER AT, 1991, AM J SPORTS MED, V19, P56; Versace J., 1971, REV SEVERITY INDEX; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	16	49	49	1	13	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JAN	2003	10	1					85	90		10.1197/aemj.10.1.85			6	Emergency Medicine	Emergency Medicine	632YH	WOS:000180252100014	12511322	Bronze			2021-06-18	
J	Scott, CW; Sobotka-Briner, C; Wilkins, DE; Jacobs, RT; Folmer, JJ; Frazee, WJ; Bhat, RV; Ghanekar, SV; Aharony, D				Scott, CW; Sobotka-Briner, C; Wilkins, DE; Jacobs, RT; Folmer, JJ; Frazee, WJ; Bhat, RV; Ghanekar, SV; Aharony, D			Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; SELECTIVE NONPEPTIDE INHIBITORS; SH-SY5Y NEUROBLASTOMA-CELLS; TRAUMATIC BRAIN INJURY; DEPRIVED PC12 CELLS; POTENT; DEATH; ACTIVATION; SUBSTRATE; CLEAVAGE	Caspase-3 is an intracellular cysteine protease, activated as part of the apoptotic response to cell injury. Its interest as a therapeutic target has led many to pursue the development of inhibitors. To date, only one series of nonpeptidic inhibitors have been described, and these have limited selectivity within the caspase family. Here we report the properties of a series of anilinoquinazolines (AQZs) as potent small molecule inhibitors of caspase-3. The AQZs inhibit human caspase-3 with K-i values in the 90 to 800 nM range. A subset of AQZs are equipotent against caspase-6, although most lack activity against this isoform and caspase-1, -2, -7, and -8. The AQZs inhibit endogenous caspase-3 activity toward a cell permeable, exogenously added substrate in staurosporine-treated SH-SY5Y cells. The AQZs reduce biochemical and cellular features of apoptosis that are thought to be a consequence of caspase-3 activation including DNA fragmentation, TUNEL staining, and the various morphological features that define the terminal stages of apoptotic cell death. Moreover, the AQZs also inhibit apoptosis induced by nerve growth factor withdrawal from differentiated PC12 cells. Thus, the AQZs represent a new and structurally novel class of inhibitors, some of which selectively inhibit caspase-3 and will thereby allow evaluation of the role of caspase-3 activity in various cellular models of apoptosis.	AstraZeneca Pharmaceut, Dept Lead Discovery, St Petersburg 198103, Russia; AstraZeneca Pharmaceut, Neurosci Lab, St Petersburg 198103, Russia; AstraZeneca Pharmaceut, Dept Chem, St Petersburg 198103, Russia	Scott, CW (corresponding author), AstraZeneca Pharmaceut, Dept Lead Discovery, LW208,1800 Concord Pike, St Petersburg 198103, Russia.						Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haviv R, 1997, J NEUROSCI RES, V50, P69, DOI 10.1002/(SICI)1097-4547(19971001)50:1<69::AID-JNR8>3.0.CO;2-J; JACOBS RT, Patent No. 0121598; Karanewsky DS, 1998, BIOORG MED CHEM LETT, V8, P2757, DOI 10.1016/S0960-894X(98)00498-3; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee D, 2001, J MED CHEM, V44, P2015, DOI 10.1021/jm0100537; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Liu JX, 1999, BIOORG MED CHEM LETT, V9, P3231; Lopez E, 2000, MOL BRAIN RES, V85, P61, DOI 10.1016/S0169-328X(00)00235-7; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nobel CSI, 1997, CHEM RES TOXICOL, V10, P1319, DOI 10.1021/tx970131m; Nuttall ME, 2001, DRUG DISCOV TODAY, V6, P85, DOI 10.1016/S1359-6446(00)01601-9; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Rigamonti D, 2000, J NEUROSCI, V20, P3705; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Stefanis L, 1998, J NEUROSCI, V18, P9204; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xu DG, 1999, J NEUROSCI, V19, P5026; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	32	49	53	1	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JAN	2003	304	1					433	440		10.1124/jpet.102.039651			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	626UR	WOS:000179892200053	12490620				2021-06-18	
J	Uzan, M; Albayram, S; Dashti, SGR; Aydin, S; Hanci, M; Kuday, C				Uzan, M; Albayram, S; Dashti, SGR; Aydin, S; Hanci, M; Kuday, C			Thalamic proton magnetic resonance spectroscopy in vegetative state induced by traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; MR SPECTROSCOPY; IN-VIVO; NEUROPATHOLOGY; DYSFUNCTION	Objectives: To determine whether proton magnetic resonance spectroscopy (MRS), a newer radiographic technology, would be useful in the evaluation of the thalamus of patients in vegetative states resulting from traumatic brain injury. Methods: 14 victims of severe traumatic brain injury who were in the vegetative state and whose magnetic resonance images of the thalamus were normal underwent bilateral thalamic proton (MRS) studies. The N-acetyl aspartate to creatine (NAA:Cr) and choline to creatine (Cho:Cr) ratios were obtained for each patient. The proton thalamic MRS findings of patients who were in a persistent vegetative state (n = 8) and in patients who had regained awareness after being in the vegetative state (n = 6) were compared with proton thalamic MRS findings in five healthy volunteers. Results: While conventional magnetic resonance imaging suggested that each patient had a normal thalamus, proton MRS indicated that the thalamus of each patient in the series was damaged. The NAA:Cr ratio was significantly lower in the thalami of both the patients who remained in a persistent vegetative state for the duration of the study and in those who regained awareness after being in the vegetative state (p < 0.001). In addition, NAA:Cr ratios were lower in the group of patients who remained in a persistent vegetative state than in the group of patients who regained awareness after, being in the vegetative state (p < 0.001). Conclusions: Results suggest that the NAA:Cr ratio within the thalamus is significant and that thalamic MRS may be helpful when attempting to determine the degree of severity of neuronal and axonal injury in patients in the vegetative state.	Istanbul Univ, Cerrahpasa Med Sch, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Sch, Dept Radiol, Istanbul, Turkey	Uzan, M (corresponding author), POB 5, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Uzan, Mustafa/D-6571-2019; Dashti, Reza/B-1368-2013; HANCI, MURAT/A-7976-2016	Dashti, Reza/0000-0002-2257-262X; HANCI, MURAT/0000-0001-9261-6686; Uzan, Mustafa/0000-0001-7214-380X			Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CASTAIGNE P, 1981, ANN NEUROL, V10, P127, DOI 10.1002/ana.410100204; Castillo M, 1998, NEUROIMAG CLIN N AM, V8, P733; Castillo M, 1996, AM J NEURORADIOL, V17, P1; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cecil KM, 1998, NEUROIMAG CLIN N AM, V8, P863; CELESIA GG, 1993, NEUROLOGY, V43, P1457, DOI 10.1212/WNL.43.8.1457; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; DANZE F, 1989, Neurosurgical Review, V12, P477, DOI 10.1007/BF01790694; DEMAEREL P, 1994, LANCET, V344, P1234, DOI 10.1016/S0140-6736(94)90552-5; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; FACON E, 1958, Rev Neurol (Paris), V98, P117; GADIAN DG, 1993, MAGNET RESON MED, V30, P1, DOI 10.1002/mrm.1910300102; JACOBSON KB, 1959, J GEN PHYSIOL, V43, P323, DOI 10.1085/jgp.43.2.323; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; RELKIN NR, 1990, ANN NEUROL, V28, P221; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; TALLAN HH, 1957, J BIOL CHEM, V224, P41; UZAN M, 1997, TURK NEUROSURG, V7, P60; Wang ZYJ, 1998, NEUROIMAG CLIN N AM, V8, P781; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7	39	49	55	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2003	74	1					33	38		10.1136/jnnp.74.1.33			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	632DA	WOS:000180207400010	12486263	Bronze, Green Published			2021-06-18	
J	Greiffenstein, MF; Baker, WJ; Gola, T; Donders, J; Miller, L				Greiffenstein, MF; Baker, WJ; Gola, T; Donders, J; Miller, L			The Fake Bad Scale in atypical and severe closed head injury litigants	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						Fake Bad Scale; MMPI; litigation; post-concussion syndrome; severe brain trauma	MMPI-2 VALIDITY SCALES; MCMI-II; CLAIMS	The correlational and diagnostic properties of Lees-Haley's MMPI-2 Fake Bad Scale (FBS) were examined in litigating atypical minor, litigating moderate-severe, and non-litigating moderate-severe head injury samples. Overall, the FBS was sensitive to both litigation status and nonconforming versus conforming symptom courses. The FBS appeared superior to the MMPI-2 F and F-K scales in differentiating atypical from real brain-injury outcomes. High FBS scorers also had higher scores on somatic complaining (Hs, Hy) and to a lesser degree with psychotic complaints (F, Pa, Sc). FBS showed significant associations with various neuropsychological symptom validity measures. FBS appears to capture a hybrid of infrequent symptom reporting styles with an emphasis on unauthentic physical complaints. However, FBS also correlated with documented abnormal neurological signs within a litigating moderate-severe brain-injury group. Its use as a symptom infrequency measure may have to be modified in more severe injury litigants, as some FBS items may reflect true long-term outcome in severe cerebral dysfunction. (C) 2002 Wiley Periodicals, Inc. J Clin Psychol 58: 1591-1600, 2002.	Psychol Syst Inc, Royal Oak, MI 48067 USA	Greiffenstein, MF (corresponding author), Psychol Syst Inc, Suite 103,26862 Woodward Ave, Royal Oak, MI 48067 USA.						BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; FOX DD, 1995, J CLIN PSYCHOL, V51, P42, DOI 10.1002/1097-4679(199501)51:1<42::AID-JCLP2270510108>3.0.CO;2-Z; Greene, 2000, MMPI 2 INTERPRETIVE; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GRILLO J, 1994, J CLIN PSYCHOL, V50, P651, DOI 10.1002/1097-4679(199407)50:4<651::AID-JCLP2270500424>3.0.CO;2-C; HEATON R, 1990, EXPANDED NORMS HALST; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1991, PSYCHOL REP, V68, P208; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Reitan RM., 1985, HALSTEAD REITAN NEUR; Salekin R. T., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; Van Gaasbeek JK, 2001, ARCH CLIN NEUROPSYCH, V16, P813; WOYCHYSHYN CA, 1992, J PERS ASSESS, V58, P138, DOI 10.1207/s15327752jpa5801_13	21	49	49	0	7	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	DEC	2002	58	12					1591	1600		10.1002/jclp.10077			10	Psychology, Clinical	Psychology	622EH	WOS:000179633200011	12455024				2021-06-18	
J	Mickeviciene, D; Schrader, H; Nestvold, K; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T				Mickeviciene, D; Schrader, H; Nestvold, K; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T			A controlled historical cohort study on the post-concussion syndrome	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						concussion; headache; post-concussion syndrome	TRAUMATIC BRAIN INJURY; MINOR HEAD-INJURY; POSTCONCUSSION SYNDROME; POSTTRAUMATIC HEADACHE; EXPECTATION; ETIOLOGY; MIGRAINE; SYMPTOMS; WHIPLASH; PAIN	In Lithuania, expectation of chronic symptoms after minor head injury is less than in western countries and possibilities for monetary compensation are minimal. Therefore, an opportunity exists to study the post-concussion syndrome (PCS) without several confounding factors present in western societies. We sent questionnaires about symptoms attributed to PCS to 200 subjects who had a concussion with loss of consciousness between 35 and 22 months before the study. For each study subject, a sex- and age-matched control person with minor non-head injury was identified. These controls received similar questionnaires. All the responding post-concussion patients stated that they had had acute headache after the trauma but this headache had disappeared in 96% of cases within 1 month. Headache and dizziness at the time of the questioning were not significantly more prevalent in the patients with concussion than in the controls, and there was no significant difference concerning subjective cognitive dysfunction. Scores of visual analogue scales of symptoms attributed to PCS showed no significant differences except for depression, alcohol intolerance and worry about brain injury, which were more frequent in the concussion group. No specific effect of the head injury was detected when various definitions and different constellations of core symptoms of PCS were used. These findings question the validity of the PCS as a useful clinical entity.	Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway; Red Cross Hosp, Dept Neurol, Kaunas, Lithuania; Red Cross Hosp, Traumatol Emergency Ward, Kaunas, Lithuania; Med Univ Clin, Dept Neurol, Kaunas, Lithuania; Cent Hosp Akershus, Nordbyhagen, Norway	Schrader, H (corresponding author), Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway.	harald.schrader@medisin.ntnu.no		Schrader, Harald/0000-0001-9975-1960			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALVES WM, 1990, NEUROLOGICAL SURG, P2219; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Guidetti V, 1998, CEPHALALGIA, V18, P455, DOI 10.1046/j.1468-2982.1998.1807455.x; Hasvold T, 1996, SCAND J PRIM HEALTH, V14, P92, DOI 10.3109/02813439608997077; JIN HQ, 1991, INT J EPIDEMIOL, V20, P230, DOI 10.1093/ije/20.1.230; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; Kelly JP, 1997, NEUROLOGY, V48, P581; Long C J, 1983, Psychiatr Med, V1, P35; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Obelieniene D, 1999, J NEUROL NEUROSUR PS, V66, P279, DOI 10.1136/jnnp.66.3.279; Poole GV, 1997, J TRAUMA, V42, P711, DOI 10.1097/00005373-199704000-00022; *SBU, 2000, LAKARTIDNINGEN, V97, P5493; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0	23	49	50	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	NOV	2002	9	6					581	587		10.1046/j.1468-1331.2002.00497.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	620RZ	WOS:000179547400005	12453072				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Recovery in memory function in the first year following TBI in children	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; ADOLESCENTS; MOTOR	Primary objective: To examine memory skills, at acute, 6- and 12-monthly stages, following childhood traumatic brain injury (TBI). Research design: Prospective, longitudinal, between-group design, comparing pre-injury and post-injury intellectual and memory measures, across three levels of injury severity. Methods and procedures: Investigation of memory skills in a group of 76 children who had Sustained a mild, moderate or severe TBI. Specific tests were used to measure immediate and short-term memory, and more complex multi-trial learning. Main outcomes and results: The severe TBI group exhibited greater deficits on memory tasks, irrespective of modality, in the acute, 6- and 12-month post-injury stages, in comparison to mild and moderate TBI groups. Performance was dependent on both injury severity and task demands. Conclusions: Memory difficulties are present during the acute, 6- and 12-months following childhood TB1. With a clearer understanding of the memory deficits following TBI, appropriate strategies call be taught and interventions implemented for these children.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	catroppc@cryptic.rch.unimelb.edu.au					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson V A, 1996, Appl Neuropsychol, V3, P128, DOI 10.1207/s15324826an0303&4_5; ANDERTON DJ, 1979, POWDER METALL, V22, P14, DOI 10.1179/pom.1979.22.1.14; Baddeley A, 1990, HUMAN MEMORY THEORY; BADDLEY A, 2000, HUMAN MEMORY THEORY; BARON I, 1996, PEDIAT NEUROPSYCHOLO; BJORKLUND DF, 1984, CHILDRENS THINKING D; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHORAZY AJL, 1985, HEAD INJURY REHABILI; COLOMBO M, 1994, BEHAV NEUROSCI, V108, P443, DOI 10.1037/0735-7044.108.3.443; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Cowan Nelson, 1995, ATTENTION MEMORY INT; Daniel A. E., 1983, POWER PRIVILEGE PRES; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; Harris JR, 1996, J COMMUN DISORD, V29, P79, DOI 10.1016/0021-9924(94)00035-2; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Pressley M, 1997, INTRO MEMORY DEV CHI; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Siegler R. S., 1991, CHILDRENS THINKING; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; VANZOMERON AH, 1994, CLIN NEUROPSYCHOLOGY; Walsh K., 1994, NEUROPSYCHOLOGY CLIN; WECHSLER D, 1991, MANUAL WECHSLER INTE, V111; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	39	49	49	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2002	16	5					369	384		10.1080/02699050110104444			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	553TX	WOS:000175692500001	12097221				2021-06-18	
J	DeRoss, AL; Adams, JE; Vane, DW; Russell, SJ; Terella, AM; Wald, SL				DeRoss, AL; Adams, JE; Vane, DW; Russell, SJ; Terella, AM; Wald, SL			Multiple head injuries in rats: Effects on behavior	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	31st Annual Meeting of the Western-Trauma-Association	FEB 24-MAR 01, 2001	BIG SKY, MONTANA	Western Trauma Assoc		head injury; multiple concussions	TRAUMATIC BRAIN INJURY; CHRONIC-STAGE CONTUSION; FLUID-PERCUSSION MODEL; DIFFUSE AXONAL INJURY; HISTOLOGICAL-FINDINGS; DYSFUNCTION; MECHANISMS; MEMORY	Background. Evidence suggests that mild head injuries in humans can result in cumulative damage. No investigation to date has considered the effects of multiple subacute mild head injuries in an animal model. Methods. Forty-one male Long-Evans hooded rats were trained in a Morris water maze. All animals were fitted with a hollow intracranial screw. Concussions were generated using a fluid percussion device. Animals were then evaluated in the water maze until performance returned to baseline. Control animals received no concussions. The remaining animals were randomized to receive one, two, or three concussions. Animals were allowed to return to baseline after each concussion and were then killed. Motor performance was evaluated on a balance beam both before and after concussions. Results: After one concussion, 85% of animals showed performance deviation from baseline as measured by time to reach the platform, returning to baseline within a mean of 14.0 trials. After two concussions, 48% of animals showed deviation, with a mean return to baseline of 6.8 trials. After three concussions, 25% of animals showed deviation, with a mean return to baseline of 2.3 trials. Of postconcussive animals, 42% developed new inconsistent baseline levels of performance. Balance beam performance was unaffected. Conclusion. Multiple concussions cause immediate transient impairment in spatial recognition and have extended effects on baseline performance in rats. Motor performance is not affected.	Univ Vermont, Dept Surg, Burlington, VT 05401 USA; Childrens Med Ctr, Dayton, OH USA	Vane, DW (corresponding author), Univ Vermont, Dept Surg, Fletcher 4,MCHV, Burlington, VT 05401 USA.						ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; STEIN DG, 1994, PROG BRAIN RES, V100, P203; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; UNTERHARNSCHEID.F, 1970, TEX REP BIOL MED, V28, P435; WALLER MB, 1960, PSYCHOL REP, V7, P99; WOODS PJ, 1961, PSYCHOL REP, V9, P433; Yamaki T, 1998, BRAIN RES PROTOC, V3, P100, DOI 10.1016/S1385-299X(98)00030-0; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2	21	49	51	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2002	52	4					708	714		10.1097/00005373-200204000-00017			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	540ZP	WOS:000174961000019	11956388				2021-06-18	
J	Pratico, D; Reiss, P; Tang, LX; Sung, S; Rokach, J; McIntosh, TK				Pratico, D; Reiss, P; Tang, LX; Sung, S; Rokach, J; McIntosh, TK			Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						isoprostanes; lipid peroxidation; oxidative stress; traumatic brain injury	CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ISOPROSTANES; RATS; F-2-ISOPROSTANES; GENERATION; BIOMARKERS; RADICALS; ALPHA	Traumatic brain injury is a common event associated with neurological dysfunction. Oxidative damage, may contribute to some of these pathologic changes. We used a specific and sensitive marker of lipid peroxidation, the isoprostane 8,12-iso-iPF(2alpha)-VI, to investigate whether local and also systemic lipid peroxidation were induced following lateral fluid percussion (FP) brain injury in the rat. Animals were anesthetized and subjected to lateral FP brain injury of moderate severity, or to sham injury as controls. Urine was collected before anesthesia (baseline), 6 and 24 h after injury. Blood was collected at baseline, 1, 6 and 24 h after injury. Animals were killed 24 h after surgery and their brains removed for biochemical analysis. No significant difference was observed at baseline (preinjury) for urine and plasma 8,12-iso-FF2alpha-VI levels between injured and sham-operated animals. By contrast, plasma and urinary levels increased significantly already at 1 and further increased 24 h following brain injury, when compared to sham-operated animals, Finally, compared with sham, injured animals had a significant increase in brain 8,12-iso-iPF(2alpha)-VI levels. These results demonstrate that moderate brain injury induces widespread brain lipid peroxidation, which is accompanied by a similar increase in urine and plasma. Peripheral measurement of 8,12-iso-iPF(2alpha)-VI levels after brain injury may be a reliable marker of brain oxidative damage.	Univ Penn, Ctr Expt Therapeut, Sch Med, Philadelphia, PA 19014 USA; Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19014 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Florida Inst Technol, Dept Chem, Claude Pepper Inst, Melbourne, FL 32901 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Pratico, D (corresponding author), Univ Penn, Ctr Expt Therapeut, Sch Med, BRB 2-3,Room 812,412 Curie Blvd, Philadelphia, PA 19014 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020	Rokach, Joshu/0000-0003-1814-7505	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803] Funding Source: Medline		De Zwart LL, 1999, FREE RADICAL BIO MED, V26, P202, DOI 10.1016/S0891-5849(98)00196-8; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Hou X, 2000, STROKE, V31, P516, DOI 10.1161/01.STR.31.2.516; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Povlishock J T, 1992, Hum Cell, V5, P345; Pratico D, 2001, LIPIDS, V36, pS45, DOI 10.1007/s11745-001-0681-0; Pratico D, 1998, J INVEST MED, V46, P51; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 1998, FASEB J, V12, P1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 1999, J NEUROCHEM, V73, P736, DOI 10.1046/j.1471-4159.1999.0730736.x; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.3.CO;2-0; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TORBATI D, 1991, FASEB J, V5, pA891; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	34	49	52	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2002	80	5					894	898		10.1046/j.0022-3042.2002.00777.x			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	527CY	WOS:000174169500020	11948253	Bronze			2021-06-18	
J	Behringer, W; Safar, P; Kentner, R; Wu, XR; Kagan, VE; Radovsky, A; Clark, RSB; Kochanek, PM; Subramanian, M; Tyurin, VA; Tyurina, TY; Tisherman, TA				Behringer, W; Safar, P; Kentner, R; Wu, XR; Kagan, VE; Radovsky, A; Clark, RSB; Kochanek, PM; Subramanian, M; Tyurin, VA; Tyurina, TY; Tisherman, TA			Antioxidant Tempol enhances hypothermic cerebral preservation during prolonged cardiac arrest in dogs	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral ischemia; cardiopulmonary resuscitation; DNA damage; hemorrhage; outcome; reperfusion injury	PERMEABLE RADICAL SCAVENGER; SUPEROXIDE-DISMUTASE MIMICS; CLOSED-HEAD INJURY; NITROXIDE RADICALS; CARDIOPULMONARY-RESUSCITATION; CIRCULATORY ARREST; HEMORRHAGIC-SHOCK; AORTIC FLUSH; BRAIN-DAMAGE; ISCHEMIA	The authors are systematically exploring pharmacologic preservation for temporarily unresuscitable exsanguination cardiac arrest in dogs. They hypothesized that the antioxidant Tempol improves cerebral outcome when added to aortic saline flush at the start of cardiac arrest. In study A, no drug (n = 8), Tempol 150 mg/kg (n = 4), or Tempol 300 mg/kg (n = 4) was added to 25 mL/kg saline flush at 24 degreesC (achieving mild cerebral hypothermia) at the start of 20-minute cardiac arrest. In study B, no drug (n = 8) or Tempol 300 mg/kg (n = 7) was added to 50 mL/kg saline flush at 2 degreesC (achieving moderate cerebral hypothermia) at the start of 40-minute cardiac arrest. Cardiac arrest was reversed with cardiopulmonary bypass. Mild hypothermia lasted for 12 hours, controlled ventilation was sustained to 24 hours, and intensive care was provided for up to 72 hours. In study A, overall performance category 1 or 2 (good outcome) was achieved in all eight dogs treated with Tempo] compared with three of eight dogs in the control group (P = 0.03). In study B, good outcome was achieved in all seven dogs treated with Tempol versus only two of 8 dogs in the control group (P = 0.007). In both studies, neurologic deficit scores were significantly better in the Tempol group, but not total histologic damage scores. At 72 hours, electron paramagnetic resonance spectroscopy of Tempol revealed direct evidence for its presence in the brain. Single- and double-strand DNA damage, nitrotyrosine immunostaining, total antioxidant reserve, and ascorbate acid levels were similar between groups, and thiol levels were decreased after Tempol in study B. The authors conclude that when added to aortic saline flush at the start of prolonged cardiac arrest, the antioxidant Tempol can enhance mild or moderate hypothermic cerebral preservation in terms of improved functional outcome. The mechanisms involved in this beneficial effect need further clarification.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA	Safar, P (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Tyurina, Yulia/0000-0003-0287-2091; Behringer, Wilhelm/0000-0003-2261-3193; Tyurin, Vladimir/0000-0002-3474-1697			Beaulieu C, 1998, J CEREBR BLOOD F MET, V18, P1022; Behringer W, 1999, CRIT CARE MED, V27, pA65, DOI 10.1097/00003246-199912001-00151; Behringer W, 2001, RESUSCITATION, V50, P205, DOI 10.1016/S0300-9572(01)00337-9; Behringer W, 2001, RESUSCITATION, V49, P83, DOI 10.1016/S0300-9572(00)00336-1; Behringer W, 2000, ACAD EMERG MED, V7, P1341, DOI 10.1111/j.1553-2712.2000.tb00489.x; Behringer W, 2000, ANESTHESIOLOGY, V93, P1491, DOI 10.1097/00000542-200012000-00022; BEHRINGER W, 2001, CRIT CARE MED S, V28, pA65; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bellamy R, 1996, CRIT CARE MED, V24, pS24; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; BOTHE HW, 1986, STROKE, V17, P1160, DOI 10.1161/01.STR.17.6.1160; Capone A, 1996, J TRAUMA, V40, P388, DOI 10.1097/00005373-199603000-00011; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Damiani E, 2000, FREE RADICAL BIO MED, V28, P1257, DOI 10.1016/S0891-5849(00)00242-2; Hahn SM, 1999, FREE RADICAL BIO MED, V27, P529, DOI 10.1016/S0891-5849(99)00099-4; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; Kenter K, 2000, J SHOULDER ELB SURG, V9, P1, DOI 10.1016/S1058-2746(00)80023-3; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LIVESAY JJ, 1983, ANN THORAC SURG, V36, P19, DOI 10.1016/S0003-4975(10)60643-1; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356; RADOVSKY A, 1995, STROKE, V26, P2127, DOI 10.1161/01.STR.26.11.2127; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SCHLEIEN CL, 1990, STROKE, V21, P1185, DOI 10.1161/01.STR.21.8.1185; STERZ F, 1990, STROKE, V21, P1178, DOI 10.1161/01.STR.21.8.1178; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; TYURINA YY, 1995, TOXICOL APPL PHARM, V131, P277, DOI 10.1006/taap.1995.1070; VAAGENES P, 1984, CRIT CARE MED, V12, P846, DOI 10.1097/00003246-198410000-00002; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Woods RJ, 1999, J TRAUMA, V47, P1028, DOI 10.1097/00005373-199912000-00007; Woods RJ, 2000, RESUSCITATION, V44, P47, DOI 10.1016/S0300-9572(99)00164-1; Wright RO, 1999, ANN EMERG MED, V34, P646, DOI 10.1016/S0196-0644(99)70167-8; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	40	49	49	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2002	22	1					105	117		10.1097/00004647-200201000-00013			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	505TD	WOS:000172930900013	11807400	Bronze			2021-06-18	
J	Hutchinson, PJ; O'Connell, MT; Al-Rawi, PG; Kett-White, CR; Gupta, AK; Maskell, LB; Pickard, JD; Kirkpatrick, PJ				Hutchinson, PJ; O'Connell, MT; Al-Rawi, PG; Kett-White, CR; Gupta, AK; Maskell, LB; Pickard, JD; Kirkpatrick, PJ			Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; TRANSIENT FOREBRAIN ISCHEMIA; SUBSTANTIA-NIGRA-RETICULATA; TRAUMATIC BRAIN-INJURY; IN-VIVO; NEURONAL DAMAGE; INTRACEREBRAL MICRODIALYSIS; GENERAL-ANESTHETICS; RAT HIPPOCAMPUS; GLUTAMATE	Objectives: Increases in the extracellular concentration of the excitatory amino acids glutamate and aspartate during cerebral ischaemia in patients are well recognised. Less emphasis has been placed on the concentrations of the inhibitory amino acid neurotransmitters, notably gamma-amino-butyric acid (GABA), despite evidence from animal studies that GABA may act as a neuroprotectant in models of ischaemia, The objective of this study was to investigate the concentrations of various excitatory, inhibitory and non-transmitter amino acids under basal conditions and during periods of cerebral ischaemia in patients with head injury or a subarachnoid haemorrhage. Methods: Cerebral microdialysis was established in 12 patients with head injury (n=7) or subarachnoid haemorrhage (n=5). Analysis was performed using high performance liquid chromatography for a total of 19 (excitatory, inhibitory and non-transmitter) amino acids. Patients were monitored in neurointensive care or during aneurysm clipping. Results: During stable periods of monitoring the concentrations of amino acids were relatively constant enabling basal values to be established. In six patients, cerebral ischaemia was associated with increases (up to 1350 fold) in the concentration of GABA, in addition to the glutamate and aspartate. Parallel increases in the concentration of glutamate and GABA were found (r=0.71, p<0.005). Conclusions: The results suggest that, in the human brain, acute cerebral ischaemia is not accompanied by an imbalance between excitatory and inhibitory amino acids, but by an increase in all neurotransmitter amino acids. These findings concur with the animal models of ischaemia and raise the possibility of an endogenous GABA mediated neuroprotective mechanism in humans.	Univ Cambridge, Addenbrookes Hosp, Acad Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Acad Dept Neurosurg, Box 167, Cambridge CB2 2QQ, England.	p.hutch@which.net		O'Connell, Mark/0000-0001-6272-8767	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Antkowiak B, 1999, ANESTHESIOLOGY, V91, P500, DOI 10.1097/00000542-199908000-00025; Bachli H, 1996, NEUROL RES, V18, P370; BALDWIN HA, 1994, BRIT J PHARMACOL, V112, P188, DOI 10.1111/j.1476-5381.1994.tb13050.x; Belelli D, 1999, NEUROCHEM INT, V34, P447, DOI 10.1016/S0197-0186(99)00037-6; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BOURDELAIS AJ, 1992, J NEUROCHEM, V58, P2311, DOI 10.1111/j.1471-4159.1992.tb10979.x; BULLOCK R, 1994, J NEUROSURG, V80, P595; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CAMPBELL K, 1993, BRAIN RES, V614, P241, DOI 10.1016/0006-8993(93)91041-P; CHOI DW, 1987, J NEUROSCI, V7, P357; CROSS AJ, 1991, BRIT J PHARMACOL, V104, P406, DOI 10.1111/j.1476-5381.1991.tb12443.x; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DURING MJ, 1993, LANCET, V341, P1607; FINKJENSEN A, 1992, EUR J PHARMACOL, V220, P197, DOI 10.1016/0014-2999(92)90748-S; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; Green AR, 1998, PHARMACOL TOXICOL, V83, P90, DOI 10.1111/j.1600-0773.1998.tb01449.x; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HAGBERG H, 1987, NEUROSCI LETT, V78, P311, DOI 10.1016/0304-3940(87)90379-X; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; JENNETT B, 1975, LANCET, V1, P480; JOHANSEN FF, 1991, ACTA NEUROL SCAND, V84, P1; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; Krasowski MD, 1998, MOL PHARMACOL, V53, P530; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; Matsumoto K, 1996, J CEREBR BLOOD F MET, V16, P114, DOI 10.1097/00004647-199601000-00014; MELDRUM B, 1985, BRIT J ANAESTH, V57, P44, DOI 10.1093/bja/57.1.44; Mendelowitsch A, 1998, ACTA NEUROCHIR, V140, P349, DOI 10.1007/s007010050108; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; *MRC, 1998, NEUR AC BRAIN INJ TR; NAKATA N, 1993, STROKE, V24, P458, DOI 10.1161/01.STR.24.3.458; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; Orser BA, 1998, TOXICOL LETT, V101, P217, DOI 10.1016/S0378-4274(98)00188-X; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; POTASHNER SJ, 1979, J NEUROCHEM, V32, P103, DOI 10.1111/j.1471-4159.1979.tb04516.x; RAVINDRAN J, 1994, NEUROSCI LETT, V176, P209, DOI 10.1016/0304-3940(94)90084-1; Robertson CS, 1998, NEUROL RES, V20, pS91; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHUAIB A, 1994, BRAIN RES, V666, P99, DOI 10.1016/0006-8993(94)90287-9; SHUAIB A, 1992, BRAIN RES, V590, P13, DOI 10.1016/0006-8993(92)91076-Q; SHUAIB A, 1993, EXP NEUROL, V123, P284, DOI 10.1006/exnr.1993.1160; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH SE, 1994, J NEURAL TRANSM-GEN, V97, P161, DOI 10.1007/BF01277951; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; SYDSERFF SG, 1995, BRIT J PHARMACOL, V114, P1631, DOI 10.1111/j.1476-5381.1995.tb14950.x; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; TIMMERMAN W, 1992, N-S ARCH PHARMACOL, V345, P661, DOI 10.1007/BF00164580; TORP R, 1993, EXP BRAIN RES, V96, P365, DOI 10.1007/BF00234106; UCHIYAMATSUYUKI Y, 1994, J NEUROCHEM, V62, P1074; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wahlgren NG, 1999, STROKE, V30, P21, DOI 10.1161/01.STR.30.1.21; WESTERINK BHC, 1989, N-S ARCH PHARMACOL, V339, P603, DOI 10.1007/BF00168650; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; YOU ZB, 1994, NEUROREPORT, V5, P2301, DOI 10.1097/00001756-199411000-00024; Zhang Jianjun, 1994, Chinese Medical Sciences Journal, V9, P225	78	49	55	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2002	72	1					99	105		10.1136/jnnp.72.1.99			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	506LD	WOS:000172973300019	11784833	Green Published, Bronze			2021-06-18	
J	Esselman, PC; Ptacek, JT; Kowalske, K; Cromes, GF; deLateur, BJ; Engrav, LH				Esselman, PC; Ptacek, JT; Kowalske, K; Cromes, GF; deLateur, BJ; Engrav, LH			Community integration after burn injuries	JOURNAL OF BURN CARE & REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; QUESTIONNAIRE; RETURN; WORK	Evaluation of community integration is a meaningful outcome criterion after major burn injury. The Community Integration Questionnaire (CIQ) was administered to 463 individuals with major burn injuries. The CIQ results in Total, Home Integration, Social Integration, and Productivity scores. The purposes of this study were to determine change in CIQ scores over time and what burn injury and demographic factors predict CIQ scores. The CIQ scores did not change significantly from 6 to 12 to 24 months postburn injury. Home integration scores were best predicted by sex and living situation; Social Integration scores by marital status; and Productivity scores by functional outcome, burn severity, age, and preburn work factors. The data demonstrate that individuals with burn injuries have significant difficulties with community integration due to burn and nonburn related factors. CIQ scores did not improve over time but improvement may have occurred before the initial 6-month postburn injury follow-up in this study.	Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA; Bucknell Univ, Dept Psychol, Lewisburg, PA 17837 USA; Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX USA; Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA; Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA	Esselman, PC (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.						BLADES B, 1982, J TRAUMA, V22, P872, DOI 10.1097/00005373-198210000-00012; BLALOCK SJ, 1994, J TRAUMA, V36, P508, DOI 10.1097/00005373-199404000-00009; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; ENGRAV LH, 1987, PLAST RECONSTR SURG, V79, P927, DOI 10.1097/00006534-198706000-00012; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; HELM P A, 1992, Journal of Burn Care and Rehabilitation, V13, P53, DOI 10.1097/00004630-199201000-00012; KOWALSKE K, 1998, J BURN CARE REHABIL, V19, pS150; MUNSTER AM, 1987, J TRAUMA, V27, P425, DOI 10.1097/00005373-198704000-00015; PATTERSON DR, 1993, PSYCHOL BULL, V113, P362, DOI 10.1037/0033-2909.113.2.362; Saffle Jeffrey R., 1996, Journal of Burn Care and Rehabilitation, V17, P353, DOI 10.1097/00004630-199607000-00013; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Staley Marlys, 1996, Journal of Burn Care and Rehabilitation, V17, P362, DOI 10.1097/00004630-199607000-00014; Tanttula K, 1997, BURNS, V23, P341, DOI 10.1016/S0305-4179(97)89876-2; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; Wrigley Michael, 1995, Journal of Burn Care and Rehabilitation, V16, P445	20	49	50	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0273-8481			J BURN CARE REHABIL	J. Burn Care Rehabil.	MAY-JUN	2001	22	3					221	227		10.1097/00004630-200105000-00007			7	Emergency Medicine; Rehabilitation; Surgery	Emergency Medicine; Rehabilitation; Surgery	606TP	WOS:000178749800004	11403244				2021-06-18	
J	Ding, YC; Yao, B; Lai, Q; McAllister, JP				Ding, YC; Yao, B; Lai, Q; McAllister, JP			Impaired motor learning and diffuse axonal damage in motor and visual systems of the rat following traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						motor learning; traumatic brain injury; axon degeneration; motor system; visual pathway	CLOSED-HEAD-INJURY; CONTROLLED CORTICAL IMPACT; LIGHT MICROSCOPIC RESPONSE; COGNITIVE DEFICITS; NEUROBEHAVIORAL PERFORMANCE; TERMINAL DEGENERATION; MODERATE HYPOTHERMIA; SILVER IMPREGNATION; BEHAVIORAL DEFICITS; ALCOHOL EXPOSURE	Cognitive-motor functioning or motor skill learning is impaired in humans following traumatic brain injury. A more complete understanding of the mechanisms involved in disorders of motor skill learning is essential for any effective rehabilitation. The specific goals of this study were to examine motor learning disorders, and their relationship to pathological changes in adult rats with mild to moderate closed head injury. Motor learning deficits were determined by comparing the ability to complete a series of complex motor learning tasks with simple motor activity. The extent of neuronal damage was determined using silver impregnation. At all post-injury time points (day 7 to day 14) statistically significant deficits were observed in parallel bar traversing, foot placing, ladder climbing, and rope climbing. Performance improved with time, but never reached control levels. In contrast, no deficits were found in simple motor activity skills tested with beam balance and runway traverse. Histologically, axonal degeneration was widely distributed in several brain areas that relate to motor learning, including the while matter of sensorimotor cortex, corpus callosum, striatum, thalamus and cerebellum. Additionally, severely damaged axons were observed in the primary visual pathway, including the optic chiasm, optic tract, lateral geniculate nuclei, and superior colliculus. These findings suggest that motor learning deficits could be detected in mild or moderate brain injury, and this deficit could be attributed to a diffuse axonal injury distributed both in the motor and the visual systems.	Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Educ, Div Hlth Phys Educ & Recreat, Detroit, MI USA	Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Lande Med Res Bldg,Room 48550, Detroit, MI 48201 USA.	yding@neurosurgery.wayne.edu	McAllister, James P./N-9657-2019				Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Asanuma H, 1997, NEUROREPORT, V8, pR1; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CRAIN BJ, 1988, NEUROSCIENCE, V27, P387; Croce R, 1996, PERCEPT MOTOR SKILL, V82, P507, DOI 10.2466/pms.1996.82.2.507; DING YC, 1999, J NEUROTRAUM, V16, P1004; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Du F, 1998, NEUROSCIENCE, V82, P1165; Eccles J C, 1978, Exp Brain Res, V31, P153; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GALLYAS F, 1980, STAIN TECHNOL, V55, P299, DOI 10.3109/10520298009067258; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; GALLYAS F, 1982, ACTA HISTOCHEM, V70, P99, DOI 10.1016/S0065-1281(82)80102-5; GALLYAS F, 1982, HISTOCHEMISTRY, V74, P423, DOI 10.1007/BF00493441; GALLYAS F, 1980, STAIN TECHNOL, V55, P281, DOI 10.3109/10520298009067256; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Goodlett CR, 1996, PHARMACOL BIOCHEM BE, V55, P531, DOI 10.1016/S0091-3057(96)00248-1; GORDON WA, 1985, ARCH PHYS MED REHAB, V66, P353; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Kleim JA, 1996, J NEUROSCI, V16, P4529; Klintsova AY, 1998, BRAIN RES, V800, P48, DOI 10.1016/S0006-8993(98)00495-8; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LUNDYEKMAN L, 1998, NEUROSCIENCE FUNDAME, P315; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MELCER T, 1995, NEUROTOXICOL TERATOL, V17, P103, DOI 10.1016/0892-0362(94)00058-L; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; MILLER J D, 1989, Neurosurgical Review, V12, P441; Morrison RS, 1996, J NEUROSCI, V16, P1337; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; PURVES D, 1997, NEUROSCIENCE, P329; Salthouse T.A., 1994, NEUROPSYCHOLOGY, V8, P535, DOI [DOI 10.1037/0894-4105.8.4.535, 10.1037/0894-4105.8.4.535]; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Toth Z, 1998, J NEUROSCI, V18, P4285; Toth Z, 1997, J NEUROSCI, V17, P8106	69	49	51	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					193	202		10.1179/016164101101198334			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200012	11320599				2021-06-18	
J	Martin, TA; Donders, J; Thompson, E				Martin, TA; Donders, J; Thompson, E			Potential of and problems with new measures of psychometric intelligence after traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; CLINICAL UTILITY	Objective: Examination of the concurrent and criterion validities of the General Ability Measure for Adults (GAMA) and the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) in patients with traumatic brain injury (TBI). Study Design: Correlational methods and multivariate analyses of variance. Setting: Regional rehabilitation center. Participants: Prospective series of consecutive rehabilitation referrals, including 60 adults with TBI and no confounding premorbid histories. Main Outcome Measures: GAMA and WAIS-III IQ and factor index scores were obtained within 1 year after injury and were compared with each other and with measures of injury severity. Results: GAMA and WAIS-III summary IQ scores demonstrated substantial covariance (supporting concurrent validity), but neither was sufficiently sensitive to injury severity. The WAIS-III Processing Speed (PS) index was the only measure that clearly demonstrated criterion validity. Conclusions: GAMA and WAIS-III summary IQ scores measure similar abilities but may not be sensitive to degree of injury severity in individuals with TBI. In contrast, the WAIS-III PS index appears to have promise in the evaluation of sequelae of TBI.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P345, DOI 10.1080/13854049708400463; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 1999, ARCH PHYS MED REHAB, V80, P346, DOI 10.1016/S0003-9993(99)90150-8; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Fastenau PS, 1996, J CLIN EXP NEUROPSYC, V18, P444; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton RK, 1996, J CLIN EXP NEUROPSYC, V18, P449, DOI 10.1080/01688639608409001; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; Naglieri JA, 1997, GEN ABILITY MEASURE; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	15	49	49	0	3	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2000	45	4					402	408		10.1037/0090-5550.45.4.402			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	374AC	WOS:000165321400005					2021-06-18	
J	McDonald, S				McDonald, S			Exploring the cognitive basis of right-hemisphere pragmatic language disorders	BRAIN AND LANGUAGE			English	Article							BRAIN-DAMAGED PATIENTS; CLOSED-HEAD-INJURY; PROCEDURAL DISCOURSE; COMPREHENSION; ABILITY; APPRECIATION; DEFICITS; REQUESTS; ADULTS; SKILLS	Despite considerable interest in the linguistic dimensions of right-hemisphere (RH) pragmatic language disorders, the cognitive bases for these are rarely examined. This study investigated two alternative explanations. First, RH pragmatic language disorders may reflect failure of the RH to synthesise incoming and preexisting information, verbal and visuospatial. In this case language and visuospatial performance should covary. Alternatively such disorders may reflect damage to executive control of all cognitive processing secondary to frontal system failure. In this case language and executive function would be associated. Further, in the former case, subjects should be insensitive to the plausibility of information, whereas in the latter they would be fixated by the literal meaning of information and therefore highly sensitive to plausibility. Eighteen patients with RH damage were compared to 20 marched controls on a range of language and neuropsychological tasks. Pragmatic performance was generally correlated to RH (visuospatial) function, not to executive function. Nonetheless RH patients were found to have problems ignoring plausibility. Thus the specific RH hypothesis described needs to be reconsidered. (C) 2000 Academic Press.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BENOWITZ LI, 1990, NEUROPSYCHOLOGIA, V28, P231, DOI 10.1016/0028-3932(90)90017-I; Benton A, 1989, MULTILINGUAL APHASIA; Benton A., 1994, MULTILINGUAL APHASIA; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BROOKSHIRE RH, 1984, BRAIN LANG, V21, P21, DOI 10.1016/0093-934X(84)90033-6; Brownell H, 1997, BRAIN LANG, V57, P60, DOI 10.1006/brln.1997.1834; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; BROWNELL HH, 1992, BRAIN LANG, V43, P121, DOI 10.1016/0093-934X(92)90025-A; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Corballis MC, 1997, BRAIN LANG, V57, P100, DOI 10.1006/brln.1997.1835; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P15, DOI DOI 10.1080/13854049308401883; Darby D., 1999, NEUROPSYCHOLOGY CLIN; DELIS DC, 1983, CORTEX, V19, P43, DOI 10.1016/S0010-9452(83)80049-5; DIGGS CC, 1987, BRAIN LANG, V30, P130, DOI 10.1016/0093-934X(87)90033-2; FLAVELL JH, 1975, DEV ROLE TAKING COMM; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; FRITH CD, 1993, COGNITIVE NEUROPSYCH; GARDNER H, 1975, BRAIN, V98, P399, DOI 10.1093/brain/98.3.399; GARDNER H, 1975, SHATTERED MIND PERSO; GRZYBEK P, 1993, NARRATIVE DISCOURSE; HECAEN H, 1978, CEREBRAL CORRELATES; HIER DB, 1980, APPL PSYCHOLINGUIST, V1, P279, DOI 10.1017/S0142716400000564; Hillis Trupe E., 1985, CLIN APHASIOLOGY, V15, P83; HIRST W, 1984, BRAIN LANG, V23, P26, DOI 10.1016/0093-934X(84)90003-8; Hooper, 1983, HOOPER VISUAL ORG TE; HOUGH MS, 1990, BRAIN LANG, V38, P253, DOI 10.1016/0093-934X(90)90114-V; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; JOANETTE Y, 1986, BRAIN LANG, V29, P81, DOI 10.1016/0093-934X(86)90035-0; Johnson-Laird P. N., 1983, COGNITIVE SCI LANGUA; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; KERTESZ A, 1996, BLACKWELL DICT NEURO; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; LEVY J, 1972, BRAIN, V95, P61, DOI 10.1093/brain/95.1.61; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MACKISACK EL, 1987, CLIN APHASIOLOGY, V17, P143; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCFIE J, 1975, ASSESSMENT ORGANIC I; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; MOLLOY R, 1990, DISCOURSE ABILITY BR; NEBES RD, 1974, HEMISPHERIC DISCONNE; Newcombe F., 1969, MISSILE WOUNDS BRAIN; NORTH AJ, 1986, INT J AGING HUM DEV, V23, P267, DOI 10.2190/BPF0-2BWD-BGNQ-HWCW; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; PENDLETON MG, 1982, J CLIN NEUROPSYCHOL, V4, P307, DOI 10.1080/01688638208401139; PICARD C, 1995, J INT NEUROPSYCH SOC, V1, P205; PIERCY M, 1960, BRAIN, V83, P225, DOI 10.1093/brain/83.2.225; RAO SM, 1990, NEUROBEHAVIOURAL ASP; REHAK A, 1992, BRAIN LANG, V42, P320, DOI 10.1016/0093-934X(92)90104-M; RIVERS DL, 1980, BRAIN LANG, V10, P348, DOI 10.1016/0093-934X(80)90061-9; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; ROMAN M, 1987, BRAIN LANG, V31, P151, DOI 10.1016/0093-934X(87)90066-6; SCHNEIDERMAN EI, 1988, BRAIN LANG, V34, P38, DOI 10.1016/0093-934X(88)90123-X; SCHNEIDERMAN EI, 1992, BRAIN LANG, V43, P107, DOI 10.1016/0093-934X(92)90024-9; SERGENT J, 1988, HDB NEUROPSYCHOLOGY, V1; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; TOMPKINS CA, 1987, BRAIN COGNITION, V6, P361, DOI 10.1016/0278-2626(87)90133-3; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; ULATOWSKA HK, 1983, BRAIN LANG, V18, P315, DOI 10.1016/0093-934X(83)90023-8; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; ULATOWSKA HK, 1986, BRAIN LANG, V28, P24, DOI 10.1016/0093-934X(86)90088-X; ULATOWSKA HK, 1990, DISCOURSE ABILITY BR; ULATOWSKA HK, 1988, NEUROPSYCHOLOGICAL S; VANLANCKER D, 1991, BRAIN COGNITION, V17, P64, DOI 10.1016/0278-2626(91)90067-I; WAPNER W, 1981, BRAIN LANG, V14, P15, DOI 10.1016/0093-934X(81)90061-4; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEINSTEIN EA, 1971, J PSYCHIATR RES, V8, P1; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Winner E., 1977, BRAIN, V100, P719	86	49	53	0	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	OCT 15	2000	75	1					82	107		10.1006/brln.2000.2342			26	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	365LN	WOS:000089952900006	11023640				2021-06-18	
J	Chapman, SB; McKinnon, L				Chapman, SB; McKinnon, L			Discussion of developmental plasticity: Factors affecting cognitive outcome after pediatric traumatic brain injury	JOURNAL OF COMMUNICATION DISORDERS			English	Article						pediatric traumatic brain injury; language; developmental plasticity; cognition; long-term outcome	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; DISCOURSE; SYSTEMS; REORGANIZATION	Current research on plasticity has altered the over simplistic view of greater capacity in the developing brain after injury. In another paper in this issue, Dennis provides a model to elucidate the complexity uf the multiple factors that influence recovery after brain injury in children. The authors present a brief summary of findings from their longitudinal research in neurobehavioral recovery after traumatic brain injury in children and adolescents that elaborates on the framework of Dennis. The discussion highlights the psychobiological factors that interact to define developmental plasticity and outlines promising directions for future research to elucidate and promote long-term recovery in pediatric brain-injured populations. (C) 2000 by Elsevier Science Inc.	Univ Texas, Callier Ctr Commun Disorders, Brain Res & Treatment Ctr, Dallas, TX 75235 USA	Chapman, SB (corresponding author), Univ Texas, Callier Ctr Commun Disorders, Brain Res & Treatment Ctr, 1966 Inwood Rd, Dallas, TX 75235 USA.	schapman@utdallas.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS21889-16] Funding Source: Medline		Anderson SW, 1999, NAT NEUROSCI, V2, P1032; BATES E, 1992, AC APH M TOR ONT CAN; Booth JR, 1999, PROG NEURO-PSYCHOPH, V23, P669, DOI 10.1016/S0278-5846(99)00025-1; BROOKSHIRE BL, IN PRESS J INT NEURO; BUCHWALD JS, 1990, CLIN PERINATOL, V17, P57; CASE R, 1982, J EXP CHILD PSYCHOL, V33, P386, DOI 10.1016/0022-0965(82)90054-6; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1997, M AM ASS ADV SCI 199; CHAPMAN SB, 1995, CONSEQUENCES TRAUMAT, P95; CHAPMAN SB, 1996, M AM ASS ADV SCI BAL; CHAPMAN SB, 1999, BRAIN DAM B, P235; Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0; CULHANE KA, 1993, THESIS U HOUSTON HOU; Edeline JM, 1999, PROG NEUROBIOL, V57, P165, DOI 10.1016/S0301-0082(98)00042-2; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Greenough WT, 1999, NAT NEUROSCI, V2, P203, DOI 10.1038/6300; HERTZPANNIER L, 1999, J NEURORADIOLOGY S, V26; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, IN PRESS NEUROLOGY, V54, P647; LEVIN HS, 2000, UNPUB WORD FLUENCY R; LEVIN HS, 1995, 3 INT NEUR S TOR ONT; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; MCKINNON L, 1999, NATL AC NEUR ABSTR, pC81; PENNINGTON BF, 1994, WORKING MEMORY FUNCT; REINIS S, 1980, DEV BRAIN; SPINELLI DN, 1990, CLIN PERINATOL, V17, P77; STEIN DG, 1995, BRAIN REPAIR; Taylor H., 1995, RECOVERY TRAUMATIC B, P188; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500	34	49	50	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2000	33	4					333	344		10.1016/S0021-9924(00)00029-0			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	354AQ	WOS:000089308000006	11001160				2021-06-18	
J	Morrison, B; Meaney, DF; Margulies, SS; McIntosh, TK				Morrison, B; Meaney, DF; Margulies, SS; McIntosh, TK			Dynamic mechanical stretch of organotypic brain slice cultures induces differential genomic expression: Relationship to mechanical parameters	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article; Proceedings Paper	Bioengineering Conference	JUN 16-20, 1999	BIG SKY, MONTANA			genomic expression; in vitro model; traumatic brain injury; stretch injury; cDNA array	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; GROWTH-FACTOR; RAT-BRAIN; ENDOTHELIAL-CELLS; NEURONAL INJURY; C-FOS; MODEL; APOPTOSIS; TRAUMA	Although the material properties of biological tissues are reasonably well established recent studies have suggested that the biological response of brain tissue and its constituent cells may also be viscoelastic and sensitive to both the magnitude and rate of a mechanical stimulus. Given the potential involvement of changes in gene expression lit the pathogenic sequelae after head trauma, we analyzed thr expression of 22 genes related to cell death and survival and found that a number of these genes were differentially regulated after mechanical stretch of nil organotypic br-ain slice culture. Twenty-four hours after stretch, the expression of DNF, NGF, and TrkA was significantly increased, whereas that of bcl-2, CREB, and GAD(65) was significantly decreased (MANOVA followed by ANOVA, p < 0.05). Expression of CREB and GAD(65) was negatively correlated with strain, whereas expression of APP695 was negatively correlated,vith strain rate (all p < 0.05). This study demonstrates that a subset of genes involved in cell death and survival are differentially regulated after dynamic stretch in vitro and that the expression of specific genes is correlated with mechanical parameters of that stretch.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Morrison, B (corresponding author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.		Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		Allen SP, 1997, HYPERTENSION, V30, P203, DOI 10.1161/01.HYP.30.2.203; CARGILL RS, 1996, J NEUROTRAUM, V13, P396; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chow N, 1998, P NATL ACAD SCI USA, V95, P9620, DOI 10.1073/pnas.95.16.9620; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Conti AC, 1998, J NEUROSCI, V18, P5663; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HUMMEL TJ, 1971, PSYCHOL BULL, V76, P49, DOI 10.1037/h0031323; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Liu FQ, 1996, SURF REV LETT, V3, P157, DOI 10.1142/S0218625X96000310; LYALL F, 1994, J HYPERTENS, V12, P1139; MACKLER SA, 1993, MOL PHARMACOL, V44, P308; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; PAUWELS PJ, 1989, MOL PHARMACOL, V36, P525; PLEASURE SJ, 1989, J NEUROSCI, V9, P698; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; STEVENS J, 1986, APPL MULTIVARIATE ST, P51; Sumpio Bauer E., 1997, American Journal of Physiology, V273, pC1441; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Zhang ZH, 1999, ANN BIOMED ENG, V27, P419, DOI 10.1114/1.203	43	49	50	0	6	ASME-AMER SOC MECHANICAL ENG	NEW YORK	THREE PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731			J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JUN	2000	122	3					224	230		10.1115/1.429650			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	404QB	WOS:000167111000004	10923289				2021-06-18	
J	Jaworski, DM				Jaworski, DM			Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury	CELL AND TISSUE RESEARCH			English	Article						glia; glioma; pituitary adenylate cyclase-activating polypeptide; reactive gliosis; receptor; vasoactive intestinal peptide; traumatic brain injury; rat (Sprague Dawley); human	VASOACTIVE-INTESTINAL-PEPTIDE; TERMINAL EXTRACELLULAR DOMAIN; HUMAN NEUROBLASTOMA-CELLS; MOLECULAR-CLONING; DIFFERENTIAL EXPRESSION; FUNCTIONAL EXPRESSION; TISSUE DISTRIBUTION; INTERLEUKIN-6 IL-6; UP-REGULATION; I RECEPTOR	Pituitary adenylate cyclase-activating polypeptide (PACAP) is a bioactive peptide with diverse activities in the nervous system. In addition to its more classic role as a neurotransmitter, PACAP functions as a neurotrophic factor. PACAP exerts these activities by binding to PACAP-selective (PAC1) or nonselective (VPAC1, VPAC2) receptors (-R). Glial cells also exhibit PACAP binding, which is associated with the increased proliferation of astrocytes. The present report demonstrates a distinct spatiotemporal regulation of PACAP, PAC1-R, VPAC1-R, and VPAC2-R expression in primary cultured rat astrocytes. To determine the role of PACAP and PAC1-R expression on glial proliferation, two in vivo models were examined - human brain tumors of glial origin and the reactive gliosis induced by a penetrating stab wound to the mature rat brain. Relative to normal human brain, PAC1-R expression is significantly upregulated in glioma, particularly oligodendrogliomas. While similar polymerase chain reaction (PCR) analysis does not detect PACAP expression, in situ hybridization studies reveal PACAP expression in a limited number of cells within the tumor. In sharp contrast, neither PACAP nor PAC1-R expression are upregulated consequent to injury. These results suggest a distinct role for PACAP and PAC1-R in glioma development and nervous system response to injury.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA	Jaworski, DM (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, Given C454, Burlington, VT 05405 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35874] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035874] Funding Source: NIH RePORTER		ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Banks WA, 1996, ANN NY ACAD SCI, V805, P270; BARRES BA, 1991, J NEUROSCI, V11, P3685; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; Brandenburg CA, 1997, J NEUROSCI, V17, P4045; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; BRENNEMAN DE, 1987, J CELL BIOL, V104, P1603, DOI 10.1083/jcb.104.6.1603; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Ciani E, 1999, MOL BRAIN RES, V69, P290, DOI 10.1016/S0169-328X(99)00116-3; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DEUTSCH PJ, 1993, J NEUROSCI RES, V35, P312, DOI 10.1002/jnr.490350311; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Gillardon F, 1998, MOL BRAIN RES, V61, P207, DOI 10.1016/S0169-328X(98)00202-2; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; Grimaldi M, 1999, EUR J NEUROSCI, V11, P2767, DOI 10.1046/j.1460-9568.1999.00693.x; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOSOYA M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P199, DOI 10.1016/0167-4781(92)90488-L; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; Larsen JO, 1997, MOL BRAIN RES, V46, P109, DOI 10.1016/S0169-328X(96)00279-3; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; Ma W, 1999, NEUROSCIENCE, V93, P335, DOI 10.1016/S0306-4522(99)00145-1; MAY V, 1995, J NEUROCHEM, V65, P978; Moller K, 1997, BRAIN RES, V775, P166, DOI 10.1016/S0006-8993(97)00923-2; Moroo I, 1998, BRAIN RES, V795, P191, DOI 10.1016/S0006-8993(98)00291-1; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROBBERECHT P, 1994, PEPTIDES, V15, P661, DOI 10.1016/0196-9781(94)90092-2; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SUZUKI N, 1994, EUR J BIOCHEM, V223, P147, DOI 10.1111/j.1432-1033.1994.tb18976.x; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; TATSUNO I, 1991, PEPTIDES, V12, P617, DOI 10.1016/0196-9781(91)90110-B; Tatsuno I, 1996, ANN NY ACAD SCI, V805, P482; Vertongen P, 1997, NEUROPEPTIDES, V31, P409, DOI 10.1016/S0143-4179(97)90033-0; Vertongen P, 1996, NEUROPEPTIDES, V30, P491, DOI 10.1016/S0143-4179(96)90015-3; VERTONGEN P, 1995, PEPTIDES, V16, P713, DOI 10.1016/0196-9781(95)00036-J; Vertongen P, 1996, J CELL PHYSIOL, V167, P36, DOI 10.1002/(SICI)1097-4652(199604)167:1<36::AID-JCP4>3.0.CO;2-D; Villalba M, 1997, J NEUROSCI, V17, P83; WASCHEK JA, 1995, DEV NEUROSCI-BASEL, V17, P1, DOI 10.1159/000111268; Zhang YZ, 1998, NEUROREPORT, V9, P2833, DOI 10.1097/00001756-199808240-00027; Zhang YZ, 1996, NEUROSCIENCE, V74, P1099, DOI 10.1016/S0306-4522(96)00168-6; Zhou XR, 1999, J NEUROSCI RES, V57, P953, DOI 10.1002/(SICI)1097-4547(19990915)57:6<953::AID-JNR21>3.3.CO;2-I; Zupan V, 1998, J NEUROCHEM, V70, P2165	55	49	50	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0302-766X			CELL TISSUE RES	Cell Tissue Res.	MAY	2000	300	2					219	230		10.1007/s004410000184			12	Cell Biology	Cell Biology	321KZ	WOS:000087455800002	10867818				2021-06-18	
J	Lombroso, CT				Lombroso, CT			Can early postnatal closed head injury induce cortical dysplasia?	EPILEPSIA			English	Article						cortical microdysplasia; perinatal head trauma; epileptogenesis	NEURONAL MIGRATION DISORDERS; CEREBRAL-CORTEX; EPILEPSY; MICROGYRIA; MODEL; MALFORMATIONS; PATHOGENESIS; LESIONS; PERIOD; BRAIN	Purpose: Increased availability of surgically resected epileptogenic tissues reveals often unsuspected cortical dysplasia (CD). There is some controversy about the ontogenic stages in which these occur. Although most take place during neuroblast proliferation and migration, there is some evidence for some CD occurring during postmigrational intrinsic cortical organization. It has been shown that various kinds of focal cortical manipulations in rats, if performed within 3-4 postnatal days, lead to the genesis of various cortical malformations including a four-layered microgyrus or an unlayered CD. It is not known whether such events also might occur in the human brain. Methods: Two children sustained minor head trauma within 3-4 postnatal days and later developed intractable epilepsy, which was relieved by surgery. Neuropathologic analysis of the resected tissues revealed an unsuspected microdysplastic cortex immediately adjacent to a focal, modest meningeal fibrosis, presumably secondary to the old closed head trauma. Results: The main histologic features were a disorganized, unlayered cortex; abnormal clusters of neurons, often with complex, randomly oriented proximal dendritic patterns with absent apical orientation; the presence of a number of heterotopic small and large neurons in the white matter; absence of inflammatory infiltrates, of hemosiderine, of reactive gliosis, or of an excessive number of blood vessels. The morphologic features in these surgical specimens suggest that these focal malformations occur because of a regional disorder of postmigrational intrinsic cortical remodeling. Conclusions: The clinical histories and the pathologic findings lend some support to the hypothesis that minor morbid events occuring in the immediate postnatal period may lead to microdysplasia in the human similar to those induced in rat pups. The animal model could be helpful to clarify the genesis of some cases of CD and of the epileptogenicity often manifesting later in life.	Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Lombroso, CT (corresponding author), 319 Longwood Ave, Boston, MA 02115 USA.						BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; Battaglia G, 1996, EPILEPSY RES, V26, P49, DOI 10.1016/S0920-1211(96)00039-3; Bielschowsky M., 1923, J PSYCHOL NEUROL, V30, P29; BREDICK N, 1981, SOC NEUR ABSTR, V7, P153; CAVINESS VS, 1982, DEV BRAIN RES, V4, P293, DOI 10.1016/0165-3806(82)90141-9; COWEN D, 1970, J NEUROPATH EXP NEUR, V29, P21, DOI 10.1097/00005072-197001000-00003; DUONG T, 1994, ACTA NEUROPATHOL, V87, P493, DOI 10.1007/BF00294176; DVORAK K, 1977, ACTA NEUROPATHOL, V38, P203; ECLIN FA, 1952, ELECTROENCEPHALOGR C, V4, P147; EVRARD P, 1982, NAISSANCE CERVEAU, P49; FERRER I, 1993, EXP BRAIN RES, V94, P261; FERRER I, 1991, ANAT EMBRYOL, V184, P517, DOI 10.1007/BF01236058; FERRER I, 1992, ACTA NEUROPATHOL, V83, P647, DOI 10.1007/BF00299415; FERRER I, 1993, CHILD NERV SYST, V9, P403, DOI 10.1007/BF00306193; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; HUMPHREYS P, 1991, J NEUROPATH EXP NEUR, V50, P145, DOI 10.1097/00005072-199103000-00006; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; Kemper TL, 1984, CEREBRAL DOMINANCE B, P75; Kuzniecky RI, 1996, J CLIN NEUROPHYSIOL, V13, P468, DOI 10.1097/00004691-199611000-00002; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; MATTIA D, 1995, NEUROLOGY, V45, P1391, DOI 10.1212/WNL.45.7.1391; MCBRIDE MC, 1982, ACTA NEUROPATHOL, V57, P93, DOI 10.1007/BF00685375; MEENCKE HJ, 1985, EPILEPSIA, V26, P368, DOI 10.1111/j.1528-1157.1985.tb05665.x; MEENCKE HJ, 1995, TYPICAL ABSENCES REL, P122; MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001; PALMINI A, 1994, EPILEPSIA, V35, P965, DOI 10.1111/j.1528-1157.1994.tb02541.x; PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410; Rojiani AM, 1996, J NEUROPATH EXP NEUR, V55, P178, DOI 10.1097/00005072-199602000-00006; SARNAT HB, 1991, CAN J NEUROL SCI, V18, P196, DOI 10.1017/S0317167100031668; SARNAT HB, 1987, AM J DIS CHILD, V141, P969, DOI 10.1001/archpedi.1987.04460090046022; Spreafico R, 1998, NEUROLOGY, V50, P27, DOI 10.1212/WNL.50.1.27; SUZUKI M, 1991, ACTA NEUROPATHOL, V82, P93, DOI 10.1007/BF00293950; TAYLOR DC, 1975, PSYCHOL MED, V5, P249, DOI 10.1017/S0033291700056609; TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369; URICH H, 1976, GREENFIELDS NEUROPAT, P361	35	49	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0013-9580			EPILEPSIA	Epilepsia	FEB	2000	41	2					245	253		10.1111/j.1528-1157.2000.tb00148.x			9	Clinical Neurology	Neurosciences & Neurology	282RH	WOS:000085231900019	10691125	Bronze			2021-06-18	
J	Nybo, T; Koskiniemi, M				Nybo, T; Koskiniemi, M			Cognitive indicators of vocational outcome after severe traumatic brain injury (TBI) in childhood	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; AGE; PRESCHOOLERS; INFANTS	Recent studies suggest that plasticity does not benefit outcome when diffuse cerebral pathology of the young child's brain is concerned. Thirty-three patients with severe traumatic brain injury (TBI) at preschool age were followed-up until adulthood. After the age of 18 years, a thorough neurological, neuropsychological and social evaluation, including detailed patient history and assessment of identity, was made by the team. When the youngest patients were 21 years old, the study was completed, with a questionnaire assessing employment status and ability to live independently. Twenty-seven per cent of the patients worked full time, 21% had subsidised work, 37% lived independently at home and 15% needed help with every-day functions. Tests measuring speed, executive and memory functions were significantly associated with vocational outcome, as was the sense identity, which was independent of the test scores. The results support the recent reports on the vulnerability of a young child's brain to early trauma. The study also strongly suggests that the final assessment of outcome after childhood TBI should be done in adulthood.	Finnish Inst Occupat Hlth, Dept Occupat Med, Brain Work Lab, Helsinki 00250, Finland; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland	Nybo, T (corresponding author), Finnish Inst Occupat Hlth, Dept Occupat Med, Brain Work Lab, Topeliuksenkatu 41 A A, Helsinki 00250, Finland.	taina.nybo@occuphealth.fi					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; GURLAND BJ, 1972, ARCH GEN PSYCHIAT, V27, P259; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; SMITH A, 1983, J CONSULT CLIN PSYCH, V51, P768, DOI 10.1037/0022-006X.51.5.768; Starr L B, 1982, Soc Work Res Abstr, V18, P28; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	28	49	49	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	1999	13	10					759	766					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800002	10576460				2021-06-18	
J	Bigler, ED				Bigler, ED			Neuroimaging in pediatric traumatic head injury: Diagnostic considerations and relationships to neurobehavioral outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						computed tomography (CT); fMRI; magnetic resonance (MR) imaging; MEG; MRS; neuroimaging; SPECT; traumatic brain injury	BRAIN INJURY; ENLARGEMENT; CHILDREN; ATROPHY; MEMORY; MR	Contemporary neuorimaging techniques in child traumatic brain injury are reviewed, with an emphasis on compurerized tomography (CT) and magnetic resonance (,MR) imaging. A brief overview of MR spectroscopy (MRS), functional MR imaging (fMRI), single-photon emission computed tomography (SPECT), and magnetoencephalography (MEG) is also provided because these techniques will likely constitute important neuroimaging techniques of the future. Numerous figures are provided to illustrate the multifaceted maimer in which traumatic deficits can be imaged and the rule of neuroimaging information as it relates to TBI outcome.	Brigham Young Univ, Dept Psychol, Provo, UT 84604 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 Spencer W Kimball Tower, Provo, UT 84604 USA.						Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BERRY M, 1998, CNS INJURIES CELLULA; Bigler E, 1997, DIAGNOSTIC CLIN NEUR; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIGLER ED, 1996, NEUROIMAGING, V1; BIGLER ED, 1996, NEUROIMAGING, V2; BIGLER ED, 1997, CHILDHOOD TRAUMATIC; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gean A, 1994, IMAGING HEAD TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Graham DI, 1996, NEUROTRAUMA, P43; Hopkins RO, 1997, NEUROPSYCHOL REV, V7, P87, DOI 10.1023/B:NERV.0000005946.46506.a9; JESSELL T, 1991, PRINCIPLES NEURAL SC, P259; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEWINE JD, 1995, FUNCTIONAL BRAIN IMA, P369; MARION DW, 1999, TRAUMATIC BRAIN INJU; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Orrison WW, 1995, FUNCTIONAL BRAIN IMA; Osborn AG, 1994, DIAGNOSTIC NEURORADI; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Prichard JW, 1998, NEUROSCIENTIST, V4, P231, DOI 10.1177/107385849800400411; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RYSER DK, 1996, INT PERSPECTIVES TRA, P79; SANDERS JA, 1995, FUNCTIONAL BRAIN IMA, P419; SOWELL ER, 1996, NEUROIMAGING, V1; THATCHER RW, 1994, FUNCTIONAL NEUROIMAG; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0	43	49	49	2	7	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1999	14	4					406	423		10.1097/00001199-199908000-00009			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	224LW	WOS:000081901400010	10407213				2021-06-18	
J	Engelborghs, K; Verlooy, J; Van Reempts, J; Van Deuren, B; Van De Ven, M; Borgers, M				Engelborghs, K; Verlooy, J; Van Reempts, J; Van Deuren, B; Van De Ven, M; Borgers, M			Temporal changes in intracranial pressure in a modified experimental model of closed head injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; intracranial pressure; experimental model; neurotrauma; diffuse axonal injury; histological study; rat	TRAUMATIC BRAIN INJURY; AXONAL INJURY; EDEMA; RATS	Object. The authors describe an experimental model of closed head injury in rodents that was modified from one developed by Marmarou and colleagues. This modification allows dual control of the dynamic process of impact compared with impulse loading that occurs at the moment of primary brain injury. The principal element in this weight-drop model is an adjustable table that supports the mt at the moment of impact from weights positioned at different heights (accelerations). The aim was to obtain reproducible pathological intracranial pressure (ICPs) while maximally reducing the incidence of mortality and skull fractures. Methods. Intracranial pressure was investigated in different experimental settings, including two different rat strains and various impact-acceleration conditions and posttrauma survival times. Identical impact-acceleration injuries produced a considerably higher mortality rate in Wistar rats than in Sprague-Dawley rats (5% and 0%, respectively). Gradually increasing severity of impact-acceleration conditions resulted in findings of a significant correlation between the degree of traumatic challenge and increased ICP at 4 hours (p < 0.001, R-2 = 0.73). When the impact-acceleration ratio was changed to result in a more seven head injury, the ICP at 4, 24, and 72 hours was significantly elevated in comparison with that seen in sham-injured rats (4 hours: 19.7 +/- 2.8 mm Hg, p = 0.004; 24 hours: 21.8 +/- 1.1 mm Hg, p = 0.002; 72 hours: 11.9 +/- 2.5 mm Hg, p = 0.009). Comparison of the rise in ICP between moderate and severe impact-acceleration injury at 4 and 24 hours revealed a significantly higher value after severe injury (4 hours: p = 0.008; 24 hours: p = 0.004). Continuous recordings showed that ICP mounted very rapidly to peak values, which declined gradually toward a pathological level dependent on the severity of the primary insult. Histological examination after severe trauma revealed evidence of irreversible neuronal necrosis, diffuse axonal injury, petechial bleeding, glial swelling, and perivascular edema. Conclusions. This modified closed head injury model mimics several clinical features of traumatic injury and produces reliable, predictable, and reproducible ICP elevations with concomitant morphological alterations.	Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; Janssen Res Fdn, Dept Life Sci Neuropathol, B-2340 Beerse, Belgium	Engelborghs, K (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.						Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engelborghs K, 1997, ACT NEUR S, V70, P123; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; STALHAMMAR D, 1987, BRAIN INJURY, V1, P93; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	24	49	50	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1998	89	5					796	806		10.3171/jns.1998.89.5.0796			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168TE	WOS:000078708100015	9817418				2021-06-18	
J	Max, JE; Castillo, CS; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Arndt, S				Max, JE; Castillo, CS; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Arndt, S			Posttraumatic stress symptomatology after childhood traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							SCHOOL-AGE CHILDREN; MAJOR DEPRESSION; HEAD-INJURY; DISORDER; ADOLESCENTS; POPULATION; RELIABILITY; SCALE	The purpose of this study was to quantify and to identify predictors of posttraumatic stress disorder (PTSD) symptomatology after traumatic brain injury (TBT). Fifty children aged 6 to 14 years, hospitalized after TBI, were assessed soon after TBI regarding injury severity and preinjury psychiatric, socioeconomic, family functioning, and family psychiatric history status; neuroimaging was also analyzed. Psychiatric assessments were repeated 3, 6, 12, and 24 months after TBI. Only 2 of 46 (4%) subjects with at least one follow-up assessment developed PTSD. However, the frequency with which subjects experienced at least one PTSD symptom ranged from 68% in the first 3 months to 12% at 2 years in assessed children. The presence of an internalizing disorder at time of injury followed by greater injury severity were the most consistent predictors of PTSD symptomatology. It is apparent, therefore, that PTSD and subsyndromal posttraumatic stress disturbances occur despite neurogenic amnesia. These problems should be treated, particularly if symptoms persist beyond 3 months.	Cedar Ctr, Cedar Rapids, IA USA; Univ Iowa, Dept Psychiat, Iowa City, IA USA	Max, JE (corresponding author), 5215 Fiore Terrace,218, San Diego, CA 92122 USA.		Robin, Donald/F-2109-2010; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH40856, MHCRC43271, MH31593] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040856, P30MH043271, R37MH031593, P50MH043271, R01MH031593] Funding Source: NIH RePORTER		ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BRENT DA, 1995, J AM ACAD CHILD PSY, V34, P209, DOI 10.1097/00004583-199502000-00016; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Epstein Richard S., 1994, P285; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kasanin J, 1929, J NERV MENT DIS, V69, P385, DOI 10.1097/00005053-192904000-00002; KRAUS JF, 1987, PEDIATRICS, V79, P501; MARTINI DR, 1992, SCI P 39 ANN M AM AC, V8; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1997, NEUROCASE, V3, P127; MAZ JE, 1998, J AM ACAD CHILD ADOL, V37, P297; McCullagh P., 1989, GEN LINEAR MODELS; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; TEASDALE G, 1974, LANCET, V2, P81; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18	27	49	49	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	OCT	1998	186	10					589	596		10.1097/00005053-199810000-00001			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	127JQ	WOS:000076347800001	9788634				2021-06-18	
J	Barnfield, TV; Leathem, JM				Barnfield, TV; Leathem, JM			Incidence and outcomes of traumatic brain injury and substance abuse in a New Zealand prison population	BRAIN INJURY			English	Article							HEAD-INJURY; PERSONALITY; SCALE; COMA	The present study investigated the rates and perceived effects of past traumatic brain injury (TBI) and substance use in a prison population. Responses to a questionnaire indicated that 86.4% of the 118 respondents had sustained a TBI, with 56.7% reporting more than one, and rates of illicit substance use were higher than the general population. Maori reported 12% more TBI and more substance use than non-Maori. All those with TBI reported difficulties with general memory and socialization on a problem rating scale, but there was no relationship between level of difficulty and severity of TBI. problems with interpersonal relationships, family, and finances were associated with greater substance use.	Massey Univ, Dept Psychol, Palmerston North, New Zealand; Palmerston N Hosp, Child Adolescent & Family Hlth Counselling Unit, Palmerston North, New Zealand	Leathem, JM (corresponding author), Massey Univ, Dept Psychol, POB 11-222, Palmerston North, New Zealand.						*ACC REH COMP INS, 1993, ACC INJ STAT 1992; BAILEY J, 1984, CD2343; BLACK S, 1993, DRUGS NZ SURVEY 1990; BOWDEN SC, 1994, NEUROPSYCHOLOGY CLIN; BRAYBROOK B, 1992, CENSUS PRISON INMATE; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROWNING MD, 1992, ALCOHOL HEALTH RES W, V16, P280; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; CARLIN AS, 1991, FORENSIC NEUROPSYCHO, P202; *DEP STAT NZ, 1991 CENS POP DWELL, P194; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EAMES P, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P134; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; FRANCESCHI M, 1984, J NEUROL NEUROSUR PS, V47, P1134, DOI 10.1136/jnnp.47.10.1134; GREER BG, 1986, J REHABILITATION JAN, P34; GRIMMER B, 1994, THESIS PALMERSTON N; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HARLOW CW, 1991, DRUGS JAIL INMATES 1; JONES GA, 1989, ALCOHOL HEALTH RES W, V13, P105; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KAPLAN HI, 1991, SYNOPSIS PSYCHI BEHA; LANGLEY M J, 1990, Brain Injury, V4, P77, DOI 10.3109/02699059009026151; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN HS, 1992, NEUROBEHAVIOURAL SEQ; MILLER L, 1992, INT J LAW PSYCHIAT, V15, P303, DOI 10.1016/0160-2527(92)90005-L; MORSE PA, 1992, CLIN SYNDROMES ADULT; MURPHY L, 1996, THESIS MASSEY U PALM; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; POMARE EW, 1988, HAUORA MAORI STANDAR; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1986, NEUROPSYCHOLOGIAL RE; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schafer J, 1994, NEUROPSYCHOLOGY, V8, P100, DOI 10.1037/0894-4105.8.1.100; SPICER P, 1993, CONVICTION SENTENCIN; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; TARTER RE, 1986, ALCOHOL CLIN EXP RES, V10, P128, DOI 10.1111/j.1530-0277.1986.tb05059.x; TEASDALE G, 1974, LANCET, V2, P81; *US DEP JUST, 1983, BUR JUST STAT B; VANHOEVEN KH, 1991, INT J ADDICT, V26, P1089, DOI 10.3109/10826089109058943; WYLLIE A, 1989, DRINKING NZ SURVEY 1	46	49	49	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1998	12	6					455	466		10.1080/026990598122421			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZU400	WOS:000074193300002	9638323				2021-06-18	
J	Sinz, EH; Kochanek, PM; Heyes, MP; Wisniewski, SR; Bell, MJ; Clark, RSB; DeKosky, ST; Blight, AR; Marion, DW				Sinz, EH; Kochanek, PM; Heyes, MP; Wisniewski, SR; Bell, MJ; Clark, RSB; DeKosky, ST; Blight, AR; Marion, DW			Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	27th Annual Meeting of the Society-of-Neuroscience	OCT 25-30, 1997	NEW ORLEANS, LOUISIANA	Soc Neurosci		head injury; macrophage; hypothermia; inflammation; tryptophan; kynurenine	CONVERT L-TRYPTOPHAN; INTRAVENTRICULAR INFUSION; MONONUCLEAR PHAGOCYTES; NEURONAL SURVIVAL; ATTENUATION; METABOLISM; MECHANISM; ISCHEMIA; DISEASE; MK-801	We tested the hypothesis that quinolinic acid, a tryptophan-derived N-methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. We also sought to determine whether therapeutic hypothermia reduced CSF quinolinic acid after injury. Samples of CSF (n = 230) were collected from ventricular catheters in 39 patients (16 to 73 years Old) during the first week after TBI, (Glasgow Coma Scale [GCS] < 8). As part of an ongoing study, patients were randomized within 6 hours after injury to either hypothermia (32 degrees C) or normothermia (37 degrees C) treatments for 24 hours. Otherwise, patients received standard neurointensive care. Quinolinic acid was measured by mass spectrometry. Univariate and multivariate analyses were used to compare CSF quinolinic acid concentrations with age, gender, GCS, time after injury, mortality, and treatment (hypothermia versus normothermia). Quinolinic acid concentration in CSF increased maximally to 463 +/- 128 nmol/L (mean +/- SEM) at 72 to 83 hours after TBI. Normal values for quinolinic acid concentration in CSF are less than 50 nmol/L. Quinolinic acid concentration was increased 5- to 50-fold in many patients. There was a powerful association between time after TBI and increased quinolinic acid (P < 0.00001), and quinolinic acid was higher in patients who died than in survivors (P = 0.003), Age, gender, GCS, and treatment (32 degrees C versus 37 degrees C) did not correlate with CSF quinolinic acid. These data reveal a large increase in quinolinic acid concentration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; NIMH, Bethesda, MD 20892 USA; Univ N Carolina, Chapel Hill, NC USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, 434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021	Kochanek, Patrick/0000-0002-2627-913X; Sinz, Elizabeth/0000-0001-7129-6193; DeKosky, Steven/0000-0003-3743-2758; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER		Balasingam V, 1996, J NEUROSCI, V16, P2945; BAZZETT TJ, 1994, NEUROSCIENCE, V60, P837, DOI 10.1016/0306-4522(94)90266-6; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BLIGHT AR, 1993, BRAIN RES, V632, P314, DOI 10.1016/0006-8993(93)91167-Q; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; HEYES MP, 1995, J NEUROL SCI, V133, P112, DOI 10.1016/0022-510X(95)00164-W; Heyes MP, 1996, BIOCHEM J, V320, P595, DOI 10.1042/bj3200595; Heyes MP, 1997, J NEUROCHEM, V68, P280; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HEYES MP, 1993, BIOCHEM SOC T, V21, P83, DOI 10.1042/bst0210083; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCLAIN CJ, 1987, J LAB CLIN MED, V118, P226; Misztal M, 1996, NEUROPHARMACOLOGY, V35, P449, DOI 10.1016/0028-3908(96)00005-6; Misztal M, 1996, EUR J PHARMACOL, V296, P1, DOI 10.1016/0014-2999(95)00682-6; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; STONE TW, 1993, PHARMACOL REV, V45, P309; SUSEL Z, 1991, NEUROSCI LETT, V121, P234, DOI 10.1016/0304-3940(91)90693-N; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YAMADA K, 1990, NEUROSCI LETT, V118, P128, DOI 10.1016/0304-3940(90)90265-B	34	49	51	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	1998	18	6					610	615		10.1097/00004647-199806000-00002			6	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	ZT870	WOS:000074136600002	9626184	Bronze			2021-06-18	
J	Rao, AM; Dogan, A; Hatcher, JF; Dempsey, RJ				Rao, AM; Dogan, A; Hatcher, JF; Dempsey, RJ			Fluorometric assay of nitrite and nitrate in brain tissue after traumatic brain injury and cerebral ischemia	BRAIN RESEARCH			English	Article						traumatic brain injury (TBI); cerebral ischemia; nitric oxide synthase (NOS); NO end product; nitrite/nitrate (NOx); 2,3-diaminonaphthalene (DAN); cortex; hippocampus	ORNITHINE DECARBOXYLASE ACTIVITY; OXIDE SYNTHASE ACTIVITY; EDEMA FORMATION; BLOOD-FLOW; IN-VIVO; GLUTAMATE; RAT; PATHOPHYSIOLOGY; MICRODIALYSIS; REPERFUSION	Nitric oxide synthase (NOS) is distributed within the brain, and nitric oxide (NO) is felt to be involved in the pathophysiology of deterioration after head injury and cerebral ischemia. This study determined the levels of the stable end products of NOS (NOx = nitrite + nitrate) after traumatic brain injury (TBI) and transient cerebral ischemia. A fluorometric assay using nitrate reductase and the NADPH regenerating system was used to quantitate NOx in ultrafiltered (10-kDa cutoff) cortical and hippocampal extracts after reduction of nitrate. In TBI rats, both the plasma and tissue showed a sharp increase in NOx levels 5 min after injury. Plasma NOx returned to control levels by 2 h after injury. Ipsilateral-cortex NOx levels returned to control levels similar to 6 h after injury and remained constant from 6-24 h. Contralateral-cortex returned near to control levels after 1 h. Hippocampus also followed a similar trend. In gerbils, there was a significant elevation in tissue NOx levels immediately after 10 min transient cerebral ischemia, which gradually returned to control levels over 24 h reperfusion. This striking burst of NO synthesis immediately after injury is clearly evident whether the injury is head trauma or ischemia, or whether the measurements were performed on tissue or plasma. It is unknown whether endothelial NOS, neuronal NOS, or both caused the elevation of the NO end products seen after the CNS insults. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Wisconsin, Dept Neurol Surg, Ctr Clin Sci, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, Ctr Clin Sci, H4-336,600 Highland Ave, Madison, WI 53792 USA.	dempsey@neuro-novell.neurosurg.wisc.edu	Dogan, Aclan/AAF-8305-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31220, R01 NS 28000] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS028000] Funding Source: NIH RePORTER		ARCHER S, 1993, FASEB J, V7, P349; Balkan S, 1997, ACTA NEUROL SCAND, V95, P140, DOI 10.1111/j.1600-0404.1997.tb00085.x; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FELDMAN PL, 1993, CHEM ENG NEWS, V20, P26; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUMURA E, 1994, J CEREBR BLOOD F MET, V14, P487, DOI 10.1038/jcbfm.1994.60; Kumura E, 1996, AM J PHYSIOL-CELL PH, V270, pC748; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MONCADA S, 1991, PHARMACOL REV, V43, P109; OHTA T, 1986, ANAL CHEM, V58, P3132, DOI 10.1021/ac00127a047; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Rao AM, 1997, MOL BRAIN RES, V44, P134, DOI 10.1016/S0169-328X(96)00245-8; RAO AM, 1995, J NEUROCHEM, V65, P2639; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Salter M, 1996, J NEUROCHEM, V66, P1683; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Shibata M, 1996, BRAIN RES, V734, P86, DOI 10.1016/S0006-8993(96)00617-8; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I	42	49	50	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 18	1998	793	1-2					265	270		10.1016/S0006-8993(98)00183-8			6	Neurosciences	Neurosciences & Neurology	ZX807	WOS:000074557400028	9630667				2021-06-18	
J	Cherian, L; Hannay, HJ; Vagner, G; Goodman, JC; Contant, CF; Robertson, CS				Cherian, L; Hannay, HJ; Vagner, G; Goodman, JC; Contant, CF; Robertson, CS			Hyperglycemia increases neurological damage and behavioral deficits from post-traumatic secondary ischemic insults	JOURNAL OF NEUROTRAUMA			English	Article						hyperglycemia; traumatic brain injury; cortical impact injury; secondary insults; cerebral ischemia; Morris water maze; behavioral deficits	CONTROLLED CORTICAL IMPACT; CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; BRAIN INJURY; MODERATE HYPOTHERMIA; PARENTERAL-NUTRITION; FOREBRAIN ISCHEMIA; RATS; GLUCOSE; PROTECTION	The effects of post-traumatic administration of glucose 2.0 g/kg was compared to saline infusion with and without control of brain temperature at 37 degrees C on behavioral and histological measures of brain injury after controlled cortical impact injury complicated by a secondary ischemic insult. The glucose infusion increased blood glucose concentration from 114 +/- 4 to 341 +/- 76 mg/dl prior to the secondary ischemic insult, The resulting outcome measures were significantly worse in the glucose infusion group than in either control group, Mortality rate was significantly increased by the glucose administration, from 0% to 55% (p < 0.001). The median contusion volume was increased from 7.9 to 64.2 by glucose administration (p < 0.001) and the neuronal loss in the CA1 and CA3 areas of the hippocampus were greater in the glucose infusion group. In the animals that survived for the 2 weeks of behavioral studies, the duration of beam balance was shorter; the percent of animals that could balance on the beam for at least 60 s was less, the percent of animals that could perform the beam-walking task was less, and the length of time required to find the platform in the Morris water maze task was longer in the glucose infusion group. These studies demonstrate that the infusion of glucose after the cortical impact injury significantly increases the damage caused by posttraumatic ischemic insults. The adverse effect on neurological outcome could not be explained by the temperature effects of glucose infusion.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Univ Houston, Dept Psychol, Houston, TX 77004 USA	Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.			Hannay, H. Julia/0000-0001-7023-912X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cipolla MJ, 1997, STROKE, V28, P405, DOI 10.1161/01.STR.28.2.405; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COMBS DJ, 1989, J NEUROSURG, V70, P623, DOI 10.3171/jns.1989.70.4.0623; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duckrow RB, 1995, BRAIN RES, V703, P145, DOI 10.1016/0006-8993(95)01077-7; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; HAMM RJ, 1994, NEUROBIOLOGY CENTRAL; HANNAY HJ, 1993, 11 ANN NEUR S WASH D; HSU SSF, 1991, AM J PHYSIOL, V261, pH398; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MYERS RE, 1976, J NEUROPATH EXP NEUR, V35, P301, DOI 10.1097/00005072-197605000-00011; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; SILBERMAN H, 1986, JPEN-PARENTER ENTER, V10, P151, DOI 10.1177/0148607186010002151; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; YIP PK, 1991, NEUROLOGY, V67, P76; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	36	49	52	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					307	321		10.1089/neu.1998.15.307			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300002	9605346				2021-06-18	
J	Roman, MJ; Delis, DC; Willerman, L; Magulac, M; Demadura, TL; de la Pena, JL; Loftis, C; Walsh, J; Kracun, M				Roman, MJ; Delis, DC; Willerman, L; Magulac, M; Demadura, TL; de la Pena, JL; Loftis, C; Walsh, J; Kracun, M			Impact of pediatric traumatic brain injury on components of verbal memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; HUNTINGTONS-DISEASE; KORSAKOFFS SYNDROME; ALZHEIMER-TYPE; CHILDREN; ADOLESCENTS; DEMENTIA; RECOGNITION; SEVERITY; AMNESIA	This 3-month longitudinal study examined spared and impaired components of verbal learning and memory after pediatric traumatic brain injury (TBT), using the California Verbal Learning Test for Children. School-aged participants with severe or mild-to-moderate TBI were compared to traumatically injured control subjects without head trauma. Participants were initially evaluated approximately I month post injury, and again 3 months later. At Times 1 and 2, participants with severe TBI displayed deficits in immediate recall, delayed recall, and recognition accuracy, consistent with a mild encoding deficit. In both evaluations, participants with mild-to-moderate TBI performed similarly to controls. On average, mild verbal encoding deficits appear to be associated with severe, but not mild-to-moderate, pediatric TBI in the first several months post injury.	Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Dept Vet Affairs Med Ctr, San Diego, CA USA; Univ Texas, Austin, TX 78712 USA; Scripps La Jolla Med Ctr, La Jolla, CA USA	Delis, DC (corresponding author), VA Med Ctr, Psychol Serv, 116-B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Loftis, Christopher/AAD-5507-2019				BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BIJUR PE, 1990, PEDIATRICS, V86, P337; Brown A.L., 1983, COGNITIVE DEV, V3, P77; BUTTERS N, 1985, NEUROPSYCHOLOGIA, V23, P729, DOI 10.1016/0028-3932(85)90080-6; BUTTERS N, 1986, CORTEX, V22, P11, DOI 10.1016/S0010-9452(86)80030-2; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; DELIS D, 1994, CALIFORNIA VERBAL LE; DELIS DC, 1991, PSYCHOL ASSESSMENT, V3, P19, DOI DOI 10.1037/1040-3590.3.1.19; DIMEN S, 1987, NEUROBEHAVIORAL RECO, P73; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FRIDLUND AJ, 1994, CALIFORNIA VERBAL LE; FULD PA, 1982, ANN NEUROL, V11, P155, DOI 10.1002/ana.410110208; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KOPELMAN MD, 1985, NEUROPSYCHOLOGIA, V23, P623, DOI 10.1016/0028-3932(85)90064-8; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LEZAK MD, 1995, NEUROPSCYHOLGOICAL A; MARTONE M, 1986, J CLIN EXP NEUROPSYC, V8, P161, DOI 10.1080/01688638608401309; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MOELY BE, 1969, DEV PSYCHOL, V1, P26, DOI 10.1037/h0026804; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; NEIMARK E, 1971, DEV PSYCHOL, V5, P427, DOI 10.1037/h0031601; Pang D, 1985, HEAD INJURY REHABILI, P3; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Schneider W., 1989, MEMORY DEV 2 20; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHAFFER D, 1995, TRAUMATIC HEAD INJUR, P55; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1990, TRAUMATIC BRAIN INJU, P251; TROSTER AI, 1993, J CLIN EXP NEUROPSYC, V15, P773, DOI 10.1080/01688639308402595; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON RS, 1983, J CLIN NEUROPSYCHOL, V5, P337, DOI 10.1080/01688638308401181; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B	49	49	49	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1998	20	2					245	258		10.1076/jcen.20.2.245.1168			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	122GG	WOS:000076063100013	9777479				2021-06-18	
J	Di, X; Bullock, R; Watson, J; Fatouros, P; Chenard, B; White, F; Corwin, F				Di, X; Bullock, R; Watson, J; Fatouros, P; Chenard, B; White, F; Corwin, F			Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage and cytotoxic brain edema after middle cerebral artery occlusion in the feline brain	STROKE			English	Article						brain edema; glutamate antagonist; cats	APPARENT DIFFUSION-COEFFICIENT; BLOOD-FLOW; GLUTAMATE ANTAGONIST; CELL-CULTURE; CPP-ENE; RAT; STROKE; MK-801; SENSITIVITY; INJURY	Background and Purpose The purpose of this study was to test the hypothesis that the neuroprotective compound CP101,606 will ameliorate the increase in lactate, retard the development of cytotoxic edema, and decrease the infarct volume after ischemic stroke. Methods Seventeen adult cats were allocated to control (n=7) and CP101,606-treated groups (n=10). Transorbital middle cerebral artery occlusion was performed under anesthesia. Extracellular fluid lactate by microdialysis as well as infarct volume measurement by triphenyltetrazolium chloride (TTC)-stained section, with and without neuroprotective agents, was used to determine the value of these potential ''surrogate markers'' of ischemic damage. Results The control group showed an increased dialysate lactate (15.5% increase) at 30 minutes and a peak (332.0% increase) in dialysate lactate at 1 hour after middle cerebral artery occlusion compared with the drug-treated group. Significant differences between control and drug-treated groups were seen in the rate of fall of the apparent diffusion coefficient at both 1 and 5 hours. A close correlation was seen between the 1- and 5-hour apparent diffusion coefficient maps and the TTC-stained sections. There was a significantly smaller lesion in the CP101,606-treated group (62.9% reduction in infarct size compared with the control group; P<.001). Conclusions CP101,606 ranks very highly among the current neuroprotection candidates for clinical trials, and its excellent safety record in both animals and phase II studies in conscious, moderate head injury patients suggests that it will be highly effective in human occlusive stroke.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV RADIAT BIOL, RICHMOND, VA 23298 USA; PFIZER INC, GROTON, CT USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BARTLETT SE, 1994, LIFE SCI, V54, P687, DOI 10.1016/0024-3205(94)00552-4; BULLOCK R, 1994, J CEREBR BLOOD F MET, V14, P466, DOI 10.1038/jcbfm.1994.57; BULLOCK R, 1990, J CEREBR BLOOD F MET, V10, P668, DOI 10.1038/jcbfm.1990.120; BULLOCK R, 1990, STROKE, V21, P32; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; CHOI DW, 1988, J NEUROSCI, V8, P185; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; GROSSET DG, 1992, STROKE, V23, P674, DOI 10.1161/01.STR.23.5.674; HASEGAWA Y, 1994, J CEREBR BLOOD F MET, V14, P383, DOI 10.1038/jcbfm.1994.49; HoehnBerlage M, 1995, NMR BIOMED, V8, P345, DOI 10.1002/nbm.1940080708; HOEHNBERLAGE M, 1995, MAGN RESON MED, V34, P824, DOI 10.1002/mrm.1910340607; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JONES SC, 1994, ACTA NEUROCHIR, P207; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOHNO K, 1995, J COMPUT ASSIST TOMO, V19, P982, DOI 10.1097/00004728-199511000-00027; LASSEN NA, 1990, CLIN NEUROPHARMACOL, V13, pS1, DOI 10.1097/00002826-199013003-00001; LEBIHAN D, 1991, MAGNET RESON MED, V19, P221, DOI 10.1002/mrm.1910190206; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; NISHIJO H, 1995, BRAIN RES BULL, V37, P89, DOI 10.1016/0361-9230(94)00258-4; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; PEREZTREPICHIO AD, 1995, STROKE, V26, P667, DOI 10.1161/01.STR.26.4.667; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PorteraCailliau C, 1996, J NEUROCHEM, V66, P692, DOI 10.1046/j.1471-4159.1996.66020692.x; SHARKEY J, 1994, BRAIN RES, V651, P27, DOI 10.1016/0006-8993(94)90677-7; SIESJO BK, 1991, FUND CLIN PHARMACOL, V5, P755, DOI 10.1111/j.1472-8206.1991.tb00765.x; UTO A, 1994, METAB BRAIN DIS, V9, P333, DOI 10.1007/BF02098880	35	49	49	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	1997	28	11					2244	2251		10.1161/01.STR.28.11.2244			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	YE841	WOS:A1997YE84100025	9368572				2021-06-18	
J	Wade, LD; Canning, CG; Fowler, V; Felmingham, KL; Baguley, IJ				Wade, LD; Canning, CG; Fowler, V; Felmingham, KL; Baguley, IJ			Changes in postural sway and performance of functional tasks during rehabilitation after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BALANCE; SCALE; REACH	Objective: To investigate changes in postural sway while standing, walking parameters, and performance of functional tasks during rehabilitation in a group of traumatic brain injury (TBI) patients. Design: Descriptive. Setting: Inpatient brain injury rehabilitation unit. Participants: Thirteen subjects undergoing rehabilitation after severe TBI. Outcome Measures: Two assessments were performed, 2 to 6 weeks apart that included the following: postural sway in three stance conditions; temporal and spatial parameters of walking; functional assessments of walking, standing up, reaching while standing, and stair climbing. Results: There were significant reductions in postural sway in all stance conditions (p<.05) and significant increases in velocity of walking (p<.05), stride length (p<.01), and left and right step lengths (p<.01). Performance on all functional tasks improved (p<.05) except for functional reach. There were no significant correlations between changes in postural sway and changes in walking parameters or functional assessments. Conclusion: This study demonstrated significant improvements in postural sway, walking parameters, and functional tasks during a relatively short period of rehabilitation after severe TBI. Improvements in standing balance appear to be independent of improvements in walking performance, suggesting that different mechanisms underlie improved control of these tasks. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	UNIV SYDNEY,FAC HLTH SCI,SCH PHYSIOTHERAPY,SYDNEY,NSW 2006,AUSTRALIA	Wade, LD (corresponding author), WESTMEAD HOSP,BRAIN INJURY REHABIL UNIT,BRAIN INJURY REHABIL PROGRAMME,WESTMEAD,NSW 2145,AUSTRALIA.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; Carr JH, 1990, KEY ISSUES NEUROLOGI, P1; CARR JH, 1987, MOVEMENT SCI FDN PHY, P31; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; KEITH RA, 1987, ADV CLIN REHABILITAT, P6; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; OLVER JH, 1994, P 2 ANN SCI M AUSTR, P198; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHUMWAYCOOK A, 1988, ARCH PHYS MED REHAB, V69, P395; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TEASDALE G, 1974, LANCET, V2, P81; WEINER DK, 1993, ARCH PHYS MED REHAB, V74, P796, DOI 10.1016/0003-9993(93)90003-S; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	15	49	49	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1997	78	10					1107	1111		10.1016/S0003-9993(97)90136-2			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YA044	WOS:A1997YA04400010	9339161				2021-06-18	
J	Bara, BG; Tirassa, M; Zettin, M				Bara, BG; Tirassa, M; Zettin, M			Neuropragmatics: Neuropsychological constraints on formal theories of dialogue	BRAIN AND LANGUAGE			English	Article							CLOSED-HEAD-INJURY; PROPER NAMES; COMMUNICATION; MIND; REPRESENTATION; COMPREHENSION; DISCOURSE; DECEPTION; REQUESTS; APHASIA	We are interested in the validation of a cognitive theory of human communication, grounded in a speech acts perspective. The theory we refer to is outlined, and a number of predictions are drawn from it. We report a series of protocols administered to 13 brain-injured subjects and to a comparable control group. The tasks included direct and indirect speech acts, irony, deceits, failures of communication and theory of mind inferences. All the predicted trends of difficulty are consistently verified; in particular, difficulty increases from direct/indirect speech acts to irony, from irony to deceits, and from deceits to failure recovery. This trend symmetrically shows both in the successful situation and in the failure situation. Further, failure situations prove more difficult to handle than the relevant successful situation. in sharp contrast with previous literature, there is no difference between the subjects comprehension of direct and indirect speech acts. The results are discussed in the light of our theoretical approach. (C) 1997 Academic Press.	UNIV TURIN,CTR COGNIT SCI,I-10123 TURIN,ITALY; PRESIDIO OSPED AUSILIATRICE,TURIN,ITALY							AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; AIRENTI G, 1989, STRUCTURE MULTIMODAL; AIRENTI G, 1984, COMPUTATIONAL MODELS; AIRENTI G, 1983, P 8 INT JOINT C ART; AIRENTI G, 1983, COGNITIVE SCI, V17, P197; AIRENTI G, 1991, P 1 WORLD C FUND ART; ALLEN JF, 1980, ARTIF INTELL, V15, P143, DOI 10.1016/0004-3702(80)90042-9; APPELT DE, 1985, PLANNING ENGLISH SEN; ASTINGTON JW, 1988, DEV THEORIE SMIND; AUSTIN JL, 1962, HOW TO DO THINGS WOR; BARA BG, 1984, COMPUTATIONAL MODELS; Bara Bruno G., 1995, COGNITIVE SCI DEV AP; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Brown Penelope, 1987, POLITENESS SOME UNIV, DOI [10.1017/CBO9780511813085, DOI 10.2307/3587263]; BURLING R, 1993, CURR ANTHROPOL, V343, P25; Byrne R. W., 1988, MACHIAVELLIAN INTELL; Chomsky N., 1980, RULES REPRESENTATION; Chomsky Noam, 1957, SYNTACTIC STRUCTURES; Chomsky Noam, 1965, ASPECTS THEORY SYNTA; Clark H., 1992, ARENAS LANGUAGE USE; Clark Herbert H., 1981, ELEMENTS DISCOURSE U; CLARK HH, 1979, COGNITIVE PSYCHOL, V11, P430, DOI 10.1016/0010-0285(79)90020-3; Cohen P. R., 1990, INTENTIONS COMMUNICA; COHEN PR, 1979, COGNITIVE SCI, V3, P177, DOI DOI 10.1207/S15516709COG0303_1; COHEN PR, 1991, P 12 INT JOINT C ART; COHEN PR, 1985, P 23 ANN M ASS COMP; COHEN PR, 1990, INBTENTIONS COMMUNIC; COLOMBETTI M, 1993, ARTIF INTELL, V62, P341, DOI 10.1016/0004-3702(93)90082-M; DAVIS AG, 1981, LANGUAGE INTERVENTIO; DAVIS AG, 1985, ADULOT APHASIA REHAB; DEBLESER R, 1986, PRAGMATICS ED; FEYEREISEN P, 1982, BRAIN LANG, V16, P191, DOI 10.1016/0093-934X(82)90083-9; Foldi N.S., 1983, LANGUAGE FUNCTIONS B; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Frith CD., 1992, COGN NEUROPSYCHOL; FRITH U, 1991, TRENDS NEUROSCI, V14, P433, DOI 10.1016/0166-2236(91)90041-R; Gazdar G., 1981, ELEMENTS DISCOURSE U; Grice H.P, 1989, STUDIES WAY WORDS; GRICE HP, 1957, PHILOS REV, V66, P377, DOI 10.2307/2182440; GUILFORD AM, 1982, J COMMUN DISORD, V15, P337, DOI 10.1016/0021-9924(82)90001-6; HARMAN G, 1977, LANGUAGE, V53, P417, DOI 10.2307/413111; HEESCHEN C, 1979, ABILITY BRAIN DAMAGE; HIRST W, 1984, BRAIN LANG, V23, P26, DOI 10.1016/0093-934X(84)90003-8; HOLLAND AL, 1982, J SPEECH HEAR DISORD, V47, P50, DOI 10.1044/jshd.4701.50; Howard D., 1987, APHASIA THERAPY HIST; JOANETTE Y, 1986, BRAIN LANG, V29, P81, DOI 10.1016/0093-934X(86)90035-0; Joanette Y., 1990, DISCOURSE ABILITY BR; Karmiloff-Smith A, 1992, MODULARITY DEV PERSP; KOSSLYN SM, 1992, J COGNITIVE NEUROSCI, V4, P96, DOI 10.1162/jocn.1992.4.1.96; Leech Geoffrey, 1983, PRINCIPLES PRAGMATIC; LESLIE AM, 1992, COGNITION, V43, P225, DOI 10.1016/0010-0277(92)90013-8; LESLIE AM, 1994, COGNITION, V50, P211, DOI 10.1016/0010-0277(94)90029-9; LESLIE AM, 1987, PSYCHOL REV, V94, P412, DOI 10.1037/0033-295X.94.4.412; Levinson S.C., 1983, PRAGMATICS; Lewis D., 1969, CONVENTION PHILOS ST; MARR D, 1977, ARTIF INTELL, V9, P37, DOI 10.1016/0004-3702(77)90013-3; Marr D., 1982, VISION COMPUTATIONAL; MCCARTHY J, 1980, ARTIF INTELL, V13, P27, DOI 10.1016/0004-3702(80)90011-9; MCCARTHY J, 1969, MACHINE INTELLIGENCE, V4; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; Morgan J., 1975, SYNTAX SEMANTICS, V3; MORGAN JL, 1990, INTENTIONS COMMUNICA; PAGE EB, 1963, J AM STAT ASSOC, V58, P216, DOI 10.2307/2282965; PENN C, 1988, BRAIN INJURY, V1, P3; Penn C., 1987, APHASIOLOGY, V1, P235, DOI [10.1080/02687038708248840, DOI 10.1080/02687038708248840]; PERNER J, 1987, BRIT J DEV PSYCHOL, V5, P125, DOI 10.1111/j.2044-835X.1987.tb01048.x; Perner J, 1991, UNDERSTANDING REPRES; PERRAULT CR, 1980, AM J COMPUTATIONAL L, V6, P167; POLLACK ME, 1990, INTENTIONS COMMUNICA; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Premack D., 1986, GAVAGAI FUTURE HIST; RECANATI F, 1995, COGNITIVE SCI, V19, P207, DOI 10.1207/s15516709cog1902_2; REITER R, 1980, ARTIF INTELL, V13, P81, DOI 10.1016/0004-3702(80)90014-4; Schiffer S., 1972, MEANING; Searle J., 1992, REDISCOVERY MIND; Searle J., 1985, FDN ILLOCUTIONARY LO; Searle John, 1969, SPEECH ACTS; Searle John, 1975, SYNTAX SEMANTICS, V3; SEARLE JR, 1980, BEHAV BRAIN SCI, V3, P417, DOI 10.1017/S0140525X00006038; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SEMENZA C, 1988, COGNITIVE NEUROPSYCH, V5, P711, DOI 10.1080/02643298808253279; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHERRATT SM, 1990, APHASIOLOGY, V4, P539, DOI 10.1080/02687039008248506; Sperber D., 1986, RELEVANCE COMMUNICAT; STEMMER B, 1994, BRAIN LANG, V46, P565, DOI 10.1006/brln.1994.1031; STRAWSON PF, 1964, PHILOS REV, V73, P439, DOI 10.2307/2183301; TIRASSA M, 1997, P 2 EUR C COGN SCI M; Wellman H. M., 1990, CHILDS THEORY MIND; WEYLMAN ST, 1989, BRAIN LANG, V36, P362; WHITEN A, 1988, BEHAV BRAIN SCI, V11, P233, DOI 10.1017/S0140525X00049682; Whiten A., 1991, NATURAL THEORIES MIN; WILCOX MJ, 1978, BRAIN LANG, V6, P362, DOI 10.1016/0093-934X(78)90069-X; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5	95	49	50	0	6	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.	AUG	1997	59	1					7	49		10.1006/brln.1997.1812			43	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	XQ279	WOS:A1997XQ27900003	9262850	Green Accepted			2021-06-18	
J	Dombovy, ML; Olek, AC				Dombovy, ML; Olek, AC			Recovery and rehabilitation following traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; DISABILITY; SCALE	Although most patients are discharged following traumatic brain injury (TBI) with 'good recovery', recent reports indicate that many have persistent neuropsychological deficits. The purposes of this study were to: (1) determine if functional, neuropsychological and social outcome at 3 and 6 months in patients hospitalized following TBI could be ascertained via telephone follow-up, and (2) assess use of rehabilitation services in this population. Patients were identified through acute hospital admissions. A trained nurse practitioner abstracted data from acute charts. Using the Functional independence Measure (FIM), Neurobehavioral Rating Scale (NRS), Telephone Interview for Cognitive Status (TICS), and a social questionnaire she obtained follow-up information at 3 and 6 months post-injury. Of 74 patients initially identified, 51 and 48 were available at 3 and 6 months, respectively. Most experienced mild to moderate TBI. Physical disability was minimal at follow-up as indicated by the FIM. Approximately half of the patients were rated cognitively impaired on the TICS at 3 months and over one-third remained impaired at 6 months. At 6 months 60.5% remained unemployed. Only eight of the 67 discharged survivors received any rehabilitation services. A brief telephone follow-up appears to be a cost-effective way to ascertain functional and neuropsychological outcome in TBI survivors. Since few of these patients received rehabilitation, a telephone follow-up may identify those who would potentially benefit from additional rehabilitation services.	UNIV ROCHESTER,DEPT NEUROL,ROCHESTER,NY; UNIV ROCHESTER,DEPT ORTHOPED REHABIL,ROCHESTER,NY	Dombovy, ML (corresponding author), ST MARYS HOSP,DEPT PHYS MED & REHABIL,89 GENESEE ST,ROCHESTER,NY 14611, USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1159/000264678; Brooks D. N, 1990, REHABILITATION ADULT, P163; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Granger CV, 1986, GUIDE USE UNIFORM DA; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT WB, 1975, EPILEPSY NONMISSLE I; KATZ DI, 1994, HDB NEUROREHABILITAT, P493; Kraus Jess F., 1994, P3; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Miller Norman S., 1994, P471; PLASSMAN BL, 1994, NEUROPSY NEUROPSY BE, V7, P235; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; *STAT U NY RES FDN, 1990, UN DAT SET MED REH I; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WONG PP, 1996, BRAIN INJURY, V8, P509; Yablon Stuart A., 1994, P805	29	49	50	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1997	11	5					305	318		10.1080/026990597123467			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WW455	WOS:A1997WW45500001	9146836				2021-06-18	
J	Hatton, J; Rapp, RP; Kudsk, KA; Brown, RO; Luer, MS; Bukar, JG; Chen, SA; McClain, CJ; Gesundheit, N; Dempsey, RJ; Young, B				Hatton, J; Rapp, RP; Kudsk, KA; Brown, RO; Luer, MS; Bukar, JG; Chen, SA; McClain, CJ; Gesundheit, N; Dempsey, RJ; Young, B			Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: A Phase II safety and efficacy trial	JOURNAL OF NEUROSURGERY			English	Article						brain injury; insulin-like growth factor-I; nitrogen balance; Glasgow Coma Scale; nutritional support; nutrition; treatment outcome	THERMAL-INJURY; NUTRITIONAL MARKERS; HORMONE; BRAIN; RECEPTOR; SUPPORT; NEURONS; BINDING; TRAUMA; MALNUTRITION	The purpose of this study was to determine the effect of insulin-like growth factor-I (IGF-I) on the catabolic state and clinical outcome of head-injured patients. Thirty-three patients between the ages of 18 and 59 years with isolated traumatic head injury and Glasgow Coma Scale (GCS) scores of 4 to 10 were randomized to one of two groups. All patients received standard neurosurgical intensive care plus aggressive nutritional support. the patients in the treatment group also received intravenous therapy with continuous IGF-I (0.01 mg/kg/hour). During the 14-day dosing period, the control patients lost weight, whereas treated patients gained weight despite a significantly higher measured energy expenditure and lower caloric intake (p = 0.02). Daily glucose concentrations and nitrogen outputs were greater in control patients (p = 0.03) throughout the study period. During Week 1, only treated patients achieved positive nitrogen balance. Fifteen of 17 treated and 13 of 16 control patients survived the Ist week. No deaths occurred in patients whose serum IGF-I concentrations were higher than 350 ng/ml. Dichotomized Glasgow Outcome Scale scores for patients with baseline GCS scores of 5 to 7 improved from poor to good for eight of 12 treated patients but for only three of 11 control patients (p = 0.06). Eight of 11 treated patients with serum IGF-I concentrations that were at least 350 ng/ml achieved moderate-to-good outcome scores at 6 months, compared to only one of five patients with lower concentrations (p < 0.05). These findings indicate that pharmacological concentrations of IGF-I may improve clinical outcome and nitrogen utilization in patients with moderate-to-severe head injury.	UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT SURG, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT MED, LEXINGTON, KY 40536 USA; UNIV TENNESSEE, COLL MED, DEPT SURG, MEMPHIS, TN USA; UNIV TENNESSEE, COLL PHARM, DEPT CLIN PHARM, MEMPHIS, TN USA; GENENTECH INC, SAN FRANCISCO, CA 94080 USA	Hatton, J (corresponding author), UNIV KENTUCKY, ALBERT B CHANDLER MED CTR,DEPT PHARM,COLL PHARM, C-117, 800 ROSE ST, LEXINGTON, KY 40536 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR02602] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER		AGUADO F, 1994, NEUROSCIENCE, V59, P641, DOI 10.1016/0306-4522(94)90183-X; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; BAXTER RC, 1991, MODERN CONCEPTS INSU, P371; BEHRMAN SW, 1995, JPEN-PARENTER ENTER, V19, P41, DOI 10.1177/014860719501900141; BERMANN M, 1994, J CLIN INVEST, V94, P138, DOI 10.1172/JCI117299; BIVINS BA, 1986, J TRAUMA, V26, P980, DOI 10.1097/00005373-198611000-00004; BLUM WF, 1990, ACTA PAEDIATR SCAND, P55; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BUONPANE EA, 1989, CRIT CARE MED, V17, P126, DOI 10.1097/00003246-198902000-00004; CHENG B, 1992, J NEUROSCI, V12, P1558; CHWALS WJ, 1991, CRIT CARE MED, V19, P1317, DOI 10.1097/00003246-199110000-00015; CIOFFI WG, 1994, ANN SURG, V220, P310, DOI 10.1097/00000658-199409000-00007; CLEMMONS DR, 1992, J CLIN ENDOCR METAB, V75, P234, DOI 10.1210/jc.75.1.234; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CREWS FT, 1992, J NEUROCHEM, V58, P1205, DOI 10.1111/j.1471-4159.1992.tb11330.x; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DAHN MS, 1988, ARCH SURG-CHICAGO, V123, P1409; DEKEYSER J, 1994, NEUROSCI LETT, V172, P93; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FLEMING RYD, 1992, J TRAUMA, V32, P698, DOI 10.1097/00005373-199206000-00005; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; FRANK HJL, 1986, DIABETES, V35, P654, DOI 10.2337/diabetes.35.6.654; FRUIN AH, 1986, SURG NEUROL, V25, P25, DOI 10.1016/0090-3019(86)90109-6; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; GUAN J, 1993, J CEREBR BLOOD F MET, V13, P609, DOI 10.1038/jcbfm.1993.79; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; GUYDA HJ, 1991, MODERN CONCEPTS INSU, P99; HARRIS JA, 1919, 279 CARN I WASH DC; JACOB V, 1990, AM J CLIN NUTR, V52, P39; JENNETT B, 1975, LANCET, V1, P480; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; KUPFER SR, 1993, J CLIN INVEST, V91, P391, DOI 10.1172/JCI116212; Lehmann S, 1992, Nutr Clin Pract, V7, P27, DOI 10.1177/011542659200700127; LIEBERMAN SA, 1992, J CLIN ENDOCR METAB, V75, P30, DOI 10.1210/jc.75.1.30; LIEBERMAN SA, 1994, J CLIN ENDOCR METAB, V78, P404, DOI 10.1210/jc.78.2.404; MARIE C, 1991, CEREBROVAS BRAIN MET, V3, P29; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; MASTERS BA, 1993, ANN NY ACAD SCI, V692, P89; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MINUTO F, 1989, JPEN-PARENTER ENTER, V13, P392, DOI 10.1177/0148607189013004392; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PICCOLBONI D, 1991, NUTRITION, V7, P177; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RECIOPINTO E, 1988, NEUROCHEM INT, V12, P397, DOI 10.1016/0197-0186(88)90021-6; ROBERTSON CS, 1988, J TRAUMA, V28, P1523, DOI 10.1097/00005373-198811000-00002; ROTHMAN LB, 1995, J IES, V38, P36; SANDBERGNORDQVIST AC, 1992, MOL BRAIN RES, V12, P275, DOI 10.1016/0169-328X(92)90094-R; TEASDALE G, 1974, LANCET, V2, P81; WATERS DC, 1986, SURGERY, V100, P531; WILMORE DW, 1974, SURG GYNECOL OBSTET, V138, P875; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZIEGLER TR, 1990, JPEN-PARENTER ENTER, V14, P574, DOI 10.1177/0148607190014006574	66	49	50	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	1997	86	5					779	786		10.3171/jns.1997.86.5.0779			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WV756	WOS:A1997WV75600006	9126892				2021-06-18	
J	DiScala, C; Osberg, JS; Savage, RC				DiScala, C; Osberg, JS; Savage, RC			Children hospitalized for traumatic brain injury: Transition to postacute care	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						head injury; pediatrics; trauma; traumatic brain injury	HEAD-INJURY; FOLLOW-UP; REHABILITATION; OUTCOMES; CENTERS; FAMILY	Objectives: To document causes, course of acute care, and outcomes in a large sample of children and adolescents (N=24,021) hospitalized for traumatic brain injury. Special focus is given to patterns of referral to rehabilitation and educational services at the time of discharge from acute care. Design: Descriptive statistics applied to a multicenter data collection on pediatric trauma. Setting: Seventy-six pediatric trauma centers or children's hospitals in the United States that reported to the National Pediatric Trauma Registry between October 1988 and April 1996. Data Set: Demographics, cause of injury, time and place of occurrence, severity of injury, utilization of resources during acute care, in hospital death rate, functional limitations, discharge disposition, and discharge recommendation for children who sustained a traumatic brain injury associated or not with injury to other body region. Results: Two thirds of the children were male and 77.8% were one to 14 years of age. Injuries occurred mostly between noon and midnight (67.7%) and on the road (50.0%) or at home (32.0%). Nearly all injuries (90%) were unintentional, most children (63.6%) sustained injuries to other body regions, and the anatomical severity of the injuries was ten times higher than in children without traumatic brain injury. Over 40% of the children were in the intensive care unit, 20% had one or more surgical intervention, the average length of stay was six days, the median two days. The in-hospital death rate was 6.1% and 22.2% of the children developed functional limitations from the injury. At the time of discharge from acute care, most children returned home. In the group with four to nine limitations, half of the children were discharged to a rehabilitation facility. Of the children with functional limitations who returned home, physical therapy was recommended in 23.7% of the cases, occupational therapy in 13.2% of the cases, and speech therapy in 10.1% of the cases. Of those of school age discharged home with functional limitations, 1.8% were referred to special education. Conclusion: The majority of children with traumatic brain injury and functional limitations due to the injury return home at time of discharge from acute care with limited referral to potentially beneficial services. To correct these deficiencies, more research is needed to identify nonmedical factors affecting referrals.	BEN MAY INST, NORWOOD, MA USA	DiScala, C (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, DEPT PM&R, RES & TRAINING CTR REHABIL & CHILDHOOD TRAUMA, BOSTON, MA 02111 USA.						[Anonymous], 1990, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BLACK P, 1971, P INT S HEAD INJURIE; *BMDP, 1985, BMDP STAT SOFTWARE; *BORL INT, 1993, QUATTR PRO WIND VERS; *BRAIN INJ ASS, 1996, DIR BRAIN INJ REH SE; BROGAN DR, 1981, ARCH PHYS MED REHAB, V62, P215; *CARF NAT ADV COMM, 1996, REH ACCR COMM STAND; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DISCALA C, 1988, NATL PEDIAT TRAUMA R; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P685; FINESTONE HM, 1992, AM J PHYS MED REHAB, V71, P288, DOI 10.1097/00002060-199210000-00007; GANS JS, 1983, ARCH PHYS MED REHAB, V64, P176; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KWON IW, 1985, ARCH PHYS MED REHAB, V66, P415; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; LESCOHIER I, 1993, PEDIATRICS, V91, P721; McLaughlin Anne Marie, 1993, Brain Injury, V7, P45, DOI 10.3109/02699059309008155; *NAT CTR HLTH STAT, 1992, NAT HLTH INT SURV TO; Osberg JS, 1997, BRAIN INJURY, V11, P11; Osberg JS, 1996, PEDIATRICS, V98, P890; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; OSBERG JS, IN PRESS ARCH PHYS M; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RESNICK C, 1993, SOC WORK HEALTH CARE, V18, P49, DOI 10.1300/J010v18n02_03; ROSENTHAL M, 1989, COMPREHENSIVE NEUROL, V2; SCHUMAN JE, 1976, ARCH PHYS MED REHAB, V57, P343; TATE DG, 1994, ARCH PHYS MED REHAB, V75, P407, DOI 10.1016/0003-9993(94)90164-3; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; *WHO, 1989, INT CLASS DIS, V1; WRIGHT CJ, 1988, PEDIAT TRAUMA CARE; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149; YVISAKER M, 1991, J HEAD TRAUMA REHABI, V6, P10; 1991, FED REG, V137	40	49	49	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1997	12	2					1	10		10.1097/00001199-199704000-00002			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WT782	WOS:A1997WT78200003					2021-06-18	
J	Cornford, EM; Hyman, S; Cornford, ME; Caron, MJ				Cornford, EM; Hyman, S; Cornford, ME; Caron, MJ			Glut1 glucose transporter activity in human brain injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier glucose transporter; Glut1 isoform; immunogold electron microscopy; quantitative; luminal and abluminal capillary membranes; human serum albumin	ELECTRON-MICROSCOPIC IMMUNOGOLD; DEVELOPMENTAL MODULATION; ALZHEIMERS-DISEASE; BARRIER; LOCALIZATION; MEMBRANES; PROTEIN; RATS; ACID	The principal glucose transporter at the blood-brain barrier (BBB) is the Glut1 isoform, and transporter density is believed to be an index of cerebral metabolic rate. In the present study, glucose transporter expression was studied in tissue resected 7-8 h after acute traumatic brain injuries in 2 patients. Light microscopic immunochemistry indicated a zone of complete loss of the Glut1 glucose transporter isoform in microvessel endothelial cells adjacent to sites of small vessel injury, concentrically surrounded by a narrow zone of variable Glut1, and distally surrounded by capillaries with typically immunoreactive endothelia in nondisrupted parenchyma. Variably reactive capillaries displayed alternating sectors of greatly reduced and highly reactive Glut1 density, suggesting a high density and low density of transporter activity in contiguous endothelial cells. Quantitative electron microscopic immunogold analyses demonstrated that the transporter was predominantly localized to the luminal and abluminal endothelial membranes, with lesser reactivity in cytoplasm; pericyte Glut1 was minimally above background levels. In endothelial sectors with reduced Glut1 transporter immunoreactivity, the luminal:abluminal ratio of Glut1 epitopes was less than unity; while it is greater than unity in highly reactive endothelial cells. The number of Glut1-immunoreactive sites per micrometer of capillary membrane was not signficantly different from previous reported Glut1 density in seizure resections, and about 2- to 3-fold higher than in human red cells. In the same tissue samples, qualitative immunogold electron microscopy of human serum albumin indicated leakage of this protein (MW 65,000) from the vascular space into pericapillary regions. Thus the high Glut1 density observed in capillaries from acutely injured brain occurs concomitantly with compromised barrier function.	VET ADM MED CTR, SW REG VET ADM EPILEPSY CTR, NEUROL SERV, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, DIV NEUROSURG, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, BRAIN RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT PATHOL, LOS ANGELES, CA 90509 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT SURG, LOS ANGELES, CA 90509 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DIV NEUROSURG, LOS ANGELES, CA 90509 USA	Cornford, EM (corresponding author), VET ADM MED CTR, SW REG VA EPILEPSY CTR W127B, RES SERV, LOS ANGELES, CA 90073 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308, NS 25554] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS025554, P50NS030308] Funding Source: NIH RePORTER		BALDWIN SA, 1989, METHOD ENZYMOL, V174, P39; CORNFORD EM, 1995, J NEUROPATH EXP NEUR, V54, P842, DOI 10.1097/00005072-199511000-00011; CORNFORD EM, 1994, J CEREBR BLOOD F MET, V14, P106, DOI 10.1038/jcbfm.1994.15; CORNFORD EM, 1993, J CEREBR BLOOD F MET, V13, P841, DOI 10.1038/jcbfm.1993.106; CORNFORD EM, 1994, BRAIN RES, V663, P7, DOI 10.1016/0006-8993(94)90457-X; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CUNNINGHAM VJ, 1986, J CEREBR BLOOD F MET, V6, P305, DOI 10.1038/jcbfm.1986.53; DICK APK, 1986, J NEUROCHEM, V46, P1406, DOI 10.1111/j.1471-4159.1986.tb01755.x; DICK APK, 1984, P NATL ACAD SCI-BIOL, V81, P7233, DOI 10.1073/pnas.81.22.7233; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DWYER KJ, 1993, ENDOCRINOLOGY, V132, P558, DOI 10.1210/en.132.2.558; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; HORWOOD N, 1994, VIRCHOWS ARCH, V425, P69; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kumagai AK, 1996, BRAIN RES, V706, P313, DOI 10.1016/0006-8993(95)01335-0; LIWNICZ BH, 1990, NEUROSURGERY, V26, P409, DOI 10.1227/00006123-199003000-00006; LOBERG EM, 1992, ACTA NEUROPATHOL, V84, P234; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHINOHARA Y, 1990, ACT NEUR S, V51, P90; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; SMITH GM, 1991, BRAIN RES, V543, P111, DOI 10.1016/0006-8993(91)91054-5; VORBRODT AW, 1994, FOLIA HISTOCHEM CYTO, V32, P63; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	27	49	49	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					523	536		10.1089/neu.1996.13.523			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600005	8913969				2021-06-18	
J	Shaver, EG; Duhaime, AC; Curtis, M; Gennarelli, LM; Barrett, R				Shaver, EG; Duhaime, AC; Curtis, M; Gennarelli, LM; Barrett, R			Experimental acute subdural hematoma in infant piglets	PEDIATRIC NEUROSURGERY			English	Article						acute subdural hematoma; cranial window model; histopathology; piglet	CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; WHITE-MATTER; RAT; INJURY; PATHOGENESIS; HYPOTENSION; REDUCTION; REMOVAL; DAMAGE	Traumatic acute subdural hematoma is associated with high mortality in the pediatric population, yet the pathophysiology remains poorly understood. The objective of this study was to develop a pediatric model of acute subdural hematoma, and to evaluate the resultant histopathological changes in the brain. Ten 3-week-old piglets were studied. A 5-mm craniotomy was made in the right frontal skull. A small silastic tube was inserted through the underlying intact dura into the subdural space. A craniotomy was made posterior to the right coronal suture with underlying dura left intact (closed cranial window model). Injection of 5 ml autologous, nonheparinized blood was accomplished through the silastic tube. Animals were sacrificed after 72 h or 1 week. During the subdural injection, intracranial pressure rose to 62 +/- 8 mm Hg, and returned to baseline within 1 h of surgery. Mean arterial blood pressure increased transiently. Cresyl violet and hematoxyIin and eosin staining demonstrated extensive areas of white matter necrosis under the hematoma after 72 h survival (n = 7). Zones of necrosis were also noted in cortex, but were less extensive than those seen in white matter. These results differ from adult rodent models in which cortex is primarily affected. This is the first reported pediatric model of traumatic acute subdural hematoma. This model can be used in future studies to investigate pharmacological or other therapies which may improve outcome after this type of injury.	CHILDRENS HOSP PHILADELPHIA,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104							BARKS JDE, 1992, BRAIN PATHOL, V2, P235, DOI 10.1111/j.1750-3639.1992.tb00697.x; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; Duhaime A.C., 1993, J NEUROTRAUMA S1, V10, pS59; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; DUHAIME AC, 1995, J NEUROTRAUM, V13, P79; FERN R, 1993, J PHARMACOL EXP THER, V266, P1549; FERN R, 1995, J NEUROSCI 2, V15, P669; GREISEN G, 1992, BRAIN PATHOL, V2, P223, DOI 10.1111/j.1750-3639.1992.tb00695.x; KENNEDY C, 1979, ANN NEUROL, V6, P176; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; KURODA Y, 1992, NEUROSURGERY, V30, P687; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MENT LR, 1985, J NEUROSURG, V63, P899, DOI 10.3171/jns.1985.63.6.0899; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; PHEUNPATHOM N, 1993, SURG NEUROL, V40, P22; PRYDS O, 1991, ANN NEUROL, V30, P321, DOI 10.1002/ana.410300302; RORKE LB, 1992, BRAIN PATHOL, V2, P211, DOI 10.1111/j.1750-3639.1992.tb00694.x; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; YOUNG RSK, 1982, ANN NEUROL, V12, P445	22	49	49	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	SEP	1996	25	3					123	129		10.1159/000121109			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	WV516	WOS:A1996WV51600004	9144710				2021-06-18	
J	Clark, RSB; Carlos, TM; Schiding, JK; Bree, M; Fireman, LA; DeKosky, ST; Kochanek, PM				Clark, RSB; Carlos, TM; Schiding, JK; Bree, M; Fireman, LA; DeKosky, ST; Kochanek, PM			Antibodies against Mac-1 attenuate neutrophil accumulation after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						CD11b; Mac-1; head injury; neutrophil; rat; traumatic brain injury	LEUKOCYTE ADHESION MOLECULES; INFLAMMATORY INJURY; CEREBRAL-ISCHEMIA; L-SELECTIN; MONOCYTES; INFILTRATION; GRANULOCYTES; INHIBITION; EXPRESSION; REDUCTION	Neutrophils (PMN) accumulate and are associated with cerebrovascular disturbances after experimental traumatic or ischemic brain injury, and meningitis. We hypothesized that posttraumatic PMN accumulation in brain is mediated by the PMN adhesion receptor Mac-1 (CD11b/CD18). Anesthetized rats were randomized to receive 2 mg/kg intravenously of murine monoclonal antibody to rat Mac-1 (1-B6) or anti-Mac-1 F(ab)2' [1-B6F(ab)2'] fragment (Repligen Corp., Cambridge, MA), Control rats were treated with isotype matched control antibody. Rats were subjected to percussive trauma to the right parietal cortex 30 min after treatment. Rats were killed 24 h posttrauma, and PMN accumulation was assessed by myeloperoxidase (MPO) activity. The presence of 1-B6F(ab)2' bound to PMN in brain after trauma was assessed by immunohistochemistry. Complete blood cell counts were obtained before treatment and 24 h after trauma, Brain MPO activity was reduced by 43% in the 1-B6-treated rats vs. controls (0.31 +/- 0.09 vs 0.55 +/- 0.10 U/g, n = 6/group, p = 0.013) and by 34% in the 1-B6F(ab)2'-treated rats vs. controls (0.43 +/- 0.10 vs, 0.65 +/- 0.09 U/g, n = 6/group, p = 0.006). Systemic neutropenia developed in the 1-B6-treated rats (absolute PMN count decreased by 73% vs. baseline) but not in rats treated with 1-B6F(ab)2' (absolute PMN count increased by 26 and 25% vs. baseline in treated and controls, respectively). Immunohistochemical staining showed 1-B6F(ab)2' on the surface of infiltrated PMN 24 h after trauma. Mac-1 mediates posttraumatic PMN accumulation in brain, This accumulation can be attenuated by 34%, without reducing circulating PMN, using an anti-Mac-1 F(ab)2' fragment; however, some PMN coated with 1-B6F(ab)2' still infiltrate into traumatized tissue, These results are similar to those reported in models of cerebral ischemia, and suggest the participation of multiple PMN adhesion pathways after ischemic and traumatic brain injury.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15260 USA; REPLIGEN CORP, CAMBRIDGE, MA 02139 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15260 USA			Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758			ALBELDA SM, 1994, FASEB J, V8, P504; Barman T.E., 1985, ENZYME HDB, VI, P234; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; Carlos T. M., 1995, Journal of Neurotrauma, V12, P458; CARLOS TM, 1994, BLOOD, V84, P2068; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; HARKNESS JE, 1989, BIOL MED RABBITS ROD, P47; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; LUNDAHL J, 1994, INFLAMMATION, V18, P67, DOI 10.1007/BF01534599; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; MULLIGAN MS, 1993, J CLIN INVEST, V91, P577, DOI 10.1172/JCI116237; MULLIGAN MS, 1992, J IMMUNOL, V148, P1847; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; MULLIGAN MS, 1993, J IMMUNOL, V150, P2401; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; TOROK C, 1993, ARCH DIS CHILD-FETAL, V68, P561, DOI 10.1136/adc.68.5_Spec_No.561; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	34	49	49	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1996	13	6					333	341		10.1089/neu.1996.13.333			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UZ052	WOS:A1996UZ05200006	8835801				2021-06-18	
J	Taylor, AE; Cox, CA; Mailis, A				Taylor, AE; Cox, CA; Mailis, A			Persistent neuropsychological deficits following whiplash: Evidence for chronic mild traumatic brain injury?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							DIGIT RECOGNITION TEST; HEAD-INJURY; PAIN	Objective: To investigate claims of neuropsychological evidence for acquired brain damage (axonal degeneration) in chronic whiplash. Design: Fifteen whiplash patients (Whiplash) were compared with 10 patients who had documented moderate-to-severe head injury (Mod-Sev), and with 24 patients who had chronic pain syndrome (CPS) and no history of head injury on two tests of mental efficiency considered highly sensitive to and specific for the subtle effects of brain trauma. All 3 groups, assessed 4 years after onset in a teaching hospital setting were matched for age, education, and IQ. Exclusion criteria included narcotics/benzodiazepines or (suspected) malingering. Subjective ratings of depression and pain were collected as well as objective indices of outcome (return to work/school). Measures: Neuropsychological test scores were subjected to ANOVA followed by regression analysis regarding the possible effects of age, IQ, pain, and mood ratings. Results: No differences between the Whiplash, Mod-Sev, or CPS groups on the neuropsychological tests emerged. IQ was strongly related to mental efficiency. Counterintuitively, Mod-Sev patients complained of less depression and pain than did Whiplash or CPS patients (where no differences were seen) and displayed a better outcome. Finally, although results from 3 of the original 18 patients in the Whiplash group were later discarded for malingering, no malingering was detected in the 2 other groups. Conclusions: The theory of neuronal degeneration in the etiology of whiplash-related cognitive complaints was not supported, nor was the specificity of neuropsychological tests in detecting the subtle effects of brain trauma. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV TORONTO, DEPT MED, TORONTO, ON M5S 1A1, CANADA; TORONTO HOSP, DEPT PSYCHOL, TORONTO, ON, CANADA; UNIV TORONTO, PLAYFAIR NEUROSCI UNIT, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT REHABIL MED, TORONTO, ON M5S 1A1, CANADA							[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1993, CLIN NEUROPSYCHOL, V7, P104, DOI DOI 10.1080/13854049308401892; BINDER LM, 1991, J CLIN CONSULTING PS, V3, P171; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Graham JR, 1990, MMPI 2 ASSESSING PER; GRIGSBY J, 1993, ARCH CLIN NEUROPSYCH, V9, P2; GRONWALL D, 1989, MILD HEAD INJURY, P154; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1837; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Mailis Angela, 1993, Pain Clinic, V6, P71; MALONEY A, 1988, CLIN ASSESSMENT MALI, P84; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; *PSYCH CORP, 1987, WECHSL MEM SCAL REV; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; ROGERS R, 1988, CLIN ASSESSMENT MALI; SHAPIRO AP, 1993, SPINE STATE ART REV, V7, P455; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Stuss D.T., 1987, CLIN NEUROPSYCHOL, V1, P139, DOI DOI 10.1080/13854048708520046; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vernon-Wilkinson R, 1993, ARCH CLIN NEUROPSYCH, V9, P2	34	49	50	1	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1996	77	6					529	535		10.1016/S0003-9993(96)90290-7			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	UP731	WOS:A1996UP73100001	8831467				2021-06-18	
J	PIKE, BR; HAMM, RJ				PIKE, BR; HAMM, RJ			POSTINJURY ADMINISTRATION OF BIBN-99, A SELECTIVE MUSCARINIC M(2) RECEPTOR ANTAGONIST, IMPROVES COGNITIVE PERFORMANCE FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	BRAIN RESEARCH			English	Article						BIBN 99; CHOLINERGIC; M2 ANTAGONIST; MEMORY; MORRIS WATER MAZE; MUSCARINIC; RATS; TRAUMATIC BRAIN INJURY; TREATMENT	CLOSED-HEAD-INJURY; AUTORECEPTORS; IMPAIRMENT; RECOVERY; DEFICITS; BEHAVIOR; RELEASE; MOTOR; CNS; M2	Mild to moderate traumatic brain injury (TBI) is associated with enduring impairments of cognitive function in both humans acid animals. However, few experiments have investigated the role of post-injury pharmacologic strategies for attenuating the observed cognitive impairment after TBI. This investigation examined the effects of selective blockade of the presynaptic muscarinic M2 autoreceptor with BIBN 99 on cognitive recovery following rodent TBI. Experiment 1 investigated the effects of delayed post-injury administration of BIBN 99 on cognitive performance following moderate central fluid percussion TBI (2.1 +/- 0.05 atm). On days 11-15 after injury-cognitive performance was assessed with a Morris water maze (MWM) task. One hour before MWM testing injured rats were injected (s.c.) with either vehicle (n = 9), 0.5 (n = 8), or 1.0 (n = 8) mg/kg of BIBN 99. Results indicated that injured rats receiving the delayed post-injury treatment with BIBN 99 performed no better than injured-vehicle treated rats. In experiment 2, injured rats were injected (s.c.) once daily with either vehicle (n = 9), 0.5 (n = 9), or 1.0 (n = 9) mg/kg of BIBN 99 throughout the duration of the experiment beginning 24 h after TBI. Sham-injured animals injected (s.c.) with vehicle (n = 9) or 1.0 (n = 8) mg/kg of BIBN 99 were included for comparison. On days 11-15 after injury, cognitive performance was assessed with the MWM procedure. Results of the second experiment indicated that both doses of BIBN 99 were effective in attenuating cognitive deficits in the MWM as compared to the injured-vehicle treated animals (P < 0.05 for both comparisons). The results also revealed that sham-injured animals were unaffected by the 1.0 mg/kg dose of BIBN 99 on MWM performance. Thus, cholinergic enhancement by selective blockade of the presynaptic M(2) autoreceptor is an efficacious strategy for the post-injury amelioration of cognitive deficits following experimental TBI. However, time and duration of administration may be important factors that affect the efficacy of treatment.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		ALLAOUA H, 1993, SYNAPSE, V15, P39, DOI 10.1002/syn.890150105; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BYMASTER FP, 1994, J PHARMACOL EXP THER, V269, P282; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1994, J NEUROTRAUM, V11, P107; DOODS H, 1993, EUR J PHARMACOL, V242, P23, DOI 10.1016/0014-2999(93)90005-3; DOODS HN, 1993, LIFE SCI, V52, P497, DOI 10.1016/0024-3205(93)90307-O; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Grady M. S., 1992, Society for Neuroscience Abstracts, V18, P172; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HOSS W, 1990, BRAIN RES, V517, P195, DOI 10.1016/0006-8993(90)91026-D; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; LAPCHAK PA, 1989, BRAIN RES, V496, P285, DOI 10.1016/0006-8993(89)91075-5; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Liu S. J., 1993, Society for Neuroscience Abstracts, V19, P1881; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODELL DM, IN PRESS J NEUROTRAU; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; POTTER LT, 1984, TRENDS PHARM SCI S, V5, P22; RICHARD J W, 1991, Society for Neuroscience Abstracts, V17, P781; RICHARDS MH, 1990, BRIT J PHARMACOL, V99, P753, DOI 10.1111/j.1476-5381.1990.tb13002.x; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SCHMITTEREDGECO.ME, 1992, J CLIN EXP NEUROPSYC, V14, P717; SHANNON HE, 1994, J PHARMACOL EXP THER, V269, P271; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Wilson A., 1993, Society for Neuroscience Abstracts, V19, P1813	51	49	49	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 17	1995	686	1					37	43		10.1016/0006-8993(95)00448-Y			7	Neurosciences	Neurosciences & Neurology	RK557	WOS:A1995RK55700006	7583269				2021-06-18	
J	SIOUTOS, PJ; OROZCO, JA; CARTER, LP; WEINAND, ME; HAMILTON, AJ; WILLIAMS, FC				SIOUTOS, PJ; OROZCO, JA; CARTER, LP; WEINAND, ME; HAMILTON, AJ; WILLIAMS, FC			CONTINUOUS REGIONAL CEREBRAL CORTICAL BLOOD-FLOW MONITORING IN HEAD-INJURED PATIENTS	NEUROSURGERY			English	Article						BRAIN ISCHEMIA; CEREBRAL BLOOD FLOW; THERMAL DIFFUSION FLOWMETRY; TRAUMATIC BRAIN INJURY	TRAUMATIC BRAIN INJURY; XENON ENHANCED CT; THERMAL-DIFFUSION; INTRAOPERATIVE MEASUREMENT; INTRAVENTRICULAR PRESSURE; COMATOSE PATIENTS; METABOLISM; ISCHEMIA; CLEARANCE; PERFUSION	CONTINUOUS REGIONAL CEREBRAL cortical blood flow (rCoBF) was monitored with thermal diffusion flowmetry in 56 severely head-injured patients. Adequate, reliable data were accumulated from 37 patients (21 acute subdural hematomas, 10 cerebral contusions, 4 epidural hematomas, and 2 intracerebral hematomas). The thermal sensor was placed at the time of either craniotomy or burr hole placement. In 15 patients, monitoring was initiated within 8 hours of injury. One-third of the comatose patients monitored within 8 hours had rCoBF measurements of 18 ml per 100 g per minute or less, consistent with previous reports of significant ischemia in the early postinjury period. Initial rCoBF measurements were similar in the patients with Glasgow Coma Scale scores of 3 to 7 and in those with scores of 8 or greater. In patients with poor outcomes, rCoBF measurements did not change significantly from initial measurements; however, in those patients who had better outcomes, final rCoBF measurements were higher than initial rCoBF measurements. The patients who had better outcomes experienced normalization of rCoBF during the period of monitoring, and patients with poor outcomes had markedly reduced final rCoBF. These changes were statistically significant. When management was based strictly upon the intracranial pressure, examples of inappropriate treatment were found. For example, hyperemia and increased intracranial pressure treated with mannitol caused further rCoBF increase, and elevated intracranial pressure with low cerebral blood flow treated with hyperventilation increased the severity of ischemia. In 3 (5%) of 56 patients, wound infections developed. Continuous rCoBF monitoring in head-injured patients offers new therapeutic and prognostic insights into their management.	UNIV OKLAHOMA,SCH MED,DEPT NEUROSURG,OKLAHOMA CITY,OK; UNIV ARIZONA,SCH MED,DEPT SURG,NEUROSURG SECT,TUCSON,AZ							AGNOLI A, 1969, CEREBRAL BLOOD FLOW, P31; ARBIT E, 1989, NEUROSURGERY, V24, P166, DOI 10.1227/00006123-198902000-00003; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARTER LP, 1973, STROKE, V4, P917, DOI 10.1161/01.STR.4.6.917; CARTER LP, 1973, J NEUROL NEUROSUR PS, V36, P906, DOI 10.1136/jnnp.36.6.906; CARTER LP, 1983, NEUROSURGERY, V12, P620; CARTER LP, 1978, NEUROSURGERY, V2, P223; CARTER LP, 1981, STROKE, V12, P513, DOI 10.1161/01.STR.12.4.513; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; DRAYER BP, 1978, STROKE, V9, P123, DOI 10.1161/01.STR.9.2.123; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GAINES C, 1983, STROKE, V14, P66, DOI 10.1161/01.STR.14.1.66; GOKASLAN ZL, 1989, J NEUROSURG, V70, pA323; GOPINATH SP, 1993, 1993 AANS ANN M BOST; GUR D, 1982, STROKE, V13, P750, DOI 10.1161/01.STR.13.6.750; HERSCHOVICH P, 1987, CEREBRAL BLOOD FLOW, P257; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KETY SS, 1945, AM J PHYSIOL, V143, P53; LASSEN NA, 1959, PHYSIOL REV, V39, P183; MALLETT BL, 1965, CLIN SCI, V29, P179; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MEYER JS, 1981, STROKE, V12, P426, DOI 10.1161/01.STR.12.4.426; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSENBLUM BR, 1987, J NEUROSURG, V66, P396, DOI 10.3171/jns.1987.66.3.0396; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221	38	49	50	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1995	36	5					943	949		10.1227/00006123-199505000-00009			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QV351	WOS:A1995QV35100031	7791986				2021-06-18	
J	CARDENAS, DD; MCLEAN, A; FARRELLROBERTS, L; BAKER, L; BROOKE, M; HASELKORN, J				CARDENAS, DD; MCLEAN, A; FARRELLROBERTS, L; BAKER, L; BROOKE, M; HASELKORN, J			ORAL PHYSOSTIGMINE AND IMPAIRED MEMORY IN ADULTS WITH BRAIN INJURY	BRAIN INJURY			English	Article							ALZHEIMERS PRESENILE-DEMENTIA; HEAD-INJURY; MNESIC PERFORMANCES; SCOPOLAMINE; DISEASE	The purpose of this study was to examine the effects of physostigmine, a cholinergic agonist, on memory loss after traumatic brain injury (TBI), as compared to placebo or scopolamine, a cholinergic antagonist, using a double-blind, placebo-controlled design. Each subject received each active drug and placebo. Neuropsychological measures (Wechsler Memory Scale I and II, Selective Reminding Test, Trail-Making Test, Parts A and B, Digit Symbol, and Memory Questionnaire) and measures of clinical balance were completed at baseline, after each drug phase, and at 1 month follow-up. Thirty-six subjects completed the study with results showing an improvement in memory scores in 44% of subjects (responders) while taking oral physostigmine. The most sensitive measure was the Selective Reminding Test, specifically Long-term Storage. The impact of drugs on standing balance as compared to placebo was improved standing time in the responders: (1) with physostigmine when standing tandem with eyes closed (p<0.05), and (2) with scopolamine when standing on one foot with eyes closed (p<0.05). Results support the potential benefit of cholinergic agonists on memory after TBI and the need for further research of possible clinical markers for the drug.	NEUROCARE INC,CONCORD,CA; VET ADM MED CTR,SEATTLE,WA; TUFTS UNIV,SCH MED,BOSTON,MA 02111	CARDENAS, DD (corresponding author), UNIV WASHINGTON,DEPT REHABIL MED,RJ-30,SEATTLE,WA 98195, USA.						BARTUS RT, 1979, SCIENCE, V206, P1087, DOI 10.1126/science.227061; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS DN, 1975, CORTEX, V11, P328; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Butler PF, 1932, J AMER MED ASSOC, V99, P1329, DOI 10.1001/jama.1932.02740680025006; CAINE ED, 1981, PSYCHOPHARMACOLOGY, V74, P74, DOI 10.1007/BF00431761; CALTAGIRONE C, 1982, INT J NEUROSCI, V16, P247, DOI 10.3109/00207458209147153; CALTAGIRONE C, 1983, INT J NEUROSCI, V18, P143, DOI 10.3109/00207458308985888; COYE MJ, 1986, J OCCUP MED, V28, P519; DAVIS KL, 1978, LIFE SCI, V23, P1729, DOI 10.1016/0024-3205(78)90100-5; DAVIS KL, 1978, SCIENCE, V201, P272, DOI 10.1126/science.351807; DEUTSCH JA, 1971, SCIENCE, V174, P788, DOI 10.1126/science.174.4011.788; Drachman D.A., 1979, NUTR BRAIN, P351; Grober E, 1989, J Cogn Neurosci, V1, P327, DOI 10.1162/jocn.1989.1.4.327; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; LEVIN ED, 1990, BEHAV NEURAL BIOL, V54, P271, DOI 10.1016/0163-1047(90)90639-N; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Martin HE, 1925, J AMER MED ASSOC, V84, P1407, DOI 10.1001/jama.1925.02660450015009; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; MOHS R, 1980, AGING 1980S, P181; MOHS RC, 1982, ALZHEIMERS DISEASE R, P351; PARROTT AC, 1987, NEUROPSYCHOBIOLOGY, V17, P53, DOI 10.1159/000118371; PETERS BH, 1982, AGING ALZHEIMERS DIS, P421; PIETERKARK RA, 1977, NEUROLOGY, V27, P70; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; REUSCH J, 1944, AM J PSYCHIAT, V100, P480; RIDLEY RM, 1988, BRAIN RES, V456, P71, DOI 10.1016/0006-8993(88)90348-4; Ritvo M, 1927, AM J ROENTGENOL RADI, V18, P301; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHARPLESS NS, 1985, LANCET, V1, P1397; SMITH CM, 1982, ALZHEIMERS DISEASE R, P405; SULLIVAN EV, 1982, ALZHEIMERS DISEASE R, P361; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; THAL LJ, 1983, ANN NEUROL, V13, P491, DOI 10.1002/ana.410130504; THAL LJ, 1983, NEW ENGL J MED, V308, P720; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; ZEISEL S, 1981, NATURE, V293, P187, DOI 10.1038/293187a0	41	49	50	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1994	8	7					579	587		10.3109/02699059409151010			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PH426	WOS:A1994PH42600001	7804294				2021-06-18	
J	PADULA, WV; ARGYRIS, S; RAY, J				PADULA, WV; ARGYRIS, S; RAY, J			VISUAL-EVOKED POTENTIALS (VEP) EVALUATING TREATMENT FOR POSTTRAUMA VISION SYNDROME (PTVS) IN PATIENTS WITH TRAUMATIC BRAIN INJURIES (TBI)	BRAIN INJURY			English	Article								Post-trauma vision syndrome (PTVS), which is characterized by binocular function problems, may bc caused by dysfunction of the ambient visual process which is part of the sensory-motor feedback loop rather than specific oculomotor disturbance. Clinically, PTVS frequently presents with symptoms of diplopia, blur, seeing movement in the spatial environment, vertigo, and hallucination-like experiences. Visual evoked potentials (P100) were used to evaluate an experimental group (n = 10) of subjects who suffered a traumatic brain injury, and a control group (n = 10). A new treatment using prisms and bi-nasal occluders which affected amplitude responses of the VEP was evaluated. The results demonstrate the amplitude of the VEP is a function of cortical binocular integration, and that this is influenced by dysfunction of the ambient visual process. The results also demonstrate that base-in prism and bi-nasal occluders arc an effective means to treat ambient vision disturbances resulting from head trauma which causes PTVS.	GARDEN STATE REHABIL HOSP,TOMS RIVER,NJ							Carrol R., 1984, ARCH OPHTHALMOL-CHIC, V88, P57; CINOTTI A, 1980, J AM GERIATR SOC, V28, P84, DOI 10.1111/j.1532-5415.1980.tb00211.x; FIRSCHING R, 1990, NEUROSURG REV, V13, P141, DOI 10.1007/BF00383655; GIANUTSOS R, J AM OPTOM ASSOC, V69, P573; Halliday A M, 1973, Trans Ophthalmol Soc U K, V93, P315; HART C, 1964, P ROYAL SOC MED, V62; LIEBOWITZ HW, IN PRESS ORG REPRESE; NASHOLD BS, 1972, ARCH OPHTHALMOL-CHIC, V88, P245; PADULA WV, 1988, BEHAVIORAL VISION AP; REGAN D, 1977, OPHTHALMOLOGICA, V175, P159, DOI 10.1159/000308649; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; RUTKOWSKI PC, 1982, J AM ACADEMY OPHTHAL, V73, P660; Soden R, 1983, J Am Optom Assoc, V54, P451; STANWORTH A, 1974, BRIT J OPHTHALMOL, V58, P266, DOI 10.1136/bjo.58.3.266; STREFF J, 1992, NEUROOPTOMETRIC REHA, V2, P1; TREVARTHEN C, 1973, BRAIN, V96, P547, DOI 10.1093/brain/96.3.547; WICK RE, 1968, J AM ACADEMY OPTOMET, V59, P475	17	49	49	0	11	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1994	8	2					125	133		10.3109/02699059409150964			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NA029	WOS:A1994NA02900002	8193632				2021-06-18	
J	THEODOROS, DG; MURDOCH, BE; CHENERY, HJ				THEODOROS, DG; MURDOCH, BE; CHENERY, HJ			PERCEPTUAL SPEECH CHARACTERISTICS OF DYSARTHRIC SPEAKERS FOLLOWING SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							ACQUIRED BRAIN INJURY; VERBAL IMPAIRMENT; TRAUMATIC DYSARTHRIA; VOWEL DISTORTION; LANGUAGE; RECOVERY	The perceptual speech characteristics of a group of 20 severely closed head-injured (CHI) subjects were compared with those of a normal non-neurologically impaired control group matched for age and sex. The CHI subjects were found to be significantly less intelligible than the controls, and exhibited deficits in the prosodic, resonatory, articulatory, respiratory and phonatory aspects of speech production. The most frequently occurring deviant speech dimensions related to disturbances of prosody, resonance, articulation and respiration, with those deviant speech dimensions pertaining to phonation being less apparent in the speech of the CHI subjects. The findings are discussed in relation to the heterogeneity of the CHI population and the effects of CHI on neuromuscular function. The study highlights the need for accurate, instrumental physiological evaluation of the motor subsystems involved in speech production.		THEODOROS, DG (corresponding author), UNIV QUEENSLAND,DEPT SPEECH & HEARING,ST LUCIA,QLD 4072,AUSTRALIA.		Chenery, Helen J/F-5194-2010; Murdoch, Bruce E/C-1397-2012; Theodoros, Deborah/F-1362-2010				BELLAIRE K, 1986, J COMMUN DISORD, V19, P271, DOI 10.1016/0021-9924(86)90033-X; CANTER GJ, 1965, J SPEECH HEAR DISORD, V30, P217, DOI 10.1044/jshd.3003.217; Chenery H.J., 1990, AUST J HUMAN COMMUN, V18, p19 ; Darley F., 1975, MOTOR SPEECH DISORDE; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HARDY J, 1961, THESIS U IOWA; HARTMANN E, 1984, BRIT J DISORD COMMUN, V19, P253; HERMAN K, 1965, 8TH P INT C NEUR VIE, V1; HIXON TJ, 1973, NORMAL ASPECTS SPEEC, P75; HOLM S, 1979, SCAND J STAT, V6, P65; HOODIN RB, 1989, J COMMUN DISORD, V22, P169, DOI 10.1016/0021-9924(89)90014-2; HOODIN RB, 1989, FOLIA PHONIATR, V41, P249, DOI 10.1159/000265976; Juraimi A., 2005, SEMINARS SPEECH LANG, V24, P20; KENT R, 1975, J SPEECH HEAR DISORD, V40, P115, DOI 10.1044/jshd.4001.115; KENT RD, 1975, J SPEECH HEAR DISORD, V40, P467, DOI 10.1044/jshd.4004.467; KENT RD, 1982, BRAIN LANG, V15, P259, DOI 10.1016/0093-934X(82)90060-8; LEHISTE I, 1965, BIBLIOTHECA PHONETIC, V2; LEVIN HS, 1981, ACQUIRED APHASIA, P427; LOGEMANN JA, 1978, J SPEECH HEAR DISORD, V43, P47, DOI 10.1044/jshd.4301.47; LUCHSINGER R, 1970, SPRACHE STORUNGEN, V2; LUZZATTI C, 1989, APHASIOLOGY, V3, P643, DOI 10.1080/02687038908249030; METTER EJ, 1985, SPEECH LANGUAGE EVAL, P343; MORRIS RJ, 1989, J COMMUN DISORD, V22, P23, DOI 10.1016/0021-9924(89)90004-X; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; MURDOCH BE, 1989, AUSTR J HUMAN COMMUN, V17, P21; Murdoch Bruce E., 1990, AUSTR J HUMAN COMMUN, V18, P83; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; NETSELL R, 1979, ARCH PHYS MED REHAB, V60, P502; RUSK H, 1969, LATE EFFECTS HEAD IN, P327; Sarno M, 1985, SPEECH LANGUAGE EVAL, P323; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; Simmons N., 1983, CLIN DYSARTHRIA, P283; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VOGEL M, 1982, FOLIA PHONIATR, V34, P150, DOI 10.1159/000265644; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; VONCRAMON D, 1984, ZENTRALE STIMMSTOERU; Weismer G., 1984, DYSARTHRIAS PHYSL AC, P101; WUNDERLI J, 1962, Schweiz Arch Neurol Neurochir Psychiatr, V90, P74; Yorkston K. M., 1984, DYSARTHRIAS PHYSL AC, P131; Yorkston K.M., 1981, ASSESSMENT INTELLIGE; Yorkston K. M., 1988, CLIN MANAGEMENT DYSA; YORKSTON KM, 1981, J SPEECH HEAR DISORD, V46, P296, DOI 10.1044/jshd.4603.296; YORKSTON KM, 1989, ARCH PHYS MED REHAB, V70, P313; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215; ZIEGLER W, 1983, PHONETICA, V40, P63; ZIEGLER W, 1983, PHONETICA, V40, P312, DOI 10.1159/000261698	51	49	49	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1994	8	2					101	124		10.3109/02699059409150963			24	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NA029	WOS:A1994NA02900001	8193631				2021-06-18	
J	SIETSEMA, JM; NELSON, DL; MULDER, RM; MERVAUSCHEIDEL, D; WHITE, BE				SIETSEMA, JM; NELSON, DL; MULDER, RM; MERVAUSCHEIDEL, D; WHITE, BE			THE USE OF A GAME TO PROMOTE ARM REACH IN PERSONS WITH TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						DEVELOPMENTAL TASKS; MOTOR CONTROL; MOVEMENT ANALYSIS; NEURODEVELOPMENTAL THERAPY	CEREBRAL-PALSY; ADDED-PURPOSE; PERFORMANCE; OCCUPATION	This study tested a principle of occupational therapy and motor learning theory in the context of neurodevelopmental treatment techniques. Ten trials of occupationally embedded intervention (playing Simon,(TM) a computer-controlled game) were compared with 10 trials of rote arm-reach exercise. A counterbalanced design was structured so that each subject experienced each condition one week apart Subjects were 17 men and 3 women with traumatic brain injury who exhibited mild to moderate spasticity in the upper extremity. Maximum distance from hip to wrist during active reach of the affected extremity was measured by digitization of videotape with the Motion Analysis(TM) EV-3D system. Results indicated that the use of the game elicited significantly more range of motion than the rote exercise (t (19) = 5 77, p < .001). These results support the use of an occupationally embedded intervention for persons with traumatic brain injury and add to the theoretical base of occupational therapy.	NETWORK BRAIN INJURY PROGRAM, GRAND RAPIDS, MI USA; WESTERN MICHIGAN ARTHRIT INST, GRAND RAPIDS, MI USA; WESTERN MICHIGAN UNIV, DEPT OCCUPAT THERAPY, KALAMAZOO, MI 49008 USA; NOVACARE, GRAND RAPIDS, MI USA; MARY FREE BED HOSP & REHABIL CTR, GRAND RAPIDS, MI USA; WESTERN MICHIGAN UNIV, DEPT IND ENGN, KALAMAZOO, MI 49008 USA							Bernstein N., 1967, COORDINATION REGULAT; BLOCH MW, 1989, AM J OCCUP THER, V43, P25, DOI 10.5014/ajot.43.1.25; BOBATH B, 1971, ABNORMAL POSTURAL RE; BOBATH B, 1979, ADULT HEMIPLEGIA EVA; Carr J, 1987, MOTOR RELEARNING PRO; Christiansen C., 1991, OCCUPATIONAL THERAPY; DAVIS PM, 1985, STEPS FOLLOW GUIDE T; DOW PW, 1989, OCCUPATIONAL THERAPY, P484; EGGERS O, 1983, OCCUPATIONALO THERAP; FIDLER GS, 1978, AM J OCCUP THER, V32, P305; Fitts PM., 1967, LEARNING SKILLED PER; HECK SA, 1988, AM J OCCUP THER, V42, P577, DOI 10.5014/ajot.42.9.577; KIELHOFNER G, 1980, AM J OCCUP THER, V34, P572, DOI 10.5014/ajot.34.9.572; KIRCHER MA, 1984, AM J OCCUP THER, V38, P165, DOI 10.5014/ajot.38.3.165; KLUZIK J, 1990, PHYS THER, V70, P65, DOI 10.1093/ptj/70.2.65; MALKMUS D, 1980, REHABILITATION HEAD; Marteniuk RG, 1979, PHYSIOTHER CAN, V31, P187; MATHIOWETZ VG, 1992, THESIS U MINNESOTA; MCPHERSON JJ, 1991, AM J OCCUP THER, V45, P123, DOI 10.5014/ajot.45.2.123; MILLER L, 1987, Occupational Therapy in Mental Health, V7, P55, DOI 10.1300/J004v07n01_04; Mosey AC., 1986, PSYCHOSOCIAL COMPONE; Mullins C., 1987, PHYSICAL OCCUPATIONA, V5, P29, DOI 10.1300/J148v05n03_04; NELSON DL, 1988, AM J OCCUP THER, V42, P633, DOI 10.5014/ajot.42.10.633; NELSON DL, 1989, TOP GERIATR REHABIL, V4, P12; SABARI JS, 1991, AM J OCCUP THER, V45, P523, DOI 10.5014/ajot.45.6.523; Schmidt R. A., 1988, MOTOR CONTROL LEARNI; STEINBECK TM, 1986, AM J OCCUP THER, V40, P529, DOI 10.5014/ajot.40.8.529; WEST WL, 1984, AM J OCCUP THER, V38, P15, DOI 10.5014/ajot.38.1.15; YODER RM, 1989, AM J OCCUP THER, V43, P581, DOI 10.5014/ajot.43.9.581	29	49	50	0	11	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JAN	1993	47	1					19	24		10.5014/ajot.47.1.19			6	Rehabilitation	Rehabilitation	KC858	WOS:A1993KC85800003	8418672				2021-06-18	
J	DOEZEMA, D; KING, JN; TANDBERG, D; ESPINOSA, MC; ORRISON, WW				DOEZEMA, D; KING, JN; TANDBERG, D; ESPINOSA, MC; ORRISON, WW			MAGNETIC-RESONANCE-IMAGING IN MINOR HEAD-INJURY	ANNALS OF EMERGENCY MEDICINE			English	Article						CONCUSSION, BRAIN; HEAD INJURY; MAGNETIC RESONANCE IMAGING		Study objectives: To investigate the role of cranial magnetic resonance (MR) imaging in evaluating patients discharged from the emergency department after minor head injury. Design: A prospective blinded cohort study. Setting: University hospital ED. Type of participants: Fifty-eight patients with minor head injury who were discharged from the ED with written head injury instructions. Patients admitted to the hospital were excluded. Interventions: Ultra-low-field cranial MR scans were performed on patients within 24 hours of discharge. Scans were read blindly by two radiologists. Measurements and main results: Fisher's exact test was used to compare symptoms in patients with abnormal and normal MR scans. There was no significant difference in symptoms between patients with abnormal and those with normal scans (P > .10). The proportion of abnormal MR scans was analyzed using the binomial distribution. Six of the 58 patients (10.3%) had traumatic intracranial abnormalities (proportion, 0.103; SD, 0.04; 95% CI, 0.04 - 0.21). Three had cortical contusions, and three had small subdural hematomas. Two of the six patients with abnormal MR scans, both with small subdural hematomas, had normal computed tomography scans. Conclusion: Ten percent of patients discharged from the ED after minor head injury had abnormal ultra-low-field cranial MR scans. Additional research is needed to establish the clinical importance of this unexpected observation.		DOEZEMA, D (corresponding author), UNIV NEW MEXICO,DIV EMERGENCY MED,620 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.							0	49	51	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	DEC	1991	20	12					1281	1285		10.1016/S0196-0644(05)81065-0			5	Emergency Medicine	Emergency Medicine	GR823	WOS:A1991GR82300001	1746728				2021-06-18	
J	SCHWARZ, N; BUCHINGER, W; GAUDERNAK, T; RUSSE, F; ZECHNER, W				SCHWARZ, N; BUCHINGER, W; GAUDERNAK, T; RUSSE, F; ZECHNER, W			INJURIES TO THE CERVICAL-SPINE CAUSING VERTEBRAL ARTERY TRAUMA - CASE-REPORTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							DISLOCATIONS; REDUCTION; HEAD; NECK	In four patients with lesions of the vertebral artery resulting from cervical spine injury, two were due to unilateral facet dislocation and two to fractures of the dens. There was one arterial occlusion with minor vertebrobasilar symptoms, and an arterial lesion with thrombosis causing embolic occlusion of the basilar artery with lethal outcome. In one patient a fresh fracture of the dens caused dislocation of C1/2 with reversible occlusion of the left and stenosis of the right vertebral artery, resulting in unconsciousness. In a patient with pseudarthrosis of the dens an aneurysm of the vertebral artery could be detected. Cerebellar or cerebral symptoms associated with cervical spine injury should be investigated by vertebral angiography because vertebral arterial injury may be more common than suspected and may simulate traumatic brain damage.	UNFALLKRANKENHAUS LORENZ BOEHLER, VIENNA, AUSTRIA	SCHWARZ, N (corresponding author), UNFALLKRANKENHAUS MEIDLING, KUNDRATSTR 37, A-1120 VIENNA, AUSTRIA.						AEBI M, 1986, CLIN ORTHOP RELAT R, P244; ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; ARGENSON C, 1980, ANAT CLIN, V2, P29; aternus KS., 1985, ARTERIA VERTEBRALIS, P61; CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849; COTLER HB, 1986, CLIN ORTHOP RELAT R, V214, P185; DRAGON R, 1981, AM J SURG, V141, P497, DOI 10.1016/0002-9610(81)90147-1; FAST A, 1987, SPINE, V12, P840, DOI 10.1097/00007632-198711000-00003; Gallie WE., 1939, AM J SURG, V46, P495, DOI DOI 10.1016/S0002-9610(39)90309-0; GEORGE B, 1989, NEUROSURGERY, V24, P206, DOI 10.1227/00006123-198902000-00009; GEORGE B, 1987, VERTEBRAL ARTERY; GOLUEKE P, 1987, J TRAUMA, V27, P856, DOI 10.1097/00005373-198708000-00003; GURDJIAN ES, 1963, J NEUROSURG, V20, P418, DOI 10.3171/jns.1963.20.5.0418; HAYES P, 1980, J TRAUMA, V20, P904, DOI 10.1097/00005373-198010000-00018; HEILBRUN MP, 1972, J NEUROSURG, V37, P219, DOI 10.3171/jns.1972.37.2.0219; Hummel A, 1988, Unfallchirurgie, V14, P311; KATIRJI MB, 1985, ARCH NEUROL-CHICAGO, V42, P242, DOI 10.1001/archneur.1985.04060030060010; LEWIN W, 1965, BRIT J SURG, V52, P223, DOI 10.1002/bjs.1800520320; MEIER DE, 1981, ARCH SURG-CHICAGO, V116, P236; OSTI OL, 1989, J BONE JOINT SURG BR, V71, P275; REID JDS, 1988, J TRAUMA, V28, P1007, DOI 10.1097/00005373-198807000-00016; SABISTON CP, 1988, J TRAUMA, V28, P832, DOI 10.1097/00005373-198806000-00020; SCHMITT HP, 1977, ARCH ORTHOP TRAUM SU, V87, P235, DOI 10.1007/BF00415211; SHERMAN DG, 1981, STROKE, V12, P2, DOI 10.1161/01.STR.12.1.2; SIMEONE FA, 1968, J NEUROSURG, V29, P540, DOI 10.3171/jns.1968.29.5.0540; SINGH S, 1971, Neurology India, V19, P172; SIX EG, 1981, J NEUROSURG, V54, P814, DOI 10.3171/jns.1981.54.6.0814; THOMAS GI, 1959, SURGERY, V46, P747	28	49	53	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1991	31	1					127	133		10.1097/00005373-199101000-00025			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EU220	WOS:A1991EU22000025	1986118				2021-06-18	
J	ROBINSON, SE; MARTIN, RM; DAVIS, TR; GYENES, CA; RYLAND, JE; ENTERS, EK				ROBINSON, SE; MARTIN, RM; DAVIS, TR; GYENES, CA; RYLAND, JE; ENTERS, EK			THE EFFECT OF ACETYLCHOLINE DEPLETION ON BEHAVIOR FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article										ROBINSON, SE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,BOX 613,MCV STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07288, NS24413] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024413] Funding Source: NIH RePORTER		BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1984, BRAIN RES, V311, P267, DOI 10.1016/0006-8993(84)90089-1; ISHII S, 1969, LATE EFFECTS HEAD IN, P123; KATAYAMA Y, 1985, BRAIN RES, V334, P366, DOI 10.1016/0006-8993(85)90234-3; KATAYAMA Y, 1984, BRAIN RES, V296, P241, DOI 10.1016/0006-8993(84)90062-3; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; Newcombe F, 1980, Int Rehabil Med, V2, P133; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBINSON SE, 1986, J NEUROCHEM, V46, P1632, DOI 10.1111/j.1471-4159.1986.tb01786.x; ROSNER MJ, 1982, 5TH P INT S INTR PRE, P154; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUGE D, 1946, J NEUROSURG, V11, P77; RUTHERFORD WH, 1977, LANCET, V1, P1; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Siegel S., 1956, NONPARAMETRIC STAT B; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEDFORD CE, 1987, J PHARMACOL EXP THER, V240, P476; Toglia JU, 1969, LATE EFFECTS HEAD IN, P72; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Winer BJ., 1971, STAT PRINCIPLES EXPT	39	49	49	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 12	1990	509	1					41	46		10.1016/0006-8993(90)90306-V			6	Neurosciences	Neurosciences & Neurology	CP931	WOS:A1990CP93100006	2306637				2021-06-18	
J	DAVIDOFF, G; THOMAS, P; JOHNSON, M; BERENT, S; DIJKERS, M; DOLJANAC, R				DAVIDOFF, G; THOMAS, P; JOHNSON, M; BERENT, S; DIJKERS, M; DOLJANAC, R			CLOSED HEAD-INJURY IN ACUTE TRAUMATIC SPINAL-CORD INJURY - INCIDENCE AND RISK-FACTORS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									UNIV MICHIGAN,MED CTR,DEPT PHYS MED & REHABIL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PSYCHIAT,ANN ARBOR,MI 48109; SE MICHIGAN SPINAL CORD INJURY SYST,DETROIT,MI; REHABIL INST,DETROIT,MI; DETROIT RECEIVING HOSP,DETROIT,MI				Dijkers, Marcel/0000-0002-8362-5596	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01120-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001120] Funding Source: NIH RePORTER		BAILES JE, 1986, 12TH P ANN M AM SPIN, P211; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF G, 1986, 12TH P ANN M AM SPIN, P119; DAVIDOFF G, IN PRESS ARCH PHYS M; DAVIDOFF G, 1986, ARCH PHYS MED REHABI, V67, P653; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DUBO H, 1984, 10TH P ANN M AM SPIN, P35; FISCHER VD, 1976, ZBL NEUROCHIR, V37, P25; FOX DJ, 1976, DOCUMENTATION MIDAS; GUTTMANN L, 1963, P S SPINAL INJURIES, P81; Harris P, 1968, Paraplegia, V5, P215; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LIU YK, 1984, SPINE, V9, P329, DOI 10.1097/00007632-198405000-00001; Meinecke F W, 1968, Paraplegia, V5, P196; RICHARDS JS, 1986, ARCH PHYS MED REHAB, V67, P658; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; TORRES F, 1961, ARCH NEUROL-CHICAGO, V5, P28, DOI 10.1001/archneur.1961.00450130030005; WAGNER KA, 1983, ARCH PHYS MED REHAB, V64, P519; YOUNG JS, 1982, SPINAL CORD INJURY S, P34; 1985, SAS USERS GUIDE STAT, P21	31	49	51	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1988	69	10					869	872					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	Q5535	WOS:A1988Q553500008	3178454				2021-06-18	
J	PORTER, RJ; MILLER, RA				PORTER, RJ; MILLER, RA			DIABETES INSIPIDUS FOLLOWING CLOSED HEAD INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																BEATTIE J, 1938, HYPOTHALAMUS, P69; Biggart JH, 1939, J PATHOL BACTERIOL, V48, P405, DOI 10.1002/path.1700480214; Dandy WE, 1940, J AMER MED ASSOC, V114, P312; DREYFUS G, 1931, DIABETE INSIPIDE; Fink EB, 1928, ARCH PATHOL, V6, P102; FISHER C, 1938, DIABETES INSIPIDUS N; Fitz R, 1914, ARCH INTERN MED, V14, P706; HEINBECKER R, 1941, AM J PHYSIOL, V133, P582; Holbourn AHS, 1943, LANCET, V2, P438; Jones GM, 1944, ARCH INTERN MED, V74, P81, DOI 10.1001/archinte.1944.00210200002001; Kahler O., 1886, Z HEILK, V7, P105; Kourilsky R, 1942, REV NEUROL-FRANCE, V74, P264; Leigh AD, 1943, LANCET, V1, P38; MAGOUN HW, 1939, T AM NEUROL A, V65, P63; Rabinowitch IM, 1921, ARCH INTERN MED, V28, P355, DOI 10.1001/archinte.1921.00100150120007; RAND CW, 1937, B LOS ANGELES NEUROL, V2, P163; RIDDOCH G, 1938, HYPOTHALAMUS, P119; ROWBOTHAM SF, 1945, ACUTE INJURIES HEAD, P300; Rowntree LG, 1924, J AMER MED ASSOC, V83, P399, DOI 10.1001/jama.1924.02660060003002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1943, INJURIES SKULL BRAIN, P104; RUSSELL WR, 1942, BRIT MED J, V2, P521; SYMONDS CP, 1943, INJURIES SKULL BRAIN, P65; Traquair HM, 1935, BRAIN, V58, P398, DOI 10.1093/brain/58.3.398; TURNER JH, 1928, ARCH PEDIATR, V45, P433; Turner JWA, 1943, BRAIN, V66, P140; Warkany J, 1939, AM J DIS CHILD, V57, P603, DOI 10.1001/archpedi.1939.01990030117013	27	49	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1948	11	4					258	262		10.1136/jnnp.11.4.258			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	XY263	WOS:A1948XY26300003	18894645	Green Published, Bronze			2021-06-18	
J	Scott, WW				Scott, WW			Physiology of concussion	ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article									Univ Chicago, Dept Physiol, Chicago, IL USA							ARMSTRONG HG, IN PRESS MIL SURG; Cannon WB, 1901, AM J PHYSIOL, V6, P91; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; Dixon WE, 1914, J PHYSIOL-LONDON, V48, P317; Eyster JAE, 1909, J EXP MED, V11, P489, DOI 10.1084/jem.11.3.489; GERARD R. W., 1937, Annual Review of Biochemistry, V6, P419, DOI 10.1146/annurev.bi.06.070137.002223; GERARD RW, IN PRESS RES NERV ME; Hamilton WF, 1934, AM J PHYSIOL, V107, P427; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MCFARLAND RA, 1932, ARCH PSYCHOL; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; Moore LM, 1919, AM J PHYSIOL, V50, P352; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; SEIBERT EG, 1918, MIL SURG, V42, P145; Weiss S, 1933, MEDICINE, V12, P297, DOI 10.1097/00005792-193309000-00003; WIGGERS CJ, 1937, PHYSL HLTH DIS, P816; WINTERSTEIN CE, 1937, LANCET, V2, P719; Wolff HG, 1936, PHYSIOL REV, V16, P0545	19	49	49	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0096-6754			ARCH NEURO PSYCHIATR		FEB	1940	43	2					270	283		10.1001/archneurpsyc.1940.02280020078006			14	Psychiatry	Psychiatry	V23YC	WOS:000201617400006					2021-06-18	
J	Willis, EF; MacDonald, KPA; Nguyen, QH; Garrido, AL; Gillespie, ER; Harley, SBR; Bartlett, PF; Schroder, WA; Yates, AG; Anthony, DC; Rose-John, S; Ruitenberg, MJ; Vukovic, J				Willis, Emily F.; MacDonald, Kelli P. A.; Nguyen, Quan H.; Garrido, Adahir Labrador; Gillespie, Ellen R.; Harley, Samuel B. R.; Bartlett, Perry F.; Schroder, Wayne A.; Yates, Abi G.; Anthony, Daniel C.; Rose-John, Stefan; Ruitenberg, Marc J.; Vukovic, Jana			Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner	CELL			English	Article							PROGENITOR-CELL; STEM-CELLS; IN-VIVO; INTERLEUKIN-6; NEURONS; INFLAMMATION; INJURY; DEGENERATION; REVEALS; DOUBLECORTIN	Cognitive dysfunction and reactive microglia are hallmarks of traumatic brain injury (TBI), yet whether these cells contribute to cognitive deficits and secondary inflammatory pathology remains poorly understood. Here, we show that removal of microglia from the mouse brain has little effect on the outcome of TBI, but inducing the turnover of these cells through either pharmacologic or genetic approaches can yield a neuroprotective microglial phenotype that profoundly aids recovery. The beneficial effects of these repopulating microglia are critically dependent on interleukin-6 (IL-6) trans-signaling via the soluble IL-6 receptor (IL-6R) and robustly support adult neurogenesis, specifically by augmenting the survival of newborn neurons that directly support cognitive function. We conclude that microglia in the mammalian brain can be manipulated to adopt a neuroprotective and pro-regenerative phenotype that can aid repair and alleviate the cognitive deficits arising from brain injury.	[Willis, Emily F.; Garrido, Adahir Labrador; Gillespie, Ellen R.; Harley, Samuel B. R.; Ruitenberg, Marc J.; Vukovic, Jana] Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld, Australia; [Willis, Emily F.; Harley, Samuel B. R.; Bartlett, Perry F.; Vukovic, Jana] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [MacDonald, Kelli P. A.; Schroder, Wayne A.] QIMR Berghofer Med Res Inst, Dept Immunol, Brisbane, Qld, Australia; [Nguyen, Quan H.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Yates, Abi G.; Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Lab Expt Neuropathol, Oxford OX1 3QT, England; [Rose-John, Stefan] Christian Albrechts Univ Kiel, Biochem Inst, Kiel, Germany; [Schroder, Wayne A.] Griffith Univ, Sch Environm & Sci, Brisbane, Qld, Australia	Vukovic, J (corresponding author), Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld, Australia.; Vukovic, J (corresponding author), Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia.	j.vukovic@uq.edu.au	MacDonald, Kelli/AAV-5365-2020; Anthony, Daniel C/F-7765-2010; Willis, Emily/ABF-7570-2020	Anthony, Daniel C/0000-0003-1380-6655; Willis, Emily/0000-0002-3756-5318	Australian Research Council Discovery Early Career Research AwardAustralian Research Council [DE150101578]; National Health and Medical Research Council (NHMRC) projectNational Health and Medical Research Council of Australia [1124503]; Herdsman Fellowship in Medical Science (UQ); SpinalCure Australia; Wings for Life Spinal Cord Research Foundation; NHMRCNational Health and Medical Research Council of Australia [1060538, 1163835]; UQ-StemCARE funding	We thank J. Yu, K.C. Leong, R. Adams, and N. Kurniawan for experimental assistance; the staff of UQ's Biological Resources Facility for breeding and maintaining the animals in this study; G.R. Hill for vavcre x IL6R mouse line, Alan Ho for statistical assistance; T. Bruxner for RNA-seq assistance; V. Nink for flow cytometry assistance; R. Tweedale for editorial assistance; N. Valmas for graphic design; and S. Millard, S. Thor, J. Goetz, and B. Key for critical reading and comments on the manuscript. Imaging was performed at the School of Biomedical Sciences and the Queensland Brain Institute (QBI)'s Advanced Microscopy Facilities. Behavioral tests were performed at the QBI's Behavior and Surgical Facility. FACS was performed at the QBI's Flow Cytometry Facility. RNA-seq library preparation and sequencing was performed at the Institute for Molecular Bioscience Sequencing Facility (UQ). We acknowledge QIMR Berghofer scientific services, the Genome Informatics Group and Medical Genomics Groups for their support in the RNA-seq analysis, and A. Lam and D. Pham for assisting with generating and analyzing the spatial transcriptomics data. J.V. is the recipient of an Australian Research Council Discovery Early Career Research Award (DE150101578) and National Health and Medical Research Council (NHMRC) project grant (1124503). E.F.W. is supported by the Herdsman Fellowship in Medical Science (UQ). M.J.R. is supported by SpinalCure Australia, the Wings for Life Spinal Cord Research Foundation, and the NHMRC (1060538 and 1163835). A.L.G. was supported by UQ-StemCARE funding.	Bellver-Landete V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08446-0; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Biber K, 2008, NEUROPSYCHOPHARMACOL, V33, P2237, DOI 10.1038/sj.npp.1301612; Bradley CK, 2007, GENESIS, V45, P145, DOI 10.1002/dvg.20274; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585; Campbell IL, 2014, J NEUROSCI, V34, P2503, DOI 10.1523/JNEUROSCI.2830-13.2014; Cheng XW, 2011, CELL RES, V21, P338, DOI 10.1038/cr.2010.141; Codeluppi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092649; Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Elmore MRP, 2018, AGING CELL, V17, DOI 10.1111/acel.12832; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Garbers C, 2018, METHODS MOL BIOL, V1725, P127, DOI 10.1007/978-1-4939-7568-6_11; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Godwin JW, 2013, P NATL ACAD SCI USA, V110, P9415, DOI 10.1073/pnas.1300290110; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Haage V, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0665-y; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hickman S, 2018, NAT NEUROSCI, V21, P1359, DOI 10.1038/s41593-018-0242-x; Hilla AM, 2017, J NEUROSCI, V37, P6113, DOI 10.1523/JNEUROSCI.0584-17.2017; Hodge RD, 2012, J NEUROSCI, V32, P6275, DOI 10.1523/JNEUROSCI.0532-12.2012; Hoeffel G, 2018, CELL IMMUNOL, V330, P5, DOI 10.1016/j.cellimm.2018.01.001; Hong H, 2016, INT NEUROUROL J, V20, pS2, DOI 10.5213/inj.1632604.302; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Ma SH, 2015, CELL CALCIUM, V58, P286, DOI 10.1016/j.ceca.2015.06.006; Martin M., 2011, EMBNET J, V17, P200; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Ngwenya LB, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01014; Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285; Ogilvy S, 1999, BLOOD, V94, P1855; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rice RA, 2017, GLIA, V65, P931, DOI 10.1002/glia.23135; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Scott G, 2018, BRAIN, V141, P459, DOI 10.1093/brain/awx339; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101; Timper K, 2017, CELL REP, V19, P267, DOI 10.1016/j.celrep.2017.03.043; Vukovic J, 2013, J NEUROSCI, V33, P6603, DOI 10.1523/JNEUROSCI.3064-12.2013; Vukovic J, 2012, J NEUROSCI, V32, P6435, DOI 10.1523/JNEUROSCI.5925-11.2012; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; Weber MD, 2019, BIOL PSYCHIAT, V85, P667, DOI 10.1016/j.biopsych.2018.10.009; Willis EF, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00197; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; Yang P, 2012, EXP NEUROL, V236, P19, DOI 10.1016/j.expneurol.2012.03.019; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	67	48	49	17	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2020	180	5					833	+		10.1016/j.cell.2020.02.013			30	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	KT7JN	WOS:000519189800006	32142677	Bronze	Y	N	2021-06-18	
J	Alawieh, A; Langley, EF; Weber, S; Adkins, D; Tomlinson, S				Alawieh, Ali; Langley, E. Farris; Weber, Shannon; Adkins, DeAnna; Tomlinson, Stephen			Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						chronic injury; complement; inflammation; therapy	CONTROLLED CORTICAL IMPACT; MEMBRANE ATTACK COMPLEX; ALTERNATIVE PATHWAY; INHIBITION; MOUSE; RECOVERY; SYSTEM; C3; NEUROPATHOLOGY; DYSFUNCTION	The complement system is implicated in promoting acute secondary injury after traumatic brain injury (TBI), but its role in chronic post-traumatic neuropathology remains unclear. Using various injury-site targeted complement inhibitors that block different complement pathways and activation products, we investigated how complement is involved in neurodegeneration and chronic neuroinflammation after TBI in a clinically relevant setting of complement inhibition. The current paradigm is that complement propagates post-TBI neuropathology predominantly through the terminal membrane attack complex (MAC), but the focus has been on acute outcomes. Following controlled cortical impact in adult male mice, we demonstrate that although inhibition of the MAC (with CR2-CD59) reduces acute deficits, inhibition of C3 activation is required to prevent chronic inflammation and ongoing neuronal loss. Activation of C3 triggered a sustained degenerative mechanism of microglial and astrocyte activation, reduced dendritic and synaptic density, and inhibited neuroblast migration several weeks after TBI. Moreover, inhibiting all complement pathways (with CR2-Crry), or only the alternative complement pathway (with CR2-fH), provided similar and significant improvements in chronic histological, cognitive, and functional recovery, indicating a key role for the alternative pathway in propagating chronic post-TBI pathology. Although we confirm a role for the MAC in acute neuronal loss after TBI, this study shows that upstream products of complement activation generated predominantly via the alternative pathway propagate chronic neuroinflammation, thus challenging the current concept that the MAC represents a therapeutic target for treating TBI. A humanized version of CR2fH has been shown to be safe and non-immunogenic in clinical trials.	[Alawieh, Ali; Langley, E. Farris; Weber, Shannon] Med Univ South Carolina, Med Scientist Training Program, Charleston, SC 29425 USA; [Alawieh, Ali; Langley, E. Farris; Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Adkins, DeAnna] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Adkins, DeAnna; Tomlinson, Stephen] Ralph Johnson VA Med Ctr, Charleston, SC 29401 USA	Tomlinson, S (corresponding author), Dept Microbiol & Immunol, 173 Ashley Ave,BSB 204,MSC 504, Charleston, SC 29425 USA.	tomlinss@musc.edu	Alawieh, Ali/AAM-1420-2020; Alawieh, Ali/AAM-1898-2020	Alawieh, Ali/0000-0003-2601-8850; Adkins, DeAnna L/0000-0002-3063-5731; tomlinson, stephen/0000-0002-6281-2122	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P20GM109040, U54GM10494, U54GM10491, P30 CA138313, S10 OD018113]; Department of Veterans AffairsUS Department of Veterans Affairs [1I01RX001141, 1I21RX002363]; American Heart Association Predoctoral FellowshipAmerican Heart Association [15PRE25250009]; Center for Oral Health Research (NIGMS Award) [P30GM103331]; Josh Spruill Imaging Facility [NIH-NIGMS P30 GM103342]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA138313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103342, P30GM103331, P20GM109040] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD018113] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I21RX002363, I01RX001141] Funding Source: NIH RePORTER	This work was supported by Grants from the NIH (1P20GM109040, U54GM10494, U54GM10491) to D.A. and S.T., the Department of Veterans Affairs (Merit Award 1I01RX001141 and 1I21RX002363) to S.T., and an American Heart Association Predoctoral Fellowship to A. A. (15PRE25250009); and the use of the MUSC Cell and Molecular Imaging Core (supported by awards from the NIH P30 CA138313 and S10 OD018113), the Center for Oral Health Research (NIGMS Award P30GM103331), and the Josh Spruill Imaging Facility (NIH-NIGMS P30 GM103342).	Alawieh A, 2016, IMMUNOL REV, V274, P270, DOI 10.1111/imr.12470; Alawieh A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0464-8; Alawieh A, 2015, ONCOTARGET, V6, P21769, DOI 10.18632/oncotarget.4844; Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Carroll MC, 1998, SEMIN IMMUNOL, V10, P279, DOI 10.1006/smim.1998.0120; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holers VM, 2004, CURR DIRECT AUTOIMMU, V7, P33; Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068; Janeway C.A., 2001, COMPLEMENT SYSTEM IN; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Marshall KM, 2014, J EXP MED, V211, P1793, DOI 10.1084/jem.20131902; Metz Gerlinde A, 2009, J Vis Exp, DOI 10.3791/1204; Neher MD, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-90; Patil SS, 2009, BEHAV BRAIN RES, V198, P58, DOI 10.1016/j.bbr.2008.10.029; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Rich MC, 2016, NEUROSCI LETT, V617, P188, DOI 10.1016/j.neulet.2016.02.025; Risitano A.M., 2015, BLOOD, V126, P2137; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	41	48	49	1	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 7	2018	38	10					2519	2532		10.1523/JNEUROSCI.2197-17.2018			14	Neurosciences	Neurosciences & Neurology	FZ6EC	WOS:000427689100012	29437855	Green Published, Bronze			2021-06-18	
J	Vella, MA; Crandall, ML; Patel, MB				Vella, Michael A.; Crandall, Marie L.; Patel, Mayur B.			Acute Management of Traumatic Brain Injury	SURGICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Intracranial hypertension; Secondary injury; Hyperosmolar therapy; Barbiturate coma; Decompressive craniectomy	CEREBRAL PERFUSION-PRESSURE; REFRACTORY INTRACRANIAL HYPERTENSION; PROTHROMBIN COMPLEX CONCENTRATE; ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; CONTROLLED-TRIAL; BLOOD-FLOW; EASTERN ASSOCIATION; ENTERAL NUTRITION	Traumatic brain injury (TBI) is a leading cause of death and disability in patients with trauma. Management strategies must focus on preventing secondary injury by avoiding hypotension and hypoxia and maintaining appropriate cerebral perfusion pressure (CPP), which is a surrogate for cerebral blood flow. CPP can be maintained by increasing mean arterial pressure, decreasing intracranial pressure, or both. The goal should be euvolemia and avoidance of hypotension. Other factors that deserve important consideration in the acute management of patients with TBI are venous thromboembolism, stress ulcer, and seizure prophylaxis, as well as nutritional and metabolic optimization.	[Vella, Michael A.] Vanderbilt Univ, Med Ctr, Dept Surg, Sect Surg Sci,Med Ctr North, CCC-4312,1161 21st Ave South, Nashville, TN 37232 USA; [Vella, Michael A.] Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA; [Crandall, Marie L.] Univ Florida, Dept Surg, Div Acute Care Surg, 655 West 8th St, Jacksonville, FL 32209 USA; [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Vanderbilt Brain Inst,Ctr Hlth Serv Res, Dept Surg,Sect Surg Sci,Div Trauma Surg Crit Care, 1211 21st Ave South,Med Arts Bldg,Suite 404, Nashville, TN 37212 USA; [Patel, Mayur B.] Tennessee Valley Healthcare Syst, Nashville Vet Affairs Med Ctr, Surg Serv, 1310 24th Ave South, Nashville, TN 37212 USA	Patel, MB (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Brain Inst,Ctr Hlth Serv Res, Dept Surg,Sect Surg Sci,Div Trauma Surg Crit Care, 1211 21st Ave South,Med Arts Bldg,Suite 404, Nashville, TN 37212 USA.; Patel, MB (corresponding author), Tennessee Valley Healthcare Syst, Nashville Vet Affairs Med Ctr, Surg Serv, 1310 24th Ave South, Nashville, TN 37212 USA.	mayur.b.patel@vanderbilt.edu	Crandall, Marie/L-9066-2019	Crandall, Marie/0000-0002-6536-3123	National Institutes of Health (Bethesda, MD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NHLBI R01 HL111111, NIGMS R01 GM120484]; REDCap from NCATS/NIH [UL1 TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER	M.B. Patel is supported by National Institutes of Health (Bethesda, MD) NHLBI R01 HL111111 and NIGMS R01 GM120484. This work was also supported by REDCap UL1 TR000445 from NCATS/NIH. The authors have no other disclosures relevant to this article.	Acosta-Escribano J, 2010, INTENS CARE MED, V36, P1532, DOI 10.1007/s00134-010-1908-3; Alali AS, 2017, ANN SURG; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; [Anonymous], 2012, HEAD TRAUM ATLS ADV, P148; Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Cameron John L, 2017, MANAGEMENT TRAUMATIC; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chiang YH, 2012, J NEUROTRAUM, V29, P75, DOI 10.1089/neu.2011.1801; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Crandall M, 2014, BRAIN INJURY, V28, P1359, DOI 10.3109/02699052.2014.919533; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Dorfman JD, 2011, NEUROCRIT CARE, V15, P516, DOI 10.1007/s12028-011-9549-0; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; HALLORAN LG, 1980, AM J SURG, V139, P44, DOI 10.1016/0002-9610(80)90228-7; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasky MR, 1998, J TRAUMA, V44, P527, DOI 10.1097/00005373-199803000-00020; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; MacLaren R, 2014, JAMA INTERN MED, V174, P564, DOI 10.1001/jamainternmed.2013.14673; Mahmoodpoor A, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Marion DW, 2006, NEUROSURGERY, V58, P655; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; Matsushima K, 2015, AM J SURG, V209, P413, DOI 10.1016/j.amjsurg.2014.08.019; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nwachuku EL, 2014, NEUROCRIT CARE, V20, P49, DOI 10.1007/s12028-013-9885-3; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Patel MB, 2015, ENCY TRAUMA CARE, P1711; Phelan HA, 2012, J NEUROTRAUM, V29, P1821, DOI 10.1089/neu.2012.2459; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000; Prabhakar Hemanshu, 2014, J Anaesthesiol Clin Pharmacol, V30, P318, DOI 10.4103/0970-9185.137260; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Schirmer CM, 2012, NEUROCRIT CARE, V16, P184, DOI 10.1007/s12028-011-9580-1; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Siegal DM, 2013, J THROMB THROMBOLYS, V35, P391, DOI 10.1007/s11239-013-0885-0; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stocchetti N, 2004, ANESTH ANALG, V99, P230, DOI 10.1213/01.ane.0000130393.08355.d4; SYDENHAM E, 2009, COCHRANE DATABASE SY; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zeiler FA, 2014, NEUROCRIT CARE, V21, P163, DOI 10.1007/s12028-013-9950-y	96	48	54	1	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	OCT	2017	97	5					1015	+		10.1016/j.suc.2017.06.003			17	Surgery	Surgery	FL0EV	WOS:000413885300007	28958355	Green Accepted			2021-06-18	
J	Andrabi, SS; Parvez, S; Tabassum, H				Andrabi, Syed Suhail; Parvez, Suhel; Tabassum, Heena			Progesterone induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in rats	DISEASE MODELS & MECHANISMS			English	Article						Progesterone; Cerebral ischemia; Neurobehavior; Mitochondria; Apoptosis; Neuroprotection	INDUCED OXIDATIVE STRESS; TRAUMATIC BRAIN-INJURY; ACETYLCHOLINESTERASE ACTIVITY; PERMEABILITY TRANSITION; ANIMAL-MODELS; CELL-DEATH; COMPLEX I; STROKE; ISCHEMIA/REPERFUSION; OUTCOMES	Organelle damage and increases in mitochondrial permeabilization are key events in the development of cerebral ischemic tissue injury because they cause both modifications in ATP turnover and cellular apoptosis/necrosis. Early restoration of blood flow and improvement of mitochondrial function might reverse the situation and help in recovery following an onset of stroke. Mitochondria and related bioenergetic processes can be effectively used as pharmacological targets. Progesterone (P4), one of the promising neurosteroids, has been found to be neuroprotective in various models of neurological diseases, through a number of mechanisms. This influenced us to investigate the possible role of P4 in the mitochondria-mediated neuroprotective mechanism in an ischemic stroke model of rat. In this study, we have shown the positive effect of P4 administration on behavioral deficits and mitochondrial health in an ischemic stroke injury model of transient middle cerebral artery occlusion (tMCAO). After induction of tMCAO, the rats received an initial intraperitoneal injection of P4 (8 mg/kg body weight) or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 12 and 18 h. Behavioral assessment for functional deficits included grip strength, motor coordination and gait analysis. Findings revealed a significant improvement with P4 treatment in tMCAO animals. Staining of isolated brain slices from P4-treated rats with 2,3,5-triphenyltetrazolium chloride (TTC) showed a reduction in the infarct area in comparison to the vehicle group, indicating the presence of an increased number of viable mitochondria. P4 treatment was also able to attenuate mitochondrial reactive oxygen species (ROS) production, as well as block the mitochondrial permeability transition pore (mPTP), in the tMCAO injury model. In addition, it was also able to ameliorate the altered mitochondrial membrane potential and respiration ratio in the ischemic animals, thereby suggesting that P4 has a positive effect on mitochondrial bioenergetics. In conclusion, these results demonstrate that P4 treatment is beneficial in preserving the mitochondrial functions that are altered in cerebral ischemic injury and thus can help in defining better therapies.	[Andrabi, Syed Suhail; Parvez, Suhel] Jamia Hamdard, Dept Med Elementol & Toxicol, New Delhi 110062, India; [Tabassum, Heena] Jamia Hamdard, Dept Biochem, New Delhi 110062, India	Tabassum, H (corresponding author), Jamia Hamdard, Dept Biochem, New Delhi 110062, India.	heenatabassum@jamiahamdard.ac.in		Tabassum, Heena/0000-0001-8699-5309	Department of Biotechnology, Ministry of Science and Technology, Government of IndiaDepartment of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India [BT/Bio-CARe/01/10219/2013-14]; Science and Engineering Research Board (SERB-EMR) [2016/001070/HS]; Senior Research Fellowship from University Grants Commission-Basic Science Research (UGC-BSR) [F.25-1/2013-14(BSR)/7-91/2007(BSR)]	This work was funded by the Department of Biotechnology, Ministry of Science and Technology, Government of India, for the financial grant (DBT BioCARe Program, sanction no. BT/Bio-CARe/01/10219/2013-14 to H.T.); Science and Engineering Research Board (SERB-EMR grant no. 2016/001070/HS to S.P.). S.S.A. is a recipient of a Senior Research Fellowship from University Grants Commission-Basic Science Research (UGC-BSR) [grant no. F.25-1/2013-14(BSR)/7-91/2007(BSR)].	Affonso AC, 2013, METAB BRAIN DIS, V28, P493, DOI 10.1007/s11011-013-9396-0; Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Andrabi SS, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/384750; Ashafaq M., 2016, MOL NEUROBIOL; Ashafaq M, 2012, NEUROCHEM RES, V37, P1747, DOI 10.1007/s11064-012-0786-1; Ashafaq M, 2012, NUTR RES, V32, P133, DOI 10.1016/j.nutres.2011.12.014; Avasarala J, 2015, STROKE, V46, pE234, DOI 10.1161/STROKEAHA.115.010716; Bennett DA, 2014, GLOB HEART, V9, P107, DOI 10.1016/j.gheart.2014.01.001; Cai J, 2015, NEUROSCI LETT, V600, P238, DOI 10.1016/j.neulet.2015.06.023; Chaudhary S, 2012, NEUROSCIENCE, V225, P258, DOI 10.1016/j.neuroscience.2012.08.060; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; de Lores Arnaiz Georgina Rodriguez, 2014, Int J Biomed Sci, V10, P85; De Nicola AF, 2013, CNS NEUROL DISORD-DR, V12, P1205; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Drose S, 2016, BBA-BIOENERGETICS, V1857, P946, DOI 10.1016/j.bbabio.2015.12.013; Fayaz SM, 2015, CNS NEUROL DISORD-DR, V14, P654, DOI 10.2174/1871527314666150429113239; Gaignard P, 2016, J CEREBR BLOOD F MET, V36, P562, DOI 10.1177/0271678X15610338; Javadov S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00076; Jin Z, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030351; Kalogeris T, 2014, REDOX BIOL, V2, P702, DOI 10.1016/j.redox.2014.05.006; Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7; Khatri N, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00199; Kim G, 2013, J PHYS THER SCI, V25, P1227, DOI 10.1589/jpts.25.1227; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025; Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033860; Liang JM, 2013, J INT MED RES, V41, P618, DOI 10.1177/0300060513476587; Liu Y, 2009, CELL ADHES MIGR, V3, P94, DOI 10.4161/cam.3.1.7516; Manzanero S, 2013, NEUROCHEM INT, V62, P712, DOI 10.1016/j.neuint.2012.11.009; McCann SK, 2014, STROKE, V45, P3055, DOI 10.1161/STROKEAHA.114.006304; Morton RA, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0079-15.2015; Nicholls DG, 2015, J BIOENERG BIOMEMBR, V47, P63, DOI 10.1007/s10863-014-9573-9; Novgorodov SA, 2016, J BIOL CHEM, V291, P1957, DOI 10.1074/jbc.M115.668228; Peplow PV, 2015, NEURAL REGEN RES, V10, P1186, DOI 10.4103/1673-5374.162687; Rasheed MZ, 2017, PROTOPLASMA, V254, P33, DOI 10.1007/s00709-015-0930-2; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sanderson TH, 2013, MOL NEUROBIOL, V47, P9, DOI 10.1007/s12035-012-8344-z; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Schumacher M, 2016, J STEROID BIOCHEM, V160, P53, DOI 10.1016/j.jsbmb.2015.11.010; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Tabassum H, 2007, HUM EXP TOXICOL, V26, P509, DOI 10.1177/0960327107072392; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Vaibhav K, 2013, PHARMACOL BIOCHEM BE, V113, P53, DOI 10.1016/j.pbb.2013.10.008; Vishnoi S, 2015, NEUROSCIENCE, V311, P22, DOI 10.1016/j.neuroscience.2015.10.008; Wali B, 2014, BRAIN, V137, P486, DOI 10.1093/brain/awt319; Wang JP, 2009, BRAIN RES BULL, V79, P426, DOI 10.1016/j.brainresbull.2009.05.018; Waseem M, 2016, MITOCHONDRION, V31, P1, DOI 10.1016/j.mito.2016.08.005; Waseem M, 2016, PROTOPLASMA, V253, P417, DOI 10.1007/s00709-015-0821-6; Wasik A, 2014, NEUROTOX RES, V25, P323, DOI 10.1007/s12640-013-9425-0; Wei J, 2013, ACTA PHARMACOL SIN, V34, P1485, DOI 10.1038/aps.2013.160; Weinreb O, 2016, BRIT J PHARMACOL, V173, P2080, DOI 10.1111/bph.13318; Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yousuf S, 2014, J CEREBR BLOOD F MET, V34, P297, DOI 10.1038/jcbfm.2013.198	55	48	49	2	13	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	1754-8403	1754-8411		DIS MODEL MECH	Dis. Model. Mech.	JUN 1	2017	10	6					787	796		10.1242/dmm.025692			10	Cell Biology; Pathology	Cell Biology; Pathology	EX4FT	WOS:000403189500010	28363987	DOAJ Gold, Green Published			2021-06-18	
J	Hume, PA; Theadom, A; Lewis, GN; Quarrie, KL; Brown, SR; Hill, R; Marshall, SW				Hume, Patria A.; Theadom, Alice; Lewis, Gwyn N.; Quarrie, Kenneth L.; Brown, Scott R.; Hill, Rosamund; Marshall, Stephen W.			A Comparison of Cognitive Function in Former Rugby Union Players Compared with Former Non-Contact-Sport Players and the Impact of Concussion History	SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; LONG-TERM; RECURRENT CONCUSSION; CONSENSUS STATEMENT; EARLY ADULTHOOD; RISK; IMPAIRMENT; DEPRESSION; LEAGUE	Aim This study investigated differences in cognitive function between former rugby and non-contact-sport players, and assessed the association between concussion history and cognitive function. Methods Overall, 366 former players (mean +/- standard deviation [SD] age 43.3 +/- 8.2 years) were recruited from October 2012 to April 2014. Engagement in sport, general health, sports injuries and concussion history, and demographic information were obtained from an online self-report questionnaire. Cognitive functioning was assessed using the online CNS Vital Signs neuropsychological test battery. Cohen's d effect size statistics were calculated for comparisons across player groups, concussion groups (one or more self-reported concussions versus no concussions) and between those groups with CNS Vital Signs age- matched norms (US norms). Individual differences within groups were represented as SDs. Results The elite-rugby group (n = 103) performed worse on tests of complex attention, processing speed, executive functioning, and cognitive flexibility than the non-contact-sport group (n = 65), and worse than the community-rugby group (n = 193) on complex attention. The community-rugby group performed worse than the non-contact group on executive functioning and cognitive flexibility. Compared with US norms, all three former player groups performed worse on verbal memory and reaction time; rugby groups performed worse on processing speed, cognitive flexibility and executive functioning; and the community-rugby group performed worse on composite memory. The community-rugby group and non-contact-sport group performed slightly better than US norms on complex attention, as did the elite-rugby group for motor speed. All three player groups had greater individual differences than US norms on composite memory, verbal memory and reaction time. The elite-rugby group had greater individual differences on processing speed and complex attention, and the community-rugby group had greater individual differences on psychomotor speed and motor speed. The average number of concussions recalled per player was greater for elite rugby and community rugby than non-contact sport. Former players who recalled one or more concussions (elite rugby, 85 %; community rugby, 77 %; non-contact sport, 23 %) had worse scores on cognitive flexibility, executive functioning, and complex attention than players who did not recall experiencing a concussion. Conclusions Past participation in rugby or a history of concussion were associated with small to moderate neurocognitive deficits (as indicated by worse CNS Vital Signs scores) in athletes post retirement from competitive sport.	[Hume, Patria A.; Brown, Scott R.] Auckland Univ Technol, Sports Performance Res Inst New Zealand, Fac Hlth & Environm Sci, Private Bag 92006, Auckland 1142, New Zealand; [Theadom, Alice] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Lewis, Gwyn N.] Auckland Univ Technol, Hlth & Rehabil Res Inst, Auckland, New Zealand; [Quarrie, Kenneth L.] New Zealand Rugby, Wellington, New Zealand; [Hill, Rosamund] Auckland City Hosp, Dept Neurol, Auckland, New Zealand; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA	Hume, PA (corresponding author), Auckland Univ Technol, Sports Performance Res Inst New Zealand, Fac Hlth & Environm Sci, Private Bag 92006, Auckland 1142, New Zealand.	patria.hume@aut.ac.nz	Hume, Patria Anne/P-1084-2017; Hume, Patria/AAN-5514-2021	Hume, Patria/0000-0003-1847-8128; Brown, Scott/0000-0003-3063-8040	World Rugby (IRB); Sport Performance Research Institute New Zealand (SPRINZ); National Institute for Stroke and Applied Neurosciences (NISAN); Health and Rehabilitation Research Institute (HRRI) of AUT; NZR	The study was funded by World Rugby (IRB), the Sport Performance Research Institute New Zealand (SPRINZ), the National Institute for Stroke and Applied Neurosciences (NISAN), and the Health and Rehabilitation Research Institute (HRRI) of AUT, and NZR.	Alberts J, 2015, KINESIOLOGY REV, V4, P39; Alexander DG, 2015, BRAIN INJURY, V29, P1113, DOI 10.3109/02699052.2015.1031699; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arnaiz E, 2004, J NEUROL NEUROSUR PS, V75, P1275, DOI 10.1136/jnnp.2003.015032; Austin D, 2011, J STRENGTH COND RES, V25, P1659, DOI 10.1519/JSC.0b013e3181da781c; Boyd A., 2015, CNS VITAL SIGNS MANU; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Bruscoli M, 2004, INT PSYCHOGERIATR, V16, P129, DOI 10.1017/S1041610204000092; Carney N, 2014, NEUROSURGERY, V75, pS1, DOI 10.1227/NEU.0000000000000434; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dretsch MN, 2015, J NEUROTRAUM, V32, P1301, DOI 10.1089/neu.2014.3810; England Professional Rugby Injury Surveillance Project Steering Group, 2014, ENGL PROF RUGB INJ S; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; GRONWALL D, 1974, LANCET, V2, P605; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hopkins WG., 2002, NEW VIEW STAT; Hume PA, 2015, IRB NZR AUT RUGBYHEA; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; King D, 2014, J SCI MED SPORT, V17, P250, DOI 10.1016/j.jsams.2013.05.007; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King DA, 2016, J NEUROSURG-PEDIATR, V18, P65, DOI 10.3171/2015.12.PEDS15605; Kirkwood G, 2015, BRIT J SPORT MED, V49, P506, DOI 10.1136/bjsports-2014-093774; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Quarrie KL, 2014, BRIT J SPORT MED, V48, P1589, DOI 10.1136/bjsports-2014-094112; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Statistics New Zealand, 2006, STAT NZ CENS DAT; Theadom A, 2014, J SCI MED SPORT, V17, P591, DOI 10.1016/j.jsams.2014.02.001; West S., 2011, NEUROREHAB NEURAL RE, V25, P3	53	48	48	3	46	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JUN	2017	47	6					1209	1220		10.1007/s40279-016-0608-8			12	Sport Sciences	Sport Sciences	EV7HD	WOS:000401945600013	27558141				2021-06-18	
J	Lindquist, LK; Love, HC; Elbogen, EB				Lindquist, Lisa K.; Love, Holly C.; Elbogen, Eric B.			Traumatic Brain Injury in Iraq and Afghanistan Veterans: New Results From a National Random Sample Study	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DEPLOYED MILITARY PERSONNEL; PSYCHIATRIC-DISORDERS; SUICIDE RISK; DEPRESSION; ASSOCIATION; PREVALENCE; DIAGNOSES; SYMPTOMS; SOLDIERS	This study randomly sampled post -9/11 military veterans and reports on causes, predictors, and frequency of traumatic brain injury (TBI) (N=1,388). A total of 17.3% met criteria for TBI during military service, with about one-half reporting multiple head injuries, which were related to higher rates of posttraumatic stress disorder, depression, back pain, and suicidal ideation. The most common mechanisms of TBI included blasts (33.1%), objects hitting head (31.7%), and fall (13.5%). TBI was associated with enlisted rank, male gender, high combat exposure, and sustaining TBI prior to military service. Clinical and research efforts in veterans should consider TBI mechanism, effects of cumulative TBI, and screening for premilitary TBI.	[Lindquist, Lisa K.; Love, Holly C.] Univ North Carolina Chapel Hill, Dept Psychiat, Chapel Hill, NC USA; [Elbogen, Eric B.] Durham Vet Affairs Med Ctr, Durham, NC 27705 USA; [Elbogen, Eric B.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA	Elbogen, EB (corresponding author), Durham Vet Affairs Med Ctr, Durham, NC 27705 USA.; Elbogen, EB (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA.	eric.elbogen@duke.edu			Mid-Atlantic Mental Illness Research, Education and Clinical Center; Office of Research and Development Clinical Science, Department of Veterans AffairsUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense [W81XWH1110796]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988] Funding Source: NIH RePORTER	Supported by the Mid-Atlantic Mental Illness Research, Education and Clinical Center, the Office of Research and Development Clinical Science, Department of Veterans Affairs, the Department of Defense (grant W81XWH1110796), and the National Institute of Mental Health (grant R01MH080988).	Adams RS, 2012, J HEAD TRAUMA REHAB, V27, P349, DOI 10.1097/HTR.0b013e318268db94; Amick MM, 2013, J INT NEUROPSYCH SOC, V19, P792, DOI 10.1017/S1355617713000544; Armed Forces Health Surveillance Center, 2013, EXT CAUS TRAUM BRAIN; Beckham JC, 2008, MIL MED, V173, P448, DOI 10.7205/MILMED.173.5.448; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Center DMD, 2010, FY2009 ANN DEM PROF, V08-10; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Dillman D.A., 2009, INTERNET MAIL MIXED; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FERRANS CE, 1992, RES NURS HEALTH, V15, P29, DOI 10.1002/nur.4770150106; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Gray GC, 2000, AM J EPIDEMIOL, V151, P63, DOI 10.1093/oxfordjournals.aje.a010123; Hellmuth JC, 2012, J TRAUMA STRESS, V25, P527, DOI 10.1002/jts.21732; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King DW, 2003, MANUAL DEPLOYMENT RI; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; McDonald SD, 2009, J ANXIETY DISORD, V23, P247, DOI 10.1016/j.janxdis.2008.07.007; Pogoda T, 2014, J HEAD TRAUMA REHABI; Regasa LE, 2016, J HEAD TRAUMA REHAB, V31, pE28, DOI 10.1097/HTR.0000000000000155; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scholten A.C., 2016, J NEUROTRAUMA; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Steadman HJ, 2000, LAW HUMAN BEHAV, V24, P83, DOI 10.1023/A:1005478820425; Straus MA, 2005, VIOLENCE WOMEN CLASS; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	37	48	48	1	3	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2017	29	3					254	259		10.1176/appi.neuropsych.16050100			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	FE5CN	WOS:000408229700008	28121256	Green Accepted, Bronze			2021-06-18	
J	Hammond, NE; Taylor, C; Finfer, S; Machado, FR; An, YZ; Billot, L; Bloos, F; Bozza, F; Cavalcanti, AB; Correa, M; Du, B; Hjortrup, PB; Li, Y; McIntryre, L; Saxena, M; Schortgen, F; Watts, NR; Myburgh, J				Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Machado, Flavia R.; An, YouZhong; Billot, Laurent; Bloos, Frank; Bozza, Fernando; Cavalcanti, Alexandre Biasi; Correa, Maryam; Du, Bin; Hjortrup, Peter B.; Li, Yang; McIntryre, Lauralyn; Saxena, Manoj; Schortgen, Frederique; Watts, Nicola R.; Myburgh, John		Fluid-TRIPS Fluidos Investigators; George Inst Global Hlth; ANZICS Clinical Trials Grp; BRICNet; REVA Res Network	Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: An international cross-sectional study	PLOS ONE			English	Article							IN-HOSPITAL MORTALITY; HYDROXYETHYL STARCH 130/0.4; CRITICALLY-ILL ADULTS; KIDNEY INJURY; ASSOCIATION; SEPSIS; SALINE; CHOICE; SCORE; SHOCK	Background In 2007, the Saline versus Albumin Fluid Evaluation D Translation of Research Into Practice Study (SAFE-TRIPS) reported that 0.9% sodium chloride (saline) and hydroxyethyl starch (HES) were the most commonly used resuscitation fluids in intensive care unit (ICU) patients. Evidence has emerged since 2007 that these fluids are associated with adverse patient-centred outcomes. Based on the published evidence since 2007, we sought to determine the current type of fluid resuscitation used in clinical practice and the predictors of fluid choice and determine whether these have changed between 2007 and 2014. Methods In 2014, an international, cross-sectional study was conducted (Fluid-TRIPS) to document current patterns of intravenous resuscitation fluid use and determine factors associated with fluid choice. We examined univariate and multivariate associations between patients and prescriber characteristics, geographical region and fluid type. Additionally, we report secular trends of resuscitation fluid use in a cohort of ICUs that participated in both the 2007 and 2014 studies. Regression analysis were conducted to determine changes in the administration of crystalloid or colloid between 2007 and 2014. Findings In 2014, a total of 426 ICUs in 27 countries participated. Over the 24 hour study day, 1456/ 6707 (21.7%) patients received resuscitation fluid during 2716 resuscitation episodes. Crystalloids were administered to 1227/1456 (84.3%) patients during 2208/2716 (81.3%) episodes and colloids to 394/1456 (27.1%) patients during 581/2716 (21.4%) episodes. In multivariate analyses, practice significantly varied between geographical regions. Additionally, patients with a traumatic brain injury were less likely to receive colloid when compared to patients with no trauma (adjusted OR 0.24; 95% CI 0.1 to 0.62; p = 0.003). Patients in the ICU for one or more days where more likely to receive colloid compared to patients in the ICU on their admission date (adjusted OR 1.75; 95% CI 1.27 to 2.41; p = < 0.001). For secular trends in fluid resuscitation, 84 ICUs in 17 countries contributed data. In 2007, 527/1663 (31.7%) patients received fluid resuscitation during 1167 episodes compared to 491/1763 (27.9%) patients during 960 episodes in 2014. The use of crystalloids increased from 498/1167 (42.7%) in 2007 to 694/960 (72.3%) in 2014 (odds ratio (OR) 3.75, 95% confidence interval (CI) 2.95 to 4.77; p = < 0.001), primarily due to a significant increase in the use of buffered salt solutions. The use of colloids decreased from 724/1167 (62.0%) in 2007 to 297/960 (30.9%) in 2014 (OR 0.29, 95% CI 0.19 to 0.43; p = < 0.001), primarily due to a decrease in the use of HES, but an overall increase in the use of albumin. Conclusions Clinical practices of intravenous fluid resuscitation have changed between 2007 and 2014. Geographical location remains a strong predictor of the type of fluid administered for fluid resuscitation. Overall, there is a preferential use of crystalloids, specifically buffered salt solutions, over colloids. There is now an imperative to conduct a trial determining the safety and efficacy of these fluids on patient-centred outcomes.	[Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Correa, Maryam; Li, Yang; Saxena, Manoj; Watts, Nicola R.; Myburgh, John] George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia; [Hammond, Naomi E.; Finfer, Simon] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, Sydney, NSW, Australia; [Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Billot, Laurent] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Hammond, Naomi E.; Saxena, Manoj; Myburgh, John] Univ New South Wales, Fac Med, St George Clin Sch, Sydney, NSW, Australia; [Machado, Flavia R.] Univ Fed Sao Paulo, Pain & Intens Care Dept, Anesthesiol, Sao Paulo, Brazil; Peking Univ, Peoples Hosp, Dept Crit Care Med, Beijing, Peoples R China; George Inst Global Hlth, Stat Div, Sydney, NSW, Australia; Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany; DOr Inst Res & Educ, Rio De Janeiro, Brazil; Hosp Coracao, Res Inst, Sao Paulo, Brazil; Peking Union Med Coll Hosp, Med Intens Care Unit, Beijing, Peoples R China; Copenhagen Univ Hosp, Rigshosp, Dept Intens Care, Copenhagen, Denmark; Ottawa Hosp, Res Inst, Dept Med Crit Care, Ottawa, ON, Canada; St George Hosp, Dept Intens Care Med, Sydney, NSW, Australia; Reanimat Med Grp Hosp Henri Mondor, Assistance Publ Hop Paris, Creteil, France	Hammond, NE (corresponding author), George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Univ New South Wales, Fac Med, St George Clin Sch, Sydney, NSW, Australia.	nhammond@georgeinstitute.org.au	Biondi, Rodrigo S/H-5212-2016; Christian, Michael/AAZ-4452-2020; Billot, Laurent/Y-1241-2019; Bozza, Fernando A/A-2618-2013; Christian, Mike/AAO-6338-2020; Colombo, Riccardo/AAK-9081-2020; Bloos, Frank/AAY-8265-2020; Du, Bin/K-4283-2013; Cavalcanti, Alexandre/K-5529-2013	Biondi, Rodrigo S/0000-0002-9242-6062; Christian, Michael/0000-0001-9644-9950; Billot, Laurent/0000-0002-4975-9793; Bozza, Fernando A/0000-0003-4878-0256; Christian, Mike/0000-0001-9644-9950; Colombo, Riccardo/0000-0002-9616-803X; Bloos, Frank/0000-0002-0767-7941; Deeb, Ahmad/0000-0002-3680-7338; Hammond, Naomi/0000-0002-6559-7747; Finfer, Simon/0000-0002-2785-5864; Du, Bin/0000-0001-6237-2895; Cavalcanti, Alexandre/0000-0003-2798-6263; Saxena, Manoj/0000-0002-0385-6731; Schortgen, Frederique/0000-0003-1756-7508; Banner-Goodspeed, Valerie/0000-0002-7644-2521	Baxter Healthcare; CSL Behring; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP1039312]	This study was partially supported by unrestricted fluid grants from Baxter Healthcare and CSL Behring paid to The George Institute for Global Health. NH received a National Health and Medical Research Council of Australia Postgraduate Scholarship (2012-2014) that has supported part of this work [APP1039312]. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; or decision to submit the manuscript for publication.	Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; EMA, 2013, PRAC REC SUSP MARK A; FDA, 2013, HYDR STARCH SOL FDA; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Hammond NE, 2015, INTENS CARE MED, V41, P1611, DOI 10.1007/s00134-015-3878-y; Hammond Naomi, 2015, Rev. bras. ter. intensiva, V27, P309, DOI 10.5935/0103-507X.20150053; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krajewski ML, 2015, BRIT J SURG, V102, P24, DOI 10.1002/bjs.9651; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MHRA, 2013, HYDR STARCH HES PROD; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; R Core Team, 2018, R LANG ENV STAT COMP; Raghunathan K, 2015, ANESTHESIOLOGY, V123, P1385, DOI 10.1097/ALN.0000000000000861; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; TGA, 2014, HYDR STRACH VOL VOL; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356	30	48	50	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2017	12	5							e0176292	10.1371/journal.pone.0176292			21	Multidisciplinary Sciences	Science & Technology - Other Topics	EU8UR	WOS:000401314500003	28498856	DOAJ Gold, Green Published			2021-06-18	
J	Palacios, EM; Yuh, EL; Chang, YS; Yue, JK; Schnyer, DM; Okonkwo, DO; Valadka, AB; Gordon, WA; Maas, AIR; Vassar, M; Manley, GT; Mukherjee, P				Palacios, Eva M.; Yuh, Esther L.; Chang, Yi-Shin; Yue, John K.; Schnyer, David M.; Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Vassar, Mary; Manley, Geoffrey T.; Mukherjee, Pratik			Resting-State Functional Connectivity Alterations Associated with Six-Month Outcomes in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive and behavioral outcome; rsfMRI; TBI	DEFAULT-MODE NETWORK; CONCUSSED INDIVIDUALS; FMRI; DISRUPTION; ROBUST; MRI	Brain lesions are subtle or absent in most patients with mild traumatic brain injury (mTBI) and the standard clinical criteria are not reliable for predicting long-term outcome. This study investigates resting-state functional MRI (rsfMRI) to assess semiacute alterations in brain connectivity and its relationship with outcome measures assessed 6 months after injury. Seventy-five mTBI patients were recruited as part of the prospective multicenter Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) pilot study and compared with matched 47 healthy subjects. Patients were classified following radiological criteria: CT/MRI positive, evidence of lesions; CT/MRI negative, without evidence of brain lesions. rsfMRI data were acquired and then processed using probabilistic independent component analysis. We compared the functional connectivity of the resting-state networks (RSNs) between patients and controls, as well as group differences in the interactions between RSNs, and related both to cognitive and behavioral performance at 6 months post-injury. Alterations were found in the spatial maps of the RSNs between mTBI patients and healthy controls in networks involved in behavioral and cognition processes. These alterations were predictive of mTBI patients' outcomes at 6 months post-injury. Moreover, different patterns of reduced network interactions were found between the CT/MRI positive and CT/MRI negative patients and the control group. These rsfMRI results demonstrate that even mTBI patients not showing brain lesions on conventional CT/MRI scans can have alterations of functional connectivity at the semiacute stage that help explain their outcomes. These results suggest rsfMRI as a sensitive biomarker both for early diagnosis and for prediction of the cognitive and behavioral performance of these patients.	[Palacios, Eva M.; Yuh, Esther L.; Chang, Yi-Shin; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0946,185 Berry St, San Francisco, CA 94107 USA; [Yue, John K.; Vassar, Mary; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yue, John K.; Vassar, Mary; Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Yuh, Esther L.; Yue, John K.; Vassar, Mary; Manley, Geoffrey T.; Mukherjee, Pratik] San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94110 USA; [Yuh, Esther L.; Yue, John K.; Vassar, Mary; Manley, Geoffrey T.; Mukherjee, Pratik] Ctr Trauma, San Francisco, CA USA; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Gordon, Wayne A.] Ichan Sch Med Mt Sinai, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium	Mukherjee, P (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0946,185 Berry St, San Francisco, CA 94107 USA.	pratik.mukherjee@ucsf.edu	Maas, Andrew IR/C-5584-2013; Yue, John K/P-1348-2015	Maas, Andrew IR/0000-0003-1612-1264; Yue, John K/0000-0001-9694-7722	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069409, NS069409-02S1, NS60776]; Department of Defense United States Army Medical Research Acquisition ActivityUnited States Department of Defense [W81XWH-13-1-0441]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, R01NS060776, RC2NS069409] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) grants NS069409 and NS069409-02S1 (principal investigator [PI]: G.T.M.) and NS60776 (PI: P.M.) and Department of Defense United States Army Medical Research Acquisition Activity W81XWH-13-1-0441 (PI: G.T.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke (NINDS) or the NIH.	Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2012, NEUROIMAGE, V62, P1137, DOI 10.1016/j.neuroimage.2011.10.035; Di X, 2015, J NEUROPHYSIOL, V114, P2785, DOI 10.1152/jn.00893.2014; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Griffanti L, 2014, NEUROIMAGE, V95, P232, DOI 10.1016/j.neuroimage.2014.03.034; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Roiser J.P, 2016, MINIMUM STAT STAN DA; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smallwood J, 2012, BRAIN RES, V1428, P60, DOI 10.1016/j.brainres.2011.03.072; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2015, NAT NEUROSCI, V18, P1565, DOI 10.1038/nn.4125; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Spreng RN, 2014, J NEUROSCI, V34, P14108, DOI 10.1523/JNEUROSCI.2815-14.2014; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; van Schouwenburg MR, 2010, J NEUROSCI, V30, P9910, DOI 10.1523/JNEUROSCI.1111-10.2010; Vatansever D, 2017, HUM BRAIN MAPP, V38, P41, DOI 10.1002/hbm.23341; Vatansever D, 2015, J NEUROSCI, V35, P15254, DOI 10.1523/JNEUROSCI.2135-15.2015; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	36	48	50	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1546	1557		10.1089/neu.2016.4752			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500006	28085565	Green Published			2021-06-18	
J	Gill, J; Merchant-Borna, K; Jeromin, A; Livingston, W; Bazarian, J				Gill, Jessica; Merchant-Borna, Kian; Jeromin, Andreas; Livingston, Whitney; Bazarian, Jeffrey			Acute plasma tau relates to prolonged return to play after concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; ICE HOCKEY PLAYERS; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; EXERCISE; ENCEPHALOPATHY; BIOMARKERS; MANAGEMENT; IMPACT	Objective: To determine whether tau changes after sport-related concussion (SRC) relate to return to play (RTP). Methods: Collegiate athletes underwent preseason plasma sampling and cognitive testing and were followed. After a SRC (n = 46), athletes and controls (n 5 37) had sampling at 6 hours, and at 24 hours, 72 hours, and 7 days after SRC. A sample of 21 nonathlete controls were compared at baseline. SRC athletes were grouped by long (. 10 days, n = 23) and short (< 10 days, n = 18) RTP. Total tau was measured using an ultrasensitive immunoassay. Results: Both SRC and athlete controls had significantly higher mean tau at baseline compared to nonathlete healthy controls (F-101,(3) = 19.644, p, < 0.01). Compared to SRC athletes with short RTP, those with long RTP had higher tau concentrations overall, after controlling for sex (F-39,1 = 3.59, p = 0.022), compared to long RTP athletes, at 6 (p, 0.01), 24 (p, 0.01), and 72 hours (p = 0.02). Receiver operator characteristic analyses showed that higher plasma tau 6 hours postSRC was a significant predictor of RTP.10 days (area under the curve 0.81; 95% confidence interval 0.62-0.97, p = 0.01). Conclusions: Elevated plasma tau concentration within 6 hours following a SRC was related to having a prolonged RTP, suggesting that tau levels may help inform RTP.	[Gill, Jessica; Livingston, Whitney] NINR, NIH, Bethesda, MD 20892 USA; [Merchant-Borna, Kian; Bazarian, Jeffrey] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY USA; [Jeromin, Andreas] Quanterix Corp, Lexington, MA USA	Gill, J (corresponding author), NINR, NIH, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017		NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Nursing Research Intramural Research Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000033] Funding Source: NIH RePORTER	This work was supported by funds from the NIH/NICHD (award no.K24HD064754) and the NIH, National Institute of Nursing Research Intramural Research Program.	Stocchero CMA, 2014, APPL PHYSIOL NUTR ME, V39, P340, DOI 10.1139/apnm-2013-0308; Anderson JM, 2008, BRAIN, V131, P1736, DOI 10.1093/brain/awn119; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Bolouri H., 2015, BRAIN NEUROTRAUMA MO; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Knaepen K, 2010, SPORTS MED, V40, P765, DOI 10.2165/11534530-000000000-00000; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AUST FAM PHYSICIAN, V39, P12; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCulloch KL, 2015, J HEAD TRAUMA REHAB, V30, P56, DOI 10.1097/HTR.0000000000000104; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Oldenburg C, 2016, BRAIN INJURY, V30, P146, DOI 10.3109/02699052.2015.1089598; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Saur L, 2014, BRAIN STRUCT FUNCT, V219, P293, DOI 10.1007/s00429-012-0500-8; Shahim P, 2015, DIVING HYPERB MED, V45, P240; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028	35	48	49	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 7	2017	88	6					595	602		10.1212/wnl.0000000000003587			8	Clinical Neurology	Neurosciences & Neurology	EP4HR	WOS:000397342100015	28062722	Other Gold, Green Published			2021-06-18	
J	Ellis, MJ; Cordingley, DM; Vis, S; Reimer, KM; Leiter, J; Russell, K				Ellis, Michael J.; Cordingley, Dean M.; Vis, Sara; Reimer, Karen M.; Leiter, Jeff; Russell, Kelly			Clinical predictors of vestibulo-ocular dysfunction in pediatric sports-related concussion	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						sports-related concussion; vestibulo-ocular dysfunction; postconcussion syndrome; predictor; trauma	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; PROLONGED RECOVERY; GENDER-DIFFERENCES; ADOLESCENTS; REHABILITATION; MANAGEMENT; DISORDERS; DIZZINESS	OBJECTIVE There were 2 objectives of this study. The first objective was to identify clinical variables associated with vestibulo-ocular dysfunction (VOD) detected at initial consultation among pediatric patients with acute sports-related concussion (SRC) and postconcussion syndrome (PCS). The second objective was to reexamine the prevalence of VOD in this clinical cohort and evaluate the effect of VOD on length of recovery and the development of PCS. METHODS A retrospective review was conducted for all patients with acute SRC and PCS who were evaluated at a pediatric multidisciplinary concussion program from September 2013 to May 2015. Acute SRS was defined as present; ing < 30 days postinjury, and PCS was defined according to the International Classification of Diseases, 10th Revision criteria and included being symptomatic 30 days or longer postinjury. The initial assessment included clinical history and physical examination performed by 1 neurosurgeon. Patients were assessed for VOD, defined as the presence of more than 1 subjective vestibular and oculomotor complaint (dizziness, diplopia, blurred vision, etc.) and more than 1 objective physical examination finding (abnormal near point of convergence, smooth pursuits, saccades, or vestibulo-ocular reflex testing). Poisson regression analysis was used to identify factors that increased the risk of VOD at initial presentation and the development of PCS. RESULTS Three hundred ninety-nine children, including 306 patients with acute SRC and 93 with PCS, were included. Of these patients, 30.1% of those with acute SRC (65.0% male, mean age 13.9 years) and 43.0% of those with PCS (41.9% male, mean age 15.4 years) met the criteria for VOD at initial consultation. Independent predictors of VOD at initial consultation included female sex, preinjury history of depression, posttraumatic amnesia, and presence of dizziness, blurred vision, or difficulty focusing at the time of injury. Independent predictors of PCS among patients with acute SRC included the presence of VOD at initial consultation, preinjury history of depression, and posttraumatic amnesia at the time of injury. CONCLUSIONS This study identified important potential risk factors for the development of VOD following pediatric SRC. These results provide confirmatory evidence that VOD at initial consultation is associated with prolonged recovery and is an independent predictor for the development of PCS. Future studies examining clinical prediction rules in pediatric concussion should include VOD. Additional research is needed to elucidate the natural history of VOD following SRC and establish evidence-based indications for targeted vestibular rehabilitation.	[Ellis, Michael J.; Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB, Canada; [Ellis, Michael J.; Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada; [Ellis, Michael J.; Cordingley, Dean M.; Vis, Sara; Reimer, Karen M.; Leiter, Jeff] Pan Am Concuss Program, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada; [Ellis, Michael J.; Russell, Kelly] Childrens Hosp Res Inst Manitoba, Canada North Concuss Network, Winnipeg, MB, Canada	Ellis, MJ (corresponding author), Pan Am Concuss Program, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com		Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation; Winnipeg Jets True North Foundation; Manitoba Health Research Council	All phases of this study were supported by a grant from the Pan Am Clinic Foundation, Winnipeg Jets True North Foundation, and the Manitoba Health Research Council.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Bedgood A, 2015, CLIN J SPORT MED, V25, pE26, DOI 10.1097/JSM.0000000000000114; Bittencourt J, 2013, NEUROPSYCH DIS TREAT, V9, P1393, DOI 10.2147/NDT.S45931; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2003, J ATHL TRAINING, V38, P238; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15600; Ellis MJ, 2016, CURR SPORT MED REP, V15, P27, DOI 10.1249/JSR.0000000000000223; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Reneker JC, 2015, J SCI MED SPORT, V18, P366, DOI 10.1016/j.jsams.2014.05.002; Rommelse NNJ, 2008, BRAIN COGNITION, V68, P391, DOI 10.1016/j.bandc.2008.08.025; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Winograd-Gurvich C, 2006, NEUROSCI RES, V56, P253, DOI 10.1016/j.neures.2006.07.003; Wu H, 2015, PEDIAT EMERG CARE; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	41	48	49	1	21	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JAN	2017	19	1					38	45		10.3171/2016.7.PEDS16310			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EG0LS	WOS:000390724900006	27689244	Bronze			2021-06-18	
J	Dippel, G; Chmielewski, W; Muckschel, M; Beste, C				Dippel, Gabriel; Chmielewski, Witold; Mueckschel, Moritz; Beste, Christian			Response mode-dependent differences in neurofunctional networks during response inhibition: an EEG-beamforming study	BRAIN STRUCTURE & FUNCTION			English	Article						Beamforming; EEG; Temporo-parietal junction; Theta frequency; Response inhibition	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; NEURAL MECHANISMS; HEALTHY CONTROLS; TASK; THETA; OSCILLATIONS; PERFORMANCE; CORTEX	Response inhibition processes are one of the most important executive control functions and have been subject to intense research in cognitive neuroscience. However, knowledge on the neurophysiology and functional neuroanatomy on response inhibition is biased because studies usually employ experimental paradigms (e.g., sustained attention to response task, SART) in which behavior is susceptible to impulsive errors. Here, we investigate whether there are differences in neurophysiological mechanisms and networks depending on the response mode that predominates behavior in a response inhibition task. We do so comparing a SART with a traditionally formatted task paradigm. We use EEG-beamforming in two tasks inducing opposite response modes during action selection. We focus on theta frequency modulations, since these are implicated in cognitive control processes. The results show that a response mode that is susceptible to impulsive errors (response mode used in the SART) is associated with stronger theta band activity in the left temporo-parietal junction. The results suggest that the response modes applied during response inhibition differ in the encoding of surprise signals, or related processes of attentional sampling. Response modes during response inhibition seem to differ in processes necessary to update task representations relevant to behavioral control.	[Dippel, Gabriel; Chmielewski, Witold; Mueckschel, Moritz; Beste, Christian] Tech Univ Dresden, Dept Child & Adolescent Psychiat, Cognit Neurophysiol, Fac Med, Schubertstr 42, D-01309 Dresden, Germany	Beste, C (corresponding author), Tech Univ Dresden, Dept Child & Adolescent Psychiat, Cognit Neurophysiol, Fac Med, Schubertstr 42, D-01309 Dresden, Germany.	christian.beste@uniklinikum-dresden.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [BE4045/10-2]	This work was supported by a Grant from the Deutsche Forschungsgemeinschaft BE4045/10-2 to CB.	Aron AR, 2014, TRENDS COGN SCI, V18, P177, DOI 10.1016/j.tics.2013.12.003; Band GPH, 1999, ACTA PSYCHOL, V101, P179, DOI 10.1016/S0001-6918(99)00005-0; Bari A, 2013, PROG NEUROBIOL, V108, P44, DOI 10.1016/j.pneurobio.2013.06.005; Beste C, 2012, NEUROIMAGE, V62, P137, DOI 10.1016/j.neuroimage.2012.05.019; Beste C, 2011, NEUROPSYCHOLOGIA, V49, P3484, DOI 10.1016/j.neuropsychologia.2011.08.024; Beste C, 2010, HUM BRAIN MAPP, V31, P621, DOI 10.1002/hbm.20892; Beste C, 2010, NEUROPSYCHOLOGIA, V48, P366, DOI 10.1016/j.neuropsychologia.2009.09.023; Bressler SL, 2015, CURR OPIN NEUROBIOL, V31, P62, DOI 10.1016/j.conb.2014.08.010; Busch NA, 2010, P NATL ACAD SCI USA, V107, P16048, DOI 10.1073/pnas.1004801107; Carter L, 2013, BRAIN COGNITION, V82, P35, DOI 10.1016/j.bandc.2013.02.002; Cavanagh JF, 2014, TRENDS COGN SCI, V18, P414, DOI 10.1016/j.tics.2014.04.012; Cavanagh JF, 2012, PSYCHOPHYSIOLOGY, V49, P220, DOI 10.1111/j.1469-8986.2011.01293.x; Chmielewski WX, 2016, BRAIN STRUCT FUNCT, V221, P3949, DOI 10.1007/s00429-015-1137-1; Cohen MX, 2014, TRENDS NEUROSCI, V37, P480, DOI 10.1016/j.tins.2014.06.004; Cohen MX, 2013, J NEUROPHYSIOL, V110, P2752, DOI 10.1152/jn.00479.2013; De Blasio FM, 2013, INT J PSYCHOPHYSIOL, V87, P279, DOI 10.1016/j.ijpsycho.2012.09.016; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; Fallgatter AJ, 2001, J NEURAL TRANSM, V108, P679, DOI 10.1007/s007020170045; Fassbender C, 2009, EUR J NEUROSCI, V29, P181, DOI 10.1111/j.1460-9568.2008.06557.x; Fiebelkorn IC, 2013, NEUROIMAGE, V69, P126, DOI 10.1016/j.neuroimage.2012.11.021; Geng JJ, 2013, NEUROSCI BIOBEHAV R, V37, P2608, DOI 10.1016/j.neubiorev.2013.08.010; Gross J, 2001, P NATL ACAD SCI USA, V98, P694, DOI 10.1073/pnas.98.2.694; Harper J, 2014, CLIN NEUROPHYSIOL, V125, P124, DOI 10.1016/j.clinph.2013.06.025; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Herrmann CS, 2001, NEUROSCI BIOBEHAV R, V25, P465, DOI 10.1016/S0149-7634(01)00027-6; Huster RJ, 2013, INT J PSYCHOPHYSIOL, V87, P217, DOI 10.1016/j.ijpsycho.2012.08.001; Kenemans JL, 2005, INT J PSYCHOPHYSIOL, V58, P59, DOI 10.1016/j.ijpsycho.2005.03.009; Landau AN, 2012, CURR BIOL, V22, P1000, DOI 10.1016/j.cub.2012.03.054; McVay JC, 2009, J EXP PSYCHOL LEARN, V35, P196, DOI 10.1037/a0014104; Muckschel M, 2016, NEUROIMAGE, V125, P342, DOI 10.1016/j.neuroimage.2015.09.075; Muckschel M, 2014, CEREB CORTEX, V24, P2120, DOI 10.1093/cercor/bht066; NUNEZ PL, 1991, J CLIN NEUROPHYSIOL, V8, P397, DOI 10.1097/00004691-199110000-00005; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; Ocklenburg S, 2011, NEUROIMAGE, V55, P1771, DOI 10.1016/j.neuroimage.2011.01.035; Oostenveld R, 2003, CLIN NEUROPHYSIOL, V114, P1194, DOI 10.1016/S1388-2457(03)00059-2; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Quetscher C, 2015, BRAIN STRUCT FUNCT, V220, P3555, DOI 10.1007/s00429-014-0873-y; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche RAP, 2005, EXP BRAIN RES, V160, P60, DOI 10.1007/s00221-004-1985-z; Rondi-Reig L, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00205; Staub B, 2014, ACTA PSYCHOL, V146, P51, DOI 10.1016/j.actpsy.2013.12.003; Stevenson H, 2011, BRAIN COGNITION, V77, P215, DOI 10.1016/j.bandc.2011.08.007; TallonBaudry C, 1997, J NEUROSCI, V17, P722; VanRullen R, 2007, P NATL ACAD SCI USA, V104, P19204, DOI 10.1073/pnas.0707316104; VanRullen R, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00203; Vossel S, 2014, NEUROSCIENTIST, V20, P150, DOI 10.1177/1073858413494269; Womelsdorf T, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00210; Yordanova J, 2004, NEUROIMAGE, V22, P590, DOI 10.1016/j.neuroimage.2004.01.040	52	48	48	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	NOV	2016	221	8					4091	4101		10.1007/s00429-015-1148-y			11	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	EA1LA	WOS:000386352500015	26608829				2021-06-18	
J	Khalin, I; Alyautdin, R; Wong, TW; Gnanou, J; Kocherga, G; Kreuter, J				Khalin, Igor; Alyautdin, Renad; Wong, Tin Wui; Gnanou, Justin; Kocherga, Ganna; Kreuter, Joerg			Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury	DRUG DELIVERY			English	Article						Blood-brain barrier; brain-derived neurotrophic factor; drug-delivery; nanoparticles; traumatic brain injury	POLY(BUTYL CYANOACRYLATE) NANOPARTICLES; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN; FUNCTIONAL RECOVERY; BODY DISTRIBUTION; DRUG-DELIVERY; ANIMAL-MODELS; FACTOR BDNF; RAT; CELLS	Currently, traumatic brain injury (TBI) is the leading cause of death or disabilities in young individuals worldwide. The multi-complexity of its pathogenesis as well as impermeability of the blood-brain barrier (BBB) makes the drug choice and delivery very challenging. The brain-derived neurotrophic factor (BDNF) regulates neuronal plasticity, neuronal cell growth, proliferation, cell survival and long-term memory. However, its short half-life and low BBB permeability are the main hurdles to be an effective therapeutic for TBI. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles coated by surfactant can enable the delivery of a variety of molecules across the BBB by receptor-mediated transcytosis. This study examines the ability of PLGA nanoparticles coated with poloxamer 188 (PX) to deliver BDNF into the brain and neuroprotective effects of BNDF in mice with TBI. C57bl/6 mice were subjected to weight-drop closed head injuries under anesthesia. Using enzyme-linked immunosorbent assay, we demonstrated that the intravenous (IV) injection of nanoparticle-bound BDNF coated by PX (NP-BDNF-PX) significantly increased BDNF levels in the brain of sham-operated mice (p<0.001) and in both ipsi-(p<0.001) and contralateral (p<0.001) parts of brain in TBI mice compared to controls. This study also showed using the passive avoidance (PA) test, that IV injection of NP-BDNF-PX 3h post-injury prolonged the latent time in mice with TBI thereby reversing cognitive deficits caused by brain trauma. Finally, neurological severity score test demonstrated that our compound efficiently reduced the scores at day 7 after the injury indicating the improvement of neurological deficit in animals with TBI. This study shows that PLGA nanoparticles coated with PX effectively delivered BDNF into the brain, and improved neurological and cognitive deficits in TBI mice, thereby providing a neuroprotective effect.	[Khalin, Igor; Gnanou, Justin] Natl Def Univ Malaysia, Fac Med & Def Hlth, Kuala Lumpur, Malaysia; [Alyautdin, Renad] Sci Ctr Expertise Med Applicat Prod, Moscow, Russia; [Wong, Tin Wui] Univ Teknol MARA, Nondestruct Biomed & Pharmaceut Res Ctr, iPROMISE, Selangor, Malaysia; [Kocherga, Ganna] Int Med Ctr Oftalm, Ophthalm Microsurg Dept, Kharkov, Ukraine; [Kreuter, Joerg] Goethe Univ, Inst Pharmaceut Technol, Frankfurt, Germany	Khalin, I (corresponding author), Natl Def Univ Malaysia, Fac Med & Def Hlth, Kuala Lumpur, Malaysia.	igor@upnm.edu.my	Alyautdin, Renad N/L-9261-2014	Alyautdin, Renad N/0000-0002-4647-977X; Khalin, Igor/0000-0003-1041-5747	Ministry of Higher Education of MalaysiaMinistry of Education, Malaysia [RAGS/2013/UPNM/SKK/01/2]	The authors report no conflicts of interest in this work. The study was supported by a grant from the Ministry of Higher Education of Malaysia (RAGS/2013/UPNM/SKK/01/2).	Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098; Alyautdin RN, 1998, J MICROENCAPSUL, V15, P67, DOI 10.3109/02652049809006836; ANDERSON KD, 1995, J COMP NEUROL, V357, P296, DOI 10.1002/cne.903570209; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Casalbore P, 2010, J CELL PHYSIOL, V224, P710, DOI 10.1002/jcp.22170; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cowansage Kiriana K, 2010, Curr Mol Pharmacol, V3, P12; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gelperina S, 2010, EUR J PHARM BIOPHARM, V74, P157, DOI 10.1016/j.ejpb.2009.09.003; Geral Claire, 2013, Pharmaceutics, V5, P127, DOI 10.3390/pharmaceutics5010127; Grafman J, 2015, TRAUMATIC BRAIN IN 1; Graham D.I., 2002, GREENFIELDS NEUROPAT; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Khalin I, 2016, NEURAL REGEN RES, V11, P630, DOI 10.4103/1673-5374.180749; Khalin I, 2015, INT J NANOMED, V10, P3245, DOI 10.2147/IJN.S77480; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Klein AB, 2011, INT J NEUROPSYCHOPH, V14, P347, DOI 10.1017/S1461145710000738; Kober M, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/15/155501; Kreuter J, 2000, BLOOD-BRAIN BARRIER AND DRUG DELIVERY TO THE CNS, P205; KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J; Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008; Kume T, 1997, BRAIN RES, V756, P200, DOI 10.1016/S0006-8993(97)00195-9; Kurakhmaeva KB, 2009, J DRUG TARGET, V17, P564, DOI 10.1080/10611860903112842; LI JT, 1994, LANGMUIR, V10, P4475, DOI 10.1021/la00024a016; Liu ZH, 2007, J HUAZHONG U SCI-MED, V27, P233, DOI 10.1007/s11596-007-0304-x; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI [10.1586/erm.09.15, 10.1586/ERM.09.15]; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139; Moghimi SM, 1997, BBA-GEN SUBJECTS, V1336, P1, DOI 10.1016/S0304-4165(97)00060-3; Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Pardridge WM, 2016, EXPERT OPIN DRUG DEL, V13, P963, DOI 10.1517/17425247.2016.1171315; PARDRIDGE WM, 1994, PHARMACEUT RES, V11, P738, DOI 10.1023/A:1018940732550; Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j.jconrel.2006.10.015; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Quertemont E, 2004, PSYCHOPHARMACOLOGY, V177, P84, DOI 10.1007/s00213-004-1911-x; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Sakane T, 1997, PHARMACEUT RES, V14, P1085, DOI 10.1023/A:1012117815460; Schroeder U, 2000, LIFE SCI, V66, P495, DOI 10.1016/S0024-3205(99)00619-0; Sharma A, 2012, EXPERT OPIN DRUG MET, V8, P47, DOI 10.1517/17425255.2012.637916; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Steiniger SCJ, 2004, INT J CANCER, V109, P759, DOI 10.1002/ijc.20048; Tosi G, 2010, J CONTROL RELEASE, V145, P49, DOI 10.1016/j.jconrel.2010.03.008; Wagner S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032568; Wallace SJ, 2012, DRUG DELIV TRANSL RE, V2, P284, DOI 10.1007/s13346-012-0064-4; Wang ZT, 2013, J MOL NEUROSCI, V49, P409, DOI 10.1007/s12031-012-9908-0; Wohlfart S, 2012, J CONTROL RELEASE, V161, P264, DOI 10.1016/j.jconrel.2011.08.017; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076; Zensi A, 2009, J CONTROL RELEASE, V137, P78, DOI 10.1016/j.jconrel.2009.03.002; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X; Zheng WH, 2004, J NEUROCHEM, V89, P844, DOI 10.1111/j.1471-4159.2004.02350.x; Zhu JM, 2011, J INT MED RES, V39, P488, DOI 10.1177/147323001103900216	67	48	48	2	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-7544	1521-0464		DRUG DELIV	Drug Deliv.	NOV	2016	23	9					3520	3528		10.1080/10717544.2016.1199609			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EF1TU	WOS:000390108500034	27278330	Bronze			2021-06-18	
J	Roux, A; Muller, L; Jackson, SN; Post, J; Baldwin, K; Hoffer, B; Balaban, CD; Barbacci, D; Schultz, A; Gouty, S; Cox, BM; Woods, AS				Roux, Aurelie; Muller, Ludovic; Jackson, Shelley N.; Post, Jeremy; Baldwin, Katherine; Hoffer, Barry; Balaban, Carey D.; Barbacci, Damon; Schultz, Albert; Gouty, Shawn; Cox, Brian M.; Woods, Amina S.			Mass spectrometry imaging of rat brain lipid profile changes over time following traumatic brain injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Controlled cortical impact; Mass spectrometry imaging; Silver nanoparticles implantation; Lipids	POSTTRAUMATIC EPILEPSY; CHOLESTEROL-METABOLISM; SILVER NANOPARTICLES; PHOSPHOLIPASE-C; CERAMIDE; DISEASE; MECHANISMS; SPHINGOMYELIN; APOPTOSIS; SECTIONS	Background: Mild traumatic brain injury (TBI) is a common public health issue that may contribute to chronic degenerative disorders. Membrane lipids play a key role in tissue responses to injury, both as cell signals and as components of membrane structure and cell signaling. This study demonstrates the ability of high resolution mass spectrometry imaging (MSI) to assess sequences of responses of lipid species in a rat controlled cortical impact model for concussion. New method: A matrix of implanted silver nanoparticles was implanted superficially in brain sections for matrix-assisted laser desorption (MALDI) imaging of 50 mu m diameter microdomains across unfixed cryostat sections of rat brain. Ion-mobility time-of-flight MS was used to analyze and map changes over time in brain lipid composition in a rats after Controlled Cortical Impact (CCI) TBI. Results: Brain MS images showed changes in sphingolipids near the CCI site, including increased ceramides and decreased sphingomyelins, accompanied by changes in glycerophospholipids and cholesterol derivatives. The kinetics differed for each lipid class; for example ceramides increased as early as 1 day after the injury whereas other lipids changes occurred between 3 and 7 days post injury. Comparison with existing method(s): Silver nanoparticles MALDI matrix is a sensitive new tool for revealing previously undetectable cellular injury response and remodeling in neural, glial and vascular structure of the brain. Conclusions: Lipid biochemical and structural changes after TBI could help highlighting molecules that can be used to determine the severity of such injuries as well as to evaluate the efficacy of potential treatments. (C) 2016 Published by Elsevier B.V.	[Roux, Aurelie; Muller, Ludovic; Jackson, Shelley N.; Post, Jeremy; Baldwin, Katherine; Woods, Amina S.] NIDA, Struct Biol Unit, Integrat Neurosci Branch, NIH,IRP, Baltimore, MD 21224 USA; [Gouty, Shawn; Cox, Brian M.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Dept Pharmacol, Bethesda, MD 20814 USA; [Barbacci, Damon; Schultz, Albert] Ionwerks Inc, Houston, TX 77002 USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15213 USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA; [Hoffer, Barry] Univ Hosp Cleveland, Cleveland, OH 44106 USA	Woods, AS (corresponding author), NIDA, Struct Biol Unit, Integrat Neurosci Branch, NIH,IRP, Baltimore, MD 21224 USA.	awoods@intra.nida.nih.gov	Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	U.S. Department of DefenseUnited States Department of Defense; Center for Neuroscience and Regenerative Medicine (CNRM), Rockville, MD; Intramural Research Program of the National Institute on Drug Abuse, NIH; NIH SBIR Phase IIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44DA030853-03 5R44DA036263-03]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R44DA030853, R44DA036263, ZIADA000589] Funding Source: NIH RePORTER	The authors declare no competing financial interests. This work was supported in part by a grant from the U.S. Department of Defense and the Center for Neuroscience and Regenerative Medicine (CNRM), Rockville, MD and by the Intramural Research Program of the National Institute on Drug Abuse, NIH. Ionwerks gratefully acknowledges support of this work through NIH SBIR Phase II grants R44DA030853-03 5R44DA036263-03". The authors acknowledge Dr. Mari Prieto and Glen Gregory of the Thermo Fisher Corporation for technical and instrumentation advice. The authors also thank Gregory Bull for his technical support. The opinions and assertions contained herein are the personal opinions of the authors and are not to be construed as official or reflecting the views of the Uniformed Services University, the Department of Defense, NIDA or the NIH.	Adibhatla RM, 2006, AAPS J, V8, pE314; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Altura BM, 2002, BRAIN RES BULL, V58, P271, DOI 10.1016/S0361-9230(02)00772-4; Aureli M, 2014, GLYCOCONJUGATE J, V31, P449, DOI 10.1007/s10719-014-9541-y; Colsch B, 2010, GLYCOBIOLOGY, V20, P661, DOI 10.1093/glycob/cwq031; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Delvolve AM, 2011, ANAL METHODS-UK, V3, P1729, DOI 10.1039/c1ay05107e; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez JA, 2011, ANAL BIOANAL CHEM, V401, P29, DOI 10.1007/s00216-011-4696-x; Fernandis AZ, 2007, CURR OPIN LIPIDOL, V18, P121, DOI 10.1097/MOL.0b013e328082e4d5; Gorska M, 2002, HORM METAB RES, V34, P466, DOI 10.1055/s-2002-33597; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Hauser KF, 2005, FRONT BIOSCI-LANDMRK, V10, P216, DOI 10.2741/1522; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Ichi I, 2007, NUTRITION, V23, P570, DOI 10.1016/j.nut.2007.04.014; Ionescu N, 2013, INDIAN J CLIN BIOCHE, V28, P361, DOI 10.1007/s12291-013-0327-y; Jackson SN, 2014, ANAL BIOANAL CHEM, V406, P1377, DOI 10.1007/s00216-013-7525-6; Jackson SN, 2005, ANAL CHEM, V77, P4523, DOI 10.1021/ac050276v; Jin JF, 2008, J BIOL CHEM, V283, P26509, DOI 10.1074/jbc.M801597200; Kim JH, 2011, NEUROSCIENCE, V185, P125, DOI 10.1016/j.neuroscience.2011.04.018; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Muller L, 2015, KIDNEY INT, V88, P186, DOI 10.1038/ki.2015.3; National Institute of Neurological Disorders and Stroke, 2002, TRAUM BRAIN INJ HOPE; Novgorodov Sergei A, 2011, Int J Biochem Mol Biol, V2, P347; Olney J, 1978, KAINIC ACID TOOL NEU, P95; OLNEY JW, 1993, APMIS, V101, P103; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Piomelli D, 2005, PROSTAG OTH LIPID M, V77, P23, DOI 10.1016/j.prostaglandins.2004.09.006; Piomelli D, 2007, NAT REV NEUROSCI, V8, P743, DOI 10.1038/nrn2233; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Roux A, 2015, ACS CHEM NEUROSCI, V6, P247, DOI 10.1021/cn500174c; Schull S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.62; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Stiban J, 2010, ADV EXP MED BIOL, V688, P60; Sturley SL, 2004, BBA-MOL CELL BIOL L, V1685, P83, DOI 10.1016/j.bbalip.2004.08.014; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Taniguchi M, 2014, BBA-MOL CELL BIOL L, V1841, P692, DOI 10.1016/j.bbalip.2013.12.003; Waggie KS, 1999, LAB ANIM SCI, V49, P358; Wang HYJ, 2012, ANAL BIOANAL CHEM, V404, P113, DOI 10.1007/s00216-012-6077-5; Wang HYJ, 2010, RAPID COMMUN MASS SP, V24, P2057, DOI 10.1002/rcm.4620; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Wenk MR, 2010, CELL, V143, P888, DOI 10.1016/j.cell.2010.11.033; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118; Woods AS, 2006, AAPS J, V8, pE391, DOI 10.1007/BF02854910; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Woods AS, 2006, J PROTEOME RES, V5, P1017, DOI 10.1021/pr060016+; Yu ZF, 2000, J MOL NEUROSCI, V15, P85, DOI 10.1385/JMN:15:2:85	55	48	48	0	46	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2016	272				SI		19	32		10.1016/j.jneumeth.2016.02.004			14	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EA6LF	WOS:000386740000003	26872743	Bronze, Green Accepted			2021-06-18	
J	Koga, S; Dickson, DW; Bieniek, KF				Koga, Shunsuke; Dickson, Dennis W.; Bieniek, Kevin F.			Chronic Traumatic Encephalopathy Pathology in Multiple System Atrophy	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						alpha-Synuclein; Aging-related tau astrogliopathy; Chronic traumatic encephalopathy; Head trauma; Multiple system atrophy; Tau	REPETITIVE HEAD-INJURY; NEUROPATHOLOGICAL CRITERIA; BRAIN; DIAGNOSIS; SPECTRUM; DISEASE; MSA	Chronic traumatic encephalopathy (CTE) is a progressive neuro(d)egenerative disorder associated with repetitive traumatic brain injury. Multiple system atrophy (MSA) is a Parkinsonian disorder that can result in repetitive falls with associated head trauma. We hypothesized that patients with neurodegenerative disorders like MSA could develop CTE pathology. Therefore, we assessed CTE pathology in 139 MSA cases in our brain bank. Sections from convexity cerebral cortices were screened by immunohistochemistry with anti-phospho-tau antibody. For cases with suggestive CTE pathology, further sections of basal forebrain and hippocampus were immunostained. Consensus criteria were used to make the diagnosis of CTE and aging-related tau astrogliopathy (ARTAG) was differentiated from CTE pathology. Pertinent clinical information was derived from the available records and online searches. Of the 139 MSA cases, 8 (6%) had CTE pathology and 10 (8%) had ARTAG pathology. All 8 cases with CTE were male and 4 of them had a documented history of contact sports. The median age at death in MSA with CTE was younger than in MSA without CTE or MSA with ARTAG (60, 67, and 74 years, respectively; p = 0.002). Even without a known history of contact sports or head trauma, a small subset of cases with MSA had CTE pathology.	[Koga, Shunsuke; Dickson, Dennis W.; Bieniek, Kevin F.] Mayo Clin, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA	Bieniek, KF (corresponding author), Mayo Clin, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	bieniek.kevin@mayo.edu	Koga, Shunsuke/ABE-7206-2020	Koga, Shunsuke/0000-0001-8868-9700; Bieniek, Kevin/0000-0003-4922-864X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS072187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG003949, P50AG016574] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG016574, P01 AG003949] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS072187] Funding Source: Medline		Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, NEUROCHIRURG HOMMAGE, P131; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Fanciulli A, 2015, NEW ENGL J MED, V372, P249, DOI 10.1056/NEJMra1311488; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geser F, 2006, MOVEMENT DISORD, V21, P179, DOI 10.1002/mds.20678; Koga S, 2015, NEUROLOGY, V85, P404, DOI 10.1212/WNL.0000000000001807; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Ozawa T, 2004, BRAIN, V127, P2657, DOI 10.1093/brain/awh303; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Trojanowski JQ, 2007, NEUROPATH APPL NEURO, V33, P615, DOI 10.1111/j.1365-2990.2007.00907.x; Wenning GK, 1997, MOVEMENT DISORD, V12, P133, DOI 10.1002/mds.870120203	24	48	49	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	OCT	2016	75	10					963	970		10.1093/jnen/nlw073			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	EC3ET	WOS:000388009200006	27543120	Bronze, Green Published			2021-06-18	
J	Aisiku, IP; Yamal, JM; Doshi, P; Benoit, JS; Gopinath, S; Goodman, JC; Robertson, CS				Aisiku, Imo P.; Yamal, Jose-Miguel; Doshi, Pratik; Benoit, Julia S.; Gopinath, Shankar; Goodman, Jerry C.; Robertson, Claudia S.			Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury	CRITICAL CARE			English	Article						TBI; ARDS; ALI; Cytokines; Plasma; CSF	TUMOR-NECROSIS-FACTOR; ACUTE LUNG INJURY; RISK PATIENTS; BRONCHOALVEOLAR; INTERLEUKIN-1; INFLAMMATION; MORTALITY; FAILURE; SEPSIS	Background: Patients with severe traumatic brain injury (TBI) are at risk of the development of acute respiratory distress syndrome (ARDS). TBI and ARDS pathophysiologic mechanisms are known to independently involve significant inflammatory responses. The literature on the association between plasma inflammatory cytokines and ARDS in patients with TBI is sparse. Methods: The study was a secondary analysis of the safety of a randomized trial of erythropoietin and transfusion threshold in patients with severe TBI. Inflammatory markers within the first 24 hours after injury were compared in patients who developed ARDS and patients without ARDS, using Cox proportional hazards models. Results: There were 200 patients enrolled in the study. The majority of plasma and cerebrospinal fluid (CSF) cytokine levels were obtained within 6 hours. Plasma proinflammatory markers IL-6 and IL-8 and anti-inflammatory marker IL-10 were associated with the development of ARDS (adjusted hazard ratio (HR) = 1.55, confidence interval (CI) = 1.14, 2.11, P = 0.005 for IL-6; adjusted HR = 1.32, CI = 1.10, 1.59, P = 0.003 for IL-8). Conclusion: Plasma markers of IL-6, IL-8, and IL-10 are associated with ARDS in patients with severe TBI.	[Aisiku, Imo P.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA; [Yamal, Jose-Miguel] Univ Texas Houston, Sch Publ Hlth, Div Biostat, Houston, TX USA; [Doshi, Pratik] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med & Internal Med, Houston, TX 77030 USA; [Benoit, Julia S.] Univ Houston, Coll Optometry, Texas Inst Measurement Evaluat & Stat, Dept Basic Vis Sci, Houston, TX USA; [Gopinath, Shankar; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Goodman, Jerry C.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Aisiku, IP (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.	iaisiku@partners.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA125123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	NIH Grant: P01-NS38660.	Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Donnelly SC, 1996, ANN INTERN MED, V125, P191, DOI 10.7326/0003-4819-125-3-199608010-00005; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Gattinoni L, 2010, CRIT CARE MED, V38, pS539, DOI 10.1097/CCM.0b013e3181f1fcf7; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; GORIS RJA, 1990, INTENS CARE MED, V16, pS192, DOI 10.1007/BF01709699; Gullo JD, 2011, NEUROCRIT CARE, V14, P194, DOI 10.1007/s12028-010-9462-y; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kuchnicka K, 2013, ANAESTH INTENSIVE TH, V45, P164, DOI 10.5603/AIT.2013.0034; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maier S, 2000, SHOCK, V14, P187, DOI 10.1097/00024382-200014020-00019; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013; Parsons PE, 1997, AM J RESP CRIT CARE, V155, P1469, DOI 10.1164/ajrccm.155.4.9105096; Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schutte H, 1996, EUR RESPIR J, V9, P1858, DOI 10.1183/09031936.96.09091858; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; SILER TM, 1989, EXP LUNG RES, V15, P881, DOI 10.3109/01902148909069633; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x	29	48	55	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	SEP 15	2016	20								288	10.1186/s13054-016-1470-7			10	Critical Care Medicine	General & Internal Medicine	DW6ME	WOS:000383764400001	27630085	DOAJ Gold, Green Published			2021-06-18	
J	Zhang, AL; Sing, DC; Rugg, CM; Feeley, BT; Senter, C				Zhang, Alan L.; Sing, David C.; Rugg, Caitlin M.; Feeley, Brian T.; Senter, Carlin			The Rise of Concussions in the Adolescent Population	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						concussion; traumatic brain injury (TBI); trends; epidemiology; adolescents; youth	TRAUMATIC BRAIN-INJURY; EMERGENCY-DEPARTMENT VISITS; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; TRENDS; EPIDEMIOLOGY; STATEMENT; DEPRESSION; AWARENESS; DEFICITS	Background: Concussion injuries have been highlighted to the American public through media and research. While recent studies have shown increased traumatic brain injuries (TBIs) diagnosed in emergency departments across the United States, no studies have evaluated trends in concussion diagnoses across the general US population in various age groups. Purpose: To evaluate the current incidence and trends in concussions diagnosed across varying age groups and health care settings in a large cross-sectional population. Study Design: Descriptive epidemiological study. Methods: Administrative health records of 8,828,248 members of a large private-payer insurance group in the United States were queried. Patients diagnosed with concussion from years 2007 through 2014 were stratified by year of diagnosis, age group, sex, classification of concussion, and health care setting of diagnosis (eg, emergency department vs physician's office). Chi-square testing was used for statistical analysis. Results: From a cohort of 8,828,248 patients, 43,884 patients were diagnosed with a concussion. Of these patients, 55% were male and over 32% were in the adolescent age group (10-19 years old). The highest incidence of concussion was seen in patients aged 15 to 19 years (16.5/1000 patients), followed by those aged 10 to 14 years (10.5/1000 patients), 20 to 24 years (5.2/1000 patients), and 5 to 9 years (3.5/1000 patients). Overall, there was a 60% increase in concussion incidence from 2007 to 2014. The largest increases were in the 10- to 14-year (143%) and 15- to 19-year (87%) age groups. Based on International Classification of Disease-9th Revision classification, 29% of concussions were associated with some form of loss of consciousness. Finally, 56% of concussions were diagnosed in the emergency department and 29% in a physician's office, with the remainder in urgent care clinics or inpatient settings. Conclusion: The incidence of concussion diagnosed in the general US population is increasing, driven largely by a substantial rise in the adolescent age group. The youth population should be prioritized for ongoing work in concussion education, diagnosis, treatment, and prevention. Clinical Relevance: The rise of concussions in the adolescent age group across the general population is concerning, and clinical efforts to prevent these injuries are needed.	[Zhang, Alan L.; Sing, David C.; Rugg, Caitlin M.; Feeley, Brian T.; Senter, Carlin] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Zhang, Alan L.; Sing, David C.; Rugg, Caitlin M.; Feeley, Brian T.; Senter, Carlin] Univ Calif San Francisco, Dept Orthopaed Surg, 1500 Owens St,Box 3004, San Francisco, CA 94158 USA; [Senter, Carlin] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA	Zhang, AL (corresponding author), Univ Calif San Francisco, Dept Orthopaed Surg, 1500 Owens St,Box 3004, San Francisco, CA 94158 USA.	alan.zhang@ucsf.edu					Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown JA, 2015, BMC SPORTS SCI MED R, V7, DOI 10.1186/s13102-015-0019-4; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Centers for Disease Control and Prevention, 2014, TRAUMATIC BRAIN INJU; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Dean PJA, 2015, BRAIN INJURY, V29, P1211, DOI 10.3109/02699052.2015.1035334; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Mitka M, 2010, JAMA-J AM MED ASSOC, V304, P1775, DOI 10.1001/jama.2010.1487; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Piercy KL, 2015, AM J PUBLIC HEALTH, V105, P421, DOI 10.2105/AJPH.2014.302325; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; Sing DC, 2015, ARTHROSCOPY, V31, P2307, DOI 10.1016/j.arthro.2015.06.008; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; U.S Department of Health and Human Services, 2012, PHYS ACT GUID AM MID; US Department of Health and Human Services, 2008, 2008 PHYS ACT GUID A; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Zhang AL, 2013, ARTHROSCOPY, V29, P623, DOI 10.1016/j.arthro.2012.11.004; Zhang AL, 2012, AM J SPORT MED, V40, P1144, DOI 10.1177/0363546512436944; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696; Zuckerman SL, 2016, AM J SPORT MED, V44, pNP5, DOI 10.1177/0363546515623241; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	45	48	48	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	AUG	2016	4	8							2325967116662458	10.1177/2325967116662458			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DV6II	WOS:000383037100004	27579334	DOAJ Gold, Green Published			2021-06-18	
J	Nixdorf, I; Frank, R; Beckmann, J				Nixdorf, Insa; Frank, Raphael; Beckmann, Juergen			Comparison of Athletes' Proneness to Depressive Symptoms in Individual and Team Sports: Research on Psychological Mediators in Junior Elite Athletes	FRONTIERS IN PSYCHOLOGY			English	Article						depression; junior elite athletes; team sports; individual sports; attribution	SOCCER PLAYERS; SELF-ESTEEM; PERFECTIONISM; PREVALENCE; BURNOUT; RISK; COHESION; GENDER; HEALTH; CONCUSSION	Depression among elite athletes is a topic of increasing interest and public awareness. Currently, empirical data on elite athletes' depressive symptoms are rare. Recent results indicate sport-related mechanisms and effects on depression prevalence in elite athlete samples; specific factors associated with depression include overtraining, injury, and failure in competition. One such effect is that athletes competing in individual sports were found to be more prone to depressive symptoms than athletes competing in team sports. The present study examined this effect by testing three possible, psychological mediators based on theoretical and empirical assumptions: namely, cohesion in team or training groups; perception of perfectionistic expectations from others; and negative attribution after failure. In a cross-sectional study, 199 German junior elite athletes (M-age = 14.96; SD = 1.56) participated and completed questionnaires on perfectionism, cohesion, attribution after failure, and depressive symptoms. Mediation analysis using path analysis with bootstrapping was used for data analysis. As expected, athletes in individual sports showed higher scores in depression than athletes in team sports [t(197) = 2.05; p < 0.05; d = 0.30]. Furthermore, negative attribution after failure was associated with individual sports (beta = 0.27; p < 0.001), as well as with the dependent variable depression (beta = 0.26; p < 0.01). Mediation hypothesis was supported by a significant indirect effect (beta = 0.07; p < 0.05). Negative attribution after failure mediated the relationship between individual sports and depression scores. Neither cohesion nor perfectionism met essential criteria to serve as mediators: cohesion was not elevated in either team or individual sports, and perfectionism was positively related to team sports. The results support the assumption of previous findings on sport specific mechanisms (here the effect between individual and team sports) contributing to depressive symptoms among elite athletes. Additionally, attribution after failure seems to play an important role in this regard and could be considered in further research and practitioners in the field of sport psychology.	[Nixdorf, Insa; Frank, Raphael; Beckmann, Juergen] Tech Univ Munich, Dept Sport Psychol, D-80290 Munich, Germany	Nixdorf, I (corresponding author), Tech Univ Munich, Dept Sport Psychol, D-80290 Munich, Germany.	insa.nixdorf@tum.de	Nixdorf, Raphael/J-7289-2016	Nixdorf, Raphael/0000-0002-3512-8819	German Federal Institute of Sport Science (Bundesinstitut fur Sportwissenschitft) [IIA1-071001/14-15]; German Federal Institute of Sport Science (BISp); German Research Foundation (DFG)German Research Foundation (DFG); Technical University of Munich (TUM)	The present study was funded (grant number: IIA1-071001/14-15) by the German Federal Institute of Sport Science (Bundesinstitut fur Sportwissenschitft; BISp) based on a decision of the German Bundestag. This work was supported by the German Research Foundation (DFG) and the Technical University of Munich (TUM) in the framework of the Open Access Publishing Program.	ABRAMSON LY, 1989, PSYCHOL REV, V96, P358, DOI 10.1037/0033-295X.96.2.358; Alloy LB, 2006, J ABNORM PSYCHOL, V115, P145, DOI 10.1037/0021-843X.115.1.145; Appaneal RN, 2009, J SPORT EXERCISE PSY, V31, P60, DOI 10.1123/jsep.31.1.60; Armstrong LE, 2002, SPORTS MED, V32, P185, DOI 10.2165/00007256-200232030-00003; Armstrong S, 2009, J AM COLL HEALTH, V57, P521, DOI 10.3200/JACH.57.5.521-526; Ashby JS, 2002, J COUNS DEV, V80, P197, DOI 10.1002/j.1556-6678.2002.tb00183.x; Au ACY, 2009, ADOLESCENCE, V44, P851; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; CARRON AV, 1985, J SPORT PSYCHOL, V7, P244, DOI 10.1123/jsp.7.3.244; Enns M.W., 2002, PERFECTIONISM THEORY, P33, DOI [10.1037/10458-002., DOI 10.1037/10458-002, 10.1037/10458-002]; Evans MB, 2015, SCAND J MED SCI SPOR, V25, pE139, DOI 10.1111/sms.12235; Evans MB, 2012, CAN PSYCHOL, V53, P301, DOI 10.1037/a0030202; Fleet GL., 2002, PERFECTIONISM THEORY, P5, DOI [DOI 10.1037/10458-001, 10.1037/10458-001]; Frank R, 2013, DEUT Z SPORTMED, V64, P320, DOI 10.5960/dzsm.2013.088; FROST RO, 1990, COGNITIVE THER RES, V14, P449, DOI 10.1007/BF01172967; Gotwals JK, 2012, CAN PSYCHOL, V53, P263, DOI 10.1037/a0030288; Gouttebarge V, 2015, OCCUP MED-OXFORD, V65, P190, DOI 10.1093/occmed/kqu202; Gulliver A, 2015, J SCI MED SPORT, V18, P255, DOI 10.1016/j.jsams.2014.04.006; Hammond T, 2013, CLIN J SPORT MED, V23, P273, DOI 10.1097/JSM.0b013e318287b870; Hanrahan S.J., 1990, AUST J SCI MED SPORT, V22, P97; Hanrahan S. J., 2008, ADV SPORT PSYCHOL, P99; Hanrahan SJ, 2009, J SCI MED SPORT, V12, P508, DOI 10.1016/j.jsams.2008.01.005; Hautzinger M., 2011, ALLGEMEINE DEPRESSIO; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; HEWITT PL, 1991, J ABNORM PSYCHOL, V100, P98, DOI 10.1037/0021-843X.100.1.98; HEWITT PL, 1991, J PERS SOC PSYCHOL, V60, P456, DOI 10.1037/0022-3514.60.3.456; Hill AP, 2008, PSYCHOL SPORT EXERC, V9, P630, DOI 10.1016/j.psychsport.2007.09.004; Hill AP, 2013, J SPORT EXERCISE PSY, V35, P18, DOI 10.1123/jsep.35.1.18; HULL JG, 1991, J PERS SOC PSYCHOL, V61, P85, DOI 10.1037/0022-3514.61.1.85; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Jacobi F, 2004, PSYCHOL MED, V34, P597, DOI 10.1017/S0033291703001399; Jowett GE, 2013, SPORT EXERC PERFORM, V2, P48, DOI 10.1037/a0029770; Junge A., 2016, BMJ OPEN SPORT EXERC, V2, DOI [10.1136/bmjsem-2015-000087, DOI 10.1136/BMJSEM-2015-000087]; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Madigan DJ, 2015, J SPORT EXERCISE PSY, V37, P305, DOI 10.1123/jsep.2014-0266; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Martin K. A., 1997, Journal of Sport Behavior, V20, P435; Nixdorf I, 2013, J CLIN SPORT PSYCHOL, V7, P313, DOI 10.1123/jcsp.7.4.313; Norton PJ, 2000, DEPRESS ANXIETY, V12, P193, DOI 10.1002/1520-6394(2000)12:4<193::AID-DA2>3.0.CO;2-X; Ohlert J, 2012, INT J SPORT EXERC PS, V10, P39, DOI 10.1080/1612197X.2012.645129; PUFFER JC, 1992, CLIN SPORT MED, V11, P327; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCANLAN TK, 1984, PSYCHOL F SPORT, P118; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Stoeber J., 2004, HALLESCHE BERICHTE P, V7; Stoeber J, 2006, PERS SOC PSYCHOL REV, V10, P295, DOI 10.1207/s15327957pspr1004_2; Tracy JL, 2004, PSYCHOL INQ, V15, P103, DOI 10.1207/s15327965pli1502_01; van de Pol PKC, 2015, J APPL SOC PSYCHOL, V45, P697, DOI 10.1111/jasp.12331; Widmeyer W. N., 1992, ADV SPORT PSYCHOL, P163; Wolanin A, 2016, BRIT J SPORT MED, V50, P167, DOI 10.1136/bjsports-2015-095756; Wolanin A, 2015, CURR SPORT MED REP, V14, P56, DOI 10.1249/JSR.0000000000000123; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b	53	48	50	1	33	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	JUN 17	2016	7								893	10.3389/fpsyg.2016.00893			8	Psychology, Multidisciplinary	Psychology	DO7JF	WOS:000377957900002	27378988	DOAJ Gold, Green Published			2021-06-18	
J	Kontos, AP; Sufrinko, A; Elbin, RJ; Puskar, A; Collins, MW				Kontos, Anthony P.; Sufrinko, Alicia; Elbin, R. J.; Puskar, Alicia; Collins, Michael W.			Reliability and Associated Risk Factors for Performance on the Vestibular/Ocular Motor Screening (VOMS) Tool in Healthy Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						college; concussion; baseline testing; vestibular; ocular motor	MOTION SICKNESS; SEX-DIFFERENCES; NORMATIVE DATA; CONCUSSION; SUSCEPTIBILITY; CONVERGENCE; SYMPTOMS; MIGRAINE; SPORTS; PREVALENCE	Background: The Vestibular/Ocular Motor Screening (VOMS) is a newly developed screening tool that evaluates vestibular and ocular motor symptom (eg, headache, dizziness, nausea, fogginess) provocation after a sport-related concussion. Baseline data on the VOMS are needed to extend the application of this measure to broad age groups and to document normal variations in performance. Purpose: The primary purpose of this study was to examine the internal consistency of the VOMS in a large sample of healthy, nonconcussed collegiate athletes. The secondary purpose was to investigate the effects of patient sex and history of motion sickness, migraines, and concussions on baseline VOMS scores. Study Design: Cohort study; Level of evidence, 2. Methods: A total of 263 National Collegiate Athletic Association Division I athletes (mean SD age, 19.85 1.35 years) completed self-reported demographic and medical history at preseason physical examinations and baseline screening. Internal consistency of the VOMS was assessed with Cronbach . A series of univariate nonparametric tests ((2) with odds ratios [ORs] and 95% CIs) were used to examine the associations among medical history risk factors and VOMS clinical cutoff scores (score of 2 for any individual VOMS symptom, near point of convergence [NPC] distance of 5 cm), with higher scores representing greater symptom provocation. Results: Internal consistency of the VOMS was high (Cronbach = .97), and 89% of athletes scored below cutoff levels (ie, 11% false-positive rate). Female athletes (OR, 2.99 [95% CI, 1.34-6.70]; P = .006) and those with a personal history of motion sickness (OR, 7.73 [95% CI, 1.94-30.75]; P = .009) were more likely to have 1 VOMS scores above cutoff levels. No risk factors were associated with increased odds of an abnormal NPC distance. Conclusion: The VOMS possesses internal consistency and an acceptable false-positive rate among healthy Division I collegiate student-athletes. Female sex and a history of motion sickness were risk factors for VOMS scores above clinical cutoff levels among healthy collegiate student-athletes. Results support a comprehensive baseline evaluation approach that includes an assessment of premorbid vestibular and oculomotor symptoms.	[Kontos, Anthony P.; Sufrinko, Alicia; Elbin, R. J.; Puskar, Alicia; Collins, Michael W.] Univ Pittsburgh, Pittsburgh, PA USA; [Kontos, Anthony P.; Sufrinko, Alicia; Puskar, Alicia; Collins, Michael W.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA; [Elbin, R. J.] Univ Arkansas, Off Sport Concuss Res, Fayetteville, AR 72701 USA	Kontos, AP (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; Grand Alliance of the Concussion Assessment, Research and Education Consortium; National Collegiate Athletic Association; Department of Defense (United States Army Medical Research Acquisition Activity)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Research Program [W81XWH-14-2-0151]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: M.W.C. is a cofounder and 10% shareholder of ImPACT Applications Inc. This research was supported in part by grants to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) and from the Grand Alliance of the Concussion Assessment, Research and Education Consortium, funded in part by the National Collegiate Athletic Association and the Department of Defense (United States Army Medical Research Acquisition Activity). This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Research Program (award No. W81XWH-14-2-0151).	Black FO, 2002, AM J OBSTET GYNECOL, V186, pS204, DOI 10.1067/mob.2002.122602; Boldingh MI, 2011, CEPHALALGIA, V31, P1211, DOI 10.1177/0333102411409074; Borsting Eric, 2005, Optometry, V76, P588, DOI 10.1016/j.optm.2005.07.007; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bucci MP, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00981; Buckley TA, 2014, CONCUSSIONS ATHLETIC, P139, DOI [10.1007/978-1-4939-0295-8, DOI 10.1007/978-1-4939-0295-8]; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Cullen KE, 2012, TRENDS NEUROSCI, V35, P185, DOI 10.1016/j.tins.2011.12.001; Dobie T, 2001, AVIAT SPACE ENVIR MD, V72, P13; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Elbin RJ, 2013, TRANSL STROKE RES, V4, P425, DOI 10.1007/s12975-012-0237-y; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Furman Joseph M, 2012, Continuum (Minneap Minn), V18, P1102, DOI 10.1212/01.CON.0000421621.18407.96; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jokerst MD, 1999, AVIAT SPACE ENVIR MD, V70, P962; KAYAN A, 1984, BRAIN, V107, P1123, DOI 10.1093/brain/107.4.1123; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Langhagen T, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00292; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maples WC, 2007, OPTOMETRY VISION SCI, V84, P224, DOI 10.1097/OPX.0b013e3180339f44; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mostofsky SH, 2001, NEUROLOGY, V57, P423, DOI 10.1212/WNL.57.3.423; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murdin L, 2015, J NEUROL NEUROSUR PS, V86, P585, DOI 10.1136/jnnp-2014-308331; Park AHY, 1998, PERCEPT MOTOR SKILL, V87, P1202, DOI 10.2466/pms.1998.87.3f.1202; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Saman Yougan, 2012, Front Neurol, V3, P116, DOI 10.3389/fneur.2012.00116; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman M, 2008, OPHTHAL EPIDEMIOL, V15, P24, DOI 10.1080/09286580701772037; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Zur O, 2015, DISABIL REHABIL, V37, P2197, DOI 10.3109/09638288.2014.1002577	43	48	48	2	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2016	44	6					1400	1406		10.1177/0363546516632754			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DO5KJ	WOS:000377821700012	26980845				2021-06-18	
J	Solomon, GS; Kuhn, AW; Zuckerman, SL; Casson, IR; Viano, DC; Lovell, MR; Sills, AK				Solomon, Gary S.; Kuhn, Andrew W.; Zuckerman, Scott L.; Casson, Ira R.; Viano, David C.; Lovell, Mark R.; Sills, Allen K.			Participation in Pre-High School Football and Neurological, Neuroradiological, and Neuropsychological Findings in Later Life: A Study of 45 Retired National Football League Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; football; National Football League; exposure; youth	TEST-RETEST RELIABILITY; CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; CONSTRUCT-VALIDITY; ONLINE VERSION; IMPACT; SENSITIVITY; SYMPTOMS	Background: A recent study found that an earlier age of first exposure (AFE) to tackle football was associated with long-term neurocognitive impairment in retired National Football League (NFL) players. Purpose: To assess the association between years of exposure to pre-high school football (PreYOE) and neuroradiological, neurological, and neuropsychological outcome measures in a different sample of retired NFL players. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Forty-five former NFL players were included in this study. All participants prospectively completed extensive history taking, a neurological examination, brain magnetic resonance imaging, and a comprehensive battery of neuropsychological tests. To measure the associations between PreYOE and these outcome measures, multiple regression models were utilized while controlling for several covariates. Results: After applying a Bonferroni correction for multiple comparisons, none of the neurological, neuroradiological, or neuropsychological outcome measures yielded a significant relationship with PreYOE. A second Bonferroni-corrected analysis of a subset of these athletes with self-reported learning disability yielded no significant relationships on paper-and-pencil neurocognitive tests but did result in a significant association between learning disability and computerized indices of visual motor speed and reaction time. Conclusion: The current study failed to replicate the results of a prior study, which concluded that an earlier AFE to tackle football might result in long-term neurocognitive deficits. In 45 retired NFL athletes, there were no associations between PreYOE and neuroradiological, neurological, and neuropsychological outcome measures.	[Solomon, Gary S.; Zuckerman, Scott L.; Sills, Allen K.] Vanderbilt Univ, Vanderbilt Sports Concuss Ctr, Sch Med, Dept Neurol Surg, Med Ctr North T-4224, Nashville, TN 37212 USA; [Kuhn, Andrew W.] Univ Michigan Hlth Syst, MedSport Sports Med & Phys Therapy, Ann Arbor, MI USA; [Casson, Ira R.] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Dept Neurol, Hempstead, NY 11550 USA; [Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI USA; [Viano, David C.] Wayne State Univ, Dept Biomed Engn & Radiol, Detroit, MI USA; [Lovell, Mark R.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA	Solomon, GS; Sills, AK (corresponding author), Vanderbilt Univ, Vanderbilt Sports Concuss Ctr, Sch Med, Dept Neurol Surg, Med Ctr North T-4224, Nashville, TN 37212 USA.	gary.solomon@vanderbilt.edu	Solomon, Gary/K-9011-2019; Kuhn, Andrew W/AAM-4820-2020	Kuhn, Andrew W/0000-0003-1836-7575	Tennessee Titans (National Football League [NFL]); Nashville Predators (National Hockey League); athletic departments of several universities; NFL	One or more of the authors has declared the following potential conflict of interest or source of funding: No grants or outside funding supported this work. G.S.S. receives consulting fees from the Tennessee Titans (National Football League [NFL]), the Nashville Predators (National Hockey League), and the athletic departments of several universities. In addition, he is a member of the ImPACT Advisory Board, receives reimbursement for expenses to board meetings, and also receives royalties from book sales. M.R.L. is chairman and chief scientific officer of ImPACT and served as a member of the NFL's Mild Traumatic Brain Injury (MTBI) Committee from 1994 to 2009. I.R.C. served as a member of the MTBI Committee from 1994 to 2009 and as a cochair from 2007 to 2009. He has consulted for law firms and insurance companies. D.C.V. served as a member of the MTBI Committee from 1994 to 2009 and as a cochair from 2007 to 2009. A.K.S. serves as an unaffiliated neurological consultant for NFL games. Examinations of the 45 NFL retirees were sponsored by the NFL and coordinated with the NFL Players Association.	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Andrikopoulos J, 2015, NEUROLOGY; [Anonymous], 1906, JAMA-J AM MED ASSOC, VXLVI, P122; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babyak MA, RESCALING CONTINUOUS; Beck AT., 1996, BECK DEPRESSION INVE, V2; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Delis DC, 2000, CALIFORNIA VERBAL LE; Diamond AB, 2014, PHYSICIAN SPORTSMED, V42, P20, DOI 10.3810/psm.2014.09.2071; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Foley C, 2014, CURR SPORT MED REP, V13, P390, DOI 10.1249/JSR.0000000000000104; Folstein MF, 2001, MINI MENTAL STATE EX; HOLM S, 1979, SCAND J STAT, V6, P65; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kutcher JS., WEAK SCI MAKES BIG M; Larrabee G. J., 2015, NEUROLOGY; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Lezak M, 2004, CONTROLLED WORD ASS; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Maroon JC, 2015, NEUROLOGY; Mautner K, 2015, CLIN J SPORT MED, V25, P355, DOI 10.1097/JSM.0000000000000151; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Partington J. E., 1949, PSYCHOL SERVICE CTR, V1, P9; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	62	48	48	1	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2016	44	5					1106	1115		10.1177/0363546515626164			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DL4JD	WOS:000375599600004	26888877				2021-06-18	
J	Hall, ED; Wang, JA; Bosken, JM; Singh, IN				Hall, Edward D.; Wang, Juan A.; Bosken, Jeffrey M.; Singh, Indrapal N.			Lipid peroxidation in brain or spinal cord mitochondria after injury	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article						Oxidative stress; Traumatic brain injury; Spinal cord injury; Mitochondria; Lipid peroxidation; Antioxidant	MEDIATED CYTOSKELETAL DEGRADATION; TRAUMATIC BRAIN; CYCLOSPORINE-A; ANTIOXIDANT THERAPIES; OXIDATIVE DAMAGE; IMPAIRED MITOCHONDRIAL; PEROXYNITRITE; DYSFUNCTION; RAT; PROTECTION	Extensive evidence has demonstrated an important role of oxygen radical formation (i.e., oxidative stress) as a mediator of the secondary injury process that occurs following primary mechanical injury to the brain or spinal cord. The predominant form of oxygen radical-induced oxidative damage that occurs in injured nervous tissue is lipid peroxidation (LP). Much of the oxidative stress in injured nerve cells initially begins in mitochondria via the generation of the reactive nitrogen species peroxynitrite (PN) which then can generate multiple highly reactive free radicals including nitrogen dioxide (aEuro cent NO2), hydroxyl radical (aEuro cent OH) and carbonate radical (aEuro cent CO3). Each can readily induce LP within the phospholipid membranes of the mitochondrion leading to respiratory dysfunction, calcium buffering impairment, mitochondrial permeability transition and cell death. Validation of the role of LP in central nervous system secondary injury has been provided by the mitochondrial and neuroprotective effects of multiple antioxidant agents which are briefly reviewed.	[Hall, Edward D.; Wang, Juan A.; Bosken, Jeffrey M.; Singh, Indrapal N.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA; [Hall, Edward D.] Univ Kentucky, Med Ctr, Anat & Neurobiol Neurosurg Neurol & Phys Med & Re, Room B477,Biomed & Biol Sci Res Bldg, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institute of Neurological Disorders Stroke (NINDS) [R01 NS046566, R01 NS083405, R01 NS084857, P01 NS058484, R21 NS077434, P30 NS051220]; Kentucky Spinal Cord & Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, R21NS077434, P01NS058484, R01NS083405, R01NS084857, P30NS051220] Funding Source: NIH RePORTER	The research described in the authors' laboratory was partially funded by grants from the National Institute of Neurological Disorders & Stroke (NINDS) including R01 NS046566, R01 NS083405, R01 NS084857, P01 NS058484, R21 NS077434 and P30 NS051220 and grants from the Kentucky Spinal Cord & Head Injury Research Trust.	Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Valdez LB, 2000, FREE RADICAL BIO MED, V29, P349, DOI 10.1016/S0891-5849(00)00301-4; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, FREE RADICAL RES, V43, P604, DOI 10.1080/10715760902977432; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Zanella B, 2002, BIOCHEM BIOPH RES CO, V290, P1010, DOI 10.1006/bbrc.2001.6284	43	48	52	0	8	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	APR	2016	48	2					169	174		10.1007/s10863-015-9600-5			6	Biophysics; Cell Biology	Biophysics; Cell Biology	DJ7SX	WOS:000374413700007	25595872	Green Accepted			2021-06-18	
J	Hakkarainen, TW; Arbabi, S; Willis, MM; Davidson, GH; Flum, DR				Hakkarainen, Timo W.; Arbabi, Saman; Willis, Margaret M.; Davidson, Giana H.; Flum, David R.			Outcomes of Patients Discharged to Skilled Nursing Facilities After Acute Care Hospitalizations	ANNALS OF SURGERY			English	Article						post-acute care outcomes; skilled nursing facility; trauma	TRAUMATIC BRAIN-INJURY; MORTALITY; SURVIVAL	Objectives:To evaluate previously independent older patients discharged to skilled nursing facilities (SNFs) and identify risk factors for failure to return home and death and development of a predictive tool to determine likelihood of adverse outcome.Background:Little is known about the likelihood of return to home, and higher than expected mortality rates in SNFs have recently been described, which may represent an opportunity for quality improvement.Methods:Retrospective cohort of older hospitalized patients discharged to SNFs during 2007 to 2009 in 5 states using Centers for Medicare & Medicaid Services linked minimum data set data from SNFs. We assessed mortality, hospital readmission, discharge to home, and logistic regression models for predicting risk of each outcome.Results:Of 416,997 patients, 3.8% died during the initial SNF stay, 28.6% required readmission, and 60.5% were ultimately discharged home. Readmission to a hospital was the strongest predictor of death in the years after SNF admission (unadjusted hazard ratio, 28.2; 95% confidence interval, 27.2-29.3; P<0.001). Among all patients discharged to SNFs, 7.8% eventually died in an SNF and overall 1-year mortality was 26.1%. Risk factors associated with mortality and failure to return home were increasing age, male sex, increasing comorbidities, decreased cognitive function, decreased functional status, parenteral nutrition, and pressure ulcers.Conclusions:A large proportion of older patients discharging to SNFs never return home. A better understanding of the natural history of patients sent to SNFs after hospitalization and risk factors for failure to return to home, readmission, and death should help identify opportunities for interventions to improved outcome.	Univ Washington, Comparat Effectiveness Res Translat Network, Surg Outcomes Res Ctr, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent Res Ctr, Seattle, WA 98195 USA	Davidson, GH (corresponding author), Univ Washington, Dept Surg, 1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.	ghd@uw.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1T32DK070555-01A1]; Washington State's Life Science Discovery Fund and Agency for Healthcare Research and Quality through Surgical Care and Outcomes Assessment Program (SCOAP) [1 R01 HS 20025-01]; Comparative Effectiveness Research Translation Network (CERTAIN); Harborview Injury Prevention Research Center; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS020025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK070555] Funding Source: NIH RePORTER	Supported by NIH training grant 1T32DK070555-01A1 and by the Washington State's Life Science Discovery Fund and Agency for Healthcare Research and Quality Grant Number 1 R01 HS 20025-01 through the Surgical Care and Outcomes Assessment Program (SCOAP), the Comparative Effectiveness Research Translation Network (CERTAIN), and the Harborview Injury Prevention Research Center. None of the authors have any financial or personal conflicts of interests pertaining to this work.	Aitken LM, 2010, J AM GERIATR SOC, V58, P442, DOI 10.1111/j.1532-5415.2010.02728.x; [Anonymous], 2013, C MED PAYM POL; Claridge JA, 2010, J AM COLL SURGEONS, V210, P788, DOI 10.1016/j.jamcollsurg.2009.12.035; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Cook CH, 1999, J AM COLL SURGEONS, V189, P437, DOI 10.1016/S1072-7515(99)00191-X; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Fleischman RJ, 2010, J AM GERIATR SOC, V58, P1843, DOI 10.1111/j.1532-5415.2010.03065.x; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Legner VJ, 2009, ANN SURG, V249, P250, DOI 10.1097/SLA.0b013e318195e12f; Mor V, 2011, HLTH AFF MILLWOOD, V29, P57; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Ouslander JG, 2009, J AM MED DIR ASSOC, V10, P644, DOI 10.1016/j.jamda.2009.07.001; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Yu P, 2011, J SURG RES, V170, pE217, DOI 10.1016/j.jss.2011.05.040	16	48	48	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	FEB	2016	263	2					280	285		10.1097/SLA.0000000000001367			6	Surgery	Surgery	DD8TP	WOS:000370200100014	26445466	Green Accepted			2021-06-18	
J	Johnson, VE; Stewart, W; Weber, MT; Cullen, DK; Siman, R; Smith, DH				Johnson, Victoria E.; Stewart, William; Weber, Maura T.; Cullen, D. Kacy; Siman, Robert; Smith, Douglas H.			SNTF immunostaining reveals previously undetected axonal pathology in traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						Traumatic brain injury; TBI; Concussion; Mild TBI; Diffuse axonal injury; Spectrin breakdown; SNTF; Axonal pathology; Amyloid precursor protein; Neurofilaments	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; DYNAMIC STRETCH INJURY; CALPAIN ACTIVATION; CORPUS-CALLOSUM; CYCLOSPORINE-A; HIPPOCAMPAL DAMAGE; SURROGATE MARKERS; FORENSIC PRACTICE	Diffuse axonal injury (DAI) is a common feature of severe traumatic brain injury (TBI) and may also be a predominant pathology in mild TBI or "concussion". The rapid deformation of white matter at the instant of trauma can lead to mechanical failure and calcium-dependent proteolysis of the axonal cytoskeleton in association with axonal transport interruption. Recently, a proteolytic fragment of alpha-II spectrin, "SNTF", was detected in serum acutely following mild TBI in patients and was prognostic for poor clinical outcome. However, direct evidence that this fragment is a marker of DAI has yet to be demonstrated in either humans following TBI or in models of mild TBI. Here, we used immunohistochemistry (IHC) to examine for SNTF in brain tissue following both severe and mild TBI. Human severe TBI cases (survival < 7d; n = 18) were compared to age-matched controls (n = 16) from the Glasgow TBI archive. We also examined brains from an established model of mild TBI at 6, 48 and 72 h post-injury versus shams. IHC specific for SNTF was compared to that of amyloid precursor protein (APP), the current standard for DAI diagnosis, and other known markers of axonal pathology including non-phosphorylated neurofilament-H (SMI-32), neurofilament-68 (NF-68) and compacted neurofilament-medium (RMO-14) using double and triple immunofluorescent labeling. Supporting its use as a biomarker of DAI, SNTF immunoreactive axons were observed at all time points following both human severe TBI and in the model of mild TBI. Interestingly, SNTF revealed a subpopulation of degenerating axons, undetected by the gold-standard marker of transport interruption, APP. While there was greater axonal co-localization between SNTF and APP after severe TBI in humans, a subset of SNTF positive axons displayed no APP accumulation. Notably, some co-localization was observed between SNTF and the less abundant neurofilament subtype markers. Other SNTF positive axons, however, did not co-localize with any other markers. Similarly, RMO-14 and NF-68 positive axonal pathology existed independent of SNTF and APP. These data demonstrate that multiple pathological axonal phenotypes exist post-TBI and provide insight into a more comprehensive approach to the neuropathological assessment of DAI.	[Johnson, Victoria E.; Stewart, William; Weber, Maura T.; Cullen, D. Kacy; Siman, Robert; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stewart, William] Queen Elizabeth Glasgow Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Perelman Sch Med, Penn Ctr Brain Injury & Repair, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@upenn.edu		Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS056202, NS038104, NS092389]; US Department of DefenseUnited States Department of Defense [PT110785]; NHS Research Scotland Career Research Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS092398, R01NS038104] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants NS056202 (D. H. Smith and R. Siman), NS038104 (D. H. Smith), NS092389 (D. H. Smith), the US Department of Defense Grant PT110785 (D. H. Smith) and the NHS Research Scotland Career Research Fellowship (W. Stewart). We would like to thank Dr. John Wolf and Michael Grovola for their assistance with confocal imaging.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Baines AJ, 2009, BIOCHEM SOC T, V37, P796, DOI 10.1042/BST0370796; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CAMPBELL MJ, 1989, J COMP NEUROL, V282, P191, DOI 10.1002/cne.902820204; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MAXWELL WL, 1991, J ANAT, V176, P71; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 1999, ACT NEUR S, V73, P15; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R., 2015, J NEUROTRAU IN PRESS; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yamazaki T, 1997, J NEUROSCI, V17, P1004	83	48	48	1	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JAN	2016	131	1					115	135		10.1007/s00401-015-1506-0			21	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DA2CB	WOS:000367601800008	26589592	Green Accepted			2021-06-18	
J	Mishra, V; Shuai, B; Kodali, M; Shetty, GA; Hattiangady, B; Rao, XL; Shetty, AK				Mishra, Vikas; Shuai, Bing; Kodali, Maheedhar; Shetty, Geetha A.; Hattiangady, Bharathi; Rao, Xiaolan; Shetty, Ashok K.			Resveratrol Treatment after Status Epilepticus Restrains Neurodegeneration and Abnormal Neurogenesis with Suppression of Oxidative Stress and Inflammation	SCIENTIFIC REPORTS			English	Article							TEMPORAL-LOBE EPILEPSY; NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELL; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; GRANULE CELLS; KAINIC ACID; RAT MODEL; THERAPEUTIC IMPLICATIONS	Antiepileptic drug therapy, though beneficial for restraining seizures, cannot thwart status epilepticus (SE) induced neurodegeneration or down-stream detrimental changes. We investigated the efficacy of resveratrol (RESV) for preventing SE-induced neurodegeneration, abnormal neurogenesis, oxidative stress and inflammation in the hippocampus. We induced SE in young rats and treated with either vehicle or RESV, commencing an hour after SE induction and continuing every hour for three-hours on SE day and twice daily thereafter for 3 days. Seizures were terminated in both groups two-hours after SE with a diazepam injection. In contrast to the vehicle-treated group, the hippocampus of animals receiving RESV during and after SE presented no loss of glutamatergic neurons in hippocampal cell layers, diminished loss of inhibitory interneurons expressing parvalbumin, somatostatin and neuropeptide Y in the dentate gyrus, reduced aberrant neurogenesis with preservation of reelin + interneurons, lowered concentration of oxidative stress byproduct malondialdehyde and pro-inflammatory cytokine tumor necrosis factor-alpha, normalized expression of oxidative stress responsive genes and diminished numbers of activated microglia. Thus, 4 days of RESV treatment after SE is efficacious for thwarting glutamatergic neuron degeneration, alleviating interneuron loss and abnormal neurogenesis, and suppressing oxidative stress and inflammation. These results have implications for restraining SE-induced chronic temporal lobe epilepsy.	[Mishra, Vikas; Shuai, Bing; Kodali, Maheedhar; Shetty, Geetha A.; Hattiangady, Bharathi; Rao, Xiaolan; Shetty, Ashok K.] Scott & White Mem Hosp & Clin, Texas A&M Hlth Sci Ctr, Coll Med, Inst Regenerat Med, Temple, TX 76502 USA; [Mishra, Vikas; Shuai, Bing; Kodali, Maheedhar; Shetty, Geetha A.; Hattiangady, Bharathi; Rao, Xiaolan; Shetty, Ashok K.] Cent Texas Vet Hlth Care Syst, Olin E Teague Vet Affairs Med Ctr, Res Serv, Temple, TX USA; [Mishra, Vikas; Shuai, Bing; Kodali, Maheedhar; Shetty, Geetha A.; Hattiangady, Bharathi; Rao, Xiaolan; Shetty, Ashok K.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Mol & Cellular Med, College Stn, TX USA	Shetty, AK (corresponding author), Scott & White Mem Hosp & Clin, Texas A&M Hlth Sci Ctr, Coll Med, Inst Regenerat Med, Temple, TX 76502 USA.	Shetty@medicine.tamhsc.edu	Shetty, Ashok K/A-2428-2008; Shetty, Ashok/AAT-7273-2020	Shetty, Ashok K/0000-0001-5049-6671; Shetty, Ashok/0000-0001-5049-6671; Mishra, Vikas/0000-0001-7162-5882	State of Texas (Emerging Technology Funds); Department of Veterans Affairs (VA Merit Award) [I01 BX002351]; Veterans AffairsUS Department of Veterans Affairs [I01BX002351] Funding Source: NIH RePORTER	This study was supported by the State of Texas (Emerging Technology Funds to A.K.S.) and the Department of Veterans Affairs (VA Merit Award, I01 BX002351 to A.K.S.). Dr. Shetty is also Research Career Scientist at the Olin E. Teague Veterans' Medical Center, Central Texas Veterans Health Care System Temple, Texas. We thank MegaResveratrol (Candlewood Stars Inc., 60 Newtown Road, Danbury CT, USA) for supplying resveratrol to this study for no fee. The summary information on various genes discussed in this study was obtained from GeneCards (human gene database at: http://www.genecards.org), National Center for Biotechnology Information (NCBI at: http://www.ncbi.nlm.nih.gov/gene) and Online Mendelian Inheritance in Man (OMIM at: http://www.omim.org). The contents of this article suggest the views of authors and do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.	Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Ben-Ari Y., 2012, JASPERS BASIC MECH E; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Cho KO, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7606; Chung JH, 2012, TRENDS CELL BIOL, V22, P546, DOI 10.1016/j.tcb.2012.07.004; Coras R, 2010, BRAIN, V133, P3359, DOI 10.1093/brain/awq215; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Detampel P, 2012, DRUG METAB REV, V44, P253, DOI 10.3109/03602532.2012.700715; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Fellin T, 2005, TRENDS MOL MED, V11, P530, DOI 10.1016/j.molmed.2005.10.007; Friedman LK, 2013, NEUROSCIENCE, V230, P39, DOI 10.1016/j.neuroscience.2012.10.063; Furukawa A, 2011, NEUROBIOL DIS, V43, P706, DOI 10.1016/j.nbd.2011.05.024; Gong C, 2007, J NEUROSCI, V27, P1803, DOI 10.1523/JNEUROSCI.3111-06.2007; Gupta YK, 2002, PHARMACOLOGY, V65, P170, DOI 10.1159/000058044; Gupta YK, 2002, PHARMACOL BIOCHEM BE, V71, P245, DOI 10.1016/S0091-3057(01)00663-3; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; Hattiangady B, 2008, EXP NEUROL, V212, P468, DOI 10.1016/j.expneurol.2008.04.040; Hattiangady B, 2011, AGING DIS, V2, P1; Hattiangady B, 2010, HIPPOCAMPUS, V20, P97, DOI 10.1002/hipo.20594; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hester MS, 2014, EPILEPSY BEHAV, V38, P105, DOI 10.1016/j.yebeh.2013.12.022; Houser CR, 2014, ADV EXP MED BIOL, V813, P151, DOI 10.1007/978-94-017-8914-1_12; Janigro D, 2013, EPILEPSIA, V54, P30, DOI 10.1111/epi.12271; Kim HJ, 2013, NEUROCHEM RES, V38, P117, DOI 10.1007/s11064-012-0897-8; Kleen JK, 2012, JASPERS BASIC MECH E; Kodali M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08075; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; Kuruba R, 2009, EPILEPSY BEHAV, V14, P65, DOI 10.1016/j.yebeh.2008.08.020; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Loscher W., 2012, JASPERS BASIC MECH E; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; McCloskey DP, 2006, EUR J NEUROSCI, V24, P2203, DOI 10.1111/j.1460-9568.2006.05101.x; Menon B, 2012, SEIZURE-EUR J EPILEP, V21, P780, DOI 10.1016/j.seizure.2012.09.003; Murray AJ, 2011, NAT NEUROSCI, V14, P297, DOI 10.1038/nn.2751; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2012, JASPERS BASIC MECH E, V4; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Rao MS, 2006, J NEUROSCI RES, V83, P1088, DOI 10.1002/jnr.20802; Rao MS, 2005, EUR J NEUROSCI, V21, P464, DOI 10.1111/j.1460-9568.2005.03853.x; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Rao MS, 2006, AGING CELL, V5, P545, DOI 10.1111/j.1474-9726.2006.00243.x; Sankar R, 2012, JASPERS BASIC MECH E; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scharfman HE, 2002, NEUROSCIENCE, V111, P71, DOI 10.1016/S0306-4522(01)00599-1; Scharfman Helen E., 2002, Epilepsy Curr, V2, P63, DOI 10.1046/j.1535-7597.2002.00023.x; Scharfman HE, 2012, EPILEPSIA, V53, P98, DOI 10.1111/j.1528-1167.2012.03480.x; Schwaller B, 2004, MOL CELL NEUROSCI, V25, P650, DOI 10.1016/j.mcn.2003.12.006; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Shetty AK, 2011, PHARMACOL THERAPEUT, V131, P269, DOI 10.1016/j.pharmthera.2011.04.008; Shetty GA, 2013, AGE, V35, P2165, DOI 10.1007/s11357-012-9507-6; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Sun AY, 1997, NEUROCHEM RES, V22, P1187, DOI 10.1023/A:1021968526696; Temkin N. R., 2004, EPILEPSY RES, V60, P80; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Waldau B, 2010, STEM CELLS, V28, P1153, DOI 10.1002/stem.446; Waldbaum S, 2010, EPILEPSY RES, V88, P23, DOI 10.1016/j.eplepsyres.2009.09.020; Wang HM, 2013, PHARMACOL BIOCHEM BE, V105, P134, DOI 10.1016/j.pbb.2012.12.016; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wasterlain CG, 2013, EPILEPSIA, V54, P78, DOI 10.1111/epi.12285; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu Z, 2009, NEUROCHEM RES, V34, P1393, DOI 10.1007/s11064-009-9920-0; Zini R, 1999, DRUG EXP CLIN RES, V25, P87	73	48	50	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	DEC 7	2015	5								17807	10.1038/srep17807			19	Multidisciplinary Sciences	Science & Technology - Other Topics	CX7CQ	WOS:000365859100001	26639668	DOAJ Gold, Green Published			2021-06-18	
J	Ruseva, MM; Ramaglia, V; Morgan, BP; Harris, CL				Ruseva, Marieta M.; Ramaglia, Valeria; Morgan, B. Paul; Harris, Claire L.			An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						traumatic brain injury; complement; therapy; CD59; CRIg	MEMBRANE ATTACK COMPLEX; MYELIN PHAGOCYTOSIS; ALTERNATIVE PATHWAY; HEAD-INJURY; ACTIVATION; INHIBITION; EXPRESSION; SYSTEM; C3; CD59	Activation of complement is a key determinant of neuropathology and disability after traumatic brain injury (TBI), and inhibition is neuroprotective. However, systemic complement is essential to fight infections, a critical complication of TBI. We describe a targeted complement inhibitor, comprising complement receptor of the Ig superfamily (CRIg) fused with complement regulator CD59a, designed to inhibit membrane attack complex (MAC) assembly at sites of C3b/iC3b deposition. CRIg and CD59a were linked via the IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited MAC formation and prevented complement-mediated lysis in vitro. CD59-2a-CRIg dimer bound C3b-coated surfaces with submicromolar affinity (K-D). In experimental TBI, CD59-2a-CRIg administered post-trauma homed to sites of injury and significantly reduced MAC deposition, microglial accumulation, mitochondrial stress, and axonal damage and enhanced neurologic recovery compared with placebo controls. CD59-2a-CRIg inhibited MAC-induced inflammasome activation and IL-1 beta production in microglia. Given the important anti-infection roles of complement opsonization, site-targeted inhibition of MAC should be considered to promote recovery postneurotrauma.	[Ruseva, Marieta M.; Morgan, B. Paul; Harris, Claire L.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales; [Ramaglia, Valeria] Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, NL-1105 AZ Amsterdam, Netherlands	Harris, CL (corresponding author), Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales.	harriscl@cardiff.ac.uk		Morgan, Paul/0000-0003-4075-7676	Cardiff University; Brain Foundation of the Netherlands Fellowship [F2010 (1)-05]	We thank Iliana Michailidou for technical support with in situ hybridization. This work was funded by a Cardiff University PhD studentship (to M.M.R.) and Brain Foundation of the Netherlands Fellowship F2010 (1)-05 (to V.R.).	Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Baas F, 2014, TRAUMATIC BRAIN INJU, P79; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Burk AM, 2012, SHOCK, V37, P348, DOI 10.1097/SHK.0b013e3182471795; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412270-00015; Dorado L, 2014, CURR CARDIOL REV, V10, P327, DOI 10.2174/1573403X10666140320144637; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Harris CL, 2003, IMMUNOLOGY, V109, P117, DOI 10.1046/j.1365-2567.2003.01628.x; Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039; Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Lai AY, 2006, J NEUROIMMUNOL, V175, P97, DOI 10.1016/j.jneuroim.2006.03.001; Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Ma YF, 2015, J IMMUNOL, V194, P2855, DOI 10.4049/jimmunol.1303477; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; MERI S, 1990, IMMUNOLOGY, V71, P1; Morgan B P, 2000, Methods Mol Biol, V150, P61; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Plurad DS, 2010, AM SURGEON, V76, P43; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Qiao Q, 2014, FASEB J, V28, P4986, DOI 10.1096/fj.14-258046; Ramaglia V, 2007, J NEUROSCI, V27, P7663, DOI 10.1523/JNEUROSCI.5623-06.2007; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rossi S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-56; Rostami E, 2013, J NEUROTRAUM, V30, P1954, DOI 10.1089/neu.2012.2583; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Ruseva MM, 2014, METHODS MOL BIOL, V1100, P75, DOI 10.1007/978-1-62703-724-2_6; RUSEVA MM, 2009, MOL IMMUNOL, V46, P2865, DOI DOI 10.1016/J.MOLIMM.2009.05.317; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607; Zhang R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-109	45	48	48	0	6	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 17	2015	112	46					14319	14324		10.1073/pnas.1513698112			6	Multidisciplinary Sciences	Science & Technology - Other Topics	CW7IA	WOS:000365170400065	26578778	Green Published, Bronze, Green Accepted			2021-06-18	
J	Bondi, CO; Semple, BD; Noble-Haeusslein, LJ; Osier, ND; Carlson, SW; Dixon, CE; Giza, CC; Kline, AE				Bondi, Corina O.; Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Osier, Nicole D.; Carlson, Shaun W.; Dixon, C. Edward; Giza, Christopher C.; Kline, Anthony E.			Found in translation: Understanding the biology and behavior of experimental traumatic brain injury	NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS			English	Article; Proceedings Paper	2014 Annual Meeting of the International-Behavioral-Neuroscience-Society (IBNS 2014)	JUN 10-15, 2014	Las Vegas, NV			Attentional set-shifting test (AST); Closed head injury; Concussion; Controlled cortical impact (CCI); Environmental enrichment (EE); Fluid percussion (FP); Neurorehabilitation; Pediatrics; Social behavior	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; FLUID PERCUSSION INJURY; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; MEDIATED FUNCTIONAL IMPROVEMENT; GLUTATHIONE-PEROXIDASE ACTIVITY; COLLEGIATE FOOTBALL PLAYERS; SOCIAL APPROACH BEHAVIORS; EARLY-ONSET STIMULATION; SCENT MARKING BEHAVIOR	The aim of this review is to discuss in greater detail the topics covered in the recent symposium entitled "Traumatic brain injury: laboratory and clinical perspectives," presented at the 2014 International Behavioral Neuroscience Society annual meeting. Herein, we review contemporary laboratory models of traumatic brain injury (TBI) including common assays for sensorimotor and cognitive behavior. New modalities to evaluate social behavior after injury to the developing brain, as well as the attentional set-shifting test (AST) as a measure of executive function in TBI, will be highlighted. Environmental enrichment (EE) will be discussed as a preclinical model of neurorehabilitation, and finally, an evidence-based approach to sports-related concussion will be considered. The review consists predominantly of published data, but some discussion of ongoing or future directions is provided. (C) 2014 Elsevier Ltd. All rights reserved.	[Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Osier, Nicole D.; Carlson, Shaun W.; Dixon, C. Edward; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bondi, Corina O.; Dixon, C. Edward; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA; [Kline, Anthony E.] Univ Pittsburgh, Psychol, Pittsburgh, PA USA; [Kline, Anthony E.] Univ Pittsburgh, Crit Care Med, Pittsburgh, PA USA; [Osier, Nicole D.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Dixon, C. Edward] Univ Pittsburgh, Neurol Surg, Pittsburgh, PA USA; [Dixon, C. Edward] Vet Affairs Pittsburgh Hthcare Syst, Pittsburgh, PA USA; [Semple, Bridgette D.; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Neurol Surg, San Francisco, CA 94143 USA; [Semple, Bridgette D.; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Grad Program Phys Med & Rehabil Sci, San Francisco, CA 94143 USA; [Semple, Bridgette D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3052, Australia; [Giza, Christopher C.] Univ Calif Los Angeles, Pediat Neurol & Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Kline, AE (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, 3471 Fifth Ave Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu	Osier, Nicole/Q-7913-2017; Meijer, Anna/K-5118-2016	Osier, Nicole/0000-0002-2903-6774; Bondi, Corina/0000-0002-5733-4912; Carlson, Shaun/0000-0002-1413-5075	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD069620, NS060005, NS084967, NS050159, NS077767, NS060672, NS079061, NS027544, HD061504, F31NR014957]; Veterans AffairsUS Department of Veterans Affairs [B6761R]; CJ Martin Overseas Biomedical Postdoctoral Fellowship from the National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1052505]; Joseph Drown Foundation; NCAA; Today's and Tomorrow's Children Fund; UCLA BIRC; UCLA Steve Tisch BrainSPORT Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504, R01HD069620, T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060672, R01NS039847, R01NS060005, R01NS084967, R01NS027544, R01NS077767, R01NS050159, R01NS079061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR014957, T32NR009759] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001127] Funding Source: NIH RePORTER	The authors appreciate the detailed work of Michael Farmer in recreating the Marmarou TBI model depicted in Fig. 1C. This work was supported, in part, by National Institutes of Health grants HD069620, NS060005, NS084967 (AEK), NS050159, NS077767 (UN-H), NS060672, NS079061 (CED), NS027544, HD061504 (CCG), F31NR014957 (NDO), Veterans Affairs B6761R (CED), a CJ Martin Overseas Biomedical Postdoctoral Fellowship from the National Health and Medical Research Council of Australia #1052505 (BD), the Joseph Drown Foundation, NCAA, Today's and Tomorrow's Children Fund, UCLA BIRC, UCLA Steve Tisch BrainSPORT Program (CCG).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Arakawa H, 2008, BEHAV BRAIN RES, V190, P97, DOI 10.1016/j.bbr.2008.02.009; Arakawa H, 2007, BEHAV BRAIN RES, V182, P73, DOI 10.1016/j.bbr.2007.05.007; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; BEAN NJ, 1982, PHYSIOL BEHAV, V28, P31, DOI 10.1016/0031-9384(82)90097-X; Beauchamp MH, 2013, BRAIN INJURY, V27, P896, DOI 10.3109/02699052.2013.775486; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bigler ED, 2013, NEUROREHABILITATION, V32, P707, DOI 10.3233/NRE-130896; Birrell JM, 2000, J NEUROSCI, V20, P4320; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bondi CO, 2008, NEUROPSYCHOPHARMACOL, V33, P320, DOI 10.1038/sj.npp.1301410; Bondi CO, 2014, J NEUROTRAUM, V31, P926, DOI 10.1089/neu.2013.3295; Bondi CO, 2010, PROG NEURO-PSYCHOPH, V34, P913, DOI 10.1016/j.pnpbp.2010.04.016; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Broberg BV, 2009, PSYCHOPHARMACOLOGY, V206, P631, DOI 10.1007/s00213-009-1540-5; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brooks JM, 2012, NEUROPSYCHOPHARMACOL, V37, P2476, DOI 10.1038/npp.2012.106; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Budinich CS, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/378307; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cao AH, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-10; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Chudasama Y, 2006, BIOL PSYCHOL, V73, P19, DOI 10.1016/j.biopsycho.2006.01.005; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Crawley JN, 2007, BRAIN PATHOL, V17, P448, DOI 10.1111/j.1750-3639.2007.00096.x; Crawley Jacqueline N, 2012, Dialogues Clin Neurosci, V14, P293; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIAMOND MC, 1966, J COMP NEUROL, V128, P117, DOI 10.1002/cne.901280110; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; Dias R, 1996, BEHAV NEUROSCI, V110, P872, DOI 10.1037/0735-7044.110.5.872; Dias R, 1997, J NEUROSCI, V17, P9285; Didus E, 1999, Pediatr Rehabil, V3, P177; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duvoisin RM, 2011, BEHAV BRAIN RES, V221, P50, DOI 10.1016/j.bbr.2011.02.049; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; FANSELOW MS, 1988, J EXP PSYCHOL ANIM B, V14, P187, DOI 10.1037/0097-7403.14.2.187; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fenn A. M., 2013, BIOL PSYCHIAT, V25; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FILE SE, 1978, BRIT J PHARMACOL, V62, P19, DOI 10.1111/j.1476-5381.1978.tb07001.x; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALEF BG, 1983, J COMP PSYCHOL, V97, P358, DOI 10.1037/0735-7036.97.4.358; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Goetghebeur PJD, 2010, PSYCHOPHARMACOLOGY, V212, P635, DOI 10.1007/s00213-010-1990-9; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; GUAN XB, 1994, BEHAV BRAIN RES, V61, P87, DOI 10.1016/0166-4328(94)90011-6; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hammerschmidt K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041133; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Heyes S. B., 2012, DEV SOCIAL NEUROSCIE, P325; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Hurst JL, 2004, BIOESSAYS, V26, P1288, DOI 10.1002/bies.20147; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Kelly M P, 1996, Appl Neuropsychol, V3, P147, DOI 10.1207/s15324826an0303&4_7; Kennedy Sidney H, 2008, Dialogues Clin Neurosci, V10, P271; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Konrad KN, 2000, BRAIN INJURY, V14, P859; Koolhaas JM, 2013, JOVE-J VIS EXP, DOI 10.3791/4367; Kooy RF, 1996, AM J MED GENET, V64, P241, DOI 10.1002/(SICI)1096-8628(19960809)64:2<241::AID-AJMG1>3.0.CO;2-X; Kos T, 2011, PSYCHOPHARMACOLOGY, V214, P911, DOI 10.1007/s00213-010-2102-6; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kudryavtseva N N, 2003, Neurosci Behav Physiol, V33, P461, DOI 10.1023/A:1023411217051; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lapiz-Bluhm MDS, 2008, J NEUROENDOCRINOL, V20, P1115, DOI 10.1111/j.1365-2826.2008.01772.x; LATORRE JC, 1968, EXP NEUROL, V22, P493, DOI 10.1016/0014-4886(68)90144-1; Leber AB, 2006, VIS COGN, V14, P565, DOI 10.1080/13506280500193438; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lippert-Gruner M, 2007, PHYSIOL RES, V56, P359; Liston C, 2006, J NEUROSCI, V26, P7870, DOI 10.1523/JNEUROSCI.1184-06.2006; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinez A, 2010, BRAIN PATHOL, V20, P281, DOI 10.1111/j.1750-3639.2009.00326.x; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McAlonan K, 2003, BEHAV BRAIN RES, V146, P97, DOI 10.1016/j.bbr.2003.09.019; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miczek KA, 2001, BEHAV BRAIN RES, V125, P167, DOI 10.1016/S0166-4328(01)00298-4; MICZEK KA, 1979, PSYCHOPHARMACOLOGY, V60, P253, DOI 10.1007/BF00426664; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Milde-Busch A, 2010, HEADACHE, V50, P1104, DOI 10.1111/j.1526-4610.2010.01706.x; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Millis Scott R., 1993, Brain Injury, V7, P53, DOI 10.3109/02699059309008156; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Molina J, 2008, HUM MOL GENET, V17, P2486, DOI 10.1093/hmg/ddn148; Monaco CM, 2014, J NEUROTRAUM, V31, P1934, DOI 10.1089/neu.2014.3541; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Moy SS, 2008, BEHAV BRAIN RES, V191, P118, DOI 10.1016/j.bbr.2008.03.015; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Muthuraju S, 2012, BASAL GANGLIA, V2, P143, DOI 10.1016/j.baga.2012.06.004; Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; NJUNGE K, 1991, PHARMACOL BIOCHEM BE, V38, P63, DOI 10.1016/0091-3057(91)90590-X; Norman KA, 2003, PSYCHOL REV, V110, P611, DOI 10.1037/0033-295X.110.4.611; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Ohayon S, 2013, J NEUROSCI METH, V219, P10, DOI 10.1016/j.jneumeth.2013.05.013; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pepin M, 2000, BRAIN INJURY, V14, P563; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pietropaolo S, 2004, PHYSIOL BEHAV, V81, P443, DOI 10.1016/j.physbeh.2004.02.022; Potts Mathew B, 2006, NeuroRx, V3, P143; Prins M. L., 2010, DEV NEUROSCI, V32, P431; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Rosema S, 2014, J NEUROTRAUM, V13, P13; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Rudy JW, 1999, BEHAV NEUROSCI, V113, P867, DOI 10.1037/0735-7044.113.5.867; Ryan BC, 2008, BEHAV BRAIN RES, V193, P235, DOI 10.1016/j.bbr.2008.06.002; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; SAHAKIAN BJ, 1992, J ROY SOC MED, V85, P399; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scattoni ML, 2011, GENES BRAIN BEHAV, V10, P44, DOI 10.1111/j.1601-183X.2010.00623.x; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Shin SS, 2013, J NEUROTRAUM, V30, P259, DOI 10.1089/neu.2012.2462; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Spencer CM, 2005, GENES BRAIN BEHAV, V4, P420, DOI 10.1111/j.1601-183X.2005.00123.x; Spencer-Smith M, 2009, DEV NEUROREHABIL, V12, P279, DOI 10.3109/17518420903090701; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sullivan JR, 2010, APPL NEUROPSYCHOL, V17, P93, DOI 10.1080/09084281003708852; Sullivan S, 2013, J NEUROTRAUM, V30, P1770, DOI 10.1089/neu.2013.2913; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tait D. S, 2014, CURR PHARM DES; Tait DS, 2007, EUR J NEUROSCI, V25, P3719, DOI 10.1111/j.1460-9568.2007.05612.x; Tanaka K, 2012, BIOL CHEM, V393, P217, DOI 10.1515/hsz-2011-0285; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Terranova ML, 2005, CURR PROTOC TOXICOL, V13, P101; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; WALSH RN, 1969, J COMP NEUROL, V137, P361, DOI 10.1002/cne.901370309; Wan CH, 2014, J NEUROSCI RES, V92, P1, DOI 10.1002/jnr.23305; Wang F, 2011, SCIENCE, V334, P693, DOI 10.1126/science.1209951; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Whitney G, 1979, AM ZOOLOGIST, P19; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Wohr M, 2011, GENES BRAIN BEHAV, V10, P35, DOI 10.1111/j.1601-183X.2010.00582.x; Wohr M, 2013, BEHAV BRAIN RES, V251, P5, DOI 10.1016/j.bbr.2013.05.047; Wohr M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020631; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Wrenn C. C., 2004, CURR PROTOC NEUROSCI, V8; Wrenn CC, 2003, BEHAV NEUROSCI, V117, P21, DOI 10.1037/0735-7044.117.1.21; Wright MJ, 2014, J CLIN EXP NEUROPSYC, V36, P268, DOI 10.1080/13803395.2014.884543; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yang M, 2012, J NEUROSCI, V32, P6525, DOI 10.1523/JNEUROSCI.6107-11.2012; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Yang Mu, 2009, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0824s48; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033; Young DM, 2010, P NATL ACAD SCI USA, V107, P11074, DOI 10.1073/pnas.1005620107; Young JW, 2010, COGN AFFECT BEHAV NE, V10, P243, DOI 10.3758/CABN.10.2.243; YOUNG SL, 1994, BEHAV NEUROSCI, V108, P19, DOI 10.1037/0735-7044.108.1.19; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhou C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3146814; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	338	48	48	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-7634	1873-7528		NEUROSCI BIOBEHAV R	Neurosci. Biobehav. Rev.	NOV	2015	58						123	146		10.1016/j.neubiorev.2014.12.004			24	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DA0PD	WOS:000367498700010	25496906	Green Accepted			2021-06-18	
J	Perrone, D; Aelterman, J; Pizurica, A; Jeurissen, B; Philips, W; Leemans, A				Perrone, Daniele; Aelterman, Jan; Pizurica, Aleksandra; Jeurissen, Ben; Philips, Wilfried; Leemans, Alexander			The effect of Gibbs ringing artifacts on measures derived from diffusion MRI	NEUROIMAGE			English	Article						Gibbs ringing artifact; Diffusion MRI; Diffusion tensor imaging; Diffusion kurtosis imaging; Data quality; Fractional anisotropy; Mean diffusivity	TRAUMATIC BRAIN-INJURY; INTRAVOXEL INCOHERENT MOTIONS; AMYOTROPHIC-LATERAL-SCLEROSIS; WHITE-MATTER ABNORMALITIES; EDDY-CURRENT ARTIFACTS; LINEAR LEAST-SQUARES; ECHO-PLANAR IMAGES; TENSOR MRI; CORPUS-CALLOSUM; WATER DIFFUSION	Diffusion-weighted (DW) magnetic resonance imaging (MRI) is a unique method to investigate microstructural tissue properties noninvasively and is one of the most popular methods for studying the brain white matter in vivo. To obtain reliable statistical inferences with diffusion MRI, however, there are still many challenges, such as acquiring high-quality DW-MRI data (e.g., high SNR and high resolution), careful data preprocessing (e.g., correcting for subject motion and eddy current induced geometric distortions), choosing the appropriate diffusion approach (e.g., diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), or diffusion spectrum MRI), and applying a robust analysis strategy (e.g., tractography based or voxel based analysis). Notwithstanding the numerous efforts to optimize many steps in this complex and lengthy diffusion analysis pipeline, to date, a well-known artifact in MRI -i.e., Gibbs ringing (GR)-has largely gone unnoticed or deemed insignificant as a potential confound in quantitative DW-MRI analysis. Considering the recent explosion of diffusion MRI applications in biomedical and clinical applications, a systematic and comprehensive investigation is necessary to understand the influence of GR on the estimation of diffusion measures. In this work, we demonstrate with simulations and experimental DW-MRI data that diffusion estimates are significantly affected by GR artifacts and we show that an off-the-shelf GR correction procedure based on total variation already can alleviate this issue substantially. (C) 2015 Elsevier Inc. All rights reserved.	[Perrone, Daniele; Aelterman, Jan; Pizurica, Aleksandra; Philips, Wilfried] Univ Ghent, iMinds IPI, B-9000 Ghent, Belgium; [Jeurissen, Ben] Univ Antwerp, Dept Phys, iMinds Vis Lab, Antwerp, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands	Perrone, D (corresponding author), Univ Ghent, iMinds IPI, Sint Pietersnieuwstr 41, B-9000 Ghent, Belgium.	daniele.perrone@telin.ugent.be	Pizurica, Aleksandra/AAG-4687-2021; Pizurica, Aleksandra/K-6866-2015; Jeurissen, Ben/C-3246-2011; Leemans, Alexander/A-1784-2011	Pizurica, Aleksandra/0000-0002-9322-4999; Jeurissen, Ben/0000-0002-3488-9819; Leemans, Alexander/0000-0002-9306-6126; Aelterman, Jan/0000-0002-5543-2631	Fund for Scientific Research - Flanders (FWO)FWO [G.0.690.10.N.10]; Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [639.072.411]; Interuniversity Attraction Poles Program (IUAP)Belgian Federal Science Policy Office [P7/11]	This work was financially supported by the Fund for Scientific Research - Flanders (FWO, Grant G.0.690.10.N.10). The research of A.L. is supported by VIDI Grant 639.072.411 from the Netherlands Organization for Scientific Research (NWO). B.J. also acknowledges the Interuniversity Attraction Poles Program (IUAP); Grant number: P7/11.	Alexander AL, 1997, MAGN RESON MED, V38, P1016, DOI 10.1002/mrm.1910380623; Alexander DC, 2005, ANN NY ACAD SCI, V1064, P113, DOI 10.1196/annals.1340.018; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Archibald R, 2002, IEEE T MED IMAGING, V21, P305, DOI 10.1109/TMI.2002.1000255; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Bakir T, 2000, IEEE T MED IMAGING, V19, P585, DOI 10.1109/42.870664; Barker G, 2001, P 9 M INT SOC MAGN R, P1546; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Ben-Amitay S, 2012, MAGN RESON MED, V67, P1694, DOI 10.1002/mrm.23186; Blain CRV, 2011, J NEUROL NEUROSUR PS, V82, P843, DOI 10.1136/jnnp.2010.236018; Block KT, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/184123; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carballedo A, 2012, AM J MED GENET B, V159B, P537, DOI 10.1002/ajmg.b.32060; Chambolle A, 2004, J MATH IMAGING VIS, V20, P89; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; Colby JB, 2012, NEUROIMAGE, V59, P3227, DOI 10.1016/j.neuroimage.2011.11.004; Collier Q, 2015, MAGN RESON MED, V73, P2174, DOI 10.1002/mrm.25351; De Bondt T, 2013, EUR RADIOL, V23, P57, DOI 10.1007/s00330-012-2572-5; De Groof G, 2006, NEUROIMAGE, V29, P754, DOI 10.1016/j.neuroimage.2005.09.022; De Groof G, 2009, J NEUROSCI, V29, P13557, DOI 10.1523/JNEUROSCI.1788-09.2009; Dell'Acqua F, 2010, NEUROIMAGE, V49, P1446, DOI 10.1016/j.neuroimage.2009.09.033; den Dekker AJ, 2014, PHYS MEDICA, V30, P725, DOI 10.1016/j.ejmp.2014.05.002; Descoteaux M, 2011, MED IMAGE ANAL, V15, P603, DOI 10.1016/j.media.2010.07.001; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Di Paola M, 2010, J ALZHEIMERS DIS, V20, P67, DOI 10.3233/JAD-2010-1370; Gallichan D, 2010, HUM BRAIN MAPP, V31, P193, DOI 10.1002/hbm.20856; Gooijers J, 2013, HUM BRAIN MAPP, V34, P241, DOI 10.1002/hbm.21429; Hemels MA, 2012, PEDIATR CRIT CARE ME, V13, P678, DOI 10.1097/PCC.0b013e3182455778; Hsu JL, 2008, NEUROIMAGE, V39, P566, DOI 10.1016/j.neuroimage.2007.09.017; Hsu JL, 2012, NEUROIMAGE, V59, P1098, DOI 10.1016/j.neuroimage.2011.09.041; Hsu JL, 2010, NEUROIMAGE, V49, P32, DOI 10.1016/j.neuroimage.2009.08.031; Huang X, 2005, P ANN INT IEEE EMBS, P1367; Huppi PS, 2006, SEMIN FETAL NEONAT M, V11, P489, DOI 10.1016/j.siny.2006.07.006; Irfanoglu MO, 2012, NEUROIMAGE, V61, P275, DOI 10.1016/j.neuroimage.2012.02.054; Jambawalikar S, 2010, SKELETAL RADIOL, V39, P1073, DOI 10.1007/s00256-010-0974-5; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jeurissen B, 2014, NEUROIMAGE, V103, P411, DOI 10.1016/j.neuroimage.2014.07.061; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Jezzard P, 1998, MAGNET RESON MED, V39, P801, DOI 10.1002/mrm.1910390518; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Jones DK, 2004, MAGN RESON MED, V52, P979, DOI 10.1002/mrm.20283; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Knoll F, 2011, MAGN RESON MED, V65, P480, DOI 10.1002/mrm.22595; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Kodl CT, 2008, DIABETES, V57, P3083, DOI 10.2337/db08-0724; Kwan RKS, 1996, LECT NOTES COMPUT SC, V1131, P135; Landman BA, 2009, MAGN RESON IMAGING, V27, P741, DOI 10.1016/j.mri.2009.01.001; Langen M, 2012, CORTEX, V48, P183, DOI 10.1016/j.cortex.2011.05.018; Latt J, 2013, J MAGN RESON IMAGING, V37, P610, DOI 10.1002/jmri.23857; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1989, MAGNET RESON MED, V10, P324; Leemans A, 2005, MAGN RESON MED, V53, P944, DOI 10.1002/mrm.20418; Leemans A., 2009, P INT SOC MAG RESON, V17, P3537, DOI DOI 10.1093/occmed/kqr069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Liang Z-P, 2000, IEEE PRESS SERIES BI; MERBOLDT KD, 1989, MAGNET RESON MED, V9, P423, DOI 10.1002/mrm.1910090316; Metzler-Baddeley C, 2012, NEUROLOGY, V79, P2233, DOI 10.1212/WNL.0b013e31827689e8; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; O'Sullivan M, 2010, STROKE, V41, pS154, DOI 10.1161/STROKEAHA.110.595314; Ooi MB, 2013, MAGN RESON MED, V69, P803, DOI 10.1002/mrm.24285; Panagiotaki E, 2012, NEUROIMAGE, V59, P2241, DOI 10.1016/j.neuroimage.2011.09.081; Perrone D., 2011, 10 BELG DAY BIOM ENG; Perrone D, 2012, 4 ANN M ISMRM BEN CH, P99; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Poot DHJ, 2010, IEEE T MED IMAGING, V29, P819, DOI 10.1109/TMI.2009.2037915; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Reijmer YD, 2013, DIABETES CARE, V36, P137, DOI 10.2337/dc12-0493; Reijmer YD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044074; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Rovaris M, 2007, J NEUROIMAGING, V17, p27S, DOI 10.1111/j.1552-6569.2007.00133.x; RUDIN LI, 1992, PHYSICA D, V60, P259, DOI 10.1016/0167-2789(92)90242-F; Sage CA, 2009, HUM BRAIN MAPP, V30, P3657, DOI 10.1002/hbm.20794; Sarra SA, 2006, NUMER ALGORITHMS, V41, P17, DOI 10.1007/s11075-005-9003-5; Setsompop K, 2013, NEUROIMAGE, V80, P220, DOI 10.1016/j.neuroimage.2013.05.078; Sexton CE, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.05.019; Sisti HM, 2012, LEARN MEMORY, V19, P351, DOI 10.1101/lm.026534.112; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sullivan EV, 2006, NEUROSCI BIOBEHAV R, V30, P749, DOI 10.1016/j.neubiorev.2006.06.002; Surova Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066022; Szczepankiewicz F, 2013, NEUROIMAGE, V76, P145, DOI 10.1016/j.neuroimage.2013.02.078; Tax CMW, 2015, MAGN RESON MED, V73, P794, DOI 10.1002/mrm.25165; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Ugurbil K, 2013, NEUROIMAGE, V80, P80, DOI 10.1016/j.neuroimage.2013.05.012; Van Camp N, 2009, NMR BIOMED, V22, P697, DOI 10.1002/nbm.1381; van der Aa NE, 2011, STROKE, V42, P3410, DOI 10.1161/STROKEAHA.111.624858; van der Jagt PKN, 2012, NEUROIMAGE, V62, P1792, DOI 10.1016/j.neuroimage.2012.06.001; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Van Hecke W, 2010, J MAGN RESON IMAGING, V31, P1492, DOI 10.1002/jmri.22198; Van Hecke W, 2009, J MAGN RESON IMAGING, V30, P25, DOI 10.1002/jmri.21817; Van Hecke W, 2008, J MAGN RESON IMAGING, V27, P978, DOI 10.1002/jmri.21338; Veraart J, 2013, NEUROIMAGE, V81, P335, DOI 10.1016/j.neuroimage.2013.05.028; Veraart J, 2013, MAGN RESON MED, V70, P972, DOI 10.1002/mrm.24529; Veraart J, 2011, MAGN RESON MED, V66, P678, DOI 10.1002/mrm.22835; Verhoeven JS, 2012, CEREB CORTEX, V22, P2263, DOI 10.1093/cercor/bhr292; Verhoeven JS, 2010, HUM BRAIN MAPP, V31, P470, DOI 10.1002/hbm.20880; Vos SB, 2012, NEUROIMAGE, V59, P2208, DOI 10.1016/j.neuroimage.2011.09.086; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Walker L, 2011, NEUROIMAGE, V54, P1168, DOI 10.1016/j.neuroimage.2010.08.048; Wang HC, 2012, ARCH NEUROL-CHICAGO, V69, P1340, DOI 10.1001/archneurol.2012.633; Wang SM, 2005, ANN NY ACAD SCI, V1064, P61, DOI 10.1196/annals.1340.013; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; White Tonya, 2008, Top Magn Reson Imaging, V19, P97, DOI 10.1097/RMR.0b013e3181809f1e; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072	128	48	49	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 15	2015	120						441	455		10.1016/j.neuroimage.2015.06.068			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CS4DK	WOS:000362025000039	26142273				2021-06-18	
J	Buckley, TA; Burdette, G; Kelly, K				Buckley, Thomas A.; Burdette, Glenn; Kelly, Kassandra			Concussion-Management Practice Patterns of National Collegiate Athletic Association Division II and III Athletic Trainers: How the Other Half Lives	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; return to play; baseline testing	SPORT-RELATED CONCUSSION; MEDICINE PROFESSIONALS; POSITION STATEMENT; CLINICAL PRACTICES; FOOTBALL PLAYERS; BASE	Context: The National Collegiate Athletic Association (NCAA) has published concussion-management practice guidelines consistent with recent position and consensus statements. Whereas NCAA Division I athletic trainers appear highly compliant, little is known about the concussion-management practice patterns of athletic trainers at smaller institutions where staffing and resources may be limited. Objective: To descriptively define the concussion-management practice patterns of NCAA Division II and III athletic trainers. Design: Cross-sectional study. Setting: Web-based questionnaire. Patients or Other Participants: A total of 755 respondents (response rate = 40.2%) from NCAA Division II and Division III institutions. Main Outcome Measure(s): The primary outcome measures were the rate of multifaceted concussion-assessment techniques, defined as 3 or more assessments; the specific practice patterns of each assessment battery; and tests used during a clinical examination. Results: Most respondents indicated using a multifaceted assessment during acute assessment (Division II = 76.9%, n = 473; Division III = 76.0%, n = 467) and determination of recovery (Division II = 65.0%, n = 194; Division III = 63.1%, n = 288) but not at baseline (Division II = 43.1%, n = 122; Division III = 41.0%, n = 176). Typically, when a postconcussion assessment was initiated, testing occurred daily until baseline values were achieved, and most respondents (80.6% [244/278]) reported using a graded exercise protocol before return to participation. Conclusions: We found limited use of the multifaceted assessment battery at baseline but higher rates at both acute assessment and return-to-participation time points. A primary reason cited for not using test-battery components was a lack of staffing or funding for the assessments. We observed limited use of neuropsychologists to interpret neuropsychological testing. Otherwise, most respondents reported concussion-management protocols consistent with recommendations, including a high level of use of objective measures and incorporation of a progressive return-to-participation protocol.	[Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Burdette, Glenn] Georgia So Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA; [Kelly, Kassandra] Georgia So Univ, Dept Intercollegiate Athlet, Statesboro, GA 30460 USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Human Performance Lab 144, 541 South Coll Ave, Newark, DE 19716 USA.	tbuckley@udel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Diamond D., 2012, ARIZONA JUST BROKE N; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fulks DL, 2013, 2004 2012 NCAA DIVIS, P11; Fulks DL, 2013, 2004 2012 NCAA DIVIS, P9; Fulks DL, 2013, 2004 2012 NCAA DIVIS, P13; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Klossner D, 2013, 2013 14 NCAA SPORTS, P56; Klossner D, 2010, 2010 2011 NCAA SPORT, P52; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Rigby J, 2013, J ATHL TRAINING, V48, P636, DOI 10.4085/1062-6050-48.3.10; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schwarz A, 2011, NY TIMES, pB16; Williams RM, 2014, SPORTS HEALTH, V6, P434, DOI 10.1177/1941738114545612; Wolverton B, 2013, CHRONICLE HIGHER ED	32	48	48	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	AUG	2015	50	8					879	888		10.4085/1062-6050-50.7.04			10	Sport Sciences	Sport Sciences	CW7MO	WOS:000365183500014	26196701	Green Published, Bronze			2021-06-18	
J	Kehoe, A; Rennie, S; Smith, JE				Kehoe, A.; Rennie, S.; Smith, J. E.			Glasgow Coma Scale is unreliable for the prediction of severe head injury in elderly trauma patients	EMERGENCY MEDICINE JOURNAL			English	Article							BRAIN-INJURY; MORTALITY; WORSE; AGE	Objectives and background Elderly patients comprise an ever-increasing proportion of major trauma patients. The presenting GCS in elderly patients with traumatic brain injury (TBI) may not reflect the severity of injury as accurately as it does in the younger patient population. However, GCS is often used as part of the decision tool to define the population transferred directly to a major trauma centre. The aim of this study was to explore the relationship between age and presenting GCS in patients with isolated TBI. Methods A retrospective database review was undertaken using the Trauma Audit and Research Network database. All patients presenting to Derriford Hospital, Plymouth, between 1 January 2009 and 31 May 2014 with isolated TBI were included. Demographic, mechanistic, physiological, resource use and outcome data were collected. Abbreviated injury scale (AIS) was recorded for all patients. Patients were categorised into those older and younger than 65 years on presentation. Distribution of GCS, categorised into severe (GCS 3-8), moderate (GCS 9-12) and mild TBI (13-15), was compared between the age groups. Median GCS at each AIS level was also compared. Results The distribution of GCS differed between young and old patients with TBI (22.1% vs 9.8% had a GCS 3-8, respectively) despite a higher burden of anatomical injury in the elderly group. Presenting GCS was higher in the elderly at each level of AIS. The difference was more apparent in the presence of more severe injury (AIS 5). Conclusions Elderly patients who have sustained isolated severe TBI may present with a higher GCS than younger patients. Triage tools using GCS may need to be modified and validated for use in elderly patients with TBI.	[Kehoe, A.; Rennie, S.; Smith, J. E.] Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England; [Smith, J. E.] Royal Ctr Def Med Res & Acad, Acad Dept Mil Emergency Med, Med Directorate, Joint Med Command, Birmingham, W Midlands, England	Smith, JE (corresponding author), Derriford Hosp, Emergency Dept, Derriford Rd, Plymouth PL6 8DH, Devon, England.	jasonesmith@doctors.org.uk	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421			*ASS ADV AUT MED, 1994, INJ IMP SCAL 1994; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Field V., 2012, EMERG MED J, V19, P737; Harrison DA, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17230; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Potter D, 2013, J R Nav Med Serv, V99, P16; Santos AP, 2014, EMERG MED J, V31, P148, DOI 10.1136/emermed-2012-201782; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Yates D, 2007, BMJ-BRIT MED J, V335, P719, DOI 10.1136/bmj.39331.702951.47	17	48	48	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	AUG	2015	32	8					613	615		10.1136/emermed-2013-203488			3	Emergency Medicine	Emergency Medicine	CN7BK	WOS:000358588300007	25280479				2021-06-18	
J	Song, J; Wang, L; Cai, CB; Qi, XQ				Song, Jia; Wang, Lun; Cai, Cuobiao; Qi, Xiaoqiang			Nonlinear fractional order proportion-integral-derivative active disturbance rejection control method design for hypersonic vehicle attitude control	ACTA ASTRONAUTICA			English	Article						Hypersonic vehicle; (NFOPID mu)-D-lambda; Active disturbance rejection control; Natural selection particle swarm algorithm; Control	MODEL	Near space hypersonic vehicle model is nonlinear, multivariable and couples in the reentry process, which are challenging for the controller design. In this paper, a nonlinear fractional order proportion integral derivative ((NFOPID mu)-D-lambda) active disturbance rejection control (ADRC) strategy based on a natural selection particle swarm (NSPSO) algorithm is proposed for the hypersonic vehicle flight control. The (NFOPID mu)-D-lambda ADRC method consists of a tradting-differentiator (TD), an (NFOPID mu)-D-lambda controller and an extended state observer (ESO). The (NFOPID mu)-D-lambda controller designed by combining an (FOPID mu)-D-lambda method and a nonlinear states error feedback control law (NLSEF) is to overcome concussion caused by the NLSEF and conversely compensate the insufficiency for relatively simple and rough signal processing caused by the (FOPID mu)-D-lambda method. The TD is applied to coordinate the contradiction between rapidity and overshoot By attributing all uncertain factors to unknown disturbances, the ESO can achieve dynamic feedback compensation for these disturbances and thus reduce their effects. Simulation results show that the (NFOPID mu)-D-lambda ADRC method can make the hypersonic vehicle six-degree-of-freedom nonlinear model track desired nominal signals accurately and fast, has good stability, dynamic properties and strong robustness against external environmental disturbances. (C) 2015 IAA Published by Elsevier Ltd. All rights reserved.	[Song, Jia; Wang, Lun; Cai, Cuobiao] Beihang Univ, Sch Astronaut, Beijing 100191, Peoples R China; [Qi, Xiaoqiang] Beijing Inst Mech & Elect Engn, Beijing 100074, Peoples R China	Song, J (corresponding author), Beihang Univ, Sch Astronaut, Beijing 100191, Peoples R China.	songjia@buaa.edu.cn			National Science FoundationNational Science Foundation (NSF) [51206007]; Aeronautical Science Foundation of China [2013ZC51]	This work was supported by National Science Foundation (No. 51206007) and Aeronautical Science Foundation of China (2013ZC51).	Albano M, 2013, ACTA ASTRONAUT, V87, P30, DOI 10.1016/j.actaastro.2013.02.003; Duan HB, 2012, SCI CHINA TECHNOL SC, V55, P2965, DOI 10.1007/s11431-012-5036-x; Han J., 2008, ACTIVE DISTURBANCE R; Han Jing-qing, 2002, Control Engineering China, V9, P13; Han JQ, 2009, IEEE T IND ELECTRON, V56, P900, DOI 10.1109/TIE.2008.2011621; Huang Y., 2000, CHINESE SCI BULL, V45, P1373; Huang YQ, 2013, CHINESE J AERONAUT, V26, P948, DOI 10.1016/j.cja.2013.04.036; Huang YQ, 2013, J SYST ENG ELECTRON, V24, P118, DOI 10.1109/JSEE.2013.00015; Jiang B., 2011, P IMECHE 1, V225; Lian C. B., 2013, J CENT S U SCI TECHN, V44, P92; Podlubny I, 1999, IEEE T AUTOMAT CONTR, V44, P208, DOI 10.1109/9.739144; Pu ZQ, 2014, ACTA ASTRONAUT, V101, P16, DOI 10.1016/j.actaastro.2014.01.025; Qi Naiming, 2012, Journal of Projectiles, Rockets, Missiles and Guidance, V32, P49; Qin Changmao, 2011, Transactions of Nanjing University of Aeronautics & Astronautics, V28, P240; Shahriar K., 2005, P AIAA GUID NAV CONT; Shaughnessy J.D., 1990, TM102610 NASA; Shaughnessy JD, 1990, 102610 NASA; Voland RT, 2006, ACTA ASTRONAUT, V59, P181, DOI 10.1016/j.actaastro.2006.02.021; Wang J, 2013, J SYST ENG ELECTRON, V24, P288, DOI 10.1109/JSEE.2013.00036; Wei J. X., 2009, EVOLUTIONARY ALGORIT, P24; Xu B, 2013, NONLINEAR DYNAM, V73, P1849, DOI 10.1007/s11071-013-0908-6; [薛定宇 XUE Dingyu], 2007, [控制理论与应用, Control Theory & Applications], V24, P771; Zhang X. B., 2013, P 25 CHIN CONTR DEC; Zhang Z, 2012, SCI CHINA INFORM SCI, V55, P2243, DOI 10.1007/s11432-011-4455-9; [周啟航 Zhou Qihang], 2012, [计算机仿真, Computer Simulation], V29, P90	25	48	52	2	99	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0094-5765	1879-2030		ACTA ASTRONAUT	Acta Astronaut.	JUN-JUL	2015	111						160	169		10.1016/j.actaastro.2015.02.026			10	Engineering, Aerospace	Engineering	CI2NY	WOS:000354585500014					2021-06-18	
J	Fuller, CW; Taylor, A; Raftery, M				Fuller, Colin W.; Taylor, Aileen; Raftery, Martin			Epidemiology of concussion in men's elite Rugby-7s (Sevens World Series) and Rugby-15s (Rugby World Cup, Junior World Championship and Rugby Trophy, Pacific Nations Cup and English Premiership)	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONSENSUS STATEMENT; POSITION STATEMENT; INJURIES; UNION; SPORT	Objective To determine the incidence, nature and causes of concussions sustained during men's elite professional Rugby-7s and Rugby-15s. Design A prospective cohort study recording injuries classified as a time-loss concussion. Population Players competing in the following tournaments: Rugby 15s-English Premiership (2007/2008 to 2010/2011), Rugby World Cup (2007, 2011), Pacific Nations Cup (2012, 2013), Junior World Championship (2008, 2010-2013), Junior World Rugby Trophy (2008, 2010-2013); Rugby 7s-Sevens World Series (2008/2009, 2010/2011 to 2012/2013). Method The study was implemented according to the international consensus statement for epidemiological studies in rugby union; the main outcome measures included the number, incidence (number of concussions/1000 player-match-hours), mean and median severity (days absence) and cause of concussion. Results The incidence of concussion in Rugby-7s was significantly higher than that in Rugby-15s (risk ratio=1.84; p<0.001). The severity of concussions were significantly higher in Rugby-7s than Rugby-15s (mean-Rugby-7s: 19.2, Rugby-15s: 10.1; median-Rugby 7s: 20, Rugby-15s: 7; p<0.001). The main causes of concussion were tackling (44.1%) in Rugby-7s and collisions (43.6%) in Rugby-15s. Significantly more (risk ratio=1.49; p=0.004) concussed players were removed immediately from the game in Rugby-7s (69.7%) compared to Rugby-15s (46.7%). Conclusions Six actions were identified to improve the management of concussion in rugby: implement a pitch-side concussion assessment protocol; improve compliance with return-to-play protocols; work with referees to review the nature and consequences of collisions; improve players' tackle technique; investigate the forces involved in tackles and collisions; and evaluate reasons for the higher incidence of concussions in Rugby-7s.	[Fuller, Colin W.; Taylor, Aileen; Raftery, Martin] Int Rugby Board, Dublin 2, Ireland	Fuller, CW (corresponding author), Int Rugby Board, Huguenot House, Dublin 2, Ireland.	colin.fuller@f-marc.com			International Rugby Board; Rugby Football Union	The epidemiological studies were funded by the International Rugby Board (Rugby World Cup, Junior World Championship, Junior World Rugby Trophy, Pacific Nations Cup, Sevens World Series) and the Rugby Football Union (English Premiership). Data collection studies were funded by the International Rugby Board and the Rugby Football Union.	Abu Zaho M, 1984, TITLE ERROR, V1; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, CLIN J SPORT MED, V17, P182, DOI 10.1097/JSM.0b013e31805930b0; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, CLIN J SPORT MED, V20, P179, DOI 10.1097/JSM.0b013e3181df1eea; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Higham DG, 2012, J SCI MED SPORT, V15, P277, DOI 10.1016/j.jsams.2011.11.256; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Kelly JP, 1997, NEUROLOGY, V48, P581; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kirkwood B. R., 2003, ESSENTIAL MEDICAL ST; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Orchard J., 1995, SPORT HLTH, V11, P39; Patricios JS, 2014, BRIT J SPORT MED, V48, P76, DOI 10.1136/bjsports-2013-093031; Raftery M, 2014, BRIT J SPORT MED, V48, P79, DOI 10.1136/bjsports-2013-093051; West TA, 2008, J NEUROTRAUM, V38, P975; White PE, 2014, BRIT J SPORT MED, V48, P130, DOI 10.1136/bjsports-2013-092720	25	48	48	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	7					478	483		10.1136/bjsports-2013-093381			6	Sport Sciences	Sport Sciences	CD6ZA	WOS:000351238500012	24659504				2021-06-18	
J	Delaney, JS; Lamfookon, C; Bloom, GA; Al-Kashmiri, A; Correa, JA				Delaney, J. Scott; Lamfookon, Charles; Bloom, Gordon A.; Al-Kashmiri, Ammar; Correa, Jose A.			Why University Athletes Choose Not to Reveal Their Concussion Symptoms During a Practice or Game	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; symptoms; team sports; university; reasons	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; HEAD-INJURIES; SOCCER PLAYERS; INTERNATIONAL-CONFERENCE; CEREBRAL CONCUSSION; CONSENSUS STATEMENT; SPORT HELD; EPIDEMIOLOGY; PREVENTION	Objective: To determine why athletes decide not to seek medical attention during a game or practice when they believe they have suffered a concussion. Design: A retrospective survey. Setting: University Sport Medicine Clinic. Participants: A total of 469 male and female university athletes from several varsity team sports were participated in the study. Main Outcome Measures: Athletes were surveyed about the previous 12 months to identify specific reasons why those athletes who believed they had suffered a concussion during a game or practice decided not to seek attention at that time, how often these reasons occurred, and how important these reasons were in the decision process. Results: Ninety-two of the 469 athletes (19.6%) believed they had suffered a concussion within the previous 12 months while playing their respective sport, and 72 of these 92 athletes (78.3%) did not seek medical attention during the game or practice at least once during that time. Sports in which athletes were more likely to not reveal their concussion symptoms were football and ice hockey. The reason "Did not feel the concussion was serious/severe and felt you could still continue to play with little danger to yourself," was listed most commonly (55/92) as a cause for not seeking medical attention for a presumed concussion. Conclusions: A significant percentage of university athletes who believed they had suffered a concussion chose not to seek medical attention at the time of injury. Improved education of players, parents, and coaches about the dangers of continuing to play with concussion symptoms may help improve reporting.	[Delaney, J. Scott] McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; [Delaney, J. Scott] McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; [Lamfookon, Charles] McGill Univ, Royal Coll Emergency Med, Residency Program, Montreal, PQ, Canada; [Bloom, Gordon A.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada; [Al-Kashmiri, Ammar] Khoula Hosp, Dept Emergency Med, Muscat, Oman; [Correa, Jose A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	j.delaney@staff.mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				[Anonymous], 1999, JAMA, V282, P974; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Rutherford DS, 1999, CLIN J SPORT MED, V9, P209, DOI 10.1097/00042752-199910000-00005; Shapcott EJB, 2007, NEUROREHABILITATION, V22, P161; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1	39	48	48	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2015	25	2					113	125		10.1097/JSM.0000000000000112			13	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	CD3RP	WOS:000350998200007	24949831				2021-06-18	
J	Kostyun, RO; Milewski, MD; Hafeez, I				Kostyun, Regina O.; Milewski, Matthew D.; Hafeez, Imran			Sleep Disturbance and Neurocognitive Function During the Recovery From a Sport-Related Concussion in Adolescents	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; sleep; ImPACT; athletes	4TH INTERNATIONAL-CONFERENCE; PREDICT PROTRACTED RECOVERY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; ACADEMIC-PERFORMANCE; CONSENSUS STATEMENT; DAYTIME SLEEPINESS; SYMPTOMS; PATTERNS	Background: Sleep disturbances are a hallmark sign after a sport-related concussion (SRC). Poor sleep has been shown to adversely affect baseline neurocognitive test scores, but it is not comprehensively understood how neurocognitive function is affected by disrupted sleep during recovery from a concussion. Purpose: To identify the correlation between adolescent athletes' neurocognitive function and their self-reported sleep quantity and sleep disturbance symptoms during recovery from SRC. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Immediate Post-Concussion Assessment and Cognition Testing (ImPACT) data were retrospectively collected for 545 adolescent athletes treated for SRC at a sports medicine concussion clinic. Patients were stratified into groups based on 2 criteria: self-reported sleep duration and self-reported sleep disturbance symptoms during postinjury ImPACT testing. Sleep duration was classified as short (<7 hours), intermediate (7-9 hours), and long (>9 hours). Sleep disturbance symptoms were self-reported as part of the Post-Concussion Symptom Scale (PCSS) as either sleeping less than normal, sleeping more than normal, or having trouble falling asleep. One-way analyses of variance were conducted to examine the effects that sleep duration as well as self-reported sleep disturbance symptoms had on composite scores. A total of 1067 ImPACT tests were analyzed: test 1, 545; test 2, 380; and test 3, 142. Results: Sleeping fewer than 7 hours the night before testing correlated with higher PCSS scores (P < .001), whereas sleeping longer than 9 hours correlated with worse visual memory (P = .01), visual motor speed (P <.001), and reaction time (P = .04) composite scores. With regard to self-reported sleep disturbance symptoms, patients demonstrated worse composite scores during ImPACT testing when they self-reported sleeping more than normal (ImPACT test 1: verbal memory, P < .001; visual motor speed, P = .05; reaction time, P = .01; ImPACT test 2: verbal memory, P < .001; visual memory, P < .001; visual motor speed, P < .001; reaction time, P = .01). Adolescent patients recovering from SRC demonstrated higher (worse) PCSS scores (P < .001) when they sensed that their sleep had been disrupted. Conclusion: Adolescent patients who perceive that their sleep is somehow disrupted after SRC may report a greater number of concussion symptoms during their recovery. In addition, the study results suggest that sleeping more than normal may identify an individual who continues to be actively recovering from concussion, given the correlation between lower neurocognitive function and this self-reported symptom.	[Kostyun, Regina O.; Milewski, Matthew D.; Hafeez, Imran] Elite Sports Med, Farmington, CT USA	Kostyun, RO (corresponding author), Connecticut Childrens Med Ctr, Elite Sports Med, 399 Farmington Ave, Farmington, CT 06032 USA.	rkostyun@connecticutchildrens.org	Meijer, Anna/K-5118-2016				Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; CARSKADON M A, 1990, Pediatrician, V17, P5; Carskadon MA, 1998, SLEEP, V21, P871, DOI 10.1093/sleep/21.8.871; CHALLAMEL MJ, 1994, SLEEP, V17, pS17, DOI 10.1093/sleep/17.suppl_8.S17; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Drake C, 2003, SLEEP, V26, P455; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Eaton DK, 2010, J ADOLESCENT HEALTH, V46, P399, DOI 10.1016/j.jadohealth.2009.10.011; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Galland BC, 2012, SLEEP MED REV, V16, P213, DOI 10.1016/j.smrv.2011.06.001; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kotagal S, 2009, CHILD ADOL PSYCH CL, V18, P967, DOI 10.1016/j.chc.2009.04.006; Krueger JM, 2003, FRONT BIOSCI-LANDMRK, V8, pD511, DOI 10.2741/1031; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Milewski MD, 2014, J PEDIATR ORTHOPED, V34, P129, DOI 10.1097/BPO.0000000000000151; Neveus T, 2001, ACTA PAEDIATR, V90, P1450; Ohayon MM, 2000, J AM ACAD CHILD PSY, V39, P1549, DOI 10.1097/00004583-200012000-00019; Perez-Chada D, 2007, SLEEP, V30, P1698, DOI 10.1093/sleep/30.12.1698; Philip P, 2004, J SLEEP RES, V13, P105, DOI 10.1111/j.1365-2869.2004.00399.x; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Trockel MT, 2000, J AM COLL HEALTH, V49, P125, DOI 10.1080/07448480009596294; Wolfson AR, 2003, SLEEP MED REV, V7, P491, DOI 10.1016/S1087-0792(03)90003-7; Wolfson AR, 1998, CHILD DEV, V69, P875, DOI 10.1111/j.1467-8624.1998.tb06149.x; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yang CK, 2005, PEDIATRICS, V115, P250, DOI 10.1542/peds.2004-0815G; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	54	48	48	4	35	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					633	640		10.1177/0363546514560727			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500016	25520301				2021-06-18	
J	Rubenstein, R; Chang, BG; Davies, P; Wagner, AK; Robertson, CS; Wang, KKW				Rubenstein, Richard; Chang, Binggong; Davies, Peter; Wagner, Amy K.; Robertson, Claudia S.; Wang, Kevin K. W.			A Novel, Ultrasensitive Assay for Tau: Potential for Assessing Traumatic Brain Injury in Tissues and Biofluids	JOURNAL OF NEUROTRAUMA			English	Article						severe traumatic brain injury; EIMAF; rolling circle amplification; total and phosphorylated tau; brain and biofluids	FIBRILLARY ACIDIC PROTEIN; PAIRED HELICAL FILAMENTS; NEURON-SPECIFIC ENOLASE; CORTICAL IMPACT INJURY; SERUM S-100B PROTEIN; C-TERMINAL HYDROLASE; ALZHEIMERS-DISEASE; HEAD-INJURY; NEUROFIBRILLARY TANGLES; RISK-FACTOR	Traumatic brain injury (TBI) is a cause of death and disability and can lead to tauopathy-related dementia at an early age. Pathologically, TBI results in axonal injury that is coupled to tau hyperphosphorylation, leading to microtubule instability and tau-mediated neurodegeneration. This suggests that the forms of this protein might serve as neuroinjury-related biomarkers for diagnosis of injury severity and prognosis of the neurological damage prior to clinical expression. We initially determined whether we could detect tau in body fluids using a highly sensitive assay. We used a novel immunoassay, enhanced immunoassay using multi-arrayed fiberoptics (EIMAF) either alone or in combination with rolling circle amplification (a-EIMAF) for the detection of total (T) and phosphorylated (P) tau proteins from brains and biofluids (blood, CSF) of rodents following controlled cortical impact (CCI) and human patients post severe TBI (sTBI). This assay technology for tau is the most sensitive to date with a detection limit of approximately 100 ag/mL for either T-tau and P-tau. In the rodent models, T-tau and P-tau levels in brain and blood increased following CCI during the acute phase and remained high during the chronic phase (30 d). In human CSF samples, T-tau and P-tau increased during the sampling period (5-6 d). T-tau and P-tau in human serum rose during the acute phase and decreased during the chronic stage but was still detectable beyond six months post sTBI. Thus, EIMAF has the potential for assessing both the severity of the proximal injury and the prognosis using easily accessible samples.	[Rubenstein, Richard; Chang, Binggong] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA; [Rubenstein, Richard; Chang, Binggong] Suny Downstate Med Ctr, Dept Physiol Pharmacol, Brooklyn, NY 11203 USA; [Davies, Peter] Litwin Zucker Ctr Res Alzheimers Dis, Feinstein Inst Med Res, Manhasset, NY USA; [Wagner, Amy K.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	Rubenstein, R (corresponding author), Suny Downstate Med Ctr, Dept Neurol, Box 1213,450 Clarkson Ave, Brooklyn, NY 11203 USA.	richard.rubenstein@downstate.edu		Wang, Kevin/0000-0002-9343-6473			Acker CM, 2013, NEUROBIOL AGING, V34, P338, DOI 10.1016/j.neurobiolaging.2012.05.010; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Chang BG, 2009, J VIROL METHODS, V159, P15, DOI 10.1016/j.jviromet.2009.02.019; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Davies P, 2000, METH MOLEC MED, V32, P361, DOI 10.1385/1-59259-195-7:361; Dawson HN, 2001, J CELL SCI, V114, P1179; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Feijoo C, 2005, J CELL SCI, V118, P397, DOI 10.1242/jcs.01655; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ihara Y, 2001, NEUROBIOL AGING, V22, P123, DOI 10.1016/S0197-4580(00)00200-1; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402; Li LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084336; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Mattsson N, 2012, BIOMARK MED, V6, P409, DOI [10.2217/BMM.12.39, 10.2217/bmm.12.39]; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rajput A, 2006, NEUROLOGY, V67, P1506, DOI 10.1212/01.wnl.0000240220.33950.0c; Rankin CA, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-12; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rubenstein R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066352; Rubenstein R, 2012, J GEN VIROL, V93, P1375, DOI 10.1099/vir.0.038802-0; Rubenstein R, 2011, J VIROL, V85, P9031, DOI 10.1128/JVI.05111-11; Rubenstein R, 2010, J GEN VIROL, V91, P1883, DOI 10.1099/vir.0.020164-0; Santpere G, 2009, ACTA NEUROPATHOL, V117, P227, DOI 10.1007/s00401-008-0478-8; Sato S, 2006, J NEUROCHEM, V98, P1573, DOI 10.1111/j.1471-4159.2006.04059.x; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, ACT NEUR S, V81, P205; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	87	48	50	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					342	352		10.1089/neu.2014.3548			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700006	25177776	Green Published			2021-06-18	
J	Lourbopoulos, A; Erturk, A; Hellal, F				Lourbopoulos, Athanasios; Ertuerk, Ali; Hellal, Farida			Microglia in action: how aging and injury can change the brain's guardians	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						microglia; stroke; traumatic brain injury; inflammation; aging	ACTIVATED MICROGLIA; RESIDENT MICROGLIA; HEMATOPOIETIC STEM; COMMON VARIANTS; CELL-DEATH; IN-VITRO; CNS; REVEALS; MECHANISM; FATE	Neuroinflarnmation, the inflammatory response in the central nervous system (CNS), is a major determinant of neuronal function and survival during aging and disease progression. Microglia, as the resident tissue-macrophages of the brain, provide constant support to surrounding neurons in healthy brain. Upon any stress signal (such as trauma, ischemia, inflammation) they are one of the first cells to react. Local and/or peripheral signals determine microglia stress response, which can vary within a continuum of states from beneficial to detrimental for neuronal survival, and can be shaped by aging and previous insults. In this review, we discuss the roles of microglia upon an ischemic or traumatic injury, and give our perspective how aging may contribute to microglia behavior in the injured brain. We speculate that a deeper understanding of specific microglia identities will pave the way to develop more potent therapeutics to treat the diseases of aging brain.	[Lourbopoulos, Athanasios; Hellal, Farida] Univ Munich, Sch Med, Inst Stroke & Dementia Res ISD, Lab Expt Stroke Res, D-81377 Munich, Germany; [Ertuerk, Ali] Univ Munich, Sch Med, Inst Stroke & Dementia Res ISD, Lab Acute Brain Injury, D-81377 Munich, Germany	Hellal, F (corresponding author), Univ Munich, Sch Med, Inst Stroke & Dementia Res ISD, Lab Expt Stroke Res, Campus Grosshadern,Feodor Lynen Str 17, D-81377 Munich, Germany.	farida.hellal@med.uni-muenchen.de	Hellal, Farida/D-1834-2015	Hellal, Farida/0000-0002-9344-1846			Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Berg A, 2012, EXP NEUROL, V237, P8, DOI 10.1016/j.expneurol.2012.06.008; Boimel M, 2010, EXP NEUROL, V224, P472, DOI 10.1016/j.expneurol.2010.05.010; Bouchlaka MN, 2013, J EXP MED, V210, P2223, DOI 10.1084/jem.20131219; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Duering M, 2012, NEUROLOGY, V79, P2025, DOI 10.1212/WNL.0b013e3182749f39; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Famakin BM, 2014, AGING DIS, V5, P307, DOI 10.14336/AD.2014.0500307; Flanary BE, 2007, REJUV RES, V10, P61, DOI 10.1089/rej.2006.9096; Floden AM, 2011, J ALZHEIMERS DIS, V25, P279, DOI 10.3233/JAD-2011-101014; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hefendehl JK, 2014, AGING CELL, V13, P60, DOI 10.1111/acel.12149; Hellwig S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00071; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Hristova M, 2010, GLIA, V58, P11, DOI 10.1002/glia.20896; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; HU XM, 2012, STROKE, V43, P3063, DOI DOI 10.1161/STR0KEAHA.112.659656; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Ito U, 2007, STROKE, V38, P2577, DOI 10.1161/STROKEAHA.107.484394; Jacquin A, 2014, J ALZHEIMERS DIS, V40, P1029, DOI 10.3233/JAD-131580; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Lee Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/297241; Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lyons A, 2007, J NEUROSCI, V27, P8309, DOI 10.1523/JNEUROSCI.1781-07.2007; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Miller KR, 2007, NEURON GLIA BIOL, V3, P245, DOI 10.1017/S1740925X08000136; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001; Napoli I, 2010, EXP NEUROL, V225, P24, DOI 10.1016/j.expneurol.2009.04.024; Narantuya D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011746; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Neumann J, 2015, ACTA NEUROPATHOL, V129, P259, DOI 10.1007/s00401-014-1355-2; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Okaya T, 2005, SHOCK, V24, P421, DOI 10.1097/01.shk.0000181282.14050.11; Orre M, 2014, NEUROBIOL AGING, V35, P2746, DOI 10.1016/j.neurobiolaging.2014.06.004; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Perego C, 2013, JOVE-J VIS EXP, DOI 10.3791/50605; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Perez-de-Puig I, 2015, ACTA NEUROPATHOL, V129, P239, DOI 10.1007/s00401-014-1381-0; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Puntener U, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-146; Radlinska BA, 2009, ANN NEUROL, V66, P825, DOI 10.1002/ana.21796; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raj DDA, 2014, NEUROBIOL AGING, V35, P2147, DOI 10.1016/j.neurobiolaging.2014.03.025; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rozovsky I, 1998, NEUROBIOL AGING, V19, P97, DOI 10.1016/S0197-4580(97)00169-3; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Starossom SC, 2012, IMMUNITY, V37, P249, DOI 10.1016/j.immuni.2012.05.023; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Takeuchi H, 2006, NEUROBIOL DIS, V22, P33, DOI 10.1016/j.nbd.2005.09.014; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Tremblay Marie-Eve, 2011, Commun Integr Biol, V4, P220, DOI 10.4161/cib.4.2.14506; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Varvel NH, 2012, P NATL ACAD SCI USA, V109, P18150, DOI 10.1073/pnas.1210150109; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang JP, 2013, INT J MOL MED, V31, P172, DOI 10.3892/ijmm.2012.1179; Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1; Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Wu LJ, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/586426; Wynne AM, 2010, BRAIN BEHAV IMMUN, V24, P1190, DOI 10.1016/j.bbi.2010.05.011; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yan BC, 2014, J NEUROL SCI, V337, P129, DOI 10.1016/j.jns.2013.11.034; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zindler E, 2010, BEST PRACT RES-CLIN, V24, P551, DOI 10.1016/j.bpa.2010.11.001	108	48	49	0	23	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	FEB 23	2015	9								54	10.3389/fncel.2015.00054			8	Neurosciences	Neurosciences & Neurology	CB9MT	WOS:000349956500001	25755635	DOAJ Gold, Green Published			2021-06-18	
J	Laredo, SA; Steinman, MQ; Robles, CF; Ferrer, E; Ragen, BJ; Trainor, BC				Laredo, Sarah A.; Steinman, Michael Q.; Robles, Cindee F.; Ferrer, Emilio; Ragen, Benjamin J.; Trainor, Brian C.			Effects of defeat stress on behavioral flexibility in males and females: modulation by the mu-opioid receptor	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Barnes maze; orbitofrontal cortex; Peromyscus californicus; sex differences; social defeat	TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; BETA-FUNALTREXAMINE; GENDER-DIFFERENCES; PREFRONTAL CORTEX; ANXIETY DISORDERS; CORTICAL-LESIONS; CALIFORNIA MICE; MESSENGER-RNA; COPING STYLES	Behavioral flexibility is a component of executive functioning that allows individuals to adapt to changing environmental conditions. Independent lines of research indicate that the mu opioid receptor (MOR) is an important mediator of behavioral flexibility and responses to psychosocial stress. The current study bridges these two lines of research and tests the extent to which social defeat and MOR affect behavioral flexibility and whether sex moderates these effects in California mice (Peromyscus californicus). Males and females assigned to social defeat or control conditions were tested in a Barnes maze. In males, defeat impaired behavioral flexibility but not acquisition. Female performance was unaffected by defeat. MOR binding in defeated and control mice in the orbitofrontal cortex (OFC), striatum and hippocampus was examined via autoradiography. Stressed males had reduced MOR binding in the OFC whereas females were unaffected. The MOR antagonist beta-funaltrexamine (1mg/kg) impaired performance in males naive to defeat during the reversal phase but had no effect on females. Finally, we examined the effects of the MOR agonist morphine (2.5 and 5mg/kg) on stressed mice. As expected, morphine improved behavioral flexibility in stressed males. The stress-induced deficits in behavioral flexibility in males are consistent with a proactive coping strategy, including previous observations that stressed male California mice exhibit strong social approach and aggression. Our pharmacological data suggest that a down-regulation of MOR signaling in males may contribute to sex differences in behavioral flexibility following stress. This is discussed in the framework of coping strategies for individuals with mood disorders.	[Laredo, Sarah A.; Steinman, Michael Q.; Robles, Cindee F.; Ferrer, Emilio; Ragen, Benjamin J.; Trainor, Brian C.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA; [Laredo, Sarah A.; Trainor, Brian C.] Univ Calif Davis, Anim Behav Grad Grp, Davis, CA 95616 USA; [Steinman, Michael Q.; Trainor, Brian C.] Univ Calif Davis, Mol Cellular & Integrat Physiol Grad Grp, Davis, CA 95616 USA; [Ragen, Benjamin J.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA	Laredo, SA (corresponding author), Univ Calif Davis, One Shields Ave, Davis, CA 95616 USA.	salaredo@scripps.edu; bctrainor@ucdavis.edu	Trainor, Brian C./L-3618-2016	Trainor, Brian C./0000-0002-4627-5478	NSFNational Science Foundation (NSF); NIH National Research Service from NIMH [F31 MH095253-01, R01MH085069]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH095253, R01MH085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007456] Funding Source: NIH RePORTER	The authors thank Karen Bales, Robert Berman, Simona Ghetti and Charles Heyser for thoughtful comments on the manuscript, Andrea Silva for technical assistance and Cindy Clayton for animal care. This research was funded by a Graduate Research Fellowship awarded by the NSF to S.A.L., an NIH National Research Service Award F31 MH095253-01 from NIMH to M.Q.S., and R01MH085069 to B.C.T.	Bales KL, 2007, NEUROSCIENCE, V144, P38, DOI 10.1016/j.neuroscience.2006.09.009; Bernal SA, 2007, BEHAV BRAIN RES, V177, P126, DOI 10.1016/j.bbr.2006.10.028; Bissonette GB, 2008, J NEUROSCI, V28, P11124, DOI 10.1523/JNEUROSCI.2820-08.2008; Bissonette GB, 2012, NEUROPHARMACOLOGY, V62, P1168, DOI 10.1016/j.neuropharm.2011.03.011; Bond AB, 2007, J COMP PSYCHOL, V121, P372, DOI 10.1037/0735-7036.121.4.372; Bondi CO, 2008, NEUROPSYCHOPHARMACOL, V33, P320, DOI 10.1038/sj.npp.1301410; Boulougouris V, 2007, BEHAV BRAIN RES, V179, P219, DOI 10.1016/j.bbr.2007.02.005; Bruchas MR, 2007, J NEUROSCI, V27, P11614, DOI 10.1523/JNEUROSCI.3769-07.2007; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Cahill L, 2006, NAT REV NEUROSCI, V7, P477, DOI 10.1038/nrn1909; Castane A, 2010, BEHAV BRAIN RES, V210, P74, DOI 10.1016/j.bbr.2010.02.017; Channon S, 1996, J AFFECT DISORDERS, V39, P107, DOI 10.1016/0165-0327(96)00027-4; Cook CD, 2000, PSYCHOPHARMACOLOGY, V150, P430, DOI 10.1007/s002130000453; Coppens CM, 2010, PHILOS T R SOC B, V365, P4021, DOI 10.1098/rstb.2010.0217; Davis RN, 2000, COGNITIVE THER RES, V24, P699, DOI 10.1023/A:1005591412406; DeRubeis RJ, 1999, AM J PSYCHIAT, V156, P1007; Dickstein DP, 2010, PSYCHOL MED, V40, P1089, DOI 10.1017/S0033291709991462; Farahmandfar M, 2010, BEHAV BRAIN RES, V211, P156, DOI 10.1016/j.bbr.2010.03.013; Garety P, 1997, BRIT J PSYCHIAT, V171, P420, DOI 10.1192/bjp.171.5.420; GAULIN SJC, 1989, ANIM BEHAV, V37, P322, DOI 10.1016/0003-3472(89)90121-8; GAULIN SJC, 1986, AM NAT, V127, P74, DOI 10.1086/284468; Ghods-Sharifi S, 2008, NEUROBIOL LEARN MEM, V89, P567, DOI 10.1016/j.nlm.2007.10.007; Goel N, 2009, J NEUROENDOCRINOL, V21, P415, DOI 10.1111/j.1365-2826.2009.01843.x; Gonzales K.L., 2011, FRONT ENDOCRINOL, V2, P18, DOI DOI 10.3389/FEND0.2011; Grant MM, 2001, BIOL PSYCHIAT, V50, P35, DOI 10.1016/S0006-3223(00)01072-6; Greenberg GD, 2014, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00223; Hofmann SG, 2008, J CLIN PSYCHIAT, V69, P621, DOI 10.4088/jcp.v69n0415; Isovich E, 2001, EUR J NEUROSCI, V13, P1254, DOI 10.1046/j.0953-816x.2001.01492.x; Jamot L, 2003, GENES BRAIN BEHAV, V2, P80, DOI 10.1034/j.1601-183X.2003.00013.x; Jasarevic E, 2012, ANIM BEHAV, V84, P1141, DOI 10.1016/j.anbehav.2012.08.015; Jasarevic E, 2011, P NATL ACAD SCI USA, V108, P11715, DOI 10.1073/pnas.1107958108; Jonasson Z, 2005, NEUROSCI BIOBEHAV R, V28, P811, DOI 10.1016/j.neubiorev.2004.10.006; Kanagaratnam P, 2007, J ANXIETY DISORD, V21, P510, DOI 10.1016/j.janxdis.2006.06.008; KAVALIERS M, 1987, PHARMACOL BIOCHEM BE, V27, P477, DOI 10.1016/0091-3057(87)90351-0; Koolhaas JM, 1999, NEUROSCI BIOBEHAV R, V23, P925, DOI 10.1016/S0149-7634(99)00026-3; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lapiz-Bluhm MDS, 2010, INT J NEUROPSYCHOPH, V13, P997, DOI 10.1017/S1461145710000039; Liberzon I, 2007, BIOL PSYCHIAT, V61, P1030, DOI 10.1016/j.biopsych.2006.06.021; Liston C, 2006, J NEUROSCI, V26, P7870, DOI 10.1523/JNEUROSCI.1184-06.2006; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MARTIN TJ, 1995, J PHARMACOL EXP THER, V272, P1135; McAlonan K, 2003, BEHAV BRAIN RES, V146, P97, DOI 10.1016/j.bbr.2003.09.019; McArdle J. J, 1990, HDB PSYCHOL AGING; Meilandt WJ, 2004, J NEUROSCI, V24, P2953, DOI 10.1523/JNEUROSCI.5569-03.2004; Milner TA, 2013, SYNAPSE, V67, P757, DOI 10.1002/syn.21683; Murmu MS, 2006, EUR J NEUROSCI, V24, P1477, DOI 10.1111/j.1460-9568.2006.05024.x; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nikulina EM, 1999, NEUROREPORT, V10, P3015, DOI 10.1097/00001756-199909290-00026; OLSON GA, 1979, PHARMACOL BIOCHEM BE, V11, P341, DOI 10.1016/0091-3057(79)90146-1; Quednow BB, 2008, INT J NEUROPSYCHOPH, V11, P655, DOI 10.1017/S1461145707008322; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; RIBBLE DO, 1991, BEHAV ECOL SOCIOBIOL, V29, P161, DOI 10.1007/BF00166397; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; SHERRY DF, 1992, TRENDS NEUROSCI, V15, P298, DOI 10.1016/0166-2236(92)90080-R; Silva AL, 2010, BEHAV BRAIN RES, V208, P528, DOI 10.1016/j.bbr.2009.12.038; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; Steinman MQ, 2015, PSYCHONEUROENDOCRINO, V51, P122, DOI 10.1016/j.psyneuen.2014.09.009; Steinman MQ, 2011, EUR J NEUROSCI, V33, P361, DOI 10.1111/j.1460-9568.2010.07528.x; Taylor S, 1996, J BEHAV THER EXP PSY, V27, P1, DOI 10.1016/0005-7916(95)00058-5; Tebbich S, 2010, PHILOS T R SOC B, V365, P1099, DOI 10.1098/rstb.2009.0291; Trainor BC, 2013, HORM BEHAV, V63, P543, DOI 10.1016/j.yhbeh.2013.01.011; Trainor BC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017405	63	48	48	1	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2015	41	4					434	441		10.1111/ejn.12824			8	Neurosciences	Neurosciences & Neurology	CC0UW	WOS:000350054000004	25615538	Green Accepted			2021-06-18	
J	Wade, SL; Kurowski, BG; Kirkwood, MW; Zhang, NH; Cassedy, A; Brown, TM; Nielsen, B; Stancin, T; Taylor, G				Wade, Shari L.; Kurowski, Brad G.; Kirkwood, Michael W.; Zhang, Nanhua; Cassedy, Amy; Brown, Tanya M.; Nielsen, Britt; Stancin, Terry; Taylor, Gerry			Online Problem-Solving Therapy After Traumatic Brain Injury: A Randomized Controlled Trial	PEDIATRICS			English	Article							EXECUTIVE DYSFUNCTION; FUNCTIONAL RECOVERY; ATTENTION PROBLEMS; UNITED-STATES; CHILDREN; OUTCOMES; INTERVENTIONS; PREDICTORS; MILD; ADOLESCENTS	BACKGROUND: Pediatric traumatic brain injury (TBI) contributes to impairments in functioning in everyday settings. Evidence suggests that online family problem-solving therapy (FPST) may be effective in reducing adolescent behavioral morbidity. This article examines the efficacy of Counselor-Assisted Problem Solving (CAPS), a form of online FPST in improving long-term functional outcomes of adolescents with TBI relative to Internet resources only. METHODS: Children, aged 12 to 17 years, who were hospitalized in the previous 7 months for TBI were enrolled in a multisite, assessor-blinded randomized controlled trial. Consented participants were randomly assigned to CAPS or an Internet resource comparison (IRC) condition. Outcomes were assessed at baseline and at follow-ups 6, 12, and 18 months postbaseline. The Child and Functional Assessment Scale and the Iowa Family Interaction Rating Scale (IFIRS) served as primary outcomes of child and family functioning respectively. RESULTS: For the Child and Functional Assessment Scale total, we found a significant group x time interaction, with less impaired functioning for the CAPS group than for the IRC group at the final follow-up. Parent education moderated the efficacy of CAPS on overall rates of impairment and school/work functioning, with the advantage of CAPS over IRC evident at the final follow-up only for participants with less-educated parents. Neither group differences nor group x time interactions were found for the IFIRS. CONCLUSIONS: Relatively brief, online treatment shortly after injury may result in long-term improvements in child functioning, particularly among families of lower socioeconomic status. Clinical implementation of CAPS during the initial months postinjury should be considered.	[Wade, Shari L.; Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Zhang, Nanhua; Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA; [Zhang, Nanhua; Cassedy, Amy] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Nielsen, Britt; Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Div Pediat Psychol, Cleveland, OH 44109 USA; [Nielsen, Britt; Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Taylor, Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, Gerry] Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Case Med Ctr, Cleveland, OH 44106 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA.		Zhang, Nanhua/L-7606-2015; Nielsen, Britt/S-5796-2019; Stancin, Terry/L-7993-2019	Zhang, Nanhua/0000-0001-5796-3404	National Institutes of Health grant from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; National Institute of Disability and Rehabilitation Research, Department of Education [H133G050239]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD074683-01A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425, UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	Supported in part by National Institutes of Health grant R01-MH073764 from the National Institute of Mental Health; a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; grant H133G050239 from the National Institute of Disability and Rehabilitation Research, Department of Education; and National Institute of Child Health and Human Development grant 1K23HD074683-01A1. Funded by the National Institutes of Health (NIH).	Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Andrews G, 2010, PLOS ONE, V5, DOI DOI 10.1371/JOURNAL.PONE.0010939; Backeljauw B, 2014, PM&R, V6, P814, DOI 10.1016/j.pmrj.2014.04.004; Blaha RZ, 2015, J HEAD TRAUMA REHAB, V30, pE33, DOI 10.1097/HTR.0000000000000059; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cushing CC, 2010, J PEDIATR PSYCHOL, V35, P937, DOI 10.1093/jpepsy/jsq023; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Hodges K, 1998, J BEHAV HEALTH SER R, V25, P325, DOI 10.1007/BF02287471; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Penate W, 2012, INT J CLIN HLTH PSYC, V12, P475; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; TEASDALE G, 1974, LANCET, V2, P81; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; van 't Hooft I, 2007, NEUROREHABILITATION, V22, P109; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2014, REHABIL PSYCHOL, V59, P1, DOI 10.1037/a0034911; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Webb MS, 2010, AM J HEALTH PROMOT, V25, P109, DOI 10.4278/ajhp.090123-LIT-25; Wechsler D, 2003, WISC 4 ADM MANUAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Xue Y, 2004, J CLIN CHILD ADOLESC, V33, P516, DOI 10.1207/s15374424jccp3303_9; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387	41	48	49	0	20	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2015	135	2					E487	E495		10.1542/peds.2014-1386			9	Pediatrics	Pediatrics	CE0PX	WOS:000351507800001	25583911	Green Published			2021-06-18	
J	Drexel, M; Puhakka, N; Kirchmair, E; Hortnagl, H; Pitkanen, A; Sperk, G				Drexel, Meinrad; Puhakka, Noora; Kirchmair, Elke; Hoertnagl, Heide; Pitkanen, Asla; Sperk, Guenther			Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injury	NEUROPHARMACOLOGY			English	Article						Epilepsy; GABA; Lateral fluid-percussion injury; Neurosteroid	RAT HIPPOCAMPUS; DENTATE GYRUS; IMMUNOCYTOCHEMICAL DISTRIBUTION; POSTTRAUMATIC EPILEPSY; MESSENGER-RNAS; CARDIAC-ARREST; INHIBITION; NEURONS; MODEL; GAMMA	Traumatic brain injury is a major cause of death and disability worldwide and often associated with post-traumatic epilepsy. We recently demonstrated that TBI induces acquired GABA(A) receptors channelopathy that associates with hyperexcitability in granule cell layer (GCL). We now assessed the expression of GABA(A) and GABA(B) receptor subunit mRNAs between 6 h and 6 months post-TBI in the hippocampus and thalamus. The expression of major GABA(A) receptor subunit mRNAs (alpha 1, alpha 2, alpha 5, beta 2, beta 3, gamma 2 and delta) was, often bilaterally, down-regulated in the GCL and in the CA3 pyramidal cells. Instead, expression of alpha 4 (GCL, CA3, CA1), alpha 5 (CA1) and gamma 2 (GCL, CA3, CA1) mRNA was up-regulated after 10 d and/or 4 months. Many of these changes were reversible. In the thalamus, we found decreases in alpha 1, alpha 4, beta 2, gamma 2 and delta mRNAs in the laterodorsal thalamus and in the area combining the posterior thalamic nuclear group, ventroposterolateral and ventroposteromedial complex at 6 h to 4 months post-TBI. Unlike in the hippocampus, thalamic subunit down-regulations were irreversible and limited to the ipsilateral side. However, contralaterally there was up-regulation of the subunits delta and alpha 4 6 h and 4 months after TBI, respectively. PCR array analysis suggested a mild long-lasting GABA(A) receptor channelopathy in the GCL and thalamus after TBI. Whereas TBI induces transient changes in the expression of GABAA receptor subunits in the hippocampus (presumably representing compensatory mechanisms), alterations of GABA(A) receptor subunit mRNAs in the thalamus are long-lasting and related to degeneration of receptor-containing neurons in thalamo-cortical relay nuclei. This article is part of the Special Issue entitled 'GABAergic Signaling in Health and Disease'. (C) 2014 The Authors. Published by Elsevier Ltd.	[Drexel, Meinrad; Kirchmair, Elke; Hoertnagl, Heide; Sperk, Guenther] Med Univ Innsbruck, Dept Pharmacol, A-6020 Innsbruck, Austria; [Puhakka, Noora; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-40211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FI-70211 Kuopio, Finland	Drexel, M (corresponding author), Med Univ Innsbruck, Dept Pharmacol, Peter Mayr Str 1a, A-6020 Innsbruck, Austria.	Meinrad.drexel@i-med.ac.at		Drexel, Meinrad/0000-0002-2705-9673	European UnionEuropean Commission [LSH-CT-2006-037315]; Austrian Research FundsAustrian Science Fund (FWF) [I00660, P26680]; Academy of FinlandAcademy of FinlandEuropean Commission; European Science FoundationEuropean Science Foundation (ESF)European Commission	The study was supported by the European Union Grant FP6 EPICURE (LSH-CT-2006-037315), by the Austrian Research Funds (I00660, P26680, to G.S.), by the Academy of Finland (A.P.), and the European Science Foundation EUROCORES Programme Euro-Epinomics (Epigennet). We thank Prof. Werner Sieghart (Medical University Vienna) for providing the GABA<INF>A</INF> receptor antibodies. We want to thank Dr. Jari Nissinen and Mr. Jarmo Hartikainen for help with the experiments.	Bailey MES, 1999, BBA-GENE STRUCT EXPR, V1447, P307, DOI 10.1016/S0167-4781(99)00167-0; Ben-Ari Y, 2011, EPILEPSY CURR, V11, P192, DOI 10.5698/1535-7511-11.6.192; Bencsits E, 1999, J BIOL CHEM, V274, P19613, DOI 10.1074/jbc.274.28.19613; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Campagna-Slater V, 2007, J MOL GRAPH MODEL, V25, P721, DOI 10.1016/j.jmgm.2006.06.001; Chandra D, 2006, P NATL ACAD SCI USA, V103, P15230, DOI 10.1073/pnas.0604304103; Connelly WM, 2013, J NEUROSCI, V33, P3780, DOI 10.1523/JNEUROSCI.4989-12.2013; Drexel M, 2011, NEUROSCIENCE, V189, P316, DOI 10.1016/j.neuroscience.2011.05.021; Drexel M, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00142; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; Fritschy JM, 1999, NEUROCHEM INT, V34, P435, DOI 10.1016/S0197-0186(99)00040-6; Furtinger S, 2003, MOL BRAIN RES, V113, P107, DOI 10.1016/S0169-328X(03)00097-4; Furtinger S, 2003, NEUROSCI LETT, V352, P141, DOI 10.1016/j.neulet.2003.08.046; Gassmann M, 2012, NAT REV NEUROSCI, V13, P380, DOI 10.1038/nrn3249; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; GRUBER B, 1993, SYNAPSE, V15, P221, DOI 10.1002/syn.890150307; Gupta PK, 2014, J NEUROTRAUM, V31, P1439, DOI 10.1089/neu.2013.3221; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Huberfeld G, 2007, J NEUROSCI, V27, P9866, DOI 10.1523/JNEUROSCI.2761-07.2007; Huusko N., 2014, NEUROSCIENCE; Huusko N., 2013, BRAIN STRUCT FUNCT; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; KAWAI K, 1995, ACTA NEUROPATHOL, V89, P262; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loup F, 2000, J NEUROSCI, V20, P5401, DOI 10.1523/JNEUROSCI.20-14-05401.2000; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mohler H, 1998, LIFE SCI, V62, P1611, DOI 10.1016/S0024-3205(98)00116-7; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; Nishimura T, 2005, NEUROSCIENCE, V134, P691, DOI 10.1016/j.neuroscience.2005.04.013; Niskanen JP, 2013, J NEUROTRAUM, V30, P546, DOI 10.1089/neu.2012.2416; Nymann-Andersen J, 2002, J NEUROCHEM, V80, P815, DOI 10.1046/j.0022-3042.2002.00762.x; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; Pirker S, 2003, J NEUROPATH EXP NEUR, V62, P820, DOI 10.1093/jnen/62.8.820; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reddy Doodipala Samba, 2011, Front Endocrinol (Lausanne), V2, P38, DOI 10.3389/fendo.2011.00038; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; ROSS DT, 1995, BRAIN RES, V683, P117, DOI 10.1016/0006-8993(95)00344-P; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Scimemi A, 2005, J NEUROSCI, V25, P10016, DOI 10.1523/JNEUROSCI.2520-05.2005; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Sperk G, 1998, EPILEPSY RES, V32, P129, DOI 10.1016/S0920-1211(98)00046-1; Sperk G, 2004, ADV EXP MED BIOL, V548, P92; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Swanson L.W., 1992, BRAIN MAPS STRUCTURE; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Tao WC, 2013, J NEUROSCI, V33, P3738, DOI 10.1523/JNEUROSCI.4829-12.2013; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020; Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007	69	48	50	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JAN	2015	88				SI		122	133		10.1016/j.neuropharm.2014.08.023			12	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AU9ZD	WOS:000345949500015	25229716	Other Gold, Green Published			2021-06-18	
J	Iverson, GL; Schatz, P				Iverson, Grant L.; Schatz, Philip			Advanced topics in neuropsychological assessment following sport-related concussion	BRAIN INJURY			English	Article						Cognitive functioning; concussion; mild traumatic brain injury; neuropsychological assessment; psychometrics; reliable change	TEST-RETEST RELIABILITY; SCHOOL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; PROFESSIONAL FOOTBALL; BASE RATES; INTERNATIONAL-CONFERENCE; CLINICAL-SIGNIFICANCE; COGNITIVE IMPAIRMENT; INTERPRETING CHANGE	Objective: This study examined seven topics relating to neuropsychological assessment following sport-related concussion: (i) traditional vs. computerized tests; (ii) the value of baseline, pre-season testing; (iii) invalid baseline scores and poor effort; (iv) when to assess following injury; (v) the reliability of neuropsychological tests; (vi) reliable change methodology; and (vii) new methods for identifying cognitive impairment. Main results: Baseline testing can be helpful for quantifying cognitive deficits following injury and for assessing recovery. At present, however, there is insufficient evidence to conclude that having baseline test results is clearly superior to not having baseline test results. Although invalid baseline test performance can be detected in some athletes, validity indicators cannot determine the extent to which the results were due to deliberately poor performance, confusion or misunderstanding regarding some aspect of the test, distractions in group testing environments or some combination of factors. When interpreting baseline and post-injury data, sophisticated psychometric methods (e.g. reliable change, multivariate base rates) are available to assist with more accurate identification of cognitive impairment and the serial monitoring of recovery. Conclusions: The value of neuropsychological assessment in the management of sport-related concussion has a strong empirical foundation. Additional research is needed, however, to refine its use.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown, MA 02129 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] MassGeneral Hosp Children Sport Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.; Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Iverson, GL (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Neuropsychol Outcome Assessment Lab, 79-96 Thirteenth St, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu		Iverson, Grant/0000-0001-7348-9570	ImPACT Applications, Inc.; CNS Vital Signs; Psychological Assessment Resources (PAR, Inc.)	Grant Iverson, PhD, has been reimbursed by the government, professional scientific bodies and commercial organizations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences and symposiums. He has a clinical and consulting practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including professional athletes). He has received research funding from several test publishing companies, including ImPACT Applications, Inc., CNS Vital Signs and Psychological Assessment Resources (PAR, Inc.). He has not received research support from ImPACT Applications, Inc. in the past 3 years. He receives royalties from two books relating to neuropsychology and one test (WCST-64). Philip Schatz, PhD, has served as a consultant to the International Brain Research Foundation, the Sports Concussion Center of New Jersey and ImPACT Applications, Inc., to study the effects of concussion in high school and collegiate athletes. However, these entities had no role in the conceptualization or content of the current manuscript or the decision to submit for publication.	[Anonymous], SPORTINGNEWS, V2012; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT., 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2013, PRACT RESOUR MENT, P75, DOI 10.1016/B978-0-12-386934-0.00002-X; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chelune GJ, 2003, PREDICTION IN FORENSIC AND NEUROPSYCHOLOGY, P123; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P498; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Franzen M. D., 1989, RELIABILITY VALIDITY; Franzen MD, 2000, RELIABILITY VALIDITY, V2nd; Gardner A, 2012, APPL NEUROPSYCH-ADUL, V19, P90, DOI 10.1080/09084282.2011.643945; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner R.L., 2008, NEUROPSYCHOLOGY COUR, P243; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson G. L., 2011, HDB SPORT NEUROPSYCH, P131; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 1998, INT J GERIATR PSYCH, V13, P661, DOI 10.1002/(SICI)1099-1166(1998100)13:10<661::AID-GPS838>3.0.CO;2-0; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Iverson GL, 2012, NEUROPSYCHOLOGICAL A, P360; Iverson GL, 2009, BRIT J SPORT MED, V43, pi100; Iverson GL, 2007, J INT NEUROPSYCH SOC, V13, P65; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; JACOBSON NS, 1988, BEHAV ASSESS, V10, P133; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Putukian M, 2012, ANN C 4 INT CONS C C; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, CLIN NEUROPSYCHOL, V27, P1265, DOI 10.1080/13854046.2013.845247; Resch JE, 2012, EQUIVALENCE ALTERNAT; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wechsler D., 2003, WECHSLER INTELLIGENC	99	48	48	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					263	275		10.3109/02699052.2014.965214			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500015	25313596				2021-06-18	
J	Stokum, JA; Sours, C; Zhuo, JC; Kane, R; Shanmuganathan, K; Gullapalli, RP				Stokum, Jesse A.; Sours, Chandler; Zhuo, Jiachen; Kane, Robert; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			A longitudinal evaluation of diffusion kurtosis imaging in patients with mild traumatic brain injury	BRAIN INJURY			English	Article						ANAM; diffusion kurtosis imaging; longitudinal analysis; mild traumatic brain injury	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; AXONAL INJURY; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; MODERATE; WHITE; PERFORMANCE; ATTENUATION; ORIENTATION; SEVERITY	Primary objective: To investigate longitudinal diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI) changes in white and grey matter in patients with mild traumatic brain injury (mTBI). Research design: A prospective case-control study. Methods and procedures: DKI data was obtained from 24 patients with mTBI along with cognitive assessments within 10 days, 1 month and 6 months post-injury and compared with age-matched control (n = 24). Fractional anisotropy (FA), mean diffusivity (MD), radial diffusion (lambda(r)), mean kurtosis (MK) and radial kurtosis (K-r) were extracted from the thalamus, internal capsule and corpus callosum. Main outcomes and results: Results demonstrate reduced K-r and MK in the anterior internal capsule in patients with mTBI across the three visits, and reduced MK in the posterior internal capsule during the 10 day time point. Correlations were observed between the change in MK or K-r between 1-6 months and the improvements in cognition between the 1 and 6 month visits in the thalamus, internal capsule and corpus callosum. Conclusions: These data demonstrate that DKI may be sensitive in tracking pathophysiological changes associated with mTBI and may provide additional information to conventional DTI parameters in evaluating longitudinal changes following TBI.	[Stokum, Jesse A.; Sours, Chandler; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; [Kane, Robert] Georgetown Univ, Sch Med, Washington, DC USA	Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu			US ArmyUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]	The authors report no conflicts of interest. This work was partly supported by the grants W81XWH-08-1-0725 and W81XWH-12-1-0098 from the US Army.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 1998, J MAGN RESON, V131, P69, DOI 10.1006/jmre.1997.1313; Axer H, 2000, J NEUROSCI METH, V94, P165, DOI 10.1016/S0165-0270(99)00132-6; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Falangola MF, 2013, MAGN RESON IMAGING, V31, P840, DOI 10.1016/j.mri.2013.02.008; Falangola MF, 2008, J MAGN RESON IMAGING, V28, P1345, DOI 10.1002/jmri.21604; Gong NJ, 2013, MAGN RESON IMAGING, V31, P688, DOI 10.1016/j.mri.2012.10.027; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kamagata K, 2013, MAGN RESON IMAGING, V31, P1501, DOI 10.1016/j.mri.2013.06.009; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Raab P, 2010, RADIOLOGY, V254, P876, DOI 10.1148/radiol.09090819; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reich S, 2005, VALIDATION ANAM TEST; Sours C, 2014, BRAIN IMAGING BEHAV; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Umene-Nakano W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087890; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	52	48	52	2	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	1					47	57		10.3109/02699052.2014.947628			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AW1WC	WOS:000346078000007	25259786				2021-06-18	
J	Wu, CH; Hung, TH; Chen, CC; Ke, CH; Lee, CY; Wang, PY; Chen, SF				Wu, Chun-Hu; Hung, Tai-Ho; Chen, Chien-Cheng; Ke, Chia-Hua; Lee, Chun-Yen; Wang, Pei-Yi; Chen, Szu-Fu			Post-Injury Treatment with 7,8-Dihydroxyflavone, a TrkB Receptor Agonist, Protects against Experimental Traumatic Brain Injury via PI3K/Akt Signaling	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; NEURONAL INJURY; MOTOR FUNCTION; BLOOD-BRAIN; MOUSE MODEL; BDNF; PATHWAYS; KINASE	Tropomyosin-related kinase B (TrkB) signaling is critical for promoting neuronal survival following brain damage. The present study investigated the effects and underlying mechanisms of TrkB activation by the TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) on traumatic brain injury (TBI). Mice subjected to controlled cortical impact received intraperitoneal 7,8-DHF or vehicle injection 10 min post-injury and subsequently daily for 3 days. Behavioral studies, histology analysis and brain water content assessment were performed. Levels of TrkB signaling-related molecules and apoptosis-related proteins were analyzed. The protective effect of 7,8-DHF was also investigated in primary neurons subjected to stretch injury. Treatment with 20 mg/kg 7,8-DHF attenuated functional deficits and brain damage up to post-injury day 28. 7,8-DHF also reduced brain edema, neuronal death, and apoptosis at day 4. These changes were accompanied by a significant decrease in cleaved caspase-3 and increase in Bcl-2/Bax ratio. 7,8-DHF enhanced phosphorylation of TrkB, Akt (Ser473/Thr308), and Bad at day 4, but had no effect on Erk 1/2 phosphorylation. Moreover, 7,8-DHF increased brain-derived neurotrophic factor levels and promoted cAMP response element-binding protein (CREB) activation. This beneficial effect was attenuated by inhibition of TrkB or PI3K/Akt. 7,8-DHF also promoted survival and reduced apoptosis in cortical neurons subjected to stretch injury. Remarkably, delayed administration of 7,8-DHF at 3 h post-injury reduced brain tissue damage. Our study demonstrates that activation of TrkB signaling by 7,8-DHF protects against TBI via the PI3K/Akt but not Erk pathway, and this protective effect may be amplified via the PI3K/Akt-CREB cascades.	[Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan; [Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Chen, Chien-Cheng; Ke, Chia-Hua; Lee, Chun-Yen; Wang, Pei-Yi; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan	Chen, SF (corresponding author), Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/ABD-1800-2020; Hung, Tai-Ho/C-7584-2011; WU, CHUN-HU/P-3958-2018	Hung, Tai-Ho/0000-0003-2354-7060; WU, CHUN-HU/0000-0001-6851-7936	National Science Council of Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [NSC 101-2314-B-350-001-MY3]; Cheng Hsin General Hospital	Funding provided by the National Science Council of Taiwan, R.O.C.(NSC 101-2314-B-350-001-MY3) and the Cheng Hsin General Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Granado-Serrano AB, 2006, J NUTR, V136, P2715; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Castello NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091453; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen J, 2011, NEUROSCI LETT, V499, P181, DOI 10.1016/j.neulet.2011.05.054; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Han XH, 2014, NEUROCHEM INT, V64, P18, DOI 10.1016/j.neuint.2013.10.018; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Hung PL, 2013, STROKE, V44, P2275, DOI 10.1161/STROKEAHA.113.001552; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Jeon SJ, 2011, NEUROSCI RES, V69, P214, DOI 10.1016/j.neures.2010.11.008; Jiang ML, 2013, HUM MOL GENET, V22, P2462, DOI 10.1093/hmg/ddt098; Jiang SN, 2013, MOL THER, V21, P1985, DOI 10.1038/mt.2013.183; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Kong ANT, 2000, ARCH PHARM RES, V23, P1, DOI 10.1007/BF02976458; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Park HY, 2012, INT J MOL MED, V29, P1146, DOI 10.3892/ijmm.2012.935; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Swart C, 2014, EXP GERONTOL, V58, P279, DOI 10.1016/j.exger.2014.09.003; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Tsai T, 2013, MOL CELL NEUROSCI; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang B, 2014, J MOL HISTOL, V45, P129, DOI 10.1007/s10735-013-9539-y; Wiese S, 1999, EUR J NEUROSCI, V11, P1668, DOI 10.1046/j.1460-9568.1999.00585.x; Xie LF, 2010, CARDIOVASC RES, V87, P628, DOI 10.1093/cvr/cvq138; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Y, 2006, BRAIN RES, V1111, P227, DOI 10.1016/j.brainres.2006.07.005	49	48	51	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2014	9	11							e113397	10.1371/journal.pone.0113397			25	Multidisciplinary Sciences	Science & Technology - Other Topics	AX4MM	WOS:000346906600045	25415296	DOAJ Gold, Green Published			2021-06-18	
J	Donega, V; Nijboer, CH; Braccioli, L; Slaper-Cortenbach, I; Kavelaars, A; van Bel, F; Heijnen, CJ				Donega, Vanessa; Nijboer, Cora H.; Braccioli, Luca; Slaper-Cortenbach, Ineke; Kavelaars, Annemieke; van Bel, Frank; Heijnen, Cobi J.			Intranasal Administration of Human MSC for Ischemic Brain Injury in the Mouse: In Vitro and In Vivo Neuroregenerative Functions	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; THERAPY POSITION STATEMENT; STROMAL CELLS; NEONATAL ENCEPHALOPATHY; INTERNATIONAL-SOCIETY; HYPOXIA-ISCHEMIA; TRANSPLANTATION; NEUROGENESIS; CYTOKINES; FATE	Intranasal treatment with C57BL/6 MSCs reduces lesion volume and improves motor and cognitive behavior in the neonatal hypoxic-ischemic (HI) mouse model. In this study, we investigated the potential of human MSCs (hMSCs) to treat HI brain injury in the neonatal mouse. Assessing the regenerative capacity of hMSCs is crucial for translation of our knowledge to the clinic. We determined the neuroregenerative potential of hMSCs in vitro and in vivo by intranasal administration 10 d post-HI in neonatal mice. HI was induced in P9 mouse pups. 1 x 10(6) or 2 x 10(6) hMSCs were administered intranasally 10 d post-HI. Motor behavior and lesion volume were measured 28 d post-HI. The in vitro capacity of hMSCs to induce differentiation of mouse neural stem cell (mNSC) was determined using a transwell co-culture differentiation assay. To determine which chemotactic factors may play a role in mediating migration of MSCs to the lesion, we performed a PCR array on 84 chemotactic factors 10 days following sham-operation, and at 10 and 17 days post-HI. Our results show that 2610 6 hMSCs decrease lesion volume, improve motor behavior, and reduce scar formation and microglia activity. Moreover, we demonstrate that the differentiation assay reflects the neuroregenerative potential of hMSCs in vivo, as hMSCs induce mNSCs to differentiate into neurons in vitro. We also provide evidence that the chemotactic factor CXCL10 may play an important role in hMSC migration to the lesion site. This is suggested by our finding that CXCL10 is significantly upregulated at 10 days following HI, but not at 17 days after HI, a time when MSCs no longer reach the lesion when given intranasally. The results described in this work also tempt us to contemplate hMSCs not only as a potential treatment option for neonatal encephalopathy, but also for a plethora of degenerative and traumatic injuries of the nervous system.	[Donega, Vanessa; Nijboer, Cora H.; Braccioli, Luca; Heijnen, Cobi J.] Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Utrecht, Netherlands; [Slaper-Cortenbach, Ineke] Univ Med Ctr Utrecht, Cell Therapy Facil, Dept Clin Pharm, Utrecht, Netherlands; [Kavelaars, Annemieke; Heijnen, Cobi J.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA; [van Bel, Frank] Univ Med Ctr Utrecht, Dept Neonatol, Utrecht, Netherlands	Heijnen, CJ (corresponding author), Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Utrecht, Netherlands.	CJHeijnen@mdanderson.org	Donega, Vanessa/M-8058-2014; Braccioli, Luca/P-8142-2019		Zon-MW Project [116002003]	This study was supported by Zon-MW Project (no 116002003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borlongan CV, 2011, PEDIATR RES, V70, P3, DOI 10.1203/PDR.0b013e31821d0d00; Croft AP, 2009, EXP NEUROL, V216, P329, DOI 10.1016/j.expneurol.2008.12.010; Dammann O, 2011, PEDIATR RES, V70, P1, DOI 10.1203/01.pdr.0000403893.61640.b6; de Haan M, 2006, DEVELOPMENTAL SCI, V9, P350, DOI 10.1111/j.1467-7687.2006.00499.x; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Donega V, 2014, EXP NEUROL, V261, P53, DOI 10.1016/j.expneurol.2014.06.009; Donega V, 2013, J CEREBR BLOOD F MET, V33, P625, DOI 10.1038/jcbfm.2013.3; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gonzalo-Daganzo R, 2009, CYTOTHERAPY, V11, P278, DOI 10.1080/14653240902807018; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Lee JA, 2010, PEDIATR RES, V67, P42, DOI 10.1203/PDR.0b013e3181bf594b; Liu H, 2006, BRAIN, V129, P2734, DOI 10.1093/brain/awl207; Prins HJ, 2009, TISSUE ENG PT A, V15, P3741, DOI 10.1089/ten.TEA.2008.0666; RANSOHOFF RM, 1993, FASEB J, V7, P592; Reglero-Real N, 2012, CELL MOL LIFE SCI, V69, P3079, DOI 10.1007/s00018-012-0987-4; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Titomanlio L, 2011, ANN NEUROL, V70, P698, DOI 10.1002/ana.22518; Toyama K, 2009, EXP NEUROL, V216, P47, DOI 10.1016/j.expneurol.2008.11.010; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002; van Handel M, 2007, EUR J PEDIATR, V166, P645, DOI 10.1007/s00431-007-0437-8; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Velthoven CTJ, 2014, MOL THER, V22, P645, DOI 10.1038/mt.2013.260; van Velthoven CTJ, 2012, ANN NEUROL, V71, P785, DOI 10.1002/ana.23543; van Velthoven CTJ, 2010, J NEUROSCI, V30, P9603, DOI 10.1523/JNEUROSCI.1835-10.2010; Velthoven C, 2011, BRAIN BEHAV IMMUN, V25, P1342; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wang CC, 2008, CARDIOVASC RES, V77, P515, DOI 10.1093/cvr/cvm046; Yang B, 2012, STEM CELLS DEV, V21, P3332, DOI 10.1089/scd.2012.0037; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	40	48	50	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e112339	10.1371/journal.pone.0112339			9	Multidisciplinary Sciences	Science & Technology - Other Topics	AU4DF	WOS:000345558500047	25396420	DOAJ Gold, Green Published			2021-06-18	
J	Cournoyer, J; Tripp, BL				Cournoyer, Janie; Tripp, Brady L.			Concussion Knowledge in High School Football Players	JOURNAL OF ATHLETIC TRAINING			English	Article						head injuries; education; symptoms; consequences; adolescent	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SPORTS; EPIDEMIOLOGY; MANAGEMENT; STATEMENT; CHILDREN	Context: Participating in sports while experiencing symptoms of a concussion can be dangerous. An athlete's lack of knowledge may be one factor influencing his or her decision to report symptoms. In an effort to enhance concussion education among high school athletes, legislation in Florida has attempted to address the issue through parental consent forms. Objective: To survey high school varsity football players to determine their level of knowledge about concussions after the initiation of new concussion-education legislation. Design: Cross-sectional study. Setting: Descriptive survey administered in person during a team meeting. Patients or Other Participants: A total of 334 varsity football players from 11 high schools in Florida. Main Outcome Measure(s): Participants completed a survey and identified the symptoms and consequences of a concussion among distractors. They also indicated whether they had received education about concussions from a parent, formal education, neither, or both. Results: The most correctly identified symptoms were headache (97%), dizziness (93%), and confusion (90%), and the most correctly identified consequence was persistent headache (93%). Participants reported receiving education from their parents (54%) or from a formal source (60%). Twenty-five percent reported never receiving any education regarding concussions. No correlations were found between the method of education and the knowledge of symptoms or consequences of concussion. Conclusions: The high school football players we surveyed did not have appropriate knowledge of the symptoms and consequences of concussions. Nausea or vomiting, neck pain, grogginess, difficulty concentrating, and personality or behavioral changes were often missed by participants, and only a small proportion correctly identified brain hemorrhage, coma, and death as possible consequences of inappropriate care after a concussion. Even with parents or guardians signing a consent form indicating they discussed concussion awareness with their child, 46% of athletes suggested they had not.	[Cournoyer, Janie; Tripp, Brady L.] Univ Florida, Gainesville, FL USA	Cournoyer, J (corresponding author), Univ Ottawa, A106,200 Lees Ave, Ottawa, ON K1S 5S9, Canada.	jcournoyer@ufl.edu		Cournoyer, Janie/0000-0001-9043-7756; Tripp, Brady/0000-0002-9090-1851			[Anonymous], 2007, HEADS CONC YOUTH SPO; [Anonymous], 1999, JAMA-J AM MED ASSOC, V282, P964; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cook Rebecca S, 2006, J Trauma Nurs, V13, P58; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 2000, SEMIN NEUROL, V20, P165, DOI 10.1055/s-2000-9835; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	25	48	48	0	30	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2014	49	5					654	658		10.4085/1062-6050-49.3.34			5	Sport Sciences	Sport Sciences	AY4NN	WOS:000347555600012	25162779	Green Published			2021-06-18	
J	Schmidt, JD; Guskiewicz, KM; Blackburn, JT; Mihalik, JP; Siegmund, GP; Marshall, SW				Schmidt, Julianne D.; Guskiewicz, Kevin M.; Blackburn, J. Troy; Mihalik, Jason P.; Siegmund, Gunter P.; Marshall, Stephen W.			The Influence of Cervical Muscle Characteristics on Head Impact Biomechanics in Football	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; mild traumatic brain injury; neck musculature; neck strength; neck stiffness	SEGMENT DYNAMIC STABILIZATION; NECK SEGMENT; FUNCTIONAL-ANATOMY; GENDER-DIFFERENCES; STRENGTH; STIFFNESS; COLLEGIATE; INJURY; SPINE; PLAYERS	Background: An athlete is thought to reduce head acceleration after impact by contracting the cervical musculature, which increases the effective mass of the head. Purpose: To compare the odds of sustaining higher magnitude in-season head impacts between athletes with higher and lower preseason performance on cervical muscle characteristics. Study Design: Cohort study; Level of evidence, 2. Methods: Forty-nine high school and collegiate American football players completed a preseason cervical testing protocol that included measures of cervical isometric strength, muscle size, and response to cervical perturbation. Head impact biomechanics were captured for each player using the Head Impact Telemetry System. A median split was used to categorize players as either high or low performers for each of the following outcome measures: isometric strength (peak torque, rate of torque development), muscle size (cross-sectional area), and response to cervical perturbation (stiffness, angular displacement, muscle onset latency). The odds of sustaining moderate and severe head impacts were computed against the reference odds of sustaining mild head impacts across cervical characteristic categorizations. Results: Linemen with stronger lateral flexors and composite cervical strength had about 1.75 times' increased odds of sustaining moderate linear head impacts rather than mild impacts compared with weaker linemen. Players who developed extensor torque more quickly had 2 times the increased odds of sustaining severe linear head impacts (odds ratio [OR], 2.10; 95% CI, 1.08-4.05) rather than mild head impacts. However, players with greater cervical stiffness had reduced odds of sustaining both moderate (OR, 0.77; 95% CI, 0.61-0.96) and severe (OR, 0.64; 95% CI, 0.46-0.89) head impacts compared with players with less cervical stiffness. Conclusion: The study findings showed that greater cervical stiffness and less angular displacement after perturbation reduced the odds of sustaining higher magnitude head impacts; however, the findings did not show that players with stronger and larger neck muscles mitigate head impact severity.	[Schmidt, Julianne D.; Guskiewicz, Kevin M.; Blackburn, J. Troy; Mihalik, Jason P.; Siegmund, Gunter P.; Marshall, Stephen W.] Univ N Carolina, Chapel Hill, NC 27514 USA	Schmidt, JD (corresponding author), Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA.	schmidtj@uga.edu	Siegmund, Gunter P/B-7003-2013	Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233; Siegmund, Gunter/0000-0003-2387-941X; Mihalik, Jason/0000-0001-6085-8322			Almosnino S, 2010, J ATHL TRAINING, V45, P453, DOI 10.4085/1062-6050-45.5.453; Almosnino S, 2009, BMC SPORTS SCI MED R, V1, DOI 10.1186/1758-2555-1-22; Alricsson M, 2004, AVIAT SPACE ENVIR MD, V75, P23; Andersen LL, 2008, J BIOMECH, V41, P2029, DOI 10.1016/j.jbiomech.2008.03.016; Anthropology Research Project, 1978, ANTHR SOURC BOOK; Arts IMP, 2010, MUSCLE NERVE, V41, P32, DOI 10.1002/mus.21458; Banerjee R, 2004, AM J SPORT MED, V32, P1077, DOI 10.1177/0363546504265605; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Blackburn JT, 2011, CLIN BIOMECH, V26, P278, DOI 10.1016/j.clinbiomech.2010.10.002; Boden BP, 2000, ORTHOPEDICS, V23, P573, DOI 10.3928/0147-7447-20000601-15; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Burnett A, 2007, J ELECTROMYOGR KINES, V17, P635, DOI 10.1016/j.jelekin.2006.06.003; Burnett Angus F, 2005, Work, V25, P205; Cheng CH, 2008, EUR J APPL PHYSIOL, V103, P647, DOI 10.1007/s00421-008-0760-4; de Koning CHP, 2008, EUR SPINE J, V17, P905, DOI 10.1007/s00586-008-0656-3; de Leva P, 1996, J BIOMECH, V29, P1223, DOI 10.1016/0021-9290(95)00178-6; Eckner JT, 2014, AM J SPORT MED, V42, P566, DOI 10.1177/0363546513517869; Falla D, 2002, EUR J APPL PHYSIOL, V87, P542, DOI 10.1007/s00421-002-0661-x; Falla D, 2002, CLIN NEUROPHYSIOL, V113, P57, DOI 10.1016/S1388-2457(01)00708-8; Falla D, 2012, CLIN J PAIN, V28, P628, DOI 10.1097/AJP.0b013e31823e9378; Granata KP, 2002, J ELECTROMYOGR KINES, V12, P119, DOI 10.1016/S1050-6411(02)00002-0; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hedlund J, 2000, Inj Prev, V6, P82, DOI 10.1136/ip.6.2.82; Hildenbrand KJ, 2013, J STRENGTH COND RES, V27, P3173, DOI 10.1519/JSC.0b013e31828a1fe2; Hurd WJ, 2006, KNEE SURG SPORT TR A, V14, P60, DOI 10.1007/s00167-005-0624-y; Kubo K, 2007, MED SCI SPORT EXER, V39, P1801, DOI 10.1249/mss.0b013e31813e630a; Mansell J, 2005, J ATHL TRAINING, V40, P310; MAYOUXBENHAMOU MA, 1989, ERGONOMICS, V32, P513, DOI 10.1080/00140138908966121; MCGILL S, 1994, SPINE, V19, P696, DOI 10.1097/00007632-199403001-00009; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; MORGAN DL, 1977, AM J PHYSIOL, V232, pC45; O'Sullivan C, 2009, MANUAL THER, V14, P572, DOI 10.1016/j.math.2008.12.005; Panjabi MM, 1998, CLIN BIOMECH, V13, P11, DOI 10.1016/S0268-0033(97)00057-0; Portero R, 2013, J BIOMECH, V46, P925, DOI 10.1016/j.jbiomech.2012.12.009; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; REID SE, 1981, AVIAT SPACE ENVIR MD, V52, P78; Rezasoltani A, 2002, J REHABIL RES DEV, V39, P423; Rezasoltani A, 1999, SCAND J MED SCI SPOR, V9, P214; Rezasoltani A, 1998, CLIN REHABIL, V12, P36, DOI 10.1191/026921598673972662; Seng KY, 2002, CLIN BIOMECH, V17, P545, DOI 10.1016/S0268-0033(02)00067-0; Siegmund GP, 2008, EXERC SPORT SCI REV, V36, P76, DOI 10.1097/JES.0b013e318168f1ce; Simoneau M, 2008, J BIOMECH, V41, P2097, DOI 10.1016/j.jbiomech.2008.05.002; Sommerich CM, 2000, J ELECTROMYOGR KINES, V10, P377, DOI 10.1016/S1050-6411(00)00033-X; Strimpakos N, 2004, ARCH PHYS MED REHAB, V85, P1309, DOI 10.1016/j.apmr.2003.08.104; Swartz EE, 2005, J ATHL TRAINING, V40, P155; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Uemura Naoya, 2008, Nihon Hotetsu Shika Gakkai Zasshi, V52, P494; Vasavada AN, 1998, SPINE, V23, P412, DOI 10.1097/00007632-199802150-00002; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; WILSON GJ, 1991, INT J SPORTS MED, V12, P403, DOI 10.1055/s-2007-1024702; Ylinen JJ, 1999, CLIN BIOMECH, V14, P217, DOI 10.1016/S0268-0033(98)00063-1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	57	48	48	0	65	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2014	42	9					2056	2066		10.1177/0363546514536685			11	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AP9GQ	WOS:000342387400003	24928761				2021-06-18	
J	Holowka, DW; Marx, BP; Gates, MA; Litman, HJ; Ranganathan, G; Rosen, RC; Keane, TM				Holowka, Darren W.; Marx, Brian P.; Gates, Margaret A.; Litman, Heather J.; Ranganathan, Gayatri; Rosen, Raymond C.; Keane, Terence M.			PTSD Diagnostic Validity in Veterans Affairs Electronic Records of Iraq and Afghanistan Veterans	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article						PTSD; veterans; diagnosis; electronic medical record; electronic health record	HEALTH INFORMATION-TECHNOLOGY; POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; ADMINISTRATIVE DATA; PRIMARY-CARE; AMBULATORY-CARE; MEDICAL-CARE; QUALITY; SCALE; PREVALENCE	Objective: Administrative planning and policy decisions frequently rely on diagnostic data extracted from large electronic databases. However, the accuracy of this diagnostic information is uncertain. The present study examined the degree to which various diagnoses of posttraumatic stress disorder (PTSD) within Department of Veterans Affairs (VA) electronic databases were concordant with PTSD diagnostic status determined by standardized diagnostic interview. Method: We interviewed 1,649 veterans of the Iraq and Afghanistan wars using the PTSD Module of the Structured Clinical Interview for DSM-IV (SCID). Participants also completed other interview-based and self-report measures of psychopathology and provided consent to access their electronic medical records (EMRs). Results: Concordance between database diagnosis and SCID diagnosis was 72.3% for current PTSD and 79.4% for lifetime PTSD. We observed associations between concordance status and combat exposure, PTSD symptom presentation, comorbid anxiety and depression, and psychosocial impairment. Veterans with false-negative PTSD diagnoses in the EMR were more likely to report lower levels of combat exposure, panic, and PTSD avoidance symptoms. Veterans with false-positive PTSD diagnoses in the EMR were more likely to report treatment seeking for emotional problems and less overall functional impairment. Conclusions: Although the majority of participants were concordant for PTSD status, over 25% of EMR diagnoses differed from those obtained in the diagnostic interview, with varying proportions of false positives and false negatives. Overall, those individuals with the most and least severe symptom presentations in the diagnostic interview were more likely to be accurately classified.	[Holowka, Darren W.; Marx, Brian P.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Holowka, Darren W.; Marx, Brian P.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA; [Gates, Margaret A.; Litman, Heather J.; Ranganathan, Gayatri; Rosen, Raymond C.] New England Res Inst, Watertown, MA 02172 USA	Holowka, DW (corresponding author), Rhode Isl Hosp, Dept Psychiat, Potter 2,593 Eddy St, Providence, RI 02903 USA.	dholowka@lifespan.org	Marx, Brian/AAK-5072-2020; Keane, Terence/I-8253-2014	Keane, Terence/0000-0002-0482-3149; Gates Kuliszewski, Margaret/0000-0002-2111-6227			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Blake D. D., 1990, BEHAV THER, V13, P187; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blumenthal D, 2011, NEW ENGL J MED, V365, P2426, DOI 10.1056/NEJMsr1112158; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Brown SH, 2003, INT J MED INFORM, V69, P135, DOI 10.1016/S1386-5056(02)00131-4; Byrne CM, 2010, HEALTH AFFAIR, V29, P629, DOI 10.1377/hlthaff.2010.0119; Castro F., 2011, TREATING PTSD MILITA, P23; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; Dick R.S., 1991, COMPUTER BASED PATIE; Dick RS, 1997, COMPUTER BASED PATIE; Farmer SA, 2013, JAMA-J AM MED ASSOC, V309, P349, DOI 10.1001/jama.2012.191276; First M.B., 2004, COMPREHENSIVE HDB PS, P134, DOI DOI 10.1002/CPP; Ford EW, 2009, J AM MED INFORM ASSN, V16, P274, DOI 10.1197/jamia.M3042; Frayne SM, 2010, AM J MED QUAL, V25, P42, DOI 10.1177/1062860609346347; Gravely AA, 2011, J REHABIL RES DEV, V48, P21, DOI 10.1682/JRRD.2009.08.0116; Harris SB, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-347; Hawthorne G, 2006, SOC PSYCH PSYCH EPID, V41, P164, DOI 10.1007/s00127-005-0986-y; Holowka DW, 2012, PSYCHOL TRAUMA-US, V4, P285, DOI 10.1037/a0023267; Jackson JC, 2011, J TRAUMA STRESS, V24, P609, DOI 10.1002/jts.20688; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Jha AK, 2009, NEW ENGL J MED, V360, P1628, DOI 10.1056/NEJMsa0900592; Kang HK, 2005, NEW ENGL J MED, V352, P1289, DOI 10.1056/NEJMp058024; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Liaw S.-T., 2012, ELECT J HLTH INFORM, V7, pe1; Linder JA, 2007, ARCH INTERN MED, V167, P1400, DOI 10.1001/archinte.167.13.1400; Magruder KM, 2005, GEN HOSP PSYCHIAT, V27, P169, DOI 10.1016/j.genhosppsych.2004.11.001; Marx B. P., 2009, ANN M INT SOC TRAUM; Newman-Toker DE, 2009, JAMA-J AM MED ASSOC, V301, P1060, DOI 10.1001/jama.2009.249; Norman GR, 2010, MED EDUC, V44, P94, DOI 10.1111/j.1365-2923.2009.03507.x; Rosen CS, 2004, J TRAUMA STRESS, V17, P213, DOI 10.1023/B:JOTS.0000029264.23878.53; Rosen RC, 2012, INT J METH PSYCH RES, V21, P5, DOI 10.1002/mpr.355; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schiff GD, 2010, NEW ENGL J MED, V362, P1066, DOI 10.1056/NEJMp0911734; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Shear MK, 2000, AM J PSYCHIAT, V157, P581, DOI 10.1176/appi.ajp.157.4.581; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Szeto HC, 2002, AM J MANAG CARE, V8, P37; Trinh NHT, 2011, INT J MED INFORM, V80, P533, DOI 10.1016/j.ijmedinf.2011.03.014; Trivedi AN, 2011, MED CARE, V49, P76, DOI 10.1097/MLR.0b013e3181f53575; U.S. Department of Veterans Affairs, 2013, MILL VET PROGR PARTN; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wright A, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-36; Yuan Y, 2011, J STAT SOFTW, V45, P1	49	48	48	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X	1939-2117		J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	AUG	2014	82	4					569	579		10.1037/a0036347			11	Psychology, Clinical	Psychology	AS3FY	WOS:000344164000003	24731235				2021-06-18	
J	Stocchetti, N; Picetti, E; Berardino, M; Buki, A; Chesnut, RM; Fountas, KN; Horn, P; Hutchinson, PJ; Iaccarino, C; Kolias, AG; Koskinen, LO; Latronico, N; Maas, AIR; Payen, JF; Rosenthal, G; Sahuquillo, J; Signoretti, S; Soustiel, JF; Servadei, F				Stocchetti, Nino; Picetti, Edoardo; Berardino, Maurizio; Buki, Andras; Chesnut, Randall M.; Fountas, Kostas N.; Horn, Peter; Hutchinson, Peter J.; Iaccarino, Corrado; Kolias, Angelos G.; Koskinen, Lars-Owe; Latronico, Nicola; Maas, Andrews I. R.; Payen, Jean-Francois; Rosenthal, Guy; Sahuquillo, Juan; Signoretti, Stefano; Soustiel, Jean F.; Servadei, Franco			Clinical applications of intracranial pressure monitoring in traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Intracranial pressure; Monitoring; Management	SEVERE HEAD-INJURY; INITIAL COMPUTERIZED-TOMOGRAPHY; CEREBRAL PERFUSION-PRESSURE; WAKE-UP TEST; DECOMPRESSIVE CRANIECTOMY; SURGICAL-MANAGEMENT; SCAN; HYPERTENSION; MORTALITY; PREDICTORS	Intracranial pressure (ICP) monitoring has been for decades a cornerstone of traumatic brain injury (TBI) management. Nevertheless, in recent years, its usefulness has been questioned in several reports. A group of neurosurgeons and neurointensivists met to openly discuss, and provide consensus on, practical applications of ICP in severe adult TBI. A consensus conference was held in Milan on October 5, 2013, putting together neurosurgeons and intensivists with recognized expertise in treatment of TBI. Four topics have been selected and addressed in pro-con presentations: 1) ICP indications in diffuse brain injury, 2) cerebral contusions, 3) secondary decompressive craniectomy (DC), and 4) after evacuation of intracranial traumatic hematomas. The participants were asked to elaborate on the existing published evidence (without a systematic review) and their personal clinical experience. Based on the presentations and discussions of the conference, some drafts were circulated among the attendants. After remarks and further contributions were collected, a final document was approved by the participants. The group made the following recommendations: 1) in comatose TBI patients, in case of normal computed tomography (CT) scan, there is no indication for ICP monitoring; 2) ICP monitoring is indicated in comatose TBI patients with cerebral contusions in whom the interruption of sedation to check neurological status is dangerous and when the clinical examination is not completely reliable. The probe should be positioned on the side of the larger contusion; 3) ICP monitoring is generally recommended following a secondary DC in order to assess the effectiveness of DC in terms of ICP control and guide further therapy; 4) ICP monitoring after evacuation of an acute supratentorial intracranial hematoma should be considered for salvageable patients at increased risk of intracranial hypertension with particular perioperative features.	[Stocchetti, Nino] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Physiopathol & Transplant, Neuro ICU, Milan, Italy; [Picetti, Edoardo] Azienda Osped Univ Parma, Div Anesthesia & Intens Care, I-43100 Parma, Italy; [Berardino, Maurizio] AOU Citta Salute & Sci, Orthoped & Trauma Hosp, Anesthesia & ICU, Turin, Italy; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Buki, Andras] Clin Neurosci Image Ctr Hungarian Acad Sci HAS, Pecs, Hungary; [Chesnut, Randall M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Chesnut, Randall M.] Univ Washington, Dept Orthopaed Surg, Sch Med, Seattle, WA 98195 USA; [Chesnut, Randall M.] Univ Washington, Sch Global Hlth, Seattle, WA 98195 USA; [Fountas, Kostas N.] Univ Thessaly, Sch Med, Dept Neurosurg, Larisa, Greece; [Horn, Peter] Dr Horst Schmidt Klin HSK, Dept Neurosurg, Wiesbaden, Germany; [Hutchinson, Peter J.; Kolias, Angelos G.] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Hutchinson, Peter J.; Kolias, Angelos G.] Univ Cambridge, Cambridge, England; [Iaccarino, Corrado; Servadei, Franco] Azienda Osped Univ Parma, ASMN IRCCS Reggio Emilia, Div Neurotraumatol Neurosurg, Reggio Emilia, Italy; [Koskinen, Lars-Owe] Umea Univ Hosp, Dept Neurosurg, S-90185 Umea, Sweden; [Latronico, Nicola] Spedali Civil Brescia, Dept Anesthesia & Crit Care Med, Univ Brescia, I-25125 Brescia, Italy; [Maas, Andrews I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Payen, Jean-Francois] CHU Grenoble, Pole Anesthesie Reanimat, F-38043 Grenoble 9, France; [Rosenthal, Guy] Hadassah Hebrew Univ, Dept Neurosurg, Med Ctr, Jerusalem, Israel; [Sahuquillo, Juan] Univ Autonoma Barcelona, Dept Neurosurg, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Signoretti, Stefano] Azienda Osped S Camillo Forlanini, Dept Head & Neck Surg, Div Neurosurg, Rome, Italy; [Soustiel, Jean F.] Bar Ilan Univ, Dept Neurosurg, Galilee Med Ctr, Fac Med, Nahariyya, Israel	Picetti, E (corresponding author), Azienda Osped Univ Parma, Div Anesthesia & Intens Care, Via Gramsci 14, I-43100 Parma, Italy.	edoardopicetti@hotmail.com	Koskinen, Lars-Owe/AAQ-8957-2020; Sahuquillo, Juan/B-3577-2008; Stocchetti, Nino/O-7444-2017; Iaccarino, Corrado/ABE-2361-2020; Signoretti, stefano/AAL-5631-2020; Iaccarino, Corrado/L-3190-2013; Payen, Jean-Francois/L-6667-2014; LATRONICO, Nicola/F-1557-2010	Sahuquillo, Juan/0000-0003-0713-5875; Stocchetti, Nino/0000-0003-3250-6834; Iaccarino, Corrado/0000-0002-5133-6327; Signoretti, stefano/0000-0002-8086-1622; Iaccarino, Corrado/0000-0002-5133-6327; Koskinen, Lars-Owe/0000-0003-3528-8502; Kolias, Angelos/0000-0003-3992-0587; LATRONICO, Nicola/0000-0002-2521-5871; Chesnut, Randall/0000-0001-6377-3666; Servadei, Franco/0000-0002-3595-3464; Hutchinson, Peter/0000-0002-2796-1835	Codman (a division of Ethicon Ltd.); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NIHR-RP-R3-12-013] Funding Source: researchfish	We gratefully acknowledge the financial support by Codman (a division of Ethicon Ltd.)	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bratton SL, 2007, J NEUROTRAUM, V24, pS37; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cortnum S, 2010, NEUROSURGERY, V66, P900, DOI [10.1227/01.NEU.0000367722.66098.21, 10.1227/01. NEU.0000367722.66098.21]; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Hutchinson PJ, 2011, CRIT CARE S1, V15, P312; Iaccarino C, 2008, TELERADIOLOGY, P181; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kolias AG, 2013, BRIT J NEUROSURG, V27, P330, DOI 10.3109/02688697.2013.779365; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Marion DW, 2006, NEUROSURGERY, V58, P655; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Peterson EC, 2011, J TRAUMA, V71, P1588, DOI 10.1097/TA.0b013e31822b791d; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ropper AH, 2012, NEW ENGL J MED, V367, P2539, DOI 10.1056/NEJMe1212289; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Servadei F, 2000, NEUROSURGERY, V46, P70; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Tagliaferri F, 2012, ACTA NEUROCHIR, V154, P919, DOI 10.1007/s00701-012-1318-0; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Zweckberger K, 2011, NEUROL RES, V33, P875, DOI 10.1179/1743132811Y.0000000017	46	48	51	0	17	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	AUG	2014	156	8					1615	1622		10.1007/s00701-014-2127-4			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AM3BA	WOS:000339724900029	24849391				2021-06-18	
J	Ilvesmaki, T; Luoto, TM; Hakulinen, U; Brander, A; Ryymin, P; Eskola, H; Iverson, GL; Ohman, J				Ilvesmaki, Tero; Luoto, Teemu M.; Hakulinen, Ullamari; Brander, Antti; Ryymin, Pertti; Eskola, Hannu; Iverson, Grant L.; Ohman, Juha			Acute mild traumatic brain injury is not associated with white matter change on diffusion tensor imaging	BRAIN			English	Article						concussion; traumatic brain injury; magnetic resonance imaging; diffusion tensor imaging; statistical analysis	POSTTRAUMATIC AMNESIA; AXONAL INJURY; HEAD-INJURY; CONCUSSION; SCALE; DTI	Methodological limitations can confound DTI studies of traumatic brain injury. Using strict enrolment criteria to obtain an exceptionally homogeneous patient sample, Ilvesmaki et al. reveal that mild traumatic brain injury is not associated with DTI abnormalities detectable with tract-based spatial statistics. Changes in DTI measures are, however, seen with age.This study was designed to (i) evaluate the influence of age on diffusion tensor imaging measures of white matter assessed using tract-based spatial statistics; (ii) determine if mild traumatic brain injury is associated with microstructural changes in white matter, in the acute phase following injury, in a large homogenous sample that was carefully screened for pre-injury medical, psychiatric, or neurological problems; and (iii) examine if injury severity is related to white matter changes. Participants were 75 patients with acute mild traumatic brain injury (age = 37.2 +/- 12.0 years, 45 males and 30 females) and 40 controls (age = 40.6 +/- 12.2 yrs, 20 males and 20 females). Age effects were analysed by comparing control subgroups aged 31-40, 41-50, and 51-60 years against a group of 18-30-year-old control subjects. Widespread statistically significant areas of abnormal diffusion tensor measures were observed in older groups. Patients and controls were compared using age and gender as covariates and in age- and gender-matched subgroups. Subgroups of patients with more severe injuries were compared to age-and gender-matched controls. No significant differences were detected in patient-control or severity analyses (all P-value > 0.01). In this large, carefully screened sample, acute mild traumatic brain injury was not associated with diffusion tensor imaging abnormalities detectable with tract-based spatial statistics.	[Ilvesmaki, Tero; Brander, Antti; Eskola, Hannu] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, Tampere, Finland; [Ilvesmaki, Tero; Hakulinen, Ullamari; Eskola, Hannu] Tampere Univ Technol, Dept Elect & Commun Engn, FIN-33101 Tampere, Finland; [Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland; [Hakulinen, Ullamari; Ryymin, Pertti] Tampere Univ Hosp, Dept Radiol & Med Phys, Med Imaging Ctr, Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Ilvesmaki, T (corresponding author), Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, Tampere, Finland.	tero.ilvesmaki@pshp.fi	Luoto, Teemu/W-6468-2018; Eskola, Hannu/G-4279-2014	Luoto, Teemu/0000-0002-7329-3284; Eskola, Hannu/0000-0003-1673-2305; Iverson, Grant/0000-0001-7348-9570; Ohman, Juha/0000-0002-6592-1367	Emil Aaltonen foundation	This work was supported by a grant by the Emil Aaltonen foundation to T.I.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Hakulinen U, 2012, BMC MED IMAGING, V12, DOI 10.1186/1471-2342-12-30; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stadlbauer A, 2008, RADIOLOGY, V247, P179, DOI 10.1148/radiol.2471070707; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yoon B, 2008, ARCH GERONTOL GERIAT, V47, P129, DOI 10.1016/j.archger.2007.07.004	25	48	48	1	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2014	137		7				1876	1882		10.1093/brain/awu095			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AK7ZL	WOS:000338646800015	24818956	Bronze			2021-06-18	
J	Kadom, N; Khademian, Z; Vezina, G; Shalaby-Rana, E; Rice, A; Hinds, T				Kadom, Nadja; Khademian, Zarir; Vezina, Gilbert; Shalaby-Rana, Eglal; Rice, Amy; Hinds, Tanya			Usefulness of MRI detection of cervical spine and brain injuries in the evaluation of abusive head trauma	PEDIATRIC RADIOLOGY			English	Article						Cervical spine; Brain; Child abuse; Magnetic resonance imaging; Pediatric	HYPOXIC-ISCHEMIC INJURY; YOUNG-CHILDREN; SUBDURAL HEMORRHAGE; INFANTS	In the evaluation of children younger than 3 years with intracranial hemorrhage it can be difficult to determine whether the cause of hemorrhage was traumatic, and if so, whether abusive head trauma (AHT) is a possibility. Cervical spine MRI is not a routine part of the nationally recommended imaging workup for children with suspected abusive head trauma. There is increasing evidence that spinal injuries are found at autopsy or MRI in abused children. However the prevalence of cervical spine injuries in children evaluated for abusive head trauma is unknown. We sought to determine both the incidence and the spectrum of cervical spine and brain injuries in children being evaluated for possible abusive head trauma. We also examined the relationship between cervical and brain MRI findings and selected study outcome categories. This study is a 3-year retrospective review of children evaluated for abusive head trauma. Inclusion criteria were: children with head trauma seen at our institution between 2008 and 2010, age younger than 36 months, availability of diagnostic-quality brain and cervical spine MRI, and child abuse team involvement because abusive head trauma was a possibility. A child abuse pediatrician and pediatric radiologists, all with board certification, were involved in data collection, image interpretation and data analysis. Statistical analysis was performed using Stata v12.1. The study included 74 children (43 boys, 31 girls) with a mean age of 164 days (range, 20-679 days). Study outcomes were categorized as: n = 26 children with accidental head trauma, n = 38 with abusive head trauma (n = 18 presumptive AHT, n = 20 suspicious for AHT), and n = 10 with undefined head trauma. We found cervical spine injuries in 27/74 (36%) children. Most cervical spine injuries were ligamentous injuries. One child had intrathecal spinal blood and two had spinal cord edema; all three of these children had ligamentous injury. MRI signs of cervical injury did not show a statistically significant relationship with a study outcome of abusive head trauma or help discriminate between accidental and abusive head trauma. Of the 30 children with supratentorial brain injury, 16 (53%) had a bilateral hypoxic-ischemic pattern. There was a statistically significant relationship between bilateral hypoxic-ischemic brain injury pattern and abusive head trauma (P < 0.05). In addition, the majority (81%) of children with bilateral hypoxic-ischemic brain injuries had cervical injuries. Although detection of cervical spine injuries by MRI does not discriminate between accidental and abusive head trauma, it can help to distinguish a traumatic from non-traumatic intracranial subdural hemorrhage. Cervical MRI should be considered in children with acute intracranial bleeds and otherwise non-contributory history, physical examination and ophthalmological findings. There is a statistically significant relationship between diffuse hypoxic-ischemic brain injury patterns and abusive head trauma. The high incidence of cervical injuries in children with hypoxic-ischemic injuries suggests a causal relationship. Overall, increased utilization of brain and spine MRI in children being evaluated for abusive head trauma can be helpful.	[Kadom, Nadja; Khademian, Zarir; Vezina, Gilbert; Shalaby-Rana, Eglal] Childrens Natl Med Ctr, Dept Diagnost Imaging & Radiol, Washington, DC 20010 USA; [Hinds, Tanya] Childrens Natl Med Ctr, Child & Adolescent Protect Ctr, Washington, DC 20010 USA; [Kadom, Nadja] Boston Univ, Med Ctr, Boston, MA 02118 USA	Kadom, N (corresponding author), Boston Univ, Med Ctr, 820 Harrison Ave,FGH Bldg,3rd Floor, Boston, MA 02118 USA.	nkpiano@gmail.com		Hinds, Tanya/0000-0003-2308-9143			Anderson SE, 2012, RADIOLOGY, V262, P567, DOI 10.1148/radiol.11102115; Boos SC, 2011, CHILD ABUSE NEGLECT, P396; Brennan LK, 2009, J NEUROS-PEDIATR, V3, P232, DOI 10.3171/2008.11.PEDS0835; Brockmeyer DL, 2012, CHILD NERV SYST, V28, P699, DOI 10.1007/s00381-012-1696-x; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; Choudhary AK, 2012, RADIOLOGY, V262, P216, DOI 10.1148/radiol.11102390; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Foerster BR, 2009, J PEDIATR-US, V154, P573, DOI 10.1016/j.jpeds.2008.09.051; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Goradia D, 2007, AM J NEURORADIOL, V28, P209; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hymel Kent P, 2002, Child Maltreat, V7, P329, DOI 10.1177/107755902237263; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kemp AM, 2010, ARCH DIS CHILD, V95, P355, DOI 10.1136/adc.2009.169110; Kemp AM, 2002, ARCH DIS CHILD, V86, P98, DOI 10.1136/adc.86.2.98; Koumellis P, 2009, ARCH DIS CHILD, V94, P216, DOI 10.1136/adc.2008.141671; McKinney AM, 2008, PEDIATR RADIOL, V38, P164, DOI 10.1007/s00247-007-0673-0; Schoenwaelder M, 2009, EMERG RADIOL, V16, P129, DOI 10.1007/s10140-008-0749-7; Zimmerman RA, 2007, J NEURORADIOLOGY, V34, P109, DOI 10.1016/j.neurad.2007.01.124	21	48	48	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	JUL	2014	44	7					839	848		10.1007/s00247-014-2874-7			10	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	AK1XW	WOS:000338213600009	24557483				2021-06-18	
J	Alosco, ML; Fedor, AF; Gunstad, J				Alosco, Michael L.; Fedor, Andrew F.; Gunstad, John			Attention deficit hyperactivity disorder as a risk factor for concussions in NCAA division-I athletes	BRAIN INJURY			English	Article						ADHD; NCAA athletes; risk factors; sports-related concussion	TRAUMATIC BRAIN-INJURY; MEDICINE POSITION STATEMENT; FOOTBALL PLAYERS; CHILDREN; SPORT; HISTORY; SOCIETY; IMPACT	Objective: Sports-related concussions are associated with both acute and long-term consequences. Past work has identified novel risk factors and modifiers for concussions, including mood and neuropsychiatric disorders. Attention Deficit Hyperactivity Disorder (ADHD) is a common neuropsychiatric disorder that may also contribute to concussion risk, although no study has examined this possibility. Methods: One hundred and thirty-nine NCAA Division-I athletes at Kent State University (KSU) self-reported a history of prior concussion and diagnostic history of ADHD as part of a larger concussion management programme at KSU. Results: ADHD was prevalent (10.1%) and 18.0% of the sample reported a prior history of at least one concussion injury. 50.4% of athletes with ADHD reported a history of at least one prior concussion vs 14.4% of athletes without ADHD, which represented a significant difference (p<0.01). Analyses showed that athletes with ADHD were more likely to report a past history of concussions than those without ADHD (F (1,133) = 4.31, p = 0.04). Conclusion: ADHD is prevalent in NCAA Division-I athletes and associated with history of past concussions. If replicated, these findings could have important implications in the prevention and management of concussions in athletes with ADHD.	[Alosco, Michael L.; Fedor, Andrew F.; Gunstad, John] Kent State Univ, Dept Psychol, Kent, OH 44242 USA	Alosco, ML (corresponding author), Kent State Univ, Dept Psychol, Kent, OH 44242 USA.	malosco@kent.edu	Meijer, Anna/K-5118-2016		National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK075119, HL089311]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL089311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK075119, R56DK075119] Funding Source: NIH RePORTER	Indirect support for this work included National Institutes of Health (NIH) grants DK075119 and HL089311. The authors report no conflicts of interest.	Alosco ML, 2012, INT J ATHL THER TRAI, V17, P22, DOI 10.1123/ijatt.17.5.22; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; Bonfield CM, 2013, J NEUROSURG-PEDIATR, V12, P97, DOI 10.3171/2013.5.PEDS12424; Chuang TC, 2013, PSYCHIAT RES-NEUROIM, V211, P186, DOI 10.1016/j.pscychresns.2012.11.008; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; FAIGEL HC, 1995, J ADOLESCENT HEALTH, V16, P174, DOI 10.1016/1054-139X(94)00049-K; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey WJ, 1997, ADAPT PHYS ACT Q, V14, P189, DOI 10.1123/apaq.14.3.189; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Putukian M, 2011, CLIN J SPORT MED, V21, P392, DOI 10.1097/JSM.0b013e3182262eb1	17	48	48	2	22	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2014	28	4					472	474		10.3109/02699052.2014.887145			3	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AF5GL	WOS:000334741900011	24564766				2021-06-18	
J	Gao, S; Zhao, P; Lin, C; Sun, YX; Wang, YL; Zhou, ZC; Yang, DJ; Wang, XL; Xu, HZ; Zhou, F; Cao, LM; Zhou, W; Ning, K; Chen, X; Xu, J				Gao, Shane; Zhao, Peng; Lin, Chao; Sun, Yuxi; Wang, Yilei; Zhou, Zhichong; Yang, Danjing; Wang, Xianli; Xu, Hongzhen; Zhou, Fei; Cao, Limei; Zhou, Wei; Ning, Ke; Chen, Xu; Xu, Jun			Differentiation of Human Adipose-Derived Stem Cells into Neuron-Like Cells Which Are Compatible with Photocurable Three-Dimensional Scaffolds	TISSUE ENGINEERING PART A			English	Article							MARROW STROMAL CELLS; HUMAN BONE-MARROW; IN-VITRO DIFFERENTIATION; MURINE; TISSUE; PROTEIN; PROGENITORS; INCREASE; RAT	Multipotent human adipose-derived stromal/stem cells (hADSCs) hold a great promise for cell-based therapy for many devastating human diseases, such as spinal cord injury and stroke. If exogenous hADSCs can be cultured in a three-dimensional (3D) scaffold with effective proliferation and differentiation capacity, it will better mimic the in vivo environment, which will have profound impact on the therapeutic application of hADSCs. In this study, a group of elastic-dominant, porous bioscaffolds from photocurable chitosan and gelatin were fabricated and proven to be biocompatible with both hADSCs and hADSC-derived neuron-like cells (hADSC-NLCs) in vitro. The identity of harvested hADSCs was confirmed by their positive immunostaining of mesenchymal stem cell surface markers, CD29, CD44, and CD105, and also positive expression of stem markers, Sox-2, Oct-4, c-Myc, Nanog, and Klf4. Their multipotency was further confirmed by trilineage differentiation of hADSCs toward adipocyte, osteoblast, and chondrocyte. It was found that hADSCs could be conditioned to differentiate into neurons in vitro as determined by immunostaining the markers of Tuj1, MAP2, NeuN, and Synapsin. The hADSCs and hADSC-NLCs were proven to be biocompatible with 3D scaffold, which actually facilitated the proliferation and differentiation of hADSCs in vitro, by MTT assay and their neuronal gene expression profiling. Moreover, hADSC-NLCs, which were mixed with 3D scaffold and transplanted into traumatic brain injury mouse model, survived in vivo and led to the better repair of the damaged brain area. The immunohistochemical studies revealed that 3D scaffold indeed improved the viability of transplanted cells, their ability to incorporate into the in vivo neural circuit, and their capacity for tissue repair. This study indicates that hADSCs would have great therapeutic application potential as seeding cells for in vivo transplantation to treat various neurological diseases when co-applied with porous chitosan/gelatin bioscaffolds.	[Gao, Shane; Sun, Yuxi; Wang, Yilei; Zhou, Zhichong; Yang, Danjing; Wang, Xianli; Ning, Ke; Xu, Jun] Tongji Univ, Sch Med, East Hosp, Shanghai 200092, Peoples R China; [Zhao, Peng; Lin, Chao; Xu, Hongzhen; Zhou, Wei] Tongji Univ, Sch Med, Inst Biomed Engn & Nano Sci, Shanghai 200092, Peoples R China; [Zhou, Fei; Cao, Limei; Chen, Xu] Jiangsu Univ, Shanghai Peoples Hosp 8, Shanghai 200233, Peoples R China; [Ning, Ke] Univ Sheffield, Dept Neurosci, Sheffield Inst Translat Neurosci SITranN, Sheffield, S Yorkshire, England	Chen, X (corresponding author), Jiangsu Univ, Shanghai Peoples Hosp 8, Shanghai 200233, Peoples R China.	cxwp65@163.com; xunymc2000@yahoo.com	Ning, Ke/B-4561-2009	Ning, Ke/0000-0002-0771-1134	Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2010CB945200, 2012CB966300, 2011CB966200]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271369, 81070910]; National program for support of Top-notch young professionals; New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET) [NCET-10-0606]; Shanghai Rising-Star program [11QA1407100]; Projects of International Cooperation and Exchanges NSFC [81261130318]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities	This study is supported by the following grants: the Ministry of Science and Technology of China (2010CB945200, 2012CB966300, 2011CB966200); the National Natural Science Foundation of China (81271369, 81070910); National program for support of Top-notch young professionals; New Century Excellent Talents in University (NCET-10-0606); Shanghai Rising-Star program (11QA1407100); Projects of International Cooperation and Exchanges NSFC (81261130318); and the Fundamental Research Funds for the Central Universities.	Ashjian PH, 2003, PLAST RECONSTR SURG, V111, P1922, DOI 10.1097/01.PRS.0000055043.62589.05; Case J, 2005, ANN NY ACAD SCI, V1044, P183, DOI 10.1196/annals.1349.024; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Figueroa MP, 2007, MICRON, V38, P668, DOI 10.1016/j.micron.2006.08.004; Fujimura J, 2005, BIOCHEM BIOPH RES CO, V333, P116, DOI 10.1016/j.bbrc.2005.05.096; Gao S, 2009, INT J MED MUSHROOMS, V11, P1, DOI 10.1615/IntJMedMushr.v11.i1.10; Germain N, 2010, J CELL BIOCHEM, V111, P535, DOI 10.1002/jcb.22747; Gong HP, 2000, J BIOMED MATER RES, V52, P285; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138; Guilak F, 2006, J CELL PHYSIOL, V206, P229, DOI 10.1002/jcp.20463; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Gupta AN, 2007, J PHYS CHEM B, V111, P10137, DOI 10.1021/jp070745s; Cardozo AJ, 2011, J MOL NEUROSCI, V44, P186, DOI 10.1007/s12031-011-9503-9; Leipzig ND, 2009, BIOMATERIALS, V30, P6867, DOI 10.1016/j.biomaterials.2009.09.002; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Pemg CK, 2008, J BIOMED MATER RES A, V84A, P622, DOI 10.1002/jbm.a.31291; Ribeiro D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015786; Rosso F, 2005, J CELL PHYSIOL, V203, P465, DOI 10.1002/jcp.20270; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Safford KM, 2004, EXP NEUROL, V187, P319, DOI 10.1016/j.expneurol.2004.01.027; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Schmitt C, 1998, CRIT REV FOOD SCI, V38, P689, DOI 10.1080/10408699891274354; Schwartz Z, 2011, AM J VET RES, V72, P42, DOI 10.2460/ajvr.72.1.42; Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587; Suon S, 2004, STEM CELLS DEV, V13, P625, DOI 10.1089/scd.2004.13.625; Takeuchi S, 2013, TURK NEUROSURG, V23, P349, DOI 10.5137/1019-5149.JTN.7023-12.1; Welstead G Grant, 2008, J Vis Exp, DOI 10.3791/734; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yaghoobi MM, 2005, NEUROSCI LETT, V390, P81, DOI 10.1016/j.neulet.2005.08.011; Yamamoto M, 2003, BIOMATERIALS, V24, P4375, DOI 10.1016/S0142-9612(03)00337-5; Yang LQ, 2011, NEUROREPORT, V22, P370, DOI 10.1097/WNR.0b013e3283469615; Yuan Y, 2004, BIOMATERIALS, V25, P4273, DOI 10.1016/j.biomaterials.2003.11.029; ZEMAN L, 1972, MACROMOLECULES, V5, P513, DOI 10.1021/ma60028a030; Zhu YX, 2008, CELL BIOCHEM FUNCT, V26, P664, DOI 10.1002/cbf.1488; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	41	48	50	1	31	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341	1937-335X		TISSUE ENG PT A	Tissue Eng. Part A	APR 1	2014	20	7-8					1271	1284		10.1089/ten.tea.2012.0773			14	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Cell Biology; Engineering; Materials Science	AE6NG	WOS:000334110000015	24251600	Green Published			2021-06-18	
J	Gerber, MR; Iverson, KM; Dichter, ME; Klap, R; Latta, RE				Gerber, Megan R.; Iverson, Katherine M.; Dichter, Melissa E.; Klap, Ruth; Latta, Rachel E.			Women Veterans and Intimate Partner Violence: Current State of Knowledge and Future Directions	JOURNAL OF WOMENS HEALTH			English	Article							CARDIOVASCULAR-DISEASE; HIGH-RISK; QUITLINES; HEALTH	Intimate partner violence (IPV) is a serious public health concern for all; however, women who experience IPV are more likely to sustain injury and report adverse health consequences. An expanding body of research suggests that experience of IPV is common in women veterans (WV), particularly those who access Veterans Health Administration (VA) services. With unprecedented numbers of women serving in the military and subsequently becoming veterans, it is critical that clinicians and advocates caring for WV understand the impact of IPV on this population. WV have unique risk factors for experiencing IPV, including high rates of premilitary trauma, as well as military sexual trauma and posttraumatic stress disorder (PTSD). Correlates of IPV, traumatic brain injury (TBI) and homelessness, are common among this group. Although research on WV health and IPV is emergent, evidence suggests that IPV results in multiple health sequelae and increased healthcare utilization. In this context, we next discuss clinical and policy implications for VA. A number of targeted interventions and treatments are available for WV who experience IPV, including evidence-based mental health services. VA is well situated to implement screening programs for WV to facilitate referral to needed services and treatments available both within and outside its facilities. As the population of WV expands, future research will be needed to determine best practices; many avenues of inquiry exist. Finally, WV are strong and resilient; it is crucial that those who work with them recognize evidence of IPV and refer to needed services and evidence-based treatment to enable strength-based recovery.	[Gerber, Megan R.] VA Boston Healthcare Syst, Women Vet Hlth Program, Boston, MA USA; [Gerber, Megan R.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Dichter, Melissa E.] Philadelphia VA Med Ctr, VA Ctr Hlth Equ Res & Promot CHERP, Philadelphia, PA USA; [Klap, Ruth] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA; [Latta, Rachel E.] Edith Nourse Rogers Mem Vet Adm Hosp, New England Mental Illness Res Educ & Clin Ctr MI, Bedford, MA 01730 USA	Gerber, MR (corresponding author), VA Boston Healthcare Syst, Women Vet Hlth Program, 150 South Huntington Ave PC11, Jamaica Plain, MA 01230 USA.	Megan.gerber@va.gov	Dichter, Melissa/AAC-5054-2021; Gerber, Megan/N-1418-2016	Gerber, Megan/0000-0002-8444-5554	VA Health Services Research and Development (HSRD)US Department of Veterans Affairs [CDA-10-029]; VA HSR&D Career Development Award [CDA-10-202]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSRD SDR [10-012]; Department of Veterans Affairs, Patient Care Services, Women's Health ServicesUS Department of Veterans Affairs	Funding was provided by VA Health Services Research and Development (HSR&D) Career Development Award CDA-10-029 (KI); VA HSR&D Career Development Award CDA-10-202 (MD); and Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSR&D SDR 10-012 (RK). This work was also supported in part by the Department of Veterans Affairs, Patient Care Services, Women's Health Services (RK). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.	American Heart Association, 2013, STAT FACT SHEET WOM; Centers for Disease Control and Prevention, GLANC 2011 TOB US TA; Centers for Disease Control and Prevention, 2013, WOM HEART DIS FACT S; Centers for Disease Control and Prevention, 2014, BEST PRACT COMPR TOB; Centers for Disease Control and Prevention, 2010, EL DISP CARD HLTH CV; Fiore M., 2008, TREATING TOBACCO USE; Heisch J, 2009, JUNEAU EMPIRE   1007; Hemingway H, 2008, CIRCULATION, V117, P1526, DOI 10.1161/CIRCULATIONAHA.107.720953; Howard G, 2008, STROKE, V39, P283, DOI 10.1161/STROKEAHA.107.510529; Howard G, 2007, ANN EPIDEMIOL, V17, P689, DOI 10.1016/j.annepidem.2007.03.019; Juneau Borough Clerk, 2009, OCT OFF EL RES; Keller PA, 2010, PREV CHRONIC DIS, V7; Mobley LR, 2006, AM J PREV MED, V30, P327, DOI 10.1016/j.amepre.2005.12.001; Mosca L, 2006, CIRCULATION, V113, P525, DOI 10.1161/CIRCULATIONAHA.105.588103; North American Quitline Consortium, OV NAQC 2009 ANN SUR; Ossip-Klein DJ, 2003, AM J MED SCI, V326, P201, DOI 10.1097/00000441-200310000-00010; US Department of Health and Human Services, 2014, HLTH CONS SMOK 50 YE; Vaid I, 2011, J WOMENS HEALTH, V20, P977, DOI 10.1089/jwh.2011.2850; Vidrine JI, 2013, JAMA INTERN MED, V173, P458, DOI 10.1001/jamainternmed.2013.3751; Warner DD, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110343	20	48	48	0	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	APR 1	2014	23	4					302	309		10.1089/jwh.2013.4513			8	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	AE4EO	WOS:000333934900132	24506440				2021-06-18	
J	Senol, N; Naziroglu, M; Yuruker, V				Senol, Nilgun; Naziroglu, Mustafa; Yuruker, Vehbi			N-Acetylcysteine and Selenium Modulate Oxidative Stress, Antioxidant Vitamin and Cytokine Values in Traumatic Brain Injury-Induced Rats	NEUROCHEMICAL RESEARCH			English	Article						Antioxidants; Inflammation; N-acetylcysteine; Oxidative stress; Traumatic brain injury; Selenium	DORSAL-ROOT GANGLION; MOLECULAR PATHWAYS; SPINAL-CORD; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; CELL-DEATH; IN-VITRO; ACTIVATION; CHANNELS; ACID	It has been suggested that oxidative stress plays an important role in the pathophysiology of traumatic brain injury (TBI). N-acetylcysteine (NAC) and selenium (Se) display neuroprotective activities mediated at least in part by their antioxidant and anti-inflammatory properties although there is no report on oxidative stress, antioxidant vitamin, interleukin-1 beta (IL)-1 beta and IL-4 levels in brain and blood of TBI-induced rats. We investigated effects of NAC and Se administration on physical injury-induced brain toxicity in rats. Thirty-six male Sprague-Dawley rats were equally divided into four groups. First and second groups were used as control and TBI groups, respectively. NAC and Se were administrated to rats constituting third and forth groups at 1, 24, 48 and 72 h after TBI induction, respectively. At the end of 72 h, plasma, erythrocytes and brain cortex samples were taken. TBI resulted in significant increase in brain cortex, erythrocytes and plasma lipid peroxidation, total oxidant status (TOS) in brain cortex, and plasma IL-1 beta values although brain cortex vitamin A, beta-carotene, vitamin C, vitamin E, reduced glutathione (GSH) and total antioxidant status (TAS) values, and plasma vitamin E concentrations, plasma IL-4 level and brain cortex and erythrocyte glutathione peroxidase (GSH-Px) activities decreased by TBI. The lipid peroxidation and IL-1 beta values were decreased by NAC and Se treatments. Plasma IL-4, brain cortex GSH, TAS, vitamin C and vitamin E values were increased by NAC and Se treatments although the brain cortex vitamin A and erythrocyte GSH-Px values were increased through NAC only. In conclusion, NAC and Se caused protective effects on the TBI-induced oxidative brain injury and interleukin production by inhibiting free radical production, regulation of cytokine-dependent processes and supporting antioxidant redox system.	[Senol, Nilgun; Yuruker, Vehbi] Suleyman Demirel Univ, Fac Med, Dept Surg, TR-32200 Isparta, Turkey; [Naziroglu, Mustafa] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey	Naziroglu, M (corresponding author), Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.	mustafanaziroglu@sdu.edu.tr					Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Caliskan AM, 2010, J MEMBRANE BIOL, V237, P51, DOI 10.1007/s00232-010-9305-y; Cimen MYB, 2008, CLIN CHIM ACTA, V390, P1, DOI 10.1016/j.cca.2007.12.025; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; DESAI ID, 1984, METHOD ENZYMOL, V105, P138, DOI 10.1016/S0076-6879(84)05019-9; Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015; Fang KM, 2013, BIOL TRACE ELEM RES, V152, P66, DOI 10.1007/s12011-012-9596-1; Freire MAM, 2012, W INDIAN MED J, V61, P751; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; JAGOTA SK, 1982, ANAL BIOCHEM, V127, P178, DOI 10.1016/0003-2697(82)90162-2; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Joshi YB, 2012, BIOFACTORS, V38, P90, DOI 10.1002/biof.195; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Lee HP, 2009, EXPERT REV NEUROTHER, V9, P1615, DOI 10.1586/ERN.09.86; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marini H, 2004, EXP NEUROL, V188, P178, DOI 10.1016/j.expneurol.2004.03.023; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Moore M, 2013, SOC WORK HEALTH CARE, V52, P498, DOI 10.1080/00981389.2012.714447; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Naziroglu M, 2013, NEUROSCIENCE, V242, P151, DOI 10.1016/j.neuroscience.2013.03.032; Naziroglu M, 2004, TOXICOLOGY, V195, P221, DOI 10.1016/j.tox.2003.10.012; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2013, CELL MOL NEUROBIOL, V33, P589, DOI 10.1007/s10571-013-9936-5; Naziroglu M, 2012, BIOL TRACE ELEM RES, V150, P3, DOI 10.1007/s12011-012-9479-5; Naziroglu M, 2012, NEUROCHEM RES, V37, P2065, DOI 10.1007/s11064-012-0850-x; Naziroglu M, 2012, J RECEPT SIG TRANSD, V32, P134, DOI 10.3109/10799893.2012.672994; Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4; Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8; Naziroglu M, 2008, J MEMBRANE BIOL, V225, P39, DOI 10.1007/s00232-008-9132-6; Oksay T, 2013, ANDROLOGIA, V45, P171, DOI 10.1111/j.1439-0272.2012.01329.x; Ozgul C, 2012, PHYSIOL BEHAV, V106, P122, DOI 10.1016/j.physbeh.2012.01.014; Ozmen I, 2007, NEUROCHEM RES, V32, P19, DOI 10.1007/s11064-006-9217-5; Paredes SD, 2009, AGE, V31, P179, DOI 10.1007/s11357-009-9107-2; PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SUZUKI J, 1990, JPN J VET SCI, V52, P1281; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Yeo JE, 2008, CELL PHYSIOL BIOCHEM, V21, P225, DOI 10.1159/000113764; Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004; Zhang LJ, 2012, NEUROCHEM INT, V61, P1220, DOI 10.1016/j.neuint.2012.09.002	45	48	49	1	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	APR	2014	39	4					685	692		10.1007/s11064-014-1255-9			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AD6JN	WOS:000333365000008	24519543				2021-06-18	
J	Thelin, EP; Nelson, DW; Bellander, BM				Thelin, Eric P.; Nelson, David W.; Bellander, Bo-Michael			Secondary Peaks of S100B in Serum Relate to Subsequent Radiological Pathology in Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						S100B; Biomarkers; Neuro-intensive care; Traumatic brain injury; Secondary injury; Outcome	CRITICALLY-ILL PATIENTS; PROGNOSTIC VALUE; INTRAHOSPITAL TRANSPORT; COMPUTED-TOMOGRAPHY; CEREBRAL INFARCTION; S-100B PROTEIN; RISK-FACTORS; HEAD-INJURY; DAMAGE; INSULTS	Patients suffering from severe traumatic brain injury (TBI) often develop secondary brain lesions that may worsen outcome. S100B, a biomarker of brain damage, has been shown to increase in response to secondary cerebral deterioration. The aim of this study was to analyze the occurrence of secondary increases in serum levels of S100B and their relation to potential subsequent radiological pathology present on CT/MRI-scans. Retrospective study from a trauma level 1 hospital, neuro-intensive care unit. 250 patients suffering from TBI were included. Inclusion required a minimum of two radiological examinations and at least three serum samples of S100B, with at least one > 48 h after trauma. Secondary pathological findings on CT/MRI, present in 39 % (n = 98) of the patients, were highly correlated to secondary increases of a parts per thousand yen0.05 mu g/L S100B (P < 0.0001, pseudo-R (2) 0.532). Significance remained also after adjusting for known important TBI predictors. In addition, secondary radiological findings were significantly correlated to outcome (Glasgow Outcome Score, GOS) in uni-(P < 0.0001, pseudo-R (2) 0.111) and multivariate analysis. The sensitivity and specificity of detecting later secondary radiological findings was investigated at three S100B cut-off levels: 0.05, 0.1, and 0.5 mu g/L. A secondary increase of a parts per thousand yen0.05 mu g/L had higher sensitivity (80 %) but lower specificity (89 %), compared with a secondary increase of a parts per thousand yen0.5 mu g/L (16 % sensitivity, 98 % specificity), to detect secondary radiological findings. Secondary increases in serum levels of S100B, even as low as a parts per thousand yen0.05 mu g/L, beyond 48 h after TBI are strongly correlated to the development of clinically significant secondary radiological findings.	[Thelin, Eric P.; Bellander, Bo-Michael] Karolinska Inst, Karolinska Univ Hosp Solna, Sect Neurosurg, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Nelson, David W.] Karolinska Inst, Sect Anesthesiol & Intens Care, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Thelin, EP (corresponding author), Karolinska Inst, Karolinska Univ Hosp Solna, Sect Neurosurg, Dept Clin Neurosci, R2 02, S-17176 Stockholm, Sweden.	eric.thelin@ki.se; david.nelson@karolinska.se; bo-michael.bellander@karolinska.se	Viani, Rafael/V-1196-2018; Thelin, Eric Peter/K-2144-2012	Thelin, Eric Peter/0000-0002-2338-4364			Acker JE, 2004, ADV TRAUMA LIFE SUPP; Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bouvier D, 2012, ANN BIOL CLIN-PARIS, V70, P269, DOI 10.1684/abc.2012.0701; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Einav S, 2008, BMC CLIN PATHOL, V8, DOI 10.1186/1472-6890-8-9; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gunnarsson T, 2000, Neurosurg Focus, V9, pe5; HAIMOTO H, 1987, LAB INVEST, V57, P489; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Lovell MA, 2001, ANAESTH INTENS CARE, V29, P400, DOI 10.1177/0310057X0102900412; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1990, ACT NEUR S, V51, P300; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Moritz S, 2010, J NEUROSURG ANESTH, V22, P21, DOI 10.1097/ANA.0b013e3181bdf50d; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Persson Malin Elisabet, 2012, Front Neurol, V3, P170, DOI 10.3389/fneur.2012.00170; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; TEASDALE G, 1974, LANCET, V2, P81; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Tong WS, 2012, BRAIN INJURY, V26, P1136, DOI 10.3109/02699052.2012.666437; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; USUI A, 1989, CLIN CHEM, V35, P1942; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	64	48	49	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2014	20	2					217	229		10.1007/s12028-013-9916-0			13	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AD0XA	WOS:000332956400007	24146416				2021-06-18	
J	Huang, MX; Nichols, S; Baker, DG; Robb, A; Angeles, A; Yurgil, KA; Drake, A; Levy, M; Song, T; Mclay, R; Theilmann, RJ; Diwakar, M; Risbrough, VB; Ji, ZW; Huang, C; Chang, DG; Harrington, DL; Muzzatti, L; Canive, JM; Edgar, JC; Chen, YH; Lee, RR				Huang, Ming-Xiong; Nichols, Sharon; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Drake, Angela; Levy, Michael; Song, Tao; McLay, Robert; Theilmann, Rebecca J.; Diwakar, Mithun; Risbrough, Victoria B.; Ji, Zhengwei; Huang, CharlesW.; Chang, Douglas G.; Harrington, Deborah L.; Muzzatti, Laura; Canive, Jose M.; Edgar, J. Christopher; Chen, Yu-Han; Lee, Roland R.			Single-subject-based whole-brain MEG slow-wave imaging approach for detecting abnormality in patients with mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Magnetoencephalography; Traumatic brain injury; Slow-wave; Blast; Axonal injury	DIFFUSE AXONAL INJURY; SIGNAL SPACE SEPARATION; WHITE-MATTER INJURY; HEAD-INJURY; DELTA WAVES; POSTCONCUSSIVE SYNDROME; CLINICAL MANAGEMENT; STATE; MAGNETOENCEPHALOGRAPHY; LOCALIZATION	Traumatic brain injury (TBI) is a leading cause of sustained impairment in military and civilian populations. However, mild TBI (mTBI) can be difficult to detect using conventional MRI or CT. Injured brain tissues in mTBI patients generate abnormal slow-waves (1-4 Hz) that can be measured and localized by resting-state magnetoencephalography (MEG). In this study, we develop a voxel-based whole-brain MEG slow-wave imaging approach for detecting abnormality in patients with mTBI on a single-subject basis. A normative database of resting-state MEG source magnitude images (1-4 Hz) from 79 healthy control subjects was established for all brain voxels. The high resolution MEG source magnitude images were obtained by our recent Fast-VESTAL method. In 84 mTBI patients with persistent post-concussive symptoms (36 from blasts, and 48 from non-blast causes), our method detected abnormalities at the positive detection rates of 84.5%, 86.1%, and 83.3% for the combined (blast-induced plus with non-blast causes), blast, and non-blastmTBI groups, respectively. We found that prefrontal, posterior parietal, inferior temporal, hippocampus, and cerebella areas were particularly vulnerable to head trauma. The result also showed that MEG slow-wave generation in prefrontal areas positively correlated with personality change, trouble concentrating, affective lability, and depression symptoms. Discussion is provided regarding the neuronal mechanisms of MEG slow-wave generation due to deafferentation caused by axonal injury and/or blockages/limitations of cholinergic transmission in TBI. This study provides an effective way for using MEG slow-wave source imaging to localize affected areas and supports MEG as a tool for assisting the diagnosis of mTBI. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license	[Huang, Ming-Xiong; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Risbrough, Victoria B.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Risbrough, Victoria B.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Risbrough, Victoria B.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Huang, Ming-Xiong; Song, Tao; Theilmann, Rebecca J.; Diwakar, Mithun; Ji, Zhengwei; Harrington, Deborah L.; Muzzatti, Laura; Lee, Roland R.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92121 USA; [Nichols, Sharon] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92121 USA; [Baker, Dewleen G.; Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92121 USA; [Baker, Dewleen G.; Risbrough, Victoria B.] VA Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Drake, Angela] Natl Univ, San Diego, CA USA; [Levy, Michael] Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92121 USA; [McLay, Robert] Naval Med Ctr San Diego, San Diego, CA USA; [Huang, CharlesW.] Westview High Sch, San Diego, CA USA; [Chang, Douglas G.] Univ Calif San Diego, Dept Orthopaed, San Diego, CA 92121 USA; [Canive, Jose M.] New Mexico VA Healthcare Syst, Albuquerque, NM USA; [Canive, Jose M.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA; [Canive, Jose M.] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; [Edgar, J. Christopher; Chen, Yu-Han] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Edgar, J. Christopher; Chen, Yu-Han] Univ Penn, Philadelphia, PA 19104 USA	Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Risbrough, Victoria/X-3344-2019; Levy, Michael/AAL-4647-2020; Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838; Chang, Douglas/0000-0001-7006-6206	Department of Veterans AffairsUS Department of Veterans Affairs [I01-CX000499, NURC-022-10F, NEUC-044-06S]; National Football League Charity Grant [20105076]; McDonnell Foundation via Brain Trauma Foundation [220020185]; MRS-II from Headquarters Marine Corps [N62645-11-C-4037]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007198] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000499, I01CX000146] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Grants from the Department of Veterans Affairs to M.X. Huang (I01-CX000499, NURC-022-10F, NEUC-044-06S), D.L. Harrington (I01-CX000146), National Football League Charity Grant (20105076, M. X. Huang and R. R. Lee), McDonnell Foundation via Brain Trauma Foundation (220020185, PI: J. Ghajar, site PIs: R.R. Lee and M.X. Huang), and MRS-II (Navy BUMED contract #N62645-11-C-4037) from Headquarters Marine Corps (D.G. Baker, M.A. Geyer, M.X. Huang, V.B. Risbrough). We acknowledge the MRS-II administrative core, Anjana Patel, Andrew De La Rosa, and members of the MRS-II Team, including logistic coordinators, clinician-interviewers, and data collection staff. We thank the staff at the Veterans Medical Research Foundation (VRMF). We also thank the Marine and veteran volunteers for military service and participation in this study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson N. R., 2013, PHYSL BEHAV; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cohen D., 2002, P 13 INT C BIOM, P919; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Downing PE, 2001, SCIENCE, V293, P2470, DOI 10.1126/science.1063414; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fisch B., 1999, FISCH SPEHLMANNS EEG; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Huang M, 1998, EVOKED POTENTIAL, V108, P32, DOI 10.1016/S0168-5597(97)00091-9; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE, V84, P585, DOI 10.1016/j.neuroimage.2013.09.022; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang MX, 2006, NEUROIMAGE, V31, P1025, DOI 10.1016/j.neuroimage.2006.01.029; Huang MX, 2005, NEUROIMAGE, V28, P99, DOI 10.1016/j.neuroimage.2005.05.036; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; Niedermeyer E, 2005, ELECTROENCEPHALOGRAP; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson S.E., 1999, RECENT ADV BIOMAGNET, P302, DOI DOI 10.1016/J.NEUROIMAGE.2018.05.016; Rockstroh BS, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-44; Rowan A.J., 2003, PRIMER EEG MINI ATLA; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Schaul N, 1998, ELECTROEN CLIN NEURO, V106, P101, DOI 10.1016/S0013-4694(97)00111-9; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Sekihara K, 2001, IEEE T BIO-MED ENG, V48, P760, DOI 10.1109/10.930901; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S, 2004, Neurol Clin Neurophysiol, V2004, P35; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Weiner KS, 2010, NEUROIMAGE, V52, P1559, DOI 10.1016/j.neuroimage.2010.04.262; Wienbruch C, 2007, J NEUROSCI METH, V163, P119, DOI 10.1016/j.jneumeth.2007.02.018; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	75	48	48	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						109	119		10.1016/j.nicl.2014.06.004			11	Neuroimaging	Neurosciences & Neurology	CB5LF	WOS:000349667800014	25009772	DOAJ Gold, Green Published			2021-06-18	
J	Susarla, BTS; Villapol, S; Yi, JH; Geller, HM; Symes, AJ				Susarla, Bala T. S.; Villapol, Sonia; Yi, Jae-Hyuk; Geller, Herbert M.; Symes, Aviva J.			Temporal patterns of cortical proliferation of glial cell populations after traumatic brain injury in mice	ASN NEURO			English	Article						astrocytes; BrdU; microglia; neurogenesis; NG2; proliferation; traumatic brain injury (TBI)	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; ENHANCED NEUROGENESIS; SUBVENTRICULAR ZONE; EXPRESSING CELLS; IMPACT INJURY; SPINAL-CORD; SCAR; ASTROCYTES; MICROGLIA	TBI (traumatic brain injury) triggers an inflammatory cascade, gliosis and cell proliferation following cell death in the pericontusional area and surrounding the site of injury. In order to better understand the proliferative response following CCI (controlled cortical impact) injury, we systematically analyzed the phenotype of dividing cells at several time points post-lesion. C57BL/6 mice were subjected to mild to moderate CCI over the left sensory motor cortex. At different time points following injury, mice were injected with BrdU (bromodeoxyuridine) four times at 3-h intervals and then killed. The greatest number of proliferating cells in the pericontusional region was detected at 3 dpi (days post-injury). At 1 dpi, NG2(+) cells were the most proliferative population, and at 3 and 7 dpi the Iba-1(+) microglial cells were proliferating more. A smaller, but significant number of GFAP(+) (glial fibrillary acidic protein) astrocytes proliferated at all three time points. Interestingly, at 3 dpi we found a small number of proliferating neuroblasts [DCX+ (doublecortin)] in the injured cortex. To determine the cell fate of proliferative cells, mice were injected four times with BrdU at 3 dpi and killed at 28 dpi. Approximately 70% of proliferative cells observed at 28 dpi were GFAP+ astrocytes. In conclusion, our data suggest that the specific glial cell types respond differentially to injury, suggesting that each cell type responds to a specific pattern of growth factor stimulation at each time point after injury.	[Susarla, Bala T. S.; Villapol, Sonia; Yi, Jae-Hyuk; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Susarla, Bala T. S.; Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Yi, Jae-Hyuk; Geller, Herbert M.] NHLBI, Dev Neurobiol Sect, Div Intramural Res, NIH, Bethesda, MD 20892 USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Symes, Aviva/S-7471-2016	Symes, Aviva/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113; Geller, Herbert/0000-0002-7048-6144	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300604-11.0-60855]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZIAHL006021] Funding Source: NIH RePORTER	This work was funded by a grant from the Center for Neuroscience and Regenerative Medicine [grant number 300604-11.0-60855].	ADRIAN EK, 1962, J NEUROPATH EXP NEUR, V21, P597, DOI 10.1097/00005072-196210000-00007; Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Beach JR, 1999, OCCUP MED-OXFORD, V49, P377, DOI 10.1093/occmed/49.6.377; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butt AM, 2005, J ANAT, V207, P695, DOI 10.1111/j.1469-7580.2005.00458.x; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cao Y, 1999, TALANTA, V49, P377, DOI 10.1016/S0039-9140(98)00386-5; CAVANAGH JB, 1970, J ANAT, V106, P471; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gensert JM, 2001, J NEUROBIOL, V48, P75, DOI 10.1002/neu.1043; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Liu L, 2000, EXP BRAIN RES, V131, P64, DOI 10.1007/s002219900273; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marin-Teva JL, 2011, NEURON GLIA BIOL, V7, P25, DOI 10.1017/S1740925X12000014; Nakagomi T, 2012, STEM CELLS DEV, V21, P2350, DOI 10.1089/scd.2011.0657; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Qiu Lin, 2007, Neurosci Bull, V23, P46, DOI 10.1007/s12264-007-0007-0; Qu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067094; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhu XQ, 2008, NEURON GLIA BIOL, V4, P19, DOI 10.1017/S1740925X09000015	59	48	48	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro		2014	6	3							e00143	10.1042/AN20130034			12	Neurosciences	Neurosciences & Neurology	AJ2BT	WOS:000337460700003	24670035	DOAJ Gold, Green Published			2021-06-18	
J	Bedi, SS; Hetz, R; Thomas, C; Smith, P; Olsen, AB; Williams, S; Xue, HS; Aroom, K; Uray, K; Hamilton, J; Mays, RW; Cox, CS				Bedi, Supinder S.; Hetz, Robert; Thomas, Chelsea; Smith, Philippa; Olsen, Alex B.; Williams, Stephen; Xue, Hasen; Aroom, Kevin; Uray, Karen; Hamilton, Jason; Mays, Robert W.; Cox, Charles S., Jr.			Intravenous Multipotent Adult Progenitor Cell Therapy Attenuates Activated Microglial/Macrophage Response and Improves Spatial Learning After Traumatic Brain Injury	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Adult stem cells; Neuroimmune; Rat model; Stem/progenitor cell	MARROW MONONUCLEAR-CELLS; MOUSE SPINAL-CORD; INFLAMMATORY RESPONSE; TNF-ALPHA; MICROGLIA; NEUROINFLAMMATION; ASTROCYTES; EXPRESSION; DAMAGE; RATS	We previously demonstrated that the intravenous delivery of multipotent adult progenitor cells (MAPCs) after traumatic brain injury (TBI) in rodents provides neuroprotection by preserving the blood-brain barrier and systemically attenuating inflammation in the acute time frame following cell treatment; however, the long-term behavioral and anti-inflammatory effects of MAPC administration after TBI have yet to be explored. We hypothesized that the intravenous injection of MAPCs after TBI attenuates the inflammatory response (as measured by microglial morphology) and improves performance at motor tasks and spatial learning (Morris water maze [MWM]). MAPCs were administered intravenously 2 and 24 hours after a cortical contusion injury (CCI). We tested four groups at 120 days after TBI: sham (uninjured), injured but not treated (CCI), and injured and treated with one of two concentrations of MAPCs, either 2 million cells per kilogram (CCI-2) or 10 million cells per kilogram (CCI-10). CCI-10 rats showed significant improvement in left hind limb deficit on the balance beam. On the fifth day of MWM trials, CCI-10 animals showed a significant decrease in both latency to platform and distance traveled compared with CCI. Probe trials revealed a significant decrease in proximity measure in CCI-10 compared with CCI, suggesting improved memory retrieval. Neuroinflammation was quantified by enumerating activated microglia in the ipsilateral hippocampus. We observed a significant decrease in the number of activated microglia in the dentate gyrus in CCI-10 compared with CCI. Our results demonstrate that intravenous MAPC treatment after TBI in a rodent model offers long-term improvements in spatial learning as well as attenuation of neuroinflammation.	[Bedi, Supinder S.; Hetz, Robert; Thomas, Chelsea; Smith, Philippa; Olsen, Alex B.; Williams, Stephen; Xue, Hasen; Aroom, Kevin; Uray, Karen; Cox, Charles S., Jr.] Univ Texas Houston, Dept Pediat Surg, Hlth Sci Ctr Houston, Houston, TX USA; [Hetz, Robert; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Houston, Dept Surg, Hlth Sci Ctr Houston5, Houston, TX USA; [Hamilton, Jason; Mays, Robert W.] Athersys Inc, Cleveland, OH USA; [Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA	Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu		Uray, Karen/0000-0001-6997-459X; Aroom, Kevin/0000-0003-1504-0585	Small Business Innovation Research (SBIR)United States Department of Agriculture (USDA); Athersys [NIH SBIR 1U44-NS077511-01]; Brown Foundation, Inc.; Children's Memorial Hermann Hospital Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS077511] Funding Source: NIH RePORTER	We thank Dr. Pramod Dash for advice on the spatial learning experiments. This project was funded by a Small Business Innovation Research (SBIR) agreement with Athersys (NIH SBIR 1U44-NS077511-01) and by grants from the Brown Foundation, Inc., and the Children's Memorial Hermann Hospital Foundation.	Bannerman DM, 2012, NAT NEUROSCI, V15, P1153, DOI 10.1038/nn.3166; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Belarbi K, 2012, BRAIN BEHAV IMMUN, V26, P18, DOI 10.1016/j.bbi.2011.07.225; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; GAYTAN F, 1994, J ANDROL, V15, P558; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Savitz SI, 2011, ANN NEUROL, V70, P59, DOI 10.1002/ana.22458; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; Terry AV, 2009, FRONT NEUROSCI, P267; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Xuan AG, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-202	36	48	49	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	DEC	2013	2	12					953	960		10.5966/sctm.2013-0100			8	Cell & Tissue Engineering	Cell Biology	263JH	WOS:000327804400009	24191266	DOAJ Gold, Green Published			2021-06-18	
J	Izzy, S; Compton, R; Carandang, R; Hall, W; Muehlschlegel, S				Izzy, Saef; Compton, Rebecca; Carandang, Raphael; Hall, Wiley; Muehlschlegel, Susanne			Self-Fulfilling Prophecies Through Withdrawal of Care: Do They Exist in Traumatic Brain Injury, Too?	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Withdrawal of care; Prognostication; Self-fulfilling prophecies	PROGNOSTICATION; SUPPORT; IMPACT	We examined factors associated with withdrawal of care (WOC) in moderate-severe traumatic brain injury (msTBI) patients, and how WOC may affect short-term mortality and receipt of neurosurgery. Variability in msTBI-related outcome prognostication by clinicians from different specialties was also assessed. Rates of WOC, factors associated with WOC, and the relation between WOC and in-hospital case-fatality rate (CFR) and neurosurgery were determined in 232 prospectively enrolled msTBI patients in the ongoing OPTIMISM Study at a level-1 trauma center. In a concomitant web-based survey with clinical vignettes, outcome prognostication comfort, treatment aggressiveness, and WOC recommendations were examined among 106 respondents from neurology, neurocritical care, neurosurgery, trauma and anesthesia/critical care. The average age of the study sample was 53 years, with a median Glasgow Coma Scale of 6. The in-hospital CFR was 36 and 68 % of patients had WOC. Factors independently associated with WOC were advanced age, pupillary reactivity, lower intensive care unit-length-of-stay, pre- and in-hospital cardiac arrest, herniation, intracranial pressure crisis, and pre-existing endocrine disease. Inclusion of WOC in our multivariable regression model predicting in-hospital CFRs negated all other variables. Survey results suggested that in younger patients, some clinicians prognosticated overly pessimistically based upon data available at the time of presentation. In our msTBI cohort, WOC was the most important predictor of in-hospital mortality. We identified several important independent predictors of WOC. Large within-center variability in msTBI outcome prognostication with varying levels of possible clinical nihilism exists, which may form the basis of self-fulfilling prophecies.	[Izzy, Saef; Compton, Rebecca; Carandang, Raphael; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Neurol Neurocrit Care, Worcester, MA 01655 USA; [Carandang, Raphael; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Worcester, MA 01655 USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01655 USA	Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol Neurocrit Care, 55 Lake Ave North, Worcester, MA 01655 USA.	susanne.muehlschlegel@umassmemorial.org			University of Massachusetts Medical School Faculty Scholar Award; National Institute of Health Clinical Translational Science Award [5UL1TR000161]; Worcester Research Foundation	This study was funded in part by the University of Massachusetts Medical School Faculty Scholar Award (S. M.) (funded by the National Institute of Health Clinical Translational Science Award (5UL1TR000161) to the University of Massachusetts Medical School). Funding was also provided by the Worcester Research Foundation (S. M. and R.C.).	[Anonymous], 2013, TRAUM BRAIN INJ STAT; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Garland A, 2013, CHEST, V143, P214, DOI 10.1378/chest.12-1531; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009; Johnston SC, 2000, MUSCLE NERVE, V23, P839, DOI 10.1002/(SICI)1097-4598(200006)23:6<839::AID-MUS1>3.0.CO;2-V; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Rabinstein AA, 2010, NEUROLOGY, V74, P1086, DOI 10.1212/WNL.0b013e3181d7d928; Sheth KN, 2012, NEUROLOGY, V78, P1793, DOI 10.1212/WNL.0b013e3182583034; Stacey D, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3, 10.1002/14651858.CD001431.pub4]; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Wilson ME, 2013, INTENS CARE MED, V39, P1009, DOI 10.1007/s00134-013-2896-x	17	48	50	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2013	19	3					347	363		10.1007/s12028-013-9925-z			17	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	257OB	WOS:000327393200014	24132565				2021-06-18	
J	Selwyn, R; Hockenbury, N; Jaiswal, S; Mathur, S; Armstrong, RC; Byrnes, KR				Selwyn, Reed; Hockenbury, Nicole; Jaiswal, Shalini; Mathur, Sanjeev; Armstrong, Regina C.; Byrnes, Kimberly R.			Mild Traumatic Brain Injury Results in Depressed Cerebral Glucose Uptake: An (18)FDG PET Study	JOURNAL OF NEUROTRAUMA			English	Article						glucose uptake; LFP; motor function; PET; rat	FLUID PERCUSSION INJURY; HEAD-INJURY; BLOOD-FLOW; NERVOUS-SYSTEM; AXONAL INJURY; F-18-FDG PET; IN-VIVO; RAT; MODEL; METABOLISM	Moderate to severe traumatic brain injury (TBI) in humans and rats induces measurable metabolic changes, including a sustained depression in cerebral glucose uptake. However, the effect of a mild TBI on brain glucose uptake is unclear, particularly in rodent models. This study aimed to determine the glucose uptake pattern in the brain after a mild lateral fluid percussion (LFP) TBI. Briefly, adult male rats were subjected to a mild LFP and positron emission tomography (PET) imaging with F-18-fluorodeoxyglucose ((18)FDG), which was performed prior to injury and at 3 and 24 h and 5, 9, and 16 days post-injury. Locomotor function was assessed prior to injury and at 1, 3, 7, 14, and 21 days after injury using modified beam walk tasks to confirm injury severity. Histology was performed at either 10 or 21 days post-injury. Analysis of function revealed a transient impairment in locomotor ability, which corresponds to a mild TBI. Using reference region normalization, PET imaging revealed that mild LFP-induced TBI depresses glucose uptake in both the ipsilateral and contralateral hemispheres in comparison with sham-injured and naive controls from 3 h to 5 days post-injury. Further, areas of depressed glucose uptake were associated with regions of glial activation and axonal damage, but no measurable change in neuronal loss or gross tissue damage was observed. In conclusion, we show that mild TBI, which is characterized by transient impairments in function, axonal damage, and glial activation, results in an observable depression in overall brain glucose uptake using (18)FDG-PET.	[Selwyn, Reed; Jaiswal, Shalini; Mathur, Sanjeev] Uniformed Serv Univ Hlth Sci, Dept Radiol, Bethesda, MD 20814 USA; [Hockenbury, Nicole; Armstrong, Regina C.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Selwyn, Reed; Jaiswal, Shalini; Mathur, Sanjeev; Armstrong, Regina C.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room B2048,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu	mathur, sanjeev k/A-5937-2012	Byrnes, Kimberly/0000-0002-7501-7734	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense	This work was funded by the Department of Defense in the Center for Neuroscience and Regenerative Medicine. The authors thank Yujia Zhao, Guzal Khayrullina, and Alexander Gordon for technical assistance, and the Uniformed Services University Biomedical Instrumentation Center/Histopathology department for assistance with the Fast blue and silver staining procedures.	Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buck D, 2012, J NUCL MED, V53, P1269, DOI 10.2967/jnumed.111.102608; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Fueger BJ, 2006, J NUCL MED, V47, P999; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kleffelgaard I, 2012, DISABIL REHABIL, V34, P788, DOI 10.3109/09638288.2011.619624; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Marklund N, 2009, J NEUROTRAUM, V26, P1281, DOI [10.1089/neu.2008.0827, 10.1089/neu.2008-0827]; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nehlig A, 2007, GLIA, V55, P1238, DOI 10.1002/glia.20376; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38; Shimoji K, 2004, J NUCL MED, V45, P665; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	54	48	49	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2013	30	23					1943	1953		10.1089/neu.2013.2928			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AI0FA	WOS:000336520400003	23829400				2021-06-18	
J	Bell, MJ; Adelson, PD; Hutchison, JS; Kochanek, PM; Tasker, RC; Vavilala, MS; Beers, SR; Fabio, A; Kelsey, SF; Wisniewski, SR				Bell, Michael J.; Adelson, P. David; Hutchison, James S.; Kochanek, Patrick M.; Tasker, Robert C.; Vavilala, Monica S.; Beers, Sue R.; Fabio, Anthony; Kelsey, Sheryl F.; Wisniewski, Stephen R.		Multiple Med Therapies Pediat	Differences in Medical Therapy Goals for Children With Severe Traumatic Brain Injury-An International Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cerebral hypoperfusion; hypoxia; intracranial hypertension; pediatric neurocritical care; pediatric traumatic brain injury; secondary Injuries	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; PROGNOSTIC-FACTORS; PEDIATRIC-PATIENTS; HYPERTONIC SALINE; UNITED-STATES; HYPOTHERMIA; EXPERIENCE; MANAGEMENT; DISABILITY	Objectives: To describe the differences in goals for their usual practice for various medical therapies from a number of international centers for children with severe traumatic brain injury. Design: A survey of the goals from representatives of the international centers. Setting: Thirty-two pediatric traumatic brain injury centers in the United States, United Kingdom, France, and Spain. Patients: None. Interventions: None. Measurements and Main Results: A survey instrument was developed that required free-form responses from the centers regarding their usual practice goals for topics of intracranial hypertension therapies, hypoxia/ischemia prevention and detection, and metabolic support. Cerebrospinal fluid diversion strategies varied both across centers and within centers, with roughly equal proportion of centers adopting a strategy of continuous cerebrospinal fluid diversion and a strategy of no cerebrospinal fluid diversion. Use of mannitol and hypertonic saline for hyperosmolar therapies was widespread among centers (90.1% and 96.9%, respectively). Of centers using hypertonic saline, 3% saline preparations were the most common but many other concentrations were in common use. Routine hyperventilation was not reported as a standard goal and 31.3% of centers currently use Pbo(2) monitoring for cerebral hypoxia. The time to start nutritional support and glucose administration varied widely, with nutritional support beginning before 96 hours and glucose administration being started earlier in most centers. Conclusions: There were marked differences in medical goals for children with severe traumatic brain injury across our international consortium, and these differences seemed to be greatest in areas with the weakest evidence in the literature. Future studies that determine the superiority of the various medical therapies outlined within our survey would be a significant advance for the pediatric neurotrauma field and may lead to new standards of care and improved study designs for clinical trials.	[Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Hutchison, James S.] Univ Toronto, Dept Crit Care Med, Toronto, CA USA; [Tasker, Robert C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; [Tasker, Robert C.] Boston Childrens Hosp, Div Crit Care, Boston, MA USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesia, Seattle, WA 98195 USA; [Beers, Sue R.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Fabio, Anthony; Kelsey, Sheryl F.; Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol & Biostat, Pittsburgh, PA USA	Bell, MJ (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Tasker, Robert C/R-5837-2019; O'brien, Nicole/E-3776-2011; Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019; Peters, Mark/AAD-7518-2019	Kochanek, Patrick M/0000-0002-2627-913X; Peters, Mark/0000-0003-3653-4808; Kilbaugh, Todd/0000-0002-4959-3092; Meyer, Philippe G/0000-0002-3829-6631; Wisniewski, Stephen/0000-0002-3877-9860; Thomas, Neal/0000-0002-7991-7510; Tasker, Robert/0000-0003-3647-8113; Shellington, David/0000-0001-6708-6978; Fabio, Anthony/0000-0002-6808-4939	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Arizona Biomedical Research Commission; Baxter Foundation; Codman; Ontario Neurotranining; CIHRCanadian Institutes of Health Research (CIHR); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; US ArmyUnited States Department of Defense; DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); Laerdal Foundation; AHAAmerican Heart Association [W81XWH-10-0623, NIH NS070324, T32HD040686 US Army W81XWH-09-2-0187]; Eli LillyEli Lilly;  [HD0499893];  [HD08003];  [NS070324];  [T32HD040686];  [W81XWH-09-2-0187];  [NS072308];  [MH56612];  [MH085722];  [CE001630];  [NS052478];  [NS069247]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD008003] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE001630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH056612, R10MH056612, R01MH085722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS070324, R01NS072308, U01NS052478, R01NS069247, U01NS081041] Funding Source: NIH RePORTER	Dr. Bell (HD0499893, HD08003, and NS072308), Dr. Adelson (NS052478), Dr. Kochanek (NS070324, T32HD040686, W81XWH-09-2-0187, and W81XWH-10-0623), Dr. Vavilala (NS072308), Dr. Beers (MH56612 and MH085722), Dr. Fabio (CE001630), and Dr. Wisniewski (NS052478 and NS069247) received federal grants. Dr. Bell's institution received grant support (HD0499893, HD08003, and NS072308). Dr. Bell received support for article research from NIH and HD0499893, HD08003, and NS072308. Dr. Adelson is employed by the Phoenix Children's Hospital and provided expert testimony for various medical legal cases. Dr. Adelson's institution received grant support from Arizona Biomedical Research Commission, Baxter Foundation, and Codman. Dr. Hutchison is employed by SickKids, Toronto; provided expert testimony for CMPA; and lectured for the Japanese Intensive Care Society and as visiting professor. Dr. Hutchinson's institution received grant support from Ontario Neurotranining, NIH, and CIHR. Dr. Kochanek received grant support from the National Institutes of Health (NIH), the US Army, DARPA, Laerdal Foundation, and AHA (NIH NS070324 and T32HD040686 US Army W81XWH-09-2-0187 and W81XWH-10-0623); is a co-provisional patent holder on 3 patents; and received support for article research from NIH and the US Army. Dr. Tasker received royalties from Oxford University Press (Oxford Handbook of Paediatrics). Dr. Vavilala received support for article research from NIH. Dr. Beers is employed by the University of Pittsburgh and University of Pittsburgh Physicians, provided expert testimony for various institutions, received royalties from John Wiley & Sons and Springer, and received support for travel from the National Academy of Neuropsychology (airfare to Board meeting). Dr. Beers' institution received grant support from Family Pathways to Early Onset Suicide Attempt, Psychiatric Outcomes of Children with High-and Low-Risk for Depression, Oxidative Lipidomics in Pediatric Traumatic Brain Injury, TBI Biological Diagnosis via High Definition Tractography Asymmetry Screening, High Definition Fiber Tracking Biological Diagnosis of TBI Providing Actionable Clinical Report of Quantified Damage. Dr. Wisniewski consulted for Cyberonic Inc. (2005-2009); Ima RX, Therapeutics, Inc. (2006); Bristol-Myers Squibb Company (2007-2008); Organon (2007); Case-Western University (2007); Singapore Clinical Research Institute (2009); Dey Pharmaceuticals (2010); Venebio (2010); and Dey (2010) and received grant support from Eli Lilly (2012). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Curry R, 2008, PEDIATR CRIT CARE ME, V9, P141, DOI 10.1097/PCC.0B013e318166870e; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; randomized A, 2006, PEDIATR CRIT CARE ME, V7, P56; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; WISE B L, 1961, Surg Forum, V12, P398; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	29	48	48	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	OCT	2013	14	8					811	818		10.1097/PCC.0b013e3182975e2f			8	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AI0EF	WOS:000336518300015	23863819	Green Accepted			2021-06-18	
J	Corrigan, JD; Bogner, J; Mellick, D; Bushnik, T; Dams-O'Connor, K; Hammond, FM; Hart, T; Kolakowsky-Hayner, S				Corrigan, John D.; Bogner, Jennifer; Mellick, Dave; Bushnik, Tamara; Dams-O'Connor, Kristen; Hammond, Flora M.; Hart, Tessa; Kolakowsky-Hayner, Stephanie			Prior History of Traumatic Brain Injury Among Persons in the Traumatic Brain Injury Model Systems National Database	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Brain injuries; Craniocerebral trauma; Depression; Rehabilitation	VALIDITY; IDENTIFICATION; RELIABILITY; TBI; REPRESENTATIVENESS; PREDICTORS; OUTCOMES; SCALE	Objective: To determine the association between demographic, psychosocial, and injury-related characteristics and traumatic brain injury (TBI) occurring prior to a moderate or severe TBI requiring rehabilitation. Design: Secondary data analysis. Setting: TBI Model System inpatient rehabilitation facilities. Participants: Persons (N=4464) 1, 2, 5, 10, 15, or 20 years after TBI resulting in participation in the TBI Model System National Database. Interventions: Not applicable. Main Outcome Measures: History of TBI prior to the TBI Model System Index injury, pre-Index injury demographic and behavioral characteristics, Index injury characteristics, post-Index injury behavioral health and global outcome. Results: Twenty percent of the cohort experienced TBIs preceding the TBI Model System Index injury-80% of these were mild and 40% occurred before age 16. Pre- and post-Index injury behavioral issues, especially substance abuse, were highly associated with having had a prior TBI. Greater severity of the pre-Index injury as well as occurrence before age 6 often showed stronger associations. Unexpectedly, pre-Index TBI was associated with less severe Index injuries and better functioning on admission and discharge from rehabilitation. Conclusions: Findings suggest that earlier life TBI may have important implications for rehabilitation after subsequent TBI, especially for anticipating behavioral health issues in the chronic stage of recovery. Results provide additional evidence for the potential consequences of early life TBI, even if mild. (c) 2013 by the American Congress of Rehabilitation Medicine	[Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Mellick, Dave] Craig Hosp, Res Dept, Englewood, CO USA; [Bushnik, Tamara] NYU, Langone Sch Med, New York, NY USA; [Bushnik, Tamara; Kolakowsky-Hayner, Stephanie] Rehabil Res Ctr, Santa Clara Valley Med Ctr, San Jose, CA USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Bogner, Jennifer/E-2773-2011; Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Bushnik, Tamara/0000-0003-3328-257X	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, U.S. Department of Education, Traumatic Brain Injury Model System Centers [H133A070029, H133A070022, H133A070033, H113A070040, H133A070038, H113A070074, HI33A0120085]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	Supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, U.S. Department of Education, Traumatic Brain Injury Model System Centers (grant nos. H133A070029, H133A070022, H133A070033, H113A070040, H133A070038, H113A070074, HI33A0120085).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSSI JS, 1985, EDUC PSYCHOL MEAS, V45, P737, DOI 10.1177/0013164485454004; Satz P, 2011, J CLIN EXP NEUROPSYC, V33, P121, DOI 10.1080/13803395.2010.493151; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; *TRAUM BRAIN INJ M, 2013, SYLL; Turner H.M., 2006, CICSD, V33, P42, DOI [10.1044/cicsd_33_S_42, DOI 10.1044/CICSD_33_S_42]; Warner M, 2005, INJURY PREV, V11, P282, DOI 10.1136/ip.2004.006965; Warner M, 2000, Vital Health Stat 10, P1; Whiteneck G, 2001, COLORADO TRAUMATIC B; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	48	48	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1940	1950		10.1016/j.apmr.2013.05.018			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100012	23770276	Green Accepted			2021-06-18	
J	Kruer, RM; Harris, LH; Goodwin, H; Kornbluth, J; Thomas, KP; Slater, LA; Haut, ER				Kruer, Rachel M.; Harris, Lindsay H.; Goodwin, Haley; Kornbluth, Joshua; Thomas, Katherine P.; Slater, Leigh A.; Haut, Elliott R.			Changing trends in the use of seizure prophylaxis after traumatic brain injury: A shift from phenytoin to levetiracetam	JOURNAL OF CRITICAL CARE			English	Article						Seizure; Seizure prophylaxis; Levetiracetam; Phenytoin; Traumatic brain injury	INTRAVENOUS LEVETIRACETAM	Purpose: Current guidelines for traumatic brain injury (TBI) recommend antiepileptic drugs (AEDs) for 7 days after injury to decrease posttraumatic seizure risk. Phenytoin decreases seizure risk 73% vs placebo during this time. Levetiracetam (LEV) is an alternative; however, no published data validate comparable efficacy. Our objective was to evaluate seizure incidence 7 days after TBI in patients treated with phenytoin (PHT) vs LEV and to characterize practice of AED selection. Methods: A retrospective observational study was conducted using a Trauma Registry (Collector Trauma Registry; Digital Innovation, Inc, Forrest Hill, Md) to evaluate patients with TBI. Patients with an initial Head/Neck Abbreviated Injury Scale score of 3 or higher and a Glasgow Coma Scale of 8 or less were included. Results: Of 109 patients, 89 received PHT, and 20, LEV. Two patients experienced posttraumatic seizure, 1 in each group. Sixty-eight patients survived to hospital discharge; 65% received prophylactic AED greater than 7 days. Ninety-eight percent of 81 patients admitted between 2000 and 2007 received PHT, whereas 64% of 28 patients admitted between 2008 and 2010 received LEV. Conclusion: Only 2 patients experienced posttraumatic seizure after receiving AED, indicating low incidence. Most surviving to hospital discharge received AED prophylaxis greater than 7 days despite guideline recommendations. After approval of intravenous LEV, a trend favoring LEV was observed. (C) 2013 Elsevier Inc. All rights reserved.	[Kruer, Rachel M.; Harris, Lindsay H.; Goodwin, Haley] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA; [Kornbluth, Joshua] Johns Hopkins Univ Hosp, Div Neurocrit Care, Dept Neurol, Baltimore, MD 21287 USA; [Thomas, Katherine P.] Intermt Med Ctr, Dept Med, Div Neurol, Murray, UT 84107 USA; [Slater, Leigh A.; Haut, Elliott R.] Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA; [Slater, Leigh A.; Haut, Elliott R.] Johns Hopkins Univ Hosp, Dept Anesthesiol Crit Care Med ACCM, Baltimore, MD 21287 USA; [Slater, Leigh A.; Haut, Elliott R.] Johns Hopkins Univ Hosp, Dept Emergency Med, Baltimore, MD 21287 USA	Kruer, RM (corresponding author), Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA.	rkruer1@jhmi.edu	Kornbluth, Joshua/U-7807-2019; Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X			Bratton SL, 2007, J NEUROTRAUM, V24, P83; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2007, TRAUMATIC BRAIN INJU; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kazerooni R, 2010, CLINICOECONOMIC OUTC, V2, P15; Paton L, 2007, AVOIDING COMMON ICU, P458; Pieracci FM, 2012, J TRAUMA ACUTE CARE, V72, P276, DOI 10.1097/TA.0b013e31823df31f; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Winter ME, 2008, CLIN PHARMACOKINET, P247	11	48	49	1	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	OCT	2013	28	5							883.e9	10.1016/j.jcrc.2012.11.020			5	Critical Care Medicine	General & Internal Medicine	217QM	WOS:000324374700061	23566730				2021-06-18	
J	Vakhtin, AA; Calhoun, VD; Jung, RE; Prestopnik, JL; Taylor, PA; Ford, CC				Vakhtin, Andrei A.; Calhoun, Vince D.; Jung, Rex E.; Prestopnik, Jillian L.; Taylor, Paul A.; Ford, Corey C.			Changes in intrinsic functional brain networks following blast-induced mild traumatic brain injury	BRAIN INJURY			English	Article						Blast; cognition; functional magnetic resonance imaging (fMRI); independent component analysis (ICA); mild traumatic brain injury (mTBI); resting state networks (RSN)	DIFFUSE AXONAL INJURY; WHITE-MATTER; POSTCONCUSSIVE SYMPTOMS; IRAQ; CONNECTIVITY; ATTENTION; AFGHANISTAN; MECHANISMS; COMPONENTS; SEQUELAE	Objective: Blast-induced mild traumatic brain injuries (mTBI) commonly go undetected by computed tomography and conventional magnetic resonance imaging (MRI). This study was used to investigate functional brain network abnormalities in a group of blast-induced mTBI subjects using independent component analysis (ICA) of resting state functional MRI (fMRI) data. Methods: Twenty-eight resting state networks of 13 veterans who sustained blast-induced mTBI were compared with healthy controls across three fMRI domains: blood oxygenation level-dependent spatial maps, time course spectra and functional connectivity. Results: The mTBI group exhibited hyperactivity in the temporo-parietal junctions and hypoactivity in the left inferior temporal gyrus. Abnormal frequencies in default-mode (DMN), sensorimotor, attentional and frontal networks were detected. In addition, functional connectivity was disrupted in six network pairs: DMN-basal ganglia, attention-sensorimotor, frontal-DMN, attention-sensorimotor, attention-frontal and sensorimotor-sensorimotor. Conclusions: The results suggest white matter disruption across certain attentional networks. Additionally, given their elevated activity relative to controls', the temporo-parietal junctions of blast mTBI subjects may be compensating for diffuse axonal injury in other cortical regions.	[Vakhtin, Andrei A.; Prestopnik, Jillian L.; Ford, Corey C.] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; [Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA; [Calhoun, Vince D.] Univ New Mexico, Dept Comp Sci, Albuquerque, NM 87131 USA; [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA; [Calhoun, Vince D.; Ford, Corey C.] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; [Calhoun, Vince D.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA; [Jung, Rex E.] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Taylor, Paul A.] Sandia Natl Labs, Multiscale Dynam Mat Modeling Dept, Albuquerque, NM 87185 USA	Ford, CC (corresponding author), 1 Univ New Mexico, Hlth Sci Ctr, Dept Neurol, MSC10 5620, Albuquerque, NM 87131 USA.	cford@salud.unm.edu			US Naval Health Research Center, Office of Naval Research; United States Department of Energy's National Nuclear Security AdministrationNational Nuclear Security Administration [DE-AC04-94AL85000]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006841] Funding Source: NIH RePORTER	This work was funded through the US Naval Health Research Center, Office of Naval Research, through project funding manager Mr James Mackiewicz. Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the United States Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000. The authors report no conflicts of interest.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bockholt Henry J, 2010, Front Neuroinform, V3, P36, DOI 10.3389/neuro.11.036.2009; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun VD, 2011, FRONT PSYCHIATRY, V2, P1; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Delis DC, 2000, CALIFORNIA VERBAL LE; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Garrity AG, 2007, AM J PSYCHIAT, V164, P450, DOI 10.1176/appi.ajp.164.3.450; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Heaton R., 1993, WISCONSIN CARD SORTI; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horsfield MA, 2002, NMR BIOMED, V15, P570, DOI 10.1002/nbm.787; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jafri MJ, 2008, NEUROIMAGE, V39, P1666, DOI 10.1016/j.neuroimage.2007.11.001; Koch W, 2010, NEUROIMAGE, V51, P280, DOI 10.1016/j.neuroimage.2009.12.008; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nardo D, 2011, NEURON, V69, P1015, DOI 10.1016/j.neuron.2011.02.020; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scott Adam, 2011, Front Neuroinform, V5, P33, DOI 10.3389/fninf.2011.00033; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519	43	48	49	0	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2013	27	11					1304	1310		10.3109/02699052.2013.823561			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	217YQ	WOS:000324399800010	24020442	Green Accepted			2021-06-18	
J	Tung, KC; Uh, J; Mao, D; Xu, F; Xiao, GH; Lu, HZ				Tung, Kuang-Chi; Uh, Jinsoo; Mao, Deng; Xu, Feng; Xiao, Guanghua; Lu, Hanzhang			Alterations in resting functional connectivity due to recent motor task	NEUROIMAGE			English	Article						Resting state; Functional connectivity MRI; Motor cortex; Blood oxygenation	POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; STATE FMRI; DEFAULT-MODE; ALZHEIMERS-DISEASE; HEALTHY-SUBJECTS; MENTAL-IMAGERY; BOLD SIGNAL; NETWORK; CORTEX	The impact of recent experiences of task performance on resting functional connectivity MRI (fcMRI) has important implications for the design of many neuroimaging studies, because, if an effect is present, the fcMRI scan then must be performed before any evoked fMRI or after a time gap to allow it to dissipate. The present study aims to determine the effect of simple button presses, which are used in many cognitive fMRI tasks as a response recording method, on later acquired fcMRI data. Human volunteers were subject to a 23-minute button press motor task. Their resting-state brain activity before and after the task was assessed with fcMRI. It was found that, compared to the pre-task resting period, the post-task resting fcMRI revealed a significantly higher (p = 0.002, N = 24) cross correlation coefficient (CC) between left and right motor cortices. These changes were not present in sham control studies that matched the paradigm timing but had no actual task. The amplitude of fcMRI signal fluctuation (AF) also demonstrated an increase in the post-task period compared to pre-task. These changes were observed using both the right-hand-only task and the two-hand task. Study of the recovery time course of these effects revealed that the CC changes lasted for about 5 min while the AF change lasted for at least 15 min. Finally, voxelwise analysis revealed that the pre/post-task differences were also observed in several other brain regions, including the auditory cortex, visual areas, and the thalamus. Our data suggest that the recent performance of the simple button press task can result in elevated fcMRI CC and AF in relevant brain networks and that fcMRI scan should be performed either before evoked fMRI or after a sufficient time gap following fMRI. (C) 2013 Elsevier Inc. All rights reserved.	[Tung, Kuang-Chi; Uh, Jinsoo; Mao, Deng; Xu, Feng; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Tung, Kuang-Chi; Mao, Deng; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Mol Biophys Grad Program, Dallas, TX 75390 USA; [Uh, Jinsoo; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Xiao, Guanghua] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Div Biostat, Dallas, TX 75390 USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA	Lu, HZ (corresponding author), Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hanzhang.lu@utsouthwestern.edu	Xu, Feng/K-7760-2015	Xu, Feng/0000-0001-7958-3787	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH084021, R01 NS067015, R01 AG042753, R21 NS078656, R21 AG034318]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078656, R01NS067015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG034318, R01AG042753] Funding Source: NIH RePORTER	This study was supported in part by NIH grants R01 MH084021 (to HL), R01 NS067015 (to HL), R01 AG042753 (to HL), R21 NS078656 (to HL), and R21 AG034318 (to HL). The authors are grateful to Dr. Janet Jerrow for scientific editing of the manuscript.	Albert NB, 2009, CURR BIOL, V19, P1023, DOI 10.1016/j.cub.2009.04.028; Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Baria AT, 2011, J NEUROSCI, V31, P7910, DOI 10.1523/JNEUROSCI.1296-11.2011; Barnes A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006626; Baumann S, 2005, ANN NY ACAD SCI, V1060, P186, DOI 10.1196/annals.1360.038; Binkofski F, 2000, HUM BRAIN MAPP, V11, P273, DOI 10.1002/1097-0193(200012)11:4<273::AID-HBM40>3.0.CO;2-0; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bluhm RL, 2007, SCHIZOPHRENIA BULL, V33, P1004, DOI 10.1093/schbul/sbm052; Boecker H, 2002, NEUROIMAGE, V17, P999, DOI 10.1006/nimg.2002.1139; Chang C, 2009, NEUROIMAGE, V47, P1448, DOI 10.1016/j.neuroimage.2009.05.012; CHAVIS DA, 1976, BRAIN RES, V117, P369, DOI 10.1016/0006-8993(76)90089-5; Chen HF, 2009, NEUROIMAGE, V47, P1844, DOI 10.1016/j.neuroimage.2009.06.026; Cingolani LA, 2008, NEURON, V58, P749, DOI 10.1016/j.neuron.2008.04.011; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2005, EXP BRAIN RES, V167, P587, DOI 10.1007/s00221-005-0059-1; Dechent P, 2004, COGNITIVE BRAIN RES, V19, P138, DOI 10.1016/j.cogbrainres.2003.11.012; Deiber MP, 1998, NEUROIMAGE, V7, P73, DOI 10.1006/nimg.1997.0314; Fukunaga M, 2008, J CEREBR BLOOD F MET, V28, P1377, DOI 10.1038/jcbfm.2008.25; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Hanakawa T, 2002, CEREB CORTEX, V12, P1157, DOI 10.1093/cercor/12.11.1157; Hasson U, 2009, P NATL ACAD SCI USA, V106, P10841, DOI 10.1073/pnas.0903253106; He HJ, 2012, NEUROIMAGE, V59, P2339, DOI 10.1016/j.neuroimage.2011.09.018; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Hoffman KL, 2002, SCIENCE, V297, P2070, DOI 10.1126/science.1073538; Hong LE, 2009, ARCH GEN PSYCHIAT, V66, P431, DOI 10.1001/archgenpsychiatry.2009.2; Iseki K, 2008, NEUROIMAGE, V41, P1021, DOI 10.1016/j.neuroimage.2008.03.010; Kasess CH, 2008, NEUROIMAGE, V40, P828, DOI 10.1016/j.neuroimage.2007.11.040; Klingner CM, 2013, HUM BRAIN MAPP, V34, P2343, DOI 10.1002/hbm.22074; la Fougere C, 2010, NEUROIMAGE, V50, P1589, DOI 10.1016/j.neuroimage.2009.12.060; Leonardo M, 1995, HUM BRAIN MAPP, V3, P83, DOI 10.1002/hbm.460030205; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; Liu HH, 2006, NEUROREPORT, V17, P19, DOI 10.1097/01.wnr.0000195666.22714.35; Lowe MJ, 2002, RADIOLOGY, V224, P184, DOI 10.1148/radiol.2241011005; Luchinger R, 2012, NEUROIMAGE, V60, P1426, DOI 10.1016/j.neuroimage.2012.01.031; Lushnikova I, 2009, HIPPOCAMPUS, V19, P753, DOI 10.1002/hipo.20551; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Munzert J, 2009, PROG BRAIN RES, V174, P219, DOI 10.1016/S0079-6123(09)01318-1; Nair DG, 2003, COGNITIVE BRAIN RES, V15, P250, DOI 10.1016/S0926-6410(02)00197-0; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Peltier SJ, 2005, BRAIN RES, V1057, P10, DOI 10.1016/j.brainres.2005.06.078; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; Salvador R, 2007, NEUROIMAGE, V35, P83, DOI 10.1016/j.neuroimage.2006.12.001; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stevens WD, 2010, CEREB CORTEX, V20, P1997, DOI 10.1093/cercor/bhp270; Stinear CM, 2006, BRAIN RES, V1095, P139, DOI 10.1016/j.brainres.2006.04.008; Tambini A, 2010, NEURON, V65, P280, DOI 10.1016/j.neuron.2010.01.001; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tomasi D, 2012, MOL PSYCHIATR, V17, P549, DOI 10.1038/mp.2011.81; van den Heuvel M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002001; Waites AB, 2005, HUM BRAIN MAPP, V24, P59, DOI 10.1002/hbm.20069; Wang K, 2007, HUM BRAIN MAPP, V28, P967, DOI 10.1002/hbm.20324; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wig GS, 2011, ANN NY ACAD SCI, V1224, P126, DOI 10.1111/j.1749-6632.2010.05947.x; Xu F, 2011, J CEREBR BLOOD F MET, V31, P58, DOI 10.1038/jcbfm.2010.153; Xu G, 2007, NEUROLOGY, V69, P1650, DOI 10.1212/01.wnl.0000296941.06685.22; Yang H, 2007, NEUROIMAGE, V36, P144, DOI 10.1016/j.neuroimage.2007.01.054; Yoshida M, 2009, NEUROSCI RES, V64, P118, DOI 10.1016/j.neures.2009.02.002; Zhang S, 2012, CEREB CORTEX, V22, P99, DOI 10.1093/cercor/bhr088; Zhou Y, 2007, NEUROSCI LETT, V417, P297, DOI 10.1016/j.neulet.2007.02.081	65	48	48	0	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	SEP	2013	78						316	324		10.1016/j.neuroimage.2013.04.006			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	165MV	WOS:000320488900031	23583747	Green Accepted			2021-06-18	
J	[Anonymous]				[Anonymous]			Team Physician Consensus Statement: 2013 Update	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							CONTINUING MEDICAL-EDUCATION; SPORTS-MEDICINE; SCHOOL-HEALTH; CONCUSSION; ILLNESSES									Almquist J, 2008, J ATHL TRAINING, V43, P416, DOI 10.4085/1062-6050-43.4.416; [Anonymous], 2008, MED SCI SPORT EXER, V40, P1997, DOI 10.1249/MSS.0b013e31818acdcb; [Anonymous], 2001, MED SCI SPORT EXER, V33, P1789; [Anonymous], 2006, MED SCI SPORT EXER, V38, P2030, DOI 10.1249/MSS.0b013e31802b37a6; [Anonymous], 2000, MED SCI SPORT EXER, V32, P877; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], 2004, MED SCI SPORT EXER, V36, P2004; [Anonymous], 2007, MED SCI SPORT EXER, V39, P2058, DOI 10.1249/mss.0b013e31815a76ea; [Anonymous], 2010, MED SCI SPORT EXER, V42, P820, DOI 10.1249/MSS.0b013e3181d19a0b; Barrow MW, 1998, AM FAM PHYSICIAN, V58, P749; Binkley HM, 2002, J ATHL TRAINING, V37, P329; BLACK JL, 1991, J SCHOOL HEALTH, V61, P245, DOI 10.1111/j.1746-1561.1991.tb07392.x; Dikic N, 2013, BRIT J SPORT MED, V47, P701, DOI 10.1136/bjsports-2012-091838; Dunn WR, 2007, AM J SPORT MED, V35, P840, DOI 10.1177/0363546506295177; Griffin LY, 2003, MED SCI SPORT EXER, V35, P1785; Hart KA, 1999, AM J PHYS MED REHAB, V78, P561, DOI 10.1097/00002060-199911000-00014; Herring Stanley A, 2012, Med Sci Sports Exerc, V44, P2446, DOI 10.1249/MSS.0b013e3182750534; Holm S, 2011, BRIT J SPORT MED, V45, P1170, DOI 10.1136/bjsm.2011.086124; Hsu AC, 2012, MED SCI SPORT EXER, V44, P178, DOI 10.1249/MSS.0b013e318275044f; Kane SM, 2009, CLIN ORTHOP RELAT R, V467, P412, DOI 10.1007/s11999-008-0589-5; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; McCrory P, 2003, BRIT J SPORT MED, V37, P472, DOI 10.1136/bjsm.37.6.472; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mitten MJ, 2002, ST JOHNS LAW REV, P76; MUHLEMANN R, 1984, SOZ PRAVENTIV MED, V29, P227, DOI 10.1007/BF02075890; Murthy AM, 2012, BULL HOSP JT DIS, V70, P56; Olson DE, 2013, BRIT J SPORT MED, V47, P5, DOI 10.1136/bjsports-2012-091936; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Ribbans B, 2013, BRIT J SPORT MED, V47, P40, DOI 10.1136/bjsports-2011-090439; Stockard A R, 1997, J Am Osteopath Assoc, V97, P89; Stovitz Steven D, 2006, Curr Sports Med Rep, V5, P120; Viola T, 2013, BRIT J SPORT MED, V47, P60, DOI 10.1136/bjsports-2012-091460	33	48	48	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2013	45	8					1618	1622		10.1249/MSS.0b013e31829ba437			5	Sport Sciences	Sport Sciences	300KT	WOS:000330463500024	23860390				2021-06-18	
J	Sripada, RK; Rauch, SAM; Tuerk, PW; Smith, E; Defever, AM; Mayer, RA; Messina, M; Venners, M				Sripada, Rebecca K.; Rauch, Sheila A. M.; Tuerk, Peter W.; Smith, Erin; Defever, Andrew M.; Mayer, Rebecca A.; Messina, Michael; Venners, Margaret			Mild Traumatic Brain Injury and Treatment Response in Prolonged Exposure for PTSD	JOURNAL OF TRAUMATIC STRESS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; RANDOMIZED CONTROLLED-TRIAL; THERAPY; VETERANS; IRAQ; METAANALYSIS; AFGHANISTAN; MECHANISMS; CLINICIAN	A proportion of U.S. veterans returning from Iraq and Afghanistan have experienced mild traumatic brain injury (mTBI), which is associated with increased risk for developing posttraumatic stress disorder (PTSD). Prolonged Exposure (PE) has proven effectiveness in the treatment of PTSD; however, some clinicians have reservations about using PE with individuals with a history of mTBI. We examined the impact of PE for veterans with PTSD and with or without a history of mTBI in a naturalistic sample of 51 veterans who received PE at a Veterans Health Administration PTSD clinic. We also analyzed previously collected data from a controlled trial of 22 veterans randomly assigned to PE or present centered therapy. For both sets of data, we found that PE reduced symptom levels and we also did not detect an effect for mTBI, suggesting that PE may be helpful for individuals with PTSD and a history of mTBI.	[Sripada, Rebecca K.; Rauch, Sheila A. M.; Smith, Erin; Defever, Andrew M.; Mayer, Rebecca A.; Messina, Michael; Venners, Margaret] Univ Michigan, Sch Med, VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA; [Tuerk, Peter W.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA	Sripada, RK (corresponding author), VA Serious Mental Illness Treatment Resource & Ev, Ann Arbor, MI USA.	rekaufma@umich.edu	Rauch, Sheila A.M./K-4450-2015	Sripada, Rebecca/0000-0002-2844-3458			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bisson JI, 2007, BRIT J PSYCHIAT, V190, P97, DOI 10.1192/bjp.bp.106.021402; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2006, COGN BEHAV PRACT, V13, P17, DOI 10.1016/j.cbpra.2005.03.002; Carlson K, 2009, ASSESSMENT TREATMENT; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Defense Manpower Data Center, 2009, CONT TRACK SYST; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Foa E. B., 2007, PROL EXP THER PTSD T; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Gilboa-Schechtman E, 2010, J AM ACAD CHILD PSY, V49, P1034, DOI 10.1016/j.jaac.2010.07.014; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; *IND REV GROUP, 2007, REB TRUST REP REH CA; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Powers MB, 2010, CLIN PSYCHOL REV, V30, P635, DOI 10.1016/j.cpr.2010.04.007; Quirk GJ, 2008, NEUROPSYCHOPHARMACOL, V33, P56, DOI 10.1038/sj.npp.1301555; Rauch S. A. M., 2013, CHANGES SYMPTO UNPUB; Rauch S, 2006, J CONTEMP PSYCHOTHER, V36, P61, DOI 10.1007/s10879-006-9008-y; Rauch SAM, 2012, J REHABIL RES DEV, V49, P679, DOI 10.1682/JRRD.2011.08.0152; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Raudenbush S. W., 2004, HLM 6 HIERARCHICAL L; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SNIJDERS TAB, 1994, SOCIOL METHOD RES, V22, P342, DOI 10.1177/0049124194022003004; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thorp SR, 2012, AM J GERIAT PSYCHIAT, V20, P276, DOI 10.1097/JGP.0b013e3182435ee9; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494; U.S. Department of Defense, 1998, JOINT TACTICS TECHNI, V3-07.2; U.S. Department of Veterans Affairs & Department of Defense (VA/DoD), 2010, VA DOD CLIN PRACTICE; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P83; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers FW, 1991, PCL S DSM 4; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f	48	48	48	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867			J TRAUMA STRESS	J. Trauma Stress	JUN	2013	26	3					369	375		10.1002/jts.21813			7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	157GA	WOS:000319882800009	23696427				2021-06-18	
J	Singh, IN; Gilmer, LK; Miller, DM; Cebak, JE; Wang, JA; Hall, ED				Singh, Indrapal N.; Gilmer, Lesley K.; Miller, Darren M.; Cebak, John E.; Wang, Juan A.; Hall, Edward D.			Phenelzine mitochondrial functional preservation and neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						lipid peroxidation; mitochondria; phenelzine; traumatic brain injury; 4-hydroxy-2-nonenal	CYCLOSPORINE-A ANALOG; SPINAL-CORD; REACTIVE ALDEHYDES; OXIDATIVE STRESS; FREE-RADICALS; CELL-DEATH; DAMAGE; PEROXYNITRITE; DYSFUNCTION; INHIBITION	Phenelzine (PZ) is a scavenger of the lipid peroxidation (LP)-derived reactive aldehyde 4-hydroxynonenal (4-HNE) due to its hydrazine functional group, which can covalently react with 4-HNE. In this study, we first examined the ability of PZ to prevent the respiratory depressant effects of 4-HNE on normal isolated brain cortical mitochondria. Second, in rats subjected to controlled cortical impact traumatic brain injury (CCI-TBI), we evaluated PZ (10 mg/kg subcutaneously at 15 minutes after CCI-TBI) to attenuate 3-hour post-TBI mitochondrial respiratory dysfunction, and in separate animals, to improve cortical tissue sparing at 14 days. While 4-HNE exposure inhibited mitochondrial complex I and II respiration in a concentration-dependent manner, pretreatment with equimolar concentrations of PZ antagonized these effects. Western blot analysis demonstrated a PZ decrease in 4-HNE in mitochondrial proteins. Mitochondria isolated from peri-contusional brain tissue of CCI-TBI rats treated with vehicle at 15 minutes after injury showed a 37% decrease in the respiratory control ratio (RCR) relative to noninjured mitochondria. In PZ-treated rats, RCR suppression was prevented (P<0.05 versus vehicle). In another cohort, PZ administration increased spared cortical tissue from 86% to 97% (P<0.03). These results suggest that PZ's neuroprotective effect is due to mitochondrial protection by scavenging of LP-derived 4-HNE. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 593-599; doi:10.1038/jcbfm.2012.211; published online 16 January 2013	[Singh, Indrapal N.; Gilmer, Lesley K.; Miller, Darren M.; Cebak, John E.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBRSB Room 477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2P30 NS051220, 2P01 NS058484, 1T32 DA022378, 1T32 077889]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, P01NS058484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA022378] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health Grants 2P30 NS051220, 2P01 NS058484, 1T32 DA022378, 1T32 077889 and funding from the Kentucky Spinal Cord and Head Injury Research Trust.	Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; MacKenzie EM, 2008, NEUROCHEM RES, V33, P430, DOI 10.1007/s11064-007-9448-0; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; Raza H, 2006, TOXICOL APPL PHARM, V216, P309, DOI 10.1016/j.taap.2006.06.001; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song MS, 2010, J NEUROCHEM, V114, P1405, DOI 10.1111/j.1471-4159.2010.06857.x; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Wood PL, 2006, BRAIN RES, V1095, P190, DOI 10.1016/j.brainres.2006.04.038; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x	35	48	49	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2013	33	4					593	599		10.1038/jcbfm.2012.211			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	117CR	WOS:000316930200016	23321786	Green Published, Bronze			2021-06-18	
J	Maghool, F; Khaksari, M; Khachki, AS				Maghool, Fatemeh; Khaksari, Mohammad; Khachki, Ali Siahposht			Differences in brain edema and intracranial pressure following traumatic brain injury across the estrous cycle: Involvement of female sex steroid hormones	BRAIN RESEARCH			English	Article						Traumatic brain injury; Estrous cycle; Brain edema; Intracranial pressure; Cerebral perfusion pressure; Sex steroid hormone	FOCAL CEREBRAL-ISCHEMIA; CONTUSION INJURY; BLOOD-FLOW; PROGESTERONE; RATS; EXPRESSION; GENDER; STROKE; MODEL; FLUID	It has been shown that sex steroid hormones have profound neuroprotective effects in experimental traumatic brain injury (TBI). Because the endogenous hormone levels are proven to differ with estrous cycle stage, we evaluated whether estrous cycle stage affects various outcomes following diffuse TBI. TBI was induced by Marmarou's method in normal cycling and in ovariectomized rats with physiologically relevant restoration of hormonal levels by hormone capsule implantation. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) were measured before and different times after TBI and brain edema was assessed at 24 h after trauma. Results indicated that after TB!, water content (WC) in traumatic proestrous (TP) rats was less than the one in traumatic non-proestrous (TNP) and ovariectomized (TOVX) and also in high estradiol (HE) and progesterone (HP) was statistically less than in TBI untreated groups.There was no significant difference in WC between high doses hormone treated and TP and also between TNP, TOVX, low estradiol (LE) and progesterone (LP) groups. At 4 h and 24 h after trauma, there was a significant difference in ICP between TP, HE and HP compared to TNP and other TBI nontreated groups. Also in these times, the CPP increased in TP and hormone treated groups compared with TOVX, but the difference between TNP and TOVX was not significant. The results indicate that the estrous cycle has a prominent role in TBI outcome's and the difference in female sex steroid levels might be the reason of the different neuroprotective effects in proestrous and non-proestrous groups. (C) 2012 Elsevier B.V. All rights reserved.	[Maghool, Fatemeh] Kerman Univ Med Sci, Sch Med, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad; Khachki, Ali Siahposht] Kerman Univ Med Sci, Sch Med, Physiol Res Ctr, Kerman, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Sch Med, Physiol Res Ctr, Kerman, Iran.	Khaksar38@yahoo.co.uk	Haddad, Mohammad Khaksari/AAB-9025-2019; Maghool, Fatemeh/ABI-7612-2020	Haddad, Mohammad Khaksari/0000-0003-0770-4281; 	Kerman Neuroscience Research Center; Kerman Physiology Research Center	This work was supported financially by the Kerman Neuroscience and Kerman Physiology Research Centers. We thank Dr. Nader Shahrokhi and Dr. Aliasghar Pourshanazari for their cooperation in this study and Dr. Nouzar Nakhaee for assisting in the statistical analyses.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290; Carswell HVO, 1999, HYPERTENSION, V33, P681, DOI 10.1161/01.HYP.33.2.681; Consiglio AR, 2000, BRAIN RES PROTOC, V5, P109, DOI 10.1016/S1385-299X(99)00062-8; DEPAOLO LV, 1979, BIOL REPROD, V21, P1015, DOI 10.1095/biolreprod21.4.1015; DEPAOLO LV, 1986, BIOL REPROD, V35, P320, DOI 10.1095/biolreprod35.2.320; Deurveilher S, 2008, AM J PHYSIOL-REG I, V295, pR1328, DOI 10.1152/ajpregu.90576.2008; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Gabrielian L, 2011, J NEUROTRAUM, V28, P2103, DOI 10.1089/neu.2011.1785; Gibson CL, 2006, J CEREBR BLOOD F MET, V26, P1103, DOI 10.1038/sj.jcbfm.9600270; Gilkes CE., 2009, SURGERY, V27, P139; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Krause DN, 2002, INT CONGR SER, V1235, P395, DOI 10.1016/S0531-5131(02)00211-X; LALORAYA M, 1988, BIOCHEM BIOPH RES CO, V157, P146, DOI 10.1016/S0006-291X(88)80025-1; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Liao SL, 2001, NEUROSCI LETT, V297, P159, DOI 10.1016/S0304-3940(00)01704-3; Long J. A., 1922, Memoirs of the University of California, V6, P1; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MANDL AM, 1951, J EXP BIOL, V28, P576; Marik P, 1999, J EMERG MED, V17, P711, DOI 10.1016/S0736-4679(99)00055-4; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MATSUDA T, 1991, LIFE SCI, V48, P1627, DOI 10.1016/0024-3205(91)90122-R; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Ono H, 2002, CLIN EXP PHARMACOL P, V29, P73, DOI 10.1046/j.1440-1681.2002.03600.x; Patro A, 2009, INDIAN J NEUROTRAUM, V6, P11, DOI 10.1016/S0973-0508(09)80021-X; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Santizo RA, 2000, STROKE, V31, P2231, DOI 10.1161/01.STR.31.9.2231; Sarkaki A.R., 2011, J NEUROTRAUMA; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Strom JO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-39; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Vink R, 2003, ACT NEUR S, V86, P257; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	78	48	50	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 25	2013	1497						61	72		10.1016/j.brainres.2012.12.014			12	Neurosciences	Neurosciences & Neurology	099FS	WOS:000315607500007	23262351				2021-06-18	
J	Colville, GA; Pierce, CM				Colville, Gillian A.; Pierce, Christine M.			Children's Self-Reported Quality of Life After Intensive Care Treatment	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						outcomes; posttraumatic stress; quality of life; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; GENERIC CORE SCALES; EVENT SCALE; THE-LITERATURE; HEALTH; SURVIVORS; UNIT; VALIDITY; IMPACT; RELIABILITY	Objectives: Study was to establish children's own views of their outcome. Design: Prospective cohort study: A number of studies have reported on parental/clinician reports of children's quality of life after intensive care treatment. The aim of this Setting: Twenty-one bed PICU in a tertiary Children's Hospital. Patients: Ninety-seven children aged over 7 yr, with no preexisting learning difficulties, consecutively admitted to PICU over an 18 month period Interventions: Patients completed the Pediatric Quality of Life Inventory and a post-traumatic stress screener, at 3 months and again at 1 year (n = 72) after discharge from PICU. Measurements and Main Results: At 3 months post-discharge, the mean total Pediatric Quality of Life Inventory score reported by the PICU group was lower than that reported in the literature for a non-clinical community sample (PICU mean = 79.1 vs community mean = 83.9, p = 0.003), but by 1 year, they were comparable (82.2, p = 0.388). The mean physical functioning subscale score remained lower (PICU mean=81.6 vs. community mean=88.5, p = 0.01), but improved significantly from 73.4 at 3 months (p = 0.001). Sub-group analyses revealed that the elective group reported higher emotional functioning than the community sample (91.0, p = 0.005 at 3 months and 88.2, p = 0.038 at 1 year vs community mean=78.5), and made significant gains in social functioning between timepoints (79.1 to 91.4, p = 0.015). Finally, although total PedsQL scores at 1 year were not associated with measures of severity of illness during admission, they were significantly negatively associated with concurrent post-traumatic stress symptom scores (r = -0.40, p = 0.001). Conclusions: The self-report version of the Pediatric Quality of Life Inventory proved to be a feasible and sensitive tool for assessing health related quality of life in this group of PICU survivors. (Pediatr Crit Care Med 2013; 14:e85-e92)	[Colville, Gillian A.; Pierce, Christine M.] Great Ormond St Hosp Sick Children, Paediat Intens Care Unit, London WC1N 3JH, England; [Colville, Gillian A.] St George Hosp, Paediat Psychol Serv, London, England	Colville, GA (corresponding author), Great Ormond St Hosp Sick Children, Paediat Intens Care Unit, Great Ormond St, London WC1N 3JH, England.	gcolvill@sgul.ac.uk	Colville, Gillian/ABH-3180-2020	Colville, Gillian/0000-0001-8530-2822	Health Foundation, United Kingdom	This research was funded by a Leading Practice Through Research award to the first author, from The Health Foundation, United Kingdom. We gratefully acknowledge comments on earlier drafts of this manuscript from Dr Mark Peters at Great Ormond Street Children's Hospital.	Ambuehl J, 2007, SWISS MED WKLY, V137, P312; Calvert S, 2008, DEV MED CHILD NEUROL, V50, P426, DOI 10.1111/j.1469-8749.2008.02061.x; Colville G, 2008, AM J RESP CRIT CARE, V177, P976, DOI 10.1164/rccm.200706-857OC; Colville G, 2008, PEDIATR CLIN N AM, V55, P605, DOI 10.1016/j.pcl.2008.02.006; Colville G, 2012, INTENS CARE MED, V38, P1523, DOI 10.1007/s00134-012-2612-2; Conlon NP, 2009, PEDIATR CRIT CARE ME, V10, P41, DOI 10.1097/PCC.0b013e31819371f6; Davydow DS, 2010, ARCH PEDIAT ADOL MED, V164, P377, DOI 10.1001/archpediatrics.2010.10; Dossetor DR, 1996, J PAEDIATR CHILD H, V32, P519, DOI 10.1111/j.1440-1754.1996.tb00966.x; Eiser C, 2001, J DEV BEHAV PEDIATR, V22, P248, DOI 10.1097/00004703-200108000-00007; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; GEMKE RJBJ, 1995, ARCH DIS CHILD, V73, P196, DOI 10.1136/adc.73.3.196; Graham RJ, 2009, CRIT CARE MED, V37, P2064, DOI 10.1097/CCM.0b013e3181a00578; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Janssens L, 2008, QUAL LIFE RES, V17, P701, DOI 10.1007/s11136-008-9339-0; Jayshree M, 2003, Indian Pediatr, V40, P303; Jones S, 2006, PEDIATRICS, V118, P2101, DOI 10.1542/peds.2006-1455; Knoester H, 2007, EUR J PEDIATR, V166, P1119, DOI 10.1007/s00431-007-0573-1; Knoester H, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-21; Landolt MA, 2009, J PEDIATR PSYCHOL, V34, P14, DOI 10.1093/jpepsy/jsm088; Mistry RD, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-5; Morrison Anne L, 2002, Pediatr Crit Care Med, V3, P1, DOI 10.1097/00130478-200201000-00001; Morrison W, 2010, PEDIATR CRIT CARE ME, V11, P630, DOI 10.1097/PCC.0b013e3181d50462; Namachivayam P, 2010, PEDIATR CRIT CARE ME, V11, P549, DOI 10.1097/PCC.0b013e3181ce7427; Noyes J, 2000, J ADV NURS, V31, P1206, DOI 10.1046/j.1365-2648.2000.01376.x; Noyes J, 2007, J ADV NURS, V58, P1, DOI 10.1111/j.1365-2648.2006.04191.x; Pearson GA, 2001, ARCH DIS CHILD, V84, P125, DOI 10.1136/adc.84.2.125; Perrin S, 2005, BEHAV COGN PSYCHOTH, V33, P487, DOI 10.1017/S1352465805002419; Rennick JE, 2009, J CHILD HEALTH CARE, V13, P128, DOI 10.1177/1367493509102472; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Smith P, 2003, PERS INDIV DIFFER, V34, P315, DOI 10.1016/S0191-8869(02)00047-8; Stallard P, 1999, J CHILD PSYCHOL PSYC, V40, P1075, DOI 10.1111/1469-7610.00525; Taylor A, 2003, INTENS CARE MED, V29, P795, DOI 10.1007/s00134-003-1690-6; Taylor A, 2000, CLIN INTENSIVE CARE, V11, P239; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; Townsend P., 1988, HLTH DEPRIVATION INE; Upton Penney, 2005, Health Qual Life Outcomes, V3, P22, DOI 10.1186/1477-7525-3-22; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2003, DIABETES CARE, V26, P631, DOI 10.2337/diacare.26.3.631; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c; World Health Organization, 1948, CONST WHO CONST BAS; Yule W., 1997, CHILD PSYCHOL PORTFO, P35	45	48	50	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	FEB	2013	14	2					E85	E92		10.1097/PCC.0b013e3182712997			8	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	088GC	WOS:000314820800004	23337805				2021-06-18	
J	Gao, X; Chen, JH				Gao, Xiang; Chen, Jinhui			Moderate traumatic brain injury promotes neural precursor proliferation without increasing neurogenesis in the adult hippocampus	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neurogenesis; Neural stem/progenitor cells; Gliogenesis; Hippocampal dentate gyrus; Subgranular zone	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; STEM-CELL NICHE; DENTATE GYRUS; PROGENITOR CELLS; NEURONAL DIFFERENTIATION; ENHANCED NEUROGENESIS; REACTIVE ASTROCYTES; MOUSE HIPPOCAMPUS; GRANULE CELLS	Traumatic brain injury (TBI) promotes neural stem/progenitor cell (NSC) proliferation in the adult hippocampus; however, it remains inconclusive whether proliferation of these cells results in newly generated mature neurons, leading to increased neurogenesis. When we traced the fates of proliferating cells labeled with bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) we found that the number of BrdU-positive cells increased in the hippocampus of TBI mice compared to the sham control. However, double immunostaining to distinguish their cell types showed that most of these cells were glia, and that only a small subpopulation is newborn granular neurons. There was no significant difference with respect to neurogenesis in the adult hippocampus between the injured and the control mice. These results indicate that TBI promotes cell proliferation including astrocyte activation and NSC proliferation. Nevertheless, the majority of the BrdU-positive cells are glia. The neurogenesis is not increased by TBI. These data suggest that TBI activates through promotion of NSC proliferation an innate repair and/or plasticity mechanism in the brain. However, additional intervention is required to increase neurogenesis for successfully repairing the damaged brain following TBI. (c) 2012 Elsevier Inc. All rights reserved.	Indiana Univ Sch Med, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA	Chen, JH (corresponding author), Indiana Univ, 950 W Walnut St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research [SCBI 200-12]; Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, NIH [RR025761, 1R21NS072631-01A]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported by funding from the Indiana Spinal Cord & Brain Injury Research Grants (SCBI 200-12), the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, NIH grants RR025761 and 1R21NS072631-01A.	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Encinas JM, 2008, EXP NEUROL, V210, P274, DOI 10.1016/j.expneurol.2007.10.021; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Filippov V, 2003, MOL CELL NEUROSCI, V23, P373, DOI 10.1016/S1044-7431(03)00060-5; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Prigatano GP, 2005, ACT NEUR S, V93, P39; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Wurmser AE, 2004, SCIENCE, V304, P1253, DOI 10.1126/science.1099344; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	54	48	50	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2013	239						38	48		10.1016/j.expneurol.2012.09.012			11	Neurosciences	Neurosciences & Neurology	073TH	WOS:000313765000005	23022454	Green Accepted			2021-06-18	
J	Johnston, DT; Deuster, PA; Harris, WS; MacRae, H; Dretsch, MN				Johnston, Daniel T.; Deuster, Patricia A.; Harris, William S.; MacRae, Holden; Dretsch, Michael N.			Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed US Servicemembers	NUTRITIONAL NEUROSCIENCE			English	Article						Omega-3; Neurocognition; Omega-3 index; Performance; Military; Brain	N-3 FATTY-ACIDS; RATING DEPRESSION SCALE; TRAUMATIC BRAIN-INJURY; SLEEP QUALITY INDEX; DOCOSAHEXAENOIC ACID; DIETARY-INTAKE; OMEGA-3 INDEX; VALIDITY; HEALTH; RISK	Objective: To explore the cross-sectional relationships between blood eicosapentaenoic acid + docosahexaenoic acid (HSOmega-3 Index (R)) and sleep disorders, depression, anxiety, and neurocognitive performance in Servicemembers deployed to Iraq. Methods: Servicemembers with mild-to-moderate depression by the Patient Health Questionnarie-9 from two US military camps were invited to participate in this study. A battery of validated psychosocial (Pittsburgh Sleep Quality Index, and Zung Depression, Zung Anxiety, Epworth Sleepiness, and Combat Experiences scales) and computerized neurocognitive tests were completed by each participant. Five neurocognitive domain scores were calculated - Processing Speed, Complex Attention, Reaction Time, Cognitive Flexibility (CF), and Executive Function (EF). A drop of blood was also collected on an anti-oxidant-treated filter paper card and sent for HS-Omega-3 Index (R) analysis. An analysis of variance contrast was used to test for linear trends between quartiles of the HS-Omega-3 Index (R) for both EF and CF. Results: The mean HS-Omega-3 Index (R) was 3.5 +/- 0.7% (n = 78). The HS-Omega-3 Index (R) was not significantly associated with scores for anxiety, depression, or sleep, whether assessed as continuous or dichotomous variables, but was directly associated with CF and EF (P < 0.02 and 0.01, respectively), especially in the 81% who reported poor sleep quality. In those with poor sleep quality (n = 63), EF and CF were higher (P = 0.005) in subjects with Omega-3 levels above versus below the mean. Conclusion: Optimal neurocognitive performance is essential during deployment. Our finding that EF and CF were positively related to HS-Omega-3 Index (R) suggests that improving omega-3 status through an increase in omega-3 intake may improve neurocognitive performance and confer an element of resilience to poor sleep.	[Johnston, Daniel T.] USA, Comprehens Soldier Fitness Performance Resilience, Headquarters Dept, Washington, DC 20310 USA; [Deuster, Patricia A.] Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Dept Mil & Emergency Med, Bethesda, MD 20814 USA; [Harris, William S.] Univ S Dakota, Sanford Sch Med, Sioux Falls, SD 57105 USA; [Harris, William S.] OmegaQuant Analyt LLC, Sioux Falls, SD 57105 USA; [Harris, William S.] Hlth Diagnost Lab Inc, Richmond, VA USA; [MacRae, Holden] Pepperdine Univ, Div Nat Sci, Malibu, CA 90265 USA; [Dretsch, Michael N.] USA, Aeromed Res Lab USAARL, Ft Rucker, AL USA	Johnston, DT (corresponding author), 2530 Crystal Dr,Rm 1628, Arlington, VA 22203 USA.	Daniel.Johnston@us.army.mil	Harris, William Stephen/T-1674-2019; Deuster, Patricia A/G-3838-2015	Harris, William Stephen/0000-0003-3042-9353; Deuster, Patricia A/0000-0002-7895-0888			Amin AA, 2008, PSYCHOSOM MED, V70, P856, DOI 10.1097/PSY.0b013e318188a01e; Assies J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010635; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; BIGGS JT, 1978, BRIT J PSYCHIAT, V132, P381, DOI 10.1192/bjp.132.4.381; Bistrian BR, 2011, JPEN-PARENTER ENTER, V35, P556, DOI 10.1177/0148607111416122; Block Robert C, 2008, Open Biomark J, V1, P1, DOI 10.2174/1875318300801010001; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carney RM, 2009, JAMA-J AM MED ASSOC, V302, P1651, DOI 10.1001/jama.2009.1487; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Colangelo LA, 2009, NUTRITION, V25, P1011, DOI 10.1016/j.nut.2008.12.008; CONNOR WE, 1992, NUTR REV, V50, P21; Esposito-Smythers C, 2011, J FAM PSYCHOL, V25, P497, DOI 10.1037/a0024534; Gao Q, 2011, J NUTR HEALTH AGING, V15, P32, DOI 10.1007/s12603-011-0010-z; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Han DH, 2011, PSYCHIAT INVEST, V8, P221, DOI 10.4306/pi.2011.8.3.221; Harris WS, 2004, PREV MED, V39, P212, DOI 10.1016/j.ypmed.2004.02.030; Harris WS, 2012, J NUTR IN PRESS; Hayashino Y, 2010, SLEEP MED, V11, P366, DOI 10.1016/j.sleep.2009.05.021; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Innis SM, 2007, J NUTR, V137, P855; Institute of Medicine [IOM], 2011, NUTR TRAUM BRAIN INJ; Jackson ML, 2011, PROG BRAIN RES, V190, P53, DOI 10.1016/B978-0-444-53817-8.00003-7; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450; Jugovac D, 2011, EXP PSYCHOL, V1, P11; Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lafourcade M, 2011, NAT NEUROSCI, V14, P345, DOI 10.1038/nn.2736; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Lemke SL, 2010, AM J CLIN NUTR, V92, P766, DOI 10.3945/ajcn.2009.29072; Lin PY, 2010, BIOL PSYCHIAT, V68, P140, DOI 10.1016/j.biopsych.2010.03.018; Lucas M, 2011, AM J CLIN NUTR, V93, P1337, DOI 10.3945/ajcn.111.011817; Lucas M, 2010, J AM COLL NUTR, V29, P211, DOI 10.1080/07315724.2010.10719836; Luxton DD, 2010, DEPRESS ANXIETY, V27, P1027, DOI 10.1002/da.20730; Lyche P, 2011, CLIN NEUROPSYCHOL, V25, P359, DOI 10.1080/13854046.2010.547518; Martins JG, 2009, J AM COLL NUTR, V28, P525, DOI 10.1080/07315724.2009.10719785; MIKESELL RH, 1970, PERCEPT MOTOR SKILL, V30, P22, DOI 10.2466/pms.1970.30.1.22; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Milte CM, 2011, PROSTAG LEUKOTR ESS, V84, P153, DOI 10.1016/j.plefa.2011.02.002; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Najmi S, 2012, DEPRESS ANXIETY, V29, P243, DOI 10.1002/da.20900; Oddy WH, 2011, DEPRESS ANXIETY, V28, P582, DOI 10.1002/da.20822; Owen C, 2008, CURR OPIN PSYCHIATR, V21, P19, DOI 10.1097/YCO.0b013e3282f29841; Ozias MK, 2007, J NUTR, V137, P125; Pascoe MC, 2011, CLIN NUTR, V30, P407, DOI 10.1016/j.clnu.2011.03.013; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Riviere LA, 2011, BRIT J PSYCHIAT, V198, P136, DOI 10.1192/bjp.bp.110.084863; Romera I, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-4; Sands SA, 2005, LIPIDS, V40, P343, DOI 10.1007/s11745-006-1392-2; Srygley JM, 2009, BRAIN RES, V1253, P92, DOI 10.1016/j.brainres.2008.11.067; Sublette ME, 2011, J CLIN PSYCHIAT, V72, P1577, DOI 10.4088/JCP.10m06634; Suganuma H, 2010, NEUROPATHOLOGY, V30, P597, DOI 10.1111/j.1440-1789.2010.01114.x; Tan ZS, 2012, NEUROLOGY, V78, P658, DOI 10.1212/WNL.0b013e318249f6a9; Tassoni D, 2008, ASIA PAC J CLIN NUTR, V17, P220; Thoma P, 2011, PSYCHIAT RES, V189, P373, DOI 10.1016/j.psychres.2011.07.030; Uauy R, 1996, LIPIDS, V31, pS167, DOI 10.1007/BF02637071; van de Rest O, 2008, NEUROLOGY, V71, P430, DOI 10.1212/01.wnl.0000324268.45138.86; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Yurko-Mauro K, 2010, ALZHEIMERS DEMENT, V6, P456, DOI 10.1016/j.jalz.2010.01.013; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V13, P508, DOI 10.1001/archpsyc.1965.01730060026004; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P380	67	48	48	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1028-415X	1476-8305		NUTR NEUROSCI	Nutr. Neurosci.	JAN	2013	16	1					30	38		10.1179/1476830512Y.0000000025			9	Neurosciences; Nutrition & Dietetics	Neurosciences & Neurology; Nutrition & Dietetics	087OL	WOS:000314771400005	22748167				2021-06-18	
J	Aksu, I; Ates, M; Baykara, B; Kiray, M; Sisman, AR; Buyuk, E; Baykara, B; Cetinkaya, C; Gumus, H; Uysal, N				Aksu, Ilkay; Ates, Mehmet; Baykara, Basak; Kiray, Muge; Sisman, Ali Riza; Buyuk, Erkan; Baykara, Burak; Cetinkaya, Caner; Gumus, Hikmet; Uysal, Nazan			Anxiety correlates to decreased blood and prefrontal cortex IGF-1 levels in streptozotocin induced diabetes	NEUROSCIENCE LETTERS			English	Article						Diabetes; Anxiety; IGF-1; SOD; MDA; Corticosterone; Prefrontal cortex	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; GENE-EXPRESSION; PITUITARY; RECEPTOR; RATS; MICE; AXIS; RESPONSIVENESS; INVOLVEMENT	It is well known that diabetes mellitus may cause neuropsychiatric disorders such as anxiety disorders. Diabetes may also cause reduced IGF-1 (insulin like growth factor-1) levels in brain and blood. The purpose of the present study was to investigate the relationship between diabetes induced anxiety and IGF-1 levels in diabetic rats. The anxiety levels of rats were assessed 2 weeks after intraperitoneal injection of streptozotocin. Diabetic rats had higher levels of anxiety, as they spent more time in closed branches in elevated-plus-maze-test and less time in the center cells of open-field-arena. Prefrontal cortex (PFC) IGF-1 levels and neuron numbers were decreased and apoptosis was increased in diabetic rats. Blood IGF-1 levels decreased in a time dependent fashion following streptozotocin injection while blood corticosterone levels increased. They had higher malondialdehyde levels and lower superoxide dismutase enzyme activity. Oxidative stress may negatively affect blood and PFC tissue IGF-1 levels. Reduction in IGF-1 may cause PFC damage, which may eventually trigger anxiety in diabetic rats. Therapeutic strategies that increase blood and brain tissue IGF-1 levels may be promising to prevent psychiatric sequelae of diabetes mellitus. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Aksu, Ilkay; Kiray, Muge; Cetinkaya, Caner; Gumus, Hikmet; Uysal, Nazan] Dokuz Eylul Univ, Fac Med, Dept Physiol, TR-35210 Alsancak, Turkey; [Ates, Mehmet] Dokuz Eylul Univ, High Sch Phys Therapy & Rehabil Histol & Embryol, TR-35210 Alsancak, Turkey; [Baykara, Basak] Dokuz Eylul Univ, Fac Med, Vocat Sch Hlth Serv, TR-35210 Alsancak, Turkey; [Sisman, Ali Riza] Dokuz Eylul Univ, Fac Med, Dept Biochem, Izmir, Turkey; [Buyuk, Erkan] Montefiore Med Ctr, Albert Einstein Coll Med, Div Reprod Endocrinol & Infertil, Dept Obstet Gynecol & Womens Hlth, Bronx, NY 10467 USA; [Baykara, Burak] Dokuz Eylul Univ, Fac Med, Dept Child & Adolescent Psychiat, Izmir, Turkey	Uysal, N (corresponding author), Dokuz Eylul Univ, Fac Med, Dept Physiol, TR-35210 Alsancak, Turkey.	nazan.uysal@deu.edu.tr	ates, mehmet/P-4503-2019; Baykara, Basak/AAC-6504-2019; Baykara, Huseyin Burak/AAH-4898-2020; cetinkaya, caner/A-1290-2019; CETINKAYA, CANER/O-7248-2019; Gumus, Hikmet/I-8335-2016	ates, mehmet/0000-0002-8310-1979; Baykara, Basak/0000-0002-4178-2235; Baykara, Huseyin Burak/0000-0002-1530-0159; cetinkaya, caner/0000-0002-5642-6794; CETINKAYA, CANER/0000-0002-5642-6794; Gumus, Hikmet/0000-0001-7671-4868; Uysal, Nazan/0000-0002-2348-7427			Ajilore O, 2010, PSYCHIAT RES-NEUROIM, V184, P63, DOI 10.1016/j.pscychresns.2010.07.003; ASPLIN CM, 1989, J CLIN ENDOCR METAB, V69, P239, DOI 10.1210/jcem-69-2-239; Bishop S, 2004, NAT NEUROSCI, V7, P184, DOI 10.1038/nn1173; Chan O, 2002, ENDOCRINOLOGY, V143, P1761, DOI 10.1210/en.143.5.1761; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; Collins MM, 2009, DIABETIC MED, V26, P153, DOI 10.1111/j.1464-5491.2008.02648.x; Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH1882, DOI 10.1152/ajpheart.412.2008; DENICOLA AF, 1977, HORM METAB RES, V9, P469, DOI 10.1055/s-0028-1093502; Enhamre E, 2012, NEUROSCI LETT, V523, P82, DOI 10.1016/j.neulet.2012.06.050; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; Gurpinar T, 2012, SCI WORLD J, DOI 10.1100/2012/498489; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Kern S, 2008, PSYCHONEUROENDOCRINO, V33, P517, DOI 10.1016/j.psyneuen.2008.01.010; Kim MJ, 2009, J NEUROSCI, V29, P11614, DOI 10.1523/JNEUROSCI.2335-09.2009; Kumar TP, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-43; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Maiese K, 2007, CURR MED CHEM, V14, P1729; MAYHAN WG, 1993, AM J PHYSIOL, V265, pH152; MEEHAN WP, 1986, PHYSIOL BEHAV, V38, P301, DOI 10.1016/0031-9384(86)90098-3; Mitschelen M, 2011, NEUROSCIENCE, V185, P50, DOI 10.1016/j.neuroscience.2011.04.032; Miyata S, 2007, BRAIN RES, V1147, P233, DOI 10.1016/j.brainres.2007.02.001; Mizoguchi K, 2010, J ETHNOPHARMACOL, V127, P70, DOI 10.1016/j.jep.2009.09.048; NOGUEIRA CR, 1994, GEN PHARMACOL, V25, P909, DOI 10.1016/0306-3623(94)90095-7; OLCHOVSKY D, 1990, ENDOCRINOLOGY, V126, P53, DOI 10.1210/endo-126-1-53; Ozdemir D, 2012, NEUROSCI LETT, V507, P84, DOI 10.1016/j.neulet.2011.11.059; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; PLOTSKY PM, 1992, ENDOCRINOLOGY, V130, P1931, DOI 10.1210/en.130.4.1931; Quirk GJ, 2006, CURR OPIN NEUROBIOL, V16, P723, DOI 10.1016/j.conb.2006.07.004; Revsin Y, 2009, NEUROPSYCHOPHARMACOL, V34, P747, DOI 10.1038/npp.2008.136; Rosen JB, 1998, PSYCHOL REV, V105, P325, DOI 10.1037/0033-295X.105.2.325; ROY MS, 1993, METABOLISM, V42, P696, DOI 10.1016/0026-0495(93)90235-G; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SCRIBNER KA, 1991, ENDOCRINOLOGY, V129, P99, DOI 10.1210/endo-129-1-99; Serbedzija P, 2009, BRAIN RES, V1303, P179, DOI 10.1016/j.brainres.2009.09.063; Sharma AN, 2010, PHYSIOL BEHAV, V101, P381, DOI 10.1016/j.physbeh.2010.07.002; Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007; Si W, 2010, J NEUROCHEM, V115, P475, DOI 10.1111/j.1471-4159.2010.06947.x; SIMON GE, 1995, ARCH GEN PSYCHIAT, V52, P850; Torres-Aleman I, 2010, DEV NEUROBIOL, V70, P384, DOI 10.1002/dneu.20778; Trejo JI, 2007, MOL PSYCHIATR, V12, P1118, DOI 10.1038/sj.mp.4002076; Uysal N, 2005, NEUROENDOCRINOL LETT, V26, P419; van Raalte DH, 2010, EUR J ENDOCRINOL, V162, P729, DOI 10.1530/EJE-09-1034; Yan H, 2011, J ENDOCRINOL, V211, P27, DOI 10.1530/JOE-11-0200	44	48	48	1	39	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 7	2012	531	2					176	181		10.1016/j.neulet.2012.10.045			6	Neurosciences	Neurosciences & Neurology	058CX	WOS:000312612800023	23123774				2021-06-18	
J	Rafaels, KA; Bass, CR; Panzer, MB; Salzar, RS; Woods, WA; Feldman, SH; Walilko, T; Kent, RW; Capehart, BP; Foster, JB; Derkunt, B; Toman, A				Rafaels, Karin A.; Bass, Cameron R. 'Dale'; Panzer, Matthew B.; Salzar, Robert S.; Woods, William A.; Feldman, Sanford H.; Walilko, Tim; Kent, Richard W.; Capehart, Bruce P.; Foster, Jonathan B.; Derkunt, Burcu; Toman, Amanda			Brain injury risk from primary blast	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Primary blast; brain injury; injury risk; ferret	ADULT-RAT BRAIN; IMPULSE NOISE; HEAD-INJURY; NEURONS; OVERPRESSURE; NEUROTRAUMA; EXPOSURE	BACKGROUND: Military service members are often exposed to at least one explosive event, and many blast-exposed veterans present with symptoms of traumatic brain injury. However, there is little information on the intensity and duration of blast necessary to cause brain injury. METHODS: Varying intensity shock tube blasts were focused on the head of anesthetized ferrets, whose thorax and abdomen were protected. Injury evaluations included physiologic consequences, gross necropsy, and histologic diagnosis. The resulting apnea, meningeal bleeding, and fatality were analyzed using logistic regressions to determine injury risk functions. RESULTS: Increasing severity of blast exposure demonstrated increasing apnea immediately after the blast. Gross necropsy revealed hemorrhages, frequently near the brain stem, at the highest blast intensities. Apnea, bleeding, and fatality risk functions from blast exposure to the head were determined for peak overpressure and positive-phase duration. The 50% risk of apnea and moderate hemorrhage were similar, whereas the 50% risk of mild hemorrhage was independent of duration and required lower overpressures (144 kPa). Another fatality risk function was determined with existing data for scaled positive-phase durations from 1 millisecond to 20 milliseconds. CONCLUSION: The first primary blast brain injury risk assessments for mild and moderate/severe injuries in a gyrencephalic animal model were determined. The blast level needed to cause a mild/moderate brain injury may be similar to or less than that needed for pulmonary injury. The risk functions can be used in future research for blast brain injury by providing realistic injury risks to guide the design of protection or evaluate injury. (J Trauma Acute Care Surg. 2012;73:895-901. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Woods, William A.] Univ Virginia, Dept Emergency Med, Charlottesville, VA USA; [Rafaels, Karin A.; Salzar, Robert S.; Kent, Richard W.; Foster, Jonathan B.; Derkunt, Burcu] Univ Virginia, Ctr Appl Biomech, Charlottesville, VA USA; [Feldman, Sanford H.] Univ Virginia, Ctr Comparat Med, Charlottesville, VA USA; [Toman, Amanda] Tech Support Working Grp, Arlighton, VA USA; [Bass, Cameron R. 'Dale'; Panzer, Matthew B.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Capehart, Bruce P.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27706 USA; [Capehart, Bruce P.] Durham VA Med Ctr, Operat Enduring Freedom Operat Iraqi Freedom Vet, Durham, NC USA; [Capehart, Bruce P.] Durham VA Med Ctr, Mental Hlth Serv Line, Durham, NC USA; [Walilko, Tim] Appl Res Associates, Rocky Mt Div, Littleton, CO USA	Rafaels, KA (corresponding author), USA, Res Lab, ATTN RDRL SLB W, 328 Hopkins Rd, Aberdeen Proving Ground, MD 21005 USA.	kar3k@virginia.edu	Feldman, Sanford/AAH-7070-2021		TSWG [W91CRB-09-C-0015]; University of Virginia School of Engineering and Applied Sciences; UVA Center for Applied Biomechanics; UVA Center for Comparative Medicine; Duke University Pratt School of Engineering; Department of Biomedical Engineering	We gratefully acknowledge support from TSWG under contract W91CRB-09-C-0015, the University of Virginia School of Engineering and Applied Sciences, the UVA Center for Applied Biomechanics, the UVA Center for Comparative Medicine for animal support, the Duke University Pratt School of Engineering and the Department of Biomedical Engineering.	Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Axelsson H, 1996, J TRAUMA, V40, pS31, DOI 10.1097/00005373-199603001-00006; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bogo V, 1971, DASA2659 DEF NUCL AG; Bowen I G, 1968, DASA2113 DEP DEF; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CLEMEDSON CJ, 1953, AM J PHYSIOL, V174, P316; Clemedson CJ, 1949, ACTA PHYSL SCAND, V18, P1; DODD KT, 1990, J OCCUP ENVIRON MED, V32, P260, DOI 10.1097/00043764-199003000-00015; Eppinger R., 1984, 840885 SAE; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Hooker DR, 1924, AM J PHYSIOL, V67, P219; Hosmer D, 1989, APPL LOGISTIC REGRES; Hutsler JJ, 2005, BRAIN RES, V1052, P71, DOI 10.1016/j.brainres.2005.06.015; Hyde D., 2004, CONWEP 2 1 0 8 COMPU; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Krohn PL, 1941, 249 RC MIN HOM SEC C; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rasband W. S, 2012, IMAGEJ; Richmond D R, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P35; Risling M, 2005, FOIR0756SE SWED DEF; Romba J, 1959, 1159 HUM ENG LAB; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; SMART IHM, 1986, J ANAT, V146, P141; Stuhmiller JH, 1997, TOXICOLOGY, V121, P91, DOI 10.1016/S0300-483X(97)03658-5; Wood GW, 2010, PERS ARM SYST S QUEB; Yelverton JT, 1997, SCI FDN TRAUMA, P189; Zhu F, 2010, P STAPP CAR CRASH C	40	48	48	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2012	73	4					895	901		10.1097/TA.0b013e31825a760e			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	029OL	WOS:000310505100017	22836001				2021-06-18	
J	Johnson, B; Gay, M; Zhang, K; Neuberger, T; Horovitz, SG; Hallett, M; Sebastianelli, W; Slobounov, S				Johnson, Brian; Gay, Michael; Zhang, Kai; Neuberger, Thomas; Horovitz, Silvina G.; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			The Use of Magnetic Resonance Spectroscopy in the Subacute Evaluation of Athletes Recovering from Single and Multiple Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						concussion; H-1-MRS; MTBI; multiple MTBI	ACETYL-L-ASPARTATE; CORPUS-CALLOSUM; MR SPECTROSCOPY; MITOCHONDRIAL BIOGENESIS; N-ACETYLASPARTATE; TEMPORAL WINDOW; CONCUSSION; GRAY; ABNORMALITIES; VULNERABILITY	Advanced neuroimaging techniques have shown promise in highlighting the subtle changes and nuances in mild traumatic brain injury (MTBI) even though clinical assessment has shown a return to pre-injury levels. Here we use H-1-magnetic resonance spectroscopy (H-1-MRS) to evaluate the brain metabolites N-acetyl aspartate (NAA), choline (Cho), and creatine (Cr) in the corpus callosum in MTBI. Specifically, we looked at the NAA/Cho, NAA/Cr, and Cho/Cr ratios in the genu and splenium. We recruited 20 normal volunteers (NV) and 28 student athletes recovering from the subacute phase of MTBI. The MTBI group was categorized based upon the number of MTBIs and time from injury to H-1-MRS evaluation. Significant reductions in NAA/Cho and NAA/Cr ratios were seen in the genu of the corpus callosum, but not in the splenium, for MTBI subjects, regardless of the number of MTBIs. MTBI subjects recovering from their first MTBI showed the greatest alteration in NAA/Cho and NAA/Cr ratios. Time since injury to H-1-MRS acquisition was based upon symptom resolution and did not turn out to be a significant factor. We observed that as the number of MTBIs increased, so did the length of time for symptom resolution. Unexpected findings from this study are that MTBI subjects showed a trend of increasing NAA/Cho and NAA/Cr ratios that coincided with increasing number of MTBIs.	[Johnson, Brian; Gay, Michael; Zhang, Kai; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Johnson, Brian; Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Orthopaed Surg & Rehabil, University Pk, PA 16802 USA; [Horovitz, Silvina G.; Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150; Horovitz, Silvina G./0000-0002-5501-5918	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury."	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Arun P, 2009, NEUROCHEM INT, V55, P219, DOI 10.1016/j.neuint.2009.03.003; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Covaciu L, 2010, J MAGN RESON IMAGING, V31, P807, DOI 10.1002/jmri.22107; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Degaonkar MN, 2005, J MAGN RESON IMAGING, V22, P175, DOI 10.1002/jmri.20353; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gutsaeva DR, 2008, J NEUROSCI, V28, P2015, DOI 10.1523/JNEUROSCI.5654-07.2008; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maniega SM, 2008, STROKE, V39, P2467, DOI 10.1161/STROKEAHA.107.507020; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stefan D, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/10/104035; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	60	48	49	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2297	2304		10.1089/neu.2011.2294			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900005	22780855	Green Published			2021-06-18	
J	Fujita, M; Wei, EP; Povlishock, JT				Fujita, Motoki; Wei, Enoch P.; Povlishock, John T.			Intensity- and Interval-Specific Repetitive Traumatic Brain Injury Can Evoke Both Axonal and Microvascular Damage	JOURNAL OF NEUROTRAUMA			English	Article						injury severity and timing; repetitive traumatic brain injury; rats; second-impact syndrome	HEAD-INJURY; IMPACT; HYPOTHERMIA; RATS; ENCEPHALOPATHY; VULNERABILITY; CONCUSSION; ARTERIOLAR; SPORTS; WINDOW	In the experimental setting several investigators have recently reported exacerbations of the burden of axonal damage and other neuropathological changes following repetitive traumatic brain injuries (TBI) that were sustained at intervals from hours to days following the initial insult. These same studies also revealed that prolonging the interval between the first and second insult led to a reduction in the burden of neuropathological changes and/or their complete elimination. Although demonstrating the capability of repetitive TBI to evoke increased axonal and other neuropathological changes, these studies did not address the potential for concomitant microvascular dysfunction or damage, although vascular dysfunction has been implicated in the second-impact syndrome. In this study we revisit the issue of repetitive injury in a well-controlled animal model in which the TBI intensity was bracketed from subthreshold to threshold insults, while the duration of the intervals between the injuries varied. Employing cranial windows to assess vascular reactivity and post-mortem amyloid precursor protein (APP) analysis to determine the burden of axonal change, we recognized that subthreshold injuries, even when administered in repeated fashion over a short time frame, evoked neither axonal nor vascular change. However, with an elevation of insult intensity, repetitive injuries administered within 3-h time frames caused dramatic axonal damage and significant vascular dysfunction bordering on a complete loss of vasoreactivity. If, however, the interval between the repetitive injury was extended to 5 h, the burden of axonal change was reduced, as was the overall magnitude of the ensuing vascular dysfunction. With the extension of the interval between injuries to 10 h, neither axonal nor vascular changes were found. Collectively, these studies reaffirm the existence of significant axonal damage following repetitive TBI administered within a relatively short time frame. Additionally, they also demonstrate that these axonal changes parallel changes in the cerebral microcirculation, which also may have adverse consequences for the injured brain.	[Fujita, Motoki; Wei, Enoch P.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Fujita, Motoki] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD055813, NS047463]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	We thank Susan Walker and Lynn Davis for their excellent technical assistance. This study was supported by National Institutes of Health grants HD055813 and NS047463.	Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujita M, 2011, J NEUROTRAUM, V28, P1209, DOI 10.1089/neu.2011.1852; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Oda Y, 2011, J CEREBR BLOOD F MET, V31, P1143, DOI 10.1038/jcbfm.2010.208; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	30	48	50	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2172	2180		10.1089/neu.2012.2357			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900005	22559115	Green Published			2021-06-18	
J	Hanks, RA; Rapport, LJ; Wertheimer, J; Koviak, C				Hanks, Robin A.; Rapport, Lisa J.; Wertheimer, Jeffrey; Koviak, Carole			Randomized Controlled Trial of Peer Mentoring for Individuals With Traumatic Brain Injury and Their Significant Others	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Caregivers; Depression; Mentors; Quality of life; Rehabilitation; Social support	SPINAL-CORD-INJURY; SOCIAL SUPPORT; COMMUNITY INTEGRATION; PROGRAM; ADJUSTMENT; VALIDITY; ADULTS	Hanks RA, Rapport LJ, Wertheimer J, Koviak C. Randomized controlled trial of peer mentoring for individuals with traumatic brain injury and their significant others. Arch Phys Med Rehabil 2012;93:1297-1304. Objectives: for persons with traumatic brain injury (TBI) and their significant others, and to determine the relationship of this mentoring program to 3 main outcomes: (1) emotional wellbeing; (2) post-TBI quality of life; and (3) community integration. Design: Randomized controlled trial. Setting: Midwestern rehabilitation hospital. Participants: Persons with TBI (n = 96) and significant others/caregiver; (n = 62). Interventions: Persons with TBI and friends/caregivers who knew the person prior to their injury were randomly assigned to a treatment (mentored) or no-treatment (no mentoring) control group immediately prior to discharge from the rehabilitation unit and were mentored for up to 2 years. Main Outcome Measures: Peer Mentoring Questionnaire; Brief Symptom Inventory-18; Family Assessment Device; Coping Inventory for Stressful Situations; Short Michigan Alcohol ScreeningTest; Medical Outcomes Study 12-Item Short-Form Health Survey; and Community Integration Measure. Result: Eighty-eight percent of individuals who were involved in the mentoring program reported positive experiences. t tests revealed that among persons with TBI, individuals who received mentoring had significantly better behavioral control and less chaos in the living environment (P = .04), lower alcohol use (P = .01), less emotion-focused (P = .04) and avoidance coping (P = .03), and good physical quality of life (P = .04) compared with those who did not receive mentoring. Among significant others, mentored individuals demonstrated greater community integration (P = .03) than the nonmentored control group. Conclusions: Mentoring can be an effective way to benefit mood and healthy coping after TBI, and it can help to prevent maladaptive behaviors, such as substance abuse and behavioral dyscontrol, in the living situation.	[Hanks, Robin A.] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Wertheimer, Jeffrey] Cedars Sinai Med Ctr, Dept Psychol, Los Angeles, CA 90048 USA; [Koviak, Carole] Rehabil Inst Michigan, Dept Res, Detroit, MI USA	Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.	rhanks@med.wayne.edu			U.S. Department of Education-National Institute of Disability Research and Rehabilitation-The Traumatic Brain Injury Model Systems Project [H133A020515]	Supported by the U.S. Department of Education-National Institute of Disability Research and Rehabilitation-The Traumatic Brain Injury Model Systems Project (grant no. H133A020515).	Allen TD, 2004, J APPL PSYCHOL, V89, P127, DOI 10.1037/0021-9010.89.1.127; Boschen KA, 2003, INT J REHABIL RES, V26, P157, DOI 10.1097/00004356-200309000-00001; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Endler E, 1990, J PERS SOC PSYCHOL, V58, P844; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hopman-Rock M, 2002, J AGING PHYS ACTIV, V10, P364, DOI 10.1123/japa.10.4.364; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Quine S, 1998, EDUC GERONTOL, V24, P661, DOI 10.1080/0360127980240704; Rini C, 2007, J CLIN ONCOL, V25, P163, DOI 10.1200/JCO.2006.08.8567; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Shem K, 2011, SPINAL CORD, V49, P544, DOI 10.1038/sc.2010.166; Sherman JE, 2004, REHABIL PSYCHOL, V49, P140, DOI 10.1037/0090-5550.49.2.140; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P30, DOI 10.1097/HTR.0b013e3182048f7c; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; TEASDALE G, 1974, LANCET, V2, P81; Thoits PA, 2000, HEALTH PSYCHOL, V19, P264, DOI 10.1037//0278-6133.19.3.264; Veith EM, 2006, REHABIL PSYCHOL, V51, P289, DOI 10.1037/0090-5550.51.4.289; Ware J.E., 1998, SF 12 SCORE SF 12 PH, V2; Whittemore R, 2000, QUAL HEALTH RES, V10, P260, DOI 10.1177/104973200129118408; WHYTE WF, 1991, PARTICIPATORY ACTION	25	48	48	0	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1297	1304		10.1016/j.apmr.2012.04.027			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700001	22840826				2021-06-18	
J	Lu, CW; Czosnyka, M; Shieh, JS; Smielewska, A; Pickard, JD; Smielewski, P				Lu, Cheng-Wei; Czosnyka, Marek; Shieh, Jiann-Shing; Smielewska, Anna; Pickard, John D.; Smielewski, Peter			Complexity of intracranial pressure correlates with outcome after traumatic brain injury	BRAIN			English	Article						complexity; intracranial pressure; multiscale entropy; traumatic brain injury; outcome	MULTISCALE ENTROPY ANALYSIS; HEART-RATE-VARIABILITY; APPROXIMATE ENTROPY; BLOOD-PRESSURE; PLATEAU WAVES; TIME-SERIES; AUTOREGULATION; HYPERTENSION; DYNAMICS; SYSTEM	This study applied multiscale entropy analysis to investigate the correlation between the complexity of intracranial pressure waveform and outcome after traumatic brain injury. Intracranial pressure and arterial blood pressure waveforms were low-pass filtered to remove the respiratory and pulse components and then processed using a multiscale entropy algorithm to produce a complexity index. We identified significant differences across groups classified by the Glasgow Outcome Scale in intracranial pressure, pressure-reactivity index and complexity index of intracranial pressure (P < 0.0001; P = 0.001; P < 0.0001, respectively). Outcome was dichotomized as survival/death and also as favourable/unfavourable. The complexity index of intracranial pressure achieved the strongest statistical significance (F = 28.7; P < 0.0001 and F = 17.21; P < 0.0001, respectively) and was identified as a significant independent predictor of mortality and favourable outcome in a multivariable logistic regression model (P < 0.0001). The results of this study suggest that complexity of intracranial pressure assessed by multiscale entropy was significantly associated with outcome in patients with brain injury.	[Lu, Cheng-Wei; Czosnyka, Marek; Pickard, John D.; Smielewski, Peter] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB0 2QQ, England; [Lu, Cheng-Wei] Far Eastern Mem Hosp, Dept Anaesthesiol, Taipei 220, Taiwan; [Lu, Cheng-Wei; Shieh, Jiann-Shing] Yuan Ze Univ, Dept Mech Engn, Tao Yuan 220, Taiwan; [Smielewska, Anna] Addenbrookes Hosp, Publ Hlth Lab, Dept Virol, Cambridge CB0 2QQ, England	Smielewski, P (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Level 4,A Block, Cambridge CB0 2QQ, England.	ps10011@cam.ac.uk		Smielewska, Anna/0000-0002-6200-6876; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; NIHRNational Institute for Health Research (NIHR); Center for Dynamical Biomarkers and Translational Medicine; National Science CouncilMinistry of Science and Technology, Taiwan [NSC 100-2911-I-008-001]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B, G1000183B, G0001354, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), NIHR Senior Investigator Awards (J.D.P.). This research was also supported by the Center for Dynamical Biomarkers and Translational Medicine which is sponsored by National Science Council (grant number: NSC 100-2911-I-008-001).	Angelini L, 2007, ARTIF INTELL MED, V41, P237, DOI 10.1016/j.artmed.2007.07.012; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Balestreri M, 2005, ACT NEUR S, V95, P25; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Buchman Timothy G, 2004, Curr Opin Crit Care, V10, P378, DOI 10.1097/01.ccx.0000139369.65817.b6; Burr RL, 2008, IEEE T BIO-MED ENG, V55, P2509, DOI 10.1109/TBME.2008.2001286; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; Catarino A, 2011, CLIN NEUROPHYSIOL, V122, P2375, DOI 10.1016/j.clinph.2011.05.004; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE10; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; Goldstein B, 1998, CRIT CARE MED, V26, P352, DOI 10.1097/00003246-199802000-00040; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hornero R, 2006, CRIT CARE MED, V34, P87, DOI 10.1097/01.CCM.0000190426.44782.F0; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; Hornero R, 2007, MED BIOL ENG COMPUT, V45, P617, DOI 10.1007/s11517-007-0194-x; Hu X, 2006, IEEE T BIO-MED ENG, V53, P195, DOI 10.1109/TBME.2005.862546; Hu X, 2008, MED ENG PHYS, V30, P631, DOI 10.1016/j.medengphy.2007.07.002; JENNETT B, 1975, LANCET, V1, P480; LEMAIRE JJ, 1994, COMPUT METH PROG BIO, V42, P1, DOI 10.1016/0169-2607(94)90133-3; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Manor B, 2010, J APPL PHYSIOL, V109, P1786, DOI 10.1152/japplphysiol.00390.2010; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Mizuno T, 2010, CLIN NEUROPHYSIOL, V121, P1438, DOI 10.1016/j.clinph.2010.03.025; Norris PR, 2008, SHOCK, V30, P17, DOI 10.1097/SHK.0b013e318164e4d0; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Protzner AB, 2010, ARCH ITAL BIOL, V148, P289; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Riordan WP, 2009, J SURG RES, V156, P283, DOI 10.1016/j.jss.2009.03.086; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Santamarta D, 2010, CHILD NERV SYST, V26, P1683, DOI 10.1007/s00381-010-1244-5; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Takahashi T, 2010, NEUROIMAGE, V51, P173, DOI 10.1016/j.neuroimage.2010.02.009; Trunkvalterova Z, 2008, PHYSIOL MEAS, V29, P817, DOI 10.1088/0967-3334/29/7/010; Turianikova Z, 2011, PHYSIOL MEAS, V32, DOI 10.1088/0967-3334/32/9/006; Ursino M, 1997, J APPL PHYSIOL, V82, P1256	42	48	51	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2012	135		8				2399	2408		10.1093/brain/aws155			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	984DQ	WOS:000307170300019	22734128	Green Published, Bronze			2021-06-18	
J	Beaulieu-Bonneau, S; Morin, CM				Beaulieu-Bonneau, Simon; Morin, Charles M.			Sleepiness and fatigue following traumatic brain injury	SLEEP MEDICINE			English	Article						Brain injury; Sleepiness; Fatigue; Sleep; Neurological disorders; Case-control study	DAYTIME SLEEPINESS; UNITED-STATES; RISK-FACTORS; CLINICAL-USE; POPULATION; PREVALENCE; INSTRUMENT; DISORDERS; FREQUENCY; INSOMNIA	Objectives: To compare individuals with traumatic brain injury (TBI) to healthy controls (CTLs) on measures of sleepiness, fatigue, and sleep, and explore correlates of sleepiness and fatigue separately for each group. Methods: Participants were 22 adults with moderate/severe TBI (time since injury >= 1 year; mean = 53.0 +/- 37.1 months) and 22 matched healthy CTLs. They underwent one night of polysomnographic (PSG) recording of their sleep followed the next day by the Maintenance of Wakefulness Test (MWT). They also completed a 14-day sleep diary, the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire (FOSQ), and the Multidimensional Fatigue Inventory (MFI). Results: There were no significant group differences on measures of objective (MWT) or subjective (ESS) sleepiness, both groups being quite alert. However, TBI participants reported greater consequences of sleepiness on their general productivity (FOSQ), spent more time in bed at night, and napped more frequently and for a longer time during the day. Subjective fatigue was significantly higher in TBI participants on the general, physical, and mental fatigue MFI subscales. There were no between-group differences on any sleep parameters derived either from PSG or sleep diary. Conclusions: Fatigue appeared to be a more prominent symptom than sleepiness when assessed between 1 and 11 years after TBI. Participants with TBI used compensatory strategies such as increasing time spent in bed and daytime napping in this sample. Future research should document the time course of sleepiness and fatigue after TBI and investigate treatment options. (C) 2012 Elsevier B.V. All rights reserved.	[Beaulieu-Bonneau, Simon; Morin, Charles M.] Univ Laval, Ecole Psychol, Quebec City, PQ G1V 0A6, Canada	Beaulieu-Bonneau, S (corresponding author), Univ Laval, Ecole Psychol, Pavillon Felix Antoine Savard 2325,Rue Bibliotheq, Quebec City, PQ G1V 0A6, Canada.	Simon.Beaulieu-Bonneau.1@ulaval.ca	Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895; Beaulieu-Bonneau, Simon/0000-0002-9544-5023	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This study was supported by a doctoral fellowship awarded to Simon Beaulieu-Bonneau, M.Ps., by the Canadian Institutes of Health Research. We are grateful to Hans Ivers, Ph.D., for statistical support, and to Marie-Christine Ouellet, Ph.D., for comments on the manuscript.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Arand D, 2005, SLEEP, V28, P123, DOI 10.1093/sleep/28.1.123; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dauvilliers Y, 2003, J NEUROL NEUROSUR PS, V74, P1667, DOI 10.1136/jnnp.74.12.1667; Duntley SP, 2005, ISS CLIN COGN NEUROP, P209; Edinger JD., 2004, DUKE STRUCTURED INTE; First MB., 1997, STRUCTURED CLIN INTE; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 1994, SLEEP, V17, P701; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Lin Jin-Mann S, 2009, Popul Health Metr, V7, P18, DOI 10.1186/1478-7954-7-18; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Ministere de la sante et des services sociaux du Quebec & Societe d'assurance automobile du Quebec, 2005, OR MIN TRAUM CRAN LE; MONK TH, 1987, SLEEP, V10, P343, DOI 10.1093/sleep/10.4.343; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Neu D, 2010, ACTA NEUROL BELG, V110, P15; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pallesen S, 2007, SLEEP, V30, P619, DOI 10.1093/sleep/30.5.619; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schwarz R, 2003, ONKOLOGIE, V26, P140, DOI 10.1159/000069834; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Singer S, 2011, BRIT J CANCER, V105, P445, DOI 10.1038/bjc.2011.251; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; *SPSS INC, 2008, SPSS 16 0 WIND; Tabachnik B. G., 2007, USING MULTIVARIATE S, V5th; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Weaver TE, 1997, SLEEP, V20, P835; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	49	48	50	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457			SLEEP MED	Sleep Med.	JUN	2012	13	6					598	605		10.1016/j.sleep.2012.02.010			8	Clinical Neurology	Neurosciences & Neurology	972TZ	WOS:000306304700008	22425680	Green Accepted			2021-06-18	
J	Xiong, Y; Zhang, YL; Mahmood, A; Meng, YL; Zhang, ZG; Morris, DC; Chopp, M				Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Zhang, Zheng Gang; Morris, Daniel C.; Chopp, Michael			Neuroprotective and neurorestorative effects of thymosin beta 4 treatment initiated 6 hours after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						neuroprotection; neurogenesis; rat; thymosin beta 4; traumatic brain injury	MARROW STROMAL CELLS; HIPPOCAMPAL CA3 REGION; NITRIC-OXIDE DONOR; COGNITIVE RECOVERY; CORTICAL IMPACT; DENTATE GYRUS; FUNCTIONAL RECOVERY; ADULT NEUROGENESIS; EPITHELIAL-CELLS; NERVOUS-SYSTEM	Object. Thymosin beta 4 (T beta 4) is a regenerative multifunctional peptide. The aim of this study was to test the hypothesis that T beta 4 treatment initiated 6 hours postinjury reduces brain damage and improves functional recovery in rats subjected to traumatic brain injury (TBI). Methods. Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex in young adult male Wistar rats. The rats were randomly divided into the following groups: 1) saline group (n = 7); 2) 6 mg/kg T beta 4 group (n = 8); and 3) 30 mg/kg T beta 4 group (n = 8). Thymosin beta 4 or saline was administered intraperitoneally starting at 6 hours postinjury and again at 24 and 48 hours. An additional group of 6 animals underwent surgery without TBI (sham-injury group). Sensorimotor function and spatial learning were assessed using the modified Neurological Severity Score and the Morris water maze test, respectively. Animals were euthanized 35 days after injury, and brain sections were processed to assess lesion volume, hippocampal cell loss, cell proliferation, and neurogenesis after T beta 4 treatment. Results. Compared with saline administration, T beta 4 treatment initiated 6 hours postinjury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell lass, and enhanced cell proliferation and neurogenesis in the injured hippocampus. The high dose of T beta 4 showed better beneficial effects compared with the low-dose treatment. Conclusions. Thymosin beta 4 treatment initiated 6 hours postinjury provides both neuroprotection and neurorestoration after TBI, indicating that T beta 4 has promising therapeutic potential in patients with TBI. These data warrant further investigation of the optimal dose and therapeutic window of T beta 4 treatment for TBI and the associated underlying mechanisms. (http://thejns.org/doi/abs/10.3171/2012.1.JNS111729)	[Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Morris, Daniel C.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, R01NS062002, P50NS023393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG038648] Funding Source: NIH RePORTER	This work was supported by NIH grants No. R01 NS62002 (to Dr. Xiong) and No. P01 NS023393 (to Dr. Chopp). Drs. Z. G. Zhang, Morris, and Chopp have applied for a patent for the use of T beta 4 as a treatment for stroke, neurological disease, and injury.	Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bubb MR, 2003, VITAM HORM, V66, P297, DOI 10.1016/S0083-6729(03)01008-2; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Choi SY, 2007, BIOCHEM BIOPH RES CO, V362, P587, DOI 10.1016/j.bbrc.2007.08.031; Crockford D, 2007, ANN NY ACAD SCI, V1112, P385, DOI 10.1196/annals.1415.051; Crockford D, 2010, ANN NY ACAD SCI, V1194, P179, DOI 10.1111/j.1749-6632.2010.05492.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dong JH, 2005, NEUROREPORT, V16, P1629, DOI 10.1097/01.wnr.0000183326.21241.48; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fine JD, 2007, ANN NY ACAD SCI, V1112, P396, DOI 10.1196/annals.1415.017; Freeman KW, 2011, FASEB J, V25, P907, DOI 10.1096/fj.10-169417; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Gullo C, 2006, BBA-REV CANCER, V1765, P223, DOI 10.1016/j.bbcan.2006.01.001; Hinkel R, 2008, CIRCULATION, V117, P2232, DOI 10.1161/CIRCULATIONAHA.107.758904; Ho JHC, 2008, BRIT J OPHTHALMOL, V92, P992, DOI 10.1136/bjo.2007.136747; Ho JHC, 2007, INVEST OPHTH VIS SCI, V48, P27, DOI 10.1167/iovs.06-0826; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kohler SJ, 2011, P NATL ACAD SCI USA, V108, P10326, DOI 10.1073/pnas.1017099108; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mora CA, 1997, INT J IMMUNOPHARMACO, V19, P1, DOI 10.1016/S0192-0561(97)00005-2; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; Morris DC, 2010, ANN NY ACAD SCI, V1194, P112, DOI 10.1111/j.1749-6632.2010.05469.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Paulussen M, 2009, PEPTIDES, V30, P1822, DOI 10.1016/j.peptides.2009.07.010; Philp D, 2004, MECH AGEING DEV, V125, P113, DOI 10.1016/j.mad.2003.11.005; Philp D, 2007, ANN NY ACAD SCI, V1112, P95, DOI 10.1196/annals.1415.009; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Qiu FY, 2009, J CARDIOVASC PHARM, V53, P209, DOI 10.1097/FJC.0b013e318199f326; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reti R, 2008, EUR J ORAL SCI, V116, P424, DOI 10.1111/j.1600-0722.2008.00569.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Riley PR, 2009, BIOCHEM SOC T, V37, P1218, DOI 10.1042/BST0371218; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Ruff D, 2010, ANN NY ACAD SCI, V1194, P223, DOI 10.1111/j.1749-6632.2010.05474.x; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Sierra A, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00047; Smart Nicola, 2007, Angiogenesis, V10, P229, DOI 10.1007/s10456-007-9077-x; Smart N, 2007, ANN NY ACAD SCI, V1112, P171, DOI 10.1196/annals.1415.000; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2007, ANN NY ACAD SCI, V1112, P114, DOI 10.1196/annals.1415.004; Sosne G, 2010, FASEB J, V24, P2144, DOI 10.1096/fj.09-142307; Srivastava D, 2007, ANN NY ACAD SCI, V1112, P161, DOI 10.1196/annals.1415.048; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Yang H, 2010, CELL MOL NEUROBIOL, V30, P149, DOI 10.1007/s10571-009-9439-6; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	86	48	51	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1081	1092		10.3171/2012.1.JNS111729			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800024	22324420	Green Accepted			2021-06-18	
J	Verdejo-Garcia, A; Betanzos-Espinosa, P; Lozano, OM; Vergara-Moragues, E; Gonzalez-Saiz, F; Fernandez-Calderon, F; Bilbao-Acedos, I; Perez-Garcia, M				Verdejo-Garcia, A.; Betanzos-Espinosa, P.; Lozano, O. M.; Vergara-Moragues, E.; Gonzalez-Saiz, F.; Fernandez-Calderon, F.; Bilbao-Acedos, I.; Perez-Garcia, M.			Self-regulation and treatment retention in cocaine dependent individuals: A longitudinal study	DRUG AND ALCOHOL DEPENDENCE			English	Article						Cocaine; Executive functions; Orbitofrontal cortex; Self-regulation; Retention; Therapeutic community	TRAUMATIC BRAIN-INJURY; IOWA GAMBLING TASK; DECISION-MAKING; GRAY-MATTER; ORBITOFRONTAL CORTEX; SUBSTANCE-ABUSERS; DAMAGE; VALIDITY; BEHAVIOR; EMOTION	Background: We aimed to explore the association between baseline executive functioning and treatment outcome in Therapeutic Communities (TCs). Methods: We used a longitudinal descriptive design: a baseline neuropsychological assessment was performed within the first 30 days of treatment in TCs. Once participants finished or abandoned treatment, the information about time of stay in treatment was computed for each individual. The study was conducted across six TCs located in the region of Andalusia (Spain): Cartaya, Almonte, Mijas, Los Palacios, La Linea, and Tarifa. Participants were 131 patients with cocaine dependence who initiated and finished treatment in TCs between January 2009 and December 2010 (2 years). Cognitive assessment was composed of general measures of executive functioning: Letter Number Sequencing (working memory) and Similarities (reasoning), and executive tasks sensitive to ventromedial prefrontal cortex dysfunction, including the Delis-Kaplan Stroop test (inhibition/cognitive switching), the Revised-Strategy Application Test (strategy application/multitasking), and the Iowa Gambling Task (decision-making). The outcome measure was retention, defined as time in TC treatment (number of days). Results: Poor executive functioning significantly predicted shorter treatment retention in cocaine dependent individuals on TC residential treatment (14% of explained variance). Reduced performance on the R-SAT, a multitasking test taxing the ability to develop and apply the best strategy to organize multiple sub-routine tasks in order to achieve a long-term goal, was the most powerful predictor of treatment retention. Conclusions: Self-regulation deficits predict the capacity to remain in residential treatment among cocaine dependents. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Verdejo-Garcia, A.; Betanzos-Espinosa, P.; Perez-Garcia, M.] Univ Granada, Dept Clin Psychol, E-18071 Granada, Spain; [Verdejo-Garcia, A.; Perez-Garcia, M.] Univ Granada, Inst Neurosci F Oloriz, E-18071 Granada, Spain; [Lozano, O. M.; Fernandez-Calderon, F.] Univ Huelva, Dept Psychol, Huelva, Spain; [Vergara-Moragues, E.; Gonzalez-Saiz, F.; Fernandez-Calderon, F.; Bilbao-Acedos, I.] Fdn Andaluza Atenc Drogodependencias & Incorp Soc, Seville, Spain; [Gonzalez-Saiz, F.] Unidad Gest Clin Hosp Jerez, Unidad Salud Mental Comunitaria Villamartin, Cadiz, Spain	Verdejo-Garcia, A (corresponding author), Univ Granada, Fac Psicol, Campus Cartuja S-N, E-18071 Granada, Spain.	averdejo@ugr.es	Calderon, Fermin Fernandez/Y-5665-2019; Lozano, Oscar M./C-6070-2011; Garcia, Miguel Perez/F-9630-2010; Vergara-Moragues, Esperanza/H-9787-2015	Calderon, Fermin Fernandez/0000-0002-2981-1670; Lozano, Oscar M./0000-0003-2722-6563; Garcia, Miguel Perez/0000-0003-4775-7556; Vergara-Moragues, Esperanza/0000-0003-2669-631X; Verdejo-Garcia, Antonio/0000-0001-8874-9339	Junta de AndaluciaJunta de Andalucia [P07.HUM 03089]; COPER-NICO from the Plan Nacional sobre Drogas-Ministerio de Sanidad y Consumo	This work has been funded by grants: P07.HUM 03089 from the Junta de Andalucia (Proyectos de Excelencia 2007) and COPER-NICO from the Plan Nacional sobre Drogas-Ministerio de Sanidad y Consumo (Convocatoria 2009).	Aharonovich E, 2006, DRUG ALCOHOL DEPEN, V81, P313, DOI 10.1016/j.drugalcdep.2005.08.003; Aharonovich E, 2003, DRUG ALCOHOL DEPEN, V71, P207, DOI 10.1016/S0376-8716(03)00092-9; Aklin WM, 2009, PERS INDIV DIFFER, V46, P454, DOI 10.1016/j.paid.2008.11.018; Alfonso JP, 2011, DRUG ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025; Alia-Klein N, 2011, ARCH GEN PSYCHIAT, V68, P283, DOI 10.1001/archgenpsychiatry.2011.10; Arenas F., 2003, PROGRAMA INTERVENCIO; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Belsey DA., 1991, CONDITIONING DIAGNOS; Bickel WK, 2011, BIOL PSYCHIAT, V69, P260, DOI 10.1016/j.biopsych.2010.08.017; Birnboim S., 2011, CAN J OCCUP THER, V71, P47; Blume AW, 2009, ANN BEHAV MED, V37, P117, DOI 10.1007/s12160-009-9093-8; Bowden-Jones H, 2005, J NEUROPSYCH CLIN N, V17, P417, DOI 10.1176/appi.neuropsych.17.3.417; Buckley MJ, 2009, SCIENCE, V325, P52, DOI 10.1126/science.1172377; Burgess P.W., 2010, PSYCHOL RES, V63, P279; Cato MA, 2004, J INT NEUROPSYCH SOC, V10, P453, DOI 10.1017/S1355617704103123; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dreher JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003227; Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1; European Monitoring Centre for Drugs and Drug Addiction, 2010, EUR MON CTR DRUGS DR; Faggiano F, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002208; Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0; Knapp WP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003023.pub2; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Langleben DD, 2008, AM J PSYCHIAT, V165, P390, DOI 10.1176/appi.ajp.2007.07010070; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Li XR, 2010, HUM BRAIN MAPP, V31, P410, DOI 10.1002/hbm.20875; National Institute on Drug Abuse, 2011, UND DRUG AB ADD; Passetti F, 2008, DRUG ALCOHOL DEPEN, V94, P82, DOI 10.1016/j.drugalcdep.2007.10.008; Passetti F, 2011, DRUG ALCOHOL DEPEN, V118, P12, DOI 10.1016/j.drugalcdep.2011.02.015; Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761; Peirce JM, 2009, AM J DRUG ALCOHOL AB, V35, P48, DOI 10.1080/00952990802455444; Reske M, 2008, ANN NY ACAD SCI, V1141, P270, DOI 10.1196/annals.1441.011; Sellitto M, 2010, J NEUROSCI, V30, P16429, DOI 10.1523/JNEUROSCI.2516-10.2010; Simpson DD, 1999, ARCH GEN PSYCHIAT, V56, P507, DOI 10.1001/archpsyc.56.6.507; Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324; Smith LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005338.pub2; Streeter CC, 2008, NEUROPSYCHOPHARMACOL, V33, P827, DOI 10.1038/sj.npp.1301465; Substance Abuse and Mental Health Services Administration & Office of Applied Studies, 2009, DASIS SER S, V(SMA) 09-4360; Tanabe J, 2009, BIOL PSYCHIAT, V65, P160, DOI 10.1016/j.biopsych.2008.07.030; Torrens M, 2004, AM J PSYCHIAT, V161, P1231, DOI 10.1176/appi.ajp.161.7.1231; Tranel D, 2007, J CLIN EXP NEUROPSYC, V29, P319, DOI 10.1080/13803390600701376; Turner TH, 2009, J SUBST ABUSE TREAT, V37, P328, DOI 10.1016/j.jsat.2009.03.009; Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V90, P48, DOI 10.1016/j.drugalcdep.2007.02.010; Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V86, P139, DOI 10.1016/j.drugalcdep.2006.05.024; Verdejo-Garcia A, 2006, PSYCHOL BELG, V46, P55, DOI 10.5334/pb-46-1-2-55; Wechsler D, 1997, WAIS 3 ADM SCORING M; Woicik PA, 2011, NEUROPSYCHOLOGIA, V49, P1660, DOI 10.1016/j.neuropsychologia.2011.02.037; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	52	48	48	0	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	APR 1	2012	122	1-2					142	148		10.1016/j.drugalcdep.2011.09.025			7	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	925CW	WOS:000302739300020	22018602				2021-06-18	
J	Sadaka, F; Patel, D; Lakshmanan, R				Sadaka, Farid; Patel, Darshan; Lakshmanan, Rekha			The FOUR Score Predicts Outcome in Patients After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Coma; Traumatic brain injur; Full Outline of UnResponsiveness (FOUR) score; Glasgow coma scale	COMA SCALE; PRACTICAL SCALE; HEAD-INJURY; VALIDATION; SEVERITY; CARE; CONSCIOUSNESS; SYSTEM	The most widely used and most studied coma score to date is the Glasgow Coma Scale (GCS), which is used worldwide to assess level of consciousness and predict outcome after traumatic brain injury (TBI). Our aim was to determine whether the Full Outline of UnResponsiveness (FOUR) score is an accurate predictor of outcome in TBI patients and to compare its performance to GCS. We prospectively identified TBI patients admitted to our Neuro-ICU between July 2010 and February 2011. We enrolled 51 patients. The FOUR score and GCS were determined by one of the investigators. Outcomes were in-hospital mortality, and poor neurologic outcome (Glasgow Outcome Scale (GOS) 1-3 and Modified Rankin Scale (mRS) score 3-6) at 3-6 months. There was a high degree of internal consistency for both the FOUR score (Cronbach's alpha = 0.89) and GCS (Cronbach's alpha = 0.85). In terms of predictive power for in-hospital mortality, the area under the receiver operating characteristic (ROC) curve was 0.93 for FOUR score and 0.89 for GCS. In terms of predictive power of poor neurologic outcome at 3-6 months, the area under the ROC curve was 0.85 for FOUR score and 0.83 for GCS as evidenced by GOS 1-3, and 0.80 for FOUR score and 0.78 for GCS as evidenced by mRS 3-6. The odds ratio (OR) for in-hospital mortality was 0.64 (0.46-0.88) from FOUR score and 0.63 (0.45-0.89) from GCS, for poor neurologic outcome was 0.67 (0.53-0.85) from FOUR score and 0.65 (0.51-0.83) from GCS for GOS, and was 0.71 (0.57-0.87) from FOUR score and 0.71 (0.57-0.87) from GCS for mRS. The FOUR score is an accurate predictor of outcome in TBI patients. It has some advantages over GCS, such as all components of FOUR score but not GCS can be rated in intubated patients.	[Sadaka, Farid; Patel, Darshan; Lakshmanan, Rekha] St Louis Univ, St Johns Mercy Med Ctr, St Louis, MO 63141 USA	Sadaka, F (corresponding author), St Louis Univ, St Johns Mercy Med Ctr, 621 S New Ballas Rd,Suite 4006B, St Louis, MO 63141 USA.	farid.sadaka@mercy.net					Akavipat P, 2009, NEUROL MED-CHIR, V49, P565, DOI 10.2176/nmc.49.565; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Champion HR, 1996, J TRAUMA, V40, P42, DOI 10.1097/00005373-199601000-00009; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Champion HR, 1996, J TRAUMA, V40, P48; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Fugate JE, 2010, NEUROCRIT CARE, V13, P205, DOI 10.1007/s12028-010-9407-5; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GORMICAN SP, 1982, ANN EMERG MED, V11, P132, DOI 10.1016/S0196-0644(82)80237-0; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kornbluth J, 2011, NEUROCRIT CARE, V14, P134, DOI 10.1007/s12028-010-9409-3; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1979, JACEP-J AM COLL EMER, V8, P64, DOI 10.1016/S0361-1124(79)80039-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Weiss N, 2009, REV NEUROL-FRANCE, V165, P796, DOI 10.1016/j.neurol.2009.01.045; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	24	48	51	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	FEB	2012	16	1					95	101		10.1007/s12028-011-9617-5			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	881QW	WOS:000299502500013	21845490				2021-06-18	
J	Mao, JC; Pace, E; Pierozynski, P; Kou, ZF; Shen, YM; VandeVord, P; Haacke, EM; Zhang, XG; Zhang, JS				Mao, Johnny C.; Pace, Edward; Pierozynski, Paige; Kou, Zhifeng; Shen, Yimin; VandeVord, Pamela; Haacke, E. Mark; Zhang, Xueguo; Zhang, Jinsheng			Blast-Induced Tinnitus and Hearing Loss in Rats: Behavioral and Imaging Assays	JOURNAL OF NEUROTRAUMA			English	Article						behavioral testing; blast; hearing loss; MRI; tinnitus; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DORSAL COCHLEAR NUCLEUS; SALICYLATE-INDUCED TINNITUS; SPONTANEOUS NEURAL ACTIVITY; WHITE-MATTER INTEGRITY; DIFFUSION-TENSOR; INFERIOR COLLICULUS; PREPULSE INHIBITION; AUDITORY-CORTEX; INTENSE SOUND	The current study used a rat model to investigate the underlying mechanisms of blast-induced tinnitus, hearing loss, and associated traumatic brain injury (TBI). Seven rats were used to evaluate behavioral evidence of tinnitus and hearing loss, and TBI using magnetic resonance imaging following a single 10-msec blast at 14 psi or 194 dB sound pressure level (SPL). The results demonstrated that the blast exposure induced early onset of tinnitus and central hearing impairment at a broad frequency range. The induced tinnitus and central hearing impairment tended to shift towards high frequencies over time. Hearing threshold measured with auditory brainstem responses also showed an immediate elevation followed by recovery on day 14, coinciding with behaviorally-measured results. Diffusion tensor magnetic resonance imaging results demonstrated significant damage and compensatory plastic changes to certain auditory brain regions, with the majority of changes occurring in the inferior colliculus and medial geniculate body. No significant microstructural changes found in the corpus callosum indicates that the currently adopted blast exposure mainly exerts effects through the auditory pathways rather than through direct impact onto the brain parenchyma. The results showed that this animal model is appropriate for investigation of the mechanisms underlying blast-induced tinnitus, hearing loss, and related TBI. Continued investigation along these lines will help identify pathology with injury/recovery patterns, aiding development of effective treatment strategies.	[Mao, Johnny C.; Pace, Edward; Zhang, Xueguo; Zhang, Jinsheng] Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA; [Kou, Zhifeng; Shen, Yimin; Haacke, E. Mark] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI 48202 USA; [Pierozynski, Paige; Zhang, Jinsheng] Wayne State Univ, Coll Liberal Arts & Sci, Dept Commun Sci & Disorders, Detroit, MI 48202 USA; [VandeVord, Pamela] Wayne State Univ, Coll Engn, Dept Biomed Engn, Detroit, MI 48202 USA; [VandeVord, Pamela] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI USA	Zhang, JS (corresponding author), Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 5E UHC,4201 St Antoine, Detroit, MI 48202 USA.	jinzhang@med.wayne.edu	VandeVord, Pamela/B-4606-2012		Wayne State University; Department of DefenseUnited States Department of Defense [W81XWH-11-2-0031]	This work was supported by the Wayne State University start-up funds and the Department of Defense (grant award #W81XWH-11-2-0031).	Adams P.F., 1995, VITAL HLTH STAT, P101; Andersson G, 2004, NORD J PSYCHIAT, V58, P287, DOI 10.1080/08039480410005792; Andersson G, 1998, AUDIOLOGY, V37, P174; Andersson G, 2002, CLIN PSYCHOL REV, V22, P977, DOI 10.1016/S0272-7358(01)00124-6; AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; Basta D, 2005, NEUROSCI LETT, V381, P199, DOI 10.1016/j.neulet.2005.02.034; Bauer CA, 2008, J NEUROSCI RES, V86, P2564, DOI 10.1002/jnr.21699; Belli S, 2008, EUR ARCH OTO-RHINO-L, V265, P279, DOI 10.1007/s00405-007-0440-8; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bowen GP, 2003, CEREB CORTEX, V13, P815, DOI 10.1093/cercor/13.8.815; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Breeze J, 2011, J LARYNGOL OTOL, V125, P13, DOI 10.1017/S0022215110002215; Brozoski TJ, 2007, HEARING RES, V228, P168, DOI 10.1016/j.heares.2007.02.003; Brozoski TJ, 2002, J NEUROSCI, V22, P2383, DOI 10.1523/JNEUROSCI.22-06-02383.2002; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Campbell LE, 2007, EUR J NEUROSCI, V26, P2327, DOI 10.1111/j.1460-9568.2007.05858.x; Chang YS, 2004, FUNGAL DIVERS, V15, P15; CHEN GD, 1995, HEARING RES, V82, P158, DOI 10.1016/0378-5955(94)00174-O; Clarkson C, 2010, ACTA OTO-LARYNGOL, V130, P326, DOI [10.3109/00016480903150536, 10.1080/00016480903150536]; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Crippa Alessandro, 2010, Open Neuroimag J, V4, P16, DOI 10.2174/1874440001004010016; Cronlein T, 2007, PROG BRAIN RES, V166, P227, DOI 10.1016/S0079-6123(07)66021-X; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Dror V, 2010, BRAIN RES, V1308, P176, DOI 10.1016/j.brainres.2009.10.032; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Eggermont JJ, 2000, HEARING RES, V142, P89, DOI 10.1016/S0378-5955(00)00024-1; Erlandsson SI, 2000, BRIT J AUDIOL, V34, P11, DOI 10.3109/03005364000000114; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Finlayson PG, 2009, HEARING RES, V256, P104, DOI 10.1016/j.heares.2009.07.006; Folmer RL, 2000, AM J OTOLARYNG, V21, P287, DOI 10.1053/ajot.2000.9871; Folmer RL, 1999, OTOLARYNG HEAD NECK, V121, P48, DOI 10.1016/S0194-5998(99)70123-3; Geckle L., 2004, FORC HLTH PROT C ALB; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Groschel M, 2010, J NEUROTRAUM, V27, P1499, DOI 10.1089/neu.2009.1246; Guitton Matthieu J., 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/80904; HALFORD JBS, 1991, J PSYCHOSOM RES, V35, P383, DOI 10.1016/0022-3999(91)90033-K; Hebert S, 2007, EAR HEARING, V28, P649; Henry JA, 2009, J REHABIL RES DEV, V46, P619, DOI 10.1682/JRRD.2008.11.0157; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holt AG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014260; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Husain FT, 2011, BRAIN RES, V1369, P74, DOI 10.1016/j.brainres.2010.10.095; Johnston M, 1996, GEN HOSP PSYCHIAT, V18, P257, DOI 10.1016/0163-8343(96)00039-4; Kaltenbach JA, 1996, AUDIT NEUROSCI, V3, P57; Kaltenbach JA, 2004, NEUROSCI LETT, V355, P121, DOI 10.1016/j.neulet.2003.10.038; Kaltenbach JA, 1998, HEARING RES, V124, P78, DOI 10.1016/S0378-5955(98)00119-1; Kaltenbach JA, 2000, HEARING RES, V140, P165, DOI 10.1016/S0378-5955(99)00197-5; Kaltenbach JA, 2011, HEARING RES, V276, P52, DOI 10.1016/j.heares.2010.12.003; Kantarci K, 2010, NEUROLOGY, V74, P1814, DOI 10.1212/WNL.0b013e3181e0f7cf; Kim HJ, 2005, AM J NEURORADIOL, V26, P208; Kim JN, 1997, HEARING RES, V103, P169, DOI 10.1016/S0378-5955(96)00173-6; Kimura M, 1999, HEARING RES, V135, P146, DOI 10.1016/S0378-5955(99)00104-5; Komiya H, 2000, ACTA OTO-LARYNGOL, V120, P750; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kraus KS, 2010, NEUROSCIENCE, V167, P1216, DOI 10.1016/j.neuroscience.2010.02.071; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lanting CP, 2010, HEARING RES, V267, P78, DOI 10.1016/j.heares.2010.04.006; Lanting CP, 2009, HEARING RES, V255, P1, DOI 10.1016/j.heares.2009.06.009; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Leske M C, 1981, ASHA, V23, P229; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; LEWIS JE, 1994, CLIN OTOLARYNGOL, V19, P50, DOI 10.1111/j.1365-2273.1994.tb01147.x; LIBERMAN MC, 1978, ACTA OTO-LARYNGOL, P5; Lin Y, 2008, J MAGN RESON IMAGING, V28, P598, DOI 10.1002/jmri.21464; Lockwood AH, 2001, NEUROLOGY, V56, P472, DOI 10.1212/WNL.56.4.472; LOEB M, 1967, J ACOUST SOC AM, V42, P453, DOI 10.1121/1.1910600; Lutz J, 2007, ACAD RADIOL, V14, P692, DOI 10.1016/j.acra.2007.02.014; Lutz J, 2008, ARTHRITIS RHEUM-US, V58, P3960, DOI 10.1002/art.24070; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Marciano E, 2003, INT J AUDIOL, V42, P4, DOI 10.3109/14992020309056079; McFeely WJ, 1999, OTOLARYNG HEAD NECK, V121, P367, DOI 10.1016/S0194-5998(99)70222-6; MCKENNA L, 1991, CLIN OTOLARYNGOL, V16, P452, DOI 10.1111/j.1365-2273.1991.tb01038.x; McKenna L, 2000, TINNITUS HDB, P59; Melcher JR, 2000, J NEUROPHYSIOL, V83, P1058; Miller EJ, 2010, NEUROSCIENCE, V165, P601, DOI 10.1016/j.neuroscience.2009.10.036; Mrena R, 2004, ACTA OTO-LARYNGOL, V124, P946, DOI 10.1080/00016480310017045; Mrena R, 2004, INT J AUDIOL, V43, P177, DOI 10.1080/14992020400050025; Mrena R, 2002, AUDIOL NEURO-OTOL, V7, P122, DOI 10.1159/000057660; Mulders WHAM, 2009, NEUROSCIENCE, V164, P733, DOI 10.1016/j.neuroscience.2009.08.036; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Norena AJ, 2005, J NEUROSCI, V25, P699, DOI 10.1523/JNEUROSCI.2226-04.2005; Norena AJ, 2003, HEARING RES, V183, P137, DOI 10.1016/S0378-5955(03)00225-9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Penner M.J., 1995, INT TINNITUS J, V1, P79; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Robinson Shannon K, 2003, Int Tinnitus J, V9, P97; Rossiter S, 2006, J SPEECH LANG HEAR R, V49, P150, DOI 10.1044/1092-4388(2006/012); Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Saunders GH, 2009, NOISE HEALTH, V11, P14, DOI 10.4103/1463-1741.45308; Seki S, 2003, HEARING RES, V180, P28, DOI 10.1016/S0378-5955(03)00074-1; Shargorodsky J, 2010, AM J MED, V123, P711, DOI 10.1016/j.amjmed.2010.02.015; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Shulman Abraham, 2009, Int Tinnitus J, V15, P119; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Silva AC, 2004, NMR BIOMED, V17, P532, DOI 10.1002/nbm.945; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smits M, 2007, NEURORADIOLOGY, V49, P669, DOI 10.1007/s00234-007-0231-3; Sobin C, 2005, AM J PSYCHIAT, V162, P1090, DOI 10.1176/appi.ajp.162.6.1090; Solano-Castiella E, 2010, NEUROIMAGE, V49, P2958, DOI 10.1016/j.neuroimage.2009.11.027; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stevens C, 2007, INT J AUDIOL, V46, P208, DOI 10.1080/14992020601102329; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Swerdlow NR, 2001, PSYCHOPHARMACOLOGY, V156, P194, DOI 10.1007/s002130100799; Takahashi K, 2007, BIOL PSYCHIAT, V62, P148, DOI 10.1016/j.biopsych.2006.06.035; Turner JG, 2008, AM J AUDIOL, V17, pS185, DOI 10.1044/1059-0889(2008/08-0006); Turner JG, 2006, BEHAV NEUROSCI, V120, P188, DOI 10.1037/0735-7044.120.1.188; Turner Oliver, 2007, Ann Gen Psychiatry, V6, P26, DOI 10.1186/1744-859X-6-26; Tyler RS, 2007, PROG BRAIN RES, V166, P425, DOI 10.1016/S0079-6123(07)66041-5; TYLER RS, 1983, J SPEECH HEAR RES, V26, P59, DOI 10.1044/jshr.2601.59; Walton JP, 1997, J COMP PHYSIOL A, V181, P161, DOI 10.1007/s003590050103; Wang H, 2009, NEUROSCIENCE, V164, P747, DOI 10.1016/j.neuroscience.2009.08.026; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wu CM, 2009, AM J NEURORADIOL, V30, P1773, DOI 10.3174/ajnr.A1681; Wu CM, 2009, AUDIOL NEURO-OTOL, V14, P248, DOI 10.1159/000191282; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yang G, 2007, HEARING RES, V226, P244, DOI 10.1016/j.heares.2006.06.013; Zhang JS, 2011, JARO-J ASSOC RES OTO, V12, P185, DOI 10.1007/s10162-010-0246-z; Zhang JS, 2010, BRAIN RES, V1311, P37, DOI 10.1016/j.brainres.2009.11.032; Zhang JS, 1998, NEUROSCI LETT, V250, P197, DOI 10.1016/S0304-3940(98)00482-0	132	48	49	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					430	444		10.1089/neu.2011.1934			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300022	21933015	Green Published			2021-06-18	
J	He, YL; Qu, SY; Wang, J; He, XS; Lin, W; Zhen, HN; Zhang, X				He, Yalong; Qu, Shuoyao; Wang, Jiang; He, Xiaosheng; Lin, Wei; Zhen, Haining; Zhang, Xiang			Neuroprotective effects of osthole pretreatment against traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Apoptosis; Neuroprotective effect; Osthole; Oxidative stress; Secondary brain damage; Traumatic brain injury	EXPERIMENTAL ANIMAL-MODELS; CENTRAL-NERVOUS-SYSTEM; INDUCED FATTY LIVER; CNIDIUM-MONNIERI; ALZHEIMERS-DISEASE; HEAD-INJURY; LIPID-PEROXIDATION; OXIDATIVE STRESS; CELL-DEATH; OXYGEN	Osthole, a coumarin compound isolated from the plant-derived herb Cnidium monnieri, has been the subject of considerable interest because of its broad spectrum of pharmacological properties. The aim of this study was to investigate the potential protective effects of osthole in adult rats in the setting of traumatic brain injury (TBI). We employed Feeney's weight-drop model to ascertain whether intraperitoneal administration of osthole (10 mg/kg, 20 mg/kg and 40 mg/kg) 30 mm before TBI could reduce the severity of neurological deficits, cerebral edema, and hippocampal neuron loss. The levels of malondialdehyde (MDA) and glutathione (GSH), the activity of superoxide dismutase (SOD), the expressions of Bcl-2, Bax, and active caspase-3, and the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive apoptotic cells were also measured to characterize the antioxidative and antiapoptotic properties. A significant reduction of neurological deficits, cerebral edema and hippocampal neuron loss was observed in the osthole pretreatment groups (20 mg/kg and 40 mg/kg, but not 10 mg/kg) by 24 h after TBI compared with the TB! group. Furthermore, pretreatment with osthole (40 mg/kg) significantly increased the activity of SOD, the level of GSH, and the ratio of Bcl-2/Bax, and also reduced the level of MDA, the expression of active caspase-3, and the number of apoptotic cells at 24 h after TBI. In summary, these results suggested that osthole had a neuroprotective effect against TBI, and the protection may be associated with its antioxidative and antiapoptotic functions. (C) 2011 Elsevier BM. All rights reserved.	[He, Yalong; Wang, Jiang; He, Xiaosheng; Lin, Wei; Zhen, Haining; Zhang, Xiang] Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Xijing Hosp, Dept Neurosurg, Xian 710032, Shanxi, Peoples R China	Zhang, X (corresponding author), Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Xijing Hosp, Dept Neurosurg, 127 Changle Western Rd, Xian 710032, Shanxi, Peoples R China.	xzhang@fmmu.edu.cn					Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield DA, 1997, J NEUROCHEM, V68, P2451; Chao XD, 2010, BRAIN RES, V1363, P206, DOI 10.1016/j.brainres.2010.09.052; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen XH, 2010, EUR J PHARMACOL, V629, P40, DOI 10.1016/j.ejphar.2009.12.008; Chou SY, 2007, PHYTOTHER RES, V21, P226, DOI 10.1002/ptr.2044; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ji HJ, 2010, EUR J PHARMACOL, V636, P96, DOI 10.1016/j.ejphar.2010.03.038; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092; Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738; Liang HJ, 2009, CHEM-BIOL INTERACT, V181, P309, DOI 10.1016/j.cbi.2009.08.003; Liu WB, 2010, NEUROCHEM INT, V57, P206, DOI 10.1016/j.neuint.2010.05.011; Luszczki JJ, 2009, EUR J PHARMACOL, V607, P107, DOI 10.1016/j.ejphar.2009.02.022; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsuda H, 2002, BIOL PHARM BULL, V25, P809, DOI 10.1248/bpb.25.809; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura T, 2009, J NAT MED-TOKYO, V63, P21, DOI 10.1007/s11418-008-0277-5; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nishio S, 1997, ACT NEUR S, V70, P84; Nunomura A, 1999, J NEUROSCI, V19, P1959; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Song F, 2006, WORLD J GASTROENTERO, V12, P4359, DOI 10.3748/wjg.v12.i27.4359; Sun F, 2009, DIGEST LIVER DIS, V41, P127, DOI 10.1016/j.dld.2008.01.011; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang SJ, 2008, NEUROCHEM INT, V53, P416, DOI 10.1016/j.neuint.2008.09.013; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Wu SN, 2002, BIOCHEM PHARMACOL, V63, P199, DOI 10.1016/S0006-2952(01)00873-5; Zhang JJ, 2011, PHYTOTHER RES, V25, P638, DOI 10.1002/ptr.3315; Zhang QY, 2007, PLANTA MED, V73, P13, DOI 10.1055/s-2006-951724	48	48	50	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 18	2012	1433						127	136		10.1016/j.brainres.2011.11.027			10	Neurosciences	Neurosciences & Neurology	895ZB	WOS:000300534100015	22153917				2021-06-18	
J	Benson, RR; Gattu, R; Sewick, B; Kou, ZF; Zakariah, N; Cavanaugh, JM; Haacke, EM				Benson, Randall R.; Gattu, Ramtilak; Sewick, Bradley; Kou, Zhifeng; Zakariah, Nisrine; Cavanaugh, John M.; Haacke, E. Mark			Detection of hemorrhagic and axonal pathology in mild traumatic brain injury using advanced MRI: Implications for neurorehabilitation	NEUROREHABILITATION			English	Article						Diffusion tensor imaging; susceptibility-weighted imaging; hemorrhagic pathology; axonal pathology and mild traumatic brain injury	WORKING-MEMORY CAPACITY; GLASGOW COMA SCALE; LEARNING-DISABILITIES; IMAGING FINDINGS; CORPUS-CALLOSUM; STRETCH-INJURY; HEAD-INJURY; DIFFUSION; CHILDREN; IMPACT	Introduction: There is a need to more accurately diagnose milder traumatic brain injuries with increasing awareness of the high prevalence in both military and civilian populations. Magnetic resonance imaging methods may be capable of detecting a number of the pathoanatomical and pathophysiological consequences of focal and diffuse traumatic brain injury. Susceptibility-weighted imaging (SWI) detects heme iron and reveals even small venous microhemorrhages occurring in diffuse vascular injury. Diffusion tensor imaging (DTI) reveals axonal injury by detecting alterations in water flow in and around injured axons. The overarching hypothesis of this paper is that newer, advanced MR imaging generates sensitive biomarkers of regional brain injury which allows for correlation with clinical signs and symptoms. Methods: Studies involving subjects with a history of traumatic brain injury as well as healthy, non-trauma controls were used. Analysis involved comparison of TBI patients' imaging results with healthy controls as well as correlation of imaging findings with clinical measures of injury severity. An additional animal study of Sprague-Dawley albino rats compared imaging results with histopathological findings after the animals were sacrificed and stained for b-APP. Results: SWI revealed small foci of hemosiderin for some patients while aggregate lesion volume on SWI correlated with clinical injury severity indices. Similarly, DTI showed striking group differences for fractional anisotropy over the white matter globally, while tract and voxel-based regional results colocalized with SWI and FLAIR lesions in some cases and correlated with clinical deficits. For the rats, correlations were seen between imaging findings and staining of axonal injury. Discussion: Animal data gave important tissue correlations with imaging results. SWI and DTI are commercially available sequences that can improve the diagnostic and prognostic ability of the trauma clinician. These biomarkers of regional brain injury which are present in imaging shortly after acute injury and persist indefinitely can inform clinicians and researchers about not only injury severity but also which neurobehavioral systems were injured. Analogous to stroke rehabilitation, having an understanding of the distribution of brain injury should ultimately allow for development ofmore effective rehabilitation strategies and more efficient clinical interventional trials.	[Benson, Randall R.] Ctr Neurol Studies, Novi, MI 48375 USA; [Gattu, Ramtilak; Kou, Zhifeng; Haacke, E. Mark] Wayne State Univ, Sch Med, Dept Diagnost Radiol, Detroit, MI USA; [Sewick, Bradley] Spectrum Rehabil, Southfield, MI USA; [Zakariah, Nisrine; Cavanaugh, John M.] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA	Benson, RR (corresponding author), Ctr Neurol Studies, 43000 W 9 Mile Rd,Suite 116, Novi, MI 48375 USA.	drbenson@neurologicstudies.com					Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Benson R. R., 2009, VARIATION DTI FA FUN; Benson R. R., 2009, AM AC NEUR ANN M; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Binder DK, 2000, NEUROSURGERY, V47, P9, DOI 10.1097/00006123-200007000-00003; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Brambilla P, 2011, PSYCHOL MED, V25, P1; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CERVOSNAVARRO J, 1991, CRIT REV NEUROBIOL, V6, P149; Chalela JA, 2000, STROKE, V31, P680, DOI 10.1161/01.STR.31.3.680; CHOPP M, 1984, Magnetic Resonance Imaging, V2, P329, DOI 10.1016/0730-725X(84)90199-1; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Dodson MB, 2010, WORK, V36, P449, DOI 10.3233/WOR-2010-1044; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; EHRLICH MF, 1994, PSYCHOL RES-PSYCH FO, V56, P110, DOI 10.1007/BF00419718; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gattu R., 2009, EFFECT VOXEL SIZE DT; Gattu R., 2008, AGEING FRACTIONAL AN; Gattu R., 2012, P INT SOC MAGN RES M; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grossman RI, 2003, NEURORADIOLOGY REQUI, P243; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hattori N, 2003, J NUCL MED, V44, P1709; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; HOSSMANN KA, 1994, J CEREBR BLOOD F MET, V14, P723, DOI 10.1038/jcbfm.1994.93; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Hyndman OR, 1939, ARCH NEURO PSYCHIATR, V42, P735, DOI 10.1001/archneurpsyc.1939.02270220151009; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson J, 2003, CHILD DEV, V74, P1594, DOI 10.1046/j.1467-8624.2003.00626.x; Just MA, 1996, PSYCHOL REV, V103, P773, DOI 10.1037/0033-295X.103.4.773; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kou Z., 2007, ISMRM ESMRMB; Kou Z., 2008, CLIN MR NEUROIMAGING; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krave U, 2011, J NEUROTRAUM, V28, P57, DOI 10.1089/neu.2010.1431; KWONG KK, 1995, MAGNET RESON MED, V34, P878, DOI 10.1002/mrm.1910340613; Leon-Carrion J, 2008, BRAIN INJURY, V22, P61, DOI 10.1080/02699050701824143; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marton K, 2003, J SPEECH LANG HEAR R, V46, P1138, DOI 10.1044/1092-4388(2003/089); Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; McCrea M., 2008, OXFORD WORKSHOP SERI, Vxv, P205; Miller L, 2001, NEUROREHABILITATION, V16, P109; Nakai T, 1996, JMRI-J MAGN RESON IM, V6, P445, DOI 10.1002/jmri.1880060306; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Passolunghi MC, 2012, J LEARN DISABIL-US, V45, P341, DOI 10.1177/0022219411400746; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Scheel M. E., 2009, J VISION, V9, DOI [10.1167/9.8.772, DOI 10.1167/9.8.772]; Shimony JS, 2009, BIOL PSYCHIAT, V66, P245, DOI 10.1016/j.biopsych.2009.02.032; Singer M, 1996, MEM COGNITION, V24, P733, DOI 10.3758/BF03201098; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Talavage T. M., 2010, J NEUROTRAUMA; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Vanderploeg RD, 2001, NEUROREHABILITATION, V16, P245; Varkuti B., 2012, NEUROREHABIL NEURAL; Wallace BE, 2001, J HEAD TRAUMA REHAB, V16, P165, DOI 10.1097/00001199-200104000-00006; Wasserman T, 2012, APPL NEUROPSYCH-ADUL, V19, P42, DOI 10.1080/09084282.2011.643940; WEINER MW, 1987, ANN NY ACAD SCI, V508, P287, DOI 10.1111/j.1749-6632.1987.tb32911.x; WEINTRAUB S, 1983, ARCH NEUROL-CHICAGO, V40, P463, DOI 10.1001/archneur.1983.04210070003003; Williams RF, 2008, J AM COLL SURGEONS, V206, P962, DOI 10.1016/j.jamcollsurg.2007.12.016; Work SS, 2011, ADV THER, V28, P586, DOI 10.1007/s12325-011-0031-3; Wortzel HS, 2008, J AM ACAD PSYCHIATRY, V36, P310	90	48	48	0	28	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	3					261	279		10.3233/NRE-2012-0795			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	028QC	WOS:000310436200004	23093454				2021-06-18	
J	Chourdakis, M; Kraus, MM; Tzellos, T; Sardeli, C; Peftoulidou, M; Vassilakos, D; Kouvelas, D				Chourdakis, Michael; Kraus, Michaela M.; Tzellos, Thrasivoulos; Sardeli, Chrysanthi; Peftoulidou, Maria; Vassilakos, Dimitrios; Kouvelas, Dimitrios			Effect of Early Compared With Delayed Enteral Nutrition on Endocrine Function in Patients With Traumatic Brain Injury: An Open-Labeled Randomized Trial	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article						traumatic brain injury; early enteral nutrition; endocrine function; thyroid-stimulating hormone; triiodothyronine (T3); thyroxine (T4); cortisol; testosterone	HEAD-INJURY; ILL PATIENTS; UNITED-STATES; MORTALITY; RESPONSES; ABNORMALITIES; HYPOGONADISM; DYSFUNCTION; SECONDARY; SEPSIS	Background: Traumatic brain injury (TBI) results in a hypermetabolic and hypercatabolic status in which adequate nutrition support is essential to improve clinical outcome. The endocrine system of a patient with TBI is also affected and may play a critical role in either the metabolic or the immunologic response to the trauma. In the present study, the effect of standard, delayed enteral feeding (DEF), compared with early (within 24-48 hours) enteral feeding (EEF), on the endocrine function of patients with TBI was investigated. Methods: This comparative, prospective, open-labeled, randomized study included TBI patients admitted to the intensive care unit (ICU). Injury severity was assessed by the Glasgow Coma Scale and predicted mortality by the Acute Physiology and Chronic Health Evaluation II. Twenty-five patients received DEF and 34 patients received EEF. The effect of the onset of nutrition on pituitary, thyroidal, gonadal, and adrenal function was investigated on days 6 and 12 after admission to the hospital. Results: Levels of thyroid-stimulating hormone, free triiodothyronine, free thyroxine, and testosterone (in males) of DEF patients declined in comparison to levels of the day of admission to the ICU. The decrease of hormonal values was less pronounced in the EEF group. Cortisol concentrations rose in the DEF group; a lesser hormonal change was found in the EEF group. Deaths during the study for the DEF group and EEF group were 2 and 3, respectively. Conclusions: EEF may exert beneficial effects on the hormonal profile of TBI patients, possibly contributing to a better clinical outcome in this patient group. (JPEN J Parenter Enteral Nutr. 2012; 36: 108-116)	[Chourdakis, Michael; Kraus, Michaela M.; Tzellos, Thrasivoulos; Sardeli, Chrysanthi; Kouvelas, Dimitrios] Aristotle Univ Thessaloniki, Dept Pharmacol, Sch Med, GR-54006 Thessaloniki, Greece; [Chourdakis, Michael; Peftoulidou, Maria; Vassilakos, Dimitrios] Aristotle Univ Thessaloniki, Dept Anesthesiol, Sch Med, AHEPA Hosp, GR-54006 Thessaloniki, Greece; [Chourdakis, Michael; Peftoulidou, Maria; Vassilakos, Dimitrios] Aristotle Univ Thessaloniki, ICU, Sch Med, AHEPA Hosp, GR-54006 Thessaloniki, Greece	Kouvelas, D (corresponding author), Aristotle Univ Thessaloniki, Dept Pharmacol, Sch Med, POB 1532, GR-54006 Thessaloniki, Greece.	kouvelas@auth.gr	Sardeli, Chrysanthi/ABF-1093-2020	Sardeli, Chrysanthi/0000-0002-6410-2992; Kouvelas, Dimitrios/0000-0003-3615-9745; Chourdakis, Michael/0000-0002-9490-8356			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Antonelli M, 2009, INTENS CARE MED, V35, P30, DOI 10.1007/s00134-008-1371-6; BAUE AE, 1984, ARCH SURG-CHICAGO, V119, P1125; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cameron P, 1995, AUST NZ J SURG, V65, P848, DOI 10.1111/j.1445-2197.1995.tb00574.x; Carlotti APCP, 2008, QJM-INT J MED, V101, P197, DOI 10.1093/qjmed/hcm127; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiolero R, 1994, New Horiz, V2, P432; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; DOCTER R, 1993, CLIN ENDOCRINOL, V39, P499, DOI 10.1111/j.1365-2265.1993.tb02401.x; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Eskelinen Seija I, 2007, Endocr Pract, V13, P743; Frankenfield David, 2006, Nutr Clin Pract, V21, P430, DOI 10.1177/0115426506021005430; Galanos AN, 1997, CRIT CARE MED, V25, P1962, DOI 10.1097/00003246-199712000-00010; KALSBEEK WD, 1980, J NEUROSURG S, pS19; KAPTEIN EM, 1982, J CLIN INVEST, V69, P526, DOI 10.1172/JCI110478; LEE SC, 1994, BRAIN INJURY, V8, P571; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Ligtenberg JJM, 2001, INTENS CARE MED, V27, P1567, DOI 10.1007/s001340101050; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; McClave SA, 2009, NUTR CLIN PRACT, V24, P305, DOI 10.1177/0884533609335176; Miller KK, 2009, PITUITARY, V12, P116, DOI 10.1007/s11102-008-0121-7; Misra M, 2010, ENDOCR DEV, V17, P197, DOI 10.1159/000262540; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Roberts P R, 1995, New Horiz, V3, P506; Shulga A, 2009, MOL CELL NEUROSCI, V42, P408, DOI 10.1016/j.mcn.2009.09.002; Shutov A A, 1980, Zh Vopr Neirokhir Im N N Burdenko, P23; Siafakas N M, 1999, Monaldi Arch Chest Dis, V54, P154; Smrcka M, 2007, BRATISL MED J, V108, P144; STERNBACH H A, 1983, Journal of the American Medical Association, V249, P1618, DOI 10.1001/jama.249.12.1618; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; VANDENBERGHE G, 1994, CLIN ENDOCRINOL, V41, P563; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Wilson RF, 1998, J HEAD TRAUMA REHAB, V13, P11, DOI 10.1097/00001199-199802000-00005; Wilson RF, 2001, NEUROL RES, V23, P121, DOI 10.1179/016164101101198451; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	50	48	59	1	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	JAN	2012	36	1					108	116		10.1177/0148607110397878			9	Nutrition & Dietetics	Nutrition & Dietetics	874XS	WOS:000298992000014	21965459				2021-06-18	
J	Oleksiak, M; Smith, BM; St Andre, JR; Caughlan, CM; Steiner, M				Oleksiak, Michael; Smith, Bridget M.; St Andre, Justin R.; Caughlan, Carly M.; Steiner, Monica			Audiological issues and hearing loss among Veterans with mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						adult; audiology; auditory dysfunction; blast injuries; brain injuries; hearing; hearing loss; mTBI; tinnitus; Veterans; wounds and injuries	TYMPANIC MEMBRANE PERFORATION; OPERATION ENDURING FREEDOM; IRAQI FREEDOM; WAR VETERANS; IMPAIRMENT; DYSFUNCTION	We examined the prevalence, severity, etiology, and treatment of audiology problems among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Veterans with mild traumatic brain injury (TBI). A retrospective chart review was performed of 250 Veterans with mild TBI. Results of a comprehensive second-level mild TBI evaluation and subsequent visits to audiology were evaluated. We found the vast majority (87%) of Veterans reported some level of hearing disturbance and those involved in blast injuries reported a higher incidence of hearing disturbance than those with other injury etiologies. Audiology referrals were given to 75 Veterans and 37 attended. At this visit, Veterans reported tinnitus (75.7%) and hearing loss (59.8%). Nearly half (48.6%) of Veterans were diagnosed with conductive hearing loss, sensorineural hearing loss, or central auditory dysfunction. An additional 24.3% of Veterans had subclinical levels of auditory dysfunction. Our study has highlighted the increased prevalence of hearing loss among OIF/OEF Veterans and, thus, the need for appropriate referrals and treatment. Strategies to address perceived stigma associated with hearing loss may increase attendance at follow-up visits. Additionally, while only a third of audiograms were found to be abnormal, advanced testing resulted in a significant percentage of our population being diagnosed with auditory dysfunction.	[Oleksiak, Michael; Smith, Bridget M.; St Andre, Justin R.] Edward Hines Jr VA Hosp, Dept Vet Affairs VA Ctr Management Complex Chron, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA; [Oleksiak, Michael; Smith, Bridget M.] Loyola Univ Chicago, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA; [Caughlan, Carly M.; Steiner, Monica] Edward Hines Jr VA Hosp, Hines, IL 60141 USA	Oleksiak, M (corresponding author), Edward Hines Jr VA Hosp, Res Serv, 5000 South 5th Ave 151H, Hines, IL 60141 USA.	MichaelOleksiak@gmail.com			VA Office of Research and Development, Health Services Research and Development ServiceUS Department of Veterans Affairs [IIR 07-188-3]	This study was supported by the VA Office of Research and Development, Health Services Research and Development Service (grant IIR 07-188-3).	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Chandler D., 2006, BLAST RELATED EAR IN; Chermak GD, 2007, J AM ACAD AUDIOL, V18, P428, DOI 10.3766/jaaa.18.5.7; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Erler Susan F, 2002, Am J Audiol, V11, P83, DOI 10.1044/1059-0889(2002/020); Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Henry JA, PROGR AUDIOLOGIC TIN; HERBST KG, 1980, BMJ-BRIT MED J, V281, P903, DOI 10.1136/bmj.281.6245.903; HETU R, 1993, AUDIOLOGY, V32, P363; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; Myers P, 2009, ASHA ACCESS AUDIOLOG, V8; Myers Paula J., 2009, Seminars in Hearing, V30, P5, DOI 10.1055/s-0028-1111103; Myers PJ, 2008, PERSPECT AUDIOL, V4, P21; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; PATOW CA, 1994, OTOLARYNG HEAD NECK, V110, P211, DOI 10.1177/019459989411000211; RICHARDSON ED, 1994, CLIN NEUROPSYCHOL, V8, P416, DOI 10.1080/13854049408402044; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Roberts M A, 1994, Appl Neuropsychol, V1, P45, DOI 10.1207/s15324826an0101&2_9; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Wallhagen MI, 2010, GERONTOLOGIST, V50, P66, DOI 10.1093/geront/gnp107; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	27	48	51	0	15	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					995	1003		10.1682/JRRD.2011.01.0001			9	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100005	23341275	Bronze			2021-06-18	
J	Payen, JF; Dupuis, C; Trouve-Buisson, T; Vinclair, M; Broux, C; Bouzat, P; Genty, C; Monneret, D; Faure, P; Chabre, O; Bosson, JL				Payen, Jean-Francois; Dupuis, Clement; Trouve-Buisson, Thibaut; Vinclair, Marc; Broux, Christophe; Bouzat, Pierre; Genty, Celine; Monneret, Denis; Faure, Patrice; Chabre, Olivier; Bosson, Jean-Luc			Corticosteroid after etomidate in critically ill patients: A randomized controlled trial	CRITICAL CARE MEDICINE			English	Article						adrenal insufficiency; critical care; etomidate; outcome	RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; SEPTIC SHOCK; ENDOTRACHEAL INTUBATION; ADRENAL INSUFFICIENCY; INDUCTION AGENT; HYDROCORTISONE; SEPSIS; EMERGENCY; BAD	Objective: To investigate the effects of moderate-dose hydrocortisone on hemodynamic status in critically ill patients throughout the period of etomidate-related adrenal insufficiency. Design: Randomized, controlled, double-blind trial (NCT00862381). Setting: University hospital emergency department and three intensive care units. Interventions: After single-dose etomidate (H0) for facilitating endotracheal intubation, patients without septic shock were randomly allocated at H6 to receive a 42-hr continuous infusion of either hydrocortisone at 200 mg/day (HC group; n = 49) or saline serum (control group; n = 50). Measurements and Main Results: After completion of a corticotrophin stimulation test, serum cortisol and 11 beta-deoxycortisol concentrations were subsequently assayed at H6, H12, H24, and H48. Forty-eight patients were analyzed in the HC group and 49 patients in the control group. Before treatment, the diagnostic criteria for etomidate-related adrenal insufficiency were fulfilled in 41 of 45 (91%) and 38 of 45 (84%) patients in the HC and control groups, respectively. The proportion of patients with a cardiovascular Sequential Organ Failure Assessment score of 3 or 4 declined comparably over time in both HC and control groups: 65% vs. 67% at H6, 65% vs. 69% at H12, 44% vs. 54% at H24, and 34% vs. 45% at H48, respectively. Required doses of norepinephrine decreased at a significantly higher rate in the HC group compared with the control group in patients treated with norepinephrine at H6. No intergroup differences were found regarding the duration of mechanical ventilation, intensive care unit length of stay, or 28-day mortality. Conclusion: These findings suggest that critically ill patients without septic shock do not benefit from moderate-dose hydrocortisone administered to overcome etomidate-related adrenal insufficiency. (Crit Care Med 2012; 40:29-35)	[Payen, Jean-Francois; Dupuis, Clement; Trouve-Buisson, Thibaut; Vinclair, Marc; Broux, Christophe; Bouzat, Pierre] Albert Michallon Hosp, Dept Anesthesiol & Crit Care, Grenoble, France; [Chabre, Olivier] Albert Michallon Hosp, Dept Endocrinol, Grenoble, France; [Payen, Jean-Francois; Bouzat, Pierre] Univ Grenoble 1, Grenoble Inst Neurosci, Grenoble, France; [Payen, Jean-Francois; Bouzat, Pierre] Univ Grenoble 1, INSERM U836, Grenoble, France; [Genty, Celine; Bosson, Jean-Luc] Michallon Hosp, Clin Res Ctr INSERM 003, Grenoble, France; UJF Grenoble 1, CNRS, TIMC IMAG, UMR 5525, Grenoble, France; [Monneret, Denis; Faure, Patrice] Albert Michallon Hosp, Dept Biochem, Grenoble, France; Univ Grenoble 1, INSERM U1042, Lab HP2, Grenoble, France	Payen, JF (corresponding author), Albert Michallon Hosp, Dept Anesthesiol & Crit Care, Grenoble, France.	jfpayen@ujf-grenoble.fr	Bouzat, Pierre/L-6881-2014; Payen, Jean-Francois/L-6667-2014; Bouzat, Pierre/AAC-4105-2019; bosson, jean-luc/AAP-5163-2020	Bouzat, Pierre/0000-0003-4667-6738; bosson, jean-luc/0000-0003-0967-6026; CHABRE, Olivier/0000-0001-8756-7218	Delegation Regionale de la Recherche Clinique, Hopital Michallon, Grenoble, France	Supported in part by a grant from the Delegation Regionale de la Recherche Clinique 2008, Hopital Michallon, Grenoble, France. The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.	Absalom A, 1999, ANAESTHESIA, V54, P861; Andrade FM, 2010, INTENS CARE MED, V36, P1266, DOI 10.1007/s00134-010-1878-5; Annane D, 2005, INTENS CARE MED, V31, P325, DOI 10.1007/s00134-005-2560-1; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Baird CRW, 2009, EMERG MED J, V26, P576, DOI 10.1136/emj.2008.067801; Bloomfield R, 2006, CRIT CARE, V10, DOI 10.1186/cc5020; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Briegel J, 1999, CRIT CARE MED, V27, P723, DOI 10.1097/00003246-199904000-00025; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Cuthbertson BH, 2009, INTENS CARE MED, V35, P1868, DOI 10.1007/s00134-009-1603-4; de Jong MFC, 2007, CLIN ENDOCRINOL, V66, P732, DOI 10.1111/j.1365-2265.2007.02814.x; den Brinker M, 2008, INTENS CARE MED, V34, P163, DOI 10.1007/s00134-007-0836-3; Dmello D, 2010, CHEST, V138, P1327, DOI 10.1378/chest.10-0790; Edwin SB, 2010, ANN PHARMACOTHER, V44, P1307, DOI 10.1345/aph.1M664; Fengler BT, 2008, AM J EMERG MED, V26, P229, DOI 10.1016/j.ajem.2007.03.032; GOODING JM, 1979, ANESTH ANALG, V58, P40; Hildreth AN, 2008, J TRAUMA, V65, P573, DOI 10.1097/TA.0b013e31818255e8; Hoen S, 2005, CRIT CARE MED, V33, P2737, DOI 10.1097/01.CCM.0000189743.55352.0E; Jabre P, 2009, LANCET, V374, P293, DOI 10.1016/S0140-6736(09)60949-1; Jackson WL, 2005, CHEST, V127, P1031, DOI 10.1378/chest.127.3.1031; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jones AE, 2006, CHEST, V130, P941, DOI 10.1378/chest.130.4.941; Kamp R, 2007, CRIT CARE, V11, DOI 10.1186/cc5939; Liouber-Friedman D, 2007, CRIT CARE MED, V35, P1012, DOI 10.1097/01.CCM.0000259465.92018.6E; Malerba G, 2005, INTENS CARE MED, V31, P388, DOI 10.1007/s00134-004-2550-8; Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba; Morris C, 2005, ANAESTHESIA, V60, P737, DOI 10.1111/j.1365-2044.2005.04325.x; Murray H, 2005, CHEST, V127, P707, DOI 10.1378/chest.127.3.707; Nicolas-Robin A, 2010, ANESTHESIOLOGY, V112, P1204, DOI 10.1097/ALN.0b013e3181d4f34d; Oglesby AJ, 2004, EMERG MED J, V21, P655, DOI 10.1136/emj.2003.009043; Oppert M, 2005, CRIT CARE MED, V33, P2457, DOI 10.1097/01.CCM.0000186370.78639.23; Prigent H, 2004, CRIT CARE, V8, P243, DOI 10.1186/cc2878; Ray DC, 2007, CRIT CARE, V11, DOI 10.1186/cc5916; Riche FC, 2007, INTENS CARE MED, V33, P1761, DOI 10.1007/s00134-007-0770-4; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; SILVERMAN HJ, 1993, CRIT CARE MED, V21, P31, DOI 10.1097/00003246-199301000-00010; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tekwani KL, 2010, ANN EMERG MED, V56, P481, DOI 10.1016/j.annemergmed.2010.05.034; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vinclair M, 2008, INTENS CARE MED, V34, P714, DOI 10.1007/s00134-007-0970-y; Warner KJ, 2009, J TRAUMA, V67, P45, DOI 10.1097/TA.0b013e3181a92a70	45	48	51	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2012	40	1					29	35		10.1097/CCM.0b013e31822d7938			7	Critical Care Medicine	General & Internal Medicine	866KO	WOS:000298379800005	21926601				2021-06-18	
J	Resnik, L; Bradford, DW; Glynn, SM; Jette, AM; Hernandez, CJ; Wills, S				Resnik, Linda; Bradford, Daniel W.; Glynn, Shirley M.; Jette, Alan M.; Hernandez, Caitlin Johnson; Wills, Sharon			Issues in defining and measuring veteran community reintegration: Proceedings of the Working Group on Community Reintegration, VA Rehabilitation Outcomes Conference, Miami, Florida	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						community integration; community reintegration; disability evaluation; International Classification of Health, Disability, and Functioning; measurement; OIF/OEF; outcome assessment; role functioning; social functioning; veteran	DEVELOPING CORE SETS; POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; INTERNATIONAL CLASSIFICATION; BIPOLAR DISORDER; MEASURING PARTICIPATION; ENVIRONMENTAL-FACTORS; MULTIPLE-SCLEROSIS; PHYSICAL-THERAPY	In January 2010, the Department of Veterans Affairs (VA) Rehabilitation Research and Development Service convened a State of the Art (SOTA) conference to advance the field of outcome measurement for rehabilitation-related studies. This article reports on the proceedings of the SOTA Working Group on Community Reintegration. We explored the use of the International Classification of Health, Disability, and Functioning as a theoretical framework for measuring community reintegration; identified key dimensions of community reintegration that could and/or should be measured; discussed challenges in measuring community reintegration; suggested steps to enhance community reintegration measurement; proposed future research that focuses on outcomes measures for community reintegration and the study of community reintegration outcomes; and made policy recommendations that would facilitate community reintegration research within the VA.	[Resnik, Linda] Providence Dept Vet Affairs VA Med Ctr, Providence, RI USA; [Resnik, Linda] Brown Univ, Dept Community Hlth, Publ Hlth Program, Providence, RI 02912 USA; [Bradford, Daniel W.] Durham VA Med Ctr, Psychosocial Rehabil & Recovery Ctr, Durham, NC USA; [Bradford, Daniel W.] Duke Univ Hosp, Durham, NC USA; [Glynn, Shirley M.] VA Greater Angeles Healthcare Syst, West Los Angeles Med Ctr, Los Angeles, CA USA; [Glynn, Shirley M.] Univ Calif Los Angeles Hlth Syst, Sch Med, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA; [Jette, Alan M.] Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Inst, Boston, MA USA; [Hernandez, Caitlin Johnson] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA; [Wills, Sharon] Cent Texas Vet Hlth Care Syst, Ctr Trauma Recovery, Posttraumat Stress Disorder Clin Team, Austin Outpatient Clin, Austin, TX USA; [Wills, Sharon] Texas A&M Hlth Sci Ctr, Sch Med, Bryan, TX USA	Resnik, L (corresponding author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA.	Linda.Resnik@va.gov		Jette, Alan/0000-0002-2117-9973	VA RRD	This material is the result of work supported by VA RR&D.	[Anonymous], 2001, INT CLASS FUNCT DIS; Biering-Sorensen F, 2006, SPINAL CORD, V44, P541, DOI 10.1038/sj.sc.3101918; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 2009, ARCH PHYS MED REHAB, V90, pS36, DOI 10.1016/j.apmr.2009.04.024; BRUSTEIN J, 2006, GOTHAM GAZETTE   MAR, P4; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; Cardol M, 1999, DISABIL REHABIL, V21, P97, DOI 10.1080/096382899297819; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cieza A, 2004, J REHABIL MED, V36, P128, DOI 10.1080/16501960410016055; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Freeman TW, 2001, J NERV MENT DIS, V189, P317, DOI 10.1097/00005053-200105000-00008; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Haley SM, 2006, PHYS THER, V86, P735, DOI 10.1093/ptj/86.5.735; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hooley JM, 2007, ANNU REV CLIN PSYCHO, V3, P329, DOI 10.1146/annurev.clinpsy.2.022305.095236; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Jette AM, 2007, DISABIL REHABIL, V29, P1742, DOI 10.1080/09638280601164790; JETTE AM, 1994, PHYS THER, V74, P380, DOI 10.1093/ptj/74.5.380; Johnston Mark, 2002, J Spinal Cord Med, V25, P11; Kesselring J, 2008, MULT SCLER J, V14, P252, DOI 10.1177/1352458507082615; Khan F, 2007, J REHABIL MED, V39, P63, DOI 10.2340/16501977-0002; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreuter M, 2000, SPINAL CORD, V38, P2, DOI 10.1038/sj.sc.3100933; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCFARLANE WR, 1995, FAM PROCESS, V34, P127, DOI 10.1111/j.1545-5300.1995.00127.x; MCFARLANE WR, 1994, NEW DIRECTIONS MENTA, V62, P13, DOI DOI 10.1002/YD.23319946204; McGill C.W., 1984, FAMILY CARE SCHIZOPH; Miklowitz DJ, 2000, BIOL PSYCHIAT, V48, P582, DOI 10.1016/S0006-3223(00)00931-8; Miklowitz DJ, 2003, ARCH GEN PSYCHIAT, V60, P904, DOI 10.1001/archpsyc.60.9.904; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; *NATL COAL HOM VET, 2011, NCHV PLAN END HOM VE; Noreau L, 2002, TECHNOL DISABIL, V14, P113, DOI [10.3233/TAD-2002-14306, DOI 10.3233/TAD-2002-14306]; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; President's New Freedom Commission on Mental Health, 2003, ACH PROM TRANSF MENT; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; ROSENHECK R, 1994, AM J PSYCHIAT, V151, P421; *SAB CTR MIDDL EAS, 2011, IR IND; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; SCHOOLER NR, 1979, RESOURCE MAT COMMUNI; Schuntermann MF, 2005, INT J REHABIL RES, V28, P93, DOI 10.1097/00004356-200506000-00001; Smith Mark W, 2005, Ment Health Serv Res, V7, P89, DOI 10.1007/s11020-005-3780-2; Stucki A, 2004, J REHABIL MED, V36, P107, DOI 10.1080/16501960410016064; STUCKI A, 2008, DISABILITY HLTH SLEE, V9, P191, DOI DOI 10.1016/J.SLEEP.2007.01.019; Szkudlarek B, 2010, INT J INTERCULT REL, V34, P1, DOI 10.1016/j.ijintrel.2009.06.006; Trigg R, 2000, CLIN REHABIL, V14, P288, DOI 10.1191/026921500678119607; Tschiesner U, 2007, EUR ARCH OTO-RHINO-L, V264, P1215, DOI 10.1007/s00405-007-0335-8; Ustun TB, 2003, DISABIL REHABIL, V25, P565, DOI 10.1080/0963828031000137063; Vieta E, 2007, BIPOLAR DISORD, V9, P16, DOI 10.1111/j.1399-5618.2007.00322.x; Whiteneck G., 2006, WORKSH DIS AM NEW LO; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; 2008, VA HDB, V1160	63	48	50	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	1					87	100		10.1682/JRRD.2010.06.0107			14	Rehabilitation	Rehabilitation	149ES	WOS:000319302400010	22492341	Bronze			2021-06-18	
J	Wolf, GK; Strom, TQ; Kehle, SM; Eftekhari, A				Wolf, Gregory K.; Strom, Thad Q.; Kehle, Shannon M.; Eftekhari, Afsoon			A Preliminary Examination of Prolonged Exposure Therapy With Iraq and Afghanistan Veterans With a Diagnosis of Posttraumatic Stress Disorder and Mild to Moderate Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						evidence-based treatments; posttraumatic stress disorder; prolonged exposure therapy; psychotherapy; traumatic brain injury; Veterans	SERVICE MEMBERS; COMBAT VETERANS; WAR VETERANS; PTSD; SUICIDALITY; SYMPTOMS; OUTCOMES	Objective: Preliminary examination of the effectiveness of prolonged exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) with Operation Enduring Freedom and Operation Iraqi Freedom Veterans who have experienced traumatic brain injury (TBI). Participants: Ten Veterans with a history of mild to moderate TBI and chronic PTSD. Setting: Outpatient Mental Health/PTSD clinics and polytrauma centers at 2 VA medical centers. Measures: Comprehensive evaluation that included clinical interview, neuropsychologic evaluation, and/or neuroimaging; Posttraumatic Stress Disorder Checklist and Beck Depression Inventory-Second Edition. Procedures: Standard implementation of the PE manual was used in all cases with slight adjustments to account for Veterans' residual cognitive deficits. Veterans completed between 8 and 18 sessions. Results: Veterans demonstrated significant reductions in total PTSD and depression symptoms from pre- to posttreatment. Within-group effect sizes were large. Conclusions: These findings suggest that PE can be safely and effectively implemented with Veterans with PTSD, a history of mild to moderate TBI, and current cognitive impairment.	[Wolf, Gregory K.] James A Haley Vet Affairs Med Ctr, Tampa, FL USA; [Strom, Thad Q.; Kehle, Shannon M.] Univ Minnesota, Dept Vet Affairs Med Ctr, Minneapolis, MN USA; [Strom, Thad Q.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Eftekhari, Afsoon] Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA	Wolf, GK (corresponding author), James A Haley VA Med Ctr MHBS, 13000 Bruce B Downs, Tampa, FL 33612 USA.	Gregory.Wolf2@va.gov		Strom, Thad/0000-0001-6743-9999			Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blake D. D., 1990, BEHAV THER, V13, P187; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2006, COGN BEHAV PRACT, V13, P17, DOI 10.1016/j.cbpra.2005.03.002; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cohen J., 1969, STAT POWER ANAL BEHA; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Department of Veterans Affairs, 2010, VA CONS C PRACT REC; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Feeny NC, 2003, COGN BEHAV PRACT, V10, P85, DOI 10.1016/S1077-7229(03)80011-1; Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI 10.1037/1040-3590.11.3.303; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; Foa EB, 2007, PROLONGED EXPOSURE T; Gawande A, 2005, NEW ENGL J MED, V352, P1497; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2007, TREATM PTSD ASS EV; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; KEANE TM, 1989, BEHAV THER, V20, P245, DOI 10.1016/S0005-7894(89)80072-3; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI 10.1176/appi.ajp.163.4.652; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Rosen CS, 2004, J TRAUMA STRESS, V17, P213, DOI 10.1023/B:JOTS.0000029264.23878.53; Rothbaum BO, 2005, J TRAUMA STRESS, V18, P607, DOI 10.1002/jts.20069; Rothbaum BO, 2000, EFFECTIVE TREATMENTS FOR PTSD, P60; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Weathers F. W., 1993, ANN M INT SOC TRAUM; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	43	48	48	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					26	32		10.1097/HTR.0b013e31823cd01f			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400003	22218201				2021-06-18	
J	Rostami, E; Krueger, F; Zoubak, S; Dal Monte, O; Raymont, V; Pardini, M; Hodgkinson, CA; Goldman, D; Risling, M; Grafman, J				Rostami, Elham; Krueger, Frank; Zoubak, Serguei; Dal Monte, Olga; Raymont, Vanessa; Pardini, Matteo; Hodgkinson, Colin A.; Goldman, David; Risling, Marten; Grafman, Jordan			BDNF Polymorphism Predicts General Intelligence after Penetrating Traumatic Brain Injury	PLOS ONE			English	Article							NEUROTROPHIC FACTOR GENE; FACTOR VAL66MET POLYMORPHISM; TRKB MESSENGER-RNA; BIPOLAR DISORDER; CONFERS SUSCEPTIBILITY; MOLECULAR-CLONING; APOLIPOPROTEIN-E; CANDIDATE GENES; HUMAN-MEMORY; ASSOCIATION	Neuronal plasticity is a fundamental factor in cognitive outcome following traumatic brain injury. Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, plays an important role in this process. While there are many ways to measure cognitive outcome, general cognitive intelligence is a strong predictor of everyday decision-making, occupational attainment, social mobility and job performance. Thus it is an excellent measure of cognitive outcome following traumatic brain injury (TBI). Although the importance of the single-nucleotide polymorphisms polymorphism on cognitive function has been previously addressed, its role in recovery of general intelligence following TBI is unknown. We genotyped male Caucasian Vietnam combat veterans with focal penetrating TBI (pTBI) (n = 109) and non-head injured controls (n = 38) for 7 BDNF single-nucleotide polymorphisms. Subjects were administrated the Armed Forces Qualification Test (AFQT) at three different time periods: pre-injury on induction into the military, Phase II (10-15 years post-injury, and Phase III (30-35 years post-injury). Two single-nucleotide polymorphisms, rs7124442 and rs1519480, were significantly associated with post-injury recovery of general cognitive intelligence with the most pronounced effect at the Phase II time point, indicating lesion-induced plasticity. The genotypes accounted for 5% of the variance of the AFQT scores, independently of other significant predictors such as pre-injury intelligence and percentage of brain volume loss. These data indicate that genetic variations in BDNF play a significant role in lesion-induced recovery following pTBI. Identifying the underlying mechanism of this brain-derived neurotrophic factor effect could provide insight into an important aspect of post-traumatic cognitive recovery.	[Rostami, Elham; Risling, Marten] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Dal Monte, Olga] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD USA; [Zoubak, Serguei; Hodgkinson, Colin A.; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA; [Zoubak, Serguei] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophtalmol & Genet, Genoa, Italy; [Pardini, Matteo] Univ Genoa, Magnet Resonance Res Ctr Nervous Syst Dis, Genoa, Italy; [Zoubak, Serguei] Henry Jackson Fdn Adv Mil Med, Rockville, MD USA; [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ USA; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Raymont, Vanessa] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England	Rostami, E (corresponding author), Karolinska Inst, Dept Neurosci, Stockholm, Sweden.	jgrafman@kesslerfoundation.org	Dal Monte, Olga/P-3759-2018; Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020; Pardini, Matteo/F-8414-2010	Dal Monte, Olga/0000-0002-7823-4769; Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Pardini, Matteo/0000-0002-4740-1982; Grafman, Jordan H./0000-0001-8645-4457	U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	This work was supported by the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study). No external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDREASEN NC, 1993, AM J PSYCHIAT, V150, P130; Bueller JA, 2006, BIOL PSYCHIAT, V59, P812, DOI 10.1016/j.biopsych.2005.09.022; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conner JM, 1997, J NEUROSCI, V17, P2295; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; DeCarli C, 2005, NEUROBIOL AGING, V26, P491, DOI 10.1016/j.neurobiolaging.2004.05.004; Domschke K, 2010, INT J NEUROPSYCHOPH, V13, P93, DOI 10.1017/S1461145709000030; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.011.2008; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; FLOOD DG, 1988, NEUROBIOL AGING, V9, P453, DOI 10.1016/S0197-4580(88)80098-8; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gao BL, 2000, J NEUROPSYCH CLIN N, V12, P385, DOI 10.1176/appi.neuropsych.12.3.385; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gottfredson LS, 1997, INTELLIGENCE, V24, P13, DOI 10.1016/S0160-2896(97)90011-8; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Hall D, 2003, AM J HUM GENET, V73, P370, DOI 10.1086/377003; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Hayashi M, 2001, BRAIN RES, V918, P191, DOI 10.1016/S0006-8993(01)03002-5; Heldt SA, 2007, MOL PSYCHIATR, V12, P656, DOI 10.1038/sj.mp.4001957; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hodgkinson CA, 2008, ALCOHOL ALCOHOLISM, V43, P505, DOI 10.1093/alcalc/agn032; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huang R, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.044883; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jung RE, 2007, BEHAV BRAIN SCI, V30, P135, DOI 10.1017/S0140525X07001185; Kadish I, 2009, J ALZHEIMERS DIS, V18, P429, DOI 10.3233/JAD-2009-1157; KatohSemba R, 1997, J NEUROCHEM, V69, P34; Kaufman A. S., 1990, ASSESSING ADOLESCENT; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kolb B., 1995, BRAIN PLASTICITY BEH; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Lemos C, 2010, CEPHALALGIA, V30, P1375, DOI 10.1177/0333102410368443; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lipsky RH, 2007, ANN NY ACAD SCI, V1122, P130, DOI 10.1196/annals.1403.009; Liu LX, 2008, PSYCHIAT GENET, V18, P267, DOI 10.1097/YPG.0b013e3283060f59; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Luebke JI, 2003, J COMP NEUROL, V460, P573, DOI 10.1002/cne.10668; Luikart BW, 2006, PROG BRAIN RES, V157, P15, DOI 10.1016/S0079-6123(06)57002-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mercader JM, 2007, GENES BRAIN BEHAV, V6, P706, DOI 10.1111/j.1601-183X.2007.00301.x; Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288; Nishimura K, 2007, BIOCHEM BIOPH RES CO, V356, P200, DOI 10.1016/j.bbrc.2007.02.135; Okada T, 2006, MOL PSYCHIATR, V11, P695, DOI 10.1038/sj.mp.4001822; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Resnick SM, 2003, J NEUROSCI, V23, P3295; Ribases M, 2003, MOL PSYCHIATR, V8, P745, DOI 10.1038/sj.mp.4001281; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Ronnlund M, 2006, INTELLIGENCE, V34, P63, DOI 10.1016/j.intell.2005.06.004; Ryan JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P311, DOI 10.1016/S0887-6177(99)00019-0; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Seitz RJ, 2005, ACT NEUR S, V93, P65; Shimada A, 1999, NEUROBIOL AGING, V20, P125, DOI 10.1016/S0197-4580(99)00044-5; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Strenze T, 2007, INTELLIGENCE, V35, P401, DOI 10.1016/j.intell.2006.09.004; Szczepankiewicz A, 2009, INT ARCH ALLERGY IMM, V149, P343, DOI 10.1159/000205580; Szeszko PR, 2005, MOL PSYCHIATR, V10, P631, DOI 10.1038/sj.mp.4001656; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Toulopoulou T, 2004, BIOL PSYCHIAT, V56, P447, DOI 10.1016/j.biopsych.2004.06.026; Tsai SJ, 2004, NEUROPSYCHOBIOLOGY, V49, P13, DOI 10.1159/000075333; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Volkow ND, 1998, ANN NEUROL, V44, P143, DOI 10.1002/ana.410440125; WARRINGTON EK, 1986, NEUROPSYCHOLOGIA, V24, P223, DOI 10.1016/0028-3932(86)90055-2; Wechsler D., 1958, MEASUREMENT APPRAISA; Wechsler D., 1939, MEASUREMENT ADULT IN; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Witelson SF, 2006, BRAIN, V129, P386, DOI 10.1093/brain/awh696; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Xiromerisiou G, 2007, NEUROSCI LETT, V415, P59, DOI 10.1016/j.neulet.2006.12.038	97	48	50	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2011	6	11							e27389	10.1371/journal.pone.0027389			13	Multidisciplinary Sciences	Science & Technology - Other Topics	852HZ	WOS:000297349700038	22087305	DOAJ Gold, Green Published			2021-06-18	
J	Kontos, AP; Dolese, A; Elbin, RJ; Covassin, T; Warren, BL				Kontos, Anthony P.; Dolese, Angela; Elbin, R. J., III; Covassin, Tracey; Warren, Barbara L.			Relationship of soccer heading to computerized neurocognitive performance and symptoms among female and male youth soccer players	BRAIN INJURY			English	Article						neurocognitive test; sex differences; soccer; soccer heading; symptoms; youth	HIGH-SCHOOL; CONCUSSION; RECOVERY; INJURIES; BRAIN; FREQUENCY	Primary objective: The purpose of this study was to investigate the relationship between soccer heading and computerized neurocognitive performance and symptoms in female and male youth soccer players. Research design: Cross-sectional and prospective design. Methods and procedures: A total of 63 (27 females, 36 males) youth soccer players aged 13-18 years (M == 15.89, SD == 1.17) participated in the study. Participants completed the Immediate Post-concussion Assessment and Cognitive Test (ImPACT) and symptom report. Main outcomes: Computerized neurocognitive performance (e.g., verbal and visual memory, motor processing, and reaction time) and symptoms. Results: There were no differences in neurocognitive performance or symptoms among low-, moderate-, and high-exposure header groups. The current sample outperformed the 10th percentile norms for neurocognitive and symptom scores. Males headed the ball more frequently and reported lower verbal and visual memory and motor processing speed scores than females. Conclusion: The current findings did not support a relationship between soccer heading and computerized neurocognitive performance and symptoms. The researchers suggest that any purported effects of soccer heading in youth are subtle and may affect only a small number of athletes. The reported sex differences in heading exposure warrant further attention.	[Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Sch Med, UPMC Ctr Sports Med,Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; [Dolese, Angela] Univ New Orleans, Athlet Dept, New Orleans, LA 70148 USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Warren, Barbara L.] Univ Puget Sound, Tacoma, WA 98416 USA	Kontos, AP (corresponding author), Univ Pittsburgh, UPMC Sports Med Concuss Program, Sch Med, UPMC Ctr Sports Med,Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15203 USA.	mail-akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310			Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; COLLINS M, 2004, CURR OPIN ORTHOP, V15, P100; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, BRIT J SPORT MED, V41, P370, DOI 10.1136/bjsm.2006.032334; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lees K., 1988, SCI FOOTBALL, P385; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Lovell MR, 2006, IMPACT CONCUSSION MA; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Oliaro SM, 1998, J ATHL TRAINING, V33, P36; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schmitt DM, 2003, BRIT J SPORT MED, V37, P233; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	31	48	48	2	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2011	25	12					1234	1241		10.3109/02699052.2011.608209			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WF	WOS:000295615200010	21902552				2021-06-18	
J	Wilde, EA; Newsome, MR; Bigler, ED; Pertab, J; Merkley, TL; Hanten, G; Scheibel, RS; Li, XQ; Chu, ZL; Yallampalli, R; Hunter, JV; Levin, HS				Wilde, Elisabeth A.; Newsome, Mary R.; Bigler, Erin D.; Pertab, Jon; Merkley, Tricia L.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Chu, Zili; Yallampalli, Ragini; Hunter, Jill V.; Levin, Harvey S.			Brain imaging correlates of verbal working memory in children following traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Working memory; Sternberg Item Recognition; Functional magnetic resonance imaging (fMRI); Diffusion tensor imaging (DTI); Volumetric; Cortical thickness; Traumatic brain injury; Children	DIFFUSE AXONAL INJURY; EVENT-RELATED FMRI; PREFRONTAL CORTEX; CEREBRAL-CORTEX; ACTIVATION; MODERATE; MRI; TASK; IMPAIRMENTS; REGIONS	Neural correlates of working memory (WM) based on the Sternberg Item Recognition Task (SIRT) were assessed in 40 children with moderate-to-severe traumatic brain injury (TBI) compared to 41 demographically-comparable children with orthopedic injury (OI). Multiple magnetic resonance imaging (MRI) methods assessed structural and functional brain correlates of WM, including volumetric and cortical thickness measures on all children: functional MRI (fMRI) and diffusion tensor imaging (DTI) were performed on a subset of children. Confirming previous findings, children with TBI had decreased cortical thickness and volume as compared to the OI group. Although the findings did not confirm the predicted relation of decreased frontal lobe cortical thickness and volume to SIRT performance, left parietal volume was negatively related to reaction time (RI). In contrast, cortical thickness was positively related to SIRT accuracy and RT in the OI group, particularly in aspects of the frontal and parietal lobes, but these relationships were less robust in the TBI group. We attribute these findings to disrupted fronto-parietal functioning in attention and WM. fMRI results from a subsample demonstrated fronto-temporal activation in the OI group, and parietal activation in the TBI group, and DTI findings reflected multiple differences in white matter tracts that engage fronto-parietal networks. Diminished white matter integrity of the frontal lobes and cingulum bundle as measured by DTI was associated with longer RI on the SIRT. Across modalities, the cingulate emerged as a common structure related to performance after TBI. These results are discussed in terms of how different imaging modalities tap different types of pathologic correlates of brain injury and their relationship with WM. (C) 2011 Elsevier B.V. All rights reserved.	[Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Merkley, Tricia L.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Yallampalli, Ragini; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Scheibel, Randall S.; Yallampalli, Ragini; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Bigler, Erin D.; Pertab, Jon; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, DC USA; [Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Merkley, Tricia L.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Yallampalli, Ragini; Levin, Harvey S.] Phys Med & Rehabil Alliance Baylor Coll Med, Houston, TX USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Neurol, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by NIH grant NS-21889, Neurobehavioral Outcome of Head Injury in Children. The South Central Mental Illness Research, Education, and Clinical Center (MIRECC) provided equipment and laboratory space for the analysis of the fMRI data. We gratefully acknowledge the assistance of Alyssa P. Ibarra and Philip C. Burton.	Baddeley A. D., 1986, WORKING MEMORY; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bijur P., 1995, TRAUMATIC HEAD INJUR; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Casey B., 2002, ENCY HUMAN BRAIN, V1, P145; Cazalis Fabienne, 2011, Front Neurol, V1, P158, DOI 10.3389/fneur.2010.00158; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; *COMM INJ SCAL, 1990, ABBR INJ SCAL; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Narayanan NS, 2005, NEUROPSYCHOLOGY, V19, P223, DOI 10.1037/0894-4105.19.2.223; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; TEASDALE G, 1974, LANCET, V2, P81; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	55	48	48	1	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		86	96		10.1016/j.ijpsycho.2011.04.006			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600010	21565227	Green Accepted			2021-06-18	
J	Ashworth, F; Gracey, F; Gilbert, P				Ashworth, Fiona; Gracey, Fergus; Gilbert, Paul			Compassion Focused Therapy After Traumatic Brain Injury: Theoretical Foundations and a Case Illustration	BRAIN IMPAIRMENT			English	Article						compassion; positive emotion; emotion regulation; brain injury	COGNITIVE-BEHAVIORAL THERAPY; ADJUSTMENT; OXYTOCIN; PEOPLE; HEART	Acquired brain injury (ABI) commonly results in a range of interacting difficulties including regulating emotion, managing social interactions and cognitive changes. Emotional adjustment to ABI can be difficult and requires adaptation of standard psychological therapies. This article outlines a case where cognitive-behavioural therapy (CBT) was of limited effectiveness but was significantly enhanced with compassion focused therapy (CFT). This article describes Jenny, a 23-year-old woman who suffered a traumatic brain injury 3 years prior to attending rehabilitation. Jenny presented with low self-esteem and mental health difficulties. Neuropsychological assessment revealed executive functioning difficulties. Jenny entered a holistic neuropsychological rehabilitation program aimed at improving complex interacting difficulties, receiving CBT as part of this. As CBT was of limited effectiveness, reformulation of Jenny's difficulties was presented to her based on CFT. The CFT intervention employed aimed to help Jenny develop self-validation and acceptance through producing feelings of kindness and warmth. Shifting the affective textures to the self is a key process for CFT. Self-report Measures of mental health and self-esteem showed positive changes and the usefulness of CFT for Jenny. Adaptations in the context of Jenny's ABI are discussed. In conclusion, CFT may be useful in conceptualising emotional responses and developing intervention in rehabilitation after ABI, especially because CFT is based on a neurophysiological model of affect regulation that pays particular attention to the importance of affiliative emotions in the regulation of threat-focused emotion and self-construction.	[Ashworth, Fiona; Gracey, Fergus] Princess Wales Hosp, Oliver Zangwill Ctr, Ely CB6 1DN, Cambs, England; [Gilbert, Paul] Univ Derby, Mental Hlth Res Unit, Derby DE22 1GB, England	Ashworth, F (corresponding author), Princess Wales Hosp, Oliver Zangwill Ctr, Lynn Rd, Ely CB6 1DN, Cambs, England.	Fiona.ashworth@ozc.nhs.uk		Gilbert, paul/0000-0001-8431-9892; Gracey, Fergus/0000-0002-1416-7894			Allen N. B., 2005, COMPASSION CONCEPTUA, P239; Andrews, 1998, SHAME INTERPERSONAL, P3; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bennett-Levy J, 2004, OXFORD GUIDE BEHAV E, P1, DOI DOI 10.1093/MED:PSYCH/9780198529163.003.0001; Bennett-Levy J, 2003, BEHAV COGN PSYCHOTH, V31, P261, DOI 10.1017/S1352465803003035; Bjorklund DF, 1997, PSYCHOL BULL, V122, P153, DOI 10.1037/0033-2909.122.2.153; Bowen C., 2010, RELATIONAL APPROACH; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779; Crane R, 2009, MINDFULNESS BASED CO; Dalgleish T, 2004, NAT REV NEUROSCI, V5, P583, DOI 10.1038/nrn1432; Depue RA, 2005, BEHAV BRAIN SCI, V28, P313; Dewar BK, 2007, NEUROPSYCHOL REHABIL, V17, P602, DOI 10.1080/09602010601051610; Fennell M., 1999, OVERCOMING LOW SELF; Fennell MJV., 1997, BEHAV COGN PSYCHOTH, V25, P1, DOI [10.1017/S1352465800015368, DOI 10.1017/S1352465800015368]; Gilbert P, 2004, BRIT J CLIN PSYCHOL, V43, P31, DOI 10.1348/014466504772812959; Gilbert P., 2000, GENES COUCH EXPLORAT, P118; Gilbert P., 2009, COMPASSIONATE MIND; Gilbert P., 1989, HUMAN NATURE SUFFERI; Gilbert P, 2005, COMPASSION CONCEPTUA, P263; Gilbert P., 2010, COMPASSION FOCUSED T; Gilbert P., 1984, DEPRESSION PSYCHOL B; Gilbert P., 2005, COMPASSION CONCEPTUA; Gilbert P, 2006, CLIN PSYCHOL PSYCHOT, V13, P353, DOI 10.1002/cpp.507; Gilbert P, 2010, INT J COGN THER, V3, P95, DOI 10.1521/ijct.2010.3.2.95; GOLDSTEIN K, 1959, J INDIV PSYCHOL, V15, P5; Gracey F., 2011, SOCIAL CURE IDENTITY; Gracey F, 2009, NEUROPSYCHOL REHABIL, V22, P1; Gracey F, 2007, NEUROPSYCHOL REHABIL, V17, P106, DOI 10.1080/09602010500505260; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Klinger E., 1977, MEANING VOID INNER E; Laithwaite H. M, 2010, THESIS U GLASGOW; LeDoux J., 1998, EMOTIONAL BRAIN; Lee D. A., 2005, COMPASSION CONCEPTUA, P326; Longe O, 2010, NEUROIMAGE, V49, P1849, DOI 10.1016/j.neuroimage.2009.09.019; Lutz A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001897; MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615; Mayhew SL, 2008, CLIN PSYCHOL PSYCHOT, V15, P113, DOI 10.1002/cpp.566; Mikulincer M., 2007, ATTACHMENT ADULTHOOD; Perdices M, 2005, BRAIN IMPAIR, V6, DOI [10.1375/brim.2005.6.3.219, DOI 10.1375/brim.2005.6.3.219]; Porges SW, 2007, BIOL PSYCHOL, V74, P301, DOI 10.1016/j.biopsycho.2006.08.007; POWER MJ, 1997, COGNITION EMOTION OR; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; ROBSON P, 1989, PSYCHOL MED, V19, P513, DOI 10.1017/S003329170001254X; Singer JL., 2006, IMAGERY PSYCHOTHERAP; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Spielberger C., 1988, MANUAL STATE TRAIT A; Stopa L, 2009, IMAGERY THREATENED S; Stott R, 2007, J COGN PSYCHOTHER, V21, P37, DOI 10.1891/088983907780493313; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Teasdale JD., 1993, AFFECT COGNITION CHA; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Whyte J, 2006, NEUROPSYCHOL REHABIL, V19, P807; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; Wilson B.A., 2009, NEUROPSYCHOL REHABIL, P1; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12	63	48	49	0	31	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	SEP	2011	12	2			SI		128	139		10.1375/brim.12.2.128			12	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	837BH	WOS:000296165600006					2021-06-18	
J	Bryan, C; Anestis, M				Bryan, Craig; Anestis, Michael			Reexperiencing Symptoms and the Interpersonal-Psychological Theory of Suicidal Behavior Among Deployed Service Members Evaluated for Traumatic Brain Injury	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						suicide; PTSD; pain; interpersonal-psychological theory	POSTTRAUMATIC-STRESS-DISORDER; RISK; VETERANS; SAMPLES; ADULTS; DEATH; TESTS; PTSD	Recent evidence suggests that military suicide rates now exceed those of the general public. Numerous recent efforts to address this growing concern have focused on the interpersonal psychological theory of suicidal behavior (IPTS). In the current study, we explored the relationships among reexperiencing symptoms of posttraumatic stress disorder and the three components of the IPTS in a sample of deployed military personnel examined for traumatic brain injury. Results indicated that reexperiencing symptoms were directly related to the acquired capability for suicide, but their relationships to perceived burdensomeness and thwarted belongingness were statistically explained by general mental health distress. Results indicate that mental rehearsal of painful and provocative experiences may have an impact on suicide risk. (C) 2011 Wiley Periodicals, Inc. J Clin Psychol 67: 856-865, 2011.	[Bryan, Craig] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA; [Anestis, Michael] Florida State Univ, Tallahassee, FL 32306 USA	Bryan, C (corresponding author), 7550 W IH-10,Suite 1325, San Antonio, TX 78229 USA.	bryanc3@uthscsa.edu		Bryan, Craig/0000-0002-9714-0733			Anestis M., 2009, J MENTAL HEALTH COUN, V31, P60, DOI [10.17744/mehc.31.1.u394h1470248844n, DOI 10.17744/MEHC.31.1.U394H1470248844N, DOI 10.17744/MEHC.31.1.U394H1470]; ANESTIS MD, J PSYCHIAT IN PRESS; Bender T. W., 2007, IMPULSIVITY SU UNPUB; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner L.A., 2008, J MENT HLTH COUNS, V30, P211; Briggs N., 2006, DISS ABSTR INT B, V37, p4755B; BRYAN C, J CLIN PSYC IN PRESS; Bryan CJ, 2010, PERS INDIV DIFFER, V48, P347, DOI 10.1016/j.paid.2009.10.023; CelestHealth Solutions, 2008, CELESTHEALTH SOL CLI; Hartl TL, 2005, J NERV MENT DIS, V193, P464, DOI 10.1097/01.nmd.0000168238.13252.b3; HENDIN H, 1991, AM J PSYCHIAT, V148, P586; Herman D., 1993, ANN CONV INT SOC TRA; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2009, J ABNORM PSYCHOL, V118, P634, DOI 10.1037/a0016500; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; Kotler M, 2001, J NERV MENT DIS, V189, P162, DOI 10.1097/00005053-200103000-00004; Krysinska K, 2010, ARCH SUICIDE RES, V14, P1, DOI 10.1080/13811110903478997; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; Lorge E, 2008, ARMY RESPONDS RISING; Osborne J. W., 2008, BEST PRACTICES QUANT, P239; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; ROTHBERG JM, 1990, JAMA-J AM MED ASSOC, V264, P2241, DOI 10.1001/jama.264.17.2241; Selby EA, 2007, BEHAV MODIF, V31, P867, DOI 10.1177/0145445507300874; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697	26	48	48	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	SEP	2011	67	9					856	865		10.1002/jclp.20808			10	Psychology, Clinical	Psychology	811WN	WOS:000294248200003	21520082				2021-06-18	
J	Schonberger, M; Ponsford, J; Gould, KR; Johnston, L				Schoenberger, Michael; Ponsford, Jennie; Gould, Kate R.; Johnston, Lisa			The Temporal Relationship Between Depression, Anxiety, and Functional Status after Traumatic Brain Injury: A Cross-lagged Analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Depression; Anxiety; Functional status; Prospective studies; Longitudinal studies	STRUCTURED INTERVIEWS; HEALTH; MODEL; REHABILITATION; DISORDERS; MODERATE; OUTCOMES; ASSOCIATION; MULTICENTER; IMPAIRMENT	Poor functional status and high rates of anxiety and depression have been reported in individuals who have sustained a traumatic brain injury (TBI). However, it is unclear whether psychiatric disorders after TBI are a cause or a consequence of functional limitations. The current study aimed to investigate the temporal relationship between anxiety, depression and functional impairment following TBI. The study has a prospective, longitudinal single-group design. Anxiety and depression, assessed using the Structured Clinical Interview for DSM-IV, and functional changes, assessed with the Glasgow Outcome Scale-Extended, were measured six and 12 months post-injury in 122 individuals who had sustained a TBI (79% male, mean age 35 years, mean duration of post-traumatic amnesia 24 days, mean Glasgow Coma Scale score 9.2). Cross-lagged analyses were conducted within a structural equation modelling framework. Functional changes six months post-injury predicted depression and anxiety one year after the injury. Anxiety and depression, in turn, were not predictive of later functional status. This study adds to our understanding of the temporal relationship between depression, anxiety and functional status after TBI. The results indicate the importance of supporting brain injured individuals in coping with the functional consequences of their injury in order promote psychological well-being. (JINS, 2011, 17, 781-787)	[Schoenberger, Michael; Ponsford, Jennie; Gould, Kate R.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Schoenberger, Michael; Ponsford, Jennie; Gould, Kate R.; Johnston, Lisa] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Schonberger, M (corresponding author), Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Engelberger Str 41, D-79106 Freiburg, Germany.	michael.schoenberger@psychologie.uni-freiburg.de	Gould, Kate/AAA-5511-2020	Gould, Kate/0000-0002-3564-7408	Victorian Neurotrauma Initiative	Funding for this study was provided by the Victorian Neurotrauma Initiative. The authors have no financial involvement or interests.	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First MB., 2002, STRUCTURED CLIN INTE; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GOULD KR, 2011, PSYCHOL MED; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Muthen B., 1997, ROBUST INFERENCE USI; Muthen B., 2010, MPLUS VERSION 6; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; PELZ DC, 1964, AM SOCIOL REV, V29, P836, DOI 10.2307/2090866; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; POPPER K, 1963, CONJECTURES REFITTAT; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	47	48	49	0	17	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2011	17	5					781	787		10.1017/S1355617711000701			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	821KV	WOS:000294974800003	21729404				2021-06-18	
J	Tavender, EJ; Bosch, M; Green, S; O'Connor, D; Pitt, V; Phillips, K; Bragge, P; Gruen, RL				Tavender, Emma J.; Bosch, Marije; Green, Sally; O'Connor, Denise; Pitt, Veronica; Phillips, Kate; Bragge, Peter; Gruen, Russell L.			Quality and Consistency of Guidelines for the Management of Mild Traumatic Brain Injury in the Emergency Department	ACADEMIC EMERGENCY MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINES; IMPLEMENTATION; LIMITATIONS; DIAGNOSIS; CHILDREN	Objectives: The objective was to provide an overview of the recommendations and quality of evidence-based clinical practice guidelines (CPGs) for the emergency management of mild traumatic brain injury (mTBI), with a view to informing best practice and improving the consistency of recommendations. Methods: Electronic searches of health databases (MEDLINE, EMBASE, The Cochrane Library, PsycINFO), CPG clearinghouse websites, CPG developer websites, and Internet search engines up to January 2010 were conducted. CPGs were included if 1) they were published in English and freely accessible, 2) their scope included the management of mTBI in the emergency department (ED), 3) the date of last search was within the past 10 years (2000 onward), 4) systematic methods were used to search for evidence, and 5) there was an explicit link between the recommendations and the supporting evidence. Four authors independently assessed the quality of the included CPGs using the Appraisal of Guidelines, Research and Evaluation (AGREE) Instrument. The authors extracted and categorized recommendations according to initial clinical assessment, imaging, management, observation, discharge planning, and patient information and follow-up. Results: The search identified 18 potential CPGs, of which six met the inclusion criteria. The included CPGs varied in scope, target population, size, and guideline development processes. Four CPGs were assessed as "strongly recommended." The majority of CPGs did not provide information about the level of stakeholder involvement (mean AGREE standardized domain score = 57%, range = 25% to 81%), nor did they address the organizational/cost implications of applying the recommendations or provide criteria for monitoring and review of recommendations in practice (mean AGREE standardized domain score = 46.6%, range = 19% to 94%). Recommendations were mostly consistent in terms of the use of the Glasgow Coma Scale (GCS) score (adult and pediatric) to assess the level of consciousness, initial assessment criteria, the use of computed tomography (CT) scanning as imaging investigation of choice, and the provision of patient information. The CPGs defined mTBI in a variety of ways and described different rules to determine the need for CT scanning and therefore used different criteria to identify high-risk patients. Conclusions: Higher-quality CPGs for mTBI are consistent in their recommendations about assessment, imaging, and provision of patient information. There is not, however, an agreed definition of mTBI, and the quality of future CPGs could be improved with better reporting of stakeholder involvement, procedures for updating, and greater consideration of the applicability of the recommendations (cost implications, monitoring procedures). Nevertheless, guideline developers may benefit from adapting existing CPGs to their local context rather than investing in developing CPGs de novo. ACADEMIC EMERGENCY MEDICINE 2011; 18:880-889 (C) 2011 by the Society for Academic Emergency Medicine	[Tavender, Emma J.; Pitt, Veronica; Bragge, Peter; Gruen, Russell L.] Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; [Bosch, Marije; Green, Sally; O'Connor, Denise; Phillips, Kate] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3181, Australia	Tavender, EJ (corresponding author), Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia.	emma.tavender@monash.edu	O'Connor, Denise/ABC-6655-2020	O'Connor, Denise/0000-0002-6836-122X; Green, Sally Elizabeth/0000-0002-9564-9050; Tavender, Emma/0000-0002-7230-712X; Bragge, Peter/0000-0003-0745-5131	Victorian Neurotrauma Initiative; Department of Surgery, Monash UniversityMonash University; Monash UniversityMonash University	The Neurotrauma Evidence Translation Project is funded by the Victorian Neurotrauma Initiative. Emma Tavender is funded by a Faculty Postgraduate Research Scholarship (FPRS), Department of Surgery, Monash University.; Conflict of interest: KP = Transport Accident Commission, Victoria Australia-Clinical Advisor on Client treatment programs; Independent Rehabilitation Services-Rehabilitation of neurotrauma patients; Solicitors-Expert opinion of Neurotrauma patients; Monash University-PhD Scholarship. The other authors have no additional disclosures or conflicts of interest to report.	American College of Radiology, ACR APPR CRIT HEAD T; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brouwers MC, 2010, CAN MED ASSOC J, V182, P1045, DOI 10.1503/cmaj.091714; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US E; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; CUSHMAN JG, PRACTICE MANAGEMENT; de Andrade AF, 2001, WORLD J SURG, V25, P1186; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fervers B, 2006, INT J QUAL HEALTH C, V18, P167, DOI 10.1093/intqhc/mzi108; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Grimshaw J, 2006, J GEN INTERN MED, V21, pS14, DOI 10.1111/j.1525-1497.2006.00357.x; Grol R, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c306; Hegarty K, 2009, BRIT J GEN PRACT, V59, P322, DOI 10.3399/bjgp09X420581; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keris V, 2007, WORLD J SURG, V31, P1352, DOI 10.1007/s00268-007-9002-x; Misso ML, 2008, MED J AUSTRALIA, V189, P394, DOI 10.5694/j.1326-5377.2008.tb02086.x; *MOT ACC AUTH NEW, GUID MILD TRAUM BRAI; National Institute for Health and Clinical Excellence, HEAD INJ TRIAG ASS I; *NEW S WAL DEP HLT, AC MAN HEAD INJ CHIL; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; REED D, ADULT TRAUMA CLIN PR; *ROYAL COLL PAED C, EARL MAN PAT HEAD IN; Rusnak M, 2008, BRATISL MED J, V109, P374; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Scottish Intercollegiate Guidelines Network, 2009, EARL MAN PAT HEAD IN; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; The AGREE Collaboration, AGREE INSTR; Turner T, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-45; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527	40	48	49	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2011	18	8			SI		880	889		10.1111/j.1553-2712.2011.01134.x			10	Emergency Medicine	Emergency Medicine	807AJ	WOS:000293860400014	21843224	Bronze			2021-06-18	
J	Folkersma, H; Dingley, JCF; van Berckel, BNM; Rozemuller, A; Boellaard, R; Huisman, MC; Lammertsma, AA; Vandertop, WP; Molthoff, CFM				Folkersma, Hedy; Dingley, Jessica C. Foster; van Berckel, Bart N. M.; Rozemuller, Annemieke; Boellaard, Ronald; Huisman, Marc C.; Lammertsma, Adriaan A.; Vandertop, W. Peter; Molthoff, Carla F. M.			Increased cerebral (R)-[C-11]PK11195 uptake and glutamate release in a rat model of traumatic brain injury: a longitudinal pilot study	JOURNAL OF NEUROINFLAMMATION			English	Article							LAYER HIGH-RESOLUTION; NEURONAL INJURY; AMINO-ACIDS; HEAD-INJURY; MICROGLIA; HIPPOCAMPUS; ACTIVATION; RECEPTORS; REPAIR; PET	Background: The aim of the present study was to investigate microglia activation over time following traumatic brain injury (TBI) and to relate these findings to glutamate release. Procedures: Sequential dynamic (R)-[C-11]PK11195 PET scans were performed in rats 24 hours before (baseline), and one and ten days after TBI using controlled cortical impact, or a sham procedure. Extracellular fluid (ECF) glutamate concentrations were measured using cerebral microdialysis. Brains were processed for histopathology and (immuno)-histochemistry. Results: Ten days after TBI, (R)-[C-11]PK11195 binding was significantly increased in TBI rats compared with both baseline values and sham controls (p < 0.05). ECF glutamate values were increased immediately after TBI (27.6 +/- 14.0 mu mol.L-1) as compared with the sham procedure (6.4 +/- 3.6 mu mol.L-1). Significant differences were found between TBI and sham for ED-1, OX-6, GFAP, Perl's, and Fluoro-Jade B. Conclusions: Increased cerebral uptake of (R)-[C-11]PK11195 ten days after TBI points to prolonged and ongoing activation of microglia. This activation followed a significant acute posttraumatic increase in ECF glutamate levels.	[Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam Med Ctr, Neurosurg Ctr Amsterdam, NL-1081 HV Amsterdam, Netherlands; [Dingley, Jessica C. Foster; van Berckel, Bart N. M.; Boellaard, Ronald; Huisman, Marc C.; Lammertsma, Adriaan A.; Molthoff, Carla F. M.] Vrije Univ Amsterdam Med Ctr, Dept Nucl Med, NL-1081 HV Amsterdam, Netherlands; [Dingley, Jessica C. Foster; van Berckel, Bart N. M.; Boellaard, Ronald; Huisman, Marc C.; Lammertsma, Adriaan A.; Molthoff, Carla F. M.] Vrije Univ Amsterdam Med Ctr, PFT Res, NL-1081 HV Amsterdam, Netherlands; [Rozemuller, Annemieke] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Folkersma, H (corresponding author), Vrije Univ Amsterdam Med Ctr, Neurosurg Ctr Amsterdam, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	h.folkersma@amc.nl	Vandertop, William P./K-9288-2018; Rozemuller, Annemieke/C-2084-2008	Boellaard, Ronald/0000-0002-0313-5686; Lammertsma, Adriaan/0000-0003-1237-2891	Dutch Brain Foundation [9F01.21]; Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [016.066.309]	The authors thank M. van Gelder for expert technical assistance in the animal experiments and P. Kostense from the Department of Epidemiology & Biostatistics for statistical support. This study was funded by the Dutch Brain Foundation (Grant-ID 9F01.21) and by the Netherlands Organization for Scientific Research (NWO, Grant-ID 016.066.309).	Boellaard R, 2003, PHYS MED BIOL, V48, P429, DOI 10.1088/0031-9155/48/4/302; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265; de Jong HWAM, 2007, PHYS MED BIOL, V52, P1505, DOI 10.1088/0031-9155/52/5/019; Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Farber K, 2005, BRAIN RES REV, V48, P133, DOI 10.1016/j.brainresrev.2004.12.003; Fei Z, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-96; Folkersma H, 2009, J NUCL MED, V50, P1975, DOI 10.2967/jnumed.109.067512; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; Heiss WD, 2004, J NUCL MED, V45, P1811; Hume SP, 1998, EUR J NUCL MED, V25, P173, DOI 10.1007/s002590050211; Ito F, 2010, ANN NUCL MED, V24, P163, DOI 10.1007/s12149-009-0339-0; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kropholler MA, 2006, J CEREBR BLOOD F MET, V26, P1431, DOI 10.1038/sj.jcbfm.9600289; Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4; Liu GJ, 2009, EUR J NEUROSCI, V29, P1108, DOI 10.1111/j.1460-9568.2009.06659.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHAH F, 1994, NUCL MED BIOL, V21, P573, DOI 10.1016/0969-8051(94)90022-1; Suma T, 2008, NEUROL RES, V30, P420, DOI 10.1179/016164107X251745; Takeuchi H, 2008, EXP NEUROL, V214, P144, DOI 10.1016/j.expneurol.2008.08.001; Toyama H, 2008, ANN NUCL MED, V22, P417, DOI 10.1007/s12149-008-0136-1; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196	32	48	50	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 14	2011	8								67	10.1186/1742-2094-8-67			7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	790EK	WOS:000292571100001	21672189	DOAJ Gold, Green Published			2021-06-18	
J	Gomez-Pinilla, F				Gomez-Pinilla, Fernando			The combined effects of exercise and foods in preventing neurological and cognitive disorders	PREVENTIVE MEDICINE			English	Article						Neurotrophin; Synaptic plasticity; Brain trauma; Diet; Omega-3-fatty acids	TRAUMATIC BRAIN-INJURY; CAMP-RESPONSIVE ELEMENT; SATURATED-FAT DIET; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; DOCOSAHEXAENOIC ACID; METABOLIC DEPRESSION; ENERGY-METABOLISM; OXIDATIVE STRESS; HUMAN-MEMORY	Objective. Exercise and select diets have important influences on health and plasticity of the nervous system, and the molecular mechanisms involved with these actions are starting to be elucidated. New evidence indicates that exercise, in combination with dietary factors, exerts its effects by affecting molecular events related to the management of energy metabolism and synaptic plasticity. Methods. Published studies in animals and humans describing the effects of exercise and diets in brain plasticity and cognitive abilities are discussed. Results. New evidence indicates that exercise and select diets exert their effects by affecting molecular events related to the management of energy metabolism and synaptic plasticity. An important instigator in the molecular machinery stimulated by exercise is brain-derived neurotrophic factor (BDNF), which acts at the interface of metabolism and plasticity. Conclusions. Recent studies show that selected dietary factors share similar mechanisms with exercise, and in some cases they can complement the action of exercise. Therefore, exercise and dietary management appear as a non-invasive and effective strategy to counteract neurological and cognitive disorders. (C) 2011 Elsevier Inc. All rights reserved.	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	Fgomezpi@ucla.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465-06, NS068473, NS56413]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC1NS068473, R01NS050465, R01NS056413] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Awards NS50465-06, NS068473, and NS56413.	AGRAWAL R, 2010, 2010 NEUR M PLANN SO; Andres-Lacueva C, 2005, NUTR NEUROSCI, V8, P111, DOI 10.1080/10284150500078117; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Cammarota M, 2000, NEUROCHEM RES, V25, P567, DOI 10.1023/A:1007590415556; Chao HT, 2009, P NATL ACAD SCI USA, V106, P4577, DOI 10.1073/pnas.0901518106; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Chytrova G, 2010, BRAIN RES, V1341, P32, DOI 10.1016/j.brainres.2009.05.018; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Feng JA, 2007, PEDIATR RES, V61, p58R, DOI 10.1203/pdr.0b013e3180457635; Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x; Gomez-Pinilla F, 2010, NEUROSCIENCE, V168, P130, DOI 10.1016/j.neuroscience.2010.02.070; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jacka FN, 2010, AM J PSYCHIAT, V167, P305, DOI 10.1176/appi.ajp.2009.09060881; Joseph JA, 2003, NUTR NEUROSCI, V6, P153, DOI 10.1080/1028415031000111282; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Lyons WE, 1999, P NATL ACAD SCI USA, V96, P15239, DOI 10.1073/pnas.96.26.15239; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nestler EJ, 2009, BIOL PSYCHIAT, V65, P189, DOI 10.1016/j.biopsych.2008.10.030; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Song DK, 1998, BRAIN RES, V799, P176, DOI 10.1016/S0006-8993(98)00474-0; Suzuki H, 1998, MECH AGEING DEV, V101, P119, DOI 10.1016/S0047-6374(97)00169-3; Sweatt JD, 2009, BIOL PSYCHIAT, V65, P191, DOI 10.1016/j.biopsych.2008.09.002; Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659; Tsuchida A, 2002, DIABETES OBES METAB, V4, P262, DOI 10.1046/j.1463-1326.2002.00206.x; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Waddington C. H., 1942, Endeavour London, V1, P18; Wei QY, 2006, BBA-GEN SUBJECTS, V1760, P70, DOI 10.1016/j.bbagen.2005.09.008; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313	66	48	49	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0091-7435	1096-0260		PREV MED	Prev. Med.	JUN 1	2011	52			1			S75	S80		10.1016/j.ypmed.2011.01.023			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	779DS	WOS:000291758900013	21281667	Green Accepted			2021-06-18	
J	Ro, YS; Shin, SD; Holmes, JF; Song, KJ; Park, JO; Cho, JS; Lee, SC; Kim, SC; Hong, KJ; Park, CB; Cha, WC; Lee, EJ; Kim, YJ; Ahn, KO; Ong, MEH				Ro, Young Sun; Shin, Sang Do; Holmes, James F.; Song, Kyoung Jun; Park, Ju Ok; Cho, Jin Sung; Lee, Seung Chul; Kim, Seong Chun; Hong, Ki Jeong; Park, Chang Bae; Cha, Won Chul; Lee, Eui Jung; Kim, Yu Jin; Ahn, Ki Ok; Ong, Marcus Eng Hock		Traumatic Brain Injury Res Network	Comparison of Clinical Performance of Cranial Computed Tomography Rules in Patients With Minor Head Injury: A Multicenter Prospective Study	ACADEMIC EMERGENCY MEDICINE			English	Article							NEW-ORLEANS CRITERIA; EMERGENCY-DEPARTMENT; CT; MANAGEMENT; VALIDATION; DIAGNOSIS	Objectives: The objective was to compare the predictive performance of three previously derived cranial computed tomography (CT) rules, the Canadian CT Head Rule (CCHR), the New Orleans Criteria (NOC), and National Emergency X-Ray Utilization Study (NEXUS)-II, for detecting clinically important traumatic brain injury (TB!) and the need for neurosurgical intervention in patients with blunt head trauma. Methods: This was a prospective, multicenter, observational cohort study of patients with blunt head trauma from June 2008 to May 2009. The historical and physical examination components of the CCHR, NOC, and NEXUS-II were documented on a data collection form and the performance of each of the three rules was compared. Patient eligibility for each specific rule was defined exactly as previously described for each specific rule. To compare the three decision rules in terms of sensitivity and specificity, an intersection cohort satisfying inclusion criteria of all three decision rules was derived. The primary outcome was clinically important TBI, and the secondary outcome was neurosurgical intervention. The sensitivity and specificity of each rule were calculated with 95% confidence intervals (95% CIs). We also calculated the potential reduction rate in cranial CT scan utilization realized by theoretical implementation of these rules. Results: A total of 7,131 patients were prospectively enrolled, including 692 (9.7%) with clinical TBI. Among the enrolled population, patients eligible for CCHR, NOC, and NEXUS-II totaled 696, 677, and 2,951, respectively. The sensitivity and specificity for clinically important brain injury were as follows: CCHR, 112 of 144 (79.2%, 95% CI = 70.8% to 86.0%) and 228 of 552 (41.3%, 95% CI = 37.3% to 45.5%); NOC, 91 of 99 (91.9%, 95% CI = 84.7% to 96.5%) and 125 of 558 (22.4%, 95% CI = 19.0% to 26.1%); and NEXUS-II, 511 of 576 (88.7%, 95% CI = 85.8% to 91.2%) and 1,104 of 2,375 (46.5%, 95% CI = 44.5% to CI = 59.0% to 100.0%) and 38.3% (95% CI = 34.5% to 41.9%); NOC, 100% (95% CI = 54.1% to 100.0%) and 20.4% (95% CI = 17.4% to 23.7%); and NEXUS-II, 95.1% (95% CI = 90.1% to 98.0%) and 41.4% (95% CI = 39.5% to 43.2%). Among the enrolled population, intersection patients of CCHR, NOC, and NEXUS-II totaled 588. The sensitivity and specificity for clinically important brain injury were as follows: CC FIR, 73 of 98 (74.5%, 95% CI = 64.7% to 82.8%) and 201 of 490 (41.0%, 95% CI = 36.6% to 45.5%); NOC, 89 of 98 (90.8%, 95% CI = 83.3% to 95.7%) and 112 of 490 (22.9%, 95% CI = 19.2% to 26.8%); and NEXUS-II, 82 of 98 (83.7%, 95% CI = 74.8% to 90.4%) and 172 of 490 (35.1%, 95% CI = 30.9% to 39.5%). The potential reduction in emergency CT scans by using these decision rules would have been higher with the NEXUS-II rule (39.6%, 95% CI = 37.8% to 41.4%) than with the CCHR rule (27.0%, 95% CI = 23.7% to 30.3%) or NOC rule (20.2%, 95% CI = 17.2% to 23.3%). Conclusions: For clinically important TBI, the three cranial CT decision rules had much lower sensitivities in this population than the original published studies, while the specificities were comparable to those studies. The sensitivities for neurosurgical intervention, however, were comparable to the original studies. The NEXUS-II rule showed the highest reduction rate for CT scans compared to other rules, but failed to identify all undergoing neurosurgical intervention for their original inclusion cohort. ACADEMIC EMERGENCY MEDICINE 2011; 18:597-604 (C) 2011 by the Society for Academic Emergency Medicine	[Ro, Young Sun; Shin, Sang Do; Park, Chang Bae; Lee, Eui Jung] Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Holmes, James F.] UC Davis Med Ctr, Dept Emergency Med, Davis, CA USA; [Hong, Ki Jeong] Seoul Natl Univ, Dept Emergency Med, Boramae Hosp, Seoul, South Korea; [Park, Ju Ok] Jeju Natl Univ, Dept Emergency Med, Cheju, South Korea; [Cho, Jin Sung] Gachon Univ, Sch Med Sci, Dept Emergency Med, Inchon, South Korea; [Lee, Seung Chul] Dongkuk Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Kim, Seong Chun] Gyeongsang Natl Univ, Coll Med, Dept Emergency Med, Kyoungnam, South Korea; [Hong, Ki Jeong] Daegu Emergency Med Informat Ctr, Gyeongbuk, South Korea; [Cha, Won Chul] Seoguipo Med Ctr, Dept Emergency Med, Cheju, South Korea; [Kim, Yu Jin] Seoul Natl Univ, Dept Emergency Med, Bundang Hosp, Seoul, South Korea; [Ahn, Ki Ok] Seoul Fire Serv Acad Seoul, EMS Educ & Training Ctr, Seoul, South Korea; [Ong, Marcus Eng Hock] Singapore Gen Hosp, Dept Emergency Med, Singapore 0316, Singapore	Shin, SD (corresponding author), Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	shinsangdo@snuh.org	안, 기옥/L-5596-2019; Shin, Sang/J-5523-2012	안, 기옥/0000-0002-8446-3269; Hong, Ki Jeong/0000-0003-3334-817X	Korean Centers for Disease Control and Prevention	The Traumatic Brain Injury Research Network of Korea (TBI Network) is an ED-based clinical research network for traumatic brain injury was constructed in 2007 and, at present, seven Ells are participating to this network: Seoul National University Hospital, Dongkuk University Ilsan Hospital, Seoul National University Boramae Medical Center, Jeju National University Hospital, Gyeongsang National University Hospital, Gachon University Gil Hospital, and Seoul National University Bundang Hospital. The Korean Centers for Disease Control and Prevention supported this study financially.	Boyle A, 2004, EMERG MED J, V21, P426, DOI 10.1136/emj.2002.002063; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; MCCAIG LF, 2002, ADV DATA, V327, P1; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell I.G., 2000, ACAD EMERG MED, V7, P572; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; *WHO ICECI COORD M, TEST ICECI REV FILED; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	21	48	49	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUN	2011	18	6					597	604		10.1111/j.1553-2712.2011.01094.x			8	Emergency Medicine	Emergency Medicine	781BP	WOS:000291905900005	21676057				2021-06-18	
J	Shein, NA; Shohami, E				Shein, Na'ama A.; Shohami, Esther			Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SUBEROYLANILIDE HYDROXAMIC ACID; CREB-BINDING-PROTEIN; VALPROIC ACID; MOUSE MODEL; HDAC INHIBITOR; MEDIATED NEUROPROTECTION; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY RESPONSE; ISOFORM SELECTIVITY	Histone deacetylase (HDAC) inhibitors are emerging as a novel class of potentially therapeutic agents for treating acute injuries of the central nervous system (CNS). In this review, we summarize data regarding the effects of HDAC inhibitor administration in models of acute CNS injury and discuss issues warranting clinical trials. We have previously shown that the pan-HDAC inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h after injury. Using a well-characterized, clinically relevant mouse model of closed head injury, we demonstrated that a single dose of ITF2357 administered 24 h after injury improves neurobehavioral recovery and reduces tissue damage. ITF2357-induced functional improvement was found to be sustained up to 14 d after trauma and was associated with augmented histone acetylation. Single postinjury administration of ITF2357 also attenuated injury-induced inflammatory responses, as indicated by reduced glial accumulation and activation as well as enhanced caspase-3 expression within microglia/macrophages after treatment. Because no specific therapeutic intervention is currently available for treating brain trauma patients, the ability to affect functional outcome by postinjury administration of HDAC inhibitors within a clinically feasible timeframe may be of great importance. Furthermore, a growing body of evidence indicates that HDAC inhibitors are beneficial for treating various forms of acute CNS injury including ischemic and hemorrhagic stroke. Because HDAC inhibitors are currently approved for other use, they represent a promising new avenue of treatment, and their use in the setting of CNS injury warrants clinical evaluation. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00038	[Shein, Na'ama A.; Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, Jerusalem, Israel.	esty@cc.huji.ac.il					Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Atweh GF, 1999, BLOOD, V93, P1790; Avila AM, 2007, J CLIN INVEST, V117, P659, DOI 10.1172/JCI29562; Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Bertrand P, 2010, EUR J MED CHEM, V45, P2095, DOI 10.1016/j.ejmech.2010.02.030; Bieliauskas AV, 2008, CHEM SOC REV, V37, P1402, DOI 10.1039/b703830p; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Butler KV, 2008, CURR PHARM DESIGN, V14, P505; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Candelario-Jalil E, 2009, CURR OPIN INVEST DR, V10, P644; Carlisi D, 2008, INT J ONCOL, V32, P177; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DeFina P, 2009, CLIN NEUROPSYCHOL, V23, P1391, DOI 10.1080/13854040903058978; Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043; Emsley HCA, 2002, J CEREBR BLOOD F MET, V22, P1399, DOI 10.1097/01.WCB.0000037880.62590.28; Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Gallen Christopher C, 2004, NeuroRx, V1, P165, DOI 10.1602/neurorx.1.1.165; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gaub P, 2010, CELL DEATH DIFFER, V17, P1392, DOI 10.1038/cdd.2009.216; Gerstner T, 2008, EXPERT OPIN PHARMACO, V9, P285, DOI [10.1517/14656566.9.2.285, 10.1517/14656566.9.2.285 ]; Glauben R, 2008, GUT, V57, P613, DOI 10.1136/gut.2007.134650; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hildmann C, 2007, APPL MICROBIOL BIOT, V75, P487, DOI 10.1007/s00253-007-0911-2; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Huuskonen J, 2004, BRIT J PHARMACOL, V141, P874, DOI 10.1038/sj.bjp.0705682; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin KL, 2001, J MOL NEUROSCI, V16, P49, DOI 10.1385/JMN:16:1:49; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kilgore M, 2010, NEUROPSYCHOPHARMACOL, V35, P870, DOI 10.1038/npp.2009.197; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kozikowski AP, 2007, J MED CHEM, V50, P3054, DOI 10.1021/jm070178x; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Langley B, 2008, J NEUROSCI, V28, P163, DOI 10.1523/JNEUROSCI.3200-07.2008; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Langley B, 2009, STROKE, V40, P2899, DOI 10.1161/STROKEAHA.108.540229; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Marinova Z, 2009, J NEUROCHEM, V111, P976, DOI 10.1111/j.1471-4159.2009.06385.x; Matalon S, 2010, JAIDS-J ACQ IMM DEF, V54, P1, DOI 10.1097/QAI.0b013e3181d3dca3; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rivieccio MA, 2009, P NATL ACAD SCI USA, V106, P19599, DOI 10.1073/pnas.0907935106; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Thomas EA, 2008, P NATL ACAD SCI USA, V105, P15564, DOI 10.1073/pnas.0804249105; Thomas EA, 2009, MOL NEUROBIOL, V40, P33, DOI 10.1007/s12035-009-8067-y; Vecsey CG, 2007, J NEUROSCI, V27, P6128, DOI 10.1523/JNEUROSCI.0296-07.2007; Vojinovic J, 2011, ARTHRITIS RHEUM-US, V63, P1452, DOI 10.1002/art.30238; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Witt KA, 2008, MICROVASC RES, V75, P91, DOI 10.1016/j.mvr.2007.06.004; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yildirim F, 2008, EXP NEUROL, V210, P531, DOI 10.1016/j.expneurol.2007.11.031; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	91	48	53	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	MAY-JUN	2011	17	5-6					448	456		10.2119/molmed.2011.00038			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	776HS	WOS:000291525700013	21274503	DOAJ Gold, Green Published			2021-06-18	
J	Hays, AN; Lazaridis, C; Neyens, R; Nicholas, J; Gay, S; Chalela, JA				Hays, Angela N.; Lazaridis, Christos; Neyens, Ron; Nicholas, Joyce; Gay, Sarah; Chalela, Julio A.			Osmotherapy: Use Among Neurointensivists	NEUROCRITICAL CARE			English	Article						Osmotherapy; Cerebral edema; Intracranial pressure; Intracranial hypertension; Traumatic brain injury; Hypertonic saline; Mannitol; Survey; Neurocritical care	TRAUMATIC BRAIN-INJURY; HYPERTONIC SALINE RESUSCITATION; INCREASED INTRACRANIAL-PRESSURE; CEREBRAL-BLOOD-FLOW; INTRACEREBRAL HEMORRHAGE; MANNITOL SOLUTION; OXYGENATION; THERAPY; CARE; HYPOTENSION	Cerebral edema and raised intracranial pressure are common problems in neurological intensive care. Osmotherapy, typically using mannitol or hypertonic saline (HTS), has become one of the first-line interventions. However, the literature on the use of these agents is heterogeneous and lacking in class I studies. The authors hypothesized that clinical practice would reflect this heterogeneity with respect to choice of agent, dosing strategy, and methods for monitoring therapy. An on-line survey was administered by e-mail to members of the Neurocritical Care Society. Multiple-choice questions regarding use of mannitol and HTS were employed to gain insight into clinician practices. A total of 295 responses were received, 79.7% of which were from physicians. The majority (89.9%) reported using osmotherapy as needed for intracranial hypertension, though a minority reported initiating treatment prophylactically. Practitioners were fairly evenly split between those who preferred HTS (54.9%) and those who preferred mannitol (45.1%), with some respondents reserving HTS for patients with refractory intracranial hypertension. Respondents who preferred HTS were more likely to endorse prophylactic administration. Preferred dosing regimens for both agents varied considerably, as did monitoring parameters. Treatment of cerebral edema using osmotically active substances varies considerably between practitioners. This variation could hamper efforts to design and implement multicenter trials in neurocritical care.	[Hays, Angela N.] Med Univ S Carolina, Div Adult Neurol, Dept Neurosci, Charleston, SC 29425 USA	Hays, AN (corresponding author), Med Univ S Carolina, Div Adult Neurol, Dept Neurosci, Charleston, SC 29425 USA.	haysa@musc.edu					Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Alvarez B, 1998, FREE RADICAL BIO MED, V24, P1331, DOI 10.1016/S0891-5849(98)00005-7; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bhardwaj A, 2007, CURR NEUROL NEUROSCI, V7, P513, DOI 10.1007/s11910-007-0079-2; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gasco J, 2005, ACTA NEUROCHIR SUPPL, V95, P73; Hartl R, 1997, ACT NEUR S, V70, P40; HARTMANN A, 1990, ACT NEUR S, V51, P168; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Kalita J, 2004, J NEUROL SCI, V224, P19, DOI 10.1016/j.jns.2004.05.019; Korenkov AI, 2000, NEUROSURG REV, V23, P145, DOI 10.1007/PL00011946; Lee SC, 2005, J CLIN NEUROSCI, V12, P520, DOI 10.1016/j.jocn.2004.07.016; Maioriello AV, 2002, J NEUROSURG, V97, P687, DOI 10.3171/jns.2002.97.3.0687; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Palma L, 2006, J Neurosurg Sci, V50, P63; Poli-De-Figueiredo L. F., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P201; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rozet I, 2007, ANESTHESIOLOGY, V107, P697, DOI 10.1097/01.anes.0000286980.92759.94; SADICK NS, 1991, J DERMATOL SURG ONC, V17, P65, DOI 10.1111/j.1524-4725.1991.tb01595.x; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Sankar T, 2008, J NEUROSURG, V108, P1010, DOI 10.3171/JNS/2008/108/5/1010; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1988, SURGERY, V104, P553; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	43	48	52	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2011	14	2					222	228		10.1007/s12028-010-9477-4			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	738SY	WOS:000288663800012	21153930				2021-06-18	
J	Uttl, B; Kibreab, M				Uttl, Bob; Kibreab, Mekale			Self-Report Measures of Prospective Memory Are Reliable but Not Valid	CANADIAN JOURNAL OF EXPERIMENTAL PSYCHOLOGY-REVUE CANADIENNE DE PSYCHOLOGIE EXPERIMENTALE			English	Article; Proceedings Paper	3rd International Conference on Prospective Memory	JUL, 2010	Vancouver, CANADA			prospective memory; self-reports; measurement; reliability; validity	EVERYDAY PROSPECTIVE MEMORY; TRAUMATIC BRAIN-INJURY; RETROSPECTIVE MEMORY; QUESTIONNAIRE PRMQ; COMPREHENSIVE ASSESSMENT; SUBJECTIVE MEMORY; NORMATIVE DATA; PERFORMANCE; ADULTS; PREDICT	Are self-report measures of prospective memory (ProM) reliable and valid? To examine this question, 240 undergraduate student volunteers completed several widely used self-report measures of ProM including the Prospective Memory Questionnaire (PMQ), the Prospective and Retrospective Memory Questionnaire (PRMQ), the Comprehensive Assessment of Prospective Memory (CAPM) questionnaire, self-reports of retrospective memory (RetM), objective measures of ProM and RetM, and measures of involvement in activities and events, memory strategies and aids use, personality and verbal intelligence. The results showed that both convergent and divergent validity of ProM self-reports are poor, even though we assessed ProM using a newly developed, reliable continuous measure. Further analyses showed that a substantial proportion of variability in ProM self-report scores was due to verbal intelligence, personality (conscientiousness, neuroticism), activities and event involvement (busyness), and use of memory strategies and aids. ProM self-reports have adequate reliability, but poor validity and should not be interpreted as reflecting ProM ability.	[Uttl, Bob] Mt Royal Univ, Dept Psychol, Calgary, AB T3E 6K6, Canada; [Kibreab, Mekale] Univ Calgary, Dept Psychol, Calgary, AB T2N 1N4, Canada	Uttl, B (corresponding author), Mt Royal Univ, Dept Psychol, 4825 Mt Royal Gate SW, Calgary, AB T3E 6K6, Canada.	buttl@mtroyal.ca		Kibreab, Mekale/0000-0001-8813-6006			Brandimonte M. A., 2001, PSICOLOGICA, V22, P97; Chan RCK, 2010, NEUROPSYCHOL REHABIL, V20, P459, DOI 10.1080/09602010903425710; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Costa P., 1992, REVISED NEO PERSONAL; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; Cuttler C, 2007, SCAND J PSYCHOL, V48, P215, DOI 10.1111/j.1467-9450.2007.00570.x; Cuttler C, 2009, J ANXIETY DISORD, V23, P813, DOI 10.1016/j.janxdis.2009.03.006; Ellis J, 1999, BRIT J PSYCHOL, V90, P9, DOI 10.1348/000712699161233; Fleming J, 2009, BRAIN IMPAIR, V10, P34, DOI 10.1375/brim.10.1.34; Foster ER, 2009, NEUROPSYCHOLOGY, V23, P347, DOI 10.1037/a0014692; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Graf P, 2002, LIFESPAN DEV HUMAN M, P255; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; Heffernan TM, 2006, J ADOLESCENT HEALTH, V39, P138, DOI 10.1016/j.jadohealth.2005.10.010; Kaplan R. M., 2008, PSYCHOL TESTING PRIN; Kliegel M, 2006, CURR PSYCHOL, V25, P182, DOI 10.1007/s12144-006-1002-8; Kvavilashvili L, 1998, APPL COGNITIVE PSYCH, V12, P533, DOI 10.1002/(SICI)1099-0720(1998120)12:6<533::AID-ACP538>3.0.CO;2-1; Macan T, 2010, PERS INDIV DIFFER, V48, P725, DOI 10.1016/j.paid.2010.01.015; Mantyla T, 2003, MEM COGNITION, V31, P15, DOI 10.3758/BF03196078; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Martin M, 2003, AGING CLIN EXP RES, V15, P77; Meacham J. A., 1982, MEMORY OBSERVED REME, P327; Meeks JT, 2007, CONSCIOUS COGN, V16, P997, DOI 10.1016/j.concog.2006.09.005; Pearman A, 2005, J GERONTOL B-PSYCHOL, V60, pP153, DOI 10.1093/geronb/60.3.P153; RABBITT P, 1995, APPL COGNITIVE PSYCH, V9, pS127, DOI 10.1002/acp.2350090709; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Ronnlund M, 2008, SCAND J PSYCHOL, V49, P11, DOI 10.1111/j.1467-9450.2007.00600.x; Royle J, 2008, DISABIL REHABIL, V30, P114, DOI 10.1080/09638280701223876; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thone-Otto AT, 2008, PROSPECTIVE MEMORY C; Uttl B, 2006, AGING NEUROPSYCHOL C, V13, P141, DOI 10.1080/138255890969618; Uttl B, 2005, DYNAMIC COGNITIVE PROCESSES, P273, DOI 10.1007/4-431-27431-6_12; Uttl B, 2005, PSYCHOL SCI, V16, P460; UTTL B, 2002, MEMORY QUESTIONNAIRE; UTTL B, 2002, WORDS A40 MULTIPLE C; UTTL B, 2002, ACTIVITIES EVENT INV; UTTL B, 2002, MEMORY AIDS QU UNPUB; Uttl B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012539; Uttl B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001568; Waugh N., 1999, THESIS GRIFFITH U BR	43	48	50	1	17	CANADIAN PSYCHOLOGICAL  ASSOC	OTTAWA	141 LAURIER AVE WEST, STE 702, OTTAWA, ONTARIO K1P 5J3, CANADA	1196-1961			CAN J EXP PSYCHOL	Can. J. Exp. Psychol.-Rev. Can. Psychol. Exp.	MAR	2011	65	1			SI		57	68		10.1037/a0022843			12	Psychology, Experimental	Psychology	739RV	WOS:000288736600009	21443331				2021-06-18	
J	Kemp, K; Gordon, D; Wraith, DC; Mallam, E; Hartfield, E; Uney, J; Wilkins, A; Scolding, N				Kemp, K.; Gordon, D.; Wraith, D. C.; Mallam, E.; Hartfield, E.; Uney, J.; Wilkins, A.; Scolding, N.			Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						fusion; mesenchymal stem cells; Purkinje cells; stem cell; transplantation	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW-CELLS; STROMAL CELLS; NEURONS; ENCEPHALOMYELITIS; CYTOKINES; TRANSPLANTATION; EXPRESSION	Aims: We explored whether cellular fusion and heterokaryon formation between human and rodent cells in the cerebellum of mice occurs after intravenous injection of human bone marrow-derived mesenchymal stem cells (MSCs). The influence of central nervous system inflammation on this process was also assessed. In addition, we examined whether tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma, factors associated with inflammation, increase cellular fusion between human MSCs and rodent cerebellar neurons in vitro. Methods and results: Human MSCs were intravenously injected into mice with experimental autoimmune encephalomyelitis (EAE) and control mice. After 22 days, mouse Purkinje cells expressing human Golgi Zone were found within the Purkinje cell layer of the cerebellum, indicating that fusion and heterokaryon formation had occurred. The numbers of heterokaryons in the cerebellum were markedly increased in mice with EAE compared with control mice. Rodent cerebellar neuronal cells labelled with enhanced green fluorescent proteinin vitro were co-cultured with human bone marrow-derived MSCs in the presence of TNF-alpha and/or IFN-gamma to determine their influence on fusion events. We found that fusion between MSCs and cerebellar neurons did occur in vitro and that the frequency of cellular fusion increased in the presence of TNF-alpha and/or IFN-gamma. Conclusions: We believe that this is the first paper to define fusion and heterokaryon formation between human MSCs and rodent cerebellar neurons in vivo. We have also demonstrated that fusion between these cell populations occurs in vitro. These findings indicate that MSCs may be potential therapeutic agents for cerebellar diseases, and other neuroinflammatory and neurodegenerative disorders.	[Kemp, K.; Gordon, D.; Mallam, E.; Wilkins, A.; Scolding, N.] Univ Bristol, Multiple Sclerosis & Stem Cell Grp, Inst Clin Neurosci, Bristol, Avon, England; [Wraith, D. C.] Univ Bristol, Dept Cellular & Mol Med, Bristol, Avon, England; [Hartfield, E.; Uney, J.] Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol, Avon, England	Kemp, K (corresponding author), Frenchay Hosp, Burden Ctr, MS Labs, 1st Floor, Bristol BS16 1JB, Avon, England.	kevin.kemp@bristol.ac.uk	; Kemp, Kevin/B-9755-2017	Scolding, Neil/0000-0001-9177-1043; Kemp, Kevin/0000-0003-1465-1309; Wraith, David/0000-0003-2147-5614	Multiple Sclerosis Society of Great Britain and Northern Ireland; Wellcome TrustWellcome TrustEuropean Commission; Ataxia UK; Ataxia UK [7160] Funding Source: researchfish	We would like to acknowledge the Multiple Sclerosis Society of Great Britain and Northern Ireland, the Wellcome Trust and Ataxia UK for support.	Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; Bae JS, 2005, HUM GENE THER, V16, P1006, DOI 10.1089/hum.2005.16.1006; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Bennaceur-Griscelli A, 2001, BLOOD, V97, P435, DOI 10.1182/blood.V97.2.435; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001; Gordon D, 2008, NEUROSCI LETT, V448, P71, DOI 10.1016/j.neulet.2008.10.040; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Juedes AE, 2000, J IMMUNOL, V164, P419, DOI 10.4049/jimmunol.164.1.419; Kemp K, 2010, J NEUROCHEM, V114, P1569, DOI 10.1111/j.1471-4159.2009.06553.x; Kozorovitskiy Y, 2003, NAT CELL BIOL, V5, P952, DOI 10.1038/ncb1103-952; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3; Lee PH, 2008, CLIN PHARMACOL THER, V83, P723, DOI 10.1038/sj.clpt.6100386; Magrassi L, 2007, J NEUROSCI, V27, P9885, DOI 10.1523/JNEUROSCI.2539-07.2007; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400; MARES V, 1973, BRAIN RES, V53, P273, DOI 10.1016/0006-8993(73)90214-X; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; O'Neill EJ, 2006, J NEUROIMMUNOL, V178, P1, DOI 10.1016/j.jneuroim.2006.05.030; Okuda Y, 1998, J INTERF CYTOK RES, V18, P415, DOI 10.1089/jir.1998.18.415; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Rice CM, 2004, LANCET, V364, P193, DOI 10.1016/S0140-6736(04)16633-6; Scolding N, 2008, J NEUROL SCI, V265, P111, DOI 10.1016/j.jns.2007.08.009; Singec I, 2008, NAT CELL BIOL, V10, P503, DOI 10.1038/ncb0508-503; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962	43	48	50	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	2011	37	2					166	178		10.1111/j.1365-2990.2010.01122.x			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	704OR	WOS:000286062800004	20819172	Green Published			2021-06-18	
J	Rattka, M; Brandt, C; Bankstahl, M; Broer, S; Loscher, W				Rattka, Marta; Brandt, Claudia; Bankstahl, Marion; Broeer, Sonja; Loescher, Wolfgang			Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats	NEUROPHARMACOLOGY			English	Article						Epilepsy; Epileptogenesis; Seizure threshold; Neuronal hyperexcitability; Antiepileptogenesis; Disease modification	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; SPONTANEOUS RECURRENT SEIZURES; ANTIEPILEPTIC DRUGS; GABAERGIC INHIBITION; LITHIUM-PILOCARPINE; VALPROIC ACID; IN-VIVO; MODEL; EPILEPTOGENESIS	A variety of acute brain insults bear the risk of subsequent development of chronic epilepsy. Enhanced understanding of the brain alterations underlying this process may ultimately lead to interventions that prevent, interrupt or reverse epileptogenesis in people at risk. Various interventions have been evaluated in rat models of symptomatic epilepsy, in which epileptogenesis was induced by status epilepticus (SE) or traumatic brain injury (TBI). Paradoxically, recent data indicated that administration of proconvulsant drugs after TBI or SE exerts antiepileptogenic or disease-modifying effects, although epilepsy is often considered to represent a decrease in seizure threshold. Surprisingly, to our knowledge, it is not known whether alterations in seizure threshold occur during the latent period following SE. This prompted us to study seizure threshold during and after the latent period following SE induced by lithium/pilocarpine in rats. Timed intravenous infusion of the GABA(A) receptor antagonist pentylenetetrazole (PTZ) was used for this purpose. The duration of the latent period was determined by continuous video/EEG monitoring. Compared to control seizure threshold determined before SE, threshold significantly decreased two days after SE, but returned to pre-SE control thereafter. Moreover, the duration of PTZ-induced seizures was significantly increased throughout the latent period, which ranged from 6 to 10 days after SE. This increased susceptibility to PTZ likely reflects the complex alterations in GABA-mediated transmission that occur during the latent period following SE. The data will allow developing dosing regimens for evaluation of whether treatment with subconvulsant doses of PTZ during the latent period affects the development of epilepsy. (C) 2010 Elsevier Ltd. All rights reserved.	[Rattka, Marta; Brandt, Claudia; Bankstahl, Marion; Broeer, Sonja; Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Rattka, Marta; Brandt, Claudia; Bankstahl, Marion; Broeer, Sonja; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany	Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973; Broer, Sonja/0000-0002-7969-6586; Bankstahl, Marion/0000-0002-5775-188X	Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [Lo 274/11-1]	We thank P. Demmer, N. Ernst, M. Kruger, and M. Topfer for skilful technical assistance. The study was supported by a grant (Lo 274/11-1) from the Deutsche Forschungsgemeinschaft (Bonn, Germany).	Amado D, 1998, EPILEPSY RES, V32, P266, DOI 10.1016/S0920-1211(98)00057-6; Armstrong C, 2009, EPILEPSIA, V50, P1657, DOI 10.1111/j.1528-1167.2009.02173.x; Bankstahl JP, 2008, EPILEPSY RES, V82, P70, DOI 10.1016/j.eplepsyres.2008.07.007; Ben-Ari Yehezkel, 2006, Critical Reviews in Neurobiology, V18, P135; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; BROWNING RA, 1990, EPILEPSY RES, V6, P1, DOI 10.1016/0920-1211(90)90002-D; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Coulter DA, 2001, INT REV NEUROBIOL, V45, P237; Dichter MA, 2009, ARCH NEUROL-CHICAGO, V66, P443, DOI 10.1001/archneurol.2009.10; Dudek FE, 2009, NEUROTHERAPEUTICS, V6, P319, DOI 10.1016/j.nurt.2009.01.020; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; FINN DA, 1994, J PHARMACOL EXP THER, V271, P164; Freichel C, 2006, NEUROSCIENCE, V141, P2177, DOI 10.1016/j.neuroscience.2006.05.040; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Goffin K, 2007, EXP NEUROL, V205, P501, DOI 10.1016/j.expneurol.2007.03.008; Golarai G, 2001, J NEUROSCI, V21, P8523; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Khazipov R, 2003, J NEUROSCI, V23, P5337; Kohling R, 2002, SCIENCE, V298, P1350; Kucker S, 2010, NEUROBIOL DIS, V37, P661, DOI 10.1016/j.nbd.2009.12.002; Kuteykin-Teplyakov K, 2009, EPILEPSIA, V50, P887, DOI 10.1111/j.1528-1167.2008.01916.x; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2010, EPILEPSY BEHAV, V19, P105, DOI 10.1016/j.yebeh.2010.06.035; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; LOSCHER W, 1983, NEUROCHEM INT, V5, P405, DOI 10.1016/0197-0186(83)90069-4; MACDONALD RL, 1977, NATURE, V267, P720, DOI 10.1038/267720a0; Mann EO, 2008, CURR OPIN NEUROL, V21, P155, DOI 10.1097/WCO.0b013e3282f52f5f; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Nehlig A, 2002, EPILEPSY RES, V51, P189, DOI 10.1016/S0920-1211(02)00125-0; PACHECO MF, 1981, COMP BIOCHEM PHYS C, V68, P99, DOI 10.1016/0306-4492(81)90044-7; Pathak HR, 2007, J NEUROSCI, V27, P14012, DOI 10.1523/JNEUROSCI.4390-07.2007; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/14656566.5.4.777; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; POLLACK GM, 1985, J PHARMACOL METHOD, V13, P135, DOI 10.1016/0160-5402(85)90057-9; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RAMANJANEYULU R, 1984, EUR J PHARMACOL, V98, P337, DOI 10.1016/0014-2999(84)90282-6; Rigoulot MA, 2003, EPILEPSIA, V44, P529, DOI 10.1046/j.1528-1157.2003.50502.x; Scharfman HE, 2006, EPILEPSIA, V47, P1423, DOI 10.1111/j.1528-1167.2006.00672.x; Sirven JI, 2009, EPILEPSY CURR, V9, P164, DOI 10.1111/j.1535-7511.2009.01330.x; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; WAHNSCHAFFE U, 1992, EPILEPSY RES, V13, P199, DOI 10.1016/0920-1211(92)90053-V; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; Woolley CS, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb02601.x; Wu K, 2001, NEUROSCIENCE, V104, P379, DOI 10.1016/S0306-4522(01)00043-4; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zhang GJ, 2004, J NEUROCHEM, V88, P91, DOI 10.1046/j.1471-4159.2003.02124.x	57	48	50	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB-MAR	2011	60	2-3					505	512		10.1016/j.neuropharm.2010.11.005			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	717NL	WOS:000287054600039	21075125				2021-06-18	
J	Khaksari, M; Soltani, Z; Shahrokhi, N; Moshtaghi, G; Asadikaram, G				Khaksari, Mohammad; Soltani, Zahra; Shahrokhi, Nader; Moshtaghi, Gholamreza; Asadikaram, Gholamreza			The role of estrogen and progesterone, administered alone and in combination, in modulating cytokine concentration following traumatic brain injury	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article							INFLAMMATORY RESPONSE; CORTICAL CONTUSION; CEREBRAL-ISCHEMIA; OVARIAN HORMONES; FEMALE RATS; EXPRESSION; ESTRADIOL; RECEPTOR; STEROIDS; BARRIER	Cytokines play an important role in the pathophysiology of traumatic brain injury (TBI). This study was designed to determine the effects of administering progesterone (P) and estrogen (E), alone and in combination, on brain water content, blood-brain barrier (BBB) disturbance, and brain level of cytokines following diffuse TBI. Ovariectomized rats were divided into 9 groups, treated with vehicle, E1, E2, P1, P2, E1+P1, E1+P2, E2+P1, and E2+P2. Levels of BBB disruption (5 h), cytokines, and water content (24 h) were evaluated after TBI induced by the Marmarou method. Physiological (E1 and P1) and pharmacological (E2 and P2) doses of estrogen and progesterone were administered 30 min after TBI. Water content in the E1+P2-treated group was higher than in the E1-treated group. The inhibitory effect of E2 on water content was reduced by adding progesterone. The inhibitory effect of E1 and E2 on Evans blue content was reduced by treatment with E1+P1 and E2+P2, respectively. The brain level of IL-1 beta was reduced in E1 and E2, after TBI. In the E2+P2-treated group, this level was higher than in the E2-treated group. The brain level of TGF-beta was also elevated by the administration of progesterone and estrogen alone, and reduced when the hormones were administered in combination. In conclusion, a combined administration of progesterone and estrogen inhibited the decreasing effects of administration of progesterone and estrogen alone on water content and BBB disruption that mediated to change the proinflammatory cytokines.	[Khaksari, Mohammad; Soltani, Zahra] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Bam Int Unit, Kerman, Iran; [Shahrokhi, Nader] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Moshtaghi, Gholamreza] Kerman Univ Med Sci, Dept Biochem, Kerman, Iran; [Asadikaram, Gholamreza] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran.	khaksar38@yahoo.co.uk	Shahrokhi, Nader/AAV-3747-2020; Haddad, Mohammad Khaksari/AAB-9025-2019; Asadikaram, Gholamreza/AAG-4437-2021; Soltani, Zahra/AAC-1350-2019	Shahrokhi, Nader/0000-0002-0149-7819; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Asadikaram, Gholamreza/0000-0002-9100-0756; Soltani, Zahra/0000-0002-8423-6189; Asadi karam, Gholamreza/0000-0002-6417-5200	neuroscience and physiology research centers of Kerman University of Medical Sciences	The present study was financially supported by the neuroscience and physiology research centers of Kerman University of Medical Sciences.	Baulieu EE, 1996, CELL MOL NEUROBIOL, V16, P143, DOI 10.1007/BF02088173; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chi OZ, 2004, HORM METAB RES, V36, P272, DOI 10.1055/s-2004-814478; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Crandall C, 2006, J WOMENS HEALTH, V15, P14, DOI 10.1089/jwh.2006.15.14; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; del Zoppo GJ, 2000, THROMB RES, V98, pV73; DeVries HE, 1997, PHARMACOL REV, V49, P143; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hatthachote P, 1999, ENDOCRINOLOGY, V140, P2533, DOI 10.1210/en.140.6.2533; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028; Jonsson Daniel, 2007, Swed Dent J Suppl, P11; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Koski CL, 2004, ENDOCRINOLOGY, V145, P95, DOI 10.1210/en.2003-0803; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Ospina JA, 2004, AM J PHYSIOL-HEART C, V286, pH2010, DOI 10.1152/ajpheart.00481.2003; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Simpkins J. W., 1997, AM J MED, V103, p19S, DOI 10.1016/s0002-9343(97)00260-x; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tibbetts TA, 1999, BIOL REPROD, V60, P1158, DOI 10.1095/biolreprod60.5.1158; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Yuan K, 2002, J PERIODONTOL, V73, P701, DOI 10.1902/jop.2002.73.7.701	44	48	49	0	7	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	JAN	2011	89	1					31	40		10.1139/Y10-103			10	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	699BB	WOS:000285637800004	21186375	Green Accepted			2021-06-18	
J	Brochard, S; Robertson, J; Medee, B; Remy-Neris, O				Brochard, Sylvain; Robertson, Johanna; Medee, Beatrice; Remy-Neris, Olivier			What's new in new technologies for upper extremity rehabilitation?	CURRENT OPINION IN NEUROLOGY			English	Article						new technology; robotic; telerehabilitation; upper limb; virtual reality	UPPER-LIMB REHABILITATION; ROBOT-ASSISTED THERAPY; VIRTUAL-REALITY; STROKE; ARM; FEASIBILITY; CHILDREN; MOTOR; TELEMEDICINE; IMPAIRMENT	Purpose of review The field of new technologies for upper-limb rehabilitation is exploding. The review presents new trends and studies of effectiveness from recent literature regarding robots, virtual reality and telerehabilitation for neurorehabilitation of the upper limb. Recent findings There appears to be a greater focus on technological developments than on clinical trials or studies to evaluate the mechanisms behind the effectiveness of these systems. Developments are most abundant in the field of robotics. However, the first well designed and powered randomized-controlled trial on robot rehabilitation has appeared, confirming that the effectiveness of robot therapy lies in the number of repetitions provided. There is a move towards studies in populations other than stroke, particularly cerebral palsy with a few studies on multiple sclerosis and traumatic brain injury. There is also an increasing trend for the use of robotic devices as evaluation tools. Summary Despite the fact that new technologies are based on knowledge from motor control and learning literature and that they provide an exciting potential for varied rehabilitation, recent evidence suggests that the only contribution to clinical practice currently is the provision of intensive, repetitive movements.	[Brochard, Sylvain; Medee, Beatrice; Remy-Neris, Olivier] CHU Brest, Serv Med Phys & Readaptat, F-29285 Brest, France; [Brochard, Sylvain; Medee, Beatrice; Remy-Neris, Olivier] INSERM, UMR S 650, IFR 148, Brest, France; [Brochard, Sylvain; Remy-Neris, Olivier] Univ Europeenne Bretagne, Brest, France; [Robertson, Johanna] Hop Poincare, Serv Med Phys & Readaptat, Garches, France; [Robertson, Johanna] Univ Paris 05, Fac Med, CNRS, Lab Neurophys & Physiol,UMR 8119, Paris, France	Brochard, S (corresponding author), Ctr Hosp Univ Morvan, Serv Med Phys & Readaptat, 5 Ave Foch, F-29200 Brest, France.	sylvain.brochard@chu-brest.fr	Brochard, Sylvain/G-6416-2013; Brochard, Sylvain/AAI-7291-2021	Brochard, Sylvain/0000-0002-4950-1696; remy-neris, olivier/0000-0001-6862-8433			Adamovich SV, 2009, IEEE T NEUR SYS REH, V17, P512, DOI 10.1109/TNSRE.2009.2028830; Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; Adamovich SV, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-28; Bonato P, 2009, STUD HEALTH TECHNOL, V145, P145, DOI 10.3233/978-1-60750-018-6-145; Bovolenta F, 2009, J REHABIL MED, V41, P971, DOI 10.2340/16501977-0402; Buschfort R, 2010, J REHABIL MED, V42, P310, DOI 10.2340/16501977-0517; Carpinella I, 2009, J REHABIL MED, V41, P966, DOI 10.2340/16501977-0401; Colizzi L, 2009, J REHABIL MED, V41, P1011, DOI 10.2340/16501977-0407; CONNELLY L, 2009, EMBC 2009 ANN INT C, P2434; CULMER P, 2010, NEUROREHABI IN PRESS; Culmer PR, 2010, IEEE-ASME T MECH, V15, P575, DOI 10.1109/TMECH.2009.2030796; Culmer PR, 2009, J NEUROSCI METH, V184, P184, DOI 10.1016/j.jneumeth.2009.07.025; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; Edwards DJ, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-3; Feng X, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-15; Frascarelli F, 2009, EUR J PHYS REHAB MED, V45, P135; Frascarelli F, 2009, J REHABIL MED, V41, P988, DOI 10.2340/16501977-0412; Golomb MR, 2010, ARCH PHYS MED REHAB, V91, P1, DOI 10.1016/j.apmr.2009.08.153; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; Huang VS, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-5; JARRASSE N, 2009, METHODOLOGY DESIGN K, P1958; Joo LY, 2010, J REHABIL MED, V42, P437, DOI 10.2340/16501977-0528; Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553; Krebs HI, 2009, DEV MED CHILD NEUROL, V51, P140, DOI 10.1111/j.1469-8749.2009.03416.x; Krebs HI, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-6; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Lange B, 2009, EUR J PHYS REHAB MED, V45, P143; LENZI T, 2009, EMBC 2009 ANN INT C, P2430; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Lucca LF, 2009, J REHABIL MED, V41, P1003, DOI 10.2340/16501977-0405; Marchal-Crespo L, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-20; Masiero S, 2009, J REHABIL MED, V41, P981, DOI 10.2340/16501977-0404; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Merians AS, 2009, EUR J PHYS REHAB MED, V45, P123; Mumford N, 2010, BRAIN INJURY, V24, P780, DOI 10.3109/02699051003652807; Mumford N, 2009, BRAIN INJURY, V23, P179, DOI 10.1080/02699050802695566; Nef Tobias, 2009, Applied Bionics and Biomechanics, V6, P127, DOI 10.1080/11762320902840179; Pignolo L, 2009, J REHABIL MED, V41, P955, DOI 10.2340/16501977-0434; Piron L, 2009, J REHABIL MED, V41, P1016, DOI 10.2340/16501977-0459; Prange GB, 2009, NEUROREHAB NEURAL RE, V23, P478, DOI 10.1177/1545968308328720; Qiu QY, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-40; Rand D, 2009, EUR J PHYS REHAB MED, V45, P113; Reinkensmeyer David J, 2009, Annu Int Conf IEEE Eng Med Biol Soc, V2009, P2439, DOI 10.1109/IEMBS.2009.5335353; Robertson JVG, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-45; ROBERTSON JVG, 2010, RETHINKING PHYS REHA; Saposnik G, 2010, STROKE, V41, pE220; Schwamm LH, 2009, STROKE, V40, P2635, DOI 10.1161/STROKEAHA.109.192361; Squeri V, 2009, J REHABIL MED, V41, P961, DOI 10.2340/16501977-0400; Staubli P, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-46; Stienen AHA, 2009, IEEE T ROBOT, V25, P628, DOI 10.1109/TRO.2009.2019147; Timmermans AAA, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-1; Volpe BT, 2009, ARCH NEUROL-CHICAGO, V66, P1086, DOI 10.1001/archneurol.2009.182; WEIGHTMAN APH, 2009, J ENG DES; Wille D, 2009, DEV NEUROREHABIL, V12, P44, DOI 10.1080/17518420902773117; WOOD KA, 2009, EMBC 2009 ANN INT C, P5973	56	48	50	1	60	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2010	23	6					683	687		10.1097/WCO.0b013e32833f61ce			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	675SJ	WOS:000283852400021	20852420				2021-06-18	
J	Kaulfers, AMD; Backeljauw, PF; Reifschneider, K; Blum, S; Michaud, L; Weiss, M; Rose, SR				Kaulfers, Anne-Marie D.; Backeljauw, Philippe F.; Reifschneider, Kent; Blum, Samantha; Michaud, Linda; Weiss, Moshe; Rose, Susan R.			Endocrine Dysfunction following Traumatic Brain Injury in Children	JOURNAL OF PEDIATRICS			English	Article							ANTERIOR-PITUITARY FUNCTION; POSTTRAUMATIC HYPOPITUITARISM; PRECOCIOUS PUBERTY; THYROID-FUNCTION; GROWTH-HORMONE; THYROTROPIN; CHILDHOOD; HYPOTHYROIDISM; DISORDERS; PHASE	Objective To identify the incidence of endocrine dysfunction in children following traumatic brain injury (TBI). Study design This was a prospective evaluation of 31 children after TBI. Inclusion criteria included Glasgow Coma Scale score <= 12 and age 1.5-18 years. We evaluated thyroid function, insulin-like growth factor I, insulin-like growth factor-binding protein 3, and cortisol at 1, 3, 6, and 12 months after injury, and assessed prolactin at 3 and 6 months. At 6 months, we also assessed overnight spontaneous growth hormone secretion, nocturnal thyrotropin surge, adrenal reserve, and serum and urine osmolarity. Results The average patient age was 11.6 years, and mean Glascow Coma Scale score was 6. The incidence of endocrine dysfunction was 15% at 1 month, 75% at 6 months, and 29% at 12 months. At 12 months after injury, 14% had precocious puberty, 9% had hypothyroidism, and 5% had growth hormone deficiency. Endocrine dysfunction at 1 year did not correlate with the severity of injury. Conclusions Endocrine dysfunction after TBI is common in children, but most cases resolve by 1 year. We recommend endocrine surveillance at both 6 and 12 months following moderate or severe TBI to ensure early intervention for persistent or late-occurring endocrine sequelae. (J Pediatr 2010;157:894-9).	[Kaulfers, Anne-Marie D.; Backeljauw, Philippe F.; Blum, Samantha; Weiss, Moshe; Rose, Susan R.] Univ Cincinnati, Med Ctr, Div Endocrinol, Cincinnati Childrens Hosp,Coll Med, Cincinnati, OH 45267 USA; [Michaud, Linda] Univ Cincinnati, Med Ctr, Div Phys Med & Rehabil, Cincinnati Childrens Hosp,Coll Med, Cincinnati, OH 45267 USA; [Reifschneider, Kent] Childrens Hosp Kings Daughters, Div Endocrinol, Norfolk, VA USA	Rose, SR (corresponding author), 3333 Burnet Ave,MLC 7012, Cincinnati, OH 45229 USA.	susan.rose@cchmc.org			Pfizer, IncPfizer; National Institutes of Health (General Clinical Research Center)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR08084]; National Center for Research Resources (US Public Health Service)United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR026314]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314, M01RR008084] Funding Source: NIH RePORTER	Supported by Pfizer, Inc (independent investigator-initiated research grant), National Institutes of Health (General Clinical Research Center Grant M01 RR08084), and National Center for Research Resources (US Public Health Service Grant UL1 RR026314). The authors declare no conflicts of interest.	Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Baldelli Roberto, 2005, Pituitary, V8, P255, DOI 10.1007/s11102-006-6050-4; BLENDONOHY P M, 1991, Brain Injury, V5, P63, DOI 10.3109/02699059108998513; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Gandrud LM, 2004, GROWTH HORM IGF RES, V14, P185, DOI 10.1016/j.ghir.2003.11.003; Kazlauskaite R, 2008, J CLIN ENDOCR METAB, V93, P4245, DOI 10.1210/jc.2008-0710; Mariani R, 1996, ARCH PEDIATRIE, V3, P796, DOI 10.1016/0929-693X(96)82164-6; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; PAXSON CL, 1976, PEDIATRICS, V57, P893; Pena KS, 2001, AM FAM PHYSICIAN, V63, P1763; Persani L, 2000, J CLIN ENDOCR METAB, V85, P3631, DOI 10.1210/jc.85.10.3631; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; ROSE SR, 1990, J CLIN ENDOCR METAB, V70, P1750, DOI 10.1210/jcem-70-6-1750; Rose SR, 1999, J PEDIATR ENDOCR MET, V12, P167; ROSE SR, 1989, J CLIN ENDOCR METAB, V68, P1086, DOI 10.1210/jcem-68-6-1086; ROSE SR, 2010, J PEDIAT; Schneider Harald J, 2007, Pediatr Endocrinol Rev, V4, P205; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; Singh S, 2008, INT J CARDIOL, V125, P41, DOI 10.1016/j.ijcard.2007.02.027; SOCKALOSKY JJ, 1987, J PEDIATR-US, V110, P373, DOI 10.1016/S0022-3476(87)80497-3; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; Verrotti A, 2008, J PEDIATR ENDOCR MET, V21, P401; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009	30	48	49	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	DEC	2010	157	6					894	899		10.1016/j.jpeds.2010.07.004			6	Pediatrics	Pediatrics	681JG	WOS:000284307200008	20797728				2021-06-18	
J	McAllister, TW				McAllister, Thomas W.			Genetic Factors Modulating Outcome After Neurotrauma	PM&R			English	Article								Wide variation in outcomes after neurotrauma, despite apparently similar injury severity, suggests that host factors may influence the recovery process. Genetically determined individual differences might be one such factor. The study of the genetic modulation of outcome after neurotrauma is at an early stage. Nevertheless, several important components of the response to neurotrauma can be identified in which genetic differences contribute to variability in outcome. These components include genetic modulators of pre- and postinjury cognitive reserve and behavioral homeostasis, and processes that modulate cytotoxic injury cascades (extent of injury) and injury repair. This work reviews what is known of the role of genetic variation in outcome after neurotrauma with a focus on clinical outcomes after traumatic brain injury. Polymorphisms reported to influence outcome after traumatic brain injury that illustrate important underlying mechanisms are emphasized. PM R 2010;2:S241-S252	Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, Lebanon, NH 03756 USA	McAllister, TW (corresponding author), Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176, 1R01HD047242, 1R01HD48638]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS055020]; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638, R01HD047242, R01HD048176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER	Disclosures: 8, grants NICHD R01 HD048176, 1R01HD047242, and 1R01HD48638; NINDS 1R01NS055020; and CDC R01/CE001254	Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Amouyel P, 1996, NEUROSCI LETT, V217, P203, DOI 10.1016/0304-3940(96)13092-5; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Ariza M, 2006, J NEUROPSYCH CLIN N, V18, P39, DOI 10.1176/appi.neuropsych.18.1.39; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Bellivier F, 2000, BIOL PSYCHIAT, V48, P319, DOI 10.1016/S0006-3223(00)00891-X; Blum K, 1997, MOL PSYCHIATR, V2, P239, DOI 10.1038/sj.mp.4000261; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Capurso C, 2004, EXP GERONTOL, V39, P1567, DOI 10.1016/j.exger.2004.07.006; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X; Comings DE, 2003, MOL PSYCHIATR, V8, P10, DOI 10.1038/sj.mp.4001095; Comings DE, 1996, PHARMACOGENETICS, V6, P223, DOI 10.1097/00008571-199606000-00004; COOK EH, 1995, AM J HUM GENET, V56, P993; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Deary IJ, 2009, HUM GENET, V126, P215, DOI 10.1007/s00439-009-0655-4; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Dutcher SA, 2001, NEUROL RES, V23, P203, DOI 10.1179/016164101101198343; Ebstein RP, 2000, EUR J PHARMACOL, V410, P205, DOI 10.1016/S0014-2999(00)00852-9; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Flashman L.A., 2004, J NEUROPSYCHIATRY CL, V16, P238; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Ibelgaufts PDH., HORST IBELGAUFTS COP; Institute of Medicine, 2009, GULF WAR HLTH, V7; Joiner TE, 2003, J AFFECT DISORDERS, V77, P273, DOI 10.1016/S0165-0327(02)00171-4; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kaneko N, 2009, NEUROSCI RES, V63, P155, DOI 10.1016/j.neures.2008.12.001; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; Kempermann G, 2002, E SCHERING RES FDN W, V35, P17; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Lang UE, 2004, J NEURAL TRANSM, V111, P387, DOI 10.1007/s00702-003-0100-0; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Laws SM, 2002, MOL PSYCHIATR, V7, P768, DOI 10.1038/sj.mp.4001083; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Liljequist R, 1997, BEHAV BRAIN RES, V82, P195, DOI 10.1016/S0166-4328(97)80989-8; Lim KC, 2003, NEUROBIOL AGING, V24, P1135, DOI 10.1016/j.neurobiolaging.2003.09.003; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Lipsky RH, 2003, ANN NY ACAD SCI, V1003, P22, DOI 10.1196/annals.1300.003; Lu B, 2000, PROG BRAIN RES, V128, P231; MacDonald JL, 2009, PROG NEUROBIOL, V88, P170, DOI 10.1016/j.pneurobio.2009.04.002; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Mann JJ, 2000, ARCH GEN PSYCHIAT, V57, P729, DOI 10.1001/archpsyc.57.8.729; Martinez-Lucas P, 2005, INTENS CARE MED, V31, P1168, DOI 10.1007/s00134-005-2715-0; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McAllister T, 2009, INT NEUR SOC M SANT; McAllister T, 2008, SINGLE NUCLEOTIDE PO; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; McAllister TW, 2005, J NEUROPSYCHIATRY CL, V17, P287; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Mihailescu S, 2000, ARCH MED RES, V31, P131, DOI 10.1016/S0188-4409(99)00087-9; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morley KI, 2001, BEHAV GENET, V31, P511, DOI 10.1023/A:1013337209957; Mufson EJ, 1999, EXP NEUROL, V158, P469, DOI 10.1006/exnr.1999.7086; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Parasuraman R, 2002, NEUROPSYCHOLOGY, V16, P254, DOI 10.1037//0894-4105.16.2.254; Pola R, 2002, NEUROREPORT, V13, P1645, DOI 10.1097/00001756-200209160-00015; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Quan N, 2002, HISTOL HISTOPATHOL, V17, P273, DOI 10.14670/HH-17.273; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramasubbu R, 2006, J NEUROPSYCH CLIN N, V18, P96, DOI 10.1176/appi.neuropsych.18.1.96; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Richard F, 2001, NEUROLOGY, V56, P1593, DOI 10.1212/WNL.56.11.1593; ROBERTS GW, 1990, NEUROPATH APPL NEURO, V16, P3, DOI 10.1111/j.1365-2990.1990.tb00927.x; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Saykin A, 2005, ALZH ASS INT C PREV; Schaffer DV, 2004, NEUROMOL MED, V5, P1, DOI 10.1385/NMM:5:1:001; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; Stam AH, 2009, J NEUROL NEUROSUR PS, V80, P1125, DOI 10.1136/jnnp.2009.177279; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tanriverdi T, 2006, SURG NEUROL, V65, P7, DOI 10.1016/j.surneu.2005.05.024; Teasdale TW, 1997, BRIT MED J, V315, P569; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; TIRET L, 1992, AM J HUM GENET, V51, P197; Uryu K, 2004, NEUROBIOL AGING S1, V25, pP2; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang JC, 2004, HUM MOL GENET, V13, P1903, DOI 10.1093/hmg/ddh194; Weiland S, 2000, BEHAV BRAIN RES, V113, P43, DOI 10.1016/S0166-4328(00)00199-6; Weinberger DR, 2001, BIOL PSYCHIAT, V50, P825, DOI 10.1016/S0006-3223(01)01252-5; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wong AHC, 2000, EUR J PHARMACOL, V410, P183; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153	121	48	50	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12		2			S241	S252		10.1016/j.pmrj.2010.10.005			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LT	WOS:000208412600005	21172686				2021-06-18	
J	Skandsen, T; Finnanger, TG; Andersson, S; Lydersen, S; Brunner, JF; Vik, A				Skandsen, Toril; Finnanger, Torun G.; Andersson, Stein; Lydersen, Stian; Brunner, Jan F.; Vik, Anne			Cognitive Impairment 3 Months After Moderate and Severe Traumatic Brain Injury: A Prospective Follow-Up Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Craniocerebral trauma; Longitudinal studies; Neuropsychological tests; Neuropsychology; Prognosis; Rehabilitation	HEAD-INJURY; TBI; RECOVERY; VALIDITY; SEQUELAE; MEMORY; TESTS; SCALE; SPEED	Skandsen T, Finnanger TG, Andersson S, Lydersen S. Brunner JF, Vik A. Cognitive impairment 3 months after moderate and severe traumatic brain injury: a prospective follow-up study. Arch Phys Med Rehabil 2010;91: 1904-13. Objective: To explore the magnitude and frequency of cognitive impairment 3 months after moderate to severe traumatic brain injury (TBI), and to evaluate its relationship to disability at 1-year follow-up. Design: Prospective follow-up study. Setting: Regional level I trauma center. Participants: Patients aged 15 to 65 years with definite TBI, defined as Glasgow Coma Scale score of 3 to 13 and injury documented by magnetic resonance imaging (n=59) or computed tomography (n=2); healthy volunteers (n=47) served as controls. Interventions: Not applicable. Main Outcome Measures: Neuropsychological assessment 3 months postinjury and Glasgow Outcome Scale Extended (GOSE) at 3 and 12 months postinjury. Results: Patients with TBI performed worse than controls, most consistently in terms of information processing speed and verbal memory. However, a maximum of only 43% of patients with TBI had impaired test scores (defined as <1.5 SD below mean of normative data) on any one measure. Based on a selection of 9 tests, a 0 or 1 impaired score was seen in 46 (98%) of 47 controls, in 20 (57%) of 35 patients with moderate TBI, and in 9 (35%) of 26 patients with severe TBI. At 1 year postinjury, disability (defined as GOSE score <= 6) was present in 57% of those with 2 or more impaired test scores and in 21% of those with 0 or 1 impaired score (P=.005). Conclusions: In this sample of patients with recent, definite TBI and healthy volunteers, we found that TBI affected cognition in moderate as well as severe cases. The presence of cognitive impairment was associated with future disability. However, half of the patients with moderate TBI and even one third of those with severe TBI had a normal cognitive assessment 3 months postinjury.	[Skandsen, Toril; Brunner, Jan F.] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Finnanger, Torun G.] Univ Trondheim Hosp, St Olavs Hosp, Dept Child & Adolescence Psychiat, N-7006 Trondheim, Norway; [Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, N-7006 Trondheim, Norway; [Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway; [Lydersen, Stian] Norwegian Univ Sci & Technol, Unit Appl Clin Res, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway; [Andersson, Stein] Oslo Univ Hosp, Dept Neuropsychiat & Psychosomat Med, Oslo, Norway	Skandsen, T (corresponding author), Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Brunner, Jan Ferenc/0000-0002-8576-678X	Liaison Committee; Central Norway Regional Health Authority; Norwegian University of Science and Technology	Supported by a research grant from Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Conners C., 2000, CONNERS CONTINUOUS P; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Grissom R. J., 2005, EFFECT SIZES RES BRO; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner R.L., 2008, NEUROPSYCHOLOGY COUR, P243; Hill BD, 2010, J CLIN EXP NEUROPSYC, V32, P315, DOI 10.1080/13803390903032529; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Matthews C, 1964, INSTRUCTION MANUAL A; Meyers J., 1995, REY COMPLEX FIGURE T; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Reitan RM, 2008, APPL NEUROPSYCHOL, V15, P33, DOI 10.1080/09084280801917350; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A., 2002, SYMBOL DIGIT MODALIT; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Strong CAH, 2008, J CLIN EXP NEUROPSYC, V30, P885, DOI 10.1080/13803390701858224; Taylor L B, 1969, Clin Neurosurg, V16, P269; Trahan DE, 1988, CONTINOUS VISUAL MEM; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	52	48	53	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2010	91	12					1904	1913		10.1016/j.apmr.2010.08.021			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	700KY	WOS:000285738900013	21112433				2021-06-18	
J	D'Onofrio, G; Jauch, E; Jagoda, A; Allen, MH; Anglin, D; Barsan, WG; Berger, RP; Bobrow, BJ; Boudreaux, ED; Bushnell, C; Chan, YF; Currier, G; Eggly, S; Ichord, R; Larkin, GL; Laskowitz, D; Neumar, RW; Newman-Toker, DE; Quinn, J; Shear, K; Todd, KH; Zatzick, D				D'Onofrio, Gail; Jauch, Edward; Jagoda, Andrew; Allen, Michael H.; Anglin, Deirdre; Barsan, William G.; Berger, Rachel P.; Bobrow, Bentley J.; Boudreaux, Edwin D.; Bushnell, Cheryl; Chan, Yu-Feng; Currier, Glenn; Eggly, Susan; Ichord, Rebecca; Larkin, Gregory L.; Laskowitz, Daniel; Neumar, Robert W.; Newman-Toker, David E.; Quinn, James; Shear, Katherine; Todd, Knox H.; Zatzick, Douglas		Roundtable External Participants; Roundtable Steering Comm; Fed Participants	NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies	ANNALS OF EMERGENCY MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CLINICAL POLICY; DIAGNOSTIC-TEST; CARE; US; STROKE; INTERVENTION; DEPARTMENTS; MANAGEMENT; MEDICINE	Study objective: The Institute of Medicine Committee on the Future of Emergency Care in the United States Health System (2003) identified a need to enhance the research base for emergency care. As a result, a National Institutes of Health (NIH) Task Force on Research in Emergency Medicine was formed to enhance NIH support for emergency care research. Members of the NIH Task Force and academic leaders in emergency care participated in 3 Roundtable discussions to prioritize current opportunities for enhancing and conducting emergency care research. We identify key research questions essential to advancing the science of emergency care and discuss the barriers and strategies to advance research by exploring the collaboration between NIH and the emergency care community. Methods: Experts from emergency medicine, neurology, psychiatry, and public health assembled to review critical,areas in need of investigation, current gaps in knowledge, barriers, and opportunities. Neurologic emergencies included cerebral resuscitation, pain, stroke, syncope, traumatic brain injury, and pregnancy. Mental health topics included suicide, agitation and delirium, substances, posttraumatic stress, violence, and bereavement. Results: Presentations and group discussion firmly established the need for translational research to bring basic science concepts into the clinical arena. A coordinated continuum of the health care system that ensures rapid identification and stabilization and extends through discharge is necessary to maximize overall patient outcomes. There is a paucity of well-designed, focused research on diagnostic testing, clinical decisionmaking, and treatments in the emergency setting. Barriers include the limited number of experienced researchers in emergency medicine, limited dedicated research funding, and difficulties of conducting research in chaotic emergency environments stressed by crowding and limited resources. Several themes emerged during the course of the roundtable discussion, including the need for development of (1) a research infrastructure for the rapid identification, consent, and tracking of research subjects that incorporates innovative informatics technologies, essential for future research; (2) diagnostic strategies and tools necessary to understand key populations and the process of medical decisionmaking, including the investigation of the pathobiology of symptoms and symptom-oriented therapies; (3) collaborative research networks to provide unique opportunities to form partnerships, leverage patient cohorts and clinical and financial resources, and share data; (4) formal research training programs integral for creating new knowledge and advancing the science and practice of emergency medicine; and (5) recognit on that emergency care is part of an integrated system from emergency medical services dispatch to discharge. The NIH Roundtable "Opportunities to Advance Research on Neurological and Psychiatric Emergencies" created a framework to guide future emergency medicine-based research initiatives. Conclusion: Emergency departments provide the portal of access to the health care system for most patients with acute neurologic and psychiatric illness. Emergency physicians and colleagues are primed to investigate neurologic and psychiatric emergencies that will directly improve the delivery of care and patient outcomes. [Ann Emerg Med. 2010;56:551-564.]	[D'Onofrio, Gail; Larkin, Gregory L.] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Jauch, Edward] Med Univ S Carolina, Charleston, SC USA; [Jagoda, Andrew; Chan, Yu-Feng] Mt Sinai Sch Med, New York, NY USA; [Allen, Michael H.] Univ Colorado Denver, Denver, CO USA; [Anglin, Deirdre] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Barsan, William G.] Univ Michigan, Ann Arbor, MI 48109 USA; [Berger, Rachel P.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; [Bobrow, Bentley J.] Mayo Clin, Coll Med, Rochester, MN 55905 USA; [Boudreaux, Edwin D.] Cooper Univ Hosp, Camden, NJ USA; [Bushnell, Cheryl] Wake Forest Univ, Winston Salem, NC 27109 USA; [Currier, Glenn] Univ Rochester, Med Ctr, Rochester, NY 14627 USA; [Eggly, Susan] Wayne State Univ, Sch Med, Detroit, MI 48202 USA; [Ichord, Rebecca; Neumar, Robert W.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Laskowitz, Daniel] Duke Univ, Med Ctr, Durham, NC 27706 USA; [Newman-Toker, David E.] Johns Hopkins Univ, Baltimore, MD 21218 USA; [Quinn, James] Stanford Univ, Stanford, CA 94305 USA; [Shear, Katherine] Columbia Univ, New York, NY 10027 USA; [Todd, Knox H.] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA; [Zatzick, Douglas] Univ Washington, Sch Med, Seattle, WA 98195 USA	D'Onofrio, G (corresponding author), Dept Emergency Med, 464 Congress Ave,Ste 260, New Haven, CT 06519 USA.	gail.donofrio@yale.edu; jauch@musc.edu; andy.jagoda@mssm.edu; michael.allen@ucdenver.edu; anglin@usc.edu; wbarsan@umich.edu; rachel.p.berger@gmail.com; bobrow.bentley@mayo.edu; boudreaux-edwin@cooperhealth.edu; cbushnel@wfubmc.edu; yu-fengyvonne.chan@mountsinai.org; glenn_currier@urmc.rochester.edu; susaneggly@wayne.edu; ichord@email.chop.edu; gluke.larkin@yale.edu; danl@neuro.duke.edu; neumarr@uphs.upenn.edu; toker@jhu.edu; quinn@stanforid.edu; ks2394@columbia.edu; ktodd@chpnet.org; dzatzick@u.washington.edu	Allen, Michael H/A-8776-2011; Kopp, Jeffrey/O-2681-2015	Allen, Michael H/0000-0002-6479-9793; Boudreaux, Edwin/0000-0002-3223-6371; Guerrero, Giovanna/0000-0003-4931-8530; Kopp, Jeffrey/0000-0001-9052-186X; LARKIN, GREGORY LUKE/0000-0002-8655-7824; Eggly, Susan/0000-0002-8137-6098; Jauch, Edward/0000-0002-3533-4364; D'Onofrio, Gail/0000-0002-3833-1871			Allen MH, 2005, J PSYCHIAT PRACT S1, V11, p[5, 110]; Allen Michael H, 2005, J Psychiatr Pract, V11 Suppl 1, P5, DOI 10.1097/00131746-200511001-00002; Barsan WG, 2004, ANN EMERG MED, V44, P407, DOI 10.1016/j.annemergmed.2004.06.024; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bushnell CD, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b664; Claassen CA, 2005, BRIT J PSYCHIAT, V186, P352, DOI 10.1192/bjp.186.4.352; Cunningham RM, 2009, ACAD EMERG MED, V16, P1078, DOI 10.1111/j.1553-2712.2009.00552.x; D'Onofrio G, 2004, ALCOHOL RES HEALTH, V28, P63; Grieve AP, 2005, CLIN TRIALS, V2, P340, DOI 10.1191/1740774505cn094oa; Han JH, 2009, ACAD EMERG MED, V16, P193, DOI 10.1111/j.1553-2712.2008.00339.x; Havard A, 2008, ADDICTION, V103, P368, DOI 10.1111/j.1360-0443.2007.02072.x; Huff JS, 2007, ANN EMERG MED, V49, P431, DOI 10.1016/j.annemergmed.2007.02.001; Hypothermia After Cardiac Arrest Study Group, 2002, NEW ENGL J MED, V346, P550; Kattah JC, 2009, STROKE, V40, P3504, DOI 10.1161/STROKEAHA.109.551234; Krug E.G., 2002, WORLD REPORT VIOLENC; Larkin GL, 2008, CRISIS, V29, P73, DOI 10.1027/0227-5910.29.2.73; Larkin GL, 2009, ACAD EMERG MED, V16, P1110, DOI 10.1111/j.1553-2712.2009.00545.x; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Levetown M, 2008, PEDIATRICS, V121, pE1441, DOI 10.1542/peds.2008-0565; Lukens TW, 2006, ANN EMERG MED, V47, P79, DOI 10.1016/j.annemergmed.2005.10.002; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; Majersik JJ, 2008, RESUSCITATION, V77, P189, DOI 10.1016/j.resuscitation.2007.11.023; Meert KL, 2007, J PEDIATR-US, V151, P50, DOI 10.1016/j.jpeds.2007.01.050; MEERT KL, 2007, J PEDIAT, V151, pE51; Mitchell C, 2009, INTIMATE PARTNER VIO; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Newman-Toker DE, 2008, MAYO CLIN PROC, V83, P765, DOI 10.4065/83.7.765; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Quinn J, 2004, ACAD EMERG MED, V11, P1245, DOI 10.1197/j.aem.2004.08.020; Ramchandren S, 2007, AM J NEURORADIOL, V28, P1085, DOI 10.3174/ajnr.A0506; SALTZMAN L, 1999, PREVENTION NCFL VERS; Simon NM, 2007, COMPR PSYCHIAT, V48, P395, DOI 10.1016/j.comppsych.2007.05.002; Todd KH, 2007, ANN EMERG MED, V50, pS37, DOI 10.1016/j.annemergmed.2007.06.146; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2009, PSYCHIATRY, V72, P346, DOI 10.1521/psyc.2009.72.4.346; 2006, ANN NEUROL, V60, pA12	40	48	49	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	NOV	2010	56	5					551	564		10.1016/j.annemergmed.2010.06.562			14	Emergency Medicine	Emergency Medicine	681DY	WOS:000284292800020	21036295				2021-06-18	
J	Warner, MA; O'Keeffe, T; Bhavsar, P; Shringer, R; Moore, C; Harper, C; Madden, CJ; Sarode, R; Gentilello, LM; Diaz-Arrastia, R				Warner, Matthew A.; O'Keeffe, Terence; Bhavsar, Premal; Shringer, Rashmi; Moore, Carol; Harper, Caryn; Madden, Christopher J.; Sarode, Ravi; Gentilello, Larry M.; Diaz-Arrastia, Ramon			Transfusions and long-term functional outcomes in traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						transfusion; anemia; traumatic brain injury; functional outcome; long-term outcome; mortality	SEVERE HEAD-INJURY; BLOOD-CELL TRANSFUSION; TISSUE OXYGEN; CEREBRAL OXYGENATION; MORTALITY; HYPOXIA; ANEMIA; MULTICENTER; DISABILITY; PO-2	Object. In this paper, the authors' goal was to examine the relationship between transfusion and long-term functional outcomes in moderately anemic patients (lowest hematocrit [HCT] level 21-30%) with traumatic brain injury (TBI). While evidence suggests that transfusions are associated with poor hospital outcomes, no study has examined transfusions and long-term functional outcomes in this population. The preferred transfusion threshold remains controversial. Methods. The authors performed a retrospective review of patients who were admitted with TBI between September 2005 and November 2007, extracting data such as HCT level, status of red blood cell transfusion, admission Glasgow Coma Scale (GCS) score, serum glucose, and length of hospital stay. Outcome measures assessed at 6 months were Glasgow Outcome Scale-Extended score, Functional Status Examination score, and patient death. A multivariate generalized linear model controlling for confounding variables was used to assess the association between transfusion and outcome. Results. During the study period, 292 patients were identified, and 139 (47.6%) met the criteria for moderate anemia. Roughly half (54.7%) underwent transfusions. Univariate analyses showed significant correlations between outcome score and patient age, admission GCS score, head Abbreviated Injury Scale score, number of days with an HCT level < 30%, highest glucose level, number of days with a glucose level > 200 mg/dl, length of hospital stay, number of patients receiving a transfusion, and transfusion volume. In multivariate analysis, admission GCS score, receiving a transfusion, and transfusion volume were the only variables associated with outcome (F = 2.458, p = 0.007; F = 11.694, p = 0.001; and F = 1.991, p = 0.020, respectively). There was no association between transfusion and death. Conclusions. Transfusions may contribute to poor long-term functional outcomes in anemic patients with TBI. Transfusion strategies should be aimed at patients with symptomatic anemia or physiological compromise, and transfusion volume should be minimized. (DOI: 10.3171/2009.12.JNS091337)	[Warner, Matthew A.; Bhavsar, Premal; Shringer, Rashmi; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Neurol, Dallas, TX 75390 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Neurol Surg, Dallas, TX 75390 USA; [Gentilello, Larry M.] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Surg, Dallas, TX 75390 USA; [Sarode, Ravi] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Pathol, Dallas, TX 75390 USA; [O'Keeffe, Terence] Arizona Hlth Sci Ctr, Dept Surg, Tucson, AZ 85724 USA	Diaz-Arrastia, R (corresponding author), UTSW, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); NIH-NICDHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; US Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This work was supported, in part, by the Doris Duke Charitable Foundation (to M.A.W.), and NIH-NICDH (Grant Nos. R01 HD48179 and U01 HD42652) and US Department of Education Grant (Grant No. H133 A020526) (to RD-A.).	Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Bardt TF, 1998, ACT NEUR S, V71, P153; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dings J, 1998, NEUROL RES, V20, pS71; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Shahlaie K., 2004, YOUMANS NEUROLOGICAL, P5039; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	27	48	49	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					539	546		10.3171/2009.12.JNS091337			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100017	20113158				2021-06-18	
J	Yang, L; Afroz, S; Michelson, HB; Goodman, JH; Valsamis, HA; Ling, DSF				Yang, Lie; Afroz, Sonia; Michelson, Hillary B.; Goodman, Jeffrey H.; Valsamis, Helen A.; Ling, Douglas S. F.			Spontaneous Epileptiform Activity in Rat Neocortex after Controlled Cortical Impact Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; epileptogenesis; ictal; interictal; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; NEURONS IN-VIVO; POSTTRAUMATIC EPILEPSY; SEIZURE ACTIVITY; EPILEPTOGENESIS; VITRO; INHIBITION; MICE; MECHANISMS	A hallmark of severe traumatic brain injury (TBI) is the development of post-traumatic epilepsy (PTE). However, the mechanisms underlying PTE remain poorly understood. In this study, we used a controlled cortical impact (CCI) model in rats to examine post-traumatic changes in neocortical excitability. Neocortical slices were prepared from rats at 7-9 days (week 1) and 14-16 days (week 2) after CCI injury. By week 2, we observed a substantial gray matter lesion with a cavity that extended to the hippocampal structure. Fluoro-Jade B staining of slices revealed active neuronal degeneration during weeks 1 and 2. Intracellular and extracellular recordings obtained from layer V revealed evoked and spontaneous epileptiform discharges in neocortices of CCI-injured rats. At week 1, intracellular recordings from pyramidal cells revealed evoked epileptiform firing that was synchronized with population events recorded extracellularly, suggestive of increased excitability. This activity was characterized by bursts of action potentials that were followed by recurrent, repetitive after-discharges. At week 2, both spontaneous and evoked epileptiform firing were recorded in slices from injured rats. The evoked discharges resembled those observed at week 1, but with longer burst durations. Spontaneous activity included prolonged, ictal-like discharges lasting up to 8-10 sec, and briefer interictal-like burst events (<1 sec). These results indicate that during the first 2 weeks following severe CCI injury, there is a progressive development of neocortical hyperexcitability that ultimately leads to spontaneous epileptiform firing, suggesting a rapid epileptogenic process.	[Yang, Lie; Afroz, Sonia; Michelson, Hillary B.; Goodman, Jeffrey H.; Ling, Douglas S. F.] SUNY Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; [Michelson, Hillary B.; Goodman, Jeffrey H.; Ling, Douglas S. F.] SUNY Downstate Med Ctr, Program Neural & Behav Sci, Brooklyn, NY 11203 USA; [Yang, Lie; Michelson, Hillary B.; Goodman, Jeffrey H.; Valsamis, Helen A.; Ling, Douglas S. F.] SUNY Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Brooklyn, NY 11203 USA; [Goodman, Jeffrey H.] New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA; [Valsamis, Helen A.] Kings Cty Hosp, Neurol Serv, Brooklyn, NY USA	Ling, DSF (corresponding author), SUNY Downstate Med Ctr, Dept Physiol & Pharmacol, 450 Clarkson Ave,Box 29, Brooklyn, NY 11203 USA.	douglas.ling@downstate.edu	Goodman, Jeffrey/AAG-8734-2020		Research Foundation of SUNY Principal Investigator Incentive program	The authors wish to thank Dr. Robert K.S. Wong for helpful comments and suggestions in the preparation of this manuscript, and Dr. David Brody and Katherine Schwetye for generously providing training and instruction in the CCI technique. This work was supported by funds from the Research Foundation of SUNY Principal Investigator Incentive program (to D.S.F.L).	Abdelmalik PA, 2005, EPILEPSIA, V46, P356, DOI 10.1111/j.0013-9580.2005.34204.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Antuono M, 2010, EPILEPSIA, V51, P423, DOI 10.1111/j.1528-1167.2009.02273.x; Destexhe A, 2003, NAT REV NEUROSCI, V4, P739, DOI 10.1038/nrn1198; Destexhe A, 1999, J NEUROPHYSIOL, V81, P1531; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fuortes MG, 2008, EPILEPSY RES, V82, P38, DOI 10.1016/j.eplepsyres.2008.07.002; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMMOND EJ, 1980, EPILEPSIA, V21, P3, DOI 10.1111/j.1528-1157.1980.tb04039.x; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kohling R, 2000, J NEUROSCI, V20, P6820, DOI 10.1523/JNEUROSCI.20-18-06820.2000; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Ling DSF, 1995, J NEUROPHYSIOL, V74, P2329; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PRINCE DA, 1984, ANN NEUROL, V16, pS59, DOI 10.1002/ana.410160710; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1975, ELECTROEN CLIN NEURO, V38, P1, DOI 10.1016/0013-4694(75)90204-7; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Timofeev I, 2010, NEUROSCIENTIST, V16, P19, DOI 10.1177/1073858409333545; Traub RD, 1996, EPILEPSIA, V37, P879, DOI 10.1111/j.1528-1157.1996.tb00042.x; YABLON SA, 2007, BRAIN INJURY MED PRI, P443; Yang L, 1997, J NEUROPHYSIOL, V78, P2804; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005	42	48	51	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1541	1548		10.1089/neu.2009.1244			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900017	20504156				2021-06-18	
J	Leventhal, JM; Martin, KD; Asnes, AG				Leventhal, John M.; Martin, Kimberly D.; Asnes, Andrea G.			Fractures and Traumatic Brain Injuries: Abuse Versus Accidents in a US Database of Hospitalized Children	PEDIATRICS			English	Article						accidents; injury; maltreatment	YOUNG-CHILDREN	OBJECTIVE: The goal was to use a national database to determine the incidence of abusive traumatic brain injuries (TBIs) and/or fractures and the frequency of abuse versus accidents among children <36 months of age. METHODS: We used the 2006 Kids' Inpatient Database and classified cases into 3 types of injuries, that is, (1) TBI only, (2) TBI and fracture, or (3) fracture only. Groups 2 and 3 were divided into 3 patterns, that is, (1) skull fractures, (2) skull and nonskull fractures, or (3) nonskull fractures. For each type and pattern, we compared abuse, accidental falls, other accidents, and motor vehicle accidents. RESULTS: The incidence of TBIs and/or fractures attributable to abuse was 21.9 cases per 100 000 children <36 months of age and 50.0 cases per 100 000 children <12 months of age. In the abuse group, 29.9% of children had TBIs only, 28.3% TBIs and fractures, and 41.8% fractures only. Abused children were younger and were more likely to be enrolled in Medicaid. For TBI only, falls were more common than abuse in the first 2 months of life but abuse was more common from 2 to 7 months. For TBI and skull fracture, falls were more common during the first year of life. For skull fracture only, almost all injuries were attributable to falls. CONCLUSIONS: There was overlap in TBIs and fractures attributable to abuse. Among <12-month-old children, TBIs and/or fractures attributable to abuse occurred in 1 of 2000. Falls occurred more commonly than abuse, even among very young children. Pediatrics 2010; 126: e104-e115	[Leventhal, John M.; Asnes, Andrea G.] Yale Univ, Dept Pediat, Sch Med, New Haven, CT 06520 USA; [Martin, Kimberly D.] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Med, New Haven, CT 06520 USA	Leventhal, JM (corresponding author), Yale Univ, Dept Pediat, Sch Med, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu			Department of Pediatrics, School of Medicine, Yale University	Funding was provided by the Child Abuse Funds, Department of Pediatrics, School of Medicine, Yale University.	*AG HEALTHC RES QU, AG HEALTHC RES QUAL; Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Agran PF, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.3.e45; Barr RG, 2009, PEDIATRICS, V123, P972, DOI 10.1542/peds.2008-0908; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Berger LM, 2005, CHILD ABUSE NEGLECT, V29, P107, DOI 10.1016/j.chiabu.2004.02.006; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KING J, 1988, J PEDIATR ORTHOPED, V8, P585; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Leventhal JM, 2005, CHILD ABUSE NEGLECT, V29, P209, DOI 10.1016/j.chiabu.2005.02.008; LEVENTHAL JM, 1993, AM J DIS CHILD, V147, P87, DOI 10.1001/archpedi.1993.02160250089028; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; National Center for Health Statistics Centers for Medicare and Medicaid Services, 1999, INT CLASS DIS 9 REV; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; United States Census Bureau, POP EST; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	21	48	48	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2010	126	1					E104	E115		10.1542/peds.2009-1076			12	Pediatrics	Pediatrics	619LF	WOS:000279431000037	20530077				2021-06-18	
J	Spikman, JM; van der Naalt, J				Spikman, Jacoba M.; van der Naalt, Joukje			Indices of Impaired Self-Awareness in Traumatic Brain Injury Patients with Focal Frontal Lesions and Executive Deficits: Implications for Outcome Measurement	JOURNAL OF NEUROTRAUMA			English	Article						executive functions; frontal lesions; impaired self-awareness; outcome; traumatic brain injury	CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; PREDICTORS; MODERATE; ATTENTION; MILD; MRI; ADULTS; METAANALYSIS	In patients with moderate to severe traumatic brain injury (TBI), impairments of self-awareness are frequently found and associated with worse functional outcome and poor compliance with rehabilitation. The aim of this study was to investigate whether indications of impaired self-awareness could be found in TBI patients with frontal lesions and executive function deficits. Twenty-two TBI patients with focal frontal injuries were compared to 29 TBI patients without focal frontal injuries visible on neuroimaging. No differences were found on several outcome measures, including the Glasgow Outcome Scale-Extended (GOS-E), the Differential Outcome Scale (DOS), and return to work (RTW), although the frontal injury patients were more severely injured as indicated by the Glasgow Coma Scale (GCS) and duration of post-traumatic amnesia (PTA), and had impaired performance on a neuropsychological test of executive functioning. Even more so, the frontal injury group had a significantly lower score on the Sickness Impact Profile (SIP), indicating that they had fewer complaints than the patients without frontal injury, and scored significantly higher on the percentage of recovery (PoR) score, which expresses the extent of recovery as a percentage of their previous level of functioning. In contrast to the non-frontal-injury group, their PoR scores were not related to RTW, reflecting an erroneous perception of their actual working status. The positive results on these different outcome measures, which are partly or entirely self-reported, were seen as an indication of an impaired self-evaluative ability in the frontal injury patients. To determine outcome in a patient with frontal injuries and executive dysfunction, the judgment of several relevant other persons in the patient's life (e.g., partners, therapists, and employers) of the patient's daily life functioning should be sought.	[Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, NL-9700 RB Groningen, Netherlands; [Spikman, Jacoba M.; van der Naalt, Joukje] Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands	Spikman, JM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.m.spikman@rug.nl		Spikman, Jacoba/0000-0002-6477-0763			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; JACOBS HM, 1993, THESIS U UTRECHT UTR; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Murrey GJ, 2005, BRAIN INJURY, V19, P599, DOI 10.1080/02699050400025257; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Salthouse TA, 2007, BRAIN COGNITION, V63, P279, DOI 10.1016/j.bandc.2006.09.006; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Silver H, 2009, DEMENT GERIATR COGN, V27, P292, DOI 10.1159/000204916; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; SPSS-Inc, 2007, SPSS WIND VERS 16 0; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	56	48	48	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1195	1202		10.1089/neu.2010.1277			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100004	20380551				2021-06-18	
J	Jiang, FX; Yurke, B; Schloss, RS; Firestein, BL; Langrana, NA				Jiang, Frank Xue; Yurke, Bernard; Schloss, Rene S.; Firestein, Bonnie L.; Langrana, Noshir A.			Effect of Dynamic Stiffness of the Substrates on Neurite Outgrowth by Using a DNA-Crosslinked Hydrogel	TISSUE ENGINEERING PART A			English	Article							CELL-ADHESION MOLECULE; CENTRAL-NERVOUS-SYSTEM; MECHANICAL-PROPERTIES; BRAIN-TISSUE; NEURAL DEVELOPMENT; GEL STIFFNESS; SPINAL-CORD; GROWTH; EXTENSION; SURFACES	Central nervous system tissues, like other tissue types, undergo constant remodeling, which potentially leads to changes in their mechanical stiffness. Moreover, mechanical compliance of central nervous system tissues can also be modified under external load such as that experienced in traumatic brain or spinal cord injury, and during pathological processes. Thus, the neuronal responses to the dynamic stiffness of the microenvironment are of significance. In this study, we induced decrease in stiffness by using a DNA-crosslinked hydrogel, and subjected rat spinal cord neurons to such dynamic stiffness. The neurons respond to the dynamic cues as evidenced by the primary neurite structure, and the response from each neurite property (e. g., axonal length and primary dendrite number) is consistent with the behavior on static gels of same substrate rigidity, with one exception of mean primary dendrite length. The results on cell population distribution confirm the neuronal responses to the dynamic stiffness. Quantification on the focal adhesion kinase expression in the neuronal cell body on dynamic gels suggests that neurons also modify adhesion in coping with the dynamic stiffnesses. The results reported here extend the neuronal mechanosensing capability to dynamic stiffness of extracellular matrix, and give rise to a novel way of engineering neurite outgrowth in time dimension.	[Jiang, Frank Xue; Schloss, Rene S.; Langrana, Noshir A.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Yurke, Bernard] Boise State Univ, Dept Mat Sci & Engn, Boise, ID 83725 USA; [Yurke, Bernard] Boise State Univ, Dept Elect & Comp Engn, Boise, ID 83725 USA; [Firestein, Bonnie L.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Langrana, Noshir A.] Rutgers State Univ, Dept Mech & Aerosp Engn, Piscataway, NJ 08854 USA	Langrana, NA (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	langrana@rutgers.edu		Firestein, Bonnie/0000-0002-1679-3565	New Jersey Commission on Spinal Cord Research [07A-019-SCR1]	This study was supported by a grant from the New Jersey Commission on Spinal Cord Research (Grant # 07A-019-SCR1). This work was performed toward the partial fulfillment of the Ph.D. requirements of the first author. We thank Dr. Penelope Georges for assistance in experiments.	ABBOTT NL, 1995, LANGMUIR, V11, P16, DOI 10.1021/la00001a005; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; BONANOMI D, 2006, INTRACELLULAR MECHAN, P155; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; BUSKIRK DR, 1980, NATURE, V285, P488, DOI 10.1038/285488a0; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; CROSSIN KL, 1989, CLIN CHEM, V35, P738; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; De R, 2007, NAT PHYS, V3, P655, DOI 10.1038/nphys680; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Dityatev A., 2006, MOL MECH SYNAPTOGENE; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; ESCUIN S, 2006, INTRACELLULAR MECH N, P1; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fass JN, 2003, BIOPHYS J, V85, P623, DOI 10.1016/S0006-3495(03)74506-8; Fischer TM, 2005, ANN BIOMED ENG, V33, P1229, DOI 10.1007/s10439-005-5509-1; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; GARNER JA, 1986, J NEUROSCI, V6, P3242; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Giniger E, 2002, DIFFERENTIATION, V70, P385, DOI 10.1046/j.1432-0436.2002.700801.x; Goffin JM, 2006, J CELL BIOL, V172, P259, DOI 10.1083/jcb.200506179; Gunn JW, 2005, J BIOMED MATER RES A, V72A, P91, DOI 10.1002/jbm.a.30203; Hachiya NS, 2008, MED HYPOTHESES, V70, P1034, DOI 10.1016/j.mehy.2007.06.043; Heidemann S R, 1991, Curr Opin Neurobiol, V1, P339, DOI 10.1016/0959-4388(91)90050-H; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Huang S, 2005, CANCER CELL, V8, P175, DOI 10.1016/j.ccr.2005.08.009; Janmey PA, 2009, CELL MOTIL CYTOSKEL, V66, P597, DOI 10.1002/cm.20382; Jiang FX, 2010, BIOMATERIALS, V31, P1199, DOI 10.1016/j.biomaterials.2009.10.050; Jiang FX, 2008, ANN BIOMED ENG, V36, P1565, DOI 10.1007/s10439-008-9530-z; JIANG FX, 2009, THESIS RUTGERS U NEW; JIANG X, 2007, OPEN NEUROSCI J, V1, P7; Kostic A, 2007, J CELL SCI, V120, P3895, DOI 10.1242/jcs.009852; LAFONT F, 1993, J CELL SCI, V104, P433; Lahann J, 2005, MRS BULL, V30, P185, DOI 10.1557/mrs2005.50; Leach JB, 2007, J NEURAL ENG, V4, P26, DOI 10.1088/1741-2560/4/2/003; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; LEVITAN IB, 1997, NEURON CELL MOL BIOL; LEVITAN IB, 1991, J CELL BIOL, V114, P143; Li L, 2008, ANN BIOMED ENG, V36, P865, DOI 10.1007/s10439-008-9458-3; Li YQ, 2001, BIOTECHNOL PROGR, V17, P348, DOI 10.1021/bp010005f; LIN D, 2006, J MATER RES, V20, P1456, DOI DOI 10.1557/JMR.2005.0186; Lin DC, 2004, J BIOMECH ENG-T ASME, V126, P104, DOI 10.1115/1.1645529; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; MILLER PD, 1994, J NEUROSCI, V14, P4217; Mrksich M, 2005, MRS BULL, V30, P180, DOI 10.1557/mrs2005.49; MULLER D, ROLE NCAM S IN PRESS; Petroll WM, 2004, INVEST OPHTH VIS SCI, V45, P3466, DOI 10.1167/iovs.04-0361; Petroll WM, 2003, CELL MOTIL CYTOSKEL, V55, P254, DOI 10.1002/cm.10126; POOLE AR, 1986, BIOCHEM J, V236, P1; Prag S, 2002, J CELL SCI, V115, P283; Reinhart-King CA, 2005, BIOPHYS J, V89, P676, DOI 10.1529/biophysj.104.054320; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; Roy I, 2003, CHEM BIOL, V10, P1161, DOI 10.1016/j.chembiol.2003.12.004; Savtchenko LP, 2004, SYNAPSE, V51, P270, DOI 10.1002/syn.10300; Shreiber DI, 2003, BIOPHYS J, V84, P4102, DOI 10.1016/S0006-3495(03)75135-2; Small DH, 1996, J NEUROCHEM, V67, P889; Solon J, 2007, BIOPHYS J, V93, P4453, DOI 10.1529/biophysj.106.101386; Sparrey CJ, 2008, SPINE, V33, pE812, DOI 10.1097/BRS.0b013e3181894fd3; Sundararaghavan HG, 2009, BIOTECHNOL BIOENG, V102, P632, DOI 10.1002/bit.22074; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.3.CO;2-L; Sytnyk V, 2006, J CELL BIOL, V174, P1071, DOI 10.1083/jcb.200604145; Toga AW, 2003, ANNU REV BIOMED ENG, V5, P119, DOI 10.1146/annurev.bioeng.5.040202.121611; Trotter JA, 2000, BIOCHEM SOC T, V28, P357, DOI 10.1042/0300-5127:0280357; Tseng Y, 2002, CURR OPIN COLLOID IN, V7, P210, DOI 10.1016/S1359-0294(02)00050-X; TUNG PS, 1992, J CELL PHYSIOL, V152, P410, DOI 10.1002/jcp.1041520224; VANDENPOL AN, 1986, J CELL BIOL, V102, P2281, DOI 10.1083/jcb.102.6.2281; VIIDIK A, 1968, Journal of Biomechanics, V1, P3, DOI 10.1016/0021-9290(68)90032-8; Wang XJ, 2008, LANGMUIR, V24, P5942, DOI 10.1021/la704006z; Willits RK, 2004, J BIOMAT SCI-POLYM E, V15, P1521, DOI 10.1163/1568562042459698; Wottawah F, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.098103; Yang J, 2005, MRS BULL, V30, P189, DOI 10.1557/mrs2005.51; Yeo WS, 2003, J AM CHEM SOC, V125, P14994, DOI 10.1021/ja038265b; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041; Yousaf MN, 2001, P NATL ACAD SCI USA, V98, P5992, DOI 10.1073/pnas.101112898; Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524; ZHENG J, 1991, J NEUROSCI, V11, P1117	81	48	49	1	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341			TISSUE ENG PT A	Tissue Eng. Part A	JUN	2010	16	6					1873	1889		10.1089/ten.tea.2009.0574			17	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Cell Biology; Engineering; Materials Science	602UQ	WOS:000278164800008	20067396				2021-06-18	
J	Hanly, JG; Omisade, A; Su, L; Farewell, V; Fisk, JD				Hanly, John G.; Omisade, Antonina; Su, Li; Farewell, Vernon; Fisk, John D.			Assessment of Cognitive Function in Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Multiple Sclerosis by Computerized Neuropsychological Tests	ARTHRITIS AND RHEUMATISM			English	Article							TRAUMATIC BRAIN-INJURY; ASSESSMENT METRICS; NEUROPSYCHIATRIC EVENTS; INITIAL VALIDATION; DYSFUNCTION; IMPAIRMENT; PERFORMANCE; PREVALENCE; CRITERIA; INDEX	Objective. Computerized neuropsychological testing may facilitate screening for cognitive impairment in systemic lupus erythematosus (SLE). This study was undertaken to compare patients with SLE, patients with rheumatoid arthritis (RA), and patients with multiple sclerosis (MS) with healthy controls using the Automated Neuropsychological Assessment Metrics (ANAM). Methods. Patients with SLE (n = 68), RA (n = 33), and MS (n = 20) were compared with healthy controls (n = 29). Efficiency of cognitive performance on 8 ANAM subtests was examined using throughput (TP), inverse efficiency (IE), and adjusted IE scores. The latter is more sensitive to higher cognitive functions because it adjusts for the impact of simple reaction time on performance. The results were analyzed using O'Brien's generalized least squares test. Results. Control subjects were the most efficient in cognitive performance. MS patients were least efficient overall (as assessed by TP and IE scores) and were less efficient than both SLE patients (P = 0.01) and RA patients (P < 0.01), who did not differ. Adjusted IE scores were similar between SLE patients, RA patients, and controls, reflecting the impact of simple reaction time on cognitive performance. Thus, 50% of SLE patients, 61% of RA patients, and 75% of MS patients had impaired performance on >= 1 ANAM subtest. Only 9% of RA patients and 11% of SLE patients had impaired performance on >= 4 subtests, whereas this was true for 20% of MS patients. Conclusion. ANAM is sensitive to cognitive impairment. While such computerized testing may be a valuable screening tool, our results emphasize the lack of specificity of slowed performance as a reliable indicator of impairment of higher cognitive function in SLE patients.	[Hanly, John G.; Omisade, Antonina; Fisk, John D.] Dalhousie Univ, Halifax, NS, Canada; [Su, Li; Farewell, Vernon] Univ Cambridge, Cambridge, England; [Su, Li; Farewell, Vernon] Inst Publ Hlth, Cambridge, England	Hanly, JG (corresponding author), Nova Scotia Rehabil Ctr, Div Rheumatol, 2nd Floor,1341 Summer St, Halifax, NS B3H 4K4, Canada.	john.hanly@cdha.nshealth.ca	Fisk, John D/N-7796-2015	Fisk, John D/0000-0003-3512-8015; Farewell, Vernon/0000-0001-6704-5295; Su, Li/0000-0003-0919-3462	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-57752]; Capital Health Research Fund, Canada; Multiple Sclerosis Society of Canada; Medical Research Council, UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [U.1052.00.009]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105261167] Funding Source: researchfish	Dr. Hanly's work was supported by the Canadian Institutes of Health Research (grant MOP-57752) and the Capital Health Research Fund, Canada. Dr. Omisade is recipient of a Multiple Sclerosis Society of Canada research studentship. Drs. Su and Farewell's work was supported by the Medical Research Council, UK (grant U.1052.00.009). Dr. Fisk's work was supported by the Multiple Sclerosis Society of Canada and the Capital Health Research Fund, Canada (pilot grant).	Ainiala H, 2001, ARTHRIT RHEUM-ARTHR, V45, P419, DOI 10.1002/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Brey RL, 2002, NEUROLOGY, V58, P1214, DOI 10.1212/WNL.58.8.1214; Brunner HI, 2007, ARTHRIT RHEUM-ARTHR, V57, P1174, DOI 10.1002/art.23005; CARBOTTE RM, 1986, J NERV MENT DIS, V174, P357, DOI 10.1097/00005053-198606000-00008; Carlomagno S, 2000, J NEUROL, V247, P273, DOI 10.1007/s004150050583; CHRISTIE J, 1995, MEM COGNITION, V23, P547, DOI 10.3758/BF03197256; Correa Denise D, 2007, Curr Opin Support Palliat Care, V1, P57, DOI 10.1097/SPC.0b013e32813a328f; Dallow NS, 2008, PHARM STAT, V7, P53, DOI 10.1002/pst.268; Denburg SD, 2003, LUPUS, V12, P883, DOI 10.1191/0961203303lu497oa; GINSBURG KS, 1992, ARTHRITIS RHEUM, V35, P776, DOI 10.1002/art.1780350711; Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303; Hanly JG, 2007, ARTHRITIS RHEUM-US, V56, P265, DOI 10.1002/art.22305; Hanly JG, 2005, BEST PRACT RES CL RH, V19, P799, DOI 10.1016/j.berh.2005.04.003; HANLY JG, 1992, J RHEUMATOL, V19, P562; Hanly JG, 1997, ANN NY ACAD SCI, V823, P60, DOI 10.1111/j.1749-6632.1997.tb48379.x; Hanly JG, 1997, ARTHRITIS RHEUM, V40, P1542, DOI 10.1002/art.1780400825; Hanly JG, 2009, J RHEUMATOL, V36, P1449, DOI 10.3899/jrheum.081133; HAY EM, 1994, ANN RHEUM DIS, V53, P298, DOI 10.1136/ard.53.5.298; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Holliday SL, 2003, LUPUS, V12, P697, DOI 10.1191/0961203303lu442oa; Kozora E, 1996, ARTHRITIS RHEUM, V39, P2035, DOI 10.1002/art.1780391213; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Levinson D, 2005, ARCH CLIN NEUROPSYCH, V20, P403, DOI 10.1016/j.acn.2004.09.001; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Liang MH, 1999, ARTHRITIS RHEUM-US, V42, P599; Lofstad GE, 2009, ACTA PAEDIATR, V98, P180, DOI 10.1111/j.1651-2227.2008.01055.x; McLaurin EY, 2005, NEUROLOGY, V64, P297, DOI 10.1212/01.WNL.0000149640.78684.EA; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Petri M, 2008, J RHEUMATOL, V35, P1776; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Reeves D, 1996, NCRFSR9601; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Reicker LI, 2007, ARCH CLIN NEUROPSYCH, V22, P655, DOI 10.1016/j.acn.2007.04.008; Roebuck-Spencer TM, 2006, ARTHRIT RHEUM-ARTHR, V55, P434, DOI 10.1002/art.21992; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Tombaugh TN, 2007, ARCH CLIN NEUROPSYCH, V22, P25, DOI 10.1016/j.acn.2006.06.013; Townsend J.T., 1983, STOCHASTIC MODELING; Waterloo K, 2002, RHEUMATOLOGY, V41, P411, DOI 10.1093/rheumatology/41.4.411; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	48	51	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0004-3591	1529-0131		ARTHRITIS RHEUM-US	Arthritis Rheum.	MAY	2010	62	5					1478	1486		10.1002/art.27404			9	Rheumatology	Rheumatology	619LT	WOS:000279432400032	20155829	Bronze, Green Accepted			2021-06-18	
J	Siegert, RJ; Jackson, DM; Tennant, A; Turner-Stokes, L				Siegert, Richard J.; Jackson, Diana M.; Tennant, Alan; Turner-Stokes, Lynne			FACTOR ANALYSIS AND RASCH ANALYSIS OF THE ZARIT BURDEN INTERVIEW FOR ACQUIRED BRAIN INJURY CARER RESEARCH	JOURNAL OF REHABILITATION MEDICINE			English	Article						carer; brain injury; burden; Zarit Burden Interview; factor analysis; Rasch analysis	QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; MEASUREMENT MODEL; STROKE PATIENTS; DEPRESSION; CAREGIVERS; CRITERIA; VERSION; IMPACT	Objective: To examine the dimensionality of the Zarit Burden Interview in a sample of carers of adults with acquired brain injury. Design: A cross-sectional UK survey using postal questionnaires. Participants: A sample of 222 carers; 43 men (19.4%) and 179 women (80.6%); mean age 54 years. Types of brain injury included traumatic brain injury (49.5%), stroke (25.9%), brain infection (17.3%), hypoxia (4.1%), and "other" (3.2"A). Methods: Exploratory and confirmatory factor analysis and Rasch analysis. Results: Unidimensionality was tested using confirmatory factor analysis, which showed a poor fit. The underlying structure of the Zarit Burden Interview was explored using principal components analysis and varimax rotation. This revealed 3 factors, although 1 comprised only 2 items. The 2 major factors identified were personal strain and role strain. They were then examined using Rasch analysis, which identified 2 brief and reliable unidimensional scales. There was no evidence of differential item functioning for different types of carer/brain injury. Conclusion: The Zarit Burden Interview is a promising measure for the assessment of burden in carers of people with an acquired brain injury. It offers 2 reliable, brief subscales of personal strain and role strain for this purpose. However, it remains for these 2 brief subscales to be validated clinically in future research.	[Siegert, Richard J.; Jackson, Diana M.; Turner-Stokes, Lynne] Kings Coll London, Dept Palliat Care Policy & Rehabil, London SE5 9RJ, England; [Tennant, Alan] Univ Leeds, Fac Med & Hlth, Leeds, W Yorkshire, England; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, London, England	Siegert, RJ (corresponding author), Kings Coll London, Guys Kings Coll Hosp, Dept Palliat Care Policy & Rehabil, Sch Med,Weston Educ Ctr, 3rd Floor,Cutcombe Rd,Denmark Hill, London SE5 9RJ, England.	richard.siegert@kcl.ac.uk	Jackson, Diana/C-3846-2009; Turner-Stokes, Lynne/F-4418-2012; Siegert, Richard J./K-2030-2019	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	Department of HealthEuropean Commission [030/0066]; Dunhill Medical TrustDunhill Medical Trust; Luff Foundation	The authors are grateful to all the carers who participated in this research project, and to representatives of Headway, The Encephalitis Society and The Meningitis Trust for their help with recruitment. The project was commissioned and funded by the Department of Health (R&D grant 030/0066), but conducted and written up by an external group of researchers. The views expressed are not necessarily those of the Department of Health. Financial support for the preparation of this manuscript was provided by the Dunhill Medical Trust and the Luff Foundation.	Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Ankri J, 2005, INT J GERIATR PSYCH, V20, P254, DOI 10.1002/gps.1275; Babakus E., 1988, J ACAD MARKET SCI, V16, P95; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; Boyer F, 2006, J REHABIL MED, V38, P309, DOI 10.1080/16501970600731578; Cano SJ, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-58; Heinemann AW, 2005, REHABIL PSYCHOL, V50, P6, DOI 10.1037/0090-5550.50.1.6; Hobart JC, 2007, LANCET NEUROL, V6, P1094, DOI 10.1016/S1474-4422(07)70290-9; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Knight B. G., 2000, J CLIN GEROPSYCHOLOG, V6, P249, DOI DOI 10.1023/A:1009530711710; Kreiner S, 2004, COMMUN STAT-THEOR M, V33, P1239, DOI 10.1081/STA-120030148; Molyneux GJ, 2008, INT PSYCHOGERIATR, V20, P1193, DOI 10.1017/S1041610208007515; O'Rourke N, 2003, GERONTOLOGIST, V43, P121, DOI 10.1093/geront/43.1.121; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; PARAG V, 2003, CEREBROVASC DIS, V25, P548; Pomeranz JL, 2008, REHABIL COUNS BULL, V51, P251, DOI 10.1177/0034355208317317; Smith AB, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-19; Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Thompson B., 2004, EXPLORATORY CONFIRMA; Tooth L, 2008, QUAL LIFE RES, V17, P267, DOI 10.1007/s11136-007-9300-7; van Heugten C, 2006, J REHABIL MED, V38, P153, DOI 10.1080/16501970500441898; Visser-Meily JMA, 2004, CLIN REHABIL, V18, P601, DOI 10.1191/0269215504cr776oa; WHITLATCH CJ, 1991, GERONTOLOGIST, V31, P9, DOI 10.1093/geront/31.1.9; Wright B.D., 1982, RATING SCALE ANAL; Zarit S., 1987, INSTRUCTIONS BURDEN	28	48	50	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	APR	2010	42	4					302	309		10.2340/16501977-0511			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	598HY	WOS:000277827500003	20461331	DOAJ Gold			2021-06-18	
J	Bagnato, S; Boccagni, C; Prestandrea, C; Sant'Angelo, A; Castiglione, A; Galardi, G				Bagnato, S.; Boccagni, C.; Prestandrea, C.; Sant'Angelo, A.; Castiglione, A.; Galardi, G.			Prognostic value of standard EEG in traumatic and non-traumatic disorders of consciousness following coma	CLINICAL NEUROPHYSIOLOGY			English	Article						Level of cognitive functioning (LCF); Synek scale; Altered consciousness; Traumatic brain injury; Vegetative state; Minimally conscious state	PERSISTENT VEGETATIVE STATE; AGE-RELATED DIFFERENCES; SEVERE HEAD-INJURY; BRAIN-DAMAGE; ALPHA-COMA; RECOVERY; SCALE; NEUROPATHOLOGY; POTENTIALS; ADULTS	Objective: To investigate the prognostic value of standard electroencephalogram (EEG) in predicting the improvement of the level of consciousness in patients suffering from severe disturbances of consciousness following coma caused by acute brain injuries. Methods: A standard EEG was recorded at admission in our rehabilitation department in a total of 46 patients with impaired consciousness states following coma (22 patients with traumatic brain injuries, 24 patients with non-traumatic brain injuries). We quantified the EEG abnormalities using the scale of Synek (1988) and correlated them with the basal level of cognitive functioning (LCF) scale score and with its variation after three months. Results: EEG scores correlated with LCF scores at admission (p < 0.01) and with LCF scores' variation after three months (p < 0.01) in patients with traumatic brain injury; EEG scores correlated only with LCF scores variation after three months (p < 0.01) in patients with non-traumatic brain injury. Conclusions: Standard EEG, analysed using the Synek scale, has a good prognostic value in both groups of patients with disorders of consciousness. Significance: This work may have implications for clinical care, rehabilitative programs and medical-legal decisions in patients with impaired consciousness states following coma due to acute brain injuries. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Bagnato, S.; Boccagni, C.; Sant'Angelo, A.; Castiglione, A.; Galardi, G.] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurorehabil Unit, I-90015 Cefalu, PA, Italy; [Bagnato, S.; Boccagni, C.; Prestandrea, C.; Sant'Angelo, A.; Galardi, G.] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurophysiol Unit, I-90015 Cefalu, PA, Italy	Galardi, G (corresponding author), Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurorehabil Unit, I-90015 Cefalu, PA, Italy.	giuseppe.galardi@hsrgiglio.it	Bagnato, Sergio/H-6842-2013	Bagnato, Sergio/0000-0002-6289-1887; Boccagni, Cristina/0000-0002-6317-015X			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Beaumont JG, 2005, NEUROPSYCHOL REHABIL, V15, P184, DOI 10.1080/09602010443000489; Coleman MR, 2005, J NEUROL NEUROSUR PS, V76, P432, DOI 10.1136/jnnp.2004.045930; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; DUFFY FH, 1984, ANN NEUROL, V16, P430, DOI 10.1002/ana.410160403; DUFFY FH, 1993, NEUROBIOL AGING, V14, P73, DOI 10.1016/0197-4580(93)90025-7; FAUVAGE B, 1993, CRIT CARE MED, V21, P472, DOI 10.1097/00003246-199303000-00029; Fischer C., 2002, Annales de Readaptation et de Medecine Physique, V45, P448, DOI 10.1016/S0168-6054(02)00295-7; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kaplan PW, 2000, CLIN NEUROPHYSIOL, V111, P584, DOI 10.1016/S1388-2457(99)00303-X; Kaplan PW, 1999, CLIN NEUROPHYSIOL, V110, P205, DOI 10.1016/S1388-2457(98)00046-7; Lescot T, 2009, ANN NY ACAD SCI, V1157, P71, DOI 10.1111/j.1749-6632.2008.04120.x; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; Wijdicks EFM, 2005, MAYO CLIN PROC, V80, P1037, DOI 10.4065/80.8.1037; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; YOUNG GB, 1994, ELECTROEN CLIN NEURO, V91, P93, DOI 10.1016/0013-4694(94)90030-2	30	48	49	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2010	121	3					274	280		10.1016/j.clinph.2009.11.008			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	556AE	WOS:000274557800005	20005157				2021-06-18	
J	Ciurli, P; Bivona, U; Barba, C; Onder, G; Silvestro, D; Azicnuda, E; Rigon, J; Formisano, R				Ciurli, Paola; Bivona, Umberto; Barba, Carmen; Onder, Graziano; Silvestro, Daniela; Azicnuda, Eva; Rigon, Jessica; Formisano, Rita			Metacognitive unawareness correlates with executive function impairment after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Executive functions; Metacognitive self-awareness; Perseverative errors; Severe TBI; Neuropsychological rehabilitation; SA assessment	COMPETENCE RATING-SCALE; CLOSED-HEAD-INJURY; SELF-AWARENESS; BEHAVIORAL LIMITATIONS; PRACTICAL SCALE; REHABILITATION; DEFICITS; ADULTS; COMA; CONSCIOUSNESS	The aim of this study was to evaluate clinical, neuropsychological, and functional differences between severe traumatic brain injury (TBI) outpatients with good and/or heightened metacognitive self-awareness (SA) and those with impaired metacognitive SA, assessed by the Patient Competency Rating Scale (PCRS). Fifty-two outpatients were recruited from a neurorehabilitation hospital based on the following inclusion criteria: 1) age ? 15 years; 2) diagnosis of severe TBI: 3) availability of neuroimaging data; 4) post-traumatic amnesia resolution; 5) provision of informed consent. Measures: A neuropsychological battery was used to evaluate attention, memory and executive functions. SA was assessed by the PCRS. which was administered to patients and close family members. Patients were divided into two groups representing those with and without SA. Patients with poor SA had more problems than those with good SA in some components of the executive system. as indicated by the high percentage of perseverative errors and responses they made on the Wisconsin Card Sorting Test. Moreover. a decrease in metacognitive SA correlated significantly with time to follow commands (TFC). This study suggests the importance of integrating an overall assessment of cognitive functions with a specific evaluation of SA to treat self-awareness and executive functions together during, the rehabilitation process. (JINS, 2010, 16, 360-368.)	[Ciurli, Paola] Fdn Santa Lucia, Serv Diag & Riabilitaz Neuropsicol, Postcoma Unit, I-00179 Rome, Italy; [Barba, Carmen] Childrens Hosp Meyer, Pediat Neurol Unit, Florence, Italy; [Onder, Graziano] Catholic Univ, Dept Geriatr, Rome, Italy; [Rigon, Jessica] San Camillo Hosp, Dept Neuropsychol, Venice Lido, Italy	Ciurli, P (corresponding author), Fdn Santa Lucia, Serv Diag & Riabilitaz Neuropsicol, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy.	p.ciurli@hsantalucia.it	Azicnuda, Eva/K-9010-2016	barba, carmen/0000-0001-5445-5842			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; APOLLONIO I, 2005, J NEUROL SCI, V26, P108; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Basso A, 1987, Funct Neurol, V2, P189; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; CROSSON C, 1989, J HEAD TRAUMA REHAB, V4, P46; DERENZI E, 1962, BRAIN, V85, P556, DOI DOI 10.1093/BRAIN/85.4.665; Dirette DK, 2007, BRAIN INJURY, V21, P1131, DOI 10.1080/02699050701687326; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Formisano R, 2005, ACT NEUR S, V93, P201; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P285, DOI 10.1097/00001199-200507000-00001; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Heaton R., 1993, WISCONSIN CARD SORTI; HEATON RK, 2000, ORG SPECIALI; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Hoofien D, 2006, ISR J PSYCHIATR REL, V43, P296; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mukhopadhyay P, 2008, PROG BRAIN RES, V168, P95, DOI 10.1016/S0079-6123(07)68008-X; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Orsini A., 2003, B PSICOL APPL, V239, P73; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1991, BNI Q, V7, P27; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROUECHE JR, 1987, COGNITIVE REHABILITA, V1, P4; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TRUDEL TM, 1998, REHABIL PSYCHOL, V43, P276; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zimmerman P., 1992, TEST BATTERIE AUFMER	71	48	49	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2010	16	2					360	368		10.1017/S135561770999141X			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	562DZ	WOS:000275030900017	20109243				2021-06-18	
J	Sadasivan, S; Zhang, ZQ; Larner, SF; Liu, MC; Zheng, WR; Kobeissy, FH; Hayes, RL; Wang, KKW				Sadasivan, Shankar; Zhang, Zhiqun; Larner, Stephen F.; Liu, Ming C.; Zheng, Wenrong; Kobeissy, Firas H.; Hayes, Ronald L.; Wang, Kevin K. W.			Acute NMDA toxicity in cultured rat cerebellar granule neurons is accompanied by autophagy induction and late onset autophagic cell death phenotype	BMC NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; ALPHA-SYNUCLEIN; UP-REGULATION; APOPTOSIS; ACTIVATION; PROTEASE; NECROSIS; DISEASE; MARKER; MICE	Background: Autophagy, an intracellular response to stress, is characterized by double membrane cytosolic vesicles called autophagosomes. Prolonged autophagy is known to result in autophagic (Type II) cell death. This study examined the potential role of an autophagic response in cultured cerebellar granule neurons challenged with excitotoxin N-methyl-D-aspartate (NMDA). Results: NMDA exposure induced light chain-3 (LC-3)-immunopositive and monodansylcadaverine (MDC) fluorescent dye-labeled autophagosome formation in both cell bodies and neurites as early as 3 hours post-treatment. Elevated levels of Beclin-1 and the autophagosome-targeting LC3-II were also observed following NMDA exposure. Prolonged exposure of the cultures to NMDA (8-24 h) generated MDC-, LC3-positive autophagosomal bodies, concomitant with the neurodegenerative phase of NMDA challenge. Lysosomal inhibition studies also suggest that NMDA-treatment diverted the autophagosome-associated LC3-II from the normal lysosomal degradation pathway. Autophagy inhibitor 3-methyladenine significantly reduced NMDA-induced LC3-II/LC3-I ratio increase, accumulation of autophagosomes, and suppressed NMDA-mediated neuronal death. ATG7 siRNA studies also showed neuroprotective effects following NMDA treatment. Conclusions: Collectively, this study shows that autophagy machinery is robustly induced in cultured neurons subjected to prolonged exposure to excitotoxin, while autophagosome clearance by lysosomal pathway might be impaired. Our data further show that prolonged autophagy contributes to cell death in NMDA-mediated excitotoxicity.	[Sadasivan, Shankar; Kobeissy, Firas H.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA; [Zhang, Zhiqun; Larner, Stephen F.; Liu, Ming C.; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA	Sadasivan, S (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA.	shankar.sadasivan@stjude.org; kwang@banyanbio.com	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMMED-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01-A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER	The authors wish to thank Drs. William Dunn, Jr. and Lucia Notterpek (University of Florida) for their insights and opinions in this work. This work was supported by the Department of Defense grant DAMMED-03-1-0066 and NIH grant R01 NS049175-01-A1. KKW and RLH own stocks and receive royalties from and are executive officers of Banyan Biomarkers Inc. and as such may benefit financially as a result of the outcome of this research or work reported in this publication.	ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280; Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Dickson DW, 2007, AM J PATHOL, V170, P16, DOI 10.2353/ajpath.2007.061011; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Du L, 2009, J BIOL CHEM, V284, P2383, DOI 10.1074/jbc.M804396200; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; FERRER I, 1995, ACTA NEUROPATHOL, V90, P504; Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ito S, 2007, INT J ONCOL, V31, P261; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012; Linton SD, 2005, J MED CHEM, V48, P6779, DOI 10.1021/jm050307e; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; Mizushima N, 2007, AUTOPHAGY, V3; Munafo DB, 2001, J CELL SCI, V114, P3619; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sadasivan S, 2006, APOPTOSIS, V11, P1573, DOI 10.1007/s10495-006-7690-6; Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200; Tarabal O, 2005, MOL CELL NEUROSCI, V29, P283, DOI 10.1016/j.mcn.2005.03.003; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	53	48	52	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	FEB 18	2010	11								21	10.1186/1471-2202-11-21			11	Neurosciences	Neurosciences & Neurology	566MM	WOS:000275374800001	20167092	DOAJ Gold, Green Published			2021-06-18	
J	Ranaivo, HR; Wainwright, MS				Ranaivo, Hantamalala Ralay; Wainwright, Mark S.			Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways	BRAIN RESEARCH			English	Article						Albumin; Astrocyte; Microglia; Cytokines; Mitogen activated protein kinase	TRAUMATIC BRAIN-INJURY; SIGNAL-REGULATED KINASE; ACUTE ISCHEMIC STROKE; FACTOR OLEIC-ACID; NEUROLOGICAL DEFICIT; FLUID RESUSCITATION; REACTIVE ASTROCYTES; NEURONAL INJURY; POTENT TRIGGER; HEAD-INJURY	Following acute brain injury, albumin may gain access to the brain parenchyma. Clinical studies indicate a protective role for albumin in stroke but an increase in mortality associated with albumin administration following traumatic brain injury. We investigated the effects of albumin on astrocyte and microglial activation, and the role of mitogen-activated protein kinases (MAPK) in these responses. Albumin activated ERK1/2, p38 MAPK and JNK signaling pathways in astrocytes, and induced the production of interleukin (IL)-1 beta, inducible nitric oxide (NO) synthase, the NO metabolite nitrite, and the chemokine CX3CL1 while reducing the level of S100B. The release of inflammatory markers by astrocytes was partially dependent on p38 MAPK and ERK1/2 pathways, but not JNK. In microglia, albumin exposure activated all three MAPK pathways and produced an increase in IL-1 beta and nitrite. Inhibition of p38 MAPK in microglia leads to an increased level of 11,10, while inhibition of all three MAPKs suppressed the release of nitrite. These results suggest that albumin activates astrocytes and microglia, inducing inflammatory responses involved both in the mechanisms of cellular injury and repair via activation of MAPK pathways, and thereby implicate glial activation in the clinical responses to administration of albumin. (c) 2009 Elsevier B.V. All rights reserved.	Northwestern Univ, Dept Pediat, Div Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Ctr Interdisciplinary Res Pediat Crit Illness & I, Feinberg Sch Med, Chicago, IL 60611 USA	Wainwright, MS (corresponding author), Childrens Mem Hosp, Div Neurol 51, 2300 Childrens Plaza, Chicago, IL 60614 USA.	m-wainwright@northwestern.edu	Ritter, Stefanie L/D-9312-2012		Davee Foundation; Medical Research junior Board Foundation; Lyndsey Whittingham Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 NS044998]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS044998] Funding Source: NIH RePORTER	We are grateful for the technical assistance of Fatima Patel. Dr. Wainwright is supported by the Davee Foundation, Medical Research junior Board Foundation, the Lyndsey Whittingham Foundation, and by NIH grant K08 NS044998.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Belayev L, 2005, STROKE, V36, P326, DOI 10.1161/01.STR.0000152949.31366.3d; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Bento-Abreu A, 2008, J NEUROCHEM, V106, P1149, DOI 10.1111/j.1471-4159.2008.05462.x; Bhat NR, 1998, J NEUROSCI, V18, P1633; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Calvo CF, 2005, J NEUROSCI RES, V80, P707, DOI 10.1002/jnr.20511; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Edwards P, 2005, LANCET, V365, P1957; Ellis EF, 2007, J NEUROCHEM, V101, P1463, DOI 10.1111/j.1471-4159.2007.04515.x; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Friedman WJ, 2005, MOL NEUROBIOL, V32, P133, DOI 10.1385/MN:32:2:133; Ginsberg MD, 2006, BIOCHEM SOC T, V34, P1323, DOI 10.1042/BST0341323; Grande PO, 2008, ACTA ANAESTH SCAND, V52, P738, DOI 10.1111/j.1399-6576.2008.01688.x; Harper SJ, 2003, EXPERT OPIN THER TAR, V7, P187, DOI 10.1517/14728222.7.2.187; Hooper C, 2005, J NEUROCHEM, V92, P1363, DOI 10.1111/j.1471-4159.2005.02982.x; Hooper C, 2009, J NEUROCHEM, V109, P694, DOI 10.1111/j.1471-4159.2009.05953.x; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nadal A, 1996, J PHYSIOL-LONDON, V492, P737, DOI 10.1113/jphysiol.1996.sp021342; Nadal A, 2001, Prog Brain Res, V132, P367; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nimmagadda A, 2008, STROKE, V39, P198, DOI 10.1161/STROKEAHA.107.495598; Palesch YY, 2006, STROKE, V37, P2107, DOI 10.1161/01.STR.0000231389.34701.b5; Ravizza T, 2008, NEUROBIOL DIS, V29, P142, DOI 10.1016/j.nbd.2007.08.012; Re DB, 2006, NAT NEUROSCI, V9, P859; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Sheng WS, 2009, J NEUROIMMUNE PHARM, V4, P244, DOI 10.1007/s11481-009-9147-5; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Somera-Molina KC, 2009, BRAIN RES, V1282, P162, DOI 10.1016/j.brainres.2009.05.073; Tabernero A, 2002, J BIOL CHEM, V277, P4240, DOI 10.1074/jbc.M108760200; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; WAHLSTROM MR, 2008, ACTA ANAESTHESIOLOGI, V53, P18; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Zhao TZ, 2009, NEUROL SCI, V30, P379, DOI 10.1007/s10072-009-0123-x	48	48	49	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 8	2010	1313						222	231		10.1016/j.brainres.2009.11.063			10	Neurosciences	Neurosciences & Neurology	559YQ	WOS:000274869100022	19961838	Green Accepted			2021-06-18	
J	Glang, A; Koester, MC; Beaver, S; Clay, J; McLaughlin, K				Glang, Ann; Koester, Michael C.; Beaver, Sherry; Clay, Janet; McLaughlin, Karen			Online Training in Sports Concussion for Youth Sports Coaches	INTERNATIONAL JOURNAL OF SPORTS SCIENCE & COACHING			English	Article						Coach Education; E-Learning; Traumatic Brain Injury	TRAUMATIC BRAIN-INJURY; CONTINUING MEDICAL-EDUCATION; HIGH-SCHOOL; INTERACTIVE MULTIMEDIA; PHYSICAL-ACTIVITY; FOOTBALL PLAYERS; CONTROLLED-TRIAL; HEAD-INJURY; MANAGEMENT; TECHNOLOGY	The purpose of this study was to evaluate ACTive: Athletic Concussion Training using Interactive Video Education, an interactive e-learning program designed to train community coaches of youth ages 10-18 in effective sports concussion prevention and management practices. Seventy-five youth sports coaches from across the country completed the study over the Internet. Results of a randomized control trial demonstrated significant differences between treatment and control participants on measures of: (a) knowledge about sports concussion, management, and prevention; (b) attitudes about the importance of preventing sports concussion; and (c) intention and self-efficacy in sports concussion management and prevention. The results suggest that ACTive is an effective method of training youth sports coaches who are in an important position to reduce risks associated with sports concussion.	[Glang, Ann; Beaver, Sherry; Clay, Janet; McLaughlin, Karen] Oregon Ctr Appl Sci Inc, Eugene, OR 97401 USA; [Koester, Michael C.] Slocum Ctr Orthoped & Sports Med, Eugene, OR 97401 USA	Glang, A (corresponding author), Oregon Ctr Appl Sci Inc, 260 E 11th Ave, Eugene, OR 97401 USA.	aglang@orcasinc.com			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R44HD056610, R43HD056610] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43 HD056610, R43 HD056610-01] Funding Source: Medline		AJZEN I, 1977, PSYCHOL BULL, V84, P888, DOI 10.1037/0033-2909.84.5.888; AJZEN I, 1973, J PERS SOC PSYCHOL, V27, P41, DOI 10.1037/h0034440; Ajzen I., 1980, UNDERSTANDING ATTITU, V278; *ASTD, 2001, STAT IND REP 2001; BAILEY B, GETTING COMPLETE PIC; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bandura A., 1969, PRINCIPLES BEHAV MOD; Bandura A, 1997, SELFEFFICACY EXERCIS; BECKER MH, 1974, HLTH ED MONOGR, V2, P342; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Casebeer L, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-37; *CDC, 2005, HEADS CONC HIGH SCH; Chambers M, 2002, TELEMED J E-HEALTH, V8, P343, DOI 10.1089/15305620260353234; Cohen J, 1988, STAT POWER BEHAV SCI; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Danaher BG, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e12; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fordis M, 2005, JAMA-J AM MED ASSOC, V294, P1043, DOI 10.1001/jama.294.9.1043; Fotheringham MJ, 2000, AM J PREV MED, V19, P111, DOI 10.1016/S0749-3797(00)00185-9; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gianotti SM, 2009, J SCI MED SPORT, V12, P371, DOI 10.1016/j.jsams.2008.01.002; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Glang A, 2007, J HEAD TRAUMA REHAB, V22, P198, DOI 10.1097/01.HTR.0000271121.42523.3a; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hugenholtz NIR, 2008, OCCUP MED-OXFORD, V58, P370, DOI 10.1093/occmed/kqn053; Irvine AB, 2003, J APPL GERONTOL, V22, P269, DOI 10.1177/0733464803022002006; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kobb R, 2003, TELEMED J E-HEALTH, V9, P189, DOI 10.1089/153056203766437525; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Marcus BH, 2000, AM J PREV MED, V19, P121, DOI 10.1016/S0749-3797(00)00186-0; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2005, J ATHL TRAINING, V40, P123; National Federation of State High School Associations, 2006, PART HIGH SCH SPORTS; Noell J, 1999, AM J PREV MED, V17, P269, DOI 10.1016/S0749-3797(99)00093-8; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OSBORN ZH, 2005, ANN M AM PSYCH ASS W; Patel DR, 2000, MED CLIN N AM, V84, P983, DOI 10.1016/S0025-7125(05)70270-4; Peterson L, 1996, HEALTH PSYCHOL, V15, P124; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Russ-Eft D., 2002, HUMAN RESOURCE DEV R, V1, P45, DOI DOI 10.1177/1534484302011003; Schwebel DC, 2002, J SAFETY RES, V33, P301, DOI 10.1016/S0022-4375(02)00028-2; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; U.S. Dept. of Health and Human Services, 2006, RES BAS WEB DES US G; Vandelanotte C, 2005, ANN BEHAV MED, V29, P138, DOI 10.1207/s15324796abm2902_8; *WAMMI, 1997, NOM MAN AG; Wiersma LD, 2005, RES Q EXERCISE SPORT, V76, P324; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	63	48	48	2	30	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1747-9541	2048-397X		INT J SPORTS SCI COA	Int. J. Sports Sci. Sci. Coach.		2010	5	1					1	11		10.1260/1747-9541.5.1.1			11	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Sciences - Other Topics; Psychology	581XM	WOS:000276559100002	20640175	Green Accepted			2021-06-18	
J	Kennedy, JE; Cullen, MA; Amador, RR; Huey, JC; Leal, FO				Kennedy, Jan E.; Cullen, Maren A.; Amador, Ricardo R.; Huey, Judith C.; Leal, Felix O.			Symptoms in military service members after blast mTBI with and without associated injuries	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; blast injury; PTSD; associated injuries; PCS	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; PTSD CHECKLIST; PSYCHOMETRIC PROPERTIES; CIVILIAN VERSION; PREVALENCE; VETERANS; IRAQ; PCL	Traumatic combat events can lead to neurobehavioral and stress-related symptoms among military troops. Physical injuries received during combat are associated with increased symptom report [8]. The effect of a concurrent mild traumatic brain injury (mTBI) on this relationship is unknown and forms the basis for this report. Subjects included a cohort of 274 male service members who received a blast-related mTBI during deployment in Iraq. They completed symptom ratings on the Posttraumatic Stress Disorder Checklist-Civilian version (PCL-C) and Neurobehavioral Symptom Inventory (NSI). Service members with mTBI, but no other associated physical injuries had higher symptom ratings than those who received mTBI plus associated injuries. Results suggest that in the presence of an invisible injury, such as mTBI, associated bodily injuries may be at least partially protective against the development of stress and neurobehavioral symptoms. It is proposed that an invisible wound, such as mTBI, creates ambiguity regarding the etiology of symptoms and expected course of recovery and leads to increased emotional and somatic symptom report. However, the observable nature of an associated physical injury and the systematic rehabilitation involved in recovery from such an injury provide a focus for attention and measurable progress toward recovery that serve to reduce emotionally-based symptom reports.	[Kennedy, Jan E.; Cullen, Maren A.; Amador, Ricardo R.; Huey, Judith C.; Leal, Felix O.] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA	Kennedy, JE (corresponding author), Wilford Hall USAF Med Ctr, DVBIC, 59 MDOS SGO5N,2200 Berquist Dr Suite 1, Lackland AFB, TX 78236 USA.	jan.kennedy@lackland.af.mil					American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037/0022-006X.66.3.586; *ASS ADV AUT MED, 2007, ABBR INJ SCAL 2005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; PITMAN RK, 1989, AM J PSYCHIAT, V146, P667; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Steinmann M, 2009, ALTRUISM RECONSIDERE, P1; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; WEATHERS FW, 1993, PTSD CHECKLIST PCL D	19	48	48	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	26	3					191	197		10.3233/NRE-2010-0555			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300003	20448309				2021-06-18	
J	Scott, D; Tonmyr, L; Fraser, J; Walker, S; McKenzie, K				Scott, Debbie; Tonmyr, Lil; Fraser, Jenny; Walker, Sue; McKenzie, Kirsten			The utility and challenges of using ICD codes in child maltreatment research: A review of existing literature	CHILD ABUSE & NEGLECT			English	Article						Child maltreatment; ICD; Health data	SHAKEN-BABY-SYNDROME; PUBLIC-HEALTH SURVEILLANCE; TRAUMATIC BRAIN-INJURIES; YOUNG-CHILDREN; PHYSICAL ABUSE; UNITED-STATES; HOSPITALIZED CHILDREN; PEDIATRIC INJURIES; HEAD-INJURY; INFANTS	Objective: The objectives of this article are to explore the extent to which the International Statistical Classification of Diseases and Related Health Problems (ICD) has been used in child abuse research, to describe how the ICD system has been applied, and to assess factors affecting the reliability of ICD coded data in child abuse research. Methods: PubMed, CINAHL, PsychInfo and Google Scholar were searched for peer reviewed articles written since 1989 that used ICD as the classification system to identify cases and research child abuse using health databases. Snowballing strategies were also employed by searching the bibliographies of retrieved references to identify relevant associated articles. The papers identified through the search were independently screened by two authors for inclusion, resulting in 47 studies selected for the review. Due to heterogeneity of studies meta-analysis was not performed. Results: This paper highlights both utility and limitations of ICD coded data. ICD codes have been widely used to conduct research into child maltreatment in health data systems. The codes appear to be used primarily to determine child maltreatment patterns within identified diagnoses or to identify child maltreatment cases for research. Conclusions: A significant impediment to the use of ICD codes in child maltreatment research is the under ascertainment of child maltreatment by using coded data alone. This is most clearly identified and, to some degree, quantified, in research where data linkage is used. Practice implications: The importance of improved child maltreatment identification will assist in identifying risk factors and creating programs that can prevent and treat child maltreatment and assist in meeting reporting obligations under the CRC. (C) 2009 Elsevier Ltd. All rights reserved.	[Scott, Debbie; Walker, Sue; McKenzie, Kirsten] Queensland Univ Technol, Natl Ctr Hlth Informat Res & Training, Sch Publ Hlth, Brisbane, Qld 4059, Australia; [Tonmyr, Lil] Publ Hlth Agcy Canada, Hlth Surveillance & Epidemiol Div, Ottawa, ON, Canada; [Fraser, Jenny] Queensland Univ Technol, Sch Nursing & Midwifery, Brisbane, Qld 4059, Australia	Scott, D (corresponding author), Queensland Univ Technol, Natl Ctr Hlth Informat Res & Training, Sch Publ Hlth, Victoria Pk Rd, Brisbane, Qld 4059, Australia.		Scott, Deborah/ABB-9055-2020; Walker, Susan/V-8101-2019; Vallmuur, Kirsten/I-9833-2012; Fraser, Jennifer/B-1120-2015; Vallmuur, Kirsten/AAL-9526-2021	Walker, Susan/0000-0002-3953-7724; Vallmuur, Kirsten/0000-0002-3760-0822; Fraser, Jennifer/0000-0003-0111-9137; Vallmuur, Kirsten/0000-0002-3760-0822; Scott, Deborah/0000-0002-4530-584X			Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Arbogast KB, 2005, PEDIATRICS, V116, P180, DOI 10.1542/peds.2004-2671; Barlow KM, 1998, SCOT MED J, V43, P112, DOI 10.1177/003693309804300407; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Benger JR, 2002, BRIT MED J, V324, P780, DOI 10.1136/bmj.324.7340.780; Brown D, 2004, AM J PUBLIC HEALTH, V94, P558, DOI 10.2105/AJPH.94.4.558; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; Chang DC, 2005, J PEDIATR SURG, V40, P114, DOI 10.1016/j.jpedsurg.2004.09.019; Chang DC, 2004, J TRAUMA, V57, P1189, DOI 10.1097/01.TA.0000145076.05111.E1; Ellison K, 2008, MICH HIST REV, V34, P162; EWIGMAN B, 1993, PEDIATRICS, V91, P330; Guenther E, 2009, J PEDIATR-US, V154, P272, DOI 10.1016/j.jpeds.2008.07.047; Herman-Giddens M E, 1991, N C Med J, V52, P634; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Jaudes PK, 2008, CHILD ABUSE NEGLECT, V32, P671, DOI 10.1016/j.chiabu.2007.08.007; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kelly P, 2008, J PAEDIATR CHILD H, V44, P99, DOI 10.1111/j.1440-1754.2007.01234.x; King WJ, 2003, CAN MED ASSOC J, V168, P155; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Leslie LK, 2000, CHILD ABUSE NEGLECT, V24, P465, DOI 10.1016/S0145-2134(00)00116-2; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2007, CHILD ABUSE NEGLECT, V31, P311, DOI 10.1016/j.chiabu.2006.07.004; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; Limbos MAP, 1998, PEDIATRICS, V102, P53, DOI 10.1542/peds.102.1.53; Loder RT, 2007, J PEDIATR ORTHOPED, V27, P421, DOI 10.1097/01.bpb.0000271328.79481.07; McPhilips H, 2001, Inj Prev, V7, P150, DOI 10.1136/ip.7.2.150; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; Olsen SJ, 1996, EPIDEMIOLOGY, V7, P644, DOI 10.1097/00001648-199611000-00015; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; PECLET MH, 1990, J PEDIATR SURG, V25, P85, DOI 10.1016/S0022-3468(05)80169-1; Petridou E, 2001, SCAND J PUBLIC HEALT, V29, P279, DOI 10.1177/14034948010290041301; Ricci L, 2003, CHILD ABUSE NEGLECT, V27, P271, DOI 10.1016/S0145-2134(03)00006-1; Rovi S, 1999, J Am Med Womens Assoc (1972), V54, P211; Rovi S, 2004, AM J PUBLIC HEALTH, V94, P586, DOI 10.2105/AJPH.94.4.586; Rovi Sue, 2003, Violence Vict, V18, P491, DOI 10.1891/vivi.2003.18.5.491; Saluja G, 2007, Int J Inj Contr Saf Promot, V14, P19, DOI 10.1080/17457300601049618; Sanders T., 2003, CHILD ABUSE REV, V12, P358; Schnitzer PG, 2008, AM J PUBLIC HEALTH, V98, P296, DOI 10.2105/AJPH.2006.087783; Schnitzer PG, 2004, AM J PREV MED, V27, P379, DOI 10.1016/j.amepre.2004.08.007; Siegel CD, 1996, ARCH PEDIAT ADOL MED, V150, P1077, DOI 10.1001/archpedi.1996.02170350079014; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; SMITH JAS, 1991, CHILD ABUSE NEGLECT, V15, P437, DOI 10.1016/0145-2134(91)90027-B; Spencer N, 2005, PEDIATRICS, V116, P609, DOI 10.1542/peds.2004-1882; SPIVEY MI, 2008, J EMERGENCY MED; STRAIT RT, 1995, PEDIATRICS, V96, P667; Thyen U, 1997, CHILD ABUSE NEGLECT, V21, P187, DOI 10.1016/S0145-2134(96)00144-5; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Trokel M, 2004, CHILD MALTREATMENT, V9, P111, DOI 10.1177/1077559503260310; Truman Thomas L, 2002, Child Maltreat, V7, P138; United Nations, 1990, CONV RIGHTS CHILD; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277; World Health Organization, 2005, CHILD AD INJ PREV GL; World Health Organization, 2006, PREVENTING CHILD MAL	55	48	48	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	NOV	2009	33	11			SI		791	808		10.1016/j.chiabu.2009.08.005			18	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	523FL	WOS:000272057400004	19853915	Green Published			2021-06-18	
J	Sviri, GE; Aaslid, R; Douville, CM; Moore, A; Newell, DW				Sviri, Gill E.; Aaslid, Rune; Douville, Colleen M.; Moore, Anne; Newell, David W.			Time course for autoregulation recovery following severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						brain injury; autoregulation; blood flow; transcranial Doppler ultrasound; outcome	DYNAMIC CEREBRAL AUTOREGULATION; SEVERE HEAD-INJURY; PRACTICAL SCALE; FLOW	Object. The aim of the present study was to evaluate the time course for cerebral autoregulation (AR) recovery following severe traumatic brain injury (TBI) Methods. Thirty-six patients (27 males and 9 females, mean +/- SEM age 33 +/- 15.1 years) with severe TBI underwent serial dynamic AR studies with leg cuff deflation as a stimulus, until recovery of the AR responses was measured. Results. The AR was impaired (AR index < 2.8) in 30 (83%) of 36 patients on Days 3-5 after injury, and in 19 individuals (53%) impairments were found on Days 9-11 after the injury. Nine (25%) of 36 patients exhibited a poor AR response (AR index < 1) on postinjury Days 12-14, which eventually recovered on Days 15-23. Fifty-eight percent of the patients with a Glasgow Coma Scale score of 3-5, 50% of those with diffuse brain injury, 54% of those with elevated intracranial pressure, and 40% of those with poor outcome had no AR recovery in the first 11 days after injury. Conclusions. Autoregulation recovery after severe TBI can be delayed, and failure to recover during the 2nd week after injury occurs mainly in patients with a lower Glasgow Coma Scale score, diffuse brain injury, elevated ICP, or unfavorable outcome. The finding suggests that perfusion pressure management should be considered in some of the patients for a period of at least 2 weeks. (DOI: 10.3171/2008.10.17686)	[Sviri, Gill E.] Technion Israel Inst Technol, Rambam Med Ctr, Dept Neurol Surg, Haifa, Israel; [Aaslid, Rune; Douville, Colleen M.; Moore, Anne; Newell, David W.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Aaslid, Rune; Douville, Colleen M.; Moore, Anne; Newell, David W.] Swedish Neurosci Inst, Seattle, WA USA	Sviri, GE (corresponding author), Technion Israel Inst Technol, Rambam Maimonides Med Ctr, Dept Neurosurg, POB 31096, Haifa, Israel.	sviri@u.washington.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 NS02128-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS002128] Funding Source: NIH RePORTER	This work was supported by Midcareer Investigator Award (NIH Grant No. K24 NS02128-01A1) to Dr. Newell.	Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014	14	48	50	1	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					695	700		10.3171/2008.10.17686			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000011	19392589				2021-06-18	
J	Hosseini, AH; Lifshitz, J				Hosseini, Ario H.; Lifshitz, Jonathan			Brain Injury Forces of Moderate Magnitude Elicit the Fencing Response	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD INJURY; CONCUSSION; SEVERITY; CONCUSSIVE CONVULSION; TONIC POSTURING; ASYMMETRICAL TONIC NECK	DIFFUSE AXONAL INJURY; CONCUSSIVE CONVULSIONS; AGREEMENT STATEMENT; COMA; SPORT; DAMAGE; MODEL	HOSSEINI, A. H., and J. LIFSHITZ. Brain Injury Forces of Moderate Magnitude Elicit the Fencing Response. Med Sci. Sports Exerc., Vol. 41, No. 9, pp. 1687-1697, 2009. Introduction: Traumatic brain injury is heterogeneous, both in its induction and ensuing neurological sequelae. In this way, medical care depends on accurately identifying the severity of injury-related forces. Clinically, injury severity is determined by a combination of the Glasgow Coma Scale, length of unconsciousness, posttraumatic amnesia, and persistence of neurological sequelae. In the laboratory, injury severity is gauged by the biomechanical forces and the acute suppression of neurological reflexes. The present communication describes and validates the "fencing response" as an overt indicator of injury force magnitude and midbrain localization to aid in injury identification and classification. Methods: Using YouTube (TM), the Internet video database, videos were screened for head injury resulting in unconsciousness and documented for the fencing response. Adult male rats were subjected to midline fluid percussion brain injury at two severities, observed for acute neurological reflexes and the midbrain evaluated histopathologically. Results: Tonic posturing (fencing response) has been observed to precede convulsions in sports injuries at the moment of impact, where extension and flexion of opposite arms occurs despite body position or gravity. Of the 35 videos identified by an impact to the head and period of unconsciousness, 66% showed a fencing response at the moment of impact, regardless of the side of impact, without ensuing convulsion. Similarly, diffuse brain-injured rats demonstrate a fencing response upon injury at moderate (1.9 atm, 39/44 animals) but not mild severity (1.1 atm, 0/19 animals). The proximity of the lateral vestibular nucleus to the cerebellar peduncles makes it vulnerable to mechanical forces that initiate a neurochemical storm to elicit the neuromotor response, disrupt the blood-brain barrier, and alter the nuclear volume. Conclusions: Therefore, the fencing response likely indicates neurological disturbance unique from convulsion associated with mechanical forces of moderate magnitude imparted on the midbrain and can assist in guiding medical care after injury.	[Hosseini, Ario H.; Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, B463,BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	jlifshitz@uky.edu			University of Kentucky Chandler Medical Center;  [P30 NINDS-NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	Supported, in part, by the University of Kentucky Chandler Medical Center and P30 NINDS-NS051220. Special thanks to Ms. Amanda M. Lisembee and Ms. Kelley D. Hall for technical assistance. The schematic images of the fencing response were prepared by Mr. Tom Dolan at the Teaching & Academic Support Center, University of Kentucky. The authors thank the reviewers and Dr. Theresa C. Thomas for their constructive comments and suggestions. The results of the present study do not constitute endorsement by the American College of Sports Medicine.	Aghakhani Y, 2004, NEUROLOGY, V62, P2256, DOI 10.1212/WNL.62.12.2256; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Clarke KS, 1998, CLIN SPORT MED, V17, P1, DOI 10.1016/S0278-5919(05)70056-9; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Giza CC, 2001, J ATHL TRAINING, V36, P228; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JENNETT B, 1977, LANCET, V1, P878; JENSEN EBV, 1993, J MICROSC-OXFORD, V170, P35, DOI 10.1111/j.1365-2818.1993.tb03321.x; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P1; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LI VG, 1998, NEUROREPORT, V9, P2539; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LINDSAY KW, 1976, J PHYSIOL-LONDON, V261, P583, DOI 10.1113/jphysiol.1976.sp011575; LUCCARINI P, 1992, ARCH ITAL BIOL, V130, P127; Matsuyama K, 2000, J NEUROPHYSIOL, V84, P2237; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 1999, NEUROLOGY, V52, P1888, DOI 10.1212/WNL.52.9.1888; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; PAXINOS G, 2007, RAT BRAIN STEREOTAXI, P122; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tandrup T, 1997, J MICROSC-OXFORD, V186, P108, DOI 10.1046/j.1365-2818.1997.2070765.x; TEASDALE G, 1974, LANCET, V2, P81; Xiong GX, 2001, EXP BRAIN RES, V141, P204, DOI 10.1007/s002210100867	52	48	48	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2009	41	9					1687	1697		10.1249/MSS.0b013e31819fcd1b			11	Sport Sciences	Sport Sciences	488GU	WOS:000269338200001	19657303				2021-06-18	
J	Moran, LM; Taylor, HG; Ganesalingam, K; Gastier-Foster, JM; Frick, J; Bangert, B; Dietrich, A; Nuss, KE; Rusin, J; Wright, M; Yeates, KO				Moran, Lisa M.; Taylor, H. Gerry; Ganesalingam, Kalaichelvi; Gastier-Foster, Julie M.; Frick, Jessica; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Rusin, Jerome; Wright, Martha; Yeates, Keith O.			Apolipoprotein E4 as a Predictor of Outcomes in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies/Society-of-Pediatric-Research	APR 29-MAY 02, 2006	San Francisco, CA	Pediat Acad Soc, Soc Pediat Res		APO E; neuropsychology; pediatric brain injury	E EPSILON-4 ALLELE; HEAD-INJURY; E GENOTYPE; POSTCONCUSSIVE SYMPTOMS; ALZHEIMERS-DISEASE; E POLYMORPHISM; APOE GENOTYPE; ASSOCIATION; CHILDREN; RECOVERY	The epsilon 4 allele of the apolipoprotein E (APOE) gene has been linked to negative outcomes among adults with traumatic brain injury (TBI) across the spectrum of severity, with preliminary evidence suggesting a similar pattern among children. This study investigated the relationship of the APOE epsilon 4 allele to outcomes in children with mild TBI. Participants in this prospective, longitudinal study included 99 children with mild TBI between the ages of 8 and 15 recruited from consecutive admissions to Emergency Departments at two large children's hospitals. Outcomes were assessed acutely in the Emergency Department and at follow-ups at 2 weeks, 3 months, and 12 months post-injury. Among the 99 participants, 28 had at least one epsilon 4 allele. Children with and without an epsilon 4 allele did not differ demographically. Children with an epsilon 4 allele were significantly more likely than those without an epsilon 4 allele to have a Glasgow Coma Scale score of less than 15, but the groups did not differ on any other measures of injury severity. Those with an epsilon 4 allele exhibited better performance than children without an epsilon 4 allele on a test of constructional skill, but the groups did not differ on any other neuropsychological tests. Children with and without an epsilon 4 allele also did not differ on measures of post-concussive symptoms. Overall, the findings suggest that the APOE epsilon 4 allele is not consistently related to the outcomes of mild TBI in children.	[Yeates, Keith O.] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Moran, Lisa M.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Ganesalingam, Kalaichelvi; Gastier-Foster, Julie M.; Dietrich, Ann; Nuss, Kathryn E.; Yeates, Keith O.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Gastier-Foster, Julie M.; Frick, Jessica] Nationwide Childrens Hosp, Dept Lab Med, Columbus, OH 43205 USA; [Gastier-Foster, Julie M.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Gastier-Foster, Julie/E-3105-2011	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD39834, HD44099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER		*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; AYR LK, 2007, DISS ABSTR INT B, V68, P4121; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BEERY KE, 1989, REVISED ADM SCORING; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Delis D, 1994, MANUAL CALIFORNIA VE; Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Higgins GA, 1997, PHARMACOL BIOCHEM BE, V56, P675, DOI 10.1016/S0091-3057(96)00420-0; JENNETT B, 1975, LANCET, V1, P480; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jofre-Monseny L, 2008, MOL NUTR FOOD RES, V52, P131, DOI 10.1002/mnfr.200700322; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kuroda MM, 2007, PEDIATRICS, V119, P306, DOI 10.1542/peds.2006-1083; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MITTENBERG W, 1997, CLIN NEUROPSYCHOL, V11, P205; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Quinn TJ, 2004, NEUROPATH APPL NEURO, V30, P569, DOI 10.1111/j.1365-2990.2004.00581.x; SAHAKIAN BJ, 1992, J ROY SOC MED, V85, P399; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; World Health Organization, 1992, ICD 10 CLASS MENT BE; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	49	48	48	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1489	1495		10.1089/neu.2008.0767			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200006	19645623	Green Published			2021-06-18	
J	White, CL; Griffith, S; Caron, JL				White, Carole L.; Griffith, Stephen; Caron, Jean-Louis			Early Progression of Traumatic Cerebral Contusions: Characterization and Risk Factors	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	40th Annual Meeting of the Canadian-Congress-of-Neurological-Sciences	JUN 14-18, 2005	Ottawa, CANADA	Canadian Congress Neurolog Sci		Traumatic brain injury; Intracerebral hematoma; Progressive hemorrhagic injury; Outcomes; Coagulopathy	BRAIN-INJURY; HEAD-INJURY; COMPUTED-TOMOGRAPHY; HEMORRHAGE; COAGULOPATHY; PREDICTORS; LESIONS	Background: Traumatic intracerebral contusions carry a high rate of early progression and are associated with morbidity and mortality. Our objectives were to better characterize the prevalence of progression of traumatic contusions, risk factors, and the association with outcome. Methods: Participants were 46 patients with traumatic intracerebral contusion who underwent a repeat computed tomography (CT) scan within 24 hours of injury. Hemorrhage volume on the CT scan was quantified using the ABC/2 technique. Univarite and multivariate statistics were used to define growth (percentage increase and absolute volume increase), to examine the relationship between the risk factors of interest and hemorrhage expansion, and with neurologic function and discharge destination. Results: Sixty-five percent of the patients experienced progression in the size of the lesion in the initial 24 hours postinjury. The international normalized ratio was significantly higher in the group that demonstrated progression. Deterioration on the Glasgow Coma Score was associated with a threefold risk of hemorrhage expansion being found on the CT as defined by percentage increase (odds ratio [OR] = 3.43; 95% confidence interval [CI]: 0.90 to 13.10) and similarly when defined as absolute increase in volume (OR = 3.32; 95% CI: 0.96 to 11.41). Controlling for injury severity, there was an association between hemorrhage growth and death with those displaying progression more likely to die during hospitalization (OR = 1.08; 95% CI: 0,97 to 1.20). Conclusion: A high proportion of intraccrebral contusions evolve in size very early in the postinjury period and are associated with negative outcomes. There is still not a proven therapy for limiting the expansion although the association of an elevated international normalized ratio with expansion suggests that coagulation abnormalities must be actively corrected.	[Griffith, Stephen; Caron, Jean-Louis] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA; [White, Carole L.; Caron, Jean-Louis] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA	Caron, JL (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr,MC 7843, San Antonio, TX 78229 USA.	caron@uthscsa.edu					Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	32	48	54	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2009	67	3					508	514		10.1097/TA.0b013e3181b2519f			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	493IL	WOS:000269729900013	19741392				2021-06-18	
J	Hill, JJ; Mobo, BHP; Cullen, MR				Hill, James J., III; Mobo, Ben Hur P., Jr.; Cullen, Mark R.			Separating Deployment-Related Traumatic Brain Injury and Posttraumatic Stress Disorder in Veterans Preliminary Findings from the Veterans Affairs Traumatic Brain Injury Screening Program	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Academic-Physiatrists	FEB 24-28, 2009	Colorado Springs, CO	Assoc Acad Physiatrists		Military Personnel; Veterans Disability Claims; Disability Evaluation; Closed Head Injuries; Brain Injuries; Brain Concussion	IRAQ; AFGHANISTAN	Objective: Traumatic brain injury in returning Iraq and Afghanistan combat veterans has been the subject of numerous articles by the popular press and congressional inquires. Recent research has questioned the accuracy of the traumatic brain injury diagnosis in veterans with depression and/or posttraumatic stress disorder and the validity of the Veterans Affairs traumatic brain injury screening tool to identify traumatic brain injury in returning combat veterans. Design: Medical records of all combat veterans in the Veterans Affairs Connecticut Healthcare System who both screened positive for traumatic brain injury and received clinical evaluation for traumatic brain injury during the first year of the Veterans Affairs traumatic brain injury screening program were reviewed to explore the relationship between posttraumatic stress disorder and self-reported symptoms attributed to deployment-related traumatic brain injury. Results: Ninety-four combat veterans identified from positive traumatic brain injury screens were seen in the Veterans Affairs Connecticut Healthcare System from April 1, 2007, to March 30, 2008. Eighty-five percent of the veterans with positive screens met the American Congress of Rehabilitation Medicine definition of probable traumatic brain injury, Symptom reporting was similar for veterans with and without a history of traumatic brain injury. Veterans with both posttraumatic stress disorder and traumatic brain injury were more likely to report falling as a mechanism of injury and indicated that they had suffered a head injury during deployment (P <= 0.10). Veterans with both posttraumatic stress disorder and traumatic brain injury reported more exposures and symptoms compared with veterans with a history of traumatic brain injury. Conclusions: Veterans who screen positive for mild traumatic brain injury by the Veterans Affairs traumatic brain injury screening tool have high rates of posttraumatic stress disorder, which suggests that interdisciplinary rehabilitation teams need to include mental health professionals with expertise in posttraumatic stress disorder. Because both traumatic brain injury and posttraumatic stress disorder are defined in, part, by the same events and the same self-reported symptoms, the Veterans Affairs traumatic brain injury screening tool does not distinguish between these two commonly reported diagnoses in Operation Enduring Freedom/Operation Iraqi Freedom combat veterans.	[Hill, James J., III; Mobo, Ben Hur P., Jr.; Cullen, Mark R.] Yale Univ, Sch Med, Yale Occupat & Environm Med Program, New Haven, CT 06510 USA; [Cullen, Mark R.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Cullen, Mark R.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; [Hill, James J., III; Mobo, Ben Hur P., Jr.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA	Hill, JJ (corresponding author), Yale Univ, Sch Med, Yale Occupat & Environm Med Program, 135 Coll St,3rd Floor, New Haven, CT 06510 USA.			cullen, mark/0000-0001-7996-1864; Hill 3rd, James/0000-0001-9504-0993			Centers for Disease Control & Prevention, 2003, MMWR MORB MORTAL WKL, V52; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; *CONGR RES SERV, US MIL CAS STAT OP I; *DOD HLTH CAR, 2008, GAO08615 DOD HLTH CA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2009, LONG TERM CONS TRAUM, V7; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LeonCarrion J, 2006, STUD NEUROPSYCH DEV, P1; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tanielian T, 2008, INVISIBLE WOUNDS WAR; *US GOV ACC OFF, 2008, GAO08276; Vanderploeg RD, 2004, VETERANS HLTH INITIA; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1991, PCL M DSM 4	16	48	49	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2009	88	8					605	614		10.1097/PHM.0b013e3181ae0f83			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	476VW	WOS:000268475400001	19620825				2021-06-18	
J	Blake, H; Batson, M				Blake, H.; Batson, M.			Exercise intervention in brain injury: a pilot randomized study of Tai Chi Qigong	CLINICAL REHABILITATION			English	Article							SELF-DESCRIPTION QUESTIONNAIRE; PHYSICAL-ACTIVITY; SOCIAL SUPPORT; INDIVIDUALS; BEHAVIORS; PROGRAM; REHABILITATION; AQUATICS; OUTCOMES; BALANCE	Objective: To examine the effects of a brief Tai Chi Chuan Qigong ('Qigong') exercise intervention on individuals with traumatic brain injury. Design: A single-centre randomized controlled trial pilot study. Setting: A registered charity day centre in the community. Subjects: Twenty individuals with traumatic brain injury. Intervention: Intervention participants attended a Qigong exercise session for one hour per week over eight weeks. Control participants engaged in non-exercise-based social and leisure activities for the same intervention period. Measures: Outcome was assessed at baseline and post intervention using the General Health Questionnaire-12, the Physical Self-Description Questionnaire and the Social Support for Exercise Habits Scale, to measure perceived mood, self-esteem, flexibility, coordination, physical activity and social support. Results: Groups were comparable at baseline. After the intervention, mood was improved in the exercise group when compared with controls (U = 22.0, P = 0.02). Improvements in self-esteem (Z = 2.397, P = 0.01) and mood (Z = - 2.032, P = 0.04) across the study period were also evident in the exercise group only. There were no significant differences in physical functioning between groups. In view of the sample size, these findings are inconclusive. Conclusions: This study provides preliminary evidence that a brief Qigong exercise intervention programme may improve mood and self-esteem for individuals with traumatic brain injury. This needs to be tested in a large-scale randomized trial.	[Blake, H.] Univ Nottingham, Sch Nursing Midwifery & Physiotherapy, Queens Med Ctr, Fac Med & Hlth Sci, Nottingham NG7 2AH, England; [Batson, M.] Univ Nottingham, Inst Work Hlth & Org, Nottingham NG7 2RD, England	Blake, H (corresponding author), Univ Nottingham, Sch Nursing Midwifery & Physiotherapy, Queens Med Ctr, Fac Med & Hlth Sci, Nottingham NG7 2AH, England.	Holly.Blake@nottingham.ac.uk			Headway House, Nottingham	The Qigong intervention was funded by Headway House, Nottingham.	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bhambhani Y, 2005, ARCH PHYS MED REHAB, V86, P268, DOI 10.1016/j.apmr.2004.04.022; Blake H, 2008, INT J THER REHABIL, V15, P180, DOI 10.12968/ijtr.2008.15.4.29037; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dault MC, 2002, BRAIN INJURY, V16, P231, DOI 10.1080/02699050110103300; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Driver S, 2005, BRAIN INJURY, V19, P1067, DOI 10.1080/02699050500149338; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Dupoy M, 2002, J I AGEING HLTH, V8, P17; Durstine JL, 2000, SPORTS MED, V30, P207, DOI 10.2165/00007256-200030030-00005; Gemmell C, 2006, BRAIN INJURY, V20, P151, DOI 10.1080/02699050500442998; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Goldberg D, GEN HLTH QUESTIONNAI; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Hardy GE, 1999, PSYCHOL ASSESSMENT, V11, P159, DOI 10.1037/1040-3590.11.2.159; Hassett LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006123.pub2; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Jackson D, 2001, CLIN REHABIL, V15, P535, DOI 10.1191/026921501680425252; Jarmey C., 2003, THEORY PRACTICE TAIJ; MARSH HW, 1994, J SPORT EXERCISE PSY, V16, P270, DOI 10.1123/jsep.16.3.270; Marsh HW, 1996, RES Q EXERCISE SPORT, V67, P249, DOI 10.1080/02701367.1996.10607952; MCAULEY E, 1994, J SPORT EXERCISE PSY, V16, P45; Mills N., 2000, J BODYW MOV THER, V4, P39, DOI DOI 10.1054/JBMT.1999.0139; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; POWELL KE, 1994, MED SCI SPORT EXER, V26, P851; Rimmer JH, 1999, PHYS THER, V79, P495, DOI 10.1093/ptj/79.5.495; SALLIS JF, 1987, PREV MED, V16, P825, DOI 10.1016/0091-7435(87)90022-3; Shapira MY, 2001, ARCH PHYS MED REHAB, V82, P1283, DOI 10.1053/apmr.2001.25152; Tsang HWH, 2008, J HEALTH PSYCHOL, V13, P857, DOI 10.1177/1359105308095057; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493	31	48	51	0	27	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JUL	2009	23	7					589	598		10.1177/0269215508101736			10	Rehabilitation	Rehabilitation	472ZE	WOS:000268171400002	19237436	Green Accepted			2021-06-18	
J	Wade, SL; Oberjohn, K; Burkhardt, A; Greenberg, I				Wade, Shari L.; Oberjohn, Karen; Burkhardt, Abby; Greenberg, Ira			Feasibility and Preliminary Efficacy of a Web-Based Parenting Skills Program for Young Children With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; intervention; online; parenting skills; telehealth; treatment	PSYCHIATRIC-DISORDERS; INTERACTION THERAPY; UNITED-STATES; BEHAVIOR; ADOLESCENTS; REHABILITATION; RESPONSIVENESS; ADAPTATION; PREVALENCE; PREDICTORS	Objective: To report the feasibility and preliminary efficacy of a Web-based parenting skills program to reduce behavior problems following traumatic brain Injury (TBI) in young children. Methods: Families of 9 children between the ages of 3 and 8 years with TBI, injured less than 24 months earlier, participated in a pilot study of a Web-based parenting skills program designed to increase positive parenting skills and to improve caregiver stress management and coping. The program consisted of 10 core sessions and up to 4 supplemental sessions. Each session consisted of self-guided didactic information, video modeling skills, and exercises. Online sessions were followed by synchronous sessions providing in vivo coaching of target skills. Results: Caregivers completed an average of 12 sessions (range 5-24). Ratings of ease of use and satisfaction were high. Paired t tests revealed significant improvements in target parenting behaviors between baseline and session 2 and between sessions 2 and 4. These improvements were maintained at follow-up. Among the 5 families who completed the follow-up assessment, there were trends for reductions in the overall number of behavior problems. Conclusions: This study provides preliminary evidence of the potential feasibility and efficacy of an online parenting skills intervention for improving positive parenting skills and for reducing child behavior problems following early TBI.	[Wade, Shari L.] Univ Cincinnati, Med Ctr, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp,Coll Med, Cincinnati, OH 45229 USA; [Greenberg, Ira] Miami Univ, Oxford, OH 45056 USA	Wade, SL (corresponding author), Univ Cincinnati, Med Ctr, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			National Institute of Disability and Rehabilitation Research	This project was supported by a Field-initiated research grant from the National Institute of Disability and Rehabilitation Research (Dr Wade). The authors acknowledge the contributions of Erna Olafson, PhD; Erica Pearl, Psyl); and Christopher Kaeponer PhD, in the development and refinement of the intervention materials. Also the authors acknowledge the assistance of Taulina Osinska and Tara Lane in data coding and entry. Results reported in this article were presented in part at the 2 0 0 8 meeting of the Society for Computers in Psychology in Chicago, Illinois.	Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BOGGS SR, 1990, J CLIN CHILD PSYCHOL, V19, P75, DOI 10.1207/s15374424jccp1901_9; Bradley RH, 2007, DEV PSYCHOL, V43, P1390, DOI 10.1037/0012-1649.43.6.1390; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Burns G. L., 1991, PSYCHOL ASSESSMENT J, V3, P202, DOI [10.1037/1040-3590.3.2.202, DOI 10.1037/1040-3590.3.2.202]; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; Eyberg S., 1988, CHILD FAM BEHAV THER, V10, P33, DOI [DOI 10.1300/J019V10N01_04, 10.1300/J019v10n01_04]; Eyberg S.M., 2005, MANUAL DYADIC PARENT, V3rd ed; EYBERG SM, 1995, PSYCHOPHARMACOL BULL, V31, P83; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Harwood MD, 2004, J CLIN CHILD ADOLESC, V33, P601, DOI 10.1207/s15374424jccp3303_17; Harwood MD, 2006, J ABNORM CHILD PSYCH, V34, P335, DOI 10.1007/s10802-006-9025-z; Kerr C, 2006, J MED INTERNET RES, V8, DOI 10.2196/jmir.8.3.e13; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; ROTHBAUM F, 1994, PSYCHOL BULL, V116, P55, DOI 10.1037/0033-2909.116.1.55; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Smith KE, 2006, PEDIATRICS, V117, P1608, DOI 10.1542/peds.2005-1284; Steelman LM, 2002, J APPL DEV PSYCHOL, V23, P135, DOI 10.1016/S0193-3973(02)00101-6; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	37	48	48	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					239	247		10.1097/HTR.0b013e3181ad6680			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000003	19625863				2021-06-18	
J	Dennis, AM; Haselkorn, ML; Vagni, VA; Garman, RH; Janesko-Feldman, K; Bayir, H; Clark, RSB; Jenkins, LW; Dixon, CE; Kochanek, PM				Dennis, Alia Marie; Haselkorn, M. Lee; Vagni, Vincent A.; Garman, Robert H.; Janesko-Feldman, Keri; Bayir, Huelya; Clark, Robert S. B.; Jenkins, Larry W.; Dixon, C. Edward; Kochanek, Patrick M.			Hemorrhagic Shock after Experimental Traumatic Brain Injury in Mice: Effect on Neuronal Death	JOURNAL OF NEUROTRAUMA			English	Article						blast; controlled cortical impact; delayed neuronal death; hippocampus; hypotension; mouse; polytrauma; resuscitation; secondary insult; selective vulnerability	CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; ENERGY PHOSPHATE-METABOLISM; NITRIC-OXIDE SYNTHASE; HEAD-INJURY; INTRACRANIAL-PRESSURE; RATS; RESUSCITATION; HYPOTENSION; MILD	Traumatic brain injury (TBI) from blast injury is often complicated by hemorrhagic shock (HS) in victims of terrorist attacks. Most studies of HS after experimental TBI have focused on intracranial pressure; few have explored the effect of HS on neuronal death after TBI, and none have been done in mice. We hypothesized that neuronal death in CA1 hippocampus would be exacerbated by HS after experimental TBI. C57BL6J male mice were anesthetized with isoflurane, mean arterial blood pressure (MAP) was monitored, and controlled cortical impact (CCI) delivered to the left parietal cortex followed by continued anesthesia (CCI-only), or either 60 or 90 min of volume-controlled HS. Parallel 60- or 90-min HS-only groups were also studied. After HS (+/-CCI), 6% hetastarch was used targeting MAP of >= 50 mm Hg during a 30-min Pre-Hospital resuscitation phase. Then, shed blood was re-infused, and hetastarch was given targeting MAP of >= 60 mm Hg during a 30-min Definitive Care phase. Neurological injury was evaluated at 24 h (fluorojade C) or 7 days (CA1 and CA3 hippocampal neuron counts). HS reduced MAP to 30-40 mm Hg in all groups, p < 0.05 versus CCI-only. Ipsilateral CA1 neuron counts in the 90-min CCI + HS group were reduced at 16.5 +/- 14.1 versus 30.8 +/- 6.8, 32.3 +/- 7.6, 30.6 +/- 2.2, 28.1 +/- 2.2 neurons/100 mu m in CCI-only, 60-min HS-only, 90-min HS-only, and 60-min CCI + HS, respectively, all p < 0.05. CA3 neuron counts did not differ between groups. Fluorojade C staining confirmed neurodegeneration in CA1 in the 90-min CCI + HS group. Our data suggest a critical time window for exacerbation of neuronal death by HS after CCI and may have implications for blast injury victims in austere environments where definitive management is delayed.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Jenkins, Larry W.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Garman, Robert H.] Vet Pathol Inc, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; , Alia Marie/0000-0003-3158-7943	United States ArmyUnited States Department of Defense [PR054755 W81XWH-06-01-0247]; National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-38087 NS-30318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, R01NS038087, P01NS030318] Funding Source: NIH RePORTER	We thank Marci Provins and Fran Mistrick for preparation of the manuscript. We thank the United States Army (grant PR054755 W81XWH-06-01-0247) and the National Institutes of Neurological Disorders and Stroke (grants NS-38087 NS-30318 to P. M. K.) for support.	BARRON KD, 1988, ACTA NEUROPATHOL, V75, P295, DOI 10.1007/BF00690538; Barzo P, 1997, ACT NEUR S, V70, P243; Bedell EA, 1998, J NEUROTRAUM, V15, P985, DOI 10.1089/neu.1998.15.985; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Dennis AM, 2006, CRIT CARE MED, V34, pA5, DOI 10.1097/00003246-200612002-00017; DeWitt D S, 1995, New Horiz, V3, P376; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Holcomb JB, 2003, J TRAUMA, V54, pS46, DOI 10.1097/01.TA.0000051936.91915.A2; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mahoney EJ, 2003, J TRAUMA, V55, P1065, DOI 10.1097/01.TA.0000100381.89107.93; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MYERS SI, 1994, J APPL PHYSIOL, V76, P2304; NELSON LR, 1979, NEURAL TRAUMA, P297; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; Siesjo BK, 1978, BRAIN ENERGY METABOL, P398; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; VATNER SF, 1974, J CLIN INVEST, V54, P225, DOI 10.1172/JCI107757; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305	52	48	50	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					889	899		10.1089/neu.2008.0512			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600007	18781889	Green Published, Green Accepted			2021-06-18	
J	Howard, JL; Cipolle, MD; Horvat, SA; Sabella, VM; Reed, JF; Fulda, G; Tinkoff, G; Pasquale, MD				Howard, Jerry Lee, II; Cipolle, Mark D.; Horvat, Sarah A.; Sabella, Victoria M.; Reed, James F., III; Fulda, Gerard; Tinkoff, Glen; Pasquale, Michael D.			Preinjury Warfarin Worsens Outcome in Elderly Patients Who Fall From Standing	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		CT scan; Elderly; Emergency department triage; Fall from standing; INR correction; Mortality; Outcome; Warfarin	INTRACRANIAL HEMORRHAGE; TRAUMA PATIENTS; ANTICOAGULATION; IMPACT; RISK	Introduction. Fall from standing (FFS) has become one of the most common mechanisms of injury for admission to the trauma center in the elderly population. Many of these patients present anticoagulated with warfarin. This two-center study was designed to examine the effects of preinjury warfarin use on outcome in the elderly. Methods A retrospective review of prospectively collected registry data at two Level I trauma centers was conducted from 2003 to 2006. The study population included patients age 2:65 admitted to the trauma center after an FFS. These centers are relatively close geographically and have similar patient demographics. Data collected included: age, Injury Severity Score, Abbreviated Injury Score (AIS) for head, mortality, admission Glasgow Coma Score, and admission international normalized ratio (INR). Patients were divided into two groups based on the preinjury condition of warfarin use. Statistical differences were determined by impaired t test for continuous variables and chi(2) and odds ratios (ORs) for dichotomous variables. Results. Of the 27,812 patients admitted to these two trauma centers over this time period, 2,791 (10.0%) were of age >= 65 and admitted after an FFS. INR was 2.8 +/- 1.1 in warfarin group (+warf). The number of patients with AIS head 4 and 5 was similar between groups (-warf 22.1 %, +warf 25.9%). Overall, preinjury warfarin use bad a negative effect on the in-hospital mortality rate, +warf 8.6% and -warf 5.7% (OR 1.54,1.09-2.19, p = 0.015). There was no difference in mortality between groups in patients with an AIS head <4. The negative impact of preinjury warfarin use on mortality was most pronounced in patients with an AIS head 4 and 5 who presented awake (Glasgow Coma Score 14 and 15), + warf 13.5 % and -warf 6.4% (OR 2.30, 95% confidence interval 1.12-4.70,p = 0.019). Conclusion. Preinjury warfarin use has an adverse effect on outcome (mortality) in elderly FFS patients. Importantly, this effect is most prominent in patients admitted awake with significant findings on computed tomography scan. This argues for rapid emergency department triage to computed tomography scan and rapid INR correction in this population.	[Howard, Jerry Lee, II; Horvat, Sarah A.; Sabella, Victoria M.; Pasquale, Michael D.] Lehigh Valley Hlth Network, Dept Surg, Div Trauma Surg Crit Care, Allentown, PA 18105 USA; [Cipolle, Mark D.; Reed, James F., III; Fulda, Gerard; Tinkoff, Glen] Christiana Care Hlth Syst, Dept Surg, Div Trauma Surg Crit Care, Newark, DE USA	Pasquale, MD (corresponding author), Lehigh Valley Hlth Network, Dept Surg, Div Trauma Surg Crit Care, Cedar Crest & I-78,POB 689, Allentown, PA 18105 USA.	sally.lutz@lvh.com					*AM COLL SURG, 2006, NAT TRAUM DAT NTDB; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cappuzzo Kimberly A, 2005, Consult Pharm, V20, P601, DOI 10.4140/TCP.n.2005.601; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Fleming B, 2001, CAN FAM PHYSICIAN, V47, P727; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Garvin R, 2006, J FAM PRACTICE, V55, P157; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Kalina M, 2008, AM SURGEON, V74, P858; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Saab M, 1996, J ACCID EMERG MED, V13, P208; Singer DE, 2004, CHEST, V126, p429S, DOI 10.1378/chest.126.3_suppl.429S; Wellman M, 1999, J Fam Pract, V48, P498; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	23	48	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1518	1524		10.1097/TA.0b013e3181a59728			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	457PN	WOS:000266944500002	19509609				2021-06-18	
J	Bao, F; Bailey, CS; Gurr, KR; Bailey, SI; Rosas-Arellano, MP; Dekaban, GA; Weaver, LC				Bao, Feng; Bailey, Christopher S.; Gurr, Kevin R.; Bailey, Stewart I.; Rosas-Arellano, M. Patricia; Dekaban, Gregory A.; Weaver, Lynne C.			Increased oxidative activity in human blood neutrophils and monocytes after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Inflammation; Oxidative damage; Neutrophil; Macrophage; Oxidative enzyme; Trauma	MULTIPLE ORGAN FAILURE; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; BRAIN-INJURY; POLYMORPHONUCLEAR NEUTROPHILS; LEUKOCYTE MOBILIZATION; INFLAMMATORY RESPONSE; SUPEROXIDE-PRODUCTION; RATS; TRAUMA	Traumatic injury can cause a systemic inflammatory response, increasing oxidative activity of circulating leukocytes and potentially exacerbating the original injury, as well as causing damage to initially unaffected organs. Although the importance of intraspinal inflammation after human spinal cord injury is appreciated, the role of the systemic inflammatory response to this injury is not widely recognised. We investigated oxidative activity of blood leukocytes from nine cord-injured subjects and six trauma controls (bone fractures without CNS injury) at 6 h-2 weeks after injury, comparing values to those of ten uninjured Subjects. Neutrophil and monocyte free radical production, evaluated by flow cytometry, increased significantly more in cord injury subjects than in trauma controls (6-fold vs 50% increases). In leukocyte homogenates, the concentration of free radicals increased significantly more in cord injury subjects (2-fold) than in the trauma controls (1.6-fold) as did activity of myeloperoxidase (2.3-fold vs. 1.7-fold). Moreover, in homogenates and blood smears, expression of the NADPH oxidase subunit gp91(phox) and of the oxidative enzyme, inducible nitric oxide synthetase was 20-25% greater in cord injury subjects than in trauma controls. Expression of the pro-inflarnmatory transcription factor NF-kappa B and of cyclooxygenase-2 increased similarly after both injuries. Finally, aldehyde products of tissue-damaging lipid peroxidation also increased significantly more in the plasma of spinal cord injury subjects than in trauma controls (2.6 fold vs. 1.9-fold). Spinal cord injury causes a particularly intense systemic inflammatory response. Limiting this response briefly after cord injury should protect the spinal cord and tissues/organs outside the CNS from secondary damage. (c) 2008 Elsevier Inc. All rights reserved.	[Bao, Feng; Dekaban, Gregory A.; Weaver, Lynne C.] Univ Western Ontario, Schulich Sch Med & Dent, Robarts Res Inst, Spinal Cord Injury Team,BioTherapeut Res Grp, London, ON N6A 5K8, Canada; [Bailey, Christopher S.; Gurr, Kevin R.; Bailey, Stewart I.; Rosas-Arellano, M. Patricia] Univ Western Ontario, London Hlth Sci Ctr, Div Orthopaed Surg, London, ON N6A 5K8, Canada	Weaver, LC (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Robarts Res Inst, Spinal Cord Injury Team,BioTherapeut Res Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.	lcweaver@robarts.ca	Bailey, Chris S/L-7522-2015; Weaver, Lynne C/K-8491-2013; Dekaban, Gregory A./L-1987-2013	Bailey, Chris S/0000-0001-5508-8415; Dekaban, Gregory A./0000-0002-3087-4660	New Emerging Team grant from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [RMN63187]	We especially thank all of the volunteers and patients for contributing to this study. We appreciate that the SCI and trauma subjects made the decision to contribute to this research, and permitted the blood samples to be drawn, under circumstances when their own personal needs were very great. We also thank all of the fellows, nurses and staff at the University Health Sciences Centre Victoria Hospital Campus and Robarts Research Institute who facilitated our work by coordinating the timely acquisition and transport of samples to our laboratory. We appreciate the advice of our flow cytometry manager, Dr. Kristin Chadwick, assistance with the assays by summer student Ms. Maria Pineda, and data preparation by Ms. Eilis Hamilton. The authors appreciate the constructive critique of the manuscript by Dr. Canio Polosa. This research was funded by a New Emerging Team grant from the Canadian Institutes of Health Research (RMN63187).	BAKSHI R, 1990, J NEUROSCI, V10, P3793; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Baskaran H, 2000, J SURG RES, V93, P88, DOI 10.1006/jsre.2000.5955; Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Botha AJ, 1996, BRIT J SURG, V83, P1407, DOI 10.1002/bjs.1800831027; Brandt E, 2000, J LEUKOCYTE BIOL, V68, P125; Campagnolo DI, 1997, AM J PHYS MED REHAB, V76, P276, DOI 10.1097/00002060-199707000-00005; Campbell SJ, 2008, J NEUROPATH EXP NEUR, V67, P223, DOI 10.1097/NEN.0b013e3181654957; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; CASSATELLA MA, 1995, EUR J IMMUNOL, V25, P1, DOI 10.1002/eji.1830250102; Cruse J M, 2000, J Spinal Cord Med, V23, P129; CRUSE JM, 1992, IMMUNOL RES, V11, P104, DOI 10.1007/BF02918615; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; GAY JC, 1984, BLOOD, V64, P780; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Maiorov DN, 1997, AM J PHYSIOL-HEART C, V272, pH625; MATHIAS CJ, 1975, CLIN SCI MOL MED, V49, P291, DOI 10.1042/cs0490291; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Menzebach A, 2003, BRIT J ANAESTH, V91, P546, DOI 10.1093/bja/aeg219; MOORE EE, 1994, J TRAUMA, V37, P881, DOI 10.1097/00005373-199412000-00002; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Riegger T, 2007, EUR J NEUROSCI, V25, P1743, DOI 10.1111/j.1460-9568.2007.05447.x; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Shih HC, 1999, AM J EMERG MED, V17, P15, DOI 10.1016/S0735-6757(99)90005-0; Sokal R.R., 1981, BIOMETRY PRINCIPLES; Sunil VR, 2002, RESP RES, V3, DOI 10.1186/rr171; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; TANAKA H, 1991, ANN SURG, V214, P187, DOI 10.1097/00000658-199108000-00014; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Trabold B, 2007, SCAND CARDIOVASC J, V41, P59, DOI 10.1080/14017430601085948; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	42	48	50	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2009	215	2					308	316		10.1016/j.expneurol.2008.10.022			9	Neurosciences	Neurosciences & Neurology	400TG	WOS:000262890900013	19056384				2021-06-18	
J	Giza, CC; Kolb, B; Harris, NG; Asarnow, RF; Prins, ML				Giza, Christopher C.; Kolb, Bryan; Harris, Neil G.; Asarnow, Robert F.; Prins, Mayumi L.			Hitting a moving target: Basic mechanisms of recovery from acquired developmental brain injury	DEVELOPMENTAL NEUROREHABILITATION			English	Article						experience-dependent plasticity; environmental; age; pediatric; child	CHONDROITIN SULFATE PROTEOGLYCANS; FLUID PERCUSSION INJURY; CEREBRAL HYPOXIA-ISCHEMIA; AGE-DEPENDENT DIFFERENCES; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; CLOSED-HEAD-INJURY; RAT-BRAIN; FUNCTIONAL RECOVERY; ENVIRONMENTAL ENRICHMENT	Acquired brain injuries represent a major cause of disability in the pediatric population. Understanding responses to developmental acquired brain injuries requires knowledge of the neurobiology of normal development, age-at-injury effects and experience-dependent neuroplasticity. In the developing brain, full recovery cannot be considered as a return to the premorbid baseline, since ongoing maturation means that cerebral functioning in normal individuals will continue to advance. Thus, the recovering immature brain has to 'hit a moving target' to achieve full functional recovery, defined as parity with age-matched uninjured peers. This review will discuss the consequences of developmental injuries such as focal lesions, diffuse hypoxia and traumatic brain injury (TBI). Underlying cellular and physiological mechanisms relevant to age-at-injury effects will be described in considerable detail, including but not limited to alterations in neurotransmission, connectivity/network functioning, the extracellular matrix, response to oxidative stress and changes in cerebral metabolism. Finally, mechanisms of experience-dependent plasticity will be reviewed in conjunction with their effects on neural repair and recovery.	[Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Mattel Childrens Hosp UCLA, Div Pediat Neurol, Los Angeles, CA USA; [Kolb, Bryan] Univ Lethbridge, Dept Neurosci, Lethbridge, AB T1K 3M4, Canada; [Asarnow, Robert F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	Giza, CC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Room 18-218B Semel Inst,10833 Le Conte Blvd, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739; Harris, Neil/0000-0002-1965-6750	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057420, NS027544, NS052406, NS055910]; Child Neurology Foundation/Winokur Family Foundation; UCLA FGP; Thrasher Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910, R01NS027544, K02NS057420, R01NS052406] Funding Source: NIH RePORTER	Supported by grants from the National Institutes of Health (C. C. G. NS057420, NS027544, M. L. P. NS052406, N.G.H. NS055910), the Child Neurology Foundation/Winokur Family Foundation (C. C. G.), UCLA FGP (C. C. G., M. L. P.) and the Thrasher Research Foundation (C.C.G.).	Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; ASPBERG A, 1992, DEV BRAIN RES, V66, P55, DOI 10.1016/0165-3806(92)90139-N; Aya-ay J, 2005, EXP NEUROL, V193, P149, DOI 10.1016/j.expneurol.2004.11.021; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bavelier D, 2006, TRENDS COGN SCI, V10, P512, DOI 10.1016/j.tics.2006.09.006; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; BERKER EA, 1986, ARCH NEUROL-CHICAGO, V43, P1065, DOI 10.1001/archneur.1986.00520100069017; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Branchi I, 2004, BEHAV PHARMACOL, V15, P353, DOI 10.1097/00008877-200409000-00006; Bredy TW, 2003, EUR J NEUROSCI, V18, P2903, DOI 10.1111/j.1460-9568.2003.02965.x; Broca P, 1865, B SOC ANTHR BMSAP, V6, P377; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; CHIRON C, 1992, J NUCL MED, V33, P696; Chou IC, 2001, STROKE, V32, P2192, DOI 10.1161/hs0901.095656; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cirulli F, 2003, NEUROSCI BIOBEHAV R, V27, P73, DOI 10.1016/S0149-7634(03)00010-1; Cirulli F, 2009, NEUROSCI BIOBEHAV R, V33, P573, DOI 10.1016/j.neubiorev.2008.09.001; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Collignon O, 2009, EXP BRAIN RES, V192, P343, DOI 10.1007/s00221-008-1553-z; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CREMER JE, 1976, BIOCHIM BIOPHYS ACTA, V448, P633, DOI 10.1016/0005-2736(76)90120-6; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Curtiss S, 2001, BRAIN LANG, V79, P379, DOI 10.1006/brln.2001.2487; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Danysz W, 1998, PHARMACOL REV, V50, P597; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Dean JM, 2005, MOL BRAIN RES, V139, P242, DOI 10.1016/j.molbrainres.2005.05.026; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIAMOND MC, 1983, EXP NEUROL, V81, P1, DOI 10.1016/0014-4886(83)90153-X; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIAMOND MC, 1975, BEHAV BIOL, V14, P163, DOI 10.1016/S0091-6773(75)90161-3; Dreiem A, 2005, TOXICOL SCI, V87, P156, DOI 10.1093/toxsci/kfi224; Driscoll I, 2007, BRAIN RES, V1178, P38, DOI 10.1016/j.brainres.2007.08.031; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FIELD TM, 1986, PEDIATRICS, V77, P654; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Finger S, 1999, J Hist Neurosci, V8, P269, DOI 10.1076/jhin.8.3.269.1824; Follett PL, 2000, J NEUROSCI, V20, P9235; Fredriksson A, 2004, BEHAV BRAIN RES, V153, P367, DOI 10.1016/j.bbr.2003.12.026; Fumagalli F, 2007, PROG NEUROBIOL, V81, P197, DOI 10.1016/j.pneurobio.2007.01.002; GIBB, 2009, COMMUNICATION; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Gucuyener K, 1999, CLIN NEUROL NEUROSUR, V101, P171, DOI 10.1016/S0303-8467(99)00035-9; GUNN AJ, 2000, CURRENT OPINIONS PED, V12, P115; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HALLIWELL C, 2009, PRENATAL CHOLI UNPUB; HARRIS N, 2009, J NEUROSCIE IN PRESS; Harris N, 2006, J NEUROTRAUM, V23, P1019; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Henderson ST, 2008, NEUROTHERAPEUTICS, V5, P470, DOI 10.1016/j.nurt.2008.05.004; Hotz GA, 2006, BRAIN INJURY, V20, P879, DOI 10.1080/02699050600832635; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; JACOBS B, 1993, J COMP NEUROL, V327, P97, DOI 10.1002/cne.903270108; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Johnston MV, 2004, BRAIN DEV-JPN, V26, P73, DOI 10.1016/S0387-7604(03)00102-5; Johnston MV, 2003, EXP NEUROL, V184, pS37, DOI 10.1016/S0014-4886(03)00355-8; Kaufman J, 2006, BIOL PSYCHIAT, V60, P669, DOI 10.1016/j.biopsych.2006.09.002; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kennard MA, 1943, J NEUROPHYSIOL, V6, P181; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; Kennard MA, 1942, MT SINAI J MED, V9, P594; KENNARD MA, 1940, ARCH NEUROLOGY PSYCH, V48, P227; Kolb B, 1996, BEHAV BRAIN RES, V79, P1, DOI 10.1016/0166-4328(95)00254-5; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; Kolb B, 2003, NEUROBIOL LEARN MEM, V79, P1, DOI 10.1016/S1074-7427(02)00021-7; Kolb B, 1997, BEHAV BRAIN RES, V89, P61, DOI 10.1016/S0166-4328(97)00058-2; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; KOLB B, 2009, TACTILE STIMUL UNPUB; Koppe G, 1997, CELL TISSUE RES, V288, P33, DOI 10.1007/s004410050790; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lander C, 1997, J NEUROSCI, V17, P1928; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Law AJ, 2003, EUR J NEUROSCI, V18, P1197, DOI 10.1046/j.1460-9568.2003.02850.x; LEONG SF, 1984, BIOCHEM J, V218, P131, DOI 10.1042/bj2180131; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lewis TL, 2005, DEV PSYCHOBIOL, V46, P163, DOI 10.1002/dev.20055; Liu D, 2000, NAT NEUROSCI, V3, P799; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Manning SM, 2008, J NEUROSCI, V28, P6670, DOI 10.1523/JNEUROSCI.1702-08.2008; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Marsh EB, 2009, CORTEX, V45, P677, DOI 10.1016/j.cortex.2008.06.012; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matsui F, 2005, J NEUROSCI RES, V81, P837, DOI 10.1002/jnr.20603; MAVELLI I, 1982, BIOCHEM J, V204, P535, DOI 10.1042/bj2040535; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald J W, 1993, NIDA Res Monogr, V133, P185; McLean C, 2004, SEMIN PERINATOL, V28, P425, DOI 10.1053/j.semperi.2004.10.005; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; MILLER B, 1995, J COMP NEUROL, V355, P615, DOI 10.1002/cne.903550410; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Monfils MH, 2008, EXP BRAIN RES, V185, P453, DOI 10.1007/s00221-007-1172-0; Monfils MH, 2006, EUR J NEUROSCI, V24, P739, DOI 10.1111/j.1460-9568.2006.04939.x; Monfils MH, 2005, NEUROSCIENCE, V134, P1, DOI 10.1016/j.neuroscience.2005.04.006; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NEDERGAARD M, 1987, Neurological Research, V9, P241; NEHLIG A, 1991, NEUROSCIENCE, V40, P871, DOI 10.1016/0306-4522(91)90018-J; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NEHLIG A, 1987, NEUROCHEM RES, V12, P641, DOI 10.1007/BF00971014; Okamoto M, 2003, EXP NEUROL, V184, P179, DOI 10.1016/S0014-4886(03)00251-6; Okamoto M, 2001, CELL TISSUE RES, V306, P217, DOI 10.1007/s004410100441; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Prakash A, 2008, CURR OPIN ANESTHESIO, V21, P565, DOI 10.1097/ACO.0b013e32830f44e4; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Ptito M, 2008, EXP BRAIN RES, V184, P193, DOI 10.1007/s00221-007-1091-0; Pu YL, 2000, AM J NEURORADIOL, V21, P203; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Rho JM, 2001, J CHILD NEUROL, V16, P271, DOI 10.2310/7010.2001.18013; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SCHANBERG SM, 1987, CHILD DEV, V58, P1431, DOI 10.2307/1130683; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; SCHEETZ AJ, 1994, FASEB J, V8, P745; Seyfried Thomas N, 2005, Nutr Metab (Lond), V2, P30, DOI 10.1186/1743-7075-2-30; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Spencer S, 2008, LANCET NEUROL, V7, P525, DOI 10.1016/S1474-4422(08)70109-1; Stefovska VG, 2008, ANN NEUROL, V64, P434, DOI 10.1002/ana.21463; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tang YP, 1999, NATURE, V401, P63; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Towfighi J, 1997, DEV BRAIN RES, V100, P149, DOI 10.1016/S0165-3806(97)00036-9; Trainor LJ, 2005, DEV PSYCHOBIOL, V46, P262, DOI 10.1002/dev.20059; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Tsujimoto S, 2008, NEUROSCIENTIST, V14, P345, DOI 10.1177/1073858408316002; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; Vannucci RC, 1997, ANN NY ACAD SCI, V835, P234, DOI 10.1111/j.1749-6632.1997.tb48634.x; VANNUCCI RC, 1993, APMIS, V101, P89; VANNUCCI RC, 1987, PEDIATR RES, V21, P524, DOI 10.1203/00006450-198706000-00002; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; VOLKMAR FR, 1972, SCIENCE, V176, P1445, DOI 10.1126/science.176.4042.1445; VOORHIES TM, 1986, NEUROLOGY, V36, P1115, DOI 10.1212/WNL.36.8.1115; Voss P, 2008, NEUROIMAGE, V40, P746, DOI 10.1016/j.neuroimage.2007.12.020; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Weiner H. L., 2000, HEAD INJURY, P419; Werker JF, 2005, DEV PSYCHOBIOL, V46, P233, DOI 10.1002/dev.20060; WEST RW, 1972, BEHAV BIOL, V7, P279, DOI 10.1016/S0091-6773(72)80207-4; Wilson MT, 2000, J COMP NEUROL, V424, P532, DOI 10.1002/1096-9861(20000828)424:3<532::AID-CNE10>3.0.CO;2-Z; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; 2005, BRAIN, V128, P1536	199	48	50	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	5					255	268		10.3109/17518420903087558			14	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FS	WOS:000207788500002	19956795	Green Accepted			2021-06-18	
J	Levack, WMM; Siegert, RJ; Dean, SG; McPherson, KM				Levack, William M. M.; Siegert, Richard J.; Dean, Sarah G.; McPherson, Kath M.			Goal planning for adults with acquired brain injury: How clinicians talk about involving family	BRAIN INJURY			English	Article						Goal setting; family; rehabilitation; stroke; traumatic brain injury	QUALITY-OF-LIFE; REHABILITATION PROCESS; STROKE REHABILITATION; PATIENT; PARTICIPATION; PROFESSIONALS; CARE; INTERVENTIONS; COMMUNICATION; EXPERIENCES	Primary objective: Although family involvement is frequently identified as a key element of successful rehabilitation, questions remain about 'how' clinicians can best involve them. This study explored how clinicians talk about the involvement of families in goal-planning during rehabilitation of adults with acquired brain injury. Research design: Qualitative study drawing on grounded theory to elicit practitioner perspectives. Methods and procedures: Nine clinicians from a range of professional backgrounds were interviewed. Interview data were transcribed and analysed using the constant comparative method of grounded theory. NVivo software was used to assist with data management. Main outcomes and results: While family were often considered valuable contributors to the goal-planning process, they were also seen as potential barriers to the negotiation of goals between clinicians and patients and to patient-clinician relationships. Clinicians described restricting involvement of family members in situations where such involvement was thought not to be in the best interests of the patient. Conclusions: Goal-planning appeared patient-centred rather than family-centred. Further, clinicians identified concerns about extending family involvement in goal-planning. If clinicians intend to address the needs of family members as well as patients, current approaches to goal-planning (and rehabilitation funding) may need to be reconsidered.	[Levack, William M. M.; Dean, Sarah G.] Univ Otago, Rehabil Teaching & Res Unit, Wellington Sch Med & Hlth Sci, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, London, England; [McPherson, Kath M.] Auckland Univ Technol, Div Rehabil & Occupat Studies, Auckland, New Zealand	Levack, WMM (corresponding author), Univ Otago Wellington, Rehabil Teaching & Res Unit, POB 7343, Wellington, New Zealand.	william.levack@otago.ac.nz	Siegert, Richard J./K-2030-2019; Siegert, Richard/C-3241-2009; Levack, William Mark Magnus/F-9607-2018	Levack, William Mark Magnus/0000-0001-6631-908X; McPherson, Kath/0000-0003-0487-8497; Siegert, Richard/0000-0002-3074-0929; McPherson, Kathryn/0000-0003-1240-8882; Dean, Sarah/0000-0002-3682-5149			Abreu BC, 2002, BRAIN INJURY, V16, P691, DOI 10.1080/02699050210128942; Arnetz JE., 2004, ADV PHYSIOTHER, V6, P50, DOI DOI 10.1080/14038190310017147; Baker SM, 2001, PHYS THER, V81, P1118, DOI 10.1093/ptj/81.5.1118; BASKETT J, 2003, LIFE STROKE NZ GUIDE; BECKER MC, 1974, ARCH PHYS MED REHAB, V55, P87; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Boschen K, 2007, NEUROREHABILITATION, V22, P19; *CAN STROK NETW HE, 2006, CAN STROK STRAT CAN; Carswell Anne, 2004, Can J Occup Ther, V71, P210; Conneeley AL, 2004, BR J OCCUP THER, V67, P248, DOI DOI 10.1177/030802260406700603; Davis A, 1992, CLIN REHABIL, V6, P237; Duff J, 2004, CLIN REHABIL, V18, P275, DOI 10.1191/0269215504cr720oa; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; ELSWORTH JD, 1999, TOP STROKE REHABIL, V6, P51; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Holliday RC, 2005, NEUROREHAB NEURAL RE, V19, P227, DOI 10.1177/1545968305279206; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; Kuipers P, 2003, DISABIL REHABIL, V25, P154, DOI 10.1080/0963828021000024898; Law M., 2005, CANADIAN OCCUPATIONA, V4th ed; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Levack WMM, 2006, BRAIN INJURY, V20, P1439, DOI 10.1080/02699050601118422; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; LEVACK WMM, 2008, THESIS U OTAGO WELLI; Lewin SA, 2001, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003267; Lynch EB, 2008, J REHABIL MED, V40, P518, DOI 10.2340/16501977-0203; MacGregor K, 2006, J AM BOARD FAM MED, V19, P215, DOI 10.3122/jabfm.19.3.215; Macpherson R., 1999, J MENTAL HLTH, V8, P95; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; Man DWK, 2003, BRAIN INJURY, V17, P437, DOI 10.1080/0269905031000070152; Marks JA, 1995, CLIN REHABIL, V9, P320; Mastos M, 2007, CLIN REHABIL, V21, P47, DOI 10.1177/0269215506073494; McCann Terence V, 2003, Nurse Res, V11, P7; McClain Colleen, 2005, Top Stroke Rehabil, V12, P56, DOI 10.1310/ELB1-EGKF-QUQC-VFE9; McMillan TM, 1999, NEUROPSYCHOL REHABIL, V9, P241, DOI 10.1080/096020199389356; Melville LL, 2002, AM J OCCUP THER, V56, P650, DOI 10.5014/ajot.56.6.650; *MIN HLTH, 2002, HE KOR OR MAOR HLTH; Monaghan J, 2005, CLIN REHABIL, V19, P194, DOI 10.1191/0269215505cr837oa; Morse J., 2002, README 1 USERS GUIDE; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Parry RH, 2004, CLIN REHABIL, V18, P668, DOI 10.1191/0269215504cr745oa; Playford ED, 2000, CLIN REHABIL, V14, P491, DOI 10.1191/0269215500cr343oa; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Randall KE, 2000, PHYS THER, V80, P1197, DOI 10.1093/ptj/80.12.1197; Rochette A, 2007, J REHABIL MED, V39, P513, DOI 10.2340/16501977-0082; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Sohlberg MM, 2001, J HEAD TRAUMA REHAB, V16, P498, DOI 10.1097/00001199-200110000-00008; Stern P N, 1980, Image (IN), V12, P20; Strauss A., 1998, BASICS QUALITATIVE R; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Turner-Stokes L, 2000, CLIN REHABIL, V14, P468, DOI 10.1191/0269215500cr349oa; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Visser-Meily A, 2006, DISABIL REHABIL, V28, P1557, DOI 10.1080/09638280600648215; WADE DT, 1999, TOP STROKE REHABIL, V6, P1; Wade DT, 1999, TOP STROKE REHABIL, V6, P16; Walker AJ, 2005, BRAIN INJURY, V19, P1237, DOI 10.1080/02699050500309411; Wallace SE, 2007, BRAIN INJURY, V21, P1371, DOI 10.1080/02699050701785088; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle E, 1999, DISABIL REHABIL, V21, P80, DOI 10.1080/096382899298016	61	48	48	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	3					192	202	PII 908622880	10.1080/02699050802695582			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100002	19205955				2021-06-18	
J	Rapoport, MJ; Chan, F; Lanctot, K; Herrmann, N; McCullagh, S; Feinstein, A				Rapoport, M. J.; Chan, F.; Lanctot, K.; Herrmann, N.; McCullagh, S.; Feinstein, A.			An open-label study of citalopram for major depression following traumatic brain injury	JOURNAL OF PSYCHOPHARMACOLOGY			English	Article; Proceedings Paper	18th Annual Meeting of the American-Neuropsychiatric-Association	FEB 17-20, 2007	Tucson, AZ	Amer Neuropsychiat Assoc		traumatic brain injury; major depression; citalopram; selective serotonin reuptake inhibitors	CARE	Major depression is associated with substantial psychosocial dysfunction and post-concussive symptomatology following traumatic brain injury (TBI). Studies to date of anti-depressant treatment for major depression post-TBI have been limited by small sample size. The goal of the present study is to examine the rates of response and remission associated with citalopram treatment for major depression following traumatic brain injury. Subjects with major depression following mild-to moderate TBI were treated with open-label citalopram with a starting dose of 20 mg/day to a maximum of 50 mg/day for either 6 weeks (n = 54) or 10 weeks (n = 26). The Hamilton Depression Rating Scale (HAMD) was used to assess depression severity. Response was defined by a 50% reduction in HAMD score, and remission was defined by a HAMD score of <= 7. The mean HAMD at baseline and 6 weeks were 23.66 (SD 6.8) and 16.30 (SD 9.3), respectively (t[53] = 7.157, p < 0.0001). The mean HAMD at 10 weeks was 12.96 (SD 7.9) (t[25] = 7.323, p < 0.0001). At 6 weeks, 54 subjects were assessed and 27.7% responded with 24.1% in remission. At 10 weeks, 26 subjects were assessed and 46.2% responded with 26.9% in remission. The response rate in the present sample was substantially lower than previously reported for patients with TBI, but comparable to the results of the largest effectiveness trial of citalopram for general out-patients with major depression in the absence of TBI.	[Rapoport, M. J.; Chan, F.; Lanctot, K.; Herrmann, N.; McCullagh, S.; Feinstein, A.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	Rapoport, MJ (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Lanctot, Krista L./AAY-4820-2020; Rapoport, Mark/AAD-8581-2020	Lanctot, Krista L./0000-0001-7024-6637; 			CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; First MB, 1996, STRUCTURE CLIN INTER; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GUY W, 1976, US DHEW PUBLICATION; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa	17	48	48	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-8811	1461-7285		J PSYCHOPHARMACOL	J. Psychopharmacol.	NOV	2008	22	8					860	864		10.1177/0269881107083845			5	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	377FN	WOS:000261237200006	18208921				2021-06-18	
J	Sadasivan, S; Dunn, WA; Hayes, RL; Wang, KKW				Sadasivan, Shankar; Dunn, William A., Jr.; Hayes, Ronald L.; Wang, Kevin K. W.			Changes in autophagy proteins in a rat model of controlled cortical impact induced brain injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						traumatic brain injury; autophagy; beclin-1-bcl-2 ratio; MAP-LC3	HUNTINGTONS-DISEASE MODELS; REDUCE TOXICITY; UP-REGULATION; BECLIN-1; INHIBITION; MICE; NEURODEGENERATION; RAPAMYCIN	Autophagy has been implicated in several neurodegenerative diseases and recently its role in acute brain injury has received increased interest. In our study, we investigated the profiles of autophagy-linked proteins (MAP-LC3 (Atg8), beclin-1 (Atg6) and the beclin-1-binding protein, bcl-2, following controlled cortical impact injury in rats-a model for moderate-to-severe traumatic brain injury. We observed significant increases in the levels of the processed form of LC3 (LC3-II) in the ipsilateral cortex 2 h to 2 days after injury when compared to sham. Furthermore, the beclin-1/bcl-2 ratio in the ipsilateral cortex was found to have increased from 1 and 2 days after injury. Since both of these changes are established autophagy-enabling events, and, based on these data, we propose that autophagy, plays a role in the manifestation of cell injury following brain trauma. (C) 2008 Elsevier Inc. All rights reserved.	[Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Sadasivan, Shankar] Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; [Dunn, William A., Jr.] Univ Florida, Dept Anat, Gainesville, FL 32610 USA; [Dunn, William A., Jr.] Univ Florida, Dept Cell Biol, Gainesville, FL 32610 USA; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL 32610 USA	Wang, KKW (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	kwang@banyanbio.com	Sadasivan, Shankar/C-9620-2009	Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01-A1] Funding Source: Medline		Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Floto RA, 2007, AUTOPHAGY, V3, P620, DOI 10.4161/auto.4898; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; HE Y, 2007, J CEREB BLOOD FLOW M; KING MA, 2008, MOL PHARM; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Sarkar S, 2008, HUM MOL GENET, V17, P170, DOI 10.1093/hmg/ddm294; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; UCHIYAMA Y, 2008, AUTOPHAGY, V4; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Zhu JH, 2003, BRAIN PATHOL, V13, P473	24	48	53	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	SEP 5	2008	373	4					478	481		10.1016/j.bbrc.2008.05.031			4	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	334FU	WOS:000258208500005	18486600				2021-06-18	
J	Todis, B; Glang, A				Todis, Bonnie; Glang, Ann			Redefining success: Results of a qualitative study of postsecondary transition outcomes for youth with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						postsecondary education; special education; TBI transition outcomes	MODERATE; CHILDREN; FAMILY	Objectives: Identify factors that influence postsecondary education outcomes for students with traumatic brain injury (TBI). Design: Qualitative longitudinal. Participants: Thirty-three young adults with TBI, their parents, and knowledgeable others. Results: Students with TBI who received transition services that linked them with disability services and support agencies were more likely to complete postsecondary programs. Internal factors such as positive attitude and determination were also associated with success. Conclusions: Survey items measuring constructs such as "use of accommodations," "enrolled in special education," and "high school graduation" mask a range of experiences. Transition supports geared to the postsecondary education goals of students with TBI are needed.	[Todis, Bonnie; Glang, Ann] Teaching Res Inst, Eugene, OR 97401 USA	Todis, B (corresponding author), Teaching Res Inst, 99 W l0th Ave,Suite 370, Eugene, OR 97401 USA.	todisb@wou.edu					Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; Benz MR, 1997, EXCEPT CHILDREN, V63, P151, DOI 10.1177/001440299706300201; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Braga WL, 2000, INT HDB NEUROPSYCHOL, P283; Cairns R. B., 1994, LIFELINES RISKS PATH; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Garmezy N, 1988, STUDIES PSYCHOSOCIAL, P29; GLANG A, 2003, RESILIENCE STUDENTS; Hasazi SB, 1999, EXCEPT CHILDREN, V65, P555; KEOUGH B, 1993, LEARNING DISABILITIE, V8, P3; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; Miles M.B., 1994, QUALITATIVE DATA ANA; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; *QSR INT PY LTD, 2002, N6 QSR; RUTTER M, 1998, STUDIES PSYCHOSOCIAL; STAINBACK S, 1984, EXCEPT CHILDREN, V50, P400; Stewart Debra, 2006, Phys Occup Ther Pediatr, V26, P5, DOI 10.1300/J006v26n04_02; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; TEASDALE G, 1974, LANCET, V2, P81; TODIS B, 1998, RESILIENCE STUDENTS; TODIS B, 2000, J HEAD TRAUMA REHABI; *US DEP ED, 2004, 26 ANN REP C IMPL IN; Wagner M., 2005, HIGH SCH 1 LOOK POST; Wehmeyer M, 1997, EXCEPT CHILDREN, V63, P245, DOI 10.1177/001440299706300207; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	31	48	48	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					252	263		10.1097/01.HTR.0000327257.84622.bc			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900007	18650769				2021-06-18	
J	Mathews, MS; Smith, WS; Wintermark, M; Dillon, WP; Binder, DK				Mathews, Marlon S.; Smith, Wade S.; Wintermark, Max; Dillon, William P.; Binder, Devin K.			Local cortical hypoperfusion imaged with CT perfusion during postictal Todd's paresis	NEURORADIOLOGY			English	Article						Todd's paralysis; epilepsy; perfusion; stroke; ischemia	TEMPORAL-LOBE EPILEPSY; STATUS EPILEPTICUS; FOCAL EPILEPSIES; PARALYSIS; AMNESIA; MRI; SEIZURES; EEG	Introduction Postictal ("Todd's") paralysis, or "epileptic hemiplegia," is a well-known complication of focal or generalized epileptic seizures. However, it is unclear whether the pathophysiology of Todd's paralysis is related to alterations in cerebral perfusion. We report CT perfusion findings in a patient presenting with postictal aphasia and right hemiparesis. Methods A 62-year-old woman with a history of alcohol abuse, closed head injury and posttraumatic epilepsy, presented with acute onset aphasia and right hemiparesis. A non-contrast head CT scan demonstrated no acute hemorrhage. Left hemispheric ischemia was suspected, and the patient was considered for acute thrombolytic therapy. MRI revealed a subtle increase in signal intensity involving the left medial temporal, hippocampal and parahippocampal regions on both T2-weighted FLAIR and diffusion-weighted sequences. CT angiography and CT perfusion study were performed. The CT perfusion study and CT angiography demonstrated a dramatic reduction in cerebral blood flow and blood volume involving the entire left hemisphere, but with relative symmetry of mean transit time, ruling out a large vessel occlusion. Results Clinical resolution of the aphasia and hemiparesis occurred within a few hours, and correlated with normalization of perfusion to the left hemisphere (detected by MR perfusion). Conclusion This unique case is the first in which clinical evidence of Todd's paralysis has been correlated with reversible postictal hemispheric changes on CT and MR perfusion studies. This is important because CT perfusion study is being used more and more in the diagnosis of acute stroke, and one needs to be careful to not misinterpret the data.	[Wintermark, Max; Dillon, William P.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Smith, Wade S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mathews, Marlon S.; Binder, Devin K.] Univ Calif Irvine, Dept Neurol Surg, Irvine, CA USA	Mathews, MS (corresponding author), 101 City Dr S,Bldg 56,Suite 400, Orange, CA 92868 USA.	mmathews@uci.edu		Wintermark, Max/0000-0002-6726-3951			Adam C, 2000, CAN J NEUROL SCI, V27, P49, DOI 10.1017/S0317167100051970; BANSAL SK, 1991, ITAL J NEUROL SCI, V12, P75, DOI 10.1007/BF02337617; Binder DK, 2004, NEUROSURGERY, V54, P480, DOI 10.1227/01.NEU.0000103490.49537.37; Bravais L.F., 1827, RECHERCHES SYMPTOMES; EFRON R, 1961, BRAIN, V84, P381, DOI 10.1093/brain/84.3.381; El-Koussy M, 2002, EUR RADIOL, V12, P568, DOI 10.1007/s003300100999; Fisher RS, 2000, EPILEPSY BEHAV, V1, P52, DOI 10.1006/ebeh.2000.0023; Gallmetzer P, 2004, NEUROLOGY, V62, P2160, DOI 10.1212/WNL.62.12.2160; Gowers WR, 1901, EPILEPSY OTHER CHRON; HELMCHEN C, 1994, NERVENARZT, V65, P700; HELMSTAEDTER C, 1994, EPILEPSIA, V35, P1073, DOI 10.1111/j.1528-1157.1994.tb02557.x; Higuchi Tsukasa, 1998, No To Hattatsu, V30, P403; Hughlings Jackson J., 1881, BRAIN, V3, P433; Kellinghaus C, 2004, NEUROLOGY, V62, P289, DOI 10.1212/01.WNL.0000103287.50054.85; Kim JA, 2001, AM J NEURORADIOL, V22, P1149; KOSNIK E, 1976, NEUROLOGY, V26, P248, DOI 10.1212/WNL.26.3.248; Lazeyras F, 2000, NEUROLOGY, V55, P1677, DOI 10.1212/WNL.55.11.1677; Leutmezer F, 2003, EPILEPSIA, V44, P582, DOI 10.1046/j.1528-1157.2003.32802.x; Maheu G, 2004, EPILEPSIA, V45, P1459, DOI 10.1111/j.0013-9580.2004.11604.x; MEYER JS, 1959, BRAIN, V82, P162, DOI 10.1093/brain/82.2.162; Nelissen N, 2006, NEUROIMAGE, V32, P684, DOI 10.1016/j.neuroimage.2006.04.185; Oh JB, 2004, SEIZURE-EUR J EPILEP, V13, P509, DOI 10.1016/j.seizure.2003.12.005; Parmar H, 2006, NEUROLOGY, V66, P1732, DOI 10.1212/01.wnl.0000218207.18707.f4; Reynolds EH, 2004, EPILEPSIA, V45, P985, DOI 10.1111/j.0013-9580.2004.12004.x; SALIH MA, 1997, CHILD NERV SYST, V21, P257; SALMON JH, 1968, ARCH OPHTHALMOL-CHIC, V79, P523; TASSINARI CA, 1991, EPILEPSIA, V32, P882, DOI 10.1111/j.1528-1157.1991.tb05545.x; Todd R. B, 1849, LONDON MED GAZ, V8, P661; Todd RB, 1855, CLIN LECT PARALYSIS; Weinand ME, 1997, J NEUROSURG, V86, P226, DOI 10.3171/jns.1997.86.2.0226; Zeman AZJ, 1998, J NEUROL NEUROSUR PS, V64, P435, DOI 10.1136/jnnp.64.4.435	31	48	50	1	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	MAY	2008	50	5					397	401		10.1007/s00234-008-0362-1			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	292HG	WOS:000255256500003	18278489				2021-06-18	
J	Tawil, I; Stein, DM; Mirvis, SE; Scalea, TM				Tawil, Isaac; Stein, Deborah M.; Mirvis, Stuart E.; Scalea, Thomas M.			Posttraumatic cerebral infarction: Incidence, outcome, and risk factors	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	37th Annual Meeting of the Western-Trauma-Association	FEB 25-MAR 02, 2007	Steamboat Springs, CO	Western Trauma Assoc		posttramnatic cerebral infarction; traumatic brain injury; blunt cerebrovascular injury; factor VIIa; secondary brain injury	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DECOMPRESSIVE CRANIECTOMY; BRAIN-INJURY; FACTOR-VIIA; SECONDARY; SPASM	Background., Outcome in patients with traumatic brain injury (TBI) is often affected by secondary insults including post-traumatic cerebral infarction (PTCI). The incidence of PTCI after TBI was previously reported to be 2% with no mortality impact. We suspected that recent advances in imaging modalities and treatment might affect incidence and outcome. We sought to define the incidence and mortality impact of PTCI. We also identified risk factors associated with PTCI. Methods. We retrospectively reviewed all patients admitted between 2004 and 2006 with severe TBI (brain Abbreviated Injury Scale [AIS] score >2, Glasgow Coma Scale score [GCS] <9). Demographics, injury specifics, and clinical data were abstracted. All brain imaging studies were reviewed with an attending trauma radiologist. Statistical analysis of outcome data were performed using chi(2) and Student's t test and multivariate analysis was performed using logistic regression to identify independent risk factors. Results: Of the 384 patients identified with severe TBI; 93% sustained a blunt injury, 75% were men. Mortality was 21 %, and 48 % had a brain AIS score of 5. Mean age was 36 years (11-90 years), admission GCS score was 5 (3-8), and Injury Severity Score was 32 (9-75). Thirtyone (8%) had a confirmed PTCI. The PTCI group had a significantly increased mortality (45% vs. 19%,p < 0.002), hospital length of stay (LOS) (25 days vs. 18 days, p < 0.02), and intensive care unit LOS (21 days vs. 15 days, p < 0.03). In multivariate analysis, sex, age, Injury Severity Score, Revised Trauma Score, admission GCS, and brain AIS were not associated with PTCI; whereas the presence of blunt cerebral vascular injury [odds ratio (OR) 4.0, 95% confidence interval (CI) 1.9-8.7], the need for craniotomy (OR 3.0, 95% CI 1.2-6.9), or treatment with recombinant factor VIIa (OR 3.1, 95% CI 1.1-8.0) were each independently associated with an increased risk of PTCI. Conclusions: The incidence of PTCI in patients with severe TBI is higher after severe brain injury than previously thought. PTCI has a significant impact on mortality and LOS. The presence of a blunt cerebral vascular injury, the need for craniotomy, or treatment with factor VIIa are risk factors for PTCL Recognition of this secondary brain insult and the associated risk factors may help identify the group at risk and tailor management of patients with severe TBI.	[Tawil, Isaac; Stein, Deborah M.; Mirvis, Stuart E.; Scalea, Thomas M.] Univ New Mexico, Dept Surg, Div Trauma Crit Care, Albuquerque, NM 87131 USA	Tawil, I (corresponding author), Univ New Mexico, Dept Surg, Div Trauma Crit Care, Albuquerque, NM 87131 USA.	itawil@salud.unm.edu; iker510@gmail.com		Stein, Deborah/0000-0003-3683-3963			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; BURNEY RE, 1995, ANN EMERG MED, V25, P187, DOI 10.1016/S0196-0644(95)70322-5; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; MIRVIS SE, 1990, AM J NEURORADIOL, V11, P355; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SATO M, 1986, NEUROSURGERY, V18, P300, DOI 10.1227/00006123-198603000-00007; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Server A, 2001, ACTA RADIOL, V42, P254; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Spain DA, 2006, J TRAUMA, V60, P751; Stein Deborah M, 2004, Curr Opin Crit Care, V10, P520, DOI 10.1097/01.ccx.0000144770.96342.65; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11	23	48	58	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					849	853		10.1097/TA.0b013e318160c08a			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	287UN	WOS:000254942100001	18404047				2021-06-18	
J	Jiang, SC; Ballerini, P; Buccella, S; Giuliani, P; Jiang, C; Huang, XJ; Rathbone, MP				Jiang, Shucui; Ballerini, Patrizia; Buccella, Silvana; Giuliani, Patricia; Jiang, Cai; Huang, Xinjie; Rathbone, Michel P.			Remyelination after chronic spinal cord injury is associated with proliferation of endogenous adult progenitor cells after systemic administration of guanosine	PURINERGIC SIGNALLING			English	Article						cell proliferation; functional recovery; guanine; guanosine; immunohistochemistry; myelination; oligodendrocyte; precursors; spinal cord	MULTIPLE-SCLEROSIS LESIONS; CENTRAL-NERVOUS-SYSTEM; OLIGODENDROCYTE PRECURSOR CELLS; INDUCED NEURITE OUTGROWTH; MATURE OLIGODENDROCYTES; GROWTH-FACTOR; EXTRACELLULAR GUANOSINE; INFLAMMATORY RESPONSE; MONOCLONAL-ANTIBODY; PURINE NUCLEOSIDES	Axonal demyelination is a consistent pathological sequel to chronic brain and spinal cord injuries and disorders that slows or disrupts impulse conduction, causing further functional loss. Since oligodendroglial progenitors are present in the demyelinated areas, failure of remyelination may be due to lack of sufficient proliferation and differentiation of oligodendroglial progenitors. Guanosine stimulates proliferation and differentiation of many types of cells in vitro and exerts neuroprotective effects in the central nervous system (CNS). Five weeks after chronic traumatic spinal cord injury (SCI), when there is no ongoing recovery of function, intraperitoneal administration of guanosine daily for 2 weeks enhanced functional improvement correlated with the increase in myelination in the injured cord. Emphasis was placed on analysis of oligodendrocytes and NG2-positive (NG2+) cells, an endogenous cell population that may be involved in oligodendrocyte replacement. There was an increase in cell proliferation (measured by bromodeoxyuridine staining) that was attributable to an intensification in progenitor cells (NG2+ cells) associated with an increase in mature oligodendrocytes (determined by Rip+ staining). The numbers of astroglia increased at all test times after administration of guanosine whereas microglia only increased in the later stages (14 days). Injected guanosine and its breakdown product guanine accumulated in the spinal cords; there was more guanine than guanosine detected. We conclude that functional improvement and remyelination after systemic administration of guanosine is due to the effect of guanosine/guanine on the proliferation of adult progenitor cells and their maturation into myelin-forming cells. This raises the possibility that administration of guanosine may be useful in the treatment of spinal cord injury or demyelinating diseases such as multiple sclerosis where quiescent oligodendroglial progenitors exist in demyelinated plaques.	[Jiang, Shucui] McMaster Univ, Hlth Sci Ctr, Dept Surg Neurosurg Neurobiol, Hamilton, ON L8N 3Z5, Canada; [Jiang, Cai; Huang, Xinjie; Rathbone, Michel P.] McMaster Univ, Hlth Sci Ctr, Dept Med Neurol Neuropharmacol, Hamilton, ON L8N 3Z5, Canada; [Ballerini, Patrizia; Buccella, Silvana; Giuliani, Patricia] Univ G dAnnunzio, Univ GD Annunzio, Dept Biomed Sci, I-66013 Chieti, Italy	Jiang, SC (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Surg Neurosurg Neurobiol, 4E15,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	jiangs@mcmaster.ca	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763			Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bansal R, 1997, J NEUROSCI RES, V50, P215; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Baumann N, 2001, PHYSIOL REV, V81, P871; Blakemore WF, 2000, NOVART FDN SYMP, V231, P289, DOI 10.1002/0470870834.ch17; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Bruck W, 2003, J NEUROL SCI, V206, P181, DOI 10.1016/s0022-510x(02)00191-0; BUNGE MB, 1961, J BIOPHYS BIOCHEM CY, V10, P67, DOI 10.1083/jcb.10.1.67; BUNGE RP, 1993, ADV NEUROL, V59, P75; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Ciccarelli R, 1999, GLIA, V25, P93, DOI 10.1002/(SICI)1098-1136(19990101)25:1<93::AID-GLIA9>3.3.CO;2-E; Ciccarelli R, 2000, GLIA, V29, P202, DOI 10.1002/(SICI)1098-1136(20000201)29:3<202::AID-GLIA2>3.0.CO;2-C; Cohen RI, 1996, J NEUROSCI, V16, P6433; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Di Iorio P, 2004, GLIA, V46, P356, DOI 10.1002/glia.20002; Di Iorio P, 2002, GLIA, V38, P179, DOI 10.1002/glia.10055; Di Iorio P, 2001, DRUG DEVELOP RES, V52, P303, DOI 10.1002/ddr.1128; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; FRESSINAUD C, 1995, J NEUROSCI RES, V40, P285, DOI 10.1002/jnr.490400302; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; GILSON J, 1993, NEUROPATH APPL NEURO, V19, P173, DOI 10.1111/j.1365-2990.1993.tb00424.x; Goddard DR, 2001, MOL CELL NEUROSCI, V18, P557, DOI 10.1006/mcne.2001.1025; Gruner JA, 1996, BRAIN RES, V729, P90, DOI 10.1016/S0006-8993(96)00366-6; Gysbers JW, 1996, INT J DEV NEUROSCI, V14, P19, DOI 10.1016/0736-5748(95)00083-6; GYSBERS JW, 1992, NEUROREPORT, V3, P997, DOI 10.1097/00001756-199211000-00013; Gysbers JW, 2000, NEUROSCIENCE, V96, P817, DOI 10.1016/S0306-4522(99)00588-6; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Horner PJ, 2000, J NEUROSCI, V20, P2218; Jiang S, 2004, INT J IMMUNOPATH PH, V17, P353, DOI 10.1177/039463200401700315; Jiang SC, 2003, NEUROREPORT, V14, P2463, DOI 10.1097/00001756-200312190-00034; Jiang SC, 2003, EXP NEUROL, V181, P79, DOI 10.1016/S0014-4886(02)00030-4; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Levine JM, 1999, EXP NEUROL, V160, P333, DOI 10.1006/exnr.1999.7224; Ludwin S K, 1988, Adv Neurol, V47, P215; Lytle JM, 2007, EUR J NEUROSCI, V25, P1711, DOI 10.1111/j.1460-9568.2007.05390.x; Mason JL, 2000, J NEUROSCI RES, V61, P251, DOI 10.1002/1097-4547(20000801)61:3<251::AID-JNR3>3.0.CO;2-W; McDonald JW, 2006, J NEUROTRAUM, V23, P345, DOI 10.1089/neu.2006.23.345; McMorris FA, 1996, BRAIN PATHOL, V6, P313, DOI 10.1111/j.1750-3639.1996.tb00858.x; MCMORRIS FA, 1993, ANN NY ACAD SCI, V692, P321; McTigue DM, 1998, J NEUROSCI, V18, P5354; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Nait-Oumesmar B, 2007, P NATL ACAD SCI USA, V104, P4694, DOI 10.1073/pnas.0606835104; Norton WT, 1996, NEUROCHEM RES, V21, P495, DOI 10.1007/BF02527715; Pettifer KM, 2004, NEUROREPORT, V15, P833, DOI 10.1097/00001756-200404090-00019; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; RATHBONE MP, NUCLEOSIDES IN PRESS; Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8; Rosano C, 1999, GLIA, V27, P189, DOI 10.1002/(SICI)1098-1136(199909)27:3<189::AID-GLIA1>3.0.CO;2-I; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Stankoff B, 2002, J NEUROSCI, V22, P9221; Traversa U, 2002, BRIT J PHARMACOL, V135, P969, DOI 10.1038/sj.bjp.0704542; VICK RS, 1992, J NEUROTRAUM, V9, pS93; Williams A, 2007, GLIA, V55, P1300, DOI 10.1002/glia.20546; Wilson HC, 2006, J NEUROIMMUNOL, V176, P162, DOI 10.1016/j.jneuroim.2006.04.014; Wolswijk G, 1998, J NEUROSCI, V18, P601; Yan HL, 2000, J NEUROSCI RES, V62, P329, DOI 10.1002/1097-4547(20001101)62:3<329::AID-JNR2>3.0.CO;2-C; Zhang R, 2006, NEUROBIOL DIS, V24, P345, DOI 10.1016/j.nbd.2006.07.012	70	48	49	0	4	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1573-9538	1573-9546		PURINERG SIGNAL	Purinergic Signal.	MAR	2008	4	1					61	71		10.1007/s11302-007-9093-8			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	341NG	WOS:000258720600005	18368534	Green Published, Bronze			2021-06-18	
J	Kennedy, MRT; Krause, MO; Turkstra, LS				Kennedy, Mary R. T.; Krause, Miriam O.; Turkstra, Lyn S.			An electronic survey about college experiences after traumatic brain injury	NEUROREHABILITATION			English	Article						College; post-secondary education; study skills; cognition; psychosocial; services; higher education	HEAD-INJURY; STUDENTS	For many with traumatic brain injury (TBI), going to college is a realistic goal; however there is little documentation of the challenges faced by those with TBI who attend college. The primary purposes of this study were to document the academic challenges (studying, in-class experiences, time management, psychosocial aspects) reported by adults with TBI, and to investigate relationships between these challenges and the physical, cognitive and psychosocial consequences of TBI. An electronic anonymous survey was distributed. Of the 35 respondents with TBI, nearly all reported the need to review material more and a majority reported that others do not understand their problems. In-class experiences of being nervous before tests, forgetting what is said in class, and getting overwhelmed in class were also reported by a majority. Those who reported more physical, cognitive and psychosocial consequences of their injury also identified more academic challenges as well, although cognitive consequences alone predicted academic challenges better than all of the consequences combined. Psychosocial aspects also predicted academic challenges to a lesser extent. In spite of these findings, nearly half of the respondents had not heard of or had never accessed campus disability services. To develop effective on-campus service delivery models, additional research is needed to understand why students do or do not make use of existing services.	[Kennedy, Mary R. T.] Univ Minnesota, Dept Speech Language Hearing Sci, Minneapolis, MN 55455 USA; [Turkstra, Lyn S.] Univ Wisconsin, Madison, WI USA	Kennedy, MRT (corresponding author), Univ Minnesota, Dept Speech Language Hearing Sci, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenne047@umn.edu		Krause, Miriam/0000-0002-6798-3991			BUETHE C, 1989, J COLL STUDENT DEV, V30, P172; COOK J, 1991, J HEAD TRAUMA REHAB, V6, P64; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Harris JR, 1997, J HEAD TRAUMA REHAB, V12, P67, DOI 10.1097/00001199-199704000-00007; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JOHNSTONE B, 1994, J CLIN PSYCHOL MED S, V1, P375, DOI 10.1007/BF01991080; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; Marschark M, 2000, J HEAD TRAUMA REHAB, V15, P1227, DOI 10.1097/00001199-200012000-00004; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Prince S, 2002, J MED SPEECH-LANG PA, V10, P19; Savage RC, 1987, J HEAD TRAUMA REHAB, V2, P1; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; TURKSTRA L, 2004, PERSPECTIVES, V14, P19	16	48	48	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2008	23	6					511	520					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200007	19127004				2021-06-18	
J	Ownsworth, T; Little, T; Turner, B; Hawkes, A; Shum, D				Ownsworth, Tamara; Little, Trudi; Turner, Ben; Hawkes, Anna; Shum, David			Assessing emotional status following acquired brain injury: The clinical potential of the depression, anxiety and stress scales	BRAIN INJURY			English	Article						Acquired brain injury; assessment; emotional status	CLOSED-HEAD INJURY; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; TRIPARTITE MODEL; NORMATIVE DATA; INDIVIDUALS; PREVALENCE; INVENTORY; SYMPTOMS; DISORDER	Primary objective: To investigate the clinical potential of the Depression, Anxiety and Stress Scales (DASS 42) and its shorter version ( DASS 21) for assessing emotional status following acquired brain injury. Methods and procedures: Participants included 23 individuals with traumatic brain injury (TBI), 25 individuals with brain tumour and 29 non-clinical controls. Investigations of internal consistency, test-re-test reliability, theory-consistent differences, sensitivity to change and concurrent validity were conducted. Main outcomes and results: Internal consistency of the DASS was generally acceptable (r > 0.70), with the exception of the anxiety scale for the TBI sample. Test-re-test reliability (1-3 weeks) was sound for the depression scale (r > 0.75) and significant but comparatively lower for other scales (r = 0.60-0.73, p < 0.01). Theory-consistent differences were only evident between the brain tumour sample and non-clinical control sample on the anxiety scale (p < 0.01). Sensitivity to change of the DASS in the context of hospital discharge was demonstrated for depression and stress (p < 0.01), but not for anxiety (p > 0.05). Concurrent validity with the Hospital Anxiety and Depression Scale was significant for all scales of the DASS (p < 0.05). Conclusions: While the results generally support the clinical application of the DASS following ABI, further research examining the factor structure of existing and modified versions of the DASS is recommended.	[Ownsworth, Tamara; Little, Trudi; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Ownsworth, Tamara; Little, Trudi; Shum, David] Griffith Univ, Appl Cognit Neurosci Res Ctr, Brisbane, Qld 4111, Australia; [Turner, Ben] Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld, Australia; [Hawkes, Anna] Canc Council Queensland, Viertel Ctr Res Canc Control, Brisbane, Qld, Australia	Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Shum, David/A-3914-2008; Hawkes, Anna L/C-6370-2009	Shum, David/0000-0002-4810-9262; Ownsworth, Tamara/0000-0003-1835-7094			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Barker-Collo SL, 2007, ARCH CLIN NEUROPSYCH, V22, P519, DOI 10.1016/j.acn.2007.03.002; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; BECK AT, 1987, MANUAL BECK ANXIETY; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; CUMMINGS JL, 2002, CONCISE GUIDE NEUROP; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Domholdt E., 2005, REHABILITATION RES P; Epstein RS, 1994, NEUROPSYCHIATRY TRAU, P3; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming JM, 2006, BRAIN IMPAIR, V7, DOI [10.1375/brim.7.2.83, DOI 10.1375/BRIM.7.2.83]; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Fure B, 2006, INT J GERIATR PSYCH, V21, P382, DOI 10.1002/gps.1482; Giovagnoli AR, 1999, J NEUROL NEUROSUR PS, V67, P358, DOI 10.1136/jnnp.67.3.358; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GORDON WA, 1991, REHABIL PSYCHOL, V36, P71, DOI 10.1037/h0079078; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kaplan CP, 2000, BRAIN INJURY, V14, P251; Karlovits T, 1999, BRAIN INJURY, V13, P845; Keir ST, 2006, SUPPORT CARE CANCER, V14, P1213, DOI 10.1007/s00520-006-0087-9; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Mainio A, 2006, EUR PSYCHIAT, V21, P194, DOI 10.1016/j.eurpsy.2005.05.008; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nunnally J.C., 1967, PSYCHOMETRIC THEORY, V226; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Pringle AM, 1999, BRIT J NEUROSURG, V13, P46, DOI 10.1080/02688699944177; Rickards H, 2006, CURR OPIN PSYCHIATR, V19, P294, DOI 10.1097/01.yco.0000218601.17722.5b; Schramke CJ, 1998, J CLIN EXP NEUROPSYC, V20, P723, DOI 10.1076/jcen.20.5.723.1117; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHUM D, 2006, PSYCHOL TESTING ASSE; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Tabachnick BG, 2007, USING MULTIVARIATE S; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; WATSON D, 1995, J ABNORM PSYCHOL, V104, P15, DOI 10.1037/0021-843X.104.1.15; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; WRIGHT J, 2000, FIM TM INTERNET CTR	51	48	49	2	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					858	869		10.1080/02699050802446697			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700005	18850344				2021-06-18	
J	Tsanadis, J; Montoya, E; Hanks, RA; Millis, SR; Fichtenberg, NL; Axelrod, BN				Tsanadis, John; Montoya, Eduardo; Hanks, Robin A.; Millis, Scott R.; Fichtenberg, Norman L.; Axelrod, Bradley N.			Brain injury severity, litigation status, and self-report of postconcussive symptoms	CLINICAL NEUROPSYCHOLOGIST			English	Article						Brain injury; Postconcussion; Litigation; Malingering; Effort	RECOGNITION MEMORY TEST; MILD HEAD-INJURY; BASE RATES; DEPRESSION; PERFORMANCE; CONCUSSION; RECOVERY; ETIOLOGY; STRESS	The Postconcussive Symptom Questionnaire (PCSQ) was developed to assess the symptoms associated with the controversial diagnosis of postconcussion syndrome. We examined item endorsement on the PCSQ in two groups. The first group was made up of individuals diagnosed with moderate to severe traumatic brain injury. The second group was made up of individuals meeting criteria for mild traumatic brain injury who exhibited no evidence of neurological injury. In addition, they demonstrated poor effort during neuropsychological examination. Significant differences in item endorsement were found the majority of individual items as well as on the PCSQ indices. The poor effort mild traumatic brain injury group consistently reported more symptoms with greater severity. The results raise further questions about the validity of postconcussion symptoms.	[Tsanadis, John] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; [Tsanadis, John; Hanks, Robin A.; Millis, Scott R.; Fichtenberg, Norman L.] Wayne State Univ, Sch Med, Detroit, MI USA; [Axelrod, Bradley N.] Dept Veteran Affairs John D Dingell Med Ctr, Detroit, MI USA	Tsanadis, J (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.	jtsanadis@med.wayne.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020515] Funding Source: Medline		American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Axelrod BN, 2002, ARCH CLIN NEUROPSYCH, V17, P343, DOI 10.1016/S0887-6177(01)00119-6; Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 2005, FORENSIC NEUROPSYCHO, P298; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GREEN P, 1999, WORD MEMORY TEST; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Larrabee G, 2005, FORENSIC NEUROPSYCHO, P209; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; Lees-Haley P.R., 1988, AM J FORENSIC PSYCHO, V6, P3; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warrington EK., 1984, RECOGNITION MEMORY T; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P239, DOI 10.1016/j.acn.2005.12.004	37	48	49	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	6					1080	1092	PII 790935185	10.1080/13854040701796928			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	374CV	WOS:000261020900008	18609319				2021-06-18	
J	Chalidis, B; Stengel, D; Giannoudis, PV				Chalidis, Byron; Stengel, Dirk; Giannoudis, Peter V.			Early excision and late excision of heterotopic ossification after traumatic brain injury are equivalent: A systematic review of the literature	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; recovery; rehabilitation; traumatic brain injury	SPINAL-CORD-INJURY; ECTOPIC BONE-FORMATION; SURGICAL-TREATMENT; ELBOW; RESECTION; RADIOTHERAPY; PREVENTION; HIP; DIAGNOSIS; KNEE	Heterotopic ossification (HO) is a common complication in patients with coma after brain injury. As the optimal timing of surgical resection is still controversial and unclear, a review of the literature was performed in order to determine the impact of early operation on recurrence rate and joint mobility. We identified all types of studies dealing with surgical excision of HO in patients after head injury in major medical and publishers' databases. Publication bias and statistical heterogeneity were assessed by funnel-plot asymmetry and Galbraith regression. We abstracted demographic and outcome information from manuscripts that tabulated individual patient data (IPD) to build univariate logistic and linear regression models. Means and proportions for random-effects meta-regression analysis were also obtained. Of 318 studies originally identified, 16 observational studies enrolling 255 patients (212 men, 329 affected joints, mean age of 30.6[+/- SEM of 1.4] years) were included in the analysis. The reported overall recurrence rate in eleven studies was 38/192 (19.8%). Both IPD and meta-regression analysis failed to show a marked impact of the interval to resection on the probability of recurrence (odds ratio 1.00, 95% CI 0.98-1.03). The predicted probability of recurrence after 13, 21, and 30 months of waiting was 9%, 14%, and 19%, respectively. The length of coma period and patient's neurologic deficit were statistically significant negative predictors for both recurrence rate and functional outcome. Although no conclusive inferences can be drawn from the identified studies, the available data do not support the concept that early excision triggers later recurrence.	Univ Leeds, Sch Med, Acad Dept Trauma & Orthopaed, Leeds LS2 9JT, W Yorkshire, England; Unfallkrankenhaus, Clin Res Ctr, Dept Trauma & Orthopaed Surg, Dept Clin Epidemiol, Berlin, Germany	Chalidis, B (corresponding author), LGI Univ Hosp, Acad Dept Trauma & Orthopaed, Claredon Wing Great George St, Leeds LS1 3EX, W Yorkshire, England.		Stengel, Dirk/AAF-6470-2019; Giannoudis, Peter/AAA-3617-2020; Chalidis, Byron/AAK-8403-2020	Giannoudis, Peter/0000-0002-5205-7696; Chalidis, Byron/0000-0003-1305-2734			Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053; Banovac K, 2004, SPINAL CORD, V42, P707, DOI 10.1038/sj.sc.3101628; Banovac K, 2001, SPINAL CORD, V39, P370, DOI 10.1038/sj.sc.3101166; Beingessner DM, 2000, J HAND SURG-AM, V25A, P483, DOI 10.1053/jhsu.2000.6922; BENZ HJ, 1992, Z ORTHOP GRENZGEB, V130, P87, DOI 10.1055/s-2008-1040118; Botte MJ, 1997, ORTHOPEDICS, V20, P335; Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; de Palma L, 2002, ORTHOPEDICS, V25, P665; Denormandie P, 1999, Chir Main, V18, P99; Ebinger T, 2000, J TRAUMA, V48, P1058, DOI 10.1097/00005373-200006000-00010; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Esenwein SA, 2000, ARCH ORTHOP TRAUM SU, V120, P575, DOI 10.1007/s004020000178; Fransen M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001160.PUB2; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; Frischhut B, 1993, Acta Neurol (Napoli), V15, P114; Fuller DA, 2005, CLIN ORTHOP RELAT R, P197, DOI 10.1097/01.blo.0000170718.86747.da; GACON G, 1978, REV CHIR ORTHOP, V64, P375; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP REL 0213; HASTINGS H, 1994, HAND CLIN, V10, P417; Ippolito E, 1999, J BONE JOINT SURG AM, V81A, P783, DOI 10.2106/00004623-199906000-00005; Ippolito E, 1999, J HAND SURG-AM, V24A, P546; Ippolito E, 1999, CLIN ORTHOP RELAT R, P130, DOI 10.1097/00003086-199908000-00018; KJAERSGAARDANDERSEN P, 1991, CLIN ORTHOP RELAT R, P78; Kolessar DJ, 1996, J HEAD TRAUMA REHAB, V11, P78, DOI 10.1097/00001199-199608000-00010; Lazarus MD, 1999, NEUROREHABILITATION, V12, P145; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256-005-0958-z; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; MUHEIM G, 1973, AM J ROENTGENOL, V118, P865, DOI 10.2214/ajr.118.4.865; ORZEL JA, 1985, J NUCL MED, V26, P125; Pape HC, 2004, J BONE JOINT SURG BR, V86B, P783, DOI 10.1302/0301-620X.86B6.15356; Phillips B, 2001, OXFORD CTR EVIDENCE; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; Sarafis KA, 1999, J TRAUMA, V46, P104, DOI 10.1097/00005373-199901000-00017; Sautter-Bihl ML, 2001, STRAHLENTHER ONKOL, V177, P200, DOI 10.1007/PL00002399; Sautter-Bihl ML, 2000, SPINAL CORD, V38, P33, DOI 10.1038/sj.sc.3100847; Shehab D, 2002, J NUCL MED, V43, P346; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; TIBONE J, 1978, J BONE JOINT SURG AM, V60, P769, DOI 10.2106/00004623-197860060-00007; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628	47	48	49	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1675	1686		10.1089/neu.2007.0342			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500001	18001198				2021-06-18	
J	Maurel, JL; Autin, JM; Funes, P; Newman-Tancredi, A; Colpaert, F; Vacher, B				Maurel, Jean Louis; Autin, Jean-Marie; Funes, Philippe; Newman-Tancredi, Adrian; Colpaert, Francis; Vacher, Bernard			High-efficacy 5-HT1A Agonists for antidepressant treatment: A renewed opportunity	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							FORCED SWIMMING TEST; ADENYLYL-CYCLASE ACTIVITY; TRAUMATIC BRAIN-INJURY; RECEPTOR AGONIST; RAT MODEL; SELECTIVE ACTIVATION; RECOMBINANT HUMAN; NATIVE RAT; IN-VIVO; F-13640	We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (+/-)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.	Ctr Rech Pierre Fabre, Med Chem Div 1, F-81106 Castres, France; Ctr Rech Pierre Fabre, Task Force Chem, F-81106 Castres, France; Ctr Rech Pierre Fabre, Neurobiol Div 2, F-81106 Castres, France; Ctr Rech Pierre Fabre, Toulouse ISTMT 2, F-81106 Castres, France	Vacher, B (corresponding author), Ctr Rech Pierre Fabre, Med Chem Div 1, 17 Ave Jean Moulin, F-81106 Castres, France.	bernard.vacher@pierre-fabre.com	Newman-Tancredi, Adrian/ABI-6383-2020	Newman-Tancredi, Adrian/0000-0002-2923-5714			Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Appert-Collin A, 2005, INT J IMMUNOPATH PH, V18, P21, DOI 10.1177/039463200501800104; Assie MB, 2006, EUR NEUROPSYCHOPHARM, V16, pS233, DOI 10.1016/S0924-977X(06)70186-9; Bardin L, 2003, PHARMACOLOGY, V67, P182, DOI 10.1159/000068404; Becker OM, 2006, J MED CHEM, V49, P3116, DOI 10.1021/jm0508641; Belozertseva IV, 2007, EUR NEUROPSYCHOPHARM, V17, P172, DOI 10.1016/j.euroneuro.2006.03.002; Blier P, 1997, NEUROPSYCHOPHARMACOL, V16, P333, DOI 10.1016/S0893-133X(96)00242-4; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; Borsini F, 2001, PSYCHOPHARMACOLOGY, V159, P64, DOI 10.1007/s002130100876; Borsini F, 2002, CNS DRUG REV, V8, P117; BOSE AK, 1959, J ORG CHEM, V24, P1309, DOI 10.1021/jo01091a038; Butera JA, 2007, J MED CHEM, V50, P2543, DOI 10.1021/jm061015w; Clarke WP, 1996, J PHARMACOL EXP THER, V277, P1259; Colpaert FC, 2002, NEUROPHARMACOLOGY, V43, P945, DOI 10.1016/S0028-3908(02)00119-3; Colpaert FC, 2006, CURR OPIN INVEST DR, V7, P40; Colpaert FC, 2004, EUR J PHARMACOL, V497, P29, DOI 10.1016/j.ejphar.2004.06.026; COLPAERT FC, 1992, DRUG DEVELOP RES, V26, P21, DOI 10.1002/ddr.430260103; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P547, DOI 10.1016/j.neubiorev.2005.03.008; Davies SL, 2006, DRUG NEWS PERSPECT, V19, P632; de Paulis T, 2007, CURR OPIN INVEST DR, V8, P78; Deseure K, 2003, J PHARMACOL EXP THER, V306, P505, DOI 10.1124/jpet.103.050286; Deseure K, 2002, EUR J PHARMACOL, V456, P51, DOI 10.1016/S0014-2999(02)02640-7; Detke MJ, 1996, BEHAV BRAIN RES, V73, P43; Dremencov E, 2007, BIOL PSYCHIAT, V61, P671, DOI 10.1016/j.biopsych.2006.05.015; Evans KLJ, 2001, J PHARMACOL EXP THER, V297, P1025; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GUPTON JT, 1991, J HETEROCYCLIC CHEM, V28, P1281, DOI 10.1002/jhet.5570280520; HJORTH S, 1988, N-S ARCH PHARMACOL, V338, P463, DOI 10.1007/BF00179315; Invernizzi RW, 2003, BRIT J PHARMACOL, V139, P1281, DOI 10.1038/sj.bjp.0705341; ISODA S, 1980, CHEM PHARM BULL, V28, P1408; Iyer GR, 2007, J CLIN PHARMACOL, V47, P817, DOI 10.1177/0091270007300953; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kiss I, 2005, EUR J PHARMACOL, V523, P29, DOI 10.1016/j.ejphar.2005.09.003; KLEVEN M, 1995, EUR J PHARMACOL, V281, P219, DOI 10.1016/0014-2999(95)00324-E; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Koek W, 1998, J PHARMACOL EXP THER, V287, P266; Koek W, 2001, EUR J PHARMACOL, V420, P103, DOI 10.1016/S0014-2999(01)01011-1; la Cour CM, 2006, MOL PHARMACOL, V70, P1013, DOI 10.1124/mol.106.022756; Lange UEW, 1999, TETRAHEDRON LETT, V40, P7067, DOI 10.1016/S0040-4039(99)01460-4; Liang YM, 2002, SYNTHETIC COMMUN, V32, P153, DOI 10.1081/SCC-120001523; Liu Y, 2004, ORG LETT, V6, P209, DOI 10.1021/ol036157o; Lohse MJ, 2006, NAT METHODS, V3, P972, DOI 10.1038/nmeth1206-972; Lucki I, 1997, BEHAV PHARMACOL, V8, P523, DOI 10.1097/00008877-199711000-00010; Marazziti D, 2002, INT J NEUROPSYCHOPH, V5, P131, DOI 10.1017/S1461145702002869; MAREL J, 2002, Patent No. WO02064585; Martinez D, 2001, NEUROPSYCHOPHARMACOL, V24, P209, DOI 10.1016/S0893-133X(00)00187-1; MAUREL JL, 2003, Patent No. WO03106449; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Mico JA, 2006, TRENDS PHARMACOL SCI, V27, P348, DOI 10.1016/j.tips.2006.05.004; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Newman-Tancredi A, 2005, INT J NEUROPSYCHOPH, V8, P341, DOI 10.1017/S1461145704005000; Newman-Tancredi A, 2006, EUR NEUROPSYCHOPHARM, V16, pS232, DOI 10.1016/S0924-977X(06)70185-7; Newman-Tancredi A, 2002, MOL PHARMACOL, V62, P590, DOI 10.1124/mol.62.3.590; Ohta K, 2000, CHEM PHARM BULL, V48, P1504; Pauwels PJ, 1997, N-S ARCH PHARMACOL, V356, P551, DOI 10.1007/PL00005090; PEDIGO NW, 1981, J NEUROCHEM, V36, P220, DOI 10.1111/j.1471-4159.1981.tb02397.x; PIE PA, 2004, J MED CHEM, V47, P871; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; PORSOLT RD, 1979, EUR J PHARMACOL, V57, P201, DOI 10.1016/0014-2999(79)90366-2; Rabiner EA, 2000, NUCL MED BIOL, V27, P509, DOI 10.1016/S0969-8051(00)00120-7; Rice ASC, 2006, ANNU REV MED, V57, P535, DOI 10.1146/annurev.med.57.121304.131324; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; STOLLE WAW, 1992, J ORG CHEM, V57, P3000, DOI 10.1021/jo00037a011; Sullivan NR, 2005, N-S ARCH PHARMACOL, V371, P18, DOI 10.1007/s00210-004-1005-7; Tallarida R.J., 1987, MANUAL PHARMACOLOGIC, VSecond; TRICKLEBANK MD, 1984, EUR J PHARMACOL, V106, P271, DOI 10.1016/0014-2999(84)90714-3; Vacher B, 1999, J MED CHEM, V42, P1648, DOI 10.1021/jm9806906; Vacher B, 1998, J MED CHEM, V41, P5070, DOI 10.1021/jm9804329; VACHER B, 1998, Patent No. WO9822459; YOCCA FD, 1992, MOL PHARMACOL, V41, P1066	71	48	50	1	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	OCT 4	2007	50	20					5024	5033		10.1021/jm070714l			10	Chemistry, Medicinal	Pharmacology & Pharmacy	216II	WOS:000249871300021	17803293				2021-06-18	
J	Chlu, WT; Huang, SJ; Tsai, SH; Lin, JW; Tsai, MD; Lin, TJ; Huang, WCW				Chlu, Wen-Ta; Huang, Sheng-Jean; Tsai, Shin-Han; Lin, Jia-Wei; Tsai, Ming-Da; Lin, Tien-Jen; Huang, William C. W.			The impact of time, legislation, and geography on the epidemiology of traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						traumatic head injury; rural and urban; follow up study	HEAD-INJURY; POPULATION; URBAN; COUNTRY; TAIWAN	In 1991. a population-based epidemiologic traumatic brain injury (TBI) study was done in urban and rural areas of Taiwan; this was 5 years;cars before the helmet use law was passed and 8 years before the drink driving law was passed. In order to evaluate the impact of three major determinants (time. geography, and legislation) on the epidemiology of TBI, we conducted a prospective study in 2001 and used the 1991 data to examine the differences in TBI distribution in urban and rural Taiwan a decade after these laws were passed. In 2001, 5754 TBI cases were collected from the urban area of Taipei City. and 1474 TBI cases were collected from the rural area of Hualien County;. The TBI incidence rate in Taipei City in 2001 was estimated to be 218/100,000 population (285/100,000 for males and 152/ 100.000 for females). When compared to the 1991 data, the incidence rate in 2001 had increased by 20%. The TBI incidence rate in Hualien County; in 2001 was estimated to be 417/100.000 population (516/100,000 for males and 306/100,000 for females), this was a 37% increase over the 1991 data. Our Study found that the distribution of causes and age distribution had shifted significantly over the 10-year period. In 2001. the age group With the hi-hest incidence was 20-29 years, while in 1991 it had been the over 70 years age group. While traffic-related TBI had decreased. falls and assaults had increased in 2001. We also found that legislation, such as the helmet law, affects TBI distribution by decreasing the traffic-related TBI rate, decreasing the admission severity of TBI, and reducing TBI-related mortality. Finally. geography plays a crucial role in the outcome of TBI: over the 10 year period, Taipei had an increase in moderately severe outcomes. while Hualien had an increase in more severe outcomes. Comparative studies of TBI in urban and rural areas have shown that time. legislation. and geography are Crucial determinants of TBI epidemiology. Although time and legal interventions seem to have more of an impact. geography does affect TBI outcomes. (c) 2006 Elsevier Ltd. All rights reserved.	Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan; Taipei Med Univ, Inst Injury Prevent & Control, Taipei, Taiwan; Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Neurosurg, Taipei, Taiwan; Taipei Med Univ Hosp, Wang Fan Hosp, Taipei, Taiwan	Huang, WCW (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan.	b870ll6O@tinu.edu.tw					BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Chiu WT, 1997, J CLIN NEUROSCI, V4, P469, DOI 10.1016/S0967-5868(97)90037-0; CHIU WT, 1995, J CLIN NEUROSCI, V2, P210, DOI 10.1016/S0967-5868(95)80004-2; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; CHIU WT, 1992, J TAIPEI MED COLL, V21, P1; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENNETT B, 1975, LANCET, V11, P480; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; *MIN TRANSP COMM, 2002, ROC TRAFF ACC ASS; *MIN TRANSP COMM, 2001, ROC TREND MOT US TAI; *MIN TRANSP COMM, 2005, ROC TABL CAT MOT VEH; Schootman M, 1999, BRAIN INJURY, V13, P995; SILVERBAGE CG, 1986, THESIS GOTHENBURG U; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; *TAIW DEP HLTH, 2002, VIT STAT TAIW 2001; TEASDALE G, 1974, LANCET, V2, P81; WASTON GS, 1981, AM J PUBLIC HEALTH, V71, P297; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x; YUAN E, ROC TABLE DISTRIBUTI; YUAN E, 2001, ROC TABLE AGE COMPOS	24	48	50	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	OCT	2007	14	10					930	935		10.1016/j.jocn.2006.08.004			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	217HE	WOS:000249938200003	17646104				2021-06-18	
J	Piazza, O; Russo, E; Cotena, S; Esposito, G; Tufano, R				Piazza, O.; Russo, E.; Cotena, S.; Esposito, G.; Tufano, R.			Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain; blood-brain barrier; brain; electroencephalography; complications; infections; complications; multiple organ dysfunction syndrome; complications; neurological	TRAUMATIC BRAIN-INJURY; S100 PROTEINS; ORGAN FAILURE; DEFINITIONS; EXPRESSION	Background. Sepsis-associated encephalopathy (SAE) is defined as a diffuse cerebral dysfunction induced by the systemic response to infection without any clinical or laboratory evidence of direct infectious involvement of the central nervous system. The astroglial protein S100B has been used as a marker of severity of brain injury and as a prognostic index in trauma patients and cardiac arrest survivors. We measured S100B serum levels in patients with severe sepsis to investigate if the severity of SAE correlated with an increase in S 10013 levels. Methods. Twenty-one patients, with a diagnosis of severe sepsis, were included in this study. S100B levels were measured at intensive care unit (ICU) admission, 72 h and 7 days after admission. Their association with markers of brain dysfunction such as Glasgow coma scale (GCS), and EEG, and with sepsis-related organ failure assessment score (SOFA) and ICU mortality was investigated. Results. Fourteen patients had elevated S100B levels. The levels did not correlate with GCS at admission, EEG pattern, or SOFA scores. Also, S100B levels did not differ between patients who recovered neurologically and those who did not (P=0.62). Conclusions. In severe sepsis, an increase in S100B does not allow the physicians to distinguish patients with severe impairment of consciousness from those with milder derangements or to prognosticate neurological recovery.	Univ Naples Federico 2, I-80131 Naples, Italy; IRCCS Pascale, Naples, Italy	Piazza, O (corresponding author), Univ Naples Federico 2, Via Pansini 5 Ed 8, I-80131 Naples, Italy.	orpiazza@unina.it	Piazza, Ornella/Q-2716-2019; Russo, Emanuele/AAP-5645-2020; Piazza, Ornella/G-5339-2012	Russo, Emanuele/0000-0002-6531-5527; Piazza, Ornella/0000-0002-0316-5930			BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; BOLTON CF, 1997, SHOCK SEPSIS ORGAN F; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Consales G, 2005, Minerva Anestesiol, V71, P39; Cotena S, 2006, J NEUROSURG, V104, P435, DOI 10.3171/ped.2006.104.6.435; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Edwards MM, 2006, J NEURAL TRANSM, V113, P1709, DOI 10.1007/s00702-006-0479-5; EIDELMANN LA, 1996, JAMA-J AM MED ASSOC, V14, P470; Esen F, 2005, CRIT CARE, V9, pR18, DOI 10.1186/cc3004; Gogos CA, 2003, J INFECTION, V47, P300, DOI 10.1016/S0163-4453(03)00101-4; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; JENNETT B, 1975, LANCET, V1, P480; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liu L, 2005, J NEUROCHEM, V92, P546, DOI 10.1111/j.1471-4159.2004.02909.x; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Piazza O, 2005, Minerva Chir, V60, P477; Piazza O, 2006, BRIT J ANAESTH, V96, P141, DOI 10.1093/bja/aei629; PIAZZA O, 2006, ACUTE PAIN, V8, P87; POLLARD V, 1997, SHOCK SEPSIS ORGAN F; RUSSO E, 2006, MINERVA ANESTESIOL, V72, P217; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wilson JX, 2003, CAN J NEUROL SCI, V30, P98, DOI 10.1017/S031716710005335X; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016	26	48	52	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	OCT	2007	99	4					518	521		10.1093/bja/aem201			4	Anesthesiology	Anesthesiology	221AL	WOS:000250198700010	17650519	Bronze			2021-06-18	
J	Schultzberg, M; Lindberg, C; Aronsson, AF; Hjorth, E; Spulber, SD; Oprica, M				Schultzberg, Marianne; Lindberg, Catharina; Aronsson, Asa Forslin; Hjorth, Erik; Spulber, Stefan D.; Oprica, Mircea			Inflammation in the nervous system - Physiological and pathophysiological aspects	PHYSIOLOGY & BEHAVIOR			English	Article						Alzheimer; cytokine; excitotoxicity; interleukin; ischaemia; melanocortin; neurodegeneration; temperature	INTERLEUKIN-1 RECEPTOR ANTAGONIST; MELANOCYTE-STIMULATING HORMONE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLOBAL CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; KAINIC ACID; MESSENGER-RNA; BODY-TEMPERATURE; RAT-BRAIN; CORE TEMPERATURE	There is ample evidence for the occurrence of inflammatory processes in most major neurodegenerative disorders, both in acute conditions such as traumatic brain injury and stroke, and in chronic disorders such as Alzheimer's disease, epilepsy, amyotrophic lateral sclerosis and Parkinson's disease. Studies on inflammatory factors such as pro- and antinflammatory cytokines in experimental models of neurodegenerative disorders suggest that they are not merely bystanders, but may be involved in the neurodegenerative process. In addition, there are findings indicating that inflammatory factors may have beneficial effects on the nervous system, particularly during development of the nervous system. The challenge is to understand when, where and during which circumstances inflammation and inflammatory factors are positive or negative for neuronal survival and functioning. Some of our studies on cytokines, particularly the interleukin-1 system, are summarised and discussed in relation to neurodegeneration, cognition, and temperature changes. (C) 2007 Elsevier Inc. All rights reserved.	Karolinska Univ Hosp, Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Neurodegenerat & Neuroinflammat,Novum, SE-14186 Stockholm, Sweden	Schultzberg, M (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Neurodegenerat & Neuroinflammat,Novum, 5th Floor, SE-14186 Stockholm, Sweden.	Marianne.Schultzberg@ki.se	Spulber, Stefan/J-2989-2012; Schultzberg, Marianne/E-7076-2014	Schultzberg, Marianne/0000-0002-8314-0927; Spulber, Stefan/0000-0001-8122-6738			Ahlenius S, 2002, NEUROPHARMACOLOGY, V43, P28, DOI 10.1016/S0028-3908(02)00076-X; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aksenova MV, 1996, NEUROSCI LETT, V211, P45, DOI 10.1016/0304-3940(96)12717-8; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Aronsson AF, 2006, NEUROPEPTIDES, V40, P65, DOI 10.1016/j.npep.2005.10.006; ARONSSON AF, IN PRESS J MOL NEURO; Bazzani C, 2001, J PHARMACOL EXP THER, V297, P1082; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Brennan FX, 2003, NEUROBIOL LEARN MEM, V80, P168, DOI 10.1016/S1074-7427(03)00060-1; BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Crisby M, 2004, NEUROSCI LETT, V369, P87, DOI 10.1016/j.neulet.2004.05.057; Dantzer R, 2004, EUR J PHARMACOL, V500, P399, DOI 10.1016/j.ejphar.2004.07.040; DEL BR, 1995, NEUROSCI LETT, V188, P70; Deng JP, 2004, AM J RESP CRIT CARE, V169, P749, DOI 10.1164/rccm.200303-372OC; Diana A, 1999, NEUROSCIENCE, V89, P137, DOI 10.1016/S0306-4522(98)00274-7; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Dunn AJ, 2000, ANN NY ACAD SCI, V917, P608, DOI 10.1111/j.1749-6632.2000.tb05426.x; Eriksson C, 2000, MOL BRAIN RES, V85, P103, DOI 10.1016/S0169-328X(00)00251-5; Eriksson C, 2000, J NEUROSCI RES, V60, P266, DOI 10.1002/(SICI)1097-4547(20000415)60:2<266::AID-JNR16>3.0.CO;2-P; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Garlind A, 1999, BRAIN RES, V826, P112, DOI 10.1016/S0006-8993(99)01092-6; GIACOBINI E, 1997, ALZHEIMER INSIGHTS, V3, P8; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Goshen I, 2003, ENDOCRINOLOGY, V144, P4453, DOI 10.1210/en.2003-0338; Hassoun HT, 2002, AM J PHYSIOL-GASTR L, V282, pG1059, DOI 10.1152/ajpgi.00073.2001; Ichiyama T, 2000, ANN NY ACAD SCI, V917, P221; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Jelaso AM, 1998, J COMP NEUROL, V394, P242, DOI 10.1002/(SICI)1096-9861(19980504)394:2<242::AID-CNE8>3.0.CO;2-2; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lindberg C, 2004, J NEUROIMMUNOL, V146, P99, DOI 10.1016/j.jneuroim.2003.10.047; Lindberg C, 2005, NEUROCHEM INT, V46, P551, DOI 10.1016/j.neuint.2005.01.004; Lindberg C, 2005, J MOL NEUROSCI, V27, P1, DOI 10.1385/JMN:27:1:001; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V171, P832, DOI 10.1016/0006-291X(90)91221-D; Mouton PR, 2002, BRAIN RES, V956, P30, DOI 10.1016/S0006-8993(02)03475-3; NOBEL CSI, 1995, NEUROIMMUNOMODULAT, V2, P61, DOI 10.1159/000096873; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Oprica M, 2004, ACTA NEUROPATHOL, V108, P69, DOI 10.1007/s00401-004-0868-5; Oprica M, 2003, J CELL MOL MED, V7, P127, DOI 10.1111/j.1582-4934.2003.tb00211.x; Oprica M, 2002, PEPTIDES, V23, P143, DOI 10.1016/S0196-9781(01)00590-3; OPRICA M, IN PRESS J CELL MOL; Oprica M, 2006, CYTOKINE, V35, P77, DOI 10.1016/j.cyto.2006.07.011; PECHNICK RN, 1989, NEUROPHARMACOLOGY, V28, P829, DOI 10.1016/0028-3908(89)90175-5; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; Spulber S, 2005, NEUROREPORT, V16, P69, DOI 10.1097/00001756-200501190-00016; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Strand FL, 1999, ANN NY ACAD SCI, V897, P1, DOI 10.1111/j.1749-6632.1999.tb07874.x; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tehranian R, 2001, NEUROSCI LETT, V301, P54, DOI 10.1016/S0304-3940(01)01592-0; TURSKI L, 1980, PSYCHOPHARMACOLOGY, V71, P35, DOI 10.1007/BF00433249; Vehmas AK, 2003, NEUROBIOL AGING, V24, P321, DOI 10.1016/S0197-4580(02)00090-8; Vezzani A, 2002, EPILEPSIA, V43, P30, DOI 10.1046/j.1528-1157.43.s.5.14.x; Viviani B, 2003, J NEUROSCI, V23, P8692; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	48	57	2	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	SEP 10	2007	92	1-2					121	128		10.1016/j.physbeh.2007.05.050			8	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	219QL	WOS:000250099600022	17597167				2021-06-18	
J	Jumisko, E; Lexell, J; Soderberg, S				Jumisko, Eija; Lexell, Jan; Soderberg, Siv			Living with moderate or severe traumatic brain injury - The meaning of family members' experiences	JOURNAL OF FAMILY NURSING			English	Article						family; family members; traumatic; brain injury; phenomenological; hermeneutics; interpretation; responsibility; love; ethics; suffering; hope	CHRONIC ILLNESS; IMPACT	Traumatic brain injury (TBI) has long-lasting consequences not only for the individual with the injury but also for family members. The aim of this study is to elucidate the meaning of family members' experiences of living with an individual with moderate or severe TBI. The data have been collected by means of qualitative research interviews with 8 family member participants. A phenomenological hermeneutic interpretation (Ricouer, 1976) of the data reveal that family members struggle with their own suffering while showing compassion for the injured person. Their willingness to assume care for the injured person is derived from their feeling of natural love and the ethical demand to be responsible for the other. Hope and natural love from close relatives, the afflicted person, and other family members give the family members strength. It is important that professionals pay more attention to the suffering of close relatives.	Lulea Univ Technol, Div Nursing, Dept Hlth Sci, SE-97187 Lulea, Sweden	Jumisko, E (corresponding author), Lulea Univ Technol, Div Nursing, Dept Hlth Sci, SE-97187 Lulea, Sweden.	Eija.Jumisko@ltu.se		Lexell, Jan/0000-0001-5294-3332			Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; BENZEIN E, 1999, THESIS UMEA U SWEDEN; Benzein EG, 2000, WESTERN J NURS RES, V22, P303, DOI 10.1177/01939450022044430; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Carson P, 1993, J Neurosci Nurs, V25, P165; Chesla CA, 2005, J FAM NURS, V11, P371, DOI 10.1177/1074840705281781; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; CRISHOLM J, 2001, AXON, V23, P12; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Duff Diane, 2002, Axone, V24, P14; Engstrom Asa, 2004, Intensive Crit Care Nurs, V20, P299; Eriksson K., 1994, LIDANDE MANNISKAN; Eriksson K, 1993, MOTEN MED LIDANDE, P1; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [DOI 10.1002/J.2048-7940.2000.TB01862.X, 10.1002/j.2048-7940.2000.tb01862.x]; GRANT JS, 1997, J FAMILY NURSING, V1, P36; Guba E.G., 1989, 4 GENERATION EVALUAT; Johnson B P, 1995, J Neurosci Nurs, V27, P113; JUMISKO E, 2005, J NEUROSCIENCE NURSI, V36, P20; Kneafsey R, 2004, J CLIN NURS, V13, P601, DOI 10.1111/j.1365-2702.2004.00903.x; Kuyper MB, 1998, QUAL HEALTH RES, V8, P237, DOI 10.1177/104973239800800207; KVALE S, 1997, COMMUNICATION; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; Lindholm L, 2002, SCAND J CARING SCI, V16, P248, DOI 10.1046/j.1471-6712.2002.00093.x; Lindseth A, 2004, SCAND J CARING SCI, V18, P145, DOI 10.1111/j.1471-6712.2004.00258.x; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LOGSTRUP KE, 1956, ETISKA KRAVET; Lovasik D, 2001, Crit Care Nurs Q, V23, P24; MAY R, 1975, MODET ATT SKAPA; NADEN D, 2000, INT J HUMAN CARING, V4, P23; Nunkoosing K, 2005, QUAL HEALTH RES, V15, P698, DOI 10.1177/1049732304273903; Ohman M, 2004, QUAL HEALTH RES, V14, P396, DOI 10.1177/1049732303261692; Paterson B, 2001, Rehabil Nurs, V26, P48; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PUROLA H, 2000, THESIS U OULU FINLAN; Rehnsfeldt A, 2004, SCAND J CARING SCI, V18, P264, DOI 10.1111/j.1471-6712.2004.00281.x; Ricoeur, 1976, INTERPRETATION THEOR; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Smith J E, 2000, Care Manag J, V2, P27; Soderberg S, 2003, J ADV NURS, V42, P143, DOI 10.1046/j.1365-2648.2003.02597.x; SODERBERG S, 1999, THESIS UMEA U SWEDEN; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380	43	48	51	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1074-8407	1552-549X		J FAM NURS	J. Fam. Nurs.	AUG	2007	13	3					353	369		10.1177/1074840707303842			17	Family Studies; Nursing	Family Studies; Nursing	193AR	WOS:000248246100006	17641113				2021-06-18	
J	Smith, JS; Chang, EF; Rosenthal, G; Meeker, M; von Koch, C; Manley, GT; Holland, MC				Smith, Justin S.; Chang, Edward F.; Rosenthal, Guy; Meeker, Michele; von Koch, Cornelia; Manley, Geoffrey T.; Holland, Martin C.			The role of early follow-up computed tomography imaging in the management of traumatic brain injury patients with intracranial hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress of Neurological Surgeons Cerebrovascular Section/American-Society-of-Interventional-and-Therapeutic-Neuroradiology	APR 16-21, 2005	New Orleans, LA	Amer Assoc Neurol Surg		head injury; intracranial hemorrhage; serial CT; subarachnoid hemorrhage; traumatic brain injury	SEVERE HEAD-INJURY; CRITICALLY-ILL PATIENTS; SUBARACHNOID HEMORRHAGE; CEREBRAL VASOSPASM; EARLY DIAGNOSIS; TRANSPORT; SCAN; HYPOTENSION; CHILDREN; MODERATE	Background. The purpose of this study was to investigate whether routine follow-up computed tomography (CT) for patients with head injury, in the absence of clinical indications, alters patient management. Methods: Nonpenetrating head injury patients admitted to San Francisco General Hospital during an 18-month period were reviewed. Patients not surgically treated at presentation and with a routine follow-up head CT within 24 hours were included. Surgical and nonsurgical interventions after repeat CT were assessed. Clinical and imaging parameters were correlated with progressive hemorrhagic injury (PHI) and with delayed development of surgical lesions. Results: PHI was identified in 49 (42%) of 116 patients. None of these patients required a nonoperative intervention in response to the PHI. Six of these patients developed a neurologic change concurrent with routine follow-up imaging and required operative intervention. Thus, no patient underwent an intervention in response to a worsening head CT in the absence of clinical findings. Of the six patients who developed a surgical lesion, two had increased intracranial pressure, one had a change in pupillary examination, three had worsening mental status, and one had change in the motor examination. Univariate risk factors for development of a delayed surgical lesion included 5 to 10 mm of midline shift (p = 0.001), basal cistern effacement (p = 0.01), and higher Marshall score (p = 0.01) on initial CT imaging. Conclusion Although PHI is common with head injury, delayed interventions in the absence of clinical indicators are uncommon. Our data suggest that early follow-up CT imaging in the setting of head trauma is not routinely indicated. We suggest that assessment, based on the severity of findings on initial brain imaging and serial clinical examinations, should guide the need for follow-up imaging in the setting of head trauma.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Brain & Spinal Injury Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA	Smith, JS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779,Box 0112, San Francisco, CA 94143 USA.	jsmith1enator@gmail.com					BARANCIK JI, 1981, J TRAUMA, V21, P627, DOI 10.1097/00005373-198108000-00006; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; EHRENWERTH J, 1986, CRIT CARE MED, V14, P543, DOI 10.1097/00003246-198606000-00005; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FRENCH BN, 1977, SURG NEUROL, V7, P171; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Greene KA, 1996, J TRAUMA, V41, P964, DOI 10.1097/00005373-199612000-00004; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; GROLIMUND P, 1988, LANCET, V1, P1173; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; INDECK M, 1988, J TRAUMA, V28, P1020, DOI 10.1097/00005373-198807000-00018; INSEL J, 1986, CRIT CARE MED, V14, P539, DOI 10.1097/00003246-198606000-00004; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; RUTHERFORD WF, 1986, CRIT CARE MED, V18, pA414; SERVADEI F, 1988, NEUROSURGERY, V23, P41, DOI 10.1227/00006123-198807000-00009; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Servadei F, 2000, NEUROSURGERY, V46, P70; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sinson G, 2001, J TRAUMA, V51, P875; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; WADDELL G, 1975, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.5968.417; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533	66	48	53	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2007	63	1					75	82		10.1097/01.ta.0000245991.42871.87			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	190MI	WOS:000248062600014	17622872				2021-06-18	
J	Schneider, HJ; Samann, PG; Schneider, M; Croce, CG; Corneli, G; Sievers, C; Ghigo, E; Stalla, GK; Aimaretti, G				Schneider, H. J.; Saemann, P. G.; Schneider, M.; Croce, C. G.; Corneli, G.; Sievers, C.; Ghigo, E.; Stalla, G. K.; Aimaretti, G.			Pituitary imaging abnormalities in patients with and without hypopituitarism after traumatic brain injury	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						traumatic brain injury; hypopituitarism; MRI; sella imaging	HEAD TRAUMA	Recent evidence suggests that patients with traumatic brain injury (TBI) are at substantial risk of hypopituitarism. The pathomechanisms, however, are not completely understood yet. Little is known about the association of morphological changes in the sella region with pituitary function in TBI. In this study, we assessed morphological abnormalities of the sella region in patients with TBI and their relation to endocrine function. We studied magnetic resonance (MR) or computed tomography (CT) scans of 22 patients with TBI [17 men, S women, age (mean SD) 43.5 +/- 10.6 yr, time after trauma 17.4 +/- 15.0 yr]. Of these, 15 patients had some degree of hypopituitarism. We found abnormalities of the sella region in 80% of the patients with hypopituitarism and 29% of those without hypopituitarism (Fisher's exact test, p= 0.032). The most common abnormality was loss of volume or empty sella, followed by native signal in homogeneities, perfusion deficit, and lack of neurohypophyseal signal. Our results indicate that pituitary imaging abnormalities are more common in TBI patients with hypopituitarism than those without. Both immediate trauma-induced pathology as necrosis and hemorrhage as well as multifactorial mid- to long-term changes may underlie these abnormalities.	Max Planck Inst Psychiat, Nucl Magnet Resonance Res Grp, D-80804 Munich, Germany; Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Turin, Italy	Schneider, HJ (corresponding author), Max Planck Inst Psychiat, Nucl Magnet Resonance Res Grp, Kraepelinstr 10, D-80804 Munich, Germany.	schneider@mpipsykl.mpg.de					Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Casanueva FF, 2005, J ENDOCRINOL INVEST, V28, P299; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Castillo Mauricio, 2005, Top Magn Reson Imaging, V16, P259, DOI 10.1097/01.rmr.0000224682.91253.15; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; De Marinis L, 2005, J CLIN ENDOCR METAB, V90, P5471, DOI 10.1210/jc.2005-0288; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071	10	48	51	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1720-8386			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	APR	2007	30	4					RC9	RC12		10.1007/BF03346291			4	Endocrinology & Metabolism	Endocrinology & Metabolism	180QL	WOS:000247380500003	17556860				2021-06-18	
J	Smith, JM; Lunga, P; Story, D; Harris, N; Le Belle, J; James, MF; Pickard, JD; Fawcett, JW				Smith, Justin M.; Lunga, Precious; Story, David; Harris, Neil; Le Belle, Janel; James, Michael F.; Pickard, John D.; Fawcett, James W.			Inosine promotes recovery of skilled motor function in a model of focal brain injury	BRAIN			English	Article						plasticity; head injury; corticospinal tract; spinal cord; behavioural assessment; axon sprouting	PRIMARY SOMATOSENSORY CORTEX; SPINAL-CORD-INJURY; OCULAR DOMINANCE PLASTICITY; INDUCED MOVEMENT THERAPY; VISUAL-CORTEX; ADULT RATS; CORTICOSPINAL AXONS; STAIRCASE TEST; LIMB USE; STROKE	Recovery of function following traumatic brain injury (TBI) is partly through neuronal plasticity. However plasticity is limited in the adult CNS compared with young animals. In order to test whether treatments that enhance CNS plasticity might improve functional recovery after TBI, a new rat head injury model was developed, in which a computer-controlled impactor produced full thickness lesions of the forelimb region of the sensorimotor cortex. Behavioural deficits were seen in several sensorimotor tasks, most of which recovered spontaneously by 21 days. However, skilled paw reaching behaviour, a task that requires corticospinal function, was only similar to 40% recovered by 28 days. In order to promote plasticity inosine was infused into the lateral ventricles for 28 days. This treatment produced an almost complete recovery of skilled paw reaching ability, associated with sprouting of the uninjured corticospinal axons across the midline into the territory of the lesioned pathway. In the cervical spinal cord the number of corticospinal axons originating from the uninjured cortex that innervated the contralateral cervical cord was five times that of controls, and in the red nucleus the number of contralaterally projecting axons was four times control values. Inosine treatment did not affect recovery in unskilled behavioural tasks, most of which recovered to normal levels by 28 days without treatment. Animals were placed in an enriched environment as an alternative method to promote plasticity. This resulted in more rapid recovery in several tasks including skilled paw function, but by 28 days normally housed animals had caught up to the same level of improvement.	Univ Cambridge, Cambridge Ctr Brin Reapir, Cambridge CB1 5RH, England; Univ Calif Los Angeles, Sch Med, Dept Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA USA; GlaxoSmithKline, Neurol & GI Ctr Excellence Drug Discovery, Harlow, Essex, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England	Fawcett, JW (corresponding author), Univ Cambridge, Cambridge Ctr Brin Reapir, ED Adrian Bldg,Robinson Way, Cambridge CB1 5RH, England.	jfl08@cam.ac.uk		Fawcett, James/0000-0002-7990-4568; Harris, Neil/0000-0002-1965-6750	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0600986] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Barbay S, 2006, EXP BRAIN RES, V169, P106, DOI 10.1007/s00221-005-0129-4; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; Caggiano AO, 2005, J NEUROTRAUM, V22, P226, DOI 10.1089/neu.2005.22.226; CAO Y, 1994, P NATL ACAD SCI USA, V91, P9612, DOI 10.1073/pnas.91.20.9612; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Farr TD, 2002, STROKE, V33, P1869, DOI 10.1161/01.STR.0000020714.48349.4E; FINGER S, 1988, ARCH NEUROL-CHICAGO, V45, P1136, DOI 10.1001/archneur.1988.00520340090018; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Grill R, 1997, J NEUROSCI, V17, P5560; Grotta JC, 2004, STROKE, V35, P2699, DOI 10.1161/01.STR.0000143320.64953.c4; Hagg T, 2005, NEUROSCIENCE, V130, P875, DOI 10.1016/j.neuroscience.2004.10.018; Hensch TK, 2005, CURR TOP DEV BIOL, V69, P215, DOI 10.1016/S0070-2153(05)69008-4; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Hummel FC, 2005, CURR OPIN NEUROL, V18, P667, DOI 10.1097/01.wco.0000189876.37475.42; Irwin N, 2006, P NATL ACAD SCI USA, V103, P18320, DOI 10.1073/pnas.0605135103; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Jones TA, 1999, J NEUROSCI, V19, P10153; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Li Y, 1998, J NEUROSCI, V18, P10514; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; LORENZ KZ, 1958, SCI AM, V199, P67, DOI 10.1038/scientificamerican1258-67; Lynskey JV, 2006, J NEUROTRAUM, V23, P617, DOI 10.1089/neu.2006.23.617; Mark VW, 2004, RESTOR NEUROL NEUROS, V22, P317; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Piecharka DA, 2005, BRAIN RES BULL, V66, P203, DOI 10.1016/j.brainresbull.2005.04.013; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Pizzorusso T, 2006, P NATL ACAD SCI USA, V103, P8517, DOI 10.1073/pnas.0602657103; Raineteau O, 2001, P NATL ACAD SCI USA, V98, P6929, DOI 10.1073/pnas.111165498; Rittenhouse CD, 2006, J NEUROPHYSIOL, V95, P2947, DOI 10.1152/jn.01328.2005; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 1997, ADV NEUROL, V73, P229; Schwab ME, 2002, PROG BRAIN RES, V137, P351; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2; Whishaw IQ, 1997, BEHAV BRAIN RES, V89, P167, DOI 10.1016/S0166-4328(97)00057-0; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119; Zhao CS, 2005, BEHAV BRAIN RES, V160, P260, DOI 10.1016/j.bbr.2004.12.007; Zhao JC, 2005, EUR PHYS J E, V16, P49, DOI 10.1140/epje/e2005-00006-1; ZURN AD, 1988, P NATL ACAD SCI USA, V85, P8301, DOI 10.1073/pnas.85.21.8301	63	48	48	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2007	130		4				915	925		10.1093/brain/awl393			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	165GV	WOS:000246293300005	17293357				2021-06-18	
J	Johnson, MD; Kao, OE; Kipke, DR				Johnson, Matthew D.; Kao, Olivia E.; Kipke, Daryl R.			Spatiotemporal pH dynamics following insertion of neural microelectrode arrays	JOURNAL OF NEUROSCIENCE METHODS			English	Article						pH; brain trauma; insertion speed; microelectrode array; iridium oxide; potentiometry	TRAUMATIC BRAIN-INJURY; CORTICAL IMPACT MODEL; IRIDIUM OXIDE; SPREADING DEPRESSION; CEREBRAL-CORTEX; INTRACEREBRAL MICRODIALYSIS; HIPPOCAMPAL SLICES; DOPAMINE RELEASE; AMINO-ACIDS; SPINAL-CORD	Insertion trauma is a critical issue when assessing intracortical electrophysiological and neurochemical recordings. Previous reports document a wide variety of insertion techniques with speeds ranging from 10 mu m/s to 10 m/s. We hypothesize that insertion speed has an effect on tissue trauma induced by implantation of a neural probe. In order to monitor the neural interface during and after probe insertion, we have developed a silicon-substrate array with hydrous iridium oxide microelectrodes for potentiometric recording of extracellular pH (pH,), a measure of brain homeostasis. Microelectrode sites were sensitive to pH in the super-Nernstianrange (-85.9 mV/pH unit) and selective over other analytes including ascorbic acid, Na+, K+, Ca2+, and Mg2+. Following insertion, arrays recorded either triphasic or biphasic pH., responses, with a greater degree of prolonged acidosis for insertions at 50 mu m/s than at 0.5 mm/s or 1.0 mm/s (p < 0.05). Spatiotemporal analysis of the recordings also revealed micro-scale variability in the pH, response along the array, even when using the same insertion technique. Implants with more intense acidosis were often associated histologically with blood along the probe tract. The potentiometric microsensor array has implications not only as a useful tool to measure extracellular pH, but also as a feedback tool for delivery of pharmacological agents to treat surgical brain trauma. (c) 2006 Elsevier B.V. All rights reserved.	Univ Michigan, Dept Biomol Engn, Ann Arbor, MI 48109 USA	Kipke, DR (corresponding author), Univ Michigan, Dept Biomol Engn, 2149 LBME Bldg,1101 Beal Ave, Ann Arbor, MI 48109 USA.	dkipke@umich.edu	Johnson, Matthew/B-6276-2015	Johnson, Matthew/0000-0001-9686-5540	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000230, R21EB005022] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21-EB005022, P41-EB00230] Funding Source: Medline		AMMANN D, 1981, ANAL CHEM, V53, P2267, DOI 10.1021/ac00237a031; ANDERSON DJ, 1989, IEEE T BIO-MED ENG, V36, P693, DOI 10.1109/10.32101; Bai Q, 2000, IEEE T BIO-MED ENG, V47, P281, DOI 10.1109/10.827288; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; BENVENISTE H, 1987, J NEUROCHEM, V49, P729, DOI 10.1111/j.1471-4159.1987.tb00954.x; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Bezbaruah AN, 2002, ANAL CHEM, V74, P5726, DOI 10.1021/ac020326l; Biran R, 2005, EXP NEUROL, V195, P115, DOI 10.1016/j.expneurol.2005.04.020; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURKE LD, 1984, J ELECTROANAL CHEM, V175, P119, DOI 10.1016/S0022-0728(84)80350-2; BURKE LD, 1984, J ELECTROCHEM SOC, V131, pC298; CALDWELL PC, 1954, J PHYSIOL-LONDON, V126, P169, DOI 10.1113/jphysiol.1954.sp005201; CAMP DM, 1992, J NEUROCHEM, V58, P1706, DOI 10.1111/j.1471-4159.1992.tb10044.x; CASPERS H, 1972, EPILEPSIA, V13, P699, DOI 10.1111/j.1528-1157.1972.tb04403.x; Cham JG, 2005, J NEUROPHYSIOL, V93, P570, DOI 10.1152/jn.00369.2004; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Clapp-Lilly KL, 1999, J NEUROSCI METH, V90, P129, DOI 10.1016/S0165-0270(99)00064-3; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; DESALLES AAF, 1987, NEUROSURGERY, V20, P297, DOI 10.1227/00006123-198702000-00017; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENDRES W, 1986, NEUROSCI LETT, V72, P54, DOI 10.1016/0304-3940(86)90617-8; FOG A, 1984, SENSOR ACTUATOR, V5, P137, DOI 10.1016/0250-6874(84)80004-9; GOLDSMITH JD, 1995, HEARING RES, V83, P80, DOI 10.1016/0378-5955(94)00193-T; Grant SA, 2000, CRIT REV BIOMED ENG, V28, P159, DOI 10.1615/CritRevBiomedEng.v28.i12.270; GRICHTCHENKO II, 1994, NEUROSCIENCE, V62, P1057, DOI 10.1016/0306-4522(94)90343-3; Groothuis DR, 1998, BRAIN RES, V803, P218, DOI 10.1016/S0006-8993(98)00572-1; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hendrikse J, 1998, SENSOR ACTUAT B-CHEM, V53, P97, DOI 10.1016/S0925-4005(98)00298-6; Holson RR, 1998, BRAIN RES, V808, P182, DOI 10.1016/S0006-8993(98)00816-6; HOUSE PA, 2006, NEUROSURG FOCUS, V20; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; ICHIKAWA K, 1989, J APPL PHYSIOL, V67, P193; JENSEN W, 2003, P IEEE ENG MED BIOL; Johnson MD, 2005, IEEE T NEUR SYS REH, V13, P160, DOI 10.1109/TNSRE.2005.847373; JOHNSON MD, 2006, P IEEE ENG MED BIOL; JONES KE, 1992, ANN BIOMED ENG, V20, P423, DOI 10.1007/BF02368134; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMPSKI O, 1988, NEUROCHEM PATHOL, V9, P109; Khan AS, 2003, TRAC-TREND ANAL CHEM, V22, P503, DOI 10.1016/S0165-9936(03)00908-7; Kimelberg Harold K., 1998, P651; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KINLEN PJ, 1994, SENSOR ACTUAT B-CHEM, V22, P13, DOI 10.1016/0925-4005(94)01254-7; Kipke DR, 2003, IEEE T NEUR SYS REH, V11, P151, DOI 10.1109/TNSRE.2003.814443; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; LaManna J C, 1986, Adv Exp Med Biol, V200, P253; Liu X, 1999, IEEE Trans Rehabil Eng, V7, P315, DOI 10.1109/86.788468; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; McCreery D, 2004, IEEE T NEUR SYS REH, V12, P195, DOI 10.1109/TNSRE.2004.827223; McIntosh TK, 1996, LAB INVEST, V74, P315; Menna G, 2000, J NEUROPHYSIOL, V83, P1338; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nicolelis MAL, 2003, P NATL ACAD SCI USA, V100, P11041, DOI 10.1073/pnas.1934665100; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLTHUIS W, 1990, SENSOR ACTUAT B-CHEM, V2, P247, DOI 10.1016/0925-4005(90)80150-X; Otto KJ, 2006, IEEE T BIO-MED ENG, V53, P333, DOI 10.1109/TBME.2005.862530; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPESCHI G, 1981, J MED ENG TECHNOL, V5, P86, DOI 10.3109/03091908109042445; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Peters JL, 2004, J NEUROSCI METH, V137, P9, DOI 10.1016/j.jneumeth.2004.02.006; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Prochazka A, 2001, J PHYSIOL-LONDON, V533, P99, DOI 10.1111/j.1469-7793.2001.0099b.x; Purushothaman G, 2006, J NEUROSCI METH, V153, P86, DOI 10.1016/j.jneumeth.2005.10.015; Rennaker RL, 2005, J NEUROSCI METH, V142, P169, DOI 10.1016/j.jneumeth.2004.08.009; ROBBLEE LS, 1983, J ELECTROCHEM SOC, V130, P731, DOI 10.1149/1.2119793; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROUSCHE PJ, 1992, ANN BIOMED ENG, V20, P413, DOI 10.1007/BF02368133; SCHELLER D, 1992, NEUROSCI LETT, V135, P83, DOI 10.1016/0304-3940(92)90141-S; Schwartz AB, 2004, ANNU REV NEUROSCI, V27, P487, DOI 10.1146/annurev.neuro.27.070203.144233; Siesjo BK, 1996, ADV NEUROL, V71, P209; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Theodore WH, 2004, LANCET NEUROL, V3, P111, DOI 10.1016/S1474-4422(03)00664-1; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; URBANICS R, 1978, PFLUG ARCH EUR J PHY, V378, P47, DOI 10.1007/BF00581957; Vetter RJ, 2004, IEEE T BIO-MED ENG, V51, P896, DOI 10.1109/TBME.2004.826680; VOIPIO J, 1995, J NEUROPHYSIOL, V74, P633; VOIPIO J, 1993, PFLUG ARCH EUR J PHY, V423, P193, DOI 10.1007/BF00374394; Watson CJ, 2006, ANAL CHEM, V78, P1391, DOI 10.1021/ac0693722; WESTERINK BHC, 1988, J NEUROCHEM, V51, P683, DOI 10.1111/j.1471-4159.1988.tb01798.x; Williams JC, 1999, BRAIN RES PROTOC, V4, P303, DOI 10.1016/S1385-299X(99)00034-3	84	48	48	2	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2007	160	2					276	287		10.1016/j.jneumeth.2006.09.023			12	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	146NG	WOS:000244940600012	17084461				2021-06-18	
J	Hyllienmark, L; Amark, P				Hyllienmark, Lars; Amark, Per			Continuous EEG monitoring in a paediatric intensive care unit	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						adolescents; children; EEG; status epilepticus	TRAUMATIC BRAIN-INJURY; SEIZURES	Monitoring with continuous EEG (cEEG) has become a valuable tool in the adult neurointensive care unit. The benefits of cEEG or amplitude -integrated EEG in neonatal intensive care have also been described. The aim of the present study was to describe and evaluate the use of cEEG in a paediatric intensive care unit. The study is a description of children and adolescents with acute neurological disorders monitored by cEEG in a paediatric intensive care unit for more than 12 h. The indication for cEEG and the outcome are reported for 54 patients during a 4-year period. Twelve patients were monitored for high intracranial pressure, eight of whom died. Fourteen were monitored due to suspected, but not detected, epilepsy, their underlying diagnoses being variable. Refractory status epilepticus was the reason for cEEG in 24 cases. All of these patients survived the acute phase of status epilepticus. Four patients had seizure activity on cEEG due to global anoxia; these were not classified as status epilepticus. In conclusion, in the paediatric intensive care unit the most important indication for cEEG monitoring is in patients with suspected refractory status epilepticus where it adds to the diagnosis and choice of treatment. Continuous EEG should therefore be part of the paediatric intensive care unit technical support to select and monitor, among children with critical neurological disorders, those with refractory status epilepticus. (c) 2006 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	Karolinska Univ Hosp, Dept Neurol, SE-17176 Stockholm, Sweden; Karolinska Inst, Sect Neurol & Clin Neurophysiol, Stockholm, Sweden; Karolinska Inst, Inst Womens & Childrens Hlth, Neuropaediat Div, Stockholm, Sweden	Hyllienmark, L (corresponding author), Karolinska Univ Hosp, Dept Neurol, SE-17176 Stockholm, Sweden.	lars.hyllienmark@karolinska.se					Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; CONNELL J, 1989, ARCH DIS CHILD-FETAL, V64, P452, DOI 10.1136/adc.64.4_Spec_No.452; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Kaplan PW, 2006, J CLIN NEUROPHYSIOL, V23, P221, DOI 10.1097/01.wnp.0000220837.99490.66; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Nuwer MR, 1998, J CLIN NEUROPHYSIOL, V15, P458, DOI 10.1097/00004691-199811000-00002; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Ross C, 1999, SEIZURE-EUR J EPILEP, V8, P335, DOI 10.1053/seiz.1999.0300; RUEEGG SJ, 2003, CURR TREAT OPTION NE, V5, P93; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; WERTHEIM D, 1994, ARCH DIS CHILD-FETAL, V71, pF97, DOI 10.1136/fn.71.2.F97; Young GB, 1996, NEUROLOGY, V47, P83	16	48	52	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	MAR	2007	11	2					70	75		10.1016/j.ejpn.2006.11.005			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	150IC	WOS:000245208200002	17188917				2021-06-18	
J	Sohlberg, MM; Kennedy, M; Avery, J; Coelho, C; Turkstra, L; Ylvisaker, M; Yorkston, K				Sohlberg, McKay Moore; Kennedy, Mary; Avery, Jack; Coelho, Carl; Turkstra, Lyn; Ylvisaker, Mark; Yorkston, Kathryn			Evidence-based practice for the use of external aids as a memory compensation technique	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PRACTICE GUIDELINES; ASSISTIVE TECHNOLOGY; PAGING SYSTEM; HEAD-INJURY; REHABILITATION; IMPAIRMENTS; REMEDIATION; THERAPY; PATIENT		Univ Oregon, Eugene, OR 97403 USA; Univ Minnesota, Minneapolis, MN USA; Univ Connecticut, Storrs, CT USA; Univ Wisconsin, Madison, WI USA; Coll St Rose, Albany, NY USA; Univ Washington, Seattle, WA 98195 USA	Sohlberg, MM (corresponding author), Univ Oregon, Eugene, OR 97403 USA.	mckay@uoregon.edu					ADAMS KM, 2003, BRAIN IMPAIRMENT, V4, P31; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Cole E, 1999, NEUROREHABILITATION, V12, P39; Crowe SF, 2003, NEUROPSYCHOL REHABIL, V13, P497, DOI 10.1080/09602010343000075; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Flavell J.H., 2002, COGNITIVE DEV, V4th; Fluharty George, 1993, Brain Injury, V7, P85, DOI 10.3109/02699059309008160; GOLPER LC, 2001, EVIDENCE BASED PRACT; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HART T, 2004, J HEAD TRAUMA REHAB, V18, P725; Kennedy MRT, 2002, J MED SPEECH-LANG PA, V10, pIX; Kerns K A, 1998, Pediatr Rehabil, V2, P77; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; TURKSTRA L, 2003, TECHNICAL REPORT USE; TURKSTRA L, 2005, SEMINARS SPEECH LANG, V26; TURKSTRA L, 2005, J MED SPEECH LANGUAG; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; World Health Organization, 2001, INT CLASS FUNCT DIS; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Yorkston KM, 2001, J MED SPEECH-LANG PA, V9, P243; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146	41	48	48	0	28	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	MAR	2007	15	1					XV	LI					37	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	157PF	WOS:000245731700003					2021-06-18	
J	Winn, S; Perkins, S; Walwyn, R; Schmidt, U; Eisler, I; Treasure, J; Berelowitz, M; Dodge, L; Frost, S; Jenkins, M; Johnson-Sabine, E; Keville, S; Murphy, R; Robinson, P; Yi, I				Winn, Suzanne; Perkins, Sarah; Walwyn, Rebecca; Schmidt, Ulrike; Eisler, Ivan; Treasure, Janet; Berelowitz, Mark; Dodge, Liz; Frost, Susie; Jenkins, Mari; Johnson-Sabine, Eric; Keville, Saskia; Murphy, Rebecca; Robinson, Paul; Yi, Irene			Predictors of mental health problems and negative caregiving experiences in carers of adolescents with bulimia nervosa	INTERNATIONAL JOURNAL OF EATING DISORDERS			English	Article						adolescent; bulimia; carer mental health	TRAUMATIC BRAIN INJURY; EXPRESSED EMOTION; SCHIZOPHRENIA; BURDEN; RELATIVES; PARTNERS; DISTRESS; DEPRESSION; ILLNESS; STRESS	Objective: This exploratory study focuses on the mental health (MH) and caregiving experience of carers of adolescents with Bulimia Nervosa (BN)/Eating Disorder not otherwise specified (EDNOS), aiming to determine: levels of MH problems in carers and if a negative experience of caregiving predicts carer MH status and which factors predict a negative experience of caregiving. Method: Hundred and twelve carers and 68 adolescents with BN/EDNOS completed self-report measures (General Health Questionnaire, Experience of Caregiving Inventory, Level of Expressed Emotion, Self-report Family Inventory, Inventory of Interpersonal Problems). Results: Over half of the carers reported some MH problems and a minority (5.4%) were experiencing considerable difficulties. A negative experience of caregiving predicted carer MH status. Higher weekly contact hours and patient ratings of expressed emotion (EE) predicted a negative experience of caregiving. Conclusions: Interventions focusing on reducing EE and contact hours could prove beneficial for both patient and caregiver outcomes. (c) 2006 by Wiley Periodicals, Inc.	Inst Psychiat, Eating Disorders Unit, PO59, London SE5 8AF, England; Royal Free Hosp, Dept Child & Adolescent Psychiat, London NW3 2QG, England; St Anns Hosp, Phoenix Wing Eating Disorders Serv, London, England; Royal Free Hosp, Royal Free Eating Disorders Serv, London NW3 2QG, England	Schmidt, U (corresponding author), Inst Psychiat, Eating Disorders Unit, PO59, De Crespigny Pk, Denmark Hill, London SE5 8AF, England.	u.schmidt@iop.kcl.ac.uk	Eisler, Ivan/C-8386-2009	Treasure, Janet/0000-0003-0871-4596; Eisler, Ivan/0000-0002-8211-7514; murphy, rebecca/0000-0001-9922-2700			Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; AUERBACHBARBER S, 1998, THESIS SCI ENG, V59, P1357; BEBBINGTON P, 1994, PSYCHOL MED, V24, P707, DOI 10.1017/S0033291700027860; BEBBINGTON PE, 1995, INT J MENT HEALTH, V24, P7, DOI 10.1080/00207411.1995.11449309; Blanchard C G, 1997, Oncology (Williston Park), V11, P189; Calhoun PS, 2002, J TRAUMA STRESS, V15, P205, DOI 10.1023/A:1015251210928; Cameron JI, 2002, CANCER-AM CANCER SOC, V94, P521, DOI 10.1002/cncr.10212; COLE JD, 1988, J CLIN PSYCHOL, V44, P392, DOI 10.1002/1097-4679(198805)44:3<392::AID-JCLP2270440313>3.0.CO;2-3; Cullen JS, 1997, INT J GERIATR PSYCH, V12, P1019, DOI 10.1002/(SICI)1099-1166(199710)12:10<1019::AID-GPS677>3.0.CO;2-3; Department of Health, 1999, CAR CAR NAT STRAT CA; DOSSETOR DR, 1994, J INTELL DISABIL RES, V38, P487; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Flaskerud J H, 1998, Health Care Women Int, V19, P23, DOI 10.1080/073993398246557; GIVEN CW, 1992, RES NURS HEALTH, V15, P271, DOI 10.1002/nur.4770150406; Goldberg D, 1988, USERS GUIDE GEN HLTH; Haigh R, 2003, EUR EAT DISORD REV, V11, P125, DOI 10.1002/erv.487; Hampson R.B., 1990, SUCCESSFUL FAMILIES; Hooker K, 2002, J GERONTOL B-PSYCHOL, V57, pP453, DOI 10.1093/geronb/57.5.P453; HOROWITZ LM, 1988, J CONSULT CLIN PSYCH, V56, P885, DOI 10.1037/0022-006X.56.6.885; Hung LC, 2002, J ADV NURS, V40, P96, DOI 10.1046/j.1365-2648.2002.02344.x; KAZARIAN SS, 1990, J CLIN PSYCHOL, V46, P306, DOI 10.1002/1097-4679(199005)46:3<306::AID-JCLP2270460310>3.0.CO;2-2; King RB, 2001, RES NURS HEALTH, V24, P307, DOI 10.1002/nur.1032; KINSTON W, 1986, J FAM THER, V8, P351, DOI 10.1046/j..1986.00731.x; Lazarus R.S., 1984, STRESS APPRAISAL COP; Matthews B., 2003, PSYCHOL HEALTH MED, V8, P46, DOI DOI 10.1080/1354850021000059250; Medeiros MMD, 2000, J RHEUMATOL, V27, P76; Nijboer C, 1999, CANCER, V86, P577, DOI 10.1002/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S; Nijboer C, 2000, GERONTOLOGIST, V40, P738, DOI 10.1093/geront/40.6.738; O'Farrell P, 2000, HEART LUNG, V29, P97; PHILLIP DG, 1997, THESIS SCI ENG, V57, P5341; Rosenheck R, 2000, J CLIN PSYCHIAT, V61, P671, DOI 10.4088/JCP.v61n0913; Santonastaso P, 1997, Eat Weight Disord, V2, P44; Scazufca M, 1996, BRIT J PSYCHIAT, V168, P580, DOI 10.1192/bjp.168.5.580; Scazufca M, 1998, PSYCHOL MED, V28, P453, DOI 10.1017/S0033291797005977; Schene AH, 1998, SCHIZOPHRENIA BULL, V24, P609, DOI 10.1093/oxfordjournals.schbul.a033352; Szmukler GI, 1996, SOC PSYCH PSYCH EPID, V31, P137, DOI 10.1007/BF00785760; TELCH CF, 1994, INT J EAT DISORDER, V15, P53, DOI 10.1002/1098-108X(199401)15:1&lt;53::AID-EAT2260150107&gt;3.0.CO;2-0; Treasure J, 2001, SOC PSYCH PSYCH EPID, V36, P343, DOI 10.1007/s001270170039; VAUGHN C, 1976, BRIT J SOC CLIN PSYC, V15, P157, DOI 10.1111/j.2044-8260.1976.tb00021.x; Wagner AW, 1997, AGING MENT HEALTH, V1, P132, DOI 10.1080/13607869757227; WRIGHT S, 1985, CAUSAL MODELS SOCIAL	41	48	48	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0276-3478	1098-108X		INT J EAT DISORDER	Int. J. Eating Disord.	MAR	2007	40	2					171	178		10.1002/eat.20347			8	Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology	Psychology; Nutrition & Dietetics; Psychiatry	136ZR	WOS:000244263100011	17089419				2021-06-18	
J	Wang, H; Durham, L; Dawson, H; Song, P; Warner, DS; Sullivan, PM; Vitek, MP; Laskowitz, DT				Wang, H.; Durham, L.; Dawson, H.; Song, P.; Warner, D. S.; Sullivan, P. M.; Vitek, M. P.; Laskowitz, D. T.			An apolipoprotein e-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: Evidence of pharmacogenomic interaction	NEUROSCIENCE			English	Article						apolipoprotein E; Alzheimer's disease; closed head injury; peptide; beta amyloid	NITRIC-OXIDE PRODUCTION; TRAUMATIC BRAIN-INJURY; SYSTEM INFLAMMATORY RESPONSE; AMYLOID PRECURSOR PROTEIN; E-DEFICIENT MICE; MICROGLIAL ACTIVATION; TRANSGENIC MICE; APOE GENOTYPE; OPTICAL FRACTIONATOR; MIMETIC PEPTIDES	Apolipoprotein E (apoE) modifies glial activation and the CNS inflammatory response in an isoform-specific manner. Peptides derived from the receptor-binding region of apoE have been demonstrated to maintain the functional activity of the intact protein, and to improve histological and functional deficits after closed head injury. In the current study, APOE2, APOE3, and APOE4 targeted replacement (TR) mice expressing the human apoE protein isoforms (apoE2, apoE3 and apoE4) were used in a clinically relevant model of closed head injury to assess the interaction between the humanized apoE background and the therapeutic apoE mimetic peptide, apoE(133-149). Treatment with the apoE-mimetic peptide reduced microglial activation and early inflammatory events in all of the targeted replacement animals and was associated with histological and functional improvement in the APOE2TR and APOE3TR animals. Similarly, brain beta amyloid protein (A beta)(1-42) levels were increased as a function of head injury in all of the targeted replacement mice, while treatment with apoE pepticle suppressed A beta(1-42) levels in the APOE2TR and APOE3TR animals. These results suggest a pharmacogenomic interaction between the therapeutic effects of the apoE mimetic peptide and the human apoE protein isoforms. Furthermore, they suggest that administration of apoE-mimetic peptides may serve as a novel therapeutic strategy for the treatment of acute and chronic neurological disease. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Cognosci Inc, Res Triangle Pk, NC 27709 USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R44 NS 43954] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS043954] Funding Source: NIH RePORTER		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; Colton CA, 2001, BBA-MOL BASIS DIS, V1535, P134, DOI 10.1016/S0925-4439(00)00092-2; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Bont N, 1999, J LIPID RES, V40, P680; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Egensperger R, 1998, BRAIN PATHOL, V8, P439; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Roselaar SE, 1998, J LIPID RES, V39, P1740; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	50	48	52	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 23	2007	144	4					1324	1333		10.1016/j.neuroscience.2006.11.017			10	Neurosciences	Neurosciences & Neurology	137SS	WOS:000244313100017	17187933				2021-06-18	
J	Butcher, I; McHugh, GS; Lu, J; Steyerberg, EW; Hernandez, AV; Mushkudiani, N; Maas, AIR; Marmarou, A; Murray, GD				Butcher, Isabella; McHugh, Gillian S.; Lu, Juan; Steyerberg, Ewout W.; Hernandez, Adrian V.; Mushkudiani, Nino; Maas, Andrew I. R.; Marmarou, Anthony; Murray, Gordon D.			Prognostic value of cause of injury in traumatic brain injury: Results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						cause of injury; outcome; predictors; prognosis; traumatic brain injury	HEAD-INJURIES; VARIABLES; DATABASE	We aimed to describe and quantify the relationship between cause of injury and final outcome following traumatic brain injury (TBI). Individual patient data (N = 8708) from eight therapeutic Phase III randomized clinical trials in moderate or severe TBI, and three TBI surveys were used to investigate the relationship between cause of injury and outcome, as assessed by the Glasgow Outcome Scale (GOS) at 6 months. Proportional odds methodology was applied to quantify the strength of the association and expressed as an odds ratio in a meta-analysis. Heterogeneity across studies was assessed and associations with other predictive factors explored. In a univariate analysis, a strong association between the cause of injury and long-term outcome in moderate to severe TBI patients was observed, with consistent results across the studies. Road traffic accidents (OR 0.66, 95% CI 0.60-0.73), assaults (OR 0.66, 95% CI 0.52-0.84), and injuries sustained during sporting or recreational activities (OR 0.45, 95% CI 0.28-0.71) were all associated with better outcomes than the reference category of falls. Falls were found to be associated with an older age and with a higher incidence of mass lesions. Following adjustment for age in the analysis, the relationship between cause of injury and outcome was lost.	Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Butcher, I (corresponding author), Univ Edinburgh, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Izzy.Butcher@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; Hernandez, Adrian V./0000-0002-9999-4003; Lu, Juan/0000-0002-5389-7603	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		AMACHER AL, 1987, NEUROSURGERY, V20, P954; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNETT B, 1975, LANCET, V1, P480; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Rosenberg RI, 2005, J NEUROSURG, V102, P847, DOI 10.3171/jns.2005.102.5.0847; Sakellaropoulos GC, 1999, METHOD INFORM MED, V38, P37; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	13	48	50	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					281	286		10.1089/neu.2006.0030			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900007	17375992				2021-06-18	
J	Nakashima, T; Nakayama, N; Miwa, K; Okumura, A; Soeda, A; Iwama, T				Nakashima, T.; Nakayama, N.; Miwa, K.; Okumura, A.; Soeda, A.; Iwama, T.			Focal brain glucose hypometabolism in patients with neuropsychologic deficits after diffuse axonal injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							ALZHEIMERS-DISEASE; CINGULATE CORTEX; DEFAULT MODE; HEAD-INJURY; PET; IMAGES; PERFORMANCE; HYPOTHESIS; MEMORY; MONKEY	BACKGROUND AND PURPOSE: Neuropsychologic deficits are well-known sequelae of traumatic brain injury. However, the cerebral correlates of these deficits are still unclear. The aim of the present study was to elucidate the regions of cerebral dysfunction correlated with such neuropsychologic deficits after traumatic brain injury. METHODS: Sets of fluorine-18 fluorodeoxyglucose-positron-emission tomography (FDG-PET) images in the resting state were obtained from 12 patients with neuropsychologic deficits after diffuse axonal injury and from 32 healthy volunteers. The cortical metabolic activity of each subject's PET image sets was extracted using 3D stereotactic surface projection (3D-SSP). A "normal" data base was created using the extracted datasets of the healthy subjects. The patients' datasets were compared with the normal data base by calculating a statistical Z-score on a pixel-by-pixel basis in searches for focal metabolic abnormalities. RESULTS: Group comparisons revealed hypometabolism in the cingulate gyrus with additional involvement of the lingual gyrus and cuneus. Individual case-by-case analyses disclosed differences in the site and extent of the hypometabolism in the cingulate gyrus of each case. Predominant hypometabolism was found in the anterior cingulate gyrus of 6 patients, the middle cingulate gyrus of 2 patients, and the posterior cingulate gyrus of 4 patients. CONCLUSION: Interpretation of FDG-PET using 3D-SSP facilitates the identification of regional hypometabolism in the cerebral cortex of patients after diffuse axonal injury. Dysfunction of the cingulate gyrus, lingual gyrus, and cuneus may play a crucial role in neuropsychologic deficits after traumatic brain injury.	Kizawa Mem Hosp, Dept Neurosurg, Chubu Ryogo Ctr, Gifu 5050034, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan	Nakashima, T (corresponding author), Kizawa Mem Hosp, Dept Neurosurg, Chubu Ryogo Ctr, 630 Shimokobi, Gifu 5050034, Japan.	torinaka@quartz.ocn.ne.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19790994] Funding Source: KAKEN		Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BALEYDIER C, 1980, BRAIN, V103, P525, DOI 10.1093/brain/103.3.525; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FINN G, 1996, NATURE, V382, P626; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GRAHAM DI, 2000, HEAD INJURY, P176; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; ICHISE M, 1994, J NUCL MED, V35, P217; KADEKARO M, 1985, P NATL ACAD SCI USA, V82, P6010, DOI 10.1073/pnas.82.17.6010; Krasnow B, 2003, NEUROIMAGE, V18, P813, DOI 10.1016/S1053-8119(03)00002-8; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LEROUX PD, 2000, HEAD INJURY, P176; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Marshall SB, 1991, J NEUROSURG S, V75, P14; MATSUNAMI K, 1989, BRAIN RES BULL, V22, P829, DOI 10.1016/0361-9230(89)90026-9; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; Minoshima S, 1998, QUANTITATIVE FUNCTIONAL BRAIN IMAGING WITH POSITRON EMISSION TOMOGRAPHY, P133, DOI 10.1016/B978-012161340-2/50020-2; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Mizumura S, 2003, ANN NUCL MED, V17, P289, DOI 10.1007/BF02988523; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Stamatakis EA, 2002, J NUCL MED, V43, P476; Talairach J., 1998, COPLANAR STEREOTACTI	33	48	51	0	2	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2007	28	2					236	242					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	136ZS	WOS:000244263200013	17296986				2021-06-18	
J	Coben, JH; Steiner, CA; Miller, TR				Coben, Jeffrey H.; Steiner, Claudia A.; Miller, Ted R.			Characteristics of motorcycle-related hospitalizations: Comparing states with different helmet laws	ACCIDENT ANALYSIS AND PREVENTION			English	Article						motorcycles; injuries; hospitalizations; helmets	ECONOMIC-IMPACT; UNITED-STATES; TRAUMA; INJURIES; RATES	This study compares U.S. motorcycle-related hospitalizations across states with differing helmet laws. Cross-sectional analyses of hospital discharge data from 33 states participating in the Healthcare Cost and Utilization Project in 2001 were conducted. Results revealed that motorcyclists hospitalized from states without universal helmet laws are more likely to die during the hospitalization, sustain severe traumatic brain injury, be discharged to long-term care facilities, and lack private health insurance. This study further illustrates and substantiates the increased burden of hospitalization and long-term care seen in states that lack universal motorcycle helmet use laws. (c) 2006 Elsevier Ltd. All rights reserved.	W Virginia Univ, Dept Emergency Med, Injury Control Res Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Community Med, Injury Control Res Ctr, Morgantown, WV 26506 USA; US Dept Hlth & Human Serv, Ctr Delivery Org & Markets, Agcy Healthcare Res & Qual, Rockville, MD USA; Pacific Inst Res & Evaluat, Calverton, MD USA	Coben, JH (corresponding author), W Virginia Univ, Dept Emergency Med, Injury Control Res Ctr, POB 9151, Morgantown, WV 26506 USA.	jcoben@hsc.wvu.edu		Miller, Ted/0000-0002-0958-2639			*AG HEALTHC RES QU, 2006, HCUP REP HEALTHC COS; *AG HEALTHC RES QU, 2006, HCUP TOOLS SOFTW HEA; *AG HEALTHC RES QU, 2004, HCUP OV HEALTHC COST; AGRESTI A, 1990, CATEGORICAL DATA ANA, P54; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Branas CC, 2001, ACCIDENT ANAL PREV, V33, P641, DOI 10.1016/S0001-4575(00)00078-6; BRIED JM, 1987, CLIN ORTHOP RELAT R, P252; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; Coben JH, 2004, AM J PREV MED, V27, P355, DOI 10.1016/j.amepre.2004.08.002; Coben JH, 2003, AM J PREV MED, V24, P1, DOI 10.1016/S0749-3797(02)00578-0; Eastridge BJ, 2006, J TRAUMA, V60, P978, DOI 10.1097/01.ta.0000215582.86115.01; FLEISS JL, 1981, STATISTICAL METHODS, P71; Hotz Gillian A, 2004, Traffic Inj Prev, V5, P87, DOI 10.1080/15389580490269227; Hundley JC, 2004, J TRAUMA, V57, P944, DOI 10.1097/01.TA.0000149497.20065.F4; *INS I HIGH SAF, 2006, Q A MOT HELM US LAWS; *INS I HIGH SAF, 2006, HELM US LAWS; LAWRENCE BA, 2002, HS809242 DOT NAT HIG; Max W, 1998, J TRAUMA, V45, P550, DOI 10.1097/00005373-199809000-00023; Morris CC, 2006, ACCIDENT ANAL PREV, V38, P142, DOI 10.1016/j.aap.2005.08.004; *NAT HIGH TRAFF SA, 2004, MOT RID FAT AR INCR; *NAT HIGH TRAFF SA, 1996, 808347 DOT HS; *NAT HIGH TRAFF SA, 2004, TRAFF SAF FACTS 2004; *NAT HIGH TRAFF SA, 2003, TRAFF SAF FACTS 2003; *NAT HIGH TRAFF SA, 2004, TRAFF SAF FACTS CRAS; ORSAY E, 1995, ANN EMERG MED, V26, P455, DOI 10.1016/S0196-0644(95)70114-1; Paulozzi L. J., 2004, Morbidity and Mortality Weekly Report, V53, P1103; SHULMAN J, 2003, INVESTIGATION UTILIT; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; Ulmer R. G., 2005, 809849 DOT HS; *US DEP TRANSP FED, 2002, STAT MOT VEH REG 200	30	48	49	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2007	39	1					190	196		10.1016/j.aap.2006.06.018			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	130UT	WOS:000243825200023	16920053				2021-06-18	
J	Kreutzer, JS; Marwitz, JH; Hsu, N; Williams, K; Riddick, A				Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Hsu, Nancy; Williams, Kelli; Riddick, Amy			Marital stability after brain injury: An investigation and analysis	NEUROREHABILITATION			English	Article						brain injury; marriage; divorce	DYADIC ADJUSTMENT SCALE; HEAD-INJURY; SATISFACTION SCALE	Objective: To examine rates of separation and divorce after traumatic brain injury and identify factors relating to risk of marital breakdown. Participants: 120 persons who sustained a mild, moderate, or severe traumatic brain injury and who were married at the time of injury. Methods: Survivors were contacted between 30 and 96 months postinjury when demographic and marital status information was solicited. Injury information was obtained from medical records. Findings: A majority of patients remained married. The rate of divorce was 17% and 8% was the separation rate. People who were married longer before their injury, victims of non-violent injuries, older persons, and persons with less severe injuries were more likely to remain married. Gender, ethnicity, educational level, time elapsed since injury, and postinjury employment status were unrelated to risk for marital breakdown. Conclusion: Research findings do not support contentions that persons with brain injury are at greater risk for divorce relative to the general population. Nor do findings suggest that males are more likely to leave injured female partners. More research is needed to assess marital quality and the potential benefits of intervention programs designed to develop and maintain mutually supportive relationships.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu					Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; BUSBY DM, 1995, J MARITAL FAM THER, V21, P289, DOI 10.1111/j.1752-0606.1995.tb00163.x; Crane DR, 2000, AM J FAM THER, V28, P53, DOI 10.1080/019261800261815; Gosling J, 1999, BRAIN INJURY, V13, P785; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; KIMMEL D, 1974, J MARRIAGE FAM, V36, P57, DOI 10.2307/350994; KREIDER RM, 2005, CURRENT POPULATION R, P70; KREUTZER J, 1987, GEN HLTH HIST PROGRA; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RALEY PK, 2003, DEMOGR RES, V8, P245; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SCHUMM WR, 1983, PSYCHOL REP, V53, P567, DOI 10.2466/pr0.1983.53.2.567; STILWELL J, 1997, STUDIES, P1; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Webster G, 1999, BRAIN INJURY, V13, P593; White M. B., 1994, FAMILY PERSPECTIVE, V28, P53; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	24	48	48	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	1					53	59					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600006	17379948				2021-06-18	
J	Vanderploeg, RD; Belanger, HG; Duchnick, JD; Curtiss, G				Vanderploeg, Rodney D.; Belanger, Heather G.; Duchnick, Jennifer D.; Curtiss, Glenn			Awareness problems following moderate to severe traumatic brain injury: Prevalence, assessment methods, and injury correlates	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						awareness; brain injuries; Glasgow Coma Scale; neurobehavioral manifestations; postinjury deficits; posttraumatic amnesia; rehabilitation; self-awareness; TBI; unawareness	COMPETENCE RATING-SCALE; IMPAIRED SELF-AWARENESS; BEHAVIORS CHANGE INVENTORY; HEAD-INJURY; PRACTICAL SCALE; QUESTIONNAIRE; DEFICITS; FAMILY; CONCORDANCE; LIMITATIONS	We examined the degree to which individuals with a history of moderate to severe traumatic brain injury (TBI) are unaware of their postinjury deficits. We also examined correlates between awareness problems and injury acuteness and severity and whether awareness problems differed across behavioral domains. Self- and significant other (family member) ratings on the Key Behaviors Change Inventory (KBCI) were examined in 36 individuals an average of 2 years post-TBI. Family members reported greater problems postinjury than patients did, depending on the behavior in question and the level of patient awareness overall. Postinjury awareness problems were as prevalent as other behavioral problems measured by the KBCI but were not universally present. Some patients exhibited no awareness problems, others emergent awareness, and a minority poor awareness. Correlations revealed that as time postinjury increased, patients showed more accurate self-awareness than those whose injuries were more recent. Family members and patients agreed about preinjury functioning.	[Vanderploeg, Rodney D.; Belanger, Heather G.; Duchnick, Jennifer D.; Curtiss, Glenn] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Curtiss, Glenn] Def & Vet Brian Injury Ctr, Tampa, FL USA; [Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, 13000 N Bruce B Downs Blvd 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020				Barco P.P., 1991, COGNITIVE REHABILITA, P129; Belanger HG, 2002, CLIN NEUROPSYCHOL, V16, P251, DOI 10.1076/clin.16.3.251.13848; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DUCHNICK JD, 2002, CLIN NEUROPSYCHOL, V16, P209; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1996, BRAIN INJURY, V10, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; KOLITZ BP, 2000, THESIS U S FLORIDA T; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Sunderland A, 1984, EVERYDAY MEMORY ACTI, P191; TEASDALE G, 1974, LANCET, V2, P81; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Vanderploeg R. D., 2000, CLIN GUIDE NEUROPSYC, P195	41	48	49	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					937	949		10.1682/JRRD.2006.12.0163			13	Rehabilitation	Rehabilitation	253NL	WOS:000252524800007	18075951	Bronze			2021-06-18	
J	Chiu, WT; Huang, SJ; Hwang, HF; Tsauo, JY; Chen, CF; Tsai, SH; Lin, MR				Chiu, Wen-Ta; Huang, Sheng-Jean; Hwang, Hei-Fen; Tsauo, Jau-Yih; Chen, Chun-Fu; Tsai, Shin-Han; Lin, Mau-Roung			Use of the WHOQOL-BREF for evaluating persons with traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						health-related quality of life; injury severity; reliability; traumatic brain injury; validity	QUALITY-OF-LIFE; HEALTH; VALIDITY; REHABILITATION; INDIVIDUALS; RELIABILITY; INDICATORS; VALIDATION; TELEPHONE; SF-36	This study examined psychometric properties of a brief version of the World Health Organization Quality of Life questionnaire (WHOQOL-BREF) among persons with traumatic brain injury (TBI) and the relations of the WHOQOL-BREF domains, including physical capacity, psychological wellbeing, social relationships, and environment, to different indicators of TBI severity. Of the 354 eligible and available subjects from 22 hospitals in northern Taiwan over a 6-month period, 199 completed telephone interviews during data collection. Three indicators of TBI severity were used: the Glasgow Coma Scale, the presence of post-traumatic amnesia, and the abbreviated injury scale to the head. All domain scores of the WHOQOL-BREF had nearly symmetrical distributions: low percentages of ceiling and floor values (0 similar to 3%), low missing rates (0 similar to 0.5%) for all but one item (43.2%), and very good internal consistency (0.75 similar to 0.89) and test-retest reliability (0.74 similar to 0.95). The WHOQOL-BREF also exhibited excellent known-groups validity, as well as very good responsiveness and convergent validity with regard to employment, independence in daily life activities, social support, and depression. After adjustment for potential confounders, almost none of the domain scores of the WHOQOL-BREF significantly differed in the severity levels of the three severity indicators. In conclusion, the WHOQOL-BREF is an appropriate health-related quality of life (HRQL) instrument for persons with TBI. Furthermore, the initial severity of the TBI might not be suitable for predicting levels of HRQL in persons with TBI.	Taipei Med Univ, Inst Injury Prevent & Control, Taipei 110, Taiwan; Wan Fang Hosp, Dept Surg, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taipei Coll Nursing, Dept Nursing, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Sch & Grad Inst Phys Therapy, Taipei, Taiwan; St Marys Hosp, Dept Neurosurg, Yilan, Taiwan; Taipei Med Univ, Inst Injury Prevent & Control, Taipei, Taiwan	Lin, MR (corresponding author), Taipei Med Univ, Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 110, Taiwan.	mrlin@tmu.edu.tw		Tsauo, Jau-Yih/0000-0003-4607-4454			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Breitner J. C. S., 1990, Dementia and Geriatric Cognitive Disorders,, V1, P297, DOI [10.1159/000107157, DOI 10.1159/000107157]; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Cohen J, 1998, STAT POWER ANAL BEHA; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Curran D, 1998, OX MED PUBL, P249; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P403, DOI 10.1016/0895-4356(89)90128-5; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; HUNG JS, 1992, J FORMOS MED ASSOC, V90, P1227; Jackson RJ, 2003, AM J PUBLIC HEALTH, V93, P1382, DOI 10.2105/AJPH.93.9.1382; JENNETT B, 1975, LANCET, V1, P480; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LAZAR RB, 1989, ARCH PHYS MED REHAB, V70, P819; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; Leidy NK, 1999, EPILEPSIA, V40, P97, DOI 10.1111/j.1528-1157.1999.tb01995.x; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MAHONEY F I, 1965, Md State Med J, V14, P61; McDowell I, 1996, MEASURING HLTH GUIDE; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; OHANICK GJ, 1986, ADV PSYCHOSOM MED, V16, P173; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Revicki DA, 1997, HARVARD REV PSYCHIAT, V5, P75, DOI 10.3109/10673229709034730; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Schipper H, 1996, QUAL LIFE PHARMACOEC, V2, P11; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TENNSTEDT SL, 1992, AM J PUBLIC HEALTH, V82, P1541; Unal G, 2001, J CLIN EPIDEMIOL, V54, P587, DOI 10.1016/S0895-4356(00)00372-3; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; *WHO, 1994, MNHPSF944 WHO; *WHO, 1995, MNHPSF951 WHO; *WHOQOL TAIWAN GRO, 2000, MAN TAIW VERS WHOQOL; World Health Organization, 1996, WHOQOL BREF INTR ADM; World Health Organization, 1980, INT CLASS IMP DIS HA; Yao G, 2002, J FORMOS MED ASSOC, V101, P342; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	52	48	49	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2006	23	11					1609	1620		10.1089/neu.2006.23.1609			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	106RK	WOS:000242118200004	17115908				2021-06-18	
J	Schonberger, M; Humle, F; Teasdale, TW				Schonberger, Michael; Humle, Frank; Teasdale, Thomas W.			Subjective outcome of brain injury rehabilitation in relation to the therapeutic working alliance, client compliance and awareness	BRAIN INJURY			English	Article						therapeutic working alliance; awareness; compliance; acquired brain injury; rehabilitation; subjective outcome; process research	CLOSE RELATIVES; HEAD-INJURY; EXPERIENCE; DEFICITS	Objective: To investigate the relationship between working alliance, compliance, awareness and subjective outcome of brain injury rehabilitation. Subjects were 86 patients who were clients in an holistic neuropsychological outpatient rehabilitation programme. They had suffered a traumatic brain injury (n = 27), a cerebrovascular accident (n = 49) or some other neurological insult (n = 10). Measures: The therapeutic alliance, clients' awareness and their compliance were rated four times during the 14-week rehabilitation programme. The therapeutic alliance was rated by both clients and therapist using the Working Alliance Inventory (WAI), awareness and compliance were rated by the therapists. Clients completed the European Brain Injury Questionnaire (EBIQ) at programme start and end. Clients and therapists rated the overall success of their collaboration at programme end. Results: Clients' experience of a good emotional bond between themselves and therapists in mid-therapy was predictive for the reduction of clients' report of depressive symptoms on the EBIQ depression sub-scale (R = 0.68, n = 43, p < 0.001). Good compliance early in the programme was predictive of changes on the EBIQ. Improvement of awareness was related to the amplification of depressive symptoms (r = 0.27, n = 56, p < 0.05). Conclusions: Brain injury rehabilitation should be seen as a dynamic process that develops between clients and therapists. Future research should further investigate the relationship between process and outcome and how the therapeutic process can be optimized.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark; Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen S, Denmark	Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael.schoenberger@psy.ku.dk					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P33; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Bordin E. S., 1979, PSYCHOTHER-THEOR RES, V16, P252, DOI DOI 10.1037/H0085885; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; Cohen J., 1975, APPL MULTIPLE REGRES; Constantino M.J., 2002, COUNSELING BASED PRO, P81; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FLEMING J, 1995, BRIT J OCCUPATIONAL, V98, P55; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming JM, 1996, BRAIN INJURY, V10, P1; Henry WP., 1994, WORKING ALLIANCE THE, P51; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Lambert M.J., 2002, PSYCHOTHERAPY RELATI, P17; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Rogers CR., 1952, SCI AM, V187, P66, DOI [10.1038/scientificamerican1152-66, DOI 10.1038/SCIENTIFICAMERICAN1152-66]; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; SCHONBERGER M, 2005, NEUROPSYCHOL REHABIL, V16, P298; SCHONBERGER M, 2005, NEUROPSYCHOL REHABIL, V16, P561; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Tracey T. J., 1989, PSYCHOL ASSESS, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207]; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003	34	48	48	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2006	20	12					1271	1282		10.1080/02699050601049395			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DF	WOS:000242357800006	17132550				2021-06-18	
J	Sribnick, EA; Matzelle, DD; Ray, SK; Banik, NL				Sribnick, Eric Anthony; Matzelle, Deborah Denise; Ray, Swapan Kurnar; Banik, Naren Lal			Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						rat; calcium; neurotrauma; neurofilament protein; cytochrome c	GLUTAMATE-INDUCED APOPTOSIS; LIPID-PEROXIDATION; SECONDARY INJURY; BRAIN-INJURY; ER-ALPHA; RECEPTOR; BETA; CALCIUM; PROTEIN; DEGRADATION	Spinal cord injury (SCI) is a devastating neurologic injury, and currently, the only recommended pharmacotherapy is high-dose methylprednisolone, which has limited efficacy. Estrogen is a multi-active steroid with anti-oxidant and anti-apoptotic effects. Estrogen may modulate intracellular Ca2+ and prevent inflammation. For this study, male rats were divided into three groups. Sham-group animals received a laminectomy at T12. Injured rats received both laminectomy and 40 gram centimeter force SCI. Estrogen-group rats received 4 mg/kg 17 beta-estradiol (estrogen) at 15 min and 24 hr post-injury, and vehicle-group rats received equal volumes of dimethyl sulfoxide. Animals were sacrificed at 48 hr post-injury, and 1-cm segments of the lesion, rostral penumbra, and caudal penumbra were excised. The degradation of 68 kD neurofilament protein (NFP) and estrogen receptors (ER) was examined by Western blot analysis. Protein levels of calpain and the activities of calpain and caspase-3 were also examined. Levels of cytochrome c were determined in both cytosolic and mitochondrial fractions. Cell death with DNA fragmentation was examined using the TUNEL assay. At the lesion, samples from both vehicle and estrogen treated animals showed increased levels of 68 kD NFP degradation, calpain content, calpain activity, cytochrome c release, and degradation of ER alpha and ER beta, as compared to sham. In the caudal penumbra, estrogen treatment significantly attenuated 68 kD NFP degradation, calpain content, calpain activity, levels of cytosolic cytochrome c, and ER beta degradation. At the lesion, vehicle-treated animals displayed more TUNEL+ cells, and estrogen treatment significantly attenuated this cell death marker. We conclude that estrogen may inhibit cell death in SCI through calpain inhibition. (c) 2006 Wiley-Liss, Inc.	Med Univ S Carolina, Dept Neurosci, Div Neurol, Charleston, SC 29425 USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	baniknl@musc.edu	Sribnick, Eric/AAH-6693-2020		NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA-91460] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06-RR-015455] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM08716] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-45967, NS-38146, NS-41088, NS-31622] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA091460] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045967, R01NS031622, R01NS041088, R01NS038146] Funding Source: NIH RePORTER		Agrawal SK, 1996, J NEUROSCI, V16, P545; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1994, J NEUROSCI RES, V37, P489, DOI 10.1002/jnr.490370408; BANIK NL, 1983, NEUROCHEM RES, V8, P1389, DOI 10.1007/BF00964996; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bennett MVL, 1996, COLD SPRING HARB SYM, V61, P373; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Enari M, 1998, NATURE, V391, P43; FFRENCHCONSTANT C, 1994, J NEUROL, V242, pS29, DOI 10.1007/BF00939238; Gao G, 2000, J CELL BIOCHEM, V80, P53; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hosoda T, 2001, NEUROREPORT, V12, P1965, DOI 10.1097/00001756-200107030-00038; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kenchappa RS, 2004, FASEB J, V18, P1102, DOI 10.1096/fj.03-1075fje; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P9870, DOI 10.1073/pnas.152336999; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; Lee MO, 2002, MOL CELL ENDOCRINOL, V188, P47, DOI 10.1016/S0303-7207(01)00753-5; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Menuet A, 2004, J MOL ENDOCRINOL, V32, P975, DOI 10.1677/jme.0.0320975; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morales A, 2003, EUR J NEUROSCI, V18, P2505, DOI 10.1046/j.1460-9568.2003.02997.x; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Morin C, 2002, NEUROSCIENCE, V115, P415, DOI 10.1016/S0306-4522(02)00416-5; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; *NAT SPIN CORD INJ, 2004, SPIN CORD INJ FACTS; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ray SK, 2000, BRAIN RES PROTOC, V5, P305, DOI 10.1016/S1385-299X(00)00027-1; Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9; Ray SK, 2001, ANN NY ACAD SCI, V939, P436; Ray SK, 2001, BRAIN RES, V916, P115, DOI 10.1016/S0006-8993(01)02874-8; RAY SK, 2002, WILEY ENCY MOL MED, P435; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Springer JE, 2000, J NEUROSCI, V20, P7246; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tiidus PM, 2001, CAN J PHYSIOL PHARM, V79, P400, DOI 10.1139/cjpp-79-5-400; WAGNER BL, 1997, ESTROGENS PROGESTINS; Wang CN, 2001, J BIOL CHEM, V276, P5287, DOI 10.1074/jbc.M006406200; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang L, 2003, P NATL ACAD SCI USA, V100, P703, DOI 10.1073/pnas.242735799; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63	67	48	58	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT	2006	84	5					1064	1075		10.1002/jnr.21016			12	Neurosciences	Neurosciences & Neurology	092VG	WOS:000241124800016	16902996				2021-06-18	
J	Cutler, SM; VanLandingham, JW; Murphy, AZ; Stein, DG				Cutler, Sarah M.; VanLandingham, Jacob W.; Murphy, Anne Z.; Stein, Donald G.			Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						TBI; progesterone; GABA; silastic capsule; PGP; inflammation; apoptosis	CAPILLARY ENDOTHELIAL-CELLS; P-GLYCOPROTEIN EXPRESSION; GABA(A) RECEPTOR; NEUROACTIVE STEROIDS; FOCAL ISCHEMIA; RHESUS-MONKEYS; CEREBRAL EDEMA; NEURONAL LOSS; FEMALE RATS; WITHDRAWAL	The benefits of continuous progesterone release via subcutaneous silastic capsule implants were compared to daily subcutaneous injections in a rat model of traumatic brain injury (TBI). Adult male Sprague-Dawley rats received either bilateral frontal cortex contusions or sham surgery. Rats were injected with progesterone or vehicle at I and 6 h post-injury, then once every 24 h for six days with tapering of the dose over the final two treatments. Progesterone-packed silastic capsules were implanted post-injury while the animals were anesthetized. Behavioral assays for anxiety and locomotor activity were evaluated pre- and post-TBI. Brains were extracted eight days post-TBI and prepared for molecular assays. Decreased GABAA-4 levels complemented a decrease in anxiety behaviors on the Elevated Plus Maze for capsule compared to progesterone-injected animals prior to daily injections. All groups with implanted capsules increased locomotor activity compared to those given progesterone injections. In conclusion, steady-state progesterone treatment after TBI decreases edema and anxiety and increases activity, thus enhancing behavioral recovery. A continuous mode of pharmacological administration may prove to be more beneficial in translational and clinical testing than bolus injections over the same period of time. (c) 2006 Elsevier Inc. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA USA; Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	Cutler, SM (corresponding author), Emory Univ, Dept Emergency Med, Atlanta, GA USA.	sarahmelissa@gmail.com	Stein, Donald/AAJ-5139-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N540825, 1R01N538664] Funding Source: Medline		Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Barbaccia ML, 1997, BRIT J PHARMACOL, V120, P1582, DOI 10.1038/sj.bjp.0701046; Barbaccia ML, 2002, NEUROPHARMACOLOGY, V42, P782, DOI 10.1016/S0028-3908(02)00026-6; Biggio G, 2001, INT REV NEUROBIOL, V46, P207; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FANG SM, 1977, J PHARM SCI, V66, P1744, DOI 10.1002/jps.2600661223; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GANGRADE NK, 1992, BIOPHARM DRUG DISPOS, V13, P703, DOI 10.1002/bdd.2510130908; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gulinello M, 2003, EUR J NEUROSCI, V17, P641, DOI 10.1046/j.1460-9568.2003.02479.x; Gulinello M, 2002, NEUROPHARMACOLOGY, V43, P701, DOI 10.1016/S0028-3908(02)00171-5; Haik KL, 2000, EXP NEUROL, V163, P430, DOI 10.1006/exnr.2000.7384; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KUHL H, 1990, MATURITAS, V12, P171, DOI 10.1016/0378-5122(90)90003-O; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; LAUGHLAND DH, 1956, ANAL CHEM, V28, P817, DOI 10.1021/ac60113a012; LYLES R, 1988, OBSTET GYNECOL, V71, P44; Mima T, 1999, NEUROL RES, V21, P209, DOI 10.1080/01616412.1999.11740920; Oberye J, 2000, HUM REPROD, V15, P245, DOI 10.1093/humrep/15.2.245; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; ROBINSON J, 1981, J ENDOCRINOL, V90, P359, DOI 10.1677/joe.0.0900359; Rodgers RJ, 1997, BRAZ J MED BIOL RES, V30, P289, DOI 10.1590/S0100-879X1997000300002; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; SAMOTO K, 1994, NEUROL RES, V16, P217; SAMOTO K, 1994, ACTA NEUROCHIR, P257; Shao TC, 2003, PROSTATE, V57, P1, DOI 10.1002/pros.10266; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Smith SS, 2002, STEROIDS, V67, P519, DOI 10.1016/S0039-128X(01)00170-2; THAU RB, 1975, ENDOCRINOLOGY, V97, P454, DOI 10.1210/endo-97-2-454; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wilson ME, 1998, J ENDOCRINOL, V158, P247, DOI 10.1677/joe.0.1580247; WILSON ME, 1988, ENDOCRINOLOGY, V123, P2653, DOI 10.1210/endo-123-6-2653; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	48	48	49	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	JUL	2006	84	3					420	428		10.1016/j.pbb.2006.05.029			9	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	086XS	WOS:000240707000006	16870241				2021-06-18	
J	Kirchhoff, C; Stegmaier, J; Bogner, V; Buhmann, S; Mussack, T; Kreimeier, U; Mutschler, W; Biberthaler, P				Kirchhoff, Chlodwig; Stegmaier, Julia; Bogner, Viktoria; Buhmann, Sonja; Mussack, Thomas; Kreimeier, Uwe; Mutschler, Wolf; Biberthaler, Peter			Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						amino terminal proBNP; cerebrospinal fluid; computerized tomography; intracranial pressure; NT-proBNP; traumatic brain injury	NATRIURETIC-PEPTIDE; DIAGNOSIS; INFLAMMATION; SECRETION; ATRIAL	Outcome of patients suffering from traumatic brain injury (TBI) depends on the development of secondary brain damage. In this context, recent studies underlined the role of the natriuretic peptides-atrial natriuretic peptide and brain natriuretic peptide (BNP)-in aneurysmatic subarachnoidal hemorrhage (SAH). Especially BNP correlates with intracranial pressure and clinical outcome after SAH. Since its role in TBI remains unclear, the intracranial and systemic concentrations of N-terminal (NT)-proBNP were analyzed in patients suffering from severe TBI. We measured NT-proBNP levels in cerebrospinal fluid (CSF) and serum of 14 patients suffering from severe TBI (GCS <= 8 points) and 10 healthy control patients, using proBNP (R) assay (Roche (R) Diagnostics). Samples were collected after placement of a ventricular catheter, and at 12, 24, 48, and 72 h after TBI. CSF/serum albumin ratio (Q < a) was daily calculated. At 90 days after TBI, outcome was evaluated using the Glasgow Outcome Scale (GOS). In patients exhibiting a mean ICP of > 15 mm Hg (n = 6), the serum (800 +/- 150 pg/mL) and CSF levels (55 +/- 9 pg/mL) of NT-proBNP were significantly increased after 24 It, as compared to patients with ICP <= 15 mm of Hg (n = 8) as well as to control group. However, Q(a) as well as GOS did not significantly differ among both groups. For the first time, we evaluated intrathecal and systemic NT-proBNP concentrations in patients suffering from severe TBI. Interestingly, NT-proBNP in CSF and serum was significantly elevated in patients exhibiting an ICP of > 15 mm Hg. Further studies are currently performed to elucidate the physiologic role of NT-proBNP in TBI.	Univ Munich, Chirurg Klin & Poliklin, Klinikum Innenstadt, D-80336 Munich, Germany; Univ Munich, Inst Klin Radiol, Klinikum Grosshadern, D-80336 Munich, Germany; Univ Munich, Anasthesiol Klin, Klinikum Innenstadt, D-80336 Munich, Germany	Kirchhoff, C (corresponding author), Univ Munich, Chirurg Klin & Poliklin, Klinikum Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	Chlodwig.Kirchhoff@med.uni-muenchen.de					Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Berendes E, 2001, ANESTH ANALG, V93, P676, DOI 10.1097/00000539-200109000-00029; Charpentier J, 2004, CRIT CARE MED, V32, P660, DOI 10.1097/01.CCM.0000114827.93410.D8; de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1; Espiner EA, 2002, CLIN ENDOCRINOL, V56, P629, DOI 10.1046/j.1365-2265.2002.01285.x; Farin A, 2004, ACT NEUR S, V89, P101; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; JENNETT B, 1975, LANCET, V1, P480; Jernberg T, 2003, J AM COLL CARDIOL, V42, P1909, DOI 10.1016/j.jacc.2003.07.015; Lainchbury JG, 2003, J AM COLL CARDIOL, V42, P728, DOI 10.1016/S0735-1097(03)00787-3; Levin ER, 1998, NEW ENGL J MED, V339, P321; Ma KK, 2005, REGUL PEPTIDES, V128, P169, DOI 10.1016/j.regpep.2004.12.025; Mair J, 2001, CLIN CHEM LAB MED, V39, P571, DOI 10.1515/CCLM.2001.093; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; Sviri GE, 2003, ACTA NEUROCHIR, V145, P851, DOI 10.1007/s00701-003-0101-7; TAKAHASHI K, 1992, PEPTIDES, V13, P121, DOI 10.1016/0196-9781(92)90149-W; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497	22	48	51	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2006	23	6					943	949		10.1089/neu.2006.23.943			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	056TW	WOS:000238549000010	16774478				2021-06-18	
J	Lippert-Gruner, M; Kuchta, J; Hellmich, M; Klug, N				Lippert-Gruener, Marcella; Kuchta, Johannes; Hellmich, Martin; Klug, Norfrid			Neurobehavioural deficits after severe traumatic brain injury (TBI)	BRAIN INJURY			English	Article						neurobehavioural rating scale (NRS); traumatic brain injury	CLOSED-HEAD-INJURY; BEHAVIORAL SEQUELAE; RATING-SCALE	Objectives: Debilitating neurobehavioural sequalae often complicate traumatic brain injury (TBI). Cognitive deficits, particularly of attention, memory, information-processing speed and problems in self-perception, are very common following severe TBI. Method: The Neurobehavioural Rating Scale (NRS) is a multi-dimensional clinical-based assessment instrument designed and validated to measure neurobehavioural disturbances following TBI. This study examined 41 patients who were admitted to the intensive care unit of the Department of General Neurosurgery at Cologne University Hospital after severe TBI between January 1995 and July 2003. All 27 items of the NRS were assessed 6 and 12 months post-injury. Results: Subjects after severe TBI (GCS < 9) showed relatively high overall scores on the NRS, reflecting a high degree of overall neurobehavioural dysfunction. NRS items did not change significantly between 6 and 12 months post-trauma for anxiety, expressive deficit, emotional withdrawal, depressive mood, hostility, suspiciousness, fatigability, hallucinatory behaviour, motor retardation, unusual thought content, liability of mood and comprehension deficit. There was a tendency of improvement for inattention, somatic concern, disorientation, guilt feelings, excitement, poor planning and articulation deficits. For conceptual disorganization, disinhibition, memory deficit, agitation, inaccurate self-appraisal, decreased initiative, blunted affect and tension even a tendency for further deterioration in the post-traumatic follow-up was detected. Changes between 6 and 12 months post-TBI were statistically significant for disorientation ( improvement), inattention/reduced alertness ( improvement) and excitement ( deterioration). Conclusion: The data shows that neurobehavioural deficits after TBI do not show a general tendency to disappear over time. Some aspects related to self-appraisal, conceptual disorganization and affect may even deteriorate, thereby presenting a challenging problem for both the patients and relatives. This is in contrast to the parallel improvement of post-traumatic sensomotoric deficits.	Cologne Univ Hosp, Dept Neurosurg, D-50924 Cologne, Germany; Cologne Univ Hosp, Inst Med Stat Informat & Epidemiol, D-50924 Cologne, Germany	Kuchta, J (corresponding author), Univ Cologne, Dept Neurosurg, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	johannes.kuchta@uk-koeln.de					BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643	10	48	50	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2006	20	6					569	574		10.1080/02699050600664467			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100002	16754282				2021-06-18	
J	Pohl, M; Mehrholz, J				Pohl, M; Mehrholz, J			Immediate effects of an individually designed functional ankle-foot orthosis on stance and gait in hemiparetic patients	CLINICAL REHABILITATION			English	Article							HEMIPLEGIC GAIT; POSTURAL STABILITY; MUSCLE-ACTIVITY; CEREBRAL-PALSY; WALKING; BALANCE; RELIABILITY; PARAMETERS; SPASTICITY; LONG	Objective: To evaluate the immediate effects of individually designed functional in-shoe ankle-foot orthoses ( AFO) made of soft and hard cast on balance, standing, and gait parameters in hemiparetic patients. Design: Crossover design with randomized order of the intervention. Setting: A rehabilitation centre for adults with neurological disorders. Subjects: Twenty-eight patients with hemiparesis due to stroke or traumatic brain injury. Measures: Postural sway, standing and gait parameters based on ground reaction forces in two conditions: Patients were randomly assigned to varying sequences of wearing AFO in footwear or wearing footwear alone. Results: AFO significantly improved weight-bearing on the affected leg ( affected/unaffected side symmetry: 2.259 +/- 1.5 with AFO versus 3.49 +/- 2.5 without AFO, P < 0.05) and postural sway in stance ( 12.5 mm +/- 5.2 with AFO versus 15.7 mm +/- 6.7 without AFO, P<0.05), double stance duration ( 21.19 +/- 14.4% of gait cycle with AFO versus 25.99 +/- 21.6% of gait cycle without AFO, P < 0.05), and symmetry ratios of gait parameters such as stance duration ( 2.0 +/- 1.5 s with AFO versus 3.3 +/- 3.6 s without AFO, P < 0.05) and deceleration forces ( 1.6 +/- 0.5 with AFO versus 1.9 +/- 0.6 without AFO, P < 0.05) during gait. No significant differences were observed in all other symmetry ratios of gait parameters. Conclusion: An individually designed functional in-shoe AFO can improve stance and gait parameters, even in a single use, in patients with hemiparesis.	Klin Bavaria, Dept Early Neurol Rehabil, Kreischa, Germany; Tech Univ Dresden, Dept Publ Hlth, Dresden, Germany	Pohl, M (corresponding author), Klin Bavaria, Dept Early Rehabil, Wolfsschlucht 1-2, D-01731 Kreischa, Germany.	marcus.pohl@klinik-bavaria.de					BOBATH B, 1990, HEMIPLEGIE ERWACHSEN; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BURDETT RG, 1988, PHYS THER, V68, P1197; Burtner PA, 1999, DEV MED CHILD NEUROL, V41, P748, DOI 10.1017/S0012162299001516; Carr J. H., 2003, STROKE REHABILITATIO; Chen CL, 1999, ARCH PHYS MED REHAB, V80, P1587, DOI 10.1016/S0003-9993(99)90335-0; Churchill AJG, 2003, CLIN REHABIL, V17, P553, DOI 10.1191/0269215503cr649oa; Corcoran P J, 1970, Arch Phys Med Rehabil, V51, P69; Cross J, 2003, CLIN REHABIL, V17, P817, DOI 10.1191/0269215503cr683oa; DAVIES P, 1990, MITTELPUNKT; DIAMOND MF, 1990, PHYS THER, V70, P423, DOI 10.1093/ptj/70.7.423; EDWARDS S, 2001, NEUROLOGICAL PHYIOTH; Franceschini M, 2003, CLIN REHABIL, V17, P368, DOI 10.1191/0269215503cr622oa; Geboers JF, 2002, ARCH PHYS MED REHAB, V83, P240, DOI 10.1053/apmr.2002.27462; GLANTZ SA, 1998, BIOSTATISTIK; Gok H, 2003, CLIN REHABIL, V17, P137, DOI 10.1191/0269215503cr605oa; Hesse S, 1999, STROKE, V30, P1855, DOI 10.1161/01.STR.30.9.1855; Hesse S, 2003, CNS DRUGS, V17, P1093, DOI 10.2165/00023210-200317150-00004; Hesse S, 1996, INT J REHABIL RES, V19, P133, DOI 10.1097/00004356-199606000-00004; HESSE S, 1993, Z PHYSIOTHER, V45, P827; HESSE SA, 1994, STROKE, V25, P1999, DOI 10.1161/01.STR.25.10.1999; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Iwata M, 2003, ARCH PHYS MED REHAB, V84, P924, DOI 10.1016/S0003-9993(03)00012-1; Kirker SGB, 2000, J NEUROL NEUROSUR PS, V68, P458, DOI 10.1136/jnnp.68.4.458; Laufer Y, 2003, PHYS THER, V83, P112, DOI 10.1093/ptj/83.2.112; LeClair K, 1996, CLIN BIOMECH, V11, P176, DOI 10.1016/0268-0033(95)00027-5; LEHMANN JF, 1987, ARCH PHYS MED REHAB, V68, P763; Leung J, 2003, PHYSIOTHERAPY, V89, P39, DOI DOI 10.1016/S0031-9406(05)60668-2; MEHRHOLZ J, 2001, Z PHYSIOTHER, V53, P1334; Perry J, 1992, GAIT ANAL NORMAL PAT; Pohl M, 2003, ARCH PHYS MED REHAB, V84, P1760, DOI 10.1016/S0003-9993(03)00433-7; Romkes J, 2002, GAIT POSTURE, V15, P18, DOI 10.1016/S0966-6362(01)00178-3; SACHS L, 2004, ANGEWANDTE STAT; SCHUREN J, 1994, ARBEITEN SOFTCAST HD, P104; SIENKO TS, 2002, GAIT POSTURE, V16, P180; Stussi E, 1980, BIOMED TECH, V25, P222, DOI 10.1515/bmte.1980.25.s1.222; Tyson SF, 2001, CLIN REHABIL, V15, P53, DOI 10.1191/026921501673858908	37	48	52	0	35	HODDER ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	APR	2006	20	4					324	330		10.1191/0269215506cr951oa			7	Rehabilitation	Rehabilitation	034IZ	WOS:000236923900005	16719030				2021-06-18	
J	Kelly, G; Todd, J; Simpson, G; Kremer, P; Martin, C				Kelly, G; Todd, J; Simpson, G; Kremer, P; Martin, C			The overt behaviour scale (OBS): A tool for measuring challenging behaviours following ABI in community settings	BRAIN INJURY			English	Article						acquired brain injury; challenging behaviour; community settings; outcome measures	NEUROBEHAVIORAL RATING-SCALE; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; AGGRESSION; MANAGEMENT; VALIDITY; OUTCOMES	Objectives: The Overt Behaviour Scale (OBS) was designed as a comprehensive measure of common challenging behaviours observed after acquired brain injury (ABI) in community settings. The OBS comprises 34 items in nine categories that measure aggression, inappropriate sexual behaviour, perseveration, wandering, inappropriate social behaviour and lack of initiation. The aim of the current study was to determine the reliability, validity and responsiveness of the OBS. Method: Two adult community-based samples of people with ABI were recruited. Sample 1 ( n = 30) were concurrently evaluated on the OBS by two raters and again 1 week later to test stability. Other validating scales were also administered. Sample 2 ( n 28) were clients of the ABI Behaviour Consultancy who were treated for challenging behaviours and were administered the OBS before treatment commenced and then again 4 months later. Results: Inter-rater reliability and stability coefficients for the OBS total score was strong ( 0.97 and 0.77, respectively). Initial evidence of convergent and divergent validity was shown by the differential pattern of correlations with other measures. Moderate-to-strong coefficients ( range 0.37 - 0.66) were observed between the OBS and other measures that had behavioural content ( i. e. Mayo-Portland Adaptability Inventory, Current Behaviour Scale, Neurobehavioural Rating Scale - Revised). Divergent validity was shown by the lack of correlation between the OBS and the sub-scales of these tools that do not measure challenging behaviour. Finally, responsiveness was demonstrated with a significant decrease in OBS scores in the expected direction over the 4-month period. This improvement was confirmed by corroborating evidence from key informants. Conclusion: The OBS shows promise as a reliable, valid and responsive measure that can be used for the systematic assessment of challenging behaviours in community settings.	Epworth Med Fdn, ABI Behav Consultancy, Fitzroy, Vic 3068, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool, NSW, Australia; Deakin Univ, Sch Exercise & Nutr Sci, Geelong, Vic 3217, Australia	Kelly, G (corresponding author), Epworth Med Fdn, ABI Behav Consultancy, POB 1228, Fitzroy, Vic 3068, Australia.	glenn.kelly@abibehaviour.org.au	Kelly, Glenn/AAA-6894-2021; Kremer, Peter/I-8202-2019; Simpson, Grahame K/W-1074-2019	Kelly, Glenn/0000-0003-1670-3344; Kremer, Peter/0000-0003-2476-1958; Simpson, Grahame K/0000-0001-8156-9060			Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Barnes MP, 2001, J REHABIL MED, V33, P244; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Elsass L, 1989, P 14 ANN BRAIN IMP C, P124; Frosch S, 1997, BRAIN INJURY, V11, P891; Gardner RM, 2003, J HEAD TRAUMA REHAB, V18, P52, DOI 10.1097/00001199-200301000-00007; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; Godfrey HPD, 2003, BRAIN INJURY, V17, P427, DOI 10.1080/0269905031000066201; HULSE SH, 1958, PSYCHOL LEARNING; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; KAY SR, 1988, J NERV MENT DIS, V176, P539, DOI 10.1097/00005053-198809000-00007; Kelly G., 2004, BRAIN IMPAIR, V5, DOI [10.1375/brim.5.1.42.35398, DOI 10.1375/brim.5.1.42.35398]; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LANDIS JR, 1977, BIOMETRICS, V33, P174; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Pender N, 1999, NEUROPSYCHOL REHABIL, V9, P345, DOI 10.1080/096020199389428; PETERS M D, 1992, Brain Injury, V6, P299, DOI 10.3109/02699059209034944; Ponsford J., 1995, TRAUMATIC BRAIN INJU; RAY WA, 1992, J GERONTOL, V47, pM9, DOI 10.1093/geronj/47.1.M9; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; SORGI P, 1991, J NEUROPSYCHIAT, V3, P52; STRETTLES B, 2005, FORCED CHOICES ACCOM; Swan L, 2004, BRAIN INJURY, V18, P143, DOI 10.1080/02699050310001596923; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; Tate RL, 2004, BRAIN IMPAIR, V5, P81, DOI [10.1375/brim.5.1.81.35408, DOI 10.1375/brim.5.1.81.35408, DOI 10.1375/BRIM.5.1.81.35408]; Todd J, 2002, AUST J PSYCHOL, V54, P79; Tustin R. Don, 1991, Australia and New Zealand Journal of Developmental Disabilities, V17, P285; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Weatherman R, 1986, RURAL SPEC EDUC Q, V6, P58; Willis TJ, 2003, J HEAD TRAUMA REHAB, V18, P75, DOI 10.1097/00001199-200301000-00008; Wood RL, 2001, NEUROBEHAVIOURAL DIS; World Health Organization, 2001, INT CLASS FUNCT DIS; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	40	48	49	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					307	319		10.1080/02699050500488074			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400010	16537272				2021-06-18	
J	Worthington, AD; Melia, Y				Worthington, AD; Melia, Y			Rehabilitation is compromised by arousal and sleep disorders: Results of a survey of rehabilitation centres	BRAIN INJURY			English	Article						arousal; sleep disorder; insomnia; acquired brain injury; rehabilitation	TRAUMATIC BRAIN-INJURY; EXCESSIVE DAYTIME SLEEPINESS; PHARMACOLOGICAL-TREATMENT; INSOMNIA; DISTURBANCES; PHASE; ASSOCIATION; MANAGEMENT; COMPLAINTS; THERAPY	Primary objective: To investigate the impact of disorders of arousal and sleep disturbance on everyday living and participation in rehabilitation. Research design: Survey of rehabilitation centres based on naturalistic observation. Method: One hundred and thirty-five adults with acquired brain injury were reported by rehabilitation staff in seven centres across the UK for presence of arousal and/or sleep disturbance, the impact on rehabilitation and daily living and treatment strategies in use. Outcomes: Disturbance of arousal or sleep patterns was reported in 47% of the sample, with significant adverse effect on activity evident in two-thirds of such cases. Prevalence of disordered arousal was consistent over time for up to 10 years post-injury. Concurrent psychiatric illness, but not epilepsy, was associated with arousal and sleep disorder. Non-pharmacological interventions and benzodiazepine/hypnotic drugs were in use in 34% and 20% of cases respectively. In all cases of prescribed hypnotic drugs, period of use exceeded recommended UK guidelines. Conclusions: Long-term outcome from severe brain injury can be compromised by enduring disturbance of arousal, most commonly evidenced as sleep disorder. Treatment should be based on judicious use of medication ( beyond hypnotic drugs) and greater emphasis on non-pharmacological management.	Brain Injury Rehabil Trust, Birmingham B38 8JW, W Midlands, England	Worthington, AD (corresponding author), Brain Injury Rehabil Trust, W Heath House,54 Ivyhouse Rd,W Heath, Birmingham B38 8JW, W Midlands, England.	aworthington@birt.co.uk		Melia, Yvonne/0000-0003-4430-9379			Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; ASKENASY JJM, 1989, J NEUROLOGICAL REHAB, V3, P93; BAZIL CW, 2002, EPILEPSY CLIN SPECTR; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BEVERLEY C, 2002, J CLIN EXCELLENCE, V4, P429; Boivin DB, 2004, SLEEP, V27, P417, DOI 10.1093/sleep/27.3.417; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Busek P, 2000, Sb Lek, V101, P233; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; *DATAMOST CORP, 1994, STATMOST WIND STAT A; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Happe S, 2003, DRUGS, V63, P2725, DOI 10.2165/00003495-200363240-00003; Hauri PJ, 1997, SLEEP, V20, P1111, DOI 10.1093/sleep/20.12.1111; Ishigooka J, 1999, PSYCHIAT CLIN NEUROS, V53, P515, DOI 10.1046/j.1440-1819.1999.00578.x; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Medicis SW, 1998, J DENT RES, V77, P295; Morgan K, 2003, BRIT J GEN PRACT, V53, P923; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; Okuji Y, 2002, PSYCHIAT CLIN NEUROS, V56, P239, DOI 10.1046/j.1440-1819.2002.01012.x; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RICHTER KJ, 1995, J HEAD TRAUMA REHAB, V10, P7, DOI 10.1097/00001199-199512000-00004; Roth T, 2001, INT J CLIN PRACT, P3; Sateia MJ, 2004, LANCET, V364, P1959, DOI 10.1016/S0140-6736(04)17480-1; Siegel S., 1988, NONPARAMETRIC STAT B; Soldatos CR, 2001, CONTEMPORARY NEUROPSYCHIATRY, P405; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Walsh JK, 1999, SLEEP, V22, P371; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004	42	48	49	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					327	332		10.1080/02699050500488249			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400012	16537274				2021-06-18	
J	Kliegel, M; Jaeger, T				Kliegel, Matthias; Jaeger, Theodor			Delayed-execute prospective memory performance: The effects of age and working memory	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; RETROSPECTIVE MEMORY; EVENT; INTENTIONS; IMPAIRMENT; TIME; INDIVIDUALS; DEMENTIA; DEFICITS; YOUNGER	This study follows the novel delayed-execute prospective memory paradigm, which involves briefly delaying the execution of an intended action, a task that has been shown to produce substantial age effects. During the ongoing task, sentences were presented, and participants had to answer reading-comprehension questions and general knowledge questions. In the prospective memory task, the participant was to press a key after the presentation of a specific cue in the sentences-but not before a subsequent phase of the ongoing task was reached. In contrast to previous studies using older participants taken from very broadly defined age ranges, this study examines development of delayed-execute prospective memory more precisely by examining a total of 4 age groups: a younger age group (age range=22-31; n=27), a young-old age group (age range=60-69; n=34), a middle-old age group (age range =70-79; n=31), and an old-old age group (age range=80-91; n=35). This study investigates the dependence of (age-related) delayed-execute prospective memory performance on working memory capacity by disrupting the phonological loop during the delay period as well as its dependence on neuropsychological processes such as inhibitory control and processing speed. The results show that (a) delayed-execute prospective memory particularly declines within the group of older participants, (b) delayed-execute prospective memory is diminished when working memory load is high during the delay period, and (c) age-related performance in delayed-execute prospective memory may be mediated by inhibitory control. The findings are discussed in the context of the frontal lobe hypothesis of cognitive aging.	Univ Zurich, Dept Psychol, CH-8050 Zurich, Switzerland; Univ Saarland, Dept Psychol, D-6600 Saarbrucken, Germany	Kliegel, M (corresponding author), Univ Zurich, Dept Psychol, Binzmuhlestr 14-24, CH-8050 Zurich, Switzerland.	m.kliegel@psychologie.unizh.ch		Kliegel, Matthias/0000-0002-2001-2522			Baddeley A, 1999, BRAIN COGNITION, V41, P87, DOI 10.1006/brcg.1999.1097; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Burgess CP, 2003, J HIGH ENERGY PHYS; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; BURGESS PW, 2005, 2 INT C PROSP MEM ZU; CAEYENBERGHS K, 2005, 2 INT C PROSP MEM ZU; Cherry KE, 1999, PSYCHOL AGING, V14, P60, DOI 10.1037/0882-7974.14.1.60; Cherry KE, 2001, MEMORY, V9, P177, DOI 10.1080/09658210143000092; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; Einstein GO, 2003, J EXP PSYCHOL-APPL, V9, P147, DOI 10.1037/1076-898X.9.3.147; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Einstein GO, 2000, PSYCHOL AGING, V15, P671, DOI 10.1037//0882-7974.15.4.671; EINSTEIN GO, 1995, J EXPT PSYCHOL LEARN, V21, P284; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; ESCHEN A, 2005, 2 INT C PROSP MEM ZU; Fisk JE, 1996, PSYCHOL AGING, V11, P316, DOI 10.1037/0882-7974.11.2.316; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; GUYNN MJ, 2001, MEMORY ACTION DISTIN, P25; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; HOUX PJ, 1993, EXP AGING RES, V19, P209, DOI 10.1080/03610739308253934; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Huppert FA, 2000, APPL COGNITIVE PSYCH, V14, pS63, DOI 10.1002/acp.771; Kerns KA, 2001, CHILD NEUROPSYCHOL, V7, P162, DOI 10.1076/chin.7.3.162.8744; Kidder DP, 1997, AGING NEUROPSYCHOL C, V4, P93, DOI 10.1080/13825589708256639; Kirasic KC, 1996, PSYCHOL AGING, V11, P658, DOI 10.1037/0882-7974.11.4.658; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M, 2003, INT J PSYCHOL, V38, P193, DOI 10.1080/00207590344000114; LEHRL S, 1991, MEHRFACHWAHLWORTSCHA; Logie R, 2004, EUR J COGN PSYCHOL, V16, P441, DOI 10.1080/09541440340000114; Mantyla T, 1997, AGING NEUROPSYCHOL C, V4, P81, DOI 10.1080/13825589708256638; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; Marsh RL, 2002, PSYCHON B REV, V9, P604, DOI 10.3758/BF03196319; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Maylor EA, 1998, AGING NEUROPSYCHOL C, V5, P107, DOI 10.1076/anec.5.2.107.599; MAYLOR EA, 1993, PSYCHOL AGING, V8, P420, DOI 10.1037/0882-7974.8.3.420; Maylor EA, 1996, PSYCHOL AGING, V11, P74, DOI 10.1037/0882-7974.11.1.74; McDaniel MA, 2004, APPL COGNITIVE PSYCH, V18, P533, DOI 10.1002/acp.1002; McDaniel MA, 2003, PSYCHOL AGING, V18, P823, DOI 10.1037/0882-7974.18.4.823; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Park DC, 1997, PSYCHOL AGING, V12, P314, DOI 10.1037/0882-7974.12.2.314; Salthouse T.A., 1994, NEUROPSYCHOLOGY, V8, P535, DOI [DOI 10.1037/0894-4105.8.4.535, 10.1037/0894-4105.8.4.535]; Salthouse TA, 2004, MEM COGNITION, V32, P1133, DOI 10.3758/BF03196887; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Spieler DH, 1996, J EXP PSYCHOL HUMAN, V22, P461, DOI 10.1037/0096-1523.22.2.461; Stone M, 2001, MEMORY, V9, P165, DOI 10.1080/09658210143000100; STRONG WF, 1993, HOWARD J COMMUNICATI, V5, P18; Uttl B, 2001, CONSCIOUS COGN, V10, P451, DOI 10.1006/ccog.2001.0505; Wechsler D., 1981, WAIS R MANUAL WECHSL; West R, 2001, NEUROREPORT, V12, P2855, DOI 10.1097/00001756-200109170-00020; West R, 2001, PSYCHOL AGING, V16, P682, DOI 10.1037//0882-7974.16.4.682; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272	59	48	50	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2006	30	3					819	843		10.1207/s15326942dn3003_4			25	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	113OM	WOS:000242607200004	17083295				2021-06-18	
J	Prins, ML; Giza, CC				Prins, M. L.; Giza, C. C.			Induction of monocarboxylate transporter 2 expression and ketone transport following traumatic brain injury in juvenile and adult rats	DEVELOPMENTAL NEUROSCIENCE			English	Article						monocarboxylate transporter 2; ketones; traumatic brain injury	FUNCTION IMPROVING AGENT; BETA-HYDROXYBUTYRATE; MCT2; NEURONS; GLUCOSE; CONTUSION; ISCHEMIA; BODIES; CELLS; ADAPTATION	Based on recent work demonstrating age-dependent ketogenic neuroprotection after traumatic brain injury (TBI), it was hypothesized that the neuroprotection among early post-weaned animals was related to induced cerebral transport of ketones after injury. Regional changes in monocarboxylate transporter 2 (MCT2) were acutely examined with immunohistochemistry after sham surgery or controlled cortical impact injury among postnatal day 35 and adult rats. Both ages showed elevated MCT2 expression in the ipsilateral cerebral vasculature after TBI. Using Western blotting, MCT2 expression was 80-88% greater in microvessels isolated from postnatal day 35 rats at all time points relative to adults. The increased MCT2 expression was temporally correlated with an age-related increase in cerebral uptake of ketones, when ketones were made available after injury. Copyright (c) 2006 S. Karger AG, Basel.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Prins, ML (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Room NPI 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS02197, NS052406] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052406] Funding Source: NIH RePORTER		Baud O, 2003, J COMP NEUROL, V465, P445, DOI 10.1002/cne.10853; Boussouar F, 2003, BIOL REPROD, V69, P1069, DOI 10.1095/biolreprod.102.010074; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; CREMER JE, 1976, BIOCHIM BIOPHYS ACTA, V448, P633, DOI 10.1016/0005-2736(76)90120-6; Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; DANIEL PM, 1971, LANCET, V2, P637; Debernardi R, 2003, J NEUROSCI RES, V73, P141, DOI 10.1002/jnr.10660; Gerhart DZ, 1999, NEUROSCIENCE, V92, P367, DOI 10.1016/S0306-4522(98)00699-X; Gerhart DZ, 1997, AM J PHYSIOL-ENDOC M, V273, pE207; Gerhart DZ, 1998, GLIA, V22, P272; GO KG, 1988, METAB BRAIN DIS, V3, P257, DOI 10.1007/BF00999535; Hanu R, 2000, AM J PHYSIOL-CELL PH, V278, pC921; Hasuo H, 2003, SYNAPSE, V49, P97, DOI 10.1002/syn.10214; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; Izumi Y, 1998, J CLIN INVEST, V101, P1121, DOI 10.1172/JCI1009; Johannsson E, 2001, CIRCULATION, V104, P729, DOI 10.1161/hc3201.092286; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KATAYAMA M, 1994, JPEN-PARENTER ENTER, V18, P442, DOI 10.1177/0148607194018005442; Knott RM, 1999, DIABETOLOGIA, V42, P870, DOI 10.1007/s001250051240; Koehler-Stec EM, 1998, AM J PHYSIOL-ENDOC M, V275, pE516; Leino RL, 2001, NEUROCHEM INT, V38, P519, DOI 10.1016/S0197-0186(00)00102-9; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Maurer MH, 2004, NEUROSCI LETT, V355, P105, DOI 10.1016/j.neulet.2003.10.056; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MOORE TJ, 1976, AM J PHYSIOL, V230, P619; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pierre K, 2003, J NEUROCHEM, V86, P1468, DOI 10.1046/j.1471-4159.2003.01964.x; Pierre K, 2002, J CEREBR BLOOD F MET, V22, P586, DOI 10.1097/00004647-200205000-00010; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; Sakurai T, 2002, DIABETES, V51, P430, DOI 10.2337/diabetes.51.2.430; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SMITH JP, 2005, J NEUROCHEM, V86, P1468; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tseng MT, 2003, NEUROL RES, V25, P83, DOI 10.1179/016164103101200978; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Wahl ML, 2002, MOL CANCER THER, V1, P617; Yu R, 2001, Chin J Traumatol, V4, P218; Zhang F, 2005, J NEUROSCI RES, V79, P139, DOI 10.1002/jnr.20312; Zovein A, 2004, AM J PHYSIOL-REG I, V286, pR273, DOI 10.1152/ajpregu.00160.2003	47	48	49	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					447	456		10.1159/000094170			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600021	16943667				2021-06-18	
J	Jing, CR; Benvenisti-Zarom, L; Regan, RF				Jing, CR; Benvenisti-Zarom, L; Regan, RF			Cultured astrocytes from heme oxygenase-1 knockout mice are more vulnerable to heme-mediated oxidative injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						antioxidant; cell death; hemorrhage; knock out mouse; oxidative stress	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; CARBON-MONOXIDE; HEMOGLOBIN TOXICITY; RAT-BRAIN; SUPEROXIDE-DISMUTASE; CORTICAL ASTROCYTES; ENDOTHELIAL-CELLS; TIN-MESOPORPHYRIN; IN-VIVO	Hemin, the oxidized form of heme, is released from hemoglobin after CNS hemorrhage and may contribute to injury to surrounding tissue. The heme oxygenase (HO) enzymes catalyze the breakdown of hemin to biliverdin, carbon monoxide, and ferric iron. Although HO-2, the isoform expressed predominantly in neurons, accelerates heme-mediated neuronal injury, inhibitor studies suggest that HO-1 induction has a protective effect on astrocytes. In the present study, we directly compared the vulnerability of cultured HO-1 knockout and wildtype astrocytes to hemin. Consistent with prior observations, exposure of wild-type cultures to hemin for 24 hr resulted in protein carbonylation and concentration-dependent cell death between 10 and 60 mu M, as determined by MTT and lactate dehydrogenase release assays. In cultures prepared from mice lacking the HO-1 gene, oxidative cell injury was approximately doubled. Both protein oxidation and cell death in HO-1 knockout astrocytes were significantly reduced by pretreating cultures with an adenovirus encoding the HO-1 gene prior to hemin exposure. HO-2 expression was observed in both knockout and wild-type cultures and was not altered by HO-1 gene deletion. Cell hemin accumulation after 20 hr hemin exposure was 4.7-fold higher in knockout cells. These results support the hypothesis that HO-1 protects astrocytes from hememediated oxidative injury. Selectively increasing its expression in astrocytes may be beneficial after hemorrhagic CNS injuries. (c) 2005 Wiley-Liss, Inc.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg Room 239, Philadelphia, PA 19107 USA.	raymond.regan@jefferson.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042273] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042273] Funding Source: Medline		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BALLA G, 1992, J BIOL CHEM, V267, P18148; BEERS RF, 1952, J BIOL CHEM, V195, P133; Blumenthal SB, 2005, FASEB J, V19, P1272, DOI 10.1096/fj.04-3259com; CHANG EF, 2005, IN PRESS J CEREB BLO; Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; Grundemar L, 1997, TRENDS PHARMACOL SCI, V18, P193, DOI 10.1016/S0165-6147(97)01065-1; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kilic E, 2002, NEUROBIOL DIS, V11, P275, DOI 10.1006/nbdi.2002.0552; Kim YS, 2005, FREE RADICAL BIO MED, V39, P558, DOI 10.1016/j.freeradbiomed.2005.04.009; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Lamb NJ, 1999, BIOCHEM J, V344, P153, DOI 10.1042/0264-6021:3440153; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Ono S, 2000, J CEREBR BLOOD F MET, V20, P1066, DOI 10.1097/00004647-200007000-00006; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; QU Y, 2005, IN PRESS J CEREB BLO; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; ROGERS B, 2001, ACAD EMERG MED, V8, P510; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Schipper HM, 2004, FREE RADICAL BIO MED, V37, P1995, DOI 10.1016/j.freeradbiomed.2004.09.015; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN M, 1978, ANAL BIOCHEM, V90, P81, DOI 10.1016/0003-2697(78)90010-6; Teng ZP, 2004, NEUROBIOL DIS, V17, P179, DOI 10.1016/j.nbd.2004.07.009; Tschugguel W, 2001, J CLIN ENDOCR METAB, V86, P3833, DOI 10.1210/jc.86.8.3833; Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	51	48	48	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2005	82	6					802	810		10.1002/jnr.20681			9	Neurosciences	Neurosciences & Neurology	993GV	WOS:000233943500008	16273550				2021-06-18	
J	Warren, MW; Kobeissy, FH; Liu, MC; Hayes, RL; Gold, MS; Wang, KKW				Warren, MW; Kobeissy, FH; Liu, MC; Hayes, RL; Gold, MS; Wang, KKW			Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury	LIFE SCIENCES			English	Article						methamphetamine; drug abuse; traumatic brain injury; caspases; calpain; alpha-spectrin; tau protein; cerebral cortex; hippocampus	BREAKDOWN PRODUCTS; APOPTOSIS; CLEAVAGE; CELLS; ACTIVATION; INCREASES; PROTEASE; NEURONS; DAMAGE	Neurotoxicity in rat cortex and hippocampus following acute methamphetamine administration was characterized and compared to changes following traumatic brain injury. Doses of 10, 20, and 40 mg/kg of methamphetamine produced significant increases in calpain- and caspase-cleaved all-spectrin and tau protein fragments, suggesting cell injury or death. Changes in proteolytic products were significantly increased over vehicle controls. Use of fragment specific biomarkers detected prominent calpain-mediated protein fragments in the cortex and hippocampus while caspase-mediated protein fragments were also detected in the hippocampus. Remarkably, proteolytic product increases at the 40 mg/kg dose after 24 h were as high as those observed in experimental traumatic brain injury. Use of calpain and caspase proteolytic inhibitors may be useful in preventing methamphetamine-induced neurotoxicity. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Inst Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Div Addict Med, Gainesville, FL 32610 USA	Warren, MW (corresponding author), Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, POB 100183, Gainesville, FL 32610 USA.	warren@ufl.edu; firasko@ufl.edu; liumc@mbi.ufl.edu; hayes@mbi.ufl.edu; msgold@psychiatry.ufl.edu; kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			ALI S F, 1991, Biomedical and Environmental Sciences, V4, P207; BERNATH E, 2005, NEUROBIOLOGY AGING; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Canu N, 1998, J NEUROSCI, V18, P7061; Choi HJ, 2002, MOL CELLS, V13, P221; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Deng XL, 2002, NEUROPHARMACOLOGY, V42, P837, DOI 10.1016/S0028-3908(02)00034-5; DEVITO MJ, 1989, NEUROPHARMACOLOGY, V28, P1145, DOI 10.1016/0028-3908(89)90130-5; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Gluck MR, 2001, J NEUROCHEM, V79, P152, DOI 10.1046/j.1471-4159.2001.00549.x; Huber A, 1997, J ADDICT DIS, V16, P41, DOI 10.1300/J069v16n04_04; Ishigami Akiko, 2003, Leg Med (Tokyo), V5, P42, DOI 10.1016/S1344-6223(03)00005-1; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Larsen KE, 2002, J NEUROSCI, V22, P8951; Makino Y, 2003, J HEALTH SCI, V49, P129; Martin R, 2003, J ECON GEOGR, V3, P5, DOI 10.1093/jeg/3.1.5; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; *NIDA, 1997, METH AB NIDA CAPS; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Stumm G, 1999, FASEB J, V13, P1065; Thiriet N, 2001, MOL BRAIN RES, V90, P202, DOI 10.1016/S0169-328X(01)00093-6; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WARREN M, 2004, CLUB DRUG USE SELFIN; Xie HQ, 1997, J NEUROCHEM, V69, P1020; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x; Yen S, 1999, FEBS LETT, V461, P91, DOI 10.1016/S0014-5793(99)01427-1; Yuen Po-Wai, 1998, Drugs of the Future, V23, P741, DOI 10.1358/dof.1998.023.07.858362; 2003, DHHS PUBL	40	48	49	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	DEC 5	2005	78	3					301	309		10.1016/j.lfs.2005.04.058			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	984UO	WOS:000233330000012	16125733				2021-06-18	
J	Evans, CC; Sherer, M; Nick, TG; Nakase-Richardson, R; Yablon, SA				Evans, CC; Sherer, M; Nick, TG; Nakase-Richardson, R; Yablon, SA			Early impaired self-awareness, depression, and subjective well-being following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						impaired self-awareness; rehabilitation; traumatic brain injury	CLOSED-HEAD INJURY; LIFE SATISFACTION; PRACTICAL SCALE; RATING-SCALE; REHABILITATION; DISABILITY; TBI; CONSCIOUSNESS; QUESTIONNAIRE; DISTURBANCES	Objective: To examine the incidence and intercorrelation of early impaired self-awareness (ISA) and depression after traumatic brain injury (TBI), as well as their contributions to prediction of patients' subjective well-being at discharge from inpatient rehabilitation. Design: Inception cohort. Setting: Inpatient rehabilitation. Patients: Subjects were 96 patients with TBI seen for inpatient rehabilitation at the Methodist Rehabilitation Center. All subjects had emerged from posttraumatic amnesia prior to assessment for this study. Intervention: None. Main Outcome Measure: Subjective well-being as measured by the Satisfaction With Life Scale taken at discharge from inpatient rehabilitation. Results: Multivariable linear regression analysis revealed that ISA and functional status (Disability Rating Scale total score) at rehabilitation admission made independent contributions to prediction of subjective well-being. Bivariable correlational analyses demonstrated that frequency of depressive symptoms was inversely correlated with Satisfaction With Life Scale scores. Impaired self-awareness and depression were not correlated in this sample. Conclusions: Results support the idea that ISA is an important factor in determining subjective well-being in patients with TBI at acute rehabilitation discharge. Early interventions to decrease ISA may improve patients' functional status at rehabilitation discharge.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, University, MS 38677 USA; Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA	Evans, CC (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	cevans@mmrcrehab.org					Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HARREL FE, HMISC DESIGN LIB; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; Prigatano G. F., 2005, REHABILITATION TRAUM, P118; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP, 2003, INT REV PSYCHIATR, V15, P371, DOI 10.1080/09540260310001606755; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RADLOFF LS, 1977, APPL PSYCH MEAS, V3, P385; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, 2005, REHABILITATION TRAUM, P31; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; TEASDALE G, 1974, LANCET, V2, P81; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	55	48	48	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					488	500		10.1097/00001199-200511000-00002			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900002	16304486				2021-06-18	
J	Kozora, E; Arciniegas, DB; Filley, CM; Ellison, MC; West, SG; Brown, MS; Simon, JH				Kozora, E; Arciniegas, DB; Filley, CM; Ellison, MC; West, SG; Brown, MS; Simon, JH			Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus - Preliminary data	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						system lupus erythematosus; cognition; neurometabolites; magnetic resonance imaging volumetrics	MAGNETIC-RESONANCE-SPECTROSCOPY; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; HIPPOCAMPAL VOLUME; MULTIPLE-SCLEROSIS; WHITE-MATTER; DISEASE; PREVALENCE; DEFICITS; MARKERS	Objective: To correlate cognitive dysfunction with structural and neurometabolic brain findings in patients with non-neuropsychiatric systemic lupus erythematosus (non-NPSLE). Background: Over 25% of non-NPSLE patients have cognitive dysfunction, but the cerebral basis of this observation is not well understood. Method: Seven patients with non-NPSLE and seven control subjects were given a series of neuropsychological tests and neuroimaging with magnetic resonance imaging and magnetic resonance spectroscopy. Analyses of cognitive function and structural and neurometabolic measures of the brain were performed. Results: Compared with controls, the non-NPSLE patients were significantly impaired on a global cognitive impairment index (CII). No significant differences between the groups were found in choline/creatine (Ch/Cr), N-acetylaspartic acid/Cr, or hippocampal volumes. Ch/Cr was highly associated with CII across the sample. Conclusions: This is the first study to correlate cognitive impairment with an increase in Ch/Cr ratio among patients with SLE. These results, although preliminary, suggest that changes in cerebral white matter may be important in determining the subtle cognitive impairment that may occur in patients with SLE, even in the absence of neuropsychiatric symptoms.	ABPP, CN, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Denver, CO USA; Denver Vet Affairs Med Ctr, Denver, CO USA	Kozora, E (corresponding author), ABPP, CN, Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	Kozorae@njc.org	Arciniegas, David/A-3792-2009				APPENZELLER S, 2004, 7 ANN INT C SLE REL; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIGLER ED, 1994, FUNCTIONAL NEUROIMAG, P121; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Brey RL, 2002, NEUROLOGY, V58, P1214, DOI 10.1212/WNL.58.8.1214; Brooks WM, 1997, J RHEUMATOL, V24, P2323; Brooks WM, 1999, J RHEUMATOL, V26, P81; BUCKLEY PF, 1994, BIOL PSYCHIAT, V36, P792, DOI 10.1016/0006-3223(94)90591-6; CARBOTTE RM, 1986, J NERV MENT DIS, V174, P357, DOI 10.1097/00005053-198606000-00008; DAVIE CA, 1995, J NEUROL, V242, P522, DOI 10.1007/BF00867424; DELIS D, 1987, CALIFORNIA VERBAL LE; Filley CM, 1998, NEUROLOGY, V50, P1535, DOI 10.1212/WNL.50.6.1535; FILLEY CM, 2001, BEHAV NEUROLOGY WHIT; Friedman AW, 1999, ARTHRIT CARE RES, V12, P256, DOI 10.1002/1529-0131(199908)12:4<256::AID-ART4>3.3.CO;2-7; Golden C., 1978, STROOP COLOR WORD TE; Handa R, 2003, MAGN RESON IMAGING, V21, P1033, DOI 10.1016/S0730-725X(03)00200-5; Jackson GD, 1996, MRI NEUROANATOMY NEW; Kozora E, 1998, ARTHRITIS RHEUM-US, V41, P41, DOI 10.1002/1529-0131(199801)41:1<41::AID-ART6>3.0.CO;2-7; Kozora E, 1996, ARTHRITIS RHEUM, V39, P2035, DOI 10.1002/art.1780391213; Kozora E, 2004, ARTHRIT RHEUM-ARTHR, V51, P810, DOI 10.1002/art.20692; Leary SM, 1999, J NEUROL, V246, P1023, DOI 10.1007/s004150050507; LINKOVA L, 2004, 7 ANN INT C SLE REL; MACKAY M, 2004, 7 ANN INT C SLE REL; MEYERHOFF DJ, 1993, NEUROLOGY, V43, P509, DOI 10.1212/WNL.43.3_Part_1.509; Meyers J., 1995, REY COMPLEX FIGURE T; MOATS RA, 1994, MAGNET RESON MED, V32, P110, DOI 10.1002/mrm.1910320115; Mu QW, 1999, AM J NEURORADIOL, V20, P207; Narayana PA, 1998, ANN NEUROL, V43, P56, DOI 10.1002/ana.410430112; Nieuwenhuys RVJ., 1988, HUMAN CENTRAL NERVOU, V3rd ed.; Reitan R., 1988, HALSTEAD REITAN NEUR; ROSS B, 1994, MAGN RESON QUART, V10, P191; Rozell CL, 1998, CEPHALALGIA, V18, P209, DOI 10.1046/j.1468-2982.1998.1804209.x; Sabet A, 1998, STROKE, V29, P2254, DOI 10.1161/01.STR.29.11.2254; Sibbitt WL, 1997, AM J NEURORADIOL, V18, P1271; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M; WEKKING EM, 1991, PSYCHOTHER PSYCHOSOM, V55, P126, DOI 10.1159/000288419; West SG, 2002, DUBOIS LUPUS ERYTHEM, P693	43	48	54	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	1543-3633			COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2005	18	3					159	162		10.1097/01.wnn.0000181543.05064.4b			4	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	969LE	WOS:000232234800004	16175019				2021-06-18	
J	Mohanraj, R; Brodie, MJ				Mohanraj, R; Brodie, MJ			Outcomes in newly diagnosed localization-related epilepsies	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						epilepsy syndromes; hippocampal atrophy; cortical dysplasia; prognosis; localization-related epilepsy	HIPPOCAMPAL ATROPHY; MRI EVIDENCE; PROGNOSIS; MALFORMATIONS; MECHANISMS; SCLEROSIS; SEIZURES	A total of 558 patients with a range of locatization-related epilepsy syndromes starting treatment in a single centre were followed over a period of up to 20 years. Overall, 343 (62%) patients became seizure free for 12 months or more (responders), 92% of whom (57% of total population) remained in remission until the end of follow-up. Only 27 (5%) responders relapsed and subsequently developed refractory epilepsy. The remaining 215 (38%) patients never became seizure free for any 12-month period. There were no significant differences in outcome between cryptogenic (56% remission) and symptomatic (57% remission) epitepsies. Patients with underlying cortical atrophy (71% remission; p < 0.05) or cerebrovascular disease (70% remission; p < 0.01) did better, white those with traumatic brain injury (35% remission; p < 0.001) did worse than the remainder of the symptomatic group. Remission rates in patients with cortical dysplasias (60%), hippocampal atrophy (50%) and primary brain tumors (52%) appeared no different from those with other symptomatic epitepsies. Overall, 20-40% patients with each epilepsy syndrome reported no further seizures after starting AED treatment including 21% with hippocampal atrophy and 33% with cortical dysplasia. More than 50% of patients developing localization-related epilepsy during adolescence or in adulthood had a good outcome. Prognosis in those with underlying hippocampal. atrophy or cortical dysplasia was not always bad. (c) 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.	Western Infirm & Associated Hosp, Epilepsy Unit, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland	Brodie, MJ (corresponding author), Western Infirm & Associated Hosp, Epilepsy Unit, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland.	martin.j.brodie@clinmed.gla.ac.uk		Mohanraj, Rajiv/0000-0002-2559-148X			Andrade-Valenca LP, 2003, EPILEPSIA, V44, P807, DOI 10.1046/j.1528-1157.2003.58002.x; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Benbadis SR, 2002, SEIZURE-EUR J EPILEP, V11, P340, DOI 10.1053/seiz.2001.0613; Berg AT, 2001, EPILEPSIA, V42, P1553, DOI 10.1046/j.1528-1157.2001.21101.x; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; ELGAR CE, 2003, EPILIPSIA, V44, pS9; ENGEL J, 1998, EPILEPSY COMPREHENSI, P2405; Guerrini R, 2001, AM J MED GENET, V106, P160, DOI 10.1002/ajmg.1569; Hiratsuka M, 2001, MOL GENET METAB, V73, P298, DOI 10.1006/mgme.2001.3204; Kim WJ, 1999, EPILEPSIA, V40, P290, DOI 10.1111/j.1528-1157.1999.tb00706.x; Kobayashi E, 2003, NEUROLOGY, V60, P405, DOI 10.1212/WNL.60.3.405; Kobayashi E, 2002, ARCH NEUROL-CHICAGO, V59, P1891, DOI 10.1001/archneur.59.12.1891; Kobayashi E, 2001, NEUROLOGY, V56, P166, DOI 10.1212/WNL.56.2.166; Kumlien E, 2002, SEIZURE-EUR J EPILEP, V11, P413, DOI 10.1053/seiz.2001.0614; Kuzniecky RI, 2002, SEMIN NEUROL, V22, P279, DOI 10.1055/s-2002-36647; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Kwan P, 2001, PHARMACOL THERAPEUT, V90, P21, DOI 10.1016/S0163-7258(01)00122-X; Merschhemke M, 2003, NEUROIMAGE, V18, P642, DOI 10.1016/S1053-8119(02)00052-6; Regesta G, 1999, EPILEPSY RES, V34, P109, DOI 10.1016/S0920-1211(98)00106-5; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; Sisodiya SM, 2004, LANCET NEUROL, V3, P29, DOI 10.1016/S1474-4422(03)00620-3; Sisodiya SM, 2003, CURR OPIN NEUROL, V16, P197, DOI 10.1097/00019052-200304000-00013; Stephen LJ, 2001, EPILEPSIA, V42, P357, DOI 10.1046/j.1528-1157.2001.29000.x; Trevathan E, 2003, NEUROLOGY, V61, P432, DOI 10.1212/WNL.61.4.432	27	48	51	0	0	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	JUL	2005	14	5					318	323		10.1016/j.seizure.2005.04.002			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	949QA	WOS:000230802000004	15876543				2021-06-18	
J	Yang, WB; Dollear, M; Muthukrishnan, SR				Yang, WB; Dollear, M; Muthukrishnan, SR			One rare side effect of zolpidem - Sleepwalking: A case report	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Association-of-Academic-Physiatrists	MAR 26-30, 2003	Ft Lauderdale, FL	Assoc Acad Phys		case report; hypnotics and sedatives; rehabilitation; somnambulism	POSTMARKETING SURVEILLANCE; INSOMNIA	Zolpidem is an imidazopyridine agent indicated for the short-term treatment of insomnia. Sleepwalking is a rare side effect of zolpidem. A review of the literature produced only 2 cases. We report a case of a mate rehabilitation inpatient in his mid fifties with a history of alcoholism and traumatic brain injury who had undergone a right hip hemiarthroplasty. He had no history of somnambulism or insomnia but walked in his sleep on 2 nonconsecutive nights after taking zolpidem. He had exhibited no such behavior before taking zolpidem, on the intervening night that was he was not given medication, and after the medication was discontinued. We conclude that zolpidem can cause sleepwalking, and patients who have suffered a brain injury may be more susceptible to this side effect. Here we describe the clinical presentation and review the relevant literature on zolpidem and sleepwalking.	Univ Illinois, Dept Neurol & Rehabil, Chicago, IL USA	Yang, WB (corresponding author), VA N Texas Hlth Care Syst, Phys Med & Rehabil Serv, 4500 S Lancaster Rd, Dallas, TX 75216 USA.	wyangem@yahoo.com					CHARNEY DS, 1979, BRIT J PSYCHIAT, V135, P418, DOI 10.1192/bjp.135.5.418; GANZONI E, 1995, J INT MED RES, V23, P61, DOI 10.1177/030006059502300108; Hajak G, 1998, INT CLIN PSYCHOPHARM, V13, P157, DOI 10.1097/00004850-199807000-00002; HUAPAYA LVM, 1979, AM J PSYCHIAT, V136, P985; KALES A, 1973, BENZODIAZEPINES, P577; LANGTRY HD, 1990, DRUGS, V40, P291, DOI 10.2165/00003495-199040020-00008; MENDELSON WB, 1994, J CLIN PSYCHOPHARM, V14, P150, DOI 10.1097/00004714-199404000-00014; NICHOLSON AN, 1986, BRIT J CLIN PHARMACO, V21, P205, DOI 10.1111/j.1365-2125.1986.tb05176.x; Sauvanet JP, 1988, IMIDAZOPYRIDINES SLE, P219; SCHARF MB, 1994, J CLIN PSYCHIAT, V55, P192	10	48	49	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2005	86	6					1265	1266		10.1016/j.apmr.2004.11.022			2	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	934EK	WOS:000229689500030	15954071				2021-06-18	
J	Michael, DB; Byers, DM; Irwin, LN				Michael, DB; Byers, DM; Irwin, LN			Gene expression following traumatic brain injury in humans: analysis by microarray	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						alcohol; brain trauma; cDNA microarrays; contusion; immediate early genes; mRNA; vasculitis	NEUROTRAUMA; PATTERNS; RODENT; RATS	Global changes in gene expression were analyzed in pericontusional tissue taken during surgery from 4 patients with traumatic brain injury (TBI), in cerebral infarction tissue from a patient with vasculitis and in normal brain tissue resected during craniotomy for meningioma. Of approximately 1200 genes showing some level of expression by cDNA microarray hybridization, 104 (similar to 8%) showed differential expression in traumatized tissue. Genes controlling transcriptional regulation, intermediary and energy metabolism, signal transduction, and intercellular adhesion and recognition were differentially affected most often. Four genes previously shown to be associated with TBI (c-Fos, Jun B, HSP70, and Zif/268) were all found to be up-regulated in at least one TBI patient. Thus, the robust response to TBI of several immediate early genes is confirmed, and a longer list of candidate genes from other functional categories is suggested for further studies aimed at understanding the molecular and cellular consequences of TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Texas, Dept Biol Sci, El Paso, TX 79968 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Irwin, LN (corresponding author), Univ Texas, Dept Biol Sci, El Paso, TX 79968 USA.	lirwin@utep.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12 RR08124] Funding Source: Medline; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R15 DC005179] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR008124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R15DC005179] Funding Source: NIH RePORTER		Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Dutcher SA, 2001, NEUROL RES, V23, P203, DOI 10.1179/016164101101198343; Dutcher SA, 1998, J NEUROTRAUM, V15, P421, DOI 10.1089/neu.1998.15.421; Irwin LN, 2001, MOL BRAIN RES, V96, P163, DOI 10.1016/S0169-328X(01)00269-8; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; UNGAR G, 1963, AM LECT PHARM	13	48	51	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2005	12	3					284	290		10.1016/j.jocn.2004.11.003			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	929YU	WOS:000229383400016	15851083				2021-06-18	
J	Barker, JM; Wojtowicz, JM; Boonstra, R				Barker, JM; Wojtowicz, JM; Boonstra, R			Where's my dinner? Adult neurogenesis in free-living food-storing rodents	GENES BRAIN AND BEHAVIOR			English	Article						dentate gyrus; doublecortin; food storage; free-living populations; immunocytochemistry; Ki-67; postnatal neurogenesis; rodents; spatial memory	RAT DENTATE GYRUS; MICROTUBULE-ASSOCIATED PROTEIN; SQUIRREL SCIURUS-CAROLINENSIS; ARCTIC GROUND-SQUIRRELS; GRANULE CELL PRECURSORS; TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL NEUROGENESIS; SPATIAL MEMORY; MAMMALIAN HIPPOCAMPUS; STEREOLOGICAL METHODS	Postnatal hippocampal neurogenesis in wild mammals may play an essential role in spatial memory. We compared two species that differ in their reliance on memory to locate stored food. Yellow-pine chipmunks use a single cache to store winter food; eastern gray squirrels use multiple storage sites. Gray squirrels had three times the density of proliferating cells in the dentate gyrus (determined by Ki-67 immunostaining) than that found in chipmunks, but similar density of young neurons (determined by doublecortin immunostaining). Three explanations may account for these results. First, the larger population of young cells in squirrels may increase the flexibility of the spatial memory system by providing a larger pool of cells from which new neurons can be recruited. Second, squirrels may have a more rapid cell turnover rate. Third, many young cells in the squirrels may mature into glia rather than neurons. The densities of young neurons were higher in juveniles than in adults of both species. The relationship between adult age and cell density was more complex than that has been found in captive populations. In adult squirrels, the density of proliferating cells decreased exponentially with age, whereas in adult chipmunks the density of young neurons decreased exponentially with age.	Univ Toronto, Ctr Neurobiol Stress, Scarborough, ON M1C 1A4, Canada; Univ Toronto, Dept Physiol, Scarborough, ON M1C 1A4, Canada	Boonstra, R (corresponding author), Univ Toronto, Ctr Neurobiol Stress, 1265 Mil Trail, Scarborough, ON M1C 1A4, Canada.	boonstra@utsc.utoronto.ca	Barker, Jennifer M/B-2700-2010	Barker, Jennifer M/0000-0001-7558-1661			Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Ambrogini P, 2000, NEUROSCI LETT, V286, P21, DOI 10.1016/S0304-3940(00)01074-0; BARKALOW FS, 1975, J MAMMAL, V56, P522, DOI 10.2307/1379384; Barker JM, 2003, CAN J ZOOL, V81, P1774, DOI 10.1139/Z03-173; BEST TL, 1999, SMITHSONIAN BOOK N A, P378; Bizon JL, 2003, EUR J NEUROSCI, V18, P215, DOI 10.1046/j.1460-9568.2003.02733.x; Boonstra R, 2001, CAN J ZOOL, V79, P49, DOI 10.1139/cjz-79-1-49; Boonstra R, 2001, CAN J PHYSIOL PHARM, V79, P297, DOI 10.1139/cjpp-79-4-297; BOONSTRA R, 1993, GEN COMP ENDOCR, V91, P126, DOI 10.1006/gcen.1993.1113; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Byrom AE, 1999, CAN J ZOOL, V77, P1048, DOI 10.1139/cjz-77-7-1048; CALDAROLA J, 1998, STATVIEW 5 0 1; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cecchi GA, 2001, J COMPUT NEUROSCI, V11, P175, DOI 10.1023/A:1012849801892; Ciaroni S, 2002, MECH AGEING DEV, V123, P1341, DOI 10.1016/S0047-6374(02)00070-2; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ferbinteanu J, 2003, NEUROSCI LETT, V345, P131, DOI 10.1016/S0304-3940(03)00473-7; Ferbinteanu J, 2001, HIPPOCAMPUS, V11, P187, DOI 10.1002/hipo.1036; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Fuchs E., 1997, Society for Neuroscience Abstracts, V23, P317; Galea LAM, 1999, NEUROSCIENCE, V89, P955, DOI 10.1016/S0306-4522(98)00345-5; Geiser F, 1997, J COMP PHYSIOL B, V167, P416, DOI 10.1007/s003600050091; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Huang LY, 1998, J NEUROBIOL, V36, P410, DOI 10.1002/(SICI)1097-4695(19980905)36:3<410::AID-NEU8>3.0.CO;2-Z; JACOBS LF, 1991, ANIM BEHAV, V41, P103, DOI 10.1016/S0003-3472(05)80506-8; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Koprowski John L., 1994, Mammalian Species, V480, P1, DOI 10.2307/3504263; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kunzl C, 2003, HORM BEHAV, V43, P187, DOI 10.1016/S0018-506X(02)00017-X; Lavenex P, 2000, EUR J NEUROSCI, V12, P643, DOI 10.1046/j.1460-9568.2000.00949.x; Lavenex P, 2000, J COMP NEUROL, V425, P152; Lee DW, 1998, NEUROREPORT, V9, pR15; Macdonald IMV, 1997, ANIM BEHAV, V54, P879, DOI 10.1006/anbe.1996.0528; MCQUADE DB, 1986, ETHOLOGY, V72, P22; Merrill DA, 2003, J COMP NEUROL, V459, P201, DOI 10.1002/cne.10616; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; Ormerod BK, 2001, NEUROSCIENCE, V102, P369, DOI 10.1016/S0306-4522(00)00474-7; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PARADIS E, 1993, J WILDLIFE MANAGE, V57, P158, DOI 10.2307/3809012; Pereira ME, 2002, J MAMMAL, V83, P467, DOI 10.1644/1545-1542(2002)083<0467:TOHIEG>2.0.CO;2; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rosenbaum RS, 2001, BEHAV BRAIN RES, V127, P183, DOI 10.1016/S0166-4328(01)00363-1; Schmidt MHH, 2003, J PATHOL, V199, P18, DOI 10.1002/path.1221; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Sutton DA, 1992, MAMMALIAN SPECIES, V390, P1; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Tanapat P, 2001, J COMP NEUROL, V437, P496, DOI 10.1002/cne.1297; Tanapat P, 1998, INT J DEV NEUROSCI, V16, P235, DOI 10.1016/S0736-5748(98)00029-X; THOMPSON DC, 1977, CAN J ZOOL, V55, P1185, DOI 10.1139/z77-153; THOMPSON DC, 1980, CAN J ZOOL, V58, P701, DOI 10.1139/z80-101; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Praag H, 1999, NAT NEUROSCI, V2, P266; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Yoccoz N.G., 1991, B ECOL SOC AM, V72, P106, DOI DOI 10.2307/	82	48	50	1	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1601-1848			GENES BRAIN BEHAV	Genes Brain Behav.	MAR	2005	4	2					89	98		10.1111/j.1601-183X.2004.00097.x			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	906KL	WOS:000227639500003	15720405	Bronze			2021-06-18	
J	Watanabe, T; Okuda, Y; Nonoguchi, N; Zhao, MZ; Kajimoto, Y; Furutama, D; Yukawa, H; Shibata, MA; Otsuki, Y; Kuroiwa, T; Miyatake, SI				Watanabe, T; Okuda, Y; Nonoguchi, N; Zhao, MZ; Kajimoto, Y; Furutama, D; Yukawa, H; Shibata, MA; Otsuki, Y; Kuroiwa, T; Miyatake, SI			Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						adenovirus vector; cerebral infarction; fibroblast growth factor-2; gene therapy; middle cerebral artery occlusion	FIBROBLAST-GROWTH-FACTOR; MEDIATED GENE-TRANSFER; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; ARTERY OCCLUSION; FACTOR PROMOTES; DNA FRAGMENTATION; BLOOD-FLOW; IN-VIVO; BRAIN	Fibroblast growth factor (FGF)-2 is a potent neurotrophic and angiogenic peptide. To examine possible protective effects of FGF-2 gene expression against transient focal cerebral ischemia in rats, a replication defective, recombinant adenovirus vector expressing FGF-2, was injected intraventricularly 2 hours after middle cerebral artery occlusion (MCAO). The treatment group showed significant recovery compared with the vehicle-treated groups in terms of serial neurologic severity scores over the 35 days after MCAO. Further, 2,3,5-triphenyltetrazolium chloride staining showed that FGF-2 gene transfer decreased infarct volume by 44% as compared with that in the vehicle-treated groups at 2 days after MCAO. The same tendency of gene transfer effects on infarct volume was confirmed at 35 days after MCAO with hematoxylin/eosin staining. Enzyme-linked immunosorbent assay revealed that FGF-2 concentration was increased significantly at 2 days after MCAO, not only in cerebrospinal fluid but also in cerebral substance in the lesioned and treated animals. These results suggested that FGF-2 gene transfer using these adenoviral vectors might be a useful modality for the treatment of occlusive cerebrovascular disease even after the onset of stroke.	Osaka Med Coll, Dept Neurosurg, Takatsuki, Osaka, Japan; Osaka Med Coll, Dept Internal Med 1, Takatsuki, Osaka, Japan; Shiga Med Ctr Adults, Dept Neurosurg, Moriyama, Shiga, Japan; Osaka Med Coll, Dept Anat & Biol, Takatsuki, Osaka, Japan	Miyatake, SI (corresponding author), Osaka Med Coll, Dept Neurosurg, 2-7 Daigaku-Machi, Takatsuki, Osaka, Japan.	neu070@poh.osaka-med.ac.jp	Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Nonoguchi, Naosuke/0000-0002-4140-2415	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15590916] Funding Source: KAKEN		Akimoto M, 1999, INVEST OPHTH VIS SCI, V40, P273; AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; Ay I, 2001, MOL BRAIN RES, V87, P71, DOI 10.1016/S0169-328X(00)00285-0; Bao WL, 1999, ACTA PHARMACOL SIN, V20, P313; BARID A, 1994, CURR OPIN NEUROBIOL, V4, P78; Bogousslavsky J, 2002, CEREBROVASC DIS, V14, P239, DOI 10.1159/000065683; BORLONGAN CV, 1995, BRAIN RES, V676, P231, DOI 10.1016/0006-8993(95)00150-O; BOUSSAIRI EH, 1994, J CARDIOVASC PHARM, V23, P99, DOI 10.1097/00005344-199401000-00013; Cartmell T, 1999, J NEUROSCI, V19, P1517; Chen SH, 2002, BRAIN RES, V927, P138, DOI 10.1016/S0006-8993(01)03336-4; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525; Jiang N, 1996, J NEUROL SCI, V139, P173; Kawamata T, 1999, EXP NEUROL, V158, P89, DOI 10.1006/exnr.1999.7101; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; Kitagawa H, 1998, J NEUROSCI RES, V54, P38; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; KUMON Y, 1993, BRAIN RES, V605, P169, DOI 10.1016/0006-8993(93)91369-4; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Matsuoka N, 2000, NEUROREPORT, V11, P2001, DOI 10.1097/00001756-200006260-00039; Matsuoka N, 2003, STROKE, V34, P1519, DOI 10.1161/01.STR.0000070840.56414.3B; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; Ninomiya M, 2003, GENE THER, V10, P1152, DOI 10.1038/sj.gt.3301984; Ohara N, 2001, GENE THER, V8, P837, DOI 10.1038/sj.gt.3301475; OOBOSHI H, 1995, CIRC RES, V77, P7, DOI 10.1161/01.RES.77.1.7; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; QUENTIN B, 1992, P NATL ACAD SCI USA, V89, P2581; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SCHACHTNER SK, 1995, CIRC RES, V76, P701, DOI 10.1161/01.RES.76.5.701; Schallert T, 1997, ADV NEUROL, V73, P229; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Speliotes EK, 1996, MOL BRAIN RES, V39, P31, DOI 10.1016/0169-328X(95)00351-R; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Wada K, 2003, STROKE, V34, P2722, DOI 10.1161/01.STR.0000094421.61917.71; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yukawa H, 2000, GENE THER, V7, P942, DOI 10.1038/sj.gt.3301182	43	48	54	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2004	24	11					1205	1213		10.1097/01.WCB.0000136525.75839.41			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	869EF	WOS:000224965500002	15545913	Bronze			2021-06-18	
J	Salim, A; Miller, K; Dangleben, D; Cipolle, M; Pasquale, M				Salim, A; Miller, K; Dangleben, D; Cipolle, M; Pasquale, M			High-frequency percussive ventilation: An alternative mode of ventilation for head-injured patients with adult respiratory distress syndrome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						high-frequency percussive ventilation; intracranial pressure; adult respiratory distress syndrome; acute lung injury; severe traumatic brain injury	ACUTE LUNG INJURY; ELEVATED INTRACRANIAL-PRESSURE; TRAUMATIC BRAIN-INJURY; COMBAT CASUALTIES; PULMONARY-EDEMA; CEREBRAL INJURY; INSUFFICIENCY; HYPERTENSION; TRIAL; ARDS	Background: Adult respiratory distress syndrome develops in up to 20% of patients with severe head injury. This complicates the treatment of head-injured patients because lung-protective strategies such as high positive end-expiratory pressure (PEEP) and permissive hypercapnia may increase intracranial pressure (ICP) and reduce cerebral perfusion pressure. The use of high-frequency percussive ventilation (HFPV) is an alternate mode of ventilation that may improve oxygenation for head-injured patients while also lowering ICP. Methods: Clinical data were collected retrospectively over a 1-year period. Patients were included if they had a severe traumatic brain injury with a Glasgow Coma Score (GCS) of 8 or lower, a ventriculostomy drain for ICP measurement and cerebral spinal fluid drainage, and adult respiratory distress syndrome. Patients were switched from conventional mechanical ventilation to HFPV at the discretion of the attending trauma surgeon. Data for partial pressure of oxygen to fraction of inspired oxygen (PF) ratio, peak inspiratory pressure (PIP), ICP, partial pressure of carbon dioxide level (PC0(2)), PEEP, and mean airway pressure were compared before and then 4 and 16 hours after institution of HFPV therapy. Results: A total of 10 patients met study criteria. Data were expressed as mean standard error. There was an increase in PF ratio (91.8 +/- 13.2 vs. 269.7 +/- 34.6; p < 0.01), PEEP (14 +/- 2.5 vs. 16 +/- 3.5), and mean airway pressure (20.4 +/- 4.8 vs. 23.6 +/- 6.8) 16 hours after institution of HFPV. There was a decrease in ICP (30.9 +/- 3.4 vs. 17.4 +/- 1.7; p < 0.01), PC0(2) (37.7 +/- 4.1 vs. 32.7 +/- 1. 1; p < 0.05), and PIP (49.4 +/- 10 vs. 41 +/- 7.9; p < 0.05) at 16 hours. Overall mortality was 10%. Conclusions: Therapy with HFPV produced a significant improvement in oxygenation with a concomitant reduction in ICP during the first 16 hours. This therapy may represent an important new method for the management of adult respiratory distress syndrome among head-injured trauma patients, although the long-term outcome of HFPV still needs evaluation.	LAC & USC Med Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Surg, Div Trauma & Crit Care, Keck Sch Med, Los Angeles, CA 90089 USA; Lehigh Valley Hosp Ctr, Div Trauma & Crit Care, Allentown, PA USA	Salim, A (corresponding author), LAC & USC Med Ctr, 1200 N State St,Room 9900, Los Angeles, CA 90033 USA.	asalim@surgery.usc.edu					BARRETTE RR, 1987, RESP CARE, V32, P733; Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DAVIS BH, 1989, CELLS HEPATIC SINUSO, V2, P39; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; Eberhard LW, 2000, CRIT CARE MED, V28, P125, DOI 10.1097/00003246-200001000-00021; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; GARCIAURIA J, 1981, J NEUROSURG, V54, P632, DOI 10.3171/jns.1981.54.5.0632; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; HURST JM, 1984, NEUROSURGERY, V15, P530, DOI 10.1227/00006123-198410000-00010; HURST JM, 1988, J TRAUMA, V28, P1363, DOI 10.1097/00005373-198809000-00010; HURST JM, 1990, ANN SURG, V211, P486, DOI 10.1097/00000658-199004000-00017; KATSURADA K, 1973, SURGERY, V73, P191; LEVY B, 1995, J TRAUMA, V39, P799, DOI 10.1097/00005373-199510000-00039; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; MARTIN AM, 1969, ANN SURG, V170, P30, DOI 10.1097/00000658-196907000-00004; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; MCCLELLAN MD, 1989, J APPL PHYSIOL, V67, P1185; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; Velmahos GC, 1999, CHEST, V116, P440, DOI 10.1378/chest.116.2.440; Weisman SJ, 1939, SURGERY, V6, P722	27	48	49	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2004	57	3					542	546		10.1097/01.TA.0000135159.94744.5F			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	859YH	WOS:000224303800016	15454800				2021-06-18	
J	King, DR; Cohn, SM; Proctor, KG				King, DR; Cohn, SM; Proctor, KG			Changes in intracranial pressure, coagulation, and neurologic outcome after resuscitation from experimental traumatic brain injury with hetastarch	SURGERY			English	Article; Proceedings Paper	65th Annual Meeting of the Society-of-University-Surgeons	FEB 11-14, 2004	St Louis, MO	Soc Univ Surg			HYDROXYETHYL STARCH; HYPERTONIC SALINE; HEXTEND(R); HEMODILUTION; HEMORRHAGE; MANNITOL; SURGERY; TRIAL; PHASE; BLOOD	Background. In a model of traumatic brain injury (TBI), 2 protocols compared changes in intracranial pressure (ICP), coagulation, and neurologic outcome after intravenous fluid (IVF) resuscitation with either Hextend (HEX, 6% hetastarch in lactated electrolyte injection) or standard of care, crystalloid plus mannitol (MAN). Methods. In the nonsurvivor protocol, swine (n = 28) received a fluid percussion TBI and hemorrhage (27 +/- 3 mL/kg). At 30 minutes, resuscitation began with lactated Ringer's (LR) or HEX. After 60 minutes, MAN (1 g/kg) or placebo was given plus supplemental IVF to maintain cerebral perfusion pressure (CPP) greater than or equal to 70 mm Hg for 240 minutes. Swine in the survivor group (n = 15) also underwent TBI and hemorrhage, and resuscitation with HEX was compared to that of normal saline (NS)+MAN. Neurologic outcome and coagulation were evaluated for 72 hours. Results. In the nonsurvivor protocol, HEX, LR+MAN, and HEX+MAN attenuated the time-related rise of ICP and prevented ICP > 20 mm Hg versus LR alone (P < .05). HEX alone maintained CPP (relative to baseline) and decreased total IVF by 50% versus LR MAN (P < .05). XIAN had no additive effect with HEX. Coagulation, measured by thromboelastograph reaction time (R), was 11 +/- 1 and 9 1 minutes at baseline and after TBI (before randomization). At 240 minutes after HEX or LR+MAN, R was 6 +/- 1 or 7 +/- 2 minutes, which indicates a hypercoagulable state, but there was no difference between treatments. In the survivor protocol, ICP and CPP were similar with NS+MAN versus HEX, but IVF requirement was 161 +/- 20 versus 28 +/- 3 mL/kg (P < .05). Motor scores were higher on days 2 and 3 with HEX (P < .05). At 72 hours, R was 28 +/- 14 versus 26 +/- 6 minutes with NS+MAN versus HEX, which indicates a hypocoagulable state, but there was no difference between treatments. Conclusions. Hextend as the sole resuscitation fluid after severe TBI reduces fluid requirement, obviates the need for mannitol, improves neurologic outcome, and has no adverse effect on the coagulation profile relative to the crystalloid plus mannitol standard of care.	Univ Miami, Sch Med, Ryder Trauma Ctr,Trauma & Surg Crit Care Res Inst, Div Trauma,Dewitt Daughtry Family Dept Surg, Miami, FL 33136 USA; Univ Miami, Sch Med,Div Surg Crit Care, Trauma & Surg Crit Care Res Inst, Dewitt Daughtry Family Dept Surg, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr,Trauma & Surg Crit Care Res Inst, Div Trauma,Dewitt Daughtry Family Dept Surg, 1800 NW 10th Ave, Miami, FL 33136 USA.			King, David/0000-0003-1028-1478	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-01] Funding Source: Medline		Avorn J, 2003, CHEST, V124, P1437, DOI 10.1378/chest.124.4.1437; Boldt J, 2002, BRIT J ANAESTH, V89, P722, DOI 10.1093/bja/aef242; CROOKES BA, IN PRESS J TRAUMA; Cruz J, 2001, NEUROSURGERY, V49, P864; DAMON L, 1987, NEW ENGL J MED, V317, P964; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; Essell J H, 1993, J Cardiothorac Vasc Anesth, V7, P410, DOI 10.1016/1053-0770(93)90161-D; FIEDMAN Z, 2003, ANESTH ANALG, V96, P39; Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hartl R, 1997, ACT NEUR S, V70, P126; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Holcomb JB, 2003, J TRAUMA, V54, pS46, DOI 10.1097/01.TA.0000051936.91915.A2; JAVID M, 1964, J NEUROSURG, V21, P1059, DOI 10.3171/jns.1964.21.12.1059; Kelly ME, 2003, J TRAUMA, V55, P94, DOI 10.1097/01.TA.0000029042.37577.A6; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; McCammon AT, 2002, ANESTH ANALG, V95, P844, DOI 10.1097/00000539-200210000-00010; McIlroy DR, 2003, ANESTH ANALG, V96, P1572, DOI 10.1213/01.ANE.0000061460.59320B0; Ng KFJ, 2002, BRIT J ANAESTH, V88, P475, DOI 10.1093/bja/88.4.475; Nielsen VG, 2001, ANESTH ANALG, V93, P1106, DOI 10.1097/00000539-200111000-00007; ROBERTS I, 2003, COCHRANE DB SYST REV, V2; Roche AM, 2004, BRIT J ANAESTH, V92, pA154, DOI 10.1093/bja/aeh502; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Wilkes NJ, 2002, ANESTH ANALG, V94, P538, DOI 10.1097/00000539-200203000-00011	25	48	49	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	AUG	2004	136	2					355	363		10.1016/j.surg.2004.05.011			9	Surgery	Surgery	846LV	WOS:000223318000035	15300202				2021-06-18	
J	Collie, A; Maruff, P; Makdissi, M; McStephen, M; Darby, DG; McCrory, P				Collie, A; Maruff, P; Makdissi, M; McStephen, M; Darby, DG; McCrory, P			Statistical procedures for determining the extent of cognitive change following concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							RELIABLE CHANGE INDEXES; CLINICAL-SIGNIFICANCE; RETEST INTERVALS; TEST-PERFORMANCE; WAIS SCORES; SPORTS; RECOVERY; PLAYERS; INJURY; TESTS	Neuropsychological (NP) testing is now often used to help to determine if the cognitive function of a concussed athlete has declined. The NP test score after concussion is compared with the baseline test score. Many clinicians simply subtract one from the other and make a clinical decision about the significance or otherwise of the resulting "difference score''. Such techniques are inadequate, as they fail to account for the many factors that may confound interpretation of serially acquired cognitive test scores. This is a review of a number of alternative approaches used in other areas of medicine for differentiating "true'' changes from changes caused by these confounding factors. A case example is used to illustrate the effect that the statistical approach may have on clinical decision making.	Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia; CogState Ltd, Carlton, Vic, Australia; Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia; Univ Melbourne, Inst Brain Res, Parkville, Vic 3052, Australia	Collie, A (corresponding author), 68 Molesworth St, Melbourne, Vic 3051, Australia.	acollie@cogstate.com	Maruff, Paul/ABA-1673-2020; Maruff, Paul/AAD-2454-2021; McCrory, Paul/Q-8688-2019	Maruff, Paul/0000-0002-6947-9537; Collie, Alex/0000-0003-2617-9339			Barth JT, 1989, MILD HEAD INJURY; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CATRON DW, 1979, J CLIN PSYCHOL, V35, P352, DOI 10.1002/1097-4679(197904)35:2<352::AID-JCLP2270350226>3.0.CO;2-2; CATRON DW, 1978, PSYCHOL REP, V43, P279, DOI 10.2466/pr0.1978.43.1.279; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER D, 2001, BRIT J SPORT MED, V35, P370; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kneebone AC, 1998, ANN THORAC SURG, V65, P1320, DOI 10.1016/S0003-4975(98)00158-1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maassen GH, 2000, J CLIN EXP NEUROPSYC, V22, P622, DOI 10.1076/1380-3395(200010)22:5;1-9;FT622; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; MATARAZZO JD, 1984, J CLIN NEUROPSYCHOL, V6, P351, DOI 10.1080/01688638408401227; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCaffrey R.J., 2000, PRACTITIONERS GUIDE; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P32, DOI DOI 10.1080/13854049208404115; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Orchard J, 1998, J SCI MED SPORT, V1, P82; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Zegers F. E., 1994, ULTIMATE RELIABLE CH	34	48	48	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN 1	2004	38	3					273	278		10.1136/bjsm.2003.000293			6	Sport Sciences	Sport Sciences	823CD	WOS:000221586400010	15155425	Green Published, Bronze			2021-06-18	
J	Glang, A; Tyler, J; Pearson, S; Todis, B; Morvant, M				Glang, A; Tyler, J; Pearson, S; Todis, B; Morvant, M			Improving educational services for students with TBI through statewide consulting teams	NEUROREHABILITATION			English	Article						traumatic brain injury; pediatric TBI; students; training methods; teacher training; personnel training; staff development	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CHILDREN; SCHOOL; CHILDHOOD; REHABILITATION; ADOLESCENTS; STRATEGIES; SYMPTOMS; STAFF	Since 1991, when Traumatic Brain Injury (TBI) was established as a disability category under IDEA, educators nationwide have become increasingly aware of the unique and complex challenges these students present. Yet professionals, advocates and family members share a growing concern that the instructional needs of these students are not being met. School personnel serving these students need systematic support that includes both information about specific aspects of the student's disability and access to expert technical assistance. The goal of the TBI Team model, as developed and implemented in Iowa, Kansas, and Oregon, is to make available to schools statewide a group of well-trained peer consultants who can provide in-service training and ongoing consultation. The TBI Team model has four components: (a) needs assessment, (b) team recruitment, (c) team training, and (d) evaluation of both implementation and outcomes. Trained Team members provide in-service training, classroom consultation, and information and resources for school staff and parents. Team operations are maintained and supported through a central office at the Department of Education. Evaluation data suggest that the Team model is a cost effective and efficient approach to supporting teachers who work with students with TBI.	Western Oregon Univ, Teaching Res, Eugene, OR 97401 USA; Univ Kansas, Med Ctr, Kansas State Dept Educ Neurol Disabil Support Pro, Kansas City, KS 66103 USA; Iowa Dept Educ, Iowa City, IA USA; Univ Iowa, Ctr Excellence Disabil, Iowa City, IA USA	Glang, A (corresponding author), Western Oregon Univ, Teaching Res, 99 W 10th Ave,Suite 370, Eugene, OR 97401 USA.	anng@oregon.uoregon.edu					Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; BERGMAN A, 1999, PROTECTING OUR MOST; BIGLER ED, 1997, CHILDHOOD TRAUMATIC; Blosser J, 1997, J HEAD TRAUMA REHAB, V12, P21, DOI 10.1097/00001199-199704000-00004; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Clark E, 1999, SCHOOL PSYCHOL REV, V28, P242; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; Clark E., 1997, CHILDHOOD TRAUMATIC, P191; Coleman M. R., 2001, E613 ERIC; Colson S. E, 1992, INTERV SCH CLIN, V27, P198; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DEPOMPEI R, 2001, S BERR AW LECT BRAIN; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; Frank EM, 1997, J CHILDRENS COMMUNIC, V18, P49, DOI 10.1177/152574019701800206; FUNK P, 1996, PHYS DISABILITIES ED, P49; Garth J, 1997, Pediatr Rehabil, V1, P99; GERSTEN R, 1986, ELEMENTARY SCH J, V86, P1; Glang A., 1997, STUDENTS ACQUIRED BR; GLANG A, 1996, CHILDREN ACQUIRED BR, P149; GLANG A, 2001, COUNC EXC CHILDR 200; GLANG A, 1999, BRAIN INJURY SOURCE, V3, P10; GLANG A, 1994, LEARNING DISABILITIE, V9, P225; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; JANUS PL, 1994, ED DIMENSIONS ACQUIR, P475; JOYCE B, 1980, EDUC LEADERSHIP, V37, P379; JOYCE B, 1981, AM ED RES ASS ANN M; Kehle T. J., 1997, CHILDHOOD TRAUMATIC, P135; KLONOFF H, 1995, TRAUMATIC HEAD INJUR, pCH11; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEWIS TJ, 2002, EXAMINING EFFICACY S, P165; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; MARKOWITZ J, 2001, PROJECT FORUM NASDSE, V1, P1; MERINO MJ, 2000, TBI CHALLENGE, V4, P18; Nybo T, 1999, BRAIN INJURY, V13, P759; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Savage RC, 2001, NEUROREHABILITATION, V16, P49; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; SPARKS GM, 1983, EDUC LEADERSHIP, V41, P65; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; THURMAN DJ, 1999, COMMUNICATION    DEC; Todis B, 2004, NAT C COUNC EXC CHIL; *TUFTS U DEP REH M, 1993, 2 TUFTS U DEP REH ME; TYLER J, 2001, COUNC EXC CHILDR 200; TYLER J, 1999, 3 WORLD C BRAIN INJ; Tyler J. S., 1999, TRAUMATIC BRAIN INJU; TYLRO J, 1997, STUDENTS ACQUIRED BR, P323; VANDERCOOK T, 1989, J ASSOC PERS SEVERE, V14, P205; Veenman S., 2001, EDUC RES EVAL, V7, P385, DOI [10.1076/edre.7.4.385.8936, DOI 10.1076/EDRE.7.4.385.8936]; Walker NW, 1999, CHILD NEUROPSYCHOL, V5, P137, DOI 10.1076/chin.5.2.137.3168; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	63	48	48	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	3					219	231					13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	883HU	WOS:000226003000005	15502255				2021-06-18	
J	Johnston, AJ; Steiner, LA; Chatfield, DA; Coleman, MR; Coles, JP; Al-Rawi, PG; Menon, DK; Gupta, AK				Johnston, AJ; Steiner, LA; Chatfield, DA; Coleman, MR; Coles, JP; Al-Rawi, PG; Menon, DK; Gupta, AK			Effects of propofol on cerebral oxygenation and metabolism after head injury	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v., propofol; brain, metabolism; complications, head injury	CARBON-DIOXIDE REACTIVITY; BLOOD-PRESSURE; INTRACRANIAL-PRESSURE; SUPPRESSION; FLOW; AUTOREGULATION; PROTECTION; SATURATION; ANESTHESIA	Background. Flow-metabolism coupling is thought to be deranged after traumatic brain injury, while the effects of propofol on flow-metabolism coupling are controversial. We have used a step increase in target plasma propofol concentration in head injured patients to explore flow-metabolism coupling in these patients. Methods. Ten patients with a moderate to severe head injury received a step increase in propofol target controlled infusion of 2 mug ml(-1). Cerebral tissue gas measurements were recorded using a multimodal sensor, and regional chemistry was assessed using microdialysis. Arterial-jugular venous oxygen differences (AVDO(2)) were measured and all patients had cortical function monitoring (EEG). Results. The step increase in propofol led to a large increase in EEG burst-suppression ratio (0% (range 0-1.1) to 46.1% (range 0-61.7), P<0.05); however, this did not significantly change tissue gas levels, tissue chemistry, or AVDO(2). Conclusions. Flow-metabolism coupling remains intact during a step increase in propofol after traumatic brain injury. The EEG burst-suppression induced by propofol after traumatic brain injury does not appear to be a useful therapeutic tool in reducing the level of regional ischaemic burden.	Univ Cambridge, Dept Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Johnston, AJ (corresponding author), Univ Cambridge, Dept Anaesthesia, Box 93, Cambridge CB2 2QQ, England.	ajj29@cam.ac.uk	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011				Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Doyle PW, 1999, BRIT J ANAESTH, V83, P580; Ederberg S, 1998, ANESTH ANALG, V86, P1201, DOI 10.1097/00000539-199806000-00011; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Jansen GFA, 1999, ANESTH ANALG, V89, P358, DOI 10.1097/00000539-199908000-00021; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Lovell AT, 1999, ANESTH ANALG, V88, P554, DOI 10.1097/00000539-199903000-00017; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Nandate K, 2000, BRIT J ANAESTH, V84, P631, DOI 10.1093/bja/84.5.631; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Souter MJ, 1998, ANESTH ANALG, V86, P926, DOI 10.1097/00000539-199805000-00002; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	23	48	49	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2003	91	6					781	786		10.1093/bja/aeg256			6	Anesthesiology	Anesthesiology	752EQ	WOS:000187147200003	14633744	Bronze			2021-06-18	
J	Hagan, M; Wennersten, A; Meijer, X; Holmin, S; Wahlberg, L; Mathiesen, T				Hagan, M; Wennersten, A; Meijer, X; Holmin, S; Wahlberg, L; Mathiesen, T			Neuroprotection by human neural progenitor cells after experimental contusion in rats	NEUROSCIENCE LETTERS			English	Article						neuroprotection; human neural progenitor cells; experimental contusion	BRAIN-INJURY; FLUORO-JADE; DIFFERENTIATION; SURVIVAL; LINE	Neural progenitor/stem cells (HNPC) have been suggested to contribute essential trophic factors and promote survival of degenerating neurons after traumatic brain injury. For these reasons we hypothesize that the addition of HNPC to a post-injury region could possibly protect injured neurons. Experimental brain contusions were carried out in 18 rats. Immediately post-injury, rats were injected with 0.1 ml of medium (n = 8). dead cells (n = 4), or live cells (n = 6) in the medial border of the lesion. The rats were sacrificed 6 days post-surgery and evaluated by immunohistochemistry using a human nuclear marker (huN), hematoxylin and Fluoro-Jade (FJ). Human neural stem cells showed engraftment detectable by positive huN staining in 5/6 animals. The non-grafted animal was excluded from further analyses. Those given dead HNPC or medium showed no detectable huN immunoreactivity. A statistical comparison between the numbers of FJ positive degenerating endogenous neurons was made between rats receiving vehicle and dead cells to evaluate whether the presence of human cells would increase neuronal degeneration in comparison to vehicle alone. The rats receiving vehicle had a median of 117.5 FJ positive cells and dead progenitor cell recipients 175.0 per counted section (P < 0.05, Mann-Whitney). Consequently, the animals receiving dead human cells were chosen as controls to the animals receiving live progenitor cells. The rats that received live HNPC demonstrated significantly fewer FJ positive cells per counted section than controls (58.0 vs. 175.0, P < 0.01, Mann-Whitney). The post-traumatic perilesional environment allowed for the engraftment of live HNPC. The stepwise analysis indicated that host neuronal degeneration was higher in animals transplanted with non-viable human neuronal progenitor cells than in those receiving vehicle, indicating a bystander effect from introducing foreign antigen. In contrast, transplantation of viable progenitor cells attenuated neuronal degeneration, indicating that a potentially beneficial effect in progenitor cell transplantation is not limited to restoration by transplanted cells, but also improving survival of host cells. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Karolinska Hosp, Dept Neurosurg, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden; NS Gene AS, Copenhagen, Denmark	Mathiesen, T (corresponding author), Karolinska Hosp, Dept Neurosurg, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.	tiit.mathiesen@ks.se		Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Gray JA, 2000, CELL TRANSPLANT, V9, P153, DOI 10.1177/096368970000900203; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; MATHIESEN T, 1989, CANCER LETT, V44, P151, DOI 10.1016/0304-3835(89)90010-4; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Savaskan NE, 2000, BRAIN RES, V864, P44, DOI 10.1016/S0006-8993(00)02148-X; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; WENNERSTEN A, 2000, SFN M; WENNERSTEN A, UNPUB HUMAN NEURAL P	16	48	56	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 20	2003	351	3					149	152		10.1016/j.neulet.2003.07.021			4	Neurosciences	Neurosciences & Neurology	741DM	WOS:000186443500005	14623128				2021-06-18	
J	Bonnier, C; Nassogne, MC; Saint-Martin, C; Mesples, B; Kadhim, H; Sebire, G				Bonnier, C; Nassogne, MC; Saint-Martin, C; Mesples, B; Kadhim, H; Sebire, G			Neuroimaging of intraparenchymal lesions predicts outcome in shaken baby syndrome	PEDIATRICS			English	Article						nonaccidental head injury; traumatic brain injury; child abuse; shaken-infant syndrome; neuroimaging; outcome	NONACCIDENTAL HEAD-INJURY; DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN INJURY; CHILD-ABUSE; IMPACT SYNDROME; YOUNG-CHILDREN; PRACTICAL SCALE; EARLY INFANCY; SHAKING; DIAGNOSIS	Objective. Studies of long-term outcome on nonaccidental head injury (NAHI) in young children have shown severe neurodevelopmental sequelae in most cases. For improving the knowledge of outcome and for identifying prognostic factors, additional clinical and cerebral imaging data are needed. The aim of this study was to describe clinical and imaging features over time and to consider their value for predicting neurodevelopmental outcome. Methods. A retrospective medical record review was conducted of 23 children with confirmed NAHI, for whom an extended follow-up of 2.5 to 13 years (mean: 6 years) was contemplated. Glasgow Coma Scale scores, severity of retinal hemorrhages, presence of skull fractures, cranial growth deceleration, and sequential neuroimaging data (computed tomography and/or magnetic resonance imaging) were compared with patterns of clinical evolution assessed by the Glasgow Outcome Scale. Results. Clinical outcome showed that 14 (61%) children had severe disabilities, 8 (35%) had moderate disabilities, and 1 (4%) was normal. A low initial Glasgow Coma Scale score, severe retinal hemorrhages, presence of skull fracture, and cranial growth deceleration were significantly associated with poor developmental outcome. Eighteen of the 23 patients had abnormal magnetic resonance imaging scans. This examination disclosed atrophy when performed beyond 15 days of injury. Atrophy seemingly resulted from various brain lesions, namely, contusions, infarcts, and other lesions within the white matter. Presence of intraparenchymal brain lesions within the first 3 months was significantly associated with neurodevelopmental impairment. Severity of motor and cognitive dysfunctions was related to the extent of intraparenchymal lesions. Conclusions. Early clinical and radiologic findings in NAHI are of prognostic value for neurodevelopmental outcome.	Univ Catholique Louvain, Clin Univ St Luc, Serv Neurol Pediat, B-1200 Brussels, Belgium; Univ Catholique Louvain, Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium; Univ Paris 07, Fac Xavier Bichat, Hop Robert Debre, Serv Pediat Gen, Paris, France; ULb, CHU Brugmann, Serv Neuropathol, Brussels, Belgium	Bonnier, C (corresponding author), Univ Catholique Louvain, Clin Univ St Luc, Serv Neurol Pediat, Ave Hippocrate 10-1067, B-1200 Brussels, Belgium.			Kadhim, Hazim/0000-0003-4943-9172; Nassogne, Marie-Cecile/0000-0001-6936-1611			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bayley N., 2006, BAYLEY SCALES INFANT; BIRD CR, 1987, RADIOLOGY, V163, P373, DOI 10.1148/radiology.163.2.3562816; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRENNER SL, 1989, J NATL MED ASSOC, V81, P183; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; Collins KA, 1999, AM J FOREN MED PATH, V20, P169, DOI 10.1097/00000433-199906000-00013; Conway EE, 1998, PEDIATR ANN, V27, P677, DOI 10.3928/0090-4481-19981001-11; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; FELDMAN KW, 1980, PEDIATRICS, V65, P1079; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; Fullerton HJ, 2001, NEUROLOGY, V57, P1155, DOI 10.1212/WNL.57.7.1155; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Husson B, 2002, STROKE, V33, P1280, DOI 10.1161/01.STR.0000014504.18199.0D; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; JENNETT B, 1975, LANCET, V1, P480; Kaufman A.S., 1983, K ABC KAUFMAN ASSESS; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Matthews GP, 1996, J PEDIATR OPHTHALMOL, V33, P260, DOI 10.3928/0191-3913-19960701-13; MILLS M, 1998, J AM ASS PEDIAT OPHT, V68, P117; OLIVER JE, 1975, BRIT MED J, V2, P262, DOI 10.1136/bmj.2.5965.262; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; TEASDALE G, 1974, LANCET, V2, P81; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Wechsler D., 1974, MANUAL WECHSLER INTE; WECHSLER D, 1974, MANUAL WECHSLER PRES; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037; ZEPP F, 1992, NEUROPEDIATRICS, V23, P188, DOI 10.1055/s-2008-1071338	54	48	50	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT 1	2003	112	4					808	814		10.1542/peds.112.4.808			7	Pediatrics	Pediatrics	727NV	WOS:000185665700022	14523171				2021-06-18	
J	Raghupathi, R; Muir, JK; Fulp, CT; Pittman, RN; McIntosh, TK				Raghupathi, R; Muir, JK; Fulp, CT; Pittman, RN; McIntosh, TK			Acute activation of mitogen-activated protein kinases following traumatic brain injury in the rat: implications for posttraumatic cell death	EXPERIMENTAL NEUROLOGY			English	Article						head injury; apoptosis; neurodegeneration; traumatic axonal injury; c-Jun N-terminal kinase; extracellular signal-regulated kinase	CORTICAL IMPACT INJURY; SIGNAL-TRANSDUCTION; APOPTOSIS; EXPRESSION; PATHWAYS; ERK; CONSEQUENCES; HIPPOCAMPUS; INHIBITION; INDUCTION	The regional activation (via phosphorylation) of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) signaling pathways was examined using immunoblotting and immunohistochemistry following experimental brain injury. Anesthetized rats were subjected to lateral fluid-percussion brain injury of moderate severity (2.4-2.6 atm) and euthanized at 2, 6, 24, and 72 h after injury; sham-injured animals were surgically prepared but were not injured. Immunohistochemical. evidence of activation of JNK and ERK1/2 pathways was observed predominantly in regions that exhibit neural cell apoptosis and axonal damage following brain trauma. Activation of the ERK1/2 pathway was observed as early as 2 h and up to 72 h postinjury in nonneuronal cells in all layers of the cortex at the site of maximal injury, in the white matter below the site of maximal cortical damage and in the thalamus. In contrast, activation of JNK signaling was observed only at 24 and 72 h postinjury in a few neurons at the core of the cortical injury site. However, robust JNK activation was observed between 2 and 72 h postinjury in both axons and nonneuronal cells in the white matter below the site of maximal cortical damage and in the thalamus. Activation of ERK1/2, but not JNK, was observed in cells in the dentate hilus in the hippocampus in both hemispheres between 2 and 24 h postinjury. Immunoblotting analyses of extracts from various brain regions did not reveal significant alterations in intensities of either total or phosphorylated proteins underscoring the focal nature of the immunohistochemical observations. However, these results suggest that activation of MAP kinase signaling pathways may be associated with posttraumatic cell damage and are indicative of the heterogeneous nature of the mechanisms underlying regional cell death following TBI. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Anat & Neurobiol, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexel.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, R01-NS41561, P50-NS08803, R01-NS32465] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, R01NS032465, R01NS026818, P50NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Anderson CNG, 1999, J NEUROSCI, V19, P664; ARCHER DR, 1994, J NEUROCHEM, V62, P1119; Bhat RV, 1998, J NEUROCHEM, V70, P558; Blum S, 1999, J NEUROSCI, V19, P3535; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Eilers A, 1998, J NEUROSCI, V18, P1713; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mielke K, 1999, NEUROSCIENCE, V91, P471, DOI 10.1016/S0306-4522(98)00667-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Svensson B, 1998, J NEUROSCI RES, V52, P453, DOI 10.1002/(SICI)1097-4547(19980515)52:4<453::AID-JNR9>3.0.CO;2-8; Tong LQ, 1998, J NEUROCHEM, V71, P447; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	46	48	54	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2003	183	2					438	448		10.1016/S0014-4886(03)00166-3			11	Neurosciences	Neurosciences & Neurology	728PB	WOS:000185724600020	14552884				2021-06-18	
J	Morey, CE; Cilo, M; Berry, J; Cusick, C				Morey, CE; Cilo, M; Berry, J; Cusick, C			The effect of Aricept (R) in persons with persistent memory disorder following traumatic brain injury: a pilot study	BRAIN INJURY			English	Article							PLACEBO-CONTROLLED TRIAL; REDUCED EVOKED RELEASE; CLOSED HEAD-INJURY; ALZHEIMERS-DISEASE; DOUBLE-BLIND; ACETYLCHOLINE; DONEPEZIL; DYSFUNCTION; HIPPOCAMPAL	Primary objective : To investigate the effectiveness of donepezil hydrochloride (Aricept(R)) in treating persistent memory deficits in people with traumatic brain injury. Research design : Single subject ABAC design was used so that each participant could serve as their own control. Methods and procedures : Seven TBI survivors with persistent memory dysfunction, at least 1.5 years post-injury, underwent two 6-month trials of Aricept(R). The following tests were used to assess memory and cognition: Brief Visual Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test, Digit Span and Letter Number Sequence sub-test of the Wechsler Adult Intelligence Scale-III, Controlled Oral Word Association Test and Memory Functioning Questionnaire. Experimental intervention : During the first treatment phase, participants received 5 mg/day of Aricept(R) for 1 month, increasing to 10 mg/day of Aricept(R) for an additional 5 months. During the second treatment phase, participants received 5 mg/day of Aricept(R) for the entire 6 months. Main outcomes and results : A repeated measures analysis of variance indicated significant improvement on immediate and delayed memory portions of the BVMT-R when taking 10 mg/day of Aricept(R). Conclusions : Findings contribute to the growing body of research into the use of Aricept(R) in treating memory deficits in TBI survivors and support the need for further research.	Craig Hosp, Englewood, CO 80110 USA	Morey, CE (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80110 USA.	cmorey@craighospital.org					Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Benedict R.H.B, 1997, BRIEF VISUAL MEMORY; Benton A., 1994, MULTILINGUAL APHASIA; Benton AL, 1989, CONTROLLED ORAL WORD; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; GOLDSTEIN FC, 1991, MEMORY DISORDERS RES, P255; Kaplan E., 1983, BOSTON NAMING TEST; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; NOBILI A, 1998, DONEPEZIL DRUG EVALU, V95; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Taverni JP, 1998, BRAIN INJURY, V12, P77; *US DEP HHS, 1989, PER CENTR NERV SYST, V227; Wechsler D., 1997, WECHSLER ADULT INTEL; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203	25	48	49	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2003	17	9					809	815		10.1080/0269905031000088586			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691ML	WOS:000183610000007	12850946				2021-06-18	
J	Chapman, SB; Max, JE; Gamino, JF; McGlothlin, JH; Cliff, SN				Chapman, SB; Max, JE; Gamino, JF; McGlothlin, JH; Cliff, SN			Discourse plasticity in children after stroke: Age at injury and lesion effects	PEDIATRIC NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; NARRATIVE DISCOURSE; BRAIN; LANGUAGE; DISORDERS; DEFICITS; INFANTS; TRUTH	Studies of children with stroke indicate remarkable recovery of language after some initial delay. However, complex language abilities as measured by discourse (connected language) may be required to detect the full impact of stroke on subsequent cognitive-linguistic development. This study examined discourse ability in children with stroke as compared with orthopedic controls, age-at-injury, and lesion effects. Discourse between two groups of children was compared [stroke (n = 17) vs orthopedic control (n = 17)]. The stroke group was subdivided into early age at stroke (<1 year) and late age at stroke (>1 year). The discourse samples were analyzed along two dimensions: language and information structure. Results revealed that the stroke group performed at significantly lower levels than the orthopedic control group across discourse measures. The most important finding was a poorer outcome for early age at stroke as compared with later age at stroke. These findings alter the widespread belief of optimistic language outcomes after childhood stroke. Interestingly, no site or size-of-lesion effects, common to adult stroke, were identified. These findings identify poor long-term outcome with early brain insults at stages far removed from the onset of injury. The implication is that childhood stroke management should be revised to provide protracted follow-up and treatment. (C) 2003 by Elsevier Inc. All rights reserved.	Univ Texas, Ctr Brain Hlth, Dallas, TX 75235 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA	Chapman, SB (corresponding author), Univ Texas, Ctr Brain Hlth, 1966 Inwood Rd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01 NS 21889-16] Funding Source: Medline		ARAM DM, 1985, J CLIN EXP NEUROPSYC, V7, P55, DOI 10.1080/01688638508401242; ARAM DM, 1988, BRAIN LATERALIZATION, P417; Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, IN PRESS J HEAD TRAU; CHAPMAN SB, 2001, AAAS ANN M SCI INN E, V290, P5491; DALLOGLIO AM, 1994, DEV MED CHILD NEUROL, V36, P1076; Delis D, 1994, CALIFORNIA VERBAL LE; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; Eisele JA, 1998, BRAIN LANG, V61, P376, DOI 10.1006/brln.1997.1883; FELDMAN HM, 1992, BRAIN LANG, V42, P89, DOI 10.1016/0093-934X(92)90058-M; JOHNSON NS, 1998, CHILDRENS LANGUAGE, P315; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; MacWhinney B, 2000, BRAIN LANG, V71, P400, DOI 10.1006/brln.1999.2273; Marcus JT, 1999, J CARDIOV MAGN RESON, V1, P1, DOI 10.3109/10976649909080828; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; Nichelli P, 1995, NEUROREPORT, V6, P2309, DOI 10.1097/00001756-199511270-00010; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; REILLY JS, 1995, NEUROPSYCHOLOGIA, V33, P83, DOI 10.1016/0028-3932(94)00093-5; RIVA D, 1986, NEUROPSYCHOLOGIA, V24, P423, DOI 10.1016/0028-3932(86)90029-1; RUTTER M, 1970, CLIN DEV MED, V35, P128; STILES J, 1991, BRAIN COGNITION, V15, P201, DOI 10.1016/0278-2626(91)90026-5; Stiles Joan, 1993, P643; THAL DJ, 1991, BRAIN LANG, V40, P491, DOI 10.1016/0093-934X(91)90145-Q; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505; WULFECK BB, 1991, PEDIATR NEUROL, V7, P266, DOI 10.1016/0887-8994(91)90043-K	34	48	48	3	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	JUL	2003	29	1					34	41		10.1016/S0887-8994(03)00012-2			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	725FA	WOS:000185532100004	13679119				2021-06-18	
J	Soehle, M; Jaeger, M; Meixensberger, J				Soehle, M; Jaeger, M; Meixensberger, J			Online assessment of brain tissue oxygen autoregulation in traumatic brain injury and subarachnoid hemorrhage	NEUROLOGICAL RESEARCH			English	Article						brain tissue oxygenation; cerebral autoregulation; traumatic brain injury; subarachnoid hemorrhage; cerebral perfusion pressure; multimodal cerebral monitoring	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; SATURATION; TENSION; MANAGEMENT; METABOLISM; THERAPY; PH	Monitoring of brain tissue oxygenation (p(ti)O(2)) enables early diagnosis of secondary cerebral ischemia and may guide a cerebral perfusion pressure (CPP) orientated therapy. The purpose of our study was to explain the concept of p(ti)O(2)-autoregulation, defined as the ability of the brain to maintain p(ti)O(2) despite changes in CPP, and to show the different states of p(ti)O(2)-autoregulation we found. Microcatheters to assess ;O-2 and intracranial pressure were implanted into cerebral 'tissue at risk' of patients suffering from traumatic brain injury or subarachnoid hemorrhage. By using a multimodal neuromonitoring setup and in-house built software we assessed and displayed online the relationship between p(ti)O(2) and CPP based on a data buffer consisting of 12 h. Depending on the linear regression slope (b(pti)O(2) = Delta(pti)O(2)/DeltaCPP), we defined the state of p(ti)O(2)-autoregulation as present (0less than or equal tob(pti)O(2)less than or equal to1/6), moderate (1/6<b(ptiO2) <= 1/3), impaired (b(ptiO2)<= 1/3) or inverse (b(ptiO2) < 0). When p(ti)O(2)-autoregulation is present, an elevation in CPP is ineffective to raise p(ti)O(2). In contrast, an increase in CPP elevates p(ti)O(2) more pronounced in impaired than in moderate p(ti)O(2)-autoregulation, but decreases p(ti)O(2) in inverse p(ti)O(2)-autoregulation. We conclude that online assessment of p(ti)O(2)-autoregulation gives valuable information on which patient will benefit from an increase in CPP and which CPP should be achieved to do so.	Univ Leipzig, Dept Neurosurg, D-04103 Leipzig, Germany	Meixensberger, J (corresponding author), Univ Leipzig, Dept Neurosurg, Johannisallee 34, D-04103 Leipzig, Germany.	meix@medizin.uni-leipzig.de					ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Dings J, 1998, NEUROL RES, V20, pS71; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; DRAKE CG, 1988, J NEUROSURG, V68, P985; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HARPER AM, 1966, J NEUROL NEUROSUR PS, V29, P398, DOI 10.1136/jnnp.29.5.398; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 2000, ACT NEUR S, V76, P457; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Stocchetti N, 1998, ACT NEUR S, V71, P162; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017	25	48	48	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2003	25	4					411	417		10.1179/016164103101201580			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	703EL	WOS:000184267000016	12870270				2021-06-18	
J	Betts, R; Weinsheimer, S; Blouse, GE; Anagli, J				Betts, R; Weinsheimer, S; Blouse, GE; Anagli, J			Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CONSERVED REGION; CALMODULIN-LIKE DOMAIN; FUNCTIONAL DOMAIN; CRYSTAL-STRUCTURE; CALCIUM; PROTEIN; ACTIVATION; PURIFICATION; LOCALIZATION; DEGRADATION	Calpastatin is the natural specific inhibitor of calpain. Recent research has linked uncontrolled calpain activation to tissue damage after neuronal and cardiac ischemias, traumatic spine and brain injuries, as well as Alzheimer's disease and cataract formation. An imbalance between the activities of calpain and calpastatin is believed to be responsible for the pathological role of calpain. An important key to understanding calpain regulation by calpastatin is to determine, at the molecular level, how calpastatin interacts with calpain to inhibit its enzymatic activity. A 27-residue peptide (DPMSS-TYIEELGKREVTIPPKYRELLA) derived from subdomain 1B of the repetitive domains of calpain, named peptide B27-WT, was previously shown to be a potent inhibitor of mu- and m-calpain. In this report, a combination of beta-alanine scanning mutagenesis and kinetic measurements was used to probe, in a quantitative, systematic, and simultaneous fashion, the relative contribution of the amino acid side chain and backbone functionalities to the overall calpain-inhibitory activity of B27-WT. The study identified two "hot spots," Leu(11)-Gly(12) and Thr(17)-Ile(18)-Pro(19), in B27-WT within which the residues critical for inhibitory function are clustered. Mutation of any one of the key residues in either of the two hot spots resulted in a dramatic loss of inhibitory activity. Furthermore, it was shown that a restricted conformation of the Leu(11)-Gly(12) and Thr(17)-Ile(18)-Pro(19) backbones is required for the peptide inhibitory function. These results suggest a plausible model in which the two hot spots are situated at or near the interface(s) of the calpain-calpastatin complex and act in a concerted fashion to inhibit calpain. The information on the specific contribution of the amide bond and side chain of each key residue to the bioactivity of B27-WT will contribute to a better understanding of the mechanism of calpain inhibition and lead to novel and effective therapies based on the specific inhibition of dysregulated or overactivated calpain.	Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Protease Program, Karmanos Canc Inst, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48202 USA	Anagli, J (corresponding author), Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, 1 Ford Pl,5D, Detroit, MI 48202 USA.			Weinsheimer, Shantel/0000-0001-7486-9110	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039075] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [P60 AR20557] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39075] Funding Source: Medline		Anagli J, 1996, EUR J BIOCHEM, V241, P948, DOI 10.1111/j.1432-1033.1996.00948.x; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; COTTIN P, 1983, BIOCHIM BIOPHYS ACTA, V743, P299, DOI 10.1016/0167-4838(83)90227-3; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; De Tullio R, 1999, BIOCHEM J, V343, P467; Hao LY, 2000, BIOCHEM BIOPH RES CO, V279, P756, DOI 10.1006/bbrc.2000.4040; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; ISHIMA R, 1991, FEBS LETT, V294, P64, DOI 10.1016/0014-5793(91)81344-8; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Konno T, 1997, BBA-PROTEIN STRUCT M, V1342, P73, DOI 10.1016/S0167-4838(97)00092-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1971, ENZYMES, V3, P375; MA H, 1994, J BIOL CHEM, V269, P24430; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P1787; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; PERCZEL A, 1996, CIRCULAR DICHROISM C, P2868; Pinton P, 2001, DRUG DEVELOP RES, V52, P558, DOI 10.1002/ddr.1159.abs; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHANNON JD, 1985, INTRACELLULAR PROTEI, P233; SHIBA E, 1983, THROMB RES, V32, P207, DOI 10.1016/0049-3848(83)90031-2; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; UEMORI T, 1990, BIOCHEM BIOPH RES CO, V166, P1485, DOI 10.1016/0006-291X(90)91035-Q; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Williams J W, 1979, Methods Enzymol, V63, P437; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	41	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7800	7809		10.1074/jbc.M208350200			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	653ZK	WOS:000181466800009	12500971	Other Gold			2021-06-18	
J	AbdelMalik, P; Husted, J; Chow, EWC; Bassett, AS				AbdelMalik, P; Husted, J; Chow, EWC; Bassett, AS			Childhood head injury and expression of schizophrenia in multiply affected families	ARCHIVES OF GENERAL PSYCHIATRY			English	Article; Proceedings Paper	8th International Congress on Schizophrenia Research	APR 28-MAY 02, 2001	WHISTLER, CANADA				TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; PSYCHIATRIC-DISORDERS; RISK-FACTORS; PSYCHOSIS; CHILDREN	Background: The etiology of schizophrenia is believed to include genetic and nongenetic factors, with the pathogenesis involving abnormal neurodevelopment. We investigated whether mild head injury during brain maturation plays a role in the expression of schizophrenia in multiply affected families. Methods: We compared the history and severity of head injuries in childhood (age, less than or equal to10 years) and through adolescence (age, less than or equal to17 years) in 67 subjects with narrowly defined schizophrenia and 102 of their unaffected siblings from 23 multiply affected families. In subjects with schizophrenia, only head injuries preceding the onset of psychosis were considered. Results: Subjects in the schizophrenia group (n = 16 [23.9%]) were more likely than the unaffected siblings g. roup (n = 12 [11.8%]) to have a history of childhood head injury (P = .04; odds ratio, 2.35 [95% confidence interval, 1.03-5.36]). Subjects in the schizophrenia group with a history of childhood head injury had a significantly younger median age at onset of psychosis (20 years) compared with those with no such history (25 years; z = -2.98; P = .003). The severity of head injury ranged from minimal to mild, including concussions, but within this narrow range, severity was correlated with younger age at onset (r(s) = -0.66; P = .005). Head injury occurred a median of 12 years before the onset of psychosis. Results were similar if head injuries during adolescence were included, but did not achieve statistical significance. Conclusions: Mild childhood head injury may play a role in the expression of schizophrenia in families with a strong genetic predisposition. Prospective studies of mild head injury should consider genetic predisposition for possible long-term neurobehavioral sequelae.	Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M6J 1H4, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M6J 1H4, Canada; Univ Waterloo, Dept Hlth Studies & Gerontol, Waterloo, ON, Canada	Bassett, AS (corresponding author), Univ Toronto, Ctr Addict & Mental Hlth, 1001 Queen St W, Toronto, ON M6J 1H4, Canada.		AbdelMalik, Philip/C-8525-2017	AbdelMalik, Philip/0000-0002-7984-2088	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [97800-1] Funding Source: Medline		ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BASSETT AS, 1993, SCHIZOPHR RES, V11, P9, DOI 10.1016/0920-9964(93)90033-F; Bassett AS, 2001, SCHIZOPHRENIA BULL, V27, P417, DOI 10.1093/oxfordjournals.schbul.a006884; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GUREJE O, 1994, AM J PSYCHIAT, V151, P368; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1989, MILD HEAD INJURY, P189; LISHMAN WA, 1998, ORGANIC PSYCHIAT PSY; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCGUFFIN P, 1994, BRIT J PSYCHIAT, V164, P593, DOI 10.1192/bjp.164.5.593; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; QUAYLE K, 1997, PEDIATRICS, V99; REISS D, 1991, AM J PSYCHIAT, V148, P283; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SNOEK JW, 1989, MILD HEAD INJURY, P102; SNOW JH, 1994, PEDIAT TRAUMATIC BRA, V31; Spitzer RL, 1990, STRUCTURED CLIN INTE; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	29	48	49	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	MAR	2003	60	3					231	236		10.1001/archpsyc.60.3.231			6	Psychiatry	Psychiatry	655UZ	WOS:000181572200002	12622655	Bronze, Green Accepted			2021-06-18	
J	Chan, JHM; Tsui, EYK; Peh, WCG; Fong, D; Fok, KF; Leung, KM; Yuen, MK; Fung, KKL				Chan, JHM; Tsui, EYK; Peh, WCG; Fong, D; Fok, KF; Leung, KM; Yuen, MK; Fung, KKL			Diffuse axonal injury: detection of changes in anisotropy of water diffusion diffusion-weighted imaging	NEURORADIOLOGY			English	Article						head injury; diffuse axonal injury; diffusion-weighted imaging	TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; HEAD-INJURY; HISTOPATHOLOGIC CORRELATION; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; MR; COEFFICIENT; EDEMA; PIG	Myelinated axons of white matter demonstrate prominent directional differences in water diffusion. We performed diffusion-weighted imaging on ten patients with head injury to explore the feasibility of using water diffusion anisotropy for quantitating diffuse axonal injury. We showed significant decrease in diffusion anisotropy indices in areas with or without signal abnormality on T2 and T2*-weighted images. We conclude that the water diffusion anisotropy sensitive index a potentially useful, and quantitative way of diagnosing and assessing patients with diffuse axonal injury.	Tuen Mun Hosp, Dept Diagnost Radiol, Tuen Mun, Hong Kong, Peoples R China; Singapore Gen Hosp, Dept Diagnost Radiol, Singapore 0316, Singapore; Tuen Mun Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Optometry & Radiog, Hong Kong, Hong Kong, Peoples R China	Chan, JHM (corresponding author), Tuen Mun Hosp, Dept Diagnost Radiol, Tsing Chung Koon Rd, Tuen Mun, Hong Kong, Peoples R China.	jchm888@yahoo.com		Peh, Wilfred CG/0000-0002-9976-5462; Yuen, MK Ernest/0000-0003-4977-7120			ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Ge YL, 2002, J COMPUT ASSIST TOMO, V26, P62, DOI 10.1097/00004728-200201000-00009; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Yang Q, 1999, STROKE, V30, P2382, DOI 10.1161/01.STR.30.11.2382	26	48	49	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JAN	2003	45	1					34	38		10.1007/s00234-002-0891-y			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	644CU	WOS:000180901000006	12525952				2021-06-18	
J	de Kruijk, JR; Leffers, P; Menheere, PPCA; Meerhoff, S; Rutten, J; Twijnstra, A				de Kruijk, JR; Leffers, P; Menheere, PPCA; Meerhoff, S; Rutten, J; Twijnstra, A			Olfactory function after mild traumatic brain injury	BRAIN INJURY			English	Article							THRESHOLD; SMELL	Objective : The aim of this study was to determine the incidence of olfactory dysfunction after mild traumatic brain injury (MTBI). Damage to the olfactory bulbs or frontal cortex has been reported in MTBI, but olfactory dysfunction after MTBI has not been studied in a prospective way before. Design : Patients with first-time MTBI were included. Patients olfactory threshold values (Hyposmia Utility Kit by Olfacto-Labs(R)) were measured 2 weeks after the trauma. Associations between olfactory threshold values and individual symptoms and S-100B and NSE concentrations were examined, using multiple linear regression analysis, adjusting for the influence of age. Results : Twenty-two per cent of 111 included patients had hyposmia and 4% had anosmia. Thresholds at 2 weeks showed no significant associations with the presence of symptoms at the ER, nor with early concentrations of S-100B or NSE. Conclusions : Although a high prevalence of olfactory dysfunction was found, no correlation was found between olfactory dysfunction and acute parameters of MTBI.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Clin Chem, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Sch Med, Maastricht, Netherlands	de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.	jdk@sneu.azm.nl	Leffers, Pieter/B-8642-2009; Rutten, Joost/L-4618-2015	Rutten, Joost/0000-0002-5259-9794			de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DEKRUIJK J, IN PRESS J NEUROLOGY; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; FORTIER I, 1991, AM J IND MED, V20, P495, DOI 10.1002/ajim.4700200405; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RICHARD L, 1979, AM J OTOLARYNG, V1, P57; Savic I, 1997, ARCH NEUROL-CHICAGO, V54, P162, DOI 10.1001/archneur.1997.00550140038010; SCHECHTER PJ, 1974, J NEUROL NEUROSUR PS, V37, P802, DOI 10.1136/jnnp.37.7.802; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1275; SHERMAN AH, 1979, OTOLARYNG HEAD NECK, V87, P717, DOI 10.1177/019459987908700604; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8	14	48	48	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					73	78		10.1080/0269905021000010221			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600006	12519649				2021-06-18	
J	Perbal, S; Couillet, J; Azouvi, P; Pouthas, V				Perbal, S; Couillet, J; Azouvi, P; Pouthas, V			Relationships between time estimation, memory, attention, and processing speed in patients with severe traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						traumatic brain injury; attention; memory; information processing; duration reproduction; duration production	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; WORKING-MEMORY; TEMPORAL-ORDER; DIVIDED ATTENTION; FRONTAL-LOBE; DURATION; JUDGMENTS; DEFICITS; LESIONS	The present experiment was aimed at investigating the effects of memory and attention deficits and of information processing slowing on time estimation in patients with severe traumatic brain injury (TBI). Patients with TBI and normal control subjects reproduced and produced durations (5, 14, 38 s) in both a control counting condition and in a concurrent reading condition. They also performed finger-tapping tasks at a free rate and at a I s rate. Both groups were assessed on processing speed using a reaction-time task, and on memory and attention using a battery of neuropsychological tests. The results showed that time estimation was not less accurate in patients with TBI than in control subjects on the reproduction task or on the production task performed either in the control counting condition or in the concurrent reading condition. Conversely, duration judgments were more variable in patients with TBI than in control subjects on both tasks in both conditions. The results also showed that TBI patients exhibited slower reaction-times, and poorer working and episodic memory scores than control subjects. Most importantly, the variability index in the duration reproduction task was related to both working memory scores and processing speed measures, whereas the variability index in the duration production task was only related with the processing speed measures. The temporal performance pattern in TBI patients does not appear to reflect specific deficits in timing, but rather overall problems in attention, working memory, and processing speed mechanisms. (C) 2003 Published by Elsevier Ltd.	Hop La Pitie Salpetriere, Unit Cognit Neurosci & Cerebral Imagery, LENA, CNRS,UPR 640, F-75651 Paris 13, France; Hop Raymond Poincare, Serv Reeducat Neurol, Garches, France	Pouthas, V (corresponding author), Hop La Pitie Salpetriere, Unit Cognit Neurosci & Cerebral Imagery, LENA, CNRS,UPR 640, 47 Blvd Hop, F-75651 Paris 13, France.	viviane.pouthas@chups.jussieu.fr					ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Binkofski F, 1996, NEUROCASE, V2, P485; Block, 1996, TIME INTERNAL CLOCKS, V115, P143, DOI DOI 10.1016/S0166-4115(96)80057-4; Block R.A., 1990, COGNITIVE MODELS PSY, P59; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brown SW, 1997, PERCEPT PSYCHOPHYS, V59, P1118, DOI 10.3758/BF03205526; Casini L, 1997, MEM COGNITION, V25, P812, DOI 10.3758/BF03211325; Casini L, 1999, NEUROPSYCHOLOGY, V13, P10, DOI 10.1037/0894-4105.13.1.10; CASINI L, 1992, NATO ADV SCI INST SE, V66, P177; CHURCH RM, 1984, ANN NY ACAD SCI, V423, P556; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; Craik FIM, 1999, PERCEPT PSYCHOPHYS, V61, P549, DOI 10.3758/BF03211972; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; GIBBON J, 1984, TIMING TIME PERCEPTI, V423, P52; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; GRONDIN S, 1992, NATO ADV SCI INST SE, V66, P119; GRONDIN S, 1992, PERCEPT PSYCHOPHYS, V52, P345, DOI 10.3758/BF03209151; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Harrington DL, 1998, J NEUROSCI, V18, P1085; Harrington DL, 1999, REV NEUROSCIENCE, V10, P91, DOI 10.1515/REVNEURO.1999.10.2.91; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; MACAR F, 1994, MEM COGNITION, V22, P673, DOI 10.3758/BF03209252; MACAR F, 1980, TEMPS PERSPECTIVES P; Mangels JA, 1998, COGNITIVE BRAIN RES, V7, P15, DOI 10.1016/S0926-6410(98)00005-6; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCANDREWS MP, 1991, NEUROPSYCHOLOGIA, V29, P849, DOI 10.1016/0028-3932(91)90051-9; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miller E, 1970, Cortex, V6, P121; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mimura M, 2000, J INT NEUROPSYCH SOC, V6, P517, DOI 10.1017/S1355617700655017; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nichelli P, 1995, ANN NY ACAD SCI, V769, P183, DOI 10.1111/j.1749-6632.1995.tb38139.x; NORMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SALTHOUSE TA, 1994, DEV REV, V14, P413, DOI 10.1006/drev.1994.1016; SCHROOTSJJF, 1990, HDB PSYCHOL AGING, P45; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Sullivan EV, 1986, DEV NEUROPSYCHOL, V2, P387, DOI 10.1080/87565648609540356; SURWILLO WW, 1968, HUMAN AGING BEHAV, P1; TEASDALE G, 1974, LANCET, V2, P81; THOMAS EAC, 1978, ATTENTION PERFORM, V7, P43; Vakil E, 1998, NEUROPSY NEUROPSY BE, V11, P212; VAKIL E, 1994, NEUROPSY NEUROPSY BE, V7, P281; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Vanneste S, 1999, EXP AGING RES, V25, P49, DOI 10.1080/036107399244138; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1994, CLOSED HEAD INJURY; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wechsler D., 1981, WAIS R MANUAL WECHSL; ZAKAY D, 1993, PERCEPTION, V22, P91, DOI 10.1068/p220091	57	48	49	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2003	41	12					1599	1610		10.1016/S0028-3932(03)00110-6			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	711XC	WOS:000184765500005	12887985				2021-06-18	
J	Johnstone, B; Nossaman, LD; Schopp, LH; Holmquist, L; Rupright, SJ				Johnstone, B; Nossaman, LD; Schopp, LH; Holmquist, L; Rupright, SJ			Distribution of services and supports for people with traumatic brain injury in rural and urban Missouri	JOURNAL OF RURAL HEALTH			English	Article							STRATEGIES	New paradigms of disability suggest that many variables interact to influence the community functioning of people with traumatic brain injury (TBI), including injury severity and social, psychological, and environmental factors. Unfortunately, the majority of TBI outcome research to date has primarily focused on injury severity variables (e.g., neuroradiologic findings, loss of consciousness, posttraumatic amnesia) to the exclusion of environmental variables. Limited environmental resources such as rehabilitation professionals, facilities, and services may be significant barriers that affect outcome for people with TBI, particularly for those in rural areas. Using data from Missouri, where 32% of the population lives in rural counties, this study researched the availability of rehabilitation resources or individuals with TBI, with an emphasis on differences between rural and urban areas. Data indicated that there is a scarcity of rehabilitation professionals (i.e., physiatrists, mental health providers, rehabilitation therapists), facilities (i.e., hospitals offering comprehensive rehabilitation therapies), and services (i.e, support groups) in rural areas of the study state. The results suggest that (1) future rehabilitation researchers need to evaluate the impact of accessibility to rehabilitation services and resources on the outcome of people with TBI and (2) TBI health policy administrators need to consider how to increase rehabilitation resources for people with TBI in rural areas, including the use of rural-based training programs, rural debt-forgiveness training programs, and telehealth systems.	MU Sch Hlth Profess, Dept Hlth Psychol, Columbia, MO 65212 USA	Johnstone, B (corresponding author), MU Sch Hlth Profess, Dept Hlth Psychol, DC04600, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			*AM HOSP DIR, 2000, AM HOSP DIR ON LIN; HAGGLUND KJ, 1998, TOP SPINAL CORD INJ, V4, P28, DOI DOI 10.1310/3502-06MD-F2NK-LBGK; INNES B, 2000, J DISABIL POLICY STU, V10, P207; *MDOH, 2000, DAT STAT REP; *MO BRAIN INJ ASS, 2000, SUPP GROUPS; *MO DEP EC DEV, 2000, LAB MARK INF INF GEO; *MO DEP MENT HLTH, 2000, TREATM CTR; *MO DEP SOC SERV D, 1999, DIR LONG TERM CAR FA; *MO DEP TRANSP CUS, 1999, LIST ORG ZIP PROV TR; *MO DIV VOC REH, 2000, OFF; *MO HOSP ASS, 2000, MISS HOSP COUNT; *MO STAT BOARD REG, 1999, VAR DAT LIST LIC REG; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; *NE MISS COLL CAR, 2000, RESH RUR NURS SERV H; OMOHUNDRO J, 1983, J REHABIL, V49, P19; *RUPRI, 1999, RUPRI RUR POL CONT M; *RUR POL RES I, 2000, BACKGR INF STAT POP; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schneider M J, 1986, Annu Rev Rehabil, V5, P217; SCHOOTMAN M, 1999, BRAIN INJURY, V48, P70; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; SEELMAN KD, 1998, PLEN SESS TIDE 3 C A; *SERV IND LIV, 2000, CIL LOC DIR IND LIV; *U MISS SYST OFF S, 2000, BACKGR INF STAT POP; *US CENS BUR, 1999, MA 98 2 METR AR POP; *US CENS BUR, 1999, MA 98 3B POP EST MET; *US CENS BUR, 2000, STAT COUNT QUICK FAC; *US DEP HHS, 1997, N CAR RUR HLTH RES P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; World Health Organization, 2000, INT CLASS FUNCT DIS	31	48	48	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0890-765X	1748-0361		J RURAL HEALTH	J. Rural Health	WIN	2002	18	1					109	117		10.1111/j.1748-0361.2002.tb00882.x			9	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	552WJ	WOS:000175642800015	12043749				2021-06-18	
J	Chatfield, DA; Zemlan, FP; Day, DJ; Menon, DK				Chatfield, DA; Zemlan, FP; Day, DJ; Menon, DK			Discordant temporal patterns of S100 beta and cleaved tau protein elevation after head injury: a pilot study	BRITISH JOURNAL OF NEUROSURGERY			English	Article						head injury, outcome, S100 beta; tau protein	SERUM S-100B PROTEIN; BRAIN-INJURY; SURGERY; RELEASE; MARKER; DAMAGE	There is considerable interest in S100(beta) protein as a potential marker that can be used to quantify central nervous system injury.(1,2) However, increasing appreciation that S100(beta) may be produced by non-neural tissue (specifically adipocytes), has led to a search for more specific markers of brain injury. Recent interests have focused on a cleaved form of tau protein (c(tau)P) which is elevated in CSF from patients suffering traumatic brain injury.(3) We have investigated whether levels in peripheral blood are a satisfactory alternative to provide an accessible marker of CNS injury severity. We measured levels of S100(beta) and c(tau)P in arterial blood from 20 patients with severe head injury. When compared with normal values S100(beta) was elevated 10-fold in the first 24 hours and c(tau)P was elevated at all time points, but showed a reversal of the temporal trend observed with S100(beta). Patients with a poor outcome (GOS 1-3) had significantly higher S100(beta) levels on day one. Plasma c(tau)P levels did not correlate with outcome following head injury.	Addenbrookes Hosp, Univ Dept Anesthesia, Cambridge CB2 2QQ, England; Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA	Menon, DK (corresponding author), Addenbrookes Hosp, Univ Dept Anesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk					*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P597; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; [Anonymous], 2000, J Neurotrauma, V17, P563; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; JOHNSON GVW, 1996, ALZHEIMERS DIS REV, V1, P38; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jonsson H, 1999, ANN THORAC SURG, V68, P2202, DOI 10.1016/S0003-4975(99)00851-6; Jonsson H, 1998, ANN THORAC SURG, V65, P1639, DOI 10.1016/S0003-4975(98)00229-X; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Paglini G, 2000, NEUROCHEM RES, V25, P37, DOI 10.1023/A:1007531230651; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Taggart DP, 1997, ANN THORAC SURG, V63, P492; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	20	48	50	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2002	16	5					471	476		10.1080/0268869021000030285			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	622QW	WOS:000179658600007	12498491				2021-06-18	
J	Yeates, KO; Taylor, HG; Woodrome, SE; Wade, SL; Stancin, T; Drotar, D				Yeates, KO; Taylor, HG; Woodrome, SE; Wade, SL; Stancin, T; Drotar, D			Race as a moderator of parent and family outcomes following pediatric traumatic brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						traumatic brain injury; children; race	INITIAL YEAR; HEALTH; RELIABILITY; CHILDREN; BURDEN	Objective: To use data from a prospective, longitudinal study to determine whether race moderates parent and family outcomes during the first year following pediatric traumatic brain injuries (TBI). Method: Participants included 73 white and 18 black children with moderate to severe TBI and their families, and 32 white and 23 black children with orthopedic injuries only (OI) and their families. Assessments of parent and family functioning occurred shortly after injury (baseline) and at 6- and 12-month follow-ups. Results: Race was a significant moderator of group differences in parental psychological distress and perceived family burden, by and large independent of socioeconomic status. The negative consequences of TBI were relatively less pronounced for parents of black children than for parents of white children at baseline, but became more pronounced at the two follow-ups. Black and white parents differed in preferred coping strategies, which may partially account for their different reactions to their children's injuries. Conclusions: The sociocultural factors associated with race may moderate the effects of pediatric TBI and OI on parents and families.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Indianapolis Univ, Indianapolis, IN USA; Purdue Univ, Indianapolis, IN USA; Univ Cincinnati, Cincinnati, OH 45221 USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 R01 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Boyd-Franklin N., 1993, NORMAL FAMILY PROCES, P361; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Coll CG, 1996, CHILD DEV, V67, P1891, DOI 10.1111/j.1467-8624.1996.tb01834.x; CULVER JL, 2001, UNPUB COPING DISTRES; Derogatis L., 1982, BRIEF SYMPTOM INVENT; DRESSLER WW, 1993, MED ANTHROPOL Q, V7, P325, DOI 10.1525/maq.1993.7.4.02a00030; Greco P, 1996, J CLIN PSYCHOL MED S, V3, P337, DOI 10.1007/BF01994018; HU XH, 1993, CAN MED ASSOC J, V149, P421; KESSLER RC, 1986, J HEALTH SOC BEHAV, V27, P107, DOI 10.2307/2136310; KETCHUM KM, 2000, THESIS ST LOUIS U; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS RH, 1988, SOC SCI MED, V27, P999, DOI 10.1016/0277-9536(88)90291-2; NAVARRO V, 1991, INT J HEALTH SERV, V21, P229, DOI 10.2190/5WXM-QK9K-PTMQ-T1FG; NEIGHBORS HW, 1983, PREVENTION HUMAN SER, V2, P125; Ren XS, 1996, J EPIDEMIOL COMMUN H, V50, P269, DOI 10.1136/jech.50.3.269; STEIN REK, 1989, PUBLIC HEALTH REP, V104, P377; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; ULBRICH PM, 1989, J HEALTH SOC BEHAV, V30, P131, DOI 10.2307/2136918; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Weitzman M, 1999, PEDIATRICS, V104, P151; WETHINGTON E, 1986, J HEALTH SOC BEHAV, V27, P78, DOI 10.2307/2136504; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	34	48	48	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUN	2002	27	4					393	403		10.1093/jpepsy/27.4.393			11	Psychology, Developmental	Psychology	556PY	WOS:000175859200009	11986362	Bronze			2021-06-18	
J	Kline, AE; Bolinger, BD; Kochanek, PM; Carlos, TM; Yan, HQ; Jenkins, LW; Marion, DW; Dixon, CE				Kline, AE; Bolinger, BD; Kochanek, PM; Carlos, TM; Yan, HQ; Jenkins, LW; Marion, DW; Dixon, CE			Acute systemic administration of interleukin-10 suppresses the beneficial effects of moderate hypothermia following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						controlled cortical impact; cytokine; inflammation; Morris water maze; neutrophil; recovery; spatial learning and memory	FIBROBLAST-GROWTH-FACTOR; CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; INFLAMMATORY RESPONSE; DEFICITS; PROTECTION; NEUROPROTECTION; PHARMACOTHERAPY; RECRUITMENT	Traumatic injury to the central nervous system initiates inflammatory processes such as the synthesis of proinflammatory mediators that contribute to secondary tissue damage. Hence, administration of anti-inflammatory cytokines, such as interleukin-10 (IL-10) may be neuroprotective. Moderate hypothermia (30-32 degreesC) also decreases the pro-inflammatory response to traumatic brain injury (TBI). Thus, we hypothesized that the combination of IL-10 and hypothermia would provide synergistic neuroprotective effects after TBI. To test this hypothesis, fifty isoflurane-anesthetized rats underwent a controlled cortical impact (2.7 mm tissue deformation at 4 m/s) or sham injury and then were randomly assigned to one of five conditions (TBI/VEH Normothermia (37 degreesC), TBI/VEH Hypothermia (32 degreesC for 3 h), TBI/IL-10 Normothermia, TBI/IL-10 Hypothermia, and Sham/VEH Normothermia). Human IL-10 (5 mug) or VEH was administered (i.p.) 30 min after surgery. Function was assessed by established motor and cognitive tests on post-operative days 1-5 and 14-18, respectively. Cortical lesion volume and hippocampal CA(1)/CA(3) cell survival were quantified at 4 weeks. Brain sections from 15 additional rats were immunohistochemically assessed (MoAB RP-3) to determine neutrophil accumulation at 5 h after TBI. The administration of IL-10 after TBI produced an similar to75% reduction in the number of RP-3-positive cells in both the normothermic and hypothermic groups vs. the normothermic vehicle-treated group (P<0.05), but did not improve functional outcome. In contrast, hypothermia alone enhanced both motor and cognitive function and increased CA 3 neuronal survival after TBI. Contrary to our hypothesis, systemic administration of IL-10 combined with hypothermia did not provide synergistic neuroprotective effects after TBI. Rather, IL-10 administration suppressed the beneficial effects produced by hypothermia alone after TBI. The mechanism(s) for the negative effects of IL-10 combined with hypothermia after TBI remain to be determined. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS33150, NS40125] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318, R01NS033150, R01NS040125] Funding Source: NIH RePORTER		Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x; BAFFOUR R, 1995, J NEUROSURG, V83, P105, DOI 10.3171/jns.1995.83.1.0105; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN K, 1998, BASIC MECH NEW DRUG, P116; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Gundersen Y, 2001, ACTA ANAESTH SCAND, V45, P994, DOI 10.1034/j.1399-6576.2001.450812.x; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JONES SB, 1984, J APPL PHYSIOL, V57, P808; Kanaan SA, 1998, J NEUROIMMUNOL, V86, P142, DOI 10.1016/S0165-5728(98)00027-7; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; KLINE AE, 2001, MO CL BI CC, V2, P267; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McKeating EG, 1998, ACT NEUR S, V71, P200; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Romano MF, 1996, J IMMUNOL, V156, P2119; SANTO ED, 1997, EUR J PHARMACOL, V336, P197; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Soares HD, 1995, J NEUROSCI, V15, P8223; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zocchia C, 1997, NEUROCHEM INT, V30, P433, DOI 10.1016/S0197-0186(96)00079-4	54	48	51	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 24	2002	937	1-2					22	31	PII S0006-8993(02)02458-7	10.1016/S0006-8993(02)02458-7			10	Neurosciences	Neurosciences & Neurology	563RR	WOS:000176269800003	12020858				2021-06-18	
J	Walia, S; Sutcliffe, AJ				Walia, S; Sutcliffe, AJ			The relationship between blood glucose, mean arterial pressure and outcome after severe head injury: an observational study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article; Proceedings Paper	Meeting of the International-Trauma-Anesthesia-and-Critical-Care-Society	MAY 04-06, 2000	MAINZ, GERMANY	Int Trauma Anesthesia Critical Care Soc			CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; ADMISSION HYPERGLYCEMIA; CATECHOLAMINES; MANAGEMENT; PREDICTORS	Background and method: Hypotension and hyperglycaemia occurring in the first 24 h after severe head injury are individually associated with poor outcome but a causal effect has not been proven for either. Their combined effect is unknown and is investigated in this observational study of 338 patients with head injury, a Glasgow coma score (GCS) of 8 or less and requiring mechanical ventilation. Results: Mean arterial pressure (MAP) and blood glucose are linearly related to mortality (P < 0.0001). Regression analysis shows that each has an independent effect. Moreover, the relationship between blood glucose and mortality is stronger than the relationship between MAP and mortality. When patients are grouped according to lowest MAP, hyperglycaemia is associated with increasing mortality within each group (P < 0.0001). Conclusion: Further studies on the combined effect of hyperglycaemia. and hypotension on mortality after head injury are needed because this study suggests, but does not prove, an additive, causal association. (C) 2002 Elsevier Science Ltd. All rights reserved.	Queen Elizabeth Hosp, Neurosci Crit Care Unit, Birmingham B15 2TH, W Midlands, England; Selly Oak Hosp, Dept Anaesthesia & Intens Care, Birmingham B29 6JD, W Midlands, England	Sutcliffe, AJ (corresponding author), Queen Elizabeth Hosp, Neurosci Crit Care Unit, Birmingham B15 2TH, W Midlands, England.	ASutcli793@aol.com					Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARGULIES DR, 1994, AM SURGEON, V60, P387; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PRYSROBERTS C, 1984, MONITORING ANESTHESI, P79; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; *SAS I INC, 1999, STAT 5 01; STAMBROOK M, 1990, CAN J SURG, V33, P115; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	34	48	54	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2002	33	4					339	344	PII S0020-1383(02)00053-0	10.1016/S0020-1383(02)00053-0			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	579YH	WOS:000177206200007	12091030				2021-06-18	
J	Kirshblum, S; O'Dell, MW; Ho, C; Barr, K				Kirshblum, S; O'Dell, MW; Ho, C; Barr, K			Rehabilitation of persons with central nervous system tumors	CANCER			English	Article						tumor; cancer; spinal cord; brain; rehabilitation	QUALITY-OF-LIFE; SPINAL-CORD INJURY; MALIGNANT BRAIN-TUMORS; LOW-GRADE ASTROCYTOMA; INPATIENT REHABILITATION; POSTTRAUMATIC SEIZURES; CANCER-PATIENT; GLIOMAS; THERAPY; PROPHYLAXIS	A tumor that affects the central nervous system can have a dramatic impact on the individual affected, as well as his or her family and friends. The tumor, regardless of extent or location, may affect the physical, social, vocational, and emotional capabilities of the individual. Basic aspects of rehabilitation for patients with tumors affecting the brain and spinal cord are reviewed in this article. The authors have found that the same principles of neurorehabilitation applied to persons with traumatic brain injury, stroke, and traumatic spinal cord injury are equally appropriate for persons with brain and spinal cord tumors. These principles include the prevention of medical complications; the treatment of medical problems such as pain, spasticity, and neuropathic bowel and bladder; and the improvement of patients' mobility and activities of daily living. Rehabilitation specialists can help prevent complications, maximize function, and improve the quality of life for patients with central nervous system tumors. (C) 2001 American Cancer Society.	Kessler Inst Rehabil, Spinal Cord Injury & Ventilator Dependent Program, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Albert Einstein Coll Med, Dept Phys Med & Rehabil, Bronx, NY 10467 USA; Southside Hosp, Reg Ctr Brain Injury Rehabil, Bay Shore, NY USA; Cleveland Vet Affairs Med Ctr, Cleveland, OH USA; Eastern Virginia Univ, Sch Med, Dept Phys Med & Rehabil, Norfolk, VA USA	Kirshblum, S (corresponding author), Kessler Inst Rehabil, Spinal Cord Injury & Ventilator Dependent Program, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.						Abdulrauf SI, 1998, J NEUROSURG, V88, P513, DOI 10.3171/jns.1998.88.3.0513; ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P1263; AIKEN RD, 1994, SEMIN ONCOL, V21, P273; Batchelor T, 1996, NEUROSURG CLIN N AM, V7, P435; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS37, DOI 10.1016/S0003-9993(98)90120-4; BELL KR, 1997, 1997 ANN M AM AC PHY; BLACK PM, 1997, CANC NERVOUS SYSTEM, P24; Boake C, 1993, ARCH PHYS MED REHAB, V74, P1247; BOARINI DJ, 1985, NEUROSURGERY, V16, P290, DOI 10.1227/00006123-198503000-00002; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; Brandstater ME, 1998, REHABILITATION MED P, P1165; Buchan A C, 1972, Paraplegia, V10, P23; Clinchot DM, 1997, ARCH PHYS MED REHAB, V78, P346, DOI 10.1016/S0003-9993(97)90223-9; COHEN N, 1988, J CLIN ONCOL, V6, P1621, DOI 10.1200/JCO.1988.6.10.1621; COOK DJ, 1995, SCAND J GASTROENTERO, V30, P48, DOI 10.3109/00365529509090271; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; DROPCHO EJ, 1991, NEUROLOGY, V41, P1235, DOI 10.1212/WNL.41.8.1235; DROPCHO EJ, 1991, NEUROL CLIN, V9, P969; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; FRANCESCHETTI S, 1990, ACTA NEUROCHIR, V103, P47, DOI 10.1007/BF01420191; GIOVAGNOLI AR, 1994, ITAL J NEUROL SCI, V15, P481, DOI 10.1007/BF02334609; Glantz MJ, 1996, NEUROLOGY, V46, P985, DOI 10.1212/WNL.46.4.985; GOLDSTEIN LB, 1996, ATLAS CEREBROVASCULA; Green SB, 1997, CONTROL CLIN TRIALS, V18, P306, DOI 10.1016/S0197-2456(97)00053-6; GREENBERG MS, 1997, HDB NEUROSURGERY, V1, P240; GUTTMAN L, 1973, SPINAL CORD INJURIES; HACKING HGA, 1993, PARAPLEGIA, V31, P367, DOI 10.1038/sc.1993.61; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Huang ME, 1998, ARCH PHYS MED REHAB, V79, P1386, DOI 10.1016/S0003-9993(98)90232-5; HUNG S, 1991, P ASCO, V10, P327; Kiebert GM, 1998, EUR J CANCER, V34, P1902, DOI 10.1016/S0959-8049(98)00268-8; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; McCormick P, 1995, MERRITTS TXB NEUROLO, P405; MCDERMOTT MW, 1996, NEUROLOGICAL SURG, P2782; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P619, DOI 10.1016/S0003-9993(99)90162-4; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1253, DOI 10.1016/S0003-9993(99)90025-4; MEADOR KJ, 1995, NEUROLOGY, V45, P1494, DOI 10.1212/WNL.45.8.1494; MELLETTE SJ, 1994, SEMIN ONCOL, V21, P779; Meyers CA, 1998, J CLIN ONCOL, V16, P2522, DOI 10.1200/JCO.1998.16.7.2522; MURRAY PK, 1985, CANCER, V55, P197, DOI 10.1002/1097-0142(19850101)55:1<197::AID-CNCR2820550131>3.0.CO;2-F; MURRAY PK, 1994, ARCH PHYS MED REHAB, V65, P634; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; PATCHELL RA, 1995, NEUROL CLIN, V13, P915, DOI 10.1016/S0733-8619(18)30025-2; Perry JR, 1996, CAN J NEUROL SCI, V23, P128, DOI 10.1017/S0317167100038853; Schiavetto A, 1997, NEUROCASE, V3, P1; Schuurman PR, 1997, ACTA NEUROCHIR, V139, P2, DOI 10.1007/BF01850860; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; SLUGG PH, 1992, ARCH INTERN MED, V152, P2325, DOI 10.1001/archinte.152.11.2325; Sneed PK, 1997, SEMIN SURG ONCOL, V13, P157, DOI 10.1002/(SICI)1098-2388(199705/06)13:3<157::AID-SSU2>3.0.CO;2-6; Stewart-Amidei C, 1995, Crit Care Nurs Clin North Am, V7, P125; TAPHOORN MJB, 1994, ANN NEUROL, V36, P48, DOI 10.1002/ana.410360111; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; VANDENBERG SR, 1995, MALIGNANT BRAIN TUMO, P29; Vukovich TC, 1997, J NEUROSURG, V87, P508, DOI 10.3171/jns.1997.87.4.0508; Weitzner MA, 1997, PSYCHO-ONCOL, V6, P169, DOI 10.1002/(SICI)1099-1611(199709)6:3<169::AID-PON269>3.0.CO;2-#; YOSHIOKA H, 1994, AM J PHYS MED REHAB, V73, P199, DOI 10.1097/00002060-199406000-00009	58	48	50	0	2	JOHN WILEY & SONS INC	NEW YORK	605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0008-543X			CANCER	Cancer	AUG 15	2001	92	4		S			1029	1038		10.1002/1097-0142(20010815)92:4+<1029::AID-CNCR1416>3.0.CO;2-P			10	Oncology	Oncology	466VD	WOS:000170666100010	11519030				2021-06-18	
J	Andersen, NB; Bovim, G; Sjaastad, O				Andersen, NB; Bovim, G; Sjaastad, O			The frontotemporal peripheral nerves. Topographic variations of the supraorbital, supratrochlear and auriculotemporal nerves and their possible clinical significance	SURGICAL AND RADIOLOGIC ANATOMY			English	Article						frontotemporal sensory nerves; anaesthetic block; plastic surgery; nerve entrapment; headache	TEMPOROMANDIBULAR-JOINT; FREYS SYNDROME; NEURALGIA; HEADACHE; MIGRAINE; BLOCKADE; SURGERY	The peripheral topography of the supraorbital (SON) and supratrochlear (STN) nerves and the superficial temporal branch of the auriculotemporal nerve (ATN) was investigated in 10 cadavers. The aim was to define the optimal locations for anaesthetic nerve blocks. as well as to help surgeons prevent nerve injuries. Specific measurements on the nerve "exits" in relation to defined landmarks are presented. The variability of the supraorbital notches and peripheral branching of the dissected nerves suggests several methods for anaesthetic blocks in cases of surgical and clinical head pain. The optimum injection site for a selective SON block is 20-30 mm from the midline (range 15-33 mm), reinjection at 30-50 mm from the midline might complete inefficient nerve block. For selective SON block the distance between the main SON and STN branches (mean 15.3 mm) should also be considered. The ATN is best blocked at a point located at the level with and 10-15 mm (range 8-20 mm) anterior to the upper origin of the helix. Separate exits for the medial and lateral SON branches were observed in eight of the 20 nerves examined. Twenty of the 28 exits were foraminae completed by bony or connective tissue. In many cases both the SON and STN ascended close to the associated artery: in six cases a tissue band covered the nerve and vessel at the orbital exit. Some of the observed structures associated with the nerve might be pain-generators, however the present study does not provide any evidence for such a hypothesis.	Norwegian Univ Sci & Technol, Fac Med, Dept Clin Neurosci, Neurol Sect, N-7034 Trondheim, Norway; Norwegian Univ Sci & Technol, Fac Med, Dept Morphol, N-7034 Trondheim, Norway	Andersen, NB (corresponding author), Glostrup Cty Hosp, Dept Neurol, Copenhagen Headache Res Grp, DK-2600 Glostrup, Denmark.	noemi@dadlnet.dk					Anson B, 1963, ATLAS HUMAN ANATOMY; Becser N, 1998, SPINE, V23, P1435, DOI 10.1097/00007632-199807010-00001; BERRY AC, 1975, J ANAT, V120, P519; BOVIM G, 1992, PAIN, V51, P43, DOI 10.1016/0304-3959(92)90007-X; Caputi CA, 1997, HEADACHE, V37, P174, DOI 10.1046/j.1526-4610.1997.3703174.x; Carter JB, 1991, ARTHROSCOPY TEMPOROM, P310; DAVID SK, 1995, ARCH OTOLARYNGOL, V121, P1153; DEBENEDITTIS G, 1990, J NEUROSURG, V72, P955, DOI 10.3171/jns.1990.72.6.0955; FATAH MF, 1991, BRIT J PLAST SURG, V44, P351, DOI 10.1016/0007-1226(91)90148-D; GORDON AB, 1976, AM J SURG, V132, P54, DOI 10.1016/0002-9610(76)90290-7; GREENE MW, 1989, J ORAL MAXIL SURG, V47, P386, DOI 10.1016/0278-2391(89)90341-8; Hunstad JP, 1996, AESTHET PLAST SURG, V20, P43; JACOBSON RI, 1983, NEW ENGL J MED, V308, P1363; Kimura K, 1977, Kaibogaku Zasshi, V52, P203; KLEIN DS, 1991, ANESTH ANALG, V73, P490; KNIZE DM, 1995, PLAST RECONSTR SURG, V96, P564, DOI 10.1097/00006534-199509000-00007; LAAGE-HELLMAN J E, 1958, Acta Otolaryngol, V49, P306, DOI 10.3109/00016485809134759; Malet T, 1997, SURG RADIOL ANAT, V19, P377, DOI 10.1007/BF01628505; MARTIS C, 1969, PLAST RECONSTR SURG, V44, P603, DOI 10.1097/00006534-196912000-00016; Moore K.L., 1985, CLIN ORIENTED ANATOM; NAMKING M, 1994, J ANAT, V185, P421; PERSING JA, 1985, NEUROSURGERY, V17, P660, DOI 10.1227/00006123-198510000-00023; Rohen J. W., 1983, COLOR ATLAS ANATOMY; ROSENBLATT MA, 1989, OTOLARYNG CLIN N AM, V22, P1173; Sand T, 1998, ACTA NEUROL SCAND, V98, P333; SCOTT DB, 1989, TECHNIQUES REGIONAL, P56; Sjaastad O, 1999, HEADACHE, V39, P204, DOI 10.1046/j.1526-4610.1999.3903204.x; SPIRO RH, 1967, ANN SURG, V165, P118, DOI 10.1097/00000658-196701000-00016; STAUBERSAND J, 1989, SOBOTTAS ATLAS ANATO; TAVERAS JM, 1976, DIAGNOSTIC NEURORDIO, P1; VANDISHOECK HA, 1968, LARYNGOSCOPE, V78, P122; WALSH FB, 1957, CLIN NEUROOPHTHALMOL, P1160; WEBSTER RC, 1986, LARYNGOSCOPE, V96, P311; Weinberg S, 1996, J ORAL MAXIL SURG, V54, P40, DOI 10.1016/S0278-2391(96)90301-8; WILLIAMS PL, 1980, GRAYS ANATOMY, P1060; ZIDE BM, 1985, SURG ANATOMY ORBIT, P7	36	48	50	0	3	SPRINGER FRANCE	PARIS	22 RUE DE PALESTRO, PARIS, 75002, FRANCE	0930-1038	1279-8517		SURG RADIOL ANAT	Surg. Radiol. Anat.	APR	2001	23	2					97	104					8	Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery	439KV	WOS:000169116800007	11462869				2021-06-18	
J	Massieu, L; Del Rio, P; Montiel, T				Massieu, L; Del Rio, P; Montiel, T			Neurotoxicity of glutamate uptake inhibition in vivo: Correlation with succinate dehydrogenase activity and prevention by energy substrates	NEUROSCIENCE			English	Article						glutamate transport; 3-nitropropionic acid; pyruvate; acetoacetate; creatine	KYNURENIC ACID FORMATION; NEUROACTIVE AMINO-ACIDS; TRAUMATIC BRAIN INJURY; RAT HIPPOCAMPAL SLICES; 3-NITROPROPIONIC ACID; OXIDATIVE STRESS; IN-VIVO; NEURODEGENERATIVE DISEASES; MEDIATED NEUROTOXICITY; INDUCED HYPOGLYCEMIA	Impairment of glutamate uptake or the reverse action of its transporters has been suggested as the mechanism responsible for the increased glutamate extracellular levels associated with ischemic neuronal damage. In previous studies we have shown that glutamate uptake inhibition by L-trans-pyrrolidine-2,4-dicarboxylate (PDC) in the rat striatum and hippocampus in vivo does not induce neuronal death despite the notable increase in the extracellular levels of glutamate and aspartate. However, PDC intracerebral administration leads to neuronal death in rats chronically injected with the mitochondrial toxin 3-nitropropionic acid (3-NP), an inhibitor of succinate dehydrogenase (SDH). In the present study we have determined the time course of inhibition of SDH activity in the striatum of rats acutely injected with a single dose of 3-NP (20 mg/kg), and studied its relation to PDC neurotoxicity. PDC induced larger lesions when administered during maximum inhibition of SDH activity while smaller lesions were found when it was injected during recovery of enzyme activity. We also studied the neuroprotective effect of different energy substrates such as creatine, pyruvate, and the ketone bodies beta -hydroxybutyrate and acetoacetate in this experimental model. Our results show partial protection with all compounds except for beta -hydroxybutyrate that showed no protection, while MK-801 completely prevented PDC-induced neuronal damage. We believe that the present results might be of relevance for the understanding of the mechanisms responsible for ischemic neuronal death and its prevention. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neurociencias, Mexico City 04510, DF, Mexico	Massieu, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neurociencias, AP 70-253, Mexico City 04510, DF, Mexico.	lmassieu@ifisiol.unam.mx	del Rio Estrada, Perla/AAA-5414-2021	del Rio Estrada, Perla/0000-0003-3366-3268			ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; Blitzblau R, 1996, EUR J NEUROSCI, V8, P1840, DOI 10.1111/j.1460-9568.1996.tb01328.x; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; Brouillet E, 1998, J NEUROCHEM, V70, P794; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Daikhin Y, 1998, DEV NEUROSCI-BASEL, V20, P358, DOI 10.1159/000017331; Desagher S, 1997, J NEUROSCI, V17, P9060; Deshpande SB, 1997, EXP NEUROL, V145, P38, DOI 10.1006/exnr.1997.6457; EIMERL S, 1995, J NEUROCHEM, V65, P739; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Garcia O, 2001, J NEUROSCI RES, V64, P418, DOI 10.1002/jnr.1093; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HAMILTON BF, 1987, ACTA NEUROPATHOL, V72, P286, DOI 10.1007/BF00691103; HENNEBERRY RC, 1989, NEUROBIOL AGING, V10, P611, DOI 10.1016/0197-4580(89)90149-8; Hodgkins PS, 1998, DEV NEUROSCI-BASEL, V20, P408, DOI 10.1159/000017338; Hodgkins PS, 1998, EUR J NEUROSCI, V10, P1986, DOI 10.1046/j.1460-9568.1998.00208.x; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; Izumi Y, 1998, J CLIN INVEST, V101, P1121, DOI 10.1172/JCI1009; Izumi Y, 1997, J NEUROSCI, V17, P9448; IZUMI Y, 1994, NEUROREPORT, V5, P617, DOI 10.1097/00001756-199401000-00021; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Malcon C, 2000, BRAIN RES, V860, P195, DOI 10.1016/S0006-8993(00)02038-2; Massieu L, 1997, J NEUROCHEM, V69, P1151; Massieu L, 2000, EXP NEUROL, V165, P257, DOI 10.1006/exnr.2000.7481; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; Matthews RT, 1998, J NEUROSCI, V18, P156; Maus M, 1999, EUR J NEUROSCI, V11, P3215, DOI 10.1046/j.1460-9568.1999.00745.x; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OBRENOVITCH TP, 1993, J NEUROCHEM, V61, P178, DOI 10.1111/j.1471-4159.1993.tb03553.x; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pang Z, 1997, J NEUROSCI, V17, P3064; POLLAY M, 1980, J NEUROSCI RES, V5, P163, DOI 10.1002/jnr.490050208; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Ruiz F, 1998, NEUROREPORT, V9, P1277; Sanchez-Carbente MD, 1999, J NEUROCHEM, V72, P129; SANDBERG M, 1986, J NEUROCHEM, V47, P178; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schulz JB, 1996, NEUROCHEM INT, V29, P167, DOI 10.1016/0197-0186(95)00122-0; Schulz JB, 1996, NEUROSCIENCE, V71, P1043, DOI 10.1016/0306-4522(95)00527-7; SMALL DL, 1997, STROKE THERAPY BASIC, P65; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Volterra A, 1996, EUR J NEUROSCI, V8, P2019, DOI 10.1111/j.1460-9568.1996.tb01345.x; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WHAL F, 1994, J NEUROCHEM, V63, P1003; Xu CJ, 1997, MOL CHEM NEUROPATHOL, V32, P89, DOI 10.1007/BF02815169; ZEEVALK GD, 1992, J NEUROCHEM, V59, P1211, DOI 10.1111/j.1471-4159.1992.tb08430.x; ZEEVALK GD, 1990, J PHARMACOL EXP THER, V253, P1285	53	48	50	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	106	4					669	677		10.1016/S0306-4522(01)00323-2			9	Neurosciences	Neurosciences & Neurology	493XT	WOS:000172249300003	11682154				2021-06-18	
J	Hughes, KM; Collier, B; Greene, KA; Kurek, S				Hughes, KM; Collier, B; Greene, KA; Kurek, S			Traumatic carotid artery dissection: a significant incidental finding	AMERICAN SURGEON			English	Article							MAGNETIC-RESONANCE; CERVICAL-SPINE; BLUNT INJURY; ANGIOGRAPHY; OCCLUSION; DIAGNOSIS; SPECTRUM	Blunt traumatic carotid artery dissection remains controversial in terms of diagnostic screening, reported incidence, and management. Treatment options include observation, anticoagulation and endovascular stenting, and aggressive surgical repair of the carotid artery injury. Blunt traumatic carotid artery dissections were reviewed through a retrospective study of trauma registry records. Seven patients were identified from 3342 patients over 3 years. Six patients were identified incidentally during magnetic resonance imaging (MRI) cervical spine/brain screening and one patient during angiographic evaluation for possible penetrating neck injury without MRI/magnetic resonance angiography (MRA). A total of 189 patients underwent MRI screening over this 3-year period, demonstrating a relative incidence of 3.7 per cent, contrasting with the reported incidence of 0.08 to 0.4 per cent for all trauma patients. All seven patients suffered severe head injuries (mean Glasgow Coma Score = 4.7) requiring mean intensive care unit and hospital stays of 15.6 and 23.7 days, respectively. None of the patients showed evidence of stroke with CT scanning on presentation. None of the patients demonstrated clinical focal neurologic signs or symptoms indicating carotid injury or stroke. Six patients survived their acute trauma and were discharged to rehabilitation after initiation of observation tone patient) or anticoagulation (five patients). All six patients showed neurological improvement without deterioration clinically or radiographically. In conclusion we propose early aggressive screening through MRI/MRA of severely injured patients to detect occult carotid artery dissections. Conservative medical treatment for this occult injury has been effective in this series of patients.	Temple Univ, Conemaugh Mem Med Ctr, Dept Surg, Trauma Serv, Johnstown, PA 15905 USA; Temple Univ, Conemaugh Mem Med Ctr, Dept Surg, Div Neurosurg, Johnstown, PA 15905 USA	Hughes, KM (corresponding author), Temple Univ, Conemaugh Mem Med Ctr, Dept Surg, Trauma Serv, 1086 Franklin St, Johnstown, PA 15905 USA.						Alimi YS, 1996, J VASC SURG, V24, P249, DOI 10.1016/S0741-5214(96)70100-3; BENITO MC, 1990, J TRAUMA, V30, P116, DOI 10.1097/00005373-199001000-00021; BILLER J, 1986, ARCH NEUROL-CHICAGO, V43, P1234, DOI 10.1001/archneur.1986.00520120019010; Bok APL, 1996, J TRAUMA, V40, P968, DOI 10.1097/00005373-199606000-00017; CALDWELL HW, 1948, ANN INTERN MED, V28, P1132, DOI 10.7326/0003-4819-28-6-1132; Candon E, 1996, NEUROSURGERY, V39, P863, DOI 10.1097/00006123-199610000-00047; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cornelius R S, 1995, Neuroimaging Clin N Am, V5, P451; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; FLEMING JFR, 1968, CAN J SURG, V11, P166; FORSTER BB, 1995, CAN ASSOC RADIOL J, V46, P168; FRIEDMAN WA, 1980, NEUROSURGERY, V7, P207, DOI 10.1227/00006123-198009000-00001; GOLDBERG AL, 1988, SKELETAL RADIOL, V17, P89, DOI 10.1007/BF00365133; KRAJEWSKI LP, 1980, ANN SURG, V191, P341, DOI 10.1097/00000658-198003000-00014; Laitt RD, 1996, CLIN RADIOL, V51, P117, DOI 10.1016/S0009-9260(96)80268-6; LEROUX PD, 1990, SURG NEUROL, V34, P260, DOI 10.1016/0090-3019(90)90138-F; MOAR JJ, 1987, FORENSIC SCI INT, V34, P227, DOI 10.1016/0379-0738(87)90036-3; PERRY MO, 1980, ANN SURG, V192, P74, DOI 10.1097/00000658-198007000-00013; Prall JA, 1998, NEUROSURGERY, V42, P495, DOI 10.1097/00006123-199803000-00012; PRETRE R, 1994, SURGERY, V115, P375; Tehranzadeh J, 1996, SEMIN ULTRASOUND CT, V17, P93, DOI 10.1016/S0887-2171(96)90009-8; Verneuil A, 1872, B ACAD NATL MED, V36, P46; WATRIDGE CB, 1989, J NEUROSURG, V71, P854, DOI 10.3171/jns.1989.71.6.0854; YAMADA S, 1967, J TRAUMA, V7, P733	24	48	48	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	NOV	2000	66	11					1023	1027					5	Surgery	Surgery	372LL	WOS:000165235100008	11090011				2021-06-18	
J	Verweij, BH; Muizelaar, JP; Vinas, FC; Peterson, PL; Xiong, Y; Lee, CP				Verweij, BH; Muizelaar, JP; Vinas, FC; Peterson, PL; Xiong, Y; Lee, CP			Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose-response and time-window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral mitochondria; dose-response curve; time-window profile; preclinical trial; cerebral oxygen metabolism; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; MEMORY DEFICITS; RATS; PATHOPHYSIOLOGY; ACCUMULATION; U-101033E; RELEASE; SNX-111	Object. Determining the efficacy of a drug used in experimental traumatic brain injury (TBI) requires the use of one or more outcome measures such as decreased mortality or fewer neurological and neuropsychological deficits. Unfortunately, outcomes in these test batteries have a fairly large variability, requiring relatively large sample sizes, and administration of the tests themselves is also very time consuming. The authors previously demonstrated that experimental TBI and human TBI induce mitochondrial dysfunction. Because mitochondrial dysfunction is easy to assess compared with neurobehavioral endpoints, it might prove useful as an outcome measure to establish therapeutic rime windows and dose-response curves in preclinical drug testing. This idea was tested in a model of TBI in rats. Methods. Animals treated with the selective N-type voltage-sensitive calcium channel blocker Ziconotide (also known as SNX-111 and CI-1009) after cortical impact displayed significant improvement in brain mitochondrial function. When a single intravenous bolus injection of 4 mg/kg Ziconotide was given at different time intervals, ranging from 15 minutes before injury to 10 hours after injury, mitochondrial function was improved at all time points, but more so between 2 and 6 hours postinjury. The authors evaluated the effects on mitochondrial function of Ziconotide at different doses by administering 0.5 to 6 mg/kg as a single bolus injection 4 hours after injury, and found 4 mg/kg to be the optimum dose. Conclusions. The authors established these time-window profiles and dose-response curves on the basis of mitochondrial outcome measures in a total of 42 rats because there were such low standard deviations in these tests. Establishing similar time-window profiles and dose-response curves by using neurobehavioral endpoints would have required using 114 rats in much more elaborate experiments.	Univ Calif Davis, Med Ctr, Dept Neurosurg, Sacramento, CA 95817 USA; Wayne State Univ, Dept Neurosurg, Detroit, MI USA; Wayne State Univ, Dept Neurol, Detroit, MI USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI USA	Muizelaar, JP (corresponding author), Univ Calif Davis, Med Ctr, Dept Neurosurg, 4860 Y St,Room 3740, Sacramento, CA 95817 USA.	J.Paul.Muizelaar@UCDMC.ucdavis.edu		Xiong, Ye/0000-0001-9770-6031			Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; ERECINSKA M, 1994, PROG NEUROBIOL, V43, P37, DOI 10.1016/0301-0082(94)90015-9; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HOVDA DA, 1994, ACTA NEUROCHIR, P521; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lee C. P., 1993, V2, P41; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH DH, 1996, NOVEL THERAPIES CNS, P137; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; TAKIZAWA S, 1995, J CEREBR BLOOD F MET, V15, P611, DOI 10.1038/jcbfm.1995.75; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	29	48	48	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2000	93	5					829	834		10.3171/jns.2000.93.5.0829			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	366YL	WOS:000090033800015	11059665				2021-06-18	
J	Durham, SR; Clancy, RR; Leuthardt, E; Sun, P; Kamerling, S; Dominguez, T; Duhaime, AC				Durham, SR; Clancy, RR; Leuthardt, E; Sun, P; Kamerling, S; Dominguez, T; Duhaime, AC			CHOP Infant Coma Scale ("Infant Face Scale"): A novel coma scale for children less than two years of age	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; child; coma scales; infant; trauma	PEDIATRIC HEAD-INJURY; IMPAIRED CONSCIOUSNESS; TRAUMA; EXPERIENCE	The Glasgow Coma Scale (GCS) is the most frequently used tool worldwide for assessing the severity of neurologic injury after brain trauma, although applying this scale to infants and younger children can be problematic. The CHOP Infant Coma Scale, or Infant Face Scale (IFS), is a novel scale for children under 2 years of age which differs from other pediatric coma scales in the following ways: (1) it relies on objective behavioral observations; (2) it assesses cortical as well as brainstem function; (3) it parallels the GCS in scoring but is based on infant-appropriate behaviors; and (4) it can be applied to intubated patients. We report the results of a prospective study designed to compare interrater reliability between the IFS and GCS in children less than 2 years of age. Seventy-five hospitalized children less than 2 years of age were assessed simultaneously by a pair of observers, representing a spectrum of health care professionals, who scored the children using both the IFS and GCS, Interrater reliability for each pair of observers for each scale was assessed using the kappa (kappa) statistic. A second series of 10 infants in the intensive care unit with specific diagnoses of acute traumatic or hypoxic/ischemic brain injury were similarly assessed. In the 75 hospitalized infants with a variety of diagnoses, interrater reliability for the GCS was in the "almost perfect," "slight," and '"fair" range for the eye-opening, motor, and verbal subtests, respectively. In contrast, the IFS showed interrater reliability in the "almost perfect," "substantial," and "almost perfect" ranges for the three subtests, When applied to infants in an intensive care unit with acute traumatic brain injury or hypoxia/ischemia, the GCS interrater reliability scores were in the "fair" range, while the IFS scores were in the "almost perfect" range, The IFS demonstrates improved interrater reliability in direct comparison to the GCS, particularly in the "verbal/face" component where most pediatric coma scales are deficient, The IFS may prove to be a simple and practical bedside index of brain injury severity in children less than two years of age.	Univ Penn, Div Neurosurg, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Neurol, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Gen Surg, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Crit Care Med, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA	Durham, SR (corresponding author), Univ Penn, Div Neurosurg, Childrens Hosp Philadelphia, Sch Med, 34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.						*AM COLL SURG, 1997, ADV TRAUM LIF SUPP T; CLANCY RR, 1984, NEUROLOGY, V34, P583, DOI 10.1212/WNL.34.5.583; CLANCY RR, 1988, EPILEPSIA, V29, P256, DOI 10.1111/j.1528-1157.1988.tb03715.x; DRONGOWSKI RA, 1993, J PEDIATR SURG, V28, P1072, DOI 10.1016/0022-3468(93)90522-M; DUNCAN CC, 1981, CHILD BRAIN, V8, P299; GORDON NS, 1983, NEUROPEDIATRICS, V14, P3, DOI 10.1055/s-2008-1059545; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hofer T, 1993, J Neurosci Nurs, V25, P218; KAUFMANN CR, 1990, JAMA-J AM MED ASSOC, V263, P69, DOI 10.1001/jama.263.1.69; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SESHIA SS, 1977, DEV MED CHILD NEUROL, V19, P614; SIMPSON D, 1982, LANCET, V2, P450; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; WALKER ML, 1984, CHILD BRAIN, V11, P387; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	21	48	48	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2000	17	9					729	737		10.1089/neu.2000.17.729			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	356LM	WOS:000089444800001	11011813				2021-06-18	
J	Bode, RK; Heinemann, AW; Semik, P				Bode, RK; Heinemann, AW; Semik, P			Measurement properties of the Galveston Orientation and Amnesia Test (GOAT) and improvement patterns during inpatient rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						item weighting; posttraumatic amnesia; Rasch model; rating scale analysis; self-scoring key	HEAD-INJURY; SCALES	Objectives: To determine the measurement properties of the Galveston Orientation and Amnesia Test (GOAT) using the Rasch model and rating scale analysis (RSA). Design: Calibration of data collected weekly during rehabilitation. Setting: Six inpatient rehabilitation facilities. Participants: 77 patients admitted for their first rehabilitation after traumatic brain injury. Results: Rescoring the items as dichotomies, three strata of posttraumatic amnesia (PTA) were identified. AU items cohered to define a single construct and the item hierarchy confirmed their hypothesized ordering. Conclusions: Equal-interval measures of PTA were developed that exhibited good reliability and validity. A self-scoring key was developed to more efficiently assess PTA.	Northwestern Univ, Sch Med, Rehabil Inst Chicago, Rehabil Serv Evalual Unit, Chicago, IL 60611 USA	Bode, RK (corresponding author), Northwestern Univ, Sch Med, Rehabil Inst Chicago, Rehabil Serv Evalual Unit, 345 E Super St, Chicago, IL 60611 USA.		Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B30041] Funding Source: Medline		BODE RK, 1998, 75 ANN M AM C REH ME; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; Hamilton B., 1987, REHABILITATION OUTCO; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1996, EUROPA MEDICOPHYSICA, V32, P195; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LINACRE JM, 1999, WINSTEPS PC COMPATIB; MCARTHUR DL, 1991, ARCH PHYS MED REHAB, V72, P296; MERBITZ C, 1989, ARCH PHYS MED REHAB, V70, P308; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; Rasch G., 1980, PROBABILISTIC MODELS; SMITH R, 1997, OBJECTIVE MEASUREMEN, V4; Stevens S. S., 1946, SCIENCE, V103, P667; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wright B. D., 1982, RATING SCALE ANAL RA; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; WRIGHT BD, 1997, RASCH MEASUREMENT T, V10, P478; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	21	48	50	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2000	15	1					637	655		10.1097/00001199-200002000-00004			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	287MX	WOS:000085510800005	10745181				2021-06-18	
J	Eslinger, PJ; Biddle, KR				Eslinger, PJ; Biddle, KR			Adolescent neuropsychological development after early right prefrontal cortex damage	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; LEARNING-DISABILITIES; NARRATIVE DISCOURSE; NEURONAL PLASTICITY; EXECUTIVE FUNCTIONS; FACIAL EXPRESSIONS; COGNITIVE FUNCTION; CHILDREN	Adolescent development and pattern of recovery are described for a 15-year-old boy who sustained extensive right dorsolateral prefrontal cortex damage at age 7 from rupture and surgical treatment of a deep arteriovenous malformation. Follow-up evaluations at 4 years and most recently 8 years after illness have shown clear improvement in social-behavioral and almost all cognitive areas initially assessed. He demonstrated resolution of left hemispatial neglect and other visuospatial impairments in working memory, design fluency, and planning and organization. However, at the 8-year follow-up interval, an acquired form of attention deficit disorder remains evident. We hypothesized that this is the likely cause of comparatively lower scores in general intelligence, verbal learning and memory, discourse, and processing speed, than at the 4-year follow-up interval. New measures of emotional face and voice recognition showed only minor difficulties, principally in identifying vocal disgust and fear. Social and psychological maturation has continued to improve, with no evidence of developmental arrest or pervasive social impairment, although the individual is confused at times by complexities and nuances of social interaction. The pattern of findings 8 years after early right dorsolateral prefrontal cortex damage suggests remarkable recovery of primary visuospatial and social impairments, but lingering and somewhat worsening performance deficits which may be due to attentional difficulties and impulsive responding. Treatment of the attentional difficulties is currently being investigated.	Penn State Univ, Milton S Hershey Med Ctr,Coll Med,Dept Med, Div Neurol,Lab Neuropsychol & Cognit Neurosci, Program Biol Learning & Dev, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr,Coll Med,Dept Behav Sci, Lab Neuropsychol & Cognit Neurosci,, Program Biol Learning & Dev, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr,Coll Med, Dept Pediat,Lab Neuropsychol & Cognit Neurosci, Progrram Biol Learning & Dev, Hershey, PA 17033 USA	Eslinger, PJ (corresponding author), Penn State Univ, Milton S Hershey Med Ctr,Coll Med,Dept Med, Div Neurol,Lab Neuropsychol & Cognit Neurosci, Program Biol Learning & Dev, H037,500 Univ Dr, Hershey, PA 17033 USA.	pje2@psu.edu					Achenbach TM, 1983, MANUAL CHILD BEHAV C; ACKERLY SS, 1947, RES PUBL ASSOC RES N, V27, P479; Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AKERT K, 1960, SCIENCE, V132, P1944, DOI 10.1126/science.132.3444.1944; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; BECKER MG, 1987, DEV NEUROPSYCHOL, V3, P275, DOI 10.1080/87565648709540381; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; Benton A., 1976, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Benton AL., 1974, REVISED VISUAL RETEN; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BROWNELL HH, 1984, BRAIN LANG, V22, P253, DOI 10.1016/0093-934X(84)90093-2; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; CARPENTER CJ, 1995, J INT NEUROPSYCH SOC, V1, P173; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Denckla M.B., 1996, ATTENTION MEMORY EXE, P263; DENCKLA MB, 1976, NEUROPSYCHOLOGIA, V14, P471, DOI 10.1016/0028-3932(76)90075-0; DENCKLA MB, 1997, DEV PREFRONTAL CORTE, P283; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DESSE J, 1984, THOUGHT SPEECH PSYCH; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1080/13554799908411987; DYWAN J, 1995, J INT NEUROPSYCH SOC, V1, P121; Ekman P., 1976, PICTURES FACIAL AFFE; Eslinger P.J., 1988, HDB DICHOTIC LISTENI, P139; Eslinger P. J., 1996, ATTENTION MEMORY EXE, P367; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Eslinger PJ, 1999, DEV NEUROPSYCHOL, V15, P157, DOI 10.1080/87565649909540744; Eslinger PJ, 1999, NEUROCASE, V5, P225, DOI 10.1080/13554799908402727; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FINGER S, 1988, ARCH NEUROL-CHICAGO, V45, P1136, DOI 10.1001/archneur.1988.00520340090018; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P1, DOI 10.1080/87565649609540636; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDMAN PS, 1978, BRAIN RES, V152, P451, DOI 10.1016/0006-8993(78)91103-4; GOLDMAN PS, 1977, EXP NEUROL, V57, P588, DOI 10.1016/0014-4886(77)90091-7; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; GOLDMAN PS, 1978, SCIENCE, V202, P768, DOI 10.1126/science.102031; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.1111/j.1467-8624.1987.tb01404.x; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Guilford J.P., 1960, ALTERNATE USES MANUA; Handler J., 1994, HANDB NEUR, P125; Harris E L, 1995, J Int Neuropsychol Soc, V1, P511; Heaton R., 1993, WISCONSIN CARD SORTI; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; KAGAN J, 1964, PSYCHOL MONOGR, V78, P1; Kaplan E., 1983, BOSTON NAMING TEST; KOLB B, 1990, PROG BRAIN RES, V85, P241; Krasnegor N. A., 1997, DEV PREFRONTAL CORTE; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; MILLER EA, 1973, SCIENCE, V182, P304, DOI 10.1126/science.182.4109.304; Nies KJ, 1999, NEUROCASE, V5, P313; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pennington B. F., 1997, DEV PREFRONTAL CORTE, P265; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Peterson C., 1983, DEV PSYCHOLINGUISTIC; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Rourke BP, 1996, TOP LANG DISORD, V16, P30, DOI 10.1097/00011363-199602000-00005; RUDEL RG, 1971, NEUROPSYCHOLOGIA, V9, P401, DOI 10.1016/0028-3932(71)90004-2; RUDEL RG, 1974, NEUROPSYCHOLOGIA, V12, P95, DOI 10.1016/0028-3932(74)90031-1; SEGALOWITZ SJ, 1992, BRAIN COGNITION, V20, P1, DOI 10.1016/0278-2626(92)90058-T; SIEGEL LS, 1989, CHILD DEV, V60, P973, DOI 10.1111/j.1467-8624.1989.tb03528.x; SIEGEL LS, 1994, INT J BEHAV DEV, V17, P109, DOI 10.1177/016502549401700107; Sparrow S., 1984, VINELAND ADAPTIVE BE; STELLING MW, 1986, AM J DIS CHILD, V140, P710, DOI 10.1001/archpedi.1986.02140210108037; Stiles Joan, 1993, P643; Talley, 1993, CHILDRENS AUDITORY V; Taylor HG, 1996, DEV NEUROPSYCHOL, V12, P35, DOI 10.1080/87565649609540639; TEUBER H, 1962, Dev Med Child Neurol, V4, P3; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WIIG EH, 1988, TEST LANGUAGE COMPET; WOLF M, 1986, BRAIN LANG, V27, P360, DOI 10.1016/0093-934X(86)90025-8; WOLF M, 1986, CHILD DEV, V57, P988, DOI 10.1111/j.1467-8624.1986.tb00260.x; Woodcock R. W., 1989, WOODCOCK JOHNSON PSY	98	48	48	1	37	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2000	18	3					297	329		10.1207/S1532694203Eslinger			33	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	432UW	WOS:000168714900003	11392332				2021-06-18	
J	Beaver, AC; Cheatham, ML				Beaver, AC; Cheatham, ML			Life-threatening nail gun injuries	AMERICAN SURGEON			English	Article; Proceedings Paper	67th Annual Meeting of the Southeastern Surgical Congress	FEB 13-17, 1999	TAMPA, FLORIDA	SE Surg Congress			SUICIDE	The use of pneumatic and explosive cartridge-activated nail guns is common in the construction industry. The ease and speed of nailing these tools afford enhance productivity at the cost of increased potential for traumatic injury. Although extremity injuries are most common, life-threatening injuries to the head, neck, chest, or abdomen and pelvis may occur. During a 20-month period, eight potentially life-threatening nail gull injuries were admitted to a Level I trauma center, including injuries to the brain, eye, neck, heart, lung, and femoral artery. Mechanism of injury included nail ricochet, nail gun misuse due to inadequate training, and successful suicide. Nail guns have significant potential for causing severe debilitating injury and death. These findings indicate a need for improved safety features and user education. The various types of nail guns, their ballistic potential, and techniques for operative management are discussed.	Orlando Reg Med Ctr, Dept Surg Educ, Orlando, FL 32806 USA	Cheatham, ML (corresponding author), Orlando Reg Med Ctr, Dept Surg Educ, 86 W Underwood St, Orlando, FL 32806 USA.						Alberico G, 1997, J TRAUMA, V43, P153, DOI 10.1097/00005373-199707000-00039; Armstrong AP, 1996, J ACCID EMERG MED, V13, P210; BRAUN RM, 1971, J BONE JOINT SURG, V83, P383; CRAGG J, 1967, BRIT MED J, V4, P784, DOI 10.1136/bmj.4.5582.784; DELSOLLIEBEL MA, 1996, J ORAL MAXILLOFAC SU, V54, P1632; DENTON P, 1984, MED J AUSTRALIA, V140, P305, DOI 10.5694/j.1326-5377.1984.tb104058.x; EDLICH R F, 1986, Comprehensive Therapy, V12, P42; FREEMAN BJC, 1994, INJURY, V25, P110, DOI 10.1016/0020-1383(94)90114-7; Hoffman DR, 1997, AM FAM PHYSICIAN, V56, P1643; JOHNSON R, 1974, INJURY, V6, P37, DOI 10.1016/0020-1383(74)90168-5; Kaji T, 1996, Radiat Med, V14, P99; KENNY NW, 1992, J HAND SURG-BRIT EUR, V17B, P577, DOI 10.1016/S0266-7681(05)80245-1; KENNY NW, 1994, J HAND SURG-BRIT EUR, V19B, P263, DOI 10.1016/0266-7681(94)90187-2; KENNY NW, 1993, J TRAUMA, V36, P943; KIZER KW, 1995, J TRAUMA, V38, P382, DOI 10.1097/00005373-199503000-00016; KJAERGARD H, 1986, INJURY, V17, P49, DOI 10.1016/0020-1383(86)90018-5; Lee BL, 1996, OPHTHALMOLOGY, V103, P1453, DOI 10.1016/S0161-6420(96)30484-3; LOWRY JC, 1973, INJURY, V5, P59, DOI 10.1016/S0020-1383(73)80012-9; LYONS FR, 1983, MED J AUSTRALIA, V2, P483, DOI 10.5694/j.1326-5377.1983.tb122613.x; MCCORKELL SJ, 1986, AM J FOREN MED PATH, V7, P192, DOI 10.1097/00000433-198607030-00004; OPESKIN K, 1990, AM J FOREN MED PATH, V11, P282, DOI 10.1097/00000433-199012000-00002; PATON RW, 1986, BRIT MED J, V293, P598, DOI 10.1136/bmj.293.6547.598; SCHOR JS, 1991, SOUTHERN MED J, V84, P922, DOI 10.1097/00007611-199107000-00027; Sorrells R B, 1980, J Ark Med Soc, V76, P361; STANBRIDGE RD, 1982, INJURY, V14, P285, DOI 10.1016/0020-1383(82)90148-6; VISWANATHAN R, 1994, SCOT MED J, V39, P83, DOI 10.1177/003693309403900310; Wu W Q, 1975, Surg Neurol, V3, P83	27	48	49	0	2	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	DEC	1999	65	12					1113	1116					4	Surgery	Surgery	261FA	WOS:000083997600004	10597056				2021-06-18	
J	Burgess, ES; Drotar, D; Taylor, HG; Wade, S; Stancin, T; Yeates, KO				Burgess, ES; Drotar, D; Taylor, HG; Wade, S; Stancin, T; Yeates, KO			The Family Burden of Injury Interview: Reliability and validity studies	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; Family Burden of Injury Interview (FBII); family functioning; traumatic head injury	TRAUMATIC BRAIN INJURY; HEAD-INJURY; ASSESSMENT DEVICE; CHILDREN; SEVERITY; PREDICTORS; SCHOOL; STRESS	Objective: To assess the reliability and validity of a new instrument, the Family Burden of Injury Interview (FBII) was designed to assess the impact of childhood traumatic head injuries (THI) on the family. Participants: 99 Mothers of school-age children who experienced THL. Results: The FBII Total Score revealed group differences between families of children with severe THI and families of children with moderate THI. The measure also showed concurrent and predictive relationships to measures of the general impact of injury on families and maternal and child functioning. Conclusion: The FBII is a promising tool for measuring the impact of injury-related stressors on the family.	Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Div Behav Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychol, Cleveland, OH 44106 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metro Hlth Med Ctr, Cleveland, OH USA; Childrens Hosp, Columbus, OH 43205 USA	Drotar, D (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Div Behav Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.		Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Hobfoll SE., 1986, STRESS SOCIAL SUPPOR, P3; Holroyd J., 1987, MANUAL QUESTIONNAIRE; HU Z, 1993, CAN MED ASSOC J, V149, P421; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1987, PEDIATRICS, V79, P501; LONIGAN CJ, 1994, J AM ACAD CHILD PSY, V33, P94, DOI 10.1097/00004583-199401000-00013; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; NADER K, 1990, AM J PSYCHIAT, V147, P1526; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Stein R, 1985, PACTS PAPERS AECOM T; STEIN REK, 1984, PEDIATRICS, V73, P845; STEIN REK, 1991, PEDIATRICS, V88, P490; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; WALLANDER JL, 1989, J PEDIATR PSYCHOL, V14, P157, DOI 10.1093/jpepsy/14.2.157; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	32	48	48	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1999	14	4					394	405		10.1097/00001199-199908000-00008			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	224LW	WOS:000081901400009	10407212				2021-06-18	
J	Benavidez, DA; Fletcher, JM; Hannay, HJ; Bland, ST; Caudle, SE; Mendelsohn, DB; Yeakley, J; Brunder, DG; Harward, H; Song, J; Perachio, NA; Bruce, D; Scheibel, RS; Lilly, MA; Verger-Maestre, K; Levin, HS				Benavidez, DA; Fletcher, JM; Hannay, HJ; Bland, ST; Caudle, SE; Mendelsohn, DB; Yeakley, J; Brunder, DG; Harward, H; Song, J; Perachio, NA; Bruce, D; Scheibel, RS; Lilly, MA; Verger-Maestre, K; Levin, HS			Corpus callosum damage and interhemispheric transfer of information following closed head injury in children	CORTEX			English	Article						closed head injury; children; corpus callosum; dichotic listening	HEMISPHERIC DISCONNECTION SYNDROME; LATERALIZATION; FEATURES; LESIONS; AREAS	We evaluated the relationship of corpus callosum atrophy and/or lesions on magnetic resonance imaging (MRI) to functional hemispheric disconnection following closed head injury (CHI) in 51 pediatric patients, including mild CHI, moderate to severe CHI with extracallosal lesions, and moderate to severe CHI with callosal atrophy and/or lesions. Interhemispheric transfer of information was assessed using auditory, motor, tactile, and visual tests in patients and in 16 uninjured children. Total and regional callosal areas were measured from the midsagittal MRI slice by morphometry. The corpus callosum lesion group demonstrated a greater right ear advantage on verbal dichotic Listening than all other groups. Areas of the posterior corpus callosum were negatively correlated with laterality indices of verbal dichotic listening performance and tachistoscopic identification of verbal material. The relationship of corpus callosum atrophy and/or lesions to asymmetry in dichotic listening is consistent with previous investigation of posttraumatic hemispheric disconnection effects in adults.	Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA; Univ Houston, Dept Psychol, Houston, TX 77004 USA; Univ Texas, SW Med Sch, Dept Radiol, Dallas, TX 75230 USA; Univ Texas, Med Branch, Dept Comp Sci, Galveston, TX 77550 USA; Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Neurosurg, Dallas, TX 75230 USA	Levin, HS (corresponding author), Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, 1333 Moursund,Rm A205, Houston, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019	Hannay, H. Julia/0000-0001-7023-912X; Bland, Sondra/0000-0002-5790-089X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; BENTIN S, 1984, NEUROPSYCHOLOGIA, V22, P601, DOI 10.1016/0028-3932(84)90024-1; Bogen J.E., 1993, CLIN NEUROPSYCHOLOGY, P337; BOGEN JE, 1965, J AMER MED ASSOC, V194, P1328, DOI 10.1001/jama.194.12.1328; BOGEN JOSEPH E., 1962, BULL LOS ANGELES NEUROL SOC, V27, P169; BOLDRINI P, 1992, CORTEX, V28, P135, DOI 10.1016/S0010-9452(13)80172-4; BRIGGS G G, 1975, Cortex, V11, P230; Bryden M. P., 1988, HDB DICHOTIC LISTENI, DOI DOI 10.1002/ACP.2350040307; DAMASIO AR, 1980, J NEUROL NEUROSUR PS, V43, P351, DOI 10.1136/jnnp.43.4.351; Deloche Gerard, 1993, Brain Injury, V7, P363, DOI 10.3109/02699059309034963; DIMOND SJ, 1977, BRAIN, V100, P543, DOI 10.1093/brain/100.3.543; FONTENOT DJ, 1973, J COMP PHYSIOL PSYCH, V85, P564, DOI 10.1037/h0035210; GAZZANIGA MS, 1978, NEUROLOGY, V23, P1126; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Gordon H W, 1970, Cortex, V6, P387; GORDON HW, 1971, BRAIN, V94, P327, DOI 10.1093/brain/94.2.327; GORDON HW, 1980, J EXP PSYCHOL HUMAN, V6, P516, DOI 10.1037/0096-1523.6.3.516; GREENBLATT SH, 1973, BRAIN, V96, P307, DOI 10.1093/brain/96.2.307; HANNAY HJ, 1978, PERCEPT MOTOR SKILL, V47, P315, DOI 10.2466/pms.1978.47.1.315; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; HINES M, 1992, BEHAV NEUROSCI, V106, P3, DOI 10.1037/0735-7044.106.1.3; JEEVES MA, 1979, J NEUROL NEUROSUR PS, V42, P134, DOI 10.1136/jnnp.42.2.134; LASSONDE M, 1986, BRAIN, V109, P953, DOI 10.1093/brain/109.5.953; LASSONDE M, 1990, BRAIN LANG, V38, P195, DOI 10.1016/0093-934X(90)90110-3; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; NOBLE CE, 1961, PSYCHOL REP, V8, P487; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pandya D. N., 1986, 2 HEMISPHERES ONE BR, P47; PANDYA DN, 1971, BRAIN RES, V32, P31, DOI 10.1016/0006-8993(71)90153-3; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; ROKNE J, 1991, GRAPHICS GEMS, V3, P5; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; Sperry R.W., 1966, HARVEY LECT, V62, P293; Spreen O, 1969, NEUROSENSORY CTR COM; SPRINGER SP, 1975, NEUROPSYCHOLOGIA, V13, P341, DOI 10.1016/0028-3932(75)90011-1; STONE MG, 1986, AM MATH MON, V93, P479, DOI 10.2307/2323479; SUGISHITA M, 1987, NEUROPSYCHOLOGIA, V25, P329, DOI 10.1016/0028-3932(87)90022-4; TEASDALE G, 1974, LANCET, V2, P81; VANDERPLAS JM, 1959, J EXP PSYCHOL, V57, P147, DOI 10.1037/h0048723; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	46	48	49	0	5	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452	1973-8102		CORTEX	Cortex	JUN	1999	35	3					315	336		10.1016/S0010-9452(08)70803-7			22	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	219WG	WOS:000081630400002	10440072				2021-06-18	
J	Lore, AB; Hubbell, JA; Bobb, DS; Ballinger, ML; Loftin, KL; Smith, JW; Smyers, ME; Garcia, HD; Bittner, GD				Lore, AB; Hubbell, JA; Bobb, DS; Ballinger, ML; Loftin, KL; Smith, JW; Smyers, ME; Garcia, HD; Bittner, GD			Rapid induction of functional and morphological continuity between severed ends of mammalian or earthworm myelinated axons	JOURNAL OF NEUROSCIENCE			English	Article						axotomy; axonal regeneration; membrane fusion; neurotrauma; nerve repair; polyethylene glycol	LONG-TERM SURVIVAL; RAT SCIATIC-NERVE; SPINAL-CORD; GIANT-AXONS; WALLERIAN DEGENERATION; INDUCED RECONNECTION; POLYETHYLENE-GLYCOL; PERIPHERAL-NERVE; NEURITE GROWTH; REGENERATION	The inability to rapidly restore the loss of function that results from severance (cutting or crushing) of PNS and CNS axons is a severe clinical problem. As a novel strategy to help alleviate this problem, we have developed in vitro procedures using Ca2+-free solutions of polyethylene glycol (PEG solutions), which within minutes induce functional and morphological continuity (PEG-induced fusion) between the cut or crushed ends of myelinated sciatic or spinal axons in rats. Using a PEG-based hydrogel that binds to connective tissue to provide mechanical strength at the lesion site and is nontoxic to nerve tissues in earthworms and mammals, we have also developed in vivo procedures that permanently maintain earthworm myelinated medial giant axons whose functional and morphological integrity has been restored by PEG-induced fusion after axonal severance. In all these in vitro or in vivo procedures, the success of PEG-induced fusion of sciatic or spinal axons and myelinated medial giant axons is measured by the restored conduction of action potentials through the lesion site, the presence of intact axonal profiles in electron micrographs taken at the lesion site, and/or the intra-axonal diffusion of fluorescent dyes across the lesion site. These and other data suggest that the application of polymeric fusiogens (such as our PEG solutions), possibly combined with a tissue adherent (such as our PEG hydrogels), could lead to in vivo treatments that rapidly and permanently repair cut or crushed axons in the PNS and CNS of adult mammals, including humans.	Univ Texas, Dept Zool, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Coll Pharm, Austin, TX 78712 USA; ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; ETH Zurich, Dept Mat, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8044 Zurich, Switzerland; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	Bittner, GD (corresponding author), Univ Texas, Dept Zool, Austin, TX 78712 USA.		Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD31484] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS031256, NS31256] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD031484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031256] Funding Source: NIH RePORTER		AEBISCHER P, 1990, BRAIN RES, V531, P211, DOI 10.1016/0006-8993(90)90776-8; Ballinger ML, 1997, J NEUROBIOL, V33, P945, DOI 10.1002/(SICI)1097-4695(199712)33:7<945::AID-NEU6>3.0.CO;2-8; BITTNER GD, 1991, TRENDS NEUROSCI, V14, P188, DOI 10.1016/0166-2236(91)90104-3; BITTNER GD, 1988, AM ZOOL, V28, P1165; BITTNER GD, 1986, BRAIN RES, V367, P351, DOI 10.1016/0006-8993(86)91617-3; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; BULLOCK TH, 1965, STRUCTURE FUNCTION N, V2; BULLOCK TH, 1965, STRUCTURE FUNCTION N, V1; Chowdhury SM, 1996, J SURG RES, V61, P58, DOI 10.1006/jsre.1996.0081; DAS GD, 1986, NEURAL TRANSPLANTATO; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Eddleman CS, 1998, J NEUROSCI, V18, P4029; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; Giovanini MA, 1997, EXP NEUROL, V148, P523, DOI 10.1006/exnr.1997.6703; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; GUNTHER J, 1975, J NEUROCYTOL, V4, P55, DOI 10.1007/BF01099095; GUNTHER J, 1976, J COMP NEUROL, V168, P505, DOI 10.1002/cne.901680405; Herbert CB, 1996, J COMP NEUROL, V365, P380, DOI 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0; HUBBELL JA, 1994, BIOTECHNOL BIOENG, V43, P541, DOI 10.1002/bit.260430702; JENQ CB, 1986, BRAIN RES, V364, P45, DOI 10.1016/0006-8993(86)90986-8; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; KRAUSE TL, 1991, BRAIN RES, V561, P350, DOI 10.1016/0006-8993(91)91615-8; KRAUSE TL, 1990, P NATL ACAD SCI USA, V87, P1471, DOI 10.1073/pnas.87.4.1471; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lundborg G, 1990, Restor Neurol Neurosci, V1, P297, DOI 10.3233/RNN-1990-13418; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Miya D, 1997, J NEUROSCI, V17, P4856; OKAMURA N, 1985, J NEUROCHEM, V45, P1875, DOI 10.1111/j.1471-4159.1985.tb10546.x; PATHAK CP, 1992, J AM CHEM SOC, V114, P8311, DOI 10.1021/ja00047a065; Ramon y Cajal S, 1928, DEGENERATION REGENER; ROOTS BI, 1983, TISSUE CELL, V15, P695, DOI 10.1016/0040-8166(83)90044-7; SAWHNEY AS, 1993, MACROMOLECULES, V26, P581, DOI 10.1021/ma00056a005; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SEA T, 1995, EXP NEUROL, V133, P85, DOI 10.1006/exnr.1995.1010; SECKEL BR, 1990, MUSCLE NERVE, V13, P785, DOI 10.1002/mus.880130904; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; SOWERS AE, 1987, CELL FUSION; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484; TODOROV AT, 1992, BRAIN RES, V582, P329, DOI 10.1016/0006-8993(92)90151-X; West JL, 1996, P NATL ACAD SCI USA, V93, P13188, DOI 10.1073/pnas.93.23.13188; XIE XY, 1991, J NEUROSCI, V11, P3257; YOGEV D, 1991, BIOCHEM BIOPH RES CO, V180, P874, DOI 10.1016/S0006-291X(05)81146-5	46	48	48	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 1	1999	19	7					2442	2454					13	Neurosciences	Neurosciences & Neurology	179TD	WOS:000079344400004	10087059				2021-06-18	
J	Chervinsky, AB; Ommaya, AK; deJonge, M; Spector, J; Schwab, K; Salazar, AM				Chervinsky, AB; Ommaya, AK; deJonge, M; Spector, J; Schwab, K; Salazar, AM			Motivation for traumatic brain injury rehabilitation questionnaire (MOT-Q): Reliability, factor analysis, and relationship to MMPI-2 variables	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; IMPACT	A Likert scale questionnaire was developed to assess motivation for postacute rehabilitation by traumatic brain injury patients. Items were designed to reflect head-injured individuals' statements about their attitudes toward head injury rehabilitation. Factors such as denial of illness, anger, compliance with treatment, and medical information seeking behavior were used to assess unfavorable and favorable components of motivation. Reliability was assessed using Cronbach's Alpha, which was found to be 0.91 for the total scale. Four factor analysis derived subscales were identified: Lack of Denial, Interest in Rehabilitation, Lack of Anger, and Reliance on Professional Help. Correlation and multiple regression analyses demonstrated moderate relationships between MOT-Q and several MMPI-2 variables largely related to indicators of somatic distress, depression and capacity for self-sufficiency. Lack of Denial subscale showed the strongest relationship to MMPI-2 of all MOT-Q variables, while Interest in Rehabilitation showed the best correlation to the MOT-Q total. (C) 1998 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC USA	Chervinsky, AB (corresponding author), 492 Henry St,2F, Brooklyn, NY 11231 USA.						CALDWELL AB, 1988, MMPI SUPPLEMENTAL SC; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; DIAMOND M. DAVID, 1968, ARCH PHYS MED REHABIL, V49, P281; ELIAS MF, 1977, HDB PSYCHOL AGING, P357; Fleury J, 1994, J Nurs Meas, V2, P143; FLEURY JD, 1991, HEART LUNG, V20, P3; FOGEL ML, 1969, DIS NERV SYST, V30, P593; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GREENE RL, 1991, MMPI 2 MMPI INTERPRE; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; Herbert CM, 1989, CLIN REHABIL, V3, P125; HESSE K, 1983, J AM GERIATR SOC, V7, P586; HONKANEN R, 1991, INJURY, V22, P225, DOI 10.1016/0020-1383(91)90047-I; HOOK O, 1976, SCAND J REHABIL MED, V8, P97; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; McEwen M, 1993, West J Nurs Res, V15, P770, DOI 10.1177/019394599301500608; MCMAHON J, 1992, J ADV NURS, V17, P173, DOI 10.1111/j.1365-2648.1992.tb01872.x; Miller N. A., 1959, PSYCHOL STUDY SCI, P196; MOSQUEDA LA, 1993, CLIN GERIATR MED, V9, P689, DOI 10.1016/S0749-0690(18)30371-9; Norusis M.J., 1993, SPSS WINDOWS BASE SY; NORUSIS MJ, 1985, SPSSX ADV STAT GUID; OSTWALD SW, 1989, J APPL REHABILITATIO, V20, P22; PRIGATANO C, 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROESSLER R, 1989, J APPL REHABILITATIO, V2, P14; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stuss DT., 1991, AWARENESS DEFICIT BR, P63	33	48	48	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	1998	13	5					433	446		10.1016/S0887-6177(97)00016-4			14	Psychology, Clinical; Psychology	Psychology	ZU448	WOS:000074198000003	14590608	Bronze			2021-06-18	
J	Ilahi, OA; Strausser, DW; Gabel, GT				Ilahi, OA; Strausser, DW; Gabel, GT			Post-traumatic heterotopic ossification about the elbow	ORTHOPEDICS			English	Article								To evaluate the effect of surgical timing on the formation of heterotopic ossification about the elbow, 71 consecutive patients with elbow trauma requiring operative management were evaluated. Fourteen patients were excluded because they suffered from head injury, burns, or severe open injuries requiring surgery on two or more occasions. Sixteen patients were lost to followup, leaving a group of 41 patients. The average age of patients was 35 years. The fractures involved the olecranon in 19, distal humerus in 12, and radial head/neck in 10 patients. Six of these fractures were accompanied by a dislocation. Eleven were open injuries; the remaining 30 were closed. Bone grafting was performed in nine patients. The interval between injury and surgical intervention averaged 57 hours. None (0%) of 17 patients treated within 48 hours developed grade II, III, or IV heterotopic ossification, whereas 8 (33%) of 24 patients treated after 48 hours developed grade II, III, or IV heterotopic ossification. There were no significant differences in demographic or injury parameters between these two groups. These findings suggest that fixation of unstable elbow fractures within 48 hours of injury may reduce the formation of ectopic bone.	Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA	Ilahi, OA (corresponding author), 6560 Fannin Ste 400, Houston, TX 77030 USA.						BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; Buxton SJD, 1938, J BONE JOINT SURG, V20, P709; ELLEDGE ES, 1988, J TRAUMA, V28, P684, DOI 10.1097/00005373-198805000-00023; Frassica FJ, 1993, ELBOW ITS DISORDERS, V2, P505; GARLAND DE, 1982, CLIN ORTHOP RELAT R, V168, P38; GASTON SR, 1949, AM J SURG, V78, P631, DOI 10.1016/0002-9610(49)90300-1; Jupiter JB, 1991, INSTRUCTIONAL COURSE, V40, P41; MCLAUGHLIN HL, 1955, SURG CLIN N AM, V35, P553; MICHELSSON JE, 1983, CLIN ORTHOP RELAT R, P265; TEASDALL R, 1993, CLIN ORTHOP RELAT R, P37; Thompson H C 3rd, 1967, Clin Orthop Relat Res, V50, P129	11	48	55	0	0	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0147-7447	1938-2367		ORTHOPEDICS	Orthopedics	MAR	1998	21	3					265	268					4	Orthopedics	Orthopedics	ZE371	WOS:000072785900008	9547811				2021-06-18	
J	Max, JE; Lindgren, SD; Knutson, C; Pearson, CS; Ihrig, D; Welborn, A				Max, JE; Lindgren, SD; Knutson, C; Pearson, CS; Ihrig, D; Welborn, A			Child and adolescent traumatic brain injury: correlates of disruptive behaviour disorders	BRAIN INJURY			English	Article							SCALE; COMA	A record review focused on children and adolescents, with a history of traumatic brain injury (TBI), who were consecutively admitted to a brain injury clinic in which all new patients are psychiatrically evaluated. Correlates of post-injury oppositional defiant disorder/conduct disorder (ODD/CD) and post-injury attention deficit hyperactivity disorder (AHD) were investigated. Subjects who developed ODD/CD following TBI, when compared to subjects without a lifetime history of the disorder, had significantly more impaired family functioning, showed a trend toward a greater family history of alcohol dependence/abuse and suffered a milder TBI. In contrast, there were no variables which discriminated between subjects who developed ADHD following injury and those with no lifetime history of ADHD. It is difficult to determine whether ODD, CD and ADHD occurring after TBI in the patient is related to the TBI, directly or indirectly. Appropriate clinical assessment requires consideration of the important mediating role of family functioning, severity of injury and family psychiatric history.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 200 Hawkins Dr,1876 JPP, Iowa City, IA 52242 USA.			Ihrig, Damien/0000-0002-5083-5853	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH043271, R01MH040856, R37MH031593, R01MH031593, P30MH043271] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 40856, MHCRC 43271, MH 31593] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLACK P, 1971, HEAD INJURIES, P131; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CADORET RJ, 1995, ARCH GEN PSYCHIAT, V52, P916; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jastak S, 1984, WIDE RANGE ACHIEVEME; JEFFREY R, 1986, IOWAS SEVERITY RATIN; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEMKUHL G, 1991, BRAIN BEHAV CHILD PS, P267; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, IN PRESS BRAIN INJUR; MAX JE, IN PRESS J AM ACAD C; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1991, WECHSLER INTELLIGENC	24	48	49	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					41	52					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500004	9483336				2021-06-18	
J	McDonald, S; Pearce, S				McDonald, S; Pearce, S			Requests that overcome listener reluctance: Impairment associated with executive dysfunction in brain injury	BRAIN AND LANGUAGE			English	Article							INDIRECT SPEECH ACTS; CLOSED-HEAD-INJURY; DAMAGED PATIENTS; LANGUAGE; APPRECIATION; DEFICITS; ABILITY	Fifteen subjects with suspected executive impairment following brain injury and matched controls were tested on a request production task in which they were required to produce nonconventional requests that would overcome listener reluctance. In comparison to controls, the brain-injured subjects were less likely to produce requests that addressed the obstacle to listener compliance, less likely to produce "other" Kinds of strategies, and more inclined to make requests encompassing counterproductive comments. These performances were correlated with independent neuropsychological measures of executive function. It was found that disinhibition was positively correlated to the ability to specify the source of listener reluctance in the request as well as to the tendency to use other kinds of strategies. It was surmised that the association between disinhibition and other strategies may reflect the broad nature of the categories used in which marginally appropriate strategies, categorized as "other," may actually have reflected mildly disinhibited behavior. (C) 1998 Academic Press.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Westmead, NSW, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Benton A, 1989, MULTILINGUAL APHASIA; BROWN P, 1987, POLITENESS SOME U LA; CLARK HH, 1979, COGNITIVE PSYCHOL, V11, P430, DOI 10.1016/0010-0285(79)90020-3; CLARK HH, 1975, J VERB LEARN VERB BE, V14, P56, DOI 10.1016/S0022-5371(75)80006-5; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; DELIS D, 1987, CALIFORNIA VERBAL LE; DIAMOND A, 1989, DEV NEURAL BASIS HIG; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; FRANCIK EP, 1985, J MEM LANG, V24, P560, DOI 10.1016/0749-596X(85)90046-4; GIBBS R, 1982, TEXT, V2, P9; GIBBS R. W., 1985, LANGUAGE SOCIAL SITU, P97; GIBBS RW, 1988, DISCOURSE PROCESS, V11, P101, DOI 10.1080/01638538809544693; GIBBS RW, 1987, AM J PSYCHOL, V100, P179, DOI 10.2307/1422402; GIBBS RW, 1986, J MEM LANG, V25, P181, DOI 10.1016/0749-596X(86)90028-8; GIBBS RW, 1983, J EXP PSYCHOL LEARN, V9, P524, DOI 10.1037/0278-7393.9.3.524; GIBBS RW, 1981, J VERB LEARN VERB BE, V20, P431, DOI 10.1016/S0022-5371(81)90542-9; GOLDBERG E, 1987, FRONTAL LOBES REVISI; Heaton R., 1981, MANUAL WISCONSIN CAR; HIRST W, 1984, BRAIN LANG, V23, P26, DOI 10.1016/0093-934X(84)90003-8; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; Morgan J. L., 1975, SYNTAX SEMANTICS, V3, P59, DOI DOI 10.1017/CBO9780511609213.004; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4	42	48	51	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JAN	1998	61	1					88	104		10.1006/brln.1997.1846			17	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	YQ687	WOS:000071413200006	9448933				2021-06-18	
J	Sherman, EMS; Strauss, E; Spellacy, F				Sherman, EMS; Strauss, E; Spellacy, F			Validity of the paced auditory serial addition test (PASAT) in adults referred for neuropsychological assessment after head injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							INFORMATION-PROCESSING CAPACITY; NORMAL SAMPLE; ATTENTION; CHILDREN; RECOVERY; MEMORY	The goal of this study was to evaluate the construct and criterion-related validity of the PASAT in 441 adults referred for evaluation of possible closed-head injury (mean age of 32.7 years, SD = 12.4). Convergent evidence for the construct validity of the PASAT as an attention test was stronger than divergent evidence. Although the PASAT correlated with several measures of attention, tests tapping mathematical knowledge accounted for a substantial amount of variance in PASAT scores. Further, other tests measuring conceptually unrelated abilities, such as verbal ability, academic achievement, verbal memory, and complex motor skills were also moderately correlated with PASAT performance. The slower PASAT presentation rate was also related to one test of visual memory and to one test of visual-spatial ability. These results suggest that PASAT performance is related to several cognitive abilities Ether than attention and processing speed. PASAT scores were not related to criterion-related indices of head injury severity. Limitations regarding construct validity are discussed, as are preliminary clinical guidelines for interpretation of the PASAT.		Sherman, EMS (corresponding author), UNIV VICTORIA,DEPT PSYCHOL,POB 3050,VICTORIA,BC V8W 3P5,CANADA.						American Psychological Association American Educational Research Association & National Council on Measurement in Education, 1985, STAND ED PSYCH TEST; BRICKENCAMP R, 1981, TEST D2 AUFMERKSAMKE; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CAMPBELL DT, 1960, AM PSYCHOL, V15, P546, DOI 10.1037/h0048255; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; Cohen R. T., 1988, PSYCHOL TESTING INTR; DREARY IJ, 1991, J INDIVIDUAL DIFFERE, V12, P983; DYCHE GM, 1991, PERCEPT MOTOR SKILL, V72, P563, DOI 10.2466/PMS.72.2.563-572; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; GRAVES RG, 1985, UNPUB REY VISUAL DES; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton R. K, 1981, WISCONSIN CARD SORTI; JASTAK S, 1974, WIDE RANGE ACHIEVEME; JOHNSON DA, 1988, J CHILD PSYCHOL PSYC, V29, P199, DOI 10.1111/j.1469-7610.1988.tb00704.x; Kaplan E., 1983, BOSTON NAMING TEST; Kaplan RM, 1989, PSYCHOL TESTING PRIN; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MATEER CA, IN PRESS NEUROPSYCHO; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; MILNER B, 1971, BR MED B, V27, P271; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A. F., 1989, INTEGRATING THEORY P, P75; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; Raven J. C., 1938, PROGR MATRICES PERCE; REGARD M, 1981, THESIS U VICTORIA VI; Rey A, 1964, EXAMEN CLIN PSYCHOL; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; SCHMIDT M, 1994, ARCH CLIN NEUROPSYCH, V9, P383, DOI 10.1016/0887-6177(94)90002-7; Sherman EMS, 1995, PSYCHOL ASSESSMENT, V7, P440, DOI 10.1037//1040-3590.7.4.440; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SLICK DJ, 1995, VICTORIA REVISION HI; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spreen O., 1991, COMPENDIUM NEUROPSYC; Spreen O., 1977, NEUROSENSORY CTR COM; STRAUSS E, 1994, ARCH CLIN NEUROPSYCH, V9, P483, DOI 10.1016/0887-6177(94)90039-6; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Tiffin J., 1968, PURDUE PEGBOARD EXAM; *US DEP LAB, 1982, MAN USES GEN APT TES; *W PSYCH SERV, HOOP VIS ORG TEST VO; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILSON C, 1984, UNPUB PACED AUDITORY; WONDERLIC EF, 1992, MANUEL WONDERLIC PER	56	48	50	0	19	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	1997	11	1					34	45		10.1080/13854049708407027			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	WK256	WOS:A1997WK25600003					2021-06-18	
J	Kasemsri, T; Armstead, WM				Kasemsri, T; Armstead, WM			Endothelin production links superoxide generation to altered opioid-induced pial artery vasodilation after brain injury in pigs	STROKE			English	Article						cerebral circulation; newborn; nitric oxide; superoxide dismutase; pigs	SPINAL-CORD; CEREBRAL MICROCIRCULATION; ENDOGENOUS OPIOIDS; HEAD-INJURY; NEWBORN; FLUID; VASOSPASM; DISMUTASE; OXYGEN; TRIAL	Background and Purpose Traumatic brain injury conveys significant morbidity and mortality to infants and children. In the newborn pig, opioids contribute to pial artery vasconstriction after fluid percussion injury (FPI). FPI attenuates vasodilation and cGMP production by methionine enkephalin (Met) and leucine enkephalin (Leu) and reverses dynorphin (Dyn) from a dilator to a constrictor. Superoxide anion (O-2(-)) production contributes to altered cerebral hemodynamics after FPI, and O-2(-) scavengers partially restore decreased dilator responses after FPI. Endothelin-1 (ET-1), a purported mediator of cerebral vasospasm, has been suggested to alter nitric Oxide function and cGMP concentration. The present study was designed to determine the contribution of ET-1 to altered opioid-induced dilation after FPI and the role of O-2(-) in such altered responses. Methods Injury of moderate severity (1.9 to 2.3 atm) was produced by the lateral FPI technique in anesthetized newborn pigs equipped with a closed cranial window. Superoxide dismutase (SOD)-inhibitable nitroblue tetrazolium (NBT) reduction was determined as an index of O-2(-) generation. Results FPI increased cerebrospinal fluid ET-1 from 20+/-2 to 93+/-6 pg/mL (approximate to 10(-10) mol/L). Topical ET-1 (10(-10) mol/L) increased SOD-inhibitable NBT reduction from 1+/-1 to 16+/-3 pmol/mm(2), similar to previously reported NBT reduction after FPI(14+/-2 pmol/mm(2)). BQ123 (10(-6) mol/L), an ET-1 antagonist, blunted the NET reduction observed after FPI (4+/-1 pmol/mm(2)). Met produced pial vasodilation that was attenuated by FPI and partially restored by BQ123 pretreatment (7+/-1%, 11+/-1%, and 17+/-1% versus 3+/-1%, 6+/-1%, and 9+/-2% versus 5+/-1%, 9+/-1%, and 14+/-2% for 10(-10), 10(-8), and 10(-6) mol/L Met during control conditions, after FPI, and after FPI pretreated with BQ123, respectively). Met-induced dilation was associated with increased cerebrospinal fluid cGMP, and these biochemical changes were likewise blunted by FPI and partially restored by BQ123 (357+/-12, 455+/-15, 500+/-19, and 632+/-11 versus 264+/-4, 267+/-4, 295+/-12, and 305+/-15 versus 309+/-19, 432+/-11, 529+/-10, and 593+/-4 pg/mL for resting conditions, 10(-10), 10(-8) and 10(-6) mol/L Met during control conditions,after FPI, and after FPI pretreated with BQ123, respectively). Similar partial restoration of vascular and biochemical parameters was observed for Leu and Dyn. Conclusions These data show that ET-1, in concentrations similar to that present in cerebrospinal fluid after FPI, increases O-2(-) production. These data also indicate the opioid-induced vasodilation and cGMP production are partially restored after FPI by ET-1 receptor blockade. These data suggest that ET-1 contributes to altered cerebral hemodynamics after FPI, at least in part, through elevated O-2(-) production.	CHILDRENS HOSP, DEPT ANESTHESIA, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT ANESTHESIA, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA				, Thivakorn/0000-0001-7188-9554			ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; ARMSTEAD WM, 1991, CIRC RES, V68, P922, DOI 10.1161/01.RES.68.4.922; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; ARMSTEAD WM, 1989, AM J PHYSIOL, V257, pH707; ARMSTEAD WM, 1995, AM J PHYSIOL-HEART C, V268, pH226; BROOKS DP, 1994, J PHARMACOL EXP THER, V268, P1091; Chang Hang, 1992, Journal of the Formosan Medical Association, V91, P1182; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; DEVINE JO, 1995, BRAIN RES, V675, P257, DOI 10.1016/0006-8993(95)00081-Z; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GREENBERG DA, 1992, NEUROLOGY, V42, P25, DOI 10.1212/WNL.42.1.25; HAGAR JM, 1994, AM J PHYSIOL-HEART C, V267, pH1833; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HEMSEN A, 1991, ACTA PHYSIOL SCAND, V142, P1; HINO A, 1995, J NEUROSURG, V83, P503, DOI 10.3171/jns.1995.83.3.0503; HOSLI E, 1991, NEUROSCI LETT, V129, P55, DOI 10.1016/0304-3940(91)90719-A; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LESCOHIER I, 1993, PEDIATRICS, V91, P721; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; MILLER JD, 1994, LANCET, V344, P421; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PUSSARD G, 1995, J PHARMACOL EXP THER, V274, P969; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; VINK R, 1990, J NEUROSCI, V10, P3524; WEI EP, 1986, AM J PHYSIOL, V251, pH693; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; WILLETTE RN, 1990, AM J PHYSIOL, V259, pH1688; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZUCCARELLO M, 1995, AM J PHYSIOL-HEART C, V269, pH1009	44	48	52	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JAN	1997	28	1					190	196		10.1161/01.STR.28.1.190			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	WB814	WOS:A1997WB81400042	8996511				2021-06-18	
J	Zeilig, G; Drubach, DA; KatzZeilig, M; Karatinos, J				Zeilig, G; Drubach, DA; KatzZeilig, M; Karatinos, J			Pathological laughter and crying in patients with closed traumatic brain injury	BRAIN INJURY			English	Article							DIFFUSE AXONAL INJURY; PSEUDOBULBAR PALSY; EXPRESSION; DEPRESSION; STROKE; DAMAGE; SPECT	We report on the clinical and radiological features in 16 adult patients who suffered a traumatic brain injury and subsequently developed pathological laughter and crying. Patients with pathological laughter and crying were identified from among 301 consecutive brain-injured admissions to a trauma centre and subsequently to a rehabilitation facility. Patients displaying pathological laughter and crying had a greater severity of injury than patients without the syndrome; they also had other associated neurological features compatible with pseudobulbar palsy. Pathological laughter alone, or combined with crying, was more frequent than crying alone. An attempt to correlate clinical features with focal lesions on neuroimaging studies yielded inconsistent results. The theoretical anatomical substrate for pathological laughter and crying in patients with traumatic brain injury is discussed.	UNIV MARYLAND,SCH MED,DEPT NEUROL & REHABIL,BALTIMORE,MD 21201; TEL AVIV UNIV,DEPT FAMILY MED,IL-69978 TEL AVIV,ISRAEL; SHEPPARD PRATT HLTH SYST,BALTIMORE,MD							ACHARI AN, 1976, JAMA-J AM MED ASSOC, V235, P1469; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Beck D, 1990, ANN CLIN PSYCHIAT, V2, P255; BESSON G, 1991, ARCH NEUROL-CHICAGO, V48, P501, DOI 10.1001/archneur.1991.00530170061021; BLACK DW, 1982, J NERV MENT DIS, V170, P67, DOI 10.1097/00005053-198202000-00001; BOND RB, 1990, REHABILITATION ADULT, P61; BOROD JC, 1992, J CONSULT CLIN PSYCH, V60, P339, DOI 10.1037/0022-006X.60.3.339; BROWN JASON W., 1967, BRAIN RES, V5, P1, DOI 10.1016/0006-8993(67)90215-6; CANTU RC, 1966, J NEUROSURG, V24, P1024, DOI 10.3171/jns.1966.24.6.1024; CECCALDI M, 1994, EUR NEUROL, V34, P36, DOI 10.1159/000117005; CHEN RC, 1973, NEUROLOGY, V23, P1019, DOI 10.1212/WNL.23.10.1019; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; Davison C, 1939, ARCH NEURO PSYCHIATR, V42, P595, DOI 10.1001/archneurpsyc.1939.02270220011001; DRUBACH DA, 1994, STROKE, V25, P1061, DOI 10.1161/01.STR.25.5.1061; FLORA GC, 1970, MINN MED, V53, P539; ICHISE M, 1994, J NUCL MED, V35, P217; LAPLANE D, 1980, REV PRATICIEN, V30, P313; LEFEBRE G, 1939, B SOC PEDIAT PARIS, V37, P320; LIEBERMAN A, 1977, ARCH NEUROL-CHICAGO, V34, P717, DOI 10.1001/archneur.1977.00500230087017; LOEB C, 1990, EUR NEUROL, V30, P42, DOI 10.1159/000116638; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; PANZER MJ, 1992, J GERIATR PSYCH NEUR, V5, P195, DOI 10.1177/002383099200500403; POECK K, 1969, HDB CLIN NEUROLOGY, V3, P356; POVLISHOCK JT, 1990, NEUROBIOLOGY CENTRAL, P12; RIMEL RW, 1990, REHABILITATION ADULT, P12; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; ROSS ED, 1987, J NERV MENT DIS, V175, P165, DOI 10.1097/00005053-198703000-00007; SACKEIM HA, 1982, ARCH NEUROL-CHICAGO, V39, P210, DOI 10.1001/archneur.1982.00510160016003; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; STEVENSON GC, 1966, J NEUROSURG, V24, P544, DOI 10.3171/jns.1966.24.2.0544; TANAKA M, 1991, Electromyography and Clinical Neurophysiology, V31, P399; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; WILSON SAK, 1923, J NEUROL PSYCHOPATH, V4, P299; Wisoff J H, 1984, Neurosurgery, V15, P707	35	48	49	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1996	10	8					591	597		10.1080/026990596124160			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UZ656	WOS:A1996UZ65600005	8836516				2021-06-18	
J	Carlson, RW; Weiland, DE; Srivathsan, K				Carlson, RW; Weiland, DE; Srivathsan, K			Does a full-time, 24-hour intensivist improve care and efficiency?	CRITICAL CARE CLINICS			English	Article							NEUROMUSCULAR-BLOCKING-AGENTS; CRITICALLY ILL PATIENTS; ACUTE PHYSIOLOGY SCORE; SEVERE HEAD-INJURY; UNITED-STATES; HOSPITALIZED-PATIENTS; THERAPEUTIC EFFICACY; PRESIDENTIAL-ADDRESS; DESCRIPTIVE ANALYSIS; SCIENTIFIC SYMPOSIUM	This article reviews the hypothesis that staffing with full-time intensive care physicians leads to improvements in the management of ICUs and in the outcome for ICU patients. Variations in the professional organization of critical care units in the United States are discussed. The advantages and disadvantages of open, closed, and transitional (comanagement) ICU organizational structures are presented.		Carlson, RW (corresponding author), MARICOPA CTY GEN HOSP, DEPT INTERNAL MED, 2601 E ROOSEVELT ST, PHOENIX, AZ 85010 USA.						BIALECKI L, 1995, CHEST, V108, P1009, DOI 10.1378/chest.108.4.1009; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; BOWER RH, 1995, CRIT CARE MED, V23, P436, DOI 10.1097/00003246-199503000-00006; BRANNEY SW, 1994, CRIT CARE MED, V22, P1699; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; CARLSON R W, 1987, Acute Care, V13, P2; CERRA FB, 1993, CRIT CARE MED, V21, P457, DOI 10.1097/00003246-199303000-00026; CHARLSON ME, 1987, J CHRON DIS, V40, P705, DOI 10.1016/0021-9681(87)90107-X; CHARLSON ME, 1987, J CHRON DIS, V40, P31, DOI 10.1016/0021-9681(87)90094-4; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DASTA JF, 1992, CRIT CARE MED, V20, P563; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; DOUGHERTY CJ, 1992, JAMA-J AM MED ASSOC, V268, P2409, DOI 10.1001/jama.268.17.2409; EVANS SA, 1992, J AM COLL CARDIOL, V20, P1669, DOI 10.1016/0735-1097(92)90464-X; FRANKLIN C, 1994, CRIT CARE MED, V22, P244, DOI 10.1097/00003246-199402000-00014; FRANKLIN CM, 1988, ARCH INTERN MED, V148, P1403, DOI 10.1001/archinte.148.6.1403; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIRAUD T, 1993, CRIT CARE MED, V21, P40, DOI 10.1097/00003246-199301000-00011; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HANLEY DF, 1995, CRIT CARE MED, V23, P434, DOI 10.1097/00003246-199503000-00005; HANSEN J, 1995, CRIT CARE MED S, V23, pA31; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; KALB PE, 1989, JAMA-J AM MED ASSOC, V261, P2389, DOI 10.1001/jama.261.16.2389; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LANKEN PN, 1994, AM J RESP CRIT CARE, V149, P3, DOI 10.1164/ajrccm.149.1.8111594; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Lima C, 1995, CRIT CARE MED, V23, pA238; Marini CP NI, 1995, CRIT CARE MED, V23, pA235; MONTAZERI M, 1994, CRIT CARE MED, V22, P1044, DOI 10.1097/00003246-199406000-00027; MURRAY MJ, 1995, CRIT CARE MED, V23, P450, DOI 10.1097/00003246-199503000-00007; PARRILLO JE, 1995, CRIT CARE MED, V23, P607, DOI 10.1097/00003246-199504000-00001; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; PRAGER R, 1995, CRIT CARE MED, V23, pA239; Rafkin H, 1995, CRIT CARE MED, V23, pA59; RAINEY TG, 1994, CRIT CARE MED, V22, P1035, DOI 10.1097/00003246-199406000-00025; RAPHAELY RC, 1994, CRIT CARE MED, V22, P2013; RAPOPORT J, 1994, CRIT CARE MED, V22, P1385, DOI 10.1097/00003246-199409000-00006; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; ROBERT S, 1993, CRIT CARE MED, V21, P1487, DOI 10.1097/00003246-199310000-00016; ROMANELLI VA, 1993, CRIT CARE MED, V21, P1124, DOI 10.1097/00003246-199308000-00009; RON A, 1989, ARCH INTERN MED, V149, P338, DOI 10.1001/archinte.149.2.338; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Stucki G, 1995, Arthritis Care Res, V8, P174, DOI 10.1002/art.1790080310; THOLL DA, 1993, CRIT CARE MED, V21, P248, DOI 10.1097/00003246-199302000-00017; TIETZE KJ, 1993, CLIN PHARMACOL THER, V53, P214; TRUNET P, 1986, INTENS CARE MED, V12, P43, DOI 10.1007/BF00315371; VARON AJ, 1993, CRIT CARE MED, V21, P234; WACKSMAN R, 1996, CRIT CARE MED, V24, pA21; WATLING SM, 1994, CRIT CARE MED, V22, P884, DOI 10.1097/00003246-199405000-00028; WEILAND DE, 1995, AM J SURG, V170, P651, DOI 10.1016/S0002-9610(99)80035-X; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZIMMERMAN JE, 1995, CHEST, V108, P490, DOI 10.1378/chest.108.2.490; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010	63	48	48	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	JUL	1996	12	3					525	+		10.1016/S0749-0704(05)70260-8			1	Critical Care Medicine	General & Internal Medicine	UZ795	WOS:A1996UZ79500004	8839588				2021-06-18	
J	Stout, AK; LiSmerin, Y; Johnson, JW; Reynolds, IJ				Stout, AK; LiSmerin, Y; Johnson, JW; Reynolds, IJ			Mechanisms of glutamate-stimulated Mg2+ influx and subsequent Mg2+ efflux in rat forebrain neurones in culture	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							INDEPENDENT MG-2+ EFFLUX; CYTOSOLIC FREE MAGNESIUM; TRAUMATIC BRAIN INJURY; CORTICAL CELL-CULTURE; MOUSE CENTRAL NEURONS; DIVALENT-CATIONS; FLUORESCENT INDICATOR; NMDA RECEPTOR; HEART-CELLS; CHANNELS	1. Mag-fura-2 fluorescence microscopy and whole-cell patch-clamp recordings were used to measure glutamate-induced changes in the intracellular free Mg2+ concentration ([Mg2+](1)) and Mg2+ currents, respectively, in cultured forebrain neurones from fetal rats in the absence of extracellular Na+(Na-0(+)) and Ca2+ (Ca-0(2+)). 2. Increasing the extracellular Mg2+ concentration ([Mg2+](0)) from 9 to 70 mM significantly enhanced the maximum [Mg2+](i) induced by a 5 min 100 mu M glutamate plus 1 mu M glycine stimulation ([Mg2+](i,5 min)) from 2.04 +/- 0.07 to 2.98 +/- 0.20 mM. Increasing [Mg2+](i) upon glutamate stimulation from 0.41 +/- 0.02 to 0.81 +/- 0.08 mM min(-1). 3. The glutamate-stimulated increase in [Mg2+](i) was not altered by prior depletion on intracellular free Na+ (Na-i(+)). For paired stimulations in single neurones, the mean [Mg2+](i,5 min) was 1.95 +/- 0.17 mM under Na-+-depleted conditions and 1.94 +/- 0.16 mM under control conditions. 4. the glutamate-stimulated increase in [Mg2+](i) was significantly reduced when NMDA channel-permeant Cs+ or K+ ions were used as the Na+ substitute instead of the presumably NMDA channel-impermeant ions N-methyl-D-glucamine (NMDG), Tris or sucrose. The mean [Mg2+](i,5 min) was 0.56 +/- 0.06 and 0.74 +/- 0.08 mM in the presence of Cs-+ or K-+, respectively, compared with 2.13 +/- 0.10, 19.3 +/- 0.11 and 2.07 +/- 0.22 mM in the presence of NMDG, Tris or sucrose, respectively. 5. In whole-cell recordings performed with Cs+ as the primary intracellular cation, application of 100 mu M NMDA plus 10 mu M glycine induced inward currents that reversed around -55 mV in an extracellular solution containing 70 mM Mg2+ and 31 mM NMDG as the only cations. the currents were reversibly inhibited by DL-2-amino-5-phosphonovaleric acid (APC). In an extracellular solution containing 2 mM Mg2+ and 140 mM NMDG, NMDA plus glycine activated outward currents at potentials more depolarized than -90 mV. 6. In whole-cell recordings made with NMDG as the principal cation in the patch pipette, application NMDA plus glycine in the 70 mM Mg2+ extracellular solution induced inward currents at voltages more negative than +15 mV. The ratio of the current measured under these conditions to the current measured in an extracellular solution containing Na+ as the principal cation (0.073:1) was nearly constant from cell to cell. 7. Following a 5 min glutamate stimulation in the presence of 9 mM Mg2+, [Mg2+](i) returned to basal levels at a mean rate of 58.1 +/- 2.1 mu M min(-1). Complete removal of Na-0(+) significantly inhibited the rate of recovery to 31% of control. Raising [Mg2+](0) to 30 mM in combination with removal of Na-0(+) did not inhibit recovery significantly more than either manipulation alone (28% of control.) 8. These results suggest that glutamate-stimulated increases in [Mg2+](i) that occur in the absence of Na-0(+) and Ca-0(2+) result from Mg2+ entry through NMDA-activated ion channels. Furthermore, recovery from a glutamate-induced Mg2+ load appears to be primarily due to Mg2+ efflux via a mechanism whose characteristics are consistent with Na+-Mg2+ exchange.	UNIV PITTSBURGH, DEPT NEUROSCI, PITTSBURGH, PA 15261 USA	Stout, AK (corresponding author), UNIV PITTSBURGH, DEPT PHARMACOL, PITTSBURGH, PA 15261 USA.		Reynolds, Ian/C-4358-2008; Reynolds, Ian Jeffery/ABH-3197-2020	Reynolds, Ian/0000-0003-3028-5070	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 00944, MH 18273, MH 45817] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH045817, K02MH000944, R29MH045817] Funding Source: NIH RePORTER		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHOI DW, 1987, J NEUROSCI, V7, P357; DICHIARA G, 1981, ADV BIOCH PSYCHOPHAR, V27; EIMERL S, 1994, J NEUROCHEM, V62, P1223; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.physiol.53.1.259; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1990, FEBS LETT, V271, P149, DOI 10.1016/0014-5793(90)80394-X; GUNTHER T, 1993, MINER ELECTROL METAB, V19, P259; GUNTHER T, 1989, FEBS LETT, V247, P181, DOI 10.1016/0014-5793(89)81329-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; JAHR CE, 1990, J NEUROSCI, V10, P1830; KIEDROWSKI L, 1994, MOL PHARMACOL, V45, P1050; KIEDROWSKI L, 1994, NEURON, V12, P295, DOI 10.1016/0896-6273(94)90272-0; LiSmerin YY, 1996, J PHYSIOL-LONDON, V491, P121, DOI 10.1113/jphysiol.1996.sp021201; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MINTA A, 1989, J BIOL CHEM, V264, P19449; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; NEGULESCU PA, 1990, CELL REGUL, V1, P259; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; RAJDEV S, 1993, NEUROSCI LETT, V162, P149, DOI 10.1016/0304-3940(93)90582-6; RAJU B, 1989, AM J PHYSIOL, V256, pC540; REYNOLDS IJ, 1992, J NEUROSCI, V12, P970; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SMITH DL, 1993, MINER ELECTROL METAB, V19, P266; VANDELINDE AMQ, 1991, METAB BRAIN DIS, V6, P199, DOI 10.1007/BF00996919; VILLARROEL A, 1995, BIOPHYS J, V68, P866, DOI 10.1016/S0006-3495(95)80263-8; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WHITE RJ, 1995, J NEUROSCI, V15, P1318	40	48	48	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	MAY 1	1996	492	3					641	657		10.1113/jphysiol.1996.sp021334			17	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	UK222	WOS:A1996UK22200002	8734978	Green Published, Bronze			2021-06-18	
J	LAORR, A; GREENSPAN, A; ANDERSON, MW; MOEHRING, HD; MCKINLEY, T				LAORR, A; GREENSPAN, A; ANDERSON, MW; MOEHRING, HD; MCKINLEY, T			TRAUMATIC HIP DISLOCATION - EARLY MRI FINDINGS	SKELETAL RADIOLOGY			English	Article						HIP; MRI STUDIES; MUSCLE, INJURIES; BONE, INJURIES; HIP DISLOCATION	POSTERIOR DISLOCATION; FEMORAL-HEAD; AVASCULAR NECROSIS; MUSCLE TEARS; FRACTURES; INJURIES; KNEE	Purpose. Objective of this study was to present the spectrum of early magnetic resonance imaging (MRI) findings following traumatic dislocation of the femoral head, and to identify any associated injuries that may have therapeutic or prognostic significance and be better delineated by MRI than by conventional radiography. Patients and methods. Prospective MRI of both hips was performed on 18 patients (14 male, 4 female; age range 14-54 years; average age 30.5 years) within 5 weeks of a traumatic femoral head dislocation. The interval between the time of injury and the imaging studies ranged from 2 to 35 days (average 13.2 days). Posterior dislocation was present in 14 patients and anterior dislocation in 4 patients. In the majority of cases, we performed axial T1, coronal T1, and coronal T2* (MPGR) sequences. Images were retrospectively evaluated by consensus of three radiologists for possible abnormalities of the bone and cartilage, joint space, and soft tissues. Because all patients were treated with closed reduction, surgical correlation was not obtained. Results. All patients had a joint effusion or hemarthrosis. Of the 14 patients with posterior dislocation, isolated femoral head contusions (trabecular microfractures) were identified in 6 patients. Four patients had small femoral head fractures, and one had an osteochondral defect. Acetabular lip fractures were seen in six patients, and one patient had a labral tear. Four patients had intra-articular loose bodies and one had ligamentum teres entrapment. Twelve patients had iliofemoral ligament injury. All patients had muscle injury involving the gluteal region and medial fascial compartment, and 13 patients had anterior fascial compartment muscle injury. Seven patients with posterior dislocation had posterior fascial compartment injury. Of the four patients with anterior dislocation, two had bony contusion, two had cortical infraction, one had a labral tear, and all four had an iliofemoral ligament injury. All four patients in this group had muscle injury of the gluteal region and of the anterior and medial fascial compartments.	UNIV CALIF DAVIS, MED CTR, DEPT RADIOL, SACRAMENTO, CA 95817 USA; UNIV CALIF DAVIS, MED CTR, DEPT ORTHOPAED, SACRAMENTO, CA 95817 USA							ALLARD JC, 1992, MAGN RESON IMAGING, V10, P155, DOI 10.1016/0730-725X(92)90385-D; COOPER DE, 1991, AM J SPORT MED, V19, P322, DOI 10.1177/036354659101900319; DESMET AA, 1990, SKELETAL RADIOL, V19, P283, DOI 10.1007/BF00191673; DESMET AA, 1993, SKELETAL RADIOL, V22, P479, DOI 10.1007/BF00209094; DEUTSCH AL, 1989, RADIOLOGY, V170, P113, DOI 10.1148/radiology.170.1.2909083; ENSIGN MF, 1990, SEMIN ULTRASOUND CT, V11, P288; EPSTEIN HC, 1972, J BONE JOINT SURG AM, VA 54, P1561; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, V92, P116; FLECKENSTEIN JL, 1989, RADIOLOGY, V172, P793, DOI 10.1148/radiology.172.3.2772190; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; HOUGAARD K, 1987, J BONE JOINT SURG BR, V69, P556; KUM C K, 1990, SMJ Singapore Medical Journal, V31, P22; LYNCH TCP, 1989, RADIOLOGY, V171, P761, DOI 10.1148/radiology.171.3.2717748; MEYERS MH, 1988, CLIN ORTHOP RELAT R, P51; MINK JH, 1989, RADIOLOGY, V170, P823, DOI 10.1148/radiology.170.3.2916038; MIROVSKY Y, 1988, J TRAUMA, V28, P1597, DOI 10.1097/00005373-198811000-00016; MITCHELL DG, 1986, RADIOLOGY, V161, P199, DOI 10.1148/radiology.161.1.3763867; MITCHELL DG, 1989, CLIN ORTHOP RELAT R, V244, P60; NERUBAY J, 1976, CLIN ORTHOP RELAT R, P129; PIGGOT J, 1961, J BONE JOINT SURG BR, V43, P38; RICHARDSON P, 1990, AM J ROENTGENOL, V155, P93, DOI 10.2214/ajr.155.1.2112874; RIEGER H, 1991, ARCH ORTHOP TRAUM SU, V110, P114, DOI 10.1007/BF00393886; SHELLOCK FG, 1994, APPL RADIOL, V23, P11; SHERLOCK DA, 1988, J TRAUMA, V28, P411, DOI 10.1097/00005373-198803000-00021; SLATIS P, 1974, INJURY, V5, P188, DOI 10.1016/S0020-1383(74)80003-3; SNELL RS, 1992, CLIN ANATOMY MED STU; UPADHYAY SS, 1985, J BONE JOINT SURG BR, V67, P232; UPADHYAY SS, 1983, J BONE JOINT SURG BR, V65, P150; VONLAER L, 1986, FRAKTUREN LUXATIONEN, P142; WINGSTRAND H, 1986, ACTA ORTHOP SCAND, V57, P305, DOI 10.3109/17453678608994397; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	31	48	49	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2348	1432-2161		SKELETAL RADIOL	Skeletal Radiol.	MAY	1995	24	4					239	245					7	Orthopedics; Radiology, Nuclear Medicine & Medical Imaging	Orthopedics; Radiology, Nuclear Medicine & Medical Imaging	QY621	WOS:A1995QY62100001	7644933				2021-06-18	
J	KRAUS, JF; MCARTHUR, DL; SILBERMAN, TA				KRAUS, JF; MCARTHUR, DL; SILBERMAN, TA			EPIDEMIOLOGY OF MILD BRAIN INJURY	SEMINARS IN NEUROLOGY			English	Article							CLOSED HEAD-INJURY; TRAUMA; CHILDREN; CT; ELECTROENCEPHALOGRAPHY; JOHANNESBURG; DISABILITY; COMMUNITY; MORBIDITY; COUNTY			KRAUS, JF (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,SO CALIF INJURY PREVENT RES CTR,DEPT EPIDEMIOL,LOS ANGELES,CA 90024, USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BOHNEN N, 1991, BRIT J PSYCHIAT, V159, P860, DOI 10.1192/bjp.159.6.860; BROWN DSO, 1991, SOC SCI MED, V33, P283, DOI 10.1016/0277-9536(91)90362-G; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; CASEY R, 1986, PEDIATRICS, V78, P497; COLLINS JG, 1990, 10175 NAT CTR HLTH S; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; COSTEFF H, 1988, BRAIN DEV-JPN, V10, P371, DOI 10.1016/S0387-7604(88)80095-0; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; ENGLANDER J, 1992, BRAIN INJURY, V2, P161; ENOMOTO T, 1986, CHILD NERV SYST, V2, P72; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GODANO U, 1992, CHILD NERV SYST, V8, P136, DOI 10.1007/BF00298269; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HAAS DC, 1986, BRAIN, V109, P251, DOI 10.1093/brain/109.2.251; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jennett B, 1989, MILD HEAD INJURY, P23; KALSBECK WD, 1981, J NEUROSURG, V53, P19; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1993, UNPUB EPIDEMIOLOGY T; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1989, MILD HEAD INJURY, P189; LIGUORI G, 1989, CHILD NERV SYST, V5, P160, DOI 10.1007/BF00272119; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACKELLAR A, 1989, J PEDIATR SURG, V24, P577, DOI 10.1016/S0022-3468(89)80510-X; MacKenzie E J, 1989, Md Med J, V38, P725; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MIZRAHI EM, 1984, PEDIATRICS, V73, P419; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SELECKI BR, 1981, UNPUB INJURIES HEAD; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; VARTIAINEN E, 1985, INT J PEDIATR OTORHI, V9, P135, DOI 10.1016/S0165-5876(85)80013-6; VASQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832; WAALAND PK, 1990, COMMUNITY INTEGRATIO, P225; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; YAMOMOTO LG, 1988, CLIN PEDIATR, V27, P479	55	48	48	1	3	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0271-8235			SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					1	7		10.1055/s-2008-1041052			7	Clinical Neurology	Neurosciences & Neurology	NE151	WOS:A1994NE15100003	8029555				2021-06-18	
J	PATTERSSON, M; LORENTZON, R				PATTERSSON, M; LORENTZON, R			ICE HOCKEY INJURIES - A 4-YEAR PROSPECTIVE-STUDY OF A SWEDISH ELITE ICE HOCKEY TEAM	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						ICE HOCKEY; INJURY INCIDENCE		In this prospective study, we have investigated the incidence of injuries of different severity, types of injury, and mechanisms of injury during ice hockey practice and games. One Swedish elite hockey team was closely observed during four seasons (1986-1990). There were 376 injuries, of which 148 resulted in absence from practice or games. The incidence of injury (injuries associated with later absence) during practice was 2.6 per 1000 player-practice hours and 74.1 per 1000 player-game hours. Nuisance injuries (without any later absence) and minor injuries (absence < 1 week) constituted the vast majority (95.2%) and only 4.8% (18 cases) were classified as moderate or major injuries (absence > 1 week). Of the injuries 85% were caused by trauma and 15% by overuse. Injuries were most often localized to the lower limb (37.8%) and head/face (31.4%). The commonest injuries were contusions, lacerations/wounds, strains and sprains. Most injuries resulted from stick or player contact (predominantly checking). The results are in close agreement with those of a previous investigation of another Swedish elite hockey team covering the years 1982-1985. It should be possible to reduce the number of injuries by stricter enforcement of the hockey rules, especially against stick violations, and a more widespread use of visors.	UNIV HOSP UMEA,DEPT ORTHOPAED,SPORTS MED UNIT,S-90187 UMEA,SWEDEN								0	48	48	0	4	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC	1993	27	4					251	254		10.1136/bjsm.27.4.251			4	Sport Sciences	Sport Sciences	MW348	WOS:A1993MW34800008	8130963	Green Published, Bronze			2021-06-18	
J	PESSAR, LF; COAD, ML; LINN, RT; WILLER, BS				PESSAR, LF; COAD, ML; LINN, RT; WILLER, BS			THE EFFECTS OF PARENTAL TRAUMATIC BRAIN INJURY ON THE BEHAVIOR OF PARENTS AND CHILDREN	BRAIN INJURY			English	Article							HEAD-INJURY	Little is known about the effects of a parent's brain injury and subsequent disabilities on the children in the family. This study examines 24 families in which one parent is brain injured. In each family the children were born before the parent's injury and still lived at home at the time of interview. Reports of the uninjured parent indicate that most of the children experienced some degree of negative behavioural change after the parent's injury. In 10 of the families, significant and problematic changes occured. Types of problems included poor relationship with the injured parent, acting-out behaviour and emotional problems. Correlates of poor outcomes for the children were: (1) injured parent's gender, (2) compromised parenting performance of the injured parent, (3) compromised parenting performance of the uninjured parent and (4) depression in the uninjured parent. This study points to the importance of recognizing traumatic brain injury as a major family stressor.	SUNY,FAC RES & TRAINING,BUFFALO,NY 14260				Coad, Mary Lou/0000-0002-5791-9240			Becker DP, 1990, NEUROLOGICAL SURG, V3, P2017; BROMAN CL, 1990, AM J COMMUN PSYCHOL, V18, P643, DOI 10.1007/BF00931235; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Derogatis L. R, 1983, ADM SCORING PROCEDUR; FAHY TJ, 1967, LANCET, V2, P475; HANSELL AG, 1990, EFFECTS CHILDREN FAT; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, UNPUB DEV BRIEF SELF; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Panting A., 1972, REHABILITATION, V38, P33; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; THOMSEN IV, 1974, SCANDINAVIAN J REHAB, V6, P180; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wood R. L., 1987, BRAIN INJURY REHABIL; 1991, HLTH ACTIVITY LIMITA	20	48	49	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1993	7	3					231	240		10.3109/02699059309029675			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA170	WOS:A1993MA17000004	8508179				2021-06-18	
J	COHADON, F; RICHER, E				COHADON, F; RICHER, E			POST TRAUMATIC PERSISTENT VEGETATIVE STATES AND DEEP BRAIN-STIMULATION	NEUROCHIRURGIE			French	Article						POST TRAUMATIC VEGETATIVE STATE; THALAMIC STIMULATION	THALAMIC INTRALAMINAR NUCLEI; RAT; CONSCIOUSNESS; PROJECTIONS; CAT	In 25 cases of post traumatic vegetative state persisting 3 months after the initial injury, deep brain stimulation (DBS) has been used with the aim to activate the cortex and the hope to produce some degree of functional recovery. Electrodes were stereotaxically implanted in the centrum medianum-parafascicularis complex. Bipolar stimulation was provided daily from 8 a.m. to 8 p.m. In 12 cases no changes occured in the clinical features and overall behaviour. DBS was given up after 2 months. All these patients with a follow-up of 1 to 10 years, remained in a permanent vegetative state, 4 of them eventually deceased. In 13 cases, following 1 to 3 weeks of DBS a definite improvement was obtained with recovery of some degree of consciousness and interpersonal relationship. However all these patients, with 1 to 12 years follow-up remained severely disabled. 2 of them deceased from intercurrent causes. The practical meaning of these clinical results are questionned. We consider that the absence of response to DBS is an important argument to predict the irreversibility of post traumatic vegetative state. It is not certain that DBS is directly responsible for positive changes observed, some degree of long-term spontaneous recovery being already documented in such patients. However it seems likely that DBS accelerates recovery and possibly improves the final level of performances.		COHADON, F (corresponding author), UNIV BORDEAUX,HOP PELLEGRIN TRIPODE,NEUROCHIRURG CLIN,PL AMELIE RABA LEON,F-33076 BORDEAUX,FRANCE.						ALBE-FESSARD D, 1971, International Journal of Neuroscience, V1, P327, DOI 10.3109/00207457109146981; BENTIVOGLIO M, 1981, NEUROSCI LETT, V26, P5, DOI 10.1016/0304-3940(81)90417-1; BLOCH V, 1966, J PHYSIOL-PARIS, V58, P469; BLOCH V, 1970, PHYSIOL BEHAV, V5, P1235, DOI 10.1016/0031-9384(70)90033-8; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; COHADON F, 1984, ACTA NEUROCHIR, V33, P535; COMANS PE, 1981, BRAIN RES, V230, P337, DOI 10.1016/0006-8993(81)90411-X; HASSLER R, 1969, ELECTROEN CLIN NEURO, V27, P306, DOI 10.1016/0013-4694(69)90060-1; JONES EG, 1974, J COMP NEUROL, V154, P349, DOI 10.1002/cne.901540402; KANNO T, 1989, PACE, V12, P733, DOI 10.1111/j.1540-8159.1989.tb02724.x; KATAYAMA Y, 1991, PACE, V14, P116, DOI 10.1111/j.1540-8159.1991.tb04055.x; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; MANCIA M, 1971, BRAIN RES, V25, P368; MATSUI T, 1989, PACE, V12, P718, DOI 10.1111/j.1540-8159.1989.tb02722.x; MCLARDY T, 1968, AME NEUROL ASS, V93, P25; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; MRAOVITCH S, 1986, BRAIN RES, V380, P42, DOI 10.1016/0006-8993(86)91427-7; RICHER E, 1988, REV FR DC, V14, P205; RICHER E, 1991, TRAUMATISME CRANIEN, P75; RICHER E, 1991, NEURO PSY, V6, P428; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SCHEIBEL M E, 1972, Brain Behavior and Evolution, V6, P332; STURM V, 1979, ACTA NEUROCHIR, V47, P235, DOI 10.1007/BF01406406; TSUBOI T, 1992, ANIMAL CELL TECHNOLO, P289; TSUBOKAWA T, 1990, BRAIN INJURY, V4, P515	26	48	51	0	2	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0028-3770			NEUROCHIRURGIE	Neurochirurgie		1993	39	5					281	292					12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MP793	WOS:A1993MP79300002	8065486				2021-06-18	
J	COLLINS, JC; LEVINE, G; WAXMAN, K				COLLINS, JC; LEVINE, G; WAXMAN, K			OCCULT TRAUMATIC PNEUMOTHORAX - IMMEDIATE TUBE THORACOSTOMY VERSUS EXPECTANT MANAGEMENT	AMERICAN SURGEON			English	Article; Proceedings Paper	1992 ANNUAL MEETING OF THE SOUTHERN CALIFORNIA CHAPTER OF THE AMERICAN COLLEGE OF SURGEONS	JAN 17-19, 1992	INDIAN WELLS, CA	AMER COLL SURGEONS, SO CALIF CHAPTER			DIAGNOSIS	Occult pneumothorax is pneumothorax identified by computed tomography but not seen on conventional chest radiographs. Twenty-seven occult traumatic pneumothoraces in 26 patients were identified retrospectively at the authors' level I trauma center. Of these, 24 patients survived to discharge or transfer, 2 died of brain injury. Eleven patients were treated immediately with tube thoracostomy (TT) and 13 were observed with interval chest radiography. The authors' data support the conclusion that it is safe to withhold immediate TT in patients who are hemodynamically stable. Close clinical observation and interval chest radiography can identify those patients who require subsequent TT. Prospective study of larger numbers of patients is needed to confirm the safety and cost efficacy of this approach.	UNIV CALIF IRVINE,DEPT SURG,ORANGE,CA 92668; UNIV CALIF IRVINE,DEPT RADIOL,ORANGE,CA 92668	WAXMAN, K (corresponding author), UNIV CALIF IRVINE,MED CTR,101 CITY DR,ORANGE,CA 92668, USA.						BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAIR E, 1971, J TRAUM, V11, P129, DOI 10.1097/00005373-197102000-00005; GARRAMONE RR, 1991, SURG GYNECOL OBSTET, V173, P257; HEHIR MD, 1990, AUST NZ J SURG, V60, P529, DOI 10.1111/j.1445-2197.1990.tb07420.x; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; TOCINO IM, 1984, AM J ROENTGENOL, V143, P987, DOI 10.2214/ajr.143.5.987; WALL SD, 1983, AM J ROENTGENOL, V141, P919, DOI 10.2214/ajr.141.5.919; 1989, ADV TRAUMA LIFE SUPP	8	48	48	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	DEC	1992	58	12					743	746					4	Surgery	Surgery	KC519	WOS:A1992KC51900007	1456598				2021-06-18	
J	LYETH, BG; HAYES, RL				LYETH, BG; HAYES, RL			CHOLINERGIC AND OPIOID MEDIATION OF TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			SPINAL-CORD INJURY; PROTEIN-KINASE-C; ENDOGENOUS OPIOIDS; RAT HIPPOCAMPUS; ACETYLCHOLINE-RELEASE; CEREBRAL-ISCHEMIA; ADENYLATE-CYCLASE; NMDA RECEPTORS; ION CHANNELS; DYNORPHIN-A	There is considerable evidence for the involvement of cholinergic and opioid systems in the pathophysiological responses associated with traumatic brain injury (TBI). To some extent, interest in this area has been eclipsed by a strong focus on, and rapid progress in, studies of the role of excitatory amino aids in TBI. We present evidence that both cholinergic and opioid systems are important modulators of the pathophysiological response to TBI, potentially equally as important as excitatory amino acids. There is a relatively large body of experimental data documenting the involvement of these systems in TBI that has yielded important principles with general significance for laboratory studies of the neuropharmacology of TBI. In fact, the first demonstration of excitotoxic mechanisms of TBI involved studies of the role of acetylcholine in experimental TBI. There also are clinical data suggesting that modulation of opioid and cholinergic systems could benefit patients.	UNIV TEXAS,SCH MED,DEPT SURG,DIV NEUROSURG,HOUSTON,TX 77025	LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21458, NS 12587] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B80029] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ADLER MW, 1976, J PHARMACOL EXP THER, V198, P655; AGAJANIAN GK, 1986, BRAIN RES, V371, P290; BARABAN JM, 1987, TRENDS NEUROSCI, V10, P57, DOI 10.1016/0166-2236(87)90022-1; BERRIDGE MJ, 1989, JAMA-J AM MED ASSOC, V262, P1834; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; CHAVKIN C, 1985, BRAIN RES, V331, P366, DOI 10.1016/0006-8993(85)91565-3; CHOI DW, 1988, J NEUROSCI, V8, P185; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CONE WV, 1948, T AM NEUROL ASSOC, V73, P59; COWAN A, 1979, SCIENCE, V206, P465, DOI 10.1126/science.504986; DELAHUNTY TM, 1991, 9TH P NEUR S; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FRENK H, 1983, BRAIN RES REV, V6, P197, DOI 10.1016/0165-0173(83)90039-5; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257; HOLADAY JW, 1985, CURRENT CONCEPTS END; IWAMA T, 1986, NEUROSCI LETT, V63, P190, DOI 10.1016/0304-3940(86)90060-1; JACKISCH R, 1986, N-S ARCH PHARMACOL, V332, P156, DOI 10.1007/BF00511406; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JENKINS LW, 1989, MICHIGAN S SERIES TR, V1; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELSEY JE, 1982, BRAIN RES, V253, P337, DOI 10.1016/0006-8993(82)90705-3; LAPCHAK P A, 1987, Society for Neuroscience Abstracts, V13, P1192; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYETH BG, 1990, 8TH P NEUR S; LYETH BG, 1992, IN PRESS BRAIN RES; MACDONALD RL, 1986, J PHYSIOL-LONDON, V377, P237, DOI 10.1113/jphysiol.1986.sp016184; MACK KJ, 1985, BRAIN RES BULL, V14, P301, DOI 10.1016/0361-9230(85)90189-3; MCGEER E, 1985, CAN J PHARM, V64, P363; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MIYAZAKI S, IN PRESS BRAIN RES; Neumaier J F, 1986, NIDA Res Monogr, V75, P101; NEUMAIER JF, 1988, J PHARMACOL EXP THER, V244, P564; NICOLL RA, 1977, P NATL ACAD SCI USA, V74, P2584, DOI 10.1073/pnas.74.6.2584; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORTH RA, 1979, LIFE SCI, V24, P1527, DOI 10.1016/0024-3205(79)90014-6; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OKIYAMA K, 1990, 8TH P NEUR S; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; PERIYASAMY S, 1990, LIFE SCI, V47, P219, DOI 10.1016/0024-3205(90)90323-J; PERRY DC, 1992, IN PRESS MOL CHEM NE; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; SABOL SL, 1979, J BIOL CHEM, V254, P1913; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SIESJO BK, 1985, CEREBROVASC DIS, P187; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; TORTELLA FC, 1982, LIFE SCI, V31, P881, DOI 10.1016/0024-3205(82)90544-6; TORTELLA FC, 1987, INACTIVATION HYPERSE, P33; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; TOWER DB, 1949, CAN J RES E, V27, P120, DOI 10.1139/cjr49e-017; TURSKI WA, 1983, EXPERIENTIA, V39, P1408, DOI 10.1007/BF01990130; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; WICHMANN T, 1990, BRAIN RES, V510, P296, DOI 10.1016/0006-8993(90)91380-Y; WOLLEMANN M, 1990, J NEUROCHEM, V54, P1095, DOI 10.1111/j.1471-4159.1990.tb01934.x; WORLEY PF, 1987, P NATL ACAD SCI USA, V84, P3467, DOI 10.1073/pnas.84.10.3467; YAO JJ, 1988, NEUROPEPTIDES, V12, P177, DOI 10.1016/0143-4179(88)90051-0; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610; ZIMMERMAN RS, 1990, NEUROSURGERY, V26, P764, DOI 10.1227/00006123-199005000-00005	94	48	48	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S463	S474					12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900004	1351951				2021-06-18	
J	HAMM, RJ; JENKINS, LW; LYETH, BG; WHITEGBADEBO, DM; HAYES, RL				HAMM, RJ; JENKINS, LW; LYETH, BG; WHITEGBADEBO, DM; HAYES, RL			THE EFFECT OF AGE ON OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; BRAIN INJURY; AGE; FLUID-PERCUSSION INJURY; RAT	FLUID-PERCUSSION MODEL; MINOR HEAD-INJURIES; CONCUSSION; COMA	Age of the patient is one of the most important predictors of outcome following human traumatic brain injury. This study employs the fluid-percussion model to investigate the effects of aging on outcome following traumatic brain injury in rats. The results revealed that there was an age-associated increase in mortality rate following both low (1.7 to 1.8 atm) and moderate (2.00 to 2.25 atm) levels of traumatic brain injury. Age-related changes in systemic physiological, neurological, and histopathological indexes of brain injury were also examined following a low level of traumatic brain injury. Traumatic brain injury produced equivalent acute hypertension and increased plasma glucose levels in both young adult and aging rats. Injury produced an acute increase in heart rate in the young adult rat group, while the heart rate decreased in the aged rats. At low levels of brain injury, no significant gross histopathological alterations were produced in either age group. Neurological outcome was assessed by measuring the duration of suppression of a number of nonpostural and postural reflexes and more complex somatomotor functions (righting, escape, head support). Except for head support there was a significant age-related increase in the duration of the suppression of these reflexes following brain injury. These data demonstrate that aging is associated with an increased mortality rate and greater acute neurological deficits following traumatic brain injury. These data also demonstrate the usefulness of the fluid-percussion model for studying the mechanisms responsible for the age-related increase in vulnerability to brain injury.	VIRGINIA COMMONWEALTH UNIV,DEPT NEUROSURG,RICHMOND,VA 23284; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,VIRGINIA COMMONWEALTH UNIV BOX 2018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		BAKER H, 1978, LABORATORY RAT, V1, P411; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Collier H., 1962, ASSESSMENT PAIN MAN, P262; COTMAN CW, 1989, DRUG DEVELOP RES, V17, P331, DOI 10.1002/ddr.430170408; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FROLKIS VV, 1973, GERONTOLOGY, V19, P45; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1909, BRAIN RES, V526, P249; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1974, LANCET, V2, P81; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	20	48	48	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1991	75	6					916	921		10.3171/jns.1991.75.6.0916			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GQ946	WOS:A1991GQ94600010	1941121				2021-06-18	
J	LEVIN, HS; HIGH, WM; MEYERS, CA; VONLAUFEN, A; HAYDEN, ME; EISENBERG, HM				LEVIN, HS; HIGH, WM; MEYERS, CA; VONLAUFEN, A; HAYDEN, ME; EISENBERG, HM			IMPAIRMENT OF REMOTE MEMORY AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									PLAZA DEL ORO MED CTR,DEPT REHABIL MED,HOUSTON,TX	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377, NS 21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; DIXON WJ, 1981, BMDP STATISTICAL SOF; LEVIN HS, 1983, CORTEX, V19, P427, DOI 10.1016/S0010-9452(83)80025-2; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MAIR WGP, 1979, BRAIN, V102, P749, DOI 10.1093/brain/102.4.749; MARSLENWILSON WD, 1975, NEUROPSYCHOLOGIA, V13, P353, DOI 10.1016/0028-3932(75)90013-5; RIBOT T, 1882, DISEASES OF MEMORY E; Russell WR, 1935, LANCET, V2, P762; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1946, BRAIN, V69, P183; SANDERS HI, 1971, BRAIN, V94, P661, DOI 10.1093/brain/94.4.661; SELTZER B, 1974, NEUROLOGY, V24, P527, DOI 10.1212/WNL.24.6.527; SQUIRE LR, 1975, SCIENCE, V187, P77, DOI 10.1126/science.1109228; SQUIRE LR, 1978, NEUROPSYCHOLOGIA, V16, P313, DOI 10.1016/0028-3932(78)90025-8; SQUIRE LR, 1980, BEHAV RES METH INSTR, V12, P583, DOI 10.3758/BF03201847; SQUIRE LR, 1974, NEUROPSYCHOLOGIA, V12, P429, DOI 10.1016/0028-3932(74)90073-6; SQUIRE LR, 1975, J EXPT PSYCHOL HUMAN, V1, P50, DOI DOI 10.1037/0278-7393.1.1.50; TEASDALE G, 1974, LANCET, V2, P81; WARRINGTON EK, 1971, Q J EXP PSYCHOL, V23, P432, DOI 10.1080/14640747108400255; WILLIAMS M, 1952, J NEUROL NEUROSUR PS, V15, P54, DOI 10.1136/jnnp.15.1.54	23	48	48	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1985	48	6					556	563		10.1136/jnnp.48.6.556			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	AKM18	WOS:A1985AKM1800009	4009192	Bronze, Green Published			2021-06-18	
J	EIBEN, CF; ANDERSON, TP; LOCKMAN, L; MATTHEWS, DJ; DRYJA, R; MARTIN, J; BURRILL, C; GOTTESMAN, N; OBRIAN, P; WITTE, L				EIBEN, CF; ANDERSON, TP; LOCKMAN, L; MATTHEWS, DJ; DRYJA, R; MARTIN, J; BURRILL, C; GOTTESMAN, N; OBRIAN, P; WITTE, L			FUNCTIONAL OUTCOME OF CLOSED HEAD-INJURY IN CHILDREN AND YOUNG-ADULTS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									UNIV MINNESOTA HOSP,MINNEAPOLIS,MN 55455							BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Bruce D A, 1977, Adv Pediatr, V24, P233; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; JENNETT B, 1975, LANCET, V1, P480; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; Teuber H L, 1975, Ciba Found Symp, P159; TEW B, 1974, DEV MED CHILD NEUROL, V16, P494; WILLIAMSON JW, 1968, J AMER MED ASSOC, V204, P303, DOI 10.1001/jama.204.4.303	11	48	48	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.		1984	65	4					168	170					3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	SL726	WOS:A1984SL72600004	6712433				2021-06-18	
J	Yue, JK; Yuh, EL; Korley, FK; Winkler, EA; Sun, XY; Puffer, RC; Deng, HS; Choy, W; Chandra, A; Taylor, SR; Ferguson, AR; Huie, JR; Rabinowitz, M; Puccio, AM; Mukherjee, P; Vassar, MJ; Wang, KKW; Diaz-Arrastia, R; Okonkwo, DO; Jain, S; Manley, GT; Adeoye, OM; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Dikmen, SS; Duhaime, AC; Ellenbogen, R; Feeser, VR; Foreman, B; Gardner, RC; Gaudette, E; Giacino, J; Goldman, D; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Kramer, J; Kreitzer, N; Levin, HS; Lindsell, C; Machamer, J; Madden, C; Martin, A; McAllister, TW; McCrea, M; Merchant, R; Nelson, L; Ngwenya, LB; Noel, F; Palacios, EM; Perl, D; Robertson, C; Rosand, J; Sander, A; Satris, GG; Schnyer, DM; Seabury, SA; Sherer, M; Stein, M; Temkin, NR; Toga, A; Valadka, AB; Vespa, P; Zafonte, R				Yue, John K.; Yuh, Esther L.; Korley, Frederick K.; Winkler, Ethan A.; Sun, Xiaoying; Puffer, Ross C.; Deng, Hansen; Choy, Winward; Chandra, Ankush; Taylor, Sabrina R.; Ferguson, Adam R.; Huie, J. Russell; Rabinowitz, Miri; Puccio, Ava M.; Mukherjee, Pratik; Vassar, Mary J.; Wang, Kevin K. W.; Diaz-Arrastia, Ramon; Okonkwo, David O.; Jain, Sonia; Manley, Geoffrey T.; Adeoye, Opeolu M.; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Dikmen, Sureyya S.; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Ramana; Foreman, Brandon; Gardner, Raquel C.; Gaudette, Etienne; Giacino, Joseph; Goldman, Dana; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Kramer, Joel; Kreitzer, Natalie; Levin, Harvey S.; Lindsell, Christopher; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas W.; McCrea, Michael; Merchant, Randall; Nelson, Lindsay; Ngwenya, Laura B.; Noel, Florence; Palacios, Eva M.; Perl, Daniel; Robertson, Claudia; Rosand, Jonathan; Sander, Angelle; Satris, Gabriela G.; Schnyer, David M.; Seabury, Seth A.; Sherer, Mark; Stein, Murray; Temkin, Nancy R.; Toga, Arthur; Valadka, Alex B.; Vespa, Paul; Zafonte, Ross		TRACK-TBI Investigators	Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study	LANCET NEUROLOGY			English	Article							COMMON DATA ELEMENTS; FIBRILLARY ACIDIC PROTEIN; TERMINAL HYDROLASE-L1; TRANSFORMING RESEARCH; INTRACRANIAL LESIONS; CLINICAL KNOWLEDGE; MILD; BIOMARKERS; MODEL; S100B	Background After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein (GFAP) correlates with intracranial injury visible on CT scan. Some patients with suspected TBI with normal CT findings show pathology on MRI. We assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings. Methods TRACK-TBI is a prospective cohort study that enrolled patients with TBI who had a clinically indicated head CT scan within 24 h of injury at 18 level 1 trauma centres in the USA. For this analysis, we included patients with normal CT findings (Glasgow Coma Scale score 13-15) who consented to venepuncture within 24 h post injury and who had an MRI scan 7-18 days post injury. We compared MRI findings in these patients with those of orthopaedic trauma controls and healthy controls recruited from the study sites. Plasma GFAP concentrations (pg/mL) were measured using a prototype assay on a point-of-care platform. We used receiver operating characteristic (ROC) analysis to evaluate the discriminative ability of GFAP for positive MRI scans in patients with negative CT scans over 24 h (time between injury and venepuncture). The primary outcome was the area under the ROC curve (AUC) for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings within 24 h of injury. The Dunn Kruskal-Wallis test was used to compare GFAP concentrations between MRI lesion types with Benjamini-Hochberg correction for multiple comparisons. This study is registered with ClinicalTrials.gov, number NCT02119182. Findings Between Feb 26,2014, and June 15, 2018, we recruited 450 patients with normal head CT scans (of whom 330 had negative MRI scans and 120 had positive MRI scans), 122 orthopaedic trauma controls, and 209 healthy controls. AUC for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings was 0.777 (95% CI 0.726-0.829) over 24 h. Median plasma GFAP concentration was highest in patients with CT-negative and MRI-positive findings (414.4 pg/mL, 25-75th percentile 139.3-813.4), followed by patients with CT-negative and MRI-negative findings (74.0 pg/mL, 17.5-214.4), orthopaedic trauma controls (13.1 pg/mL, 6.9-20.0), and healthy controls (8.0 pg/mL, 3.0-14.0; all comparisons between patients with CT-negative MRI-positive findings and other groups p<0.0001). Interpretation Analysis of blood GFAP concentrations using prototype assays on a point-of-care platform within 24 h of injury might improve detection of TBI and identify patients who might need subsequent MRI and follow-up. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Yue, John K.; Winkler, Ethan A.; Choy, Winward; Chandra, Ankush; Taylor, Sabrina R.; Ferguson, Adam R.; Huie, J. Russell; Vassar, Mary J.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA; [Yue, John K.; Yuh, Esther L.; Winkler, Ethan A.; Choy, Winward; Chandra, Ankush; Taylor, Sabrina R.; Ferguson, Adam R.; Huie, J. Russell; Mukherjee, Pratik; Vassar, Mary J.; Manley, Geoffrey T.] Zudcerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA USA; [Korley, Frederick K.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Sun, Xiaoying; Jain, Sonia] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Puffer, Ross C.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA; [Puffer, Ross C.; Deng, Hansen; Rabinowitz, Miri; Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Psychiat & Neurosci, Gainesville, FL USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Ctr Neurodegenerat & Repair, Philadelphia, PA 19104 USA; [Adeoye, Opeolu M.; Foreman, Brandon; Kreitzer, Natalie; Ngwenya, Laura B.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, Baltimore, MD 21201 USA; [Boase, Kim; Chesnut, Randall; Dikmen, Sureyya S.; Ellenbogen, Richard; Machamer, Joan; Temkin, Nancy R.] Univ Washington, Seattle, WA 98195 USA; [Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Crawford, Karen; Gaudette, Etienne; Goldman, Dana; Seabury, Seth A.; Toga, Arthur] Univ Southern Calif, Los Angeles, CA 90089 USA; [Duhaime, Ann-Christine] Mass Gen Hosp, Boston, MA USA; [Feeser, V. Ramana; Merchant, Randall; Valadka, Alex B.] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Gardner, Raquel C.; Hemphill, J. Claude; Kramer, Joel; Martin, Alastair; Palacios, Eva M.; Satris, Gabriela G.] Univ Calif San Francisco, San Francisco, CA 94110 USA; [Giacino, Joseph] Spaulding Rehabil Hosp, Boston, MA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar; Levin, Harvey S.; Noel, Florence; Robertson, Claudia; Sander, Angelle] Baylor Coll Med, Houston, TX 77030 USA; [Lindsell, Christopher] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Madden, Christopher] UT Southwestern, Dallas, TX USA; [McAllister, Thomas W.] Indiana Univ, Bloomington, IN 47405 USA; [McCrea, Michael; Nelson, Lindsay] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Schnyer, David M.] UT Austin, Austin, TX USA; [Stein, Murray] Univ Calif San Diego, San Diego, CA 92103 USA; [Vespa, Paul] Univ Calif Los Angeles, Los Angeles, CA USA; [Zafonte, Ross] Harvard Med Sch, Boston, MA 02115 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Giacino, Joseph/AAF-1952-2021; Yue, John/P-1348-2015	Giacino, Joseph/0000-0002-7916-9698; Hemphill, Claude/0000-0003-4019-7525; Bodien, Yelena/0000-0003-4858-2903; Yue, John/0000-0001-9694-7722; Ferguson, Adam/0000-0001-7102-1608; Wang, Kevin/0000-0002-9343-6473	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Department of DefenseUnited States Department of Defense	Funding National Institute of Neurological Disorders and Stroke and US Department of Defense.	Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Broussard JI, 2018, BRAIN INJURY, V32, P113, DOI 10.1080/02699052.2017.1380228; Carlson AP, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10182; Chen HZ, 2017, J NEUROTRAUM, V34, P2291, DOI 10.1089/neu.2016.4870; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; Gill J, GLIAL FIBRILLARY ACI; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Luccichenti G, 2010, FUNCT NEUROL, V25, P109; Manley GT, 2017, J NEUROTRAUM, V34, P2721, DOI 10.1089/neu.2016.4729; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wayne PA, 2012, EVALUATION DETECTION; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	30	47	48	4	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					953	961		10.1016/S1474-4422(19)30282-0			9	Clinical Neurology	Neurosciences & Neurology	IX6HN	WOS:000485784000020	31451409		Y	N	2021-06-18	
J	Horti, AG; Naik, R; Foss, CA; Minn, I; Misheneva, V; Du, Y; Wang, YC; Mathews, WB; Wu, YK; Hall, A; LaCourse, C; Ahn, HH; Nam, H; Lesniak, WG; Valentine, H; Pletnikova, O; Troncoso, JC; Smith, MD; Calabresi, PA; Savonenko, AV; Dannals, RF; Pletnikov, MV; Pomper, MG				Horti, Andrew G.; Naik, Ravi; Foss, Catherine A.; Minn, Il; Misheneva, Varia; Du, Yong; Wang, Yuchuan; Mathews, William B.; Wu, Yunkou; Hall, Andrew; LaCourse, Catherine; Ahn, Hye-Hyun; Nam, Hwanhee; Lesniak, Wojciech G.; Valentine, Heather; Pletnikova, Olga; Troncoso, Juan C.; Smith, Matthew D.; Calabresi, Peter A.; Savonenko, Alena V.; Dannals, Robert F.; Pletnikov, Mikhail V.; Pomper, Martin G.			PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R)	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						neuroinflammation; positron-emission tomography; CSF1R; DAM; [C-11]CPPC	ALZHEIMERS-DISEASE; PROGENITOR-CELL; CSF-1 RECEPTOR; MOUSE MODEL; NEUROINFLAMMATION; EXPRESSION; INFLAMMATION; INHIBITOR; LIGANDS; GLIA	While neuroinflammation is an evolving concept and the cells involved and their functions are being defined, microglia are understood to be a key cellular mediator of brain injury and repair. The ability to measure microglial activity specifically and non-invasively would be a boon to the study of neuroinflammation, which is involved in a wide variety of neuropsychiatric disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Parkinson's disease, among others. We have developed [C-11]CPPC [5-cyano-N-(4-(4-[C-11]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide], a positron-emitting, high-affinity ligand that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R), the expression of which is essentially restricted to microglia within brain. [C-11] CPPC demonstrates high and specific brain uptake in a murine and nonhuman primate lipopolysaccharide model of neuroinflammation. It also shows specific and elevated uptake in a murine model of AD, experimental allergic encephalomyelitis murine model of demyelination and in postmortem brain tissue of patients with AD. Radiation dosimetry in mice indicated [C-11] CPPC to be safe for future human studies. [C-11] CPPC can be synthesized in sufficient radiochemical yield, purity, and specific radioactivity and possesses binding specificity in relevant models that indicate potential for human PET imaging of CSF1R and the microglial component of neuroinflammation.	[Horti, Andrew G.; Naik, Ravi; Foss, Catherine A.; Minn, Il; Du, Yong; Mathews, William B.; Wu, Yunkou; Hall, Andrew; Ahn, Hye-Hyun; Nam, Hwanhee; Lesniak, Wojciech G.; Valentine, Heather; Dannals, Robert F.; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA; [Misheneva, Varia; LaCourse, Catherine; Pletnikov, Mikhail V.; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21287 USA; [Wang, Yuchuan] Merck & Co Inc, West Point, PA 19486 USA; [Pletnikova, Olga; Troncoso, Juan C.; Savonenko, Alena V.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Troncoso, Juan C.; Smith, Matthew D.; Calabresi, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA	Horti, AG; Pomper, MG (corresponding author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA.; Pomper, MG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21287 USA.	ahorti1@jhmi.edu; mpomper@jhmi.edu	Pletnikov, Mikhail V/G-8709-2012; LaCourse, Catherine M/L-8604-2019; Calabresi, Peter A./AAF-2288-2019	LaCourse, Catherine M/0000-0002-9477-6920; Du, Yong/0000-0002-0237-6154; Smith, Matthew/0000-0001-6614-569X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG054802, EB024495, NS041435]; Johns Hopkins University Alzheimer's Disease Research CenterJohns Hopkins University [AG05146]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB024495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS041435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005146, R33AG054802, R21AG054802] Funding Source: NIH RePORTER	We acknowledge Dr. Xiaolei Song for providing an EAE mouse and Dr. Hiroto Kuwabara for fruitful discussions. We are grateful to Dr. Polina Sysa Shah; Paige Finley, MS; and James Engles, MS, for assistance with animal experiments. This research was supported by NIH Grants AG054802, EB024495, and NS041435 and by the Johns Hopkins University Alzheimer's Disease Research Center (Grant AG05146).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Aid S, 2010, NEUROSCI LETT, V478, P113, DOI 10.1016/j.neulet.2010.04.076; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; ALTERMAN RL, 1994, MOL CHEM NEUROPATHOL, V21, P177, DOI 10.1007/BF02815350; Bernard-Gauthier V, 2014, BIOORG MED CHEM LETT, V24, P4784, DOI 10.1016/j.bmcl.2014.09.014; Boissonneault V, 2009, BRAIN, V132, P1078, DOI 10.1093/brain/awn331; Chitu V, 2016, TRENDS NEUROSCI, V39, P378, DOI 10.1016/j.tins.2016.03.005; Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dickens AM, 2014, J NUCL MED, V55, P466, DOI 10.2967/jnumed.113.125625; Dobos N, 2012, J ALZHEIMERS DIS, V28, P905, DOI 10.3233/JAD-2011-111097; El-Gamal MI, 2018, J MED CHEM, V61, P5450, DOI 10.1021/acs.jmedchem.7b00873; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Hannestad J, 2012, NEUROIMAGE, V63, P232, DOI 10.1016/j.neuroimage.2012.06.055; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021; Illig CR, 2008, BIOORG MED CHEM LETT, V18, P1642, DOI 10.1016/j.bmcl.2008.01.059; Janssen B, 2018, MOLECULES, V23, DOI 10.3390/molecules23030607; Jones MV, 2008, J NEUROIMMUNOL, V199, P83, DOI 10.1016/j.jneuroim.2008.05.013; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Krauser JA, 2015, XENOBIOTICA, V45, P107, DOI 10.3109/00498254.2014.945988; LEE SC, 1993, J IMMUNOL, V150, P594; Lentz MR, 2010, J NEUROVIROL, V16, P368, DOI 10.3109/13550284.2010.513029; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Masgrau R, 2017, TRENDS MOL MED, V23, P486, DOI 10.1016/j.molmed.2017.04.005; Melnikova T, 2013, J NEUROSCI, V33, P3765, DOI 10.1523/JNEUROSCI.4251-12.2013; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nandi S, 2012, DEV BIOL, V367, P100, DOI 10.1016/j.ydbio.2012.03.026; Catorce MN, 2016, CURR NEUROPHARMACOL, V14, P155, DOI 10.2174/1570159X14666151204122017; Palle Pushpalatha, 2017, Med Sci (Basel), V5, DOI 10.3390/medsci5040023; Peyraud F, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0634-1; Prieto-Morin C, 2016, J NEUROL, V263, P1864, DOI 10.1007/s00415-016-8197-x; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Smith AM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-85; Tronel C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040802; Walker DG, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00244; Yan SD, 1997, NATURE, V389, P689; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]	41	47	47	4	26	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 29	2019	116	5					1686	1691		10.1073/pnas.1812155116			6	Multidisciplinary Sciences	Science & Technology - Other Topics	HJ1SN	WOS:000456944600038	30635412	Green Published, Bronze	Y	N	2021-06-18	
J	Bisicchia, E; Sasso, V; Catanzaro, G; Leuti, A; Besharat, ZM; Chiacchiarini, M; Molinari, M; Ferretti, E; Viscomi, MT; Chiurchiu, V				Bisicchia, Elisa; Sasso, Valeria; Catanzaro, Giuseppina; Leuti, Alessandro; Besharat, Zein Mersini; Chiacchiarini, Martina; Molinari, Marco; Ferretti, Elisabetta; Viscomi, Maria Teresa; Chiurchiu, Valerio			Resolvin D1 Halts Remote Neuroinflammation and Improves Functional Recovery after Focal Brain Damage Via ALX/FPR2 Receptor-Regulated MicroRNAs	MOLECULAR NEUROBIOLOGY			English	Article						Specialized pro-resolving mediators; Inflammation resolution; Neuroinflammation; Remote brain damage; Epigenetics	SPINAL-CORD-INJURY; MICROGLIAL ACTIVATION; LIPID MEDIATORS; INFLAMMATION; RESOLUTION; OMEGA-3-FATTY-ACIDS; DEGENERATION; INFECTION; PROMOTE; CELLS	Remote damage is a secondary phenomenon that usually occurs after a primary brain damage in regions that are distant, yet functionally connected, and that is critical for determining the outcomes of several CNS pathologies, including traumatic brain and spinal cord injuries. The understanding of remote damage-associated mechanisms has been mostly achieved in several models of focal brain injury such as the hemicerebellectomy (HCb) experimental paradigm, which helped to identify the involvement of many key players, such as inflammation, oxidative stress, apoptosis and autophagy. Currently, few interventions have been shown to successfully limit the progression of secondary damage events and there is still an unmet need for new therapeutic options. Given the emergence of the novel concept of resolution of inflammation, mediated by the newly identified omega 3-derived specialized pro-resolving lipid mediators, such as resolvins, we reported a reduced ability of HCb-injured animals to produce resolvin D1 (RvD1) and an increased expression of its target receptor ALX/FPR2 in remote brain regions. The in vivo administration of RvD1 promoted functional recovery and neuroprotection by reducing the activation of Iba-1+ microglia and GFAP+ astrocytes as well as by impairing inflammatory-induced neuronal cell death in remote regions. These effects were counteracted by intracerebroventricular neutralization of ALX/FPR2, whose activation by RvD1 also down-regulated miR-146b- and miR-219a-1-dependent inflammatory markers. In conclusion, we propose that innovative therapies based on RvD1-ALX/FPR2 axis could be exploited to curtail remote damage and enable neuroprotective effects after acute focal brain damage.	[Bisicchia, Elisa; Sasso, Valeria; Leuti, Alessandro; Molinari, Marco; Viscomi, Maria Teresa; Chiurchiu, Valerio] IRCCS Santa Lucia Fdn, Via Fosso di Fiorano 64, I-00143 Rome, Italy; [Catanzaro, Giuseppina; Besharat, Zein Mersini; Ferretti, Elisabetta] Sapienza Univ Rome, Dept Expt Med, Rome, Italy; [Chiacchiarini, Martina] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Ferretti, Elisabetta] IRCCS Neuromed, Pozzilli, Italy; [Chiurchiu, Valerio] Campus Biomed Univ Rome, Dept Med, Rome, Italy	Viscomi, MT; Chiurchiu, V (corresponding author), IRCCS Santa Lucia Fdn, Via Fosso di Fiorano 64, I-00143 Rome, Italy.; Chiurchiu, V (corresponding author), Campus Biomed Univ Rome, Dept Med, Rome, Italy.	mt.viscomi@hsantalucia.it; v.chiurchiu@hsantalucia.it	Leuti, Alessandro/AAB-6479-2019; Molinari, Marco/A-9624-2010; Besharat, Zein Mersini/P-4486-2019; Viscomi, Maria Teresa/AAL-6625-2021; Ferretti, Elisabetta/G-5413-2013; catanzaro, giuseppina/J-8158-2018; Viscomi, Maria Teresa/G-4173-2011	Leuti, Alessandro/0000-0002-5982-0682; Molinari, Marco/0000-0001-9808-9688; Besharat, Zein Mersini/0000-0003-0317-9854; Ferretti, Elisabetta/0000-0001-7265-6429; Chiacchiarini, Martina/0000-0001-9229-0372; catanzaro, giuseppina/0000-0001-8427-9691; Viscomi, Maria Teresa/0000-0002-9096-4967	Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM) [2015/R/8]; Italian Ministry of Health (Progetto Giovani Ricercatori Project) [GR-2010.2310524]	This work was funded by Fondazione Italiana Sclerosi Multipla (FISM) (grant 2015/R/8 to V.C.) and by the Italian Ministry of Health (Progetto Giovani Ricercatori Project Code GR-2010.2310524 to M.T.V.).	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Bays HE, 2007, AM J CARDIOL, V99, p35C, DOI 10.1016/j.amjcard.2006.11.020; Bazan NG, 2007, CURR OPIN CLIN NUTR, V10, P136, DOI 10.1097/MCO.0b013e32802b7030; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Bisicchia E, 2013, CELL MOL LIFE SCI, V70, P2191, DOI 10.1007/s00018-012-1253-5; Biswas SK, 2012, IMMUNOL RES, V53, P11, DOI 10.1007/s12026-012-8291-9; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Caiello I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107886; Catanzaro G, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2683042; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Chiurchiu V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7483; Chiurchiu V, 2011, ANTIOXID REDOX SIGN, V15, P2605, DOI 10.1089/ars.2010.3547; Codagnone M, 2017, MUCOSAL IMMUNOL; Hall JCE, 2012, J NEUROCHEM, V121, P738, DOI 10.1111/j.1471-4159.2012.07726.x; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Kong Y, 2010, J NEUROSCI, V30, P11848, DOI 10.1523/JNEUROSCI.2985-10.2010; Kongsui R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0182-7; Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010; Li LY, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-72; Michael-Titus AT, 2014, TRENDS NEUROSCI, V37, P30, DOI 10.1016/j.tins.2013.10.005; Molteni M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6978936; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599; Rey C, 2016, BRAIN BEHAV IMMUN, V55, P249, DOI 10.1016/j.bbi.2015.12.013; Rius B, 2014, FASEB J, V28, P836, DOI 10.1096/fj.13-235614; Samaddar S, 2016, ADV NEUROBIOL, V12, P27, DOI 10.1007/978-3-319-28383-8_2; Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289; Sheets KG, 2013, MOL VIS, V19, P1747; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Viscomi MT, 2008, NEUROSCIENCE, V154, P1267, DOI 10.1016/j.neuroscience.2008.04.024; Viscomi MT, 2015, CEREBELLUM, V14, P15, DOI 10.1007/s12311-014-0603-2; Viscomi MT, 2014, MOL NEUROBIOL, V50, P368, DOI 10.1007/s12035-013-8629-x; Wang G, 2016, SCI REP-UK, V6, DOI 10.1038/srep25946; Wang XZ, 2015, ALZHEIMERS DEMENT, V11, P40, DOI 10.1016/j.jalz.2013.12.024; Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8; Zhang L., 2017, SCI REP, V7; Zhu MQ, 2016, MOL NEUROBIOL, V53, P2733, DOI 10.1007/s12035-015-9544-0	47	47	47	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2018	55	8					6894	6905		10.1007/s12035-018-0889-z			12	Neurosciences	Neurosciences & Neurology	GO1YO	WOS:000439758300045	29357041				2021-06-18	
J	Mouzon, BC; Bachmeier, C; Ojo, JO; Acker, CM; Ferguson, S; Paris, D; Ait-Ghezala, G; Crynen, G; Davies, P; Mullan, M; Stewart, W; Crawford, F				Mouzon, Benoit C.; Bachmeier, Corbin; Ojo, Joseph O.; Acker, Christopher M.; Ferguson, Scott; Paris, Daniel; Ait-Ghezala, Ghania; Crynen, Gogce; Davies, Peter; Mullan, Michael; Stewart, William; Crawford, Fiona			Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							FOOTBALL LEAGUE PLAYERS; MOUSE MODEL; COGNITIVE DYSFUNCTION; HIPPOCAMPAL-LESIONS; RECOGNITION MEMORY; HEAD-INJURY; OBJECT RECOGNITION; SILENT EPIDEMIC; ENCEPHALOPATHY; TAU	Objective Exposure to repetitive concussion, or mild traumatic brain injury (mTBI), has been linked with increased risk of long-term neurodegenerative changes, specifically chronic traumatic encephalopathy (CTE). To date, preclinical studies largely have focused on the immediate aftermath of mTBI, with no literature on the lifelong consequences of mTBI in these models. This study provides the first account of lifelong neurobehavioral and histological consequences of repetitive mTBI providing unique insight into the constellation of evolving and ongoing pathologies with late survival. Methods Male C57BL/6J mice (aged 2-3months) were exposed to either single or repetitive mild TBI or sham procedure. Thereafter, animals were monitored and assessed at 24months post last injury for measures of motor coordination, learning deficits, cognitive function, and anxiety-like behavior prior to euthanasia and preparation of the brains for detailed neuropathological and protein biochemical studies. Results At 24months survival animals exposed to r-mTBI showed clear evidence of learning and working memory impairment with a lack of spatial memory and vestibule-motor vestibulomotor deficits compared to sham animals. Associated with these late behavioral deficits there was evidence of ongoing axonal degeneration and neuroinflammation in subcortical white matter tracts. Notably, these changes were also observed after a single mTBI, albeit to a lesser degree than repetitive mTBI. Interpretation In this context, our current data demonstrate, for the first time, that rather than an acute, time limited event, mild TBI can precipitate a lifelong degenerative process. These data therefore suggest that successful treatment strategies should consider both the acute and chronic nature of mTBI.	[Mouzon, Benoit C.; Bachmeier, Corbin; Ojo, Joseph O.; Ferguson, Scott; Paris, Daniel; Ait-Ghezala, Ghania; Crynen, Gogce; Mullan, Michael; Crawford, Fiona] Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA; [Mouzon, Benoit C.; Bachmeier, Corbin; Ojo, Joseph O.; Ferguson, Scott; Paris, Daniel; Ait-Ghezala, Ghania; Crynen, Gogce; Crawford, Fiona] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Mouzon, Benoit C.; Bachmeier, Corbin; Paris, Daniel; Ait-Ghezala, Ghania; Crynen, Gogce; Crawford, Fiona] Open Univ, Milton Keynes, Bucks, England; [Acker, Christopher M.; Davies, Peter] Feinstein Inst Med Res, Manhasset, NY USA; [Stewart, William] Queen Elizabeth Glasgow Univ Hosp, Glasgow, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland	Mouzon, BC (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	bmouzon@roskampinstitute.org		Ait-Ghezala, Ghania/0000-0002-9836-8617; Stewart, William/0000-0003-2199-2582; Crynen, Gogce/0000-0001-6066-9900	Department of Defense awardUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, NS094003]; DODUnited States Department of Defense [PT110785]; NHS Research Scotland Career Researched Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, R01NS038104] Funding Source: NIH RePORTER	This research was funded by a Department of Defense award (W81XWH-10-1-0759) to Dr. Fiona Crawford, and by the Roskamp Foundation. Dr. Crawford is a VA Research Career Scientist. Dr. Stewart is supported by NIH grants NS038104 & NS094003, DOD grant PT110785 and an NHS Research Scotland Career Researched Fellowship. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the U.S. Government, or the U.S. Department of Veterans Affairs, and no official endorsement should be inferred.	Acker CM, 2013, NEUROBIOL AGING, V34, P338, DOI 10.1016/j.neurobiolaging.2012.05.010; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Clark RE, 2000, J NEUROSCI, V20, P8853; DE BL, 2009, BRAIN 3, V132, P695; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Ferguson S, 2017, J NEUROTRAUM, V34, P1676, DOI 10.1089/neu.2016.4636; Forwood SE, 2005, HIPPOCAMPUS, V15, P347, DOI 10.1002/hipo.20059; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Good MA, 2007, BEHAV NEUROSCI, V121, P218, DOI 10.1037/0735-7044.121.1.218; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langston RF, 2010, HIPPOCAMPUS, V20, P1139, DOI 10.1002/hipo.20714; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lynch CE, 2016, BRAIN INJURY, V30, P1414, DOI 10.1080/02699052.2016.1219060; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Paris D, 2014, J BIOL CHEM, V289, P33927, DOI 10.1074/jbc.M114.608091; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Roberts G, 1969, BRAIN DAMAGE BOXERS; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Strain JF, 2017, J NEUROTRAUM, V34, P372, DOI 10.1089/neu.2016.4446; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Wolf JA, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00043; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	51	47	47	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	JAN	2018	5	1					64	80		10.1002/acn3.510			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FS8LX	WOS:000422664400007	29376093	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Kovacs, GG; Lee, VM; Trojanowski, JQ				Kovacs, Gabor G.; Lee, Virginia M.; Trojanowski, John Q.			Protein astrogliopathies in human neurodegenerative diseases and aging	BRAIN PATHOLOGY			English	Article						A-beta; alpha-synuclein; ARTAG; astrocyte; neurodegeneration; PAG; prion; prion protein; protein astrogliopathy; tau; TDP-43	PROGRESSIVE SUPRANUCLEAR PALSY; CHRONIC TRAUMATIC ENCEPHALOPATHY; FRONTOTEMPORAL LOBAR DEGENERATION; GLIAL FIBRILLARY TANGLES; MULTIPLE SYSTEM ATROPHY; AMYOTROPHIC-LATERAL-SCLEROSIS; ARGYROPHILIC GRAIN DISEASE; THORN-SHAPED ASTROCYTES; INCIDENTAL CORTICOBASAL DEGENERATION; SPORADIC PARKINSONS-DISEASE	Neurodegenerative diseases are characterized by progressive dysfunction and loss of neurons associated with depositions of pathologically altered proteins showing hierarchical involvement of brain regions. The role of astrocytes in the pathogenesis of neurodegenerative diseases is explored as contributors to neuronal degeneration or neuroprotection pathways, and also as potential mediators of the transcellular spreading of disease-associated proteins. Protein astrogliopathy (PAG), including deposition of amyloid-, prion protein, tau, -synuclein, and very rarely transactive response DNA-binding protein 43 (TDP-43) is not unprecedented or unusual in neurodegenerative diseases. Morphological characterization of PAG is considered, however, only for the neuropathological diagnosis and classification of tauopathies. Astrocytic tau pathology is seen in primary frontotemporal lobar degeneration (FTLD) associated with tau pathologies (FTLD-Tau), and also in the form of aging-related tau astrogliopathy (ARTAG). Importantly, ARTAG shares common features with primary FTLD-Tau as well as with the astroglial tau pathologies that are thought to be hallmarks of a brain injury-related tauopathy known as chronic traumatic encephalopathy (CTE). Supported by experimental observations, the morphological variability of PAG might reflect distinct pathogenic involvement of different astrocytic populations. PAG might indicate astrocytic contribution to spreading or clearance of disease-associated proteins, however, this might lead to astrocytic dysfunction and eventually contribute to the degeneration of neurons. Here, we review recent advances in understanding ARTAG and other related forms of PAG.	[Kovacs, Gabor G.] Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Lee, Virginia M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Inst Aging, Philadelphia, PA 19104 USA; [Lee, Virginia M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19103 USA	Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria.	gabor.kovacs@meduniwien.ac.at	Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511	National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30-AG10124, PO1-AG17586, NS088341, NS094003]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, K23NS088341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, P01AG017586] Funding Source: NIH RePORTER	Support for this work was provided by grants from the National Institute on Aging of the National Institutes of Health (P30-AG10124, PO1-AG17586, NS088341, and NS094003).	Ahmed Z, 2013, ACTA NEUROPATHOL, V126, P537, DOI 10.1007/s00401-013-1171-0; Aho L, 2010, J ALZHEIMERS DIS, V20, P1015, DOI 10.3233/JAD-2010-091681; Alexander J, 2016, NEUROBIOL AGING, V42, P199, DOI 10.1016/j.neurobiolaging.2016.03.012; Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V1911, P365; Arai N, 1996, NEUROPATHOLOGY, V16, P133, DOI 10.1111/j.1440-1789.1996.tb00168.x; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 2006, NEUROPATHOLOGY, V26, P475, DOI 10.1111/j.1440-1789.2006.00669.x; Armstrong RA, 2013, NEUROL SCI, V34, P337, DOI 10.1007/s10072-012-1006-0; Armstrong RA, 2011, ACTA NEUROPATHOL, V121, P219, DOI 10.1007/s00401-010-0753-3; Ash PEA, 2013, NEURON, V77, P639, DOI 10.1016/j.neuron.2013.02.004; Beach TG, 2009, ACTA NEUROPATHOL, V117, P169, DOI 10.1007/s00401-008-0450-7; Boluda S, 2015, ACTA NEUROPATHOL, V129, P221, DOI 10.1007/s00401-014-1373-0; Botez G, 1999, ACTA NEUROPATHOL, V98, P251, DOI 10.1007/s004010051077; BRAAK H, 1987, NEUROSCI LETT, V76, P124, DOI 10.1016/0304-3940(87)90204-7; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2007, ACTA NEUROPATHOL, V114, P231, DOI 10.1007/s00401-007-0244-3; Brettschneider J, 2015, NAT REV NEUROSCI, V16, P109, DOI 10.1038/nrn3887; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Cavaliere F, 2017, NEUROBIOL DIS, V103, P101, DOI 10.1016/j.nbd.2017.04.011; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; Delisle MB, 1999, ACTA NEUROPATHOL, V98, P62, DOI 10.1007/s004010051052; Dickson DW, 2010, CURR OPIN NEUROL, V23, P394, DOI 10.1097/WCO.0b013e32833be924; Dickson DW, 1998, BRAIN PATHOL, V8, P339; DIEDRICH JF, 1991, P NATL ACAD SCI USA, V88, P375, DOI 10.1073/pnas.88.2.375; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Evidente VGH, 2011, PARKINSONISM RELAT D, V17, P365, DOI 10.1016/j.parkreldis.2011.02.017; Feany MB, 1996, J NEUROPATH EXP NEUR, V55, P53, DOI 10.1097/00005072-199601000-00006; FEANY MB, 1995, AM J PATHOL, V146, P1388; Ferrer I, 2003, NEUROPATH APPL NEURO, V29, P23, DOI 10.1046/j.1365-2990.2003.00435.x; Ferrer I, 2015, J NEUROPATH EXP NEUR, V74, P370, DOI 10.1097/NEN.0000000000000180; Ferrer I, 2014, J NEUROPATH EXP NEUR, V73, P81, DOI 10.1097/NEN.0000000000000030; Ferrer I, 2008, BRAIN, V131, P1416, DOI 10.1093/brain/awm305; Ferrer I, 2017, BRAIN PATHOL, V27, P645, DOI 10.1111/bpa.12538; Forman MS, 2005, J NEUROSCI, V25, P3539, DOI 10.1523/JNEUROSCI.0081-05.2005; Fu YJ, 2010, ACTA NEUROPATHOL, V120, P21, DOI 10.1007/s00401-010-0649-2; Funato H, 1998, AM J PATHOL, V152, P983; Ghetti B, 2015, NEUROPATH APPL NEURO, V41, P24, DOI 10.1111/nan.12213; Ghetti B, 2011, NEURODEGENERATION MO, P110, DOI [10.1002/9781444341256.ch14, DOI 10.1002/9781444341256.CH14]; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Halliday GM, 2006, BRAIN, V129, DOI 10.1093/brain/awh720; HAUW JJ, 1990, NEUROSCI LETT, V119, P182, DOI 10.1016/0304-3940(90)90829-X; Hayashi S, 2002, ANN NEUROL, V51, P525, DOI 10.1002/ana.10163; Hedley-Whyte ET, 2009, J NEUROPATH EXP NEUR, V68, P136, DOI 10.1097/NEN.0b013e318195203; Higuchi M, 2002, NEURON, V35, P433, DOI 10.1016/S0896-6273(02)00789-4; Hogg M, 2003, ACTA NEUROPATHOL, V106, P323, DOI 10.1007/s00401-003-0734-x; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Iijima M, 1999, NEUROREPORT, V10, P497, DOI 10.1097/00001756-199902250-00010; Ikeda C, 2016, BRAIN PATHOL, V26, P488, DOI 10.1111/bpa.12319; Ikeda K, 1998, NEUROBIOL AGING, V19, pS85, DOI 10.1016/S0197-4580(98)00034-7; Ikeda K, 1996, NEUROPATHOLOGY, V16, P71, DOI 10.1111/j.1440-1789.1996.tb00158.x; IKEDA K, 1995, ACTA NEUROPATHOL, V90, P620; Irwin DJ, 2016, ANN NEUROL, V79, P272, DOI 10.1002/ana.24559; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; Kobayashi K, 2003, J NEUROL, V250, P990, DOI 10.1007/s00415-003-1137-6; Kobayashi T, 2003, ANN NEUROL, V53, P133, DOI 10.1002/ana.10447; Koga S, 2016, J NEUROPATH EXP NEUR, V75, P963, DOI 10.1093/jnen/nlw073; Komori T, 1999, BRAIN PATHOL, V9, P663; Komori T, 1998, ACTA NEUROPATHOL, V96, P401, DOI 10.1007/s004010050911; Kovacs GG, 2017, NEUROPATH APPL NEURO, V43, P191, DOI 10.1111/nan.12372; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2013, NEUROPATH APPL NEURO, V39, P166, DOI 10.1111/j.1365-2990.2012.01272.x; Kovacs GG, 2008, J NEUROPATH EXP NEUR, V67, P963, DOI 10.1097/NEN.0b013e318187a80f; Kovacs GG, 2018, BRAIN PATHOL, V28, P274, DOI 10.1111/bpa.12482; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P605, DOI 10.1093/jnen/nlx041; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P270, DOI 10.1093/jnen/nlx007; Kovacs GG, 2017, BRAIN PATHOL, V27, P332, DOI 10.1111/bpa.12411; Kovacs GG, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020189; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Kovacs GG, 2014, NEUROBIOL DIS, V69, P76, DOI 10.1016/j.nbd.2014.05.020; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Kovacs GG, 2012, ACTA NEUROPATHOL, V124, P37, DOI 10.1007/s00401-012-0964-x; Kovacs GG, 2011, ACTA NEUROPATHOL, V122, P205, DOI 10.1007/s00401-011-0819-x; Kovacs GG, 2009, INT J MOL SCI, V10, P976, DOI 10.3390/ijms10030976; Kovacs GG, 2005, AM J PATHOL, V166, P287, DOI 10.1016/S0002-9440(10)62252-3; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; Kurt MA, 1999, EXP NEUROL, V158, P221, DOI 10.1006/exnr.1999.7096; Kwong LK, 2008, NEUROSIGNALS, V16, P41, DOI 10.1159/000109758; Lace G, 2012, DEMENT GERIATR COGN, V34, P15, DOI 10.1159/000341581; Le Guennec K, 2017, MOL PSYCHIATR, V22, P1119, DOI 10.1038/mp.2016.226; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125; Lee SJ, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0173-3; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liberski PP, 2005, NEUROPATH APPL NEURO, V31, P88, DOI 10.1111/j.1365-2990.2004.00595.x; Lin WL, 2009, J NEUROPATH EXP NEUR, V68, P1167, DOI 10.1097/NEN.0b013e3181baacec; Lindstrom V, 2017, MOL CELL NEUROSCI, V82, P143, DOI 10.1016/j.mcn.2017.04.009; Ling H, 2016, BRAIN, V139, P3237, DOI 10.1093/brain/aww256; Lippa CF, 2000, ANN NEUROL, V48, P850, DOI 10.1002/1531-8249(200012)48:6<850::AID-ANA5>3.0.CO;2-V; Liu AKL, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0330-7; Lopez-Gonzalez I, 2013, BRAIN PATHOL, V23, P144, DOI 10.1111/j.1750-3639.2012.00627.x; MacDonald ST, 1996, NEURODEGENERATION, V5, P87; Mackenzie IR, 2017, ACTA NEUROPATHOL, V134, P79, DOI 10.1007/s00401-017-1716-8; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P111, DOI 10.1007/s00401-011-0845-8; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P87, DOI 10.1007/s00401-011-0838-7; Malkani R, 2006, NEUROBIOL DIS, V22, P401, DOI 10.1016/j.nbd.2005.12.001; Martinez-Maldonado A, 2016, NEUROPATH APPL NEURO, V42, P659, DOI 10.1111/nan.12339; MATTIACE LA, 1991, J NEUROPATH EXP NEUR, V50, P310; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Milenkovic I, 2013, CLIN NEUROPATHOL, V32, P69, DOI 10.5414/NP300515; Mori F, 2012, NEUROPATH APPL NEURO, V38, P322, DOI 10.1111/j.1365-2990.2011.01217.x; Mori F, 2002, EXP NEUROL, V176, P98, DOI 10.1006/exnr.2002.7929; Mori F, 2008, ACTA NEUROPATHOL, V115, P453, DOI 10.1007/s00401-007-0316-4; Munoz DG, 2007, ACTA NEUROPATHOL, V114, P347, DOI 10.1007/s00401-007-0266-x; Munoz DG, 2009, ACTA NEUROPATHOL, V118, P617, DOI 10.1007/s00401-009-0598-9; Nagele RG, 2003, BRAIN RES, V971, P197, DOI 10.1016/S0006-8993(03)02361-8; Nakamura K, 2016, NEUROPATHOLOGY, V36, P157, DOI 10.1111/neup.12243; Neumann M, 2001, ANN NEUROL, V50, P503, DOI 10.1002/ana.1223; Neumann M, 2007, J NEUROPATH EXP NEUR, V66, P177, DOI 10.1097/01.jnen.0000248554.45456.58; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Neumann M, 2011, BRAIN, V134, P2595, DOI 10.1093/brain/awr201; Neumann M, 2009, ACTA NEUROPATHOL, V118, P605, DOI 10.1007/s00401-009-0581-5; Neumann M, 2009, BRAIN, V132, P2922, DOI 10.1093/brain/awp214; NISHIMURA M, 1992, NEUROSCI LETT, V143, P35, DOI 10.1016/0304-3940(92)90227-X; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Oide T, 2006, NEUROPATH APPL NEURO, V32, P539, DOI 10.1111/j.1365-2990.2006.00767.x; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Piao YS, 2003, ACTA NEUROPATHOL, V105, P403, DOI 10.1007/s00401-002-0655-0; Pickering-Brown SM, 2004, BRAIN, V127, P1415, DOI 10.1093/brain/awh147; Plowey ED, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0388-2; Poorkaj P, 2002, ANN NEUROL, V52, P511, DOI 10.1002/ana.10340; PROBST A, 1988, ACTA NEUROPATHOL, V77, P61, DOI 10.1007/BF00688244; Reed LA, 1998, J NEUROPATH EXP NEUR, V57, P588, DOI 10.1097/00005072-199806000-00006; Ries M, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00160; Rohan Z, 2016, J NEUROPATH EXP NEUR, V75, P1100, DOI 10.1093/jnen/nlw087; Rohan Z, 2014, NEURODEGENER DIS, V14, P117, DOI 10.1159/000362929; Ros R, 2005, ARCH NEUROL-CHICAGO, V62, P1444, DOI 10.1001/archneur.62.9.1444; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Sakai K, 2006, ACTA NEUROPATHOL, V112, P341, DOI 10.1007/s00401-006-0093-5; Sakurai A, 2013, NEUROPATHOLOGY, V33, P673, DOI 10.1111/neup.12038; Santpere G, 2009, BRAIN PATHOL, V19, P177, DOI 10.1111/j.1750-3639.2008.00173.x; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Schultz C, 2000, J NEUROPATH EXP NEUR, V59, P39, DOI 10.1093/jnen/59.1.39; Schultz C, 1996, NEUROSCI LETT, V212, P103, DOI 10.1016/0304-3940(96)12787-7; Schultz C, 1999, EXP NEUROL, V160, P186, DOI 10.1006/exnr.1999.7185; Shibuya K, 2011, BRAIN RES, V1404, P50, DOI 10.1016/j.brainres.2011.06.014; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song YJC, 2009, J NEUROPATH EXP NEUR, V68, P1073, DOI 10.1097/NEN.0b013e3181b66f1b; Spillantini MG, 2000, ANN NEUROL, V48, P939; Spina S, 2007, ACTA NEUROPATHOL, V113, P461, DOI 10.1007/s00401-006-0182-5; Stanford PM, 2000, BRAIN, V123, P880, DOI 10.1093/brain/123.5.880; Surgucheva I, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0132-8; Tacik P, 2017, NEUROPATH APPL NEURO, V43, P200, DOI 10.1111/nan.12367; Tacik P, 2015, ACTA NEUROPATHOL, V130, P199, DOI 10.1007/s00401-015-1425-0; Terada S, 2000, ACTA NEUROPATHOL, V100, P464, DOI 10.1007/s004010000213; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x; Trojanowski JQ, 2007, NEUROPATH APPL NEURO, V33, P615, DOI 10.1111/j.1365-2990.2007.00907.x; Uryu K, 2008, J NEUROPATH EXP NEUR, V67, P555, DOI 10.1097/NEN.0b013e31817713b5; van Herpen E, 2003, ANN NEUROL, V54, P573, DOI 10.1002/ana.10721; Verkhratsky A, 2017, BRAIN PATHOL, V27, P629, DOI 10.1111/bpa.12537; Wakabayashi K, 2000, NEUROPATH APPL NEURO, V26, P477, DOI 10.1046/j.1365-2990.2000.00266-2.x; WAKABAYASHI K, 1994, ACTA NEUROPATHOL, V87, P545; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Walker AK, 2014, J NEUROSCI, V34, P6448, DOI 10.1523/JNEUROSCI.0248-14.2014; YAMADA T, 1990, NEUROSCI LETT, V120, P163, DOI 10.1016/0304-3940(90)90028-8; YAMADA T, 1992, NEUROSCI LETT, V135, P99, DOI 10.1016/0304-3940(92)90145-W; YAMADA T, 1993, ACTA NEUROPATHOL, V85, P308; YAMAZAKI M, 1994, ACTA NEUROPATHOL, V88, P587; Yoshida K, 2017, ACTA NEUROPATHOL, V133, P809, DOI 10.1007/s00401-016-1665-7; Yoshida M, 2014, NEUROPATHOLOGY, V34, P555, DOI 10.1111/neup.12143; Zarranz JJ, 2005, NEUROLOGY, V64, P1578, DOI 10.1212/01.WNL.0000160116.65034.12	174	47	47	1	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	SEP	2017	27	5					675	690		10.1111/bpa.12536			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	FD6MN	WOS:000407642700009	28805003	Green Accepted			2021-06-18	
J	Ganpule, S; Daphalapurkar, NP; Ramesh, KT; Knutsen, AK; Pham, DL; Bayly, PV; Prince, JL				Ganpule, Shailesh; Daphalapurkar, Nitin P.; Ramesh, Kaliat T.; Knutsen, Andrew K.; Pham, Dzung L.; Bayly, Philip V.; Prince, Jerry L.			A Three-Dimensional Computational Human Head Model That Captures Live Human Brain Dynamics	JOURNAL OF NEUROTRAUMA			English	Article						computational head model; DAI; human brain deformation	SPORTS-RELATED CONCUSSION; MATERIAL POINT METHOD; WHITE-MATTER; MECHANICAL-PROPERTIES; SOLID MECHANICS; AXONAL DAMAGE; FE MODEL; INJURY; TISSUE; IMPACT	Diffuse axonal injury (DAI) is a debilitating consequence of traumatic brain injury (TBI) attributed to abnormal stretching of axons caused by blunt head trauma or acceleration of the head. We developed an anatomically accurate, subjectspecific, three-dimensional (3D) computational model of the human brain, and used it to study the dynamic deformations in the substructures of the brain when the head is subjected to rotational accelerations. The computational head models use anatomy and morphology of the white matter fibers obtained using MRI. Subject-specific full-field shearing motions in live human brains obtained through a recently developed tagged MRI imaging technique are then used to validate the models by comparing the measured and predicted heterogeneous dynamic mechanical response of the brain. These results are used to elucidate the dynamics of local shearing deformations in the brain substructures caused by rotational acceleration of the head. Our work demonstrates that the rotational dynamics of the brain has a timescale of similar to 100 ms as determined by the shearing wave speeds, and thus the injuries associated with rotational accelerations likely occur over these time scales. After subject-specific validation using the live human subject data, a representative subject-specific head model is used to simulate a real life scenario that resulted in a concussive injury. Results suggest that regions of the brain, in the form of a toroid, encompassing the white matter, the cortical gray matter, and outer parts of the limbic system have a higher susceptibility to injury under axial rotations of the head.	[Ganpule, Shailesh; Daphalapurkar, Nitin P.; Ramesh, Kaliat T.] Johns Hopkins Univ, Hopkins Extreme Mat Inst, Baltimore, MD 21218 USA; [Knutsen, Andrew K.; Pham, Dzung L.] Henry M Jackson Fdn Adv Mil Med, Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Bayly, Philip V.] Washington Univ, Dept Mech Engn, St Louis, MO 63130 USA; [Prince, Jerry L.] Johns Hopkins Univ, Dept Elect & Comp Engn, Baltimore, MD 21218 USA	Ganpule, S (corresponding author), Johns Hopkins Univ, Hopkins Extreme Mat Inst, Baltimore, MD 21218 USA.	sganpull@jhu.edu	Daphalapurkar, Nitin/B-4397-2011; Pham, Dzung/AAR-8263-2020	Daphalapurkar, Nitin/0000-0001-5523-8874; 	National Institute of Neurological Disorders and Strokes, National Institutes of Health [R01NS055951]; Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	S.G. acknowledges Dr. Fangxu Xing for useful discussions regarding the HARP algorithm, and Amy Dagro for assistance in proofreading the manuscript. The authors acknowledge funding from the National Institute of Neurological Disorders and Strokes, National Institutes of Health (Project # R01NS055951). This work was partially supported by the Department of Defense in the Center for Neuroscience and Regenerative Medicine.	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bardenhagen SG, 2002, J COMPUT PHYS, V180, P383, DOI 10.1006/jcph.2002.7103; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazin PL, 2008, MED IMAGE ANAL, V12, P616, DOI 10.1016/j.media.2008.06.008; Budday S, 2017, ACTA BIOMATER, V48, P319, DOI 10.1016/j.actbio.2016.10.036; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cole R.H., 1948, PHYS TODAY, V1, P35, DOI [10.1063/1.3066176, DOI 10.1063/1.3066176]; Daphalapurkar NP, 2008, MECH ADV MATER STRUC, V15, P594, DOI 10.1080/15376490802470523; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Fung Y. C., 2013, BIOMECHANICS MECH PR; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Garo A, 2007, BIORHEOLOGY, V44, P51; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Guilkey JE, 2006, J BIOMECH, V39, P2074, DOI 10.1016/j.jbiomech.2005.06.017; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Herweh C, 2016, NEURORADIOLOGY, V58, P911, DOI 10.1007/s00234-016-1705-y; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ionescu I, 2006, J BIOMECH ENG-T ASME, V128, P917, DOI 10.1115/1.2372490; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Knutsen AK, 2014, J BIOMECH, V47, P3475, DOI 10.1016/j.jbiomech.2014.09.010; Lee SJ, 2014, J MECH BEHAV BIOMED, V29, P213, DOI 10.1016/j.jmbbm.2013.08.026; Legates DR, 1999, WATER RESOUR RES, V35, P233, DOI 10.1029/1998WR900018; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Moriasi DN, 2007, T ASABE, V50, P885, DOI 10.13031/2013.23153; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nairn JA, 2003, CMES-COMP MODEL ENG, V4, P649; Newman J A, 2000, Stapp Car Crash J, V44, P215; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PIERPAOLI C, 2010, ISMRM P, V18, P1597; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Romano A, 2012, MAGN RESON MED, V68, P1410, DOI 10.1002/mrm.24141; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Sadeghirad A, 2011, INT J NUMER METH ENG, V86, P1435, DOI 10.1002/nme.3110; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stalnaker R, 1969, THESIS; Sulsky D, 2004, EUR J MECH A-SOLID, V23, P423, DOI 10.1016/j.euromechsol.2004.02.007; SULSKY D, 1995, COMPUT PHYS COMMUN, V87, P236, DOI 10.1016/0010-4655(94)00170-7; Takhounts EG, 2008, STAPP CAR C, V52, P1; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Willmott CJ, 2012, INT J CLIMATOL, V32, P2088, DOI 10.1002/joc.2419; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	71	47	48	3	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2154	2166		10.1089/neu.2016.4744			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400454	28394205	Green Published			2021-06-18	
J	Majdan, M; Plancikova, D; Maas, A; Polinder, S; Feigin, V; Theadom, A; Rusnak, M; Brazinova, A; Haagsma, J				Majdan, Marek; Plancikova, Dominika; Maas, Andrew; Polinder, Suzanne; Feigin, Valery; Theadom, Alice; Rusnak, Martin; Brazinova, Alexandra; Haagsma, Juanita			Years of life lost due to traumatic brain injury in Europe: A cross-sectional analysis of 16 countries	PLOS MEDICINE			English	Article							GLOBAL BURDEN; EPIDEMIOLOGY; NEUROTRAUMA; DISEASE; IMPACT	Introduction Traumatic brain injuries (TBIs) are a major public health, medical, and societal challenge globally. They present a substantial burden to victims, their families, and the society as a whole. Although indicators such as incidence or death rates provide insight into the occurrence and outcome of TBIs in various populations, they fail to quantify the full extent of their public health and societal impact. Measures such as years of life lost (YLLs), which quantifies the number of years of life lost because the person dies prematurely due to a disease or injury, should be employed to better quantify the population impact. The aim of this study was to provide an in-depth analysis of the burden of deaths due to TBI by calculating TBI-specific YLLs in 16 European countries, analyzing their main causes and demographic patterns, using data extracted from death certificates under unified guidelines and collected in a standardized manner. Methods and findings A population-wide, cross-sectional epidemiological study was conducted in 16 European countries to estimate TBI YLLs for the year 2013. The data used for all analyses in this study were acquired from the statistical office of the European Union (Eurostat). A specifically tailored dataset of micro-level data was provided that listed the external cause of death (International Classification of Diseases-10th Revision [ICD-10] codes V01-Y98), the specific nature of injury (ICD-10 codes S00-T98), the age at death, and sex for each death. Overall number of TBI YLLs, crude and age-standardized TBI YLL rates, and TBI YLLs per case were calculated stratified for country, sex, and age. Pooled analyses were performed in order to estimate summary age-standardized rates of TBI YLLs. In order to evaluate the relative importance of TBI in the context of all injuries, proportions of TBI YLLs out of overall injury YLLs were calculated. The total number of TBI YLLs was estimated by extrapolating the pooled crude rate of TBI YLLs in the 16 analyzed countries to the total population of the 28 member states of the EU (EU-28). We found that a total of 17,049 TBI deaths occurred in 2013 in the 16 analyzed countries. These translated into a total of 374,636 YLLs. The pooled age-standardized rate of YLLs per 100,000 people per year was 259.1 (95% CI: 205.8 to 312.3) overall, 427.5 (95% CI: 290.0 to 564.9) in males, and 105.4 (95% CI: 89.1 to 121.6) in females. Males contributed substantially more to TBI YLLs than females (282,870 YLLs, 76% of all TBI YLLs), which translated into a rate ratio of 3.24 (95% CI: 3.22 to 3.27). Each TBI death was on average associated with 24.3 (95% CI: 22.0 to 26.6) YLLs overall, 25.6 (95% CI: 23.4 to 27.8) in males and 20.9 (17.9 to 24.0) in females. Falls and traffic crashes were the most common external causes of TBI YLLs. TBI contributed on average 41% (44% in males and 34% in females) to overall injury YLLs. Extrapolating our findings, about 1.3 million YLLs were attributable to TBI in the EU-28 in 2013 overall, 1.1 million in males and 271,000 in females. This study is based on administratively collected data from 16 countries, and despite the efforts to harmonize them to the greatest possible extent, there may be differences in coding practices or reporting between countries. If present, these would be inherited into our findings without our ability to control for them. The extrapolation of the pooled rates from the 16 countries to the EU-28 should be interpreted with caution. Conclusions Our study showed that TBI-related deaths and YLLs have a substantial impact at the individual and population level in Europe and present an important societal and economic burden that must not be overlooked. We provide information valuable for policy-makers, enabling them to evaluate and plan preventive activities and resource allocation, and to formulate and implement strategic decisions. In addition, our results can serve as a basis for analyzing the overall burden of TBI in the population.	[Majdan, Marek; Plancikova, Dominika; Rusnak, Martin; Brazinova, Alexandra] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, Slovakia; [Maas, Andrew] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew] Univ Antwerp, Edegem, Belgium; [Polinder, Suzanne; Haagsma, Juanita] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Feigin, Valery; Theadom, Alice] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Haagsma, Juanita] Erasmus Univ, Med Ctr, Dept Emergency Med, Rotterdam, Netherlands	Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, Slovakia.	mmajdan@truni.sk	Maas, Andrew IR/C-5584-2013; Majdan, Marek/K-5017-2012; Brazinova, Alexandra/C-4265-2016; Feigin, Valery/AAF-2313-2019; Rusnak, Martin/K-9349-2016	Maas, Andrew IR/0000-0003-1612-1264; Majdan, Marek/0000-0001-8037-742X; Brazinova, Alexandra/0000-0003-0625-256X; Feigin, Valery L./0000-0002-6372-1740; Rusnak, Martin/0000-0003-3321-1042	European Union Seventh Framework Programme (FP7) [602150]	This study was conducted within the project Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement number 602150. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], CAUS DEATH HLTH CDEA; Ao BT, 2015, NEUROEPIDEMIOLOGY, V44, P255, DOI 10.1159/000431043; Borenstein M., 2009, INTRO METAANALYSIS; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Brooks JC, 2015, ARCH PHYS MED REHAB, V96, P1000, DOI 10.1016/j.apmr.2015.02.002; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Eurostat, CAUS OF DEATH; Eurostat, POPULATION; Eurostat, 2013, REV EUR STAND POP RE; Eurostat, LIF TABL; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Majdan M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008672; Mauritz W, 2014, WIEN KLIN WOCHENSCHR, V126, P42, DOI 10.1007/s00508-013-0456-6; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Statistics New Zealand, HISTORICAL POPULATIO; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746	27	47	47	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	JUL	2017	14	7							e1002331	10.1371/journal.pmed.1002331			19	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200006	28700588	DOAJ Gold, Green Published			2021-06-18	
J	Tian, H; Sparvero, LJ; Amoscato, AA; Bloom, A; Bayir, H; Kagan, VE; Winograd, N				Tian, Hua; Sparvero, Louis J.; Amoscato, Andrew A.; Bloom, Anna; Bayir, Hulya; Kagan, Valerian E.; Winograd, Nicholas			Gas Cluster Ion Beam Time-of-Flight Secondary Ion Mass Spectrometry High-Resolution Imaging of Cardiolipin Speciation in the Brain: Identification of Molecular Losses after Traumatic Injury	ANALYTICAL CHEMISTRY			English	Article							SIALIC-ACID ESTERIFICATION; MALDI-TOF-MS; AR CLUSTER; GANGLIOSIDES; IONIZATION; SIMS; BIOSYNTHESIS; MITOCHONDRIA; HIPPOCAMPUS; SECTIONS	Gas cluster ion beam-secondary ion mass spectrometry (GCIB-SIMS) has shown the full potential of mapping intact lipids in biological systems with better than 10 mu m lateral resolution. This study investigated further the capability of GCIB-SIMS in imaging high-mass signals from intact cardiolipin (CL) and gangliosides in normal brain and the effect of a controlled cortical impact model (CCI) of traumatic brain injury (TBI) on their distribution. A combination of enzymatic and chemical treatments was employed to suppress the signals from the most abundant phospholipids (phosphatidylcholine (PC) and phosphatidylethanolamine (PE)) and enhance the signals from the low abundance CLs and gangliosides to allow their GCIB-SIMS detection at 8 and 16 mu m spatial resolution. Brain CLs have not been observed previously using other contemporary imaging mass spectrometry techniques at better than 50 mu m spatial resolution. High-resolution images of naive and injured brain tissue facilitated the comparison of CL species across three multicell layers in the CA1, CA3, and DG regions of the hippocampus. GCIB-SIMS also reliably mapped losses of oxidizable polyunsaturated CL species (but not the oxidation-resistant saturated and monounsaturated gangliosides) to regions including the CA and CA3 of the hippocampus after CCI. This work extends the detection range for SIMS measurements of intact lipids to above m/z 2000, bridging the mass range gap compared with MALDI. Further advances in high-resolution SIMS of CLs, with the potential for single cell or supra-cellular imaging, will be essential for the understanding of CL's functional and structural organization in normal and injured brain.	[Tian, Hua; Bloom, Anna; Winograd, Nicholas] Penn State Univ, Dept Chem, State Coll, PA 16802 USA; [Sparvero, Louis J.; Amoscato, Andrew A.; Bayir, Hulya; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Kagan, Valerian E.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; [Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Kagan, Valerian E.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15260 USA; [Sparvero, Louis J.; Amoscato, Andrew A.; Bayir, Hulya; Kagan, Valerian E.] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Bayir, Hulya] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bayir, Hulya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Tian, H (corresponding author), Penn State Univ, Dept Chem, State Coll, PA 16802 USA.	hut3@psu.edu	Tian, Hua/C-5684-2019	Tian, Hua/0000-0002-3598-0219; Kagan, Valerian E./0000-0002-7245-1885	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01GM113746-21, NS061817, NS076511, P01HL114453, U19AI068021]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL114453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM113746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076511, R01NS061817] Funding Source: NIH RePORTER	This work was supported by NIH Grants 5R01GM113746-21, NS061817, NS076511, P01HL114453, and U19AI068021	Amoscato AA, 2014, ANAL CHEM, V86, P6587, DOI 10.1021/ac5011876; Angerer TB, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4941064; Angerer TB, 2015, ANAL CHEM, V87, P4305, DOI 10.1021/ac504774y; Angerer TB, 2015, INT J MASS SPECTROM, V377, P591, DOI 10.1016/j.ijms.2014.05.015; Aoyagi S, 2013, ANAL BIOANAL CHEM, V405, P6621, DOI 10.1007/s00216-013-7139-z; Bladergroen MR, 2015, J PROTEOME RES, V14, P4080, DOI 10.1021/acs.jproteome.5b00538; BLAIN MG, 1990, J VAC SCI TECHNOL A, V8, P2265, DOI 10.1116/1.576748; Cherubini E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00019; Claypool SM, 2012, TRENDS BIOCHEM SCI, V37, P32, DOI 10.1016/j.tibs.2011.09.003; Colsch B, 2010, GLYCOBIOLOGY, V20, P661, DOI 10.1093/glycob/cwq031; Davies N, 2003, APPL SURF SCI, V203, P223, DOI 10.1016/S0169-4332(02)00631-1; Eibisch M, 2011, RAPID COMMUN MASS SP, V25, P2619, DOI 10.1002/rcm.5161; Feider CL, 2016, ANAL CHEM, V88, P11533, DOI 10.1021/acs.analchem.6b02798; Hill R, 2006, APPL SURF SCI, V252, P7304, DOI 10.1016/j.apsusc.2006.02.211; Hill R, 2011, SURF INTERFACE ANAL, V43, P506, DOI 10.1002/sia.3562; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hussein A A W, 2009, J FM BAGHDAD, V51, P323; Jansen BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23296; Jerigova M, 2011, MOL IMAGING BIOL, V13, P1067, DOI 10.1007/s11307-010-0460-4; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kagan VE, 2009, FREE RADICAL BIO MED, V46, P1439, DOI 10.1016/j.freeradbiomed.2009.03.004; Kollmer F, 2004, APPL SURF SCI, V231, P153, DOI 10.1016/j.apsusc.2004.03.101; Kolter T., 2012, ISRN BIOCH, V2012, DOI DOI 10.5402/2012/506160; Kooijman EE, 2017, BBA-BIOMEMBRANES, V1859, P61, DOI 10.1016/j.bbamem.2016.10.013; Maguire JJ, 2017, BBA-MOL CELL BIOL L, V1862, P8, DOI 10.1016/j.bbalip.2016.08.001; Matsuo J, 2014, APPL PHYS EXPRESS, V7, DOI 10.7567/APEX.7.056602; Ninomiya S, 2009, RAPID COMMUN MASS SP, V23, P3264, DOI 10.1002/rcm.4250; Ninomiya S, 2009, RAPID COMMUN MASS SP, V23, P1601, DOI 10.1002/rcm.4046; Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159; Rabbani S, 2011, ANAL CHEM, V83, P3793, DOI 10.1021/ac200288v; Reiding KR, 2014, ANAL CHEM, V86, P5784, DOI 10.1021/ac500335t; Roux A, 2016, J NEUROSCI METH, V272, P19, DOI 10.1016/j.jneumeth.2016.02.004; Schlame M, 2008, J LIPID RES, V49, P1607, DOI 10.1194/jlr.R700018-JLR200; Sparvero LJ, 2016, J NEUROCHEM, V139, P659, DOI 10.1111/jnc.13840; Steenackers A, 2012, MOLECULES, V17, P9559, DOI 10.3390/molecules17089559; Tian H, 2016, J AM SOC MASS SPECTR, V27, P2014, DOI 10.1007/s13361-016-1492-z; Tian H, 2016, J AM SOC MASS SPECTR, V27, P1476, DOI 10.1007/s13361-016-1423-z; Tian H, 2014, SURF INTERFACE ANAL, V46, P115, DOI 10.1002/sia.5509; Tyurina YY, 2014, NAT CHEM, V6, P542, DOI [10.1038/nchem.1924, 10.1038/NCHEM.1924]; Vickerman J, 2013, CLUSTER SECONDARY IO, P269, DOI DOI 10.1002/9781118589335.CH8; Wang HYJ, 2007, J AM SOC MASS SPECTR, V18, P567, DOI 10.1016/j.jasms.2006.10.023; Yamada I, 2001, MAT SCI ENG R, V34, P231, DOI 10.1016/S0927-796X(01)00034-1; Yu RK, 2011, J OLEO SCI, V60, P537, DOI 10.5650/jos.60.537; Zarei M, 2008, J MASS SPECTROM, V43, P716, DOI 10.1002/jms.1367	44	47	47	2	42	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	APR 18	2017	89	8					4611	4619		10.1021/acs.analchem.7b00164			9	Chemistry, Analytical	Chemistry	ES9EL	WOS:000399858800044	28306235	Green Accepted			2021-06-18	
J	Barlow, KM; Marcil, LD; Dewey, D; Carlson, HL; MacMaster, FP; Brooks, BL; Lebel, RM				Barlow, Karen M.; Marcil, Lorenzo D.; Dewey, Deborah; Carlson, Helen L.; MacMaster, Frank P.; Brooks, Brian L.; Lebel, R. Marc			Cerebral Perfusion Changes in Post-Concussion Syndrome: A Prospective Controlled Cohort Study	JOURNAL OF NEUROTRAUMA			English	Article						arterial spin labeling; cerebral blood flow; pediatric brain injury; recovery; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DEFICIT HYPERACTIVITY DISORDER; SPORTS-RELATED CONCUSSION; BLOOD-FLOW; POSTCONCUSSION SYNDROME; VASCULAR INJURY; STRESS TEST; MILD TBI; CHILDREN; SYMPTOMS	The biology of post-concussive symptoms is unclear. Symptoms are often increased during activities, and have been linked to decreased cerebrovascular reactivity and perfusion. The aim of this study was to examine cerebral blood flow (CBF) in children with different clinical recovery patterns following mild traumatic brain injury (mTBI). This was a prospective controlled cohort study of children with mTBI (ages 8 to 18 years) who were symptomatic with post-concussive symptoms at one month post-injury (symptomatic, n=27) and children who had recovered quickly (asymptomatic, n=24). Pseudo continuous arterial spin labeling magnetic resonance imaging (MRI) was used to quantify CBF. The mTBI groups were imaged at 40 days post-injury. Global and regional CBF were compared with healthy controls of similar age and sex but without a history of mTBI (n=21). Seventy-two participants (mean age: 14.1 years) underwent neuroimaging. Significant differences in CBF were found: global CBF was higher in the symptomatic group and lower in the asymptomatic group compared with controls, (F(2,69) 9.734; p<0.001). Post-injury symptom score could be predicted by pre-injury symptoms and CBF in presence of mTBI (adjusted R-2=0.424; p<0.001). Altered patterns of cerebral perfusion are seen following mTBI and are associated with the recovery trajectory. Symptomatic children have higher CBF. Children who recovered quickly, have decreased CBF suggesting that clinical recovery precedes the cerebral recovery. Further longitudinal studies are required to determine if these perfusion patterns continue to change over time.	[Barlow, Karen M.; Dewey, Deborah; MacMaster, Frank P.; Brooks, Brian L.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Barlow, Karen M.; Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Marcil, Lorenzo D.] Univ Calgary, Hlth Sci, Calgary, AB, Canada; [Dewey, Deborah] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [MacMaster, Frank P.] Univ Calgary, Dept Psychiat, Calgary, AB, Canada; [Lebel, R. Marc] Univ Calgary, Dept Radiol, Calgary, AB, Canada; [Lebel, R. Marc] Univ Calgary, Biomed Engn, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Barlow, Karen M.; Dewey, Deborah; Carlson, Helen L.; MacMaster, Frank P.; Brooks, Brian L.; Lebel, R. Marc] Alberta Childrens Prov Gen Hosp, Res Inst, Calgary, AB, Canada; [Carlson, Helen L.; Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [MacMaster, Frank P.] Alberta Hlth Serv, Strateg Clin Network Addict & Mental Hlth, Edmonton, AB, Canada; [MacMaster, Frank P.] Hotchkiss Brain Inst, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada; [Lebel, R. Marc] GE Healthcare, Calgary, AB, Canada	Barlow, KM (corresponding author), Univ Calgary, Alberta Childrens Hosp, Neurol Sect, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	Karen.Barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Carlson, Helen/0000-0002-5788-0542; Dewey, Deborah/0000-0002-1323-5832; Barlow, Karen/0000-0003-2612-8507; MacMaster, Frank/0000-0002-7159-7583	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [293375]; Faculty of Medicine, University of Calgary; Markin Undergraduate Student Research Program, University of Calgary	Drs. Barlow, Dewey, MacMaster, and Mr. Marcil have no competing financial interests. Dr. Brooks receives royalties for the sales of a pediatric forensic textbook (Oxford University Press) and pediatric neuropsychological tests (PAR Inc.). He has previously received support (in-kind test credits) from CNS Vital Signs. Dr. Lebel is a stakeholder in GE Healthcare. This study was funded by the Canadian Institutes of Health Research (grant number: 293375); the Faculty of Medicine, University of Calgary; and the Markin Undergraduate Student Research Program, University of Calgary. These funding sources had no role in the design of this study and did not have any role during its execution, analyses, interpretation of the data, or decision to submit results. The design, management, analysis, and reporting of the study were entirely independent of any manufacturers of melatonin.	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2014, J NEUROTRAUM, V31, pA59; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Barlow KM, 2016, J CHILD NEUROL, V31, P57, DOI 10.1177/0883073814543305; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Bodin D, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P9, DOI 10.1007/978-0-387-89545-1_2; Brooks BL, 2014, J NEUROTRAUM, V31, P1744, DOI 10.1089/neu.2014.3356; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Brooks BL, 2011, J CHILD NEUROL, V26, P786, DOI 10.1177/0883073810391532; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Churchill N, 2016, J NEUROTRAUMA; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gioia GA, 2008, J INT NEUROPSYCH SOC, V14, P204; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Heyer GL, 2016, CLIN J SPORT MED, V26, P40, DOI 10.1097/JSM.0000000000000183; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kim BN, 2010, J PSYCHIATR NEUROSCI, V35, P330, DOI 10.1503/jpn.090168; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Ku D. N., 1993, HEMODYNAMIC FORCES V; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Lorberboym M, 2004, J CHILD NEUROL, V19, P91, DOI 10.1177/08830738040190020201; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Metting Z, 2014, BRAIN COGNITION, V86, P24, DOI 10.1016/j.bandc.2014.01.012; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Petcharunpaisan S, 2010, WORLD J RADIOL, V2, P384, DOI 10.4329/wjr.v2.i10.384; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Urban KJ, 2014, J NEUROTRAUM, V31, pA64; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Venkat P, 2016, CROAT MED J, V57, P223, DOI 10.3325/cmj.2016.57.223; Wang J, 2006, NEUROIMAG CLIN N AM, V16, P149, DOI 10.1016/j.nic.2005.10.002; Wang JJ, 2003, J MAGN RESON IMAGING, V18, P404, DOI 10.1002/jmri.10372; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Wang Y, 2011, NEUROIMAGE, V54, P1188, DOI 10.1016/j.neuroimage.2010.08.043; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	53	47	47	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2017	34	5					996	1004		10.1089/neu.2016.4634			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EM6EI	WOS:000395405200004	27554429	Green Published, Bronze			2021-06-18	
J	Yorke, AM; Smith, L; Babcock, M; Alsalaheen, B				Yorke, Amy M.; Smith, Laura; Babcock, Mitch; Alsalaheen, Bara			Validity and Reliability of the Vestibular/Ocular Motor Screening and Associations With Common Concussion Screening Tools	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; vestibular; balance; ocular motor	SPORT-RELATED CONCUSSION; ERROR SCORING SYSTEM; KING-DEVICK TEST; FOOTBALL PLAYERS; REHABILITATION; MANAGEMENT; EPIDEMIOLOGY; CONVERGENCE; ADOLESCENTS; STATEMENT	Background: Sustaining a concussion commonly results in vestibular impairments that may be associated with balance deficits. To screen for vestibular impairments after a concussion, the Vestibular/Ocular Motor Screening (VOMS) tool was developed. The relationship between the VOMS and other concussion screening tools, such as the Balance Error Scoring System (BESS) and King-Devick (K-D), have not been explored. Hypotheses: (1) VOMS would provide reliable results and not provoke symptoms in healthy adolescents and (2) VOMS test items would measure related aspects of vestibular function that are not measured through the BESS or K-D. Study Design: Cross-sectional, descriptive. Methods: A total of 105 healthy adolescents (53 male, 52 female; mean age, 15.4 years) completed the VOMS, BESS, and K-D tests. A subsample of 21 adolescents (16 male, 5 female; mean age, 15.5 years) completed the VOMS twice. Results: The median total symptom score for all 7 VOMS items was 0 (0- 5). The majority of the individual VOMS test items total symptom scores demonstrated a significant correlation with each other (r(s) = 0.25-0.66, P < 0.02). The individual VOMS items did not demonstrate a significant relationship to the BESS or K-D. VOMS items demonstrated high agreement in total symptom scores between testing trials, with near point convergence (NPC) distance demonstrating an intraclass correlation coefficient (ICC) of 0.95 (95% CI, 0.89-0.98; P < 0.001). The MDC95 (minimal detectable change with 95 confidence) for NPC distance was 4 cm. Conclusion: The VOMS did not provoke vestibular symptoms in healthy adolescents. The VOMS items measured unique aspects of vestibular function other than those measured by the BESS or K-D with good reliability.	[Yorke, Amy M.; Smith, Laura; Babcock, Mitch; Alsalaheen, Bara] Univ Michigan Flint, Phys Therapy Dept, 303 East Kearsley,2157 William S White, Flint, MI 48502 USA; [Alsalaheen, Bara] Univ Michigan Ann Arbor, Dept Neurol, Ann Arbor, MI USA; [Alsalaheen, Bara] Univ Michigan Hlth Syst, Michigan NeuroSport, Ann Arbor, MI USA	Alsalaheen, B (corresponding author), Univ Michigan Flint, Phys Therapy Dept, 303 East Kearsley,2157 William S White, Flint, MI 48502 USA.	alsalahe@umflint.edu	Yorke, Amy/Q-4091-2019	Yorke, Amy/0000-0003-4998-0313			Alsalaheen B, 2016, SCAND J MED SCI SPOR, V26, P235, DOI 10.1111/sms.12628; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2015, PHYSICIAN SPORTSMED, V43, P221, DOI 10.1080/00913847.2015.1040717; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Dhawan PSA, 2014, NEUROL CLIN PRACT, V82, pS11; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta K.M., 2016, CONCUSSION, V1, pCNC8; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Kandel ER, 2000, PRINCIPLES NEURAL SC; Khanna NK, 2015, SPORTS HEALTH, V7, P341, DOI 10.1177/1941738115571508; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Portney LG, 2009, FDN CLIN RES APPL PR; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E	37	47	47	1	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2017	9	2					174	180		10.1177/1941738116678411			7	Sport Sciences	Sport Sciences	EY5WQ	WOS:000404052200011	27834667	Green Published			2021-06-18	
J	Garcia-Mesa, Y; Jay, TR; Checkley, MA; Luttge, B; Dobrowolski, C; Valadkhan, S; Landreth, GE; Karn, J; Alvarez-Carbonell, D				Garcia-Mesa, Yoelvis; Jay, Taylor R.; Checkley, Mary Ann; Luttge, Benjamin; Dobrowolski, Curtis; Valadkhan, Saba; Landreth, Gary E.; Karn, Jonathan; Alvarez-Carbonell, David			Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system	JOURNAL OF NEUROVIROLOGY			English	Article						Microglia; HIV regulation; HIV-associated neurocognitive disorders; NeuroAIDS	HUMAN-IMMUNODEFICIENCY-VIRUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; AIDS DEMENTIA COMPLEX; INFLAMMATORY FACTOR-I; ACIDIC PROTEIN GFAP; LARGE T-ANTIGEN; NF-KAPPA-B; RAMIFIED MICROGLIA; CELL-LINES	The major reservoirs for HIV in the CNS are in the microglia, perivascular macrophages, and to a lesser extent, astrocytes. To study the molecular events controlling HIV expression in the microglia, we developed a reliable and robust method to immortalize microglial cells from primary glia from fresh CNS tissues and commercially available frozen glial cells. Primary human cells, including cells obtained from adult brain tissue, were transformed with lentiviral vectors expressing SV40 T antigen or a combination of SVR40 T antigen and hTERT. The immortalized cells have microglia-like morphology and express key microglial surface markers including CD11b, TGF beta R, and P2RY12. Importantly, these cells were confirmed to be of human origin by sequencing. The RNA expression profiles identified by RNA-seq are also characteristic of microglial cells. Furthermore, the cells demonstrate the expected migratory and phagocytic activity, and the capacity to mount an inflammatory response characteristic of primary microglia. The immortalization method has also been successfully applied to a wide range of microglia from other species (macaque, rat, and mouse). To investigate different aspects of HIV molecular regulation in CNS, the cells have been superinfected with HIV reporter viruses and latently infected clones have been selected that reactive HIV in response to inflammatory signals. The cell lines we have developed and rigorously characterized will provide an invaluable resource for the study of HIV infection in microglial cells as well as studies of microglial cell function.	[Garcia-Mesa, Yoelvis; Checkley, Mary Ann; Luttge, Benjamin; Dobrowolski, Curtis; Karn, Jonathan; Alvarez-Carbonell, David] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; [Jay, Taylor R.; Landreth, Gary E.] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; [Valadkhan, Saba] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Alvarez-Carbonell, D (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.	yxg146@case.edu; trj29@case.edu; mxc567@case.edu; bxl244@case.edu; cxd108@case.edu; sxv46@case.edu; ge12@case.edu; jxk153@case.edu; dxa150@case.edu	Valadkhan, Saba/G-7271-2012	dobrowolski, Curtis/0000-0001-6576-8318; Jay, Taylor/0000-0003-3878-7059; Valadkhan, Saba/0000-0002-6859-4883	 [R01 DA036171];  [DP1 DA028869]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [DP1DA028869, R01DA036171] Funding Source: NIH RePORTER	We thank past and present members of the Karn laboratory: Stephanie Milne, Biswajit Das, Uri Mbonye, Kien Nguyen, Meenakshi Shukla, Paul Wille, Amy Graham, Julia Freedman, Julian Wong, Hongxia Mao, and Michael Greenberg for gifts of the materials, help, and useful discussions. We also thank Kamel Khalili (Temple), Brandon Harvey (NIDA), Kurt Hauser (VCU), and Janice Clements (JHU) for the useful discussions and materials. We thank Scott J. Howell (CWRU Visual Sciences) for the help with the time-lapse experiments, the CWRU Genomics Core for the RNA sequencing services, and the CWRU/UH Center for AIDS Research (P30 AI36219) for the flow cytometry services. This work was supported by R01 DA036171 and DP1 DA028869 (JK).	Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Alvarez-Carbonell D, 2016, TOLL LIKE RECE UNPUB; Babas T, 2003, J VIROL, V77, P208, DOI 10.1128/JVI.77.1.208-216.2003; Banati RB, 2003, BRIT MED BULL, V65, P121, DOI 10.1093/bmb/65.1.121; Becher B, 1996, GLIA, V18, P1; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; BOOTH PL, 1991, BRAIN RES, V548, P163, DOI 10.1016/0006-8993(91)91118-K; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Carrol ED, 2007, JAIDS-J ACQ IMM DEF, V44, P443, DOI 10.1097/QAI.0b013e31802f8390; Chugh P, 2007, J MOL BIOL, V366, P67, DOI 10.1016/j.jmb.2006.11.011; Churchill MJ, 2009, ANN NEUROL, V66, P253, DOI 10.1002/ana.21697; CONANT K, 1994, ADV NEUROIMMUNOL, V4, P287, DOI 10.1016/S0960-5428(06)80269-X; Darmanis S, 2015, P NATL ACAD SCI USA, V112, P7285, DOI 10.1073/pnas.1507125112; Dissing-Olesen L, 2007, NEUROSCIENCE, V149, P112, DOI 10.1016/j.neuroscience.2007.06.037; Dominguez E, 2008, J NEUROCHEM, V107, P50, DOI 10.1111/j.1471-4159.2008.05566.x; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Etemad S, 2012, J NEUROSCI METH, V209, P79, DOI 10.1016/j.jneumeth.2012.05.025; Eugenin EA, 2007, J NEUROSCI, V27, P12844, DOI 10.1523/JNEUROSCI.4154-07.2007; Eyo UB, 2013, J NEUROIMMUNE PHARM, V8, P494, DOI 10.1007/s11481-013-9434-z; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Fonken LK, 2015, BRAIN BEHAV IMMUN, V45, P171, DOI 10.1016/j.bbi.2014.11.009; FORD AL, 1995, J IMMUNOL, V154, P4309; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gorry PR, 2003, CURR HIV RES, V1, P463, DOI 10.2174/1570162033485122; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hazleton JE, 2010, HIV AIDS-RES PALLIAT, V2, P39; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hinojosa AE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-77; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Hu WH, 2014, P NATL ACAD SCI USA, V111, P11461, DOI 10.1073/pnas.1405186111; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; Jadhav VS, 2014, J NEUROCHEM, V131, P803, DOI 10.1111/jnc.12933; Janabi N, 1998, GLIA, V23, P304; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Johnson EA, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-41; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kaminska B, 2015, BIOCH BIOPHYS ACTA; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khorooshi R, 2015, ACTA NEUROPATHOL, V130, P107, DOI 10.1007/s00401-015-1418-z; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Kim YK, 2006, EMBO J, V25, P3596, DOI 10.1038/sj.emboj.7601248; Kothur K, 2016, CYTOKINE, V77, P227, DOI 10.1016/j.cyto.2015.10.001; Kowal K, 2011, FOLIA HISTOCHEM CYTO, V49, P365, DOI 10.5603/FHC.2011.0052; KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X; Lane BR, 2001, J VIROL, V75, P8195, DOI 10.1128/JVI.75.17.8195-8202.2001; Lee KM, 2004, CYTOTECHNOLOGY, V45, P33, DOI [10.1007/10.1007/s10616-004-5123-3, 10.1007/s10616-004-5123-3]; LEE SHC, 1993, AM J PATHOL, V143, P1032; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Lisi L, 2015, J NEUROCHEM; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Martin S, 2003, J NEUROSCI, V23, P1198; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nagai A, 2005, J NEUROSCI RES, V81, P342, DOI 10.1002/jnr.20478; Nagai A, 2001, NEUROBIOL DIS, V8, P1057, DOI 10.1006/nbdi.2001.0437; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Parajuli B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-268; Paris JJ, 2015, BEHAV BRAIN RES, V291, P209, DOI 10.1016/j.bbr.2015.05.021; Pearson R, 2008, J VIROL, V82, P12291, DOI 10.1128/JVI.01383-08; PERESS NS, 1993, J NEUROIMMUNOL, V48, P71, DOI 10.1016/0165-5728(93)90060-C; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Rawat P, 2016, J NEUROVIROL; Roberts ES, 2004, J NEUROPATH EXP NEUR, V63, P1255, DOI 10.1093/jnen/63.12.1255; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; ROESSMANN U, 1980, BRAIN RES, V200, P13, DOI 10.1016/0006-8993(80)91090-2; Sanchez-Guajardo V, 2013, ASN NEURO, V5, P113, DOI 10.1042/AN20120066; Satoh JI, 2015, NEUROPATHOLOGY; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; SHARER LR, 1986, HUM PATHOL, V17, P271, DOI 10.1016/S0046-8177(83)80220-2; Sheng W, 2014, CELL RES, V24, P1387, DOI 10.1038/cr.2014.154; Slepko N, 1996, GLIA, V16, P241; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Tsuda M, 2009, P NATL ACAD SCI USA, V106, P8032, DOI 10.1073/pnas.0810420106; TUIJNMAN WB, 1993, APMIS, V101, P319, DOI 10.1111/j.1699-0463.1993.tb00117.x; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; Watkins CC, 2015, HIV AIDS-RES PALLIAT, V7, P35, DOI 10.2147/HIV.S39665; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Wires ES, 2012, J NEUROVIROL, V18, P400, DOI 10.1007/s13365-012-0103-4; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Zhou MA, 2013, BRAIN RES, V1506, P105, DOI 10.1016/j.brainres.2013.02.010	97	47	48	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1355-0284	1538-2443		J NEUROVIROL	J. Neurovirol.	FEB	2017	23	1					47	66		10.1007/s13365-016-0499-3			20	Neurosciences; Virology	Neurosciences & Neurology; Virology	EM0MB	WOS:000395011300004	27873219	Other Gold, Green Published			2021-06-18	
J	Kroshus, E; Baugh, CM; Stein, CJ; Austin, SB; Calzo, JP				Kroshus, Emily; Baugh, Christine M.; Stein, Cynthia J.; Austin, S. Bryn; Calzo, Jerel P.			Concussion reporting, sex, and conformity to traditional gender norms in young adults	JOURNAL OF ADOLESCENCE			English	Article						Concussion; College; Sport; Gender; Help-seeking	STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; AGE-DIFFERENCES; INJURY; SPORT; FEMALE; RISK; SYMPTOMS; WOMEN; PAIN	This study assessed whether between-sex differences in concussion reporting intention and behavior among young adults are explained by the extent to which the individual conforms to traditional masculine norms that often characterize contemporary sport culture. A survey of college athletes in the United States (n = 328) found greater symptom reporting intention among females as compared to males, but no difference in their likelihood continued play while experiencing symptoms of a possible concussion. Greater conformity to the norms of risk-taking was associated with greater likelihood of continued play while symptomatic among female athletes but not among male athletes. These findings suggest that gendered behavior, rather than biologically determined sex, is an important consideration for concussion safety in this age group. Addressing elements of the contemporary sport ethos that reinforce risk taking in service of athletic achievement may be a relevant direction for interventions aimed at improving injury reporting among all athletes. (C) 2016 The Foundation for Professionals in Services for Adolescents. Published by Elsevier Ltd. All rights reserved.	[Kroshus, Emily] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Kroshus, Emily] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Baugh, Christine M.] Harborview Injury Prevent Res Ctr, Seattle, WA USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.; Stein, Cynthia J.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Austin, S. Bryn] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Austin, S. Bryn; Calzo, Jerel P.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Austin, S. Bryn; Calzo, Jerel P.] Boston Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA USA	Kroshus, E (corresponding author), 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@u.washington.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Calzo, Jerel/0000-0002-4656-1052			Abar C, 2008, ADDICT BEHAV, V33, P1360, DOI 10.1016/j.addbeh.2008.06.010; Ajzen I, 2011, HANDB, V1, P438; Atkinson Michael., 2010, SEXUAL SPORTS RHETOR; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; BLINDE EM, 1992, SOCIOL QUART, V33, P521, DOI 10.1111/j.1533-8525.1992.tb00141.x; Calzo JP, 2014, ANN BEHAV MED, V47, P17, DOI 10.1007/s12160-013-9570-y; Caudwell J., 1999, Journal of Sport and Social Issues, V23, P390, DOI 10.1177/0193723599234003; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Ezzell MB, 2009, SOC PROBL, V56, P111, DOI 10.1525/sp.2009.56.1.111; Fenton LT, 2010, RES Q EXERCISE SPORT, V81, P212; Figner B, 2009, J EXP PSYCHOL LEARN, V35, P709, DOI 10.1037/a0014983; Fogel C., 2011, CANADA SOCIAL SCI, V7, P1; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Graham R., 2014, SPORTS RELATED CONCU; Halbert C., 1997, Journal of Sport and Social Issues, V21, P7, DOI 10.1177/019372397021001002; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson G. L., 2012, REHABILITATION REP; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2014, INT EPIDEMIOL, V1, P1; Kline Rex B., 2015, PRINCIPLES PRACTICE, P394; Kroshus E., 2015, ANN BEHAV MED; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Lin AC, 2015, SPORTS HEALTH, V7, P124, DOI 10.1177/1941738115571570; Lugasi T, 2011, J ADOLESCENT HEALTH, V48, P429, DOI 10.1016/j.jadohealth.2010.10.016; Mahalik J. R., 2003, PSYCHOL MEN MASCULIN, V4, P3, DOI [10.1037/1524-9220.4.1.3, DOI 10.1037/1524-9220.4.1.3]; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Malcom NL, 2006, J CONTEMP ETHNOGR, V35, P495, DOI 10.1177/0891241605283571; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCreary DR, 1996, SEX ROLES, V34, P507, DOI 10.1007/BF01545029; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McDermott R C., 2016, PSYCHOL MEN MASCULIN; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Morrongiello BA, 2000, J EXP CHILD PSYCHOL, V76, P89, DOI 10.1006/jecp.2000.2572; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Collegiate Athletic Association, 2014, DIV I STEER COMM GOV; Nixon H.L., 1992, J SPORT SOCIAL ISSUE, V16, P127, DOI [DOI 10.1177/019372359201600208, 10.1177/019372359201600208]; NIXON HL, 1994, SOCIOL SPORT J, V11, P79, DOI 10.1123/ssj.11.1.79; Parent MC, 2013, PSYCHOL MEN MASCULIN, V14, P324, DOI 10.1037/a0027642; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Reyna VF, 2006, PSYCHOL SCI, P1, DOI 10.1111/j.1529-1006.2006.00026.x; Roderick M, 2006, SOCIOL HEALTH ILL, V28, P76, DOI 10.1111/j.1467-9566.2005.00483.x; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Sartore ML, 2009, SEX ROLES, V60, P100, DOI 10.1007/s11199-008-9502-7; Shakib S, 2002, SOCIOL PERSPECT, V45, P353, DOI 10.1525/sop.2002.45.4.353; Sisjord MK, 2009, INT REV SOCIOL SPORT, V44, P231, DOI 10.1177/1012690209335278; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Steinfeldt JA, 2011, PSYCHOL MEN MASCULIN, V12, P401, DOI 10.1037/a0023634; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Tracey J, 2003, J APPL SPORT PSYCHOL, V15, P279, DOI 10.1080/714044197; Vast RL, 2010, AUST PSYCHOL, V45, P132, DOI 10.1080/00050060903261538; Waldron JJ, 2005, QUEST, V57, P315, DOI 10.1080/00336297.2005.10491860; Young K., 1995, Journal of Sport and Social Issues, V19, P45, DOI 10.1177/019372395019001004; Zamarripa MX, 2003, J COUNS PSYCHOL, V50, P333, DOI 10.1037/0022-0167.50.3.333	66	47	47	2	24	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0140-1971	1095-9254		J ADOLESCENCE	J. Adolesc.	JAN	2017	54						110	119		10.1016/j.adolescence.2016.11.002			10	Psychology, Developmental	Psychology	EI7KN	WOS:000392676700012	27984789				2021-06-18	
J	Ma, MW; Wang, J; Dhandapani, KM; Brann, DW				Ma, Merry W.; Wang, Jing; Dhandapani, Krishnan M.; Brann, Darrell W.			NADPH Oxidase 2 Regulates NLRP3 Inflammasome Activation in the Brain after Traumatic Brain Injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							EXHALED BREATH CONDENSATE; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; EXPRESSION; APOCYNIN; DAMAGE; NEUROINFLAMMATION; INHIBITION; REDUCTION; NOX2	Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. After the initial primary mechanical injury, a complex secondary injury cascade involving oxidative stress and neuroinflammation follows, which may exacerbate the injury and complicate the healing process. NADPH oxidase 2 (NOX2) is a major contributor to oxidative stress in TBI pathology, and inhibition of NOX2 is neuroprotective. The NLRP3 inflammasome can become activated in response to oxidative stress, but little is known about the role of NOX2 in regulating NLRP3 inflammasome activation following TBI. In this study, we utilized NOX2 knockout mice to study the role of NOX2 in mediating NLRP3 inflammasome expression and activation following a controlled cortical impact. Expression of NLRP3 inflammasome components NLRP3 and apoptosis-associated speck-like protein containing a CARD (ASC), as well as its downstream products cleaved caspase-1 and interleukin-1 beta (IL-1 beta), was robustly increased in the injured cerebral cortex following TBI. Deletion of NOX2 attenuated the expression, assembly, and activity of the NLRP3 inflammasome via a mechanism that was associated with TXNIP, a sensor of oxidative stress. The results support the notion that NOX2-dependent inflammasome activation contributes to TBI pathology.	[Ma, Merry W.; Wang, Jing; Dhandapani, Krishnan M.; Brann, Darrell W.] Charlie Norwood VA Med Ctr, One Freedom Way, Augusta, GA 30904 USA; [Ma, Merry W.; Wang, Jing; Brann, Darrell W.] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA; [Dhandapani, Krishnan M.] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA	Brann, DW (corresponding author), Charlie Norwood VA Med Ctr, One Freedom Way, Augusta, GA 30904 USA.; Brann, DW (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.	dbrann@augusta.edu		Dhandapani, Krishnan/0000-0001-7044-1117; Brann, Darrell/0000-0002-4480-8859	United States Department of Veteran's Affairs, Biomedical Laboratory Research, and Development Service [5l101BX001117]	This research presented in this article was conducted in partial fulfillment of the Ph.D. degree requirements set forth for Merry W. Ma and was supported by a VA Merit Review Award (5l101BX001117) from the United States Department of Veteran's Affairs, Biomedical Laboratory Research, and Development Service.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Altenhofer S, 2012, CELL MOL LIFE SCI, V69, P2327, DOI 10.1007/s00018-012-1010-9; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chaubey S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054869; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cifuentes-Pagano E, 2014, ANTIOXID REDOX SIGN, V20, P2741, DOI 10.1089/ars.2013.5620; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gatto GJ, 2013, J ENZYM INHIB MED CH, V28, P95, DOI 10.3109/14756366.2011.636360; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490; Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Johnson DK, 2002, ENDOTHELIUM-J ENDOTH, V9, P191, DOI 10.1080/10623320213638; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li Z, 2015, NEUROL SCI, V36, P61, DOI 10.1007/s10072-014-1909-z; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lucke-Wold B. P., 2015, TRANSL RES, V166, pe1, DOI DOI 10.1016/J.TRSL.2015.08.005.[; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McIntosh TK, 1996, LAB INVEST, V74, P315; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Minutoli Letteria, 2016, Oxid Med Cell Longev, V2016, P2183026, DOI 10.1155/2016/2183026; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sareddy GR, 2015, P NATL ACAD SCI USA, V112, pE6673, DOI 10.1073/pnas.1516729112; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Stefanska J, 2012, PULM PHARMACOL THER, V25, P343, DOI 10.1016/j.pupt.2012.06.001; Stefanska J, 2012, EXP LUNG RES, V38, P90, DOI 10.3109/01902148.2011.649823; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Zhang M, 2016, BIOMED PHARMACOTHER, V80, P73, DOI 10.1016/j.biopha.2016.02.036; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	64	47	50	2	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2017	2017								6057609	10.1155/2017/6057609			18	Cell Biology	Cell Biology	FA4PC	WOS:000405424300001	28785377	DOAJ Gold, Green Published			2021-06-18	
J	Molet, J; Maras, PM; Kinney-Lang, E; Harris, NG; Rashid, F; Ivy, AS; Solodkin, A; Obenaus, A; Baram, TZ				Molet, Jenny; Maras, Pamela M.; Kinney-Lang, Eli; Harris, Neil G.; Rashid, Faisal; Ivy, Autumn S.; Solodkin, Ana; Obenaus, Andre; Baram, Tallie Z.			MRI uncovers disrupted hippocampal microstructure that underlies memory impairments after early-life adversity	HIPPOCAMPUS			English	Article						early-life stress; cognitive vulnerabilities; brain networks; magnetic resonance imaging (MRI); diffusion tensor imaging (DTI)	CORTICOTROPIN-RELEASING HORMONE; POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MOUSE-BRAIN; CHILDHOOD MALTREATMENT; AMYGDALA VOLUMES; DENDRITIC SPINES; TEMPORAL-LOBE; SEXUAL-ABUSE; IN-VIVO	Memory and related cognitive functions are progressively impaired in a subgroup of individuals experiencing childhood adversity and stress. However, it is not possible to identify vulnerable individuals early, a crucial step for intervention. In this study, high-resolution magnetic resonance imaging (MRI) and intra-hippocampal diffusion tensor imaging (DTI) were employed to examine for structural signatures of cognitive adolescent vulnerabilities in a rodent model of early-life adversity. These methods were complemented by neuroanatomical and functional assessments of hippocampal network integrity during adolescence, adulthood and middle-age. The high-resolution MRI identified selective loss of dorsal hippocampal volume, and intra-hippocampal DTI uncovered disruption of dendritic structure, consistent with disrupted local connectivity, already during late adolescence in adversity-experiencing rats. Memory deteriorated over time, and stunting of hippocampal dendritic trees was apparent on neuroanatomical analyses. Thus, disrupted hippocampal neuronal structure and connectivity, associated with cognitive impairments, are detectable via non-invasive imaging modalities in rats experiencing early-life adversity. These high-resolution imaging approaches may constitute promising tools for prediction and assessment of at-risk individuals in the clinic. (c) 2016 Wiley Periodicals, Inc.	[Molet, Jenny; Ivy, Autumn S.; Solodkin, Ana; Baram, Tallie Z.] UC Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; [Maras, Pamela M.; Kinney-Lang, Eli; Baram, Tallie Z.] UC Irvine, Dept Pediat, Irvine, CA 92697 USA; [Kinney-Lang, Eli; Rashid, Faisal; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; [Harris, Neil G.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA; [Solodkin, Ana; Baram, Tallie Z.] UC Irvine, Dept Neurol, Irvine, CA 92697 USA	Molet, J (corresponding author), Univ Calif Irvine, Dept Anat, Med Sci 1,ZOT 4475, Irvine, CA 92697 USA.; Molet, J (corresponding author), Univ Calif Irvine, Dept Neurobiol, Med Sci 1,ZOT 4475, Irvine, CA 92697 USA.	jenny.molet@gmail.com		Ivy, Autumn/0000-0003-1775-6253; Harris, Neil/0000-0002-1965-6750	 [MH73136];  [NS29012];  [P50MH096889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073136, P50MH096889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028912] Funding Source: NIH RePORTER	Grant numbers: MH73136, NS29012, P50MH096889.	Avishai-Eliner S, 2002, TRENDS NEUROSCI, V25, P518, DOI 10.1016/S0166-2236(02)02241-5; Ayling E, 2012, CURR PSYCHIAT REP, V14, P197, DOI 10.1007/s11920-012-0273-z; Ball G, 2013, P NATL ACAD SCI USA, V110, P9541, DOI 10.1073/pnas.1301652110; Baram TZ, 2012, AM J PSYCHIAT, V169, P907, DOI 10.1176/appi.ajp.2012.11091347; Bourgin J, 2015, EUR NEUROPSYCHOPHARM, V25, P828, DOI 10.1016/j.euroneuro.2015.02.010; Bourne JN, 2008, ANNU REV NEUROSCI, V31, P47, DOI 10.1146/annurev.neuro.31.060407.125646; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Brunson KL, 2005, J NEUROSCI, V25, P9328, DOI 10.1523/JNEUROSCI.2281-05.2005; Calamante F, 2012, NEUROIMAGE, V59, P2494, DOI 10.1016/j.neuroimage.2011.08.099; Chen YC, 2008, J NEUROSCI, V28, P2903, DOI 10.1523/JNEUROSCI.0225-08.2008; Chen YC, 2010, P NATL ACAD SCI USA, V107, P13123, DOI 10.1073/pnas.1003825107; Dere E, 2010, BEHAV BRAIN RES, V215, P162, DOI 10.1016/j.bbr.2010.03.017; Everson-Rose SA, 2003, AM J EPIDEMIOL, V158, P1083, DOI 10.1093/aje/kwg263; Goubran M, 2015, ANN NEUROL, V77, P237, DOI 10.1002/ana.24318; Hayes K, 2014, J NEUROSCI METH, V221, P103, DOI 10.1016/j.jneumeth.2013.09.014; Hodel AS, 2015, NEUROIMAGE, V105, P112, DOI 10.1016/j.neuroimage.2014.10.020; Holtmaat A, 2009, NAT REV NEUROSCI, V10, P647, DOI 10.1038/nrn2699; Ivy AS, 2008, NEUROSCIENCE, V154, P1132, DOI 10.1016/j.neuroscience.2008.04.019; Ivy AS, 2010, J NEUROSCI, V30, P13005, DOI 10.1523/JNEUROSCI.1784-10.2010; Kantarci K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00316; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Kehoe P, 1999, HIPPOCAMPUS, V9, P651, DOI 10.1002/(SICI)1098-1063(1999)9:6<651::AID-HIPO6>3.0.CO;2-P; Keller SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046791; Kerchner GA, 2010, NEUROLOGY, V75, P1381, DOI 10.1212/WNL.0b013e3181f736a1; Kim CH, 2010, EPILEPSY RES, V90, P21, DOI 10.1016/j.eplepsyres.2010.03.002; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Langston RF, 2010, HIPPOCAMPUS, V20, P1139, DOI 10.1002/hipo.20714; Lyons DM, 2001, ARCH GEN PSYCHIAT, V58, P1145, DOI 10.1001/archpsyc.58.12.1145; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P83, DOI 10.1016/0306-4522(95)00256-I; Maras PM, 2014, MOL PSYCHIATR, V19, P811, DOI 10.1038/mp.2014.12; McEwen BS, 2012, DEV NEUROBIOL, V72, P878, DOI 10.1002/dneu.20968; McEwen BS, 2003, MENT RETARD DEV D R, V9, P149, DOI 10.1002/mrdd.10074; McQuown SC, 2011, J NEUROSCI, V31, P764, DOI 10.1523/JNEUROSCI.5052-10.2011; Millan MJ, 2012, NAT REV DRUG DISCOV, V11, P141, DOI 10.1038/nrd3628; Molet J, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.200; Molet J, 2014, DEV PSYCHOBIOL, V56, P1675, DOI 10.1002/dev.21230; Nelson CA, 2007, SCIENCE, V318, P1937, DOI 10.1126/science.1143921; Norris FC, 2013, MAGN RESON MED, V70, P1380, DOI 10.1002/mrm.24573; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; Papp EA, 2014, NEUROIMAGE, V97, P374, DOI 10.1016/j.neuroimage.2014.04.001; Paus T., 2009, HDB ADOLESCENT PSYCH, V1, P95, DOI DOI 10.1002/9780470479193; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P18201, DOI 10.1073/pnas.0509232102; PYCH JC, 2008, ALZHEIMERS DEMENT, V4, pT71; Qiu AQ, 2015, ANNU REV PSYCHOL, V66, P853, DOI 10.1146/annurev-psych-010814-015340; Radley JJ, 2008, J COMP NEUROL, V507, P1141, DOI 10.1002/cne.21588; Regev L, 2014, FRONT NEUROENDOCRIN, V35, P171, DOI 10.1016/j.yfrne.2013.10.001; Rice CJ, 2008, ENDOCRINOLOGY, V149, P4892, DOI 10.1210/en.2008-0633; Schoemaker D, 2016, NEUROIMAGE, V129, P1, DOI 10.1016/j.neuroimage.2016.01.038; Segal M, 2010, HIPPOCAMPUS, V20, P1332, DOI 10.1002/hipo.20751; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHOLL DA, 1953, J ANAT, V87, P387; Sierra A, 2015, BRAIN STRUCT FUNCT, V220, P781, DOI 10.1007/s00429-013-0683-7; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Teicher MH, 2012, P NATL ACAD SCI USA, V109, pE563, DOI 10.1073/pnas.1115396109; Trivedi R, 2009, NEURORADIOLOGY, V51, P567, DOI 10.1007/s00234-009-0533-8; Ulrich-Lai YM, 2009, NAT REV NEUROSCI, V10, P397, DOI 10.1038/nrn2647; van Haren NEM, 2004, BIOL PSYCHIAT, V56, P454, DOI 10.1016/j.biopsych.2004.06.033; Vogel-Ciernia Annie, 2014, Curr Protoc Neurosci, V69, DOI 10.1002/0471142301.ns0831s69; Wang XD, 2012, EUR J NEUROSCI, V36, P2360, DOI 10.1111/j.1460-9568.2012.08148.x; Wang XD, 2011, J NEUROSCI, V31, P13625, DOI 10.1523/JNEUROSCI.2259-11.2011; Wilson RS, 2005, EXP AGING RES, V31, P393, DOI 10.1080/03610730500206683; Woon FL, 2008, HIPPOCAMPUS, V18, P729, DOI 10.1002/hipo.20437; Yassa MA, 2010, P NATL ACAD SCI USA, V107, P12687, DOI 10.1073/pnas.1002113107; Zalsman G, 2015, EUR NEUROPSYCHOPHARM, V25, P2075, DOI 10.1016/j.euroneuro.2015.08.006; Zhang JY, 2002, NEUROIMAGE, V15, P892, DOI 10.1006/nimg.2001.1012	69	47	47	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus	DEC	2016	26	12					1618	1632		10.1002/hipo.22661			15	Neurosciences	Neurosciences & Neurology	EC9YX	WOS:000388501300013	27657911	Green Accepted			2021-06-18	
J	Abaji, JP; Curnier, D; Moore, RD; Ellemberg, D				Abaji, Joseph Patrick; Curnier, Daniel; Moore, Robert Davis; Ellemberg, Dave			Persisting Effects of Concussion on Heart Rate Variability during Physical Exertion	JOURNAL OF NEUROTRAUMA			English	Article						cardiac autonomic modulation; concussion; physical activity	TRAUMATIC BRAIN-INJURY; BLOOD-PRESSURE VARIABILITY; ISOMETRIC HANDGRIP TEST; RESPIRATORY RESISTANCE; APPROXIMATE ENTROPY; RECOVERY; DEFICITS; SYSTEMS	The purpose of this study was to evaluate cardiac autonomic modulation in university athletes during the post-acute to late phase (mean, 95 days +/- 63) of injury at rest and during physical exertion. We also sought to evaluate the effect of time since injury and number of injuries on heart rate variability (HRV). We hypothesized that physical exertion would reveal persisting modifications in HRV following a concussion. We included, in a cross-sectional design, athletes who sustained a concussion and matched controls. Concussions were identified by a medical doctor using established criteria. Twelve male concussed and 12 control athletes took part in the study. Control participants were teammates who were chosen to match the concussed athletes with regard to their height, weight, education, and age. The beat-to-beat electrocardiogram intervals of the participants were measured at rest and during physical exertion (isometric hand grip contraction; IHGC), which was sustained for 3 minutes at 30% of the participants' maximum. Linear and nonlinear parameters of HRV were calculated. The ratio between low and high frequency (LF/HF) bands was calculated to assess the sympathovagal balance. During the IHGC, but not at rest, concussed athletes presented significantly lower power in HF bands, leading to a significantly higher LF/HF ratio (p <= 0.05). Thus, asymptomatic athletes still may exhibit modifications in cardiac autonomic modulation weeks to months following injury. These modifications may only become apparent during physical exertion. Monitoring HRV may aid diagnosis and provide insight about safe return to play.	[Abaji, Joseph Patrick; Curnier, Daniel; Moore, Robert Davis; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Montreal, PQ, Canada; [Curnier, Daniel; Ellemberg, Dave] Univ Montreal, Res Ctr, CHU St Justine, Montreal, PQ, Canada	Ellemberg, D (corresponding author), 2100 Eduard Montpetit, Montreal, PQ H3T 1J4, Canada.	dave.ellemberg@umontreal.ca			Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Bartels MN, 2004, RESP PHYSIOL NEUROBI, V144, P91, DOI 10.1016/j.resp.2004.08.002; Bergemalm PO, 2005, INT J AUDIOL, V44, P39, DOI 10.1080/14992020400022546; Berntson GG, 1996, BIOL PSYCHOL, V44, P1, DOI 10.1016/S0301-0511(96)05197-6; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Camm AJ, 1996, EUR HEART J, V17, P354; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denver JW, 2007, BIOL PSYCHOL, V74, P286, DOI 10.1016/j.biopsycho.2005.09.005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Gianaros PJ, 2001, PSYCHOPHYSIOLOGY, V38, P540, DOI 10.1017/S004857720100004X; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kelly JP, 1997, NEUROLOGY, V48, P581; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Khurana RK, 1996, CLIN AUTON RES, V6, P211, DOI 10.1007/BF02291136; King ML, 1997, BRAIN INJURY, V11, P445; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Marques AH, 2010, NEUROIMMUNOMODULAT, V17, P205, DOI 10.1159/000258725; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Petrofsky J, 2009, DIABETES TECHNOL THE, V11, P361, DOI 10.1089/dia.2008.0094; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Ritz T, 2000, BIOL PSYCHOL, V52, P143, DOI 10.1016/S0301-0511(99)00026-5; Ritz T, 2002, PSYCHOPHYSIOLOGY, V39, P86, DOI 10.1017/S0048577201020066; Ritz T, 2000, BIOL PSYCHOL, V55, P119, DOI 10.1016/S0301-0511(00)00075-2; Rottenberg J, 2003, PSYCHOPHYSIOLOGY, V40, P1, DOI 10.1111/1469-8986.00001; Saboul D, 2014, EUR J SPORT SCI, V14, pS282, DOI 10.1080/17461391.2012.691116; Schipke J. D., 1999, J CLIN BASIC CARDIOL, V2, P92, DOI DOI 10.1161/01.CIR.93.5.1043; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; de Araujo CGS, 2011, ARQ BRAS CARDIOL, V97, P413, DOI 10.1590/S0066-782X2011005000102; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74	47	47	47	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					811	817		10.1089/neu.2015.3989			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800002	26159461				2021-06-18	
J	Pruitt, DT; Schmid, AN; Kim, LJ; Abe, CM; Trieu, JL; Choua, C; Hays, SA; Kilgard, MP; Rennaker, RL				Pruitt, David T.; Schmid, Ariel N.; Kim, Lily J.; Abe, Caroline M.; Trieu, Jenny L.; Choua, Connie; Hays, Seth A.; Kilgard, Michael P.; Rennaker, Robert L.			Vagus Nerve Stimulation Delivered with Motor Training Enhances Recovery of Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						motor recovery; neuromodulation; traumatic brain injury; vagal nerve stimulation; vagus nerve stimulation	FOREBRAIN CHOLINERGIC SYSTEM; TREATMENT-RESISTANT DEPRESSION; CORTICAL PLASTICITY; LONG-TERM; REHABILITATION IMPROVE; FORELIMB STRENGTH; REORGANIZATION; NOREPINEPHRINE; IMPAIRMENT; ADMISSION	Traumatic Brain Injury (TBI) is one of the largest health problems in the United States, and affects nearly 2 million people every year. The effects of TBI, including weakness and loss of coordination, can be debilitating and last years after the initial injury. Recovery of motor function is often incomplete. We have developed a method using electrical stimulation of the vagus nerve paired with forelimb use by which we have demonstrated enhanced recovery from ischemic and hemorrhagic stroke. Here we have tested the hypothesis that vagus nerve stimulation (VNS) paired with physical rehabilitation could enhance functional recovery after TBI. We trained rats to pull on a handle to receive a food reward. Following training, they received a controlled-cortical impact (CCI) in the forelimb area of motor cortex opposite the trained forelimb, and were then randomized into two treatment groups. One group of animals received VNS paired with rehabilitative therapy, whereas another group received rehabilitative therapy without VNS. Following CCI, volitional forelimb strength and task success rate in all animals were significantly reduced. VNS paired with rehabilitative therapy over a period of 5 weeks significantly increased recovery of both forelimb strength and success rate on the isometric pull task compared with rehabilitative training without VNS. No significant improvement was observed in the Rehab group. Our findings indicate that VNS paired with rehabilitative therapy enhances functional motor recovery after TBI.	[Pruitt, David T.; Schmid, Ariel N.; Kim, Lily J.; Abe, Caroline M.; Choua, Connie; Kilgard, Michael P.; Rennaker, Robert L.] Univ Texas Dallas, Sch Behav Brain Sci, 800 West Campbell Rd,GR41, Richardson, TX 75080 USA; [Trieu, Jenny L.; Hays, Seth A.; Rennaker, Robert L.] Univ Texas Dallas, Erik Jonsson Sch Engn & Comp Sci, Richardson, TX 75083 USA; [Pruitt, David T.; Schmid, Ariel N.; Kim, Lily J.; Abe, Caroline M.; Trieu, Jenny L.; Choua, Connie; Hays, Seth A.; Kilgard, Michael P.; Rennaker, Robert L.] Univ Texas Dallas, Texas Biomed Device Ctr, Richardson, TX 75083 USA	Pruitt, DT (corresponding author), Univ Texas Dallas, Sch Behav Brain Sci, 800 West Campbell Rd,GR41, Richardson, TX 75080 USA.	dtp110020@utdallas.edu	, David/ABG-7327-2020; Hays, Seth/U-4701-2019; Rennaker II, Robert/K-9049-2013	, David/0000-0001-8356-0887; Hays, Seth/0000-0003-4225-241X; Rennaker II, Robert/0000-0003-1260-1973; Kilgard, Michael/0000-0002-6699-1818	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS085167, R01NS062065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC008982] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS085167, R01 NS062065] Funding Source: Medline		Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; Ben-Menachem E, 1999, NEUROLOGY, V52, P1265, DOI 10.1212/WNL.52.6.1265; BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Canning CG, 1999, ARCH PHYS MED REHAB, V80, P66, DOI 10.1016/S0003-9993(99)90309-X; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; De Ridder D, 2015, OTOL NEUROTOL, V36, P575, DOI 10.1097/MAO.0000000000000704; De Ridder D, 2014, NEUROMODULATION, V17, P170, DOI 10.1111/ner.12127; DeGiorgio CM, 2000, EPILEPSIA, V41, P1195, DOI 10.1111/j.1528-1157.2000.tb00325.x; Engineer ND, 2011, NATURE, V470, P101, DOI 10.1038/nature09656; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Follesa P, 2007, BRAIN RES, V1179, P28, DOI 10.1016/j.brainres.2007.08.045; Hays SA, 2014, STROKE, V45, P3097, DOI 10.1161/STROKEAHA.114.006654; Hays SA, 2014, NEUROREPORT, V25, P676, DOI 10.1097/WNR.0000000000000154; Hays SA, 2013, J NEUROSCI METH, V212, P329, DOI 10.1016/j.jneumeth.2012.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Khodaparast N, 2013, NEUROBIOL DIS, V60, P80, DOI 10.1016/j.nbd.2013.08.002; Khodaparast N, 2014, NEUROREHAB NEURAL RE, V28, P698, DOI 10.1177/1545968314521006; Kilgard MP, 2012, TRENDS NEUROSCI, V35, P715, DOI 10.1016/j.tins.2012.09.002; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kleim JA, 2004, J NEUROSCI, V24, P628, DOI 10.1523/JNEUROSCI.3440-03.2004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Microtransponder, 2014, VNS REH IMPR UPP LIM; Microtransponder, 2014, PAIR VAG NERV STIM V; Molina-Luna K, 2008, NEUROIMAGE, V40, P1748, DOI 10.1016/j.neuroimage.2007.11.018; Morris GL, 1999, NEUROLOGY, V53, P1731, DOI 10.1212/WNL.53.8.1731; Nemeroff CB, 2006, NEUROPSYCHOPHARMACOL, V31, P1345, DOI 10.1038/sj.npp.1301082; Nichols JA, 2011, NEUROSCIENCE, V189, P207, DOI 10.1016/j.neuroscience.2011.05.024; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Porter BA, 2012, CEREB CORTEX, V22, P2365, DOI 10.1093/cercor/bhr316; Pruitt D, 2014, BRAIN RES, V1582, P91, DOI 10.1016/j.brainres.2014.07.039; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Ramanathan D, 2009, J NEUROSCI, V29, P5992, DOI 10.1523/JNEUROSCI.0230-09.2009; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Sackeim HA, 2001, NEUROPSYCHOPHARMACOL, V25, P713, DOI 10.1016/S0893-133X(01)00271-8; Shetake JA, 2012, EXP NEUROL, V233, P342, DOI 10.1016/j.expneurol.2011.10.026; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Terry Jr R. S., 2014, VAGUS NERVE STIMULAT; Thompson JN, 2013, BRIT J NEUROSURG, V27, P24, DOI 10.3109/02688697.2012.714818; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	50	47	51	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					871	879		10.1089/neu.2015.3972			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800009	26058501	Green Published			2021-06-18	
J	Mondello, S; Shear, DA; Bramlett, HM; Dixon, CE; Schmid, KE; Dietrich, WD; Wang, KKW; Hayes, RL; Glushakova, O; Catania, M; Richieri, SP; Povlishock, JT; Tortella, FC; Kochanek, PM				Mondello, Stefania; Shear, Deborah A.; Bramlett, Helen M.; Dixon, C. Edward; Schmid, Kara E.; Dietrich, W. Dalton; Wang, Kevin K. W.; Hayes, Ronald L.; Glushakova, Olena; Catania, Michael; Richieri, Steven P.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Insight into Pre-Clinical Models of Traumatic Brain Injury Using Circulating Brain Damage Biomarkers: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						theranostic; fluid percussion injury; rat; ubiquitin carboxyl-terminal hydrolase-L1; penetrating ballistic-like brain injury; biomarkers; glial fibrillary acidic protein; Morris water maze; controlled cortical impact	BARRIER PERMEABILITY; BLOOD; FLUID; RAT; ERYTHROPOIETIN; BREAKDOWN; SEVERITY; MARKERS	Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats-namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24-4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI + VEH groups across experiments, no differences were found in the same model. GFAP was acutely increased in injured rats in each model, with significant differences in levels and temporal patterns mirrored by significant differences in delta 24-4 h GFAP levels and neuropathological and behavioral outcomes. Circulating GFAP levels at 4 and 24 h were powerful predictors of 21 day contusion volume and tissue loss. UCH-L1 showed similar tendencies, albeit with less robust differences between sham and injury groups. Significant differences were also found comparing shams across the models. Our findings (1) demonstrate that TBI models display specific biomarker profiles, functional deficits, and pathological consequence; (2) support the concept that there are different cellular, molecular, and pathophysiological responses to TBI in each model; and (3) advance our understanding of TBI, providing opportunities for a successful translation and holding promise for theranostic applications. Based on our findings, additional studies in pre-clinical models should pursue assessment of GFAP as a surrogate histological and/or theranostic end-point.	[Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Shear, Deborah A.; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Glushakova, Olena; Catania, Michael; Richieri, Steven P.] Banyan Biomarkers, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Boutte AM, 2016, J NEUROTRAUM, V33, P147, DOI 10.1089/neu.2014.3672; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; PAKKENBERG B, 1988, J MICROSC-OXFORD, V150, P1, DOI 10.1111/j.1365-2818.1988.tb04582.x; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2011, J NEUROTRAUM, V28, P2185, DOI 10.1089/neu.2011.1916; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	31	47	47	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					595	605		10.1089/neu.2015.4132			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800008	26671651				2021-06-18	
J	Dash, PK; Zhao, J; Kobori, N; Redell, JB; Hylin, MJ; Hood, KN; Moore, AN				Dash, Pramod K.; Zhao, Jing; Kobori, Nobuhide; Redell, John B.; Hylin, Michael J.; Hood, Kimberly N.; Moore, Anthony N.			Activation of Alpha 7 Cholinergic Nicotinic Receptors Reduce Blood-Brain Barrier Permeability following Experimental Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						blood-brain barrier breakdown; controlled cortical impact brain injury; inflammatory cytokines; secondary TBI pathology	VAGUS NERVE-STIMULATION; NEURONAL CELL-DEATH; IMMUNE-RESPONSE; SYSTEMIC INFLAMMATION; ALLOSTERIC MODULATION; COGNITIVE DYSFUNCTION; CEREBROSPINAL-FLUID; HEAD-INJURY; MICE; RAT	Traumatic brain injury (TBI) is a major human health concern that has the greatest impact on young men and women. The breakdown of the blood-brain barrier (BBB) is an important pathological consequence of TBI that initiates secondary processes, including infiltration of inflammatory cells, which can exacerbate brain inflammation and contribute to poor outcome. While the role of inflammation within the injured brain has been examined in some detail, the contribution of peripheral/systemic inflammation to TBI pathophysiology is largely unknown. Recent studies have implicated vagus nerve regulation of splenic cholinergic nicotinic acetylcholine receptor alpha 7 (nAChRa7) signaling in the regulation of systemic inflammation. However, it is not known whether this mechanism plays a role in TBI-triggered inflammation and BBB breakdown. Following TBI, we observed that plasma TNF-alpha and IL-1 beta levels, as well as BBB permeability, were significantly increased in nAChRa7 null mice (Chrna7(-/-)) relative to wild-type mice. The administration of exogenous IL-1 beta and TNF-alpha to brain-injured animals worsened Evans Blue dye extravasation, suggesting that systemic inflammation contributes to TBI-triggered BBB permeability. Systemic administration of the nAChRa7 agonist PNU-282987 or the positive allosteric modulator PNU-120596 significantly attenuated TBI-triggered BBB compromise. Supporting a role for splenic nAChRa7 receptors, we demonstrate that splenic injection of the nicotinic receptor blocker alpha-bungarotoxin increased BBB permeability in brain-injured rats, while PNU-282987 injection decreased such permeability. These effects were not seen when alpha-bungarotoxin or PNU-282987 were administered to splenectomized, brain-injured rats. Together, these findings support the short-term use of nAChRa7-activating agents as a strategy to reduce TBI-triggered BBB permeability.	[Dash, Pramod K.; Zhao, Jing; Kobori, Nobuhide; Redell, John B.; Hylin, Michael J.; Hood, Kimberly N.; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, POB 20036, Houston, TX 77030 USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, POB 20036, Houston, TX 77030 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019		Senator Lloyd and B.A. Bentsen Center for Stroke Research; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-087149, NS-088298]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088298, R01NS087149] Funding Source: NIH RePORTER	This research was supported by the Senator Lloyd and B.A. Bentsen Center for Stroke Research, and National Institutes of Health Grants NS-087149 and NS-088298.	Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BENNETT BR, 1989, J TRAUMA, V29, P556, DOI 10.1097/00005373-198905000-00003; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Bertrand D, 2007, BIOCHEM PHARMACOL, V74, P1155, DOI 10.1016/j.bcp.2007.07.011; Borovikova LV, 2000, NATURE, V405, P458; Bruchfeld A, 2008, MOL MED, V14, P109, DOI 10.2119/2007-00107.Bruchfeld; Chan JL, 2014, EXP NEUROL, V261, P757, DOI 10.1016/j.expneurol.2014.08.015; Clough RW, 2007, NEUROSCIENCE, V147, P286, DOI 10.1016/j.neuroscience.2007.04.043; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DIXON CE, 1991, J NEUROSCI METH, V39, P253; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Gray E, 2008, BRAIN PATHOL, V18, P86, DOI 10.1111/j.1750-3639.2007.00110.x; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hijioka M, 2012, NEUROSCIENCE, V222, P10, DOI 10.1016/j.neuroscience.2012.07.024; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; KINKADE JM, 1983, BIOCHEM BIOPH RES CO, V114, P296, DOI 10.1016/0006-291X(83)91627-3; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kox M, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0667-5; Kumaria A, 2012, BRIT J NEUROSURG, V26, P316, DOI 10.3109/02688697.2012.663517; Levine YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104530; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Lopez NE, 2012, J TRAUMA ACUTE CARE, V72, P1562, DOI 10.1097/TA.0b013e3182569875; Mazurov A, 2006, CURR MED CHEM, V13, P1567, DOI 10.2174/092986706777442011; McCrory P, 2002, J SCI MED SPORT, V5, P169, DOI 10.1016/S1440-2440(02)80002-0; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Moreno A, 1998, NMR BIOMED, V11, P93, DOI 10.1002/(SICI)1099-1492(199805)11:3<93::AID-NBM520>3.0.CO;2-H; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Olofsson PS, 2012, IMMUNOL REV, V248, P188, DOI 10.1111/j.1600-065X.2012.01138.x; Pavlov VA, 2006, BIOCHEM SOC T, V34, P1037, DOI 10.1042/BST0341037; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Shi C, 2013, NEUROL RES, V35, P263, DOI 10.1179/1743132813Y.0000000167; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stuckenholz V, 2013, J PARKINSON DIS, V3, P161, DOI 10.3233/JPD-120157; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vaccari JPD, 2016, TRANSL RES, V167, P35, DOI 10.1016/j.trsl.2015.05.003; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	60	47	51	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 2	2016	36	9					2809	2818		10.1523/JNEUROSCI.3197-15.2016			10	Neurosciences	Neurosciences & Neurology	DF2BV	WOS:000371145400022	26937017	Green Published, Bronze			2021-06-18	
J	Takala, RSK; Posti, JP; Runtti, H; Newcombe, VF; Outtrim, J; Katila, AJ; Frantzen, J; Ala-Seppala, H; Kyllonen, A; Maanpaa, HR; Tallus, J; Hossain, MI; Coles, JP; Hutchinson, P; van Gils, M; Menon, DK; Tenovuo, O				Takala, Riikka S. K.; Posti, Jussi P.; Runtti, Hilkka; Newcombe, Virginia F.; Outtrim, Joanne; Katila, Ari J.; Frantzen, Janek; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Hossain, Md. Iftakher; Coles, Jonathan P.; Hutchinson, Peter; van Gils, Mark; Menon, David K.; Tenovuo, Olli			Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 as Outcome Predictors in Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Biomarkers; GFAP; Outcome; Traumatic brain injury; UCH-L1	INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; SERUM BIOMARKERS; GFAP; S100B; MILD; PROGNOSIS; MODERATE; S100-BETA; DIAGNOSIS	OBJECTIVE: Biomarkers ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) may help detect brain injury, assess its severity, and improve outcome prediction. This study aimed to evaluate the prognostic value of these biomarkers during the first days after brain injury. METHODS: Serum UCH-L1 and GFAP were measured hi 324 patients with traumatic brain injury (TBI) enrolled in a prospective study. The outcome was assessed using the Glasgow Outcome Scale (GOS) or the extended version, Glasgow Outcome Scale-Extended (GOSE). RESULTS: Patients with full recovery had lower UCH-L1 concentrations on the second day and patients with favorable outcome had lower UCH-L1 concentrations during the first 2 days compared with patients with incomplete recovery and unfavorable outcome. Patients with full recovery and favorable outcome had significantly lower GFAP concentrations in the first 2 days than patients with incomplete recovery or unfavorable outcome. There was a strong negative correlation between outcome and UCH-L1 in the first 3 days and GFAP levels in the first 2 days. On arrival, both UCH-L1 and GFAP distinguished patients with GOS score 1-3 from patients with GOS score 4-5, but not patients with GOSE score 8 from patients with GOSE score 1-7. For UCH-L1 and GFAP to predict unfavorable outcome (GUS score <= 3), the area under the receiver operating characteristic curve was 0.727, and 0323, respectively. Neither UCHL-1 nor GFAP was independently able to predict the outcome when age, worst Glasgow Coma Scale score, pupil reactivity, Injury Severity Score, and Marshall score were added into the multivariate logistic regression model. CONCLUSIONS: GFAP and UCH-L1 are significantly associated with outcome, but they do not add predictive power to commonly used prognostic variables in a population of patients with TBI of varying severities.	[Takala, Riikka S. K.; Katila, Ari J.] Turku Univ Hosp, Intens Care Med & Pain Management, Perioperat Serv, FIN-20520 Turku, Finland; [Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, FIN-20520 Turku, Finland; [Posti, Jussi P.; Frantzen, Janek; Tenovuo, Olli] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, FIN-20520 Turku, Finland; Univ Turku, Turku, Finland; [Posti, Jussi P.; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Hossain, Md. Iftakher; Tenovuo, Olli] Univ Turku, Dept Neurol, FIN-20520 Turku, Finland; [Runtti, Hilkka; van Gils, Mark] VTT Tech Res Ctr Finland, Syst Med, Tampere, Finland; [Newcombe, Virginia F.; Outtrim, Joanne; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England	Takala, RSK (corresponding author), Turku Univ Hosp, Intens Care Med & Pain Management, Perioperat Serv, FIN-20520 Turku, Finland.	riikka.takala@gmail.com	Posti, Jussi P./Y-2908-2019	Posti, Jussi P./0000-0002-5925-5193; Liedes, Hilkka/0000-0003-4655-7675; van Gils, Mark/0000-0002-0029-1771; Ala-Seppala, Henna/0000-0002-1577-3028; Hutchinson, Peter/0000-0002-2796-1835; Newcombe, Virginia/0000-0001-6044-9035	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-270259-TBlcare]; United Kingdom National Institute of Health Research Biomedical Research Centre at Cambridge; EVO grant from Hospital District of South-West Finland; Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; United Kingdom National Institute of Health ResearchNational Institute for Health Research (NIHR); AbbottAbbott Laboratories; Baxter; Fresenius-Kabi; UCBUCB Pharma SA; PfizerPfizer; Skulle Implants Ltd.; Orion; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0508-10327, NF-SI-0512-10090, ACF-2009-14-007] Funding Source: researchfish	This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBlcare), the United Kingdom National Institute of Health Research Biomedical Research Centre at Cambridge, and a personal EVO grant (R.S.K.T.) from Hospital District of South-West Finland. V.F.N. is supported by a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. J.O., J.P.C., P.H., and D.K.M. were supported by the United Kingdom National Institute of Health Research Biomedical Research Centre at Cambridge, and D.K.M. was also supported by a Senior Investigator Award from the United Kingdom National Institute of Health Research.; R.S.K.T has received speaker's fees from Abbott, Baxter, Fresenius-Kabi, and UCB; has received financial support in the form of a congress fee and travel expenses paid by Pfizer; and is a stockholder of Orion. J.P.P. has received financial support in the form of a congress fee and travel expenses paid by Skulle Implants Ltd., J.E is member of the board of directors in BonAlive Biomaterials Ltd., P.J.H. is a director of Technicam. O.T. has received speaker's fees from Orion. The remaining authors have no financial disclosures.	Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; JENNETT B, 1976, LANCET, V1, P1031; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ohrt-Nissen S, 2011, EMERG MED J, V28, P941, DOI 10.1136/emj.2010.091363; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063; Shoemaker LD, 2012, NEUROSURGERY, V70, P518, DOI 10.1227/NEU.0b013e3182333a26; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zurek J, 2011, J TRAUMA, V71, P854, DOI 10.1097/TA.0b013e3182140c8c	37	47	53	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2016	87						8	20		10.1016/j.wneu.2015.10.066			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI3HR	WOS:000373390200003	26547005				2021-06-18	
J	Lillie, EM; Urban, JE; Lynch, SK; Weaver, AA; Stitzel, JD				Lillie, Elizabeth M.; Urban, Jillian E.; Lynch, Sarah K.; Weaver, Ashley A.; Stitzel, Joel D.			Evaluation of Skull Cortical Thickness Changes With Age and Sex From Computed Tomography Scans	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						CORTICAL THICKNESS; SKULL; CRANIAL VAULT; COMPUTED TOMOGRAPHY; AGE CHANGES	TRAUMATIC BRAIN-INJURY; PARATHYROID-HORMONE; MECHANICAL-PROPERTIES; THIN STRUCTURES; BONE; PATHOPHYSIOLOGY; DENSITY; FLEXURE; CT	Head injuries resulting from motor vehicle crashes (MVC) are extremely common, yet the details of the mechanism of injury remain to be well characterized. Skull deformation is believed to be a contributing factor to some types of traumatic brain injury (TBI). Understanding biomechanical contributors to skull deformation would provide further insight into the mechanism of head injury resulting from blunt trauma. In particular, skull thickness is thought be a very important factor governing deformation of the skull and its propensity for fracture. Previously, age- and sex-based skull cortical thickness changes were difficult to evaluate based on the need for cadaveric skulls. In this cross-sectional study, skull thickness changes with age and sex have been evaluated at homologous locations using a validated cortical density-based algorithm to accurately quantify cortical thickness from 123 high-resolution clinical computed tomography (CT) scans. The flat bones of the skull have a sandwich structure; therefore, skull thickness was evaluated for the inner and outer tables as well the full thickness. General trends indicated an increase in the full skull thickness, mostly attributed to an increase in the thickness of the diploic layer; however, these trends were not found to be statistically significant. There was a significant relationship between cortical thinning and age for both tables of the frontal, occipital, and parietal bones ranging between a 36% and 60% decrease from ages 20 to 100 years in females, whereas males exhibited no significant changes. Understanding how cortical and full skull thickness changes with age from a wide range of subjects can have implications in improving the biofidelity of age- and sex-specific finite element models and therefore aid in the prediction and understanding of TBI from impact and blast injuries. (c) 2015 American Society for Bone and Mineral Research.	[Lillie, Elizabeth M.; Urban, Jillian E.; Lynch, Sarah K.; Weaver, Ashley A.; Stitzel, Joel D.] Virginia Tech Wake Forest Univ, Ctr Injury Biomech, Winston Salem, NC USA; [Lillie, Elizabeth M.; Urban, Jillian E.; Lynch, Sarah K.; Weaver, Ashley A.; Stitzel, Joel D.] Wake Forest Univ, Bowman Gray Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA	Stitzel, JD (corresponding author), Virginia Tech Wake Forest Univ, Ctr Injury Biomech, Winston Salem, NC USA.; Stitzel, JD (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033	National Highway Traffic Safety Administration [DTN22-09-H-00242]	This work was supported by grants from the National Highway Traffic Safety Administration under Cooperative Agreement Number DTN22-09-H-00242. Views expressed are those of the authors and do not represent the views of NHTSA. We thank Callistus Nguyen and Mimin Meliyani for assisting with data collection.	Angel JL., 2005, AM J PHYS ANTHROPOL, V58, P297; Avants B, 2004, NEUROIMAGE, V23, pS139, DOI 10.1016/j.neuroimage.2004.07.010; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Chakkalakal DA, 2005, ALCOHOL CLIN EXP RES, V29, P2077, DOI 10.1097/01.alc.0000192039.21305.55; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032; Dougherty G, 1999, MED PHYS, V26, P1341, DOI 10.1118/1.598629; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEHLING PC, 1995, BONE, V17, P205, DOI 10.1016/8756-3282(95)00171-9; GALLAGHER JC, 1980, J LAB CLIN MED, V95, P373; Gayzik FS, 2011, ANN BIOMED ENG, V39, P2568, DOI 10.1007/s10439-011-0359-5; Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035; Hodgson V., 1970, P 14 STAPP CAR CRASH, P341; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; HUBBARD RP, 1971, J BIOMECH, V4, P491, DOI 10.1016/0021-9290(71)90039-X; JASLOW CR, 1990, J BIOMECH, V23, P313, DOI 10.1016/0021-9290(90)90059-C; Khan MN, 2008, CURR ONCOL, V15, pS30; Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116; Lillie EM, 2015, J ANAT, V226, P73, DOI 10.1111/joa.12259; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MARCUS R, 1984, J CLIN ENDOCR METAB, V58, P223, DOI 10.1210/jcem-58-2-223; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; Newman DL, 1998, PHYS MED BIOL, V43, P619, DOI 10.1088/0031-9155/43/3/013; Nusholtz G.S., 1984, 841657 SAE, P41; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Peterson J, 2003, ANAT REC PART A, V274A, P785, DOI 10.1002/ar.a.10096; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; Poole KES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038466; Prevrhal S, 2003, MED PHYS, V30, P1, DOI 10.1118/1.1521940; Raisz LG, 1999, CLIN CHEM, V45, P1353; Ruan J, 2001, Stapp Car Crash J, V45, P395; Saladin K., 2007, ANATOMY PHYSL UNITY; Shatsky SA, 1974, P STAPP CAR CRASH C, P351; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Treece GM, 2012, MED IMAGE ANAL, V16, P952, DOI 10.1016/j.media.2012.02.008; Treece GM, 2010, MED IMAGE ANAL, V14, P276, DOI 10.1016/j.media.2010.01.003; Urban JE, 2016, J ANAT, V229, P838, DOI 10.1111/joa.12247; Urban JE, 2012, J NEUROTRAUM, V29, P2774, DOI 10.1089/neu.2012.2373; Yoganandan N, 2007, J TRAUMA, V66, P7; Yoganandan N, 2010, ACCIDENT ANAL PREV, V42, P1370, DOI 10.1016/j.aap.2010.02.017	44	47	48	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	FEB	2016	31	2					299	307		10.1002/jbmr.2613			9	Endocrinology & Metabolism	Endocrinology & Metabolism	DD8NE	WOS:000370182900007	26255873	Bronze			2021-06-18	
J	Kroshus, E; Baugh, CM; Daneshvar, DH; Stamm, JM; Laursen, RM; Austin, SB				Kroshus, Emily; Baugh, Christine M.; Daneshvar, Daniel H.; Stamm, Julie M.; Laursen, R. Mark; Austin, S. Bryn			Pressure on Sports Medicine Clinicians to Prematurely Return Collegiate Athletes to Play After Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						conflict of interest; organizational structure; sex; college	ICE HOCKEY; TRAINERS; MANAGEMENT; DISEASE; PROFILE; POLICY; SCHOOL	Context: Anecdotal and qualitative evidence has suggested that some clinicians face pressure from coaches and other personnel in the athletic environment to prematurely return athletes to participation after a concussion. This type of pressure potentially can result in compromised patient care. Objective: To quantify the extent to which clinicians in the collegiate sports medicine environment experience pressure when caring for concussed athletes and whether this pressure varies by the supervisory structure of the institution's sports medicine department, the clinician's sex, and other factors. Design: Cross-sectional study. Setting: Web-based survey of National College Athletic Association member institutions. Patients or Other Participants: A total of 789 athletic trainers and 111 team physicians from 530 institutions. Main Outcome Measure(s): We asked participants whether they had experienced pressure from 3 stakeholder populations (other clinicians, coaches, athletes) to prematurely return athletes to participation after a concussion. Modifying variables that we assessed were the position (athletic trainer, physician) and sex of the clinicians, the supervisory structure of their institutions' sports medicine departments, and the division of competition in which their institutions participate. Results: We observed that 64.4% (n = 580) of responding clinicians reported having experienced pressure from athletes to prematurely clear them to return to participation after a concussion, and 53.7% (n = 483) reported having experienced this pressure from coaches. Only 6.6% (n = 59) reported having experienced pressure from other clinicians to prematurely clear an athlete to return to participation after a concussion. Clinicians reported greater pressure from coaches when their departments were under the supervisory purview of the athletic department rather than a medical institution. Female clinicians reported greater pressure from coaches than male clinicians did. Conclusions: Most clinicians reported experiencing pressure to prematurely return athletes to participation after a concussion. Identifying factors that are associated with variability in pressure on clinicians during concussion recovery can inform potential future strategies to reduce these pressures.	[Kroshus, Emily; Austin, S. Bryn] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Kroshus, Emily] Natl Coll Athletic Assoc, Sport Sci Inst, Indianapolis, IN USA; [Kroshus, Emily; Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Boston, MA 02115 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Austin, S. Bryn] Boston Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA USA; [Daneshvar, Daniel H.; Stamm, Julie M.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02215 USA; [Stamm, Julie M.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02215 USA; [Daneshvar, Daniel H.] Sports Legacy Inst, Boston, MA USA; [Laursen, R. Mark] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; [Austin, S. Bryn] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	National Institute of Mental Health of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER	Christine M. Baugh was supported by the National Institute of Mental Health of the National Institutes of Health under award number T32MH019733. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Acosta RV, 1977, WOMEN INTERCOLLEGIAT; Anderson LC, 2005, J MED ETHICS, V31, P88, DOI 10.1136/jme.2002.000836; [Anonymous], 2013, 2013 14 NCAA SPORTS, P56; [Anonymous], MEMB STAT; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Beale D, 2011, WORK EMPLOY SOC, V25, P5, DOI 10.1177/0950017010389228; Bramley H, 2012, CLIN PEDIATR, V51, P283, DOI 10.1177/0009922811422434; Cleveland JN, 2005, ORGANIZATIONAL FRONT, P149; Courson R, 2014, J ATHL TRAINING, V49, P128, DOI 10.4085/1062-6050-49.1.06; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Drummond JL, 2007, J ATHL TRAINING, V42, P106; Hoel H., 2001, EUR J WORK ORGAN PSY, V10, P443, DOI [10.1080/13594320143000780, DOI 10.1080/13594320143000780]; Howard B, HIGH SCH SPORTS PART; Irick E., 2011, NCAA SPORTS SPONSORS; Irick E, 2009, RACE GENDER DEMOGRAP; Kahanov L, 2010, J ATHL TRAINING, V45, P459, DOI 10.4085/1062-6050-45.5.459; Kania ML, 2009, J ATHL TRAINING, V44, P58, DOI 10.4085/1062-6050-44.1.58; King NMP, 2013, AM J BIOETHICS, V13, P13, DOI 10.1080/15265161.2013.828126; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Laursen M, 2010, COLL HLTH ACTION, V49, p[29, 1]; Laursen RM, 2010, ATHLET THER TODAY, V15, P1; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Mazerolle SM, 2012, J ATHL TRAINING, V47, P694, DOI 10.4085/1062-6050-47.6.04; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNamee M, 2013, AM J BIOETHICS, V13, P15, DOI 10.1080/15265161.2013.828123; O'Connor C, 2010, J ATHL TRAINING, V45, P386, DOI 10.4085/1062-6050-45.4.386; Partridge B, 2014, J BIOETHIC INQ, V11, P65, DOI 10.1007/s11673-013-9491-2; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Sailors PR, 2013, AM J BIOETHICS, V13, P22, DOI 10.1080/15265161.2013.828118; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Testoni D, 2013, AM J BIOETHICS, V13, P4, DOI 10.1080/15265161.2013.828114; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Waddington I, 2005, ETHICS SPORT, P182; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wolverton B, COACH MAKES CALL ATH; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	40	47	47	0	26	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP	2015	50	9					944	951		10.4085/1062-6050-50.6.03			8	Sport Sciences	Sport Sciences	CW7MQ	WOS:000365183700007	26207440	Green Published			2021-06-18	
J	Grevesse, T; Dabiri, BE; Parker, KK; Gabriele, S				Grevesse, Thomas; Dabiri, Borna E.; Parker, Kevin Kit; Gabriele, Sylvain			Opposite rheological properties of neuronal microcompartments predict axonal vulnerability in brain injury	SCIENTIFIC REPORTS			English	Article							CYTOSKELETAL STRUCTURE; MECHANICS; STIFFNESS; ACTIN; MECHANOTRANSDUCTION; MICROTUBULES; MORPHOLOGY; INTEGRINS; FILAMENTS; RIGIDITY	Although pathological changes in axonal morphology have emerged as important features of traumatic brain injury (TBI), the mechanical vulnerability of the axonal microcompartment relative to the cell body is not well understood. We hypothesized that soma and neurite microcompartments exhibit distinct mechanical behaviors, rendering axons more sensitive to a mechanical injury. In order to test this assumption, we combined protein micropatterns with magnetic tweezer rheology to probe the viscoelastic properties of neuronal microcompartments. Creep experiments revealed two opposite rheological behaviors within cortical neurons: the cell body was soft and characterized by a solid-like response, whereas the neurite compartment was stiffer and viscous-like. By using pharmacological agents, we demonstrated that the nucleus is responsible for the solid-like behavior and the stress-stiffening response of the soma, whereas neurofilaments have a predominant contribution in the viscous behavior of the neurite. Furthermore, we found that the neurite is a mechanosensitive compartment that becomes softer and adopts a pronounced viscous state on soft matrices. Together, these findings highlight the importance of the regionalization of mechanical and rigidity-sensing properties within neuron microcompartments in the preferential damage of axons during traumatic brain injury and into potential mechanisms of axonal outgrowth after injury.	[Grevesse, Thomas; Gabriele, Sylvain] Univ Mons, CIRMAP, Res Inst Biosci, Interfaces & Complex Fluids Lab,Mechanobiol & Sof, B-7000 Mons, Belgium; [Dabiri, Borna E.; Parker, Kevin Kit] Harvard Univ, Wyss Inst Biol Inspired Engn, Sch Engn & Appl Sci, Dis Biophys Grp, Cambridge, MA 02138 USA	Gabriele, S (corresponding author), Univ Mons, CIRMAP, Res Inst Biosci, Interfaces & Complex Fluids Lab,Mechanobiol & Sof, 20 Pl Parc, B-7000 Mons, Belgium.	sylvain.gabriele@umons.ac.be	GABRIELE, Sylvain/N-6412-2014	GABRIELE, Sylvain/0000-0001-8696-8052	Fonds National de la Recherche Scientifique - FNRSFonds de la Recherche Scientifique - FNRS [2.4622.11, 1.5013.11F]; Foundation for Training in Industrial and Agricultural Research (FRIA)Fonds de la Recherche Scientifique - FNRS; Fonds National de la Recherche Scientifique - FNRSFonds de la Recherche Scientifique - FNRS	This work was supported by the Fonds National de la Recherche Scientifique - FNRS under Grants "Nanomotility'' FRFC no2.4622.11 and "TIRF Microscopy'' no1.5013.11F. T.G. doctoral fellowships is supported by the Foundation for Training in Industrial and Agricultural Research (FRIA). The authors thank Josephine Lantoine for technical help with neuronal cell culture. The Mechanobiology & Soft Matter group belongs to the French research consortium GDR 3070 CellTiss. Published with the financial support of the Fonds National de la Recherche Scientifique - FNRS.	ADAMS JH, 1984, LANCET, V2, P1420; Bausch AR, 1998, BIOPHYS J, V75, P2038, DOI 10.1016/S0006-3495(98)77646-5; Benzina O, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.10.106014; Bernal R, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.018301; BOUCHARD P, 1981, P NATL ACAD SCI-BIOL, V78, P1033, DOI 10.1073/pnas.78.2.1033; Brown A, 1990, SQUID EXPT ANIMALS, P235; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Clegg DO, 2003, FRONT BIOSCI-LANDMRK, V8, pD723, DOI 10.2741/1020; Corr DT, 2009, WOUND REPAIR REGEN, V17, P250, DOI 10.1111/j.1524-475X.2009.00463.x; Dahl KN, 2005, BIOPHYS J, V89, P2855, DOI 10.1529/biophysj.105.062554; Desprat N, 2005, BIOPHYS J, V88, P2224, DOI 10.1529/biophysj.104.050278; DRAKE PF, 1984, J NEUROSCI, V4, P1173; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; Fabry B, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.148102; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Franze K, 2013, ANNU REV BIOMED ENG, V15, P227, DOI 10.1146/annurev-bioeng-071811-150045; Franze K, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/9/094601; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Granek R, 1997, J PHYS II, V7, P1761, DOI 10.1051/jp2:1997214; Grevesse T, 2013, LAB CHIP, V13, P777, DOI 10.1039/c2lc41168g; HEIJINK E, 1995, J NEUROPATH EXP NEUR, V54, P82, DOI 10.1097/00005072-199501000-00010; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Hoffman BD, 2006, P NATL ACAD SCI USA, V103, P10259, DOI 10.1073/pnas.0510348103; Iwashita M, 2014, DEVELOPMENT, V141, P3793, DOI 10.1242/dev.109637; Jiang FX, 2011, ANN BIOMED ENG, V39, P706, DOI 10.1007/s10439-010-0194-0; Jiang X., 2007, OPEN NEUROSCI J, V1, P7, DOI DOI 10.2174/1874082000701010007; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kollmannsberger P, 2011, ANNU REV MATER RES, V41, P75, DOI 10.1146/annurev-matsci-062910-100351; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Leach JB, 2007, J NEURAL ENG, V4, P26, DOI 10.1088/1741-2560/4/2/003; Lin YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004293; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Nakahari T, 2007, AM J PHYSIOL-LUNG C, V292, pL612, DOI 10.1152/ajplung.00433.2006; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; PENG I, 1986, J CELL BIOL, V102, P252, DOI 10.1083/jcb.102.1.252; Perrot R, 2009, BRAIN RES BULL, V80, P282, DOI 10.1016/j.brainresbull.2009.06.004; Pullarkat PA, 2007, PHYS REP, V449, P29, DOI 10.1016/j.physrep.2007.03.002; Riek K, 2012, NEUROIMAGE-CLIN, V1, P81, DOI 10.1016/j.nicl.2012.09.003; Rotsch C, 2000, BIOPHYS J, V78, P520, DOI 10.1016/S0006-3495(00)76614-8; Salgin S, 2012, INT J ELECTROCHEM SC, V7, P12404; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sollich P, 1998, PHYS REV E, V58, P738, DOI 10.1103/PhysRevE.58.738; Solon J, 2007, BIOPHYS J, V93, P4453, DOI 10.1529/biophysj.106.101386; Stabenfeldt SE, 2011, ACTA BIOMATER, V7, P4102, DOI 10.1016/j.actbio.2011.07.026; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]; Versaevel M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1668; Versaevel M, 2014, METHOD CELL BIOL, V121, P33, DOI 10.1016/B978-0-12-800281-0.00003-8; Versaevel M, 2013, SOFT MATTER, V9, P6665, DOI 10.1039/c3sm00147d; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Weinger JS, 2011, CURR BIOL, V21, P154, DOI 10.1016/j.cub.2010.12.038; Wen JH, 2014, NAT MATER, V13, P979, DOI [10.1038/NMAT4051, 10.1038/nmat4051]; WONG PC, 1995, J CELL BIOL, V130, P1413, DOI 10.1083/jcb.130.6.1413; Xu K, 2013, SCIENCE, V339, P452, DOI 10.1126/science.1232251; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041; Zmuda JF, 2000, J CELL SCI, V113, P2797	64	47	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 30	2015	5								9475	10.1038/srep09475			10	Multidisciplinary Sciences	Science & Technology - Other Topics	CE6IF	WOS:000351939400001	25820512	DOAJ Gold, Green Published			2021-06-18	
J	Wang, Z; Wang, Y; Wang, ZY; Gutkind, JS; Wang, ZL; Wang, F; Lu, J; Niu, G; Teng, GJ; Chen, XY				Wang, Zhe; Wang, Yu; Wang, Zhiyong; Gutkind, J. Silvio; Wang, Zhongliang; Wang, Fu; Lu, Jie; Niu, Gang; Teng, Gaojun; Chen, Xiaoyuan			Engineered Mesenchymal Stem Cells with Enhanced Tropism and Paracrine Secretion of Cytokines and Growth Factors to Treat Traumatic Brain Injury	STEM CELLS			English	Article						Mesenchymal stem cell; CXC chemokine receptor 4; Traumatic brain injury; Imaging; Angiogenesis; Neuron	MARROW STROMAL CELLS; ANTICANCER ACTIVITIES; TISSUE REGENERATION; DELIVERY-SYSTEM; TNF-ALPHA; BONE; MIGRATION; MICE; ENGRAFTMENT; APOPTOSIS	Traumatic brain injury (TBI) is the leading cause of death and disability worldwide. Mesenchymal stem cells (MSCs) are promising for the treatment of various diseases and injuries. Many strategies have been applied to attract MSCs to injury site after systemic infusion. In this study, we evidenced that the CXC chemokine receptor 4 (CXCR4)-SDF1 alpha (stromal cell-derived factor 1 alpha) axis in engineered MSCs serves not only to attract MSC migration to TBI but also to activate Akt kinase signaling pathway in MSCs to promote paracrine secretion of cytokines and growth factors. This leads to enhanced vasculogenesis and neuroprotection at the boundary of TBI for improved blood supply, recovery of axon connectivity, and behavioral ability and results in positive feedback loop to enhance additional MSC tropism to injury. These findings indicate a new aspect of SDF1 alpha in mediating CXCR4 engineered MSCs for brain trauma homing and recovery. This potential mechanism may be applicable to other injuries, where CXCR4-SDF1 alpha interaction is highly associated.	[Wang, Zhe; Wang, Yu; Wang, Zhongliang; Wang, Fu; Lu, Jie; Niu, Gang; Chen, Xiaoyuan] Natl Inst Hlth, Lab Mol Imaging & Nanomed, Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA; [Wang, Zhiyong; Gutkind, J. Silvio] Natl Inst Hlth, Oral & Pharyngeal Canc Branch, Natl Inst Dent & Craniofacial Res, Bethesda, MD USA; [Wang, Yu; Teng, Gaojun] Zhongda Hosp, Dept Radiol, Jiangsu Key Lab Mol & Funct Imaging, Nanjing 210009, Peoples R China; [Wang, Zhongliang; Wang, Fu] Xidian Univ, Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China	Teng, GJ (corresponding author), Zhongda Hosp, Dept Radiol, Jiangsu Key Lab Mol & Funct Imaging, Nanjing 210009, Peoples R China.	gjteng@vip.sina.com; shawn.chen@nih.gov	Gutkind, J. Silvio/J-1201-2016; Wang, Fu/S-7955-2017; Wang, Zhongliang/J-8674-2012	Gutkind, J. Silvio/0000-0002-5150-4482; Wang, Fu/0000-0001-9222-0833; Wang, Zhongliang/0000-0001-9388-149X	CNRM program at Henry M. Jackson Foundation; Intramural Research Program (IRP), NIBIB/NIH; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER	This work was supported, in part, by CNRM program at Henry M. Jackson Foundation, and the Intramural Research Program (IRP), NIBIB/NIH.	Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74; Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028; Brenner S, 2004, STEM CELLS, V22, P1128, DOI 10.1634/stemcells.2003-0196; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carlson KB, 2011, GLIA, V59, P267, DOI 10.1002/glia.21099; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Iglesias-Bartolome R, 2012, CELL STEM CELL, V11, P401, DOI 10.1016/j.stem.2012.06.007; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Islam O, 2009, CURR NEUROVASC RES, V6, P42, DOI 10.2174/156720209787466028; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Khoo CP, 2011, TISSUE ENG PART C-ME, V17, P895, DOI [10.1089/ten.TEC.2011.0150, 10.1089/ten.tec.2011.0150]; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Lee RH, 2006, BLOOD, V107, P2153, DOI 10.1182/blood-2005-07-2701; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Levy O, 2013, BLOOD, V122, pE23, DOI 10.1182/blood-2013-04-495119; Liu HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034608; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005; Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703; Sage EK, 2014, THORAX, V69, P638, DOI 10.1136/thoraxjnl-2013-204110; Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood-2010-10-311464; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Stephan MT, 2010, NAT MED, V16, P1035, DOI 10.1038/nm.2198; Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788; Wang F, 2014, P NATL ACAD SCI USA, V111, P5165, DOI 10.1073/pnas.1321374111; Wang Z, 2014, ADV HEALTHC MATER, V3, P1326, DOI 10.1002/adhm.201400088; Wang Z, 2014, PHARM RES-DORDR, V31, P1358, DOI 10.1007/s11095-013-1103-7; Wang Z, 2013, BIOMATERIALS, V34, P6194, DOI 10.1016/j.biomaterials.2013.05.004; Wang Z, 2011, PHARM RES-DORDR, V28, P585, DOI 10.1007/s11095-010-0308-2; Wang Z, 2010, SMALL, V6, P2576, DOI 10.1002/smll.201001122; Wang Z, 2010, BIOMATERIALS, V31, P7115, DOI 10.1016/j.biomaterials.2010.05.075; Wang Z, 2010, EXPERT OPIN DRUG DEL, V7, P159, DOI 10.1517/17425240903468696; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Yu XL, 2012, J NEUROL SCI, V316, P141, DOI 10.1016/j.jns.2012.01.001; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	52	47	51	1	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2015	33	2					456	467		10.1002/stem.1878			12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	AZ4RW	WOS:000348211300014	25346537	Bronze			2021-06-18	
J	Wang, Y; West, JD; Bailey, JN; Westfall, DR; Xiao, H; Arnold, TW; Kersey, PA; Saykin, AJ; McDonald, BC				Wang, Yang; West, John D.; Bailey, Jessica N.; Westfall, Daniel R.; Xiao, Hui; Arnold, Todd W.; Kersey, Patrick A.; Saykin, Andrew J.; McDonald, Brenna C.			Decreased Cerebral Blood Flow in Chronic Pediatric Mild TBI: An MRI Perfusion Study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PATHOPHYSIOLOGY; 3T	We evaluated cerebral blood flow (CBF) in chronic pediatric mild traumatic brain injury (mTBI) using arterial spin labeling (ASL) magnetic resonance imaging perfusion. mTBI patients showed lower CBF than controls in bilateral frontotemporal regions, with no between-group cognitive differences. Findings suggest ASL may be useful to assess functional abnormalities in pediatric mTBI.	[Wang, Yang] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; [Wang, Yang; West, John D.; Bailey, Jessica N.; Westfall, Daniel R.; Xiao, Hui; Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN 46202 USA; [Westfall, Daniel R.] Univ Illinois, Neurosci Program, Urbana, IL USA; [Xiao, Hui] Dongfang Hosp, Dept Radiol, Fuzhou, Fujian, Peoples R China; [Arnold, Todd W.; Kersey, Patrick A.] St Vincent Sports Performance, Carmel, IN USA	Wang, Y (corresponding author), Med Coll Wisconsin, Dept Biophys, Ctr Imaging Res, Dept Radiol,MFRC, 9200 West Wisconsin Ave,G2411, Milwaukee, WI 53226 USA.	yangwang@mcw.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	Indiana State Department of Health Spinal Cord and Brain Injury Fund Research Grant Program; Project Development Team within the ICTSI NIH/NCRR [RR025761]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002529, UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010133, R01AG019771] Funding Source: NIH RePORTER	This work was supported by a grant from the Indiana State Department of Health Spinal Cord and Brain Injury Fund Research Grant Program and by a Project Development Team within the ICTSI NIH/NCRR Grant Number RR025761.	Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Detre JA, 2012, J MAGN RESON IMAGING, V35, P1026, DOI 10.1002/jmri.23581; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Metting Z, 2014, BRAIN COGNITION, V86, P24, DOI 10.1016/j.bandc.2014.01.012; Wang JJ, 2003, J MAGN RESON IMAGING, V18, P404, DOI 10.1002/jmri.10372; Wang Y, 2011, NEUROIMAGE, V54, P1188, DOI 10.1016/j.neuroimage.2010.08.043	10	47	50	0	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 2	2015	40	1			SI		40	44		10.1080/87565641.2014.979927			5	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CA6IR	WOS:000349015800008	25649779	Green Published, Green Accepted			2021-06-18	
J	Mannix, R; Berglass, J; Berkner, J; Moleus, P; Qiu, JH; Andrews, N; Gunner, G; Berglass, L; Jantzie, LL; Robinson, S; Meehan, WP				Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Andrews, Nick; Gunner, Georgia; Berglass, Laura; Jantzie, Lauren L.; Robinson, Shenandoah; Meehan, William P., III			Chronic gliosis and behavioral deficits in mice following repetitive mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						closed head injury; concussion; traumatic brain injury; behavior; gliosis	COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; MOUSE MODEL; COGNITIVE IMPAIRMENT; POSTURAL STABILITY; NCAA CONCUSSION; RECOVERY-TIME; ENCEPHALOPATHY; HYPERACTIVITY; PERFORMANCE	Object. With the recent increasing interest in outcomes after repetitive mild traumatic brain injury (rmTBI; e.g., sports concussions), several models of rmTBI have been established. Characterizing these models in terms of behavioral and histopathological outcomes is vital to assess their clinical translatability. The purpose of this study is to provide an in-depth behavioral and histopathological phenotype of a clinically relevant model of rmTBI. Methods. The authors used a previously published weight-drop model of rmTBI (7 injuries in 9 days) in 2- to 3-month-old mice that produces cognitive deficits without persistent loss of consciousness, seizures, gross structural imaging findings, or microscopic evidence of structural brain damage. Injured and sham-injured (anesthesia only) mice were subjected to a battery of behavioral testing, including tests of balance (rotarod), spatial memory (Morris water maze), anxiety (open field plus maze), and exploratory behavior (hole-board test). After behavioral testing, brains were assessed for histopathological outcomes, including brain volume and microglial and astrocyte immunolabeling. Results. Compared with sham-injured mice, mice subjected to rmTBI showed increased exploratory behavior and had impaired balance and worse spatial memory that persisted up to 3 months after injury. Long-term behavioral deficits were associated with chronic increased astrocytosis and microgliosis but no volume changes. Conclusions. The authors demonstrate that their rmTBI model results in a characteristic behavioral phenotype that correlates with the clinical syndrome of concussion and repetitive concussion. This model offers a platform from which to study therapeutic interventions for rmTBI.	[Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Berglass, Laura; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Andrews, Nick; Gunner, Georgia] Boston Childrens Hosp, Neurodev Behav Core, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Jantzie, Lauren L.; Robinson, Shenandoah] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA; [Mannix, Rebekah; Qiu, Jianhua; Jantzie, Lauren L.; Robinson, Shenandoah; Meehan, William P., III] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA	Mannix, R (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		Children's Hospital Boston Intellectual and Developmental Disabilities Research Center (CHB IDDRC) [P30 RD18655]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	Dr. Andrews receives salary support from the Children's Hospital Boston Intellectual and Developmental Disabilities Research Center (CHB IDDRC, P30 RD18655). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Barreto GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027881; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Engel S, 1996, Acta Neurochir Suppl, V66, P89; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Konrad KN, 2000, BRAIN INJURY, V14, P859; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouton PR, 2002, BRAIN RES, V956, P30, DOI 10.1016/S0006-8993(02)03475-3; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; Yen YC, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00103	43	47	48	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2014	121	6					1342	1350		10.3171/2014.7.JNS14272			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AU3CP	WOS:000345490700007	25267088	Green Accepted, Bronze			2021-06-18	
J	Ashman, T; Cantor, JB; Tsaousides, T; Spielman, L; Gordon, W				Ashman, Teresa; Cantor, Joshua B.; Tsaousides, Theodore; Spielman, Lisa; Gordon, Wayne			Comparison of Cognitive Behavioral Therapy and Supportive Psychotherapy for the Treatment of Depression Following Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; participation; psychotherapy; quality of life; randomized controlled trials anxiety; social support; traumatic brain injury	SCHEDULED TELEPHONE INTERVENTION; STRUCTURED CLINICAL INTERVIEW; REHABILITATION PROGRAM; PSYCHIATRIC-DISORDERS; AXIS-I; EFFICACY; OUTCOMES; LIFE; MOOD; PREVALENCE	Objective: To determine the efficacy of 2 different interventions (cognitive behavioral therapy [CBT] and supportive psychotherapy [SPT]) to treat post-traumatic brain injury (TBI) depression. Participants: A sample of 77 community-dwelling individuals with a TBI, and a diagnosis of depression. Participants were randomized into treatment conditions either CBT or SPT and received up to 16 sessions of individual psychotherapy. Measures: Participants completed the Structured Clinical Interview for DSM-IV and self-report measures of depression (Beck Depression Inventory-Second Edition), anxiety (State-Trait Anxiety Inventory), perceived social support (Interpersonal Support Evaluation List), stressful life events (Life Experiences Survey), and quality of life (QOL) before beginning and immediately following treatment. Results: No significant differences were found at baseline between CBT and SPT groups on demographic factors (sex, age, education, race, and time since injury) or baseline measures of depression, anxiety, participation, perceived social support, stressful life events, or QOL. Analyses of variance revealed significant time effects for the Beck Depression Inventory-Second Edition, State-Trait Anxiety Inventory, and QOL outcome measures but no group effects. Intention-to-treat mixed effects analyses did not find any significant difference in patterns of scores of the outcome measures between the CBT and SPT intervention groups. Conclusions: Both forms of psychotherapy were efficacious in improving diagnoses of depression and anxiety and reducing depressive symptoms. These findings suggest that in this sample of individuals with TBI, CBT was not more effective in treating depression than SPT, though further research is needed with larger sample sizes to identify different components of these interventions that may be effective with different TBI populations. ClinicalTrials. gov Identifier: NCT00211835	[Ashman, Teresa] Shepherd Ctr, Dept Neurorehabil Psychol, Atlanta, GA 30309 USA; [Cantor, Joshua B.; Tsaousides, Theodore; Spielman, Lisa; Gordon, Wayne] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA	Ashman, T (corresponding author), Shepherd Ctr, Dept Neurorehabil Psychol, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.	teresa_ashman@shepherd.org			National Institute for Disability and Rehabilitation Research [H133B040033, H133B000001]	This study was funded by the National Institute for Disability and Rehabilitation Research grants H133B040033 and H133B000001.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrews F. M., 1976, SOCIAL INDICATORS WE; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Beck A., 1979, COGNITIVE THERAPY EM; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Beutler, 2006, PRINCIPLES THERAPEUT; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; BROOKINGS JB, 1988, AM J COMMUN PSYCHOL, V16, P137, DOI 10.1007/BF00906076; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Cabral RR, 2011, J COUNS PSYCHOL, V58, P537, DOI 10.1037/a0025266; Campbell LF, 2013, PSYCHOTHERAPY, V50, P98, DOI 10.1037/a0031817; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; Cuijpers P, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-36; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1437; Doering B, 2011, CURR OPIN PSYCHIATR, V24, P156, DOI 10.1097/YCO.0b013e328343804e; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Etchells E, 1999, J GEN INTERN MED, V14, P27, DOI 10.1046/j.1525-1497.1999.00277.x; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2003, PSYCHOSOMATICS, V44, P161; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; First M., 1997, USERS GUIDE STRUCTUR; GARDNER RM, 1992, J CLIN PSYCHOL, V48, P589, DOI 10.1002/1097-4679(199209)48:5<589::AID-JCLP2270480503>3.0.CO;2-F; Gertler P, 2012, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD009871/ABSTRACT; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Guillamondegui O.D., 2011, COMP EFFECTIVENESS R; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; HILL CE, 1992, J CONSULT CLIN PSYCH, V60, P73, DOI 10.1037/0022-006X.60.1.73; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KUIPER NA, 1986, J HUM STRESS, V12, P149, DOI 10.1080/0097840X.1986.9936781; Lambert MJ, 2013, PSYCHOTHERAPY, V50, P42, DOI 10.1037/a0030682; Levy RL, 1997, J BEHAV MED, V20, P177, DOI 10.1023/A:1025582728271; Li XH, 2012, NEUROPSYCHOPHARMACOL, V37, P77, DOI 10.1038/npp.2011.198; Lykouras L, 1998, PSYCHOPATHOLOGY, V31, P213, DOI 10.1159/000029042; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MEICHENBAUM D, 1974, PSYCHOTHER-THEOR RES, V11, P103, DOI 10.1037/h0086326; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mohr DC, 2012, JAMA-J AM MED ASSOC, V307, P2278, DOI 10.1001/jama.2012.5588; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Pinsker H, 1991, HDB SHORT TERM DYNAM, P220; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rasquin SMC, 2010, NEUROPSYCHOL REHABIL, V20, P760, DOI 10.1080/09602011.2010.484645; SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932; Schnyder U, 1998, J PSYCHOSOM RES, V45, P419, DOI 10.1016/S0022-3999(98)00008-7; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Simpson GK, 2011, J HEAD TRAUMA REHAB, V26, P290, DOI 10.1097/HTR.0b013e3182225250; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Spielberger C. D, 1970, MANUAL STATETRAIT AN; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Taylor D, 2011, BRIT J PSYCHIAT, V198, P179, DOI 10.1192/bjp.bp.110.077610; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Tsaousides T, 2013, BRAIN IMPAIR, V14, P63, DOI 10.1017/BrImp.2013.8; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wampold BE, 2013, PSYCHOTHERAPY, V50, P16, DOI 10.1037/a0030570; Wampold BE, 2011, CLIN PSYCHOL REV, V31, P1304, DOI 10.1016/j.cpr.2011.07.012; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WINSTON A, 1986, HOSP COMMUNITY PSYCH, V37, P1105	92	47	50	0	40	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					467	478		10.1097/HTR.0000000000000098			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800006	25370439				2021-06-18	
J	Spira, JL; Lathan, CE; Bleiberg, J; Tsao, JW				Spira, James L.; Lathan, Corinna E.; Bleiberg, Joseph; Tsao, Jack W.			The Impact of Multiple Concussions on Emotional Distress, Post-Concussive Symptoms, and Neurocognitive Functioning in Active Duty United States Marines Independent of Combat Exposure or Emotional Distress	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; behavioral assessments; cognitive function; head trauma; military injury	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; RECURRENT CONCUSSION; NEUROPSYCHOLOGICAL OUTCOMES; POSTCONCUSSION SYNDROME; STRESS; PERFORMANCE; DEPLOYMENT; INDEX; TIME	Controversy exists as to whether the lingering effects of concussion on emotional, physical, and cognitive symptoms is because of the effects of brain trauma or purely to emotional factors such as post-traumatic stress disorder or depression. This study examines the independent effects of concussion on persistent symptoms. The Defense Automated Neurobehavioral Assessment, a clinical decision support tool, was used to assess neurobehavioral functioning in 646 United States Marines, all of whom were fit for duty. Marines were assessed for concussion history, post-concussive symptoms, emotional distress, neurocognitive functioning, and deployment history. Results showed that a recent concussion or ever having experienced a concussion was associated with an increase in emotional distress, but not with persistent post-concussive symptoms (PPCS) or neurocognitive functioning. Having had multiple lifetime concussions, however, was associated with greater emotional distress, PPCS, and reduced neurocognitive functioning that needs attention and rapid discrimination, but not for memory-based tasks. These results are independent of deployment history, combat exposure, and symptoms of post-traumatic stress disorder and depression. Results supported earlier findings that a previous concussion is not generally associated with post-concussive symptoms independent of covariates. In contrast with other studies that failed to find a unique contribution for concussion to PPCS, however, evidence of recent and multiple concussion was seen across a range of emotional distress, post-concussive symptoms, and neurocognitive functioning in this study population. Results are discussed in terms of implications for assessing concussion on return from combat.	[Spira, James L.] US Dept Vet Affairs, Natl Ctr PTSD, Pacific Isl Div, Honolulu, HI 96819 USA; [Spira, James L.] Univ Hawaii, John A Burns Sch Med, Dept Psychiat, Honolulu, HI 96822 USA; [Lathan, Corinna E.] AnthroTronix Inc, Silver Spring, MD USA; [Bleiberg, Joseph] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence Psychol Hlth & Traum, Bethesda, MD USA; [Tsao, Jack W.] US Navy Bur Med & Surg Falls Church, Traumat Brain Injury Program, Wounded Ill & Injured Directorate, Falls Church, VA USA	Spira, JL (corresponding author), US Dept Vet Affairs, Natl Ctr PTSD, 3375 Koapaka St,I-560, Honolulu, HI 96819 USA.	James.Spira@va.gov		Bleiberg, Joseph/0000-0003-0867-5494	U.S. Navy Bureau of Medicine and Surgery, Wounded, Ill, and Injured Directorate	This work was supported by the U.S. Navy Bureau of Medicine and Surgery, Wounded, Ill, and Injured Directorate, as well as with resources and the use of facilities at the US Department of Veterans Affairs, National Center for PTSD, Pacific Islands Health Care System.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chard K.M., 2012, REHABIL PSYCHOL, V57, P13; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kennedy JE, 2003, CLIN NEUROPSYCHOL, V17, P303, DOI 10.1076/clin.17.3.303.18091; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lathan C, 2013, MIL MED, V178, P365, DOI 10.7205/MILMED-D-12-00438; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Maguen S, 2012, J TRAUMA STRESS, V25, P3, DOI 10.1002/jts.21669; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Prins A, 2004, PRIMARY CARE PSYCHIA, V9, P151, DOI 10.1185/135525703125002360; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sosnoff JJ, 2007, NEUROPSYCHOLOGY, V21, P796, DOI 10.1037/0894-4105.21.6.796; Spira J., 2013, P MIL HLTH SYST RES; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Tanelian T., 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2010, MILITARY NEUROPSYCHO, P321; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wesensten N., 2010, MILITARY NEUROPSYCHO, P297	56	47	47	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1823	1834		10.1089/neu.2014.3363			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400002	25003552	Bronze, Green Published			2021-06-18	
J	Kelly, KC; Jordan, EM; Joyner, AB; Burdette, GT; Buckley, TA				Kelly, Kassandra C.; Jordan, Erin M.; Joyner, A. Barry; Burdette, G. Trey; Buckley, Thomas A.			National Collegiate Athletic Association Division I Athletic Trainers' Concussion-Management Practice Patterns	JOURNAL OF ATHLETIC TRAINING			English	Article						baseline testing; head injuries; return to participation	ERROR SCORING SYSTEM; SPORT-RELATED CONCUSSION; MEDICINE PROFESSIONALS; PERFORMANCE; PLAYERS	Context: A cornerstone of the recent consensus statements on concussion is a multifaceted concussion-assessment program at baseline and postinjury and when tracking recovery. Earlier studies of athletic trainers' (ATs') practice patterns found limited use of multifaceted protocols; however, these authors typically grouped diverse athletic training settings together. Objective: To (1) describe the concussion-management practice patterns of National Collegiate Athletic Association (NCAA) Division I ATs, (2) compare these practice patterns to earlier studies, and (3) objectively characterize the clinical examination. Design: Cross-sectional study. Setting: Online survey. Patients or Other Participants: A total of 610 ATs from NCAA Division I institutions, for a response rate of 34.4%. Main Outcome Measure(s): The survey had 3 subsections: demographic questions related to the participant's experiences, concussion-assessment practice patterns, and concussion-recovery and return-to-participation practice patterns. Specific practice-pattern questions addressed balance, cognitive and mental status, neuropsychological testing, and self-reported symptoms. Finally, specific components of the clinical examination were examined. Results: We identified high rates of multifaceted assessments (ie, assessments using at least 3 techniques) during testing at baseline (71.2%), acute concussion assessment (79.2%), and return to participation (66.9%). The specific techniques used are provided along with their adherence with evidence-based practice findings. Respondents endorsed a diverse array of clinical examination techniques that often overlapped objective concussion-assessment protocols or were likely used to rule out associated potential conditions. Respondents were cognizant of the Third International Consensus Statement, the National Athletic Trainers' Association position statement, and the revised NCAA Sports Medicine Handbook recommendations. Conclusions: Athletic trainers in NCAA Division I demonstrated widespread use of multifaceted concussion-assessment techniques and appeared compliant with recent consensus statements and the NCAA Sports Medicine Handbook.	[Kelly, Kassandra C.; Jordan, Erin M.; Joyner, A. Barry; Burdette, G. Trey] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 144 Human Performance Lab,541 South Coll Ave, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			[Anonymous], NCAA DIV 1 INT ATHL; Bey T, 2009, WEST J EMERG MED, V10, P6; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Impact Applications Inc, IMP TEST FREQ ASK QU; Klossner D, 2010, NATL COLLEGIATE ATHL; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Onate JA, 2000, J ATHL TRAINING, V35, P155; Onate JA, 2007, J ATHL TRAINING, V42, P446; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Schwartz A., 2010, NEW YORK TIMES  0917, pD5; Schwartz A., 2010, SUICIDE REVEALS SIGN, pA1; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	28	47	47	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2014	49	5					665	673		10.4085/1062-6050-49.3.25			9	Sport Sciences	Sport Sciences	AY4NN	WOS:000347555600014	25188315	Green Published, Bronze			2021-06-18	
J	Babl, FE; Lyttle, MD; Bressan, S; Borland, M; Phillips, N; Kochar, A; Dalziel, SR; Dalton, S; Cheek, JA; Furyk, J; Gilhotra, Y; Neutze, J; Ward, B; Donath, S; Jachno, K; Crowe, L; Williams, A; Oakley, E				Babl, Franz E.; Lyttle, Mark D.; Bressan, Silvia; Borland, Meredith; Phillips, Natalie; Kochar, Amit; Dalziel, Stuart R.; Dalton, Sarah; Cheek, John A.; Furyk, Jeremy; Gilhotra, Yuri; Neutze, Jocelyn; Ward, Brenton; Donath, Susan; Jachno, Kim; Crowe, Louise; Williams, Amanda; Oakley, Ed		PREDICT Res Network	A prospective observational study to assess the diagnostic accuracy of clinical decision rules for children presenting to emergency departments after head injuries (protocol): the Australasian Paediatric Head Injury Rules Study (APHIRST)	BMC PEDIATRICS			English	Article						Head injury; Clinical decision rule; Computed tomography; Validation	COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; PREDICTION; CHALICE; CHILDHOOD; SCANS; CATCH; RISK	Background: Head injuries in children are responsible for a large number of emergency department visits. Failure to identify a clinically significant intracranial injury in a timely fashion may result in long term neurodisability and death. Whilst cranial computed tomography (CT) provides rapid and definitive identification of intracranial injuries, it is resource intensive and associated with radiation induced cancer. Evidence based head injury clinical decision rules have been derived to aid physicians in identifying patients at risk of having a clinically significant intracranial injury. Three rules have been identified as being of high quality and accuracy: the Canadian Assessment of Tomography for Childhood Head Injury (CATCH) from Canada, the Children's Head Injury Algorithm for the Prediction of Important Clinical Events (CHALICE) from the UK, and the prediction rule for the identification of children at very low risk of clinically important traumatic brain injury developed by the Pediatric Emergency Care Applied Research Network (PECARN) from the USA. This study aims to prospectively validate and compare the performance accuracy of these three clinical decision rules when applied outside the derivation setting. Methods/design: This study is a prospective observational study of children aged 0 to less than 18 years presenting to 10 emergency departments within the Paediatric Research in Emergency Departments International Collaborative (PREDICT) research network in Australia and New Zealand after head injuries of any severity. Predictor variables identified in CATCH, CHALICE and PECARN clinical decision rules will be collected. Patients will be managed as per the treating clinicians at the participating hospitals. All patients not undergoing cranial CT will receive a follow up call 14 to 90 days after the injury. Outcome data collected will include results of cranial CTs (if performed) and details of admission, intubation, neurosurgery and death. The performance accuracy of each of the rules will be assessed using rule specific outcomes and inclusion and exclusion criteria. Discussion: This study will allow the simultaneous comparative application and validation of three major paediatric head injury clinical decision rules outside their derivation setting.	[Babl, Franz E.; Lyttle, Mark D.; Bressan, Silvia; Cheek, John A.; Oakley, Ed] Royal Childrens Hosp, Dept Emergency Med, Parkville, Vic 3052, Australia; [Babl, Franz E.; Bressan, Silvia; Cheek, John A.; Ward, Brenton; Donath, Susan; Jachno, Kim; Crowe, Louise; Williams, Amanda; Oakley, Ed] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Babl, Franz E.; Donath, Susan; Jachno, Kim; Crowe, Louise; Williams, Amanda; Oakley, Ed] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Paediat, Melbourne, Vic 3010, Australia; [Babl, Franz E.] Natl Trauma Res Inst, Prahran, Vic, Australia; [Lyttle, Mark D.] Bristol Royal Hosp Children, Bristol, Avon, England; [Lyttle, Mark D.] Univ W England, Acad Dept Emergency Care, Bristol BS16 1QY, Avon, England; [Bressan, Silvia] Univ Padua, Padua, Italy; [Borland, Meredith] Princess Margaret Hosp Children, Perth, WA, Australia; [Phillips, Natalie] Univ Queensland, Royal Childrens Hosp, Brisbane, Qld, Australia; [Phillips, Natalie] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Kochar, Amit] Womens & Childrens Hosp, Adelaide, SA, Australia; [Dalziel, Stuart R.] Starship Hosp, Auckland, New Zealand; [Dalziel, Stuart R.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; [Dalton, Sarah] Childrens Hosp Westmead, Sydney, NSW, Australia; [Cheek, John A.] Monash Med Ctr, Clayton, Vic 3168, Australia; [Furyk, Jeremy] Townsville Hosp, Townsville, Qld, Australia; [Gilhotra, Yuri] Univ Queensland, Mater Childrens Hosp, Brisbane, Qld 4101, Australia; [Neutze, Jocelyn] Kidzfirst Middlemore Hosp, Auckland, New Zealand	Babl, FE (corresponding author), Royal Childrens Hosp, Dept Emergency Med, Flemington Rd, Parkville, Vic 3052, Australia.	franz.babl@rch.org.au		Lyttle, Mark/0000-0002-8634-7210; Jachno, Kim/0000-0003-2550-9674; Donath, Susan/0000-0003-2489-3977; Crowe, Louise/0000-0003-4619-9708; Furyk, Jeremy/0000-0002-9503-0928	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [GNT1046727]; Centre of Research Excellence for Paediatric Emergency Medicine, Canberra, Australia [GNT1058560]; Murdoch Childrens Research Institute, Melbourne, Australia; Queensland Emergency Medicine Research Foundation, Brisbane, Australia [EMPJ-11162]; Perpetual Philanthropic Services, Australia [2012/1140]; Auckland Medical Research Foundation [3112011]; A + Trust (Auckland District Health Board), Auckland, New Zealand; WA Health Targeted Research Funds , Perth, Australia; Townsville Hospital and Health Service Private Practice Research and Education Trust Fund, Townsville, Australia; Victorian Government's Infrastructure Support Program, Melbourne, Australia; Murdoch Children's Research Institute; Health Research Council of New ZealandHealth Research Council of New Zealand [HRC13/556]	We would like to thank participating families, emergency department staff and the site research assistants. The study is funded by grants from the National Health and Medical Research Council (project grant GNT1046727, Centre of Research Excellence for Paediatric Emergency Medicine GNT1058560), Canberra, Australia; the Murdoch Childrens Research Institute, Melbourne, Australia; the Queensland Emergency Medicine Research Foundation (EMPJ-11162), Brisbane, Australia; Perpetual Philanthropic Services (2012/1140), Australia; Auckland Medical Research Foundation (No. 3112011) and the A + Trust (Auckland District Health Board), Auckland, New Zealand; WA Health Targeted Research Funds 2013, Perth, Australia; the Townsville Hospital and Health Service Private Practice Research and Education Trust Fund, Townsville, Australia; and the Victorian Government's Infrastructure Support Program, Melbourne, Australia. FEB's time was part funded by a grant from the Murdoch Children's Research Institute. SRDs time was part funded by the Health Research Council of New Zealand (HRC13/556).	Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Gazelle GS, 2005, RADIOLOGY, V235, P361, DOI 10.1148/radiol.2352040330; Hoyle JD, 2014, PEDIATR EMERG CARE, V30, P1, DOI 10.1097/PEC.0000000000000059; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; National Center for Health Statistics Centers for Disease Control and Prevention, 2005, PUBL US DAT FIL EM D; National Center for Health Statistics Centers for Disease Control and Prevention, 1995, PUBL US DAT FIL EM D; OSMOND M, 2012, CJEM S1, V14; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4	25	47	50	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	JUN 13	2014	14								148	10.1186/1471-2431-14-148			10	Pediatrics	Pediatrics	AK3WJ	WOS:000338355600002	24927811	DOAJ Gold, Green Published			2021-06-18	
J	Duclos, C; Dumont, M; Blais, H; Paquet, J; Laflamme, E; de Beaumont, L; Wiseman-Hakes, C; Menon, DK; Bernard, F; Gosselin, N				Duclos, Catherine; Dumont, Marie; Blais, Helene; Paquet, Jean; Laflamme, Elyse; de Beaumont, Louis; Wiseman-Hakes, Catherine; Menon, David K.; Bernard, Francis; Gosselin, Nadia			Rest-Activity Cycle Disturbances in the Acute Phase of Moderate to Severe Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; sleep; circadian rhythms; actigraphy; intensive care	MECHANICALLY VENTILATED PATIENTS; CIRCADIAN-RHYTHMS; SLEEP RESTRICTION; HEAD-INJURY; ACTIGRAPHY; CONSEQUENCES; IMPACT; SCALE; CLASSIFICATION; VALIDATION	Background. Sleep-wake disturbances are among the most persistent sequelae after traumatic brain injury (TBI) and probably arise during the hospital stay following TBI. These disturbances are characterized by difficulties sleeping at night and staying awake during the day. Objective. The aim of the present study was to document rest-activity cycle consolidation in acute moderate/severe TBI using actigraphy and to assess its association with injury severity and outcome. Methods. In all, 16 hospitalized patients (27.1 +/- 11.3 years) with moderate/severe TBI wore actigraphs for 10 days, starting in the intensive care unit (ICU) when continuous sedation was discontinued and patients had reached medical stability. Activity counts were summed for daytime (7: 00-21: 59 hours) and nighttime periods (22: 00-6: 59 hours). The ratio of daytime period activity to total 24-hour activity was used to quantify rest-activity cycle consolidation. An analysis of variance was carried out to characterize the evolution of the daytime activity ratio over the recording period. Results. Rest-activity cycle was consolidated only 46.6% of all days; however, a significant linear trend of improvement was observed over time. Greater TBI severity and longer ICU and hospital lengths of stay were associated with poorer rest-activity cycle consolidation and evolution. Patients with more rapid return to consolidated rest-activity cycle were more likely to have cleared posttraumatic amnesia and have lower disability at hospital discharge. Conclusions. Patients with acute moderate/severe TBI had an altered rest-activity cycle, probably reflecting severe fragmentation of sleep and wake episodes, which globally improved over time. A faster return to rest-activity cycle consolidation may predict enhanced brain recovery.	[Duclos, Catherine; Dumont, Marie; Blais, Helene; Paquet, Jean; Laflamme, Elyse; de Beaumont, Louis; Wiseman-Hakes, Catherine; Bernard, Francis; Gosselin, Nadia] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; [Duclos, Catherine; Dumont, Marie; Wiseman-Hakes, Catherine; Bernard, Francis; Gosselin, Nadia] Univ Montreal, Montreal, PQ, Canada; [de Beaumont, Louis] Univ Quebec Trois Rivieres, Trois Rivieres, PQ GA9 5H7, Canada; [Menon, David K.] Univ Cambridge, Cambridge, England	Gosselin, N (corresponding author), Hop Sacre Coeur, Ctr Adv Res Sleep Med, 5400 Boul Gouin Ouest,Local E-0330, Montreal, PQ H4J 1C5, Canada.	nadia.gosselin@umontreal.ca	Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds pour la recherche du Quebec, Sante (FRQS); University of Montreal; Fondation Neurotrauma Marie-Robert; Reseau provincial de recherche en adaptation-readaptation (REPAR); J. A. De Seve foundation; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research was supported by the Canadian Institutes of Health Research (CIHR), by the Fonds pour la recherche du Quebec, Sante (FRQS), by the University of Montreal (studentship to CD), by the Fondation Neurotrauma Marie-Robert (studentship to CD), by the Reseau provincial de recherche en adaptation-readaptation (REPAR) (studentship to CWH), and by the J. A. De Seve foundation (studentship to CD).	Barion A, 2007, SLEEP MED, V8, P566, DOI 10.1016/j.sleep.2006.11.017; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Beecroft JM, 2008, INTENS CARE MED, V34, P2076, DOI 10.1007/s00134-008-1180-y; Bijwadia JS, 2009, CURR OPIN CRIT CARE, V15, P25, DOI 10.1097/MCC.0b013e3283220dc7; Blood ML, 1997, SLEEP, V20, P388; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chae KY, 2009, SLEEP MED, V10, P621, DOI 10.1016/j.sleep.2008.07.009; Cooper AB, 2000, CHEST, V117, P809, DOI 10.1378/chest.117.3.809; Czeisler CA, 2007, COLD SPRING HARB SYM, V72, P579, DOI 10.1101/sqb.2007.72.064; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; Dispersyn G, 2008, CHRONOBIOL INT, V25, P835, DOI 10.1080/07420520802551386; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Gehlbach BK, 2012, SLEEP, V35, P1105, DOI 10.5665/sleep.1998; Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Hagen C, 1972, RANCHO LOS AMIGOS LE; Hardin KA, 2009, CHEST, V136, P284, DOI 10.1378/chest.08-1546; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lichstein KL, 2006, SLEEP, V29, P232; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mullington JM, 2009, PROG CARDIOVASC DIS, V51, P294, DOI 10.1016/j.pcad.2008.10.003; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Natale V, 2009, SLEEP, V32, P767, DOI 10.1093/sleep/32.6.767; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Padhye NS, 2007, BIOL RES NURS, V9, P30, DOI 10.1177/1099800407303509; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robillard R, 2011, SLEEP, V34, P335, DOI 10.1093/sleep/34.3.335; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; TEASDALE G, 1974, LANCET, V2, P81; Van Der Werf YD, 2009, NAT NEUROSCI, V12, P122, DOI 10.1038/nn.2253; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Walker MP, 2004, CELL MOL LIFE SCI, V61, P3009, DOI 10.1007/s00018-004-4351-1; Wang SY, 2010, CANCER NURS, V33, pE11, DOI 10.1097/NCC.0b013e3181b3278e; Wiseman-Hakes C, 2009, CRIT REV PHYS REHABI, V21, P317, DOI DOI 10.1615/CRITREVPHYSREHABILMED.V21.I3-4.70; Wiseman-Hakes C, 2011, BRAIN INJURY, V25, P1256, DOI 10.3109/02699052.2011.608215	48	47	49	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2014	28	5					472	482		10.1177/1545968313517756			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AN6SQ	WOS:000340727700009	24379082				2021-06-18	
J	Tanner, CM; Goldman, SM; Ross, GW; Grate, SJ				Tanner, Caroline M.; Goldman, Samuel M.; Ross, G. Webster; Grate, Stephen J.			The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk	ALZHEIMERS & DEMENTIA			English	Article						Neurodegeneration; Parkinson's disease; Alzheimer's disease; Motor neuron disease; Military; Risk factors; Pesticides; Traumatic brain injury; Solvents; Gene-environment interaction	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON-DISEASE; METHYLAMINO-L-ALANINE; STRIATAL DOPAMINE TRANSPORTER; CUMULATIVE LEAD-EXPOSURE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; OCCUPATIONAL EXPOSURES; POLYCHLORINATED-BIPHENYLS; PESTICIDE EXPOSURE	Alzheimer's disease, Parkinson's disease, and motor neuron disease, the most common of the late-life neurodegenerative disorders, are in most cases thought to have complex etiologies. Common features among these disorders include insidious onset, pathological findings of protein aggregates and selected neuronal degeneration, and resulting characteristic clinical syndromes. The number of elders in the United States, including aging veterans, is increasing. Investigation of causes and preventive interventions for neurodegenerative disorders is increasingly relevant. Recent epidemiological and laboratory studies suggest that exposures years or decades before diagnosis can trigger the processes that ultimately result in a neurodegenerative disease. If this is correct, preventive measures may be needed in midlife or earlier. This article will focus on putative risk factors relevant to military service. Published by Elsevier Inc. on behalf of The Alzheimer's Association.	[Tanner, Caroline M.; Goldman, Samuel M.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA; [Tanner, Caroline M.; Goldman, Samuel M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Tanner, Caroline M.; Goldman, Samuel M.] Parkinsons Inst, Sunnyvale, CA USA; [Ross, G. Webster] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA; [Grate, Stephen J.] MSAMRMC, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA	Tanner, CM (corresponding author), San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA.	caroline.tanner@ucsf.edu	Goldman, Samuel/A-2225-2014	Goldman, Samuel/0000-0002-3039-9927	United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Publication of this article was supported by the United States Army Medical Research and Materiel Command.	Alonso A, 2010, J NEUROL NEUROSUR PS, V81, P1249, DOI 10.1136/jnnp.2009.180232; Ascherio A, 2004, AM J EPIDEMIOL, V160, P977, DOI 10.1093/aje/kwh312; Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Barrett DH, 2001, NEUROTOXICOLOGY, V22, P491, DOI 10.1016/S0161-813X(01)00051-1; Barth SK, 2009, AM J IND MED, V52, P663, DOI 10.1002/ajim.20718; Bergomi M, 2002, ENVIRON RES, V89, P116, DOI 10.1006/enrs.2002.4361; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bradley WG, 2009, AMYOTROPH LATERAL SC, V10, P7, DOI 10.3109/17482960903286009; Brimfield AA, 2012, PROG MOL BIOL TRANSL, V112, P209, DOI 10.1016/B978-0-12-415813-9.00007-6; Bronstein J, 2009, ENVIRON HEALTH PERSP, V117, P117, DOI 10.1289/ehp.11702; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Byrne S, 2012, J NEUROL NEUROSUR PS, V83, P365, DOI 10.1136/jnnp-2011-301530; Calderon-Garciduenas L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/161687; Callaghan B, 2011, NEURODEGENER DIS, V8, P1, DOI 10.1159/000315405; Caller TA, 2009, AMYOTROPH LATERAL SC, V10, P101, DOI 10.3109/17482960903278485; CHANCELLOR AM, 1993, J NEUROL NEUROSUR PS, V56, P1200, DOI 10.1136/jnnp.56.11.1200; Chen HL, 2006, AM J EPIDEMIOL, V163, P726, DOI 10.1093/aje/kwj096; Chio A, 2013, NEUROEPIDEMIOLOGY, V41, P118, DOI 10.1159/000351153; CHIO A, 1991, NEUROEPIDEMIOLOGY, V10, P174, DOI 10.1159/000110267; Chou AP, 2008, J BIOL CHEM, V283, P34696, DOI 10.1074/jbc.M802210200; Chu I, 1998, J APPL TOXICOL, V18, P285; CHU I, 1994, FUND APPL TOXICOL, V22, P457, DOI 10.1006/faat.1994.1051; Committee on Contaminated DrinkingWater at Camp Lejeune BoE-SaT Division on Earth and Life Studies ACADEMIES NRCOTN, 2009, CONT WAT SUPPL CAMP; Corrigan FM, 1998, EXP NEUROL, V150, P339, DOI 10.1006/exnr.1998.6776; Corrigan FM, 2000, J TOXICOL ENV HEAL A, V59, P229, DOI 10.1080/009841000156907; Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006; Cox PA, 2002, NEUROLOGY, V58, P956, DOI 10.1212/WNL.58.6.956; Cox PA, 2009, AMYOTROPH LATERAL SC, V10, P109, DOI 10.3109/17482960903286066; CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; de Munck E, 2013, ENVIRON TOXICOL PHAR, V36, P243, DOI 10.1016/j.etap.2013.04.007; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dinis-Oliveira RJ, 2006, NEUROTOXICOLOGY, V27, P1110, DOI 10.1016/j.neuro.2006.05.012; DUNCAN MW, 1988, LANCET, V2, P631; Elbaz A, 2004, ANN NEUROL, V55, P430, DOI 10.1002/ana.20051; Elbaz A, 2009, ANN NEUROL, V66, P494, DOI 10.1002/ana.21717; Elwan MA, 2006, TOXICOL APPL PHARM, V211, P188, DOI 10.1016/j.taap.2005.06.003; Fang F, 2006, NEUROEPIDEMIOLOGY, V27, P217, DOI 10.1159/000096956; Fang F, 2010, AM J EPIDEMIOL, V171, P1126, DOI 10.1093/aje/kwq063; Fang F, 2009, ENVIRON HEALTH PERSP, V117, P1387, DOI 10.1289/ehp.0900580; Fang F, 2009, ARCH NEUROL-CHICAGO, V66, P515, DOI 10.1001/archneurol.2009.13; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Finkelstein MM, 2007, ENVIRON RES, V104, P420, DOI 10.1016/j.envres.2007.03.002; Firestone JA, 2010, AM J IND MED, V53, P217, DOI 10.1002/ajim.20788; Fitzmaurice AG, 2013, P NATL ACAD SCI USA, V110, P636, DOI 10.1073/pnas.1220399110; FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119; FORNO LS, 1986, ANN NEUROL, V20, P449, DOI 10.1002/ana.410200403; Frisardi V, 2010, J ALZHEIMERS DIS, V20, P17, DOI 10.3233/JAD-2009-1340; Gait R, 2003, NEUROEPIDEMIOLOGY, V22, P353, DOI 10.1159/000072925; Gale CR, 1999, LANCET, V354, P2116, DOI 10.1016/S0140-6736(99)06264-9; Gash DM, 2008, ANN NEUROL, V63, P184, DOI 10.1002/ana.21288; Gatto NM, 2009, ENVIRON HEALTH PERSP, V117, P1912, DOI 10.1289/ehp.0900852; GIBBERD FB, 1980, LANCET, V2, P135; Gillette JS, 2003, TOXICOL APPL PHARM, V192, P287, DOI 10.1016/S0041-008X(03)00326-0; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P776, DOI 10.1002/ana.22629; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Goldman SM, 2013, NEUROLOGY, V79; Gordon PH, 2011, EUR J EPIDEMIOL, V26, P729, DOI 10.1007/s10654-011-9595-0; Gorell JM, 1997, NEUROLOGY, V48, P650, DOI 10.1212/WNL.48.3.650; GRANIERI E, 1988, NEUROLOGY, V38, P1604, DOI 10.1212/WNL.38.10.1604; GRAVES AB, 1990, J CLIN EPIDEMIOL, V43, P35, DOI 10.1016/0895-4356(90)90053-R; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS58, DOI 10.1093/ije/20.Supplement_2.S58; GUNNARSSON LG, 1992, BRIT J IND MED, V49, P791; GUNNARSSON LG, 1991, ACTA NEUROL SCAND, V83, P394, DOI 10.1111/j.1600-0404.1991.tb03970.x; Gurel A, 2005, J CHEM NEUROANAT, V29, P173, DOI 10.1016/j.jchemneu.2005.01.001; Haley RW, 2003, NEUROLOGY, V61, P750, DOI 10.1212/WNL.61.6.750; Harms MB, 2013, NEUROL CLIN, V31, P929, DOI 10.1016/j.ncl.2013.05.003; Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423; Horner RD, 2003, NEUROLOGY, V61, P742, DOI 10.1212/01.WNL.0000069922.32557.CA; Horner RD, 2008, NEUROEPIDEMIOLOGY, V31, P28, DOI 10.1159/000136648; Hu H, 1998, ENVIRON HEALTH PERSP, V106, P1, DOI 10.2307/3433626; Institute of Medicine (IOM), 2012, VET AG OR UPD 2012; Institute of Medicine (U. S.), 2010, UPD HLTH EFF SERV GU; IOM, 2008, VET AG OR UPD 2008; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Johnson FO, 2011, J PHARMACOL EXP THER, V338, P518, DOI 10.1124/jpet.110.174466; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; Kahn HA, 1966, EPIDEMIOLOGICAL STUD; Kamel F, 2007, HUM EXP TOXICOL, V26, P243, DOI 10.1177/0960327107070582; Kamel F, 2005, NEURODEGENER DIS, V2, P195, DOI 10.1159/000089625; Kamel F, 1999, NEUROEPIDEMIOLOGY, V18, P194, DOI 10.1159/000026211; Kamel F, 2002, EPIDEMIOLOGY, V13, P311, DOI 10.1097/00001648-200205000-00012; Kamel F, 2014, PARKINSONISM RELAT D, V20, P82, DOI 10.1016/j.parkreldis.2013.09.023; Kamel F, 2012, NEUROTOXICOLOGY, V33, P457, DOI 10.1016/j.neuro.2012.04.001; Karamyan VT, 2008, LIFE SCI, V82, P233, DOI 10.1016/j.lfs.2007.11.020; KILNESS AW, 1977, JAMA-J AM MED ASSOC, V237, P2843, DOI 10.1001/jama.237.26.2843; KORGESKI GP, 1983, AM J PSYCHIAT, V140, P1443; Kou JH, 2007, TOXICOL LETT, V171, P154, DOI 10.1016/j.toxlet.2007.05.005; KUKULL WA, 1995, AM J EPIDEMIOL, V141, P1059, DOI 10.1093/oxfordjournals.aje.a117370; Kuter K, 2010, NEUROCHEM RES, V35, P1121, DOI 10.1007/s11064-010-0163-x; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; Lesage Suzanne, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS66, DOI 10.1016/S1353-8020(11)70022-0; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Lobner D, 2009, AMYOTROPH LATERAL SC, V10, P56, DOI 10.3109/17482960903269062; Logroscino G, 2010, J NEUROL NEUROSUR PS, V81, P385, DOI 10.1136/jnnp.2009.183525; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Maher NE, 2002, NEUROLOGY, V58, P79, DOI 10.1212/WNL.58.1.79; Malek AM, 2013, NEURODEGEN DIS; Malek AM, 2012, ENVIRON RES, V117, P112, DOI 10.1016/j.envres.2012.06.007; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; McGeet PL, 2011, PROG NEUROBIOL, V95, P663, DOI 10.1016/j.pneurobio.2011.04.001; McGuire V, 1997, AM J EPIDEMIOL, V145, P1076, DOI 10.1093/oxfordjournals.aje.a009070; Miranda ML, 2008, NEUROTOXICOLOGY, V29, P964, DOI 10.1016/j.neuro.2008.05.005; Montine TJ, 2005, NEUROLOGY, V65, P768, DOI 10.1212/01.wnl.0000174523.62022.52; Morahan JM, 2006, NEUROEPIDEMIOLOGY, V27, P130, DOI 10.1159/000095552; Mortimer JA, 2012, NEUROLOGY, V79, P1174, DOI 10.1212/WNL.0b013e3182698ced; Murch SJ, 2004, ACTA NEUROL SCAND, V110, P267, DOI 10.1111/j.1600-0404.2004.00320.x; Murphy M, 2008, NEUROLOGY, V71, P1889, DOI 10.1212/01.wnl.0000336653.65605.ac; NEFZGER MD, 1968, AM J EPIDEMIOL, V88, P149, DOI 10.1093/oxfordjournals.aje.a120874; Nelson LM, 2000, AM J EPIDEMIOL, V151, P156, DOI 10.1093/oxfordjournals.aje.a010183; Pablo J, 2009, ACTA NEUROL SCAND, V120, P216, DOI 10.1111/j.1600-0404.2008.01150.x; Page WF, 2000, LANCET, V355, P843, DOI 10.1016/S0140-6736(05)72455-7; Park RM, 2005, AM J IND MED, V48, P63, DOI 10.1002/ajim.20178; Parron T, 2011, TOXICOL APPL PHARM, V256, P379, DOI 10.1016/j.taap.2011.05.006; Perl DP, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P291; Pezzoli G, 2013, NEUROLOGY, V80, P2035, DOI 10.1212/WNL.0b013e318294b3c8; Phukan J, 2012, J NEUROL NEUROSUR PS, V83, P102, DOI 10.1136/jnnp-2011-300188; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Proctor SP, 2013, J EXPO SCI ENV EPIDE; Quik M, 2008, MOVEMENT DISORD, V23, P1641, DOI 10.1002/mds.21900; Qureshi MM, 2006, AMYOTROPH LATERAL SC, V7, P173, DOI 10.1080/14660820600640596; Rao SD, 2006, EXP NEUROL, V201, P244, DOI 10.1016/j.expneurol.2006.04.017; Ravits J, 2013, AMYOTROPH LAT SCL FR, V14, P5, DOI 10.3109/21678421.2013.778548; RICAURTE GA, 1987, NEUROPHARMACOLOGY, V26, P97, DOI 10.1016/0028-3908(87)90051-7; Richardson JR, 2009, ARCH NEUROL-CHICAGO, V66, P870, DOI 10.1001/archneurol.2009.89; Ritchie GD, 2001, J TOXICOL ENV HEAL B, V4, P223, DOI 10.1080/109374001301419728; Ritz B, 2007, ARCH NEUROL-CHICAGO, V64, P990, DOI 10.1001/archneur.64.7.990; Rondeau V, 2009, AM J EPIDEMIOL, V169, P489, DOI 10.1093/aje/kwn348; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Rothstein JD, 2009, ANN NEUROL, V65, pS3, DOI 10.1002/ana.21543; Rush T, 2012, NEUROREPORT, V23, P216, DOI 10.1097/WNR.0b013e32834fe6d6; Schrag M, 2011, PROG NEUROBIOL, V94, P296, DOI 10.1016/j.pneurobio.2011.05.001; Schweizer U, 2004, BRAIN RES REV, V45, P164, DOI 10.1016/j.brainresrev.2004.03.004; Seals RM, 2013, AM J EPIDEMIOL, V178, P1265, DOI 10.1093/aje/kwt116; SEEGAL RF, 1991, NEUROTOXICOLOGY, V12, P55; SEEGAL RF, 1994, TOXICOLOGY, V86, P71, DOI 10.1016/0300-483X(94)90054-X; Seegal RF, 2010, NEUROBIOL DIS, V38, P219, DOI 10.1016/j.nbd.2010.01.009; Shcherbatykh I, 2007, J ALZHEIMERS DIS, V11, P191; Shih RA, 2007, ENVIRON HEALTH PERSP, V115, P483, DOI 10.1289/ehp.9786; Singh NK, 2013, HUM EXP TOXICOL, V32, P24, DOI 10.1177/0960327112456315; Singleton AB, 2013, MOVEMENT DISORD, V28, P14, DOI 10.1002/mds.25249; Snyder LR, 2010, J CHROMATOGR A, V1217, P4639, DOI 10.1016/j.chroma.2010.04.065; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Steenland K, 2006, EPIDEMIOLOGY, V17, P8, DOI 10.1097/01.ede.0000190707.51536.2b; Stewart WF, 2002, ENVIRON HEALTH PERSP, V110, P501, DOI 10.1289/ehp.02110501; Sutedja NA, 2007, NEUROLOGY, V69, P1508, DOI 10.1212/01.wnl.0000277463.87361.8c; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Tanner CM, 2010, MOVEMENT DISORD, V25, pS58, DOI 10.1002/mds.22721; Tanner CM, 2009, ARCH NEUROL-CHICAGO, V66, P1106, DOI 10.1001/archneurol.2009.195; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; Tanner CM, 2002, NEUROLOGY, V58, P581, DOI 10.1212/WNL.58.4.581; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Terry AV, 2012, PHARMACOL THERAPEUT, V134, P355, DOI 10.1016/j.pharmthera.2012.03.001; Vinceti M, 1997, ITAL J NEUROL SCI, V18, P87, DOI 10.1007/BF01999568; Vinceti M, 1996, EPIDEMIOLOGY, V7, P529, DOI 10.1097/00001648-199609000-00013; Vinceti M, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-77; Walton JR, 2012, J ALZHEIMERS DIS, V29, P255, DOI 10.3233/JAD-2011-111712; Wang A, 2011, EUR J EPIDEMIOL, V26, P547, DOI 10.1007/s10654-011-9574-5; Wang H, 2011, ARCH NEUROL-CHICAGO, V68, P207, DOI 10.1001/archneurol.2010.367; Weiner MW, 2013, ALZHEIMERS DEMENT, V9, P445, DOI [10.1016/j.jalz.2013.05.1769, 10.1016/j.jalz.2013.03.005]; Weisskopf MG, 2010, NEUROLOGY, V74, P1055, DOI 10.1212/WNL.0b013e3181d76a93; Weisskopf MG, 2009, J NEUROL NEUROSUR PS, V80, P558, DOI 10.1136/jnnp.2008.156976; Weisskopf MG, 2012, MOVEMENT DISORD, V27, P1659, DOI 10.1002/mds.25217; Weisskopf MG, 2010, ENVIRON HEALTH PERSP, V118, P1609, DOI 10.1289/ehp.1002339; Weisskopf MG, 2007, EPIDEMIOLOGY, V18, P59, DOI 10.1097/01.ede.0000248237.35363.29; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9; Wermuth L, 2002, NEUROLOGY, V58, P1422, DOI 10.1212/WNL.58.9.1422; Wirdefeldt K, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.02.017; Xu Q, 2010, NEUROLOGY, V75, P341, DOI 10.1212/WNL.0b013e3181ea1597	176	47	47	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S213	S225		10.1016/j.jalz.2014.04.014			13	Clinical Neurology	Neurosciences & Neurology	CP8GM	WOS:000360130700015	24924672	Other Gold			2021-06-18	
J	McCauley, SR; Wilde, EA; Barnes, A; Hanten, G; Hunter, JV; Levin, HS; Smith, DH				McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Hunter, Jill V.; Levin, Harvey S.; Smith, Douglas H.			Patterns of Early Emotional and Neuropsychological Sequelae after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						post-traumatic stress disorder; memory; mild traumatic brain injury; post-concussion syndrome; processing speed	CONCUSSION SYMPTOMS QUESTIONNAIRE; MINOR HEAD-INJURY; IDENTIFICATION TEST AUDIT; ABUSE SCREENING-TEST; HIGH-SCHOOL; PSYCHOMETRIC PROPERTIES; PRACTICAL SCALE; RECOVERY; SPORTS; RELIABILITY	Although mild traumatic brain injury (mTBI) is now recognized as a major health issue, there have been relatively few studies of its acute effects. Previous studies of mTBI assessed at 1 week or less post-injury have produced inconsistent results, spanning reports of no ill effects to findings of robust dysfunction. These gross disparities reflect study differences such as the criteria for mTBI diagnosis and selection of comparison groups. In consideration of these issues, this study investigated outcome in the first 96 hours after injury in adolescents and adults ages 12-30 years with mTBI (n=73) compared with orthopedically injured (OI, n=65) and typically developing controls (TDC, n=40). The mTBI group reported significantly greater general psychological distress, post-concussion symptom severity, and post-traumatic stress severity than OI (all p<0.0001) and TDC (all p<0.0001); the OI and TDC groups responded similarly on these variables. There was a significant GroupxAge interaction on the Total score (p<0.009), and the Cognitive (p=0.01) and Somatic (p<0.032) subscales of the Rivermead Post Concussion Symptoms Questionnaire where increasing symptom severity was associated with increasing age in the mTBI group. On neuropsychological assessment, the mTBI group performed significantly more poorly compared with OI for Verbal Selective Reminding Test (delayed recall, p=0.0003) and Symbol-Digit Modalities Test (SDMT written p=0.03; oral, p=0.001). The TDC group more robustly outperformed the mTBI group on these measures and also on the Brief Visuospatial Memory Test (delayed recall, p<0.04), Letter Fluency (p<0.02), and Category Switching (p<0.04). The TDC group outperformed the OI group on SDMT and Letter Fluency. These findings are consistent with previous reports of acute deficits in episodic memory and processing speed acutely after mTBI. Notably, however, these data also demonstrate the challenges of comparison group selection because differences were also found between the TDC and OI groups.	[McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Smith, Douglas H.] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	mccauley@bcm.edu	Meijer, Anna/K-5118-2016		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This work was supported by NIH grant P01 NS056202 (Smith, PI). The information in this manuscript and the manuscript itself has never been published either electronically or in print. None of the authors have any financial or other relationship(s) that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute for Neurological Disorders and Stroke or the National Institutes of Health.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benedict R.H., 1995, BRIEF VISUOSPATIAL M; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bohn M, 1991, VALIDITY DRUG ABUSE; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miller L, 2001, NEUROREHABILITATION, V16, P109; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Smith A., 1982, SYMBOL DIGIT MODALIT; Sosin DM, 1996, BRAIN INJURY, V10, P47; Strong CAH, 2011, J INT NEUROPSYCH SOC, V17, P230, DOI 10.1017/S1355617710001451; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sunderland A., 1983, J VERB LEARN VERB BE, V22, P727, DOI [10.1016/S0022-5371(83)90229-3, DOI 10.1093/BRAIN/AWU207]; TEASDALE G, 1974, LANCET, V2, P81; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; Weathers F, 1993, 9 ANN CONV INT SOC T; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002	66	47	47	0	35	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					914	925		10.1089/neu.2012.2826			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200004	24344952	Green Published			2021-06-18	
J	Sinclair, KL; Ponsford, JL; Taffe, J; Lockley, SW; Rajaratnam, SMW				Sinclair, Kelly L.; Ponsford, Jennie L.; Taffe, John; Lockley, Steven W.; Rajaratnam, Shantha M. W.			Randomized Controlled Trial of Light Therapy for Fatigue Following Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; light therapy; fatigue; excessive daytime sleepiness; sleep disturbance; depression	EXCESSIVE DAYTIME SLEEPINESS; PSYCHOMOTOR VIGILANCE; INTERINDIVIDUAL DIFFERENCES; BRIGHT LIGHT; ALERTNESS; SENSITIVITY; DISTURBANCE; WAVELENGTH; DEPRESSION; DISORDERS	Background. Fatigue is a common, persistent complaint following traumatic brain injury (TBI). Effective treatment is not well established. Objective. The current study aimed to investigate the efficacy of 4 weeks of light therapy for fatigue in patients with TBI. Methods. We undertook a randomized, placebo-controlled study of 4-week, 45 min/morning, home-based treatment with short wavelength (blue) light therapy ((max) = 465 nm, 84.8 mu W/cm(2), 39.5 lux, 1.74 x 10(14) photons/cm(2)/s) compared with yellow light therapy ((max) = 574 nm, 18.5 mu W/cm(2), 68 lux, 1.21 x 10(12) photons/cm(2)/s) containing less photons in the short wavelength range and a no treatment control group (n = 10 per group) in patients with TBI who self-reported fatigue and/or sleep disturbance. Assessments of fatigue and secondary outcomes (self-reported daytime sleepiness, depression, sleep quality, and sustained attention) were conducted over 10 weeks at baseline (week -2), midway through and at the end of light therapy (weeks 2 and 4), and 4 weeks following cessation of light therapy (week 8). Results. After controlling age, gender, and baseline depression, treatment with high-intensity blue light therapy resulted in reduced fatigue and daytime sleepiness during the treatment phase, with evidence of a trend toward baseline levels 4 weeks after treatment cessation. These changes were not observed with lower-intensity yellow light therapy or no treatment control conditions. There was also no significant treatment effect observed for self-reported depression or psychomotor vigilance performance. Conclusions. Blue light therapy appears to be effective in alleviating fatigue and daytime sleepiness following TBI and may offer a noninvasive, safe, and nonpharmacological alternative to current treatments.	[Sinclair, Kelly L.; Ponsford, Jennie L.; Taffe, John; Lockley, Steven W.; Rajaratnam, Shantha M. W.] Monash Univ, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.] Epworth Med Fdn, Richmond, Vic, Australia; [Lockley, Steven W.; Rajaratnam, Shantha M. W.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Lockley, Steven W.; Rajaratnam, Shantha M. W.] Harvard Univ, Sch Med, Boston, MA USA	Rajaratnam, SMW (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17,Clayton Campus, Clayton, Vic 3800, Australia.	shantha.rajaratnam@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	Transport Accident Commission; Jack Brockhoff Foundation; Centre for Integrated Research and Understanding of Sleep (CIRUS); University of SydneyUniversity of Sydney; RACV Sir Edmund Herring Memorial Scholarship	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by funding from Transport Accident Commission, Jack Brockhoff Foundation, Centre for Integrated Research and Understanding of Sleep (CIRUS), The University of Sydney, and RACV Sir Edmund Herring Memorial Scholarship. goLITE devices were donated by Apollo Health, since bought by Philips Lighting.	Anderson JL, 2009, ACTA PSYCHIAT SCAND, V120, P203, DOI 10.1111/j.1600-0447.2009.01345.x; Basner M, 2011, SLEEP, V34, P581, DOI 10.1093/sleep/34.5.581; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Brainard GC, 2005, J BIOL RHYTHM, V20, P314, DOI 10.1177/0748730405278951; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cajochen C, 2000, BEHAV BRAIN RES, V115, P75, DOI 10.1016/S0166-4328(00)00236-9; Cajochen C, 2007, SLEEP MED REV, V11, P453, DOI 10.1016/j.smrv.2007.07.009; Delis DC, 2000, CALIFORNIA VERBAL LE; DINGES DF, 1987, SLEEP, V10, P313; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Duffy JF, 2009, SLEEP MED CLIN, V4, P165, DOI 10.1016/j.jsmc.2009.01.004; Eastman CI, 1998, ARCH GEN PSYCHIAT, V55, P883, DOI 10.1001/archpsyc.55.10.883; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Field A. P, 2009, DISCOVERING STAT USI; Glickman G, 2006, BIOL PSYCHIAT, V59, P502, DOI 10.1016/j.biopsych.2005.07.006; Goel N, 2010, NEUROLOGY, V75, P1509, DOI 10.1212/WNL.0b013e3181f9615d; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; Gooley JJ, 2003, J NEUROSCI, V23, P7093, DOI 10.1523/JNEUROSCI.23-18-07093.2003; Jeste N, 2013, QUAL LIFE RES, V22, P1239, DOI 10.1007/s11136-012-0243-2; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kim H, 2007, SLEEP, V30, P1309, DOI 10.1093/sleep/30.10.1309; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Liu LQ, 2005, SUPPORT CARE CANCER, V13, P1010, DOI 10.1007/s00520-005-0824-5; Lockley SW, 2006, CURR BIOL, V16, pR795, DOI 10.1016/j.cub.2006.08.039; Lockley SW, 2006, SLEEP, V29, P161; Mills Peter R, 2007, J Circadian Rhythms, V5, P2, DOI 10.1186/1740-3391-5-2; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Phipps-Nelson J, 2003, SLEEP, V26, P695; Ponsford J, 2012, TRAUMATIC BRAIN INJU; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; StataCorp, 2009, STAT STAT SOFTW REL; Vaishnavi S., 2010, TXB TRAUMATIC BRAIN, P325; Van Dongen HPA, 2004, SLEEP, V27, P423; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Viola AU, 2008, SCAND J WORK ENV HEA, V34, P297, DOI 10.5271/sjweh.1268; Wood Angela M, 2004, Clin Trials, V1, P368; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	46	47	48	0	25	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2014	28	4					303	313		10.1177/1545968313508472			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AE8QB	WOS:000334265300002	24213962				2021-06-18	
J	Raji, CA; Tarzwell, R; Pavel, D; Schneider, H; Uszler, M; Thornton, J; van Lierop, M; Cohen, P; Amen, DG; Henderson, T				Raji, Cyrus A.; Tarzwell, Robert; Pavel, Dan; Schneider, Howard; Uszler, Michael; Thornton, John; van Lierop, Muriel; Cohen, Phil; Amen, Daniel G.; Henderson, Theodore			Clinical Utility of SPECT Neuroimaging in the Diagnosis and Treatment of Traumatic Brain Injury: A Systematic Review	PLOS ONE			English	Article							CEREBRAL-BLOOD-FLOW; EMISSION COMPUTED-TOMOGRAPHY; HYPERBARIC-OXYGEN THERAPY; POST-CONCUSSION SYNDROME; CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION THERAPY; TECHNETIUM-99M-HMPAO SPECT; PHASE-I; PSYCHIATRIC-ILLNESS; OUTCOME PREDICTION	Purpose: This systematic review evaluated the clinical utility of single photon emission computed tomography (SPECT) in traumatic brain injury (TBI). Methods: After defining a PICO Statement (Population, Intervention, Comparison and Outcome Statement), PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria were applied to identify 1600 articles. After screening, 374 articles were eligible for review. Inclusion for review was focus on SPECT in the setting of mild, moderate, or severe TBI with cerebral lobar specificity of SPECT findings. Other inclusion criteria were comparison modalities in the same subjects and articles in English. Foreign language articles, SPECT studies that did not include comparison modalities, and case reports were not included for review. Results: We identified 19 longitudinal and 52 cross-sectional studies meeting inclusion criteria. Three longitudinal studies examined diagnostic predictive value. The first showed positive predictive value increases from initial SPECT scan shortly after trauma to one year follow up scans, from 59% to 95%. Subsequent work replicated these results in a larger cohort. Longitudinal and cross sectional studies demonstrated SPECT lesion localization not detected by CT or MRI. The most commonly abnormal regions revealed by SPECT in cross-sectional studies were frontal (94%) and temporal (77%) lobes. SPECT was found to outperform both CT and MRI in both acute and chronic imaging of TBI, particularly mild TBI. It was also found to have a near 100% negative predictive value. Conclusions: This review demonstrates Level IIA evidence (at least one non-randomized controlled trial) for the value of SPECT in TBI. Given its advantages over CT and MRI in the detection of mild TBI in numerous studies of adequate quality, and given its excellent negative predictive value, it may be an important second test in settings where CT or MRI are negative after a closed head injury with post-injury neurological or psychiatric symptoms.	[Raji, Cyrus A.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA; [Henderson, Theodore] Synapt Space, Denver, CO USA; [Tarzwell, Robert] Univ British Columbia, Sch Med, Vancouver, BC V5Z 1M9, Canada; [Pavel, Dan] PathFinder Brain SPECT, Deerfield, IL USA; [Schneider, Howard] Sheppard Associates, Toronto, ON, Canada; [Uszler, Michael] St Johns Hlth Ctr, Santa Monica, CA USA; [Thornton, John] Rossiter Thornton Associates, Toronto, ON, Canada; [van Lierop, Muriel; Cohen, Phil] Lions Gate Hosp, Vancouver, BC, Canada; [Amen, Daniel G.] Amen Clin Inc, Newport Beach, CA USA	Henderson, T (corresponding author), Synapt Space, Denver, CO USA.	thesynapticspace7@gmail.com					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; Abu-Judeh H H, 2000, Nucl Med Rev Cent East Eur, V3, P5; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Agarwal D, 2005, J NEUROSURG PEDIAT, V102, P167; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Amorim BJ, 2011, ARQ NEURO-PSIQUIAT, V69, P682, DOI 10.1590/S0004-282X2011000500020; Anderson RJ, 2008, MOL INTERV, V8, P204, DOI 10.1124/mi.8.5.2; Armistead-Jehle P, 2012, J NEUROTRAUM, V29, P2513, DOI 10.1089/neu.2012.2400; Assadi M, 2007, HELL J NUCL MED, V10, P183; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; Barrett KF, 2004, UNDERSEA HYPERBAR M, V31, P395; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Center DaVBI, 2013, DOD WORLDW NUMB TBI; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048298; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; Davis P C, 2000, Radiology, V215 Suppl, P507; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Devous Sr MD, 2005, FUNCTIONAL CEREBRAL, P16; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DUCOURS JL, 1990, NUCL MED COMMUN, V11, P361, DOI 10.1097/00006231-199005000-00003; Eftekhari Mohammad, 2005, BMC Nucl Med, V5, P6, DOI 10.1186/1471-2385-5-6; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Goethals I, 2004, J NEUROTRAUM, V21, P1059, DOI 10.1089/0897715041651051; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goshen E, 1996, NUCL MED COMMUN, V17, P418, DOI 10.1097/00006231-199605000-00011; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; GRAY BG, 1992, J NUCL MED, V33, P52; Habert MO, 2011, NEUROBIOL AGING, V32, P15, DOI 10.1016/j.neurobiolaging.2009.01.013; Harch PG, 2012, J NEUROTRAUM, V29, P2516, DOI 10.1089/neu.2012.2608; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hashimoto K, 2009, J REHABIL MED, V41, P661, DOI 10.2340/16501977-0388; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Henderson TP, 2012, RELIG STUD REV, V38, P17, DOI 10.1111/j.1748-0922.2011.01578_5.x; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; ICHISE M, 1994, J NUCL MED, V35, P217; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Ito H, 1997, Ann Nucl Med, V11, P167; Jack CR, 2000, NEUROLOGY, V55, P484, DOI 10.1212/WNL.55.4.484; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jeyaraj JA, 2013, BRAIN INJURY, V27, P1338, DOI 10.3109/02699052.2013.823650; Jian X, 2009, BRAIN INJURY, V23, P445, DOI 10.1080/02699050902838157; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Juni JE, 2009, SOC NUCL MED PROCEDU; Kaloostian P, 2012, J NEUROTRAUM, V29, P727, DOI 10.1089/neu.2011.2147; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kauppinen T, 2002, NUCL MED COMMUN, V23, P1065, DOI 10.1097/00006231-200211000-00005; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kim Sunhee, 2011, Int J Mol Imaging, V2011, P813028, DOI 10.1155/2011/813028; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Laatsch L, 1997, BRAIN INJURY, V11, P851; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; LAURIN NR, 1989, J NUCL MED, V30, P1627; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lewis DH, 2006, J NEUROIMAGING, V16, P272, DOI 10.1111/j.1552-6569.2006.00034.x; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; LOUTFI ISSA, 1995, INVEST RADIOL, V30, P588, DOI 10.1097/00004424-199510000-00004; Luukkainen S, 2012, PSYCHIAT RES, V200, P767, DOI 10.1016/j.psychres.2012.04.018; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Mann NM, 2006, CLIN NUCL MED, V31, P458, DOI 10.1097/01.rlu.0000227010.72925.6d; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Metting Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064461; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; NAGAMACHI S, 1995, NUCL MED COMMUN, V16, P17, DOI 10.1097/00006231-199501000-00006; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Nobili F, 2008, J NEUROL, V255, P1344, DOI 10.1007/s00415-008-0897-4; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Office CB, 2012, VET HLTH ADM TREATME, P18; Okamoto T, 2007, EUR J NEUROL, V14, P540, DOI 10.1111/j.1468-1331.2007.01742.x; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; ROPER SN, 1991, J NUCL MED, V32, P1684; Rupright J, 1996, ARCH PHYS MED REHAB, V77, P1205, DOI 10.1016/S0003-9993(96)90150-1; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Sataloff RT, 1996, AM J OTOL, V17, P909; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Shiina G, 1998, AM J NEURORADIOL, V19, P297; Shimizu S, 2005, DEMENT GERIATR COGN, V20, P25, DOI 10.1159/000085070; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; SILVERMAN IE, 1993, J NUCL MED, V34, P1447; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber Katherine H, 2013, J Neuropsychiatry Clin Neurosci, V25, P1, DOI 10.1176/appi.neuropsych.12120401; Umile EM, 1998, BRAIN INJURY, V12, P577; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Website C, 2012, INJ PREV CONTR TRAUM; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	130	47	48	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2014	9	3							e91088	10.1371/journal.pone.0091088			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AD6ER	WOS:000333348500023	24646878	DOAJ Gold, Green Published			2021-06-18	
J	Bian, W; Hess, CP; Chang, SM; Nelson, SJ; Lupo, JM				Bian, Wei; Hess, Christopher P.; Chang, Susan M.; Nelson, Sarah J.; Lupo, Janine M.			Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T	NEURORADIOLOGY			English	Article						Cerebral microbleeds; Radiation therapy; Susceptibility-weighted imaging; 7T	TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; VASCULAR DEMENTIA; GUIDE	Cerebral microbleeds have been observed in normal-appearing brain tissue of patients with glioma years after receiving radiation therapy. The contrast of these paramagnetic lesions varies with field strength due to differences in the effects of susceptibility. The purpose of this study was to compare 3T and 7T MRI as platforms for detecting cerebral microbleeds in patients treated with radiotherapy using susceptibility-weighted imaging (SWI). SWI was performed with both 3T and 7T MR scanners on ten patients with glioma who had received prior radiotherapy. Imaging sequences were optimized to obtain data within a clinically acceptable scan time. Both T2*-weighted magnitude images and SWI data were reconstructed, minimum intensity projection was implemented, and microbleeds were manually identified. The number of microbleeds was counted and compared among datasets. Significantly more microbleeds were identified on SWI than magnitude images at both 7T (p = 0.002) and 3T (p = 0.023). Seven-tesla SWI detected significantly more microbleeds than 3T SWI for seven out of ten patients who had tumors located remote from deep brain regions (p = 0.016), but when the additional three patients with more inferior tumors were included, the difference was not significant. SWI is more sensitive for detecting microbleeds than magnitude images at both 3T and 7T. For areas without heightened susceptibility artifacts, 7T SWI is more sensitive to detecting radiation therapy-induced microbleeds than 3T SWI. Tumor location should be considered in conjunction with field strength when selecting the most appropriate strategy for imaging microbleeds.	[Bian, Wei; Nelson, Sarah J.] Univ Calif Berkeley, San Francisco, CA USA; [Bian, Wei; Nelson, Sarah J.] Univ Calif San Francisco, UCSF Grad Program Bioengn, San Francisco, CA 94143 USA; [Bian, Wei; Hess, Christopher P.; Nelson, Sarah J.; Lupo, Janine M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94158 USA; [Chang, Susan M.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Nelson, Sarah J.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	Lupo, JM (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 1700 4th St,Byers Hall Room 303,UCSF Campus Box 2, San Francisco, CA 94158 USA.	janine.lupo@ucsf.edu		Hess, Christopher/0000-0002-5132-5302	UC Discovery grant [ITL-BIO04-10148]; Graduate Education in Medical Sciences (GEMS); Howard Hughes Medical Institute (HHMI)Howard Hughes Medical Institute; General Electric HealthcareGE Healthcare; UCSF REAC Cohn & Simon Memorial Fund; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR026845] Funding Source: NIH RePORTER	The authors would like to thank Andre Cote, Adam Elkhaled, Angela Jakary and Trey Jalbert for their work in MR image acquisition and Bert Jimenez and Mary McPolin for their clinical coordination of patient MR scans. This work was supported by UC Discovery grant ITL-BIO04-10148, which is an academic-industry partnership grant with General Electric Healthcare, a UCSF REAC Cohn & Simon Memorial Fund and a fellowship from the Graduate Education in Medical Sciences (GEMS) training program funded by Howard Hughes Medical Institute (HHMI).	Ayaz M, 2010, J MAGN RESON IMAGING, V31, P142, DOI 10.1002/jmri.22001; Charidimou A, 2013, NEURORADIOLOGY, V55, P655, DOI 10.1007/s00234-013-1175-4; Charidimou A, 2011, FUTUR NEUROL, V6, P587, DOI 10.2217/FNL.11.42; Conijn MMA, 2011, AM J NEURORADIOL, V32, P1043, DOI 10.3174/ajnr.A2450; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Goos JDC, 2009, STROKE, V40, P3455, DOI 10.1161/STROKEAHA.109.558197; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Jin ZY, 2008, J MAGN RESON IMAGING, V28, P327, DOI 10.1002/jmri.21447; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Lupo JM, 2012, INT J RADIAT ONCOL, V82, pE493, DOI 10.1016/j.ijrobp.2011.05.046; Lupo JM, 2009, MAGN RESON IMAGING, V27, P480, DOI 10.1016/j.mri.2008.08.003; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SHAW EG, 1990, ARCH NEUROL-CHICAGO, V47, P1138, DOI 10.1001/archneur.1990.00530100108023; Shobha N, 2009, CAN J NEUROL SCI, V36, P376, DOI 10.1017/S0317167100007162; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; VALK PE, 1991, AM J NEURORADIOL, V12, P45; van Norden AGW, 2011, STROKE, V42, P3382, DOI 10.1161/STROKEAHA.111.629634; Werring DJ, 2010, J NEUROL SCI, V299, P131, DOI 10.1016/j.jns.2010.08.034	21	47	49	1	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	FEB	2014	56	2					91	96		10.1007/s00234-013-1297-8			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AA2TF	WOS:000330946300001	24281386	Green Accepted			2021-06-18	
J	Fan, WY; Dai, YQ; Xu, HC; Zhu, XM; Cai, P; Wang, LX; Sun, CG; Hu, CL; Zheng, P; Zhao, BQ				Fan, Wenying; Dai, Yiqin; Xu, Haochen; Zhu, Ximin; Cai, Ping; Wang, Lixiang; Sun, Chungang; Hu, Changlong; Zheng, Ping; Zhao, Bing-Qiao			Caspase-3 Modulates Regenerative Response After Stroke	STEM CELLS			English	Article						Stroke; Neurogenesis; Stroke recovery; Caspase-3; Neuronal precursor cells	FOCAL CEREBRAL-ISCHEMIA; PROGENITOR-CELL PROLIFERATION; TISSUE-PLASMINOGEN-ACTIVATOR; TRAUMATIC BRAIN-INJURY; MOUSE MODEL; SYNAPTIC PLASTICITY; STEM-CELLS; ENHANCES NEUROGENESIS; CLINICAL TRANSLATION; FUNCTIONAL RECOVERY	Stroke is a leading cause of long-lasting disability in humans. However, currently there are still no effective therapies available for promoting stroke recovery. Recent studies have shown that the adult brain has the capacity to regenerate neurons after stroke. Although this neurogenic response may be functionally important for brain repair after injury, the mechanisms underlying stroke-induced neurogenesis are not known. Caspase-3 is a major executioner and has been identified as a key mediator of neuronal death in the acute stage of stroke. Recently, however, accumulating data indicate that caspase-3 also participates in various biological processes that do not cause cell death. Here, we show that cleaved caspase-3 was increased in newborn neuronal precursor cells (NPCs) in the subventricular zone (SVZ) and the dentate gyrus during the period of stroke recovery, with no evidence of apoptosis. We observed that cleaved caspase-3 was expressed by NPCs and limited its self-renewal without triggering apoptosis in cultured NPCs from the SVZ of ischemic mice. Moreover, we revealed that caspase-3 negatively regulated the proliferation of NPCs through reducing the phosphorylation of Akt. Importantly, we demonstrated that peptide inhibition of caspase-3 activity significantly promoted the proliferation and migration of SVZ NPCs and resulted in a significant increase in subsequent neuronal regeneration and functional recovery after stroke. Together, our data identify a previously unknown caspase-3-dependent mechanism that constrains stroke-induced endogenous neurogenesis and should revitalize interest in targeting caspase-3 for treatment of stroke. Stem Cells2014;32:473-486	[Fan, Wenying; Dai, Yiqin; Xu, Haochen; Zhu, Ximin; Cai, Ping; Wang, Lixiang; Sun, Chungang; Hu, Changlong; Zheng, Ping; Zhao, Bing-Qiao] Fudan Univ, State Key Lab Med Neurobiol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Fan, Wenying; Dai, Yiqin; Xu, Haochen; Zhu, Ximin; Cai, Ping; Wang, Lixiang; Sun, Chungang; Hu, Changlong; Zheng, Ping; Zhao, Bing-Qiao] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Hu, Changlong] Fudan Univ, Sch Life Sci, Shanghai 200032, Peoples R China	Zhao, BQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	wenyingf@fudan.edu.cn; bingqiaoz@fudan.edu.cn	Hu, Changlong/AAQ-8348-2020	Hu, Changlong/0000-0002-8609-8947; Cai, Ping/0000-0003-2819-2940	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30971014, 81071062, 81271457]; National Program of Basic ResearchNational Basic Research Program of China; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2011CB503700-G]	We thank Dr. Eng H Lo (Department of Radiology, MA General Hospital, Harvard Medical School) and Dr. Mingming Ning (Cardio-Neurology Clinic, Clinical Proteomics Research Center and Department of Neurology, MA General Hospital, Harvard Medical School) for carefully reading the manuscript and many helpful discussions. This work was supported by grants from the National Natural Science Foundation of China (30971014, 81071062, and 81271457) and National Program of Basic Research, sponsored by the Ministry of Science and Technology of China (2011CB503700-G).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Braeuninger Stefan, 2009, Exp Transl Stroke Med, V1, P8, DOI 10.1186/2040-7378-1-8; Bravarenko NI, 2006, EUR J NEUROSCI, V23, P129, DOI 10.1111/j.1460-9568.2005.04549.x; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; Campbell PA, 2013, STEM CELLS, V31, P1107, DOI 10.1002/stem.1365; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 2008, STROKE, V39, P220, DOI 10.1161/STROKEAHA.107.490946; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Gilman CP, 2002, NEUROMOL MED, V2, P197, DOI 10.1385/NMM:2:2:197; Gregorian C, 2009, J NEUROSCI, V29, P1874, DOI 10.1523/JNEUROSCI.3095-08.2009; Hermann DM, 2012, LANCET NEUROL, V11, P369, DOI 10.1016/S1474-4422(12)70039-X; Hyman BT, 2012, NAT REV NEUROSCI, V13, P395, DOI 10.1038/nrn3228; Israels LG, 1999, STEM CELLS, V17, P306, DOI 10.1002/stem.170306; Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012; Jin KL, 2011, BRAIN RES, V1374, P56, DOI 10.1016/j.brainres.2010.12.037; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lo EH, 2010, NAT MED, V16, P1205, DOI 10.1038/nm.2226; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Mackey ME, 1997, STROKE, V28, P2012, DOI 10.1161/01.STR.28.10.2012; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; McLaughlin B, 2004, APOPTOSIS, V9, P111, DOI 10.1023/B:APPT.0000018793.10779.dc; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Pinan-Lucarre B, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001331; Rosell A, 2013, TRANSL STROKE RES, V4, P297, DOI 10.1007/s12975-012-0234-1; Shen J, 2012, J CEREBR BLOOD F MET, V32, P353, DOI 10.1038/jcbfm.2011.136; Shioda N, 2008, NEUROSCIENCE, V155, P876, DOI 10.1016/j.neuroscience.2008.05.056; SUN FJ, 2012, PLOS ONE, V7; Sun H, 2011, NEUROBIOL DIS, V44, P73, DOI 10.1016/j.nbd.2011.06.006; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Wagner DC, 2011, BRAIN RES, V1381, P237, DOI 10.1016/j.brainres.2011.01.041; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yan XX, 2001, J COMP NEUROL, V433, P4, DOI 10.1002/cne.1121; Yuan JY, 2006, MOL CELL, V23, P1, DOI 10.1016/j.molcel.2006.06.008; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhao BQ, 2004, BLOOD, V103, P2610, DOI 10.1182/blood-2003-03-0835; Zhou CM, 2004, J CEREBR BLOOD F MET, V24, P419, DOI 10.1097/00004647-200404000-00007	61	47	54	2	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2014	32	2					473	486		10.1002/stem.1503			14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	304JE	WOS:000330742100013	23939807	Bronze			2021-06-18	
J	Shin, W; Mahmoud, SY; Sakaie, K; Banks, SJ; Lowe, MJ; Phillips, M; Modic, MT; Bernick, C				Shin, W.; Mahmoud, S. Y.; Sakaie, K.; Banks, S. J.; Lowe, M. J.; Phillips, M.; Modic, M. T.; Bernick, C.			Diffusion Measures Indicate Fight Exposure-Related Damage to Cerebral White Matter in Boxers and Mixed Martial Arts Fighters	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; CORPUS-CALLOSUM; PROFESSIONAL BOXERS; AXONAL INJURY; YOUNG BOXER; HEAD-INJURY; MILD; ANISOTROPY; ENCEPHALOPATHY	Boxers and mixed martial arts athletes underwent brain DTI and the results were correlated with number of fights, knockouts, age, weight, and years of education. Total knockouts in boxers increased diffusivity in the corpus callosum, cingulate, pericalcarine, precuneus, and amygdala, while in martial arts athletes only the posterior cingulate was abnormal. Thus, fight exposure but not the number of fights can be used to predict microstructural brain damage. BACKGROUND AND PURPOSE: Traumatic brain injury is common in fighting athletes such as boxers, given the frequency of blows to the head. Because DTI is sensitive to microstructural changes in white matter, this technique is often used to investigate white matter integrity in patients with traumatic brain injury. We hypothesized that previous fight exposure would predict DTI abnormalities in fighting athletes after controlling for individual variation. MATERIALS AND METHODS: A total of 74 boxers and 81 mixed martial arts fighters were included in the analysis and scanned by use of DTI. Individual information and data on fight exposures, including number of fights and knockouts, were collected. A multiple hierarchical linear regression model was used in region-of-interest analysis to test the hypothesis that fight-related exposure could predict DTI values separately in boxers and mixed martial arts fighters. Age, weight, and years of education were controlled to ensure that these factors would not account for the hypothesized effects. RESULTS: We found that the number of knockouts among boxers predicted increased longitudinal diffusivity and transversal diffusivity in white matter and subcortical gray matter regions, including corpus callosum, isthmus cingulate, pericalcarine, precuneus, and amygdala, leading to increased mean diffusivity and decreased fractional anisotropy in the corresponding regions. The mixed martial arts fighters had increased transversal diffusivity in the posterior cingulate. The number of fights did not predict any DTI measures in either group. CONCLUSIONS: These findings suggest that the history of fight exposure in a fighter population can be used to predict microstructural brain damage.	[Shin, W.; Mahmoud, S. Y.; Sakaie, K.; Lowe, M. J.; Phillips, M.] Cleveland Clin, Imaging Inst, Cleveland, OH 44106 USA; [Bernick, C.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA; [Banks, S. J.; Modic, M. T.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA	Shin, W (corresponding author), Imaging Inst, 9500 Euclid Ave,Mail Code U-15, Cleveland, OH 44195 USA.	wanyong.shin@gmail.com		Banks, Sarah/0000-0001-7536-2370; SAKAIE, KEN/0000-0002-5633-4494	Imaging Institute, Cleveland Clinic	This work was supported by the Imaging Institute, Cleveland Clinic. The authors gratefully acknowledge Megan Griffiths for editing the manuscript and Dr HangJoon Jo for the helpful discussion of the data analysis. The authors also thank MR imaging technologist Trish Lake for technical support and research assistants Triny Cooper and Isaac Santa Ana for their work.	Ardekani S, 2007, MAGN RESON IMAGING, V25, P154, DOI 10.1016/j.mri.2006.09.045; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bledsoe GH, 2005, SOUTH MED J, V98, P994, DOI 10.1097/01.smj.0000182498.19288.e2; BLONSTEIN JL, 1974, LANCET, V2, P1213; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Giorgio A, 2010, NEUROIMAGE, V51, P943, DOI 10.1016/j.neuroimage.2010.03.004; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; HARVEY PKP, 1974, LANCET, V2, P928; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Mabbott DJ, 2006, NEURO-ONCOLOGY, V8, P244, DOI 10.1215/15228517-2006-002; Matthews PM, 2009, NEUROIMAG CLIN N AM, V19, P101, DOI 10.1016/j.nic.2008.08.003; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sakaie KE, 2005, J MAGN RESON IMAGING, V21, P512, DOI 10.1002/jmri.20305; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Xu JS, 2013, HUM BRAIN MAPP, V34, P1044, DOI 10.1002/hbm.21491; Yu CS, 2008, NEUROIMAGE, V40, P1533, DOI 10.1016/j.neuroimage.2008.01.063; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	46	47	47	0	9	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2014	35	2					285	290		10.3174/ajnr.A3676			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AA7LQ	WOS:000331279300016	23928146	Other Gold, Green Published			2021-06-18	
J	Horowitz, M				Horowitz, Michal			Heat Acclimation, Epigenetics, and Cytoprotection Memory	COMPREHENSIVE PHYSIOLOGY			English	Article							THERMAL CONTROL ESTABLISHMENT; TRAUMATIC BRAIN-INJURY; UNDERLYING MOLECULAR-MECHANISMS; SUBMAXILLARY SALIVARY-GLAND; ISCHEMIC CROSS-TOLERANCE; ECCRINE SWEAT GLAND; GENE-EXPRESSION; HISTONE H3; NITRIC-OXIDE; THERMOREGULATORY RESPONSES	Heat acclimation is a within-life phenotypic adaptation to heat. Plasticity of the thermoregulatory system is crucial for the induction of heat acclimation. In the last two decades, it has become clear that heat causes adaptive shifts in gene expression which adjust the protein balance. These changes are part of the evolvement of the acclimated phenotype. The molecular-cellular aspects of some acclimatory mechanisms that have only been explained by physiological-effectorial mechanisms have been discovered. This review attempts to bridge the gap between the classic physiological heat acclimation profile and the molecular/cellular mechanisms underlying the evolvement of the acclimated phenotype. Heat acclimation leads to leftward and rightward shifts in temperature thresholds of heat dissipation organs and thermal injury, respectively, thereby expanding the acclimated dynamic thermoregulatory range. Interactions between ambient temperature and afferent drives from effector organs to the hypothalamic thermoregulatory center with modifications in warm/cold sensitive neuron ratio and excitability contribute to the threshold changes. The altered threshold for thermal injury is associated with progressive enhancement of inducible cytoprotective networks, including HSP70, HSF1, and HIF-1 alpha. These molecules are also important in acclimatory kinetics. Aspects of cross-adaption, cross-tolerance and interference with heat acclimation are explained using molecular-cellular physiological interactions, with the heart, skeletal muscles, and water secretory glands as models. Lastly, the roles of epigenetic mechanisms in transcriptional regulation during induction of the acclimated phenotype, its decay, and reinduction are discussed. Posttranslational histone modifications in the promoters of hsp70 and hsp90 form part of our prototype model of heat-acclimation-mediated cytoprotective memory. (C) 2014 American Physiological Society.	Hebrew Univ Jerusalem, Fac Med Dent, Lab Environm Physiol, Jerusalem, Israel	Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Fac Med Dent, Lab Environm Physiol, Jerusalem, Israel.	m.horowitz@mail.huji.ac.il			ISF, Israel Science FoundationIsrael Science Foundation; BSFUS-Israel Binational Science Foundation; US-Israel binational fundUS-Israel Binational Science Foundation; German Israeli FoundationGerman-Israeli Foundation for Scientific Research and Development	The research of the author, cited in this review was supported over the years by the ISF, Israel Science Foundation, founded by the Israel Academy of Sciences and Humanities, BSF, US-Israel binational fund and German Israeli Foundation Research Grants.	Abbas A, 2010, PHYSIOLOGIST, V53, P24; Adolph E.F., 1964, HDB PHYSL SECTION 4, P27; Alexander R, 2012, HEAT ACCLIMATION MED; [Anonymous], 1773, DIS INCIDENTAL EUROP; Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; ARJONA AA, 1990, COMP BIOCHEM PHYS A, V95, P393, DOI 10.1016/0300-9629(90)90238-N; Assayag M, 2012, AM J PHYSIOL-REG I, V303, pR870, DOI 10.1152/ajpregu.00155.2012; Assayag M, 2010, CELL STRESS CHAPERON, V15, P651, DOI 10.1007/s12192-010-0178-x; ATTIAS J, 1988, J THERM BIOL, V13, P175, DOI 10.1016/0306-4565(88)90030-7; Bae JS, 2006, PFLUG ARCH EUR J PHY, V453, P67, DOI 10.1007/s00424-006-0098-x; Baird NA, 2006, J BIOL CHEM, V281, P38675, DOI 10.1074/jbc.M608013200; BAKER MA, 1982, J PHYSIOL-LONDON, V322, P457, DOI 10.1113/jphysiol.1982.sp014049; BAKER MA, 1993, J PHYSIOL-LONDON, V471, P679, DOI 10.1113/jphysiol.1993.sp019922; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bhusari S, 2008, J THERM BIOL, V33, P157, DOI 10.1016/j.jtherbio.2008.01.001; BLIGH J, 1973, J PHYSIOL-LONDON, V229, pP30; Bolli R, 2007, AM J PHYSIOL-HEART C, V292, pH19, DOI 10.1152/ajpheart.00712.2006; Boulant JA, 2006, J APPL PHYSIOL, V100, P1347, DOI 10.1152/japplphysiol.01064.2005; Boulant JA, 2006, AM J PHYSIOL-REG I, V290, pR1481, DOI 10.1152/ajpregu.00655.2005; BOULANT JA, 1989, NEWS PHYSIOL SCI, V4, P245; Brazaitis M, 2010, EUR J APPL PHYSIOL, V109, P771, DOI 10.1007/s00421-010-1429-3; Bromberg Z, 2004, P 1 INT M PHYS PHARM, P198; BROWN M, 1977, SCIENCE, V196, P998, DOI 10.1126/science.860130; BRUCK K, 1987, PHARMACOL THERAPEUT, V35, P163, DOI 10.1016/0163-7258(87)90106-9; Buckley BA, 2002, J EXP BIOL, V205, P3231; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; CASSUTO Y, 1968, AM J PHYSIOL, V214, P1147; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Cheung SS, 1998, J APPL PHYSIOL, V84, P1731; CHRISTMAN JV, 1980, J APPL PHYSIOL, V49, P942; CHRISTMAN JV, 1985, J APPL PHYSIOL, V58, P1923; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Cohen O, 2001, J MOL CELL CARDIOL, V33, pA22, DOI 10.1016/S0022-2828(01)90087-2; Cohen O, 2007, J APPL PHYSIOL, V103, P266, DOI 10.1152/japplphysiol.01351.2006; Dahlhoff EP, 2007, J BIOSCIENCES, V32, P477, DOI 10.1007/s12038-007-0047-7; DEAN JB, 1989, AM J PHYSIOL, V257, pR57; DERAMBURE PS, 1994, AM J PHYSIOL, V266, pR1876; DIETZ TJ, 1992, P NATL ACAD SCI USA, V89, P3389, DOI 10.1073/pnas.89.8.3389; DIETZ TJ, 1994, J EXP BIOL, V188, P333; Dokladny K, 2006, AM J PHYSIOL-GASTR L, V290, pG204, DOI 10.1152/ajpgi.00401.2005; Eynan M, 2002, J APPL PHYSIOL, V93, P2095, DOI 10.1152/japplphysiol.00304.2002; Eynan M, 2012, J APPL PHYSIOL, V113, P595, DOI 10.1152/japplphysiol.00228.2012; FEBBRAIO MA, 1994, J APPL PHYSIOL, V76, P589; FRANCESCONI R, 1982, J APPL PHYSIOL, V52, P734; Fregly MJ, 1996, COMPREHENSIVE PH S14, V1, P3; Furuyama F, 1998, PHYSIOL BEHAV, V63, P787, DOI 10.1016/S0031-9384(97)00541-6; Gaffney DK, 2000, RADIAT RES, V154, P461, DOI 10.1667/0033-7587(2000)154[0461:EOMTIL]2.0.CO;2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Garbuz D, 2003, J EXP BIOL, V206, P2399, DOI 10.1242/jeb.00429; Garrett AT, 2012, EUR J APPL PHYSIOL, V112, P1827, DOI 10.1007/s00421-011-2153-3; Garrett AT, 2011, SPORTS MED, V41, P757, DOI 10.2165/11587320-000000000-00000; Geor RJ, 2000, J APPL PHYSIOL, V89, P2283; Gershoni M, 2009, BIOESSAYS, V31, P642, DOI 10.1002/bies.200800139; Gerstberger R, 1999, NEWS PHYSIOL SCI, V14, P30; GOLDSPINK G, 1992, SYM SOC EXP BIOL, V46, P139; Haddad W, 1999, J THERM BIOL, V24, P403, DOI 10.1016/S0306-4565(99)00054-6; Haddad W, 1994, ADV PHARM SCI, P203; Haines TH, 2001, PROG LIPID RES, V40, P299, DOI 10.1016/S0163-7827(01)00009-1; HALES JRS, 1984, J THERM BIOL, V9, P113, DOI 10.1016/0306-4565(84)90048-2; HAMMEL HT, 1963, J APPL PHYSIOL, V18, P1146; HAMMEL HT, 1960, AM J PHYSIOL, V198, P481; Heled Y, 2012, AVIAT SPACE ENVIR MD, V83, P649, DOI 10.3357/ASEM.3241.2012; HENSEL H, 1981, FED PROC, V40, P2830; HIESTAND WA, 1955, P SOC EXP BIOL MED, V88, P94; HINCKEL P, 1987, CAN J PHYSIOL PHARM, V65, P1281, DOI 10.1139/y87-204; Hiranandani N, 2006, J APPL PHYSIOL, V100, P1727, DOI 10.1152/japplphysiol.01244.2005; Hom LL, 2012, CELL STRESS CHAPERON, V17, P29, DOI 10.1007/s12192-011-0283-5; Hori S, 1995, JPN J PHYSIOL, V45, P921, DOI 10.2170/jjphysiol.45.921; HORI T, 1991, JPN J PHYSIOL, V41, P1, DOI 10.2170/jjphysiol.41.1; Horowitz M, 2003, NEWS PHYSIOL SCI, V18, P215, DOI 10.1152/nips.01453.2003; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 1997, ANN NY ACAD SCI, V813, P617, DOI 10.1111/j.1749-6632.1997.tb51755.x; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; HOROWITZ M, 1988, AM J PHYSIOL, V254, pR109; HOROWITZ M, 1983, COMP BIOCHEM PHYS A, V75, P105, DOI 10.1016/0300-9629(83)90052-X; HOROWITZ M, 1986, J APPL PHYSIOL, V60, P9; Horowitz M, 2001, J THERM BIOL, V26, P357, DOI 10.1016/S0306-4565(01)00044-4; HOROWITZ M, 1983, COMP BIOCHEM PHYS A, V74, P945, DOI 10.1016/0300-9629(83)90374-2; HOROWITZ M, 1979, J APPL PHYSIOL, V47, P738; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V80, P57, DOI 10.1016/0300-9629(85)90678-4; Horowitz M, 1998, NEWS PHYSIOL SCI, V13, P218; Horowitz M, 1996, J APPL PHYSIOL, V80, P77; HOROWITZ M, 1993, PFLUG ARCH EUR J PHY, V422, P386, DOI 10.1007/BF00374295; HOROWITZ M, 1986, J MOL CELL CARDIOL, V18, P511, DOI 10.1016/S0022-2828(86)80916-6; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V82, P577, DOI 10.1016/0300-9629(85)90436-0; Horowitz M, 1999, AM J PHYSIOL-REG I, V277, pR47; HOROWITZ M, 1976, PFLUG ARCH EUR J PHY, V366, P173, DOI 10.1007/BF00585874; Horowitz M., 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P139; Horowitz M, 2006, APS M VIRG BEACH; Horowitz M, 2007, PROG BRAIN RES, V162, P373, DOI 10.1016/S0079-6123(06)62018-9; Horowitz M, 2010, MED SCI SPORT EXER, V42, P2164, DOI 10.1249/MSS.0b013e3181e303b0; Horowitz Michal, 2010, Front Biosci (Schol Ed), V2, P1068; Horowitz M, 2010, ANN NY ACAD SCI, V1188, P199, DOI 10.1111/j.1749-6632.2009.05101.x; Horowitz Michal, 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P37; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jousset A., 1884, TRAITE ACCLIMATEMENT, V1584; Kaspler P, 1997, ANN NY ACAD SCI, V813, P620, DOI 10.1111/j.1749-6632.1997.tb51756.x; Kaspler P, 2001, AM J PHYSIOL-REG I, V280, pR1688; Kaspler Pavel, 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P153; Kassahn KS, 2009, BIOL REV, V84, P277, DOI 10.1111/j.1469-185X.2008.00073.x; Katz A, 2006, J NEUROSCI, V26, P3899, DOI 10.1523/JNEUROSCI.0371-06.2006; KHUDAIBERDIEV M D, 1979, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V65, P1687; Kisliouk T, 2013, NEUROSCIENCE, V238, P114, DOI 10.1016/j.neuroscience.2013.02.020; Kisliouk T, 2011, EUR J NEUROSCI, V33, P224, DOI 10.1111/j.1460-9568.2010.07493.x; Kisliouk T, 2010, DEV NEUROBIOL, V70, P100, DOI 10.1002/dneu.20763; Kisliouk T, 2009, EUR J NEUROSCI, V30, P1909, DOI 10.1111/j.1460-9568.2009.06957.x; KLOOG Y, 1985, BIOCHIM BIOPHYS ACTA, V845, P428, DOI 10.1016/0167-4889(85)90208-3; Kodesh E, 2011, AM J PHYSIOL-REG I, V301, pR1786, DOI 10.1152/ajpregu.00465.2011; Kodesh E, 2010, MED SCI SPORT EXER, V42, P943, DOI 10.1249/MSS.0b013e3181c3ac3f; Kresfelder TL, 2006, J THERM BIOL, V31, P406, DOI 10.1016/j.jtherbio.2006.02.001; Kuennen M, 2011, AM J PHYSIOL-REG I, V301, pR524, DOI 10.1152/ajpregu.00039.2011; Kultz D, 2003, J EXP BIOL, V206, P3119, DOI 10.1242/jeb.00549; Kultz D, 2001, COMP BIOCHEM PHYS A, V130, P421, DOI 10.1016/S1095-6433(01)00440-8; Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403; Labunskay G, 2006, J NEUROBIOL, V66, P56, DOI 10.1002/neu.20191; Ladell WS, 1964, ADAPTATION ENV; LEVI E, 1993, J APPL PHYSIOL, V75, P833; Lewin B., 2000, GENES 7 OXFORD; Li GH, 2008, EUR J APPL PHYSIOL, V104, P29, DOI 10.1007/s00421-008-0772-0; Li QL, 2011, DNA CELL BIOL, V30, P247, DOI 10.1089/dna.2010.1133; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Lorenzo S, 2010, J APPL PHYSIOL, V109, P1736, DOI 10.1152/japplphysiol.00725.2010; Lorenzo S, 2010, J APPL PHYSIOL, V109, P1140, DOI 10.1152/japplphysiol.00495.2010; LYASHKO VN, 1994, P NATL ACAD SCI USA, V91, P12492, DOI 10.1073/pnas.91.26.12492; LYONS TP, 1995, AVIAT SPACE ENVIR MD, V66, P957; Magavi SS, 2000, NATURE, V405, P951; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Maloyan A, 2001, J MOL CELL CARDIOL, V33, pA72, DOI 10.1016/S0022-2828(01)90285-8; Maloyan A, 1999, AM J PHYSIOL-REG I, V276, pR1506; Maloyan A, 2002, J APPL PHYSIOL, V93, P107, DOI 10.1152/japplphysiol.01122.2001; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; Maruyama M, 2007, J PHYSIOL SCI, V57, P107, DOI 10.2170/physiolsci.RP014506; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Matsuzaki K, 2009, PFLUG ARCH EUR J PHY, V458, P661, DOI 10.1007/s00424-009-0654-2; Maughan R, 2004, J SPORT SCI, V22, P917, DOI 10.1080/02640410400005909; Mcgee SL, 2011, J APPL PHYSIOL, V110, P258, DOI 10.1152/japplphysiol.00979.2010; Miova B., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P65; Mirit E, 1999, AM J PHYSIOL-REG I, V276, pR550; Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100; MITCHELL D, 1976, J APPL PHYSIOL, V40, P768; Montain SJ, 1998, INT J SPORTS MED, V19, P87, DOI 10.1055/s-2007-971887; Moran D, 1996, J THERM BIOL, V21, P171, DOI 10.1016/0306-4565(95)00042-9; Moseley PL, 1997, J APPL PHYSIOL, V83, P1413; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NADEL ER, 1974, J APPL PHYSIOL, V37, P515; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nielsen B, 2003, SPORTS MED, V33, P1, DOI 10.2165/00007256-200333010-00001; NIELSEN B, 1993, J PHYSIOL-LONDON, V460, P467, DOI 10.1113/jphysiol.1993.sp019482; NIELSEN B, 1994, ERGONOMICS, V37, P49, DOI 10.1080/00140139408963622; Nielsen B, 1998, INT J SPORTS MED, V19, pS154, DOI 10.1055/s-2007-971984; Norris Carol E, 2002, Prog Mol Subcell Biol, V28, P19; Nowak SJ, 2003, MOL CELL BIOL, V23, P6129, DOI 10.1128/MCB.23.17.6129-6138.2003; Nybo L, 2001, J APPL PHYSIOL, V91, P2017; Nybo L, 2001, J APPL PHYSIOL, V91, P1055; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Ophir E, 2002, J EXP BIOL, V205, P2627; Oppenheim A, 1996, ISRAEL J MED SCI, V32, pS38; Pandolf KB, 1998, INT J SPORTS MED, V19, pS157, DOI 10.1055/s-2007-971985; PANDOLF KB, 1977, ERGONOMICS, V20, P399, DOI 10.1080/00140137708931642; Patberg KW, 2005, HEART RHYTHM, V2, P1376, DOI 10.1016/j.hrthm.2005.08.021; Patberg KW, 2005, CARDIOVASC RES, V68, P259, DOI 10.1016/j.cardiores.2005.05.028; Patronas P, 1998, BRAIN RES, V798, P127, DOI 10.1016/S0006-8993(98)00405-3; Paz Z, 2004, AUDIOL NEURO-OTOL, V9, P363, DOI 10.1159/000081409; Pierau FK, 1998, PROG BRAIN RES, V115, P63; Rae DE, 2008, MED SCI SPORT EXER, V40, P1193, DOI 10.1249/MSS.0b013e31816a7155; RALL JA, 1990, AM J PHYSIOL, V259, pR197; Reul JMHM, 2007, PSYCHONEUROENDOCRINO, V32, pS21, DOI 10.1016/j.psyneuen.2007.03.016; Riis ALD, 2005, AM J PHYSIOL-ENDOC M, V288, pE1265, DOI 10.1152/ajpendo.00533.2004; Ritossa F, 1996, CELL STRESS CHAPERON, V1, P97, DOI 10.1379/1466-1268(1996)001<0097:DOTHSR>2.3.CO;2; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; ROBERTS MF, 1977, J APPL PHYSIOL, V43, P133; Robinson S., THESIS HEBREW U JERU; Rolfe DFS, 1997, PHYSIOL REV, V77, P731; Rowell L.B., 1986, HUMAN CIRCULATION RE, P363, DOI DOI 10.1152/JN.00057.2012; ROWELL LB, 1967, J APPL PHYSIOL, V22, P509; ROWELL LB, 1974, PHYSIOL REV, V54, P75; Rowell LB, 1980, HDB PHYSL PERIPHERAL; Saeki A, 2000, AM J PHYSIOL-HEART C, V279, pH2855; Sailaja BS, 2012, P NATL ACAD SCI USA, V109, pE3687, DOI 10.1073/pnas.1209990110; Samuels SE, 2000, CAN J PHYSIOL PHARM, V78, P557, DOI 10.1139/cjpp-78-7-557; Sandstrom ME, 2008, CELL STRESS CHAPERON, V13, P169, DOI 10.1007/s12192-008-0022-8; SATO F, 1990, J APPL PHYSIOL, V69, P232; SATO K, 1983, AM J PHYSIOL, V245, pR203; Sawka MN, 2011, COMPR PHYSIOL, V1, P1883, DOI 10.1002/cphy.c100082; SAWKA MN, 1983, J APPL PHYSIOL, V55, P1147; SAWKA MN, 1992, J APPL PHYSIOL, V73, P368; SAWKA MN, 1996, HDB PHYSIOL SECT 4, V1, P157; SCHAIBLE TF, 1986, J APPL PHYSIOL, V60, P1435; SCHMID HA, 1993, AM J PHYSIOL, V264, pR449; Schulte PM, 2001, COMP BIOCHEM PHYS B, V128, P597, DOI 10.1016/S1096-4959(00)00357-2; Schwimmer H, 2004, MOL BRAIN RES, V130, P95, DOI 10.1016/j.molbrainres.2004.07.011; Schwimmer H, 2004, BRAIN RES, V1006, P177, DOI 10.1016/j.brainres.2004.01.064; Schwimmer H, 2006, J APPL PHYSIOL, V100, P1992, DOI 10.1152/japplphysiol.00850.2005; Seebacher F, 2009, PHYSIOL BIOCHEM ZOOL, V82, P766, DOI 10.1086/605955; Seebacher F, 2010, PHYSIOL BIOCHEM ZOOL, V83, P721, DOI 10.1086/649964; Seebacher F, 2009, J EXP BIOL, V212, P2885, DOI 10.1242/jeb.024430; SELYE H, 1950, BRIT MED J, V1, P1383, DOI 10.1136/bmj.1.4667.1383; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; SENAY LC, 1976, J APPL PHYSIOL, V40, P786; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; SHIDO O, 1990, J APPL PHYSIOL, V68, P66; Shmeeda H, 2002, AM J PHYSIOL-REG I, V283, pR389, DOI 10.1152/ajpregu.00423.2001; Shochina M, 1996, J THERM BIOL, V21, P289, DOI 10.1016/S0306-4565(96)00012-5; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Somero GN, 2011, AM J PHYSIOL-REG I, V301, pR1, DOI 10.1152/ajpregu.00719.2010; Sonna LA, 2002, J APPL PHYSIOL, V92, P2208, DOI 10.1152/japplphysiol.01002.2001; Strudler Paul K., 1996, Radiation Research, V145, P107; Sumner FB, 1913, J EXP ZOOL, V15, P315, DOI 10.1002/jez.1400150304; Sundstroem ES, 1925, J BIOL CHEM, Vlxiii; Tattersall GJ, 2012, COMPR PHYSIOL, V2, P2151, DOI 10.1002/cphy.c110055; Taylor N, 2013, COMP PHYSL IN PRESS; Tetievsky A, 2008, PHYSIOL GENOMICS, V34, P78, DOI 10.1152/physiolgenomics.00215.2007; Tetievsky A, 2010, J APPL PHYSIOL, V109, P1552, DOI 10.1152/japplphysiol.00469.2010; Thomson S, 2004, MOL CELL, V15, P585, DOI 10.1016/j.molcel.2004.08.002; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tirosh S, 2007, DEV NEUROBIOL, V67, P728, DOI 10.1002/dneu.20378; Todd G, 2005, J PHYSIOL-LONDON, V563, P621, DOI 10.1113/jphysiol.2004.077115; Tomanek L, 2002, J EXP BIOL, V205, P677; Tomanek L, 2012, INTEGR COMP BIOL, V52, P648, DOI 10.1093/icb/ics114; TRAVIS KA, 1993, AM J PHYSIOL, V264, pR1200; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Tzschentke B, 2007, POULTRY SCI, V86, P1025, DOI 10.1093/ps/86.5.1025; Tzschentke B, 2002, COMP BIOCHEM PHYS A, V131, P825, DOI 10.1016/S1095-6433(02)00020-X; Tzschentke B, 1997, ANN NY ACAD SCI, V813, P87, DOI 10.1111/j.1749-6632.1997.tb51677.x; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; Vergauwen L, 2010, COMP BIOCHEM PHYS A, V157, P149, DOI 10.1016/j.cbpa.2010.06.160; Virchow R, 1885, TAG 58 VERS DTSCH XA, P540; Walter I, 2009, J EXP BIOL, V212, P2328, DOI 10.1242/jeb.029009; Wang YJ, 2013, MOL BIOL REP, V40, P3877, DOI 10.1007/s11033-012-1977-1; Weller AS, 2007, EUR J APPL PHYSIOL, V102, P57, DOI 10.1007/s00421-007-0563-z; WYNDHAM CH, 1968, J APPL PHYSIOL, V25, P586; WYNDHAM CH, 1976, J APPL PHYSIOL, V40, P779; WYNDHAM CH, 1973, ANNU REV PHYSIOL, V35, P193, DOI 10.1146/annurev.ph.35.030173.001205; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Yakobi A, 2012, ISR SOC PHYSL PHARM; YELLON DM, 1992, J MOL CELL CARDIOL, V24, P113, DOI 10.1016/0022-2828(92)93148-D; Yoshimura H, 1960, ACCLIMATIZATION HEAT; YOUNG AJ, 1985, J APPL PHYSIOL, V59, P1929; YOUSEF MK, 1975, AM J PHYSIOL, V229, P427; Zatsepina OG, 2000, J EXP BIOL, V203, P1017; Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje	246	47	47	2	75	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2040-4603			COMPR PHYSIOL	Compr. Physiol.	JAN	2014	4	1					199	230		10.1002/cphy.c130025			32	Physiology	Physiology	AA6HL	WOS:000331199300007	24692139				2021-06-18	
J	Laborey, M; Masson, F; Ribereau-Gayon, R; Zongo, D; Salmi, LR; Lagarde, E				Laborey, Magali; Masson, Francoise; Ribereau-Gayon, Regis; Zongo, Drissa; Salmi, Louis Rachid; Lagarde, Emmanuel			Specificity of Postconcussion Symptoms at 3 Months After Mild Traumatic Brain Injury: Results From a Comparative Cohort Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; postconcussion syndrome; symptom specificity; control group	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; BASE-RATE; QUESTIONNAIRE; COMPLAINTS; OUTCOMES; ISSUES	Objective: To assess the specificity of symptoms included in various symptom lists used to identify postconcussion syndrome (PCS), by using follow-up data comparing patients with mild traumatic brain injury (MTBI) and control patients during the month prior to injury and 3 months later. Setting: The adult emergency department of a teaching hospital in Bordeaux, France. Participants: A cohort of patients with MTBI (n = 536) and a comparison group with nonhead injuries (n = 946). Main measures: Postconcussion symptoms listed in the Rivermead Postconcussion Symptoms Questionnaire (RPQ), the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and the 10th International Classification of Diseases (ICD-10). Results: Analyses were performed comparing symptom occurrence in patients with MTBI and controls, before and 3 months after injury. Eight symptoms were identified as being specific to MTBI: headache, dizziness, intolerance of stress, forgetfulness, poor concentration, taking longer to think, blurred vision, and personality change. Conclusion: The relevance of symptoms proposed to constitute PCS should be reviewed. A more specific definition of PCS would make diagnosis easier and facilitate prevention as well as treatment of patients with MTBI.	[Laborey, Magali; Salmi, Louis Rachid; Lagarde, Emmanuel] Univ Bordeaux, ISPED, Ctr INSERM, Epidemiol Biostat U897, F-33000 Bordeaux, France; [Laborey, Magali; Masson, Francoise; Ribereau-Gayon, Regis; Zongo, Drissa; Salmi, Louis Rachid; Lagarde, Emmanuel] Ctr INSERM, Epidemiol Biostat U897, INSERM, ISPED, F-33000 Bordeaux, France; [Salmi, Louis Rachid] CHU Bordeaux, F-33000 Bordeaux, France; [Masson, Francoise] Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Anesthesie Reanimat, F-33000 Bordeaux, France; [Ribereau-Gayon, Regis] Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Med Gen & Posturgences, F-33000 Bordeaux, France	Lagarde, E (corresponding author), 146 Rue Leo Saignat, F-33076 Bordeaux, France.	emmanuel.lagarde@isped.u-bordeaux2.fr	Salmi, Louis-Rachid/T-1982-2019; Regis, RIBEREAU-GAYON/U-5423-2019; Lagarde, Emmanuel/F-7132-2013	Lagarde, Emmanuel/0000-0001-8031-7400	French National Institute for Medical Research (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); EHESP School of Public Health	M.L. is the recipient of a doctoral grant from the French National Institute for Medical Research (INSERM) and the EHESP School of Public Health.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Association AP, 1994, DIAGN STAT MAN MENT; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; EVANS RW, 1992, NEUROL CLIN, V10, P815; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Greene CJ, 2008, J TRAUMA STRESS, V21, P433, DOI 10.1002/jts.20367; Greiffenstein M, 2009, CLIN NEUROPSYCHOL, V23, P286, DOI 10.1080/13854040802104873; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Organization WH, 1992, ICD 10 CLASS MENT BE; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walker E, 2011, J GEN INTERN MED, V26, P192, DOI 10.1007/s11606-010-1513-8; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	43	47	49	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					E28	E36		10.1097/HTR.0b013e318280f896			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400007	23474878				2021-06-18	
J	White, PE; Newton, JD; Makdissi, M; Sullivan, SJ; Davis, G; McCrory, P; Donaldson, A; Ewing, MT; Finch, CF				White, Peta E.; Newton, Joshua D.; Makdissi, Michael; Sullivan, S. John; Davis, Gavin; McCrory, Paul; Donaldson, Alex; Ewing, Michael T.; Finch, Caroline F.			Knowledge about sports-related concussion: is the message getting through to coaches and trainers?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Head injuries	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; RUGBY PLAYERS; NECK INJURY; MANAGEMENT; GUIDELINES; ATTITUDES; ZURICH; HEAD	Aim The need for accurate diagnosis and appropriate return-to-play decisions following a concussion in sports has prompted the dissemination of guidelines to assist managing this condition. This study aimed to assess whether key messages within these guidelines are reflected in the knowledge of coaches and sports trainers involved in community sport. Methods An online knowledge survey was widely promoted across Australia in May-August 2012 targeting community Australian Football (AF) and Rugby League (RL) coaches and sports trainers. 260 AF coaches, 161 AF sports trainers, 267 RL coaches and 228 RL sports trainers completed the survey. Knowledge scores were constructed from Likert scales and compared across football codes and respondent groups. Results General concussion knowledge did not differ across codes but sports trainers had higher levels than did coaches. There were no significant differences in either concussion symptoms or concussion management knowledge across codes or team roles. Over 90% of respondents correctly identified five of the eight key signs or symptoms of concussion. Fewer than 50% recognised the increased risk of another concussion following an initial concussion. Most incorrectly believed or were uncertain that scans typically show damage to the brain after a concussion occurs. Fewer than 25% recognised, and >40% were uncertain that younger players typically take longer to recover from concussion than adults. Conclusions The key messages from published concussion management guidelines have not reached community sports coaches and sports trainers. This needs to be redressed to maximise the safety of all of those involved in community sport.	[White, Peta E.; Donaldson, Alex; Finch, Caroline F.] Univ Ballarat, Ctr Hlth & Safe Sport, Ballarat, Vic 3353, Australia; [Newton, Joshua D.; Ewing, Michael T.] Monash Univ, Dept Mkt, Frankston, Vic, Australia; [Makdissi, Michael; Davis, Gavin; McCrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Sullivan, S. John] Univ Otago, Ctr Hlth Activ & Rehabil Res, Dunedin, New Zealand	Finch, CF (corresponding author), Univ Ballarat, Ctr Hlth & Safe Sport, Ballarat, Vic 3353, Australia.	c.finch@ballarat.edu.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568; Ewing, Michael/0000-0002-2260-2761	Victorian Sports Injury Prevention Research Grant from the Department of Planning and Community Development, Victoria; NHMRCNational Health and Medical Research Council of Australia [565900, 527952]	This work was funded by a Victorian Sports Injury Prevention Research Grant from the Department of Planning and Community Development, Victoria, Australia that paid for PW's salary. CFF was supported by an NHMRC Principal Research Fellowship (ID: 565900) and MM by an NHMRC Training Fellowship (ID: 527952).	Australian Sports Commission, 2011, PART EX RECR SPORT A; Braham RA, 2004, BRIT J SPORT MED, V38, P426, DOI 10.1136/bjsm.2002.004051; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Donaldson A, 2012, BRIT J SPORT MED, V46, P759, DOI 10.1136/bjsports-2011-090073; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; O'Donoghue EM., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511	20	47	48	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					119	+		10.1136/bjsports-2013-092785			7	Sport Sciences	Sport Sciences	276KK	WOS:000328749000013	24043666	Green Published			2021-06-18	
J	Lim, MM; Elkind, J; Xiong, GX; Galante, R; Zhu, JX; Zhang, L; Lian, J; Rodin, J; Kuzma, NN; Pack, AI; Cohen, AS				Lim, Miranda M.; Elkind, Jaclynn; Xiong, Guoxiang; Galante, Ray; Zhu, Jingxu; Zhang, Lin; Lian, Jie; Rodin, Julianna; Kuzma, Nicholas N.; Pack, Allan I.; Cohen, Akiva S.			Dietary Therapy Mitigates Persistent Wake Deficits Caused by Mild Traumatic Brain Injury	SCIENCE TRANSLATIONAL MEDICINE			English	Article							CHAIN AMINO-ACIDS; SLEEP-DEPRIVATION; SUSTAINED ATTENTION; PREVALENCE; METABOLISM; DISORDERS; DYNAMICS; LEUCINE; POWER; RATS	Sleep disorders are highly prevalent in patients with traumatic brain injury (TBI) and can significantly impair cognitive rehabilitation. No proven therapies exist to mitigate the neurocognitive consequences of TBI. We show that mild brain injury in mice causes a persistent inability to maintain wakefulness and decreases orexin neuron activation during wakefulness. We gave mice a dietary supplement of branched-chain amino acids (BCAAs), precursors for de novo glutamate synthesis in the brain. BCAA therapy reinstated activation of orexin neurons and improved wake deficits in mice with mild brain injury. Our data suggest that dietary BCAA intervention, acting in part through orexin, can ameliorate injury-induced sleep disturbances and may facilitate cognitive rehabilitation after brain injury.	[Lim, Miranda M.; Pack, Allan I.] Univ Penn, Perelman Sch Med, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA; [Lim, Miranda M.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Lim, Miranda M.; Galante, Ray; Zhu, Jingxu; Zhang, Lin; Lian, Jie; Rodin, Julianna; Pack, Allan I.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA; [Elkind, Jaclynn; Xiong, Guoxiang; Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Kuzma, Nicholas N.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Lim, MM (corresponding author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Hosp & Specialty Med, Sleep Disorders Lab, Portland, OR 92739 USA.	lmir@ohsu.edu		Pack, Allan/0000-0002-2879-0484	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HL007713, R01HL111725-01A1, R01NS069629, R01HD059288]; University of Pennsylvania Department of Medicine/Measey Research Fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD059288, R37HD059288] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111725, T32HL007713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069629] Funding Source: NIH RePORTER	Supported by NIH T32 HL007713 and University of Pennsylvania Department of Medicine/Measey Research Fellowship to M. M. L., NIH R01HL111725-01A1 to A.I P., and NIH R01NS069629 and R01HD059288 to A.S.C.	Acuna-Goycolea C, 2004, J NEUROSCI, V24, P3013, DOI 10.1523/JNEUROSCI.5416-03.2004; Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Colas D, 2005, NEUROBIOL AGING, V26, P265, DOI 10.1016/j.neurobiolaging.2004.03.004; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Fernstrom JD, 2005, J NUTR, V135, p1539S, DOI 10.1093/jn/135.6.1539S; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198; FRANKEN P, 1991, NEUROSCI LETT, V130, P141, DOI 10.1016/0304-3940(91)90382-4; Franken P, 2001, J NEUROSCI, V21, P2610, DOI 10.1523/JNEUROSCI.21-08-02610.2001; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harada M, 1976, Kumamoto Med J, V29, P110; Jeong JS, 2004, CLIN NEUROPHYSIOL, V115, P1490, DOI 10.1016/j.clinph.2004.01.001; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Karnani MM, 2011, NEURON, V72, P616, DOI 10.1016/j.neuron.2011.08.027; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McDermott CM, 2003, J NEUROSCI, V23, P9687; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moretti Davide V, 2011, Front Psychiatry, V1, P152, DOI 10.3389/fpsyt.2010.00152; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Muto Y, 2005, CLIN GASTROENTEROL H, V3, P705, DOI 10.1016/S1542-3565(05)00017-0; Naidoo N, 2011, AGING CELL, V10, P640, DOI 10.1111/j.1474-9726.2011.00699.x; Pack AI, 2007, PHYSIOL GENOMICS, V28, P232, DOI 10.1152/physiolgenomics.00139.2006; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Perouansky M, 2010, ANESTHESIOLOGY, V113, P1299, DOI 10.1097/ALN.0b013e3181f90ccc; R Core Team, 2012, R LANG ENV STAT COMP; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Ruskin DN, 2004, EUR J NEUROSCI, V19, P3121, DOI 10.1111/j.0953-816X.2004.03426.x; Sakai R, 2004, J NEUROCHEM, V88, P612, DOI 10.1111/j.1471-4159.2004.02179.x; Sakurai T, 2007, NAT REV NEUROSCI, V8, P171, DOI 10.1038/nrn2092; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vuille-Dit-Bille RN, 2012, AMINO ACIDS, V43, P1287, DOI 10.1007/s00726-011-1202-x; Vyazovskiy VV, 2011, NATURE, V472, P443, DOI 10.1038/nature10009; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W	51	47	51	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	DEC 11	2013	5	215							215ra173	10.1126/scitranslmed.3007092			12	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	275OA	WOS:000328685500004	24337480	Green Accepted			2021-06-18	
J	Tajiri, N; Kellogg, SL; Shimizu, T; Arendash, GW; Borlongan, CV				Tajiri, Naoki; Kellogg, S. Leilani; Shimizu, Toru; Arendash, Gary W.; Borlongan, Cesar V.			Traumatic Brain Injury Precipitates Cognitive Impairment and Extracellular A beta Aggregation in Alzheimer's Disease Transgenic Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; FOOTBALL-LEAGUE PLAYER; HEAD-INJURY; OLDER-ADULTS; RISK; ENCEPHALOPATHY; DAMAGE; ABNORMALITIES; HIPPOCAMPUS; PERFORMANCE	Traumatic brain injury (TBI) has become a signature wound of the wars in Iraq and Afghanistan. Many American soldiers, even those undiagnosed but likely suffering from mild TBI, display Alzheimer's disease (AD)-like cognitive impairments, suggesting a pathological overlap between TBI and AD. This study examined the cognitive and neurohistological effects of TBI in presymptomatic APP/PS1 AD-transgenic mice. AD mice and non-transgenic (NT) mice received an experimental TBI on the right parietal cortex using the controlled cortical impact model. Animals were trained in a water maze task for spatial memory before TBI, and then reevaluated in the same task at two and six weeks post-TBI. The results showed that AD mice with TBI made significantly more errors in the task than AD mice without TBI and NT mice regardless of TBI. A separate group of AD mice and NT mice were evaluated neurohistologically at six weeks after TBI. The number of extracellular beta-amyloid (A beta)-deposits significantly increased by at least one fold in the cortex of AD mice that received TBI compared to the NT mice that received TBI or the AD and NT mice that underwent sham surgery. A significant decrease in MAP2 positive cells, indicating neuronal loss, was observed in the cortex of both the AD and NT mice that received TBI compared to the AD and NT mice subjected to sham surgery. Similar changes in extracellular A beta deposits and MAP2 positive cells were also seen in the hippocampus. These results demonstrate for the first time that TBI precipitates cognitive impairment in presymptomatic AD mice, while also confirming extracellular A beta deposits following TBI. The recognition of this pathological link between TBI and AD should aid in developing novel treatments directed at abrogating cellular injury and extracellular A beta deposition in the brain.	[Tajiri, Naoki; Borlongan, Cesar V.] Univ S Florida, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Morsani Coll Med, Tampa, FL 33620 USA; [Kellogg, S. Leilani; Shimizu, Toru] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Arendash, Gary W.] NeuroEM Therapeut Inc, Scottsdale, AZ USA	Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Morsani Coll Med, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782	University of South Florida Department of Neurosurgery; Brain Repair funds; James and Esther King Biomedical Research Foundation [1KG01-33966, NIH 5U01NS055914-04, NIH 1R01NS071956-01A1]; SanBio Inc.; Celgene Cellular TherapeuticsCelgene Corporation; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	Financial support for this study was through the University of South Florida Department of Neurosurgery and Brain Repair funds. CVB is funded by the James and Esther King Biomedical Research Foundation 1KG01-33966, NIH 5U01NS055914-04 and NIH 1R01NS071956-01A1, SanBio Inc., Celgene Cellular Therapeutics, KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977; Arendash GW, 2004, BRAIN RES, V1012, P29, DOI 10.1016/j.brainres.2004.02.081; Baldauf K, 2005, BRAIN RES, V1056, P158, DOI 10.1016/j.brainres.2005.07.035; Borroni B, 2002, J NEUROL SCI, V203, P189, DOI 10.1016/S0022-510X(02)00289-7; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Davies TA, 2000, AMYLOID, V7, P153, DOI 10.3109/13506120009146830; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Jantaratnotai Nattinee, 2011, Int J Alzheimers Dis, V2011, P918280, DOI 10.4061/2011/918280; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kline RP, 2012, ANESTHESIOLOGY, V116, P603, DOI 10.1097/ALN.0b013e318246ec0b; Matsuda H, 2012, AM J NEURORADIOL, V33, P1109, DOI 10.3174/ajnr.A2935; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Mlekusch R, 2009, NEUROSCI LETT, V466, P135, DOI 10.1016/j.neulet.2009.09.043; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Palmer JC, 2010, NEUROPATH APPL NEURO, V36, P487, DOI 10.1111/j.1365-2990.2010.01084.x; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sarmiento K, 2008, J HEAD TRAUMA REHAB, V23, P164, DOI 10.1097/01.HTR.0000319933.22709.61; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shetty AK, 2009, J CELL MOL MED, V13, P2408, DOI 10.1111/j.1582-4934.2009.00675.x; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Walker DG, 2008, MICROVASC RES, V75, P411, DOI 10.1016/j.mvr.2007.10.004; Yesil Y, 2012, ARCH GERONTOL GERIAT, V55, P257, DOI 10.1016/j.archger.2011.09.016; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	37	47	48	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2013	8	11							e78851	10.1371/journal.pone.0078851			9	Multidisciplinary Sciences	Science & Technology - Other Topics	245ZC	WOS:000326503400091	24223856	DOAJ Gold, Green Published			2021-06-18	
J	Tator, CH				Tator, Charles H.			Concussions and their consequences: current diagnosis, management and prevention	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							SPORT-RELATED CONCUSSION; RECURRENT CONCUSSION; FOOTBALL PLAYERS; HEAD-INJURY; HOCKEY; RETURN; RISK		[Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Tator, Charles H.] Toronto Western Hosp, Krembil Neurosci Ctr, Canadian Sports Concuss Project, Toronto, ON, Canada; [Tator, Charles H.] Think First & Parachute Canada, Toronto, ON, Canada	Tator, CH (corresponding author), Univ Toronto, Div Neurosurg, Toronto, ON, Canada.	charles.tator@uhn.ca					Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; [Anonymous], 2000, CLIN J SPORT MED, V10, P209; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Tator CH, 2001, NEUROLOGICAL SPORTS, P261; Tator CH, 2009, CAN J NEUROL SCI, V36, P405, DOI 10.1017/S031716710000771X; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	20	47	48	0	52	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	AUG 6	2013	185	11					975	979		10.1503/cmaj.120039			5	Medicine, General & Internal	General & Internal Medicine	196ZR	WOS:000322816700029	23877672	Green Published, Bronze			2021-06-18	
J	Kurowski, BG; Wade, SL; Kirkwood, MW; Brown, TM; Stancin, T; Taylor, HG				Kurowski, Brad G.; Wade, Shari L.; Kirkwood, Michael W.; Brown, Tanya M.; Stancin, Terry; Taylor, H. Gerry			Online Problem-Solving Therapy for Executive Dysfunction After Child Traumatic Brain Injury	PEDIATRICS			English	Article						brain injury; online; therapy; executive function; child; adolescent	BEHAVIOR RATING INVENTORY; PRELIMINARY EFFICACY; YOUNG-CHILDREN; INTERVENTION; SKILLS; PREDICTORS; OUTCOMES; REHABILITATION; ADOLESCENTS; RECOVERY	OBJECTIVE: Executive dysfunction after traumatic brain injury (TBI) in children is common and leads to significant problems in functioning across multiple settings. The objective of this study was to evaluate the efficacy of a web-based counselor-assisted problem solving (CAPS) intervention compared with an Internet resource comparison (IRC) for treatment of executive dysfunction within 12 months after complicated mild to severe TBI in adolescents. We hypothesized that CAPS would significantly improve parent ratings of executive dysfunction compared with an IRC. METHODS: Participants included 132 adolescents aged 12 to 17 years who sustained a complicated mild to severe TBI within 1 to 6 months before study enrollment. Study design was a multisite, assessor-blinded, randomized controlled trial. Study sites included 3 tertiary pediatric hospitals and 2 tertiary general medical centers. The main outcome measure was primary caregiver Behavioral Rating Inventory of Executive Function Global Executive Composite at baseline and 6-month follow-up. Generalized linear models that controlled for baseline scores were used to compare the CAPS and IRC scores. RESULTS: In older teens, the CAPS group showed significant improvement in executive function behaviors at 6-month follow-up compared with the IRC group (F = 6.74, P = .01, Cohen's d = 0.63). CONCLUSIONS: Findings indicate that web-based CAPS improves primary caregiver-rated executive functioning within the first 12 months after TBI in older adolescents. Future research needs to define the optimal timing after injury for delivery of CAPS and characteristics of individuals and families who are most likely to benefit from CAPS.	[Kurowski, Brad G.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Kurowski, Brad G.; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.; Taylor, H. Gerry] Mayo Clin, Dept Psychiat & Psychol, Mayo Clin Coll Med, Rochester, MN USA; [Stancin, Terry] MetroHealth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Brown, Tanya M.] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Brown, Tanya M.] Univ Hosp, Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Stancin, Terry/L-7993-2019		Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-MH073764]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2K12 HD001097-16]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	Supported in part by a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program. Also supported in part by the National Institutes of Health (NIH) grant R01-MH073764 from the National Institute of Mental Health and NIH grant 2K12 HD001097-16. Funded by the National Institutes of Health (NIH).	Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Blake CS, 2007, J CHILD ADOL PS NURS, V20, P209, DOI 10.1111/j.1744-6171.2007.00102.x; Chan DYK, 2011, DISABIL REHABIL, V33, P2023, DOI 10.3109/09638288.2011.556207; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Clarke SA, 2012, QUAL LIFE RES, V21, P747, DOI 10.1007/s11136-011-9996-2; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Eccleston C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009660.pub2; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Galvin J, 2009, DEV NEUROREHABIL, V12, P352, DOI 10.3109/17518420903087293; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia G. A., 2003, BRIEF P BEHAV RATING; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kurowski BG, 2011, AM J PHYS MED REHABI, V90, P347; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Lochman JE, 2011, CHILD ADOL PSYCH CL, V20, P305, DOI 10.1016/j.chc.2011.01.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; McLaughlin KA, J HEAD TRAUMA REHABI; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Robin Arthur L, 2008, Adolesc Med State Art Rev, V19, P268; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, J HEAD TRAUMA REHAB	52	47	47	0	19	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2013	132	1					E158	E166		10.1542/peds.2012-4040			9	Pediatrics	Pediatrics	197HW	WOS:000322841900020	23753094	Green Published			2021-06-18	
J	Reddy, CC; Collins, M; Lovell, M; Kontos, AP				Reddy, Cara Camiolo; Collins, Michael; Lovell, Mark; Kontos, Anthony P.			Efficacy of Amantadine Treatment on Symptoms and Neurocognitive Performance Among Adolescents Following Sports-Related Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						amantadine; concussion; postconcussion symptoms	TRAUMATIC BRAIN-INJURY; RECOVERY; IMPACT; SPECIFICITY; SENSITIVITY	Objective: To evaluate the efficacy of amantadine in the treatment of symptoms and neurocognitive performance in adolescents following sports-related concussion. Participants: A clinical sample of 25 male (n = 11) and female (n = 14) adolescent subjects with an age-, sex-, and concussion history-matched group of 25 male (n = 11) and female (n = 14) control subjects. Setting: Outpatient concussion clinic. Intervention: Retrospective, case-control design. Treatment group consisted of patients treated with 100 mg of amantadine twice daily (200 mg total per day) following a period of rest. Matched controls were evaluated and treated conservatively without medication at the same concussion program prior to the start of the current amantadine protocol. Main Outcome Measures: Immediate Postconcussion Assessment and Cognitive Test computerized neurocognitive test battery and symptom report. Results: Results support significantly greater improvements from pre-to posttest in reported symptoms, verbal memory, and reaction time performance for the amantadine group than the matched controls. There were no significant differences for visual memory or visual motor processing speed. Conclusion: This study provides empirical support for amantadine as an effective pharmacologic treatment of certain concussion-related cognitive deficits and symptoms in athletes with protracted recovery of more than 3 weeks.	[Reddy, Cara Camiolo] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15219 USA; [Reddy, Cara Camiolo; Collins, Michael; Lovell, Mark; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Dept Orthoped Surg, Pittsburgh, PA 15219 USA	Reddy, CC (corresponding author), Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, 1400 Locust St D-G103, Pittsburgh, PA 15219 USA.	camice@upmc.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; Centers for Disease Control and Prevention, WHAT AR SIGNS SYMPT; Chandler M, 1998, BRAIN INJURY, V2, P309; Chen JJ, 2007, PHARMACOTHERAPY, V27, p161S, DOI 10.1592/phco.27.12part2.161S; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schneider WN, 1999, BRAIN INJURY, V13, P863; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	29	47	47	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					260	265		10.1097/HTR.0b013e318257fbc6			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900003	22613947				2021-06-18	
J	Skotak, M; Wang, F; Alai, A; Holmberg, A; Harris, S; Switzer, RC; Chandra, N				Skotak, Maciej; Wang, Fang; Alai, Aaron; Holmberg, Aaron; Harris, Seth; Switzer, Robert C.; Chandra, Namas			Rat Injury Model under Controlled Field-Relevant Primary Blast Conditions: Acute Response to a Wide Range of Peak Overpressures	JOURNAL OF NEUROTRAUMA			English	Article						cellular membrane permeability; lung injury; mortality; pathophysiological response; primary blast; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LUNG INJURY; MOUSE MODEL; SHOCK TUBE; EXPOSURE; BARRIER; MECHANISMS; EXPLOSION; DAMAGE; STRESS	We evaluated the acute (up to 24 h) pathophysiological response to primary blast using a rat model and helium driven shock tube. The shock tube generates animal loadings with controlled pure primary blast parameters over a wide range and field-relevant conditions. We studied the biomechanical loading with a set of pressure gauges mounted on the surface of the nose, in the cranial space, and in the thoracic cavity of cadaver rats. Anesthetized rats were exposed to a single blast at precisely controlled five peak overpressures over a wide range (130, 190, 230, 250, and 290 kPa). We observed 0% mortality rates in 130 and 230 kPa groups, and 30%, 24%, and 100% mortality rates in 190, 250, and 290 kPa groups, respectively. The body weight loss was statistically significant in 190 and 250 kPa groups 24 h after exposure. The data analysis showed the magnitude of peak-to-peak amplitude of intracranial pressure (ICP) fluctuations correlates well with mortality rates. The ICP oscillations recorded for 190, 250, and 290 kPa are characterized by higher frequency (10-20 kHz) than in other two groups (7-8 kHz). We noted acute bradycardia and lung hemorrhage in all groups of rats subjected to the blast. We established the onset of both corresponds to 110 kPa peak overpressure. The immunostaining against immunoglobulin G (IgG) of brain sections of rats sacrificed 24-h post-exposure indicated the diffuse blood-brain barrier breakdown in the brain parenchyma. At high blast intensities (peak overpressure of 190 kPa or more), the IgG uptake by neurons was evident, but there was no evidence of neurodegeneration after 24 h post-exposure, as indicated by cupric silver staining. We observed that the acute response as well as mortality is a non-linear function over the peak overpressure and impulse ranges explored in this work.	[Skotak, Maciej; Wang, Fang; Alai, Aaron; Holmberg, Aaron; Chandra, Namas] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA; [Harris, Seth] Univ Nebraska, Sch Vet Med & Biomed Sci, Vet Diagnost Ctr, Lincoln, NE 68588 USA; [Switzer, Robert C.] NeuroSci Associates, Knoxville, TN USA	Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Skotak, Maciej/H-4769-2019	Skotak, Maciej/0000-0003-2584-7294	U.S. Army Research Office project "Army-UNL Center of Trauma Mechanics'' [W911NF-08-10483]	Financial support under the U.S. Army Research Office project "Army-UNL Center of Trauma Mechanics'' (Contract no. W911NF-08-10483, Project Manager: Larry Russell, P.I.: Namas Chandra) is gratefully acknowledged. We are thankful to Holly Reiling, Vicky Samek, and Katherine Ellenbolt-Pinkerton (Office of Research Responsibility, UNL) for invaluable help received during the realization of this research effort. Dr. Annette Fleckenstein's (University of Utah) useful comments on experimental procedures are gratefully acknowledged. We would like to acknowledge assistance received from Mr. Brandon Perry and Mr. Kurtis Palu during rat exposure experiments.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; BROWN RFR, 1993, INT J EXP PATHOL, V74, P151; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; COOPER GJ, 1991, J BIOMECH, V24, P273, DOI 10.1016/0021-9290(91)90346-O; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gorbunov NV, 2004, CRIT CARE MED, V32, P1028, DOI 10.1097/01.CCM.0000120051.79520.B6; Guy R J, 1998, J R Nav Med Serv, V84, P79; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; LO EH, 1994, MAGN RESON IMAGING, V12, P403, DOI 10.1016/0730-725X(94)92533-X; LOBERG EM, 1991, ACTA NEUROPATHOL, V81, P479, DOI 10.1007/BF00310126; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; Michalak Z, 2012, J NEUROPATH EXP NEUR, V71, P826, DOI 10.1097/NEN.0b013e31826809a6; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Peters P, 2011, MIL MED, V176, P110, DOI 10.7205/MILMED-D-10-00300; PHILLIPS YY, 1986, ANN EMERG MED, V15, P1446, DOI 10.1016/S0196-0644(86)80940-4; Pizov R, 1999, CHEST, V115, P165, DOI 10.1378/chest.115.1.165; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; RICHMOND DR, 1962, AEROSPACE MED, V33, P1; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Sasser SM, 2006, PREHOSP EMERG CARE, V10, P165, DOI 10.1080/10903120500540912; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Tsokos M, 2003, AM J RESP CRIT CARE, V168, P549, DOI 10.1164/rccm.200304-528OC; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uversky VN, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S7; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025; Zhang JK, 1996, J TRAUMA, V40, pS77	59	47	49	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	13					1147	1160		10.1089/neu.2012.2652			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	174WB	WOS:000321186400006	23362798	Green Published			2021-06-18	
J	Tarapore, PE; Findlay, AM; LaHue, SC; Lee, H; Honma, SM; Mizuiri, D; Luks, TL; Manley, GT; Nagarajan, SS; Mukherjee, P				Tarapore, Phiroz E.; Findlay, Anne M.; LaHue, Sara C.; Lee, Hana; Honma, Susanne M.; Mizuiri, Danielle; Luks, Tracy L.; Manley, Geoffrey T.; Nagarajan, Srikantan S.; Mukherjee, Pratik			Resting state magnetoencephalography functional connectivity in traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cognition; concussion; diffuse axonal injury; functional connectivity; magnetoencephalography; traumatic brain injury	MEG RECORDINGS; HEAD TRAUMA; RECOVERY; EEG; SYNCHRONIZATION; REORGANIZATION; SCHIZOPHRENIA; PLASTICITY; COHERENCY; SYMPTOMS	Object. Traumatic brain injury (TBI) is one of the leading causes of morbidity worldwide. One mechanism by which blunt head trauma may disrupt normal cognition and behavior is through alteration of functional connectivity between brain regions. In this pilot study, the authors applied a rapid automated resting state magnetoencephalography (MEG) imaging technique suitable for routine clinical use to test the hypothesis that there is decreased functional connectivity in patients with TBI compared with matched controls, even in cases of mild TBI. Furthermore, they posit that these abnormal reductions in MEG functional connectivity can be detected even in TBI patients without specific evidence of traumatic lesions on 3-T MR images. Finally, they hypothesize that the reductions of functional connectivity can improve over time across serial MEG scans during recovery from TBI. Methods. Magnetoencephalography maps of functional connectivity in the alpha (8- to 12-Hz) band from 21 patients who sustained a TBI were compared with those from 18 age- and sex-matched controls. Regions of altered functional connectivity in each patient were detected in automated fashion through atlas-based registration to the control database. The extent of reduced functional connectivity in the patient group was tested for correlations with clinical characteristics of the injury as well as with findings on 3-T MRI. Finally, the authors compared initial connectivity maps with 2-year follow-up functional connectivity in a subgroup of 5 patients with TBI. Results. Fourteen male and 7 female patients (17-53 years old, median 29 years) were enrolled. By Glasgow Coma Scale (GCS) criteria, 11 patients had mild, 1 had moderate, and 3 had severe TBI, and 6 had no GCS score recorded. On 3-T MRI, 16 patients had abnormal findings attributable to the trauma and 5 had findings in the normal range. As a group, the patients with TBI had significantly lower functional connectivity than controls (p < 0.01). Three of the 5 patients with normal findings on 3-T MRI showed regions of abnormally reduced MEG functional connectivity. No significant correlations were seen between extent of functional disconnection and injury severity or posttraumatic symptoms (p > 0.05). In the subgroup undergoing 2-year follow-up, the second MEG scan demonstrated a significantly lower percentage of voxels with decreased connectivity (p < 0.05) than the initial MEG scan. Conclusions. A rapid automated resting-state MEG imaging technique demonstrates abnormally decreased functional connectivity that may persist for years after TBI, including cases classified as "mild" by GCS criteria. Disrupted MEG connectivity can be detected even in some patients with normal findings on 3-T MRI. Analysis of follow-up MEG scans in a subgroup of patients shows that, over time, the abnormally reduced connectivity can improve, suggesting neuroplasticity during the recovery from TBI. Resting state MEG deserves further investigation as a prognostic and predictive biomarker for TBI.	[Tarapore, Phiroz E.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94107 USA; [Findlay, Anne M.; LaHue, Sara C.; Lee, Hana; Honma, Susanne M.; Mizuiri, Danielle; Luks, Tracy L.; Nagarajan, Srikantan S.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94107 USA	Mukherjee, P (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94107 USA.	pratik@radiology.ucsf.edu		Mukherjee, Pratik/0000-0001-7473-7409	Dana Foundation Brain and Immuno-imaging Program; UCSF Research Evaluation and Allocation Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS060776, RC2 NS069409]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060776, R01NS066654, RC2NS069409, R21NS076171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC004855, R01DC006435, R01DC010145] Funding Source: NIH RePORTER	This work was supported by the Dana Foundation Brain and Immuno-imaging Program, UCSF Research Evaluation and Allocation Program, and NIH (Grant Nos. R01 NS060776 and RC2 NS069409).	AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Dalal SS, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/758973; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; Eliassen JC, 2008, TOP STROKE REHABIL, V15, P427, DOI 10.1310/tsr1505-427; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEIN G, 1988, ELECTROEN CLIN NEURO, V69, P581, DOI 10.1016/0013-4694(88)90171-X; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Guo CC, 2012, NEUROIMAGE, V61, P1471, DOI 10.1016/j.neuroimage.2012.03.027; Hinkley LBN, 2011, BIOL PSYCHIAT, V70, P1134, DOI 10.1016/j.biopsych.2011.06.029; Hinkley LBN, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.073.2009; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Le Van Quyen M, 2001, J NEUROSCI METH, V111, P83, DOI 10.1016/S0165-0270(01)00372-7; LEE RG, 1995, CAN J NEUROL SCI, V22, P257, DOI 10.1017/S0317167100039445; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LOPESDASILVA FH, 1973, ELECTROEN CLIN NEURO, V35, P627, DOI 10.1016/0013-4694(73)90216-2; Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Quigley M, 2001, AM J NEURORADIOL, V22, P294; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Sekihara K, 2004, IEEE T BIO-MED ENG, V51, P1726, DOI 10.1109/TBME.2004.827926; Sekihara K, 2001, IEEE T BIO-MED ENG, V48, P760, DOI 10.1109/10.930901; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stam CJ, 2002, J CLIN NEUROPHYSIOL, V19, P562, DOI 10.1097/00004691-200212000-00010; Stam CJ, 2003, HUM BRAIN MAPP, V19, P63, DOI 10.1002/hbm.10106; Vrba J, 2001, METHODS, V25, P249, DOI 10.1006/meth.2001.1238; Wang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021976; Westlake KP, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00008; Witte OW, 1997, ADV NEUROL, V73, P207; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	40	47	47	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1306	1316		10.3171/2013.3.JNS12398			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400031	23600939	Green Accepted			2021-06-18	
J	Arbogast, KB; McGinley, AD; Master, CL; Grady, MF; Robinson, RL; Zonfrillo, MR				Arbogast, Kristy B.; McGinley, Alexander D.; Master, Christina L.; Grady, Matthew F.; Robinson, Roni L.; Zonfrillo, Mark R.			Cognitive Rest and School-Based Recommendations Following Pediatric Concussion: The Need for Primary Care Support Tools	CLINICAL PEDIATRICS			English	Article						concussion; mild traumatic brain injury; primary care; cognitive rest; school	INTERNATIONAL-CONFERENCE; STATEMENT; SPORT	Objectives. (1) Assess pediatric primary care providers' understanding of cognitive rest for concussion and (2) describe their concussion management practices. Methods. This study included (1) a survey of general pediatric providers and (2) an electronic medical record (EMR) review of children 5 to 18 years old treated for concussion from September 1, 2010, to May 31, 2011. The survey asked about treatment recommendations for concussion, and results were coded to identify cognitive rest recommendations. The EMR review included the following: injury details, medical evaluation, and recommendations for resuming school and sports/recreation. Results. In all, 89 of 201 providers responded to the survey, and 52 of the 84 clinicians who included comments about concussion management mentioned cognitive rest (62%, 95% confidence interval [CI] = 51%-72%). Of the 91 EMRs reviewed for patients' first visits following the concussion, only 10 (11%, 95% CI = 6%-19%) included written cognitive rest recommendations. Conclusions. Although the majority of pediatric providers identified cognitive rest as important in pediatric concussion management, few provided written recommendations in the EMR.	[Arbogast, Kristy B.; McGinley, Alexander D.; Master, Christina L.; Grady, Matthew F.; Robinson, Roni L.; Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Arbogast, Kristy B.; Master, Christina L.; Grady, Matthew F.; Zonfrillo, Mark R.] Univ Penn, Philadelphia, PA 19104 USA	Arbogast, KB (corresponding author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market St,Suite 1150, Philadelphia, PA 19104 USA.	arbogast@email.chop.edu	Meijer, Anna/K-5118-2016; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Master, Christina/0000-0002-6717-4270; Arbogast, Kristy/0000-0002-1694-4562	Children's Hospital of Philadelphia; University of Pennsylvania Perelman School of Medicine Department of Pediatrics Chair's Initiatives program	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine Department of Pediatrics Chair's Initiatives program.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, P362, DOI 10.3928/00904481-20120827-07; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan Iii WP, 2010, J PEDIAT, V157; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Samuels-Kalow ME, 2012, ANN EMERG MED, V60, P152, DOI 10.1016/j.annemergmed.2011.10.023; Small EW, 2007, PEDIATRICS, V119, P1242, DOI 10.1542/peds.2007-0887; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	15	47	47	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAY	2013	52	5					397	402		10.1177/0009922813478160			6	Pediatrics	Pediatrics	134XN	WOS:000318249200003	23447397				2021-06-18	
J	Sillesen, M; Johansson, PI; Rasmussen, LS; Jin, G; Jepsen, CH; Imam, AM; Hwabejire, J; Lu, J; Duggan, M; Velmahos, G; deMoya, M; Alam, HB				Sillesen, Martin; Johansson, Par I.; Rasmussen, Lars S.; Jin, Guang; Jepsen, Cecilie H.; Imam, Ayehsa M.; Hwabejire, John; Lu, Jennifer; Duggan, Michael; Velmahos, George; deMoya, Marc; Alam, Hasan B.			Platelet activation and dysfunction in a large-animal model of traumatic brain injury and hemorrhage	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Platelets; hemorrhage; traumatic brain injury; inflammation; swine	INTRACRANIAL HEMORRHAGE; COAGULOPATHY; TISSUE; CD40; PROGRESSION; SHOCK	BACKGROUND: Traumatic brain injury (TBI) and hemorrhage are the leading causes of trauma-related mortality. Both TBI and hemorrhage are associated with coagulation disturbances, including platelet dysfunction. We hypothesized that platelet dysfunction could be detected early after injury, and that this dysfunction would be associated with early activation, as measured by circulating levels of platelet activation markers. METHODS: A total of 33 swine were allocated to TBI and hypotension (n = 27, TBI and volume-controlled 40% blood loss) or controls (n = 6, anesthesia and instrumentation only). Animals in the TBI/Hemorrhage group were left hypotensive, defined as mean arterial pressure of 35 mm Hg, for 2 hours. Blood samples were drawn at baseline and 3 minutes and 15 minutes following injury as well as following 2 hours of shock. Samples were analyzed for platelet aggregation using impedance aggregometry with agonists collagen, arachidonic acid, and adenosine diphosphate (ADP) and thromboelastography (TEG) and circulating levels of platelet activation markers transforming growth factor-A (TGF-A), CD40 ligand, and sP-selectin. RESULTS: Platelet ADP aggregation was significantly lower in the TBI/Hemorrhage group when compared with the control group 15 minutes following injury (62.4 vs. 80.4 U, p = 0.03) as well as following 2 hours of hypotension (59.9 vs. 73.5 U, p < 0.01). The latter was associated with lower TEG measured clot strength (TEG-MA, 74.1 vs. 79.4 mm, p = 0.05). No difference in collagen or arachidonic acid aggregation was observed. TGF-A levels were significantly higher in the TBI/Hemorrhage group following 2 hours of hypotension (1,764 vs. 1,252 pg/mL, p = 0.01). No differences in CD40 ligand or sP-selectin levels were observed. CONCLUSION: In this combined model of TBI and hemorrhage, a significantly lower ADP-induced platelet aggregation was detected 15 minutes following injury that was further aggravated during the 2-hour shock period. This dysfunction was associated with an increase in platelet activation marker TGF-A. (C) 2013 by Lippincott Williams & Wilkins	[Sillesen, Martin; Rasmussen, Lars S.] Copenhagen Univ Hosp, Rigshosp, Dept Anesthesia, Ctr Head & Orthoped, Copenhagen, Denmark; [Johansson, Par I.; Jepsen, Cecilie H.] Copenhagen Univ Hosp, Rigshosp, Capital Reg Blood Bank, Copenhagen, Denmark; [Sillesen, Martin; Jepsen, Cecilie H.; Imam, Ayehsa M.; Hwabejire, John; Lu, Jennifer; Duggan, Michael; Velmahos, George; deMoya, Marc; Alam, Hasan B.] Harvard Univ, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Johansson, Par I.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX USA; [Jin, Guang; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Johansson, Par I/P-9283-2015	Johansson, Par I/0000-0001-9778-5964; Rasmussen, Lars/0000-0002-7480-3004; Sillesen, Martin/0000-0001-9494-5475	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Copenhagen University Hospital, Rigshospitalet (Denmark); Laerdal Foundation (Norway); Aase and Ejnar Danielsen Foundation (Denmark); Olof Norlander Foundation (Sweden); Maersk Foundation (Denmark); Tryg Foundation (Denmark); Lundbeck Foundation (Denmark)Lundbeckfonden	The study was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H.B.A., grants from Copenhagen University Hospital, Rigshospitalet (Denmark), The Laerdal Foundation (Norway), The Aase and Ejnar Danielsen Foundation (Denmark), The Olof Norlander Foundation (Sweden), and The Maersk Foundation (Denmark) to M.S. L.S.R. has received funding from the Tryg Foundation (Denmark). P.I.J. received funding from the Lundbeck Foundation (Denmark). The Multiplate machine was on unconditional loan from US Distributor Diapharma Group Inc. (West Chester, OH) for the duration of the study, while the TEG-5000 machine was on unconditional loan from Haemonetics Corp. (Braintree, MA). These companies did not participate in study planning, execution, data analysis, or manuscript preparation.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hachem A, 2012, BIOCHEM BIOPH RES CO, V425, P58, DOI 10.1016/j.bbrc.2012.07.049; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Harr JN, 2012, SURGERY, V152, P270, DOI 10.1016/j.surg.2012.05.002; Inwald DP, 2003, CIRC RES, V92, P1041, DOI 10.1161/01.RES.0000070111.98158.6C; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Joist JH, 1998, THROMB RES, V92, pS47; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Li C., 2012, ADV HEMATOL, V2012, P1, DOI DOI 10.1155/2012/384685; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Stansbury LG, 2012, TRANSFUSION; Stissing T, 2011, CLIN APPL THROMB-HEM, V17, pE211, DOI 10.1177/1076029610397183; VALLES J, 1991, BLOOD, V78, P154; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Zhao L, 2003, PLATELETS, V14, P473, DOI 10.1080/09537100310001638562	23	47	49	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2013	74	5					1252	1259		10.1097/TA.0b013e31828c7a6b			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	149JZ	WOS:000319316600017	23609275				2021-06-18	
J	Khoury, S; Chouchou, F; Amzica, F; Giguere, JF; Denis, R; Rouleau, GA; Lavigne, GJ				Khoury, Samar; Chouchou, Florian; Amzica, Florin; Giguere, Jean-Francois; Denis, Ronald; Rouleau, Guy A.; Lavigne, Gilles J.			Rapid EEG Activity during Sleep Dominates in Mild Traumatic Brain Injury Patients with Acute Pain	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalography; mild traumatic brain injury; pain; sleep	EXCESSIVE DAYTIME SLEEPINESS; CATASTROPHIZING SCALE; COMPLAINTS; INSOMNIA; DISTURBANCES; DISORDERS; ADULTS; REHABILITATION; PREVALENCE; PERCEPTION	Chronic pain is a highly prevalent post-concussion symptom occurring in a majority of patients with mild traumatic brain injury (mTBI). About half of patients with mTBI report sleep-wake disturbances. It is known that pain can alter sleep quality in this population, but the interaction between pain and sleep is not fully understood. This study aimed to identify how pain affects subjective sleep (Pittsburgh Sleep Quality Index [PSQI]), sleep architecture, and quantitative electroencephalographic (qEEG) brain activity after mTBI. Twenty-four mTBI patients complaining of sleep-wake disturbances, with and without pain (8 and 16, respectively), were recruited 45 (+/- 22.7) days post-trauma on average. Data were compared with those of 18 healthy controls (no sleep or pain complaints). The PSQI, sleep architecture, and qEEG activity were analyzed. Pain was assessed using questionnaires and a 100-mm visual analogue scale. Patients with mTBI reported three times poorer sleep quality than controls on the PSQI. Sleep architecture significantly differed between patients with mTBI and controls but was within normal range. Global qEEG showed lower delta (deep sleep) and higher beta and gamma power (arousal) at certain EEG derivations in patients with mTBI compared with controls (p < 0.04). Patients with mTBI with pain, however, showed greater increase in rapid EEG frequency bands, mostly during REM sleep, and beta bands in non-REM sleep compared with patients with mTBI without pain and controls (p < 0.001). Pain in patients with mTBI was associated with more rapid qEEG activity, mostly during REM sleep, suggesting that pain is associated with poor sleep and is a critical factor in managing post-concussion symptoms.	[Khoury, Samar; Chouchou, Florian; Lavigne, Gilles J.] Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ H4J 1C5, Canada; [Amzica, Florin; Lavigne, Gilles J.] Univ Montreal, Fac Med Dent, Montreal, PQ H3C 3J7, Canada; [Khoury, Samar; Rouleau, Guy A.; Lavigne, Gilles J.] Univ Montreal CRCHUM, Univ Montreal CENUM, Ctr Excellence Neurosci, Ctr Rech, Montreal, PQ, Canada; [Giguere, Jean-Francois; Denis, Ronald; Lavigne, Gilles J.] Univ Montreal, Sacre Coeur Hosp, Dept Surg, Montreal, PQ, Canada	Lavigne, GJ (corresponding author), Hop Sacre Coeur, Ctr Adv Res Sleep Med, 5400 Blvd Gouin Ouest, Montreal, PQ H4J 1C5, Canada.	gilles.lavigne@umontreal.ca			FRQS's Quebec Pain Research Network, a hospital trauma fund; Research Centre at our hospital	The authors would like to thank Sophie Pelletier and Hajar El-Alaoui for sleep data analyses, and Ariane Demers, Christiane Manzini, and Isabel Roy for study coordination and subject recruitment. This study was funded by the FRQS's Quebec Pain Research Network, a hospital trauma fund, and the Research Centre at our hospital. Dr. Lavigne is a Canada Research Chair.	American Academy of Sleep Medicine (AASM), 2005, INT CLASS SLEEP DIS, V2nd; [Anonymous], 1974, Electroencephalogr Clin Neurophysiol, V37, P538; Baglioni C, 2012, CURR PSYCHIAT REP, V14, P511, DOI 10.1007/s11920-012-0308-5; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BONICA JJ, 1979, PAIN, V6, P247, DOI 10.1016/0304-3959(79)90046-0; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; De Pascalis V, 2005, INT J PSYCHOPHYSIOL, V56, P157, DOI 10.1016/j.ijpsycho.2004.11.004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Giamberardino M.A., 2012, PAIN COMORBIDITIES U; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Graversen C, 2012, BRIT J CLIN PHARMACO, V73, P363, DOI 10.1111/j.1365-2125.2011.04104.x; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Harman K, 2002, SLEEP, V25, P775; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Klein E, 2003, J SLEEP RES, V12, P35, DOI 10.1046/j.1365-2869.2003.00334.x; Lavigne G, 2000, PAIN, V84, P283, DOI 10.1016/S0304-3959(99)00213-4; Lavigne G, 2004, PAIN, V110, P646, DOI 10.1016/j.pain.2004.05.003; Lavigne GJ, 2011, CURR RHEUMATOL REP, V13, P535, DOI 10.1007/s11926-011-0209-3; Lavigne GJ, 2011, SLEEP MED, V12, P179, DOI 10.1016/j.sleep.2010.07.015; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Miro J, 2008, J PAIN, V9, P397, DOI 10.1016/j.jpain.2007.12.004; Moldofsky H, 2001, SLEEP MED REV, V5, P387, DOI 10.1053/smrv.2001.0179; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Riemann D, 2012, PHARMACOPSYCHIATRY, V45, P167, DOI 10.1055/s-0031-1299721; Smith M.T., 2007, SLEEP PAIN; Smith MT, 2009, CURR PAIN HEADACHE R, V13, P447, DOI 10.1007/s11916-009-0073-2; Stalnacke BM, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/528265; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Tang NKY, 2012, SLEEP, V35, P675, DOI 10.5665/sleep.1830; Theodorou AA, 2007, J CLIN SLEEP MED, V3, P347; Timofeev I., 2012, JASPERS BASIC MECH E; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Urbano Francisco J, 2012, Front Neurol, V3, P6, DOI 10.3389/fneur.2012.00006; Vancleef LMG, 2006, J PAIN, V7, P23, DOI 10.1016/j.jpain.2005.04.003; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wang J, 2011, NEUROSCI LETT, V499, P84, DOI 10.1016/j.neulet.2011.05.037; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; World Health Organization, 2010, GLOB STAT REP ROAD S; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249	58	47	48	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		633	641		10.1089/neu.2012.2519			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500005	23510169				2021-06-18	
J	Feng, Y; Clayton, EH; Chang, Y; Okamoto, RJ; Bayly, PV				Feng, Y.; Clayton, E. H.; Chang, Y.; Okamoto, R. J.; Bayly, P. V.			Viscoelastic properties of the ferret brain measured in vivo at multiple frequencies by magnetic resonance elastography	JOURNAL OF BIOMECHANICS			English	Article						Magnetic resonance elastography; MRE; Viscoelasticity; Brain; Shear modulus	MULTIFREQUENCY MR ELASTOGRAPHY; LIVER VISCOELASTICITY; TISSUE; SHEAR; RHEOMETRY; BEHAVIOR; INJURY; MODEL; VITRO	Characterization of the dynamic mechanical behavior of brain tissue is essential for understanding and simulating the mechanisms of traumatic brain injury (TBI). Changes in mechanical properties may also reflect changes in the brain due to aging or disease. In this study, we used magnetic resonance elastography (MRE) to measure the viscoelastic properties of ferret brain tissue in vivo. Three-dimensional (3D) displacement fields were acquired during wave propagation in the brain induced by harmonic excitation of the skull at 400 Hz, 600 Hz and 800 Hz. Shear waves with wavelengths in the order of millimeters were clearly visible in the displacement field, in strain fields, and in the curl of displacement field (which contains no contributions from longitudinal waves). Viscoelastic parameters (storage and loss moduli) governing dynamic shear deformation were estimated in gray and white matter for these excitation frequencies. To characterize the reproducibility of measurements, two ferrets were studied on three different dates each. Estimated viscoelastic properties of white matter in the ferret brain were generally similar to those of gray matter and consistent between animals and scan dates. In both tissue types G' increased from approximately 3 kPa at 400 Hz to 7 kPa at 800 Hz and G '' increased from approximately 1 kPa at 400 Hz to 2 kPa at 800 Hz. These measurements of shear wave propagation in the ferret brain can be used to both parameterize and validate finite element models of brain biomechanics. (C) 2013 Elsevier Ltd. All rights reserved.	[Feng, Y.; Clayton, E. H.; Okamoto, R. J.; Bayly, P. V.] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63130 USA; [Chang, Y.] Washington Univ, Dept Radiol, St Louis, MO 63130 USA; [Bayly, P. V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA	Bayly, PV (corresponding author), Washington Univ, Dept Mech Engn & Mat Sci, 305 Jolley Hall,Campus Box 1185,1 Brookings Dr, St Louis, MO 63130 USA.	pvb@wustl.edu	Feng, Yuan/C-7417-2011	Feng, Yuan/0000-0003-1902-3408; Bayly, Philip/0000-0003-4303-0704; Okamoto, Ruth/0000-0002-3085-3878	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support for this study was provided by the NIH grant NS055951. We gratefully acknowledge the technical assistance of Chad Faulkner, Amy Grater, and Summer Thompson from DCM for animal handling, and Bill Spees and John Engelbach from the Washington University Biomedical Magnetic Resonance Lab (BMRL) for imaging assistance.	Asbach P, 2008, MAGN RESON MED, V60, P373, DOI 10.1002/mrm.21636; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Auld BA., 1990, ACOUSTIC FIELDS WAVE; Barnette AR, 2009, PEDIATR RES, V66, P80, DOI 10.1203/PDR.0b013e3181a291d9; Boulet T, 2011, J NEUROSCI METH, V201, P296, DOI 10.1016/j.jneumeth.2011.08.019; Chang Y. V., 2011, P 19 ANN ISMRM SCI M, P3474; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Clayton EH, 2011, PHYS MED BIOL, V56, P2391, DOI 10.1088/0031-9155/56/8/005; Clayton E. H., 2012, TRANSMISSION ATTENUA; Di Ieva A, 2010, NEUROSURG REV, V33, P137, DOI 10.1007/s10143-010-0249-6; Feng Y., 2012, ASME INT MECH ENG C; Feng Y., 2012, P SEM ANN C EXP EXP; Flugge W., 1975, VISCOELASTICITY; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Hamhaber U, 2010, J MAGN RESON IMAGING, V32, P577, DOI 10.1002/jmri.22294; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Klatt D, 2010, BIORHEOLOGY, V47, P133, DOI 10.3233/BIR-2010-0565; KLEIVEN S, 2002, THESIS ROYAL I TECHN; Knutsen AK, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4002430; Kolsky H., 1963, STRESS WAVES SOLIDS; Kruse S. A., 2003, P 11 ISMRM SCI M EXH, P1084; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Margulies S, 2006, FORENSIC SCI INT, V164, P278, DOI 10.1016/j.forsciint.2005.12.018; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; McGarry MDJ, 2011, PHYS MED BIOL, V56, pN153, DOI 10.1088/0031-9155/56/13/N02; Murphy MC, 2012, MAGN RESON IMAGING, V30, P535, DOI 10.1016/j.mri.2011.12.019; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, NAT MED, V2, P601, DOI 10.1038/nm0596-601; Neal J, 2007, J ANAT, V210, P66, DOI 10.1111/j.1469-7580.2006.00674.x; Okamoto RJ, 2011, PHYS MED BIOL, V56, P6379, DOI 10.1088/0031-9155/56/19/014; Pattison AJ, 2010, J BIOMECH, V43, P2747, DOI 10.1016/j.jbiomech.2010.06.008; Qin E. G., 2012, J MAGNETIC RESONANCE; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Riek K, 2011, J BIOMECH, V44, P1380, DOI 10.1016/j.jbiomech.2010.12.031; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Romano AJ, 2005, MAGN RESON MED, V54, P893, DOI 10.1002/mrm.20607; Romano A, 2012, MAGN RESON MED, V68, P1410, DOI 10.1002/mrm.24141; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Schregel K, 2012, P NATL ACAD SCI USA, V109, P6650, DOI 10.1073/pnas.1200151109; Sinkus R, 2005, MAGN RESON IMAGING, V23, P159, DOI 10.1016/j.mri.2004.11.060; Sinkus R, 2005, MAGNET RESON MED, V53, P372, DOI 10.1002/mrm.20355; Soutas-Little R. W., 1973, ELASTICITY; Spottiswoode BS, 2007, IEEE T MED IMAGING, V26, P15, DOI 10.1109/TMI.2006.884215; Tong YY, 2003, ACM T GRAPHIC, V22, P445, DOI 10.1145/882262.882290; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Vappou J, 2007, MAGN RESON MATER PHY, V20, P273, DOI 10.1007/s10334-007-0098-7; Xu G, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4001683; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034; Zhang L, 2001, Stapp Car Crash J, V45, P369	52	47	48	2	37	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	MAR 15	2013	46	5					863	870		10.1016/j.jbiomech.2012.12.024			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	115RN	WOS:000316829700003	23352648	Green Accepted			2021-06-18	
J	Mac Donald, C; Johnson, A; Cooper, D; Malone, T; Sorrell, J; Shimony, J; Parsons, M; Snyder, A; Raichle, M; Fang, R; Flaherty, S; Russell, M; Brody, DL				Mac Donald, Christine; Johnson, Ann; Cooper, Dana; Malone, Thomas; Sorrell, James; Shimony, Joshua; Parsons, Matthew; Snyder, Abraham; Raichle, Marcus; Fang, Raymond; Flaherty, Stephen; Russell, Michael; Brody, David L.			Cerebellar White Matter Abnormalities following Primary Blast Injury in US Military Personnel	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; EXPOSURE; COMBAT; SCALE; IRAQI; DEPRESSION; VETERANS; SEQUELAE	Little is known about the effects of blast exposure on the human brain in the absence of head impact. Clinical reports, experimental animal studies, and computational modeling of blast exposure have suggested effects on the cerebellum and brainstem. In US military personnel with isolated, primary blast-related 'mild' traumatic brain injury and no other known insult, we found diffusion tensor MRI abnormalities consistent with cerebellar white matter injury in 3 of 4 subjects. No abnormalities in other brain regions were detected. These findings add to the evidence supporting the hypothesis that primary blast exposure contributes to brain injury in the absence of head impact and that the cerebellum may be particularly vulnerable. However, the clinical effects of these abnormalities cannot be determined with certainty; none of the subjects had ataxia or other detected evidence of cerebellar dysfunction. The details of the blast events themselves cannot be disclosed at this time, thus additional animal and computational modeling will be required to dissect the mechanisms underlying primary blast-related traumatic brain injury. Furthermore, the effects of possible subconcussive impacts and other military-related exposures cannot be determined from the data presented. Thus many aspects of topic will require further investigation.	[Mac Donald, Christine; Johnson, Ann; Cooper, Dana; Malone, Thomas; Sorrell, James; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Shimony, Joshua; Parsons, Matthew; Snyder, Abraham; Raichle, Marcus] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Fang, Raymond; Flaherty, Stephen] Landstuhl Reg Med Ctr, Dept Trauma Surg, Landstuhl, Germany; [Russell, Michael] USA, Rehabil & Reintegrat Div, San Antonio, TX USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0061]; United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32NS062529, 5K23HD053212, P30NS048056, P50NS06833, 5K08NS49237]; U.S. Army Medical Research Acquisition Activity [W81XWH-09-2-0057]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD053212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, F32NS062529, P30NS048056, P50NS006833] Funding Source: NIH RePORTER	The study was supported by grants from the Congressionally Directed Medical Research Program (W81XWH-08-2-0061, to Dr. Brody), the United States National Institutes of Health (F32NS062529, to Dr. Mac Donald; 5K23HD053212, to Dr. Shimony; P30NS048056, to Dr. Snyder; P50NS06833, to Drs. Raichle and Snyder; and 5K08NS49237, to Dr. Brody) and U.S. Army Medical Research Acquisition Activity (W81XWH-09-2-0057) to Dr. Russell, under a protocol approved by Brooke Army Medical Center, San Antonio, TX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Benton AL, 1983, MULTILINGUAL APHASIA; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Conners C., 2000, CONNERS CONTINUOUS P; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis DC, 2000, CALIFORNIA VERBAL LE; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Heaton R., 1993, WISCONSIN CARD SORTI; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Matthews C, 1964, INSTRUCTION MANUAL A; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mott F. W., 1917, J ROY ARMY MED CORPS, V29, P662; Mott FW, 1916, LANCET, V1, P441; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Peskind ER, 2010, NEUROIMAGE; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Reitan R. M., 1992, TRAIL MAKING TEST MA; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Smith A., 1991, SYMBOL DIGIT MODALIT; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stoodley CJ, 2009, BRAIN LANG, V110, P149, DOI 10.1016/j.bandl.2009.07.006; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Talavage T. M., 2010, J NEUROTRAUMA; Taylor L, 1991, COMPENDIUM NEUROPSYC; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 2001, WECHSLER TEST ADULT; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	53	47	47	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e55823	10.1371/journal.pone.0055823			8	Multidisciplinary Sciences	Science & Technology - Other Topics	092XV	WOS:000315157200070	23409052	DOAJ Gold, Green Published			2021-06-18	
J	Keshavan, MS; Kaneko, Y				Keshavan, Matcheri S.; Kaneko, Yoshio			Secondary psychoses: an update	WORLD PSYCHIATRY			English	Article						Secondary psychoses; temporal lobe epilepsy; velocardiofacial syndrome; NMDA receptor encephalitis; schizophrenia	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CARDIO-FACIAL SYNDROME; SCHIZOPHRENIA-LIKE PSYCHOSIS; TRAUMATIC BRAIN INJURY; PRADER-WILLI-SYNDROME; LATE-ONSET PSYCHOSIS; MULTIPLE-SCLEROSIS; PSYCHIATRIC-ILLNESS; ALZHEIMERS-DISEASE; MITOCHONDRIAL ENCEPHALOMYOPATHY	Psychotic disorders due to a known medical illness or substance use are collectively termed secondary psychoses. In this paper, we first review the historic evolution of the concept of secondary versus primary psychosis and how this distinction supplanted the earlier misleading classification of psychoses into organic and functional. We then outline the clinical features and approach to the diagnosis of secondary psychotic disorders. Features such as atypical presentation, temporal relation to detectable medical cause, evidence of direct physiological causal relationship to the etiological agent, and the absence of evidence of a primary psychotic illness that may better explain the presentation suggest consideration of a secondary psychosis. Finally, we discuss how careful studies of secondary psychotic disorders can help elucidate the pathophysiology of primary, or idiopathic, psychotic disorders such as schizophrenia. We illustrate this issue through a discussion of three secondary psychotic disorders - psychoses associated with temporal lobe epilepsy, velocardiofacial syndrome, and N-methyl D-aspartate (NMDA) receptor encephalitis - that can, respectively, provide neuroanatomical, genetic, and neurochemical models of schizophrenia pathogenesis.	[Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Keshavan, Matcheri S.; Kaneko, Yoshio] Harvard Univ, Sch Med, Boston, MA USA; [Kaneko, Yoshio] Longwood Psychiat Residency Training Program, Boston, MA USA	Keshavan, MS (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.						ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Alisky JM, 2006, MED HYPOTHESES, V67, P1090, DOI 10.1016/j.mehy.2006.01.059; Almeida OP, 2007, AUST NZ J PSYCHIAT, V41, P274, DOI 10.1080/00048670601172772; *AM PSYCHIAT ASS, 2000, DIAGN STAT MAN MENT; Amemiya S, 2000, NEUROLOGY, V55, P600, DOI 10.1212/WNL.55.4.600; Ando N, 2004, NEUROPSYCHOPHARMACOL, V29, P1251, DOI 10.1038/sj.npp.1300427; ANG AWK, 1995, PSYCHOSOM MED, V57, P299, DOI 10.1097/00006842-199505000-00013; Appenzeller S, 2008, RHEUMATOL INT, V28, P237, DOI 10.1007/s00296-007-0410-x; Babulas V, 2006, AM J PSYCHIAT, V163, P927, DOI 10.1176/appi.ajp.163.5.927; BENES FM, 1989, SCHIZOPHRENIA BULL, V15, P585, DOI 10.1093/schbul/15.4.585; Benes FM, 2003, CURR OPIN PSYCHIATR, V16, P317, DOI 10.1097/00001504-200305000-00007; Beniczky S, 2002, EUR J NEUROL, V9, P175, DOI 10.1046/j.1468-1331.2002.00353.x; Bo Mortensen P, 2007, BIOL PSYCHIAT, V61, P688, DOI 10.1016/j.biopsych.2006.05.024; Bourgeois JA, 2010, ACTA PSYCHIAT SCAND, V121, P78, DOI 10.1111/j.1600-0447.2009.01419.x; BOWEN JD, 1993, DRUG AGING, V3, P349, DOI 10.2165/00002512-199303040-00005; Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774; Brown AS, 2001, BIOL PSYCHIAT, V49, P473, DOI 10.1016/S0006-3223(01)01068-X; Brown AS, DEV NEUROBI IN PRESS; Brownlie BEW, 2000, EUR J ENDOCRINOL, V142, P438, DOI 10.1530/eje.0.1420438; Cami J, 2000, J CLIN PSYCHOPHARM, V20, P455, DOI 10.1097/00004714-200008000-00010; Carrieri PB, 2011, J NEUROPSYCH CLIN N, V23, pE6, DOI 10.1176/appi.neuropsych.23.2.E6; Chow EWC, 2006, SCHIZOPHR RES, V87, P270, DOI 10.1016/j.schres.2006.04.007; Cole JC, 2003, PHARMACOL THERAPEUT, V98, P35, DOI 10.1016/S0163-7258(03)00003-2; Curran C, 2004, BRIT J PSYCHIAT, V185, P196, DOI 10.1192/bjp.185.3.196; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Dalmau A, 1999, EUR PSYCHIAT, V14, P366, DOI 10.1016/S0924-9338(99)00234-5; Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; de Holanda NCP, 2011, J NEUROPSYCH CLIN N, V23, P384, DOI 10.1176/jnp.23.4.jnp384; DENKO JD, 1962, ACTA PSYCHIAT SCAND, V38, P7; Dolder CR, 2004, AIDS, V18, pS35, DOI 10.1097/00002030-200401001-00006; Dubovsky AN, 2012, PSYCHOSOMATICS, V53, P103, DOI 10.1016/j.psym.2011.12.007; Edwards-Lee T, 2000, BEHAVIOR AND MOOD DISORDERS IN FOCAL BRAIN LESIONS, P419; EdwardsLee T, 1997, BRAIN, V120, P1027, DOI 10.1093/brain/120.6.1027; ERARD R, 1980, J PSYCHEDEL DRUG, V12, P235, DOI 10.1080/02791072.1980.10471432; EVANS DL, 1983, AM J PSYCHIAT, V140, P218; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; FEINBERG M, 1993, DRUG AGING, V3, P335, DOI 10.2165/00002512-199303040-00004; FEINSTEIN A, 1992, BRIT J PSYCHIAT, V161, P680, DOI 10.1192/bjp.161.5.680; Feinstein A, 2004, CAN J PSYCHIAT, V49, P157, DOI 10.1177/070674370404900302; Fergusson DM, 2005, ADDICTION, V100, P354, DOI 10.1111/j.1360-0443.2005.01001.x; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI 10.1017/S0033291702006402; FOLSTEIN SE, 1987, AM J HUM GENET, V41, P168; FREYTAG HW, 1979, NERVENARZT, V50, P128; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; GALASKO D, 1988, PSYCHIAT CLIN N AM, V11, P151; GODFREY PSA, 1990, LANCET, V336, P392, DOI 10.1016/0140-6736(90)91942-4; Gonzalez-Burgos G, 2010, CURR PSYCHIAT REP, V12, P335, DOI 10.1007/s11920-010-0124-8; Guler E, 2011, INT PSYCHOGERIATR, V23, P666, DOI 10.1017/S104161021000181X; Gustafson L, 1992, Baillieres Clin Neurol, V1, P559; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; HALL RCW, 1983, PSYCHOSOMATICS, V24, P7, DOI 10.1016/S0033-3182(83)73255-X; Hambrecht M, 1996, NERVENARZT, V67, P36; HARE EH, 1959, J MENT SCI, V105, P594; HARRIS MJ, 1991, J CLIN PSYCHIAT, V52, P369; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Harrison PJ, 2003, ANN NY ACAD SCI, V1003, P94, DOI 10.1196/annals.1300.006; Heinrich Thomas W., 2003, Prim Care Companion J Clin Psychiatry, V5, P260; Herrington R. N., 1969, CURRENT PROBLEMS NEU, P1; HOLLISTER LE, 1991, J PSYCHIATR NEUROSCI, V16, P194; Huang Chin-Chang, 1992, Journal of the Formosan Medical Association, V91, P502; Hung Y-J, 2012, GEN HOSP PSYCHIAT, V34; Hutto B, 2001, PSYCHOSOMATICS, V42, P453, DOI 10.1176/appi.psy.42.6.453; Hutto BR, 1997, COMPR PSYCHIAT, V38, P305, DOI 10.1016/S0010-440X(97)90925-1; Illes J, 2006, SCIENCE, V311, P783, DOI 10.1126/science.1124665; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Irwin R, 1997, AUST NZ J PSYCHIAT, V31, P762, DOI 10.3109/00048679709062692; Jansen KLR, 2000, J PSYCHOACTIVE DRUGS, V32, P419, DOI 10.1080/02791072.2000.10400244; Jeste DV, 2000, AM J GERIAT PSYCHIAT, V8, P29, DOI 10.1097/00019442-200002000-00004; KAHAN VL, 1950, J MENT SCI, V96, P1043; Kanner AM, 1996, ARCH NEUROL-CHICAGO, V53, P258, DOI 10.1001/archneur.1996.00550030070024; Kates WR, 2011, BIOL PSYCHIAT, V69, P945, DOI 10.1016/j.biopsych.2010.10.027; Katsigiannopoulos K, 2010, PSYCHOSOMATICS, V51, P449, DOI 10.1176/appi.psy.51.5.449-a; Keshavan MS, 2011, SCHIZOPHR RES, V126, P1, DOI 10.1016/j.schres.2010.10.006; Keshavan MS, 2008, SCHIZOPHR RES, V106, P89, DOI 10.1016/j.schres.2008.07.020; KLAUS MV, 1989, ARCH DERMATOL, V125, P1644, DOI 10.1001/archderm.125.12.1644; KLOTZ M, 1957, PSYCHIAT QUART, V31, P669, DOI 10.1007/BF01568758; Kobayashi Nobuyuki, 2011, J Med Case Rep, V5, P534, DOI 10.1186/1752-1947-5-534; Kosmidis MH, 2010, INT REV PSYCHIATR, V22, P55, DOI 10.3109/09540261003589612; Kramer W, 1966, Psychiatr Neurol Neurochir, V69, P43; Kumral E, 2004, NEUROLOGY, V62, P110, DOI 10.1212/WNL.62.1.110; Larson CP, 1940, AM J PSYCHIAT, V97, P49, DOI 10.1176/ajp.97.1.49; Lawrie SM, 1997, SCHIZOPHR RES, V25, P155, DOI 10.1016/S0920-9964(97)00019-4; Lee Min-Joo, 2012, Korean J Pediatr, V55, P111, DOI 10.3345/kjp.2012.55.3.111; LEVITT AJ, 1988, BRIT J PSYCHIAT, V153, P266; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; Lisanby S. H., 1998, SEMIN CLIN NEUROPSYC, V3, P12; LOGSDAIL SJ, 1988, BRIT J PSYCHIAT, V152, P246, DOI 10.1192/bjp.152.2.246; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; MALAMUD N, 1967, ARCH NEUROL-CHICAGO, V17, P113, DOI 10.1001/archneur.1967.00470260003001; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; Martin NJ, 2000, INT PSYCHOGERIATR, V12, P117, DOI 10.1017/S1041610200006244; Masalha R, 2001, ISRAEL MED ASSOC J, V3, P701; MEADOR KJ, 1994, CAN J NEUROL SCI, V21, pS12, DOI 10.1017/S0317167100040762; Mendel L B, 1907, Science, V26, P765, DOI 10.1126/science.26.674.765; MILLER BL, 1986, J CLIN PSYCHIAT, V47, P204; MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541; Moghaddam B, 2003, NEURON, V40, P881, DOI 10.1016/S0896-6273(03)00757-8; MULDER DW, 1952, JAMA-J AM MED ASSOC, V150, P173, DOI 10.1001/jama.1952.03680030005003; Murphy KC, 1999, ARCH GEN PSYCHIAT, V56, P940, DOI 10.1001/archpsyc.56.10.940; Nagaratnam N, 2000, GEN HOSP PSYCHIAT, V22, P129, DOI 10.1016/S0163-8343(00)00064-5; Nye Elizabeth, 2002, Emerg Med (Fremantle), V14, P447, DOI 10.1046/j.1442-2026.2002.00385.x; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Papa A, 2003, AM J EMERG MED, V21, P250, DOI 10.1016/S0735-6757(03)00022-6; Papolos DF, 1996, AM J PSYCHIAT, V153, P1541; Patten SB, 2005, NEUROLOGY, V65, P1123, DOI 10.1212/01.wnl.0000178998.95293.29; Paulsen JS, 2000, J INT NEUROPSYCH SOC, V6, P815, DOI 10.1017/S1355617700677081; Payinda G, 2000, AM J PSYCHIAT, V157, P660, DOI 10.1176/appi.ajp.157.4.660; Pego-Reigosa JM, 2008, RHEUMATOLOGY, V47, P1498, DOI 10.1093/rheumatology/ken260; PETERS NL, 1989, ARCH INTERN MED, V149, P2414, DOI 10.1001/archinte.149.11.2414; POST RM, 1975, AM J PSYCHIAT, V132, P225; Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024; Prakash R, 2008, GEN HOSP PSYCHIAT, V30, P581, DOI 10.1016/j.genhosppsych.2008.04.011; PULVER AE, 1994, J NERV MENT DIS, V182, P476, DOI 10.1097/00005053-199408000-00010; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Rapoport MJ, 2001, INT J GERIATR PSYCH, V16, P123, DOI 10.1002/1099-1166(200102)16:2<123::AID-GPS260>3.0.CO;2-1; Rathbun JK, 1996, INT J NEUROSCI, V85, P221, DOI 10.3109/00207459608986684; Rizvi AA, 2007, SOUTH MED J, V100, P837, DOI 10.1097/SMJ.0b013e318063ed4e; Ropacki SA, 2005, AM J PSYCHIAT, V162, P2022, DOI 10.1176/appi.ajp.162.11.2022; RUDIN DO, 1981, BIOL PSYCHIAT, V16, P837; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Sachdev PS, 2010, SECONDARY SCHIZOPHRE; Sathya A, 2009, SINGAP MED J, V50, pe65; Schenk V W, 1967, Psychiatr Neurol Neurochir, V70, P31; SCHOFIELD A, 1983, IRISH MED J, V76, P495; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; Schrestha S, 2009, PSYCHOSOMATICS, V50, P640, DOI 10.1176/appi.psy.50.6.640-a; SELECKI B R, 1965, Med J Aust, V1, P383; Sewell DD, 1996, SCHIZOPHRENIA BULL, V22, P465, DOI 10.1093/schbul/22.3.465; Shakibai SV, 2005, PSYCHOSOMATICS, V46, P569, DOI 10.1176/appi.psy.46.6.569; Shashi V, 2006, CLIN GENET, V69, P234, DOI 10.1111/j.1399-0004.2006.00569.x; Shashi V, 2010, PSYCHIAT RES-NEUROIM, V181, P1, DOI 10.1016/j.pscychresns.2009.07.003; SHEDLACK KJ, 1994, BIOL PSYCHIAT, V35, P147, DOI 10.1016/0006-3223(94)91207-6; Shenton Martha E, 2010, Dialogues Clin Neurosci, V12, P317; SHIWACH R, 1994, ACTA PSYCHIAT SCAND, V90, P241, DOI 10.1111/j.1600-0447.1994.tb01587.x; SHPRINTZEN RJ, 1992, AM J MED GENET, V42, P141, DOI 10.1002/ajmg.1320420131; SIBLEY JT, 1992, J RHEUMATOL, V19, P47; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SLATER E, 1963, BRIT J PSYCHIAT, V109, P95, DOI 10.1192/bjp.109.458.95; SNAVELY SR, 1984, ANN INTERN MED, V101, P92, DOI 10.7326/0003-4819-101-1-92; Sobhan T, 2004, PSYCHIAT SERV, V55, P830, DOI 10.1176/appi.ps.55.7.830; STANDAGE KF, 1975, PSYCHOL MED, V5, P152, DOI 10.1017/S0033291700056403; STARKSTEIN SE, 1992, NEUROPSY NEUROPSY BE, V5, P114; Stojanovich L, 2007, AUTOIMMUN REV, V6, P421, DOI 10.1016/j.autrev.2007.02.007; SUZUKI T, 1989, J NEUROL NEUROSUR PS, V52, P920, DOI 10.1136/jnnp.52.7.920-a; Tandon R, 2008, SCHIZOPHR RES, V102, P1, DOI 10.1016/j.schres.2008.04.011; Taycan O, 2006, GEN HOSP PSYCHIAT, V28, P359, DOI 10.1016/j.genhosppsych.2006.02.006; Thirthalli J, 2006, CURR OPIN PSYCHIATR, V19, P239, DOI 10.1097/01.yco.0000218593.08313.fd; Tor P. C., 2007, SMJ Singapore Medical Journal, V48, P354; Torrey EF, 2007, SCHIZOPHRENIA BULL, V33, P727, DOI 10.1093/schbul/sbm026; Torta R, 1999, EPILEPSIA, V40, pS2, DOI 10.1111/j.1528-1157.1999.tb00883.x; Tran TM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-74; Trimble MR., 1991, PSYCHOSES EPILEPSY; Velasco PJ, 1999, PSYCHOSOMATICS, V40, P486; Vogels A, 2004, AM J MED GENET A, V127A, P238, DOI 10.1002/ajmg.a.30004; Vogels A, 2003, J MED GENET, V40, P72, DOI 10.1136/jmg.40.1.72; WAGGONER RW, 1954, AM J PSYCHIAT, V110, P904, DOI 10.1176/ajp.110.12.904; WARD MM, 1991, J RHEUMATOL, V18, P535; Watson LC, 2002, PSYCHOSOMATICS, V43, P413, DOI 10.1176/appi.psy.43.5.413; WEINBERGER DR, 1995, SCHIZOPHR RES, V16, P87, DOI 10.1016/0920-9964(95)00013-C; Wilson SAK, 1912, BRIT MED J, V1912, P1645; Yolken RH, 2009, PARASITE IMMUNOL, V31, P706, DOI 10.1111/j.1365-3024.2009.01131.x	163	47	50	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2051-5545			WORLD PSYCHIATRY	World Psychiatry	FEB	2013	12	1					4	15		10.1002/wps.20001			12	Psychiatry	Psychiatry	157BN	WOS:000319870500002	23471787	Bronze, Green Published			2021-06-18	
J	Honeybul, S; Ho, KM; Lind, CRP				Honeybul, Stephen; Ho, Kwok M.; Lind, Christopher R. P.			What Can Be Learned from the DECRA Study	WORLD NEUROSURGERY			English	Article						Decompressive craniectomy; DECRA; Neurotrauma	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; IMPACT; DEATH	BACKGROUND There has been a resurgence of interest in the use of decompressive craniectomy for severe traumatic brain injury (TBI). Numerous studies have shown that the procedure can consistently reduce intracranial pressure (ICP), and a significant number of patients achieve a good long-term functional recovery. However, there has been debate regarding clinical indications and patient selection. METHODS The DECRA (Decompressive Craniectomy in Patients with Severe Traumatic Brain Injury) study compared patients who underwent early decompressive craniectomy for diffuse TBI with patients who received standard medical therapy. Of patients, 70% in the craniectomy group had an unfavourable outcome versus 51% in the standard care group (odds ratio 2.21 [ 95% confidence interval 1.14-4.26]; P = 0.02). Based on these results, the authors concluded that decompressive craniectomy was associated with more unfavorable outcomes and that by adopting standard medical therapy rather than surgical decompression the health care system would save millions of dollars. These conclusions are not really supported by closer examination of the basic data. There were problems with randomization such that the patients in the surgical arm appeared to have sustained a more severe primary TBI, the ICP threshold of >20 mm Hg for >15 minutes did not reflect clinical practice, and there was a high crossover rate from the standard care arm to the surgical arm. Because of these problems, the DECRA trial has received a great deal of criticism, and some authorities have claimed that the results should have no influence on clinical practice. This claim is perhaps unfair, and an alternative interpretation is offered. RESULTS Overall, the results of the DECRA study showed that a relatively transient and mild increase in ICP (>20 mm Hg for 15 minutes as recruitment criterion) does not imply that there is significant ongoing secondary brain injury, and any potential improvement obtained by surgical decompression may well be offset by surgical morbidity. CONCLUSIONS The role of decompressive craniectomy when ICP continues to increase >= 20 mm Hg remains to be established. The ongoing RESCUEicp (Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intra-Cranial Pressure) study hopes to address this issue.	[Honeybul, Stephen; Lind, Christopher R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen; Lind, Christopher R. P.] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Lind, Christopher R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Cooper DJ, 2011, MED J AUSTRALIA, V194, P437, DOI 10.5694/j.1326-5377.2011.tb03053.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Hossain-Ibrahim MK, 2011, BRIT J NEUROSURG, V25, P538, DOI 10.3109/02688697.2011.584641; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Komotar RJ, 2011, NEUROSURGERY, V69, pN22, DOI 10.1227/01.neu.0000400020.24025.21; Marion DW, 2011, LANCET NEUROL, V10, P497, DOI 10.1016/S1474-4422(11)70098-9; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Vashu R, 2011, ACTA NEUROCHIR, V153, P2065, DOI 10.1007/s00701-011-1101-7; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616	25	47	48	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2013	79	1					159	161		10.1016/j.wneu.2012.08.012			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	100RB	WOS:000315717800039	23022646				2021-06-18	
J	Rodriguez-Rodriguez, A; Egea-Guerrero, JJ; Leon-Justel, A; Gordillo-Escobar, E; Revuelto-Rey, J; Vilches-Arenas, A; Carrillo-Vico, A; Dominguez-Roldan, JM; Murillo-Cabezas, F; Guerrero, JM				Rodriguez-Rodriguez, Ana; Jose Egea-Guerrero, Juan; Leon-Justel, Antonio; Gordillo-Escobar, Elena; Revuelto-Rey, Jaume; Vilches-Arenas, Angel; Carrillo-Vico, Antonio; Maria Dominguez-Roldan, Jose; Murillo-Cabezas, Francisco; Miguel Guerrero, Juan			Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults	CLINICA CHIMICA ACTA			English	Article						Traumatic brain injury; S100B; Urine; Mortality; Biomarkers	NEURON-SPECIFIC ENOLASE; S100-BETA PROTEIN; S-100B; DAMAGE; BIOMARKERS; CHILDREN; INFANTS; MARKERS; LEVEL	S100B is a calcium-binding protein released into the blood from astroglial cells due to brain injury. Some authors have described a correlation between S100B serum concentration and severity of brain damage. There is not much information about the accuracy of urinary S100B for predicting outcome after severe traumatic brain injury (TBI). 55 patients with severe TBI were included in the study. Blood and urine samples were drawn to determine S100B levels on admission and on the subsequent 24, 48, 72 and 96 h. S100B concentrations (serum and urine) were significantly higher in patients who were dead a month after the accident compared to survivors. ROC-analysis showed that S100B at 24 h post-severe TBI is a useful tool for predicting mortality (serum: AUC 0.958, urine: AUC 0.778). The best cut-offs for S100B were 0.461 mu g/L and 0.025 mu g/L (serum and urine respectively), with a sensitivity of 90% for both measurements and a specificity of 88.4% (serum) and 62.8% (urine). We can state that the determination of S100B levels both in urine and serum acts as a sensitive and an effective biomarker for the early prediction of mortality after severe TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Rodriguez-Rodriguez, Ana; Leon-Justel, Antonio; Miguel Guerrero, Juan] Univ Seville, CSIC, IBIS, Virgen del Rocio Univ Hosp,Dept Clin Biochem, Seville 41013, Spain; [Jose Egea-Guerrero, Juan; Gordillo-Escobar, Elena; Revuelto-Rey, Jaume; Carrillo-Vico, Antonio; Maria Dominguez-Roldan, Jose; Murillo-Cabezas, Francisco] Univ Seville, CSIC, IBIS, Virgen del Rocio Univ Hosp,NeuroCrit Care Unit, Seville 41013, Spain; [Vilches-Arenas, Angel] Univ Seville, Dept Prevent Med & Publ Hlth, Seville 41013, Spain	Guerrero, JM (corresponding author), Univ Seville, CSIC, IBIS, Virgen del Rocio Univ Hosp,Dept Clin Biochem, Avda Manuel Siurot S-N, Seville 41013, Spain.	guerrero@us.es	IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; Rodriguez-Rodriguez, Ana/F-4718-2016; IBIS, NEUROINMUNO/O-9306-2015; Guerrero, Josep M./Y-2929-2019; Vico, Antonio Carrillo/K-5265-2014; Vilches-Arenas, Angel/C-1167-2015; Dominguez-Roldan, Jose-Maria/M-1728-2016; Egea-Guerrero, Juan Jose/P-5080-2014	Rodriguez-Rodriguez, Ana/0000-0002-6854-9695; Guerrero, Josep M./0000-0001-5236-4592; Vico, Antonio Carrillo/0000-0002-8516-0999; Vilches-Arenas, Angel/0000-0003-2197-3760; Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Revuelto-Rey, Jaume/0000-0001-8350-9555; Egea-Guerrero, Juan Jose/0000-0002-4166-313X; Guerrero, Juan Miguel/0000-0001-7553-0119			Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Beaudeux JL, 1999, ANN BIOL CLIN-PARIS, V57, P261; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Copes W. S, P 33 ANN M ASS ADV A, P205; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Ferguson MA, 2008, TOXICOLOGY, V245, P182, DOI 10.1016/j.tox.2007.12.024; Gazzolo D, 2002, CRIT CARE MED, V30, P1356, DOI 10.1097/00003246-200206000-00037; Gazzolo D, 1999, J NEUROL SCI, V170, P32, DOI 10.1016/S0022-510X(99)00194-X; Hallen M, 2008, CLIN CHEM LAB MED, V46, P1025, DOI 10.1515/CCLM.2008.190; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hu JR, 1997, J NEUROCHEM, V69, P2294; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lee CC, 2010, J CHIN MED ASSOC, V73, P8, DOI 10.1016/S1726-4901(10)70015-0; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Portela LVC, 2002, CLIN CHEM, V48, P950; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Risso FM, 2012, CLIN CHIM ACTA, V413, P150, DOI 10.1016/j.cca.2011.09.011; Schultke E, 2009, CAN J NEUROL SCI, V36, P612, DOI 10.1017/S031716710000812X; Steiner J, 2011, CLIN CHEM LAB MED, V49, P409, DOI 10.1515/CCLM.2011.083; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	39	47	48	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	DEC 24	2012	414						228	233		10.1016/j.cca.2012.09.025			6	Medical Laboratory Technology	Medical Laboratory Technology	059DU	WOS:000312685400048	23031665				2021-06-18	
J	Garay, LI; Deniselle, MCG; Brocca, ME; Lima, A; Roig, P; De Nicola, AF				Garay, L. I.; Gonzalez Deniselle, M. C.; Brocca, M. E.; Lima, A.; Roig, P.; De Nicola, A. F.			PROGESTERONE DOWN-REGULATES SPINAL CORD INFLAMMATORY MEDIATORS AND INCREASES MYELINATION IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS	NEUROSCIENCE			English	Article						progesterone; experimental autoimmune encephalomyelitis; transcription factors; myelin proteins; proinflammatory mediators; neuroprotection	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; TRANSCRIPTION FACTOR; STEROID-HORMONES; GENE-EXPRESSION; NITRIC-OXIDE; T-CELLS; CNS	In mice with experimental autoimmune encephalomyelitis (EAE) pretreatment with progesterone improves clinical signs and decreases the loss of myelin basic protein (MBP) and proteolipid protein (PLP) measured by immunohistochemistry and in situ hybridization. Presently, we analyzed if progesterone effects in the spinal cord of EAE mice involved the decreased transcription of local inflammatory mediators and the increased transcription of myelin proteins and myelin transcription factors. C57BI/6 female mice were divided into controls, EAE and EAE receiving progesterone (100 mg implant) 7 days before EAE induction. Tissues were collected on day 17 post-immunization. Real time PCR technology demonstrated that progesterone blocked the EAE-induced increase of the proinflammatory mediators tumor necrosis factor alpha (TNF alpha) and its receptor TNFR1, the microglial marker CD11b and toll-like receptor 4 (TLR4) mRNAs, and increased mRNA expression of PLP and MBP, the myelin transcription factors NKx2.2 and Olig1 and enhanced CC1 + oligodendrocyte density respect of untreated EAE mice. Immunocytochemistry demonstrated decreased Iba1 + microglial cells. Confocal microscopy demonstrated that TNF alpha colocalized with glial-fibrillary acidic protein + astrocytes and OX-42 + microglial cells. Therefore, progesterone treatment improved the clinical signs of EAE, decreased inflammatory glial reactivity and increased myelination. Data suggest that progesterone neuroprotection involves the modulation of transcriptional events in the spinal cord of EAE mice. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Garay, L. I.; Gonzalez Deniselle, M. C.; Brocca, M. E.; Lima, A.; Roig, P.; De Nicola, A. F.] Inst Biol Medicina Expt CONICET, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Garay, L. I.; Gonzalez Deniselle, M. C.; De Nicola, A. F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1425 Buenos Aires, DF, Argentina	De Nicola, AF (corresponding author), Inst Biol Medicina Expt CONICET, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	laurainesgaray@gmaill.com; gonza-lezdeniselle@gmail.com; mebrocca@gmail.com; analia1lima@gmail.com; paulinaroig@hotmail.com; alejandrodenicola@gmail.com	Maria Elvira BROCCA, ME Brocca/K-2319-2017; Brocca, Maria Elvira/ABD-7290-2020	Maria Elvira BROCCA, ME Brocca/0000-0002-3116-7490; 	FONCYTFONCyT [PICT 2007-01044]; CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 112-200801-00542]; University of Buenos AiresUniversity of Buenos Aires [20020100100089]	This work was supported by grants from FONCYT (PICT 2007-01044), CONICET (PIP 112-200801-00542) and the University of Buenos Aires (20020100100089). There are no conflicts of interests.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Ayers MM, 2004, NEUROCHEM INT, V45, P409, DOI 10.1016/j.neuint.2003.08.018; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Cai J, 2010, GLIA, V58, P458, DOI 10.1002/glia.20937; Cammer W, 2000, BRAIN RES, V864, P213, DOI 10.1016/S0006-8993(00)02178-8; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen KB, 2011, SPINE, V36, P1350, DOI 10.1097/BRS.0b013e3181f014ec; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Elloso MM, 2005, J ENDOCRINOL, V185, P243, DOI 10.1677/joe.1.06063; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garay L, 2009, BRAIN RES, V1283, P177, DOI 10.1016/j.brainres.2009.04.057; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Giatti S, 2012, J NEUROENDOCRINOL, V24, P851, DOI 10.1111/j.1365-2826.2012.02284.x; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Guo XL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013083; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hughes MD, 2004, NEUROL CLIN, V22, P757, DOI 10.1016/j.ncl.2004.06.004; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Jiang H, 2003, P NATL ACAD SCI USA, V100, P8378, DOI 10.1073/pnas.1432871100; Kim S, 1999, NEUROLOGY, V52, P1230, DOI 10.1212/WNL.52.6.1230; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Lee J, 2003, DEV BIOL, V253, P84, DOI 10.1006/dbio.2002.0868; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Lehnardt S, 2008, J NEUROSCI, V28, P2320, DOI 10.1523/JNEUROSCI.4760-07.2008; Leitner H, 2010, MED HYPOTHESES, V75, P229, DOI 10.1016/j.mehy.2010.02.028; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Marin-Husstege M, 2004, DEV NEUROSCI-BASEL, V26, P245, DOI 10.1159/000082141; Matute C, 2005, TRENDS NEUROSCI, V28, P173, DOI 10.1016/j.tins.2005.01.006; Mc Guire C, 2011, TRENDS NEUROSCI, V34, P619, DOI 10.1016/j.tins.2011.09.002; McDonald JW, 2006, J NEUROTRAUM, V23, P345, DOI 10.1089/neu.2006.23.345; McQualter JL, 2007, J NEUROCHEM, V100, P295, DOI 10.1111/j.1471-4159.2006.04232.x; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Melcangi RC, 2003, J STEROID BIOCHEM, V85, P323, DOI 10.1016/S0960-0760(03)00228-0; Mensah-Nyagan Ayikoe G, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS169, DOI 10.1016/j.psyneuen.2009.06.004; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Muller E, 2006, NEUROENDOCRINOL LETT, V27, P675; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; Offner H, 2004, J NEUROSCI RES, V78, P603, DOI 10.1002/jnr.20330; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Palaszynski KM, 2004, J NEUROIMMUNOL, V149, P84, DOI 10.1016/j.jneuroim.2003.12.015; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Qi YC, 2001, DEVELOPMENT, V128, P2723; Roy AA, 2006, J BIOL CHEM, V281, P32684, DOI 10.1074/jbc.M604416200; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Su L, 2009, IMMUNOL LETT, V125, P151, DOI 10.1016/j.imlet.2009.07.003; Su ZD, 2011, J NEUROTRAUM, V28, P1089, DOI 10.1089/neu.2010.1597; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; TEUSCHER C, 1990, CLIN IMMUNOL IMMUNOP, V54, P442, DOI 10.1016/0090-1229(90)90057-W; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079	79	47	47	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 13	2012	226						40	50		10.1016/j.neuroscience.2012.09.032			11	Neurosciences	Neurosciences & Neurology	047TT	WOS:000311865100005	23000619				2021-06-18	
J	Behn, N; Togher, L; Power, E; Heard, R				Behn, Nicholas; Togher, Leanne; Power, Emma; Heard, Rob			Evaluating communication training for paid carers of people with traumatic brain injury	BRAIN INJURY			English	Article						Brain injury; training; paid carer; communication partner; conversation; cognitive-communication; RCT	LEARNING-DISABILITIES; DISCOURSE; REHABILITATION; QUESTIONNAIRE; PARTNERS; ADULTS; SKILLS; STAFF; RELIABILITY; INTEGRATION	Primary objective: To evaluate the effectiveness of a communication training programme for paid carers to improve their conversational interactions with people with TBI. Research design: Single blinded randomized controlled study. Methods and procedures: Ten paid carers were randomly selected from a post-acute residential rehabilitation programme and allocated to either a training or control group. Training comprised a 17-hour programme (across 8 weeks) with conversational interactions (i.e. structured and casual) between paid carers and people with TBI videotaped pre-training, post-training and at 6-months follow-up. Interactions were rated on the Adapted Measure of Support in Conversation (MSC), Adapted Measure of Participation in Conversation (MPC) and Global Impression Scales of conversation. Main outcomes and results: Trained paid carers were more able to acknowledge and reveal the competence of people with TBI. Conversations were perceived as more appropriate, interesting and rewarding compared to the control group. Improvements were confined to the structured conversation and were maintained for 6 months. Conclusions: Training paid carers has a positive effect on improving conversational interactions with people with TBI in a long-term care facility. These improvements can help to foster increased independence for the person with TBI in the home and community.	[Behn, Nicholas; Togher, Leanne; Power, Emma; Heard, Rob] Univ Sydney, Fac Hlth Sci, Lidcombe, NSW 1825, Australia	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@sydney.edu.au	Power, Emma/A-9263-2015; Togher, Leanne/AAC-7083-2019; Behn, Nicholas/AAR-1325-2020	Power, Emma/0000-0002-2638-0406; Behn, Nicholas/0000-0001-9356-9957; Togher, Leanne/0000-0002-4518-6748			Becker H., 1993, J HEAD TRAUMA REHAB, V8, P88; Bellon ML, 2006, BRAIN INJURY, V20, P1069, DOI 10.1080/02699050600909813; Bloomberg K, 2003, J INTELLECT DEV DIS, V28, P260, DOI 10.1080/1366825031000150964; Boles L, 1998, APHASIOLOGY, V12, P547, DOI 10.1080/02687039808249557; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bourgeois MS, 2001, AUGMENT ALTERN COMM, V17, P196, DOI DOI 10.1080/714043383; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burgio LD, 2001, GERONTOLOGIST, V41, P449, DOI 10.1093/geront/41.4.449; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dobson S, 2002, INT J LANG COMM DIS, V37, P41, DOI 10.1080/13682820110089362; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Ducharme JM, 2001, BRAIN INJURY, V15, P333, DOI 10.1080/02699050010005869; Fleming J, 1999, BRAIN INJURY, V13, P417; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Haahr M, 1998, LIST RANDOMISER; Hatton C, 1995, MENT HANDICAP RES, V8, P252; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kruijver IPM, 2000, PATIENT EDUC COUNS, V39, P129, DOI 10.1016/S0738-3991(99)00096-8; Lyon JG, 1997, APHASIOLOGY, V11, P693, DOI 10.1080/02687039708249416; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; McCluskey AE, 2000, BRAIN INJURY, V14, P943, DOI 10.1080/02699050050191896; McCrea JD, 2009, REHABILITATION EXECU, P341; McDonald S, 1999, COMMUNICATION DISORD; Money D, 1997, EUR J DISORDER COMM, V32, P449; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Purcell M, 2000, INT J LANG COMM DIS, V35, P147; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shelton C, 2007, BRAIN INJURY, V21, P1259, DOI 10.1080/02699050701716935; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP157; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L., 2010, TBI EXPRESS SOCIAL C; Togher L, 2010, APHASIOLOGY, V24, P914, DOI 10.1080/02687030903422478; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Turner S, 2006, APHASIOLOGY, V20, P483, DOI 10.1080/02687030600589991; Wechsler D., 2001, WECHSLER TEST ADULT; Wlodkowski R. J., 1985, ENHANCING ADULT MOTI; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	51	47	47	1	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1702	1715		10.3109/02699052.2012.722258			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700016	23163251				2021-06-18	
J	Benedict, AL; Mountney, A; Hurtado, A; Bryan, KE; Schnaar, RL; Dinkova-Kostova, AT; Talalay, P				Benedict, Andrea L.; Mountney, Andrea; Hurtado, Andres; Bryan, Kelley E.; Schnaar, Ronald L.; Dinkova-Kostova, Albena T.; Talalay, Paul			Neuroprotective Effects of Sulforaphane after Contusive Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						neuroprotection; spinal cord injury; sulforaphane	MIGRATION INHIBITORY FACTOR; TRAUMATIC BRAIN-INJURY; MURINE HEPATOMA-CELLS; KAPPA-B; QUANTITATIVE-DETERMINATION; THERAPEUTIC INTERVENTION; CHEMOPREVENTIVE AGENTS; GLUTATHIONE SYNTHESIS; NEURONAL GLUTATHIONE; FUNCTIONAL RECOVERY	Traumatic spinal cord injury (SCI) leads to oxidative stress, calcium mobilization, glutamate toxicity, the release of proinflammatory factors, and depletion of reduced glutathione (GSH) at the site of injury. Induction of the Keap1/Nrf2/ARE pathway can alleviate neurotoxicity by protecting against GSH depletion, oxidation, intracellular calcium overload, mitochondrial dysfunction, and excitotoxicity. Sulforaphane (SF), an isothiocyanate derived from broccoli, is a potent naturally-occurring inducer of the Keap1/Nrf2/ARE pathway, leading to upregulation of genes encoding cytoprotective proteins such as NAD(P)H: quinone oxidoreductase 1, and GSH-regulatory enzymes. Additionally, SF can attenuate inflammation by inhibiting the nuclear factor-kappa B (NF-kappa B) pathway, and the enzymatic activity of the proinflammatory cytokine macrophage inhibitory factor (MIF). Our study examined systemic administration of SF in a rat model of contusion SCI, in an effort to utilize its indirect antioxidant and anti-inflammatory properties to decrease secondary injury. Two doses of SF (10 or 50 mg/kg) were administered at 10 min and 72 h after contusion SCI. SF (50 mg/kg) treatment resulted in both acute and long-term beneficial effects, including upregulation of the phase 2 antioxidant response at the injury site, decreased mRNA levels of inflammatory cytokines (i.e., MMP-9) in the injured spinal cord, inactivation of urinary MIF tautomerase activity, enhanced hindlimb locomotor function, and an increased number of serotonergic axons caudal to the lesion site. These findings demonstrate that SF provides neuroprotective effects in the spinal cord after injury, and could be a candidate for therapy of SCI.	[Benedict, Andrea L.; Bryan, Kelley E.; Dinkova-Kostova, Albena T.; Talalay, Paul] Johns Hopkins Univ, Sch Med, Lewis B & Dorothy Cullman Chemoprotect Ctr, Baltimore, MD USA; [Benedict, Andrea L.; Mountney, Andrea; Bryan, Kelley E.; Schnaar, Ronald L.; Dinkova-Kostova, Albena T.; Talalay, Paul] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Hurtado, Andres] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Dinkova-Kostova, Albena T.] Univ Dundee, Med Res Inst, Dundee, Scotland; [Hurtado, Andres] Hugo W Moser Res Inst Kennedy Krieger, Int Ctr Spinal Cord Injury, Baltimore, MD USA	Talalay, P (corresponding author), Johns Hopkins Med Sch, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ptalalay@jhmi.edu	Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Dinkova-Kostova, Albena/0000-0003-0316-9859	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057338]; Lewis B. and Dorothy Cullman Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057338] Funding Source: NIH RePORTER	We are grateful to Dr. W. D. Holtzclaw, Jr., K. L. Wade, and K. K. Stephenson (Johns Hopkins University) for technical assistance. We would like to thank D. Wendell (Hugo W. Moser Research Institute at Kennedy Krieger) for help with surgical procedures and behavioral testing. This work was supported in part by NIH grant NS057338 and the Lewis B. and Dorothy Cullman Foundation.	Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Basso DM, 2004, J NEUROTRAUM, V21, P395, DOI 10.1089/089771504323004548; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brown KK, 2009, J BIOL CHEM, V284, P32425, DOI 10.1074/jbc.M109.047092; Calabrese V, 2010, ANTIOXID REDOX SIGN, V13, P1763, DOI 10.1089/ars.2009.3074; Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8; Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Elbarbry F, 2011, J MED PLANTS RES, V5, P473; Guerrero-Beltran CE, 2012, EXP TOXICOL PATHOL, V64, P503, DOI 10.1016/j.etp.2010.11.005; Escartin C, 2011, J NEUROSCI, V31, P7392, DOI 10.1523/JNEUROSCI.6577-10.2011; Garai J, 2009, CURR MED CHEM, V16, P1091, DOI 10.2174/092986709787581842; Ghosh N, 2011, FREE RADICAL RES, V45, P888, DOI 10.3109/10715762.2011.574290; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Healy ZR, 2011, CANCER EPIDEM BIOMAR, V20, P1516, DOI 10.1158/1055-9965.EPI-11-0279; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hu CQ, 2011, CHEM RES TOXICOL, V24, P515, DOI 10.1021/tx100389r; Hwang ES, 2005, J MED FOOD, V8, P198, DOI 10.1089/jmf.2005.8.198; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Mao L, 2011, J SURG RES, V170, pE105, DOI 10.1016/j.jss.2011.05.049; Mao L, 2010, ANN CLIN LAB SCI, V40, P354; Mountney A, 2010, P NATL ACAD SCI USA, V107, P11561, DOI 10.1073/pnas.1006683107; Nishio Y, 2009, ACTA NEUROPATHOL, V117, P321, DOI 10.1007/s00401-008-0476-x; Ping Z, 2010, BRAIN RES, V1343, P178, DOI 10.1016/j.brainres.2010.04.036; Schmidt BJ, 2000, BRAIN RES BULL, V53, P689, DOI 10.1016/S0361-9230(00)00402-0; Wang FZ, 2011, NEUROSCI RES, V71, P210, DOI 10.1016/j.neures.2011.07.1821; Wang XL, 2012, J NEUROTRAUM, V29, P936, DOI 10.1089/neu.2011.1922; Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1995, BIOCHEM BIOPH RES CO, V206, P748, DOI 10.1006/bbrc.1995.1106; Zhang YS, 1996, ANAL BIOCHEM, V239, P160, DOI 10.1006/abio.1996.0311; Zhang YS, 2000, CARCINOGENESIS, V21, P1175, DOI 10.1093/carcin/21.6.1175; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	57	47	55	1	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2576	2586		10.1089/neu.2012.2474			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900006	22853439	Green Published			2021-06-18	
J	Scholten, JD; Sayer, NA; Vanderploeg, RD; Bidelspach, DE; Cifu, DX				Scholten, Joel D.; Sayer, Nina A.; Vanderploeg, Rodney D.; Bidelspach, Douglas E.; Cifu, David X.			Analysis of US Veterans Health Administration comprehensive evaluations for traumatic brain injury in Operation Enduring Freedom and Operation Iraqi Freedom Veterans	BRAIN INJURY			English	Article						Traumatic brain injury; health services needs and demand; United States Department of Veterans Affairs	POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; BASE RATES; AFGHANISTAN; DEPLOYMENT; ETIOLOGY	Objective: To describe neurobehavioural symptoms in Iraq and Afghanistan war veterans evaluated for traumatic brain injury (TBI) through the Veterans Health Administration (VHA) TBI screening and evaluation programme. Design: An observational study based on VHA administrative data for all veterans who underwent TBI Comprehensive Evaluation between October 2007 and June 2010. Results: 55,070 predominantly white, non-Hispanic, male Veterans with a positive TBI screen had comprehensive TBI evaluations completed during the study period. Moderate-to-severe symptoms were common in the entire sample, both in those with and without a clinician-diagnosed TBI. However, the odds of reporting symptoms of this severity were significantly higher in those diagnosed with TBI compared to those without a TBI diagnosis, with odds ratios ranging from 1.35-2.21. TBI-specialty clinicians believed that in the majority of diagnosed TBI cases both behavioural health conditions and TBI contributed to patients' symptom presentation. Conclusions: The VHAs TBI screening and evaluation process is identifying individuals with ongoing neurobehavioural symptoms. Moderate-to-severe symptoms were more prevalent in veterans with TBI-specialty clinician determined TBI. However, the high rate of symptom reporting also present in individuals without a confirmed TBI suggest that symptom aetiology may be multi-factorial in nature.	[Scholten, Joel D.; Bidelspach, Douglas E.; Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Scholten, Joel D.] VA Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20422 USA; [Scholten, Joel D.] Georgetown Univ, Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20007 USA; [Sayer, Nina A.] Minneapolis Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Sayer, Nina A.] Univ Minnesota, Dept Med & Psychiat, Minneapolis, MN USA; [Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Bidelspach, Douglas E.] Lebanon VA Med Ctr, Lebanon, VA USA; [Cifu, David X.] Hunter Holmes McGuire VA, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA	Scholten, JD (corresponding author), VA Med Ctr, Dept Phys Med & Rehabil 117, 50 Irving St NW, Washington, DC 20422 USA.	joel.scholten@va.gov	Sayer, Nina/E-3249-2016	Cifu, David/0000-0003-1600-9387	Department of Veterans Affairs (VA) Health Services Research and Development Service (HSR&D) Quality Enhancement Research Initiative (QUERI) Locally Initiated Project [QUERI LIP PLY 10-4218]	The authors report no conflicts of interest. This research was performed at the Minneapolis VA Healthcare System, Minneapolis, MN. This manuscript represents original and valid research that has not been previously published and is not under consideration for publication elsewhere. This research was supported by a Department of Veterans Affairs (VA) Health Services Research and Development Service (HSR&D) Quality Enhancement Research Initiative (QUERI) Locally Initiated Project (QUERI LIP PLY 10-4218). The content of this report presents the findings and conclusions of the authors and does not necessarily represent the VA or HSR&D. The VA had no role in study design, analysis and interpretation of data; writing of the article; or the decision to submit it for publication.	Buzek J., 2009, NON TRADITIONAL REF, V342, P59; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Comprehensive TBI Evaluation User Guide, 2011, COMPR TBI EV US GUID; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TRAU; Environmental Epidemiology Service, 2010, AN VA HLTH CAR UT OP; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	21	47	47	0	6	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1177	1184		10.3109/02699052.2012.661914			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600002	22646489				2021-06-18	
J	Chabok, SY; Moghadam, AD; Saneei, Z; Amlashi, FG; Leili, EK; Amiri, ZM				Chabok, Shahrokh Yousefzadeh; Moghadam, Anoush Dehnadi; Saneei, Zahra; Amlashi, Fatemeh Ghazanfari; Leili, Ehsan Kazemnezhad; Amiri, Zahra Mohtasham			Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Diffuse axonal injury; neuron-specific enolase; S100BB; severe traumatic brain injury; outcome	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SERUM S-100B; PROTEIN; MARKERS; DAMAGE	BACKGROUND: Diffuse axonal injury (DAI) is a common type of traumatic brain injury, mostly associated with mild changes on computed tomography (CT) scan. Serum biomarkers might be used in the diagnosis and prognosis of this injury type. Our purpose was to determine temporal profile and predictive values of serum concentrations of protein S100BB and neuron-specific enolase (NSE) after DAI. METHODS: Twenty-eight isolated severe DAI patients (Glasgow Coma Scale score <= 8) with normal CT were enrolled in the study. Serum levels of S100BB and NSE were determined at 6 hours, 24 hours, 48 hours, and 72 hours after injury, using enzyme-linked immunosorbent assay. Clinical outcome variables of DAI comprised survival at discharge and Glasgow Outcome scale (GOS) after 3 months and also 2 years. RESULTS: S100BB concentration was maximum in 6 hours after injury (median = 280.75 ng/L) followed by a quick drop. Its value was significantly higher on third day in patients with unfavorable outcome (GOS score = 1-3) versus favorable outcome (GOS score = 4, 5) (p < 0.0001). The values of NSE had mild changes during 3 days; however, these measured values at 72 hours after trauma manifested higher in unfavorable outcome (p < 0.05). CONCLUSIONS: Increased serum concentrations of NSE and S100BB within first 3 days after DAI are associated with poor outcome despite mild CT findings. S100BB level at 72 hours after injury can predict late outcome in DAI patients. (J Trauma Acute Care Surg. 2012;72: 1654-1657. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Chabok, Shahrokh Yousefzadeh; Moghadam, Anoush Dehnadi; Saneei, Zahra; Amlashi, Fatemeh Ghazanfari; Leili, Ehsan Kazemnezhad; Amiri, Zahra Mohtasham] Poursina Hosp, Guilan Rd Trauma Res Ctr, Rasht, Guilan Province, Iran; [Chabok, Shahrokh Yousefzadeh] Guilan Univ Med Sci, Dept Neurosurg, Rasht, Guilan, Iran; [Moghadam, Anoush Dehnadi] Guilan Univ Med Sci, Dept Anesthesiol, Rasht, Guilan, Iran; [Leili, Ehsan Kazemnezhad] Guilan Univ Med Sci, Dept Biostat, Rasht, Guilan, Iran; [Amiri, Zahra Mohtasham] Guilan Univ Med Sci, Dept Social Med, Rasht, Guilan, Iran	Moghadam, AD (corresponding author), Poursina Hosp, Guilan Rd Trauma Res Ctr, Namjoo St, Rasht, Guilan Province, Iran.	dehnadi@gtrc.ir	amlashi, fatemeh ghazanfari/H-9981-2019; Mohtasham-Amiri, Zahra/C-4469-2012	amlashi, fatemeh ghazanfari/0000-0002-1306-2150; Mohtasham-Amiri, Zahra/0000-0002-4896-6248; Yousefzadeh-Chabok, Shahrokh/0000-0002-8825-3015; Ghazanfari Amlashi, Fatemeh/0000-0001-5702-1169; Dehnadi Moghadam, Anoush/0000-0002-8408-2909	Guilan Trauma and Road Traffic Accidents Research Center	Supported by Guilan Trauma and Road Traffic Accidents Research Center (www.gtrc.ir).	Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Ogata Mamoru, 2007, Legal Medicine, V9, P105, DOI 10.1016/j.legalmed.2006.11.013; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Vajtr D, 2007, Soud Lek, V52, P43; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	25	47	55	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2012	72	6					1654	1657		10.1097/TA.0b013e318246887e			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	960WH	WOS:000305422900038	22695436				2021-06-18	
J	Freund, P; Wheeler-Kingshott, CA; Nagy, Z; Gorgoraptis, N; Weiskopf, N; Friston, KJ; Thompson, AJ; Hutton, C				Freund, Patrick; Wheeler-Kingshott, Claudia A.; Nagy, Zoltan; Gorgoraptis, Nikos; Weiskopf, Nikolaus; Friston, Karl J.; Thompson, Alan J.; Hutton, Chloe			Axonal integrity predicts cortical reorganisation following cervical injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SPINAL-CORD-INJURY; VOXEL-BASED MORPHOMETRY; WHITE-MATTER; MULTIPLE-SCLEROSIS; WALLERIAN DEGENERATION; RADIAL DIFFUSIVITY; QUANTITATIVE MRI; 1.5 T; BRAIN; MOTOR	Background Traumatic spinal cord injury (SCI) leads to disruption of axonal architecture and macroscopic tissue loss with impaired information flow between the brain and spinal cord-the presumed basis of ensuing clinical impairment. Objective The authors used a clinically viable, multimodal MRI protocol to quantify the axonal integrity of the cranial corticospinal tract (CST) and to establish how microstructural white matter changes in the CST are related to cross-sectional spinal cord area and cortical reorganisation of the sensorimotor system in subjects with traumatic SCI. Methods Nine volunteers with cervical injuries resulting in bilateral motor impairment and 14 control subjects were studied. The authors used diffusion tensor imaging to assess white matter integrity in the CST, T1-weighted imaging to measure cross-sectional spinal cord area and functional MRI to compare motor task-related brain activations. The relationships among microstructural, macrostructural and functional measures were assessed using regression analyses. Results Diffusion tensor imaging revealed significant differences in the CST of SCI subjects-compared with controls-in the pyramids, the internal capsule, the cerebral peduncle and the hand area. The microstructural white matter changes observed in the left pyramid predicted increased task-related responses in the left M1 leg area, while changes in the cerebral peduncle were predicted by reduced cord area. Conclusion The observed microstructural changes suggest trauma-related axonal degeneration and demyelination, which are related to cortical motor reorganisation and macrostructure. The extent of these changes may reflect the plasticity of motor pathways associated with cortical reorganisation. This clinically viable multimodal imaging approach is therefore appropriate for monitoring degeneration of central pathways and the evaluation of treatments targeting axonal repair in SCI.	[Freund, Patrick; Gorgoraptis, Nikos; Thompson, Alan J.] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London WC1N 3BG, England; [Freund, Patrick; Nagy, Zoltan; Weiskopf, Nikolaus; Friston, Karl J.; Hutton, Chloe] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England; [Freund, Patrick] UCL, Spinal Cord Injury Ctr, Royal Natl Orthopaed Hosp, London WC1N 3BG, England; [Freund, Patrick] Swiss Parapleg Res, Nottwil, Switzerland; [Wheeler-Kingshott, Claudia A.] UCL, UCL Inst Neurol, Dept Neuroinflammat, London WC1N 3BG, England	Freund, P (corresponding author), UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, Queen Sq, London WC1N 3BG, England.	p.freund@ucl.ac.uk	Friston, Karl/D-9230-2011; Thompson, Alan J/C-2654-2008; Wheeler-Kingshott, Claudia A M Gandini/AAH-7480-2019; Nagy, Zoltan/AAI-2485-2019; Weiskopf, Nikolaus/B-9357-2008; Freund, Patrick/D-4193-2013; Weiskopf, Nikolaus/ABI-5713-2020	Friston, Karl/0000-0001-7984-8909; Thompson, Alan J/0000-0002-4333-8496; Wheeler-Kingshott, Claudia A M Gandini/0000-0002-4832-1300; Nagy, Zoltan/0000-0001-6611-6362; Weiskopf, Nikolaus/0000-0001-5239-1881; Freund, Patrick/0000-0002-4851-2246; Weiskopf, Nikolaus/0000-0001-5239-1881; Gorgoraptis, Nikos/0000-0002-2588-9235	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische Stipendien [PASMP3-124194]; Swiss Paraplegic Research (Nottwil); Wellcome TrustWellcome TrustEuropean Commission; Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR)	This work was supported by the Swiss National Science Foundation (Grant No: PBFR33-120920), Schweizerische Stiftung fur medizinische und biologische Stipendien (Grant No: PASMP3-124194), Swiss Paraplegic Research (Nottwil) and the Wellcome Trust. This work was undertaken at UCLH/UCL which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme.	Andersson JLR, 2001, NEUROIMAGE, V13, P903, DOI 10.1006/nimg.2001.0746; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Calancie B, 1996, ELECTROMYOGR MOTOR C, V101, P304, DOI 10.1016/0924-980X(96)95194-2; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Cook PA, 2006, P INT SOC MAGNETIC R, V14, P2759; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Deichmann R, 2004, NEUROIMAGE, V21, P757, DOI 10.1016/j.neuroimage.2003.09.062; Dietz V, 2010, NAT REV NEUROL, V6, P167, DOI 10.1038/nrneurol.2009.227; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Freund P, 2011, EUR J NEUROSCI, V34, P1839, DOI 10.1111/j.1460-9568.2011.07895.x; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund P, 2010, MULT SCLER J, V16, P1193, DOI 10.1177/1352458510376180; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Gonzenbach RR, 2008, CELL MOL LIFE SCI, V65, P161, DOI 10.1007/s00018-007-7170-3; Gouw AA, 2008, BRAIN, V131, P3286, DOI 10.1093/brain/awn265; Henderson LA, 2011, J NEUROSCI, V31, P2630, DOI 10.1523/JNEUROSCI.2717-10.2011; Jansons KM, 2003, LECT NOTES COMPUT SC, V2732, P672; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kapreli E, 2006, NEUROIMAGE, V32, P1709, DOI 10.1016/j.neuroimage.2006.05.043; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Lee JE, 2009, NEUROIMAGE, V44, P870, DOI 10.1016/j.neuroimage.2008.09.041; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Ward NS, 2003, BRAIN, V126, P873, DOI 10.1093/brain/awg071; Weiskopf N, 2006, NEUROIMAGE, V33, P493, DOI 10.1016/j.neuroimage.2006.07.029; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	51	47	50	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2012	83	6					629	637		10.1136/jnnp-2011-301875			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	939NA	WOS:000303816800012	22492214	Other Gold, Green Published			2021-06-18	
J	Kenning, TJ; Willcox, TO; Artz, GJ; Schiffmacher, P; Farrell, CJ; Evans, JJ				Kenning, Tyler J.; Willcox, Thomas O.; Artz, Gregory J.; Schiffmacher, Paul; Farrell, Christopher J.; Evans, James J.			Surgical management of temporal meningoencephaloceles, cerebrospinal fluid leaks, and intracranial hypertension: treatment paradigm and outcomes	NEUROSURGICAL FOCUS			English	Article						cerebrospinal fluid; otorrhea; otorhinorrhea; tegmen repair; temporal meningoencephalocele; mastoidectomy; intracranial hypertension	EMPTY SELLA; BONE; REPAIR; OTORRHEA; ENCEPHALOCELES	Object. Thinning of the tegmen tympani and mastoideum components of the temporal bone may predispose to the development of meningoencephaloceles and spontaneous CSF leaks. Surgical repair of these bony defects and associated meningoencephaloceles aids in the prevention of progression and meningitis. Intracranial hypertension may be a contributing factor to this disorder and must be fully evaluated and treated when present. The purpose of this study was to establish a treatment paradigm for tegmen defects and elucidate causative factors. Methods. The authors conducted a retrospective review of 23 patients undergoing a combined mastoidectomy and middle cranial fossa craniotomy for the treatment of a tegmen defect. Results. The average body mass index (BMI) among all patients was 33.2 +/- 7.2 kg/m(2). Sixty-five percent of the patients (15 of 23) were obese (BMI > 30 kg/m(2)). Preoperative intracranial pressures (ICPs) averaged 21.8 +/- 6.0 cm H2O, with 10 patients (43%) demonstrating an ICP > 20 cm H2O. Twenty-two patients (96%) had associated encephaloceles. Five patients underwent postoperative ventriculoperitoneal shunting. Twenty-two CSF leaks (96%) were successfully repaired at the first attempt (average follow-up 10.4 months). Conclusions. Among all etiologies for CSF leaks, those occurring spontaneously have the highest rate of recurrence. The surgical treatment of temporal bone defects, as well as the recognition and treatment of accompanying intracranial hypertension, provides the greatest success rate in preventing recurrence. After tegmen dehiscence repair, ventriculoperitoneal shunting should be considered for patients with any combination of the following high-risk factors for recurrence: spontaneous CSF leak not caused by another predisposing condition (that is, trauma, chronic infections, or prior surgery), high-volume leaks, CSF opening pressure > 20 cm H2O, BMI > 30 kg/m(2), preoperative imaging demonstrating additional cranial base cortical defects (that is, contralateral tegmen or anterior cranial base) and/or an empty sella turcica, and any history of an event that leads to inflammation of the arachnoid granulations and impairment of CSF absorption (that is, meningitis, intracranial hemorrhage, significant closed head injury, and so forth). (http://thejns.org/doi/abs/10.3171/2012.4.FOCUS1265)	[Kenning, Tyler J.; Farrell, Christopher J.; Evans, James J.] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Willcox, Thomas O.; Artz, Gregory J.; Evans, James J.] Thomas Jefferson Univ Hosp, Dept Otolaryngol, Philadelphia, PA 19107 USA; [Schiffmacher, Paul] Thomas Jefferson Univ Hosp, Dept Med Media Serv, Philadelphia, PA 19107 USA	Kenning, TJ (corresponding author), Thomas Jefferson Univ Hosp, Dept Neurol Surg, 909 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.	tyler.kenning@jeffersonhospital.org					Brown NE, 2004, LARYNGOSCOPE, V114, P800, DOI 10.1097/00005537-200405000-00002; Kari E, 2011, ACTA OTO-LARYNGOL, V131, P391, DOI 10.3109/00016489.2011.557836; Kutz JW, 2008, LARYNGOSCOPE, V118, P2195, DOI 10.1097/MLG.0b013e318182f833; Merchant SN, 2000, AM J OTOL, V21, P234, DOI 10.1016/S0196-0709(00)80015-0; Mirza S, 2005, LARYNGOSCOPE, V115, P1774, DOI 10.1097/01.mlg.0000175679.68452.75; Nahas Z, 2008, ARCH OTOLARYNGOL, V134, P509, DOI 10.1001/archotol.134.5.509; Prichard CN, 2006, OTOLARYNG HEAD NECK, V134, P767, DOI 10.1016/j.otohns.2006.01.002; Sanna M, 2010, LARYNGOSCOPE, V120, P217; Sanna M, 2009, LARYNGOSCOPE, V119, P1579, DOI 10.1002/lary.20510; Savva A, 2003, LARYNGOSCOPE, V113, P50, DOI 10.1097/00005537-200301000-00010; Schlosser RJ, 2004, OTOLARYNG HEAD NECK, V130, P443, DOI 10.1016/j.otohns.2003.12.018; Schlosser RJ, 2003, OTOLARYNG HEAD NECK, V128, P32, DOI 10.1067/mhn.2003.43; Scurry WC, 2007, OTOLARYNG HEAD NECK, V136, P961, DOI 10.1016/j.otohns.2006.11.036; Semaan MT, 2011, LARYNGOSCOPE, V121, P1765, DOI 10.1002/lary.21887; Souliere CR, 1998, SKULL BASE SURG, V8, P185, DOI 10.1055/s-2008-1058181; Wind JJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.12.E11; Woodworth BA, 2008, OTOLARYNG HEAD NECK, V138, P715, DOI 10.1016/j.otohns.2008.02.010	17	47	48	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2012	32	6							E6	10.3171/2012.4.FOCUS1265			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	954DQ	WOS:000304927100008	22655695				2021-06-18	
J	Roozenbeek, B; Chiu, YL; Lingsma, HF; Gerber, LM; Steyerberg, EW; Ghajar, J; Maas, AIR				Roozenbeek, Bob; Chiu, Ya-Lin; Lingsma, Hester F.; Gerber, Linda M.; Steyerberg, Ewout W.; Ghajar, Jamshid; Maas, Andrew I. R.			Predicting 14-Day Mortality after Severe Traumatic Brain Injury: Application of the IMPACT Models in the Brain Trauma Foundation TBI-trac (R) New York State Database	JOURNAL OF NEUROTRAUMA			English	Article						external validation; outcome; prediction models; traumatic brain injury	COMMON DATA ELEMENTS; RECOMMENDATIONS; MODERATE; TRIALS; DESIGN	Prognostic models for outcome prediction in patients with traumatic brain injury (TBI) are important instruments in both clinical practice and research. To remain current a continuous process of model validation is necessary. We aimed to investigate the performance of the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic models in predicting mortality in a contemporary New York State TBI registry developed and maintained by the Brain Trauma Foundation. The Brain Trauma Foundation (BTF) TBI-trac (R) database contains data on 3125 patients who sustained severe TBI (Glasgow Coma Scale [GCS] score <= 8) in New York State between 2000 and 2009. The outcome measure was 14-day mortality. To predict 14-day mortality with admission data, we adapted the IMPACT Core and Extended models. Performance of the models was assessed by determining calibration (agreement between observed and predicted outcomes), and discrimination (separation of those patients who die from those who survive). Calibration was explored graphically with calibration plots. Discrimination was expressed by the area under the receiver operating characteristic (ROC) curve (AUC). A total of 2513 out of 3125 patients in the BTF database met the inclusion criteria. The 14-day mortality rate was 23%. The models showed excellent calibration. Mean predicted probabilities were 20% for the Core model and 24% for the Extended model. Both models showed good discrimination with AUCs of 0.79 (Core) and 0.83 (Extended). We conclude that the IMPACT models validly predict 14-day mortality in the BTF database, confirming generalizability of these models for outcome prediction in TBI patients.	[Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Chiu, Ya-Lin; Gerber, Linda M.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA	Roozenbeek, B (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	b.roozenbeek@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [046291]; New York State Department of Health Bureau of Emergency Medical Services; Brain Trauma Foundation	Development of the IMPACT models was supported by National Institutes of Health grant 046291. The BTF TBI-trac data collection was funded through the New York State Department of Health Bureau of Emergency Medical Services and by the Brain Trauma Foundation.	Brain Trauma Foundation, 2000, MAN PROGN SEV TRAU 1; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Edwards P, 2005, LANCET, V365, P1957; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Panczykowski D., 2011, J NEUROTRAUMA; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Steyerberg E.W, 2009, CLIN PREDICTION MODE, VXXVIII; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	24	47	50	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1306	1312		10.1089/neu.2011.1988			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600003	22150207	Green Published			2021-06-18	
J	Ranaivo, HR; Hodge, JN; Choi, N; Wainwright, MS				Ranaivo, Hantamalala Ralay; Hodge, Jessica N.; Choi, Nicole; Wainwright, Mark S.			Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways	JOURNAL OF NEUROINFLAMMATION			English	Article						Matrix metalloproteinase; Astrocyte; Blood brain barrier; Mitogen-activated protein kinases	BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; RAT CORTICAL ASTROCYTES; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; INTRACEREBRAL HEMORRHAGE; TISSUE INHIBITOR; KAPPA-B; NEUROLOGICAL DEFICIT; EFFICACY ANALYSIS	Background: Astrocytes are an integral component of the blood-brain barrier (BBB) which may be compromised by ischemic or traumatic brain injury. In response to trauma, astrocytes increase expression of the endopeptidase matrix metalloproteinase (MMP)-9. Compromise of the BBB leads to the infiltration of fluid and blood-derived proteins including albumin into the brain parenchyma. Albumin has been previously shown to activate astrocytes and induce the production of inflammatory mediators. The effect of albumin on MMP-9 activation in astrocytes is not known. We investigated the molecular mechanisms underlying the production of MMP-9 by albumin in astrocytes. Methods: Primary enriched astrocyte cultures were used to investigate the effects of exposure to albumin on the release of MMP-9. MMP-9 expression was analyzed by zymography. The involvement of mitogen-activated protein kinase (MAPK), reactive oxygen species (ROS) and the TGF-beta receptor-dependent pathways were investigated using pharmacological inhibitors. The production of ROS was observed by dichlorodihydrofluorescein diacetate fluorescence. The level of the MMP-9 inhibitor tissue inhibitor of metalloproteinase (TIMP)-1 produced by astrocytes was measured by ELISA. Results: We found that albumin induces a time-dependent release of MMP-9 via the activation of p38 MAPK and extracellular signal regulated kinase, but not Jun kinase. Albumin-induced MMP-9 production also involves ROS production upstream of the MAPK pathways. However, albumin-induced increase in MMP-9 is independent of the TGF-beta receptor, previously described as a receptor for albumin. Albumin also induces an increase in TIMP-1 via an undetermined mechanism. Conclusions: These results link albumin (acting through ROS and the p38 MAPK) to the activation of MMP-9 in astrocytes. Numerous studies identify a role for MMP-9 in the mechanisms of compromise of the BBB, epileptogenesis, or synaptic remodeling after ischemia or traumatic brain injury. The increase in MMP-9 produced by albumin further implicates both astrocytes and albumin in the acute and long-term complications of acute CNS insults, including cerebral edema and epilepsy.	[Ranaivo, Hantamalala Ralay; Hodge, Jessica N.; Choi, Nicole; Wainwright, Mark S.] Childrens Mem Hosp, Dept Pediat, Div Neurol, Chicago, IL 60614 USA; [Wainwright, Mark S.] Childrens Mem Hosp, Dept Pediat, Div Crit Care, Chicago, IL 60614 USA; [Ranaivo, Hantamalala Ralay; Hodge, Jessica N.; Choi, Nicole; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Ctr Interdisciplinary Res Pediat Crit Illness & I, Chicago, IL 60611 USA	Wainwright, MS (corresponding author), Childrens Mem Hosp, Dept Pediat, Div Neurol, 2300 Childrens Plaza, Chicago, IL 60614 USA.	m-wainwright@northwestern.edu	Ritter, Stefanie L/D-9312-2012	Rubens, Jessica/0000-0001-9198-9149	Medical Research Junior Board Foundation; Lyndsey Whittingham Foundation	We thank MaryAnn Chrzaszcz and Kevin McDonough for technical assistance. Dr Wainwright is supported by the Medical Research Junior Board Foundation, and by the Lyndsey Whittingham Foundation.	Arai K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255; Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Barr TL, 2010, STROKE, V41, pE123, DOI 10.1161/STROKEAHA.109.570515; Belayev L, 2005, STROKE, V36, P326, DOI 10.1161/01.STR.0000152949.31366.3d; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Bento-Abreu A, 2008, J NEUROCHEM, V106, P1149, DOI 10.1111/j.1471-4159.2008.05462.x; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Calvo CF, 2005, J NEUROSCI RES, V80, P707, DOI 10.1002/jnr.20511; Chen WQ, 2009, J NEUROCHEM, V111, P726, DOI 10.1111/j.1471-4159.2009.06362.x; Choi MS, 2008, BRAIN RES BULL, V76, P368, DOI 10.1016/j.brainresbull.2008.02.031; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; Guo M, 2008, NEUROSCIENCE, V151, P340, DOI 10.1016/j.neuroscience.2007.10.006; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hill MD, 2007, INT J STROKE, V2, P214, DOI 10.1111/j.1747-4949.2007.00143.x; Hill MD, 2011, STROKE, V42, P1621, DOI 10.1161/STROKEAHA.110.610980; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hsieh HL, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-88; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008; Kim GW, 2009, NEUROBIOL DIS, V36, P169, DOI 10.1016/j.nbd.2009.07.008; Kochanek PM, 2010, DEV NEUROSCI-BASEL, V32, P335, DOI 10.1159/000323016; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lee SR, 2007, NEUROSCI LETT, V417, P1, DOI 10.1016/j.neulet.2007.01.017; Maddahi A, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-56; Magnoni S, 2007, GENE THER, V14, P621, DOI 10.1038/sj.gt.3302894; Michaluk P, 2011, J CELL SCI, V124, P3369, DOI 10.1242/jcs.090852; Michaluk P, 2009, J NEUROSCI, V29, P6007, DOI 10.1523/JNEUROSCI.5346-08.2009; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nadal A, 2001, Prog Brain Res, V132, P367; Palesch YY, 2006, STROKE, V37, P2107, DOI 10.1161/01.STR.0000231389.34701.b5; Ralay-Ranaivo H, 2011, J NEUROTRAUM, V28, P1757; Ranaivo HR, 2010, EXP NEUROL, V226, P310, DOI 10.1016/j.expneurol.2010.09.005; Ranaivo HR, 2010, BRAIN RES, V1313, P222, DOI 10.1016/j.brainres.2009.11.063; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Rossi JL, 2011, J NEUROSCI RES, V89, P852, DOI 10.1002/jnr.22600; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siddiqui SS, 2004, AM J PHYSIOL-LUNG C, V286, pL1016, DOI 10.1152/ajplung.00356.2003; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Takacs E, 2010, NEUROCHEM INT, V56, P799, DOI 10.1016/j.neuint.2010.03.003; Tejima E, 2007, J CEREBR BLOOD F MET, V27, P460, DOI 10.1038/sj.jcbfm.9600354; Tung WH, 2010, BRIT J PHARMACOL, V161, P1566, DOI 10.1111/j.1476-5381.2010.00982.x; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Weaver A, 2005, FASEB J, V19, P1668, DOI 10.1096/fj.04-2030fje; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Xue MZ, 2006, J NEUROSCI, V26, P10281, DOI 10.1523/JNEUROSCI.2806-06.2006; Xue MZ, 2009, BRAIN, V132, P26, DOI 10.1093/brain/awn215; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	64	47	47	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 16	2012	9								68	10.1186/1742-2094-9-68			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	993JK	WOS:000307854500001	22507553	DOAJ Gold, Green Published			2021-06-18	
J	Yuh, EL; Cooper, SR; Ferguson, AR; Manley, GT				Yuh, Esther L.; Cooper, Shelly R.; Ferguson, Adam R.; Manley, Geoffrey T.			Quantitative CT Improves Outcome Prediction in Acute Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						computer-aided detection; computed tomography; principal component analysis; quantitative CT; traumatic brain injury	COMPUTED-TOMOGRAPHY; MODERATE; CLASSIFICATION	The admission noncontrast head computed tomography (CT) scan has been demonstrated to be one of several key early clinical and imaging features in the challenging problem of prediction of long-term outcome after acute traumatic brain injury (TBI). In this study, we employ two novel approaches to the problem of imaging classification and outcome prediction in acute TBI. First, we employ the novel technique of quantitative CT (qCT) image analysis to provide more objective, reproducible measures of the abnormal features of the admission head CT in acute TBI. We show that the incorporation of quantitative, rather than qualitative, CT features results in a significant improvement in prediction of the 6-month Extended Glasgow Outcome Scale (GOS-E) score over a wide spectrum of injury severity. Second, we employ principal components analysis (PCA) to demonstrate the interdependence of certain predictive variables. Relatively few prior studies of outcome prediction in acute TBI have used a multivariate approach that explicitly takes into account the potential covariance among clinical and CT predictive variables. We demonstrate that several predictors, including midline shift, cistern effacement, subdural hematoma volume, and Glasgow Coma Scale (GCS) score are related to one another. Rather than being independent features, their importance may be related to their status as surrogate measures of a more fundamental underlying clinical feature, such as the severity of intracranial mass effect. We believe that objective computational tools and data-driven analytical methods hold great promise for neurotrauma research, and may ultimately have a role in image analysis for clinical care.	[Yuh, Esther L.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94107 USA; [Cooper, Shelly R.; Ferguson, Adam R.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94107 USA; [Yuh, Esther L.] San Francisco Gen Hosp, San Francisco, CA 94107 USA; [Yuh, Esther L.; Cooper, Shelly R.; Ferguson, Adam R.; Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94107 USA	Yuh, EL (corresponding author), Univ Calif San Francisco, Dept Radiol, 185 Berry St,Suite 350, San Francisco, CA 94107 USA.	esther.yuh@ucsf.edu		Ferguson, Adam/0000-0001-7102-1608; Cooper, Shelly/0000-0003-0026-6688	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067092, NS069537, NS069409]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, R01NS069537, R01NS067092] Funding Source: NIH RePORTER	We thank Pratik Mukherjee, M.D., Ph.D., for evaluation of a subset of computer-aided head CT interpretations for the purpose of determination of interrater reliability for the semi-automated quantitative CT measurements. We gratefully acknowledge support from National Institutes of Health grants NS067092 and NS069537 (PI: A.R.F.) and NS069409 (PI: G.T.M.).	Chesnut RM., 2000, J NEUROTRAUM, V17, P557; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; Laalo JP, 2009, J NEUROTRAUM, V26, P2169, DOI 10.1089/neu.2009.1011; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shlens J., 2009, TUTORIAL PRINCIPAL C; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tabachnik B. G., 2007, USING MULTIVARIATE S, V5th; Yuh EL, 2008, J NEUROTRAUM, V25, P1163, DOI 10.1089/neu.2008.0590	23	47	48	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					735	746		10.1089/neu.2011.2008			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900004	21970562	Green Published			2021-06-18	
J	Zhang, K; Johnson, B; Gay, M; Horovitz, SG; Hallett, M; Sebastianelli, W; Slobounov, S				Zhang, Kai; Johnson, Brian; Gay, Michael; Horovitz, Silvina G.; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			Default Mode Network in Concussed Individuals in Response to the YMCA Physical Stress Test	JOURNAL OF NEUROTRAUMA			English	Article						default mode network; resting state functional magnetic resonance imaging; subacute phase of mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; CORTICAL NETWORKS; SHORT-TERM; DYSFUNCTION; CORTEX; ABNORMALITIES; OSCILLATIONS; DISORDERS	We hypothesize that the evolution of mild traumatic brain injury (mTBI) may be related to differential effects of a concussive blow on the functional integrity of the brain default mode network (DMN) at rest and/or in response to physical stress. Accordingly, in this resting-state functional magnetic resonance imaging (fMRI) study, we examined 14 subjects 10 +/- 2 days post-sports-related mTBI and 15 age-matched normal volunteers (NVs) to investigate the possibility that the integrity of the DMN is disrupted at the resting state and/or following the physical stress test. First, all mTBI subjects were asymptomatic based upon clinical evaluation and neuropsychological (NP) assessments prior to the MRI session. Second, the functional integrity within the DMN, a main resting-state network, remained resilient to a single concussive blow. Specifically, the major regions of interest (ROIs) constituting the DMN (e. g., the posterior cingulate cortex [PCC]/precuneus area, the medial prefrontal cortex [MPFC], and left and right lateral parietal cortices [LLP and RLP]) and the connectivity within these four ROIs was similar between NVs and mTBI subjects prior to the YMCA physical stress test. However, the YMCA physical stress test disrupted the DMN, significantly reducing the magnitude of the connection between the PCC and left lateral parietal ROI, and PCC and right lateral parietal ROI, as well as between the PCC and MPFC in mTBI subjects. Thus while the DMN remained resilient to a single mTBI without exertion at 10 days post-injury, it was altered in response to limited physical stress. This may explain some clinical features of mTBI and provide some insight into its mechanism. This important finding should be considered by clinical practitioners when making decisions regarding return-to-play and clearing mTBI athletes for sports participation.	[Zhang, Kai; Johnson, Brian; Gay, Michael; Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Horovitz, Silvina G.; Hallett, Mark; Slobounov, Semyon] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Orthopaed & Med Rehabil, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	; Zhang, Kai/F-3261-2015	Horovitz, Silvina G./0000-0002-5501-5918; Zhang, Kai/0000-0002-5460-6150	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury'' awarded to Dr. Slobounov, Principal Investigator.	Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Broyd SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017325; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cherkassky VL, 2006, NEUROREPORT, V17, P1687, DOI 10.1097/01.wnr.0000239956.45448.4c; Ciftci K, 2011, ANN BIOMED ENG, V39, P1493, DOI 10.1007/s10439-011-0258-9; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fransson P, 2006, NEUROPSYCHOLOGIA, V44, P2836, DOI 10.1016/j.neuropsychologia.2006.06.017; Grabner RH, 2007, NEUROIMAGE, V38, P346, DOI 10.1016/j.neuroimage.2007.07.041; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Jang JH, 2011, SCHIZOPHR RES, V127, P58, DOI 10.1016/j.schres.2010.12.022; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; JOHNSON PB, 1993, EXP BRAIN RES, V97, P361; Kennedy DP, 2008, SOC COGN AFFECT NEUR, V3, P177, DOI 10.1093/scan/nsn011; Kennedy DP, 2006, P NATL ACAD SCI USA, V103, P8275, DOI 10.1073/pnas.0600674103; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Laird AR, 2009, J NEUROSCI, V29, P14496, DOI 10.1523/JNEUROSCI.4004-09.2009; Liddle EB, 2011, J CHILD PSYCHOL PSYC, V52, P761, DOI 10.1111/j.1469-7610.2010.02333.x; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nelson SM, 2010, NEURON, V67, P156, DOI 10.1016/j.neuron.2010.05.025; Noirhomme Q, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00160; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Sharp D, 2010, J NEUROL NEUROSUR PS, V81, pE23, DOI 10.1136/jnnp.2010.226340.25; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Supekar K, 2010, NEUROIMAGE, V52, P290, DOI 10.1016/j.neuroimage.2010.04.009; Swanson N, 2011, HUM BRAIN MAPP, V32, P654, DOI 10.1002/hbm.21055; Tian LX, 2006, NEUROSCI LETT, V400, P39, DOI 10.1016/j.neulet.2006.02.022; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Uddin LQ, 2008, J NEUROSCI METH, V169, P249, DOI 10.1016/j.jneumeth.2007.11.031; Uddin LQ, 2009, HUM BRAIN MAPP, V30, P625, DOI 10.1002/hbm.20531; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Wu X, 2011, HUM BRAIN MAPP, V32, P1868, DOI 10.1002/hbm.21153; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	71	47	47	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					756	765		10.1089/neu.2011.2125			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900006	22040294	Green Published			2021-06-18	
J	Hester, R; Nandam, LS; O'Connell, RG; Wagner, J; Strudwick, M; Nathan, PJ; Mattingley, JB; Bellgrove, MA				Hester, Robert; Nandam, L. Sanjay; O'Connell, Redmond G.; Wagner, Joe; Strudwick, Mark; Nathan, Pradeep J.; Mattingley, Jason B.; Bellgrove, Mark A.			Neurochemical Enhancement of Conscious Error Awareness	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; EVENT-RELATED FMRI; RESPONSE-INHIBITION; CINGULATE CORTEX; PREFRONTAL CORTEX; COCAINE ADDICTION; METHYLPHENIDATE; PERFORMANCE; DOPAMINE; NOREPINEPHRINE	How the brain monitors ongoing behavior for performance errors is a central question of cognitive neuroscience. Diminished awareness of performance errors limits the extent to which humans engage in corrective behavior and has been linked to loss of insight in a number of psychiatric syndromes (e. g., attention deficit hyperactivity disorder, drug addiction). These conditions share alterations in monoamine signaling that may influence the neural mechanisms underlying error processing, but our understanding of the neurochemical drivers of these processes is limited. We conducted a randomized, double-blind, placebo-controlled, cross-over design of the influence of methylphenidate, atomoxetine, and citalopram on error awareness in 27 healthy participants. The error awareness task, a go/no-go response inhibition paradigm, was administered to assess the influence of monoaminergic agents on performance errors during fMRI data acquisition. A single dose of methylphenidate, but not atomoxetine or citalopram, significantly improved the ability of healthy volunteers to consciously detect performance errors. Furthermore, this behavioral effect was associated with a strengthening of activation differences in the dorsal anterior cingulate cortex and inferior parietal lobe during the methylphenidate condition for errors made with versus without awareness. Our results have implications for the understanding of the neurochemical underpinnings of performance monitoring and for the pharmacological treatment of a range of disparate clinical conditions that are marked by poor awareness of errors.	[Nandam, L. Sanjay; Wagner, Joe; Mattingley, Jason B.; Bellgrove, Mark A.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Nandam, L. Sanjay; Wagner, Joe; Mattingley, Jason B.; Bellgrove, Mark A.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia; [Hester, Robert] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic 3010, Australia; [Strudwick, Mark] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld 4072, Australia; [O'Connell, Redmond G.] Trinity Coll Dublin, Sch Psychol, Dublin 2, Ireland; [O'Connell, Redmond G.] Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dublin 2, Ireland; [Nathan, Pradeep J.] Univ Cambridge, Dept Psychiat, Brain Mapping Unit, Cambridge CB2 2QQ, England; [Nathan, Pradeep J.] GlaxoSmithKline, Clin Unit Cambridge, Cambridge CB2 2GG, England	Bellgrove, MA (corresponding author), Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.	m.bellgrove@uq.edu.au	Strudwick, Mark W/C-3557-2009; Bellgrove, Mark/AAB-3114-2019; Hester, Robert/F-2097-2011; Mattingley, Jason/J-1537-2014	Hester, Robert/0000-0003-0982-8026; Mattingley, Jason/0000-0003-0929-9216; Bellgrove, Mark/0000-0003-0186-8349; O'Connell, Redmond/0000-0001-6949-2793	Australian Research CouncilAustralian Research Council [DP0770337]; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [519730]; Irish Research Council for Science Engineering and TechnologyIrish Research Council for Science, Engineering and TechnologyCGIAR	This work was supported by Australian Research Council Grant DP0770337 (M. A. B.), the Australian National Health and Medical Research Council [M. A. B., R. H. (Grant 519730), P.J.N., J.B.M.), and grants from the Irish Research Council for Science Engineering and Technology (R.G.O.). We thank Drs. Bruno van Swinderen and Angela Dean for comments on this manuscript and Mykalos Byrne for assistance with figures. We also thank the Wesley Hospital Pharmacy for dispensing the drugs associated with this project.	Arnsten AFT, 2011, BIOL PSYCHIAT, V69, pE89, DOI 10.1016/j.biopsych.2011.01.027; Aron AR, 2003, BIOL PSYCHIAT, V54, P1465, DOI 10.1016/S0006-3223(03)00609-7; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Barnes JJM, 2011, BIOL PSYCHIAT, V69, pE127, DOI 10.1016/j.biopsych.2010.12.040; Berridge CW, 2006, BIOL PSYCHIAT, V60, P1111, DOI 10.1016/j.biopsych.2006.04.022; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9; Carter CS, 2001, AM J PSYCHIAT, V158, P1423, DOI 10.1176/appi.ajp.158.9.1423; Castells X, 2007, ADDICTION, V102, P1871, DOI 10.1111/j.1360-0443.2007.01943.x; Chamberlain SR, 2006, SCIENCE, V311, P861, DOI 10.1126/science.1121218; Cools R, 2008, TRENDS COGN SCI, V12, P31, DOI 10.1016/j.tics.2007.10.011; Cools R, 2011, NEUROPSYCHOPHARMACOL, V36, P98, DOI 10.1038/npp.2010.121; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; de Bruijn ERA, 2006, BRAIN RES, V1105, P122, DOI 10.1016/j.brainres.2006.01.006; de Bruijn ERA, 2004, PSYCHOPHARMACOLOGY, V177, P151, DOI 10.1007/s00213-004-1915-6; Endrass T, 2007, EUR J NEUROSCI, V26, P1714, DOI 10.1111/j.1460-9568.2007.05785.x; Evers EAT, 2006, PSYCHOPHARMACOLOGY, V187, P200, DOI 10.1007/s00213-006-0411-6; Goldstein RZ, 2010, P NATL ACAD SCI USA, V107, P16667, DOI 10.1073/pnas.1011455107; Graf H, 2011, BIOL PSYCHIAT, V69, P890, DOI 10.1016/j.biopsych.2010.10.018; Hennig J, 2002, INT J NEUROPSYCHOPH, V5, P67, DOI 10.1017/s146114570200278x; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2007, NEUROPSYCHOPHARMACOL, V32, P1974, DOI 10.1038/sj.npp.1301326; Hester R, 2009, NEUROPSYCHOPHARMACOL, V34, P2450, DOI 10.1038/npp.2009.67; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Jocham G, 2009, NEUROSCI BIOBEHAV R, V33, P48, DOI 10.1016/j.neubiorev.2008.08.011; Johannes S, 2001, PSYCHOPHARMACOLOGY, V155, P100, DOI 10.1007/s002130100680; Jonkman LM, 2007, BIOL PSYCHOL, V76, P217, DOI 10.1016/j.biopsycho.2007.08.004; Kaufman JN, 2003, J NEUROSCI, V23, P7839; Keppel, 1991, DESIGN ANAL RES HDB; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Klein TA, 2007, NEUROIMAGE, V34, P1774, DOI 10.1016/j.neuroimage.2006.11.014; KRAGHSORENSEN P, 1981, ACTA PHARMACOL TOX, V48, P53; Li CSR, 2010, P NATL ACAD SCI USA, V107, P14455, DOI 10.1073/pnas.1002467107; Michelson D, 2003, BIOL PSYCHIAT, V53, P112, DOI 10.1016/S0006-3223(02)01671-2; Mintz AR, 2004, SCHIZOPHR RES, V67, P213, DOI 10.1016/S0920-9964(03)00047-1; Moeller SJ, 2010, BRAIN, V133, P1484, DOI 10.1093/brain/awq066; Murphy K, 2005, NEUROIMAGE, V27, P771, DOI 10.1016/j.neuroimage.2005.05.007; Narayanan NS, 2008, J NEUROPHYSIOL, V100, P520, DOI 10.1152/jn.00035.2008; Nathan PJ, 2000, BEHAV PHARMACOL, V11, P639, DOI 10.1097/00008877-200011000-00011; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nieuwenhuis S, 2005, PSYCHOL BULL, V131, P510, DOI 10.1037/0033-2909.131.4.510; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; NORRIS H, 1971, NEUROPHARMACOLOGY, V10, P181, DOI 10.1016/0028-3908(71)90039-6; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, NEUROPSYCHOLOGIA, V47, P1149, DOI 10.1016/j.neuropsychologia.2009.01.011; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Riba J, 2005, J NEUROSCI, V25, P4370, DOI 10.1523/JNEUROSCI.4437-04.2005; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Sauer JM, 2005, CLIN PHARMACOKINET, V44, P571, DOI 10.2165/00003088-200544060-00002; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Spencer T, 1998, AM J PSYCHIAT, V155, P693, DOI 10.1176/ajp.155.5.693; Steinhauser M, 2010, J NEUROSCI, V30, P15643, DOI 10.1523/JNEUROSCI.1899-10.2010; Volkow ND, 2005, BIOL PSYCHIAT, V57, P1410, DOI 10.1016/j.biopsych.2004.11.006; Wessel JR, 2012, ERROR AWARENESS ERRO; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Zirnheld PJ, 2004, J COGNITIVE NEUROSCI, V16, P1098, DOI 10.1162/0898929041502779	59	47	47	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	FEB 22	2012	32	8					2619	2627		10.1523/JNEUROSCI.4052-11.2012			9	Neurosciences	Neurosciences & Neurology	898DT	WOS:000300716600006	22357846	Bronze, Green Published			2021-06-18	
J	Berrout, J; Jin, M; O'Neil, RG				Berrout, Jonathan; Jin, Min; O'Neil, Roger G.			Critical role of TRPP2 and TRPC1 channels in stretch-induced injury of blood-brain barrier endothelial cells	BRAIN RESEARCH			English	Article						Blood-brain barrier; Mechanical injury; TRP channel; Endothelial cell; Calcium	LIGHT-CHAIN KINASE; CATION CHANNEL; NITRIC-OXIDE; CA2+ ENTRY; PERMEABILITY; DISRUPTION; STRESS; MECHANOSENSATION; POLYCYSTIN-1; DYSFUNCTION	The microvessels of the brain are very sensitive to mechanical stresses such as observed in traumatic brain injury (TBI). Such stresses can quickly lead to dysfunction of the microvessel endothelial cells, including disruption of blood-brain barrier (BBB). It is now evident that elevation of cytosolic calcium levels ([Ca2+]i) can compromise the BBB integrity, however the mechanism by which mechanical injury can produce a [Ca2+]i increase in brain endothelial cells is unclear. To assess the effects of mechanical/stretch injury on [Ca2+]i signaling, mouse brain microvessel endothelial cells (bEnd3) were grown to confluency on elasticized membranes and [Ca2+]i monitored using fura 2 fluorescence imaging. Application of an injury, using a pressure/stretch pulse of 50 ms, induced a rapid transient increase in [Ca2+]i. In the absence of extracellular Ca2+, the injury-induced [Ca2+] i transient was greatly reduced, but not fully eliminated, while unloading of Ca2+ stores by thapsigargin treatment in the absence of extracellular Ca2+ abolished the injury transient. Application of LOE-908 and amiloride, TRPC and TRPP2 channel blockers, respectively, both reduced the transient [Ca2+]i increase. Further, siRNA knockdown assays directed at TRPC1 and TRPP2 expression also resulted in a reduction of the injury-induced [Ca2+]i response. In addition, stretch injury induced increases of NO production and actin stress fiber formation, both of which were markedly reduced upon treatment with LOE908 and/or amiloride. We conclude that mechanical injury of brain endothelial cells induces a rapid influx of calcium, mediated by TRPC1 and TRPP2 channels, which leads to NO synthesis and actin cytoskeletal rearrangement. (C) 2011 Published by Elsevier B.V.	[Berrout, Jonathan; Jin, Min; O'Neil, Roger G.] Univ Texas Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	O'Neil, RG (corresponding author), Univ Texas Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St,Rm MSB 4-132, Houston, TX 77030 USA.	roger.g.oneil@uth.tmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK070950]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK070950] Funding Source: NIH RePORTER	The study was supported by an NIH grant DK070950 (RGO).	Abbruscato TJ, 1999, J PHARMACOL EXP THER, V289, P668; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Alessandri-Haber N, 2005, PAIN, V118, P70, DOI 10.1016/j.pain.2005.07.016; Alvarez DF, 2005, AM J RESP CRIT CARE, V172, P1153, DOI 10.1164/rccm.200506-847OC; Bai CX, 2008, EMBO REP, V9, P472, DOI 10.1038/embor.2008.29; Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4; Boueiz A, 2009, MICROVASC RES, V77, P26, DOI 10.1016/j.mvr.2008.10.005; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Brown RC, 2008, MICROCIRCULATION, V15, P359, DOI 10.1080/10739680701762656; Christensen AP, 2007, NAT REV NEUROSCI, V8, P510, DOI 10.1038/nrn2149; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Giamarchi A, 2006, EMBO REP, V7, P787, DOI 10.1038/sj.embor.7400745; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; Hicks K, 2010, AM J PHYSIOL-CELL PH, V298, pC1583, DOI 10.1152/ajpcell.00458.2009; Inoue R, 2005, CURR PHARM DESIGN, V11, P1899, DOI 10.2174/1381612054021079; Inoue R, 2009, PHARMACOL THERAPEUT, V123, P371, DOI 10.1016/j.pharmthera.2009.05.009; Kobori T, 2009, J BIOL CHEM, V284, P35507, DOI 10.1074/jbc.M109.060228; Kotttgen M, 2008, J CELL BIOL, V182, P437, DOI 10.1083/jcb.200805124; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; NAG S, 1991, STROKE, V22, P1265, DOI 10.1161/01.STR.22.10.1265; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; O'Neil RG, 2005, PFLUG ARCH EUR J PHY, V451, P193, DOI 10.1007/s00424-005-1424-4; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; Qamar S, 2007, BIOCHEM SOC T, V35, P124, DOI 10.1042/BST0350124; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Sharif-Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045; Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stiber JA, 2009, J CARDIOVASC PHARM, V54, P116, DOI 10.1097/FJC.0b013e3181aa233f; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaz R, 1998, ACTA NEUROCHIR, V140, P371, DOI 10.1007/s007010050111; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Webster Gregory D, 2008, Biomed Sci Instrum, V44, P483; Wu L, 2007, AM J PHYSIOL-RENAL, V293, pF1699, DOI 10.1152/ajprenal.00462.2006; Yamazaki D, 2007, J PHARMACOL SCI, V104, P103, DOI 10.1254/jphs.SC0070080; Yin J, 2010, CELL BIOCHEM BIOPHYS, V56, P1, DOI 10.1007/s12013-009-9067-2; Yuan Y, 1997, AM J PHYSIOL-HEART C, V272, pH1437; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635	48	47	51	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 3	2012	1436						1	12		10.1016/j.brainres.2011.11.044			12	Neurosciences	Neurosciences & Neurology	907FT	WOS:000301403900001	22192412				2021-06-18	
J	Caeyenberghs, K; Leemans, A; De Decker, C; Heitger, M; Drijkoningen, D; Linden, CV; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Leemans, A.; De Decker, C.; Heitger, M.; Drijkoningen, D.; Linden, C. Vander; Sunaert, S.; Swinnen, S. P.			Brain connectivity and postural control in young traumatic brain injury patients: A diffusion MRI based network analysis	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Graph theoretical network analysis; Motor control; Structural network; Traumatic brain injury; Postural control	BEHAVIOR RELATIONSHIPS; STRUCTURAL NETWORKS; ANATOMICAL NETWORK; PARIETAL CORTEX; HEAD-INJURY; MILD HEAD; TRACTOGRAPHY; PATTERNS; IDENTIFICATION; ARCHITECTURE	Our previous research on traumatic brain injury (TBI) patients has shown a strong relationship between specific white matter (WM) diffusion properties and motor deficits. The potential impact of TBI-related changes in network organization of the associated WM structural network on motor performance, however, remains largely unknown. Here, we used diffusion tensor imaging (DTI) based fiber tractography to reconstruct the human brain WM networks of 12 TBI and 17 control participants, followed by a graph theoretical analysis. A force platform was used to measure changes in body posture under conditions of compromised proprioceptive and/ or visual feedback. Findings revealed that compared with controls, TBI patients showed higher betweenness centrality and normalized path length, and lower values of local efficiency, implying altered network organization. These results were not merely a consequence of differences in number of connections. In particular, TBI patients displayed reduced structural connectivity in frontal, parieto-premotor, visual, subcortical, and temporal areas. In addition, the decreased connectivity degree was significantly associated with poorer balance performance. We conclude that analyzing the structural brain networks with a graph theoretical approach provides new insights into motor control deficits following brain injury. (C) 2012 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.	[Caeyenberghs, K.; De Decker, C.; Heitger, M.; Drijkoningen, D.; Swinnen, S. P.] Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Motor Control Lab, B-3001 Heverlee, Belgium; [Leemans, A.] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands; [Linden, C. Vander] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [Sunaert, S.] KULeuven, Univ Hosp, Dept Radiol, Louvain, Belgium; [Swinnen, S. P.] Katholieke Univ Leuven, Leuven Res Inst Neurosci & Dis LIND, B-3001 Heverlee, Belgium	Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Grp Biomed Sci, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@UGent.be	Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Caeyenberghs, Karen/0000-0001-7009-6843	Research Programme of the Research Foundation-Flanders (FWO)FWO [G.0482.010, G.A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]; postdoctoral fellowship of the Research Foundation-Flanders (FWO)	This work was supported by a grant from the Research Programme of the Research Foundation-Flanders (FWO) (G.0482.010 and G.A114.11) and Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a postdoctoral fellowship of the Research Foundation-Flanders (FWO).	Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Desmond JE, 1997, J NEUROSCI, V17, P9675; Frank LR, 2002, MAGN RESON MED, V47, P1083, DOI 10.1002/mrm.10156; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Ginestet CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021570; Ginestet CE, 2011, NEUROIMAGE, V55, P688, DOI 10.1016/j.neuroimage.2010.11.030; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000597; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Jantzen KJ, 2004, P NATL ACAD SCI USA, V101, P6815, DOI 10.1073/pnas.0401300101; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Leemans A., 2009, P INT SOC MAG RESON, V17, P3537, DOI DOI 10.1093/occmed/kqr069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Leunissen I., 2012, HUMAN BRAIN MAPPING; Liu T, 2008, J NEUROPHYSIOL, V100, P1557, DOI 10.1152/jn.00961.2007; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Molenberghs P, 2007, CEREB CORTEX, V17, P2703, DOI 10.1093/cercor/bhl179; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pollmann S, 2003, NEUROIMAGE, V18, P310, DOI 10.1016/S1053-8119(02)00036-8; RUBIN AM, 1995, AM J OTOL, V16, P216; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Shu N, 2011, CEREB CORTEX, V21, P2565, DOI 10.1093/cercor/bhr039; Shu N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007228; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Toxopeus CM, 2007, NEUROREPORT, V18, P1557, DOI 10.1097/WNR.0b013e3282efa0a2; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2010, J NEUROSCI, V30, P15915, DOI 10.1523/JNEUROSCI.2874-10.2010; van Wijk BCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013701; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Vos SB, 2012, NEUROIMAGE, V59, P2208, DOI 10.1016/j.neuroimage.2011.09.086; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	64	47	54	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2012	1	1					106	115		10.1016/j.nicl.2012.09.011			10	Neuroimaging	Neurosciences & Neurology	V37LG	WOS:000209276700013	24179743	DOAJ Gold, Green Published			2021-06-18	
J	Ganpule, S; Gu, L; Alai, A; Chandra, N				Ganpule, S.; Gu, L.; Alai, A.; Chandra, N.			Role of helmet in the mechanics of shock wave propagation under blast loading conditions	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						blast; head; helmet; TBI; FSI	TRAUMATIC BRAIN-INJURY; RESPONSES; IMPACTS	The effectiveness of helmets in extenuating the primary shock waves generated by the explosions of improvised explosive devices is not clearly understood. In this work, the role of helmet on the overpressurisation and impulse experienced by the head were examined. The shock wave-head interactions were studied under three different cases: (i) unprotected head, (ii) head with helmet but with varying head-helmet gaps and (iii) head covered with helmet and tightly fitting foam pads. The intensification effect was discussed by examining the shock wave flow pattern and verified with experiments. A helmet with a better protection against shock wave is suggested.	[Ganpule, S.; Alai, A.; Chandra, N.] Univ Nebraska Lincoln, Dept Engn Mech, Lincoln, NE 68588 USA; [Gu, L.] Univ Nebraska Lincoln, Dept Mech Engn, Lincoln, NE 68588 USA	Chandra, N (corresponding author), Univ Nebraska Lincoln, Dept Engn Mech, Lincoln, NE 68588 USA.	nchandra2@unl.edu	gu, linxia/A-5645-2013	gu, linxia/0000-0003-2637-0299	US Army Research Office [W911NF-08-1-0483]	The authors acknowledge the financial support provided by the US Army Research Office for the project on 'Army-UNL Center for Trauma Mechanics', Contract No. W911NF-08-1-0483. The authors thank Ruqiang Feng, Mehrdad Negahban and Erwan Plougonven at UNL for many useful discussions. The authors also thank David Mott of Naval Research Laboratory and Robert Salzar of University of Virginia for bringing their experimental work to our attention.	Aare M, 2007, INT J IMPACT ENG, V34, P596, DOI 10.1016/j.ijimpeng.2005.08.001; Anderson J.D, 2001, FUNDAMENTALS AERODYN, V3; Baker WE., 1973, EXPLOSIONS AIR; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bowen LG, 1968, DASA2113 DEP DEF; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Ganpule S, 2010, IMECE2009: PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION, VOL 2, P339; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott D.R., 2008, P 20 INT S MIL ASP B; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Rafaels KA, 2010, BLAST WAVE ATTENUATI; Reynosa MA, 1999, PERSONNEL ARMOR SYST; Taylor PA, 2009, J BIOMECH ENG, V131, P6; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	22	47	48	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.		2012	15	11					1233	1244		10.1080/10255842.2011.597353			12	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Computer Science; Engineering	032RH	WOS:000310736300010	21806412	Green Published			2021-06-18	
J	Cooper, DB; Nelson, L; Armistead-Jehle, P; Bowles, AO				Cooper, Douglas B.; Nelson, Lonnie; Armistead-Jehle, Patrick; Bowles, Amy O.			Utility of the Mild Brain Injury Atypical Symptoms Scale as a Screening Measure for Symptom Over-Reporting in Operation Enduring Freedom/Operation Iraqi Freedom Service Members with Post-Concussive Complaints	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Post-concussion syndrome; Posttraumatic stress disorder; Symptom over-reporting	POSTTRAUMATIC-STRESS-DISORDER; MMPI-2 VALIDITY SCALES; COMBAT VETERANS; COMPENSATION-SEEKING; POSTCONCUSSIVE SYMPTOMS; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; EXAGGERATION; PERFORMANCE; RBS	Evaluation of post-deployment conditions such as post-concussive syndrome (PCS) and posttraumatic stress disorder (PTSD) frequently relies upon brief, self-report checklists which are face valid and highly susceptible to potential symptom validity issues such as symptom exaggeration. We investigated the psychometric prope1rties of a 5-item measure of symptom exaggeration (mild brain injury atypical symptoms [mBIAS] scale) embedded in commonly used PCS and PTSD screening instruments in a sample of 403 patients seen in a brain injury clinic at a large military medical center. Exploratory factor analysis, examining measures of posttraumatic stress, post-concussive symptoms, and symptom over-reporting revealed a 6-factor model with the mBIAS scale items representing a unique factor. Analysis of psychometric properties demonstrated that a score of 8 on the mBIAS was optimal for the detection of symptom over-reporting (sensitivity = 0.94, specificity = 0.92) and appears to be the most favorable cut score for interpretive use. The findings provide a strong initial support for the use of the mBIAS in post-deployment populations.	[Cooper, Douglas B.] Brooke Army Med Ctr, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, MCHE DOR TBI, Ft Sam Houston, TX 78234 USA; [Nelson, Lonnie] Def & Vet Brain Injury Ctr, Washington, DC USA	Cooper, DB (corresponding author), Brooke Army Med Ctr, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, MCHE DOR TBI, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	douglas.b.cooper@us.army.mil	Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BENPORATH YS, 2008, MMPI 2 RF MINN MULT; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BUTCHER JN, 2001, MMPI 2 MAN ADM SCOR; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Casscells SW, 2007, CONSOLIDATION TRAUMA; CICCERONE K, 1995, J HEAD TRAUMA REHAB, V10, P1; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; *DEF VET BRAIN INJ, 2008, OP IR FREED OIF OP E; DELIS DC, 2007, ARCH CLIN NEUROPSYCH, V24, P145; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Engel CC, 2006, CNS SPECTRUMS, V11, P187, DOI 10.1017/S1092852900014358; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, GREENS WORD MEMORY T; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Interian A, 2004, PSYCHOSOM MED, V66, P141, DOI 10.1097/01.PSY.0000107883.14385.EC; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Labbate LA, 1998, PSYCHOTHER PSYCHOSOM, V67, P275, DOI 10.1159/000012292; McCrea M, 2008, MILD TRAUMATIC BRAIN; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; *PASW, 2010, COMP SOFTW; ROGERS R, 1992, STRUCTED INTERVIEW R; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tombaugh TN, 1996, TEST MEMORY MALINGER; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	38	47	47	1	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2011	26	8					718	727		10.1093/arclin/acr070			10	Psychology, Clinical; Psychology	Psychology	849UX	WOS:000297151900003	21873326	Bronze			2021-06-18	
J	Dong, XQ; Huang, M; Yang, SB; Yu, WH; Zhang, ZY				Dong, Xiao-Qiao; Huang, Man; Yang, Song-Bin; Yu, Wen-Hua; Zhang, Zu-Yong			Copeptin Is Associated With Mortality in Patients With Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Copeptin; Traumatic brain injury; Mortality	TERMINAL PROVASOPRESSIN COPEPTIN; CORTICOTROPIN-RELEASING HORMONE; VASOPRESSIN PRECURSOR; STABLE PEPTIDE; HEART-FAILURE; REGULATORY MECHANISMS; MYOCARDIAL-INFARCTION; PROGNOSTIC MARKER; BIOMARKER; STROKE	Background: High serum copeptin levels are associated with injury severity after traumatic brain injury (TBI). However, not much is known regarding its relation with mortality. Thus, we sought to evaluate its relation with disease mortality. Methods: Fifty healthy controls and 94 patients with acute severe TBI were included. Plasma samples were obtained on admission and at days 1, 2, 3, 5, and 7. Its concentration was measured by enzyme-linked immunosorbent assay. Results: Twenty-six patients (27.7%) died from TBI in a month. After brain injury, plasma copeptin level in patients increased during the 6-hour period immediately, peaked in 24 hours, plateaued at day 2, decreased gradually thereafter, and was substantially higher than that in healthy controls during the 7-day period. A forward stepwise logistic regression selected plasma copeptin level (odds ratio, 1.008; 95% confidence interval, 1.002-1.014; p = 0.010) as an independent predictor for 1-month mortality of patients. A multivariate linear regression showed that plasma copeptin level was negatively associated with Glasgow Coma Scale (GCS) score (t = -7.161; p < 0.001). A receiver operating characteristic curve identified plasma copeptin cutoff level (451.8 pg/mL) that predicted 1-month mortality with the optimal sensitivity (88.5%) and specificity (75.0%) values (area under curve, 0.874; 95% confidence interval, 0.789-0.933; p < 0.001). The area under curve of plasma copeptin level was similar to that of GCS score (p = 0.299). However, copeptin did not statistically significantly improve the area under curve of GCS score (p = 0.413). Conclusions: Increased plasma copeptin levels are associated with mortality after TBI.	[Dong, Xiao-Qiao; Yu, Wen-Hua; Zhang, Zu-Yong] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310000, Zhejiang, Peoples R China; [Huang, Man] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Dept Intens Care Unit, Hangzhou 310003, Zhejiang, Peoples R China; [Yang, Song-Bin] Shengzhou Peoples Hosp, Dept Neurosurg, Shenzhou, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310000, Zhejiang, Peoples R China.	huyueyu2008@163.com					Asfar P, 2006, CRIT CARE CLIN, V22, P131, DOI 10.1016/j.ccc.2005.08.007; Itoi K, 2004, J NEUROENDOCRINOL, V16, P348, DOI 10.1111/j.0953-8194.2004.01172.x; Itoi K, 1998, ENDOCR J, V45, P13, DOI 10.1507/endocrj.45.13; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kelly D, 2008, J CARD FAIL, V14, P739, DOI 10.1016/j.cardfail.2008.07.231; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; Morgenthaler Nils G, 2010, Congest Heart Fail, V16 Suppl 1, pS37, DOI 10.1111/j.1751-7133.2010.00177.x; Muller B, 2007, EUR J CLIN INVEST, V37, P145, DOI 10.1111/j.1365-2362.2007.01762.x; Seligman R, 2008, CRIT CARE, V12, DOI 10.1186/cc6780; Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Urwyler SA, 2010, STROKE, V41, P1564, DOI 10.1161/STROKEAHA.110.584649; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Voors AA, 2009, EUR HEART J, V30, P1187, DOI 10.1093/eurheartj/ehp098; Zweifel C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-34	21	47	48	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1194	1198		10.1097/TA.0b013e31821283f2			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600024	21502880				2021-06-18	
J	Lucas, S				Lucas, Sylvia			Headache Management in Concussion and Mild Traumatic Brain Injury	PM&R			English	Article							EPIDEMIOLOGY	Headache is one of the most common symptoms after traumatic brain injury (TBI), and posttraumatic headache (PTH) may be part of a constellation of symptoms that is seen in the postconcussive syndrome. PTH has no defining clinical features; currently it is classified as a secondary headache based on its close temporal relationship to the injury. A growing number of studies are characterizing PTH by using primary headache classifications. Moderate to severe PTH that is often disabling may be classified as migraine or probable migraine and is found in substantial numbers of individuals. Recent data from civilian adult, pediatric, and military populations all find that PTH may be more of a chronic problem than previously thought, with a prevalence of close to half of the injured population. In addition, if PTH definitions are strictly adhered to, then many cases of PTH may be missed, thus underestimating the scope of the problem. New headaches may be reported well after the 7 days required for diagnosis of PTH by the guidelines of the International Classification of Headache Disorders, 2nd edition. A history of headache before a head injury occurs and female gender are possible risk factors for headache after TBI. Treatment of PTH may be acute or preventive, and recommendations are made for the use of migraine-specific acute therapy when indicated. Preventive therapy may be considered when PTH is frequent, disabling, or refractory to acute therapies. Comorbid conditions should be considered when choosing an appropriate preventive therapy. The symptom of headache as a "return to play" or "return to duty" barrier must be viewed in the context of other symptoms of mild TBI. PM R 2011;3:S406-S412	Univ Washington, Med Ctr, Seattle, WA 98195 USA	Lucas, S (corresponding author), Univ Washington, Med Ctr, 1959 NE Pacific St,Box 356097, Seattle, WA 98195 USA.	lucass@uw.edu					Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume K, PHYS MED REHABIL CLI; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; GAWEL MJ, 1993, HEADACHE, V33, P96, DOI 10.1111/j.1526-4610.1993.hed3302096.x; Hoffman J, 2011, APMR ABSTRACT 2011; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; Olesen J, 2006, HEADACHES, P859; Olesen J, 2006, HEADACHES, P441; OLESEN J, 2006, HEADCHES, P251; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; RAMADAN NM, EVIDENCE BASED GUIDE; Rapoport A, 1996, HEADACHE, V36, P14, DOI 10.1046/j.1526-4610.1996.3601014.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61	24	47	47	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S406	S412		10.1016/j.pmrj.2011.07.016			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	966YK	WOS:000305873100008	22035683				2021-06-18	
J	Gacar, N; Mutlu, O; Utkan, T; Celikyurt, IK; Gocmez, SS; Ulak, G				Gacar, Nejat; Mutlu, Oguz; Utkan, Tijen; Celikyurt, Ipek Komsuoglu; Gocmez, Semil Selcen; Ulak, Guner			Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Resveratrol; Cognition; Morris water maze; Passive avoidance; Rat	LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; INDUCED COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; SELECTIVE IMPAIRMENT; RECOGNITION MEMORY; IN-VIVO; ACETYLCHOLINESTERASE; WORKING	Resveratrol (3,5,4-trihydroxy-trans-stilbene), which is found in grapes and red wine has been shown to protect neuronal cells with its antioxidant activity, improve memory function in dementia and reverse acetylcholine esterase (AChE) activity. The aim of this study was to investigate the effect of resveratrol on emotional and spatial memory in naive rats, as well as on scopolamine- and mecamylamine-induced memory impairment in the passive avoidance and Morris water maze (MWM) tests. Resveratrol (12.5, 25 and 50 mg/kg), scopolamine (0.6 mg/kg) and mecamylamine (10 mg/kg) were administered to male Wistar rats. In the passive avoidance test, there was no significant difference in the first day latency between all groups, whereas scopolamine and mecamylamine significantly shortened the second day latency compared to the control group. Resveratrol reversed the effect of scopolamine at all doses used, but it had no effect on mecamylamine-induced memory impairment in the passive avoidance test. Both scopolamine and mecamylamine significantly decreased the time spent in the escape platform quadrant during the probe trial of the MWM test compared to the control group. Resveratrol reversed the effect of scopolamine at all doses, but did not change the effect of mecamylamine in the MWM test. There were no significant differences in the locomotor activities of any of the groups. In conclusion, we suggested that resveratrol had improving effects on learning and memory by acting on muscarinic cholinergic receptors and at least in part, may reverse AChE activity. (C) 2011 Elsevier Inc. All rights reserved.	[Gacar, Nejat; Mutlu, Oguz; Utkan, Tijen; Celikyurt, Ipek Komsuoglu; Ulak, Guner] Kocaeli Univ, Fac Med, Dept Pharmacol, TR-41380 Kocaeli, Turkey; [Gocmez, Semil Selcen] Namik Kemal Univ, Fac Med, Dept Pharmacol, TR-59100 Tekirdag, Turkey	Mutlu, O (corresponding author), Kocaeli Univ, Fac Med, Dept Pharmacol, TR-41380 Kocaeli, Turkey.	mngacar@hotmail.com; oguzmutlu80@hotmail.com; tijenutkan@hotmail.com; ikomsu@hotmail.com; selcengmez@yahoo.com; gunerulak@yahoo.com	gocmez, semil selcen/G-2401-2018; Utkan, Tijen/G-2398-2018; MUTLU, OGUZ/F-5952-2018; ulak, guner/F-5624-2018; Celikyurt, Ipek Komsuoglu/F-7363-2018	gocmez, semil selcen/0000-0001-7341-4907; MUTLU, OGUZ/0000-0003-0952-0742; Celikyurt, Ipek Komsuoglu/0000-0003-0895-3490; utkan, tijen/0000-0001-5848-3680			Anekonda TS, 2006, BRAIN RES REV, V52, P316, DOI 10.1016/j.brainresrev.2006.04.004; APPLEYARD ME, 1992, TRENDS NEUROSCI, V15, P485, DOI 10.1016/0166-2236(92)90100-M; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blokland A, 1995, BRAIN RES REV, V21, P285, DOI 10.1016/0165-0173(95)00016-X; Brioni J D, 1997, Adv Pharmacol, V37, P153; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Cachard-Chastel M, 2008, BEHAV BRAIN RES, V187, P455, DOI 10.1016/j.bbr.2007.10.008; Chander V, 2005, J VASC SURG, V42, P1198, DOI 10.1016/j.jvs.2005.08.032; Chauhan Ved, 2006, Pathophysiology, V13, P195, DOI 10.1016/j.pathophys.2006.05.004; Chen RS, 2002, J AGR FOOD CHEM, V50, P1665, DOI 10.1021/jf011134e; DARTIGUES JF, 1993, THERAPIE, V48, P185; DECKER MW, 1995, LIFE SCI, V56, P545, DOI 10.1016/0024-3205(94)00488-E; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Duva CA, 1997, BEHAV NEUROSCI, V111, P1184, DOI 10.1037/0735-7044.111.6.1184; Hiramatsu M, 1998, J PHARMACOL EXP THER, V284, P858; HUNTER B, 1988, HDB PSYCHOPHARMACOLO, V19, P531; IZQUIERDO I, 1992, BEHAV NEURAL BIOL, V58, P16, DOI 10.1016/0163-1047(92)90847-W; Kuhad A, 2008, LIFE SCI, V83, P128, DOI 10.1016/j.lfs.2008.05.013; Kumar A, 2007, PHARMACOLOGY, V79, P17, DOI 10.1159/000097511; Levin ED, 1996, PSYCHOPHARMACOLOGY, V127, P25, DOI 10.1007/BF02805971; Levin ED, 1997, BEHAV PHARMACOL, V8, P236; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Mesulam MM, 2002, NEUROSCIENCE, V110, P627, DOI 10.1016/S0306-4522(01)00613-3; Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z; Monleon S, 2002, BEHAV BRAIN RES, V136, P483, DOI 10.1016/S0166-4328(02)00194-8; MORAN PM, 1993, PHARMACOL BIOCHEM BE, V45, P533, DOI 10.1016/0091-3057(93)90502-K; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Ogren SO, 1985, SOC NEUR ABSTR, V256, P11; OHNO M, 1993, PHARMACOL BIOCHEM BE, V45, P89, DOI 10.1016/0091-3057(93)90091-7; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Ozkul A, 2007, J CLIN NEUROSCI, V14, P1062, DOI 10.1016/j.jocn.2006.11.008; Pothion S, 2004, BEHAV BRAIN RES, V155, P135, DOI 10.1016/j.bbr.2004.04.008; Quincozes-Santos A, 2007, NEUROTOXICOLOGY, V28, P886, DOI 10.1016/j.neuro.2007.03.008; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Schmatz R, 2009, BRAIN RES BULL, V80, P371, DOI 10.1016/j.brainresbull.2009.08.019; Schmatz R, 2009, EUR J PHARMACOL, V610, P42, DOI 10.1016/j.ejphar.2009.03.032; Sharma M, 2002, LIFE SCI, V71, P2489, DOI 10.1016/S0024-3205(02)02083-0; SHARMA M, 2005, J PHYSIOL PHARMACOL, V49, P395; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Truelsen T, 2002, ANN NEUROL, V52, pS31; Tsuji M, 2003, NEUROPSYCHOPHARMACOL, V28, P664, DOI 10.1038/sj.npp.1300080; Uguralp S, 2005, EUR J PEDIATR SURG, V15, P114, DOI 10.1055/s-2004-830359; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002	50	47	48	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2011	99	3					316	323		10.1016/j.pbb.2011.05.017			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	800OL	WOS:000293371100005	21624386				2021-06-18	
J	Chi, Y; Fan, Y; He, L; Liu, W; Wen, XY; Zhou, S; Wang, XF; Zhang, C; Kong, H; Sonoda, L; Tripathi, P; Li, CJ; Yu, MS; Su, CA; Hu, G				Chi, Ying; Fan, Yi; He, Lei; Liu, Wei; Wen, Xiaoyun; Zhou, Sha; Wang, Xuefeng; Zhang, Cui; Kong, Hui; Sonoda, Laura; Tripathi, Prem; Li, Carrie J.; Yu, Michelle S.; Su, Chuan; Hu, Gang			Novel role of aquaporin-4 in CD4+CD25+T regulatory cell development and severity of Parkinson's disease	AGING CELL			English	Article						aquaporin-4; CD4+CD25+Treg cells; microglia; neuroinflammation; neuroprotection; Parkinson's disease	NIGROSTRIATAL DOPAMINERGIC NEURODEGENERATION; INSENSITIVE WATER CHANNEL; NITRIC-OXIDE SYNTHASE; T-CELLS; MOUSE MODEL; MULTIPLE-SCLEROSIS; MPTP MODEL; MICROGLIAL ACTIVATION; SUBSTANTIA-NIGRA; MICE	P>Aquaporin-4 (AQP4) is highly expressed in mammalian brains and is involved in the pathophysiology of cerebral disorders, including stroke, tumors, infections, hydrocephalus, epilepsy, and traumatic brain injury. We found that AQP4-deficient mice were hypersensitive to stimulations such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or lipopolysaccharide compared to wild-type (WT) littermates. In a mouse model of MPTP-induced Parkinson's disease (PD), AQP4-deficient animals show more robust microglial inflammatory responses and more severe loss of dopaminergic neurons (DNs) compared with WT mice. However, a few studies have investigated the association of abnormal AQP4 levels with immune dysfunction. Here, for the first time, we report AQP4 expression in mouse thymus, spleen, and lymph nodes. Furthermore, the significantly lower numbers of CD4+ CD25+ regulatory T cells in AQP4-deficient mice compared to WT mice, perhaps resulting from impaired thymic generation, may be responsible for the uncontrolled microglial inflammatory responses and subsequent severe loss of DNs in the substantia nigra pars compacta in the MPTP-induced PD model. These novel findings suggest that AQP4 deficiency may disrupt immunosuppressive regulators, resulting in hyperactive immune responses and potentially contributing to the increased severity of PD or other immune-associated diseases.	[Chi, Ying; He, Lei; Liu, Wei; Wen, Xiaoyun; Zhou, Sha; Wang, Xuefeng; Zhang, Cui; Su, Chuan] Nanjing Med Univ, Jiangsu Key Lab Pathogen Biol, Dept Pathogen Biol & Immunol, Nanjing 210029, Jiangsu, Peoples R China; [Chi, Ying] Minist Hlth, Jiangsu Prov Ctr Dis Prevent & Control, Key Lab Enter Pathogen Microbiol, Nanjing 210009, Jiangsu, Peoples R China; [Fan, Yi; Kong, Hui; Hu, Gang] Nanjing Med Univ, Dept Pharmacol, Jiangsu Key Lab Neurodegenerat, Nanjing 210029, Jiangsu, Peoples R China; [Sonoda, Laura; Tripathi, Prem; Li, Carrie J.; Yu, Michelle S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA	Su, CA (corresponding author), Nanjing Med Univ, Jiangsu Key Lab Pathogen Biol, Dept Pathogen Biol & Immunol, Nanjing 210029, Jiangsu, Peoples R China.	chuansu@njmu.edu.cn	Fan, Yi/Q-9252-2018; He, Lei/L-4726-2019; Fan, Yi/AAQ-1874-2021	Fan, Yi/0000-0003-1783-3220; Fan, Yi/0000-0003-1783-3220; He, Lei/0000-0002-3821-2047	National Basic Research Program of China (973 Program)National Basic Research Program of China [2006CB5007006, 2007CB513106]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30701017, 30872206]; Jiangsu Province [07KJA31023]	This work was supported by grants from the National Basic Research Program of China (973 Program) (No. 2006CB5007006 to Gang Hu and No. 2007CB513106 to Chuan Su), the National Natural Science Foundation of China (No. 30701017 to Yi Fan and No. 30872206 to Chuan Su) and a grant (No. 07KJA31023) from Jiangsu Province to Chuan Su.	Agre P, 2004, BIOSCIENCE REP, V24, P127, DOI 10.1007/s10540-005-2577-2; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Benner EJ, 2004, P NATL ACAD SCI USA, V101, P9435, DOI 10.1073/pnas.0400569101; Benner EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001376; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Chade AR, 2006, J NEURAL TRANSM-SUPP, P147; Chen HL, 2005, ANN NEUROL, V58, P963, DOI 10.1002/ana.20682; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; CHI DS, 1992, INT J IMMUNOPHARMACO, V14, P739, DOI 10.1016/0192-0561(92)90070-2; Choi DK, 2005, J NEUROSCI, V25, P6594, DOI 10.1523/JNEUROSCI.0970-05.2005; Czlonkowska A, 1996, NEURODEGENERATION, V5, P137, DOI 10.1006/neur.1996.0020; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dhib-Jalbut S, 2006, J NEUROIMMUNOL, V176, P198, DOI 10.1016/j.jneuroim.2006.03.027; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fan Y, 2005, J NEUROSCI RES, V82, P458, DOI 10.1002/jnr.20664; Fan Y, 2008, NEUROBIOL AGING, V29, P1226, DOI 10.1016/j.neurobiolaging.2007.02.015; Fontenot JD, 2005, J EXP MED, V202, P901, DOI 10.1084/jem.20050784; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GIOVANNI A, 1994, J PHARMACOL EXP THER, V270, P1008; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim WK, 2004, J IMMUNOL, V172, P7015, DOI 10.4049/jimmunol.172.11.7015; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kurkowska-Jastrzebska I, 2004, INT IMMUNOPHARMACOL, V4, P1307, DOI 10.1016/j.intimp.2004.05.006; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2006, AAPS J, V8, pE606, DOI 10.1208/aapsj080369; Lorincz MT, 2006, SEMIN NEUROL, V26, P492, DOI 10.1055/s-2006-951621; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; Matyszak MK, 1998, PROG NEUROBIOL, V56, P19, DOI 10.1016/S0301-0082(98)00014-8; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Ng SW, 2008, J LEUKOCYTE BIOL, V83, P288, DOI 10.1189/jlb.0807575; Nielsen S, 1997, J NEUROSCI, V17, P171; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1146/annurev.neuro.22.1.123; Ortiz GG, 2003, ENVIRON MOL MUTAGEN, V41, P64, DOI 10.1002/em.10133; Powrie F, 2003, SCIENCE, V299, P1030, DOI 10.1126/science.1082031; Przedborski S, 2000, RESTOR NEUROL NEUROS, V16, P135; Przedborski S, 2004, J BIOENERG BIOMEMBR, V36, P375, DOI 10.1023/B:JOBB.0000041771.66775.d5; Przedborski S, 2001, J NEUROCHEM, V76, P1265, DOI 10.1046/j.1471-4159.2001.00183.x; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; Reynolds AD, 2007, J LEUKOCYTE BIOL, V82, P1083, DOI 10.1189/jlb.0507296; Reynolds AD, 2010, J IMMUNOL, V184, P2261, DOI 10.4049/jimmunol.0901852; Reynolds AD, 2009, J IMMUNOL, V182, P4137, DOI 10.4049/jimmunol.0803982; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Smeyne RJ, 2005, MOL BRAIN RES, V134, P57, DOI 10.1016/j.molbrainres.2004.09.017; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Thomas MP, 2007, J NEUROCHEM, V100, P503, DOI 10.1111/j.1471-4159.2006.04315.x; UHL GR, 1985, LANCET, V1, P956; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	72	47	51	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1474-9726			AGING CELL	Aging Cell	JUN	2011	10	3					368	382		10.1111/j.1474-9726.2011.00677.x			15	Cell Biology; Geriatrics & Gerontology	Cell Biology; Geriatrics & Gerontology	763CR	WOS:000290531900002	21255222	Bronze			2021-06-18	
J	Grote, S; Bocker, W; Mutschler, W; Bouillon, B; Lefering, R				Grote, Stefan; Boecker, Wolfgang; Mutschler, Wolf; Bouillon, Bertil; Lefering, Rolf			Diagnostic Value of the Glasgow Coma Scale for Traumatic Brain Injury in 18,002 Patients with Severe Multiple Injuries	JOURNAL OF NEUROTRAUMA			English	Article						Abbreviated Injury Scale; Glasgow Coma Scale; Injury Severity Score; multiple trauma; traumatic brain injury; unconsciousness	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; DATA-BANK; SCORE; TALK; SERUM; DETERIORATE; PREDICTION; PROGNOSIS; MORTALITY	Although patients with severe multiple injuries may have other reasons for unconsciousness, traumatic brain injury (TBI) in these patients is frequently defined by the Glasgow Coma Scale (GCS). Nevertheless, the diagnostic value of GCS for severe TBI in the multiple-injured patient is unknown. Therefore, we investigated the diagnostic value of GCS to identify severe TBI in multiple-injured patients. The records of 18,002 severely injured adult (ISS > 16) patients from the Trauma Register of the German Society for Trauma Surgery were analyzed and initial GCS and Abbreviated Injury Scale head (AIS(head)) were recorded. A severe TBI was defined by an AIS(head) >= 3. On the other hand, unconsciousness was defined by an initial GCS <= 8. By these criteria, 6546 patients (36.3%) were unconscious, and 8746 patients (48.6%) had severe TBI. Nine percent of all cases (n = 1643) had a GCS <= 8 without severe TBI. Only 56.1% of patients with severe TBI (n = 4903) had been unconscious. Decreasing levels of unconsciousness (as defined by GCS) showed consistent rising prevalence of severe TBI (correlation coefficient r= -0.52). Approximately 20% of all multiple-injured patients arriving in the emergency department with an initial GCS of 15 had severe TBI (AIS(head) >= 3). The diagnostic value of GCS <= 8 for severe TBI in patients with multiple injuries has low sensitivity (56.1%) but higher specificity (82.2%). Our study indicates that the GCS (as defined <= 8) in unconsciousness patients with multiple injuries shows only a moderate correlation with the diagnosis of severe TBI. Nevertheless, the main reason for unconsciousness in patients with multiple injuries is TBI, since only 9% of these patients had another reason for unconsciousness. However, due to the poor sensitivity of GCS, we suggest the use of the anatomical scoring system with AIS(head) >= 3 to define severe TBI in patients with multiple injuries.	[Grote, Stefan; Boecker, Wolfgang; Mutschler, Wolf] Univ Munich, Dept Trauma Surg, D-80336 Munich, Germany; [Bouillon, Bertil] Univ Witten Herdecke, Cologne Med Ctr, Dept Orthopaed & Trauma Surg, Cologne, Germany; [Lefering, Rolf] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany	Grote, S (corresponding author), Univ Munich, Dept Trauma Surg, Nussbaumstr, D-80336 Munich, Germany.	stefan.grote@med.uni-muenchen.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [Ne 385/5]; Novo Nordisk A/S (Bagsvaerd, Denmark)Novo Nordisk	The authors are participants in the Committee on Emergency Medicine, Intensive and Trauma Care (NIS) of the German Society of Trauma Surgery (DGU). The German Trauma Registry of the DGU (German Society of Trauma Surgery) was partly funded by the Deutsche Forschungsgemeinschaft (Ne 385/5) and by a grant from Novo Nordisk A/S (Bagsvaerd, Denmark).	Association for the Advancement of Automotive Medecine, 1990, ABBR INJ SCAL AIS; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; CAYARD C, 1983, J NEUROSURG, V59, P276; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Goldschlager T, 2007, J CLIN NEUROSCI, V14, P618, DOI 10.1016/j.jocn.2006.02.018; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1981, NEUROSURGERY, V9, P201; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REILLY PL, 1975, LANCET, V2, P375; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1979, JACEP-J AM COLL EMER, V8, P64, DOI 10.1016/S0361-1124(79)80039-8; Ruchholtz S, 2000, UNFALLCHIRURG, V103, P30, DOI 10.1007/s001130050005; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	40	47	49	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					527	534		10.1089/neu.2010.1433			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200004	21265592				2021-06-18	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			The effects of attention capacity on dynamic balance control following concussion	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; STABILITY FOLLOWING CONCUSSION; DUAL-TASK INTERFERENCE; PERFORMANCE TRADE-OFFS; OBSTACLE AVOIDANCE; OLDER-ADULTS; GAIT; INSTABILITY; HEALTHY; LIFE	The purpose of this study was to examine how individuals modulate attention in a gait/cognition dual task during a 4-week period following a concussion. Ten individuals suffering from a grade 2 concussion and 10 matched controls performed a single task of level walking, a seated auditory Stroop task and a simultaneous auditory Stroop and walking task. Reaction time and accuracy were measured from the Stroop task. Dynamic balance control during gait was measured by the interaction (displacement and velocity) between the center of mass (CoM) and center of pressure (CoP) in the coronal and sagittal planes. Concussed individuals shifted from conservative control of balance (shorter separation between CoM and CoP) immediately after injury to normal balance control over 28 days post-injury. Immediately after injury, correlations analyses using each subject on each testing day as a data point showed that there was a spectrum of deficient performance among concussed individuals on the first testing day. Within a testing session, deficiencies in reaction time of processing involved in the Stroop task were commonly seen with reduce dynamic balance control. However, the prioritization was not always towards the same task between trials. There were no correlations in the control group. Information provided in this study would enhance our understanding of the interaction between attention and gait following concussion.	[Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu		Catena, Robert/0000-0001-9128-1343	Center for Disease Control and Prevention [R49/CCR021735, CCR023203]	This study was supported by the Center for Disease Control and Prevention (R49/CCR021735 and CCR023203). The authors gratefully acknowledge the assistance of Louis R. Osternig, Jacqueline Poston and Erik Noren.	Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Kelly JP, 1997, NEUROLOGY, V48, P581; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lee HJ, 2006, ARCH PHYS MED REHAB, V87, P569, DOI 10.1016/j.apmr.2005.11.033; Matthews A, 2006, NEUROSCI LETT, V400, P172, DOI 10.1016/j.neulet.2006.02.043; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Montero-Odasso M, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-35; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; ShumwayCook A, 1997, J GERONTOL A-BIOL, V52, pM232, DOI 10.1093/gerona/52A.4.M232; Siu KC, 2008, AGING CLIN EXP RES, V20, P349, DOI 10.1007/BF03324867; Siu KC, 2008, EXP BRAIN RES, V184, P115, DOI 10.1007/s00221-007-1087-9; SOLOMON GS, 2006, HEADS UP SPORT CONCU; Temprado JJ, 2001, J EXP PSYCHOL HUMAN, V27, P1303, DOI 10.1037//0096-1523.27.6.1303; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; WINTER DA, 1990, BIOMECHANICS MOTOR C, P2; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	26	47	47	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	FEB 3	2011	8								8	10.1186/1743-0003-8-8			8	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	721LC	WOS:000287354800001	21291548	DOAJ Gold, Green Published			2021-06-18	
J	Allen, BJ; Gfeller, JD				Allen, Brittany J.; Gfeller, Jeffrey D.			The Immediate Post-Concussion Assessment and Cognitive Testing battery and traditional neuropsychological measures: A construct and concurrent validity study	BRAIN INJURY			English	Article						ImPACT; sports related concussion; computer based assessment; construct validity; concurrent validity; neuropsychological assessment	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; REPEATABLE BATTERY; IMPACT; MANAGEMENT; MILD	Primary objective: This study examined the construct and concurrent validity of ImPACT, a computerized neuropsychological test battery used for evaluating sports-related concussion. Research design: Approximately 100 neurologically intact undergraduates completed ImPACT and a battery of traditional neuropsychological tests utilized by the National Football League (NFL). Methods and procedures: Participants completed the two batteries in a counterbalanced order. Factor analyses examined the component structure of ImPACT and the NFL battery's factor structure. Correlational analyses assessed relationships among variables within and across the two batteries. Main results: A four-factor solution explaining 70% of variance was found with the NFL battery, including general memory, mental processing speed, verbal memory and processing speed and auditory and verbal working memory. A five-factor solution explaining 69% of variance was found with the ImPACT battery, with components assessing forced choice efficiency, verbal and visual memory, inhibitory cognitive abilities, visual processing abilities with a memory component and a factor with a single loading from Colour Match Total Commissions. Correlations revealed a range of significant and nonsignificant correlations between the two batteries. Conclusions: While both batteries overlap regarding their assessed constructs (e.g. memory, inhibitory cognitive abilities) notable differences in their factor structures were present as well.	[Allen, Brittany J.] CoxHealth, Dept Psychol Serv, Springfield, MO 65807 USA; [Gfeller, Jeffrey D.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA	Allen, BJ (corresponding author), CoxHealth, Dept Psychol Serv, 3800 S Natl Ave,Suite 770, Springfield, MO 65807 USA.	brittany.allen1@coxhealth.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM MED ASS, 2005, CPT 2006; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton A, 1989, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Duff K, 2006, AM J GERIAT PSYCHIAT, V14, P976, DOI 10.1097/01.JGP.0000229690.70011.cd; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Garcia C, 2008, ARCH CLIN NEUROPSYCH, V23, P63, DOI 10.1016/j.acn.2007.08.008; Halstead WC, 1985, HALSTEAD REITAN NEUR; Iverson G.L., 2003, IMMEDIATE POSTCONCUS; Iverson G. L., 2003, 23 ANN M NAT AC NEUR; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell M.R., 2005, IMPACT IMMEDIATE POS; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LOVELL MR, 2004, ORTHOPEDIC TECHNOLOG, V6, P28; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Lovell MR, 2006, SPORTS NEUROPSYCHOLO, P176; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wechsler D, 1997, WAIS 3 ADM SCORING M	41	47	48	0	22	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2011	25	2					179	191		10.3109/02699052.2010.541897			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800005	21219090				2021-06-18	
J	Xiong, Y; Mahmood, A; Zhang, YL; Meng, YL; Zhang, ZG; Qu, CS; Sager, TN; Chopp, M				Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Meng, Yuling; Zhang, Zheng Gang; Qu, Changsheng; Sager, Thomas N.; Chopp, Michael			Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; carbamylated erythropoietin; functional recovery; neurogenesis; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MARROW STROMAL CELLS; SPATIAL MEMORY; HEAD-INJURY; IN-VIVO; STROKE; MICE; DERIVATIVES; RECOVERY; NEURONS	Object. Carbamylated erythropoietin (CEPO) is a modified erythropoietin molecule that does not affect hematocrit. In this study, the authors compared the efficacy of a single dose with a triple dose of CEPO treatment for traumatic brain injury (TBI) in rats. Methods. Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Carbamylated erythropoietin (50 mu g/kg) was administered intraperitoneally in rats with TBI at 6 hours (CEPO x 1) or at 6,24, and 48 hours (CEPO x 3) postinjury. Neurological function was assessed using a modified neurological severity score and foot fault and Morris water maze tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemical analysis to assess lesion volume, cell loss, cell proliferation, angiogenesis, and neurogenesis after CEPO treatment. Results. Compared with the vehicle treatment, single treatment of CEPO (6 hours) significantly reduced lesion volume and hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor functional recovery and spatial learning in rats after TBI. Importantly, triple dosing of CEPO (6,24, and 48 hours) further reduced lesion volume and improved functional recovery and neurogenesis compared with the CEPO x 1 group. Conclusions. The authors' results indicate that CEPO has considerable therapeutic potential in TBI and related pathologies and furthermore that repeated dosing in the subacute phase might have important pharmacological relevance. (DOI: 10.3171/2010.10.JNS10925)	[Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Meng, Yuling; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Sager, Thomas N.] H Lundbeck & Co AS, Neurodegenerat Sect, Div Discovery Pharmacol Res, Copenhagen, Denmark	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	This work was supported by NIH Grant Nos. R01 NS62002 (to Dr. Xiong) and P01 NS42345 (to Drs. Mahmood and Chopp). Dr. Thomas N. Sager is a full-time employee of H. Lundbeck A/S.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Doggrell SA, 2004, EXPERT OPIN INV DRUG, V13, P1517, DOI 10.1517/13543784.13.11.1517; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Lapchak PA, 2008, EXPERT OPIN INV DRUG, V17, P1175, DOI [10.1517/13543784.17.8.1175, 10.1517/13543784.17.8.1175 ]; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Mennini T, 2006, MOL MED, V12, P153, DOI 10.2119/2006-00045.Mennini; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Savino C, 2006, J NEUROIMMUNOL, V172, P27, DOI 10.1016/j.jneuroim.2005.10.016; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xu X, 2009, SURGERY, V146, P506, DOI 10.1016/j.surg.2009.03.022; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	42	47	54	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2011	114	2					549	559		10.3171/2010.10.JNS10925			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	710WU	WOS:000286548500044	21073254	Green Accepted			2021-06-18	
S	Gosseries, O; Vanhaudenhuyse, A; Bruno, MA; Demertzi, A; Schnakers, C; Boly, MM; Maudoux, A; Moonen, G; Laureys, S		Cvetkovic, D; Cosic, I		Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Schnakers, Caroline; Boly, Melanie M.; Maudoux, Audrey; Moonen, Gustave; Laureys, Steven			Disorders of Consciousness: Coma, Vegetative and Minimally Conscious States	STATES OF CONSCIOUSNESS: EXPERIMENTAL INSIGHTS INTO MEDITATION, WAKING, SLEEP AND DREAMS	Frontiers Collection		English	Article; Book Chapter						Brain injury; Coma; Consciousness; Electrophysiology; Functional neuroimaging; Locked-in syndrome; Minimally conscious state; Prognosis; Treatment; Vegetative state	LOCKED-IN SYNDROME; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; WESSEX HEAD-INJURY; PATIENTS OWN NAME; MISMATCH NEGATIVITY; BISPECTRAL INDEX; RECOVERY; SCALE; ZOLPIDEM	Consciousness can be defined by two components: arousal and awareness. Disorders of consciousness (DOC) are characterized by a disrupted relationship between these two components. Coma is described by the absence of arousal and, hence, of awareness whereas the vegetative state is defined by recovery of arousal in the absence of any sign of awareness. In the minimally conscious state, patients show preserved arousal level and exhibit discernible but fluctuating signs of awareness. The study of DOC offers unique insights to the neural correlates of consciousness. We here review the challenges posed by the clinical examination of DOC patients and discuss the contribution of functional neuroimaging and electrophysiological techniques to the bedside assessment of consciousness. These studies raise important issues not only from a clinical and ethical perspective (i.e. diagnosis, prognosis and management of DOC patients) but also from a neuroscientific standpoint, as they enrich our current understanding of the emergence and function of the conscious mind.	[Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Schnakers, Caroline; Boly, Melanie M.; Maudoux, Audrey; Laureys, Steven] Univ Liege, Coma Sci Grp, Dept Neurol, B-4000 Liege, Belgium; [Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Schnakers, Caroline; Boly, Melanie M.; Maudoux, Audrey; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, B-4000 Liege, Belgium	Laureys, S (corresponding author), Univ Liege, Coma Sci Grp, Dept Neurol, Sari Tilman B30, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/AAN-2097-2021	Laureys, Steven/0000-0002-3096-3807; Demertzi, Athena/0000-0001-8021-3759			Alkire MT, 1999, ANESTHESIOLOGY, V90, P701, DOI 10.1097/00000542-199903000-00011; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; Bauby J-D., 1997, DIVING BELL BUTTERFL; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Bruno M, 2008, J NEUROL NEUROSUR PS, V79, P2, DOI 10.1136/jnnp.2007.125294; Bruno MA, 2011, BRIT MED J OPEN; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Childs NL, 1996, BRIT MED J, V313, P944; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Clauss RP, 2000, S AFR MED J, V90, P68; Cochrane TI, 2006, ANN INTERN MED, V144, P305, DOI 10.7326/0003-4819-144-4-200602210-00021; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Dam~asio A., 1999, FEELING WHAT HAPPENS; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Demertzi A, YB INTENSIV IN PRESS; Demertzi Athena, 2008, Expert Rev Neurother, V8, P1719, DOI 10.1586/14737175.8.11.1719; Deuschl G., 1999, RECOMMENDATIONS PRAC; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Dundon Stanislaus J, 1978, J Value Inq, V12, P280; Fang SC, 2005, P ANN INT IEEE EMBS, P4604, DOI 10.1109/IEMBS.2005.1615495; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2008, AM J BIOETHICS, V8, P3, DOI 10.1080/15265160802318113; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fridman EA, 2010, BRAIN INJURY, V24, P636, DOI 10.3109/02699051003610433; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Gosseries O, 2009, NEUROLOGY OF CONSCIOUSNESS: COGNITIVE NEUROSCIENCE AND NEUROPATHOLOGY, P191, DOI 10.1016/B978-0-12-374168-4.00015-0; Guerit JM, 2002, GUIDE PRATIQUE NEURO; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2005, BOUNDARIES CONSCIOUS; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Kuebler A, 2007, CURR OPIN NEUROL, V20, P643, DOI 10.1097/WCO.0b013e3282f14782; Laureys S, 2005, NAT REV NEUROSCI, V6, P899, DOI 10.1038/nrn1789; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2005, CURR OPIN NEUROL, V18, P726, DOI 10.1097/01.wco.0000189874.92362.12; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2003, 9 ANN M ORG HUM B S1, V19; Laureys S, 2002, 2002 YB INTENSIVE CA; Laureys S, 2000, 2000 YB INTENSIVE CA; Laureys S, 2008, NAT CLIN PRACT NEURO, V4, P544, DOI 10.1038/ncpneuro0887; Laureys S, 2008, NEUROLOGY, V70, pE14, DOI 10.1212/01.wnl.0000303264.66049.c1; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Laureys S, 2006, CURR OPIN NEUROL, V19, P520, DOI 10.1097/WCO.0b013e3280106ba9; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leon-Carrion J, 2002, BRAIN INJURY, V16, P571, DOI 10.1080/02699050110119781; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Lin JS, 2000, SLEEP MED REV, V4, P471, DOI 10.1053/smrv.2000.0116; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; Maquet P, 1997, J NEUROSCI, V17, P2807; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Naatanen R, 1997, AUDIOL NEURO-OTOL, V2, P341; Naccache L, 2005, CLIN NEUROPHYSIOL, V116, P988, DOI 10.1016/j.clinph.2004.10.009; Nieuwenhuijs D, 2002, ANESTH ANALG, V94, P125, DOI 10.1097/00000539-200201000-00024; Oh H, 2003, J CLIN NURS, V12, P394, DOI 10.1046/j.1365-2702.2003.00750.x; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Plum F., 1983, DIAGNOSIS STUPOR COM; Qin PM, 2008, NEUROSCI LETT, V448, P24, DOI 10.1016/j.neulet.2008.10.029; Rappaport M, 2000, COMA NEAR COMA SCALE; ROSENBERG JH, 1995, NEUROLOGY, V45, P1012; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2005, NEUROPSYCHOL REHABIL, V15, P381, DOI 10.1080/09602010443000524; Schnakers C, 2008, BRAIN INJURY, V22, P926, DOI 10.1080/02699050802530565; SCHNAKERS C, 2004, REANIMATION, V13, P368; Schnakers C, 2005, 8 C ASS SCI STUD CON, V11; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, NEUROCASE, V15, P271, DOI 10.1080/13554790902724904; Sellers EW, 2006, IEEE T NEUR SYS REH, V14, P221, DOI 10.1109/TNSRE.2006.875580; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Sorger B, 2009, PROG BRAIN RES, V177, P275, DOI 10.1016/S0079-6123(09)17719-1; Struys M, 1998, ACTA ANAESTH SCAND, V42, P628, DOI 10.1111/j.1399-6576.1998.tb05293.x; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; TEASDALE G, 1974, LANCET, V2, P81; Tolle Patrizia, 2003, Axone, V25, P20; van der Stelt O, 2008, CLIN NEUROPHYSIOL, V119, P2172, DOI 10.1016/j.clinph.2008.07.224; Vanhaudenhuyse A, 2008, NEUROLOGY, V71, P1374, DOI 10.1212/01.wnl.0000320110.70134.60; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2009, SCHOLARPEDIA, V4, P4163; Vanhaudenhuyse A, 2007, BEHAV BRAIN SCI, V30, P529, DOI 10.1017/S0140525X0700310X; Vanhaudenhuyse A, 2008, NEUROCRIT CARE, V8, P262, DOI 10.1007/s12028-007-9016-0; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wade DT, 1996, BRIT MED J, V313, P943; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2006, MAYO CLIN PROC, V81, P1155, DOI 10.4065/81.9.1155; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wilhelm B, 2006, NEUROLOGY, V67, P534, DOI 10.1212/01.wnl.0000228226.86382.5f; Wood R L, 1992, Brain Inj, V6, P411, DOI 10.3109/02699059209008137; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	124	47	48	0	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	1612-3018		978-3-642-18046-0	FRONT COLLECT			2011							29	55		10.1007/978-3-642-18047-7_2	10.1007/978-3-642-18047-7		27	Engineering, Electrical & Electronic; Neurosciences	Engineering; Neurosciences & Neurology	BYN19	WOS:000299398300002					2021-06-18	
J	Mannix, RC; Zhang, J; Park, J; Zhang, X; Bilal, K; Walker, K; Tanzi, RE; Tesco, G; Whalen, MJ				Mannix, Rebekah C.; Zhang, Jimmy; Park, Juyeon; Zhang, Xuan; Bilal, Kiran; Walker, Kendall; Tanzi, Rudolph E.; Tesco, Giuseppina; Whalen, Michael J.			Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; genetics; developmental biology; Alzheimer's disease	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSGENIC MICE; A-BETA; APOE GENOTYPE; MOUSE MODEL; PEPTIDE; DEPOSITION	The apolipoprotein E4 (APOE4) gene leads to increased brain amyloid beta (Ab) and poor outcome in adults with traumatic brain injury (TBI); however, its role in childhood TBI is controversial. We hypothesized that the transgenic expression of human APOE4 worsens the outcome after controlled cortical impact (CCI) in adult but not immature mice. Adult and immature APOE4 mice had worse motor outcome after CCI (P < 0.001 versus wild type (WT)), but the Morris water maze performance was worse only in adult APOE4 mice (P = 0.028 at 2 weeks, P = 0.019 at 6 months versus WT), because immature APOE4 mice had performance similar to WT for up to 1 year after injury. Brain lesion size was similar in adult APOE4 mice but was decreased (P = 0.029 versus WT) in injured immature APOE4 mice. Microgliosis was similar in all groups. Soluble brain A beta(40) was increased at 48 hours after CCI in adult and immature APOE4 mice and in adult WT (P < 0.05), and was dynamically regulated during the chronic period by APOE4 in adults but not immature mice. The data suggest age-dependent effects of APOE4 on cognitive outcome after TBI, and that therapies targeting APOE4 may be more effective in adults versus children with TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 351-361; doi:10.1038/jcbfm.2010.99; published online 30 June 2010	[Mannix, Rebekah C.] Harvard Univ, Dept Med, Childrens Hosp Boston, Sch Med,Div Emergency Med, Boston, MA 02115 USA; [Zhang, Jimmy; Park, Juyeon; Zhang, Xuan; Bilal, Kiran; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; [Zhang, Jimmy; Park, Juyeon; Zhang, Xuan; Bilal, Kiran; Whalen, Michael J.] Harvard Univ, Dept Pediat, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA; [Walker, Kendall; Tesco, Giuseppina] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA; [Tanzi, Rudolph E.] Massachusetts Gen Hosp, MIND Inst, Dept Neurol, Charlestown, MA USA	Mannix, RC (corresponding author), Harvard Univ, Dept Med, Childrens Hosp Boston, Sch Med,Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.Mannix@childrens.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Mannix, Rebekah/AAD-8702-2020	Tanzi, Rudolph/0000-0002-7032-1454; 	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD052896]; Cure Alzheimer's Fund; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1RO1AGO33016]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from NICHD 5K12HD052896 (RCM), the Cure Alzheimer's Fund (RET), NIA 1RO1AGO33016 (GT), and NINDS 5RO1NS047447 (MJW).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Brewer GJ, 1998, NEUROBIOL AGING, V19, P561, DOI 10.1016/S0197-4580(98)00091-8; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 2002, J NEUROSCI, V22, P10539; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hiekikanen H, 2007, BRAIN INJURY, V21, P1307, DOI 10.1080/02699050701739549; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Johnson V. E., 2010, NAT REV NEUROSCI; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Mandrekar S, 2009, J NEUROSCI, V29, P4252, DOI 10.1523/JNEUROSCI.5572-08.2009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Nagano S, 2004, J BIOL CHEM, V279, P14673, DOI 10.1074/jbc.M313003200; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nicoll JAR, 1996, NEUROPATH APPL NEURO, V22, P515, DOI 10.1111/j.1365-2990.1996.tb01128.x; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Small DH, 2009, NEUROCHEM RES, V34, P1824, DOI 10.1007/s11064-009-9960-5; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Venkitaramani DV, 2007, J NEUROSCI, V27, P11832, DOI 10.1523/JNEUROSCI.3478-07.2007; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE	41	47	47	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2011	31	1					351	361		10.1038/jcbfm.2010.99			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	702BX	WOS:000285870700036	20588316	Bronze, Green Published			2021-06-18	
J	Lindhagen-Persson, M; Brannstrom, K; Vestling, M; Steinitz, M; Olofsson, A				Lindhagen-Persson, Malin; Brannstrom, Kristoffer; Vestling, Monika; Steinitz, Michael; Olofsson, Anders			Amyloid-beta Oligomer Specificity Mediated by the IgM Isotype - Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; PROTEIN-PRECURSOR; MOUSE MODEL; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; MEMORY LOSS; PEPTIDE	Background: Alzheimers disease (AD) has been strongly linked to an anomalous self-assembly of the amyloid-beta peptide (A beta). The correlation between clinical symptoms of AD and A beta depositions is, however, weak. Instead small and soluble A beta oligomers are suggested to exert the major pathological effects. In strong support of this notion, immunological targeting of A beta oligomers in AD mice-models shows that memory impairments can be restored without affecting the total burden of A beta deposits. Consequently a specific immunological targeting of A beta oligomers is of high therapeutic interest. Methodology/Principal Findings: Previously the generation of conformational-dependent oligomer specific anti-A beta antibodies has been described. However, to avoid the difficult task of identifying a molecular architecture only present on oligomers, we have focused on a more general approach based on the hypothesis that all oligomers expose multiple identical epitopes and therefore would have an increased binding to a multivalent receptor. Using the polyvalent IgM immunoglobulin we have developed a monoclonal anti-A beta antibody (OMAB). OMAB only demonstrates a weak interaction with A beta monomers and dimers having fast on and off-rate kinetics. However, as an effect of avidity, its interaction with A beta-oligomers results in a strong complex with an exceptionally slow off-rate. Through this mechanism a selectivity towards A beta oligomers is acquired and OMAB fully inhibits the cytotoxic effect exerted by A beta(1-42) at highly substoichiometric ratios. Anti-A beta auto-antibodies of IgM isotype are frequently present in the sera of humans. Through a screen of endogenous anti-A beta IgM auto-antibodies from a group of healthy individuals we show that all displays a preference for oligomeric A beta. Conclusions/Significance: Taken together we provide a simple and general mechanism for targeting of oligomers without the requirement of conformational-dependent epitopes. In addition, our results suggest that IgM anti-A beta auto-antibodies may exert a more specific protective mechanism in vivo than previously anticipated.	[Lindhagen-Persson, Malin; Brannstrom, Kristoffer; Vestling, Monika; Olofsson, Anders] Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; [Steinitz, Michael] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91010 Jerusalem, Israel	Lindhagen-Persson, M (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	anders.olofsson@medchem.umu.se	Brannstrom, Kristoffer/AAC-1204-2020; Brannstrom, Kristoffer/D-3648-2009		Ernst and Lili Rosenhain fund, Bruxelles, Belgium; J. C. Kempe; Swedish research councilSwedish Research CouncilEuropean Commission; Socialstyrelsen; FAMY; Medical Faculty of Umea University	This work was supported by Ernst and Lili Rosenhain fund, Bruxelles, Belgium, J. C. Kempe, the Swedish research council, Socialstyrelsen, FAMY and the Medical Faculty of Umea University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asami-Odaka A, 2005, NEURODEGENER DIS, V2, P36, DOI 10.1159/000086429; Banks WA, 2007, EXP NEUROL, V206, P248, DOI 10.1016/j.expneurol.2007.05.005; Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x; Chauhan NB, 2003, J NEUROSCI RES, V74, P142, DOI 10.1002/jnr.10721; DaSilva KA, 2009, VACCINE, V27, P1365, DOI 10.1016/j.vaccine.2008.12.044; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; Dodel R, 2010, DRUGS, V70, P513, DOI 10.2165/11533070-000000000-00000; Geylis V, 2005, NEUROBIOL AGING, V26, P597, DOI 10.1016/j.neurobiolaging.2004.06.008; Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009; Hartley DM, 2008, J BIOL CHEM, V283, P16790, DOI 10.1074/jbc.M802215200; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; KATZMAN R, 1986, NEUROL CLIN, V4, P329, DOI 10.1016/S0733-8619(18)30972-1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; MARCELLO A, 2009, NEUROBIOL AGING; Marcello A, 2009, J NEURAL TRANSM, V116, P913, DOI 10.1007/s00702-009-0224-y; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Munch G, 2002, J NEURAL TRANSM, V109, P1081, DOI 10.1007/s007020200091; Myagkova MA, 2001, B EXP BIOL MED+, V131, P127, DOI 10.1023/A:1017527508878; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nath A, 2003, NEUROMOL MED, V3, P29, DOI 10.1385/NMM:3:1:29; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; O'Nuallain B, 2008, BIOCHEMISTRY-US, V47, P12254, DOI 10.1021/bi801767k; Olofsson A, 2007, BIOCHEM J, V404, P63, DOI 10.1042/BJ20061561; Olofsson A, 2009, ANAL BIOCHEM, V385, P374, DOI 10.1016/j.ab.2008.10.034; ONUALLAIN B, J CLIN IMMUNOL S1, V30, pS37; PAUL S, J CLIN IMMUNOL S1, V30, pS43; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-48; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sudol KL, 2009, MOL THER, V17, P2031, DOI 10.1038/mt.2009.174; Szabo P, 2008, AUTOIMMUN REV, V7, P415, DOI 10.1016/j.autrev.2008.03.007; Taguchi H, 2008, J BIOL CHEM, V283, P4714, DOI 10.1074/jbc.M707983200; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; Younkin SG, 2001, NAT MED, V7, P18, DOI 10.1038/83292	55	47	49	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2010	5	11							e13928	10.1371/journal.pone.0013928			9	Multidisciplinary Sciences	Science & Technology - Other Topics	677ZN	WOS:000284036800019	21085663	DOAJ Gold, Green Published			2021-06-18	
J	Semple, BD; Frugier, T; Morganti-Kossmann, MC				Semple, Bridgette D.; Frugier, Tony; Morganti-Kossmann, M. Cristina			CCL2 modulates cytokine production in cultured mouse astrocytes	JOURNAL OF NEUROINFLAMMATION			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; BETA-CHEMOKINES; MESSENGER-RNA; FACTOR-ALPHA; TNF-ALPHA; IMMUNE-RESPONSE; GENE-EXPRESSION	Background: The chemokine CCL2 (also known as monocyte chemoattractant protein-1, or MCP-1) is upregulated in patients and rodent models of traumatic brain injury (TBI), contributing to post-traumatic neuroinflammation and degeneration by directing the infiltration of blood-derived macrophages into the injured brain. Our laboratory has previously reported that Ccl2-/- mice show reduced macrophage accumulation and tissue damage, corresponding to improved motor recovery, following experimental TBI. Surprisingly, Ccl2-deficient mice also exhibited delayed but exacerbated secretion of key proinflammatory cytokines in the injured cortex. Thus we sought to further characterise CCL2's potential ability to modulate immunoactivation of astrocytes in vitro. Methods: Primary astrocytes were isolated from neonatal wild-type and Ccl2-deficient mice. Established astrocyte cultures were stimulated with various concentrations of lipopolysaccharide (LPS) and interleukin (IL)-1 beta for up to 24 hours. Separate experiments involved pre-incubation with mouse recombinant (r) CCL2 prior to IL-1 beta stimulation in wild-type cells. Following stimulation, cytokine secretion was measured in culture supernatant by immunoassays, whilst cytokine gene expression was quantified by real-time reverse transcriptase polymerase chain reaction. Results: LPS (0.1-100 mu g/ml; 8 h) induced the significantly greater secretion of five key cytokines and chemokines in Ccl2-/- astrocytes compared to wild-type cells. Consistently, IL-6 mRNA levels were 2-fold higher in Ccl2-deficient cells. IL-1 beta (10 and 50 ng/ml; 2-24 h) also resulted in exacerbated IL-6 production from Ccl2-/- cultures. Despite this, treatment of wild-type cultures with rCCL2 alone (50-500 ng/ml) did not induce cytokine/chemokine production by astrocytes. However, pre-incubation of wild-type astrocytes with rCCL2 (250 ng/ml, 12 h) prior to stimulation with IL-1 beta (10 ng/ml, 8 h) significantly reduced IL-6 protein and gene expression. Conclusions: Our data indicate that astrocytes are likely responsible for the exacerbated cytokine response seen in vivo post-injury in the absence of CCL2. Furthermore, evidence that CCL2 inhibits cytokine production by astrocytes following IL-1 beta stimulation, suggests a novel, immunomodulatory role for this chemokine in acute neuroinflammation. Further investigation is required to determine the physiological relevance of this phenomenon, which may have implications for therapeutics targeting CCL2-mediated leukocyte infiltration following TBI.	[Semple, Bridgette D.; Frugier, Tony; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Semple, Bridgette D.; Frugier, Tony; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Frugier, Tony] Alfred Hosp, Anat Pathol Dept, Melbourne, Vic, Australia	Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia.	Cristina.Morganti-Kossmann@monash.edu		Morganti-Kossmann, Cristina/0000-0002-0807-2063; Frugier, Tony/0000-0002-1275-5158	Victorian Neurotrauma Initiative; Australian GovernmentAustralian GovernmentCGIAR; Transport Accident Commission; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	Supported by the Victorian Neurotrauma Initiative, Australian Government (Australian Postgraduate Award for BD Semple), Transport Accident Commission and National Health and Medical Research Council.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; ALOISI F, 1992, J IMMUNOL, V149, P2358; Andjelkovic AV, 1999, GLIA, V28, P225, DOI 10.1002/(SICI)1098-1136(199912)28:3<225::AID-GLIA6>3.0.CO;2-6; Andjelkovic AV, 2002, J NEUROSCI RES, V70, P219, DOI 10.1002/jnr.10372; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Berman JW, 1996, J IMMUNOL, V156, P3017; Bolin LM, 2005, CYTOKINE, V30, P47, DOI 10.1016/j.cyto.2004.11.007; Bruno V, 2000, EUR J PHARMACOL, V399, P117, DOI 10.1016/S0014-2999(00)00367-8; Chiu K, 2010, CELL MOL IMMUNOL, V7, P61, DOI 10.1038/cmi.2009.110; Croitoru-Lamoury J, 2003, GLIA, V41, P354, DOI 10.1002/glia.10181; de Souza DF, 2009, J NEUROIMMUNOL, V206, P52, DOI 10.1016/j.jneuroim.2008.10.012; Edman LC, 2008, STEM CELLS, V26, P1891, DOI 10.1634/stemcells.2007-0753; Eugenin EA, 2003, J NEUROCHEM, V85, P1299, DOI 10.1046/j.1471-4159.2003.01775.x; Felton LM, 2005, NEUROBIOL DIS, V20, P283, DOI 10.1016/j.nbd.2005.03.008; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; FREI K, 1992, J NEUROIMMUNOL, V40, P189, DOI 10.1016/0165-5728(92)90133-6; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Ge SJ, 2009, J MOL NEUROSCI, V39, P269, DOI 10.1007/s12031-009-9197-4; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Guo H, 1998, SCAND J IMMUNOL, V48, P502; Guyon A, 2009, NEUROSCIENCE, V162, P1072, DOI 10.1016/j.neuroscience.2009.05.048; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Heesen M, 1996, J NEUROSCI RES, V45, P382; Hu SX, 1999, J LEUKOCYTE BIOL, V65, P815; Hua LWL, 2000, GLIA, V30, P74, DOI 10.1002/(SICI)1098-1136(200003)30:1<74::AID-GLIA8>3.0.CO;2-C; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kremlev SG, 2004, J NEUROIMMUNOL, V149, P1, DOI 10.1016/j.jneuroim.2003.11.012; Kumai Y, 2004, J CEREBR BLOOD F MET, V24, P1359, DOI 10.1097/00004647-200412000-00005; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; LEE SC, 1993, J IMMUNOL, V150, P2659; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma MH, 2002, J NEUROSCI RES, V68, P691, DOI 10.1002/jnr.10269; MAGRIGAL JL, 2009, J NEUROSCI, V29, P263; McKimmie CS, 2010, BIOCHEM BIOPH RES CO, V394, P1006, DOI 10.1016/j.bbrc.2010.03.111; Mizutani N, 2007, J IMMUNOL, V179, P7478, DOI 10.4049/jimmunol.179.11.7478; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; Pang Y, 2001, BRAIN RES, V914, P15, DOI 10.1016/S0006-8993(01)02766-4; Quinones MP, 2008, MOL CELL NEUROSCI, V37, P96, DOI 10.1016/j.mcn.2007.08.017; Rankine EL, 2006, EUR J NEUROSCI, V24, P77, DOI 10.1111/j.1460-9568.2006.04891.x; Rezaie P, 2002, GLIA, V37, P64, DOI 10.1002/glia.1128; Rhodes J, 2009, J TRAUMA, V66, P1591, DOI 10.1097/TA.0b013e31819a0344; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; SHARIF SF, 1993, NEUROL RES, V15, P109; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Thompson WL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-35; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Weiss JM, 1998, J NEUROIMMUNOL, V91, P190, DOI 10.1016/S0165-5728(98)00183-0; Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475	61	47	47	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	OCT 14	2010	7								67	10.1186/1742-2094-7-67			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	671TU	WOS:000283534700001	20942978	DOAJ Gold, Green Published			2021-06-18	
J	Fowler, A; Stodberg, T; Eriksson, M; Wickstrom, R				Fowler, Asa; Stodberg, Tommy; Eriksson, Margareta; Wickstrom, Ronny			Long-term Outcomes of Acute Encephalitis in Childhood	PEDIATRICS			English	Article						viral; infection; cerebrospinal fluid; brain	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; WORKING-MEMORY; CHILDREN; ETIOLOGY; ENCEPHALOPATHY; QUESTIONNAIRE; EPIDEMIOLOGY; PROGNOSIS; RISK	OBJECTIVES: The aims of this study were to investigate the long-term outcomes of childhood encephalitis and to examine possible prognostic factors. METHODS: Of 93 children who were treated for acute encephalitis in 2000-2004, 71 were eligible for follow-up evaluations. A structured interview, using 2 questionnaires, was conducted with the parents. Fifteen of the children with the most-severe symptoms at the time of discharge also underwent electroencephalographic recording and tests of reaction times and working memory. RESULTS: Persisting symptoms were reported by 54% of children. The predominant symptoms were personality changes and cognitive problems. Children who made a complete recovery did so within 6 to 12 months. The only significant risk factor for sequelae was disease severity leading to admission to the ICU. The risk of subsequent epilepsy was increased for children with seizures at presentation. Most follow-up electroencephalograms showed improvement, but results had not normalized for 9 of 15 children. Children with encephalitis had slower reaction times, compared with control subjects, but no difference in working memory could be seen. CONCLUSION: Persisting symptoms after childhood encephalitis were present for a substantial number of children. Seizures increased the risk of subsequent epilepsy; the only other prognostic marker was admission to the ICU. Even children who were considered fully recovered at discharge reported persisting symptoms at follow-up evaluations. Children who made a full recovery did so within 6 to 12 months, which suggests that all children with encephalitis should be monitored for 1 year after the acute illness. Pediatrics 2010;126:e828-e835	[Fowler, Asa; Stodberg, Tommy; Wickstrom, Ronny] Karolinska Inst, Neuropediat Unit, Stockholm, Sweden; [Eriksson, Margareta] Karolinska Inst, Dept Womens & Childrens Hlth, Pediat Infect Dis Unit, Stockholm, Sweden	Fowler, A (corresponding author), Karolinska Univ Hosp, Neuropediat Unit, ALB, Q2 07, S-17176 Stockholm, Sweden.	asa.fowler@ki.se			Jerring Foundation; Swedish Insurance Association; Frimurarna Barnhuset Foundation; Barnavard Foundation; Magnus Bergvalls Foundation	This study was supported by the Jerring Foundation, the Swedish Insurance Association, the Frimurarna Barnhuset Foundation, the Barnavard Foundation, and the Magnus Bergvalls Foundation.	Amin R, 2008, PEDIATR INFECT DIS J, V27, P390, DOI 10.1097/INF.0b013e31816507b2; ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; Baruah H C, 2002, Indian Pediatr, V39, P1143; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chang Luan-Yin, 2008, Pediatrics and Neonatology, V49, P103, DOI 10.1016/S1875-9572(08)60023-6; CIZMAN M, 1993, PEDIATR INFECT DIS J, V12, P903, DOI 10.1097/00006454-199311000-00002; Clarke M, 2006, DEV MED CHILD NEUROL, V48, P294, DOI 10.1017/S0012162206000636; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Daxboeck F, 2004, J CHILD NEUROL, V19, P865, DOI 10.1177/08830738040190110401; Fowler A, 2008, EUR J PAEDIATR NEURO, V12, P484, DOI 10.1016/j.ejpn.2007.12.009; Fowlkes AL, 2008, J INFECT DIS, V198, P1685, DOI 10.1086/592988; Hokkanen L, 1996, J NEUROL NEUROSUR PS, V61, P478, DOI 10.1136/jnnp.61.5.478; Huang MC, 2006, PEDIATRICS, V118, pE1785, DOI 10.1542/peds.2006-1547; Iff T, 1998, Eur J Paediatr Neurol, V2, P233, DOI 10.1016/S1090-3798(98)80036-6; Ilias A, 2006, J CHILD NEUROL, V21, P910, DOI 10.1177/08830738060210101701; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kennedy PGE, 2004, J NEUROL NEUROSUR PS, V75, pI10, DOI 10.1136/jnnp.2003.034280; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kolski H, 1998, CLIN INFECT DIS, V26, P398, DOI 10.1086/516301; Koskiniemi M, 1997, EUR J PEDIATR, V156, P541, DOI 10.1007/s004310050658; Lahat E, 1999, ARCH DIS CHILD, V80, P69, DOI 10.1136/adc.80.1.69; Lee WT, 2007, EUR J PAEDIATR NEURO, V11, P302, DOI 10.1016/j.ejpn.2007.02.011; McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1111/j.1574-6976.2002.tb00601.x; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Ooi MH, 2008, CLIN INFECT DIS, V47, P458, DOI 10.1086/590008; Schmolck H, 2005, J CHILD NEUROL, V20, P500, DOI 10.1177/08830738050200060601; Wang IJ, 2007, EUR J PAEDIATR NEURO, V11, P63, DOI 10.1016/j.ejpn.2006.09.010; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006	30	47	47	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2010	126	4					E828	E835		10.1542/peds.2009-3188			8	Pediatrics	Pediatrics	658WW	WOS:000282526100009	20876179				2021-06-18	
J	Pardini, JE; Pardini, DA; Becker, JT; Dunfee, KL; Eddy, WF; Lovell, MR; Welling, JS				Pardini, Jamie E.; Pardini, Dustin A.; Becker, James T.; Dunfee, Kathryn L.; Eddy, William F.; Lovell, Mark R.; Welling, Joel S.			Postconcussive Symptoms Are Associated With Compensatory Cortical Recruitment During a Working Memory Task	NEUROSURGERY			English	Article						Brain function; Concussion; Functional magnetic resonance imaging; Symptoms; Working memory	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; HEMODYNAMIC-RESPONSE; CONCUSSION; RECOVERY; FOOTBALL; TIME; VISUALIZATION; SENSITIVITY; HEADACHE	BACKGROUND: The severity of sports-related concussion is often characterized by the number and severity of postconcussive symptoms (eg, headache, dizziness, difficulty concentrating). Although the level of postconcussive symptoms after injury is believed to index the severity of the neurological insult sustained, studies examining the relationship between symptom severity and neural functioning in concussed athletes remain rare. OBJECTIVE: This exploratory study examined the association between self-reported symptom severity and functional activation on a working memory task in a group of 16 recently concussed student athletes. METHODS: Functional magnetic resonance imaging was used to examine the relationship of symptom severity to brain activation during a working memory task in 16 concussed subjects. RESULTS: Findings indicated that symptom severity was associated with regionally specific hyperactivation during a working memory task, even though symptom severity was not significantly related to task accuracy. CONCLUSION: The results add to a growing body of literature that demonstrates that functional neuroimaging may have the potential to serve as a sensitive biomarker of the severity of concussion and mild traumatic brain injury.	[Welling, Joel S.] Pittsburgh Supercomp Ctr, Pittsburgh, PA 15213 USA; [Pardini, Jamie E.; Lovell, Mark R.] Univ Pittsburgh, Dept Orthoped Surg, Med Ctr, Pittsburgh, PA USA; [Pardini, Dustin A.; Becker, James T.; Dunfee, Kathryn L.] Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA; [Eddy, William F.] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; [Eddy, William F.] Carnegie Mellon Univ, Dept Machine Learning, Pittsburgh, PA 15213 USA; [Eddy, William F.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Welling, JS (corresponding author), Pittsburgh Supercomp Ctr, 300 S Craig St, Pittsburgh, PA 15213 USA.	welling@psc.edu	Pardini, Dustin/E-3615-2013	Becker, James/0000-0003-4425-4726	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD042386]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH078039] Funding Source: NIH RePORTER	This study was supported in part by funding from the National Institute of Child Health and Human Development (HD042386). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Aizenstein HJ, 2004, J COGNITIVE NEUROSCI, V16, P786, DOI 10.1162/089892904970681; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Cook R.D., 1982, RESIDUALS INFLUENCE; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Eddy WF, 1996, MAGNET RESON MED, V36, P923, DOI 10.1002/mrm.1910360615; Eddy WF, 2000, BIOMED EN S, P603; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; HARALICK RM, 1987, IEEE T PATTERN ANAL, V9, P532, DOI 10.1109/TPAMI.1987.4767941; IVERSON G, 2004, J INT NEUROPSYCH SOC, V10, P1; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Juengst SB, 2007, J NEUROSCI METH, V163, P208, DOI 10.1016/j.jneumeth.2007.03.004; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lazar NA, 2002, NEUROIMAGE, V16, P538, DOI 10.1006/nimg.2002.1107; Lazar NA, 2001, INT STAT REV, V69, P105, DOI 10.2307/1403532; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2005, APPL NEUROPSYCHOL, V21, P91; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; STUMP J, 2004, BRIT J SPORT MED, V38, P662; Talairach J., 1988, COPLANAR STEREOTACTI; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Welling JS, 2006, GRAPH MODELS, V68, P356, DOI 10.1016/j.gmod.2005.11.004	47	47	47	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2010	67	4					1020	1027		10.1227/NEU.0b013e3181ee33e2			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	654VA	WOS:000282197900044	20881565	Green Accepted			2021-06-18	
J	Baki, SGA; Schwab, B; Haber, M; Fenton, AA; Bergold, PJ				Baki, Samah G. Abdel; Schwab, Ben; Haber, Margalit; Fenton, Andre A.; Bergold, Peter J.			Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; PLACE AVOIDANCE; SPATIAL INFORMATION; BEHAVIORAL EVIDENCE; MICE; NEURODEGENERATION; SEGREGATION	Background: There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single drugs have failed clinical trials suggesting a role for drug combinations. Drug combinations acting synergistically often provide the greatest combination of potency and safety. The drugs examined (minocycline (MINO), N-acetylcysteine (NAC), simvastatin, cyclosporine A, and progesterone) had FDA-approval for uses other than TBI and limited brain injury in experimental TBI models. Methodology/Principal Findings: Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats. One week later, drugs were tested for efficacy and drug combinations tested for synergy on a hierarchy of behavioral tests that included active place avoidance testing. As monotherapy, only MINO improved acquisition of the massed version of active place avoidance that required memory lasting less than two hours. MINO-treated animals, however, were impaired during the spaced version of the same avoidance task that required 24-hour memory retention. Co-administration of NAC with MINO synergistically improved spaced learning. Examination of brain histology 2 weeks after injury suggested that MINO plus NAC preserved white, but not grey matter, since lesion volume was unaffected, yet myelin loss was attenuated. When dosed 3 hours before injury, MINO plus NAC as single drugs had no effect on interleukin-1 formation; together they synergistically lowered interleukin-1 levels. This effect on interleukin-1 was not observed when the drugs were dosed one hour after injury. Conclusions/Significance: These observations suggest a potentially valuable role for MINO plus NAC to treat TBI.	[Baki, Samah G. Abdel] Suny Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA	Baki, SGA (corresponding author), Suny Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA.	pbergold@downstate.edu		Bergold, Peter/0000-0002-6335-1380; Fenton, Andre/0000-0002-5063-1156	Traumatic Brain Injury/Post-Traumatic Stress Disorder [W81XWH-08-1-0293]	This work was supported by a Traumatic Brain Injury/Post-Traumatic Stress Disorder Congressionally Directed Medical Research Programs award W81XWH-08-1-0293 (http://cdmrp.army.mil) to P.J.B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Cimadevilla JM, 2001, BRAIN RES BULL, V54, P559, DOI 10.1016/S0361-9230(01)00448-8; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI 10.1517/14728220802517901 ; Fenton AA, 1998, P NATL ACAD SCI USA, V95, P11493, DOI 10.1073/pnas.95.19.11493; FREI E, 2003, CANC MED; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kesner RP, 2007, LEARN MEMORY, V14, P771, DOI 10.1101/lm.688207; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kubik S, 2005, J NEUROSCI, V25, P9205, DOI 10.1523/JNEUROSCI.1707-05.2005; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061; Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250; Paintlia MK, 2004, J NEUROSCI RES, V78, P347, DOI 10.1002/jnr.20261; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Russell DG, 2010, SCIENCE, V328, P852, DOI 10.1126/science.1184784; Serrano P, 2008, PLOS BIOL, V6, P2698, DOI 10.1371/journal.pbio.0060318; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vafaei AA, 2007, NEUROBIOL LEARN MEM, V88, P87, DOI 10.1016/j.nlm.2007.02.004; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang S, 2009, AM J NEURORADIOL, V30, P1907, DOI 10.3174/ajnr.A1697; Wesierska M, 2005, J NEUROSCI, V25, P2413, DOI 10.1523/JNEUROSCI.3962-04.2005; Wesierska M, 2009, NEUROBIOL LEARN MEM, V91, P41, DOI 10.1016/j.nlm.2008.09.005; White WB, 2010, NAT REV CARDIOL, V7, P303, DOI 10.1038/nrcardio.2010.55; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8	42	47	47	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2010	5	8							e12490	10.1371/journal.pone.0012490			10	Multidisciplinary Sciences	Science & Technology - Other Topics	644TX	WOS:000281405300016	20824218	DOAJ Gold, Green Published			2021-06-18	
J	Schmidt, AT; Hanten, GR; Li, XQ; Orsten, KD; Levin, HS				Schmidt, Adam T.; Hanten, Gerri R.; Li, Xiaoqi; Orsten, Kimberley D.; Levin, Harvey S.			Emotion recognition following pediatric traumatic brain injury: Longitudinal analysis of emotional prosody and facial emotion recognition	NEUROPSYCHOLOGIA			English	Article						Children; Head injury; Emotion processing; Face perception	CLOSED-HEAD INJURY; SHORT-TERM; SOCIAL-BEHAVIOR; PERCEPTION DEFICITS; READING EMOTIONS; CHILDREN; EXPRESSION; OUTCOMES; DAMAGE; ADOLESCENTS	Children with closed head injuries often experience significant and persistent disruptions in their social and behavioral functioning. Studies with adults sustaining a traumatic brain injury (TB!) indicate deficits in emotion recognition and suggest that these difficulties may underlie some of the social deficits. The goal of the current study was to examine if children sustaining a TBI exhibit difficulties with emotion recognition in terms of emotional prosody and face emotion recognition and to determine (1) how these abilities change over time and (2) what, if any, additional factors such as sex, age, and socioeconomic status (SES) affected the findings. Results provide general support for the idea that children sustaining a TBI exhibit deficits in emotional prosody and face emotion recognition performance. Further, although some gains were noted in the TBI group over the two-years following injury, factors such as SES and age at injury influenced the trajectory of recovery. The current findings indicate the relationship between TBI and emotion recognition is complex and may be influenced by a number of developmental and environmental factors. Results are discussed in terms of their similarity to previous investigations demonstrating the influence of environmental factors on behavioral recovery following pediatric TBI, and with regard to future investigations that can further explore the link between emotion recognition deficits and long-term behavioral and psychosocial recovery. (C) 2010 Elsevier Ltd. All rights reserved.	[Schmidt, Adam T.; Hanten, Gerri R.; Li, Xiaoqi; Orsten, Kimberley D.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Schmidt, AT (corresponding author), 1709 Dryden Rd,12th Floor, Houston, TX 77030 USA.	ats1978@gmail.com			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; T32 postdoctoral fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD049350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by NINDS grant # NS-21889 to HSL and by a T32 postdoctoral fellowship to ATS.	Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1285, DOI 10.1016/S0028-3932(99)00023-8; Adolphs R., 2001, NEUROPSYCHOLOGY, V15; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Ariatti A, 2008, NEUROL SCI, V29, P219, DOI 10.1007/s10072-008-0971-9; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Brazdil M, 2009, NEUROIMAGE, V47, P376, DOI 10.1016/j.neuroimage.2009.03.081; Buchanan TW, 2000, COGNITIVE BRAIN RES, V9, P227, DOI 10.1016/S0926-6410(99)00060-9; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Charbonneau S, 2003, NEUROPSYCHOLOGIA, V41, P605, DOI 10.1016/S0028-3932(02)00202-6; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dekowska M, 2008, ACTA NEUROBIOL EXP, V68, P229; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Ekman P., 1976, PICTURES FACIAL AFFE; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hanten G, 2009, TOP LANG DISORD, V29, P236, DOI 10.1097/TLD.0b013e3181b531f0; Hayes CJ, 2007, NEUROPSYCHOLOGIA, V45, P1135, DOI 10.1016/j.neuropsychologia.2006.10.015; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Herba C, 2004, J CHILD PSYCHOL PSYC, V45, P1185, DOI 10.1111/j.1469-7610.2004.00316.x; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Izard C, 2001, PSYCHOL SCI, V12, P18, DOI 10.1111/1467-9280.00304; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kotz SA, 2003, BRAIN LANG, V86, P366, DOI 10.1016/S0093-934X(02)00532-1; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Leppanen JM, 2001, SCAND J PSYCHOL, V42, P429, DOI 10.1111/1467-9450.00255; Letswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2006, ARCH PHYS MED REHAB, V87, pS1, DOI 10.1016/j.apmr.2006.09.010; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 2005, BRAIN IMPAIR, V56, P56; Meletti S, 2009, EPILEPSIA, V50, P1547, DOI 10.1111/j.1528-1167.2008.01978.x; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Moos RH, 1994, LISRES A LIFE STRESS; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TONKS J, 2007, BRAIN IMPAIR, V8, P143, DOI DOI 10.1375/BRIM.8.2.143; Tonks J, 2008, BRAIN INJURY, V22, P325, DOI 10.1080/02699050801968303; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	70	47	47	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	AUG	2010	48	10					2869	2877		10.1016/j.neuropsychologia.2010.05.029			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	642AU	WOS:000281175900008	20678980	Green Accepted			2021-06-18	
J	Borges, A; Casselman, J				Borges, Alexandra; Casselman, Jan			Imaging the trigeminal nerve	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Trigeminal neuropathy; Trigeminal neuralgia; Imaging the trigeminal nerve; Imaging technique; CT; MRI	NEUROVASCULAR COMPRESSION; MICROVASCULAR DECOMPRESSION; CRANIAL NERVES; NEURALGIA; PATHOLOGY; ANATOMY	Of all cranial nerves, the trigeminal nerve is the largest and the most widely distributed in the supra-hyoid neck. It provides sensory input from the face and motor innervation to the muscles of mastication. In order to adequately image the full course of the trigeminal nerve and its main branches a detailed knowledge of neuroanatomy and imaging technique is required. Although the main trunk of the trigeminal nerve is consistently seen on conventional brain studies, high-resolution tailored imaging is mandatory to depict smaller nerve branches and subtle pathologic processes. Increasing developments in imaging technique made possible isotropic sub-milimetric images and curved reconstructions of cranial nerves and their branches and led to an increasing recognition of symptomatic trigeminal neuropathies. Whereas MRI has a higher diagnostic yield in patients with trigeminal neuropathy, CT is still required to demonstrate the bony anatomy of the skull base and is the modality of choice in the context of traumatic injury to the nerve. Imaging of the trigeminal nerve is particularly cumbersome as its long course from the brainstem nuclei to the peripheral branches and its rich anastomotic network impede, in most cases, a topographic approach. Therefore, except in cases of classic trigeminal neuralgia, in which imaging studies can be tailored to the root entry zone, the full course of the trigeminal nerve has to be imaged. This article provides an update in the most recent advances on MR imaging technique and a segmental imaging approach to the most common pathologic processes affecting the trigeminal nerve. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Borges, Alexandra] Ctr Lisboa, Inst Portugues Oncol Francisco Gentil, Dept Radiol, P-1093 Lisbon, Portugal; [Casselman, Jan] AZ St Jan Brugge Antwerpen Hosp, Dept Radiol, Antwerp, Belgium; [Casselman, Jan] AZ St Augustinus Antwerpen Hosp, Dept Radiol, Antwerp, Belgium	Borges, A (corresponding author), Ctr Lisboa, Inst Portugues Oncol Francisco Gentil, Dept Radiol, Rua Prof Lima Basto, P-1093 Lisbon, Portugal.	borgalexandra@gmail.com					Axer H, 2007, J MAGN RESON IMAGING, V26, P905, DOI 10.1002/jmri.21088; Becker M, 2008, NEUROIMAG CLIN N AM, V18, P283, DOI 10.1016/j.nic.2007.11.002; Borges A, 2005, EUR RADIOL, V15, P511, DOI 10.1007/s00330-004-2613-9; Borges A, 2007, EUR RADIOL, V17, P2332, DOI 10.1007/s00330-006-0572-z; Borges A, 2007, EUR RADIOL, V17, P2112, DOI 10.1007/s00330-006-0575-9; Borges A, 2009, NEUROIMAG CLIN N AM, V19, P441, DOI 10.1016/j.nic.2009.06.001; Brisman R, 2004, J NEUROSURG, V100, P848, DOI 10.3171/jns.2004.100.5.0848; Brisman R, 2002, NEUROSURGERY, V50, P1261, DOI 10.1097/00006123-200206000-00015; Carvalho GA, 2000, NEUROSURGERY, V47, P1287, DOI 10.1097/00006123-200012000-00005; CASSELMAN JW, 2004, ER COURS MAGN RES IM; Chavin JM, 2003, OTOLARYNG CLIN N AM, V36, P1079, DOI 10.1016/S0030-6665(03)00124-5; Dandy W., 1934, AM J SURG, V24, P477; Delavelle J, 1998, INT J NEURORADIOL, V4, P445; DEMARCO JK, 1993, NEUROIMAG CLIN N AM, V3, P117; Devor M, 2002, J NEUROSURG, V96, P532, DOI 10.3171/jns.2002.96.3.0532; Fukuda H, 2003, SURG NEUROL, V59, P93, DOI 10.1016/S0090-3019(02)00993-X; Gass A, 1997, NEUROLOGY, V49, P1142, DOI 10.1212/WNL.49.4.1142; Go JL, 2001, SEMIN ULTRASOUND CT, V22, P502, DOI 10.1016/S0887-2171(01)90004-6; Gronseth G, 2008, NEUROLOGY, V71, P1183, DOI 10.1212/01.wnl.0000326598.83183.04; Jannetta PJ, 2003, NEUROSURGERY, V52, P1511, DOI 10.1227/01.NEU.0000068352.22859.82; Kuroiwa T, 1996, Radiat Med, V14, P235; Laine FJ, 1998, NEUROIMAG CLIN N AM, V8, P69; Lakshmi M, 2009, NEUROIMAG CLIN N AM, V19, P393, DOI 10.1016/j.nic.2009.06.004; Larrier D, 2003, OTOLARYNG CLIN N AM, V36, P1041, DOI 10.1016/S0030-6665(03)00127-0; LEBLANC A, 2001, ENCEPHALO PERIPHERAL, P79; LOURYAN S, 2004, ER COURS MAGN RES IM; Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347; LUFKIN R, 2000, TEACHING ATLAS HEAD; Lufkin RB, 2001, MRI HEAD NECK, V2nd; Majoie CBLM, 1997, RADIOLOGY, V204, P455, DOI 10.1148/radiology.204.2.9240535; Maroldi R, 1999, JBR-BTR, V82, P294; MASUR H, 1995, J NEUROL, V242, P93, DOI 10.1007/BF00887823; McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001; Muzammil S, 2009, SOUTH MED J, V102, P534, DOI 10.1097/SMJ.0b013e31819dc79b; Patel NK, 2003, BRIT J NEUROSURG, V17, P60, DOI 10.1080/0268869031000093735; Peker S, 2006, NEUROSURGERY, V59, P354, DOI 10.1227/01.NEU.0000223501.27220.69; WILSONPAWELS, 1998, CRANIAL NERVES ANATO; Yamamoto M, 2004, AM J ROENTGENOL, V182, P385, DOI 10.2214/ajr.182.2.1820385; Yoshino N, 2003, RADIOLOGY, V228, P539, DOI 10.1148/radiol.2282020439; Zakrzewska JM, 2002, CLIN J PAIN, V18, P14, DOI 10.1097/00002508-200201000-00003	40	47	51	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	MAY	2010	74	2					323	340		10.1016/j.ejrad.2010.02.006			18	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	594UW	WOS:000277565500005	20227216				2021-06-18	
J	Topjian, AA; Localio, AR; Berg, RA; Alessandrini, EA; Meaney, PA; Pepe, PE; Larkin, GL; Peberdy, MA; Becker, LB; Nadkarni, VM				Topjian, Alexis A.; Localio, A. Russell; Berg, Robert A.; Alessandrini, Evaline A.; Meaney, Peter A.; Pepe, Paul E.; Larkin, G. Luke; Peberdy, Mary Ann; Becker, Lance B.; Nadkarni, Vinay M.		Natl Registry Cardiopulm Resuscita	Women of child-bearing age have better inhospital cardiac arrest survival outcomes than do equal-aged men	CRITICAL CARE MEDICINE			English	Article						heart arrest; cardiopulmonary resuscitation; gender; women; outcome	HOSPITAL CARDIOPULMONARY-RESUSCITATION; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; TASK-FORCE; PROGESTERONE	Objectives: Estrogen and progesterone improve neurologic outcomes in experimental models of cardiac arrest and stroke. Our objective was to determine whether women of child-bearing age are more likely than men to survive to hospital discharge after in-hospital cardiac arrest. Design: Prospective, observational study. Setting: Five hundred nineteen hospitals in the National Registry of Cardiopulmonary Resuscitation database. Patients: Patients included 95,852 men and women 15-44 yrs and 56 yrs or older with pulseless cardiac arrests from January 1, 2000 through July 31, 2008. Measurements and Main Results: Patients were stratified a priori by gender and age groups (15-44 yrs and >= 56 yrs). Fixed-effects regression conditioning on hospital was used to examine the relationship between age, gender, and survival outcomes. The unadjusted survival to discharge rate for younger women of child-bearing age (15-44 yrs) was 19% (940/4887) vs. 17% (1203/7025) for younger men (p = .013). The adjusted hospital discharge difference between these younger women and men was 2.8% (95% confidence interval, 1.0% to 4.6%; p = .002), and these younger women also had a 2.6% (95% confidence interval, 0.9% to 4.3%; p = .002) absolute increase in favorable neurologic outcome. For older women compared with men (>= 56 yrs), there were no demonstrable differences in discharge rates (18% vs. 18%; adjusted difference, -0.1%; 95% confidence interval, -0.9% to 0.6%; p = .68) or favorable neurologic outcome (14% vs. 14%; adjusted difference, -0.1%; 95% confidence interval, -0.7% to 0.5%; p = .74). Conclusions: Women of child-bearing age were more likely than comparably aged men to survive to hospital discharge after in-hospital cardiac arrest, even after controlling for etiology of arrest and other important variables. (Crit Care Med 2010; 38:1254-1260)	[Topjian, Alexis A.; Berg, Robert A.; Meaney, Peter A.; Nadkarni, Vinay M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA; [Localio, A. Russell] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Alessandrini, Evaline A.] Cincinnati Childrens Hosp, Med Ctr, Div Emergency Med, Cincinnati, OH USA; [Pepe, Paul E.] Univ Texas SW Med Ctr Dallas, Dept Emergency Med, Parkland Hlth Hosp Syst, Dallas, TX 75390 USA; [Larkin, G. Luke] Yale Univ, Sch Med, Dept Surg, Emergency Med Sect, New Haven, CT 06510 USA; [Peberdy, Mary Ann] Virginia Commonwealth Univ, Dept Emergency Med & Internal Med, Richmond, VA USA; [Becker, Lance B.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Becker, Lance B.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA	Topjian, AA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA.	topjian@email.chop.edu		Meaney, Peter/0000-0001-9898-6928; LARKIN, GREGORY LUKE/0000-0002-8655-7824	Edna G. Kynett Foundation; Philips Medical Systems; Laerdal Medical; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Cardiac Science; BeneChill; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS075363] Funding Source: NIH RePORTER	The Edna G. Kynett Foundation FOCUS Junior Faculty Investigator Award provided funding for design of the study and data analysis.; Dr. Becker has received grant/research support from Philips Medical Systems, Laerdal Medical, NIH, Cardiac Science, and BeneChill. He consulted for Philips Medical Systems, NIH Data Safety Monitoring Board and Protocol Review Committee, and Gaymar Industries. He received patents from Hypothermia Induction and Reperfusion Therapies. He is a special government employee. He has received ownership, equity, and royalties from Cold Core Therapeutics, Inc. He is a member of the American Heart Association. He received speaker honoraria from Zoll Medical, Medtronics, and multiple universities. The remaining authors have not disclosed any potential conflicts of interest.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Anderson SE, 2003, PEDIATRICS, V111, P844, DOI 10.1542/peds.111.4.844; Arrich J, 2006, MEDICINE, V85, P288, DOI 10.1097/01.md.0000236954.72342.20; Carr BG, 2009, RESUSCITATION, V80, P30, DOI 10.1016/j.resuscitation.2008.09.001; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Davison A. C., 1997, BOOSTRAP METHODS THE; de Vos R, 1999, ARCH INTERN MED, V159, P845, DOI 10.1001/archinte.159.8.845; Ehlenbach WJ, 2009, NEW ENGL J MED, V361, P22, DOI 10.1056/NEJMoa0810245; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gan SC, 2000, NEW ENGL J MED, V343, P8, DOI 10.1056/NEJM200007063430102; Glickman SW, 2007, AM HEART J, V154, P1206, DOI 10.1016/j.ahj.2007.08.001; Herlitz J, 2004, RESUSCITATION, V60, P197, DOI 10.1016/j.resuscitation.2003.09.012; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kim C, 2001, CIRCULATION, V104, P2699, DOI 10.1161/hc4701.099784; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Mahapatra S, 2005, RESUSCITATION, V65, P197, DOI 10.1016/j.resuscitation.2004.10.017; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Noppens RR, 2009, J CEREBR BLOOD F MET, V29, P277, DOI 10.1038/jcbfm.2008.116; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; Pell JP, 2000, EUR HEART J, V21, P239, DOI 10.1053/euhj.1999.1629; Perers E, 1999, RESUSCITATION, V40, P133, DOI 10.1016/S0300-9572(99)00022-2; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; Vaccarino V, 2005, NEW ENGL J MED, V353, P671, DOI 10.1056/NEJMsa032214; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vukmir RB, 2003, J WOMENS HEALTH, V12, P667, DOI 10.1089/154099903322404311; Wigginton JG, 2002, CRIT CARE MED, V30, pS131, DOI 10.1097/00003246-200204001-00002; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; ZARITSKY A, 1995, PEDIATRICS, V96, P765; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	40	47	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2010	38	5					1254	1260		10.1097/CCM.0b013e3181d8ca43			7	Critical Care Medicine	General & Internal Medicine	593JD	WOS:000277449100003	20228684	Green Accepted			2021-06-18	
J	Sandler, SJI; Figaji, AA; Adelson, PD				Sandler, Simon J. I.; Figaji, Anthony A.; Adelson, P. David			Clinical applications of biomarkers in pediatric traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Biomarkers; Traumatic brain injury; Children; S100B	NEURON-SPECIFIC-ENOLASE; SEVERE HEAD-INJURY; COMPUTED-TOMOGRAPHY FINDINGS; S-100 PROTEIN MEASUREMENTS; FIBRILLARY ACIDIC PROTEIN; BILATERAL FEMUR FRACTURE; URINARY S100B PROTEIN; GLASGOW-COMA-SCALE; CEREBROSPINAL-FLUID; SERUM S100B	The diagnosis, treatment, and prediction of outcome in pediatric traumatic brain injury (TBI) present significant challenges to the treating clinician. Clinical and radiological tools for assessing injury severity and predicting outcome, in particular, lack sensitivity and specificity. In patients with mild TBI, often there is uncertainty about which patients should undergo radiological imaging and who is at risk for long term neurological sequelae. In severe TBI, often there is uncertainty about which patients will experience secondary insults and what the outcome for individual patients will be. In several other clinical specialties, biomarkers are used to diagnose disease, direct treatment, and prognosticate. However, an ideal biomarker for brain injury has not been found. In this review, we examine the various factors that must be taken into account in the search for a reliable biomarker in brain injury. We review the important studies that have investigated common biomarkers of structural brain injury, in particular S100B, neuron-specific enolase, myelin basic protein, and glial fibrillary acid protein. The potential uses and limitations of these biomarkers in the context of TBI are discussed.	[Figaji, Anthony A.] Red Cross Childrens Hosp, ZA-7700 Rondebosch, Cape Town, South Africa; [Adelson, P. David] Phoenix Childrens Neurosci Inst, Phoenix, AZ USA; [Sandler, Simon J. I.; Figaji, Anthony A.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Div Neurosurg, Sch Child & Adolescent Hlth, ZA-7925 Cape Town, South Africa	Figaji, AA (corresponding author), Red Cross Childrens Hosp, 617 ICH Bldg,Klipfontein Rd, ZA-7700 Rondebosch, Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Adelson, David/W-2083-2019	Sandler, Simon/0000-0002-1887-8677; Figaji, Anthony/0000-0002-3357-6490	South African-Swedish Links Program [GUN 2072790]	This work was supported in part by a grant from the South African-Swedish Links Program (GUN 2072790).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 1998, ACT NEUR S, V71, P250; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E4; Gazzolo D, 2005, PEDIATR RES, V58, P1170, DOI 10.1203/01.pdr.0000185131.22985.30; Gazzolo D, 2004, CLIN CHEM, V50, P941, DOI 10.1373/clinchem.2003.021048; Gazzolo D, 2004, CRIT CARE MED, V32, P131, DOI 10.1097/01.CCM.0000104116.91462.CD; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Gazzolo Diego, 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P108; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KIRINO T, 1983, J NEUROSCI, V3, P915; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Lomas JP, 2005, EMERG MED J, V22, P889, DOI 10.1136/emj.2005.031732; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mazzini GS, 2009, RESUSCITATION, V80, P144, DOI 10.1016/j.resuscitation.2008.08.024; Meybohm P, 2008, RESUSCITATION, V76, P449, DOI 10.1016/j.resuscitation.2007.09.002; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Park ES, 2000, YONSEI MED J, V41, P328, DOI 10.3349/ymj.2000.41.3.328; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Spinella Philip C, 2004, Pediatr Crit Care Med, V5, P53, DOI 10.1097/01.PCC.0000102221.98378.7D; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Subbaswamy A, 2009, NEUROCRIT CARE, V10, P129, DOI 10.1007/s12028-008-9122-7; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wright NT, 2008, J BIOMOL NMR, V42, P279, DOI 10.1007/s10858-008-9282-y	78	47	53	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2010	26	2					205	213		10.1007/s00381-009-1009-1			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	539GK	WOS:000273241700011	19902222				2021-06-18	
J	Snell, FI; Halter, MJ				Snell, Frances I.; Halter, Margaret Jordan			A SIGNATURE WOUND OF WAR Mild Traumatic Brain Injury	JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES			English	Article								Improvised explosive devices are the weapons of choice for the insurgent enemy in Iraq and Afghanistan. More soldiers are surviving these blast injuries due to improved torso protection yet are sustaining head and neck wounds in numbers that exceed those from previous wars. Although moderate and severe traumatic head injuries are easily identified and aggressively treated, mild traumatic brain injuries (m-TBIs), or concussions, had previously been deemed inconsequential and often overlooked. Recently, however, the U.S. Department of Defense and Veterans Health Administration have placed emphasis on identifying service members at risk for m-TBI because a select number continue to have disabling symptoms that can negatively affect quality of life. Research regarding the effects and treatment of blast injury are gaining momentum, but further work needs to be accomplished. This article provides a three-question screening tool that can be used to identify these at-risk veterans.	[Snell, Frances I.] Akron Community Based Outpatient Clin, Louis Stokes Cleveland VA Med Ctr, Akron, OH USA; [Halter, Margaret Jordan] Univ Akron, Coll Nursing, Akron, OH 44325 USA; [Snell, Frances I.] USA Reserves, Combat Support Hosp 256, Twinsburg, OH USA	Snell, FI (corresponding author), Akron VA Outpatient Clin, 55 W Waterloo Rd, Akron, OH 44319 USA.	Frances.Snell@va.gov					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; *DEF VET BRAIN INJ, 2005, C PROGR SERV MEMB VE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kudler Harold, 2008, N C Med J, V69, P39; LAMANCE R, 2009, MULLEN ADDRESSES SUI; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; President's Commission on Care for America's Returning Wounded Warriors, 2007, SERV SUPP SIMPL REP; Schwab KA, 2006, NEUROLOGY, V66, pA235; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *US GOV ACC OFF, 2008, PUBL US GOV ACC OFF; 2007, PTSD M TBI CHAIN TEA	19	47	47	0	8	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0279-3695	1938-2413		J PSYCHOSOC NURS MEN	J. Psychosoc. Nurs. Ment. Health Serv.	FEB	2010	48	2					22	28		10.3928/02793695-20100108-02			7	Nursing	Nursing	556IG	WOS:000274583700007	20166653				2021-06-18	
J	Bell, RS; Vo, AH; Roberts, R; Wanebo, J; Armonda, RA				Bell, Randy S.; Vo, Alexander H.; Roberts, Ryan; Wanebo, John; Armonda, Rocco A.			Wartime Traumatic Aneurysms: Acute Presentation, Diagnosis, and Multimodal Treatment of 64 Craniocervical Arterial Injuries	NEUROSURGERY			English	Article						Endovascular occlusion; Pseudoaneurysm; Traumatic intracranial aneurysms; Vascular complications of traumatic brain injury	INTERNAL CAROTID-ARTERY; INFERIOR CEREBELLAR ARTERY; MISSILE HEAD WOUNDS; INTRACRANIAL ANEURYSMS; INTRACAVERNOUS ANEURYSM; VERTEBRAL ARTERY; CEREBRAL-ARTERIES; MANAGEMENT; EPISTAXIS; RUPTURE	OBJECTIVE: Operation Iraqi Freedom has resulted in a significant number of closed and penetrating head injuries, and a consequence of both has been the accompanying neurovascular injuries. Here we review the largest reported population of patients with traumatic neurovascular disease and offer our experience with both endovascular and surgical management. METHODS: A retrospective analysis of all military casualties returning to the Walter Reed Army Medical Center and the National Naval Medical Center, Bethesda, Maryland, from April 2003 until April 2008 was performed. All patients undergoing diagnostic cerebral angiography during their inpatient stay were included in the study. RESULTS: A total of 513 war trauma-related consults were performed from April 2003 to April 2008, resulting in the evaluation of 408 patients with closed and penetrating head injuries. In this population, 279 angiographic studies were performed in 187 patients (25 closed craniocervical injuries, 162 penetrating craniocervical injuries), resulting in the detection of 64 vascular injuries in 48 patients (26.2% of those studied, 34% prevalence). Vascular injuries were characterized by traumatic intracranial aneurysms (TICAS) (n = 31), traumatic extracalvarial aneurysms (TECAs) (n = 19), arterial dissections (n = 11), and arteriovenous fistulae (n = 3). The average TICA size on admission was 4.1 mm, with an observed increase in aneurysm size in 11 cases. In the TICA/TECA group, 24 aneurysms in 23 patients were treated endovascularly with either coiling or stent-assisted coiling, resulting in preservation of the parent artery in 12 of 24 vessels (50%). The injuries in 3 patients in this group progressed despite endovascular treatment and required definitive clip exclusion. Thirteen additional aneurysms in 8 patients were treated surgically, resulting in parent artery preservation in 4 cases (30.8%). Eleven of the 13 remaining TICAs/TECAs resolved spontaneously without treatment. A total of 6 aneurysm ruptures (average size, 8.25 mm) occurred, resulting in 3 deaths. Four of 6 ruptures occurred in TICAs in which the interval size increase was noted angiographically. CONCLUSION: The management of traumatic vascular injury has evolved with technological advancement and the willingness of the neurosurgeon to intervene. Although open surgical intervention remains a viable solution, endovascular options are available and safe and can effectively temporize a patient while acute sequelae of serious head injury resolve.	[Bell, Randy S.; Roberts, Ryan; Armonda, Rocco A.] Walter Reed Army Med Ctr, Washington, DC 20307 USA; [Bell, Randy S.; Roberts, Ryan; Wanebo, John; Armonda, Rocco A.] Natl Naval Med Ctr, Bethesda, MD USA; [Vo, Alexander H.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA	Bell, RS (corresponding author), 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	Randy.bell@amedd.army.mil		Wanebo, John/0000-0003-1833-2938			AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; Aarabi B, 2001, J TRAUMA S, V51, pS26; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; Alvarez J A, 1999, J Craniomaxillofac Trauma, V5, P39; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; AOKI N, 1992, SURG NEUROL, V37, P59, DOI 10.1016/0090-3019(92)90068-X; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; Bell Randy S, 2006, Neurosurgery, V59, pS56; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; CASEY ATH, 1994, BRIT J NEUROSURG, V8, P97, DOI 10.3109/02688699409002401; Cerillo A, 1987, J Neurosurg Sci, V31, P173; Chedid MK, 2001, J NEUROSURG, V94, P637, DOI 10.3171/jns.2001.94.4.0637; Cummings TJ, 2000, NEUROL RES, V22, P165, DOI 10.1080/01616412.2000.11741055; EGNOR M R, 1991, Pediatric Neurosurgery, V17, P135, DOI 10.1159/000120583; Englund R, 1988, Ann Vasc Surg, V2, P362, DOI 10.1016/S0890-5096(06)60817-0; FELDGES A, 1989, INTENS CARE MED, V5, P400; Gallari G, 1997, J Neurosurg Sci, V41, P189; GARZAMERCADO R, 1979, NEUROSURGERY, V5, P500, DOI 10.1227/00006123-197910000-00018; Guyot LL, 2001, NEUROL RES, V23, P291, DOI 10.1179/016164101101198442; Hachemi M, 2007, CHILD NERV SYST, V23, P283, DOI 10.1007/s00381-006-0269-2; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAHN YS, 1990, CHILD NERV SYST, V6, P360, DOI 10.1007/BF00298285; HALBACH VV, 1993, J NEUROSURG, V79, P183, DOI 10.3171/jns.1993.79.2.0183; Hemphill JC, 1999, CRIT CARE CLIN, V15, P811, DOI 10.1016/S0749-0704(05)70089-0; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; HORNIBROOK J, 1981, AUST NZ J SURG, V51, P206, DOI 10.1111/j.1445-2197.1981.tb05942.x; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; Hossain M, 2002, SPINAL CORD, V40, P307, DOI 10.1038/sj.sc.3101290; Iob I, 1983, J Neurosurg Sci, V27, P187; Ishikawa T, 1997, J NEUROSURG, V86, P291, DOI 10.3171/jns.1997.86.2.0291; JAKOBSSON KE, 1984, ACTA NEUROCHIR, V71, P91, DOI 10.1007/BF01401153; JINKINS JR, 1992, AM J ROENTGENOL, V159, P365, DOI 10.2214/ajr.159.2.1632358; KOMIYAMA M, 1991, SURG NEUROL, V36, P126, DOI 10.1016/0090-3019(91)90230-7; Kumar M, 1998, NEUROSURG CLIN N AM, V9, P577; Larson P S, 2000, Neurosurg Focus, V8, pe4; Lee CY, 2004, J NEUROSURG, V100, P115, DOI 10.3171/jns.2004.100.1.0115; LEE JP, 1990, J TRAUMA, V30, P619, DOI 10.1097/00005373-199005000-00017; Levine NB, 2004, PEDIATR NEUROSURG, V40, P128, DOI 10.1159/000079855; LIN TK, 1995, NEUROSURGERY, V36, P407, DOI 10.1227/00006123-199502000-00025; MAHMOUD NA, 1979, J LARYNGOL OTOL, V93, P629, DOI 10.1017/S0022215100087508; MORARD M, 1991, NEUROSURGERY, V29, P438, DOI 10.1227/00006123-199109000-00018; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; Pipinos II, 1998, J VASC SURG, V27, P374, DOI 10.1016/S0741-5214(98)70371-4; REIBER ME, 1994, HEAD NECK-J SCI SPEC, V16, P253, DOI 10.1002/hed.2880160308; Sahjpaul RL, 1998, J NEUROSURG, V89, P822, DOI 10.3171/jns.1998.89.5.0822; Schuster JM, 1999, NEUROSURGERY, V45, P1465, DOI 10.1097/00006123-199912000-00039; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; SHALLAT RF, 1981, NEUROSURGERY, V8, P569, DOI 10.1227/00006123-198105000-00010; SORIA ED, 1988, ANGIOLOGY, V39, P609, DOI 10.1177/000331978803900708; STEINMETZ H, 1988, SURG NEUROL, V30, P305, DOI 10.1016/0090-3019(88)90304-7; Uzan M, 1998, NEUROSURGERY, V43, P1314, DOI 10.1097/00006123-199812000-00024; Voelker J L, 1997, W V Med J, V93, P317; WANG AN, 1986, SURG NEUROL, V25, P77, DOI 10.1016/0090-3019(86)90120-5	57	47	54	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2010	66	1					66	79		10.1227/01.NEU.0000361285.50218.A8			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	535KP	WOS:000272967400013	20023539	Bronze			2021-06-18	
J	Channon, S; Crawford, S				Channon, Shelley; Crawford, Sarah			Mentalising and social problem-solving after brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Social cognition; Problem-solving; Mentalising; Theory of mind; Executive function	FRONTAL-LOBE DAMAGE; PERCEPTION DEFICITS; POSTERIOR LESIONS; MIND; REHABILITATION; IMPAIRMENTS; DYSFUNCTION; COGNITION; SARCASM	This study examined the performance of adults with an acquired brain injury (ABI) on social cognition tasks assessing mentalistic interpretation and social problem-solving. These tasks were based on an earlier version described by Channon and Crawford (1999). Twenty participants with an ABI (10 resulting from a traumatic brain injury, 10 from a cerebrovascular accident), were found to be impaired relative to 20 matched control participants in interpreting scenarios involving either actions or sarcastic remarks on the Mentalistic Interpretation Task. When problem-solving ability was examined, the participants with an ABI were poorer at solving social problems on the Social Problem Resolution Task, and generated fewer responses on the Social Problem Fluency Task. They also had greater difficulty in detecting the awkward elements of the social situations, and in selecting appropriate solutions from a range of alternatives. These tasks provide a potential clinical tool for pinpointing an individual's strengths and weaknesses in everyday social communication and problem-solving, which can serve as the basis for designing individualised rehabilitation programmes.	[Channon, Shelley; Crawford, Sarah] UCL, Dept Cognit Perceptual & Brain Sci, London WC1E 6BT, England	Channon, S (corresponding author), UCL, Dept Cognit Perceptual & Brain Sci, Bedford Way Bldg,Gower St, London WC1E 6BT, England.	S.Channon@ucl.ac.uk					Abu-Akel A, 2003, BRAIN RES REV, V43, P29, DOI 10.1016/S0165-0173(03)00190-5; Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Aron AR, 2003, NAT NEUROSCI, V6, P1329; Bardenhagen FJ, 1999, NEUROCASE, V5, P325; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2004, ACTA PSYCHOL, V115, P235, DOI 10.1016/j.actpsy.2003.12.008; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Channon S, 2001, J AUTISM DEV DISORD, V31, P461, DOI 10.1023/A:1012212824307; CHANNON S, SOCIAL COGN IN PRESS; Channon S, 2007, NEUROPSYCHOLOGIA, V45, P1725, DOI 10.1016/j.neuropsychologia.2006.12.021; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Delis DC, 2001, DELISKAPLAN EXECUTIV; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Evans JJ, 2001, BRAIN DAM B, P209; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Godefroy O, 2007, BEHAVIORAL AND COGNITIVE NEUROLOGY OF STROKE, P369, DOI 10.1017/CBO9780511544880.020; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2002, AWARENESS SOCIAL INF; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; Reverberi C, 2005, NEUROPSYCHOLOGIA, V43, P460, DOI 10.1016/j.neuropsychologia.2004.06.008; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Sabbagh MA, 2004, BRAIN COGNITION, V55, P209, DOI 10.1016/j.bandc.2003.04.002; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212	44	47	49	1	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	5					739	759	PII 922728571	10.1080/09602011003794583			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	648YB	WOS:000281730300006	20526955				2021-06-18	
J	Geraci, A; Surian, L; Ferraro, M; Cantagallo, A				Geraci, Alessandra; Surian, Luca; Ferraro, Marco; Cantagallo, Anna			Theory of Mind in patients with ventromedial or dorsolateral prefrontal lesions following traumatic brain injury	BRAIN INJURY			English	Article						Theory of Mind; traumatic brain injury; prefrontal cortex; social cognition	FRONTAL-LOBE; EMOTION RECOGNITION; ASPERGER-SYNDROME; HEAD-INJURY; DEFICITS; IMPAIRMENTS; PERFORMANCE; SYSTEMS; PEOPLE; SELF	Primary objective: Previous studies on patients with traumatic brain injuries (TBI) and diffuse brain damages have reported selective deficits in mental states reasoning or 'Theory of Mind' (ToM). The goal of the current study is to investigate the fundamental role of the prefrontal cortex in two ToM components: inferential reasoning and social perception. Research design: Selective cognitive impairments following a TBI provide crucial evidence for assessing competing models of specific aspects of the cognitive system. Method and procedure: This study compared the performance of patients with predominantly focal lesions in the ventromedial (n = 11) or dorsolateral prefrontal cortex (n = 7) with matched controls (n = 20). All subjects performed two ToM tasks: the Eyes Test and the Faux-pas Test. Results: It was found that both groups of patients performed equally poorly on the Eyes Test, but only patients with predominantly lesions in the ventromedial cortex performed poorly on the Faux-pas test. The group effects on ToM tasks could not be reduced to differences in the global severity of brain injuries. Conclusions: These results provide evidence supporting some current models of the fractionation of the mindreading system and support the claim that the ventromedial cortex plays a fundamental role in inferential reasoning.	[Geraci, Alessandra; Surian, Luca] Univ Trento, Dept Cognit Sci, I-38068 Roverto, TN, Italy; [Surian, Luca] Univ Trento, Ctr Mind Brain Studies Cimec, I-38068 Roverto, TN, Italy; [Ferraro, Marco] Univ Padua, Gen Hosp, Rehabil Unit, I-35100 Padua, Italy; [Cantagallo, Anna] Hosp Univ Ferrara, Dept Rehabil, Ferrara, Italy	Geraci, A (corresponding author), Univ Trento, Dept Cognit Sci, Corso Bettini 31, I-38068 Roverto, TN, Italy.	alessandra.geraci@unitn.it	Surian, Luca/Q-2947-2019; Geraci, Alessandra/ABC-5241-2020	Geraci, Alessandra/0000-0003-1375-9190			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Appollonio I, 2005, NEUROL SCI, V26, P108, DOI 10.1007/s10072-005-0443-4; Bach LJ, 2000, COGN NEUROPSYCHIATRY, V5, P175, DOI DOI 10.1080/13546800050083520; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BARONCOHEN S, 1994, BRIT J DEV PSYCHOL, V12, P397, DOI 10.1111/j.2044-835X.1994.tb00642.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BROTHERS L, 1992, J COGNITIVE NEUROSCI, V4, P107, DOI 10.1162/jocn.1992.4.2.107; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Damasio H., 1989, LESION ANAL NEUROPSY; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Frith U, 2001, CURR DIR PSYCHOL SCI, V10, P151, DOI 10.1111/1467-8721.00137; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Grezes J, 2004, J NEUROSCI, V24, P5500, DOI 10.1523/JNEUROSCI.0219-04.2004; Hagen C., 1979, LEVELS COGNITIVE FUN; Happaney K, 2004, BRAIN COGNITION, V55, P1, DOI 10.1016/j.bandc.2004.01.001; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heaton KR, 1993, WISCONSIN CARD SORTI; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hynes CA, 2006, NEUROPSYCHOLOGIA, V44, P374, DOI 10.1016/j.neuropsychologia.2005.06.011; Jenkins AC, 2008, P NATL ACAD SCI USA, V105, P4507, DOI 10.1073/pnas.0708785105; Laiacona M., 2001, J NEUROL SCI, V21, P279; LESLIE AM, 2000, NEW COGNITIVE NEUROS, P1; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Sabbagh MA, 2004, BRAIN COGNITION, V55, P209, DOI 10.1016/j.bandc.2003.04.002; Samson D, 2005, BRAIN, V128, P1102, DOI 10.1093/brain/awh464; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Serafin M., 2004, GIORNALE ITALIANO PS, V31, P213; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Slessor G, 2007, PSYCHOL AGING, V22, P639, DOI 10.1037/0882-7974.22.3.639; Spatt J, 1997, ACTA NEUROL SCAND, V95, P173, DOI 10.1111/j.1600-0404.1997.tb00091.x; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Surian L, 1999, BRIT J DEV PSYCHOL, V17, P141, DOI 10.1348/026151099165203; Surian L, 2001, BRAIN LANG, V78, P224, DOI 10.1006/brln.2001.2465; Tager-Flusberg H, 2001, DEV AUTISM PERSPECTI; Varley R, 2001, NEUROCASE, V7, P489, DOI 10.1093/neucas/7.6.489; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	58	47	48	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	7-8					978	987		10.3109/02699052.2010.487477			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MW	WOS:000279505000007	20545452				2021-06-18	
J	Moore, EM; Bellomo, R; Nichol, A; Harley, N; MacIsaac, C; Cooper, DJ				Moore, Elizabeth M.; Bellomo, Rinaldo; Nichol, Alistair; Harley, Nerina; MacIsaac, Christopher; Cooper, D. James			The incidence of acute kidney injury in patients with traumatic brain injury	RENAL FAILURE			English	Article						kidney failure, acute; renal insufficiency, acute, brain injuries, craniocerebral trauma; acute kidney injury; traumatic brain injury	ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; CARDIAC-SURGERY; RIFLE CRITERIA; MULTICENTER EVALUATION; HOSPITALIZED-PATIENTS; REPLACEMENT THERAPY; CLINICAL-OUTCOMES; ORGAN DYSFUNCTION; FLUID THERAPY	There is limited information on the incidence of acute kidney injury (AKI) in patients with traumatic brain injury (TBI) although AKI may contribute to morbidity and mortality. We investigated the incidence of AKI in patients with moderate and severe TBI and the association of AKI with risk factors and outcomes in these patients. We studied all TBI patients over 16 years of age admitted to the two designated trauma hospitals in the state of Victoria, Australia from 1 January to 31 December 2008. Patients were included if they had head trauma and presented with a Glasgow coma scale (GCS) < 13. Prospectively collected data from the hospital trauma registries, ICUs, and pathology databases were analyzed retrospectively. Risk injury failure loss end (RIFLE) criteria were used to categorize renal function. The incidence of AKI was 9.2% (19/207). Patients who developed AKI were older, had higher severity of illness scores, and a lower GCS. Overall 42.1% of these patients died in hospital compared with 18.1% in patients without AKI. In univariable linear regression analysis, age, severity of illness, and admitting hospital were associated with AKI. After multivariable logistic regression, the occurrence of AKI was associated with age (p < 0.001) and higher APACHE III scores (p = 0.016). AKI is relatively common even in patients with TBI. Its association with age and APACHE III scores helps identify patients at higher risk of AKI.	[Moore, Elizabeth M.; Bellomo, Rinaldo; Nichol, Alistair; Cooper, D. James] Monash Univ, Australian & New Zealand Intens Care ANZIC Res Ct, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Nichol, Alistair; Cooper, D. James] Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Harley, Nerina; MacIsaac, Christopher] Royal Melbourne Hosp, Intens Care Unit, Parkville, Vic 3050, Australia	Moore, EM (corresponding author), Monash Univ, Australian & New Zealand Intens Care ANZIC Res Ct, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	Elizabeth.Moore@med.monash.edu.au	Cooper, D. James/G-7961-2013; Moore, Elizabeth/W-1687-2019	Cooper, D. James/0000-0002-5872-9051; Moore, Elizabeth/0000-0002-3881-6000; Nichol, Alistair Dualta/0000-0002-4771-5615; Bellomo, Rinaldo/0000-0002-1650-8939; Nichol, Alistair/0000-0002-4689-1238	Erythropoietin in TBI [NCT00987454]	RB, AN and DJC are investigators of a National Health and Medical Research Council/Victorian Neurotrauma Initiative funded clinical trial of Erythropoietin in TBI (NCT00987454).	Bagshaw SM, 2008, RENAL FAILURE, V30, P581, DOI 10.1080/08860220802134649; Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744; Bagshaw SM, 2009, NEPHROL DIAL TRANSPL, V24, P2739, DOI 10.1093/ndt/gfp159; Bagshaw SM, 2009, INTENS CARE MED, V35, P871, DOI 10.1007/s00134-008-1367-2; Bagshaw SM, 2009, J CRIT CARE, V24, P129, DOI 10.1016/j.jcrc.2007.12.017; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Cooper WA, 2006, CIRCULATION, V113, P1063, DOI 10.1161/CIRCULATIONAHA.105.580084; Dasta JF, 2008, NEPHROL DIAL TRANSPL, V23, P1970, DOI 10.1093/ndt/gfm908; Davenport A, 2001, AM J KIDNEY DIS, V37, P457, DOI 10.1053/ajkd.2001.22068; Guitard J, 2006, CLIN NEPHROL, V65, P103; Heringlake M, 2006, MINERVA ANESTESIOL, V72, P645; Hillis GS, 2006, CIRCULATION, V113, P1056, DOI 10.1161/CIRCULATIONAHA.105.591990; Kuitunen A, 2006, ANN THORAC SURG, V81, P542, DOI 10.1016/j.athoracsur.2005.07.047; Mathew TH, 2007, MED J AUSTRALIA, V187, P459, DOI 10.5694/j.1326-5377.2007.tb01357.x; Nijboer WN, 2010, CRIT CARE MED, V38, P1155, DOI 10.1097/CCM.0b013e3181cf6e78; Ostermann M, 2007, CRIT CARE MED, V35, P1837, DOI 10.1097/01.CCM.0000277041.13090.0A; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Ricci Z, 2009, BLOOD PURIFICAT, V27, P127, DOI 10.1159/000167019; Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F; Wahlstrom MR, 2009, ACTA ANAESTH SCAND, V53, P18, DOI 10.1111/j.1399-6576.2008.01798.x; Wetzels JFM, 2007, KIDNEY INT, V72, P632, DOI 10.1038/sj.ki.5002374; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	25	47	49	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0886-022X			RENAL FAILURE	Ren. Fail.		2010	32	9					1060	1065		10.3109/0886022X.2010.510234			6	Urology & Nephrology	Urology & Nephrology	666NI	WOS:000283121700007	20863210	Bronze			2021-06-18	
J	Pistoia, F; Mura, E; Govoni, S; Fini, M; Sara, M				Pistoia, Francesca; Mura, Elisa; Govoni, Stefano; Fini, Massimo; Sara, Marco			Awakenings and Awareness Recovery in Disorders of Consciousness	CNS DRUGS			English	Article							TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; TRANSIENT IMPROVEMENT; CONTROLLED-TRIAL; CLINICAL-USE; ZOLPIDEM; AMANTADINE; AROUSAL; SLEEP; METHYLPHENIDATE	Disorders of consciousness (DOC) include coma, vegetative state (VS) and minimally conscious state (MCS). Coma is a condition of unarousability with a complete absence of wakefulness and awareness, whereas VS is characterized by a lack of awareness despite a preserved wakefulness. Patients in coma are unconscious because they lack both wakefulness and awareness. Patients in a VS are unconscious because, although they are wakeful, they lack awareness. Patients in a MCS show minimal but definite behavioural evidence of self and environmental awareness. Coma results from diffuse bilateral hemispheric lesions or selective damage to the ascending reticular system (which is functionally connected to the cerebral cortex by intralaminar thalamic nuclei). VS is a syndrome that is considered to be the result of a disconnection of different cortical networks rather than a dysfunction of a single area or a global reduction in cortical metabolism. As revealed by functional imaging studies, clinical recovery is often associated with a functional restoration of cortico-thalamo-cortical connections. Depending on the amount of network restored, patients may regain full consciousness or remain in a MCS. Molecular and neural mediators may indirectly contribute to the above restoration processes owing to their role in the phenomenon of neural synaptic plasticity. Therefore, there is growing interest in the possible effects of drugs that act at the level of the CNS in promoting emergence from DOC. Sporadic cases of dramatic recovery from DOC after the administration of various pharmacological agents, such as baclofen, zolpidem and amantadine, have been recently supported by intriguing scientific observations. Analysis of the reported cases of recovery, with particular attention paid to the condition of the patients and to the association of their improvement with the start of drug administration, suggests that these treatments might have promoted the clinical improvement of some patients. These drugs are from various and diverging classes, but can be grouped into two main categories, CNS stimulants and CNS depressants. Some of these treatments seem to directly encourage a consciousness restoration, while others play a more determinant role in improving cognitive domains, especially in patients with residual cognitive impairment, than in the field of consciousness. Given the great interest recently generated in the scientific community by the increasing number of papers addressing this issue, further investigation of the above treatments, with particular attention paid to their mechanisms of action, the neurotransmitters involved and their effects on cortico-thalamo-cortical circuitry, is needed.	[Pistoia, Francesca; Sara, Marco] Hosp San Raffaele, Postcoma Intens & Rehabil Care Unit, I-03043 Cassino, Italy; [Pistoia, Francesca] Univ Laquila, Dept Internal Med & Publ Hlth, Laquila, Italy; [Mura, Elisa; Govoni, Stefano] Univ Pavia, Dept Expt & Appl Pharmacol, Ctr Excellence Appl Biol, I-27100 Pavia, Italy; [Fini, Massimo] IRCCS San Raffaele Pisana, Rome, Italy	Pistoia, F (corresponding author), Hosp San Raffaele, Postcoma Intens & Rehabil Care Unit, Via Gaetano Di Biasio, I-03043 Cassino, Italy.	pistoiafrancesca@hotmail.com	mura, elisa/ABD-9249-2020; Pistoia, Francesca/AAC-1027-2019; Sara, Marco/AAB-3651-2019; Fini, Massimo/AAA-9948-2021; Govoni, Stefano/K-2965-2015	Govoni, Stefano/0000-0002-7243-6837; PISTOIA, Francesca/0000-0003-0790-4240			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bates D, 2003, CLIN MED, V3, P249; Calabresi P, 2003, NEUROBIOL DIS, V12, P82, DOI 10.1016/S0969-9961(02)00016-5; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2000, S AFR MED J, V90, P68; CLAUSS RP, MED HYPOTHESES; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Coulter DA, 1997, J CHILD NEUROL, V12, pS2, DOI 10.1177/0883073897012001031; Crosby NJ, 2003, COCHRANE DB SYST REV, pCD003467, DOI DOI 10.1002/14651858; D'Aleo G, 1994, Funct Neurol, V9, P189; DeMarchi R, 2005, CAN J NEUROL SCI, V32, P4, DOI 10.1017/S0317167100016826; Fridman EA, 2010, BRAIN INJURY, V24, P636, DOI 10.3109/02699051003610433; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Ketter TA, 2003, J CLIN PSYCHOPHARM, V23, P484, DOI 10.1097/01.jcp.0000088915.02635.e8; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Lanni C, 2009, CELL MOL LIFE SCI, V66, P2985, DOI 10.1007/s00018-009-0055-x; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lee L, 2003, NEUROIMAGE, V19, P457, DOI 10.1016/S1053-8119(03)00062-4; Liepert J, 2008, CURR OPIN NEUROL, V21, P639, DOI 10.1097/WCO.0b013e32831897a3; Lo YL, 2008, ANN NEUROL, V64, P477, DOI 10.1002/ana.21183; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moein H, 2006, CLIN NEUROL NEUROSUR, V108, P539, DOI 10.1016/j.clineuro.2005.09.003; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Plum F, 1972, Contemp Neurol Ser, V10, P1; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; Rogoz Z, 2008, PHARMACOL REP, V60, P817; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sanger DJ, 2004, CNS DRUGS, V18, P9, DOI 10.2165/00023210-200418001-00004; Sanna E, 2002, EUR J PHARMACOL, V451, P103, DOI 10.1016/S0014-2999(02)02191-X; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Sara M, 2010, J NEUROTRAUM, V27, P771, DOI [10.1089/neu.2008.0804, 10.1089/neu.2008-0804]; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Showalter PEC, 2000, BRAIN INJURY, V14, P997; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Worzniak M, 1997, J FAM PRACTICE, V44, P495; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962; Zafonte RD, 1998, BRAIN INJURY, V12, P617	65	47	49	0	16	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1172-7047			CNS DRUGS	CNS Drugs		2010	24	8					625	638		10.2165/11535940-000000000-00000			14	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	640JN	WOS:000281047600001	20658796				2021-06-18	
J	Dickerson, RN; Mitchell, JN; Morgan, LM; Maish, GO; Croce, MA; Minard, G; Brown, RO				Dickerson, Roland N.; Mitchell, Jennifer N.; Morgan, Laurie M.; Maish, George O., III; Croce, Martin A.; Minard, Gayle; Brown, Rex O.			Disparate Response to Metoclopramide Therapy for Gastric Feeding Intolerance in Trauma Patients With and Without Traumatic Brain Injury	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article						metoclopramide; erythromycin; enteral feeding; motility; trauma; traumatic brain injury	CRITICALLY-ILL PATIENTS; EARLY ENTERAL NUTRITION; SEVERE HEAD-INJURY; MECHANICALLY VENTILATED PATIENTS; INTRACRANIAL-PRESSURE; CRITICAL ILLNESS; SEVERITY SCORE; CLINICAL-TRIAL; QT INTERVAL; ERYTHROMYCIN	Patients with traumatic brain injury (TBI) have delayed gastric emptying and often require prokinetic drug therapy to improve enteral feeding tolerance. The authors hypothesized that metoclopramide was less efficacious for improving gastric feeding tolerance for trauma patients with TBI compared to trauma patients Without TBI. A retrospective analysis was conducted of patients admitted to the trauma or neurosurgical intensive care unit who received gastric feeding from January 2006 to April 2008. Gastric feeding intolerance was defined by a gastric residual Volume >200 mL or emesis with abdominal distension or discomfort. Patients with gastric feeding intolerance were given metoclopramide 10 mg intravenously every 6 hours, followed by a dose escalation to 20 mg, and then combination therapy with metoclopramide and erythromycin 250 mg intravenously every 6 hours if intolerance persisted. In total, 882 trauma patients (49% with TBI) were evaluated. TBI patients had a higher incidence of gastric feeding intolerance than those without TBI (18.6% vs 10.4%, P <= .001). Efficacy rates for metoclopramide 10 mg. metoclopramide 20 mg, and metoclopramide-erythromycin were 55%, 62%, and 79%, respectively (P <= .03). Metoclopramide failure occurred in 54% of patients with TBI compared to 35% of patients without TBI, respectively (P <= .02), due to a greater prevalence of tachyphylaxis. Single-drug therapy with metoclopramide was less effective for TBI trauma patients compared to trauma patients without TBI. Combination therapy with erythromycin as first-line therapy for TBI trauma patients with gastric feeding intolerance is indicated if there are no contraindications or significant drug interactions. (JPEN J Parenter Enteral Nutr. 2009;33:646-655)	[Dickerson, Roland N.; Mitchell, Jennifer N.; Brown, Rex O.] Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, Memphis, TN 38163 USA; [Maish, George O., III; Croce, Martin A.; Minard, Gayle] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN 38163 USA; [Morgan, Laurie M.] Reg Med Ctr Memphis, Dept Pharm, Memphis, TN USA	Dickerson, RN (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, 910 Madison Bldg,Room 308, Memphis, TN 38163 USA.	rdickerson@utmem.edu		Dickerson, Roland/0000-0002-2086-6317			Anfinson Theodore J, 2002, Psychopharmacol Bull, V36, P82; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berne JD, 2002, J TRAUMA, V53, P422, DOI 10.1097/00005373-200209000-00004; BLISS DZ, 1992, AM J CLIN NUTR, V55, P753; Bochicchio GV, 2006, JPEN-PARENTER ENTER, V30, P503, DOI 10.1177/0148607106030006503; Chapman MJ, 2007, CURR OPIN CRIT CARE, V13, P187, DOI 10.1097/MCC.0b013e3280523a88; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; Davies AR, 2002, CRIT CARE MED, V30, P586, DOI 10.1097/00003246-200203000-00016; Deehan S, 2002, J NEUROSURG ANESTH, V14, P157, DOI 10.1097/00008506-200204000-00013; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Dickerson RN, 2008, NUTRITION, V24, P536, DOI 10.1016/j.nut.2008.02.008; Esparza J, 2001, INTENS CARE MED, V27, P660, DOI 10.1007/s001340100880; Fruhwald S, 2007, INTENS CARE MED, V33, P36, DOI 10.1007/s00134-006-0452-7; GARRICK T, 1988, GASTROENTEROLOGY, V95, P26, DOI 10.1016/0016-5085(88)90286-7; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; Hawkyard CV, 2007, J ANTIMICROB CHEMOTH, V59, P347, DOI 10.1093/jac/dkl537; Jooste CA, 1999, INTENS CARE MED, V25, P464, DOI 10.1007/s001340050881; Kacker V, 1999, EUR J PHARMACOL, V369, P65, DOI 10.1016/S0014-2999(99)00038-2; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kao CH, 1998, J NUCL MED, V39, P1798; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; Klodell CT, 2000, AM J SURG, V179, P168, DOI 10.1016/S0002-9610(00)00297-X; Kompan L, 1999, INTENS CARE MED, V25, P157, DOI 10.1007/s001340050809; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Landzinski J, 2008, JPEN-PARENTER ENTER, V32, P45, DOI 10.1177/014860710803200145; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liu BA, 2004, NEW ENGL J MED, V351, P1053, DOI 10.1056/NEJMp048192; MacLaren R, 2000, CRIT CARE MED, V28, P438, DOI 10.1097/00003246-200002000-00025; MacLaren R, 2001, CLIN THER, V23, P1855, DOI 10.1016/S0149-2918(00)89081-5; MacLaren R, 2008, JPEN-PARENTER ENTER, V32, P412, DOI 10.1177/0148607108319803; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Marino LV, 2003, BRIT J NEUROSURG, V17, P24, DOI 10.1080/026889031000093708; MCARTHUR CJ, 1995, INTENS CARE MED, V21, P573, DOI 10.1007/BF01700162; McClave Stephen A., 2002, Journal of Parenteral and Enteral Nutrition, V26, pS80, DOI 10.1177/014860710202600613; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; Montejo JC, 1999, CRIT CARE MED, V27, P1447, DOI 10.1097/00003246-199908000-00006; Mutlu GM, 2001, CHEST, V119, P1222, DOI 10.1378/chest.119.4.1222; Neumann DA, 2002, CRIT CARE MED, V30, P1436, DOI 10.1097/00003246-200207000-00006; Nguyen NQ, 2007, CRIT CARE MED, V35, P2561, DOI 10.1097/01.CCM.0000286397.04815.B1; Nguyen NQ, 2007, CRIT CARE MED, V35, P483, DOI 10.1097/01.CCM.0000253410.36492.E9; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Nursal TZ, 2007, J CLIN NEUROSCI, V14, P344, DOI 10.1016/j.jocn.2005.11.011; Ott L, 1999, J NEUROTRAUM, V16, P233, DOI 10.1089/neu.1999.16.233; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; Parlak I, 2005, EMERG MED J, V22, P621, DOI 10.1136/emj.2004.014712; POWER I, 1989, ANAESTHESIA, V44, P563, DOI 10.1111/j.1365-2044.1989.tb11442.x; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8; Ritz MA, 2005, INTENS CARE MED, V31, P949, DOI 10.1007/s00134-005-2663-8; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; STEWART RM, 1995, SURGERY, V117, P68, DOI 10.1016/S0039-6060(05)80232-6; Thor Piotr J, 2003, Med Sci Monit, V9, pCR392; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; van der Voort PHJ, 2001, CRIT CARE, V5, P216, DOI 10.1186/cc1026; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; ZITELLI BJ, 1987, CLIN PEDIATR, V26, P117, DOI 10.1177/000992288702600302	61	47	53	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	NOV-DEC	2009	33	6					646	655		10.1177/0148607109335307			10	Nutrition & Dietetics	Nutrition & Dietetics	514KN	WOS:000271393400009	19892902				2021-06-18	
J	Willmott, C; Ponsford, J; Hocking, C; Schonberger, M				Willmott, Catherine; Ponsford, Jennie; Hocking, Chris; Schoenberger, Michael			Factors Contributing to Attentional Impairments After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						brain injury; attention; information processing speed; working memory	CLOSED-HEAD INJURY; HEALTHY-YOUNG ADULTS; WORKING-MEMORY; DIVIDED ATTENTION; CATECHOLAMINES; DEFICITS; METHYLPHENIDATE; PERFORMANCE; HUMANS; RAT	The aim of the present study was to investigate the contribution of impaired information processing speed and strategic control of attention to performance on attentional tasks after traumatic brain injury (TBI). Forty moderately to severely injured rehabilitation inpatients and 40 healthy controls completed a selection of attentional tasks. Slowed processing speed in the TBI group was identified on the Symbol Digit Modalities Test (SDMT), 2&7 Selective Attention Test (2&7), Selective Attention (SAT), and Four Choice Reaction Time (4CRT) tasks. Impaired working memory was evident on the Letter Number Sequencing (LNS) task. Structural equation modeling revealed that the group difference in RT on the complex SAT was accounted for by slowed speed of processing on the simple SAT, and not working memory. TBI participants made more errors and missed responses on the complex version of the SAT, suggesting impairment in some aspects of strategic control of attention, and appeared unable to benefit from the automatic condition of the 2&7 Test. There was little evidence of deficit on the Sustained Attention to Response Task (SART). The present study provides evidence for a significant contribution of slowed processing speed to impaired performance on attentional tasks after TBI.	[Willmott, Catherine] Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia	Willmott, C (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia.	catherine.willmott@med.monash.edu.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035	Victorian Neurotrauma Initiative; Wenkart Foundation	This project was supported by the Victorian Neurotrauma Initiative and the Wenkart Foundation. We thank the participants who gave so generously of their time and members of the Acquired Brain Injury team at Epworth Rehabilitation.	Arnsten AFT, 2002, PRINCIPLES FRONTAL L, P51, DOI [DOI 10.1093/ACPROF:OSO/9780195134971.003.0004, 10.1093/acprof:oso/9780195134971.003.0004]; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Baddeley A. D., 1986, WORKING MEMORY; BAREGGI SR, 1975, EUR NEUROL, V13, P528, DOI 10.1159/000114709; CLARK CR, 1987, NEUROSCI BIOBEHAV R, V11, P341, DOI 10.1016/S0149-7634(87)80006-4; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; CLARK CR, 1986, PSYCHOPHARMACOLOGY, V90, P35; CLARK CR, 1987, NEUROSCI BIOBEHAV R, V11, P353, DOI 10.1016/S0149-7634(87)80007-6; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dell'Acqua R, 2001, EXP BRAIN RES, V136, P364, DOI 10.1007/s002210000586; Deluca J., 2008, INFORM PROCESSING SP, P265; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fujinaka T, 2003, NEUROL RES, V25, P35, DOI 10.1179/016164103101201094; GRAHAM DI, 1999, REHABILITATION ADULT, P19; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Karakucuk EI, 1997, NEUROPEPTIDES, V31, P259, DOI 10.1016/S0143-4179(97)90057-3; Kinsella G., 2008, INFORM PROCESSING SP, P173; KOELEGA HS, 1993, PSYCHOPHARMACOLOGY, V111, P1, DOI 10.1007/BF02257400; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Markianos M, 1996, ACTA NEUROCHIR, V138, P57, DOI 10.1007/BF01411725; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rogers RD, 1999, PSYCHOPHARMACOLOGY, V146, P482, DOI 10.1007/PL00005494; RUFF R, 1995, RUFF 2 7 SELECTIVE A; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith A., 1991, SYMBOL DIGIT MODALIT; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; TURNER G, 2008, J INT NEUROPSYCH SOC, V14, P125; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VOELBEL G, 2008, J INT NEUROPSYCHO S1, V14, P126; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; WHYTE J, PHYS MED RE IN PRESS; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	58	47	47	0	15	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2009	23	4					424	432		10.1037/a0015058			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	472IA	WOS:000268122600002	19586207				2021-06-18	
J	Leon-Carrion, J; Martin-Rodriguez, JF; Damas-Lopez, J; Martin, JMBY; Dominguez-Morales, MR				Leon-Carrion, Jose; Francisco Martin-Rodriguez, Juan; Damas-Lopez, Jesus; Manuel Barroso y Martin, Juan; Rosario Dominguez-Morales, Maria			Delta-alpha ratio correlates with level of recovery after neurorehabilitation in patients with acquired brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						Functional assessment; Quantitative EEG; Acquired brain injury; Delta-alpha ratio; Neuropsychological rehabilitation; Long-term outcome	ACUTE ISCHEMIC-STROKE; INDEPENDENT COMPONENT ANALYSIS; MINIMALLY CONSCIOUS STATE; QUANTITATIVE EEG; SYMMETRY-INDEX; INPATIENT REHABILITATION; CEREBRAL INFARCTION; CORTICAL RHYTHMS; DIFFUSION; PERFUSION	Objective: To explore the relationship between three QEEG global indexes and their association with functional outcome after neurorehabilitation in non-acute acquired brain injury (ABI) patients (traumatic brain injury and stroke). Methods: Twenty-one adult ABI patients in post-acute phase were studied. Delta-alpha ratio (DAR), Power Ratio Index (PRI) and Mean Brain Symmetry Index (mBSI) were calculated from resting-state EEG taken at admission. These indexes and other clinical variables were correlated with functional recovery achieved after six months of neurorehabilitation. Results: DAR showed the highest strength of association with the functional outcome measure (rho = -0.65, P = 0.002). The other QEEG indexes and clinical variables showed modest non-significant correlations. A posteriori group analysis showed higher DAR in patients with poor recovery as compared to good recovery patients. Conclusions: Functional recovery after neurorehabilitation appears to be associated with a number of clinical and neurophysiological variables. Among the latter, the ratio between delta and alpha may play a significant role in predicting and monitoring functional rehabilitation outcome. Significance: Neurophysiological assessment of ABI patients may be an important tool in monitoring and predicting outcomes after neurorehabilitation. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Leon-Carrion, Jose; Manuel Barroso y Martin, Juan] Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, Seville 41018, Andalucia, Spain; [Leon-Carrion, Jose; Francisco Martin-Rodriguez, Juan; Damas-Lopez, Jesus; Rosario Dominguez-Morales, Maria] Ctr Brain Injury Rehabil CRECER, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, C Camilo Jose Cela S-N, Seville 41018, Andalucia, Spain.	leoncarrion@us.es	Barroso y Martin, Juan Manuel/AAB-9758-2020	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775	Spanish Ministry of Science and Education as part of the National Plan for Scientific Research, Development and Technological Innovation; European Regional Development Fund (ERDF)European Commission [FIT-300100-2005-37, FIT-300100-2006-77]; Fundacion Cajasol de Sevilla	This study has been funded in part by the Spanish Ministry of Science and Education as part of the National Plan for Scientific Research, Development and Technological Innovation (2004-2007), and co-funded by the European Regional Development Fund (ERDF): FIT-300100-2005-37 and FIT-300100-2006-77, and the Fundacion Cajasol de Sevilla.	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Babiloni C, 2004, NEUROIMAGE, V22, P57, DOI 10.1016/j.neuroimage.2003.09.028; Baird AE, 2000, CEREBROVASC DIS, V10, P441, DOI 10.1159/000016105; Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; COBB WA, 1979, ELECTROEN CLIN NEURO, V47, P251, DOI 10.1016/0013-4694(79)90278-5; DASILVA FHL, 1977, NEUROSCI LETT, V6, P237, DOI 10.1016/0304-3940(77)90024-6; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; de Vos CC, 2008, J CLIN NEUROPHYSIOL, V25, P77, DOI 10.1097/WNP.0b013e31816ef725; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DOMINGUEZMORALE.MR, 1999, REV ESP NEUROPSICOL, V1, P105; DOODS TA, 1993, ARCH PHYS MED REHAB, V74, P531; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Finnigan SP, 2004, STROKE, V35, P899, DOI 10.1161/01.STR.0000122622.73916.d2; GALINDOLUCAS A, 2001, REV ESP NEUROPSICOL, V3, P82; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Goldman RI, 2002, NEUROREPORT, V13, P2487, DOI 10.1097/00001756-200212200-00022; Gomez CM, 2006, BRAIN RES, V1107, P151, DOI 10.1016/j.brainres.2006.06.019; Goncalves SI, 2006, NEUROIMAGE, V30, P203, DOI 10.1016/j.neuroimage.2005.09.062; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Hari R, 1997, INT J PSYCHOPHYSIOL, V26, P51, DOI 10.1016/S0167-8760(97)00755-1; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; John ER, 2006, CLIN EEG NEUROSCI, V37, P135, DOI 10.1177/155005940603700210; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Leon Carrion J., 2001, REV ESPANOLA NEUROPS, V3, P58; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Leon-Carrion J, 2008, BRAIN INJURY, V22, P61, DOI 10.1080/02699050701824143; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Machado C, 2004, CLIN EEG NEUROSCI, V35, P116, DOI 10.1177/155005940403500303; Manshanden I, 2002, CLIN NEUROPHYSIOL, V113, P1937, DOI 10.1016/S1388-2457(02)00304-8; Muresanu DF, 2008, J NEUROL SCI, V267, P112, DOI 10.1016/j.jns.2007.10.016; Murri L, 1998, NEUROPHYSIOL CLIN, V28, P249, DOI 10.1016/S0987-7053(98)80115-9; Nadeau SE, 2002, LANCET NEUROL, V1, P126, DOI 10.1016/S1474-4422(02)00044-3; NAGATA K, 1989, ELECTROEN CLIN NEURO, V72, P16, DOI 10.1016/0013-4694(89)90027-8; Niedermeyer E., 2005, ELECTROENCEPHALOGRAP, P339; Niedzwecki CM, 2008, J HEAD TRAUMA REHAB, V23, P209, DOI 10.1097/01.HTR.0000327253.61751.29; NUWER MR, 1987, NEUROLOGY, V37, P1153, DOI 10.1212/WNL.37.7.1153; Prigatano GP, 2000, JAMA-J AM MED ASSOC, V284, P1783, DOI 10.1001/jama.284.14.1783; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P420, DOI 10.1016/0013-4694(83)90224-9; Salenius S, 1995, ELECTROEN CLIN NEURO, V95, P453, DOI 10.1016/0013-4694(95)00155-7; SANDFORD AJ, 1971, BIOL RHYTHMS HUMAN P, P179; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Thatcher RW, 1999, INTRO QUANTITATIVE E, P29; TOLONEN U, 1984, PROG BRAIN RES, V62, P51; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; van Putten MJAM, 2007, CLIN NEUROPHYSIOL, V118, P2362, DOI 10.1016/j.clinph.2007.07.019; van Putten MJAM, 2004, CLIN NEUROPHYSIOL, V115, P1189, DOI 10.1016/j.clinph.2003.12.002	54	47	50	0	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUN	2009	120	6					1039	1045		10.1016/j.clinph.2009.01.021			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	463WT	WOS:000267464800005	19398371				2021-06-18	
J	Ding, JY; Kreipke, CW; Schafer, P; Schafer, S; Speirs, SL; Rafols, JA				Ding, Jamie Y.; Kreipke, Christian W.; Schafer, Patrick; Schafer, Steven; Speirs, Susan L.; Rafols, Jose A.			RETRACTED: Synapse loss regulated by matrix metalloproteinases in traumatic brain injury is associated with hypoxia inducible factor-1 alpha expression (Retracted article. See vol. 1694, pg. 150, 2018)	BRAIN RESEARCH			English	Article; Retracted Publication						Closed-head injury; Hypoxia; MnSOD; Synaptophysin; MMP; Treatment	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; OXIDATIVE STRESS; MMP EXPRESSION; CELL-DEATH; KNOCK-OUT; RAT; PLASTICITY	The present study assessed the role of matrix metalloproteinase-2 (MMP-2) and -9 in synapse loss after traumatic brain injury (TBI) and the role of hypoxia inducible factor-1 alpha (HIF-1 alpha), a transcription factor up-regulated during hypoxia, in the regulation of MMP-2 and -9 expression post-TBI. Adult male Sprague-Dawley rats (n=6 per group, 400 g-425 g) were injury using Marmarou's closed-head acceleration impact model and allowed to survive for 1,4,24 and 48 h. In another set of experiments, 30 min after TBI, animals were treated with Minocrycline (inhibitor of MMPs), or 2-Methoxyestradiol (2ME2, inhibitor of HIF-1 alpha) and sacrificed at 4 h after injury. Relative amounts of synaptophysin, a presynaptic vesicular protein, HIF-1 alpha, as well as MMP-2 and -9 were assessed by real-time PCR and Western blotting. Activity levels of MMP-2 and -9 were determined by zymography. Synaptophysin expression was significantly (p<0.05) decreased at 1 h through 48 h after TBI. A significant increase in gene and protein expressions of HIF-1 alpha, MMP-2 and -9, as well as enzyme activity of MMP-2 and -9 at the same time points was also detected. Inhibition of either MMPs or HIF-1 alpha significantly reversed the TBI-induced decrease in synaptophysin. Inhibition of HIF-1 alpha reduced expression of MMP-2 and -9. This study showed an early detection of a correlation between synaptic loss and MMP expression after TBI. The data also supports a role HIF-1 alpha in the MMP regulatory cascade in synapse loss after TBI, suggesting potential targets for reducing loss of synaptic terminals. Published by Elsevier B.V.	[Ding, Jamie Y.; Kreipke, Christian W.; Schafer, Patrick; Schafer, Steven; Speirs, Susan L.; Rafols, Jose A.] Wayne State Univ, Sch Med, Detroit, MI USA	Rafols, JA (corresponding author), 9312 Scott Hall,540 Canfield St, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39860, R01 NS039860, R01 NS039860-08] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		Agrawal SM, 2008, SEMIN CELL DEV BIOL, V19, P42, DOI 10.1016/j.semcdb.2007.06.003; Bozdagi O, 2007, J NEUROPHYSIOL, V98, P334, DOI 10.1152/jn.00202.2007; BROCK TO, 1987, J NEUROSCI, V7, P931; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carney N, 1999, Evid Rep Technol Assess (Summ), P1; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; DASH PK, 1995, J NEUROSCI, V15, P2030; Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Haddad JJ, 2005, INT IMMUNOPHARMACOL, V5, P461, DOI 10.1016/j.intimp.2004.11.009; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Le NTV, 2007, FRONT BIOSCI, V12, P1475, DOI 10.2741/2161; Leonardo CC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-34; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Li LH, 2008, ACTA NEUROPATHOL, V115, P297, DOI 10.1007/s00401-008-0339-5; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meighan SE, 2006, J NEUROCHEM, V96, P1227, DOI 10.1111/j.1471-4159.2005.03565.x; Meng HD, 2006, BRAIN RES, V1124, P197, DOI 10.1016/j.brainres.2006.09.086; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Ratan RR, 2007, J MOL MED, V85, P1331, DOI 10.1007/s00109-007-0283-1; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; Semchenko V V, 2006, Neurosci Behav Physiol, V36, P613, DOI 10.1007/s11055-006-0065-1; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Swann K, 2007, BRAIN RES, V1129, P26, DOI 10.1016/j.brainres.2006.10.061; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; VON GC, 2003, J NEUROSCI RES, V73, P803; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x	62	47	53	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 1	2009	1268						125	134		10.1016/j.brainres.2009.02.060			10	Neurosciences	Neurosciences & Neurology	444BV	WOS:000265956000013	19285046	Green Accepted			2021-06-18	
J	Herrmann, N; Rapoport, MJ; Rajaram, RD; Chan, F; Kiss, A; Ma, AK; Feinstein, A; McCullagh, S; Lanctot, KL				Herrmann, Nathan; Rapoport, Mark J.; Rajaram, Ryan D.; Chan, Florance; Kiss, Alex; Ma, Andrew K.; Feinstein, Anthony; McCullagh, Scott; Lanctot, Krista L.			Factor Analysis of the Rivermead Post-Concussion Symptoms Questionnaire in Mild-to-Moderate Traumatic Brain Injury Patients	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							DEPRESSION FOLLOWING MILD; VISION-RELATED DISABILITY; MAJOR DEPRESSION; HEAD-INJURY; NEUROPSYCHIATRIC SEQUELAE; PSYCHOLOGICAL DISTRESS; PSYCHIATRIC-DISORDERS; SOMATIC SYMPTOMS; SERTRALINE; SCALE	Posttraumatic brain injury patients with depressive symptoms were compared with nondepressed mild and moderate traumatic brain injury (TBI) patients based on their scores on the Rivermead Post-Concussion Symptoms Questionnaire (RPCSQ). A factor analysis demonstrated that the items of the RPCSQ loaded into three factors: mood and cognition, general somatic, and visual somatic symptom groups. Factor scores based on this model were calculated for each group and it was found that depressed subjects reported a greater severity of all three symptom groups compared to nondepressed patients. These results suggest that depression post-TBI may influence patient perception of postconcussion	[Lanctot, Krista L.] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada	Lanctot, KL (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Psychiat, Rm FG05,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020; Lanctot, Krista L./AAY-4820-2020	Lanctot, Krista L./0000-0001-7024-6637	Ontario Mental Health Foundation (OMHF); Ontario Neurotrauma Foundation (ONF)	We would like to acknowledge the support of the Ontario Mental Health Foundation (OMHF) and the Ontario Neurotrauma Foundation (ONF).	Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; de Coster L, 2005, INT J GERIATR PSYCH, V20, P358, DOI 10.1002/gps.1290; de Jonge P, 2006, AM J PSYCHIAT, V163, P138, DOI 10.1176/appi.ajp.163.1.138; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Deb S, 1999, AM J PSYCHIAT, V156, P374; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; First M.B., 1996, STRUCTURED CLIN INTE; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Katon W, 2001, ANN INTERN MED, V134, P917, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00017; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Rhee SH, 1999, ARTHRIT CARE RES, V12, P392, DOI 10.1002/1529-0131(199912)12:6<392::AID-ART7>3.0.CO;2-9; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Rutner D, 2006, BRAIN INJURY, V20, P1079, DOI 10.1080/02699050600909904; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Walker JG, 2006, BRIT J HEALTH PSYCH, V11, P303, DOI 10.1348/135910705X68681; Walker JG, 2006, CLIN EXP OPHTHALMOL, V34, P734, DOI 10.1111/j.1442-9071.2006.01340.x; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Waraich P, 2004, CAN J PSYCHIAT, V49, P124, DOI 10.1177/070674370404900208; Watkins LL, 2003, AM HEART J, V146, P48, DOI 10.1016/S0002-8703(03)00083-8; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	41	47	47	0	10	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	MAY	2009	21	2					181	188					8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	472SL	WOS:000268152300011	19622689	Bronze			2021-06-18	
J	Mamere, AE; Saraiva, LAL; Matos, ALM; Carneiro, AAO; Santos, AC				Mamere, A. E.; Saraiva, L. A. L.; Matos, A. L. M.; Carneiro, A. A. O.; Santos, A. C.			Evaluation of Delayed Neuronal and Axonal Damage Secondary to Moderate and Severe Traumatic Brain Injury Using Quantitative MR Imaging Techniques	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; APPARENT DIFFUSION-COEFFICIENT; WHITE-MATTER LESIONS; CLOSED-HEAD INJURY; MULTIPLE-SCLEROSIS; INVIVO DETERMINATION; ALZHEIMERS-DISEASE; VEGETATIVE STATE; CORPUS-CALLOSUM; TRANSFER RATIO	BACKGROUND AND PURPOSE: Traumatic brain injury (TBI) is a classic model of monophasic neuronal and axonal injury, in which tissue damage mainly occurs at the moment of trauma, There is some evidence of delayed progression of the neuronal and axonal loss. Our purpose was to test the hypothesis that quantitative MR imaging techniques can estimate the biologic changes secondary to delayed neuronal and axonal loss after TBI. MATERIALS AND METHODS: Nine patients (age, 11-28 years; 5 male) who sustained a moderate or severe TBI were evaluated at a mean of 3.1 years after trauma. We applied the following techniques: bicaudate (BCR) and bifrontal (BFR) ventricle-to-brain ratios; T2 relaxometry; magnetization transfer ratio (MTR); apparent diffusion coefficient (ADC); and proton spectroscopy, by using an N-acetylaspartate/creatine (NAA/Cr) ratio measured in normal-appearing white matter (NAWM) and the corpus callosum (CC). The results were compared with those of a control group. RESULTS: BCR and BFR mean values were significantly increased (P <= 05) in patients due to secondary subcortical atrophy; increased T2 relaxation time was observed in the NAWM and CC, reflecting an increase in water concentration secondary to axonal loss. Increased ADC mean values and reduced MTR mean values were found in the NAWM and CC, showing damage in the myelinated axonal fibers; and decreased NAA/Cr ratio mean values were found in the CC, indicating axonal loss. CONCLUSIONS: These quantitative MR imaging techniques could noninvasively demonstrate the neuronal and axonal damage in the NAWM and CC of human brains, secondary to moderate or severe TBI.	[Mamere, A. E.] Canc Hosp Barretos Fundacao Pio XII, Dept Radiol, Sao Paulo, Brazil; [Saraiva, L. A. L.; Matos, A. L. M.; Carneiro, A. A. O.; Santos, A. C.] Univ Sao Paulo, Dept Radiol, Sao Paulo, Brazil	Mamere, AE (corresponding author), R Antenor Duarte Vilella 1331, BR-14784400 Barretos, SP, Brazil.	mamere@uol.com.br	Mamere, Augusto/A-4509-2013; Santos, Antonio/F-5419-2012; Carneiro, Antonio Adilton O./F-3557-2012	Carneiro, Antonio Adilton O./0000-0002-1752-7170			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; ARMSPACH JP, 1991, MAGN RESON IMAGING, V9, P107, DOI 10.1016/0730-725X(91)90104-T; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bagley LJ, 1999, AM J NEURORADIOL, V20, P977; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Conti AC, 1998, J NEUROSCI, V18, P5663; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LARSSON HBW, 1989, MAGNET RESON MED, V11, P337, DOI 10.1002/mrm.1910110308; Mascalchi M, 2005, RADIOL MED, V109, P155; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Papanikolaou N, 2004, EUR RADIOL, V14, P115, DOI 10.1007/s00330-003-1946-0; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	42	47	48	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2009	30	5					947	952		10.3174/ajnr.A1477			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	446PG	WOS:000266133000014	19193759	Other Gold, Green Published			2021-06-18	
J	Clark, ME; Scholten, JD; Walker, RL; Gironda, RJ				Clark, Michael E.; Scholten, Joel D.; Walker, Robyn L.; Gironda, Ronald J.			Assessment and Treatment of Pain Associated with Combat-Related Polytrauma	PAIN MEDICINE			English	Article						Chronic Pain; Trauma; Posttraumatic Stress Syndrome; Psychosocial Factors	NURSING-HOME RESIDENTS; TRAUMATIC BRAIN-INJURY; HETEROTOPIC OSSIFICATION; BACK-PAIN; HEADACHE; MIGRAINE; PHANTOM; EXPERIENCE; MANAGEMENT; AVOIDANCE	Due to the high rates of blast injuries sustained during operations in Iraq and Afghanistan, the number of soldiers returning with massive and multiple wounds is unprecedented. While casualty survival rates have improved dramatically, the extent and impact of these wounds on soldiers' functioning pose unique challenges for their rehabilitation. Pain is highly prevalent in these individuals with polytrauma injuries and is a source of suffering, as well as an impediment to rehabilitation. However, there are a number of obstacles to effective pain treatment in this group of war-injured, including their multiple and severe injuries, the high prevalence of brain injuries, cognitive impairments and emotional distress, the prolonged and intensive rehabilitation process, and the frequent need for repeated follow-up surgeries. As a result, we believe that a comprehensive, interdisciplinary approach to pain treatment is required. In this article we describe the model of pain care that has evolved at the Tampa Polytrauma Rehabilitation Center, which incorporates medical, rehabilitative, cognitive-behavioral, and interventional treatments targeting pain intensity as well as pain-related impairments and coping. We include a case study illustrating some key aspects of our approach.	[Clark, Michael E.; Walker, Robyn L.; Gironda, Ronald J.] James A Haley Vet Affairs Hosp, Chron Pain Rehabil Program, Tampa, FL USA; [Clark, Michael E.; Scholten, Joel D.; Gironda, Ronald J.] Univ S Florida, Tampa, FL USA; [Scholten, Joel D.] James A Haley Vet Affairs Hosp, Polytrauma Rehabil Ctr, Tampa, FL USA	Clark, ME (corresponding author), Chron Pain Rehabil Program 2CW, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Michael.Clark8@va.gov					Asmundson GJG, 1997, PAIN, V69, P231, DOI 10.1016/S0304-3959(96)03288-5; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Bigal ME, 2008, HEADACHE, V48, P1157, DOI 10.1111/j.1526-4610.2008.01217.x; Bigal ME, 2008, NEUROLOGY, V71, P1821, DOI 10.1212/01.wnl.0000335946.53860.1d; BRAGANZA RJ, 2006, MANUAL PAIN MANAGEME, P231; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Buckenmaier CC, 2005, REGION ANESTH PAIN M, V30, P202, DOI 10.1016/j.rapm.2004.10.005; Castillo RC, 2006, PAIN, V124, P321, DOI 10.1016/j.pain.2006.04.020; CLARK ME, 2006, 2 ANN PAIN AW DAY BI; Clark ME, 2006, WEINERS PAIN MANAGEM, P99; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; Closs SJ, 2004, J PAIN SYMPTOM MANAG, V27, P196, DOI 10.1016/j.jpainsymman.2003.12.010; Crombez G, 1998, BEHAV MODIF, V22, P62, DOI 10.1177/01454455980221004; Cullen N, 2007, BRAIN INJURY, V21, P215, DOI 10.1080/02699050701202027; Davies Elizabeth, 2004, Nurs Stand, V19, P33; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; Fouquet B, 2003, BEST PRACT RES CL RH, V17, P1, DOI 10.1016/S1521-6942(02)00098-0; GARLAND DE, 1981, CLIN ORTHOP RELAT R, P162; Gatchel RJ, 2004, AM PSYCHOL, V59, P795, DOI 10.1037/0003-066X.59.8.795; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; HOLROYD KA, 1990, PAIN, V42, P1, DOI 10.1016/0304-3959(90)91085-W; Jackisch Christian, 2002, Clin Breast Cancer, V3, P276, DOI 10.3816/CBC.2002.n.031; Jackson VC, 2004, ICON-INT J CONST LAW, V2, P91, DOI 10.1093/icon/2.1.91; Jensen TS, 2003, PAIN, V102, P1, DOI 10.1016/S0304-3959(03)00006-X; Jordan KD, 1998, SPINE, V23, P2110, DOI 10.1097/00007632-199810010-00014; Kalra R, 2008, FED PRACT, V25, P36; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Ketz AK, 2008, ARCH PHYS MED REHAB, V89, P1127, DOI 10.1016/j.apmr.2007.11.037; Koltyn KF, 1998, BRIT J SPORT MED, V32, P20, DOI 10.1136/bjsm.32.1.20; Kooijman CM, 2000, PAIN, V87, P33, DOI 10.1016/S0304-3959(00)00264-5; Machin P, 1998, CLIN J PAIN, V14, P290, DOI 10.1097/00002508-199812000-00004; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P365; Manz B D, 2000, Pain Manag Nurs, V1, P106, DOI 10.1053/jpmn.2000.19332; Modi S, 2006, AM FAM PHYSICIAN, V73, P72; MYSIW WJ, 1993, AM J PHYS MED REHAB, V72, P184, DOI 10.1097/00002060-199308000-00002; OSGOOD PF, 1990, ACUTE MANAGEMENT BUR, P201; Pape HC, 2001, J ORTHOP TRAUMA, V15, P229, DOI 10.1097/00005131-200105000-00001; Penzien DB, 2002, APPL PSYCHOPHYS BIOF, V27, P163, DOI 10.1023/A:1016247811416; Phillip D, 2007, CEPHALALGIA, V27, P1, DOI 10.1111/j.1468-2982.2007.01239.x; *REH ACCR COMM, 2002, STAND MAN MED REH; ROBERTS CS, 1990, CLIN METHODS HIST PH, P259; Schley MT, 2008, J TRAUMA, V65, P858, DOI 10.1097/TA.0b013e31812eed9e; Sieben JM, 2002, EUR J PAIN, V6, P229, DOI 10.1053/eujp.2002.0341; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Smith D, 2002, CLIN REHABIL, V16, P1, DOI 10.1191/0269215502cr461oa; Tassorelli C, 2008, CEPHALALGIA, V28, P1023, DOI 10.1111/j.1468-2982.2008.01639.x; Tsai Pao-Feng, 2006, J Nurs Manag, V14, P90, DOI 10.1111/j.1365-2934.2006.00560.x; Veterans Health Administration, 2005, VHA HDB; *VHA NAT PAIN MAN, 2006, CONS STAT ASS PAIN P; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wu N, 2005, MED CARE, V43, P934, DOI 10.1097/01.mlr.0000173595.66356.12	55	47	51	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	APR	2009	10	3					456	469		10.1111/j.1526-4637.2009.00589.x			14	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	431QI	WOS:000265077500007	19416437	Bronze			2021-06-18	
J	Greve, K; Heinly, M; Bianchini, K; Love, J				Greve, Kevin W.; Heinly, Matthew T.; Bianchini, Kevin J.; Love, Jeffrey M.			Malingering detection with the Wisconsin Card Sorting Test in mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		Wisconsin Card Sorting Test; Malingering; Traumatic brain injury; Neuropsychological assessment	VERBAL-LEARNING TEST; NEUROCOGNITIVE DYSFUNCTION; CLASSIFICATION ACCURACY; PATIENT SAMPLES; HEAD-INJURY; PERFORMANCE; SPECIFICITY; INDICATORS; SENSITIVITY	This study evaluates the ability of several Wisconsin Card Sorting Test (WCST; Psychological Assessment Resources, 1990) variables to detect malingering in mild traumatic brain injury (TBI). The sample consisted of 373 TBI patients and 766 general clinical patients. Classification accuracy for seven indicators is reported across a range of injury severity and scores levels. Overall, most WCST scores were ineffective in discriminating malingering from non-malingering mild TBI patients. Failure-to-Maintain-Set, the Suhr Boyer formula, and the King et al. formula detected about 30% of malingerers at cutoffs associated with a false positive error rate of 11%. The clinical interpretation and use of these indicators are discussed.	[Greve, Kevin W.; Heinly, Matthew T.; Bianchini, Kevin J.; Love, Jeffrey M.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Heinly, Matthew T.; Bianchini, Kevin J.; Love, Jeffrey M.] Jefferson Neurobehav Grp, Metairie, LA USA	Greve, K (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; BINDER LM, 1993, PORTLAND DIGIT RECOG; CONDER R, 1992, MANUAL COMPUTERIZED; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; CURTIS KL, CLIN NEUROP IN PRESS; Donders J, 1999, ARCH PHYS MED REHAB, V80, P346, DOI 10.1016/S0003-9993(99)90150-8; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P., 1996, WORD MEMORY TEST USE; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2005, ARCH CLIN NEUROPSYCH, V20, P355, DOI 10.1016/j.acn.2004.09.004; Greve KW, 2002, ASSESSMENT, V9, P271, DOI 10.1177/1073191102009003006; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; GREVE KW, 2007, EVALUATION MALINGERI, P171; Heaton R., 1981, MANUAL WISCONSIN CAR; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Hilsabeck RC, 2001, ARCH CLIN NEUROPSYCH, V16, P669, DOI 10.1016/S0887-6177(00)00077-9; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; KNIGHT JA, 1986, 94 M AM PSYCH ASS WA; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2007, REFINING DIAGNOSTIC; Miller A., 2000, CLIN NEUROPSYCHOLOGI, V2, P141; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 2004, EVALUATION MALINGERE; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; *PSYCH ASS RES, 1990, WISC CARD SORT TEST; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Warrington EK., 1984, RECOGNITION MEMORY T; Williamson D. J., 2003, J FORENSIC NEUROPSYC, V3, P19	41	47	47	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					343	362	PII 793788043	10.1080/13854040802054169			20	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000011	18609328				2021-06-18	
J	Solomon, GS; Haase, RF				Solomon, Gary S.; Haase, Richard F.			Biopsychosocial characteristics and neurocognitive test performance in National Football League players: An initial assessment	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neurocognitive testing; sports concussion; mild traumatic brain injury; ImPACT; professional football athletes	SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; CONCUSSION SYMPTOMS; SPORTS; VALIDATION; HISTORY; SCORES; IMPACT	The use of neurocognitive testing in the assessment of professional athletes sustaining sports-related concussions has become widespread over the past decade. Baseline neurocognitive testing is now a requirement for athletes in the National Football League (NFL). We present preliminary normative data on a computer based neurocognitive test (Immediate Post Concussion Assessment and Cognitive Testing: ImPACT) for 159 NFL athletes. Also included are summary data on basic biopsychosocial characteristics, including medical, psychiatric, chemical dependency, concussion, learning disability/attention deficit disorder, and symptom variables, and the relevance of each to baseline neurocognitive test scores. (C) 2008 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Solomon, Gary S.] Psychiat Consultants, Nashville, TN 37203 USA; [Haase, Richard F.] SUNY Albany, Albany, NY 12222 USA	Solomon, GS (corresponding author), Psychiat Consultants, 310 25th Ave N,Suite 309, Nashville, TN 37203 USA.	Gssolomon1@yahoo.com	Solomon, Gary/K-9011-2019				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barth JT., 1989, MILD HEAD INJURY, P257; Belsley D, 1980, REGRESSION DIAGNOSTI; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Casson IR, 2008, NEUROSURGERY, V62, P204, DOI 10.1227/01.NEU.0000311079.65895.3E; *CDCP, 2008, NUMB RAT TRAUM BRAIN; CERNICH A, 2007, ARCH CLIN NEUROPSYCH, V22, P91; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; COHEN J, 2003, MULTIPLE CORRELATION; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DUCKRO PN, 1989, CEPHALALGIA, V9, P199, DOI 10.1046/j.1468-2982.1989.0903199.x; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; IVERSON GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Johnson RA, 1998, APPL MULTIVARIATE ST; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KRYST S, 1994, HEADACHE, V34, P344, DOI 10.1111/j.1526-4610.1994.hed3406344.x; LOVELL M, 2008, COMMUNICATION   0428; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell M., 2002, IMPACT CONCUSSION MA; Lovell M.R., 2004, TRAUMATIC BRAIN INJU; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; MYERS RH, 2002, GEN LINER MODELS; National Institute of Mental Health, 2008, STAT; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen D., 2006, AM J SPORTS MED, V34, P1; Wilens E, 2004, JAMA-J AM MED ASSOC, V292, P619, DOI 10.1001/jama.292.5.619	45	47	47	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2008	23	5					563	577		10.1016/j.acn.2008.05.008			15	Psychology, Clinical; Psychology	Psychology	351HN	WOS:000259415400009	18614333	Bronze			2021-06-18	
J	Stein, DM; Dutton, RP; Hess, JR; Scalea, TM				Stein, Deborah M.; Dutton, Richard P.; Hess, John R.; Scalea, Thomas M.			Low-dose recombinant factor VIIa for trauma patients with coagulopathy	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article; Proceedings Paper	65th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	SEP 28, 2006	New Orleans, LA	Eastern Assoc Surg Trauma		trauma; coagulopathy; traumatic brain injury; thromboembolic complications	ACTIVATED FACTOR-VII; LIFE-THREATENING HEMORRHAGE; JEHOVAH-WITNESS PATIENTS; COAGULATION-FACTOR VIIA; CENTRAL-NERVOUS-SYSTEM; SEVERE THROMBOCYTOPENIA; PROTHROMBIN TIME; RAPID CORRECTION; WARFARIN; INJURY	Introduction: Coagulopathy in injured patients is common and is generally treated with fresh frozen plasma (FFP). Response can be variable, thus complete correction may take hours and require large volumes of fluids. High-dose recombinant factor Vila (FVIIa, Novoseven, Novo Nordisk, Bagsvaerd, Denmark) has been used off-label to treat severe coagulopathy following trauma. Expense has limited use. Recently, we began administering low dose FVIIa (1.2 mg) to patients with mild to moderate coagulopathy after trauma, hypothesising that it would be effective and safe. Patients and methods: We retrospectively reviewed consecutive patients who received a low dose of 1.2 mg of FVIIa over a 2-year period. Factor Vila is administered after approval by a gatekeeper at the discretion of the treating physician. Demographics, injury and laboratory data were abstracted as were indications for use, source of coagulopathy, effectiveness, and complications. A two-tailed paired t-test was used to determine significant changes in coagulation parameters and blood product utilisation. Results: Eighty-one patients received 84 low doses of FVIIa. The mean age of the patients was 51 (+/- 22) with a mean ISS of 29 (+/- 11). Seventy-three per cent were mate and 67% had a traumatic brain injury (TBI) as their primary injury. The aetiology of the coagulopathy in the study population included; TBI (40%), warfarin use (22%), and cirrhosis (13%). Mean prothrombin time (PT) felt from 17.0 s (+/- 3.2) to 10.6 s (+/- 1.4) (p < 0.0001). All patients had a good clinical response with no bleeding complications. Utilisation of packed red blood cells and fresh frozen plasma were significantly Less in the 24 h after FVIIa administration as compared to the 24 h prior. Subsequent thromboembolic events were observed in 12 of the 81 patients (15%) and included; cerebrovascular accident (CVA) (6), mesenteric thrombosis (2), myocardial. infarction (MI) (1), pulmonary embolism/deep venous thrombosis (PE/DVT) (2), and atrial. thrombus (1). Only four of these events were thought to be related to the FVIIa administration, with two of the four contributing to a lethal outcome. Conclusions: Low dose FVIIa rapidly and effectively treats mild to moderate coagulopathy following injury. This low dose (1.2 mg) FVIIa is the smallest available unit dose. It costs approximately the same as 8 units of plasma and may be cost-effective in patients who require high volume factor administration. Low dose FVIIa may be effective in coagulopathic trauma patients who are not in shock but require rapid normalisation of clotting function. (C) 2008 Elsevier Ltd. All rights reserved.	[Stein, Deborah M.] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Div Crit Care,Program Trauma,Sch Med, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Div Crit Care,Program Trauma,Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu; rdutton@umaryland.edu; jhess@umm.edu; tscalea@umm.edu	Hess, John R./K-4001-2013	Hess, John R./0000-0001-8596-4420; Stein, Deborah/0000-0003-3683-3963			Barnes C, 2005, TRANSFUSION MED, V15, P145, DOI 10.1111/j.0958-7578.2005.00564.x; Bernstein DE, 1997, GASTROENTEROLOGY, V113, P1930, DOI 10.1016/S0016-5085(97)70013-1; Berntorp E, 2000, BLOOD COAGUL FIBRIN, V11, pS113, DOI 10.1097/00001721-200004001-00021; Billio A, 2002, BLOOD, V100, p83B; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Culic S, 2003, BRIT J HAEMATOL, V120, P909, DOI 10.1046/j.1365-2141.2003.04151_2.x; Viana JD, 2006, TRANSPL P, V38, P818, DOI 10.1016/j.transproceed.2006.01.045; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Dutton RP, 2003, J CLIN ANESTH, V15, P184, DOI 10.1016/S0952-8180(03)00034-5; Eikelboom JW, 2003, BLOOD COAGUL FIBRIN, V14, P713, DOI 10.1097/00001721-200312000-00004; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Geeraedts LMG, 2005, INJURY, V36, P495, DOI 10.1016/j.injury.2004.08.001; Gerotziafas GT, 2002, AM J HEMATOL, V69, P219, DOI 10.1002/ajh.10056; Haan J, 2005, AM SURGEON, V71, P414; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hedner U, 1990, Blood Coagul Fibrinolysis, V1, P307, DOI 10.1097/00001721-199008000-00009; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jabbour N, 2005, AM SURGEON, V71, P175; Jeffers L, 2002, GASTROENTEROLOGY, V123, P118, DOI 10.1053/gast.2002.34164; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Khan AZ, 2005, AM J SURG, V189, P331, DOI 10.1016/j.amjsurg.2004.11.021; Klamroth R, 2002, BLOOD, V100, p77B; Levi M, 2005, CRIT CARE MED, V33, P883, DOI 10.1097/01.CCM.0000159087.85970.38; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lodge JPA, 2005, ANESTHESIOLOGY, V102, P269, DOI 10.1097/00000542-200502000-00006; LODGE P, 2003, J HEPATOL, V36, P177; Martin S, 2002, PROF ENG, V15, P20; Martinowitz U, 2001, J TRAUMA, V51, P431, DOI 10.1097/00005373-200109000-00002; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mindikoglu AL, 2003, DIGEST DIS SCI, V48, P1130, DOI 10.1023/A:1023777031589; Mindikoglu AL, 2003, CHEST, V123, P956, DOI 10.1378/chest.123.3.956; Minniti C, 2001, BLOOD, V98, p62B; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; O'Connell NM, 2003, TRANSFUSION, V43, P1711, DOI 10.1046/j.0041-1132.2003.00577.x; Pardo M, 2003, WORLD J SURG, V27, P758, DOI 10.1007/s00268-003-6922-y; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Pathak A, 2005, Neurol India, V53, P178; Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2; Romagnoli S, 2006, ANESTH ANALG, V102, P1320, DOI 10.1213/01.ane.0000209023.96418.e5; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Surudo T, 2003, TRANSPL P, V35, P2323, DOI 10.1016/S0041-1345(03)00759-0; Tanaka KA, 2003, ANESTHESIOLOGY, V98, P1513, DOI 10.1097/00000542-200306000-00034; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Waddington DP, 2002, BRIT J HAEMATOL, V119, P286, DOI 10.1046/j.1365-2141.2002.381113.x; Watson HG, 2002, BLOOD, V100, p78B	51	47	48	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2008	39	9					1054	1061		10.1016/j.injury.2008.03.032			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	352TM	WOS:000259520300013	18656871				2021-06-18	
J	Ruchelsman, DE; Tejwani, NC; Kwon, YW; Egol, KA				Ruchelsman, David E.; Tejwani, Nirmal C.; Kwon, Young W.; Egol, Kenneth A.			Open reduction and internal fixation of capitellar fractures with headless screws	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							CORONAL SHEAR FRACTURES; DISTAL END; HUMERUS	Background: The outcome of operatively treated capitellar fractures has not been reported frequently. The purpose of the present study was to evaluate the clinical, radiographic, and functional outcomes following open reduction and internal fixation of capitellar fractures that were treated with a uniform surgical approach in order to further define the impact on the outcome of fracture type and concomitant lateral column osseous and/or ligamentous injuries. Methods: A retrospective evaluation of the upper extremity database at our institution identified sixteen skeletally mature patients (mean age, 40 +/- 17 years) with a closed capitellar fracture. In all cases, an extensile lateral exposure and articular fixation with buried cannulated variable-pitch headless compression screws was performed at a mean of ten days after the injury. Clinical, radiographic, and elbow-specific outcomes, including the Mayo Elbow Performance Index, were evaluated at a mean of 27 +/- 19 months postoperatively. Results: Six Type-I, two Type-III, and eight Type-IV fractures were identified with use of the Bryan and Morrey classification system. Four of five ipsilateral radial head fractures occurred in association with a Type-IV fracture. The lateral collateral ligament was intact in fifteen of the sixteen elbows. Metaphyseal comminution was observed in association with five fractures (including four Type-IV fractures and one Type-III fracture). Supplemental mini-fragment screws were used for four of eight Type-IV fractures and one of two Type-III fractures. All fractures healed, and no elbow had instability or weakness. Overall, the mean ulnohumeral motion was 123 degrees (range, 70 degrees to 150 degrees). Fourteen of the sixteen patients achieved a functional arc of elbow motion, and all patients had full forearm rotation. The mean Mayo Elbow Performance Index score was 92 +/- 10 points, with nine excellent results, six good results, and one fair result. Patients with a Type-IV fracture had a greater magnitude of flexion contracture (p = 0.04), reduced terminal flexion (p = 0.02), and a reduced net ulnohumeral arc (p = 0.01). An ipsilateral radial head fracture did not appear to affect ulnohumeral motion or the functional outcome. Conclusions: Despite the presence of greater flexion contractures at the time of follow-up in elbows with Type-IV fractures or fractures with an ipsilateral radial head fracture, good to excellent outcomes with functional ulnohumeral motion can be achieved following internal fixation of these complex fractures. Type-IV injuries may be more common than previously thought; such fractures often are associated with metaphyseal comminution or a radial head fracture and may require supplemental fixation. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.	[Ruchelsman, David E.; Tejwani, Nirmal C.; Kwon, Young W.; Egol, Kenneth A.] NYU, Hosp Joint Dis, Dept Orthopaed Surg, New York, NY 10003 USA	Ruchelsman, DE (corresponding author), NYU, Hosp Joint Dis, Dept Orthopaed Surg, 301 E 17th St,14th Floor, New York, NY 10003 USA.	David.Ruchelsman@nyumc.org; Nirmal.Tejwani@nyumc.org; Young.Kwon@nyumc.org; egolk01@nyumc.org		Tejwani, Nirmal/0000-0001-8578-6556; Kwon, Young/0000-0003-2465-9945			ALVAREZ E, 1975, J BONE JOINT SURG AM, V57, P1093, DOI 10.2106/00004623-197557080-00010; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; BROBERG MA, 1987, CLIN ORTHOP RELAT R, P109; Bryan R.S, 1985, ELBOW ITS DISORDERS, P325; Doornberg JN, 2007, J BONE JOINT SURG AM, V89A, P1524, DOI 10.2106/JBJS.F.00369; Dubberley JH, 2006, J BONE JOINT SURG AM, V88A, P46, DOI 10.2106/JBJS.D.02954; DUSHUTTLE RP, 1985, J TRAUMA, V25, P317, DOI 10.1097/00005373-198504000-00006; Elkowitz SJ, 2002, J ORTHOP TRAUMA, V16, P503, DOI 10.1097/00005131-200208000-00009; Elkowitz Stuart J, 2003, Bull Hosp Jt Dis, V61, P123; FOWLES JV, 1974, J BONE JOINT SURG AM, VA 56, P794, DOI 10.2106/00004623-197456040-00013; Goodman HJ, 2005, BULL HOSP JT DIS, V62, P85; GRANTHAM SA, 1981, CLIN ORTHOP RELAT R, P262; Imatani J, 2001, J SHOULDER ELB SURG, V10, P554, DOI 10.1067/mse.2001.118005; King GJW, 1999, J SHOULDER ELB SURG, V8, P351; MA YZ, 1984, CLIN ORTHOP RELAT R, P17; Mahirogullari M, 2006, J HAND SURG-BRIT EUR, V31B, P320, DOI 10.1016/j.jhsb.2006.02.002; Matelic TM, 1996, J ORTHOP TRAUMA, V10, P1, DOI 10.1097/00005131-199601000-00001; McKee MD, 1996, J BONE JOINT SURG AM, V78A, P49, DOI 10.2106/00004623-199601000-00007; Mighell MA, 2006, J ORTHOP TRAUMA, V20, P699, DOI 10.1097/01.bot.0000246411.33047.80; Morrey BF, 1985, ELBOW ITS DISORDERS, V3rd, P73; Ochner RS, 1996, J TRAUMA, V40, P199, DOI 10.1097/00005373-199602000-00005; ODRISCOLL SW, 1992, CLIN ORTHOP RELAT R, P186; Ring D, 2003, J BONE JOINT SURG AM, V85A, P232, DOI 10.2106/00004623-200302000-00008; Sano S, 2005, J SHOULDER ELB SURG, V14, P307, DOI 10.1016/j.jse.2004.09.005; Stamatis E, 2003, J ORTHOP TRAUMA, V17, P279, DOI 10.1097/00005131-200304000-00006; 1996, J ORTHOP TRAUMA S1, V10, pR5	26	47	53	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN	2008	90A	6					1321	1329		10.2106/JBJS.G.00940			9	Orthopedics; Surgery	Orthopedics; Surgery	309JL	WOS:000256456400020	18519327				2021-06-18	
J	Lima, DPD; Simao, C; Abib, SDV; de Figueiredo, LFP				de Almeida Lima, Daniela Paoli; Simao Filho, Charles; Vieira Abib, Simone de Campos; de Figueiredo, Luiz F. Poli			Quality of life and neuropsychological changes in mild head trauma - Late analysis and correlation with S100B protein and cranial CT scan performed at hospital admission	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						mild head trauma; S100B; cerebral concussion; anxiety; depression; quality of life	BRAIN-INJURY; CONCUSSION; SYMPTOMS	Introduction: mild head trauma (MHT) is defined as a transient neurological deficit after trauma with a history of impairment or loss of consciousness lasting less than 15 min and/or posttraumatic amnesia, and a Glasgow Coma Scale between 13 and 15 on hospital admission. We evaluated 50 MHT patients 18 months after the trauma, addressing signs and symptoms of post-concussion syndrome, quality of life and the presence of anxiety and depression. We correlate those findings with the S100B protein levels and cranial CT scan performed at hospital admission after the trauma. Method: patients were asked to fill out questionnaires to assess quality of life (SF36), anxiety and depression (HADS), and signs and symptoms of post-concussion syndrome. For the control group, we asked the patient's household members, who had no history of head trauma of any type, to answer the same questionnaires for comparison. Results: total quality of life index for patients with MHT was 58.16 (+/-5), lower than the 73.47 (+/-4) presented by the control group. Twenty patients (55.2%) and four (11.1%) controls were depressed. Seventeen patients (47.2%) presented anxiety, whereas only eight (22.2%) controls were considered anxious. Victims of MHT complained more frequently of loss of balance, dry mouth, pain in the arms, loss of memory and dizziness than their respective controls (p < 0.05). We found no correlation between the presence of these signs and symptoms, quality of life, presence of anxiety and depression with S100B protein levels or with presence of injury in the cranial CT performed at hospital admission. Conclusion: MHT is associated with a higher incidence of post-concussion syndrome symptoms, lower quality of life and anxiety than their respective controls even 18 months after the trauma. (C) 2007 Elsevier Ltd. All rights reserved.	[de Almeida Lima, Daniela Paoli; Simao Filho, Charles; Vieira Abib, Simone de Campos; de Figueiredo, Luiz F. Poli] Univ Sao Paulo, Sch Med, Div Res, Inst Heart,InCor,Sao Paulo & Joao XXIII Trauma Ct, Belo Horizonte, MG, Brazil	de Figueiredo, LFP (corresponding author), Univ Sao Paulo, Div Appl Physiol, Av Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.	tpoli@uol.com.br	Simao, Fabricio/A-4621-2013	Simao, Fabricio/0000-0002-6229-7618; Abib, Simone/0000-0001-9675-0380			Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Ciconelli RM, 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIFIGUEIREDO LFP, 2006, CLINICS, V61, P41; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fleminger S, 1998, J NEUROL NEUROSUR PS, V65, P809, DOI 10.1136/jnnp.65.6.809; Heck J., 2001, SPORTS MED UPDATE, V15, P46; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Joy D, 2000, J TRAUMA, V48, P490, DOI 10.1097/00005373-200003000-00020; Lehmann U, 1999, EUR J SURG, V165, P1116, DOI 10.1080/110241599750007603; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Matz P. G., 2003, SEM NEUROSURGERY, V14, P125; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	47	48	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2008	39	5					604	611		10.1016/j.injury.2007.11.008			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	298OZ	WOS:000255698300016	18329647				2021-06-18	
J	Malojcic, B; Mubrin, Z; Coric, B; Susnic, M; Spilich, GJ				Malojcic, Branko; Mubrin, Zdenko; Coric, Bojana; Susnic, Mirica; Spilich, George J.			Consequences of mild traumatic brain injury on information processing assessed with attention and short-term memory tasks	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; cognitive function; traumatic brain injury	HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE FUNCTIONS; RECOVERY; DEFICITS; EPIDEMIOLOGY; PREDICTION; MIGRAINE; HISTORY	In this investigation, we explored the impact of mild traumatic brain injury (mTBI) upon short term or working memory and attention. The performance of 37 individuals with mTBI was compared with that of 53 age, sex and education-matched controls. All participants were staff members or individuals seeking medical care at a University hospital serving a large metropolitan area. A battery of computerized tests measured sustained visual attention, short-term memory (STM), simple reaction time, and decision time. Individuals with mTBI showed a performance deficit at sustained visual attention, STM scanning and a trend towards slowing in choice decision making. These observed changes in the cognitive performance of mTBI individuals are hypothesized to be a consequence of impaired central information processing. Our results suggest that mTBI can elicit meaningful cognitive deficits for several months post-injury. Additionally, we believe that the tasks employed in the current investigation demonstrate their utility for understanding cognitive deficits in mTBI individuals.	[Malojcic, Branko; Mubrin, Zdenko; Coric, Bojana] Univ Hosp Ctr, Dept Neurol, Zagreb 10000, Croatia; [Susnic, Mirica] Trauma Clin, Dept Neurol, Zagreb, Croatia; [Spilich, George J.] Washington Coll, Dept Psychol, Chestertown, MD USA	Malojcic, B (corresponding author), Univ Hosp Ctr, Dept Neurol, Kispaticeva 12, Zagreb 10000, Croatia.	branko12@yahoo.com	Malojcic, Branko/B-7076-2018				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Atkinson L, 2001, WORLD J SURG, V25, P1224, DOI 10.1007/s00268-001-0086-4; CALLANAN MM, 1989, BRAIN, V112, P361, DOI 10.1093/brain/112.2.361; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; DeNavas-Walt C., 2006, INCOME POVERTY HLTH; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; EVANS RW, 1992, NEUROL CLIN, V10, P815; Ferraro FR, 1999, AGING NEUROPSYCHOL C, V6, P260, DOI 10.1076/1382-5585(199912)06:04;1-B;FT260; Gazzaniga M.S., 2002, COGNITIVE NEUROSCIEN; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Janculjak D, 2002, CLIN NEUROL NEUROSUR, V104, P221, DOI 10.1016/S0303-8467(02)00042-2; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kent D, 2007, AM SCI, V95, P60, DOI 10.1511/2007.63.60; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Macciocchi SN, 1998, NEUROREHABILITATION, V11, P67, DOI 10.1016/S1053-8135(98)00010-9; Malojcic B, 2000, NEUROL CROATICA, V49, P159; MUBRIN Z, 1996, EUR J NEUROL, V5, pS235; Nakamura N, 2002, NEUROL RES, V24, P45, DOI 10.1179/016164102101199530; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; PEYSER JM, 1990, ARCH NEUROL-CHICAGO, V47, P94, DOI 10.1001/archneur.1990.00530010120030; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SMITH PJ, 1981, HUM FACTORS, V23, P701; SPILICH GJ, 1992, BRIT J ADDICT, V87, P1313; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Waldie KE, 2002, NEUROLOGY, V59, P904, DOI 10.1212/WNL.59.6.904; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P239, DOI 10.1016/j.acn.2005.12.004	44	47	49	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2008	25	1					30	37		10.1089/neu.2007.0384			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	258IJ	WOS:000252861300003	18355156				2021-06-18	
J	Sveen, U; Mongs, M; Roe, C; Sandvik, L; Bautz-Holter, E				Sveen, Unni; Mongs, Malin; Roe, Cecilia; Sandvik, Leiv; Bautz-Holter, Erik			Self-rated competency in activities predicts functioning and participation one year after traumatic brain injury	CLINICAL REHABILITATION			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; RATING-SCALE; REHABILITATION; EMPLOYMENT; OUTCOMES; CONSCIOUSNESS	Objective: To investigate whether the Patient Competency Rating Scale at three months predicts global functioning and participation one year after traumatic brain injury. Design: Prospective cohort study with follow-up at 3 and 12 months post injury. The Patient Competency Rating Scale was analysed in a logistic regression model with the outcomes Community Integration Questionnaire, Glasgow Outcome Scale Extended and return to work/study. Setting: The neurosurgical department of a trauma referral centre in a metropolitan hospital. Subjects: A cohort of 70 patients with acute traumatic brain injury, ranging from mild to severe injury. Main measures: The Patient Competency Rating Scale, assessing competency in activities, was applied as a predictor. Outcomes describing community participation at 12 months were the Community Integration Questionnaire and return to work/study. Global functioning was evaluated by the Glasgow Outcome Scale Extended. Results: Factor analysis of the Patient Competency Rating Scale items yielded three domains: activities demanding cognition, interpersonal/emotional skills, and activities of daily living (ADL) competency. The first two of these domains significantly predicted return to work/study and community integration, whilst global functioning at one year was predicted by interpersonal/emotional competency. Conclusions: The Patient Competency Rating Scale at three months predicted functioning and participation one year after traumatic brain injury. This indicates that rehabilitation interventions should focus on cognitive and interpersonal competency in order to enhance participation after traumatic brain injury.	[Sveen, Unni; Mongs, Malin; Roe, Cecilia; Bautz-Holter, Erik] Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway	Sveen, U (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	Unni.sveen@uus.no					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Fleming J, 1999, BRAIN INJURY, V13, P417; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Linden MA, 2005, DISABIL REHABIL, V27, P1353, DOI 10.1080/09638280500164180; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winer B.J., 1991, STAT PRINCIPLES EXPT; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	30	47	48	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2008	22	1					45	55		10.1177/0269215507080768			11	Rehabilitation	Rehabilitation	276NT	WOS:000254149900005	18089663				2021-06-18	
J	Xiong, Y; Mahmood, A; Lu, D; Qu, C; Goussev, A; Schallert, T; Chopp, M				Xiong, Ye; Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Schallert, Timothy; Chopp, Michael			Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice	BRAIN RESEARCH			English	Article						behavior; erythropoietin; gender; mouse; neurogenesis; traumatic brain injury	CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; HEAD-INJURY; SUBVENTRICULAR ZONE; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; SPATIAL MEMORY; CARBAMYLATED ERYTHROPOIETIN; ENHANCES NEUROGENESIS; BLOOD-FLOW	The aim of this study was to investigate the role of gender in histological and functional outcome, angiogenesis, neurogenesis and therapeutic effects of recombinant human erythropoietin (rhEPO) in mice after traumatic brain injury (TBI). TBI caused both tissue loss in the cortex and cell loss in the dentate gyrus (DG) in the injured hemisphere at day 35 post TBI without a significant gender difference. After TBI, sensorimotor deficits were significantly larger in male mice compared to females, while similar spatial learning deficits were present in both genders. TBI alone significantly stimulated angiogenesis and neurogenesis in the cortex and in the DG of injured hemispheres in both genders. rhEPO at a dose of 5000 units/kg body weight administered intraperitoneally at 6 h, and 3 and 7 days after injury significantly reduced lesion volume and DG cell loss examined at day 35 after TBI as well as dramatically improved sensorimotor and spatial learning performance without an obvious gender proclivity, rhEPO significantly enhanced neurogenesis in the cortex and the DG of the ipsilateral hemisphere in male TBI mice. rhEPO did not affect angiogenesis in the ipsilateral cortex and DG in both genders after TBI. The present data demonstrate that posttraumatic administration of rhEPO improves histological and functional outcome in both genders, which may be mediated by reducing cortical tissue damage and DG cell loss in the ipsilateral hemisphere. In addition, the major gender propensity observed in the present study with mice after TBI without treatment is limited to sensorimotor deficits and cell proliferation. (C) 2007 Elsevier B.V. All rights reserved.	[Xiong, Ye; Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48063 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA	Mahmood, A (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS042345-01A20002, R01 NS52280, R01 NS052280, P01 NS042345, R01 NS052280-02, P01 NS42345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, P01NS042345] Funding Source: NIH RePORTER		Arlotta P, 2003, EXP GERONTOL, V38, P173, DOI 10.1016/S0531-5565(02)00156-0; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lagace DC, 2007, HIPPOCAMPUS, V17, P175, DOI 10.1002/hipo.20265; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Magavi SS, 2000, NATURE, V405, P951; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; Suzuki S, 2006, ENDOCRINE, V29, P209, DOI 10.1385/ENDO:29:2:209; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007	64	47	48	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 14	2007	1185						301	312		10.1016/j.brainres.2007.09.052			12	Neurosciences	Neurosciences & Neurology	247FY	WOS:000252064400032	17976541	Green Accepted			2021-06-18	
J	Tanriverdi, F; Dagli, AT; Karaca, Z; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Dagli, Ahmet Turan; Karaca, Zuleyha; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			High risk of pituitary dysfunction due to aneurysmal subarachnoid haemorrhage: a prospective investigation of anterior pituitary function in the acute phase and 12 months after the event	CLINICAL ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE; NEUROENDOCRINE DYSFUNCTION; GH DEFICIENCY; LONG-TERM; HYPOPITUITARISM; DIAGNOSIS; CORTISOL; TESTS; PREVALENCE	Objective Recent investigations have provided evidence for a high prevalence of pituitary dysfunction in patients with subarachnoid haemorrhage (SAH). However, apart from one study, all of the previous data were obtained from retrospective studies. To our knowledge there is no previously reported study in which pituitary function was investigated in the same patients immediately after SAH and 12 months later. The aim of this study was to understand the prevalence and progression of anterior pituitary hormone deficiencies both in the acute phase of SAH and 12 months after the event. Patients and design Twenty-two SAH patients (11 men, 11 women) were included in the study. Pituitary function was evaluated in the early acute phase (within 24 h of admission) and after 12 months. Results Pituitary hormone deficiencies in the acute phase were as follows: 31 center dot 8% had gonadotrophin, 22 center dot 7% had ACTH and 22 center dot 7% had GH deficiencies. At 12 months after SAH: 0 center dot 0% had gonadotrophin, 13 center dot 6% had ACTH and 36 center dot 4% had GH deficiencies. Overall, after 12 months, pituitary hormone deficiencies recovered in 15 ( 68 center dot 2%) patients and new-onset pituitary hormone deficiencies were present in nine (40 center dot 9%) patients. Conclusions GH deficiency (GHD) was the most common pituitary deficit at 12 months after SAH and the majority of the patients (87 center dot 5%) had isolated GHD. During the 12-month follow-up, pituitary function was found to either improve or worsen in a considerable number of patients.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; Univ Santiago Compostela, Sch Med, Complejo Hosp Univ, Dept Med, Santiago, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Brandt L, 2004, ACTA NEUROL SCAND, V109, P91, DOI 10.1046/j.0001-6314.2003.00189.x; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENKINS JS, 1969, BRIT MED J, V4, P707, DOI 10.1136/bmj.4.5685.707; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Orme SM, 1996, CLIN ENDOCRINOL, V45, P135, DOI 10.1046/j.1365-2265.1996.d01-1562.x; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; ZIEGLER MG, 1990, CRIT CARE MED, V18, P253, DOI 10.1097/00003246-199003000-00001	27	47	49	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	DEC	2007	67	6					931	937		10.1111/j.1365-2265.2007.02989.x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	232NC	WOS:000251025400018	17666088				2021-06-18	
J	Pineda, DA; Palacio, LG; Puerta, IC; Merchan, V; Arango, CP; Galvis, AY; Gomez, M; Aguirre, DC; Lopera, F; Arcos-Burgos, M				Pineda, David A.; Palacio, Luis Guillermo; Puerta, Isabel C.; Merchan, Vilma; Arango, Clara P.; Galvis, Astrid Yuleth; Gomez, Monica; Aguirre, Daniel Camilo; Lopera, Francisco; Arcos-Burgos, Mauricio			Environmental influences that affect attention deficit/hyperactivity disorder - Study of a genetic isolate	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY			English	Article						ADHD; hyperactivity; environmental risk factors; Colombia; genetics	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; RATED CHILD-BEHAVIOR; SCHOOL-AGE-CHILDREN; NATIONAL US SAMPLE; CLOSED-HEAD INJURY; 11 YEARS OLD; MATERNAL SMOKING; PSYCHIATRIC-DISORDERS; SEGREGATION ANALYSIS	Three independent complex segregation analyses found that the cause of Attention Deficit/Hyperactivity Disorder (ADHD) was the presence of major genes interacting with environmental influences. In order to identify potential environmental risk factors for ADHD in the Paisa community-a very well described, genetically isolated group-we randomly selected a sample of 486 children between 6 and 11 years of age. This group included 200 children with ADHD (149 males and 51 females) and 286 healthy controls (135 males and 151 females). The ADHD DSM-IV diagnosis was obtained using the DICA and BASC evaluation instruments, and the children's mothers or grandmothers filled out a questionnaire on each child's exposure to prenatal, neonatal, and early childhood risk factors. The data were analyzed using cross tabulation and stepwise logistic multiple-regression analyses. Cross tabulation associated ADHD with a variety of factors, including miscarriage symptoms, premature delivery symptoms, maternal respiratory viral infection, moderate to severe physical illness in the mother during gestation, prenatal cigarette and alcohol exposure, neonatal seizures, asphyxia or anoxia, severe neonatal illness, mild speech retardation, moderate brain injury, and febrile seizures (odds ratio >= 2, P < 0.05). Step-wise logistic multiple-regression analysis also uncovered a block of variables, including male gender, maternal illnesses, prenatal alcohol exposure, mild speech retardation, febrile seizures, and moderate brain injury (odds ratio >= 2.0, P < 0.05). Future studies on the risk of developing ADHD must include these environmental factors as covariates.	NHGRI, NIH, Med Genet Branch, Bethesda, MD 20814 USA; Univ Antioquia, Fac Med, Neurosci Grp, Medellin, Colombia; Univ San Buenaventura, Master Program Neuropsychol, Fac Psychol, Neuropsychol & Conduct Disorder Grp, Medellin, Colombia	Arcos-Burgos, M (corresponding author), NHGRI, NIH, Med Genet Branch, Bldg 35,1B-209B,35 Convent Dr MSC 1852, Bethesda, MD 20814 USA.	marcosbu@nhgri.nih.gov	Palacio, Luis/AAG-7435-2020; Pineda, David/AAE-4785-2020; Arcos-Burgos, Mauricio/H-1326-2017	Arcos-Burgos, Mauricio/0000-0002-8529-0574; Puerta Lopera, Isabel Cristina/0000-0002-3533-8015; Palacio, Luis G/0000-0002-5203-8268; Pineda, David A/0000-0002-1080-4796			Abrantes AM, 2005, J PSYCHOACTIVE DRUGS, V37, P391, DOI 10.1080/02791072.2005.10399812; Acosta MT, 2004, GENET MED, V6, P1, DOI 10.1097/01.GIM.0000110413.07490.0B; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arcos-Burgos M, 2004, MOL PSYCHIATR, V9, P252, DOI 10.1038/sj.mp.4001396; Arcos-Burgos M, 2004, AM J HUM GENET, V75, P998, DOI 10.1086/426154; Arcos-Burgos M, 2002, CLIN GENET, V61, P335, DOI 10.1034/j.1399-0004.2002.610503.x; Aronson M, 1997, DEV MED CHILD NEUROL, V39, P583; Asherson PJ, 2001, BRIT J PSYCHIAT, V179, P122, DOI 10.1192/bjp.179.2.122; Biederman J, 2005, BIOL PSYCHIAT, V57, P1215, DOI 10.1016/j.biopsych.2004.10.020; Biederman J, 2002, PSYCHOL MED, V32, P817, DOI 10.1017/S0033291702005652; Biederman J, 2002, AM J PSYCHIAT, V159, P1556, DOI 10.1176/appi.ajp.159.9.1556; Biederman J, 2002, AM J PSYCHIAT, V159, P36, DOI 10.1176/appi.ajp.159.1.36; BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Chang YC, 2000, EPILEPSIA, V41, P412, DOI 10.1111/j.1528-1157.2000.tb00182.x; Dalsgaard S, 2002, BRIT J PSYCHIAT, V181, P416, DOI 10.1192/bjp.181.5.416; Dierker LC, 2006, DRUG ALCOHOL DEPEN, V84, P144, DOI 10.1016/j.drugalcdep.2006.01.008; DOMIZIO S, 1993, CHILD NERV SYST, V9, P272, DOI 10.1007/BF00306271; Eaves L, 1993, NATURE NURTURE PSYCH, P285; Faraone S V, 2000, Curr Psychiatry Rep, V2, P143, DOI 10.1007/s11920-000-0059-6; Faraone SV, 2000, DEV REV, V20, P568, DOI 10.1006/drev.2000.0515; Faraone SV, 2000, GENET EPIDEMIOL, V18, P1; FARAONE SV, 1992, PSYCHIATR GENET, V2, P257, DOI 10.1097/00041444-199210000-00004; Faraone SV, 2001, BIOL PSYCHIAT, V50, P586, DOI 10.1016/S0006-3223(01)01146-5; Gerring J, 2000, BRAIN INJURY, V14, P205; GILLIS JJ, 1992, J ABNORM CHILD PSYCH, V20, P303, DOI 10.1007/BF00916694; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hill SY, 2000, J STUD ALCOHOL, V61, P661, DOI 10.15288/jsa.2000.61.661; Hudziak JJ, 2001, CHILD ADOL PSYCH CL, V10, P279; JAIN M, 2006, BIOL PSYCHIAT; Kamphaus RW, 1999, J CHILD PSYCHOL PSYC, V40, P607, DOI 10.1111/1469-7610.00477; Kamphaus RW, 1997, J ABNORM CHILD PSYCH, V25, P453, DOI 10.1023/A:1022681630818; Kaplan BJ, 2001, J LEARN DISABIL-US, V34, P555, DOI 10.1177/002221940103400608; Knopik VS, 2006, PSYCHOL MED, V36, P1461, DOI 10.1017/S0033291706007884; Knopik VS, 2005, PSYCHOL MED, V35, P625, DOI 10.1017/S0033291704004155; Langley K, 2005, Minerva Pediatr, V57, P359; Lopera F, 1999, REV NEUROLOGIA, V28, P660, DOI 10.33588/rn.2807.98517; Maher BS, 1999, AM J MED GENET, V88, P71, DOI 10.1002/(SICI)1096-8628(19990205)88:1<71::AID-AJMG13>3.0.CO;2-D; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, BRAIN INJURY, V12, P41; Mick E, 2002, J AM ACAD CHILD PSY, V41, P378, DOI 10.1097/00004583-200204000-00009; Mick E, 2002, J DEV BEHAV PEDIATR, V23, P16, DOI 10.1097/00004703-200202000-00004; Mick E, 1996, J AM ACAD CHILD PSY, V35, P1470, DOI 10.1097/00004583-199611000-00015; Noland JS, 2005, NEUROTOXICOL TERATOL, V27, P429, DOI 10.1016/j.ntt.2005.02.001; Palacio JD, 2004, J AM ACAD CHILD PSY, V43, P1506, DOI 10.1097/01.chi.0000142279.79805.dc; Pineda D, 1999, J ABNORM CHILD PSYCH, V27, P455, DOI 10.1023/A:1021932009936; Pineda D, 1999, J LEARN DISABIL, V32, P159, DOI 10.1177/002221949903200206; Pineda D A, 2000, Appl Neuropsychol, V7, P40, DOI 10.1207/S15324826AN0701_6; Pineda DA, 2003, INT J NEUROSCI, V113, P49, DOI 10.1080/00207450390161921; Pineda DA, 2005, PEDIATR NEUROL, V33, P15, DOI 10.1016/j.pediatrneurol.2005.02.001; Pineda DA, 2003, INT J NEUROSCI, V113, P397, DOI 10.1080/00207450390162164; Pineda DA, 2001, REV NEUROLOGIA, V32, P217, DOI 10.33588/rn.3203.2000499; Pineda DA, 1999, REV NEUROLOGIA, V28, P952, DOI 10.33588/rn.2810.98333; Pineda DA, 1999, REV NEUROLOGIA, V28, P672, DOI 10.33588/rn.2807.99011; Pineda David A, 2006, Transcult Psychiatry, V43, P362, DOI 10.1177/1363461506066983; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Reich W, 2000, J AM ACAD CHILD PSY, V39, P14, DOI 10.1097/00004583-200001000-00008; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; Rietveld MJH, 2003, AM J MED GENET B, V117B, P102, DOI 10.1002/ajmg.b.10024; Rowland AS, 2001, CAN J PSYCHIAT, V46, P931; Rowland AS, 2002, MENT RETARD DEV D R, V8, P162, DOI 10.1002/mrdd.10036; Scahill L, 2000, CHILD ADOL PSYCH CL, V9, P541; Schubert R, 2005, PEDIATR NEUROL, V32, P1, DOI 10.1016/j.pediatrneurol.2004.06.007; Shan'ko G G, 1985, Neurosci Behav Physiol, V15, P48, DOI 10.1007/BF01186449; Thapar A, 2006, MOL PSYCHIATR, V11, P714, DOI 10.1038/sj.mp.4001831; Thapar A, 2003, AM J PSYCHIAT, V160, P1985, DOI 10.1176/appi.ajp.160.11.1985; Verdoux H, 2002, AM J MED GENET, V114, P898, DOI 10.1002/ajmg.10906; Verdoux H, 2002, THERAPIE, V57, P181; Waldman ID, 1999, BEHAV GENET, V29, P373; Wechsler D., 2011, WECHLSER ABBREVIATED; Zappitelli M, 2001, CAN J PSYCHIAT, V46, P542, DOI 10.1177/070674370104600609	74	47	51	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1018-8827	1435-165X		EUR CHILD ADOLES PSY	Eur. Child Adolesc. Psych.	AUG	2007	16	5					337	346		10.1007/s00787-007-0605-4			10	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	207ZD	WOS:000249288700008	17487441				2021-06-18	
J	Hunt, TN; Ferrara, MS; Miller, LS; Macciocchi, S				Hunt, Tamerah N.; Ferrara, Michael S.; Miller, L. Stephen; Macciocchi, Stephen			The effect of effort on baseline neuropsychological test scores in high school football athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						effort; concussion; adolescent; neuropsychological tests	HEAD-INJURY; CONCUSSION; RECOVERY; EXAGGERATION; SENSITIVITY; PERFORMANCE; STATEMENT; DEFICITS; SPORT	Objective: Poor effort on baseline neuropsychological tests is expected to influence interpretation of post-concussion assessment scores. Our study examined effort in an athletic population to determine if poor effort effects neuropsychological test performance. Methods: High school athletes (N= 199) were administered a brief neuropsychological test battery, which included the Dot Counting Test (DCT) and the Rey 15-Item Test with recognition trial. One-way analyses of variance were used to compare groups with adequate and poor effort test performance. RESULTS: Most athletes (N= 177; 89%) exerted adequate effort while a number of athletes (N= 22; 11 %) exerted poor effort on the DCT. Statistically significant differences existed between effort groups (p < 0.05) on several of the neuropsychological tests. Conclusions: Poor effort was observed in the athletic population during baseline testing and athletes with poor effort displayed statistically significant differences in performance on neuropsychological tests. Adding an effort test to baseline examinations may improve post-concussion test score interpretations. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ S Carolina, Dept Phys Educ, P Blatt Phys Educ Ctr 218, Columbia, SC 29208 USA; Univ Georgia, Athens, GA 30602 USA	Hunt, TN (corresponding author), Univ S Carolina, Dept Phys Educ, P Blatt Phys Educ Ctr 218, Columbia, SC 29208 USA.	hunttn@gwm.sc.edu	Hunt, Tamerah/E-3281-2011				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [DOI 10.1300/J151v02n03_01, 10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01]; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313	19	47	47	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2007	22	5					615	621		10.1016/j.acn.2007.04.005			7	Psychology, Clinical; Psychology	Psychology	191YZ	WOS:000248169200006	17507199	Bronze			2021-06-18	
J	Liu, L; Liu, H; Jao, JF; Liu, HQ; Bergeron, A; Dong, JF; Zhang, JN				Liu, Li; Liu, Hui; Jao, Junfeng; Liu, Huiquan; Bergeron, Angela; Dong, Jing-Fei; Zhang, Jianning			Changes in circulating human endothelial progenitor cells after brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; endothelial progenitor cells	PLATELETS; MOBILIZATION; REENDOTHELIALIZATION; TRANSPLANTATION; EXPRESSION; RECRUIT; TRAUMA	Endothelial progenitor cells (EPCs) are mobilized from the bone marrow to blood circulation in response to tramatic or inflammatory stimulations. Once released, they actively seek and home to the sites of vascular injury to promote vascular repair. We monitored changes of EPC counts in peripheral blood of 29 patients with traumatic brain injury for up to 21 days. We showed that the levels of circulating EPCs within the first 48 h of injury were lower than control subjects, but increased over time-reaching plateau around 7 days post-injury at a level that was significantly higher than controls. The initial EPC reduction, which was severe in patients with severe injury Glasgow Coma Scale [GCS] < 12), differs from the acute increase in EPC counts found in patients with cardiovascular injury. The subsequent increase in circulating EPCs is primarily through bone marrow mobilization because the cells were stained predominantly for CD133, which labels immature EPCs, but not CD34 (which stains cell of endothelial lineage). The increase appeared earlier in male patients and. was greater in those younger than 50 years of age. Changes in circulating EPCs during follow-up periods correlated with platelet, but not leukocyte counts. These results suggest that EPC mobilization following traumatic brain injury may take a different course compared to that associated with body or vascular injuries.	Tianjin Med Univ, Neurol Inst, Dept Neurosurg, Tianjin, Peoples R China; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX USA	Zhang, JN (corresponding author), Neurol Inst, 154 Anshan Rd, Tianjin, Peoples R China.	jianningzhang@hotmail.com	Mordwinkin, Nicholas M/A-4347-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL71895] Funding Source: Medline		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; de Boer HC, 2006, ARTERIOSCL THROM VAS, V26, P1653, DOI 10.1161/01.ATV.0000222982.55731.f1; Dimmeler S, 2005, NEW ENGL J MED, V352, P1815, DOI 10.1056/NEJMcibr050670; Gill M, 2001, CIRC RES, V88, P167; Griese DP, 2003, CIRCULATION, V108, P2710, DOI 10.1161/01.CIR.0000096490.16596.A6; Hildbrand P, 2004, BLOOD, V104, P2010, DOI 10.1182/blood-2003-12-4219; Hristov M, 2004, J CELL MOL MED, V8, P498, DOI 10.1111/j.1582-4934.2004.tb00474.x; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; Laing AJ, 2007, J ORTHOP RES, V25, P44, DOI 10.1002/jor.20228; Langer H, 2006, CIRC RES, V98, pE2, DOI 10.1161/01.RES.0000201285.87524.9e; Lev EI, 2005, J VASC RES, V42, P408, DOI 10.1159/000087370; Lev EI, 2006, THROMB HAEMOSTASIS, V96, P498, DOI 10.1160/TH06-05-0250; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pihusch V, 2005, THROMB RES, V116, P233, DOI 10.1016/j.thromres.2004.12.010; Pintucci G, 2002, THROMB HAEMOSTASIS, V88, P834; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Wang L, 2006, J NEUROSCI, V26, P5996, DOI 10.1523/JNEUROSCI.5380-05.2006; Werner N, 2002, ARTERIOSCL THROM VAS, V22, P1567, DOI 10.1161/01.ATV.0000036417.43987.D8; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Zhu CH, 2005, J SURG RES, V125, P151, DOI 10.1016/j.jss.2004.12.006	27	47	56	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					936	943		10.1089/neu.2006.0250			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700003	17600511				2021-06-18	
J	de la Plata, CM; Hewlitt, M; de Oliveira, A; Hudak, A; Harper, C; Shafi, S; Diaz-Arrastia, R				Marquez de la Plata, Carlos; Hewlitt, Margaret; de Oliveira, Ana; Hudak, Anne; Harper, Caryn; Shafi, Shahid; Diaz-Arrastia, Ramon			Ethnic differences in rehabilitation placement and outcome after TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Hispanic; language; outcome; rehabilitation; TBI; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ACUTE MYOCARDIAL-INFARCTION; SPANISH-SPEAKING PATIENTS; HEALTH-CARE; EMERGENCY; LANGUAGE; IMPACT; COMMUNICATION; SATISFACTION; DISPARITIES	Objective: To determine whether race/ethnicity and proficiency with the English language influence access to rehabilitation services, and ultimately outcome after traumatic brain injury (TBI). Design: A retrospective correlational investigation. Setting and Participants: Postrehabilitation outpatients with blunt TBI. A total of 476 patients were examined 6 months postinjury, of which 109 (23%) were Hispanics, and of those 42 were predominantly Spanish speaking. Main Outcome Measures: Access to rehabilitation services, Glasgow Outcome Scale-Extended. Results: Insurance, age, and injury severity had the greatest influence on receipt of rehabilitation services; however, higher rates of severe disability were found among Hispanics and Spanish speakers than non-Hispanic whites and non-Hispanic English speakers, respectively. Conclusions: Insurance status has a larger influence on receipt of rehabilitation services than ethnicity or proficiency with the English language, but language proficiency is a significant predictor of severe disability.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA	de la Plata, CM (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	carlos.marquezdelaplata@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652] Funding Source: Medline		Baker DW, 1998, MED CARE, V36, P1461, DOI 10.1097/00005650-199810000-00004; Baker DW, 1996, JAMA-J AM MED ASSOC, V275, P783, DOI 10.1001/jama.275.10.783; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carrasquillo O, 1999, J GEN INTERN MED, V14, P82, DOI 10.1046/j.1525-1497.1999.00293.x; Collins KS, 1999, US MINORITY HLTH CHA; COPES WS, 1998, P 33 ANN M ASS ADV A, P205; Dubay LC, 1996, FUTURE CHILD, V6, P152, DOI 10.2307/1602499; ERZINGER S, 1991, CULT MED PSYCHIAT, V15, P91, DOI 10.1007/BF00050829; Feinberg Emily, 2002, Matern Child Health J, V6, P5, DOI 10.1023/A:1014308031534; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; *GAO, 1998, GAO PUBL; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jang M, 1998, HEALTH SOC WORK, V23, P136, DOI 10.1093/hsw/23.2.136; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McAlearney JS, 2004, J HEALTH CARE POOR U, V15, P357, DOI 10.1353/hpu.2004.0044; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; Perez-Stable EJ, 1997, MED CARE, V35, P1212, DOI 10.1097/00005650-199712000-00005; PERRY MJ, 1998, BARRIERS MEDICAL ENR; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; SEIJO R, 1991, HISPANIC J BEHAV SCI, V13, P363, DOI 10.1177/07399863910134001; SHAFI S, 2006, 65 ANN M AM ASS SURG; Shafi S, 2006, J TRAUMA, V61, P1374, DOI 10.1097/01.ta.0000246698.07125.c0; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Syed M, 2000, AM HEART J, V140, P643, DOI 10.1067/mhj.2000.109644; TEASDALE G, 1974, LANCET, V2, P81; Thrall Terese Hudson, 2002, Hosp Health Netw, V76, P30; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US BUR CENS, 2005, ANN SOC EC SUPPL CUR; *US DEP HHS, 2003, NAT HEALTHC DISP REP, P111; *US DEP HHS, 2005, NAT HEALTHC DISP REP, P90; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yu SM, 2006, AM J PUBLIC HEALTH, V96, P1449, DOI 10.2105/AJPH.2005.069500	41	47	47	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2007	22	2					113	121		10.1097/01.HTR.0000265099.29436.56			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	152NU	WOS:000245369500006	17414313				2021-06-18	
J	Hoane, MR; Gilbert, DR; Holland, MA; Pierce, JL				Hoane, Michael R.; Gilbert, David R.; Holland, Michael A.; Pierce, Jeremy L.			Nicotinamide reduces acute cortical neuronal death and edema in the traumatically injured brain	NEUROSCIENCE LETTERS			English	Article						vitamin B-3; neuroprotection; nicotinamide; rat; fluoro-jade; edema; TBI	FOCAL CEREBRAL-ISCHEMIA; COGNITIVE DEFICITS; INFARCTION; INHIBITOR; APOPTOSIS; PRECURSOR; RECOVERY; MODEL; RATS	Previous studies have shown that administration of nicotinamide (Vitamin B-3) in animal models of traumatic brain injury (TBI) and ischemia significantly reduced the size of infarction or injury and improved functional recovery. The present study evaluated the ability of nicotinamide to provide acute neuroprotection and edema reduction following TBI. Groups of rats were assigned to nicotinamide (500 mg/kg) or saline (1.0 ml/kg) treatment conditions and received contusion injuries or sham surgeries. Drug treatment was administered 15 min following injury. Brains were harvested 24 h later and either processed for histology or water content. Frozen sections were stained with the degenerating neuron stain (Fluoro-Jade (R) B) (FJ) and cell counts were performed at the site of injury. Additional brains were processed for water content (a measure of injury-induced edema). Results of this study showed that administration of nicotinamide following TBI significantly reduced the number of FJ(+) neurons in the injured cortex compared to saline-treated animals. Examination of the water content of the brains also revealed that administration of nicotinamide significantly attenuated the amount of water compared to saline-treated animals in the injured cortex. These results indicate that nicotinamide administration significantly reduced neuronal death and attenuated cerebral edema following injury. The current findings suggest that nicotinamide significantly modulates acute pathophysiological processes following injury and that this may account for its beneficial effects on recovery of function following injury. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	So Illinois Univ, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Restorat Neurosci Lab,Brain & Cognit Sci Program, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Restorat Neurosci Lab,Brain & Cognit Sci Program, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Gupta S, 2004, NEUROL RES, V26, P103, DOI 10.1179/016164104773026624; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tan A, 2006, J NEUROTRAUM, V23, P1032; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ungerstedt JS, 2003, J THROMB HAEMOST, V1, P2554, DOI 10.1046/j.1538-7836.2003.00463.x; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x	27	47	47	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 6	2006	408	1					35	39		10.1016/j.neulet.2006.07.011			5	Neurosciences	Neurosciences & Neurology	108UR	WOS:000242265200008	16987607				2021-06-18	
J	Isoniemi, H; Tenovuo, O; Portin, R; Himanen, L; Kairisto, V				Isoniemi, Heli; Tenovuo, Olli; Portin, Raija; Himanen, Leena; Kairisto, Veli			Outcome of traumatic brain injury after three decades - Relationship to ApoE genotype	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; outcome; traumatic brain injury	APOLIPOPROTEIN-E; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK; DEMENTIA; ASSOCIATION; PREVALENCE; DEFICIENCY; EPSILON-4; PREDICTS	Significant traumatic brain injury (TBI) is nearly always associated with cognitive deficits, but in a highly variable manner. Apolipoprotein E (ApoE) plays a pivotal role in CNS response to injury. To examine the association of ApoE genotype with long-term outcome in TBI patients, we determined the ApoE genotype from 61 TBI patients who had been injured over three decades earlier. All patients had been studied neuropsychologically after their injuries. The long-term outcome was evaluated with repeated neuropsychological testing and by applying various measures of everyday functioning and quality of life. After three decades, TBI patients with the ApoE e4 allele showed significantly poorer general cognitive level than those without this allele. This decline was wholly accounted for by a subgroup of these patients who had developed incident or clinical dementia, while the majority of the ApoE e4 positive patients showed no decline at all. The other outcome measures describing vocational, physical, or subjective symptom outcome did not show significant relationships to the ApoE genotype. A portion of the TBI patients with the ApoE e4 allele seem to be at risk of long-term cognitive decline.	Turku Univ Hosp, Dept Neurol, FI-20521 Turku, Finland; Turku Univ Hosp, Dept Clin Chem, FIN-20520 Turku, Finland	Tenovuo, O (corresponding author), Turku Univ Hosp, Dept Neurol, POB 52, FI-20521 Turku, Finland.	olli.tenovuo@tyks.fi		Himanen, Leena/0000-0001-7261-8027			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BENTON AL, 1963, REVISED VISUAL RETEN; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Donohoe GG, 2000, CLIN CHEM, V46, P1540; Donohoe GG, 1999, CLIN CHEM, V45, P143; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hanninen T, 2002, ACTA NEUROL SCAND, V106, P148, DOI 10.1034/j.1600-0404.2002.01225.x; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; JUVA K, 1993, ACTA NEUROL SCAND, V87, P106; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Khachaturian AS, 2004, ARCH GEN PSYCHIAT, V61, P518, DOI 10.1001/archpsyc.61.5.518; Kleifeld O, 1998, INT J DEV NEUROSCI, V16, P755, DOI 10.1016/S0736-5748(98)00084-7; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale TW, 2000, NEUROPSYCHOL REHABIL, V10, P151, DOI 10.1080/096020100389228; Wechsler D., 1955, MANUAL WECHSLER ADUL; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	44	47	51	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2006	23	11					1600	1608		10.1089/neu.2006.23.1600			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	106RK	WOS:000242118200003	17115907				2021-06-18	
J	Hoane, MR; Tan, AA; Pierce, JL; Anderson, GD; Smith, DC				Hoane, Michael R.; Tan, Arlene A.; Pierce, Jeremy L.; Anderson, Gail D.; Smith, Douglas C.			Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						behavior; GFAP; neuroprotection; recovery of function; TBI; vitamin B-3	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CONTUSION INJURY; EDEMA FORMATION; RECOVERY; VITAMIN-B-3; APOPTOSIS; EXPRESSION; INFARCTION; INHIBITOR	This study examined the ability of nicotinamide (vitamin B-3) to improve functional outcome in a dose-dependent manner following fluid percussion injury (FPI). Injured (duration of unconsciousness mean = 85.8 sec; apnea = 9.9 sec), rats were administered nicotinamide (500 or 50 mg/kg; ip) or saline at 15 min and 24 h. Serum analysis of nicotinamide concentrations were conducted 1 h following the last injection. Sensorimotor and cognitive tests were conducted for 35 days following FPI. Both the 500 and 50 mg/kg doses of nicotinamide significantly facilitated recovery on the vibrissae-forelimb placing test compared to saline treatment, which showed chronic impairments. Both treatments also significantly improved performance on the bilateral tactile adhesive removal test. On the cognitive tests, the 500 mg/kg dose, but not the 50 mg/kg dose, improved performance on a working memory task in the Morris water maze (MWM). However, acquisition of a reference memory task in the MWM was not improved. Serum analysis showed that the 500 mg/kg dose significantly raised nicotinamide concentrations by 30-fold and the 50 mg/kg dose by 3-fold compared to the saline administration. This study demonstrated that raising nicotinamide concentrations resulted in the reduction of the behavioral impairments following FPI. In fact, the 500 mg/kg dose prevented the occurrence of the behavioral deficits on the bilateral tactile removal and working memory tests. Both doses significantly reduced tissue loss and glial fibrillary acid protein (GFAP) expression in the cortex. The 500 mg/kg dose reduced GFAP expression in the hippocampus. This data suggests that nicotinamide has substantial preclinical efficacy for TBI, and there appears to be some differences in the ability of the doses to improve performance in the MWM.	So Illinois Univ, Dept Psychol, Restorat Neurosci Labs, Carbondale, IL 62901 USA; So Illinois Univ, Dept Psychol, Brain & Congnit Sci Program, Carbondale, IL 62901 USA; So Illinois Univ, Ctr Res Cognit & Neural Sci, Carbondale, IL 62901 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Labs, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647, NS041551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551, R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BARTH TM, 1990, STROKE, V21, P153; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Ellis AL, 2004, J NEUROTRAUM, V21, P1334; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gilbert DR, 2004, J NEUROTRAUM, V21, P1316; Gillmor HA, 1999, BIOMED CHROMATOGR, V13, P360, DOI 10.1002/(SICI)1099-0801(199908)13:5<360::AID-BMC893>3.0.CO;2-S; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; GREEN RG, 1970, SCHIZOPHRENIA, V2, P70; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Kolb H, 1999, DIABETES CARE, V22, pB16; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; STRATFORD MRL, 1992, RADIOTHER ONCOL, V25, P37, DOI 10.1016/0167-8140(92)90193-X; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ungerstedt JS, 2003, J THROMB HAEMOST, V1, P2554, DOI 10.1046/j.1538-7836.2003.00463.x; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129	36	47	48	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1535	1548		10.1089/neu.2006.23.1535			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500013	17020488				2021-06-18	
J	Heppner, P; Ellegala, DB; Durieux, M; Jane, JA; Lindner, JR				Heppner, P; Ellegala, DB; Durieux, M; Jane, JA; Lindner, JR			Contrast ultrasonographic assessment of cerebral perfusion in patients undergoing decompressive craniectomy for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral perfusion; microvasculature; blood flow; ultrasonography	SEVERE HEAD-INJURY; BLOOD-FLOW; ENHANCED ULTRASOUND; PRESSURE; QUANTIFICATION; MICROBUBBLES; MANAGEMENT; ECHOCARDIOGRAPHY; HYPERTENSION; DESTRUCTION	Object. The aims of this study were to determine whether contrast-enhanced ultrasonography (CEU) could be used for noninvasive evaluation of cerebral perfusion in patients with traumatic brain injury (TBI) and to assess the effect of decompressive surgery on cerebral perfusion as measured by CEU. Methods. Contrast-enhanced ultrasonography with intravenous administration of a microbubble contrast agent was performed in six patients with TBI undergoing decompressive craniectomy. Contrast-enhanced ultrasonography was performed through a bur hole before craniectomy and through the calvarial defect immediately after craniectomy and on postoperative Days 1 and 2. For the latter two studies, patients were placed in the recumbent position and at a 35 degrees incline to investigate changes in perfusion produced by modulation of intracranial pressure (ICP). Cerebral microvascular blood flow increased by almost threefold immediately after craniectomy, from a mean of 7.5 +/- 6.9 (standard deviation [SD]) to 20.9 +/- 11.6 (p < 0.05), and further improved on postoperative Day 1 (mean 37.1 +/- 13.9 [SD], p < 0.05, compared with postcraniectomy microvascular blood flow) without subsequent change on Day 2. The change in microvascular perfusion correlated inversely with the initial ICP (p < 0.01), indicating less recovery of flow when preoperative ICP was markedly elevated. On postoperative Days I and 2, head-of-bed elevation produced an increase in microvascular perfusion on CEU (mean 37 11 compared with 51 20, p < 0.05) and a small decrease in ICP (mean 16 +/- 5 mm Hg compared with 12 +/- 4 mm Hg, p < 0.05). In patients with parenchymal hematoma, CEU provided spatial information on perfusion abnormalities in the hemorrhagic core and surrounding tissues. Conclusions. Contrast-enhanced ultrasonography has potential for the intraoperative and bedside assessment of cerebral perfusion in patients with TBI. The technique may be appropriate for evaluating responses to therapies aimed at preventing secondary ischemia and for assessing regional perfusion abnormalities.	Univ Virginia, Hlth Syst, Div Cardiovasc, Charlottesville, VA USA; Univ Virginia, Hlth Syst, Dept Neurol Surg, Charlottesville, VA USA; Univ Virginia, Hlth Syst, Dept Anesthesiol, Charlottesville, VA USA; Auckland City Hosp, Dept Neurosurg, Auckland, New Zealand	Lindner, JR (corresponding author), Oregon Hlth & Sci Univ, Div Cardiovasc, UHN62, Portland, OR 97239 USA.	lindnerj@ohsu.edu		Durieux, Marcel/0000-0003-1479-7666	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK-063508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK063508] Funding Source: NIH RePORTER		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dawson D, 2002, AM J PHYSIOL-ENDOC M, V282, pE714, DOI 10.1152/ajpendo.00373.2001; Ellegala DB, 2003, CIRCULATION, V108, P336, DOI 10.1161/01.CIR.0000080326.15367.0C; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Eyding J, 2004, J NEUROL NEUROSUR PS, V75, P926, DOI 10.1136/jnnp.2003.026195; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Jayaweera AR, 1999, AM J PHYSIOL-HEART C, V277, pH2363, DOI 10.1152/ajpheart.1999.277.6.H2363; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KENNING JA, 1981, SURG NEUROL, V15, P148, DOI 10.1016/0090-3019(81)90037-9; Kern R, 2004, STROKE, V35, P1665, DOI 10.1161/01.STR.0000129332.10721.7e; KETY SS, 1945, AM J PHYSIOL, V143, P53; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Lindner JR, 2002, J AM SOC ECHOCARDIOG, V15, P396, DOI 10.1067/mje.2002.117290; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; OBRIST WD, 1967, CIRC RES, V20, P124, DOI 10.1161/01.RES.20.1.124; Rim SJ, 2001, CIRCULATION, V104, P2582, DOI 10.1161/hc4601.099400; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Seidel G, 2002, ULTRASOUND MED BIOL, V28, P183, DOI 10.1016/S0301-5629(01)00501-4; Vogel R, 2005, J AM COLL CARDIOL, V45, P754, DOI 10.1016/j.jacc.2004.11.044; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wei K, 1998, CIRCULATION, V97, P473; Wei K, 2001, J AM COLL CARDIOL, V37, P1135, DOI 10.1016/S0735-1097(00)01210-9; Winkelman C, 2000, Am J Crit Care, V9, P373; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Zauner A, 1996, ACT NEUR S, V67, P40; 2000, J NEUROTRAUMA, V17	33	47	56	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2006	104	5					738	745		10.3171/jns.2006.104.5.738			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	041CD	WOS:000237429800008	16703878				2021-06-18	
J	Hukkelhoven, CWPM; Rampen, AJJ; Maas, AIR; Farace, E; Habbema, JDF; Marmarou, A; Marshall, LF; Murray, GD; Steyerberg, EW				Hukkelhoven, CWPM; Rampen, AJJ; Maas, AIR; Farace, E; Habbema, JDF; Marmarou, A; Marshall, LF; Murray, GD; Steyerberg, EW			Some prognostic models for traumatic brain injury were not valid	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						traumatic brain injury; prognosis; models, statistical; validation studies; Glasgow Outcome Scale; mortality	LOGISTIC-REGRESSION ANALYSIS; SIMPLE CLINICAL-VARIABLES; HEAD-INJURIES; SURVIVAL; SELECTION; PREDICTION; COMA; OUTCOMES; TREE	Objective: Various prognostic models have been developed to predict outcome after traumatic brain injury (TBI). We aimed to determine the validity of six models that used baseline clinical and computed tomographic characteristics to predict mortality or unfavorable outcome at 6 months or later after severe or moderate TBI. Study Design and Setting: The validity was studied in two selected series of TBI patients enrolled in clinical trials (Tirilazad trials; n = 2,269; International Selfotel Trial; n = 409) and in two unselected series of patients consecutively admitted to participating centers (European Brain Injury Consortium [EBIC] survey; n = 796; Traumatic Coma Data Bank; n = 746). Validity was indicated by discriminative ability (AUC) and calibration (Hosmer-Lemeshow goodness-of-fit test). Results: The models varied in number of predictors (four to seven) and in development technique (two prediction trees and four logistic regression models). Discriminative ability varied widely (AUC:.61-.89), but calibration was poor for most models. Better discrimination was observed for logistic regression models compared with trees, and for models including more predictors. Further, discrimination was better when tested on unselected series that contained more heterogeneous populations. Conclusion: Our findings emphasize the need for external validation of prognostic models. The satisfactory discrimination indicates that logistic regression models, developed on large samples, can be used for classifying TBI patients according to prognostic risk. (c) 2006 Elsevier Inc. All rights reserved.	Erasmus Univ, Med Ctr, Dept Publ Hlth, Ctr Med Decis Making Sci, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Neurol Surg, NL-3000 DR Rotterdam, Netherlands; Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22903 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Calif San Diego, Dept Community Hlth Sci, La Jolla, CA 92093 USA	Steyerberg, EW (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, Ctr Med Decis Making Sci, POB 1739, NL-3000 DR Rotterdam, Netherlands.	E.Steyerberg@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Hukkelhoven, Chantal/0000-0002-0015-1883; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042691-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Baltas I, 1998, J Neurosurg Sci, V42, P85; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Clark TG, 2003, J CLIN EPIDEMIOL, V56, P28, DOI 10.1016/S0895-4356(02)00539-5; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrell Frank E., 2001, REGRESSION MODELING; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hukkelhoven CWPM, 2000, J NEUROL NEUROSUR PS, V68, P396; JENNETT B, 1975, LANCET, V1, P480; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Olshen RA, 1984, CLASSIFICATION REGRE; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Sakellaropoulos GC, 1999, METHOD INFORM MED, V38, P37; Schaan M, 2002, J TRAUMA, V52, P667, DOI 10.1097/00005373-200204000-00009; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0; TEASDALE G, 1974, LANCET, V2, P81; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; TITTERINGTON DM, 1981, J ROY STAT SOC A STA, V144, P145, DOI 10.2307/2981918; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109	42	47	50	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	FEB	2006	59	2					132	143		10.1016/j.jclinepi.2005.06.009			12	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	011FL	WOS:000235253400004	16426948				2021-06-18	
J	Gao, WM; Chadha, MS; Kline, AE; Clark, RSB; Kochanek, PM; Dixon, CE; Jenkins, LW				Gao, WM; Chadha, MS; Kline, AE; Clark, RSB; Kochanek, PM; Dixon, CE; Jenkins, LW			Immunohistochemical analysis of histone H3 acetylation and methylation - Evidence for altered epigenetic signaling following traumatic brain injury in immature rats	BRAIN RESEARCH			English	Article						epigenetic; hippocampus; pediatric; posttranslational modification; acetylation; methylation	CONTROLLED CORTICAL IMPACT; GENE-EXPRESSION; PATHWAYS; KINASE; HIPPOCAMPUS; NEURONS; MILD; CODE	Posttranslational modifications (PTMs) of histone proteins may result in altered epigenetic signaling after pediatric traumatic brain injury (TBI). Hippocampal histone H3 acetylation and methylation in immature rats after moderate TBI were measured and decreased only in CA3 at 6 h and 24 h with persistent methylation decreases up to 72 h after injury. Decreased histone H3 acetylation and methylation suggest altered hippocampal CA3 epigenetic signaling during the first hours to days after TBI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Jenkins, LW (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	ljenkins@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042648] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686, T-32 HD 40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042648-04, R01 NS042648, NS42648] Funding Source: Medline		Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dunn BK, 2003, ANN NY ACAD SCI, V983, P1, DOI 10.1111/j.1749-6632.2003.tb05957.x; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Korzus E, 2004, NEURON, V42, P961, DOI 10.1016/j.neuron.2004.06.002; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; SWANK MW, 2001, INCREASED HISTONE AC	23	47	48	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 27	2006	1070	1					31	34		10.1016/j.brainres.2005.11.038			4	Neurosciences	Neurosciences & Neurology	023BB	WOS:000236099000004	16406269	Green Accepted			2021-06-18	
J	Serino, A; Ciaramelli, E; Di Santantonio, A; Malagu, S; Servadei, F; Ladavas, E				Serino, A; Ciaramelli, E; Di Santantonio, A; Malagu, S; Servadei, F; Ladavas, E			Central executive system impairment in traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; central executive system; attentional and memory disorders	CLOSED-HEAD INJURY; DUAL-TASK PERFORMANCE; WORKING-MEMORY; ATTENTIONAL DEFICITS; DIVIDED ATTENTION; PREFRONTAL CORTEX; EPISODIC MEMORY; FRONTAL LOBES; PATTERNS; COMPLAINTS	Primary objective: This study investigated whether cognitive impairment after traumatic brain injury (TBI) can be considered a consequence of (1) a speed processing deficit or (2) an impairment of the Central Executive System (CES) of working memory. Methods and procedures: Thirty-seven TBI patients underwent a standardized battery of neuropsychological tests evaluating speed processing, sustained attention, short-term memory, working memory, divided attention, executive functions and long-term memory. Main outcomes and results: Patients showed severe deficits in working memory, divided attention, executive functions and long-term memory. Divided attention, long-term memory and executive functions deficits significantly correlated with working memory, but not with speed processing deficits. Moreover, multiple regression analyses showed that a CES impairment and not a speed processing deficit predicted divided attention, executive functions and long-term memory deficits. The severity and the site of brain lesions did not predict the level of CES or speed processing impairment. Conclusions: The cognitive impairment following TBI seem to be caused by an impairment of the Central Executive System, rather than a speed processing deficit.	Univ Bologna, Dipartimento Psicol, I-40127 Bologna, Italy; Ctr Studi & Ric Neurosci Cognit, Cesena, Italy; Osped Bufalini, Cesena, Italy	Ladavas, E (corresponding author), Univ Bologna, Dipartimento Psicol, I-40127 Bologna, Italy.	elisabetta.ladavas@unibo.it		LADAVAS, ELISABETTA/0000-0001-8930-725X; Servadei, Franco/0000-0002-3595-3464			Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; BADDELY A, 1986, WORKING MEMORY; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Braver TS, 2001, NEUROIMAGE, V14, P48, DOI 10.1006/nimg.2001.0791; Bunge SA, 2000, P NATL ACAD SCI USA, V97, P3573, DOI 10.1073/pnas.050583797; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; CULBERTSON WC, 2001, TOWER LONDON; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kuzma BB, 2000, SURG NEUROL, V53, P400; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miller E, 1970, Cortex, V6, P121; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Moscovitch M, 1997, NEUROPSYCHOLOGIA, V35, P1017, DOI 10.1016/S0028-3932(97)00028-6; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Nyberg L, 2003, NEUROPSYCHOLOGIA, V41, P371, DOI 10.1016/S0028-3932(02)00168-9; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; SPINNLER H, 1987, ITALIAN J NEUROLOGIC, V8; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; TEASDALE G, 1974, LANCET, V2, P81; Tulving E., 2000, OXFORD HDB MEMORY; Umile EM, 1998, BRAIN INJURY, V12, P577; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V79, P81; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wagner AD, 1999, NEURON, V22, P19, DOI 10.1016/S0896-6273(00)80674-1; ZIMMERMAN P, 1992, TESTBATTERIE AUFMERK; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6; ZOCCOLOTTI P, 1994, BATTERIA TEST ESAME	57	47	47	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					23	32		10.1080/02699050500309627			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000003	16403697				2021-06-18	
J	Youse, KM; Coelho, CA				Youse, KM; Coelho, CA			Working memory and discourse production abilities following closed-head injury	BRAIN INJURY			English	Article						working memory; discourse production; closed-head injury	TRAUMATIC BRAIN-INJURY; NARRATIVES; COHESION; MILD	Primary objectives: This study investigated the relationship between working memory (WM) and narrative discourse production in individuals with closed head injury (CHI). It was hypothesized that those individuals with higher performance on tests of WM would demonstrate better performance on measures of discourse production. Research design: Correlation coefficients were calculated among five discourse measures from two story narratives and scores from three sub-tests of the Wechsler Memory Scale (WMS). Methods and procedures: Fifty-five individuals with moderate-to-severe CHI were studied. Participants included 16 females and 39 males ranging in age from 16 - 69. Narrative discourse samples were elicited from all participants under two conditions: story retelling and story generation. Main outcomes and results: The results revealed a number of modest, significant correlations (r = 0.29 - 0.39, p < 0.05) between sub-tests of the WMS and measures of discourse production. Conclusions: Results supported the hypothesis. Story elicitation task differences, limitations of using simple memory span tests as indices of WM and clinical implications of the relationship between WM and discourse production are discussed.	Univ Connecticut, Dept Commun Sci, CCC SLP, Unit 1085, Storrs, CT 06269 USA	Youse, KM (corresponding author), Univ Connecticut, Dept Commun Sci, CCC SLP, Unit 1085, Storrs, CT 06269 USA.	kyouse@prodigy.net					Baddeley A. D., 1986, WORKING MEMORY; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BODY R, 1999, BRAIN DAM B, P81; Caspari I, 1998, BRAIN COGNITION, V37, P205, DOI 10.1006/brcg.1997.0970; Caspari I, 2000, J NEUROLINGUIST, V13, P15, DOI 10.1016/S0911-6044(99)00009-3; CHERNEY LR, 1998, ANAL DISCOURSE COMMU, P1; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Gathercole S. E., 1993, WORKING MEMORY LANGU; HAGEN C, 1998, REHABILITATION HEAD; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hughes D., 1997, GUIDE NARRATIVE LANG; Hunt K., 1970, MONOGRAPHS SOC RES C, V35; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Mattis S, 1976, GERIATRIC PSYCHIAT, P77; MCDONALD S, 1999, BRAIN DAM B, P19; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Murray Laura L., 2001, Seminars in Speech and Language, V22, P127; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow PC, 2000, BRAIN INJURY, V14, P397; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Wechsler D., 1945, WECHSLER MEMORY SCAL; Winter P., 1976, BEAR FLY; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	35	47	49	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					1001	1009		10.1080/02699050500109951			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700006	16263642				2021-06-18	
J	Zhang, OH; Teo, EC; Ng, HW				Zhang, OH; Teo, EC; Ng, HW			Development and validation of a C0-C7FE complex for biomechanical study	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							HUMAN CERVICAL-SPINE; NONLINEAR FINITE-ELEMENT; MECHANICAL-PROPERTIES; MODEL; HEAD; SIMULATION; COMPONENTS; VERTEBRA; INJURY; DISC	In this study, the digitized geometrical data of the embalmed skull and vertebrae (C0-C7) of a 68-year old male cadaver were processed to develop a comprehensive, geometrically accurate, nonlinear C0-C7 FE model. The biomechanical response of human neck under physiological static loadings, near vertex drop impact and rear-end impact (whiplash) conditions were investigated and compared with published experimental results. Under static loading conditions; the predicted moment-rotation relationships of each motion segment under moments in midsagittal plane and horizontal plane agreed well with experimental data. In addition, the respective predicted head impact force history and the S-shaped kinematics responses of head-neck complex under near-vertex drop impact and rear-end conditions were close to those observed in reported experiments. Although the predicted responses of the head-neck complex under any specific condition cannot perfectly match the experimental observations, the model reasonably reflected the rotation distributions among the motion segments under static moments and basic responses of head and neck under dynamic loadings. The current model may offer potentials to effectively reflect the behavior of human cervical spine suitable for further biomechanics and traumatic studies.	Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 2263, Singapore		mecteo@ntu.edu.sg	Teo, Ee Chon/F-7308-2010				Camacho DLA, 1999, J BIOMECH, V32, P293, DOI 10.1016/S0021-9290(98)00178-X; DENG YC, 1987, J BIOMECH, V20, P487, DOI 10.1016/0021-9290(87)90249-1; GIBSON LJ, 1997, CELL SOLIDS STRUCTUR; GILAD I, 1986, SPINE, V11, P154, DOI 10.1097/00007632-198603000-00010; GOEL VK, 1988, J BIOMECH, V21, P673, DOI 10.1016/0021-9290(88)90204-7; Goel VK, 1998, SPINE, V23, P684, DOI 10.1097/00007632-199803150-00008; Lee CK, 2000, SPINE, V25, P2431, DOI 10.1097/00007632-200010010-00003; Linder A, 2000, ACCIDENT ANAL PREV, V32, P261, DOI 10.1016/S0001-4575(99)00085-8; Ng HW, 2001, J SPINAL DISORD, V14, P201, DOI 10.1097/00002517-200106000-00003; Nightingale RW, 2002, J BIOMECH, V35, P725, DOI 10.1016/S0021-9290(02)00037-4; ONO K, 1997, 41 STAPP CAR C LAK B; Panjabi M M, 1998, Eur Spine J, V7, P484, DOI 10.1007/s005860050112; Panjabi MM, 1998, CLIN BIOMECH, V13, P239, DOI 10.1016/S0268-0033(98)00033-3; Panjabi MM, 1998, SPINE, V23, P17, DOI 10.1097/00007632-199801010-00005; Panjabi MM, 2001, SPINE, V26, P2692, DOI 10.1097/00007632-200112150-00012; Panjabi MM, 1998, SPINE, V23, P2684, DOI 10.1097/00007632-199812150-00007; Puttlitz CM, 2000, SPINE, V25, P1607, DOI 10.1097/00007632-200007010-00003; Race A, 2000, SPINE, V25, P662, DOI 10.1097/00007632-200003150-00003; SHIRAZIADL SA, 1984, SPINE, V9, P120, DOI 10.1097/00007632-198403000-00003; Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756-3282(97)00100-2; Stemper BD, 2004, MED BIOL ENG COMPUT, V42, P333, DOI 10.1007/BF02344708; Stemper BD, 2000, BIOMED SCI INSTRUM, V395, P331; STEMPER BD, 2004, THESIS MARQUETTE U; Teo EC, 2001, J BIOMECH, V34, P13, DOI 10.1016/S0021-9290(00)00169-X; YANG KH, 1998, 42 STAPP CAR CRASH C; Yoganandan N, 1996, SPINE, V21, P1824, DOI 10.1097/00007632-199608010-00022; Yoganandan N, 2000, J BIOMECH ENG-T ASME, V122, P623, DOI 10.1115/1.1322034; 1998, CERVICAL SPINE	28	47	71	0	10	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	OCT	2005	127	5					729	735		10.1115/1.1992527			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	968WI	WOS:000232193200001	16248301				2021-06-18	
J	Barbic, D; Pater, J; Brison, RJ				Barbic, D; Pater, J; Brison, RJ			Comparison of mouth guard designs and concussion prevention in contact sports - A multicenter randomized controlled trial	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; minor brain injury; prevention; mouth protector; controlled trial	TRAUMATIC BRAIN-INJURY; COLLEGE FOOTBALL; MOUTHGUARDS; MANAGEMENT; CLUSTER	Objectives: To compare the effectiveness of the WIPSS mouth guard to other currently used mouth guards in the prevention of concussion injuries in athletes participating in varsity football and rugby. Design: Multicenter, cluster-randomized, controlled trial comparing the WIPSS Brain-Pad mouth guard against the standard use mouth guard of choice. Teams were monitored by their respective athletic therapist, trainer, or sports physician for 1 playing season to diagnose and record incident concussion injuries and dental trauma. Concussion symptoms were also recorded at the time of injury. Setting: Five Ontario universities. Participants: University male football (394) and university male (129) and female (123) rugby athletes reporting to 2003 fall training camps. Main Outcome Measurements: The primary end point was the incidence of any diagnosed concussion events during the 2003 playing season as defined by the American Academy of Neurology Concussion Guidelines. Secondary endpoints included the incidence of dental trauma events and observed concussion symptoms. Results: There was no significant difference in the number of concussions observed between the intervention and control arms of this trial (P = 0.79; odds ratio, 1.06, in favor of controls; 95% CI 0.51, >> 1.61). No dental trauma events occurred. The 5 most common symptoms experienced by concussed athletes were dizziness, general headache, nausea, loss of visual focus, and personality changes. Conclusions: in this study, concussion rates were not significantly different for varsity football and rugby players who wore the WIPSS Brain-Pad mouth guard compared with other types of mouth guards.	Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON, Canada; Queens Univ, Clin Trials Div, Inst Canc, Kingston, ON, Canada; Queens Univ, Dept Emergency Med, Kingston, ON, Canada	Barbic, D (corresponding author), 2165 Gibraltar Rd,RR6, Kingston, ON K7L 4V3, Canada.	8db@qlink.queensu.ca					Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DONNER A, 1992, STAT MED, V11, P743, DOI 10.1002/sim.4780110605; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; GARRAWAY M, 1995, LANCET, V345, P1485; GREEN K, 1985, CANADIAN AMATEUR FOO; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 2000, SEMIN NEUROL, V20, P165, DOI 10.1055/s-2000-9835; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MASTRANGELO FA, 1989, SAFETY ICE HOCKEY, P52; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; Morton J G, 1979, N Z Dent J, V75, P151; Newsome P R, 2001, Int J Paediatr Dent, V11, P396, DOI 10.1046/j.0960-7439.2001.00304.x; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SEALS RR, 1985, J AM DENT ASSOC, V110, P904, DOI 10.14219/jada.archive.1985.0005; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	26	47	47	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2005	15	5					294	298		10.1097/01.jsm.0000171883.74056.21			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	975OR	WOS:000232672300003	16162986				2021-06-18	
J	Dockree, PM; Kelly, SP; Robertson, IH; Reilly, RB; Foxe, JJ				Dockree, PM; Kelly, SP; Robertson, IH; Reilly, RB; Foxe, JJ			Neurophysiological markers of alert responding during goal-directed behavior: A high-density electrical mapping study	NEUROIMAGE			English	Article						sustained attention; go/no-go task; high-density ERPs; lapses of attention; early visual attention; selection negativity; goal-directed behavior; delayed intentions	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; SELECTIVE ATTENTION; INTRINSIC ALERTNESS; GO/NOGO TASK; INHIBITION; POTENTIALS; HUMANS; CORTEX; COLOR	The ability to dynamically modulate the intensity of sustained attention (i.e., alertness) is an essential component of the human executive control system, allowing us to function purposefully in accordance with our goals. In this study we examine high-density ERP markers of alert responding during the fixed sequence sustained attention to response task (SART(fixed)). This paradigm has proven to be a sensitive clinical metric in patient populations with deficits in their ability to sustain attention (e.g., attention deficit hyperactivity disorder). In this task subjects withhold a button press to an infrequent no-go target (W) embedded within a predictable sequence of numbers ('1' to '9'). Our data reveal a complex pattern of effects across the trial sequence of the SART, with clear contributions from frontal and parietal cortices to sustained attentional performance. Over occipito-parietal regions, early visual attention processes were increased during trial 2 (i.e., trial in which the digit '2' was presented) and trial 3, giving rise to the so-called selection negativity (SN). Two prominent late components were manifest during trial 2: LP1 (550-800 ms) and LP2 (850-1150 ms) over occipito-parietal and central sites. We interpret the LP1 component on trial 2 as reflecting retrieval of the task goal and the subsequent LP2 as reflecting competition between the currently relevant go response and the subsequent no-go response. On trial 3, an enhanced "no-go N2" (250-450 ms) was seen fronto-centrally in the absence of the "no-go P3" that typically follows. Fronto-polar activity was also seen across all trials and may be indicative of subgoal processes to integrate the association between stimulus and goal. Prior to a lapse of attention (i.e., failure to inhibit a response to "3") the LP1 was significantly attenuated on the preceding trial 2 indicating a failure of anticipatory goal-directed processing. The results are discussed in terms of models of sustained attention involving frontal and parietal cortices. (c) 2005 Elsevier Inc. All rights reserved.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Dublin 2, Ireland; Univ Coll Dublin, Dept Elect & Elect Engn, Dublin 4, Ireland; Nathan S Kline Inst Psychiat Res, Cognit Neurophysiol Lab, Orangeburg, NY 10962 USA; CUNY City Coll, Dept Psychol, Program Cognit Neurosci, New York, NY 10031 USA	Dockree, PM (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	dockreep@tcd.ie	Reilly, Richard/N-1080-2019; Reilly, Richard B/F-7034-2011	Reilly, Richard/0000-0001-8578-1245; Reilly, Richard B/0000-0001-8578-1245; Robertson, Ian H/0000-0001-8637-561X; Kelly, Simon/0000-0003-4981-3099; Kelly, Simon/0000-0001-9983-3595; Foxe, John/0000-0002-4300-3098	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG22696] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH63434, MH65350] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH063434, R01MH065350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG022696] Funding Source: NIH RePORTER		Anllo-Vento L, 1998, HUM BRAIN MAPP, V6, P216, DOI 10.1002/(SICI)1097-0193(1998)6:4<216::AID-HBM3>3.0.CO;2-6; AnlloVento L, 1996, PERCEPT PSYCHOPHYS, V58, P191, DOI 10.3758/BF03211875; Badre D, 2004, NEURON, V41, P473, DOI 10.1016/S0896-6273(03)00851-1; Bekker EM, 2004, CLIN NEUROPHYSIOL, V115, P2001, DOI 10.1016/j.clinph.2004.04.008; Brandimonte M., 1996, PROSPECTIVE MEMORY T; Braver TS, 2002, NEUROIMAGE, V15, P523, DOI 10.1006/nimg.2001.1019; Bruin KJ, 2001, CLIN NEUROPHYSIOL, V112, P1660, DOI 10.1016/S1388-2457(01)00601-0; Comerchero MD, 1998, COGNITIVE BRAIN RES, V7, P41, DOI 10.1016/S0926-6410(98)00009-3; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Dreher JC, 2002, NEUROIMAGE, V17, P95, DOI 10.1006/nimg.2002.1169; EIMER M, 1993, BIOL PSYCHOL, V35, P123, DOI 10.1016/0301-0511(93)90009-W; FALKENSTEIN M, 1995, PERSPECTIVES EVENT S, V44, P287; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Foxe JJ, 2002, EXP BRAIN RES, V142, P139, DOI 10.1007/s00221-001-0906-7; Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030; FOXE JJ, IN PRESS EXP BRAIN R; Fu KMG, 2001, COGNITIVE BRAIN RES, V12, P145, DOI 10.1016/S0926-6410(01)00034-9; GUTHRIE D, 1991, PSYCHOPHYSIOLOGY, V28, P240, DOI 10.1111/j.1469-8986.1991.tb00417.x; HARTER MR, 1984, ANN NY ACAD SCI, V425, P210, DOI 10.1111/j.1749-6632.1984.tb23535.x; KENEMANS JL, 1993, ELECTROEN CLIN NEURO, V88, P51, DOI 10.1016/0168-5597(93)90028-N; KLIMESCH W, 1998, CLIN NEUROPHYSIOL, V108, P123; KOK A, 1986, BIOL PSYCHOL, V23, P21, DOI 10.1016/0301-0511(86)90087-6; Kok A, 2004, PSYCHOPHYSIOLOGY, V41, P9, DOI 10.1046/j.1469-8986.2003.00127.x; Lang S, 2002, CLIN NEUROPHYSIOL, V113, P1734, DOI 10.1016/S1388-2457(02)00267-5; MANGUN GR, 1991, J EXP PSYCHOL HUMAN, V17, P1057, DOI 10.1037/0096-1523.17.4.1057; MANGUN GR, 1987, CURRENT TRENDS EVENT, P118; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; MANTYLA T, 1993, PROSPECTIVE MEMORY T, P93; MCAVINUE L, 2005, NEUROPSYCHOL REHABIL, P15; McDaniel MA, 2004, J EXP PSYCHOL LEARN, V30, P605, DOI 10.1037/0278-7393.30.3.605; Molholm S, 2004, CEREB CORTEX, V14, P452, DOI 10.1093/cercor/bhh007; Molholm S, 2002, COGNITIVE BRAIN RES, V14, P115, DOI 10.1016/S0926-6410(02)00066-6; MULHOLLAND TB, 1965, NATURE, V206, P746, DOI 10.1038/206746a0; Murray MM, 2001, NEUROPSYCHOLOGIA, V39, P828, DOI 10.1016/S0028-3932(01)00004-5; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; O'Donnell BF, 1997, BRAIN TOPOGR, V10, P133, DOI 10.1023/A:1022203811678; PFEFFERBAUM A, 1985, ELECTROEN CLIN NEURO, V60, P423, DOI 10.1016/0013-4694(85)91017-X; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Posner MI, 2000, PSYCHOL BULL, V126, P873, DOI 10.1037/0033-2909.126.6.873; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Potts GF, 2004, INT J PSYCHOPHYSIOL, V52, P197, DOI 10.1016/j.ijpsycho.2003.10.005; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROBERTSON LH, 2004, COGNITIVE NEUROSCIEN; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Smid HGOM, 1999, PSYCHOPHYSIOLOGY, V36, P264, DOI 10.1017/S0048577299971135; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P563, DOI 10.1016/j.neuropsychologia.2003.11.004; West R, 2001, COGNITIVE BRAIN RES, V12, P1, DOI 10.1016/S0926-6410(01)00014-3; West R, 2005, NEUROPSYCHOLOGIA, V43, P418, DOI 10.1016/j.neuropsychologia.2004.06.012; Worden MS, 2000, J NEUROSCI, V20; Wylie GR, 2003, NEUROIMAGE, V20, P2322, DOI 10.1016/j.neuroimage.2003.08.010	56	47	48	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	SEP	2005	27	3					587	601		10.1016/j.neuroimage.2005.05.044			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	959UA	WOS:000231543600011	16024257				2021-06-18	
J	Ducreux, D; Huynh, I; Fillard, P; Renoux, J; Petit-Lacour, MC; Marsot-Dupuch, K; Lasjaunias, P				Ducreux, D; Huynh, I; Fillard, P; Renoux, J; Petit-Lacour, MC; Marsot-Dupuch, K; Lasjaunias, P			Brain MR diffusion tensor imaging and fibre tracking to differentiate between two diffuse axonal injuries	NEURORADIOLOGY			English	Article								We report here two cases of diffuse axonal injury (DAI) studied by MR diffusion tensor imaging (DTI) and fibre tracking (FT) focused on the corpus callosum. In one case, DTI and FT pattern matched the diagnosis of broken white matter tracts. In the other case there was a discrepancy between DTI and FT data that showed unaltered white matter tracts with the presence of intra-cellular oedema. These data suggested that DTI and FT are able to differentiate between traumatic cytotoxic oedema and broken fibres in the case of DAI.	Univ Paris 11, CHU Bicetre, Dept Neuroradiol, F-94270 Le Kremlin Bicetre, France; Univ N Carolina, Dept Comp Sci, Chapel Hill, NC USA	Ducreux, D (corresponding author), Univ Paris 11, CHU Bicetre, Dept Neuroradiol, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.	denis.ducreux@bct.ap-hop-paris.fr					Atlas S. W., 1996, MAGNETIC RESONANCE I; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1998, 6 ISMRM SYDN AU, P1226; FILLARD P, 2003, MICCAI, V2, P967; Holbourn AHS, 1943, LANCET, V2, P438; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; Le Bihan D, 1991, Magn Reson Q, V7, P1; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Wang HD, 1998, CHINESE MED J-PEKING, V111, P59; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1	12	47	52	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	AUG	2005	47	8					604	608		10.1007/s00234-005-1389-1			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	958CD	WOS:000231421400007	15973535				2021-06-18	
J	Bekinschtein, T; Tiberti, C; Niklison, J; Tamashiro, M; Ron, M; Carpintiero, S; Villarreal, M; Forcato, C; Leiguarda, R; Manes, F				Bekinschtein, T; Tiberti, C; Niklison, J; Tamashiro, M; Ron, M; Carpintiero, S; Villarreal, M; Forcato, C; Leiguarda, R; Manes, F			Assessing level of consciousness and cognitive changes from vegetative state to full recovery	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			MINIMALLY RESPONSIVE PATIENTS; TRAUMATIC BRAIN INJURY; TEST BATTERY; HEAD-INJURY; COMA; DISORDERS; OUTCOMES; SCALE	Although investigations addressing cognitive recovery from the vegetative state have been reported, to date there have been no detailed studies of these patients combining both neuropsychology and functional imaging to monitor and record the recovery of consciousness. This paper describes the recovery of a specific vegetative state (VS) case. The patient (OG) remained in the vegetative state for approximately two months, increasing her level of awareness to a minimally conscious state, where she continued for approximately 70 days. In the course of the ensuing 18 months, she was able to reach an acceptable level of cognitive functioning, with partial levels of independence. Throughout this two year period, she received continuous cognitive evaluation, for which several different tools were applied including coma and low functioning scales, full cognitive batteries, and structural and functional magnetic resonance imaging (MRI). We present here preliminary data on fMRI using a word presentation paradigm before and after recovery; we also discuss the difficulty of how to determine level of consciousness using the tools currently available, and the subsequent improvement in different cognitive domains. We confirm that accurate diagnosis and proper cognitive assessment are critical for the rehabilitation of patients with disorders of consciousness.	Neurol Res Inst, FLENI, Dept Neurol, Cognit Neurol Sect, RA-1428 Buenos Aires, DF, Argentina	Manes, F (corresponding author), Neurol Res Inst, FLENI, Dept Neurol, Cognit Neurol Sect, Montaneses 2325, RA-1428 Buenos Aires, DF, Argentina.	fmanes@fleni.org.ar		Bekinschtein, Tristan/0000-0001-5501-8628			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bekinschtein T, 2004, J NEUROL NEUROSUR PS, V75, P788, DOI 10.1136/jnnp.2003.034876; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2004, J HEAD TRAUMA REHAB, V19, P254, DOI 10.1097/00001199-200405000-00006; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P52, DOI 10.1016/S0003-9993(98)90208-8; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Lombardi F, 2002, CLIN REHABIL, V16, P464, DOI 10.1191/0269215502cr519oa; Mathuranath PS, 2000, NEUROLOGY, V55, P1613, DOI 10.1212/01.wnl.0000434309.85312.19; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Richer E., 2003, Annales de Readaptation et de Medecine Physique, V46, P177, DOI 10.1016/S0168-6054(03)00051-5; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson BA, 2001, BRAIN INJURY, V15, P1083, DOI 10.1080/02699050110082197; Wilson FC, 2002, NEUROREHABILITATION, V17, P231	25	47	48	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					307	322		10.1080/09602010443000443			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900018	16350974				2021-06-18	
J	Reichard, RR; Smith, C; Graham, DI				Reichard, RR; Smith, C; Graham, DI			The significance of beta-APP immunoreactivity in forensic practice	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						beta-APP; diffuse traumatic axonal injury; immunohistochemistry	AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; CEREBRAL WHITE-MATTER; HEAD-INJURY; DAMAGE; HYPOGLYCEMIA; DIAGNOSIS; AUTOPSIES; HYPOXIA; BRAIN	The neuropathologist involved in forensic work is not uncommonly confronted with a case in which there is no or only a limited history or, if available, the information is uncertain or is often conflicting. In recent years the immunohistochemical stain beta-amyloid precursor protein (beta-APP) has been used to assess the extent of axonal injury in a variety of pathological processes but in forensic practice is of greatest utility in the assessment of traumatic brain injury. Diffuse traumatic axonal injury (TAI) in humans has been demonstrated by beta-APP immunoreactivity in patients surviving at least 2 h after head injury. However, many of these patients also have an associated ischaemic injury, either focal or diffuse, which may make the interpretation of beta-APP immunoreactivity difficult. The present study was designed to evaluate if the published descriptions of the different morphological patterns and distributions of beta-APP immunoreactive axons could be used to microscopically distinguish axonal injury attributed to trauma from other causes. To test this hypothesis a total of 73 cases were reviewed. The cases were selected from six different groups based on clinical information. Immunostained sections from each case were assessed 'blind' to the clinical history, and the microscopic pattern and distribution of beta-APP positive axons were recorded. Haematoxylin and eosin (H+E) stained sections were then reviewed for each case and a final pathological diagnosis was recorded and compared to the clinical history. 62/73 (85%) cases were correctly correlated with the clinical history and in particular 14/17 (82%) cases of TAI were correctly identified. These findings indicate that the published microscopic patterns of the distribution of beta-APP positive axons in TAI and in diffuse ischaemic injury can be used, in conjunction with microscopy of H+E stained sections to determine the cause of axonal pathology in most cases.	Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ New Mexico, Med Infestigator Off, Albuquerque, NM 87131 USA	Smith, C (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland.	col.smith@ed.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AUER RN, 1989, CLIN NEUROPATHOL, V8, P63; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Dolinak D, 2000, NEUROPATH APPL NEURO, V26, P448, DOI 10.1046/j.1365-2990.2000.00273.x; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GRAHAM DI, 2001, CPD B CELL PATHOL, V3, P148; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Reichard RR, 2003, J NEUROPATH EXP NEUR, V62, P237, DOI 10.1093/jnen/62.3.237; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163	20	47	49	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	JUN	2005	31	3					304	313		10.1111/j.1365-2990.2005.00645.x			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	924YA	WOS:000229015900006	15885067				2021-06-18	
J	Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Garbe, J; Bouillon, B; Neugebauer, E; Klug, N; Lefering, R; Neiss, WF; Angelov, DN				Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Garbe, J; Bouillon, B; Neugebauer, E; Klug, N; Lefering, R; Neiss, WF; Angelov, DN			Multimodal early onset stimulation combined with enriched environment is associated with reduced CNS lesion volume and enhanced reversal of neuromotor dysfunction after traumatic brain injury in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						brain injury; enriched environment; lesion volume; neurological recovery; rat; stimulation	FLUID PERCUSSION INJURY; NEURON-SPECIFIC ENOLASE; SPATIAL MEMORY; VOLUNTARY EXERCISE; COGNITIVE FUNCTION; CEREBRAL EDEMA; UP-REGULATION; ADULT-RAT; IN-VITRO; RECOVERY	This study was designed to determine whether exposure to multimodal early onset stimulation (MEOS) combined with environmental enrichment (EE) after traumatic brain injury (TBI) would improve neurological recovery and to elucidate its morphological correlates. Male Sprague-Dawley rats were subjected to lateral fluid percussion (LFP) brain injury or to sham operation. After LFP, one-third of the animals (injured and sham) were placed under conditions of standard housing (SH), one-third were kept in EE only, and one-third received EE + MEOS. Assessment of neuromotor function 24 h post-injury using a standardized composite neuroscore test revealed an identical pattern of neurological impairment in all animals subjected to LFP. Neuromotor dysfunction in SH animals remained on a similar level throughout the experiment, while improvements were noted in both other groups 7 days post-injury (dpi). On 15 dpi, reversal of neuromotor dysfunction was significantly better in EE + MEOS animals vs. SH- and EE-only groups. In parallel, the comparison of lesion volume in EE + MEOS- vs. EE-only vs. SH rats revealed that animals exposed to EE + MEOS had consistently the lowest values (mm(3), mean +/- SD; n = 6 rats in each group) as measured in serial brain sections immunostained for neuron-specific enolase (5.2 +/- 3.4 <= 5.5 +/- 4.1 < 9.5 +/- 1.9), caspase 3-active/C3A (5.9 +/- 4.0 <= 6.4 +/- 3.9 < 10.3 +/- 1.8) and glial fibrillary acidic protein (6.0 +/- 3.4 <= 6.5 +/- 4.3 < 10.7 +/- 1.2). This first report on the effect of EE + MEOS treatment strongly indicates that the combined exposure reduces CNS scar formation and reverses neuromotor deficits after TBI in rats.	Univ Cologne, Inst Anat 1, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Biochem & Expt Div, D-5000 Cologne, Germany; Univ Witten Herdecke, Merheim Med Ctr, Dept Surg, Cologne, Germany; Univ Cologne, Fac Med, Dept Neurosurg, D-5000 Cologne, Germany; Merheim Med Ctr, Dept Neurol, Cologne, Germany	Angelov, DN (corresponding author), Univ Cologne, Inst Anat 1, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	angelov.anatomie@uni-koeln.de					Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANGELOV DN, 1994, J NEUROCYTOL, V23, P218, DOI 10.1007/BF01275526; ANGELOV DN, 1995, GLIA, V13, P113, DOI 10.1002/glia.440130205; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Czeh B, 1998, HIPPOCAMPUS, V8, P647, DOI 10.1002/(SICI)1098-1063(1998)8:6<647::AID-HIPO7>3.3.CO;2-C; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gruner ML, 2000, BRAIN INJURY, V14, P585; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; INGLIS FM, 1995, NEUROSCIENCE, V66, P81, DOI 10.1016/0306-4522(94)00578-S; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Young D, 1999, NAT MED, V5, P448	68	47	51	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2005	21	9					2406	2418		10.1111/j.1460-9568.2005.04070.x			13	Neurosciences	Neurosciences & Neurology	928PN	WOS:000229284100010	15932599				2021-06-18	
J	Maegele, M; Riess, P; Sauerland, S; Bouillon, B; Hess, S; McIntosh, TK; Mautes, A; Brockmann, M; Koebke, J; Knifka, J; Neugebauer, EAM				Maegele, M; Riess, P; Sauerland, S; Bouillon, B; Hess, S; McIntosh, TK; Mautes, A; Brockmann, M; Koebke, J; Knifka, J; Neugebauer, EAM			Characterization of a new rat model of experimental combined neurotrauma	SHOCK			English	Article						combined neurotrauma; fluid percussion; tibia fracture; inflammatory response; interleukin 6; callus formation; animal model	TRAUMATIC BRAIN-INJURY; MULTIPLE ORGAN FAILURE; HEMORRHAGIC-SHOCK; HEAD-INJURY; FRACTURE REPAIR; CEREBRAL EDEMA; MAJOR TRAUMA; INTERLEUKIN-6; SEVERITY; ASSOCIATION	Traumatic brain injury (TBI) is present in two-thirds of patients with multiple injuries and in one-third combined with injuries of the extremities. Studies on interactive effects between central and peripheral injuries are scarce due to the absence of clinically relevant models. To meet the demand for "more-hit" models, an experimental model of combined neurotrauma (CNT) incorporating a standardized TBI via lateral fluid percussion (LFP) together with a peripheral bone fracture, i.e., tibia fracture, is introduced. Sprague-Dawley rats were randomized to four experimental groups: controls (n = 10), animals with TBI (n = 30), animals with tibia fracture (n = 30), and animals with CNT (n = 30). Morphological aspects of brain and bone injury were analyzed via standard histopathological procedures and x-ray. Trauma-induced neuromotor dysfunction was assessed using a standardized neuroscore. For interactive effects between injuries, we studied the extent and temporal pattern of circulating interleukin 6 (IL-6) levels via immunoassay and callus formation at fracture sites by means of microradiography. LFP produced an ipsilateral lesion with cortical contusion, hemorrhage, mass shift, and neuronal cell loss (adjacent cortex and hippocampus CA-2/-3), along with contralateral neuromotor dysfunction. X-rays confirmed complete fractures in the middle of the bone shaft. The type of injury (P < 0.001) and time (P = 0.022) were significantly associated with increased IL-6 levels. CNT produced the highest IL-6 plasma levels with a maximum peak at 6 h after trauma (P < 0.001). Similarly, callus formation at fracture sites in CNT was significantly increased versus fracture only (P < 0,01). The CNT model mimics a variety of clinically relevant features known from human multiple injury, including TBI, and offers novel approaches for investigation of interactive mechanisms and therapeutic approaches.	Univ Cologne, Med Fac, Biochem & Expt Div, D-51109 Cologne, Germany; Univ Cologne, Med Fac, Dept Anat, D-51109 Cologne, Germany; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Saarland, Neurosurg Res Lab, Dept Neurosurg, D-66421 Homburg, Germany	Neugebauer, EAM (corresponding author), Univ Cologne, Med Fac, Biochem & Expt Div, Ostmerheimerstr 200, D-51109 Cologne, Germany.	sekretariat-neugebauer@uni-koeln.de		Sauerland, Stefan/0000-0003-1048-796X; Hess, Simone/0000-0003-0421-2863			Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BOURQUE WT, 1992, LAB ANIM SCI, V42, P369; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KURER MHJ, 1991, J BONE JOINT SU B S1, V73, P59; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; MAEGELE M, 2003, J REHAB RES S3, V40, P60; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH R, 1986, Q J MED, V61, P985; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STONE MH, 1987, J BONE JOINT SURG BR, V69, P493; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008; Wichmann MW, 1998, CRIT CARE MED, V26, P1372, DOI 10.1097/00003246-199808000-00024; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	41	47	51	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAY	2005	23	5					476	481		10.1097/01.shk.0000159929.87737.5c			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	923MH	WOS:000228913500014	15834316				2021-06-18	
J	Demetriades, D; Constantinou, C; Salim, A; Velmahos, G; Rhee, P; Chan, L				Demetriades, D; Constantinou, C; Salim, A; Velmahos, G; Rhee, P; Chan, L			Liver cirrhosis in patients undergoing laparotomy for trauma: Effect on outcomes	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							ABDOMINAL OPERATIONS; MORTALITY; SURVIVAL	BACKGROUND: There is little published work on the effect of cirrhosis on outcomes in trauma patients undergoing laparotomy. The aim of this study was to evaluate the risk of death or serious complications in cirrhotic trauma patients undergoing laparotomy as compared with that in a similar group of patients without cirrhosis. STUDY DESIGN: During a 12-year period, there were 46 patients with the diagnosis of liver cirrhosis made during laparotomy for trauma. Each patient was matched with two noncirrhotic controls on the basis of 7 criteria: age ( > 55, less than or equal to 55 years), gender, mechanism of injury (blunt, penetrating), Injury Severity Score ( less than or equal to 15, 16-25, > 25), head Abbreviated Injury Score ( < 3, greater than or equal to 3), chest Abbreviated Injury Score ( < 3, greater than or equal to 3), and abdominal. Abbreviated Injury Score ( < 3, greater than or equal to 3). Six cirrhotic patients were excluded because matching was not possible. The remaining 40 patients were matched with 80 noncirrhotic control patients selected from a pool of 4,771 patients who had trauma laparotomies. Outcomes included mortality, ARDS, pneumonia, renal failure, abdominal sepsis, disseminated intravascular coagulopathy, ICU and hospital stay, and hospital charges. Outcomes between the two study groups were compared with conditional logistic analysis. Hazard ratio (95% CI) and adjusted p value with the stepdown Bonferroni method were derived. RESULTS: The overall mortality in the cirrhotic group was significantly higher than that in the matched noncirrhotic group (45% versus 24%, hazard ratio: 7.60 [2.00, 28.94], p = 0.021). Mortality in patients with Injury Severity Score less than or equal to 15 was 29% in the cirrhotic group and 5% in the noncirrhotic group (p = 0.013) and in patients with Injury Severity Score 16-25, mortality was 56% and 11%, respectively (p = 0.024). The incidence of any of the predetermined complications was 45% in the cirrhotic group and 23% in the noncirrhotic group (p = 0.110). The mean surgical ICU stay was 11.5 days and 6.6 days, respectively (p = 0.037), and the mean hospital charges were $141,210 and $72,884, respectively (p = 0.031). CONCLUSIONS: Cirrhotic trauma patients undergoing laparotomy are at high risk of serious complications and death, even after fairly minor injuries. This group of patients should be admitted to the ICU for close monitoring and aggressive management irrespective of the severity of injuries. (C) 2004 by the American College of Surgeons.	Univ So Calif, LAC,Healthcare Network, Dept Surg, Div Trauma & Surg Crit Care, Los Angeles, CA 90031 USA	Demetriades, D (corresponding author), Univ So Calif, LAC,Healthcare Network, Dept Surg, Div Trauma & Surg Crit Care, 1200 N State St,Room 1105, Los Angeles, CA 90031 USA.						ARANHA GV, 1986, ARCH SURG-CHICAGO, V121, P275; DOBERNECK RC, 1983, AM J SURG, V146, P306, DOI 10.1016/0002-9610(83)90402-6; GARRISON RN, 1984, ANN SURG, V199, P648, DOI 10.1097/00000658-198406000-00003; Gines P, 2003, LANCET, V362, P1819, DOI 10.1016/S0140-6736(03)14903-3; Mansour A, 1997, SURGERY, V122, P730, DOI 10.1016/S0039-6060(97)90080-5; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; SIRINEK KR, 1987, ARCH SURG-CHICAGO, V122, P271; TINKOFF G, 1990, ANN SURG, V211, P172, DOI 10.1097/00000658-199002000-00009; Wahlstrom K, 2000, AM SURGEON, V66, P1071	9	47	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2004	199	4					538	542		10.1016/j.jamcollsurg.2004.06.017			5	Surgery	Surgery	860UI	WOS:000224368400003	15454135				2021-06-18	
J	Selassie, AW; Pickelsimer, EE; Frazier, L; Ferguson, PL				Selassie, AW; Pickelsimer, EE; Frazier, L; Ferguson, PL			The effect of insurance status, race, and gender on ED disposition of persons with traumatic brain injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						brain injury; emergency department; insurance status; race and gender	PROSPECTIVE-PAYMENT SYSTEM; SOCIOECONOMIC-STATUS; HEALTH-INSURANCE; MYOCARDIAL-INFARCTION; EMERGENCY-DEPARTMENT; RACIAL-DIFFERENCES; SEX-DIFFERENCES; UNITED-STATES; MEDICAL-CARE; RATES	The objective of this study was to assess the effect of insurance status and demographic characteristics on ED disposition among patients with traumatic brain injury (TBI). Statewide hospital discharge and ED datasets in South Carolina, 1996-2001, were analyzed by primary or secondary diagnosis of TBI in a multivariable logistic regression model. Of 70,671 unduplicated patients with TBI evaluated in the ED, 76% were treated and released; 26% had no insurance. The strongest predictors of hospital admission were TBI severity and preexisting health conditions. However, the uninsured and black females were less likely to be hospitalized after adjusting for demographic, clinical, and hospital characteristics (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.48-0.55 and OR, 0.79; CI, 0.72-0.87, respectively). Although this study does not infer causality, insurance status, race, and gender were significant predictors of hospital admission. These results suggest that inpatient resources are not equitably used. (C) 2004 Elsevier Inc. All rights reserved.	Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA; S Carolina Dept Hlth & Environm Control, Div Injury & Disabil Prevent, Columbia, SC 29201 USA	Selassie, AW (corresponding author), Med Univ S Carolina, Dept Biometry & Epidemiol, 135 Cannon St,POB 250835, Charleston, SC 29425 USA.	selassie@musc.edu			ODCDC CDC HHS [U17/CCU414981, U17/CCU411892] Funding Source: Medline		*ASS ADV AUT MED, 1990, ABBR INJ SCAL REV PL; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Baker DW, 2000, ARCH INTERN MED, V160, P1269, DOI 10.1001/archinte.160.9.1269; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; Baker SP, 1992, THE INJURY FACT BOOK; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P192; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CAMPBELL JA, 1998, P60208 CENS BUR US D; Canto JG, 2000, ARCH INTERN MED, V160, P817, DOI 10.1001/archinte.160.6.817; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Darlington GA, 1998, ENCY BIOSTATISTICS, P788; *DEP DIS SPEC NEED, 1999, S CAR TRAUM HEAD SPI; *DIV INJ DIS PREV, 1999, TRAUM BRAIN INJ SURV; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; Faulkner LA, 1997, AM J PREV MED, V13, P453; FLEISS JL, 1998, STAT METHODS RATES P, P58; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Harris D. Robert, 1997, Ethnicity and Disease, V7, P91; HIMMELSTEIN DU, 1995, AM J PUBLIC HEALTH, V85, P341, DOI 10.2105/AJPH.85.3.341; HOLL JL, 1995, ARCH PEDIAT ADOL MED, V149, P398, DOI 10.1001/archpedi.1995.02170160052008; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; MacKenzie EJ, 2000, J ORTHOP TRAUMA, V14, P455, DOI 10.1097/00005131-200009000-00001; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Marcin JP, 2003, AM J PUBLIC HEALTH, V93, P461, DOI 10.2105/AJPH.93.3.461; Mayberry RM, 2000, MED CARE RES REV, V57, P108, DOI 10.1177/107755800773743628; MCCARTHY ML, 1995, J TRAUMA, V39, P828, DOI 10.1097/00005373-199511000-00005; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; MILLS RJ, 2002, P60220 US DEP COMM; MILLS RJ, 2001, P60215 US DEP COMM; MISHEL L, 1998, STATE WORKING AM 199, P248; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; ROWLAND D, 1998, FUTURE US HEALTHCARE, P25; *SAS I INC, 2000, STAT AN SOFTW VERS 8; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Schoen C, 1997, HEALTH AFFAIR, V16, P163, DOI 10.1377/hlthaff.16.5.163; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SCHWAB CW, 1988, J TRAUMA, V28, P939, DOI 10.1097/00005373-198807000-00006; Sox CM, 1998, AM J MED, V105, P506, DOI 10.1016/S0002-9343(98)00324-6; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; THURMAN SJ, 1995, GUIDELINES SURVEILLA; *US CENS BUR, 1997, CURR POP SURV; *US CENS BUR, 1996, CURR POP SURV; *US CENS BUR, 1998, CURR POP SURV; *US DHHS, 1996, INT CLASS DIS CLIN M; *US DHHS CDCP DIV, 1999, REH RES DIS PREV TRA; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; Weissman JS., 1994, FALLING SAFETY NET I; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WRENN K, 1985, NEW ENGL J MED, V312, P373, DOI 10.1056/NEJM198502073120611	69	47	47	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	OCT	2004	22	6					465	473		10.1016/j.ajem.2004.07.024			9	Emergency Medicine	Emergency Medicine	872TH	WOS:000225230900006	15520941				2021-06-18	
J	O'Connor, E; Venkatesh, B; Mashongonyika, C; Lipman, J; Hall, J; Thomas, P				O'Connor, E; Venkatesh, B; Mashongonyika, C; Lipman, J; Hall, J; Thomas, P			Serum procalcitonin and C-reactive protein as markers of sepsis and outcome in patients with neurotrauma and subarachnoid haemorrhage	ANAESTHESIA AND INTENSIVE CARE			English	Article						head injury : subarachnoid haemorrhage, procalcitonin, sepsis, C-reactive protein	NOSOCOMIAL INFECTIONS; SEVERITY; CALCITONIN; EXPRESSION; MORTALITY; INJURY; ICU	This prospective study evaluated serum procalcitonin (PCT) and C-reactive protein (CRP) as markers for systemic inflammatory response syndrome (SIRS)/sepsis and mortality in patients with traumatic brain injury and subarachnoid haemorrhage. Sixty-two patients were followed for 7 days. Serum PCT and CRP were measured on days 0, 1, 4, 5, 6 and 7. Seventy-seven per cent of patients with traumatic brain injury and 83% with subarachnoid haemorrhage developed SIRS or sepsis (P= 0.75). Baseline PCT and CRP were elevated in 35% and 55% ofpatients respectively (P=0.03). There was a statistically non-significant step-wise increase in serum PCT levels from no SIRS (0.4 +/- 0.6 ng/ml) to SIRS (3.05 +/- 9.3 ng/ml) to sepsis (5.5 +/- 12.5 ng/ml). A similar trend was noted in baseline PCT in patients with mild (0.06 +/- 0.9 ng/ml), moderate (0.8 +/- 0.7 ng/ml) and severe head injury (1.2 +/- 1.9 ng/ml). Such a gradation was not observed with serum CRP There was a non-significant trend towards baseline PCT being a better marker of hospital mortality compared with baseline CRP (ROC-AUC 0.56 vs 0.31 respectively). This is the first prospective study to document the high incidence of SIRS in neurosurgical patients. In our study, serum PCT appeared to correlate with severity of traumatic brain injury and mortality. However, it could not reliably distinguish between SIRS and sepsis in this cohort. This is in pan because baseline PCT elevation seemed to correlate with severity of injury. Only a small proportion ofpatients developed sepsis, thus necessitating a larger sample size to demonstrate the diagnostic usefulness of serum PCT as a marker of sepsis. Further clinical trials with larger sample sizes are required to confirm any potential role of PCT as a sepsis and outcome indicator in patients with head injuries or subarachnoid haemorrhage.	Royal Brisbane Hosp, Dept Intens Care, Brisbane, Qld 4029, Australia	O'Connor, E (corresponding author), Univ Queensland, Princess Alexandra Hosp, Dept Intens Care, Ipswich Rd, Woolloongabba, Qld 4102, Australia.		Lipman, Jeffrey/G-2211-2010; Venkatesh, Bala/F-4700-2010	Lipman, Jeffrey/0000-0002-5965-9876; Venkatesh, Bala/0000-0002-3234-5244			ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Benador N, 1998, PEDIATRICS, V102, P1422, DOI 10.1542/peds.102.6.1422; Benoist JF, 1998, CLIN CHEM, V44, P1778; Bernard L, 1998, CLIN INFECT DIS, V27, P914, DOI 10.1086/517175; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; *BRAHMS LUMITEST P, 2000, PROC BRAHMS DIAGN IN, P1; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Chiwakata CB, 2001, J INFECT DIS, V183, P1161, DOI 10.1086/319283; DAWSONSAUDERS B, 1994, BASIC CLINICAL BIOST; Eberhard OK, 1997, ARTHRITIS RHEUM, V40, P1250, DOI 10.1002/art.9; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; HAN Y, IN PRESS PEDIAT CRIT; Herget-Rosenthal S, 2001, NEPHROL DIAL TRANSPL, V16, P975, DOI 10.1093/ndt/16.5.975; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; Kollef NH, 2000, CRIT CARE MED, V28, P3456, DOI 10.1097/00003246-200010000-00014; Leclercq R, 2001, CLIN MICROBIOL INFEC, V7, P18, DOI 10.1046/j.1469-0691.2001.00050.x; LIND L, 1995, INTENS CARE MED, V21, P63, DOI 10.1007/BF02425156; Martinez R, 2002, INTENS CARE MED, V28, P208, DOI 10.1007/s00134-001-1176-3; Muller B, 2001, J CLIN ENDOCR METAB, V86, P396, DOI 10.1210/jc.86.1.396; Rau B, 1997, GUT, V41, P832, DOI 10.1136/gut.41.6.832; Russwurm S, 2001, SHOCK, V16, P109, DOI 10.1097/00024382-200116020-00004; Singh N, 2000, CHEST, V117, P1496, DOI 10.1378/chest.117.5.1496; Wanner GA, 2000, CRIT CARE MED, V28, P950, DOI 10.1097/00003246-200004000-00007; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021	26	47	55	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	AUG	2004	32	4					465	470		10.1177/0310057X0403200402			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	846OO	WOS:000223325400002	15675205	Bronze			2021-06-18	
J	Graber, KD; Prince, DA				Graber, KD; Prince, DA			A critical period for prevention of posttraumatic neocortical hyperexcitability in rats	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CORTICAL ACTIVITY; KINDLING MODEL; C-FOS; POSTNATAL BLOCKADE; NEURONAL-ACTIVITY; GENE-EXPRESSION; AMINO-ACIDS; HEAD TRAUMA	Penetrating cortical trauma frequently results in delayed development of epilepsy. In the rat undercut model of neocortical posttraumatic hyperexcitability, suppression of neuronal activity by exposing the injured cortex to tetrodotoxin (TTX) in vivo for approximately 2 weeks prevents the expression of abnormal hypersynchronous discharges in neocortical slices. We examined the relationship between neuronal activity during the latent period after trauma and subsequent expression of hyperexcitability by varying the timing of TTX treatment. Partially isolated islands of rat sensorimotor cortex were treated with Elvax polymer containing TTX to suppress cortical activity and slices obtained for in vitro experiments 10 to 15 days later. TTX treatment was either started immediately after injury and discontinued after a variable number of days or delayed for a variable time after the lesion was placed. Immediate treatment lasting only 2 to 3 days and treatment delayed up to 3 days prevented hyperexcitability. Thus, there is a critical period for development of hyperexcitability in this model that depends on cortical activity. We propose that the hyperexcitability caused by partial cortical isolation may represent an early stage of posttraumatic epileptogenesis. A hypothetical cascade of events leading to subsequent pathophysiological activity is likely initiated at the time of injury but remains plastic during this critical period.	Stanford Univ, Ctr Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Graber, KD (corresponding author), Stanford Univ, Ctr Med, Dept Neurol & Neurol Sci, Room M016 Alway, Stanford, CA 94305 USA.	graberk@stanford.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002167, P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12151, K08 NS02167] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Carmichael ST, 2002, J NEUROSCI, V22, P6062; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DAMBROSIO R, 2003, BRAIN, V127, P1; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAKE CG, 1948, FED PROC, V7, P29; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GODDARD GV, 1983, TRENDS NEUROSCI, V6, P275, DOI 10.1016/0166-2236(83)90118-2; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 1999, EPILEPSIA, V40, P31; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; GRIGONIS AM, 1994, DEV BRAIN RES, V77, P251, DOI 10.1016/0165-3806(94)90200-3; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; HAMMOND EJ, 1980, EPILEPSIA, V21, P3, DOI 10.1111/j.1528-1157.1980.tb04039.x; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; INNOCENTI G M, 1991, Journal of Neural Transplantation and Plasticity, V2, P29; Kawatsu K, 1997, JPN J MED SCI BIOL, V50, P133, DOI 10.7883/yoken1952.50.133; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; LANGE SC, 1980, EPILEPSIA, V21, P251, DOI 10.1111/j.1528-1157.1980.tb04070.x; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYNCH JJ, 1995, J PHARMACOL EXP THER, V273, P554; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MCNAMARA JO, 1995, PSYCHIAT CLIN NEUROS, V49, pS175, DOI 10.1111/j.1440-1819.1995.tb02167.x; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mody I, 1999, Adv Neurol, V79, P631; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MURPHY TH, 1991, J NEUROCHEM, V57, P1862, DOI 10.1111/j.1471-4159.1991.tb06396.x; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nissinen Jari P. T., 2003, Epilepsia, V44, P175; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Probert AW, 1997, NEUROPHARMACOLOGY, V36, P1031, DOI 10.1016/S0028-3908(97)00072-5; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SCOVILLE WB, 1960, AM J PSYCHIAT, V117, P525, DOI 10.1176/ajp.117.6.525; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SPEHLMANN R, 1971, ARCH NEUROL-CHICAGO, V24, P401, DOI 10.1001/archneur.1971.00480350035003; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tanu MB, 2002, TOXICON, V40, P103, DOI 10.1016/S0041-0101(01)00179-9; TAUCK DL, 1985, J NEUROSCI, V5, P1016; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Tsui CC, 1996, J NEUROSCI, V16, P2463; Ueda Y, 1998, EXP NEUROL, V153, P123, DOI 10.1006/exnr.1998.6869; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, CHILD BRAIN, V10, P185	70	47	49	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUN	2004	55	6					860	870		10.1002/ana.20124			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	824VW	WOS:000221716300013	15174021				2021-06-18	
J	Hoover, RC; Motta, M; Davis, J; Saatman, KE; Fujimoto, ST; Thompson, HJ; Stover, JF; Dichter, MA; Twyman, R; White, HS; McIntosh, TK				Hoover, RC; Motta, M; Davis, J; Saatman, KE; Fujimoto, ST; Thompson, HJ; Stover, JF; Dichter, MA; Twyman, R; White, HS; McIntosh, TK			Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral edema; cognition; experimental models; head injury; motor function; neuroprotection	REGIONAL CEREBRAL EDEMA; CONTROLLED CORTICAL IMPACT; SODIUM-CHANNEL BLOCKER; COGNITIVE DYSFUNCTION; GLOBAL-ISCHEMIA; NEURONAL INJURY; GRANULE CELLS; HEAD-INJURY; TIME-COURSE; RECOVERY	The efficacy of topiramate, a novel therapeutic agent approved for the treatment of seizure disorders, was evaluated in a model of traumatic brain injury (TBI). Adult male rats were anesthetized (sodium pentobarbital, 60 mg/kg, i.p.), subjected to lateral fluid percussion brain injury (n = 60) or sham injury (n = 47) and randomized to receive either topiramate or vehicle at 30 min (30 mg/kg, i.p.), and 8, 20 and 32 h postinjury (30 mg/kg, p.o.). In Study A, memory was evaluated using a Morris water maze at 48 h postinjury, after which brain tissue was evaluated for regional cerebral edema. In Study B, animals were evaluated for motor function at 48 h and 1, 2, 3, and 4 weeks postinjury using a composite neuroscore and the rotating pole test and for learning ability at 4 weeks. Brains were analyzed for hemispheric tissue loss and hippocampal CA3 cell loss. Topiramate had no effect on posttraumatic cerebral edema or histologic damage when compared to vehicle. At 48 h, topiramate treatment improved memory function in sham but not brain-injured animals, while at one month postinjury it impaired learning performance in brain-injured but not sham animals. Topiramate significantly improved composite neuroscores at 4 weeks postinjury and rotating pole performance at I and 4 weeks postinjury, suggesting a potentially beneficial effect on motor function following TBI.	Univ Penn, Head Injury Ctr, Dept Neurosurg, Philadelphia, PA 19103 USA; Univ Penn, Head Injury Ctr, Dept Neurol, Philadelphia, PA 19103 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT USA	McIntosh, TK (corresponding author), Univ Penn, Head Injury Ctr, Dept Neurosurg, 105 C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19103 USA.	mcintosh@seas.upenn.edu		White, H. Steve/0000-0003-4550-4408	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34790] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS 08803, R01-NS40978] Funding Source: Medline		Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DeLorenzo RJ, 2000, EPILEPSIA, V41, pS40, DOI 10.1111/j.1528-1157.2000.tb06048.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Edmonds HL, 1996, LIFE SCI, V59, pPL127, DOI 10.1016/0024-3205(96)00379-7; Edmonds HL, 2001, LIFE SCI, V69, P2265, DOI 10.1016/S0024-3205(01)01306-6; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; Gibbs J, 1997, SEIZURE-EUR J EPILEP, V6, P193, DOI 10.1016/S1059-1311(97)80005-2; Gibbs JW, 2000, EPILEPSIA, V41, pS10; Golarai G, 2001, J NEUROSCI, V21, P8523; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Koh S, 2001, ANN NEUROL, V50, P366, DOI 10.1002/ana.1122; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee SR, 2000, NEUROSCI LETT, V281, P183, DOI 10.1016/S0304-3940(00)00847-8; LEVERE TE, 1989, BEHAV NEUROSCI, V103, P561, DOI 10.1037/0735-7044.103.3.561; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McLean MJ, 2000, EPILEPSIA, V41, pS21, DOI 10.1111/j.1528-1157.2000.tb06043.x; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Nakamura J, 2000, Nihon Yakurigaku Zasshi, V115, P53; NAKANISHI H, 1994, MAT SCI ENG C-BIOMIM, V2, P83, DOI 10.1016/0928-4931(94)90034-5; Niebauer M, 1999, BRAIN RES, V837, P263, DOI 10.1016/S0006-8993(99)01615-7; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Reife R, 2000, EPILEPSIA, V41, pS66; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shank RP, 2000, EPILEPSIA, V41, pS3, DOI 10.1111/j.1528-1157.2000.tb06045.x; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Skradski S, 2000, EPILEPSIA, V41, pS45; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, NEUR ABST, V19, P1877; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith-Swintosky VL, 2001, NEUROREPORT, V12, P1031, DOI 10.1097/00001756-200104170-00033; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; Taverna S, 1999, J PHARMACOL EXP THER, V288, P960; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wauquier A, 1996, EPILEPSY RES, V24, P73, DOI 10.1016/0920-1211(95)00105-0; White RA, 2000, CYTOMETRY, V41, P1; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Yang Y, 1998, BRAIN RES, V804, P169, DOI 10.1016/S0006-8993(98)00410-7; Yang Y, 2000, NEUROPHARMACOLOGY, V39, P881, DOI 10.1016/S0028-3908(99)00248-8; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang XL, 2000, EPILEPSIA, V41, pS52; Zona C, 1997, NEUROSCI LETT, V231, P123, DOI 10.1016/S0304-3940(97)00543-0	74	47	49	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					501	512		10.1089/089771504774129847			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900002	15165359				2021-06-18	
J	Levack, W; McPherson, K; McNaughton, H				Levack, W; McPherson, K; McNaughton, H			Success in the workplace following traumatic brain injury: are we evaluating what is most important?	DISABILITY AND REHABILITATION			English	Article							COMMUNITY INTEGRATION; REHABILITATION; EMPLOYMENT; PREDICTORS	Purpose: Vocational outcome, and in particular full-time paid work, is considered an important indicator of successful rehabilitation following traumatic brain injury (TBI). However it has not been established that these outcomes adequately or accurately represent the values of the people with TBI. This paper describes a study exploring the experiences of individuals who attempted returning to work following TBI, with emphasis on factors that related to perceptions of 'success' or 'failure'. Method: A phenomenological study, interviewing seven people with moderate to severe TBI was conducted. The interview data were analysed for themes relating to experiences of success or failure in the workplace. Community consultation provided additional perspectives in the interpretation and validation of results. Results: The results of this study support in part the assumption that paid employment is indicative of success following TBI. Equally prevalent were findings that challenged this assumption, including situations where: (1) return to employment contributed to catastrophic personal events, (2) feelings of success were achieved even though paid employment was not, and (3) success in the workplace was associated with factors other than hours worked or pay earned. Conclusions: This research suggests that the use of work placement as a measure of successful rehabilitation might misrepresent the perspective of individuals with TBI. A multifactorial approach to evaluating vocational rehabilitation is recommended, which incorporates the subjective experience of work.	Univ Otago, Wellington Sch Med & Hlth Sci, Rehabil Teaching & Res Unit, Wellington, New Zealand; Univ Southampton, Sch Hlth Profess & Rehabil Sci, Southampton SO17 1BJ, Hants, England; Med Res Inst New Zealand, Wellington, New Zealand	Levack, W (corresponding author), Univ Otago, Wellington Sch Med & Hlth Sci, Rehabil Teaching & Res Unit, POB 7343, Wellington, New Zealand.	wlevack@wnmeds.ac.nz	Levack, William Mark Magnus/F-9607-2018; McNaughton, Harry/AAC-6556-2020	Levack, William Mark Magnus/0000-0001-6631-908X; McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			*ACC NAT HLTH COMM, 1998, TRAUM BRAIN INJ REH; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Conneeley A. L., 2002, BRIT J OCCUPATIONAL, V65, P356; Crotty M., 1998, FDN SOCIAL RES MEANI; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Karlovits T, 1999, BRAIN INJURY, V13, P845; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1053/apmr.2000.5567; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; McPherson KM, 2001, DISABIL REHABIL, V23, P706; Morse J., 2002, READ ME 1 USERS GUID; Rice P. L., 1999, QUALITATIVE RES METH; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Ville I, 1998, DISABIL REHABIL, V20, P127, DOI 10.3109/09638289809166072; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wehman P, 2000, AM J PHYS MED REHAB, V79, P161, DOI 10.1097/00002060-200003000-00009; Zasler ND, 1997, J HEAD TRAUMA REHAB, V12, P42, DOI 10.1097/00001199-199710000-00005	23	47	49	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	MAR 4	2004	26	5					290	298		10.1080/09638280310001647615			9	Rehabilitation	Rehabilitation	801WV	WOS:000220126900005	15200244				2021-06-18	
J	Fock, J; Galea, MP; Stillman, BC; Rawicki, B; Clark, M				Fock, J; Galea, MP; Stillman, BC; Rawicki, B; Clark, M			Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury	BRAIN INJURY			English	Article							CHRONIC HEMIPARETIC PATIENTS; UPPER EXTREMITY SPASTICITY; LIMB EXTENSOR SPASTICITY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; FOOT; THERAPY; STROKE; COST; GAIT	Primary objective : The aim of this study was to assess the effect of Botulinum toxin A in the management of spastic equinus resulting from traumatic brain injury. Research design : A before-after intervention design was used without controls. Methods and procedures : Subjects were seven patients suffering from traumatic brain injury of average duration 14 (4-38) months as a result of motor vehicle trauma, who had spastic equinus interfering with gait. Experimental intervention : The patients were treated with injections of Botulinum toxin A into the spastic calf muscles: gastrocnemius, soleus and tibialis posterior. Assessments were made pre-injection and at 2 weeks and 3 months post-injection. Main outcome and results : At the end of the 3-month period, all patients showed a significant improvement in gait velocity, cadence and stride length. Conclusions : The findings suggest that Botulinum toxin A may be useful in the management of spastic equinus following traumatic brain injury.	Brighton Rehabil Ctr, Brighton, Vic 3186, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3010, Australia; Monash Univ, Dept Math & Stat, Clayton, Vic 3168, Australia	Galea, MP (corresponding author), Univ Melbourne, Sch Physiotherapy, 200 Berkeley St, Parkville, Vic 3052, Australia.		Galea, Mary/F-4242-2010	Galea, Mary/0000-0003-0045-7978			*AM AC ORTH SURG, 1965, JOINT MOT METH MEAS, P68; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BRAUN RM, 1973, J BONE JOINT SURG AM, VA 55, P580, DOI 10.2106/00004623-197355030-00015; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; GLENN MB, 1990, PRACTICAL MANAGEMENT, P227; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Radensky PW, 2001, NEUROREHAB NEURAL RE, V15, P57, DOI 10.1177/154596830101500108; Reiter F, 1998, ARCH PHYS MED REHAB, V79, P532, DOI 10.1016/S0003-9993(98)90068-5; Sheean GL, 1997, EUR J NEUROL, V4, pS41; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; Wallesch CW, 1997, EUR J NEUROL, V4, pS53; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; Wilson DJ, 1997, J NEUROL REHABIL, V11, P81; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; YOSHIMURA DM, 1992, NEUROLOGY, V42, P627, DOI 10.1212/WNL.42.3.627	21	47	49	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2004	18	1					57	63		10.1080/0269905031000149498			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	749PB	WOS:000186928200004	14660236				2021-06-18	
J	Scheibel, RS; Pearson, DA; Faria, LP; Kotrla, KJ; Aylward, E; Bachevalier, J; Levin, HS				Scheibel, RS; Pearson, DA; Faria, LP; Kotrla, KJ; Aylward, E; Bachevalier, J; Levin, HS			An fMRI study of executive functioning after severe diffuse TBI	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; WORKING-MEMORY; PREFRONTAL CORTEX; ACTIVATION; DEFICITS; INTERFERENCE; INVOLVEMENT; PERFORMANCE; ANTERIOR	Primary objective: Preliminary study of whether severe diffuse traumatic brain injury (TBI) increases extent of frontal tissue recruited by cognitive control tasks. Research design: Functional magnetic resonance imaging (fMRI) on N-back working memory (WM) and arrows inhibition tasks in a 46 year old man who had severe diffuse TBI 1 year earlier, a 44 year old man ( inhibition task) and three women ( working memory task), age 20 - 26 years. Images were acquired by 1.5 T magnet with BOLD method and PRESTO pulse sequence and analysed using SPM. Main outcomes and results: Frontal activation increased under 2-back relative to 1-back condition of working memory in all participants with more extensive activation in the TBI patient relative to controls. Frontal activation increased with inhibition on the arrows task, but was greater in the TBI patient. Conclusion: Severe diffuse TBI results in recruitment of additional neural resources for cognitive control.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Psychiat & Behav Sci, Houston, TX USA; Baylor Coll Med, Sect Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Washington, Dept Radiol, Seattle, WA 98195 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889, NS-42772] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER		BADDELEY AD, 1986, COMPTES RENDUS L A 3, V321, P167; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen J, 2000, NEUROIMAGE, V11, P378, DOI 10.1006/nimg.2000.0573; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DREWE E A, 1975, Cortex, V11, P8; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GOLDMANRAKIC PS, 1998, PREFRONTAL CORTEX EX, P87; JENNETT B, 1975, LANCET, V1, P480; Kahneman D., 1973, ATTENTION EFFORT; Kawashima R, 1996, BRAIN RES, V728, P79, DOI 10.1016/0006-8993(96)00389-7; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; PEARSON DA, 2000, SOC NEUROSCIENCE, V26, P2003; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Proctor A, 2000, BRAIN INJURY, V14, P633; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; TEASDALE G, 1974, LANCET, V2, P81; VANGELDEREN P, 1995, P NATL ACAD SCI USA, V92, P6906, DOI 10.1073/pnas.92.15.6906; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	48	47	48	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2003	17	11					919	930		10.1080/0269905031000110472			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	725GE	WOS:000185534800001	14514445				2021-06-18	
J	Mauler, F; Hinz, V; Augstein, KH; Fassbender, M; Horvath, E				Mauler, F; Hinz, V; Augstein, KH; Fassbender, M; Horvath, E			Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271	BRAIN RESEARCH			English	Article						BAY 38-7271; neuroprotection; CB1; transient middle cerebral artery occlusion; acute subdural hematoma; intracranial pressure; brain edema	ACUTE SUBDURAL-HEMATOMA; NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; RAT-BRAIN; NEUROTRANSMITTER RELEASE; AMEBOID MICROGLIA; CB2 RECEPTORS; INJURY; EXPRESSION	BAY 38-7271 is a new high-affinity cannabinoid receptor agonist with strong neuroprotective efficacy in a rat model of traumatic brain injury (acute subdural hematoma, SDH). In the present study we investigated CB1 receptor signal transduction by [S-35]GTPgammaS binding in situ and in vitro to assess changes in receptor functionality after SDH. Further, we continued to investigate the neuroprotective properties of BAY 38-7271 in the rat SDH and transient middle cerebral artery occlusion (tMCA-O) model as well as the efficacy with respect to SDH-induced brain edema. [S-35]GTPgammaS binding revealed minor attenuation of CB1 receptor functionality on brain membranes from injured hemispheres when compared to non-injured hemispheres or controls. In the rat SDH model, BAY 38-7271 displayed strong neuroprotective efficacy when administered immediately after SDH either as a 1 h (65% infarct volume reduction at 0.1 mug/kg) or short-duration (15 min) infusion (53% at 10 mug/kg). When administered as a 4 h infusion with a 5 It delay after injury, significant neuroprotection was observed (49% at 1.0 mua/kg/h). This was also observed when BAY 38-7271 was administered as a 5 h delayed 15 min short-duration infusion (64% at 3 mug/kg). In addition, the neuroprotective potential of BAY 38-7271 was demonstrated in the rat tMCA-O model. displaying pronounced neuroprotective efficacy in the cerebral cortex (91% at 1 ng/kg/h) and striatum (53% at 10 ng/kg/h). BAY 38-7271 also reduced intracranial pressure (28% at 250 ng/kg/h) and brain water content (20% at 250 ng/kg/h) when determined 24 h post-SDH. Based on these data it is concluded that the neuroprotective efficacy of BAY 38-7271 is mediated by multiple mechanisms triggered by cannabinoid receptors. (C) 2003 Elsevier B.V. All rights reserved.	Bayer Hlth Care, PH R EU CNS, D-42096 Wuppertal, Germany	Mauler, F (corresponding author), Bayer Hlth Care, PH R EU CNS, Aprather Weg 18a, D-42096 Wuppertal, Germany.						Barth F, 1998, EXPERT OPIN THER PAT, V8, P301, DOI 10.1517/13543776.8.3.301; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Cai GP, 2002, J PHARMACOL EXP THER, V302, P1105, DOI 10.1124/jpet.102.036673; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; CHAO CC, 1992, J IMMUNOL, V149, P2736; Coffey RG, 1996, BIOCHEM PHARMACOL, V52, P743, DOI 10.1016/0006-2952(96)00356-5; De Vry J, 2002, EUR J PHARMACOL, V457, P147, DOI 10.1016/S0014-2999(02)02697-3; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FUJISAWA H, 1994, ACT NEUR S, V60, P193; GAOINI Y, 1964, J AM CHEM SOC, V86, P1646; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Grundy RI, 2002, EXPERT OPIN INV DRUG, V11, P1365, DOI 10.1517/13543784.11.10.1365; Grundy RI, 2001, MOL NEUROBIOL, V24, P29; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holtz ML, 2001, BRAIN RES, V898, P49, DOI 10.1016/S0006-8993(01)02140-0; HORVATH E, 1997, J NEUROTRAUMA ABSTR, V14, P170; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.3.CO;2-G; Kim DJ, 2000, BRAIN RES, V852, P398, DOI 10.1016/S0006-8993(99)02210-6; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; LEONG SK, 1992, GLIA, V6, P39, DOI 10.1002/glia.440060106; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Lipton P, 1999, PHYSIOL REV, V79, P1431; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Molina-Holgado F, 2002, J NEUROSCI RES, V67, P829, DOI 10.1002/jnr.10165; Mu J, 1999, J PHARMACOL EXP THER, V291, P893; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2001, J CEREBR BLOOD F MET, V21, P15, DOI 10.1097/00004647-200101000-00003; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Puebla L, 2003, J NEUROCHEM, V84, P145, DOI 10.1046/j.1471-4159.2003.01510.x; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; Sim-Selley LJ, 2002, LIFE SCI, V71, P2217, DOI 10.1016/S0024-3205(02)02017-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TSUCHIDA E, 1995, J NEUROTRAUM, V12, P279, DOI 10.1089/neu.1995.12.279; Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357; Walter L, 2003, J NEUROSCI, V23, P1398; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; ZHAO Q, 1995, THESIS LUND U LUND; Zwienenberg M, 1999, J NEUROTRAUM, V16, P1095, DOI 10.1089/neu.1999.16.1095	53	47	48	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 31	2003	989	1					99	111		10.1016/S0006-8993(03)03376-6			13	Neurosciences	Neurosciences & Neurology	733GL	WOS:000185991500012	14519516				2021-06-18	
J	Salzberg-Brenhouse, HC; Chen, EY; Emerich, DF; Baldwin, S; Hogeland, K; Ranelli, S; Lafreniere, D; Perdomo, B; Novak, L; Kladis, T; Fu, K; Basile, AS; Kordower, JH; Bartus, RT				Salzberg-Brenhouse, HC; Chen, EY; Emerich, DF; Baldwin, S; Hogeland, K; Ranelli, S; Lafreniere, D; Perdomo, B; Novak, L; Kladis, T; Fu, K; Basile, AS; Kordower, JH; Bartus, RT			Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TRAUMATIC BRAIN INJURY; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; RODENT MODEL; CELL-DEATH; NEURONS; EXPRESSION; RELEASE; LIPOPOLYSACCHARIDE	Cyclooxygenases (COXs) are implicated in neurodegenerative processes associated with acute and chronic neurological diseases. Given the potential utility of COX inhibitors in treating these disorders, we examined the nonselective COX inhibitor flurbiprofen, the specific COX-1 inhibitor valeryl salicylate (VS), and the COX-2 inhibitor N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide (NS-398) for their abilities to protect striatal neurons against a quinolinic acid (QA)-induced excitotoxic lesion. Rats were administered COX inhibitors 10 min before a unilateral QA lesion of the striatum, and then tested 2 to 3 weeks later in a battery of motor tasks (bracing, placing, akinesia, and apomorphine-induced rotations). Lesion volume was assessed using immunohistochemical methods 1 month after lesioning. Orally administered flurbiprofen (50 mg) was highly neuroprotective, preserving 84 to 99% of motor performance (ED50 = 8.6-9.7 mg) while reducing lesion volume 75% (ED50 = 3.2 mg). The identities of the COX isoforms associated with QA-induced neurodegeneration were determined using VS and NS-398. Oral VS was ineffective in virtually all indices of functional neuroprotection. In contrast, oral NS-398 was highly effective, preserving approximately 83% of motor performance at 2 mg (ED50 = 0.1-0.4 mg), and reducing lesion volume 100% (ED50 = 0.4 mg). Similar results were obtained using inhaled flurbiprofen (2 mg), which preserved 88 to 100% of motor performance while reducing striatal lesion size 92%. These results demonstrate that COX-2 inhibition protects neurons from acute, excitotoxic neurodegeneration. Moreover, formulating a nonselective COX inhibitor into an inhalable preparation dramatically improves its potency in treating acute neuronal damage, a situation where the rapidity of drug delivery and onset of action is critical to clinical efficacy.	Alkermes Inc, Div Biol Res, Cambridge, MA 02139 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA	Basile, AS (corresponding author), Alkermes Inc, Div Biol Res, 88 Sidney St, Cambridge, MA 02139 USA.	anthony.basile@alkermes.com	Brenhouse, Heather C/I-8022-2016; Ranelli, Sonia/T-3424-2019	Brenhouse, Heather C/0000-0001-7591-4964; 			Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BEAL MF, 1991, J NEUROSCI, V11, P1649; Bezzi P, 1998, NATURE, V391, P281; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DAVIES NM, 1995, CLIN PHARMACOKINET, V28, P100, DOI 10.2165/00003088-199528020-00002; Emerich DF, 1996, J NEUROSCI, V16, P5168; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hawkey CJ, 2001, BEST PRACT RES CL GA, V15, P801, DOI 10.1053/bega.2001.0236; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lin H, 2002, CIRCULATION, V105, P1962, DOI 10.1161/01.CIR.0000015365.49180.05; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Luo J, 1998, J NEUROCHEM, V71, P526; Manev H, 2000, EXP GERONTOL, V35, P1201, DOI 10.1016/S0531-5565(00)00152-2; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Nakao N, 1999, NEUROSCIENCE, V88, P469, DOI 10.1016/S0306-4522(98)00197-3; Nogawa S, 1997, J NEUROSCI, V17, P2746; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Schallert T, 2000, CONT NEUROS, P131; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Vanbever R, 1999, DRUG DEVELOP RES, V48, P178, DOI 10.1002/(SICI)1098-2299(199912)48:4<178::AID-DDR5>3.3.CO;2-9; Veld BAI, 2000, NEUROBIOL AGING, V21, pS204; West MJ, 1996, J COMP NEUROL, V370, P11; Yasojima K, 2001, NEUROLOGY, V57, P952, DOI 10.1212/WNL.57.6.952; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880; Zhang J, 2001, J NEUROCHEM, V76, P855, DOI 10.1046/j.1471-4159.2001.00080.x	42	47	50	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	2003	306	1					218	228		10.1124/jpet.103.049700			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	691NW	WOS:000183613200027	12676885				2021-06-18	
J	Steiner, LA; Coles, JP; Czosnyka, M; Minhas, PS; Fryer, TD; Aigbirhio, FI; Clark, JC; Smielewski, P; Chatfield, DA; Donovan, T; Pickard, JD; Menon, DK				Steiner, LA; Coles, JP; Czosnyka, M; Minhas, PS; Fryer, TD; Aigbirhio, FI; Clark, JC; Smielewski, P; Chatfield, DA; Donovan, T; Pickard, JD; Menon, DK			Cerebrovascular pressure reactivity is related to global cerebral oxygen metabolism after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; POSITRON EMISSION TOMOGRAPHY; K+ CHANNEL FUNCTION; BLOOD-FLOW; MITOCHONDRIAL DYSFUNCTION; PERFUSION-PRESSURE; AUTOREGULATION; HEMODYNAMICS; U-101033E; ISCHEMIA	Background: After head injury, impaired cerebrovascular autoregulation has been associated with abnormally high or low cerebral blood flow. The physiological relevance of cerebral blood flow levels is difficult to assess in these patients, whose cerebral metabolic rate for oxygen (CMRO2) is known to be abnormal. Investigation of these relations requires quantitative measures of cerebral blood flow and CMRO2, to allow assessment of oxygen supply and demand relations. Objectives: To investigate the relation between dysautoregulation and global cerebral oxygen metabolism following head injury. Methods: Using positron emission tomography, global cerebral blood flow, CMRO2, and oxygen extraction fraction were determined in 22 patients who were investigated in 26 examinations on days 1 to 11 (mean (SD), 3.5 (2.3)) after head injury. Cerebrovascular pressure reactivity was assessed using a pressure reactivity index, calculated as the moving linear correlation coefficient between mean arterial blood pressure and intracranial pressure. Outcome was assessed six months after injury using the Glasgow outcome scale. Results: Low CMRO2 was associated with disturbed pressure reactivity (inverse function, R-2 = 0.21, p = 0.018) and there was a correlation between disturbed pressure reactivity and oxygen extraction fraction (quadratic function, R-2 = 0.55, p = 0.0001). There was no significant relation between pressure reactivity and cerebral blood flow. An unfavourable outcome was associated with disturbed pressure reactivity. There was no significant relation between outcome and CMRO2 or oxygen extraction fraction. Conclusions: There is a close relation between dysautoregulation and abnormal cerebral metabolism but not blood flow. Further studies are needed to determine whether metabolic dysfunction is a result of or a cause of disturbed pressure reactivity, and to establish if there is a relation between cerebral oxygen metabolism and outcome.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge, England	Steiner, LA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 167, Cambridge CB2 2QQ, England.		Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019; Donovan, Tim/AAF-3563-2019	Smielewski, Peter/0000-0001-5096-3938; Donovan, Tim/0000-0003-4112-861X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HARRIS RJ, 1984, J CEREBR BLOOD F MET, V4, P178, DOI 10.1038/jcbfm.1984.26; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; JENNETT B, 1975, LANCET, V1, P480; KANNO I, 1984, J CEREBR BLOOD F MET, V4, P224, DOI 10.1038/jcbfm.1984.31; KANNO I, 1987, J CEREBR BLOOD F MET, V7, P143, DOI 10.1038/jcbfm.1987.37; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; LAMMERTSMA AA, 1981, J COMPUT ASSIST TOMO, V5, P544, DOI 10.1097/00004728-198108000-00016; LAMMERTSMA AA, 1992, J CEREBR BLOOD F MET, V12, P291, DOI 10.1038/jcbfm.1992.39; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oshima T, 2002, ACTA ANAESTH SCAND, V46, P831, DOI 10.1034/j.1399-6576.2002.460713.x; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531	37	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2003	74	6					765	770		10.1136/jnnp.74.6.765			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	679QC	WOS:000182932600017	12754348	Bronze, Green Published			2021-06-18	
J	Esen, F; Erdem, T; Aktan, D; Kalayci, R; Cakar, N; Kaya, M; Telci, L				Esen, F; Erdem, T; Aktan, D; Kalayci, R; Cakar, N; Kaya, M; Telci, L			Effects of magnesium administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						magnesium; trauma; diffuse brain injury; blood-brain barrier; brain edema	CLOSED-HEAD INJURY; CEREBRAL EDEMA; AXONAL INJURY; NEUROTOXICITY; RELEASE; THERAPY; BLOCKER; MODEL	In this study, we examined the effects of magnesium sulfate administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats. Seventy-one adult male Sprague-Dawley rats were anesthetized, and experimental closed head trauma was induced by allowing a 450-g weight to fall from a 2-m height onto a metallic disk fixed to the intact skull. Sixty-eight surviving rats were randomly assigned to receive an intraperitoneal bolus of either 750 mumol/kg magnesium sulfate (group 4; n = 30) or I mL of saline (group 2; n = 30) 30 minutes after induction of traumatic brain injury; 39 nontraumatized animals received saline (group 1; n = 21) or magnesium sulfate (group 3; n = 18) with an identical protocol of administration. Brain water content and brain tissue specific gravity, as indicators of brain edema, were measured 24 hours after traumatic brain injury. Blood-brain barrier integrity was evaluated quantitatively 24 hours after injury by spectrophotometric assay of Evans blue dye extravasations. In the magnesium-treated injured group, brain water content was significantly reduced (left hemisphere: group 2, 83.2 +/- 0.8; group 4, 78.4 +/- 0.7 [P < .05]; right hemisphere: group 2, 83.1 +/- 0.7; group 4, 78.4 +/- 0.5. [P < .05]) and brain tissue specific gravity was significantly increased (left hemisphere: group 2, 1.0391 +/- 0.0008; group 4, 1.0437 +/- 0.001 [P < .05]; right hemisphere, group 2, 1.0384 +/- 0.001; group 4, 1.0442 +/- 0.005 [P < .05]) compared with the saline-treated injured group. Evans blue dye content in the brain tissue was significantly decreased in the magnesium-treated injured group (left hemisphere: group 2, 0.0204 +/- 0.03; group 4, 0.0013 +/- 0.0002 [P < .05]; right hemisphere: group 2, 0.0064 +/- 0.0009; group 4, 0.0013 +/- 0.0003 [P < .05]) compared with the saline-treated injured group. The findings of the present study support that beneficial effects of magnesium sulfate exist after severe traumatic brain injury in rats. These results also indicate that a blood-brain barrier permeability defect occurs after this model of diffuse traumatic brain injury, and magnesium seems to attenuate this defect.	Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, TR-34390 Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Expt Med Res Inst, TR-34390 Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Dept Physiol, TR-34390 Istanbul, Turkey	Esen, F (corresponding author), Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, Capa, TR-34390 Istanbul, Turkey.		Esen, Figen/AAS-6115-2020	ESEN, FIGEN/0000-0003-4419-4903; Cakar, Nahit/0000-0002-1302-9596			ALTURA B M, 1985, Magnesium, V4, P245; ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHOI DW, 1987, J NEUROSCI, V7, P369; CLARK AF, 1980, J BIOL CHEM, V255, P6556; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GIBSON BL, 1985, NEUROSCI LETT, V57, P13, DOI 10.1016/0304-3940(85)90033-3; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Polderman KH, 2000, CRIT CARE MED, V28, P2022, DOI 10.1097/00003246-200006000-00057; Regan RF, 1998, J NEUROCHEM, V70, P77; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SOARES HD, 1992, J NEUROCHEM, V58, P135; VANDENBRINK WA, 1990, ACTA NEUROCHIR SUPP, V55, P261; Vink R, 1990, Magnes Res, V3, P163; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1987, BIOCHEM BIOPH RES CO, V70, P895; VINK R, 1991, MAGNESIUM EXCITABLE, P695	38	47	57	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2003	15	2					119	125		10.1097/00008506-200304000-00009			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	660ZL	WOS:000181865900008	12657997				2021-06-18	
J	Mazzini, L; Cossa, FM; Angelino, E; Campini, R; Pastore, I; Monaco, F				Mazzini, L; Cossa, FM; Angelino, E; Campini, R; Pastore, I; Monaco, F			Posttraumatic epilepsy: Neuroradiologic and neuropsychological assessment of long-term outcome	EPILEPSIA			English	Article						posttraumatic epilepsy; MRI; SPECT; cognitive and behavioral disorders	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; CLOSED-HEAD-INJURY; RATING-SCALE; SEIZURES; PERSONALITY; FLUENCY; MEMORY; SPECT; MOOD	Purpose: We sought to detect the incidence and the risk factors of posttraumatic epilepsy (PTE) in rehabilitation patients; to define the influence of PTE for late clinical and functional outcome; and to assess the cognitive and behavioral features of the patients with PTE. Methods: Patients were examined with (a) cognitive and behavioral examinations, which included a clinical interview and psychometric tests performed by an expert clinical psychologist; (b) single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI); and (c) functional evaluation including the Glasgow Outcome Scale (GOS) and the Functional Independence Measure (FIM). Results: Of the 143 patients examined in this study, in 27 (19%), seizures developed after a mean time from trauma of 11.9 +/- 8.6 months. The occurrence of PTE was significantly correlated with the hypoperfusion in temporal lobes (p < 0.004), the degree of hydrocephalus (p < 0.04), the evidence of intracerebral hematoma (p < 0.01), and operative brain injury (p < 0.001). Patients with epilepsy showed a significantly higher incidence of personality disorders than did patients without epilepsy. The disinhibited behavior, irritability, and agitated and aggressive behavior were significantly more frequent and severe in PTE patients. The psychometric tests intended to explore memory, language, intelligence, attention, and spatial cognition did not show any significant difference between those with and without epilepsy. PTE also was significantly correlated with a worse functional outcome 1 year after the trauma. Conclusions: The degrees of hydrocephalus and of hypoperfusion in the temporal lobes are significant risk factors for late PTE. Another main finding of our study is the absence of influence of epilepsy on cognitive disorders; its influence on neurobehavioral disorders and functional outcome is discussed.	San Giovanni Bosco Hosp, Dept Neurol, I-10154 Turin, Italy; Fdn S Maugeri, Neuropsychol Unit, Inst Care & Res IRCCS, Sci Inst Veruno No, Verona, Italy; Univ Amedo Avogadro, Dept Neurol, Novara, Italy	Mazzini, L (corresponding author), San Giovanni Bosco Hosp, Dept Neurol, Largo Donatore Sangue 3, I-10154 Turin, Italy.	mazzini.l@libero.it	Mazzini, Letizia/AAA-2262-2021				AMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Basso A, 1987, Funct Neurol, V2, P189; Beck A.T., 1987, BECK DEPRESSION INVE; Benton AL., 1983, CONTRIBUTION NEUROPS; Blumer D, 1999, NEUROLOGY, V53, pS9; Capitani E, 1999, CORTEX, V35, P273, DOI 10.1016/S0010-9452(08)70800-1; Capitani E, 1998, CORTEX, V34, P779, DOI 10.1016/S0010-9452(08)70781-0; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chadwick D, 2000, LANCET, V355, P334, DOI 10.1016/S0140-6736(99)00452-3; Cossa FM, 1999, BRAIN INJURY, V13, P583; DELLASALA S, 1992, PSYCHOL MED, V22, P885, DOI 10.1017/S0033291700038460; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; GIBBS EL, 1948, ARCH NEURO PSYCHIATR, V60, P331, DOI 10.1001/archneurpsyc.1948.02310040002001; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Haltiner A M, 1996, J Int Neuropsychol Soc, V2, P494; HATHAWAY SR, 1967, MMPI MANUAL; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1975, EPILEPSY NONMISSILE; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Meador KJ, 2000, PHARMACOTHERAPY, V20, p185S, DOI 10.1592/phco.20.12.185S.35253; MENDEZ MF, 1993, NEUROLOGY, V43, P1073, DOI 10.1212/WNL.43.6.1073; MONACO F, 1997, NEUROPSYCHOL REHABIL, P253; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Novelli G., 1986, ARCH PSICOL NEUROL P, V2, P278; ORSINI A, 1987, ITAL J NEUROL SCI, V8, P539; Paradiso S, 2001, J NEUROL NEUROSUR PS, V70, P180, DOI 10.1136/jnnp.70.2.180; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PRAYER L, 1993, ACTA RADIOL, V34, P593; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robertson MM, 1999, EPILEPSIA, V40, pS1, DOI 10.1111/j.1528-1157.1999.tb00882.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SWANSON SJ, 1995, BRAIN, V118, P91, DOI 10.1093/brain/118.1.91; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; van Elst LT, 2000, BRAIN, V123, P234, DOI 10.1093/brain/123.2.234; Van Zomeren A. H., 1981, REACTION TIME ATTENT; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wiegartz P, 1999, NEUROLOGY, V53, pS3; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	50	47	52	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	APR	2003	44	4					569	574		10.1046/j.1528-1157.2003.34902.x			6	Clinical Neurology	Neurosciences & Neurology	667UU	WOS:000182253100012	12681007	Bronze			2021-06-18	
J	Englander, J; Cifu, DX; Wright, JM; Black, K				Englander, J; Cifu, DX; Wright, JM; Black, K			The association of early computed tomography scan findings and ambulation, self-care, and supervision needs at rehabilitation discharge and at 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	American Congress of Rehabilitation Medicine Annual Meeting	OCT, 2001	TUCSON, ARIZONA			activities of daily living; brain injuries; locomotion; rehabilitation; tomography; x-ray computed	SEVERE HEAD-INJURY; RATING-SCALE; COMA	Objective: To ascertain the association between early computed tomography (CT) scan findings and the need for assistance with ambulation, activities of daily living (ADLs), and supervision at rehabilitation discharge and at 1 year after traumatic brain injury (TBI). Design: Prospective longitudinal design. Setting: Seventeen Traumatic Brain Injury Model Systems (TBIMS) centers. Participants: A total of 1839 adults with TBI admitted to TBIMS trauma centers with subsequent acute rehabilitation; 849 were followed to 1 year after injury. Interventions: Not applicable. Main Outcome Measures: Accumulated CT scan pathology from the first week after injury; FIM(TM) instrument and Disability Rating Scale at rehabilitation discharge and 1 year after injury; and Supervision Rating Scale at 1 year. Results: Chi-square analyses showed that individuals with a midline shift greater than 5mm (lateral compression) were more likely to require the assistance of another person at discharge from acute rehabilitation with ambulation (29% vs 17%-19%, P=.02), toileting (47% vs 33%-38%, P=.05), lower-body dressing (57% vs 39%-46%, P=.015), bladder continence (32% vs 19%-23%, P=.03;), and overall supervision (53% vs 44%, P=.0006) than patients with a midline shift of lesser degree. At 1 year, 57% of patients with a midline shift greater than 5mm on acute CT scans were being supervised in the home versus 30% to 39% of those with a shift of lesser degree (P=.003); there were no significant differences in the percentages of those needing assistance for ambulation or ADLs. The association of subdural hematoma with ambulation, self-care, and supervision needs was related to the degree of midline shift but not to the presence of subdural hematoma. Individuals with subcortical contusions were more likely to require assistance at rehabilitation discharge for ambulation (32% vs 18%, P<.0001), lower-body dressing (61% vs 44%), toileting (52% vs 35%), bladder continence (34% vs 22%), and overall supervision (61% vs 44%) than those without subcortical contusions (P<.0001). At 1 year, individuals with acute subcortical contusions were more likely to need assistance with ambulation (15% vs 8%, P=.004) and stair climbing (15% vs 9%, P=.03). Those with bilateral frontal (54% vs 46%, P=.009) or bilateral temporal (58% vs 46%, P=.03) contusions were more likely to need assistance with overall supervision at rehabilitation discharge, compared with those with unilateral or no cortical contusions. Conclusions: The presence of either a midline shift greater than 5mm or a subcortical contusion on acute CT scans is associated with a greater need of assistance with ambulation, ADLs, and global supervision at rehabilitation discharge. Patients with bilateral cortical contusions require more global supervision at rehabilitation discharge but no more supervision for ambulation and ADLs. These findings may aid health care professionals and potential caregivers in planning for rehabilitation and supervision needs after rehabilitation discharge and, to a lesser extent, at 1 year after TBI.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabil Inst Michigan, Detroit, MI USA	Englander, J (corresponding author), Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, 751 S Bascom Ave, San Jose, CA 95128 USA.			Cifu, David/0000-0003-1600-9387			[Anonymous], 1997, GUIDE UNIFORM DATA S; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAUM; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; RAO N, 1984, ARCH PHYS MED REHAB, V65, P18; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118	11	47	49	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					214	220		10.1053/apmr.2003.50094			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700010	12601652				2021-06-18	
J	Hanks, RA; Wood, DL; Millis, S; Harrison-Felix, C; Pierce, CA; Rosenthal, M; Bushnik, T; High, WM; Kreutzer, J				Hanks, RA; Wood, DL; Millis, S; Harrison-Felix, C; Pierce, CA; Rosenthal, M; Bushnik, T; High, WM; Kreutzer, J			Violent traumatic brain injury: Occurrence, patient characteristics, and risk factors from the Traumatic Brain Injury Model Systems project	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; risk factors; violence	COMMUNITY INTEGRATION QUESTIONNAIRE; FUNCTIONAL INDEPENDENCE MEASURE; GLASGOW COMA SCALE; DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; UNITED-STATES; OUTCOMES; REHABILITATION; CONSCIOUSNESS; RELIABILITY	Objectives: To examine the occurrence of and characteristics associated with violent traumatic brain injury (TBI) in the Traumatic Brain Injury Model Systems (TBIMS) project for 4 of the 5 original Model Systems centers and to determine the patient characteristics of this group, as well as the risk factors for sustaining such an injury. Design: Prospective evaluation of individuals with violent TBI over a 10-year period. Setting: Four TBIMS centers. Participants: A total of 1229 individuals who received acute hospitalization and inpatient rehabilitation care for TBI. Interventions: Not applicable. Main Outcome Measure: The occurrence of a violent TBI. Results: Twenty-six percent of the participants in the TBIMS project sustained a violent TBI. This type of injury was more common in African-American men who were single and slightly older than the average TBI patient, were unemployed before injury, and had had a previous TBI. A higher injury rate was noted in the earlier part of the evaluation period. Those who sustained a violent TBI had higher levels of caregiver burden and disability, as well as decreased productivity and community reintegration at rehabilitation discharge and at 1 and 2 years postinjury. Conclusions: The occurrence of violent TBI in the TBIMS project is consistent with national trends of decreasing incidence of violent injuries in the 1990s. These results present a profile of those who have been injured through violence. The relative risks for sustaining such an injury appear to be well defined when considering demographic and temporal factors.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Craig Hosp, Englewood, CO USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Baylor Coll Med, Houston, TX 77030 USA; TIRR, Houston, TX 77030 USA; Virginia Commonwealth Univ, Richmond, VA USA	Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.			Bushnik, Tamara/0000-0003-3328-257X			Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; *CDCP, 1997, US INJ MORT STAT; Cherry D, 1998, ANN EMERG MED, V32, P51, DOI 10.1016/S0196-0644(98)70099-X; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cole TB, 1996, JAMA-J AM MED ASSOC, V275, P1709, DOI 10.1001/jama.1996.03530460013004; *CTR TBIMSND, 2001, TRAUM BRAIN INJ MOD; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TEASDALE G, 1974, LANCET, V2, P81; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226	31	47	48	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					249	254		10.1053/apmr.2003.50096			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700015	12601657				2021-06-18	
J	Lu, J; Moochhala, S; Shirhan, M; Ng, KC; Teo, AL; Tan, MH; Moore, XL; Wong, MC; Ling, EA				Lu, J; Moochhala, S; Shirhan, M; Ng, KC; Teo, AL; Tan, MH; Moore, XL; Wong, MC; Ling, EA			Neuroprotection by aminoguanidine after lateral fluid-percussive brain injury in rats: a combined magnetic resonance imaging, histopathologic and functional study	NEUROPHARMACOLOGY			English	Article						aminoguanidine; lateral fluid-percussive brain injury; neuronal apoptosis; magnetic resonance imaging; behaviour; neuroprotection	NITRIC-OXIDE SYNTHASE; CORTICAL IMPACT INJURY; CENTRAL-NERVOUS-SYSTEM; SELECTIVE-INHIBITION; DNA FRAGMENTATION; FREE-RADICALS; HEAD-INJURY; PEROXYNITRITE; APOPTOSIS; DAMAGE	The present study examined the effects of a selective inducible nitric oxide synthase (iNOS) inhibitor, aminoguanidine (AG), on neuronal cell survival and post-traumatic recovery in rats following a lateral fluid percussive brain injury. Daily treatment of AG at the dosage of 100 mg/kg or normal saline was given intraperitoneally into rats starting 2 h before or 30 min after brain injury. Treatment with AG significantly reduced lesion volumes in the brains of rats after injury, as evaluated by high-resolution magnetic resonance imaging (MRI). Immunohistochemical analysis showed a marked induction of iNOS expression in brain macrophages ipsilateral to the injury. Apoptotic neurons were observed in the ipsilateral cerebral cortex by in situ terminal transferase d-UTP nick-end labelling (TUNEL) and caspase-3 immunohistochemistry, In rats receiving prophylactic or post-injury treatment of AG. the number of degenerating neurons was markedly reduced in the cerebrum compared to those receiving saline injection. The location and extent of these pathologic changes correlated with MRI findings. Neurobehavioral studies showed that rotametric performance, grip-strength score, total and ambulatory locomotor responses and acoustic startle response were reduced in rats subjected to the injury but were significantly improved in AG-treated rats. It is suggested that inhibition of iNOS by AG may represent a potential therapeutic strategy for the treatment of traumatic brain injury. (C) 2003 Elsevier Science Ltd. All rights reserved.	NUS, Def Sci & Technol Agcy, Med Res Inst Chem Def, Singapore 117597, Singapore; Natl Canc Ctr, Brain Tumor Res Lab, Singapore, Singapore; Natl Univ Singapore, Dept Anat, Singapore 117597, Singapore	Moochhala, S (corresponding author), NUS, Def Sci & Technol Agcy, Med Res Inst Chem Def, 18 Med Dr,01-06,MD2, Singapore 117597, Singapore.	nmiv6@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			Akaike T, 1998, P SOC EXP BIOL MED, V217, P64; BUSTER BL, 1995, INFECT IMMUN, V63, P3835, DOI 10.1128/IAI.63.10.3835-3839.1995; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Castillo J, 2000, STROKE, V31, P852, DOI 10.1161/01.STR.31.4.852; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; Deckel AW, 2001, J NEUROSCI RES, V64, P99, DOI 10.1002/jnr.1057; DICKSON DW, 1994, NEUROPATH APPL NEURO, V20, P211; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Hooper DC, 2000, FASEB J, V14, P691; HOWARDJONES N, 1985, WHO CHRON, V39, P51; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Iadecola C, 1997, J NEUROSCI, V17, P9157; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Matsui T, 1999, CELL MOL NEUROBIOL, V19, P177, DOI 10.1023/A:1006966012266; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Roufail E, 1998, DIABETOLOGIA, V41, P1419, DOI 10.1007/s001250051087; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; SESSA A, 1994, AGENTS ACTIONS, V43, P69, DOI 10.1007/BF02005768; SHERMAN MP, 1992, MED HYPOTHESES, V39, P143, DOI 10.1016/0306-9877(92)90175-C; Shinoda J, 2001, BRIT J NEUROSURG, V15, P213, DOI 10.1080/02688690120057628; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith MA, 1997, J NEUROSCI, V17, P2653; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; SULLIVAN SJ, 1994, BRAIN INJURY, V8, P613, DOI 10.3109/02699059409151014; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki Y, 1999, J CEREBR BLOOD F MET, V19, P1175, DOI 10.1097/00004647-199911000-00001; Tatsumi T, 2000, J AM COLL CARDIOL, V35, P1338, DOI 10.1016/S0735-1097(00)00526-X; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yildiz G, 1998, BRIT J PHARMACOL, V124, P905, DOI 10.1038/sj.bjp.0701924; YOUDIM MBH, 1994, ANN NY ACAD SCI, V738, P64; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	59	47	50	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2003	44	2					253	263		10.1016/S0028-3908(02)00380-5			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	647DL	WOS:000181077100012	12623224				2021-06-18	
J	O'Neal, PD; Cote, GL; Motamedi, M; Chen, J; Lin, WC				O'Neal, PD; Cote, GL; Motamedi, M; Chen, J; Lin, WC			Feasibility study using surface-enhanced Raman spectroscopy for the quantitative detection of excitatory amino acids	JOURNAL OF BIOMEDICAL OPTICS			English	Article						surface-enhanced Raman scattering; excitatory amino acids; glutamate; aspartate; silver colloid	TRAUMATIC BRAIN INJURY; SCATTERING NIR-SERS; COLLOIDAL SILVER; CEREBROSPINAL-FLUID; HEAD-INJURY; MICRODIALYSIS; GLUTAMATE; NEUROTRANSMITTERS; SPECTROMETRY; HIPPOCAMPUS	The release of excitatory amino acids (EAAs) from injured neurons has been associated with secondary injury following head trauma.-The development of a rapid and sensitive method for the quantification of EAAs may provide a means for clinical management of patients affected by head trauma. We explore the potential application of surface-enhanced Raman spectroscopy (SERS) for rapid quantification of the concentration of EAAs in aqueous silver colloids. The EAAs glutamate (Glu) and aspartate (Asp) are released following head injury and have been observed to exhibit SERS spectra that should enable them to be distinguished in a complex aqueous media. Of the two EAAs, the concentration of Glu has been shown to be more indicative of injury to the central nervous system. Using 30-s scans and a 50-mW argon laser, aqueous Glu is quantifiable from 0.4 to 5 mumol/L and is spectrally distinguishable from Asp. In addition, initial in vivo microdialysis experiments suggest that this SERS system is capable of measuring chemical changes following head trauma in the rat brain. Compared with current high-performance liquid chromatography (HPLC) techniques for amino acid detection, the short scanning and processing time associated with the SERS approach enables measurement on a near-real-time basis, providing clinical information in anticipation of pharmaceutical intervention. (C) 2003 Society of Photo-Optical Instrumentation Engineers.	Texas A&M Univ, Biomed Engn Program, College Stn, TX 77843 USA; Univ Texas, Med Branch, Ctr Biomed Engn, Galveston, TX 77551 USA; Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA	O'Neal, PD (corresponding author), Texas A&M Univ, Biomed Engn Program, College Stn, TX 77843 USA.						BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BOATELL ML, 1995, J NEUROCHEM, V64, P285; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1987, J NEUROSCI, V7, P357; CHUMANOV GD, 1990, J RAMAN SPECTROSC, V21, P43, DOI 10.1002/jrs.1250210109; CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790; HENGLEIN A, 1979, J PHYS CHEM-US, V83, P2209, DOI 10.1021/j100480a006; Hillered L, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p695A; Jongsma FHM, 1997, OPT ENG, V36, P3193, DOI 10.1117/1.601529; Joseph B., 1986, PSYCHOANAL PSYCHOTHE, V2, P13; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KNEIPP K, 1994, APPL SPECTROSC, V48, P951, DOI 10.1366/0003702944029776; KNEIPP K, 1995, APPL SPECTROSC, V49, P780, DOI 10.1366/0003702953964480; KNEIPP K, 1995, SPECTROCHIM ACTA A, V51, P481, DOI 10.1016/0584-8539(94)00235-4; KRAUS JF, 1996, NEUROTRAUMA, P13; Lakke JPWF, 1986, ADV NEUROL, V45, P243; LEE NS, 1988, ANAL CHEM, V60, P442, DOI 10.1021/ac00156a014; MONTES R, 1992, ANAL CHEM, V64, P2715, DOI 10.1021/ac00046a012; NAVARRETE JTL, 1994, BIOPOLYMERS, V34, P1065, DOI 10.1002/bip.360340810; ONEAL DP, 1999, THESIS TEXAS A M U; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; SHURVELL HF, 1989, J RAMAN SPECTROSC, V20, P163, DOI 10.1002/jrs.1250200307; THOMAS RJ, 1995, J AM GERIATR SOC, V43, P1279, DOI 10.1111/j.1532-5415.1995.tb07407.x; TORRES EL, 1987, ANAL CHEM, V59, P1626, DOI 10.1021/ac00140a010; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zauner A, 1996, ACT NEUR S, V67, P40	32	47	47	2	26	SPIE-INT SOCIETY OPTICAL ENGINEERING	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668			J BIOMED OPT	J. Biomed. Opt.	JAN	2003	8	1					33	39		10.1117/1.1528208			7	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	641QA	WOS:000180755400004	12542377				2021-06-18	
J	Lu, DY; Li, Y; Mahmood, A; Wang, L; Rafiq, T; Chopp, M				Lu, DY; Li, Y; Mahmood, A; Wang, L; Rafiq, T; Chopp, M			Neural and marrow-derived stromal cell sphere transplantation in a rat model of traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; transplantation; rat	BONE-MARROW; SPINAL-CORD; ADULT-RATS; EXPRESSION; RECOVERY; NEURONS; TISSUE; NEUROTROPHIN; ASTROCYTES; DEFICITS	Object. This study was designed to investigate the effect of treatment with a novel composite material consisting of C.. F embryonic neurospheres and bone marrow-derived stromal cell spheres (NMSCSs) in a rat model of traumatic brain injury (TBI). Methods. The NMSCS composite was injected into the TBI contusion site 24 hours after injury, and all rats were killed on Day 14 after the transplantation. The Rotarod test and the neurological severity score were used to evaluate neurological function. The transplanted NMSCS was analyzed in recipient rat brains by using histological staining and laser scanning confocal microscopy. The lesion Volumes in the brains were also calculated using computer image analysis. Conclusions. Rats that received NMSCS transplants had reduced lesion volume and showed improved motor and neurological function when compared with control groups 14 days after the treatment. These results suggest that transplantation of this novel biological material (NMSCS) may be useful in the treatment of TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 42259] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER		Bi LX, 1999, CALCIFIED TISSUE INT, V64, P63, DOI 10.1007/s002239900580; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; CANEVA L, 1995, BLOOD CELL MOL DIS, V21, P73, DOI 10.1006/bcmd.1995.0011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gressens P, 2000, PEDIATR RES, V48, P725, DOI 10.1203/00006450-200012000-00004; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; Kaddis FG, 2000, BRAIN RES BULL, V51, P203, DOI 10.1016/S0361-9230(99)00216-6; KESSLAK JP, 1986, EXP NEUROL, V94, P615, DOI 10.1016/0014-4886(86)90241-4; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Laurenzi MA, 1998, J LEUKOCYTE BIOL, V64, P228; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; NETTO CA, 1993, BEHAV BRAIN RES, V58, P107, DOI 10.1016/0166-4328(93)90095-8; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Park KW, 2001, NEUROSCI RES, V40, P315, DOI 10.1016/S0168-0102(01)00242-5; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; Subramanian T, 2001, SEMIN NEUROL, V21, P103, DOI 10.1055/s-2001-13125; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403; Yurek DM, 2000, J COMP NEUROL, V423, P462, DOI 10.1002/1096-9861(20000731)423:3<462::AID-CNE9>3.0.CO;2-U; Zhang ZG, 1999, J NEUROSCI, V19, P10898; Zurita M, 2001, SURG NEUROL, V55, P249, DOI 10.1016/S0090-3019(01)00442-6	29	47	50	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2002	97	4					935	940		10.3171/jns.2002.97.4.0935			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	604MY	WOS:000178626400033	12405384				2021-06-18	
J	Rappold, JF; Coimbra, R; Hoyt, DB; Potenza, BM; Fortlage, D; Holbrook, T				Rappold, JF; Coimbra, R; Hoyt, DB; Potenza, BM; Fortlage, D; Holbrook, T			Female gender does not protect blunt trauma patients from complications and mortality	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blunt trauma; sexual dimorphism; gender differences; closed head injury; shock; complications; mortality	DEPENDENT DIFFERENCES; ESTROGEN; INFECTIONS; OUTCOMES; INJURY; IMPACT	Background. The protective effect of gender on posttraumatic mortality or acute complications (acute respiratory distress syndrome [ARDS], pneumonia, and sepsis) is unclear. To assess potential effects, we performed a retrospective case-controlled study, matching patients for injury factors including overall severity (Injury Severity Sscore), the presence of shock (systolic blood pressure [SBP] < 90 mm Hg) at admission, and the presence of closed head injury (CHI). Methods. All female patients admitted over a 6(1)/(2)-year period were reviewed and divided into four groups: group 1, SBP > 90, no CHI; group 2, SBP < 90, no CHI; group 3, SBP > 90, with CHI; and group 4, SBP < 90, with CHI. Each cohort was matched one to one with an equivalent male counterpart. Cohorts were compared for mortality or the development of ARDS, pneumonia, and systemic sepsis using standard definitions. Results: Overall, 1,229 female patients were identified for study. The average Injury Severity Score was 16.3 and overall mortality was 2.7%. Analysis of the groups described previously demonstrated no statistically significant difference in the development of ARDS, pneumonia, systemic sepsis, or overall mortality between male and female patients including patients presenting with shock, CHI, or both. Conclusion: We conclude that female gender offers no protection from the development of ARDS, pneumonia, sepsis, or decreased mortality after blunt trauma.	Univ Calif San Diego, Dept Surg, Div Trauma Crit Care & Burns, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Ctr Med, Dept Surg, Div Trauma, 200 W Arbor Dr, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			Adams CA, 2000, AM SURGEON, V66, P905; AHMED SA, 1989, J IMMUNOL, V142, P2647; *AM COLL SURG COMM, 1993, RES OPT CAR INJ PAT; Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; Angele MK, 1997, ARCH SURG-CHICAGO, V132, P1207; ANGELE MK, 1998, SURG FORUM, V49, P43; Clerici E, 1991, J Clin Lab Immunol, V34, P71; Crabtree TD, 1999, JAMA-J AM MED ASSOC, V282, P2143, DOI 10.1001/jama.282.22.2143; Eachempati SR, 1999, ARCH SURG-CHICAGO, V134, P1342, DOI 10.1001/archsurg.134.12.1342; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; KNUDSON MM, 1994, ARCH SURG-CHICAGO, V129, P448; Kollef MH, 1997, CHEST, V112, P666, DOI 10.1378/chest.112.3.666; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; O'Keefe GE, 2001, J AM COLL SURGEONS, V192, P153, DOI 10.1016/S1072-7515(00)00785-7; Offner PJ, 1999, ARCH SURG-CHICAGO, V134, P935, DOI 10.1001/archsurg.134.9.935; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Torres A, 2000, CRIT CARE MED, V28, P2799, DOI 10.1097/00003246-200008000-00020; Wichmann MW, 2000, INTENS CARE MED, V26, P167, DOI 10.1007/s001340050041; Wichmann MW, 1997, AM J PHYSIOL-CELL PH, V273, pC1335; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	23	47	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2002	53	3					436	441		10.1097/00005373-200209000-00007			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	599GA	WOS:000178324700008	12352477				2021-06-18	
J	Brown, S; Archer, P; Kruger, E; Mallonee, S				Brown, S; Archer, P; Kruger, E; Mallonee, S			Tornado-related deaths and injuries in Oklahoma due to the 3 May 1999 tornadoes	WEATHER AND FORECASTING			English	Article; Proceedings Paper	National Symposium on the Great Plains Tornado Outbreak	MAY   03, 1999	OKLAHOMA CITY, OKLAHOMA				RISK-FACTORS	During the evening hours of 3 May 1999, 58 tornadoes occurred in Oklahoma. One tornado reached F5 intensity and left a widespread path of death, injury, and destruction in and around the Oklahoma City metropolitan area. Other communities across the state were also affected. Data on persons who died or were injured were collected from medical examiner reports, hospital medical records, and follow-up questionnaires. In addition, community surveys were conducted in the damaged areas, and a random telephone survey of people in the Oklahoma City area was conducted. A total of 45 persons died, and 645 survivors were treated at a hospital for injuries/health conditions related to the tornadoes. Detailed analyses were conducted on the 40 deaths and 512 nonfatal injuries that resulted directly from the tornadoes. The average age of persons who died was significantly higher than that of injured survivors. Almost three-fourths (74%) of survivors were treated in an emergency department and released; 26% were hospitalized, with an average stay of 7 days. The most common kinds of injuries were soft-tissue injuries (cuts, bruises, and scrapes), fractures/dislocations, and brain injuries. The most common causes of injuries for survivors were being hit by flying/falling debris and being picked up or blown by the tornado. Probable causes of death included multiple injuries (50%), head injuries (23%), chest trauma (18%), and traumatic asphyxia (10%). The proportion of deaths among injured persons was higher in mobile homes, apartment buildings, and outdoors than in houses. The vast majority of persons received television warnings; few persons received warnings by weatherband radio. Survey data indicated that since the tornadoes there had been only a slight increase in the proportion of persons with a storm shelter on their home premises and in the proportion of persons who know the location of the nearest shelter. Effective preparedness plans should be developed in advance of situations with tornadic potential and implemented in a timely manner when warnings are issued. The accessibility and knowledge of the location of shelters also needs to be increased. Warning systems should be integrated and duplicative, and they should include traditional methods and new technology.	Oklahoma Dept Hlth, Injury Prevent Serv 0307, Oklahoma City, OK 73117 USA	Brown, S (corresponding author), Oklahoma Dept Hlth, Injury Prevent Serv 0307, 1000 NE 10th St, Oklahoma City, OK 73117 USA.						BALLUZ L, 1997, DISASTERS, V24, P71; Bohonos JJ, 1999, J EMERG MED, V17, P67, DOI 10.1016/S0736-4679(98)00125-5; BRENNER SA, 1992, J TRAUMA, V33, P673; CARTER AO, 1989, AM J EPIDEMIOL, V130, P1209, DOI 10.1093/oxfordjournals.aje.a115449; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1069; *CDC, 1997, MORBIDITY MORTALITY, V46, P412; *CDC, 1988, MORBIDITY MORTALITY, V37, P461; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P454; *CDC, 1994, EP INF SOFTW VERS 6; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P33; EIDSON M, 1990, INT J EPIDEMIOL, V19, P1051, DOI 10.1093/ije/19.4.1051; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; GLASS RI, 1980, SCIENCE, V207, P734, DOI 10.1126/science.207.4432.734; Howell D. C., 1997, STAT METHODS PSYCHOL; *KIWTV 9, 2000, WEATH SAF TIPS; LILLIBRIDGE SR, 1997, PUBLIC HLTH CONSEQUE, P228; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; May AK, 2000, J TRAUMA, V48, P666, DOI 10.1097/00005373-200004000-00014; *OKL EM MAN AG, 1999, 1272DROK FEMA OKL EM; SCHMIDLIN TW, 1995, DISASTERS, V19, P170, DOI 10.1111/j.1467-7717.1995.tb00367.x; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; *SPC, 2001, TORN DEATHS YEAR MON; *SPC, 2001, TORN FAT INF; *WERC, 2000, INCR SHELT PROT EXTR	24	47	50	0	8	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0882-8156			WEATHER FORECAST	Weather Forecast.	JUN	2002	17	3					343	353		10.1175/1520-0434(2002)017<0343:TRDAII>2.0.CO;2			11	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	560BP	WOS:000176061800002		Bronze			2021-06-18	
J	Gahm, C; Holmin, S; Mathiesen, T				Gahm, C; Holmin, S; Mathiesen, T			Nitric oxide synthase expression after human brain contusion	NEUROSURGERY			English	Article						brain injury; endothelial nitric oxide synthase; inducible nitric oxide synthase; inflammation; neuronal nitric oxide synthase; trauma	FOCAL CEREBRAL-ISCHEMIA; INFARCT VOLUME; ARTERY OCCLUSION; NOS INHIBITOR; RAT MODEL; INJURY; NEURONS; CELLS; GENE; NEUROTOXICITY	OBJECTIVE: Nitric oxide is a universal mediator of biological effects in the brain, and it has been implicated in the pathophysiological processes of traumatic brain injury. Experimental studies have indicated posttraumatic up-regulation of the three different isoforms of nitric oxide synthase (NOS) (i.e., inducible NOS [iNOS], endothelial NOS, and neuronal NOS) after brain trauma. This study was undertaken to investigate the cellular sources and tissue compartments of nitric oxide produced by human patients undergoing surgical treatment for contusional brain injuries. METHODS: Contused brain tissue specimens from eight consecutive patients who underwent surgical treatment for brain contusions 3 hours to 5 days after trauma were evaluated in immunohistochemical analyses. Double-staining assays were used to define which cells produced the different isoforms. RESULTS: Increases in iNOS-positive cells were detectable within 6 hours after trauma, with a peak at 8 to 23 hours. Expression of NOS after trauma was detected in neurons, macrophages, neutrophils, astrocytes, and oligodendrocytes. The cellular sources of NOS differed at different times after trauma. No detectable difference in the expression of the neuronal or endothelial isoforms was observed for trauma patients, compared with control subjects. CONCLUSION: NOS expression was up-regulated in a time-dependent manner in human brain tissue obtained from patients undergoing surgical treatment for contusional trauma. Our human data largely parallel experimental findings in rats, indicating that such trauma models are relevant for experimental studies and treatment trials.	Karolinska Inst, Neurosurg Sect, Dept Clin Neurosci, Stockholm, Sweden	Mathiesen, T (corresponding author), Karolinska Hosp, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden.			Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			ASHWAL S, 1993, J NEUROSURG ANESTH, V5, P241; BUISSON A, 1993, J NEUROCHEM, V61, P690; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Gahm C, 2000, NEUROSURGERY, V46, P169; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Heneka MT, 1998, J NEUROCHEM, V71, P88; Higuchi Y, 1996, BRAIN DEV-JPN, V18, P369, DOI 10.1016/0387-7604(96)00019-8; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOLMIN S, 1997, THESIS KAROLINSKA I, P38; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; KIRSCH JR, 2000, NITRIC OXIDE BIOL PA, P439; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Love S, 1999, BRAIN PATHOL, V9, P119; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Merrill JE, 1997, J NEUROSCI RES, V48, P372, DOI 10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.3.CO;2-5; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MINCGOLOMB D, 1994, BRIT J PHARMACOL, V112, P720, DOI 10.1111/j.1476-5381.1994.tb13136.x; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAGAFUJI T, 1995, NEUROREPORT, V6, P1541, DOI 10.1097/00001756-199507310-00019; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIKAWA T, 1994, STROKE, V25, P877, DOI 10.1161/01.STR.25.4.877; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; QUAST MJ, 1995, BRAIN RES, V677, P204, DOI 10.1016/0006-8993(95)00134-C; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; Yamanaka K, 1998, NEUROSCI RES, V31, P347, DOI 10.1016/S0168-0102(98)00052-2; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZHANG ZG, 1994, BRAIN RES, V654, P85; Zhang ZG, 1996, J CEREBR BLOOD F MET, V16, P599, DOI 10.1097/00004647-199607000-00009	45	47	50	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2002	50	6					1319	1326		10.1097/00006123-200206000-00024			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	560XE	WOS:000176106000035	12015851				2021-06-18	
J	Cunningham, RM; Maio, RF; Hill, EM; Zink, BJ				Cunningham, RM; Maio, RF; Hill, EM; Zink, BJ			The effects of alcohol on head injury in the motor vehicle crash victim	ALCOHOL AND ALCOHOLISM			English	Article							TRAUMATIC BRAIN INJURY; HOSPITAL COURSE; ETHANOL; INTOXICATION; SEVERITY	The objective of this study was to determine if alcohol potentiates the severity of traumatic brain injury (TBI) in motor vehicle crash (MVC) victims, controlling for crash severity characteristics. Prior studies evaluating effects of alcohol on TBI have not accounted for severity of crash. We evaluated severity of head injury by Marshall score [a classification scale of intracranial pathology on head computed axial tomogram (CT)], and blood-alcohol concentration (BAC), while controlling for crash characteristics [traffic accident deformity score (TAD) and belt use]. Marshall scores were determined from initial CT or autopsy reports, by a neurosurgeon, and were categorized into less severe injury (<3) and more severe (greater than or equal to3). Logistic regression using this variable as the outcome parameter and crash characteristics, age and BAC as predictors was done, and the odds ratio (OR) and 0.95 confidence interval (0.95 CI) calculated. Fifty-eight patients were analysed: 41% were BAC positive, 30% had a modified Marshall score of greater than or equal to3. Patients with positive BAC were 2.1-fold more likely to have a more severe head injury as measured on CT scan by the Marshall scores. We suggest that alcohol potentiates severity of TBI as determined from head CT among MVC victims. Further research will be needed to substantiate this finding as well as to determine its long-term effect on clinical outcome.	Univ Michigan, Med Ctr, Dept Emergency Med, Ann Arbor, MI 48109 USA	Cunningham, RM (corresponding author), Univ Michigan, Med Ctr, Dept Emergency Med, TC B134 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA009110] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01-AA09110-01] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hingson R, 1996, AM J PUBLIC HEALTH, V86, P791, DOI 10.2105/AJPH.86.6.791; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Marshall SB, 1991, J NEUROSURG S, V75, P14; MCCALL D, 1989, BIOCHEM PHARMACOL, V38, P2593, DOI 10.1016/0006-2952(89)90543-1; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVERA FP, 1997, NEW ENGL J MED, V337, P543; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SIGGINS GR, 1996, PHARM TOXIC, P175; Stein MD, 1999, PSYCHIAT CLIN N AM, V22, P351, DOI 10.1016/S0193-953X(05)70081-2; *US DEP TRANSP, 1994, TRAFF SAF FACTS ALC; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; Waller PF, 1997, ACCIDENT ANAL PREV, V29, P817, DOI 10.1016/S0001-4575(97)00051-1; WALLER PF, 1999, ACAD EMERG MED, V6, P490; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	33	47	49	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0735-0414			ALCOHOL ALCOHOLISM	Alcohol Alcohol.	MAY-JUN	2002	37	3					236	240		10.1093/alcalc/37.3.236			5	Substance Abuse	Substance Abuse	552ZC	WOS:000175649400005	12003910	Bronze			2021-06-18	
J	Lenzlinger, PM; Marx, A; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Lenzlinger, PM; Marx, A; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans	JOURNAL OF NEUROIMMUNOLOGY			English	Article						brain injuries; apoptosis; cerebrospinal fluid; soluble Fas (CD95); blood-brain barrier; neuron-specific enolase; inflammation	CORTICAL IMPACT INJURY; NEURON-SPECIFIC ENOLASE; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; MESSENGER-RNA; CELL-DEATH; MULTIPLE-SCLEROSIS; TNF-ALPHA; DNA FRAGMENTATION; MEMORY DEFICITS	The mechanisms underlying cell death following traumatic brain injury (TBI) are not fully understood. Apoptosis is believed to be one mechanism contributing to a marked and prolonged neuronal cell loss following TBL Recent data suggest a role for Fas (APO-1, CD95), a type I transmembrane receptor glycoprotein of the nerve growth factor/tumor necrosis factor superfamily, and its ligand (Fas ligand, FasL) in apoptotic events in the central nervous system. A truncated form of the Fas receptor, soluble Fas (sFas) may indicate activation of the Fas/FasL system and act as a negative feedback mechanism, thereby inhibiting Fas mediated apoptosis. Soluble Fas was measured in cerebrospinal fluid (CSF) and serum of 10 patients with severe TBI (GCS less than or equal to 8) for up to 15 days post-trauma. No sFas was detected in CSF samples from patients without neurological pathologies. Conversely, after TBI 118 out of 120 CSF samples showed elevated sFas concentrations ranging from 56 to 4327 mU/ml. Paired serum samples showed above normal (8.5 U/ml) sFas, concentrations in 5 of 10 patients. Serum levels of sFas were always higher than CSF levels. However, there was no correlation between concentrations measured in CSF and in serum (r(2) = 0.078, p = 0.02), suggesting that the concentrations in the two compartments are independently regulated. Also, no correlation was found between sFas in CSF and blood brain barrier (BBB) dysfunction as assessed by the albumin CSF/serum quotient (Q(A)), and concentrations of the cytotoxic cytokine tumor necrosis factor-alpha in CSF, respectively. Furthermore, there was no correlation with two markers of immune activation (soluble interleukin-2 receptor and neopterin) in CSF. Maximal CSF levels of sFas correlated significantly (r(2)=0.8191, p<0.001) with the early peaks of neuron-specific enolase in CSF (a marker for neuronal cell destruction), indicating that activation of the Fas mediated pathway of apoptosis may be in part the direct result of the initial trauma. However, the prolonged elevation of sFas in CSF may be caused by the ongoing inflammatory response to trauma and delayed apoptotic cell death. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Surg Res, CH-8091 Zurich, Switzerland; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Lenzlinger, PM (corresponding author), Univ Hosp, Div Trauma Surg, Dept Surg, Raeminstr 100, CH-8091 Zurich, Switzerland.	philipp.Lenzlinger@chi.usz.ch	Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS07413-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007413] Funding Source: NIH RePORTER		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Becher B, 1998, TRENDS NEUROSCI, V21, P114, DOI 10.1016/S0166-2236(97)01180-6; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bouma G J, 1995, New Horiz, V3, P384; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Choi C, 1999, J IMMUNOL, V162, P1889; Ciusani E, 1998, J NEUROIMMUNOL, V82, P5, DOI 10.1016/S0165-5728(97)00177-X; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Fassbender K, 1999, J NEUROIMMUNOL, V93, P122, DOI 10.1016/S0165-5728(98)00210-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hans VHJ, 1999, NEUROREPORT, V10, P409; JENNETT B, 1975, LANCET, V1, P480; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NISHIMURA T, 1995, BRAIN RES, V695, P137, DOI 10.1016/0006-8993(95)00699-Q; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Papoff G, 1996, J IMMUNOL, V156, P4622; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; RINK A, 1995, AM J PATHOL, V147, P1575; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Saas P, 1999, J IMMUNOL, V162, P2326; Sabri F, 2001, J NEUROIMMUNOL, V114, P197, DOI 10.1016/S0165-5728(00)00424-0; SCHMECHEL DE, 1987, NEUROSCI LETT, V76, P233, DOI 10.1016/0304-3940(87)90721-X; Shin SW, 1998, J NEUROCHEM, V71, P1773; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Sporer B, 2000, AIDS RES HUM RETROV, V16, P221, DOI 10.1089/088922200309313; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STOCKER R, 1995, MONITORING TREATMENT, P197; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; THOMAS WE, 1992, BRAIN RES REV, V17, P61	66	47	51	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	JAN	2002	122	1-2					167	174		10.1016/S0165-5728(01)00466-0			8	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	516UQ	WOS:000173575500019	11777556				2021-06-18	
J	Petrov, T; Steiner, J; Braun, B; Rafols, JA				Petrov, T; Steiner, J; Braun, B; Rafols, JA			Sources of endothelin-1 in hippocampus and cortex following traumatic brain injury	NEUROSCIENCE			English	Article						microcirculation; endothelial cells; neurons; glia; mRNA; protein synthesis	CEREBRAL BLOOD-FLOW; CENTRAL NUCLEUS; NITRIC-OXIDE; RAT; EXPRESSION; ASTROCYTES; RECEPTOR; INHIBITION; PHYSIOLOGY; AMYGDALA	Endothelin 1 (ET-1) exerts normally a powerful vasoconstrictor role in the control of the brain microcirculation. In altered states, such as following traumatic brain injury (TBI), it may contribute to the development of ischemia and/or secondary cell injury. Because little is known of ET-l's cellular compartmentalization and its association to vulnerable neurons after TBI, we assessed its expression (both mRNA and protein) in cerebral cortex and hippocampus using correlative in situ hybridization and immunocytochemical techniques. Sprague-Dawley male rats were killed at 4, 24 or 48 h after TBI (450 g from 2 m, Marmarou's model). Semiquantitative analysis of our in situ hybridization results indicated a 2.5- and a 2.0-fold increase in ET-1 mRNA content in the hippocampus and cortex respectively which persisted up to 48 h post TBI. At 4 and 24 h after TBI enzyme-linked immunosorbent assay showed a tendency for increased ET-1 synthesis. In animals subjected to TBI, qualitative immunocytochemical analysis revealed a shift in ET-1 expression from astrocytes (in control animals) to endothelial cells, macrophages and neurons. Astrocytes and macrophages were identified unequivocally by using double immunofluorescence revealing ET-1 and glial fibrillary acidic protein or ED-1, respectively, the markers being specific for these cellular types. While this redistribution was most prominent at 4 and 24 h post TBI, at 48 h the endothelial cells remained strongly ET-1 immunopositive. The results suggest that cellular types which in the intact animal synthesize little or no ET-1 provide novel sources of the peptide after TBI. These sources may contribute to the sustained cerebrovascular hypoperfusion observed post TBI. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		BARONE FC, 1995, J CARDIOVASC PHARM, V26, pS404; Cheng KS, 2001, CHINESE J ASTRON AST, V1, P1, DOI 10.1088/1009-9271/1/1/1; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; FLORY CM, 1993, LAB INVEST, V69, P396; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FUXE K, 1992, EXP BRAIN RES, V88, P131, DOI 10.1007/BF02259134; Gorlach C, 2001, PFLUG ARCH EUR J PHY, V441, P844, DOI 10.1007/s004240000495; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Hasselblatt M, 2001, GLIA, V34, P18, DOI 10.1002/glia.1036; Ho MCY, 2001, FASEB J, V15, P618, DOI 10.1096/fj.99-1022com; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MASAKI T, 1995, ANNU REV PHARMACOL, V35, P235, DOI 10.1146/annurev.pharmtox.35.1.235; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakagomi S, 2000, NEUROSCIENCE, V101, P441, DOI 10.1016/S0306-4522(00)00345-6; Onoda K, 1996, J NEUROSURG, V85, P846, DOI 10.3171/jns.1996.85.5.0846; Petrov T, 1995, J NEUROSCI RES, V42, P835, DOI 10.1002/jnr.490420612; Petrov T., 2001, Society for Neuroscience Abstracts, V27, P573; Petrov T, 1996, CELL TISSUE RES, V283, P367, DOI 10.1007/s004410050547; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; PETROV T, 2002, IN PRESS SOC NEUR AB, V28; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Rafols J. A., 2001, Society for Neuroscience Abstracts, V27, P568; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sharma AC, 1998, NEUROL RES, V20, P632; Siren AL, 2000, NEUROCHEM RES, V25, P957, DOI 10.1023/A:1007552408463; SUZUKI H, 1990, ACTA NEUROL SCAND, V81, P553; TSANG M, 1995, NEUR ABSTR, V22; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMASHITA K, 1995, PHARM PHYSL, V22, pS277; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	39	47	49	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	115	1					275	283	PII S0306-4522(02)00345-7	10.1016/S0306-4522(02)00345-7			9	Neurosciences	Neurosciences & Neurology	615DX	WOS:000179231500025	12401340				2021-06-18	
J	Sutcliffe, IT; Smith, HA; Stanimirovic, D; Hutchison, JS				Sutcliffe, IT; Smith, HA; Stanimirovic, D; Hutchison, JS			Effects of moderate hypothermia on IL-1 beta-induced leukocyte rolling and adhesion in pial microcirculation of mice and on proinflammatory gene expression in human cerebral endothelial cells	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CD18; cerebral endothelium; cytokines; hypothermia; leukocyte adhesion; neuroprotection; NF-kappa B	CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; POSTTRAUMATIC HYPOTHERMIA; MILD HYPOTHERMIA; ISCHEMIA; RAT; MOLECULES; INTERLEUKIN-8; INFILTRATION	Although the neuroprotective effects of hypothermia have been known for a long time, the molecular correlates of this neuroprotection are poorly understood. In this study, the authors investigated how hypothermia affects inflammatory responses in the brain elicited by systemic injection of IL-1 beta. Leukocyte rolling and adhesion were quantified in pial venules (20 to 50 mum) of C57/B16 mice 4 hours after intraperitoneal injection of IL-1 beta (5 mug/kg) using an open cranial window and intravital microscopy. Animals were subjected to moderate hypothermia (32 degreesC or normothermia (37 degreesC) for 1 or 4 hours after IL-lp injection. Significant increases in leukocyte rolling and adhesion were observed in IL-1 beta -injected animals as compared with sham controls. Whereas 1-hour hypothermia did not affect IL-1 beta -induced leukocyte rolling and adhesion, 4-hour hypothermia caused a reduction in both rolling and adhesion. Molecular mechanisms of hypothermic effects were investigated in cultured human cerebral endothelial cells exposed to IL-1 beta (50 U/mL) for 4 hours at 37 degreesC or 32 degreesC followed by 18 hours at 37 degreesC. Human cerebral endothelial cells exposed to IL-1 beta at 32 degreesC showed attenuated NF-kappaB activation determined by the Luciferase yellow reporter gene assay and reduced expression of IL-8 and IL-1 beta measured by reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay. Intracellular adhesion molecule-1 was induced to similar levels (threefold over control) at both temperatures. The expression of CD18 on neutrophils in vitro was not affected by either IL-1 beta or hypothermia. These findings suggest that mechanisms by which hypothermia reduces leukocyte rolling and adhesion include suppression of inflammatory gene transcription in brain endothelial cells.	Childrens Hosp Eastern Ontario, Res Inst, Div Pediat Crit Care, Dept Pediat, Ottawa, ON K1H 8L1, Canada; Natl Res Council Canada, Inst Biol Sci, Cellular Neurobiol Grp, Ottawa, ON K1A 0R6, Canada	Hutchison, JS (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Div Pediat Crit Care, Dept Pediat, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.						BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CARLOS TM, 1994, BLOOD, V84, P2068; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; Chopp M, 1996, ADV NEUROL, V71, P315; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; GERHART DZ, 1988, BRAIN RES BULL, V21, P785, DOI 10.1016/0361-9230(88)90047-0; Haddix TL, 1996, J SURG RES, V64, P176, DOI 10.1006/jsre.1996.0325; Hallenbeck JM, 1996, ADV NEUROL, V71, P281; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Ishikawa M, 1999, STROKE, V30, P1679, DOI 10.1161/01.STR.30.8.1679; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kogure K, 1996, ACT NEUR S, V66, P40; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Manning AM, 1995, J INFLAMM, V45, P283; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Mukaida N, 1998, INFLAMM RES, V47, pS151; NOURSHARGH S, 1995, BLOOD, V85, P2553, DOI 10.1182/blood.V85.9.2553.bloodjournal8592553; Ransohoff RM, 1997, J LEUKOCYTE BIOL, V62, P645; ROSENBLUM WI, 1994, AM J PATHOL, V145, P33; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Shi QA, 1999, J INTERF CYTOK RES, V19, P1363, DOI 10.1089/107999099312821; SHUAIB A, 1993, NEUROCHEM RES, V18, P663, DOI 10.1007/BF00966779; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stanimirovic D, 1997, J NEUROIMMUNOL, V76, P193, DOI 10.1016/S0165-5728(97)00057-X; Thoresen M, 1997, NEUROREPORT, V8, P3359, DOI 10.1097/00001756-199710200-00033; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; WANG XK, 1995, J NEUROTRAUM, V12, P825, DOI 10.1089/neu.1995.12.825; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009	41	47	50	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2001	21	11					1310	1319		10.1097/00004647-200111000-00007			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	491AZ	WOS:000172087000007	11702046	Bronze			2021-06-18	
J	Tan-No, K; Cebers, G; Yakovleva, T; Goh, BH; Gileva, I; Reznikov, K; Aguilar-Santelises, M; Hauser, KF; Terenius, L; Bakalkin, G				Tan-No, K; Cebers, G; Yakovleva, T; Goh, BH; Gileva, I; Reznikov, K; Aguilar-Santelises, M; Hauser, KF; Terenius, L; Bakalkin, G			Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms	EXPERIMENTAL CELL RESEARCH			English	Article						big dynorphin; cell death; apoptosis; p53	SPINAL-CORD INJURY; RAT HINDLIMB PARALYSIS; LONG-LASTING ALLODYNIA; HAMSTER OVARY CELLS; OPIOID RECEPTORS; TRAUMATIC INJURY; NMDA RECEPTOR; BINDING-SITE; PEPTIDES; PROTEIN	Dynorphin A, a prodynorphin-derived peptide, is able to induce neurological dysfunction and neuronal death. To study dynorphin cytotoxicity in vitro, prodynorphin-derived peptides were added into the culture medium of nonneuronal and neuronal cells or delivered into these cells by lipofection or electroporation. Cells were unaffected by extracellular exposure when peptides were added to the medium. In contrast, the number of viable cells was significantly reduced when dynorphin A or "big dynorphin," consisting of dynorphins A and B, was transfected into cells. Big dynorphin was more potent than dynorphin A, whereas dynorphin B; dynorphin B-29; [Arg(11,13)]- dynorphin A(1-13)-Gly-NH-(CH2)(5)-NH2, a selective kappa -opioid receptor agonist; and poly-L-lysine, a basic peptide more positively charged than big dynorphin, failed to affect cell viability. The opioid antagonist naloxone did not prevent big dynorphin cytotoxicity. Thus, the toxic effects were structure selective but not mediated through opioid receptors. When big dynorphin was delivered into cells by lipofection, it became localized predominantly in the cytoplasm and not mi the nuclei. Big dynorphin appeared to induce toxicity through an apoptotic mechanism that may involve synergistic interactions with the p53 tumor-suppressor protein. It is proposed that big dynorphin induces cell death by virtue of its net positive charge and clusters of basic amino acids that mimic (and thereby perhaps interfere with) basic domains involved in protein-protein interactions. These effects may be relevant for a pathophysiological role of dynorphins in the brain and spinal cord and for control of death of tumor cells, which express prodynorphin at high levels. (C) 2001 Academic Press.	Karolinska Inst, Dept Clin Neurosci, Sect Alcohol & Drug Addict Res, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Hematol, S-17176 Stockholm, Sweden; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Bakalkin, G (corresponding author), Karolinska Inst, Dept Clin Neurosci, Sect Alcohol & Drug Addict Res, CMM L8-01, S-17176 Stockholm, Sweden.		Hauser, Kurt/AAX-8361-2020	Tan-No, Koichi/0000-0001-6724-848X; Hauser, Kurt/0000-0001-7886-0332; Bakalkin, Georgy/0000-0002-8074-9833			Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; BAKALKIN GY, 1991, INT J PEPT PROT RES, V38, P505; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; Brown GP, 1998, J PHARMACOL EXP THER, V286, P376; CHEN L, 1995, J PHYSIOL-LONDON, V482, P575, DOI 10.1113/jphysiol.1995.sp020541; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; Claye LH, 1996, J PHARMACOL EXP THER, V277, P359; CONE RI, 1983, J NEUROSCI, V3, P2146; CORY AH, 1991, CANCER COMMUN, V3, P207; COX BM, 1985, NEUROPEPTIDES, V5, P571, DOI 10.1016/0143-4179(85)90082-4; DAY R, 1989, ENDOCRINOLOGY, V124, P2392, DOI 10.1210/endo-124-5-2392; ERNE D, 1985, BIOCHEMISTRY-US, V24, P4261, DOI 10.1021/bi00337a001; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1985, REGUL PEPTIDES, V11, P35, DOI 10.1016/0167-0115(85)90029-1; Fukuda K, 1998, ANESTH ANALG, V87, P450, DOI 10.1097/00000539-199808000-00041; GEIJER T, 1991, REGUL PEPTIDES, V34, P181, DOI 10.1016/0167-0115(91)90177-I; GEIJER T, 1995, BIOCHEM BIOPH RES CO, V215, P881, DOI 10.1006/bbrc.1995.2546; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; GIOANNINI TL, 1993, MOL PHARMACOL, V44, P796; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hauser KF, 2001, EXP NEUROL, V168, P78, DOI 10.1006/exnr.2000.7580; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Itoh H, 2000, EUR J NEUROSCI, V12, P1253, DOI 10.1046/j.1460-9568.2000.00012.x; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Laughlin TM, 1997, PAIN, V72, P253, DOI 10.1016/S0304-3959(97)00046-8; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; Malan TP, 2000, PAIN, V86, P185, DOI 10.1016/S0304-3959(00)00243-8; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; Planells-Cases R, 2000, FEBS LETT, V481, P131, DOI 10.1016/S0014-5793(00)01982-7; Remmers AE, 1999, J PHARMACOL EXP THER, V288, P827; Reznikov K, 2000, FASEB J, V14, P1754, DOI 10.1096/fj.99-0890com; Schmitt L, 1999, P NATL ACAD SCI USA, V96, P6581, DOI 10.1073/pnas.96.12.6581; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHUKLA VK, 1994, TRENDS PHARMACOL SCI, V15, P420, DOI 10.1016/0165-6147(94)90091-4; SKILLING SR, 1992, BRAIN RES, V575, P272, DOI 10.1016/0006-8993(92)90090-V; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Tang QB, 1999, J PHARMACOL EXP THER, V291, P760; Vanderah TW, 1996, PAIN, V68, P275, DOI 10.1016/S0304-3959(96)03225-3; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; WU CSC, 1986, J BIOL CHEM, V261, P3687; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Yarygin KN, 1998, BRAIN RES, V791, P99, DOI 10.1016/S0006-8993(98)00084-5; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	54	47	47	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4827			EXP CELL RES	Exp. Cell Res.	SEP 10	2001	269	1					54	63		10.1006/excr.2001.5309			10	Oncology; Cell Biology	Oncology; Cell Biology	472TP	WOS:000171001300007	11525639				2021-06-18	
J	Raja, IA; Vohra, AH; Ahmed, M				Raja, IA; Vohra, AH; Ahmed, M			Neurotrauma in Pakistan	WORLD JOURNAL OF SURGERY			English	Article							INJURIES; TRAUMA; HEAD	The incidence of head and spinal injury is on the rise in developing countries. The number of deaths and burden of disability may be reduced, if not completely stopped, through preventive measures after an epidemiological survey on trauma. The goal can be achieved to a significant extent through the use of guidelines from the countries that have achieved a reduction in the incidence of neurotrauma. To determine the incidence and outcome of neurotrauma in developing countries; a study was necessary using standardized assessment parameters for global interpretation. Such a study was conducted to determine the sociodemographic characteristics, morbidity, and mortality of patients with head and spinal injury admitted to various neurosurgical centers in Pakistan from July 1, 1995 to June 30, 1999. A total of 260,000 patients were admitted with head injury over a 4-year period. The majority of patients presented during second decade (i.e., 33.2%) followed by first and third decade. There were 195,000 (75%) males, and 65,000 (25%) females with a ratio of 3:1. Road traffic accident was the commonest cause of head trauma. Mild, moderate, and severe head injury was observed in 135,200 (52%), 78,000 (30%), and 46,800 (18%) patients, respectively. Conservative management was carried out in 176,800 (68%) patients. Surgery was required in 83,200 (32%), 50% of which had depressed skull fracture, simple or compound. Follow-up period varied from 2 months to 2 years with a mean of 11 months. Patient's outcome was assessed according to Glasgow Outcome Scale (GOS). Good outcome was observed in 174,200 (67%). The total mortality was 46,800 (18%). In this study, 2654 patients ranging in age from 5 to 70 years had spinal injuries. There were 1922 males (72%) and 732 (28%) females. British Medical Research Council Scale was used for assessment of motor power of patients with spinal trauma. Of these, 780 patients (29%) had complete spinal cord injury. Surgical intervention was performed in 1800 patients (68%) and the rest were managed conservatively.	King Edward Med Coll, Dept Neurosurg, Lahore, Pakistan	Raja, IA (corresponding author), King Edward Med Coll, Dept Neurosurg, 40-C,Zafar Ali Rd,Gulberg V, Lahore, Pakistan.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bostrom L, 1999, EUR J SURG, V165, P930; Gilthorpe MS, 1999, BRIT J ORAL MAX SURG, V37, P294, DOI 10.1054/bjom.1998.0039; JENNET B, 1994, INTRO NEUROSURGERY, P189; MacKenzie E J, 1989, Md Med J, V38, P725; MORTENSEN K, 1994, TIDSSKR NOR LAEGEFOR, V119, P1870; Muyembe VM, 1999, E AFR MED J, V76, P200; Prasad VSSV, 1999, SPINAL CORD, V37, P560, DOI 10.1038/sj.sc.3100878; Puder DR, 1999, AM J PUBLIC HEALTH, V89, P1736, DOI 10.2105/AJPH.89.11.1736; RAJA IA, 1991, P 1 INT S EP HEAD SP, P37; Rivara F P, 1999, Inj Prev, V5, P194; Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009	12	47	48	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1230	1237					8	Surgery	Surgery	471NB	WOS:000170934500023	11571963				2021-06-18	
J	Beer, R; Franz, G; Krajewski, S; Pike, BR; Hayes, RL; Reed, JC; Wang, KK; Klimmer, C; Schmutzhard, E; Poewe, W; Kampfl, A				Beer, R; Franz, G; Krajewski, S; Pike, BR; Hayes, RL; Reed, JC; Wang, KK; Klimmer, C; Schmutzhard, E; Poewe, W; Kampfl, A			Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic bra in injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astrocyte; caspase 8; neuron; oligodendrocyte; traumatic brain injury	APOPTOTIC CELL-DEATH; CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; IN-VIVO; ACTIVATED CASPASE-3; ALZHEIMERS-DISEASE; SIGNALING COMPLEX; NERVOUS-SYSTEM	Recent studies have demonstrated that the downstream caspases, such as caspase 3, act as executors of the apoptotic cascade after traumatic brain Injury (TBI) in vivo. However, little is known about the involvement of caspases in the initiation phase of apoptosis, and the interaction between these initiator caspases (e.g. caspase 8) and executor caspases after experimental brain injuries in vitro and In vivo. This study investigated the temporal expression and cell subtype distribution of procaspase 8 and-cleaved caspase 8 p20 from 1 h to 14 days after cortical impact-induced TBI in rats. Caspase 8 messenger RNA levels, estimated by semi-quantitaive RT-PCR, were elevated from 1 h to 72 h in the traumatized cortex. Western blotting revealed increased immunoreactivity for procaspase 8 and the proteolytically active subunit of caspase 8, p20, in the ipsilateral cortex from 6 to 72 h after injury, with a peak at 24 h after TBI. Similar to our previous studies, immunoreactivity for the p18 fragment of activated caspase 3 also increased in the current study from 6 to 72 h after TBI, but peaked at a later timepoint (48 h) as compared with proteolyzed caspase 8 p20. Immunohistologic examinations revealed increased expression of caspase 8 In neurons, astrocytes and oligodendrocytes. Assessment of DNA damage using TUNEL identified caspase 8- and caspase 3-immunopositive cells with apoptotic-like morphology in the cortex ipsilateral to the injury site, and immunohistochemical investigations of caspase 8 and activated caspase 3 revealed expression of both proteases in cortical layers 2-5 after TBI. Quantitative analysis revealed that the number of caspase 8 positive cells exceeds the number of caspase 3 expressing cells up to 24 h after impact injury. In contrast, no evidence of caspase 8 and caspase 3 activation was seen in the ipsilateral hippocampus, contralateral cortex and hippocampus up to 14 days after the impact. Our results provide the first evidence of caspase 8 activation after experimental TBI and suggest that this may occur in neurons, astrocytes and oligodendrocytes. Our findings also suggest a contributory role of caspase 8 activation to caspase 3 mediated apoptotic cell death after experimental TBI In vivo.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Burnham Inst, La Jolla, CA 92037 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Gainesville, FL USA	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	andreas.kampfl@uibk.ac.at	Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40182, R01 NS39091, NS36921] Funding Source: Medline		Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Charriaut-Marlangue C, 1998, BIOMED PHARMACOTHER, V52, P264, DOI 10.1016/S0753-3322(98)80012-7; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gu CH, 1999, J NEUROSCI, V19, P3043; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Hayashi T, 1998, STROKE, V29, P1007, DOI 10.1161/01.STR.29.5.1007; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.3.CO;2-Z; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; Krajewska M, 1997, CANCER RES, V57, P1605; Krinke GJ., 2000, LAB RAT; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Liu XZ, 1997, J NEUROSCI, V17, P5395; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NITATORI T, 1995, J NEUROSCI, V15, P1001; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Xerri L, 2000, J PATHOL, V192, P194, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	69	47	51	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2001	78	4					862	873		10.1046/j.1471-4159.2001.00460.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	463TV	WOS:000170494100021	11520907				2021-06-18	
J	Hartlage, LC; Durant-Wilson, D; Patch, PC				Hartlage, LC; Durant-Wilson, D; Patch, PC			Persistent neurobehavioral problems following mild traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						persistent neurobehavioral problems; brain; MTBI	CLOSED-HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL ASSESSMENT; BASE RATES; SYMPTOMS; SEQUELAE; CHILDREN; RECOVERY	Accumulating research documents typical rates in the range of 85% of mild traumatic brain injury (MTBI) showing prompt, complete resolution with 15% suffering from persistent neurobehavioral impairments. Studies of neurobehavioral symptoms of MTBI have not separated these two populations, resulting in either inconclusive or contradictory conclusions concerning the relationship of MTBI with residual behavioral problems. This project studied 70 MTBI patients with persistent neurobehavioral problems at two time intervals post-injury to determine whether there are consistent neurobehavioral patterns considered to be sequelae of MTBI A matched group of 40 normal subjects provided control data. While most behavioral problems showed improvement, 21% tended to show significant behavioral impairment compared to controls at 12 or more months post-injury. Neurochemical bases of neuronal degeneration may account for some of the behavioral deterioration following MTBI. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Augusta Neuropsychol Ctr, Evans, GA 30809 USA; US Penitentiary, Atlanta, GA USA	Hartlage, LC (corresponding author), Augusta Neuropsychol Ctr, 4227 Evans Locks Rd, Evans, GA 30809 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROWN GW, 1978, LANCET, V1, P378; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; CAVENESS WF, 1977, ANN NEUROL, V1, P507; CAVENESS WF, 1979, ADV NEUROL, P1; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; Cullum C M, 1997, Appl Neuropsychol, V4, P6, DOI 10.1207/s15324826an0401_2; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gouvier WD, 1998, CRIT ISS NE, P55; GOUVIER WD, 1988, ARCH CLIN NEUROPSYCH, V3, P279; GRONWALL D, 1975, LANCET, V2, P995; Hart WE, 1997, J COMPUT BIOL, V4, P1, DOI 10.1089/cmb.1997.4.1; HARTLAGE LB, 1988, ANN M NAT ACAD NEUR; HARTLAGE LC, 1990, NEUROPSYCHOLOGICAL A; HARTLAGE LC, 1988, ANN M NAT AC NEUR OR; HARTLAGE LC, 1989, BEHAV CHANGE INVENTO; HARTLAGE LC, 1984, AUTO TORTS, V7, P187; HATCHER I, 1996, MORE JUST BUMP HEAD; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hayes RL, 1989, MILD HEAD INJURY, P54; Hovda D. A., 1998, BRAIN INJURY SOURCE, V2, P22; HOVDA DA, 1998, BRAIN INJURY SOURCE, V2, P42; JOHNSON DJ, 1989, ANN M AM PSYCH SOC A; KIXMILLER JS, 1993, J CLIN PSYCHOL, V49, P233, DOI 10.1002/1097-4679(199303)49:2<233::AID-JCLP2270490217>3.0.CO;2-E; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kontos H.A., 1980, CLIN ASS T, V92, P111; KRAUS JF, 1989, MILD HEAD INJURY, P8; KURTZKE JF, 1993, CLIN NEUROLOGY, P66; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1989, MILD HEAD INJURY, P223; LEWIS P, 1986, ANN M AM PSYCH ASS W; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OMMAYA AK, 1982, NEUROLOGICAL INJURY; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER RS, 1994, ANAL UNDERSTANDING P; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Reitan R. M., 1986, TRAUMATIC BRAIN INJU, VI; Reynolds CR, 1998, CRIT ISS NE, P261; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTH JS, 1998, ANN M NAT AC NEUR WA; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SIEJO BK, 1985, CENTRAL NERVOUS SYST; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SPENCER J, 1992, ARCH CLIN NEUROPSYCH, V7, P457, DOI 10.1016/0887-6177(92)90159-K; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Varney N R, 1995, Appl Neuropsychol, V2, P47, DOI 10.1207/s15324826an0202_1; VARNEY NR, 1990, COGNITIVE REHABILITA, V8, P30; WHITLOCK FA, 1977, AUST NZ J PSYCHIAT, V11, P127, DOI 10.3109/00048677709159549; WILSON D, 1999, ANN M SE PSYCH ASS S; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; WOOD RLL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P3; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	85	47	47	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2001	16	6					561	570		10.1016/S0887-6177(00)00067-6			10	Psychology, Clinical; Psychology	Psychology	457GN	WOS:000170128900004	14590154	Bronze			2021-06-18	
J	Marwitz, JH; Cifu, DX; Englander, J; High, WM				Marwitz, JH; Cifu, DX; Englander, J; High, WM			A multi-center analysis of rehospitalizations five years after brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehospitalization; TBI Model Systems; traumatic brain injury	MULTICENTER ANALYSIS; COMMUNITY; IMPACT; REHABILITATION; LENGTH; STAY	Objective: To investigate the incidence and cause of rehospitalizations I and 5 years after traumatic brain injury. Design: Descriptive statistics were computed in a prospective study of the cause and incidence of rehospitalizations at years I and 5 after injury. Analysis of variance and chi-square tests were used to identify factors relating to rehospitalization factors included length of stay, admission and discharge functional status, payer source, medical complications, injury severity, and demographics. Setting: Seventeen medical centers in the federally sponsored Traumatic Brain Injury Model Systems. In each setting, the continuum of care includes emergency medical services, intensive and acute medical care. inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Eight hundred ninety five rehabilitation patients admitted to acute care within 24 hours of traumatic brain injury between 1989 and 1999 were examined at I-year follow-up. Main Outcome Measures: Incidence and cause of rehospitalization at I and 5 years after injury. Results: The incidence of rehospitalization ranged from 22.9% 1 year after injury to 17.0% at 5 years after injury. At 1 year after injury a third of the rehospitalizations were for elective reasons. At 5 years after injury the incidence of readmissions for seizures and psychiatric difficulties and general health maintenance increased substantially, T-tests and chi-square analyses were performed on the 5-year follow-up data to compare those rehospitalized for unplanned reasons with those not rehospitalized, Conclusions: There remains a relatively high rate of rehospitalization in the long term after traumatic brain injury, The costs of rehospitalization should be considered when evaluating the longterm consequences of injury.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Dept Rehabil, San Jose, CA 95128 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387			BURNS TJ, 1990, ARCH PHYS MED REHAB, V71, P138; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAVIDOFF G, 1990, ARCH PHYS MED REHAB, V71, P121; DINCIN J, 1993, HOSP COMMUNITY PSYCH, V44, P833; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; GRANT JP, 1986, NUTR CLIN PRACT, V1, P3; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	20	47	47	0	3	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					307	317		10.1097/00001199-200108000-00002			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000002	11461654				2021-06-18	
J	Ricker, JH; Hillary, FG; DeLuca, J				Ricker, JH; Hillary, FG; DeLuca, J			Functionally activated brain imaging (O-15 PET and fMRI) in the study of learning and memory after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						functional magnetic resonance imaging (fMRI); memory; neuroimaging; positron emission tomography (PET); traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; CROSSED CEREBELLAR DIASCHISIS; VERBAL MEMORY; HEAD-INJURY; GLUCOSE-METABOLISM; PREFRONTAL CORTEX; WORKING-MEMORY; SHORT-TERM; RETRIEVAL; DEFICITS	Advances in functional imaging technology and cognitive neuropsychology have resulted in paradigms in which participants can perform cognitive tasks during functional image acquisition. We will discuss the application of two approaches (oxygen-15 positron emission tomography and functional magnetic resonance imaging) that have recently been used to examine components of learning and memory following traumatic brain injury (TBI). Activated functional brain imaging findings that we will discuss may suggest possible functional reallocation and reorganization of brain substrates involved in verbal learning and memory following brain injury. The findings also are dearly in line with other research that indicates a prominent role for the frontal lobes in learning and memory functioning, and support the concept of distributed neural networks for memory-related functions, cognitive load, and the potential for examining brain re-organization after injury.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA	Ricker, JH (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jricker@kmrrec.org	Hillary, Frank/AAN-8622-2021	Ricker, Joseph/0000-0003-3415-991X			Alavi A, 1997, J NUCL MED, V38, P1717; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; Bach-y-Rita P, 1972, BRAIN MECH SENSORY S; BACHYRITA P, 1990, NEUROPSYCHOLOGIA, V28, P547, DOI 10.1016/0028-3932(90)90033-K; BARON JC, 1995, REV NEUROL, V151, P511; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P254, DOI 10.1162/jocn.1997.9.2.254; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHRISTODOULOU C, IN PRESS J NEUROL NE; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; Fiez JA, 1996, J NEUROSCI, V16, P808; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Herscovitch Peter, 1996, P89; Hobbs A, 1999, J HEAD TRAUMA REHAB, V14, P616, DOI 10.1097/00001199-199912000-00010; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; JOHNSON MK, 1992, J COGNITIVE NEUROSCI, V4, P268, DOI 10.1162/jocn.1992.4.3.268; KAPUR S, 1995, NEUROREPORT, V6, P1880, DOI 10.1097/00001756-199510020-00014; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LOUTFI ISSA, 1995, INVEST RADIOL, V30, P588, DOI 10.1097/00004424-199510000-00004; MATEER CA, 1999, REHABILITATION ADULT; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; METTER EJ, 1987, NEUROLOGY, V37, P1599, DOI 10.1212/WNL.37.10.1599; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Miyai I, 1999, ANN NEUROL, V46, P467; Mottaghy FM, 1999, EXP BRAIN RES, V128, P332, DOI 10.1007/s002210050853; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Nolde SF, 1998, NEUROREPORT, V9, P3509, DOI 10.1097/00001756-199810260-00032; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PANTANO P, 1986, BRAIN, V109, P677, DOI 10.1093/brain/109.4.677; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; RICKER JH, IN PRESS J CLIN EXP; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Stein DG, 1998, RESTORATIVE NEUROLOGY, P1; STEIN DG, 2000, INT HDB NEUROPSYCHOL, P9; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Umile EM, 1998, BRAIN INJURY, V12, P577; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491	54	47	50	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2001	16	2					191	205		10.1097/00001199-200104000-00007			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	422HH	WOS:000168112100006	11275578				2021-06-18	
J	Wong, CP; Forsyth, RJ; Kelly, TP; Eyre, JA				Wong, CP; Forsyth, RJ; Kelly, TP; Eyre, JA			Incidence, aetiology, and outcome of non-traumatic coma: a population based study	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article						coma; epidemiology; prognosis; epilepsy; meningitis; encephalitis	HEAD-INJURY; BRAIN INJURY; EPIDEMIOLOGY; CHILDHOOD; CHILDREN; SCALE	Aim-To determine the incidence, presentation, aetiology, and outcome of non-traumatic coma in children aged between 1 month and 16 years. Methods-In this prospective, population based, epidemiological study in the former Northern NHS region of the UK, cases were notified following any hospital admission or community death associated with non-traumatic coma. Coma was defined as a Glasgow Coma Score below 12 for more than six hours. Results-The incidence of non-traumatic coma was 30.8 per 100 000 children under 16 per year (6.0 per 100 000 general population per year). The age specific incidence was notably higher in the first year of life (160 per 100 000 children per year). CNS specific presentations became commoner with increasing age. In infants, nearly two thirds of presentations were with non-specific, systemic signs. Infection was the commonest overall aetiology. Aetiology remained unknown in 14% despite extensive investigation and/or autopsy. Mortality was highly dependent on aetiology, with aetiology specific mortality rates varying from 3% to 84%. With follow up to approximately 12 months, overall series mortality was 46%.	Newcastle Univ, Dept Child Hlth, Pediat Neurosci Grp, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Forsyth, RJ (corresponding author), Newcastle Univ, Dept Child Hlth, Pediat Neurosci Grp, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	r.j.forsyth@newcastle.ac.uk	Forsyth, Rob/H-9193-2019; Forsyth, Rob J/I-9226-2012	Forsyth, Rob/0000-0002-5657-4180; Forsyth, Rob J/0000-0002-5657-4180			BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; Beattie TF, 1997, ARCH DIS CHILD, V77, P82, DOI 10.1136/adc.77.1.82; Bharucha P E, 1973, Indian Pediatr, V10, P523; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Horowitz I, 1983, Int Rehabil Med, V5, P32; HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JAME SH, 1985, BRAIN INSULTS INFANT, P179; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MAZUREK AJ, 1994, J ACCID EMERG MED, V11, P9; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; OGUNMEKAN AO, 1983, J TROP PEDIATRICS, V29, P230, DOI 10.1093/tropej/29.4.230; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SESHIA SS, 1977, DEV MED CHILD NEUROL, V19, P614; SESHIA SS, 1983, DEV MED CHILD NEUROL, V25, P493; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sparrow S., 1984, VINELAND ADAPTIVE BE; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; Tasker RC, 1996, PEDIATR NEUROL, V3rd ed, P691; TEASDALE G, 1974, LANCET, V2, P81; Warren S, 1995, Alaska Med, V37, P11	29	47	49	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	MAR	2001	84	3					193	199		10.1136/adc.84.3.193			7	Pediatrics	Pediatrics	406JM	WOS:000167211700002	11207161	Green Published, Bronze			2021-06-18	
J	Langburt, W; Cohen, B; Akhthar, N; O'Neill, K; Lee, JC				Langburt, W; Cohen, B; Akhthar, N; O'Neill, K; Lee, JC			Incidence of concussion in high school football players of Ohio and Pennsylvania	JOURNAL OF CHILD NEUROLOGY			English	Article							MINOR HEAD-INJURY; COLLEGE FOOTBALL; SPORTS	Football injuries account for more concussions than any other sport in North America. A 1977 survey of high school football players in Minnesota found that 19% of players reported at least one concussion (characterized by loss of awareness) during a season. These results have not been confirmed in subsequent studies. This study sought to estimate the incidence of concussion among high school football players in our region, establish the frequency of the most common symptoms, and determine the duration of subsequent restriction from participation in the sport. The athletic boards of area high schools distributed a three-page survey to 450 high school football players. Of the 450 surveys distributed, 234 (52%) were returned, only I of which was excluded because of contradictory information. The incidence of concussion in football players was 47.2% (110/233, P < .001 versus a previously determined rate of 19%). Eighty-one of 233 players (34.9%) had multiple concussions. A total of 376 concussions were reported. The distribution of severity of the 376 reported concussive events was grade I, 87.8%; grade II, 9.9%; and grade III, 2.4%. Only 12 athletes were required to stop play for one or more games. The incidence of high school football players sustaining a concussion is much higher than previously established. The majority of these are mild (grade I) concussions. Further research is needed since multiple low-grade concussions may incur cumulative neuropsychologic impairments.	Cleveland Clin Fdn, Dept Pediat Neurol, Cleveland, OH 44195 USA	Langburt, W (corresponding author), 3540 S Poplar,Suite 200, Denver, CO 80237 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BIJUR PE, 1990, PEDIATRICS, V86, P337; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CLARK KS, 1982, ATHLETIC INJURY HEAD; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Greenspan A I, 1996, Curr Probl Pediatr, V26, P170, DOI 10.1016/S0045-9380(96)80004-1; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; *NAT ATHL INJ ILLN, 1976, NAIRS SPORT REL INC; 1966, CLIN NEUROSURG, V12, P386	16	47	48	0	9	B C DECKER INC	HAMILTON	20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	FEB	2001	16	2					83	85		10.1177/088307380101600203			3	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	473DT	WOS:000171025300003	11292230				2021-06-18	
J	McPherson, KM; Pentland, B; McNaughton, HK				McPherson, KM; Pentland, B; McNaughton, HK			Brain injury - the perceived health of carers	DISABILITY AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; SUBARACHNOID HEMORRHAGE; SURVEY QUESTIONNAIRE; SF-36; RELATIVES; FRAMEWORK; DEFICITS; PATIENT; INDEX	Purpose : This paper explores the perceived health and reported level of strain in the primary carers of severely brain injured individuals, 15-18 months after discharge from inpatient rehabilitation. Method: Seventy carers took part in a prospective descriptive study utilizing a semistructured interview and standardized measures including the SF36, The Carer Strain Index and the Relative Questionnaire. Functional consequences for the injured person were also assessed. Results : The SF36 demonstrated a trend towards lower perceived health for carers than that reported in the general population. Neither perceived health status nor level of strain differed significantly according to the type of injury sustained (haemorrhagic or traumatic) nor initial severity of injury. Factors that contributed to carers having worse health status included the injured person's level of disability and interpersonal factors such as the nature of the relationship, with spouses having lower perceived health status than parents. Conclusions : Irrespective of cause of injury, generalised health consequences result for the carers of those with disabling consequences of brain injury. Factors independent of the injured individual themselves (such as the nature of the relationship to the carer) need to be taken into consideration when exploring wellbeing of carers and planning services.	Wellington Sch Med, Wellington, New Zealand; Scottish Brain Injury Rehabil Serv, Edinburgh, Midlothian, Scotland	McPherson, KM (corresponding author), Wellington Sch Med, Wellington, New Zealand.		McNaughton, Harry/AAC-6556-2020	McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			AFFLECK JW, 1988, LANCET, V1, P230; Artiola i Fortuny L, 1981, J NEUROSURG, V54, P35; BECKER S, 1999, WERER THIS TOGETHER; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; *BRIT SOC REH, 1998, REH TRAUM BRAIN INJ, P1; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Deane M, 1996, BRIT J NEUROSURG, V10, P187; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; DRAKE CG, 1988, J NEUROSURG, V68, P985; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hobson JP, 1997, QUAL LIFE RES, V6, P213; HODGSON SP, 1996, CLIN REHABIL, V10, P337, DOI DOI 10.1177/026921559601000413; HUBERT J, 1995, LIFE HEAD INJURY; HUNT SM, 1993, BRIT MED J, V307, P125, DOI 10.1136/bmj.307.6896.125-b; HUTTER BO, 1993, NEUROSURGERY, V33, P999; JENKINSON C, 1995, QUAL LIFE RES, V4, P47, DOI 10.1007/BF00434383; Jones W R, 1996, Axone, V18, P9; KAUSAR R, 1996, CLIN REHABIL, V10, P159; KOSCIULEK JF, 1993, J REHABIL, V59, P40; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINDBERG M, 1996, CLIN REHABIL, V10, P69; LINDBERG M, 1996, CLIN REHABIL, V10, P63; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182; LYONS RA, 1994, J EPIDEMIOL COMMUN H, V48, P388, DOI 10.1136/jech.48.4.388; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin J, 1988, PREVALENCE DISABILIT; MATISON PG, 1992, ARCH PHYSICAL MED RE, V73, P926; McDowell I, 1996, MEASURING HLTH GUIDE; MCKENNA P, 1989, BRIT MED J, V299, P485, DOI 10.1136/bmj.299.6697.485; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCPHERSON K, 1998, THESIS U EDINBURGH; MCPHERSON KM, 1992, CLIN REHABIL, V7, P105; MCPHERSON KM, 1992, VALIDATION STUDIES E; MITCHLEY N, 1996, CLIN REHABIL, V10, P3; NOLAN KJ, 1995, J PSYCHIAT MENTAL HL, V2, P33; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; Payne S, 1999, PALLIATIVE MED, V13, P37, DOI 10.1191/026921699666872524; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; SANDER A, 1999, REHABILITATION ADULT, P199; SORYAL I, 1992, CLIN REHABIL, V6, P103; STENHOUSE LM, 1991, J NEUROL NEUROSUR PS, V54, P909, DOI 10.1136/jnnp.54.10.909; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON C, 1999, COCHRANE LIB; Wade DT, 1992, MEASUREMENT NEUROLOG; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WELLWOOD I, 1995, AGE AGEING, V24, P54, DOI 10.1093/ageing/24.1.54; WRIGHT L, 1992, HLTH LIFESTYLES OXFO; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	55	47	47	0	2	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	OCT	2000	22	15					683	689		10.1080/096382800445489			7	Rehabilitation	Rehabilitation	374DN	WOS:000165329300005	11087064				2021-06-18	
J	Mirski, MA; Denchev, DI; Schnitzer, MS; Hanley, DF				Mirski, MA; Denchev, DI; Schnitzer, MS; Hanley, DF			Comparison between hypertonic saline and mannitol in the reduction of elevated intracranial pressure in a rodent model of acute cerebral injury	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						hypertonic saline; mannitol; intracranial pressure; brain injury	7.5-PERCENT SODIUM-CHLORIDE; CRYOGENIC BRAIN INJURY; HEMORRHAGIC-SHOCK; CEREBROSPINAL-FLUID; CELL-VOLUME; HEAD TRAUMA; PLASMA OSMOLALITY; MULTICENTER TRIAL; NEUROLOGIC STATUS; COLLOID SOLUTIONS	Clinically both mannitol and hypertonic saline (HTS) have been used successfully to treat elevated intracranial pressure (ICP), although which therapy is superior is yet unclear. Most experimental data have been derived from animal models of brain injury using general anesthesia, which may not be applicable under other conditions. Our laboratory compared the efficacy of single, equi-osmolar bolus doses of HTS and mannitol in reducing elevated ICP in a lightly sedated, unrestrained rodent model of acute brain injury. Sprague-Dawley rats were mask anesthetized for craniectomy and placement of invasive monitors. Following emergence from anesthesia, continuous sedation was provided (0.25% halothane in oxygen). A focal, liquid nitrogen cold lesion was introduced to the right parietal cortex. Animals were continuously monitored and then treated with a single bolus of 0.9% saline (control group) or 11.0 mOsm/kg equivalents of either mannitol or HTS (experimental groups) at time of maximal ICP increase (60 minutes). Both mannitol and HTS reduced LCP, but HTS was more effective-53.9% reduction versus 35.0% (P < .01). The therapeutic action of HTS was also more durable, lasting up to 500 minutes whereas the mannitol treated animals were observed to return to, and overshoot the baseline elevated ICP by 10% to 25% by 120 minutes following dosing (P < .01). Despite these differences, brain water content was similar between groups. We conclude that HTS was more effective in reducing elevated ICP in this awake model of traumatic brain injury.	Johns Hopkins Med Inst, Baltimore, MD 21287 USA	Mirski, MA (corresponding author), Johns Hopkins Med Inst, 600 N Wolfe St,Meyer 8-134, Baltimore, MD 21287 USA.						BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BRUSSEL T, 1991, ANESTH ANALG, V73, P758; Bullock R, 1995, New Horiz, V3, P448; CANTORE C, 1964, J NEUROSURG, V21, P278; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; DIMATTIO J, 1975, PFLUG ARCH EUR J PHY, V359, P253, DOI 10.1007/BF00587383; DONATO T, 1994, ANESTH ANALG, V78, P58; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; FOXWORTHY JC, 1990, J NEUROSURG ANESTH, V2, P266; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KOFKE WA, 1993, J NEUROSURG ANESTH, V5, P1; MANINGAS PA, 1989, AM J SURG, V157, P528, DOI 10.1016/0002-9610(89)90654-5; MANNINEN PH, 1987, CAN J ANAESTH, V34, P442, DOI 10.1007/BF03014345; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MCGILLICUDDY JE, 1985, CHEST, V87, P85, DOI 10.1378/chest.87.1.85; MCMANUS ML, 1993, ANESTHESIOLOGY, V78, P1132, DOI 10.1097/00000542-199306000-00017; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MORENO M, 1969, J LAB CLIN MED, V73, P291; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; PROUGH D S, 1991, Anesthesia and Analgesia, V73, P738; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; Prough DS, 1999, J NEUROSURG ANESTH, V11, P102, DOI 10.1097/00008506-199904000-00006; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; RUDEHILL A, 1993, J NEUROSURG ANESTH, V5, P4; SAHAR A, 1978, EXP NEUROL, V60, P584, DOI 10.1016/0014-4886(78)90012-2; SCHELLER MS, 1991, J NEUROSURG ANESTH, V3, P291, DOI 10.1097/00008506-199112000-00009; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; TODD MM, 1987, ANESTHESIOLOGY, V60, P1090; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Weed LH, 1919, AM J PHYSIOL, V48, P512; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YOUNES RN, 1994, SHOCK S, V1, P2; YOUNES RN, 1992, SURGERY, V111, P70; ZORNOW MH, 1990, ACT NEUR S, V51, P324; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	59	47	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2000	12	4					334	344		10.1097/00008506-200010000-00006			11	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	360PL	WOS:000089676400006	11147382				2021-06-18	
J	Jones, DK; Dardis, R; Ervine, M; Horsfield, MA; Jeffree, M; Simmons, A; Jarosz, J; Strong, AJ				Jones, DK; Dardis, R; Ervine, M; Horsfield, MA; Jeffree, M; Simmons, A; Jarosz, J; Strong, AJ			Cluster analysis of diffusion tensor magnetic resonance images in human head injury	NEUROSURGERY			English	Article						cluster analysis; diffusion tensor; edema; magnetic resonance imaging; MRI; traumatic brain injury	TRAUMATIC BRAIN INJURY; ISCHEMIC RAT-BRAIN; ECHO-PLANAR IMAGES; APPARENT DIFFUSION; CEREBRAL-ISCHEMIA; WATER DIFFUSION; HUMAN STROKE; MRI; NMR; MODEL	OBJECTIVE: issues surrounding the nature of the edema associated with traumatic brain injury in humans, and its evolution in the acute phase, remain unresolved. This study aimed to characterize the topographical nature of the pathophysiological changes in human traumatic brain injury with diffusion tensor magnetic resonance imaging. METHODS: Multislice diffusion-weighted magnetic resonance imaging data were acquired from five patients undergoing elective ventilation for management of traumatic focal contusion or hematomas. The diffusion tensor and the Ta-weighted intensity were then computed for every voxel in the image data set for each patient The topographical distribution of abnormalities in the trace of the diffusion tensor and T2-weighted images were characterized by cluster analysis. RESULTS: In four patients with technically satisfactory data, a narrow band of tissue was observed in the periphery of focal lesions, which was characterized by selective reduction in the trace of the diffusion tensor, without any associated increase in the T2-weighted signal intensity. CONCLUSION: This change is interpreted as indicating either a partial redistribution of water from the extra- to intracellular compartment, or a reduction in the diffusivity of water in the intracellular or cytosolic environment. These diffusion and T2-weighted characteristics are also found in early ischemic change, hence, such regions may represent potentially salvageable tissue at risk of permanent damage. The study illustrates the advantage of using information contained within the diffusion tensor in addition to more conventional imaging sequences.	Kings Coll Hosp London, Sch Med, London SE5 9RS, England; St Thomas Hosp, Sch Med, Kings Coll, London SE5 9RS, England; Guys Hosp, Sch Med, Kings Coll, London SE5 9RS, England; Kings Coll London, Inst Psychiat, Old Age Psychiat Sect, London WC2R 2LS, England; Inst Psychiat, Dept Clin Neurosci, London, England; Kings Coll Hosp London, Dept Anaesthesia, London, England; Univ Leicester, Leicester Royal Infirm, Div Med Phys, Leicester LE1 7RH, Leics, England	Strong, AJ (corresponding author), Kings Coll Hosp London, Sch Med, London SE5 9RS, England.	dkj2@le.ac.uk	Simmons, Andrew/B-8848-2008; Jones, Derek K/D-1460-2009; Horsfield, Mark A/C-6569-2013	Simmons, Andrew/0000-0003-2306-5811; Horsfield, Mark A/0000-0002-0815-6697; Jones, Derek K/0000-0003-4409-8049; Strong, Anthony/0000-0003-2432-5945			Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CADOUXHUDSON TAD, 1998, 6 ANN SCI M INT SOC; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; DORAN M, 1990, J COMPUT ASSIST TOMO, V14, P856; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HASEGAWA Y, 1995, J CEREB BLOOD FLOW M, V15, P176; Haselgrove JC, 1996, MAGNET RESON MED, V36, P960, DOI 10.1002/mrm.1910360620; HELPERN JA, 1992, 11 ANN M SOC MAGN RE; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; KATAYAMA Y, IN PRESS ACTA NEUR S; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1985, CR ACAD SCI II, V301, P1109; LIU AY, 1998, 6 ANN SCI M INT SOC; MARMAROU A, IN PRESS ACTA NEUR S; MERBOLDT KD, 1985, J MAGN RESON, V64, P479, DOI 10.1016/0022-2364(85)90111-8; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Neil JJ, 1996, MAGNET RESON MED, V35, P329, DOI 10.1002/mrm.1910350310; NORRIS DG, 1994, NMR BIOMED, V7, P304, DOI 10.1002/nbm.1940070703; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Rordorf G, 1998, STROKE, V29, P939, DOI 10.1161/01.STR.29.5.939; Simmons A, 1999, INT J IMAG SYST TECH, V10, P273, DOI 10.1002/(SICI)1098-1098(1999)10:3<273::AID-IMA8>3.0.CO;2-E; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TAYLOR DG, 1985, PHYS MED BIOL, V30, P345, DOI 10.1088/0031-9155/30/4/009; TURNER R, 1990, RADIOLOGY, V177, P407, DOI 10.1148/radiology.177.2.2217777; Ulug AM, 1997, STROKE, V28, P483, DOI 10.1161/01.STR.28.3.483; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983; WICK M, 1995, STROKE, V26, P1930, DOI 10.1161/01.STR.26.10.1930; ZACHAROPOULOS N, 1998, 6 ANN SCI M INT SOC; ZHONG J, 1993, MAGN RESON MED, V30, P241, DOI 10.1002/mrm.1910300214	42	47	49	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2000	47	2					306	313		10.1097/00006123-200008000-00008			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	339WZ	WOS:000088502000017	10942003				2021-06-18	
J	Bhardwaj, A; Harukuni, I; Murphy, SJ; Alkayed, NJ; Crain, BJ; Koehler, RC; Hurn, PD; Traystman, RJ				Bhardwaj, A; Harukuni, I; Murphy, SJ; Alkayed, NJ; Crain, BJ; Koehler, RC; Hurn, PD; Traystman, RJ			Hypertonic saline worsens infarct volume after transient focal ischemia in rats	STROKE			English	Article						infarction; ischemia, focal; mannitol; osmolar concentration; reperfusion; saline solution, hypertonic	MULTIPLE-DOSE MANNITOL; INTRACRANIAL-PRESSURE; CEREBRAL-ISCHEMIA; BLOOD-FLOW; HEMORRHAGIC-SHOCK; BRAIN INJURY; HEAD-INJURY; EDEMA; RESUSCITATION; WATER	Background and Purpose-Hypertonic saline (HS) has been advocated as a hyperosmolar agent for the treatment of cerebral edema, especially after traumatic brain injury. We tested the hypothesis that continuous intravenous HS administered during reperfusion from transient focal cerebral ischemia attenuates infarct volume. Methods-Halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO) by the intraluminal occlusion technique. At the onset of reperfusion, rats received a 10-mL/kg intravenous bolus of 0.9% saline (SAL, n = 8) or 7.5% SAL (chloride acetate 50:50, n = 8) followed by a continuous infusion for 22 hours. In a second series of experiments, ischemic damage was determined in cohorts treated with equivolumetric 3% saline (n = 8) or 20% mannitol (n = 8). In a third series, regional cerebral blood now was measured ([C-14]iodoantipyrine autoradiography) at 6 hours of reperfusion in 7.5%-SAL-treated (n = 5) or SAL-treated (n = 5) animals. Results-In SAL rats, serum Na+ was 137+/-3 and 138+/-2 mEq/L (mean+/-SEM) at baseline and 22 hours of reperfusion, respectively. In 7.5% SAL, serum Naf was 136+/-2 and 154+/-2 mEq/L at baseline and reperfusion, respectively. Physiological variables and reduction in laser-Doppler signal during MCAO and early reperfusion were not different between the 2 treatment groups. Cortical infarct volume was larger in 7.5%-SAL-treated rats (121+/-14 mm(3) 30+/-3% of contralateral cortex; P<0.05) than in SAL (64+/-15 mm(3); 16+/-4% of contralateral cortex). Striatal infarct volume was unchanged by HS therapy. Ipsilateral cortical tissue volume was increased relative to the contralateral aide (by 26+/-5% with SAL; by 41+/-5% with 7.5% SAL). In contrast, ischemic damage was unaffected by 3%-SAL or 20%-mannitol treatment compared with SAL. Regional cerebral blood flow during reperfusion was heterogeneous in all animals, but there was no evidence of postischemic hypoperfusion or blood flow maldistribution in 7.5%-SAL-treated animals. Conclusions-These data demonstrate that hypernatremia resulting from postischemic HS infusion worsens cortical infarct volume in transient focal cerebral ischemia. The deleterious effect is not linked to exacerbation of delayed hypoperfusion during early reperfusion (6 hours); however, blood flow defects at later recovery time points remain to be excluded. These results may have implications for HS therapy in clinical ischemic stroke.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA	Bhardwaj, A (corresponding author), Johns Hopkins Hosp, Neurol Crit Care Div, Meyer 8-140,600 N Wolfe St, Baltimore, MD 21287 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33668, NS20020] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033668, P01NS020020] Funding Source: NIH RePORTER		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; BELL BA, 1987, LANCET, V1, P66; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GINSBERG MD, 1978, ANN NEUROL, V3, P482, DOI 10.1002/ana.410030605; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; JAFFAR JJ, 1986, J NEUROSURG, V64, P754; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P183, DOI 10.1038/jcbfm.1983.25; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KIRPATRICK PJ, 1996, NEUROSURGERY, V39, P714; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; Onar M, 1997, Electromyogr Clin Neurophysiol, V37, P213; Paczynski RP, 1997, STROKE, V28, P1437, DOI 10.1161/01.STR.28.7.1437; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; PETITO CK, 1982, J NEUROPATH EXP NEUR, V41, P423, DOI 10.1097/00005072-198207000-00005; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; ROPPER A, 1993, NEUROLOGICAL NEUROSU; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P594, DOI 10.1097/00005072-199605000-00011; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; Takahashi H, 1996, STROKE, V27, P2120, DOI 10.1161/01.STR.27.11.2120; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TOMITA M, 1981, J CEREBR BLOOD F MET, V1, P403, DOI 10.1038/jcbfm.1981.44; Treib J, 1998, EUR NEUROL, V40, P212, DOI 10.1159/000007982; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	36	47	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JUL	2000	31	7					1694	1701		10.1161/01.STR.31.7.1694			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	331LC	WOS:000088019700038	10884475	Green Published, Bronze			2021-06-18	
J	Chan, RCK				Chan, RCK			Attentional deficits in patients with closed head injury: a further study to the discriminative validity of the test of everyday attention	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; SUBJECTIVE COMPLAINTS; RECOVERY; QUESTIONNAIRE; SYMPTOMS; AROUSAL	This study aimed to explore the attentional performance of patients with dosed head injury (CHI) and to examine the discriminative validity of the Test of Everyday Attention (TEA) in this clinical population. A sample of 21 patients with CHI was recruited for this study. Another sample of matched controls was also recruited for comparison. In addition, other clinical tests of attention and questionnaires on everyday life cognitive failures were also given to the participants during the assessment session. The results showed that patients with CHI exhibited significant differences in most of the TEA subtests, as well as clinical tests of attention, as compared with the matched controls. These findings suggest that the majority of the TEA subtests are able to discriminate out those patients with attentional deficits from the normal population in terms of sustained attention, selective attention, divided attention, and attentional switching.	Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Univ Hong Kong, Dept Psychol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	ckrchan@hkusua.hku.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V19, P529; BLANCGARIN J, 1994, NEUROPSYCHOL REHABIL, V4, P359, DOI 10.1080/09602019408401606; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; CHAN RC, UNPUB VALIDATION CAN; CHAN RCK, 1999, 19 ANN C NAT AC NEUR; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Crawford JR, 1997, BRIT J CLIN PSYCHOL, V36, P609, DOI 10.1111/j.2044-8260.1997.tb01265.x; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstein G, 1996, ECOLOGICAL VALIDITY, P75; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; KERNS KA, 1996, ECOLOGICAL VALIDITY, P147; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 1989, MILD HEAD INJURY; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; PARASURAMAN R, 1984, VARIEITES ATTENTION; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBERTS A, 1990, EUR J NEUROSCI, V2, P11, DOI 10.1111/j.1460-9568.1990.tb00377.x; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; *U VICT NEUR LAB, STROOP TEST VICT VER; van Zomeren AH, 1994, CLIN NEUROPSYCHOL AT, P250; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	39	47	51	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2000	14	3					227	236		10.1080/026990500120709			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	294EE	WOS:000085897700003	10759040				2021-06-18	
J	Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Marion, DW; Ho, C				Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Marion, DW; Ho, C			Early perfusion after controlled cortical impact in rats: Quantification by arterial spin-labeled MRI and the influence of spin-lattice relaxation time heterogeneity	MAGNETIC RESONANCE IN MEDICINE			English	Article; Proceedings Paper	5th Scientific Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine	APR 12-18, 1997	VANCOUVER, CANADA	Int Soc Magnet Resonance Med		cerebral blood flow; spin-lattice relaxation time; magnetic resonance imaging (MRI); traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; PARTITION-COEFFICIENT; WATER-CONTENT; TRANSIT-TIME; INVERSION; IODOANTIPYRINE; HYPOTHERMIA; ISOFLURANE; ISCHEMIA	Early posttraumatic cerebral hypoperfusion is implicated in the evolution of secondary damage after experimental and clinical traumatic brain injury (TBI). This is the first report of cerebral blood flow (CBF) measurement by continuous arterial spin-labeled magnetic resonance imaging (MRI) early after TBI in rats using the controlled cortical impact (CCI) model. CGI reduced CBF globally at similar to 3 hr (versus normal), with 85% and 49% reductions in a contused cortical region and contralateral cortex, respectively. In contrast, a prior MRI study from this laboratory showed at 24 hr post trauma a focal CBF reduction restricted to the injury site. In vivo spin-lattice relaxation time (T-1obs), which is used in CBF quantification, was spatially heterogeneous early after CCI, a time when edema is developing in injured brain tissue. At 4.7 T, T-1obs values are increased 29% in the contusion (versus normal), consequently reducing CBF quantification to a similar degree. MRI should facilitate coupling posttraumatic CBF with long-term functional outcome. Magn Reson Med 42:673-681, 1999. (C) 1999 Wiley-Liss, Inc.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR10962, RR03631] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS30318] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [R01RR010962, P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsop DC, 1996, J CEREBR BLOOD F MET, V16, P1236, DOI 10.1097/00004647-199611000-00019; BESSON JAO, 1989, MAGN RESON IMAGING, V7, P141, DOI 10.1016/0730-725X(89)90696-6; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHI OZ, 1993, ANESTHESIOLOGY, V79, P299, DOI 10.1097/00000542-199308000-00015; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; DETRE JA, 1994, NMR BIOMED, V7, P75, DOI 10.1002/nbm.1940070112; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; HANSEN TD, 1988, ANESTHESIOLOGY, V69, P332, DOI 10.1097/00000542-198809000-00008; HENDRICH K, 1997, P ISMRM 5 ANN M VANC, P260; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JIANG Q, 1994, J CEREBR BLOOD F MET, V14, P732, DOI 10.1038/jcbfm.1994.94; KATAYAMA Y, 1997, P INTR PRESS NEUR BR, P6; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Pekar J, 1996, MAGNET RESON MED, V35, P70, DOI 10.1002/mrm.1910350110; Roberts DA, 1996, JMRI-J MAGN RESON IM, V6, P363, DOI 10.1002/jmri.1880060217; ROBERTS DA, 1994, P NATL ACAD SCI USA, V91, P33, DOI 10.1073/pnas.91.1.33; Schwab M, 1997, BRAIN RES, V749, P82, DOI 10.1016/S0006-8993(96)01165-1; Silva AC, 1997, MAGNET RESON MED, V38, P232, DOI 10.1002/mrm.1910380211; Strupp JP., 1996, NEUROIMAGE, V3, pS607, DOI DOI 10.1016/S1053-8119(96)80609-4; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Unterberg AW, 1997, ACT NEUR S, V70, P106; VANUITERT RL, 1981, BRAIN RES, V222, P365, DOI 10.1016/0006-8993(81)91039-8; WARNER DS, 1991, J CEREBR BLOOD F MET, V11, P794, DOI 10.1038/jcbfm.1991.137; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; WILLIAMS JL, 1991, AM J PHYSIOL, V261, pH252; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Ye FQ, 1996, MAGNET RESON MED, V36, P219, DOI 10.1002/mrm.1910360208; Ye FQ, 1997, MAGN RESON MED, V37, P226, DOI 10.1002/mrm.1910370215; ZHANG WG, 1992, MAGNET RESON MED, V25, P362, DOI 10.1002/mrm.1910250216; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	40	47	48	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	OCT	1999	42	4					673	681		10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	242MG	WOS:000082944400008	10502755	Bronze			2021-06-18	
J	Daniel, JC; Olesniewicz, MH; Reeves, DL; Tam, D; Bleiberg, J; Thatcher, R; Salazar, A				Daniel, JC; Olesniewicz, MH; Reeves, DL; Tam, D; Bleiberg, J; Thatcher, R; Salazar, A			Repeated measures of cognitive processing efficiency in adolescent athletes: Implications for monitoring recovery from concussion	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT	Objective: The objective of this study was to determine whether an adolescent athlete, in the absence of concussion, would be expected to show an improvement in cognitive function during the course of a high school football season. Background: At least 60,000 American high school football players suffer cerebral concussion every year, and symptoms may persist for 4 or more years in as many as 24%. Method: 34 members of a cohort of healthy athletes, aged 13-18, were administered a computerized neuropsychologic test battery from the Automated Neuropsychological Assessment Metrics (ANAM) before and after the 1997 high school football season, with a mean interval of 16.1 (range 12.3-20.4) weeks between tests. Preseason and postseason scores on eight tests were compared, with significance determined by paired t-test. For those tests in which an improvement was noted, one-way analysis of variance and Wilcoxon tests were used with both preseason and postseason data to determine if there was a measurable difference in cognitive processing efficiency between older and younger subjects. Results: Improvements in processing efficiency (p < 0.001) were noted on tests designed to measure visual scanning and sustained attention (CDS), immediate recall (CDI), and short-term memory (CDD). Older subjects generally performed better on each of these tests, though the difference was significant in only one case (postseason CDI, 17-18 year olds vs. 13-14 year olds, Wilcoxon, p = 0.043). Conclusions: Our findings suggest that ANAM is sensitive to differences and improvements in cognitive function during a 4 month interval in adolescence. They also suggest that using "return to baseline" cognitive function as the criterion for evidence of recovery from concussion may be insufficient, especially when the baseline measurement was obtained 4 or more months prior to the date of "full recovery."	USN, Med Ctr, Med Editing Div, Dept Clin Res, San Diego, CA 92134 USA; USN, Med Ctr, Dept Pediat, Adolescent Med Div, San Diego, CA 92134 USA; Uniformed Serv Univ Hlth Sci, Dept Family Med, Bethesda, MD 20814 USA; Univ Calif San Diego, Dept Family & Prevent Med, Sch Med, San Diego, CA 92103 USA; Henry M Jackson Fdn, Rockville, MD USA; USN, Med Ctr, Dept Pediat, Child Neurol Div, San Diego, CA 92152 USA; Natl Rehabil Hosp, Psychol Serv, Washington, DC USA; Vet Affairs Med Ctr, Med Res & Dev Serv, Bay Pines, FL USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA	Daniel, JC (corresponding author), USN, Med Ctr, Med Editing Div, Dept Clin Res, Code AVA,34800 Bob Wilson Dr, San Diego, CA 92134 USA.						Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fischer K. W., 1996, DEV NEUROIMAGING MAP, P263; GASTALDO E, 1997, ANAM NORMATIVE DATA; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kane R. L., 1997, NEUROPSYCHOLOGY HDB, V1, P423; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; POWELL JW, 1997, SPORTS REL CONC NERV; THATCHER RW, 1998, CORRELATIONS EEG MRI; YACOVLEV PI, 1967, REGIONAL DEV BRAIN E, P3	16	47	49	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JUL	1999	12	3					167	169					3	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	224LF	WOS:000081900000005	10456800				2021-06-18	
J	Royo, NC; Wahl, F; Stutzmann, JM				Royo, NC; Wahl, F; Stutzmann, JM			Kinetics of polymorphonuclear neutrophil infiltration after a traumatic brain injury in rat	NEUROREPORT			English	Article						inflammation; leukocytes; myeloperoxydase; polymorphonuclear; traumatic brain injury	ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; CEREBRAL-ISCHEMIA; INFLAMMATION; ACCUMULATION; RECRUITMENT; LEUKOCYTES; RILUZOLE; TISSUE; EDEMA	THE aim of our study was to assess polymorphonuclear neutrophil infiltration into the injured parenchyma after a traumatic brain injury (TBI). Myeloperoxidase (MPO) activity was assayed on the hippocampus, temporal and parietal cortex 6, 24, 48, 72, and 120 h post-trauma. MPO activity occurred in these structures from 6 h post-trauma and was maximum at 24-48 h. It was resolved by 72 h in the hippocampus and the parietal cortex, but persisted in the temporal cortex until 120 h after trauma. This suggests that neutrophil infiltration is a delayed phenomenon in the physiopathology of TBI. Considering that a large therapeutic window may be crucial in the management of TBI, inhibition of neutrophil infiltration needs to be further investigated following cerebral trauma. (C) 1999 Lippincott Williams & Wilkins.	Rhone Poulenc Rorer SA, Pharmaceut Discovery, Ischemia Trauma Dept, Vitry Sur Seine, France	Wahl, F (corresponding author), Rhone Poulenc Rorer SA, Pharmaceut Discovery, Ischemia Trauma Dept, 13 Quai Jules Guesde, Vitry Sur Seine, France.						Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YUI Y, 1991, J BIOL CHEM, V266, P3369	24	47	49	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	APR 26	1999	10	6					1363	1367		10.1097/00001756-199904260-00038			5	Neurosciences	Neurosciences & Neurology	199NH	WOS:000080488200039	10363954				2021-06-18	
J	Geurts, ACH; Knoop, JA; van Limbeek, J				Geurts, ACH; Knoop, JA; van Limbeek, J			Is postural control associated with mental functioning in the persistent postconcussion syndrome?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; MILD HEAD; SWAY; BALANCE; STABILITY; RECOVERY	Objective: To investigate whether balance is associated with mental functioning after mild traumatic brain injury (MTBI). Design: Experimental two-group design. Setting: Outpatient rehabilitation department. Patients and Other Participants: From a consecutive sample of referred MTBI patients, 15 subjects who complained of imbalance were included (8 men and 7 women, age 35.9 +/- 8.6yrs), Subjects with detectable neurologic impairments were excluded. Twenty healthy control subjects of the same age group also were tested. Main Outcome Measures: In both groups, a force platform recorded center-of-pressure (CP) fluctuations during standing and weight shifting in different conditions. For the patients, attention and mental speed were assessed with the Symbol-Digit Substitution Test of the Wechsler Adult Intelligence Scale (Dutch version), verbal learning and memory were assessed with the 15-Words Test, and emotional distress was assessed with the Symptom Checklist-90. Results: Compared with controls, patients showed an overall increase of 60% in CP velocity and an overall weight-shifting speed 25% slower (p <.005), indicating static and dynamic postural instability. Only performance on the Symbol-Digit Substitution Test was associated with both static and dynamic balance (p <.02), giving an explained variance of over 40%. Conclusion: The results indicate a possible association of balance with cognitive performance but not with emotional well-being after MTBI, suggesting an organic rather than a functional cause of postural instability. Further research is needed to assess the possible clinical implications. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Sint Maartensklin, Dept Rehabil Med, NL-6500 GM Nijmegen, Netherlands; Sint Maartensklin, Dept Res & Dev, NL-6500 GM Nijmegen, Netherlands; Sint Maartensklin, Dept Clin Neuropsychol, NL-6500 GM Nijmegen, Netherlands	Geurts, ACH (corresponding author), Sint Maartensklin, Dept Rehabil Med, POB 9011, NL-6500 GM Nijmegen, Netherlands.		Knoop, Hans/D-3264-2009; Geurts, Alexander/H-8032-2014	Knoop, Hans/0000-0001-7763-3517; Geurts, Alexander/0000-0001-7478-1119			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Arrindell WA, 1986, SCL 90 MANUAL MULTID; BERG IJ, 1993, THESIS U GRONINGEN N; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bickerstaff ER, 1989, NEUROLOGICAL EXAMINA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; *DEP NEUR U HOSP G, 1986, 15 WORDS TESTS A B D; GEURTS ACH, 1993, ARCH PHYS MED REHAB, V74, P1144; GEURTS ACH, 1994, J MOTOR BEHAV, V26, P162, DOI 10.1080/00222895.1994.9941670; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; INGERSOLL CD, 1993, SPORTS MED, V16, P342, DOI 10.2165/00007256-199316050-00005; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kleinbaum D, 1988, APPL REGRESSION ANAL; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M.D., 1987, NEUROPSYCHOL REHABIL, P41; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MAYO NE, 1991, AM J PHYS MED REHAB, V70, P118, DOI 10.1097/00002060-199106000-00002; Newton R, 1989, Brain Inj, V3, P335, DOI 10.3109/02699058909004558; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUBIN AM, 1995, AM J OTOL, V16, P216; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; STINISSEN W, 1970, MANUAL DUTCH VERSION; Swaine BR, 1996, BRAIN INJURY, V10, P263, DOI 10.1080/026990596124449; TEASDALE G, 1974, LANCET, V2, P81; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	38	47	47	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1999	80	2					144	149		10.1016/S0003-9993(99)90111-9			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	165YG	WOS:000078549000004	10025487				2021-06-18	
J	Shreiber, DI; Bain, AC; Ross, DT; Smith, DH; Gennarelli, TA; McIntosh, TK; Meaney, DF				Shreiber, DI; Bain, AC; Ross, DT; Smith, DH; Gennarelli, TA; McIntosh, TK; Meaney, DF			Experimental investigation of cerebral contusion: Histopathological and immunohistochemical evaluation of dynamic cortical deformation	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						biomechanics; brain injury; cerebral contusion	TRAUMATIC BRAIN INJURY; ACUTE SUBDURAL-HEMATOMA; EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; MISSILE HEAD-INJURY; RAT; MECHANISMS; INDEX	We used a new approach, termed dynamic cortical deformation (DCD), to study the neuronal, vascular, and glial responses that occur in focal cerebral contusions. DCD produces experimental contusion by rapidly deforming the cerebral cortex with a transient, nonablative vacuum pulse of short duration (25 milliseconds) to mimic the circumstances of traumatic injury. A neuropathological evaluation was performed on brain tissue from adult rats sacrificed 3 days following induction of either moderate (4 psi, n = 6) or high (8 psi, n = 6) severity DCD. In all animals, DCD produced focal hemorrhagic lesions at the vacuum site without overt damage to other regions. Examination of histological sections showed localized gross tissue and neuronal loss in the cortex at the injury site, with the volume of cell loss dependent upon the mechanical loading (p < 0.001). Axonal pathology shown with neurofilament immunostaining (SMI-31 and SMI-32) was observed in the subcortical white matter inferior to the injury site and in the ipsilateral internal capsule. No axonal injury was observed in the contralateral hemisphere or in any remote regions. Glial fibrillary acidic protein (GFAP) immunostaining revealed widespread reactive astrocytosis surrounding the necrotic region in the ipsilateral cortex. This analysis confirms that rapid mechanical deformation of the cortex induces focal contusions in the absence of primary damage to remote areas 3 days following injury. Although it is suggested that massive release of neurotoxic substances from a contusion may cause damage throughout the brain, these data emphasize the importance of combined injury mechanisms, e.g. mechanical distortion and excitatory amino acid mediated damage, that underlie the complex pathology patterns observed in traumatic brain injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007	Shreiber, David/0000-0001-8248-419X; Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS035712] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG122527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS-08803, R01 NS35712] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ADAMS JH, 1985, SCI FDN NEUROLOGY; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CERVOSNAVARRO J, 1991, J NEUROL SCI, V102, pS3; CHOI DW, 1987, J NEUROSCI, V7, P357; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; Eacott MJ, 1995, CRIT REV NEUROBIOL, V9, P311; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1985, NEUROSURGERY, P1531; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; MATHEW P, 1994, ACTA NEUROCHIR, P428; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; ROSS DT, 1992, SOC NEUR ABSTR, P1088; SHREIBER DI, 1996, J NEUROTRAUM, V13, P595; Smith D H, 1995, New Horiz, V3, P562; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	33	47	47	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	1999	58	2					153	164		10.1097/00005072-199902000-00005			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	172BW	WOS:000078903300005	10029098	Bronze			2021-06-18	
J	Waisman, D; Shupak, A; Weisz, G; Melamed, Y				Waisman, D; Shupak, A; Weisz, G; Melamed, Y			Hyperbaric oxygen therapy in the pediatric patient: The experience of the Israel Naval Medical Institute	PEDIATRICS			English	Article						hyperbaric oxygenation; pediatrics; carbon monoxide poisoning; crush injury; gas gangrene; necrotizing fasciitis; refractory osteomyelitis; purpura fulminans; decompression sickness; arterial gas embolism	CARBON-MONOXIDE INTOXICATION; CEREBRAL AIR-EMBOLISM; GAS-GANGRENE; NECROTIZING FASCIITIS; MECHANICAL VENTILATION; PURPURA FULMINANS; BRAIN INJURY; LEUKOCYTES; COMPLICATION; WOUNDS	The pediatric patient is to be found in hyperbaric facilities throughout the world, receiving hyperbaric oxygen (HBO) therapy for both life-threatening and chronic diseases. Objective. To review the experience accumulated at the Israel Naval Medical Institute in the treatment of pediatric patients. Design. A retrospective analysis and review of all records of patients younger than age 18 years. Results. Between 1980 and 1997, 139 pediatric patients age 2 months to 18 years (mean, 7.7 years) received HBO treatment at the Israel Naval Medical Institute. Of the children, 111 (79%) suffered from acute carbon monoxide (CO) poisoning 13 (9.2%) were treated after crush injury, traumatic ischemia, or compartment syndrome; 4 (2.8%) had clostridial myonecrosis; 1 (0.7%) had necrotizing fasciitis; 5 (3.6%) had refractory osteomyelitis; 2 (1.4%) had suffered massive air embolism; 2 (1.4%) had purpura fulminans; and 1 (0.7%) suffered from decompression sickness. Outcome, judged by neurologic sequelae, mortality, and extent of soft tissue loss and limb amputation, was favorable in 129 patients (93%). Two patients (1.4%) died, 1 as a result of CO poisoning and the other, gas gangrene; 2 of the patients in the CO group (1.4%) remained with neurologic sequelae, and 6 patients in the acute traumatic ischemia group (4.3%) underwent limb amputation. Conclusions. We had a favorable experience with 129 of a total 139 pediatric patients treated at our facility for the indications listed. A basic knowledge of HBO therapy is needed to refer the pediatric patient for treatment when indicated. The needs of the pediatric patient, especially the critically ill, require specific skills and equipment inside the hyperbaric chamber. Close collaboration between the pediatrician and the hyperbaric medicine physician is essential to ensure adequate care for infants and children.	Carmel Hosp, Dept Neonatol, IL-34362 Haifa, Israel; Carmel Hosp, Dept Otolaryngol, IL-34362 Haifa, Israel; Carmel Hosp, Dept Cardiol, IL-34362 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Haifa, Israel; Israel Naval Med Inst, Haifa, Israel; Elisha Rambam Hosp, Hyperbar Med Ctr, Haifa, Israel	Waisman, D (corresponding author), Carmel Hosp, Dept Neonatol, 7 Michal St, IL-34362 Haifa, Israel.			Waisman, Dan/0000-0002-6768-0042			BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BANAGALE RC, 1980, AM J DIS CHILD, V134, P799, DOI 10.1001/archpedi.1980.02130200067023; BarJoseph G, 1997, J PEDIATR-US, V131, P317, DOI 10.1016/S0022-3476(97)70175-6; BENESCH RE, 1972, BIOCHIM BIOPHYS ACTA, V257, P178, DOI 10.1016/0005-2795(72)90268-1; BINDER JW, 1980, CLIN TOXICOL, V16, P287, DOI 10.3109/15563658008989951; BITTERMAN H, 1993, ISRAEL J MED SCI, V29, P22; BROOK I, 1990, PEDIATR INFECT DIS J, V9, P222, DOI 10.1097/00006454-199003000-00019; BUTLER FK, 1995, SURV OPHTHALMOL, V39, P347, DOI 10.1016/S0039-6257(05)80091-8; CAMPORESI EM, 1996, HYBERBARIC OXYGEN TH; CANALE ST, 1984, J BONE JOINT SURG AM, V66A, P764, DOI 10.2106/00004623-198466050-00017; CLARK JM, 1993, PHYSL MED DIVING, P121; Dexter F, 1997, ANESTH ANALG, V84, P1203, DOI 10.1097/00000539-199706000-00006; DOLLBERG S, 1992, J INFECTION, V25, P197, DOI 10.1016/0163-4453(92)94081-8; Douglas CG, 1912, J PHYSIOL-LONDON, V44, P275; DUDGEON DL, 1971, ARCH SURG-CHICAGO, V103, P351; DUNBAR EM, 1990, POSTGRAD MED J, V66, P469, DOI 10.1136/pgmj.66.776.469; ELKHARRAT D, 1991, INTENS CARE MED, V17, P289, DOI 10.1007/BF01713940; ELLIOTT DH, 1993, PHYSL MED DIVING, P481; FEIGIN RD, 1987, NELSON TXB PEDIAT, P620; FOK TF, 1990, ACTA PAEDIATR SCAND, V79, P856, DOI 10.1111/j.1651-2227.1990.tb11566.x; FORMAN HJ, 1986, ANNU REV PHYSIOL, V48, P669; GEMELLI F, 1985, BRIT MED J, V291, P1197, DOI 10.1136/bmj.291.6503.1197; GINSBERG MD, 1976, NEUROLOGY, V26, P15, DOI 10.1212/WNL.26.1.15; GOLDBAUM L R, 1976, Annals of Clinical and Laboratory Science, V6, P372; GOZAL D, 1985, CLIN PEDIATR, V24, P132, DOI 10.1177/000992288502400302; Hampson NB, 1996, UNDERSEA HYPERBAR M, V23, P215; HART GB, 1983, J TRAUMA, V23, P991, DOI 10.1097/00005373-198311000-00006; HJORT PETER F., 1964, SCAND J HAEMATOL, V1, P169; HOHN DC, 1976, SURG FORUM, V27, P18; JAIN KK, 1990, TXB HYPERBARIC MED, P389; KOL S, 1993, ANN THORAC SURG, V55, P401, DOI 10.1016/0003-4975(93)91010-K; KUZEMKO JA, 1970, BRIT MED J, V4, P157, DOI 10.1136/bmj.4.5728.157; LACEY DJ, 1981, AM J DIS CHILD, V135, P145, DOI 10.1001/archpedi.1981.02130260037011; LAU KY, 1991, CLIN RADIOL, V43, P16, DOI 10.1016/S0009-9260(05)80347-2; Mader J T, 1990, Infect Dis Clin North Am, V4, P433; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MARINI JJ, 1989, ANN INTERN MED, V110, P699, DOI 10.7326/0003-4819-110-9-699; MELAMED Y, 1992, NEW ENGL J MED, V326, P30; MELAMED Y, 1989, MANUAL DISASTER MED, P149; MELTZER T, 1986, AM SURGEON, V52, P659; MURPHY BP, 1985, ANN SURG, V201, P242, DOI 10.1097/00000658-198502000-00019; MYERS RAM, 1981, JAMA-J AM MED ASSOC, V246, P2478, DOI 10.1001/jama.246.21.2478; NOGI J, 1989, J BONE JOINT SURG AM, V71A, P929, DOI 10.2106/00004623-198971060-00019; NYLANDER G, 1987, PLAST RECONSTR SURG, V79, P91, DOI 10.1097/00006534-198701000-00015; PA Thombs, 1995, HYPERBARIC MED PRACT, P261; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; PALMQUIST BM, 1984, BRIT J OPHTHALMOL, V68, P113, DOI 10.1136/bjo.68.2.113; Parish R A, 1986, Pediatr Emerg Care, V2, P36, DOI 10.1097/00006565-198603000-00010; Peirce EI, 1984, SURG ROUNDS, V7, P17; RISEMAN JA, 1990, SURGERY, V108, P847; ROSENTHAL E, 1985, ARCH DIS CHILD, V60, P372, DOI 10.1136/adc.60.4.372; Santamaria J P, 1995, Adv Pediatr, V42, P335; SAWIN RS, 1994, AM J SURG, V167, P481, DOI 10.1016/0002-9610(94)90239-9; SEIDEL M, 1990, PEDIATR INFECT DIS J, V9, P437, DOI 10.1097/00006454-199006000-00014; SHUPAK A, 1995, SURGERY, V118, P873, DOI 10.1016/S0039-6060(05)80278-8; SHUPAK A, 1984, ISRAEL J MED SCI, V20, P323; SKYHAR MJ, 1986, J BONE JOINT SURG AM, V68A, P1218, DOI 10.2106/00004623-198668080-00011; SLOAN EP, 1989, ANN EMERG MED, V18, P629, DOI 10.1016/S0196-0644(89)80516-5; Stephens MB, 1996, POSTGRAD MED, V99, P217; STONEY WS, 1980, ANN THORAC SURG, V29, P336, DOI 10.1016/S0003-4975(10)61481-6; Strauss M.B., 1987, J HYPERBARIC MED, V2, P147; SUKOFF MH, 1989, PEDIAT INTENSIVE CAR, P483; THOM SR, 1992, J APPL PHYSIOL, V73, P1584; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; THOM SR, 1993, TOXICOL APPL PHARM, V123, P234, DOI 10.1006/taap.1993.1242; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; TOSCANO M, 1983, THORAC CARDIOV SURG, V31, P183, DOI 10.1055/s-2007-1021975; *USN, 1993, NAVSEA PUBL, V1; VANHOESEN KB, 1989, JAMA-J AM MED ASSOC, V261, P1039, DOI 10.1001/jama.261.7.1039; VANRYNEN JL, 1987, J HYPERBARIC MED, V2, P199; VAZQUEZ RL, 1990, AM J DIS CHILD, V144, P1022, DOI 10.1001/archpedi.1990.02150330082027; WATSON CHC, 1983, J BONE JOINT SURG AM, V65, P1181, DOI 10.2106/00004623-198365080-00023; WEINSTEIN L, 1973, NEW ENGL J MED, V289, P1129, DOI 10.1056/NEJM197311222892107; WORKMAN WT, 1989, MIL MED, V154, P111; ZAMBONI WA, 1993, PLAST RECONSTR SURG, V91, P1110, DOI 10.1097/00006534-199305000-00022; Zamboni WA, 1997, ANN PLAS SURG, V39, P131, DOI 10.1097/00000637-199708000-00004; ZIMMERMAN SS, 1981, PEDIATRICS, V68, P215	77	47	49	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	1998	102	5							e53	10.1542/peds.102.5.e53			9	Pediatrics	Pediatrics	134ZT	WOS:000076774600005	9794983	Bronze			2021-06-18	
J	Nochi, M				Nochi, M			Struggling with the labeled self: People with traumatic brain injuries in social settings	QUALITATIVE HEALTH RESEARCH			English	Article							HEAD-INJURY	The sense of loss of self that individuals with traumatic brain injuries (TBI) experience when they interact with society is explored in this article. An individual with TBI believes that others possess the power to label him or her. The labels, whether their connotations are negative or positive, often contradict the individual's self-definition, making him or her feel that he or she is not understood. Many individuals with TBI devise strategies to maintain or create a shaved meaning of self in society. They try to control information about themselves or change the terms applied to them. Through these strategies, people with TBI redefine themselves as objects of medical intervention while excluding brain injuries from their identities, or the essential parts of themselves.	Univ Tokyo, Dept Cognit & Behav Sci, Tokyo, Japan	Nochi, M (corresponding author), Univ Tokyo, Dept Cognit & Behav Sci, Tokyo, Japan.						AKRIDGE RL, 1986, J REHABILITATION ADM, V10, P81; Becker H., 1963, OUTSIDERS; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Bogdan R., 1992, QUALITATIVE RES ED I; CONRAD P, 1992, ANNU REV SOCIOL, V18, P209, DOI 10.1146/annurev.so.18.080192.001233; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Dembo T., 1975, REHABIL PSYCHOL, V22, P1; Glaser B. G., 1967, DISCOVERY GROUNDED T; GLIEDMAN J, 1980, UNEXPECTED MINORITY; Goffman E., 1963, STIGMA NOTES MANAGEM; GOVE WR, 1980, LABELING DEVIANCE; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; Lewington PJ, 1993, CANADIAN J COUNSELIN, V1993, P274; Mead G. H., 1934, MIND SELF SOC STANDP; Miller L, 1996, J COGNITIVE REHABILI, V14, P8; Miller L., 1993, PSYCHOTHERAPY BRAIN; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; NOCHI M, IN PRESS SOCIAL SCI; NOCHI M, 1996, CULTURAL DIVERSITY I, P65; Parsons T., 1951, SOCIAL SYSTEM; Pollack Irwin W., 1994, P671; ROSEN SL, 1994, RAGGED EDGE DISABILI, P19; RUBIN SE, 1995, FDN VOCATIONAL REHAB; SCHEFF TJ, 1966, BEING MENTALLY ILL; STEVENS ML, 1993, J REHABIL, V59, P35; YLVISAKER M, 1987, COMMUNITY REENTRY HE; ZITNEY GA, 1995, TBI CHALLENGE, V3, P2	31	47	47	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323			QUAL HEALTH RES	Qual. Health Res.	SEP	1998	8	5					665	681		10.1177/104973239800800507			17	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	113YH	WOS:000075581100007	10621567				2021-06-18	
J	Smith, SL; Andrus, PK; Gleason, DD; Hall, ED				Smith, SL; Andrus, PK; Gleason, DD; Hall, ED			Infant rat model of the shaken baby syndrome: Preliminary characterization and evidence for the role of free radicals in cortical hemorrhaging and progressive neuronal degeneration	JOURNAL OF NEUROTRAUMA			English	Article						cortical hemorrhaging; free radicals; shaken baby syndrome; tirilazad mesylate	TRAUMATIC BRAIN INJURY; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; TIRILAZAD MESYLATE U-74006F; ENERGY PHOSPHATE-METABOLISM; EXPERIMENTAL HEAD-INJURY; MAJOR CEREBRAL-ARTERIES; EXCITATORY AMINO-ACIDS; BARRIER DISRUPTION; HYPOXIA-ISCHEMIA; LIPID-PEROXIDATION	Infants subjected to repeated episodes of violent shaking develop brain damage characterized by intracranial hemorrhage and progressive cortical atrophy. We have developed an animal model that mimics this pathological state and investigated its etiology and treatment. Anesthetized male rats, 6 days of age, were subjected to one episode of shaking per day for 3 consecutive days. Separate groups of rats were sacrificed 1 h postinjury on the third day of shaking for HPLC quantification of cortical . OH and vitamin E levels, and histological assessment of cortical hemorrhaging. Additional groups were sacrificed 7 or 14 days postinjury to demonstrate progressive neuronal degeneration via cortical wet weight comparisons. In comparison to noninjured shams, the results indicated that cortical vitamin E and . OH levels rose 53.7% (p < 0.005) and 457.1% (p < 0.001), respectively, in shaken infant rats. Brain histologies revealed a moderate-to-severe degree of cortical hemorrhaging in these animals 1 h postinjury. By 7 and 14 days postinjury, there was a 13.3% and 28.7% (p < 0.0001 vs. sham) loss of cortical tissue in shaken infants, respectively, indicating progressive neuronal degeneration. Treatment with 10 mg/kg (ip) of the 21-aminosteroid antioxidant, tirilazad mesylate, 10 min before and 2 h after each episode of shaking, resulted in a 53.1% attenuation of cortical . OH levels and a 34.9% decrease in brain hemorrhaging (p < 0.05 vs, vehicle). Tirilazad treatment did not, however, significantly effect cortical vitamin E concentrations at 1 h postinjury or the extent of progressive neuronal degeneration at either 7 or 14 days postinjury. The present animal model mimics the brain pathology seen in abused children. Our observation that tirilazad mesylate, an antioxidant-lipid peroxidation inhibitor, significantly reduces cortical . OH levels and brain hemorrhaging in shaken infant rats supports a role for oxygen radicals in the pathophysiology of this type of CNS injury. The failure of tirilazad to block progressive cortical degeneration suggests that mechanisms other than free radicals may be of prime importance in the mediation of this aspect of the pathology.	Pharmacia & Upjohn Inc, CNS Dis Res, Kalamazoo, MI 49001 USA	Smith, SL (corresponding author), Pharmacia & Upjohn Inc, CNS Dis Res, 7251-209-4,301 Henrietta St, Kalamazoo, MI 49001 USA.		Hall, Edward D/F-8930-2013				ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER RC, 1989, RADIOLOGY, V173, P653; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDINE P, 1990, J NEUROSCI METH, V35, P253, DOI 10.1016/0165-0270(90)90131-X; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; Bagenholm R, 1996, PEDIATR RES, V40, P399, DOI 10.1203/00006450-199609000-00006; Bostrom K, 1992, Acta Neurochir Suppl (Wien), V55, P25; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEHAIME AC, 1996, NEUROLOGICAL SURG, V3, P1777; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Duhaime AC, 1988, J PEDIAT NEUROSCI, V4, P77; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANCEL PC, 1996, NEUROLOGICAL SURG, V3, P1730; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENTLEMAN D, 1992, INT SURG, V77, P297; GILLAND E, 1994, DEV BRAIN RES, V83, P79, DOI 10.1016/0165-3806(94)90181-3; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; GRAFE MR, 1994, BRAIN RES, V653, P161, DOI 10.1016/0006-8993(94)90385-9; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAGBERG H, 1994, BIOL NEONATE, V66, P205; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1996, EUR J ANAESTH, V13, P279, DOI 10.1046/j.1365-2346.1996.00980.x; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1997, HDB SYNTHETIC ANTIOX, P261; Hall ED, 1993, IRON CENTRAL NERVOUS, P173; HINZMANN JS, 1992, CHEM PHYS LIPIDS, V62, P123, DOI 10.1016/0009-3084(92)90090-C; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KANAMARU K, 1991, J NEUROSURG, V74, P454, DOI 10.3171/jns.1991.74.3.0454; LIAU LM, 1996, NEUROLOGICAL SURG, V3, P1549; MACHLIN LJ, 1982, ANN NY ACAD SCI, V393, P48, DOI 10.1111/j.1749-6632.1982.tb31231.x; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1989, EXP NEUROL, V106, P289, DOI 10.1016/0014-4886(89)90162-3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Povlishock John T., 1993, P185; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; SASAKI T, 1986, NEUROSURGERY, V19, P177, DOI 10.1227/00006123-198608000-00002; SASAKI T, 1985, J NEUROSURG, V63, P433, DOI 10.3171/jns.1985.63.3.0433; SCHMIDT I, 1987, CAN J PHYSIOL PHARM, V65, P1355, DOI 10.1139/y87-214; SILVERSTEIN FS, 1986, STROKE, V17, P477, DOI 10.1161/01.STR.17.3.477; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SPAIDE RF, 1990, AM FAM PHYSICIAN, V41, P1145; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; WHYTE K M, 1989, Australasian Radiology, V33, P344, DOI 10.1111/j.1440-1673.1989.tb03308.x; ZHANG JR, 1993, J NEUROCHEM, V61, P1640, DOI 10.1111/j.1471-4159.1993.tb09798.x; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367	57	47	49	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1998	15	9					693	705		10.1089/neu.1998.15.693			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	118ZT	WOS:000075871400005	9753217				2021-06-18	
J	Paardekooper, GMRM; Cammelli, S; Zeilstra, LJW; Coppes, RP; Konings, AWT				Paardekooper, GMRM; Cammelli, S; Zeilstra, LJW; Coppes, RP; Konings, AWT			Radiation-induced apoptosis in relation to acute impairment of rat salivary gland function	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY			English	Article							PAROTID-GLAND; SUBMANDIBULAR GLANDS; SECRETORY GRANULES; X-IRRADIATION; ACINAR-CELLS; NECK-CANCER; RADIOSENSITIVITY; INJURY; THERAPY; HEAD	Purpose: To find an answer to the question: Are the acute radiation effects on salivary gland function, as seen in earlier studies, causally related to radiation-induced apoptosis? Materials and methods: Rat parotid and submandibular glands were X-irradiated with doses up to 25 Gy and morphological damage assayed up to 6 days after irradiation. Damage to the different cell types in the glands was assessed after H & E staining. Apoptotic appearance was judged by compacted chromatin and fragmentation of cells into lobulated masses. Results: In about 3% of the cells aberrant nuclei were observed after doses as low as 2 Gy and around 7.5 and 24 h after irradiation. About half of these aberrant nuclei had an apoptotic appearance. After a dose of about 5 Gy no dose-response for apoptotic cells was found, as evidenced by a plateau in the dose-effect curve. At 6 days after 2 Gy, no signs of radiation-induced apoptosis was apparent and for most cell types a value close to zero was observed. Conclusions: Radiation studies on salivary function in the rat show the typical response with respect to;lose (5-15 Gy) and time (1-3 days). This differs from reported findings with light microscopy. Therefore, the extent of apoptotis induced by radiation cannot explain the observed gland malfunction. Alternative mechanisms are proposed.	Univ Groningen Hosp, Dept Radiotherapy, NL-9700 RB Groningen, Netherlands; Univ Groningen, Dept Radiobiol, NL-9713 BZ Groningen, Netherlands	Paardekooper, GMRM (corresponding author), Univ Groningen Hosp, Dept Radiotherapy, Hanzeplein 1,Postbus 30-000, NL-9700 RB Groningen, Netherlands.		Coppes, Robert P/B-4089-2008	Coppes, Robert P/0000-0001-5503-1064			ABOK K, 1984, VIRCHOWS ARCH B, V45, P443, DOI 10.1007/BF02889885; CHENG VST, 1981, INT J RADIAT ONCOL, V7, P253, DOI 10.1016/0360-3016(81)90444-2; CHERRY CP, 1959, BRIT J RADIOL, V32, P596, DOI 10.1259/0007-1285-32-381-596; Coppes RP, 1997, RADIAT RES, V148, P240, DOI 10.2307/3579608; ELMOFTY SK, 1981, INT J RADIAT BIOL, V39, P55, DOI 10.1080/09553008114550071; ENGLISH JAMES A., 1955, JOUR DENTAL RES, V34, P4, DOI 10.1177/00220345550340011301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GAZDA MJ, 1992, INT J RADIAT ONCOL, V24, P693, DOI 10.1016/0360-3016(92)90716-U; GROSSWENDT B, 1990, PHYS MED BIOL, V35, P1233, DOI 10.1088/0031-9155/35/9/004; HENDRY JH, 1982, INT J RADIAT BIOL, V42, P621, DOI 10.1080/09553008214551601; Jones RE, 1996, ORAL SURG ORAL MED O, V81, P642, DOI 10.1016/S1079-2104(96)80068-0; Li YQ, 1996, CANCER RES, V56, P5417; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; NAGLER RM, 1993, RADIAT RES, V136, P42, DOI 10.2307/3578638; Nagler RM, 1996, ARCH ORAL BIOL, V41, P713, DOI 10.1016/S0003-9969(96)00025-8; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; PETER B, 1994, RADIAT RES, V140, P257, DOI 10.2307/3578910; PETER B, 1994, RADIAT RES, V140, P419, DOI 10.2307/3579121; PETER B, 1995, RADIAT RES, V141, P176, DOI 10.2307/3579045; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; PRATT NE, 1972, ARCH ORAL BIOL, V17, P177; SEUNTJENS J, 1987, PHYS MED BIOL, V32, P595, DOI 10.1088/0031-9155/32/5/005; Shinohara C, 1997, CANCER RES, V57, P2694; SODICOFF M, 1977, ARCH ORAL BIOL, V22, P261, DOI 10.1016/0003-9969(77)90111-X; SODICOFF M, 1974, RADIAT RES, V58, P196, DOI 10.2307/3573932; STEPHENS L C, 1989, Cancer Bulletin (Houston), V41, P106; STEPHENS LC, 1991, CANCER, V67, P1539, DOI 10.1002/1097-0142(19910315)67:6<1539::AID-CNCR2820670613>3.0.CO;2-Q; STEPHENS LC, 1986, RADIOTHER ONCOL, V7, P165; VALDEZ IH, 1993, INT J RADIAT ONCOL, V25, P41, DOI 10.1016/0360-3016(93)90143-J; VISSINK A, 1990, RADIAT RES, V124, P259, DOI 10.2307/3577837; VISSINK A, 1991, J ORAL PATHOL MED, V20, P449, DOI 10.1111/j.1600-0714.1991.tb00437.x; VISSINK A, 1992, INT J RADIAT BIOL, V61, P275, DOI 10.1080/09553009214550911	32	47	50	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0955-3002			INT J RADIAT BIOL	Int. J. Radiat. Biol.	JUN	1998	73	6					641	648		10.1080/095530098141898			8	Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	ZZ888	WOS:000074778700007	9690682				2021-06-18	
